




AMERICAN ACADEMY
OF OPHTHALMOLOGY®
Protecting Sight. Empowering Lives.

Master Index

2018–2019
BCSC
Basic and Clinical
Science Course™



American Academy of Ophthalmology Staff

Dale E. Fajardo, EdD, MBA, *Vice President, Education*

Beth Wilson, *Director, Continuing Professional Development*

Ann McGuire, *Acquisitions and Development Manager*

Stephanie Tanaka, *Publications Manager*

D. Jean Ray, *Production Manager*

Susan Malloy, *Acquisitions Editor and Program Manager*

Jasmine Chen, *Manager of E-Learning*

Beth Collins, *Medical Editor*

Eric Gerdes, *Interactive Designer*

Naomi Ruiz, *Publications Specialist*

Index by Michael Ferreira, San Marcos, California

Cover image: From BCSC Section 12, *Retina and Vitreous*. End-stage chorio-retinal atrophy in pathologic myopia. (*Courtesy of Richard F. Spaide, MD.*)

American Academy of Ophthalmology
655 Beach Street
Box 7424
San Francisco, CA 94120-7424

Copyright © 2018 American Academy of Ophthalmology. All rights reserved. No part of this publication may be reproduced without written permission.

Basic and Clinical Science Course

2018–2019

Louis B. Cantor, MD, Indianapolis, Indiana, *Senior Secretary for Clinical Education*

Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, *Secretary for Lifelong Learning and Assessment*

George A. Cioffi, MD, New York, New York, *BCSC Course Chair*

Section 1 *Update on General Medicine*

Chair: Herbert J. Ingraham, MD, Danville, Pennsylvania

Section 2 *Fundamentals and Principles of Ophthalmology*

Chair: Lawrence M. Levine, MD, Jacksonville, Florida

Section 3 *Clinical Optics*

Chair: Scott E. Brodie, MD, PhD, New York, New York

Section 4 *Ophthalmic Pathology and Intraocular Tumors*

Chair: Robert H. Rosa, Jr, MD, Temple, Texas

Section 5 *Neuro-Ophthalmology*

Chair: M. Tariq Bhatti, MD, Durham, North Carolina

Section 6 *Pediatric Ophthalmology and Strabismus*

Chair: Robert W. Hered, MD, Maitland, Florida

Section 7 *Orbit, Eyelids, and Lacrimal System*

Chair: Jill Annette Foster, MD, Columbus, Ohio

Section 8 *External Disease and Cornea*

Chair: Robert W. Weisenthal, MD, De Witt, New York

Section 9 *Intraocular Inflammation and Uveitis*

Chair: Russell W. Read, MD, PhD, Birmingham, Alabama

Section 10 *Glaucoma*

Chair: Christopher A. Girkin, MD, Birmingham, Alabama

Section 11 *Lens and Cataract*

Chair: Sharon L. Jick, MD, St Louis, Missouri

Section 12 *Retina and Vitreous*

Chair: Colin A. McCannel, MD, Los Angeles, California

Section 13 *Refractive Surgery*

Chair: M. Bowes Hamill, MD, Houston, Texas

Master Index

(*f* = figure; *t* = table. The BCSC Section number is indicated by the number preceding the period.)

A

A2E, 12.31

photoreceptor light damage and, 2.286

A constant, in IOL power determination/power prediction formulas, 11.85

A-pattern strabismus

clinical features of, 6.109

clinically significant, 6.109

definition of, 6.107

etiology of, 6.107–109, 6.108*f*

in exotropia, 6.108*f*, 6.109, 6.112

heterotopy as cause of, 6.28

horizontal rectus muscle transposition for, 6.112

identification of, 6.109

intorsion as cause of, 6.107, 6.110

medial rectus muscle displacement for, 6.110, 6.111*f*

palpebral fissure slanting associated with, 6.196

superior oblique muscle overaction associated with, 6.107

superior oblique tenotomy for, 6.112

surgical treatment of, 6.112, 6.112*t*

A-R syndrome. *See* Axenfeld-Rieger syndrome

A-scan ultrasonography/echography. *See also*

Ultrasonography/ultrasound (echography)

for axial length measurement, 3.244–245, 3.245–246*f*
in IOL power determination/selection, 11.82–83, 11.83*f*, 11.85, 11.87

in primary congenital glaucoma, 10.160

in choroidal hemangioma, 4.281, 4.282*f*

in choroidal melanoma/ciliary body melanoma, 4.265, 4.266*f*

in metastatic eye disease, 4.307

orbital, 7.31

a-wave

of ERG, 5.96, 12.46, 12.251. *See also*

Electroretinography/electroretinogram

in rod–cone dystrophies, 12.261

AA. *See* Arachidonic acid

AAION. *See* Arteritic ischemic optic neuropathy, anterior

AAO. *See* American Academy of Ophthalmology

AAP. *See* American Academy of Pediatrics

AAPOX. *See* Adult-onset asthma with periocular

xanthogranuloma

AAVs. *See* Adeno-associated viruses

Ab externo approach

for IOL dislocation repair, 11.145, 11.147*f*

for trabeculotomy, in pediatric glaucoma, 10.160, 10.161–162, 10.162*f*, 10.163

Ab interno approach, for IOL dislocation repair, 11.145

Ab interno trabeculectomy, 6.287, 10.219

cataract surgery and, 11.186

Abacavir, 1.266

Abatacept, 1.175, 6.322

Abbe number

definition of, 3.195

of polycarbonate lenses, 3.196

ABC System (International Classification System for Intraocular Retinoblastoma), 4.297, 4.297*t*

ABC transporters/transporter protein. *See* ATP-binding cassette (ABC) transporters/transporter protein

ABCA4 gene, 6.339

retinopathy caused by, 12.31

in Stargardt disease, 4.168–169, 12.271

ABCC5 gene, in primary angle closure, 10.121

ABCC6 gene, 12.87

ABCDE mnemonic, in melanoma evaluation, 1.215

Abciximab, for ischemic heart disease, 1.101*t*

non–ST-segment elevation acute coronary syndrome, 1.103–104

Abducens nerve. *See* Cranial nerve VI

Abduction

definition of, 6.33

extraocular muscles in, 5.46*f*

inferior oblique muscle, 5.46*f*

lateral rectus muscle, 5.46*f*

oblique muscles, 5.46*f*

superior oblique muscle, 5.46*f*

impaired, in younger patient, 5.201

lateral rectus muscle, 6.35*f*

nystagmus and (dissociated/disconjugate), 5.247

Aberrant nerve regeneration. *See also* specific nerve

cranial nerve III (oculomotor), 5.197–198, 5.198*f*

anisocoria and, 5.265–266

light–near dissociation and, 5.266*t*, 5.267

cranial nerve VII (facial), 5.277

superior oblique myokymia and, 5.250

synkinesis and, 5.197, 5.271, 5.271*f*, 5.277, 7.211, 7.229

Aberrations. *See also* Wavefront aberrations; *specific type*

astigmatism

irregular, 13.17–19, 13.18*f*, 13.19*f*. *See also* Irregular astigmatism

regular, 13.17, 13.18*f*

chromatic, 3.40, 3.72, 3.166, 3.199

coma, 3.275*f*, 3.275–276, 13.9, 13.12, 13.12*f*, 13.103*f*

definition of, 3.39, 3.69

first-order, 13.11

fourth-order, 13.12, 13.12*f*

higher-order, 13.11–13, 13.12*f*, 13.13*f*

keratorefractive surgery and, 3.276–277

after LASIK, 13.11, 13.12, 13.102–103, 13.103*f*

pupil size and, 3.106

after surface ablation, 13.11, 13.12, 13.13, 13.102

topography-guided laser ablation and, 13.32, 13.77

wavefront-guided/wavefront-optimized ablation and, 13.13, 13.31–32, 13.76–77

Zernike polynomials and, 3.139

after LASIK, 13.11, 13.12, 13.102–103, 13.103*f*

lower-order, 13.11, 13.11*f*

measurement/graphical representations of, 13.9–10, 13.10*f*

after photoablation, 13.11, 13.12, 13.13, 13.102–103, 13.103*f*

2 • Master Index

- piston, 13.11
- point spread function, 3.69–70
- retinal reflex, 3.159
- second-order, 13.11, 13.11*f*
- Seidel, 3.41, 3.72, 3.72*f*
- spherical, 3.42, 3.72, 3.72*f*, 3.74*f*, 3.159, 3.268–269, 3.272, 3.275–276*f*, 3.276, 13.9, 13.12, 13.12*f*, 13.102. *See also* Spherical aberration
- after LASIK, 13.12, 13.102
- after radial keratotomy, 13.50
- after surface ablation, 13.12, 13.102
- after surface ablation, 13.11, 13.12, 13.13, 13.102
- third-order, 13.12, 13.12*f*
- trefoil, 13.9, 13.12, 13.13*f*, 13.103*f*
- wavefront. *See* Wavefront aberrations
- zero-order, 13.11
- Aberrometry/aberrometers, wavefront, 3.289–292, 3.290–291*f*
- intraoperative, in IOL power determination/selection
- astigmatism and, 11.124
- after refractive surgery, 11.86
- Abetalipoproteinemia, 12.289–290
- microsomal triglyceride transfer protein (MTP)
- defects causing, 2.265
- vitamin supplements in management of, 2.203
- Ablepharon, 6.193
- Ablepharon-macrostomia syndrome, 6.193
- Abnormal head position (AHP), in torticollis, 6.82
- AbobotulinumtoxinA, 5.281, 7.238. *See also* Botulinum toxin
- ABPM. *See* Ambulatory blood pressure measurement
- Abrasions, corneal, 4.13–14, 8.398–399
- in mucous membrane pemphigoid, 8.300
- posttraumatic recurrent corneal erosion and, 8.86, 8.87, 8.398
- Abscesses
- in dacryocystitis, 7.286
- orbital, 7.47, 7.47*f*
- Absence (“petit mal”) seizures, 1.201
- Absidia*, 8.249*t*, 8.251
- Absolute scotomas, 12.327
- Absorptive lenses, 3.192–194, 3.193*f*. *See also* Sunglasses
- Abuse, elder, 1.179–180
- Abusive head trauma (AHT), 6.381–384, 6.382–383*f*, 12.365–366, 12.366*f*
- AC. *See* Accommodative convergence/vergence
- AC/A. *See* Accommodative convergence/accommodation
- AC/A ratio. *See* Accommodative convergence/accommodation (AC/A) ratio
- ACA. *See* Anterior cerebral artery
- ACAID. *See* Anterior chamber-associated immune deviation
- Acanthamoeba*, 2.361, 3.229, 8.252, 8.252*f*
- cysts, 8.252, 8.252*f*
- keratitis/ocular infection caused by, 4.78–79, 4.79*f*, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*
- confocal microscopy in diagnosis of, 8.24, 8.277, 8.278*f*
- contact lens wear and, 4.78–79, 8.276, 8.277
- herpes simplex keratitis differentiated from, 8.278
- isolation techniques for diagnosis of, 4.79, 8.211
- pathogenesis and, 8.207, 8.276
- stains and culture media for identification of, 4.79, 8.209*t*, 8.277
- treatment of, 2.361, 8.277–279
- stains and culture media for identification of, 4.79, 8.209*t*, 8.277
- Acantholysis, definition of, 4.202
- Acanthosis
- in actinic keratosis, 4.211*f*
- definition of, 4.202
- in seborrheic keratosis, 4.209
- Acarbose, for diabetes mellitus, 1.45*t*, 1.46
- ACC. *See* Adenoid cystic carcinoma
- Accelerated corneal crosslinking, 13.134. *See also* Corneal (collagen) crosslinking
- Accessory lacrimal glands, 2.22*f*, 2.23*t*, 2.29, 2.215*f*, 2.216
- of Krause, 2.20*f*, 2.22*f*, 2.23*t*, 2.29, 2.216, 4.202, 7.146*f*, 7.152, 7.252
- of Wolfring, 2.20*f*, 2.22*f*, 2.23*t*, 2.29, 2.216, 4.202, 7.146*f*, 7.152, 7.252
- Accessory molecules, in immune processing, 9.36*f*, 9.37
- Accidental trauma, 6.375–381, 6.377–378*f*, 6.380*f*. *See also* Trauma
- Accommodating intraocular lenses, 3.261, 11.122, 11.122*f*, 13.8*t*, 13.154, 13.163–164, 13.164*f*
- complications of, 11.151
- Accommodation, 2.63, 11.22–23, 11.23*t*, 13.159–162, 13.160*f*, 13.161*f*
- age-related values for, 3.176*t*
- aging affecting, 2.63, 11.23, 13.159. *See also* Presbyopia
- amplitude of, 6.188, 11.23
- age-related changes in, 3.176, 3.176*t*, 11.23
- definition of, 3.147
- description of, 3.140
- measurement of, 3.178–179
- near point of accommodation for, 3.179
- Prince rule for measuring, 3.179, 3.179*f*
- spheres method for measuring, 3.179
- changes with, 11.22–23, 11.23*t*
- nonorganic disorders and, 5.310
- contact lenses and, 3.178, 3.208–211, 3.209*f*, 3.210*t*
- definition of, 3.34, 3.123, 3.140
- dynamic retinoscopy measurements of, 6.9
- after fogging, 3.152, 3.160
- Goldberg theory of reciprocal zonular action and, 13.162
- Helmholtz hypothesis (capsular theory) of, 11.22, 13.159–160, 13.160*f*
- hypoaccommodation, 6.9
- in manifest refraction, 3.34–36
- muscarinic drugs affecting, 2.308, 2.311
- near point of
- definition of, 3.140
- measurement of, 3.179
- pupil size effects on, 3.130
- near reflex and, 2.96
- paralysis of, 3.174
- presbyopia. *See* Presbyopia
- range of, 3.140, 3.180
- refractive error progression and, 3.144
- relaxing of, 3.177. *See also* Cycloplegia/cycloplegics
- Schachar theory of, 13.160–162, 13.161*f*

- spasm of (ciliary muscle spasm), 5.310
 spectacle lens correction effects on, 3.178
 stimulating of, 3.177
 theories of, 13.159–162, 13.160f, 13.161f
 zonular fibers in, 2.64f, 2.66, 13.159, 13.160, 13.160f, 13.161, 13.161f
- Accommodative control
 definition of, 3.35
 in manifest refraction, 3.34–36
 “Rule-1” test for, 3.35
- Accommodative convergence/accommodation (AC/A)
 ratio, 5.226–227
 definition of, 6.71
 description of, 3.175, 6.39
 gradient method for, 3.177–178
 heterophoria method for, 3.177
 high
 in accommodative esotropia, 5.227, 6.90–92
 bifocal glasses for, 6.102
 in intermittent exotropia, 6.100
 measurement of, 6.71
 response, 6.71
 stimulus, 6.71
- Accommodative convergence/vergence (AC), 5.226, 6.39, 6.59. *See also* Accommodative convergence/accommodation (AC/A) ratio
 assessment of, 5.226–227
- Accommodative demand, 3.208–210, 3.209f
- Accommodative effort
 asthenoptic complaints associated with, 3.24
 definition of, 3.140
- Accommodative esodeviations
 cycloplegic examinations for, 6.11
 surgical treatment of, 6.102
- Accommodative esotropia
 amblyopia associated with, 6.91
 definition of, 6.90
 description of, 5.227, 6.57
 evaluation of, 6.91
 high AC/A ratio and, 5.227, 6.90–92
 management of, 6.91–92
 muscarinic antagonists for management of, 2.313
 nonrefractive, 6.90
 partially, 6.90–92
 pathogenesis of, 6.90–91
 refractive, 6.90–92
 refractive surgery and, 13.188
 types of, 6.86t, 6.90–91
- Accommodative excess, 3.176
- Accommodative insufficiency, 3.176
- Accommodative intraocular lenses. *See* Accommodating intraocular lenses
- Accommodative response, 3.140. *See also* Accommodation
- Accommodative tone, situations that increase, 3.35
- ACCORD EYE, 1.89
- ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, 1.39, 1.89, 12.98
- Accuracy
 saccadic eye movement, 5.221
 of screening/diagnostic test, 1.15
- ACD. *See* Anterior chamber, depth of
- ACE. *See* Angiotensin-converting enzyme
- ACE inhibitors. *See* Angiotensin-converting enzyme (ACE) inhibitors
- Acebutolol, 1.68t, 2.317f
- Acephalgic migraine (aura without headache), 5.172, 5.177, 5.291. *See also* Migraine headache
- Acetazolamide, 2.324, 2.325, 2.325t, 2.326, 10.172–173t, 10.180, 12.305, 12.393
 for cystoid macular edema, in uveitis, 9.289
 for glaucoma, 10.172–173t, 10.180
 in children, 10.165
 for idiopathic intracranial hypertension, 5.112, 6.371
 sustained-release oral preparation for, 2.301, 2.325
- Acetic acid (HAcetate/CH₃CO₂H/C₂H₄O₂), ocular injuries caused by, 8.376t
- Acetohexamide, for diabetes mellitus, 1.45t
- Acetylcholine (ACh), 2.308t, 2.309f, 2.309–310
 clinical use of, 2.309–310
 intracameral administration of, 2.300t, 2.309, 2.310
 receptors for (AChR)
 drugs affecting, 2.307f, 2.307–315, 2.308t, 2.309f, 2.310f, 2.311t, 2.314t, 2.315t. *See also* Cholinergic agents
 in myasthenia gravis, 5.323, 7.217
 synthesis/release/degradation of, 2.309, 2.309f, 2.310, 2.310f
 in tear secretion, 2.216, 2.218, 2.218f
- Acetylcholine receptor antibodies, 6.142
- Acetylcholine receptor (AChR) antibody tests, for myasthenia gravis, 5.325–326, 7.217
- Acetylcholinesterase. *See* Cholinesterase/acetylcholinesterase
- Acetylcholinesterase inhibitors. *See* Cholinesterase/acetylcholinesterase inhibitors
- Acetylcysteine
 for filamentary keratopathy, 2.306, 8.63, 8.304
 off-label use of, 2.306
- N-Acetylgalactosamine-4-sulfatase deficiency, in Maroteaux-Lamy syndrome, 8.175t
- Acetyltransferase, in isoniazid pharmacogenetics, 2.201
- ACh. *See* Acetylcholine
- Achiasma, congenital, nystagmus caused by, 5.247
- AChoA. *See* Anterior choroidal artery
- AChR. *See* Anti-acetylcholine receptor (AChR) antibodies
- Achromatic automated perimetry, 10.59. *See also* Perimetry
- Achromatopsia (monochromatism), 6.337–338, 12.250, 12.250t
 blue-cone, 2.199t, 2.264
 cerebral, 5.179
 gene defects causing, 2.264
 infantile nystagmus syndrome and, 5.236
 with myopia, racial and ethnic concentration of, 2.197
 rod, 2.264
 S-cone (blue-cone), 2.264
 ocular findings in carriers of, 2.199t
- Acid, ocular injuries caused by, 8.376t, 8.380f, 8.380–381, 8.381f. *See also* Chemical injury
 cataract and, 11.59
- Acid burns, 6.376, 8.376t, 8.380f, 8.380–381, 8.381f
- Acid-fast stain, 8.244
- Acidic fibroblast growth factor (aFGF). *See also* Fibroblast growth factor
 in aqueous humor, 2.234

4 • Master Index

- Acidosis, carbonic anhydrase inhibitors causing, 2.325–326
- aspirin interactions and, 2.336
- Acinar cells, lacrimal gland, 2.28, 2.28f
- ACIOLs (anterior chamber intraocular lenses). *See* Intraocular lenses (IOLs), anterior chamber
- ACL (*acromegaly, cutis verticis gyrata, corneal leukoma*) syndrome, congenital corneal keloids in, 8.107
- ACLS. *See* Advanced cardiac life support
- ACoA. *See* Anterior communicating artery
- Acoustic neuromas/neurofibromas, 5.330, 5.334t, 6.397, 10.156
- seventh nerve (facial) palsy and, 5.279, 5.279f
- Acquired (adaptive) immunity, 1.240, 9.9, 9.31–52. *See also* Adaptive immune response/adaptive immunity
- Acquired immunodeficiency syndrome (AIDS), 1.262–272. *See also* AIDS (acquired immunodeficiency syndrome); HIV infection/AIDS
- Acquired nonaccommodative esotropia
- basic, 6.93
- consecutive esotropia, 6.95
- cyclic esotropia, 6.93
- description of, 6.92
- divergence insufficiency, 6.94
- near reflex spasm, 6.94
- sensory esotropia, 6.93–94
- types of, 6.86t
- Acquired ocular motor apraxia, 5.223
- Acquired optic disc pit, 10.49–50
- Acquired pendular nystagmus, 5.246–247
- Acquired ptosis. *See* Ptosis
- Acquired strabismus, 6.16
- Acquired vasoproliferative lesions, 12.168
- Acrocephalopolysyndactyly (Carpenter syndrome), 8.191t
- Acrocephalopolysyndactyly type II, 8.191t
- Acrocephalosyndactyly (Apert syndrome), 6.206–207, 6.207f, 6.209f, 7.37, 7.38f, 8.191t
- Acrochordon (skin tag), 7.166, 7.166f
- Acrodermatitis chronica atrophicans, in Lyme disease, 1.251, 9.245
- Acrolentiginous melanoma, 7.185
- Acromegaly, 1.57
- Acromegaly, cutis verticis gyrata, corneal leukoma (ACL) syndrome, congenital corneal keloids in, 8.107
- Acropachy, in thyroid eye disease, 7.56
- Acrylic, for IOLs, 3.256, 11.120, 13.139t, 13.144. *See also* Foldable intraocular lenses
- glisterings and, 11.151
- ocular trauma and, 11.193
- opacification and, 11.151
- uveitis and, 11.140, 11.188
- Acrysof ReSTOR bifocal IOLs, 3.262
- ACS. *See* Acute coronary syndrome; Anterior ciliary sclerotomy
- ACTA2 gene, 6.268
- ACTH (adrenocorticotrophic hormone), in tear secretion, 2.219
- Actin, 2.245
- in immunohistochemistry, 4.33
- in adenoid cystic carcinoma, 4.231
- in retinal pigment epithelium, 2.273
- Actin filaments, 2.245
- “Actinic” band keratopathy, 4.83
- Actinic injury. *See* Photochemical (actinic) injury
- Actinic (Labrador/climatic droplet) keratopathy (spheroidal degeneration), 4.83, 4.83f, 8.115–117, 8.116f
- Actinic keratosis, 4.210–212, 4.211f, 4.212f, 7.175–176, 7.176f
- squamous cell carcinoma and, 4.211, 7.182
- Actinomyces/Actinomyces israelii/actinomycetes*, 8.208t, 8.244t, 8.248
- canaliculitis caused by, 7.284–285, 7.285f
- dacryolith formation and, 7.277
- Actinomycin-D (dactinomycin), 1.233t, 1.235
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, 1.39, 1.89, 12.98
- Activated macrophages, 9.19, 9.20f, 9.21
- Activated neutrophils, 9.16, 9.18f, 9.18–19
- Activated partial thromboplastin time (aPTT), 1.141
- Activated protein C (APC), 1.141
- deficiency of, 1.141
- resistance, 1.147
- Activation
- lymphocyte, 9.36f, 9.36–38, 9.38
- macrophage, 9.14t, 9.19–21, 9.20f
- neutrophil, 9.14t, 9.16–19, 9.18f
- Activators (drug), 2.304
- Active force generation test, 6.73
- Active immunization, 1.216–217
- Active medium, of lasers, 3.111, 3.112f
- Active pulley hypothesis, 6.28
- Active transport/secretion
- across retinal pigment epithelium, 2.273, 2.277
- in aqueous humor dynamics, 2.230, 2.323, 2.324f, 10.16
- in lens, 11.21
- epithelium as site of, 11.21
- pump–leak theory and, 11.21, 11.22f
- in lens ionic balance, 2.246
- Activities of daily living (ADL), preoperative assessment of, 1.180
- Activities of Daily Vision Scale (ADVS), 11.71
- Acuity. *See* Visual acuity
- Acuity meter, potential. *See* Potential acuity estimation/potential acuity meter (PAM) testing
- Acute brainstem syndrome, 5.117t
- Acute coronary syndrome (ACS), 1.93–95. *See also* Coronary heart disease; Myocardial infarction
- hypertension management and, 1.75
- management of, 1.100t, 1.103–105
- risk calculators/stratification for, 1.103, 1.104
- statin use in, 1.81
- Acute diencephalic syndrome, 5.117t
- Acute disseminated encephalomyelitis, optic nerve involvement and, 4.244, 4.244f
- Acute exudative polymorphous vitelliform maculopathy, 12.287
- Acute hemorrhagic conjunctivitis (AHC), 8.240, 8.240t
- Acute HIV infection, 1.264

- Acute idiopathic blind-spot enlargement (AIBSE), 5.100–101, 5.101*f*
 fundus autofluorescence in identification of, 5.90
- Acute idiopathic maculopathy (AIM), 12.228–229
- Acute lymphoblastic leukemia, 6.413
 orbital involvement and, 7.98
- Acute macular neuroretinopathy (AMN), 9.163, 12.228, 12.229*f*, 12.277
 fundus autofluorescence in identification of, 5.90
 OCT in identification of, 5.92, 5.93*f*
- Acute multifocal posterior placoid pigment epitheliopathy (AMPPPE). *See* Acute posterior multifocal placoid pigment epitheliopathy
- Acute-onset postoperative endophthalmitis, 9.261
- Acute paralytic strabismus, 6.175
- Acute posterior multifocal placoid pigment epitheliopathy (APMPPE/AMPPPE), 9.141–143*t*, 9.148*f*, 9.148–151, 9.149*f*, 9.150*f*, 9.151*f*, 12.220*t*, 12.221*f*, 12.221–222
- Acute respiratory distress, 6.230
- Acute retinal necrosis (ARN), 4.145, 4.146*f*, 9.193–198, 9.194*f*, 9.194*t*, 9.195*f*, 12.236, 12.236*f*
- Acute retinal pigment epitheliitis (ARPE/Krill disease), 9.141–143*t*, 9.164, 9.164*f*
- Acute retroviral syndrome, 1.264
- Acute seroconversion syndrome, 1.264
- Acute spastic entropion, 7.205–206
- Acute syphilitic posterior placoid chorioretinitis (ASPPC), 12.241
- Acute thyroiditis, 1.54
- Acute zonal occult outer retinopathy (AZOOR), 5.101, 9.141–143*t*, 9.164–166, 9.165*f*
 description of, 12.226–228, 12.227*f*
 electro-oculography of, 12.51
 fundus autofluorescence in identification of, 5.90
 OCT in identification of, 5.92
- Acute zonal occult outer retinopathy (AZOOR) complex, 9.166. *See also* White dot syndromes; *specific disorder*
- Acyclovir, 1.281, 2.357*t*, 2.358–359, 8.215*t*
 for acute retinal necrosis, 9.196, 12.236
 for herpes simplex virus infections, 1.258, 1.281, 2.357*t*, 2.358, 8.215*t*, 8.219, 8.222, 8.223*t*, 9.193, 9.196
 before cataract surgery, 11.175
 for herpes zoster infections, 1.258, 1.281, 2.359, 6.243, 8.229, 9.193, 9.196
 for herpetic retinitis, 12.238*t*
 for herpetic uveitis, 9.193
 for iridocyclitis, 8.222–224
 off-label use of, 2.359
 for progressive outer retinal necrosis, 9.296, 12.236
 for stromal keratitis, 8.222, 8.223*t*
- Acylureidopenicillins, 1.275
- AD. *See* Alzheimer disease
- ADA. *See* American Diabetes Association
- Adalimumab, 1.174, 6.322, 9.42, 9.107
 for Behçet disease, 9.188
 for sarcoidosis, 9.171
 for uveitis, 9.101, 9.107
- Adamantiades-Behçet disease. *See* Behçet disease
- ADAMTS4 gene, 6.268
- ADAMTS10 gene, 6.309
- ADAMTSL4 gene, 6.268
- Adaptation
 dark
 in electro-oculography, 12.50
 in full-field (Ganzfield) electroretinography, 12.42
 light, 2.262
 in electro-oculography, 12.50
 in full-field (Ganzfield) electroretinography, 12.42
- Adaptive immune response/adaptive immunity, 1.240, 9.9, 9.31–52. *See also* Immune response arc
 effector reactivities of, 9.40–52. *See also specific type*
 antibody-mediated, 9.41*f*, 9.41–44, 9.43*t*
 combined antibody and cellular, 9.50*f*, 9.50–52
 lymphocyte-mediated, 9.38–39, 9.39*f*, 9.44–49, 9.45*f*, 9.46*t*
 mediator systems affecting, 9.22*t*, 9.22–30, 9.23*f*, 9.25*f*, 9.27–28*t*. *See also* Mediators
 in viral conjunctivitis, 9.55–56
- Adaptive optics, 3.281, 3.305–306, 3.306*f*, 12.33
- Adaptive optics scanning laser ophthalmoscope, of macula, 12.13*f*
- ADC. *See* Apparent diffusion coefficient (ADC)
 technique/mapping
- ADC mapping. *See* Apparent diffusion coefficient (ADC) technique/mapping
- ADCC. *See* Antibody-dependent cellular cytotoxicity
- Add power
 of bifocal lens, 3.178–180
 higher, for low vision, 3.320
- Additions
 near-point, 3.37
 progressive. *See* Progressive addition lenses
- Additive interference, 3.100
- Adduction
 definition of, 6.33
 elevation deficiency in (double-elevator palsy), 7.213
 extraocular muscles in, 5.46*f*
 inferior rectus muscle, 5.46*f*
 medial rectus muscle, 5.46*f*
 superior rectus muscle, 5.46*f*
 nystagmus and (dissociated/disconjugate), 5.247
 overdepression in
 causes of, 6.17, 6.116*t*, 6.116–118
 description of, 6.17
 pattern strabismus and, 6.107, 6.108*f*, 6.109
 superior oblique muscle overaction as cause of, 6.118, 6.118*f*, 6.137
 overelevation in
 causes of, 6.17, 6.116*t*, 6.116–118
 description of, 6.17
 inferior oblique muscle overaction as cause of, 6.117*f*, 6.117–118
 pattern strabismus and, 6.107, 6.108*f*, 6.109
 underdepression in, 6.17
 underelevation in, 6.17
- Adefovair, 1.281
- Adenine arabinoside. *See* Vidarabine
- Adeno-associated viruses (AAVs), as vectors in gene therapy, 2.169
- Adenocarcinoma, 4.10, 4.10*t*
 of orbit, secondary, 7.96–97

6 • Master Index

- of retinal pigment epithelium, 4.180, 4.279
- sebaceous, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*, 7.183*f*, 7.183–184, 8.327, 8.337*f*, 8.337–338
- Adenoid cystic carcinoma (ACC/cylindroma)
 - of eyelid, 7.171
 - of lacrimal gland, 4.230–231, 4.231*f*, 7.91, 7.93
- Adenoma, 4.10, 4.10*t*
 - Fuchs (pseudoadenomatous hyperplasia), 4.179, 4.279
 - pituitary, 1.57–58
 - chiasmal syndromes caused by, 5.147, 5.148*f*
 - neuroimaging in evaluation of, 1.58, 5.72*t*, 5.92*f*, 5.93–94*f*
 - in pregnancy, 5.147, 5.333
 - pleomorphic (benign mixed tumor)
 - of eyelid, 7.170
 - of lacrimal gland, 4.229–230, 4.230*f*, 7.91, 7.92*f*, 7.92–93
 - of retinal pigment epithelium, 4.180, 4.279
 - sebaceous (sebaceum), 4.210*t*, 4.215, 4.216*f*, 7.170
 - of eyelid, 7.170
 - in tuberous sclerosis, 5.331*f*, 10.30
 - thyroid, 1.54, 1.55
 - of uvea/retina, 4.279
- Adenomatous polyposis, familial (FAP/Gardner syndrome), retinal manifestations of, 4.144–145, 4.269, 12.285–286
- Adenosine, for medical emergencies, 1.296*t*
- Adenoviruses (Adenoviridae)/adenoviral infection, 8.208*t*, 8.233–236
 - conjunctivitis, 4.52, 6.241–242, 8.208*t*, 8.233, 8.234*f*, 8.234–236, 8.235*f*
 - acute hemorrhagic conjunctivitis, 8.240
 - cicatricial conjunctivitis differentiated from, 8.301*t*
 - epidemic keratoconjunctivitis, 8.233, 8.234*f*, 8.234–236, 8.235*f*
 - follicular conjunctivitis, 8.233, 8.234
 - immune response to, 9.55–56
 - herpes simplex infection differentiated from, 8.213–214
 - keratitis caused by, 6.269
 - pharyngoconjunctival fever caused by, 6.242, 8.233, 8.234
- Adenylyl/adenylate cyclase
 - adrenoceptor binding and, 2.319, 2.321, 2.322
 - tear secretion and, 2.219, 2.219*f*
- Adherence issues (therapy)
 - behavioral/psychiatric disorders and, 1.188, 1.190, 1.198
 - in glaucoma management, 10.184
 - in elderly patients
 - glaucoma surgery and, 10.221
 - medication use and, 10.186
 - hypertension control and, 1.80
 - in ocular infection, 8.206
 - psychiatric medications and, 1.198
 - resistant hypertension and, 1.64
- Adherence syndrome, 6.172
- Adhesins, 8.206–207, 8.244
- Adhesion, in neutrophil recruitment and activation, 9.16, 9.17, 9.18*f*
- Adie tonic pupil, 5.256*f*, 5.263*f*, 5.263–265, 5.264*f*, 5.265*f*
 - light–near dissociation and, 5.263, 5.264*f*, 5.266*t*
 - pharmacologic testing for, 2.310, 5.256*f*, 5.264–265, 5.265*f*
- Adipose tissue, in orbit, 6.25
- Adipose tumors, of orbit, 4.238
- Adits, for neck liposuction, 7.246
- Adjustable sutures, in extraocular muscle surgery, 6.165
- ADL. *See* Activities of daily living
- Adnexa. *See* Ocular adnexa
- Ado-trastuzumab emtansine, for cancer chemotherapy, 1.236
- ADOA. *See* Autosomal dominant optic atrophy
- Adolescents. *See also* Children
 - bacterial conjunctivitis in, 6.240*f*, 6.240–241
 - glaucoma in, 10.147–167. *See also* Glaucoma, pediatric
 - hypertension in, 1.61
 - myopia in, 3.142
 - preoperative assessment in, 1.284–285
- Adrenaline. *See* Epinephrine
- Adrenergic agents, 2.308*t*, 2.316*t*, 2.316–323, 2.317*f*, 2.318*t*, 2.320*f*, 2.322*t*. *See also* Alpha (α)-adrenergic agents; Beta (β)-adrenergic agents; *specific agent*
 - angle closure caused by, 10.122
 - centrally acting, for hypertension, 1.68*t*, 1.69*t*, 1.73
 - for glaucoma, 10.176–179
 - agonists, 2.318*t*, 2.318–319, 10.172*t*, 10.177–179, 10.178*f*
 - antagonists/β-blockers, 2.230, 2.318*t*, 2.321–323, 2.322*t*, 10.164–165, 10.171–172*t*, 10.176–177
 - ocular surface toxicity of, 8.90*t*
 - for heart failure, 1.110
 - inhibitors. *See* Alpha (α)-blockers; Beta (β)-blockers
 - as miotics, 2.308, 2.308*t*, 2.309, 2.310, 2.311, 2.311*t*
 - as mydriatics, 2.314*t*, 2.317–318
- Adrenergic receptors (adrenoceptors), 2.308*t*, 2.316*t*, 2.317*f*. *See also specific type*
 - drugs affecting, 2.308*t*, 2.316*t*, 2.316–323, 2.317*f*, 2.318*t*, 2.320*f*, 2.322*t*. *See also* Adrenergic agents
 - effects mediated by, 2.316, 2.317*f*
 - locations of, 2.316
 - signal transduction and, 2.316*t*
 - in tear secretion, 2.218, 2.218*f*, 2.219, 2.219*f*
- Adrenoceptors. *See* Adrenergic receptors (adrenoceptors)
- Adrenochrome deposition, 8.118*t*, 8.131*f*, 8.131–132
- epinephrine causing, 8.131, 10.31
- Adrenocorticotrophic hormone (ACTH), in tear secretion, 2.219
- ADRP. *See* Autosomal dominant retinitis pigmentosa
- Adult cystinosis (nephropathic cystinosis), 8.181, 8.181*f*
- Adult inclusion conjunctivitis, 6.241
- Adult-onset asthma with periocular xanthogranuloma (AAPOX), 7.90, 7.91
- Adult-onset diabetes. *See* Diabetes mellitus (DM), type 2
- Adult-onset foveomacular vitelliform dystrophy (AFMVD), 4.170, 4.171*f*, 12.272, 12.276
- Adult-onset myopia, 3.143
- Adult-onset vitelliform lesions, 12.272, 12.273*f*
- Adult-onset vitelliform maculopathy
 - fluorescein angiography of, 12.68
 - spectral-domain optical coherence tomography of, 12.67–68, 12.68*f*

- Adult-onset xanthogranuloma (AOX), 7.90, 7.91
- Adult Treatment Panel (ATP) reports, 1.81–82, 1.84, 1.84*t*
- Advance directives, surgery in older patients and, 1.181
- Advanced cardiac life support (ACLS), 1.295, 1.299 pediatric (PALS), 1.295, 1.299
- Advanced Glaucoma Intervention Study (AGIS), 10.113–115
- Advanced glycation cross-link breakers, for hypertension, 1.74–75
- Advanced glycation end products, in hypertension, 1.74–75
- Advanced surface ablation (ASA). *See* Photorefractive keratectomy
- Advancement
 definition of, 6.164*t*
 of inferior oblique muscle, 6.166
 of plica semilunaris, 6.171
 of thickened Tenon capsule too close to limbus, 6.171
- Advancement flaps, 8.359, 8.359*f*
 for canthal repair, 7.195
 for eyelid repair, 7.191, 7.192, 7.193*f*, 7.194
- ADVIRC. *See* Autosomal dominant vitreoretinchoroidopathy
- Advisory Committee on Immunization Practices, 1.217
- ADVS (Activities of Daily Vision Scale), 11.71
- AED. *See* Automated external defibrillator
- Aedes aegypti* mosquito, 6.413, 12.247
- Aerial image, 3.298, 3.300, 3.300*f*
- Aerobic glycolysis, in lens glucose/carbohydrate metabolism, 11.18
- AF. *See* Atrial fibrillation; Autofluorescence
- Affective disorders (mood disorders), 1.189–190
 drugs for treatment of (mood stabilizers), 1.197–198
- Afferent fibers
 somatic, 2.103
 visceral, 2.103
- Afferent lymphatic channels, 9.21, 9.33
- Afferent phase of immune response arc, 9.33*f*, 9.33–36, 9.34*f*, 9.35*f*
 response to tuberculosis and, 9.31, 9.32
- Afferent pupillary defects, 12.352
 in amblyopia, 6.56
 in meningioma, 7.81
 in ocular trauma, 8.401
 in optic nerve glioma, 7.74
 relative (RAPD). *See* Relative afferent pupillary defect
 in traumatic optic neuropathy, 7.113
- Afferent pupillary pathway, 2.96
- Afferent signal error information, 5.40
- Afferent visual pathways, 5.23–31, 5.24*f*, 5.212
 in cortex, 5.24*f*, 5.29*f*, 5.29–31, 5.30*f*
 light–near dissociation and, 5.266, 5.266*t*
 nonorganic disorders and, 5.301–305, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*
 optic chiasm, 5.23*f*, 5.27*f*, 5.27–28, 5.28*f*
 optic nerve, 5.24*f*, 5.26–27
 optic tract, 5.23*f*, 5.28–29
 in retina, 5.23–25, 5.24*f*, 5.25*f*
 visual evoked potential testing in evaluation of, 5.95
- Affinity constant (K_m), sorbitol in cataract development and, 11.19
- aFGF. *See* Acidic fibroblast growth factor
- Aflibercept (VEGF Trap), 2.372
 for age-related macular degeneration/choroidal neovascularization, 2.372
 for branch retinal vein occlusion, 12.135
 for cancer chemotherapy, 1.234*t*, 1.235
 for central retinal vein occlusion, 12.135
 for diabetic macular edema, 12.113
 for macular edema, 4.152
 macular telangiectasia type 1 treated with, 12.161
 for neovascular age-related macular degeneration, 12.82–83
 for retinal vein occlusion, 12.135
- AFMVD. *See* Adult-onset foveomacular vitelliform dystrophy
- African Americans. *See also* Race
 sickle cell hemoglobinopathies and, 12.149, 12.154
 systemic lupus erythematosus in, 12.230
- Afterimages/afterimage test
 description of, 6.51, 6.79, 6.79*f*
 in palinopsia, 5.176
 transient monocular visual loss and, 5.164
- Afterload, 1.108–109
 reduction of, for heart failure, 1.109–110
- Against movement, in retinoscopy, 3.152, 3.153*f*, 3.155
- Against-the-rule astigmatism, 3.123, 3.139, 3.250, 8.31, 8.32*t*, 8.33*f*
- Age/aging, 1.177–185
 accommodation and, 3.176*t*
 accommodative response/presbyopia and, 2.63, 11.23, 13.159. *See also* Presbyopia
 angle-closure glaucoma and, 10.9
 antiglaucoma medication/carbonic anhydrase inhibitor use and, 2.326, 10.186
 cataracts related to, 11.5, 11.43–48. *See also* Age-related cataracts
 central retinal vein occlusion and, 12.133
 central serous chorioretinopathy and, 12.189
 choroidal thickness affected by, 12.19, 12.212
 ciliary body hyalinization and, 4.189, 4.189*f*
 ciliary muscle affected by, 2.58
 of conjunctiva, 8.112
 of cornea
 donor corneas and, 8.414, 8.416
 endothelial cell density and, 8.10, 8.23
 senile furrow degeneration and, 8.122
 corticosteroid use and, 2.332
 Descemet membrane/corneal endothelium affected by, 2.41, 2.42, 2.227
 drug toxicity and, 2.294, 2.295
 ectropion and (involutional ectropion), 7.198*f*, 7.199–201, 7.200*f*
 elder abuse and, 1.179–180
 entropion and (involutional entropion), 7.202–204, 7.203*f*, 7.204*f*, 7.205*f*
 eyelid changes associated with, 1.177, 1.178
 orbital septum changes and, 7.149
 retro-orbicularis oculi fat (ROOF) and, 7.153
 suborbicularis oculi fat (SOOF) and, 7.152
 facial changes associated with
 communication and, 7.235–236
 facial bones and, 2.7

8 • Master Index

- facial rejuvenation surgery and, 7.241–247, 7.242f, 7.243f, 7.244f, 7.245f, 7.246f. *See also specific procedure*
 - pathogenesis of, 7.236
 - physical examination of, 7.197, 7.236–237
 - skin changes and, 7.236–237
 - falls and, 1.184–185
 - giant cell arteritis and, 5.288
 - glaucoma and
 - angle-closure glaucoma, 10.9, 10.81
 - antiglaucoma medication/carbonyl anhydrase inhibitor use and, 2.326, 10.186
 - open-angle glaucoma, 10.7, 10.81–82
 - surgery and, 10.221
 - hypertension and, 1.77
 - intraocular pressure affected by, 10.22, 10.81–82
 - lens changes associated with, 2.63, 11.11, 11.43–48. *See also* Age-related cataracts; Presbyopia
 - lens proteins affected by, 2.245, 11.17
 - macular changes associated with. *See* Age-related macular degeneration/maculopathy
 - medication use and, 2.295
 - mitochondrial DNA diseases and, 2.157
 - near-point additions based on, 3.37
 - normal changes of, 1.182
 - ocular hypertension and, 10.81
 - open-angle glaucoma and, 10.7, 10.81–82
 - osteoporosis and, 1.184
 - outflow facility affected by, 10.19
 - outpatient visits and, 1.179
 - parental, chromosomal abnormalities/Down syndrome and, 2.188, 2.190
 - periorbital changes associated with, 7.229f, 7.229–230
 - pharmacologic principles affected by, 2.295
 - physiologic/pathologic eye changes and, 1.177, 1.178
 - posterior vitreous detachment and, 4.129, 12.307–308
 - presbyopia and. *See* Presbyopia
 - pseudoexfoliation/exfoliation syndrome and, 10.91
 - psychology/psychopathology of, 1.181–183
 - ptosis and, 5.273
 - refractive surgery and, 13.38
 - epithelial defects in LASIK and, 13.112
 - overcorrection in photoablation and, 13.101
 - radial keratotomy and, 13.50
 - re-treatments/enhancement and, 13.98
 - of sclera, 4.111, 4.111f, 8.128, 8.129f
 - surgical considerations and, 1.180–181
 - syneresis and, 4.128, 4.129f
 - telomeric DNA and, 2.150
 - trabecular meshwork and, 2.49, 2.51, 10.18
 - transient visual loss and, 5.161
 - vitreous changes and, 2.80, 2.252–255
 - wavefront aberrations and, 13.11
- Age-related cataracts, 11.5, 11.43–48. *See also specific type*
- cortical, 11.45–46, 11.46f, 11.47f, 11.48f, 11.49f, 11.50f
 - in diabetes mellitus, 2.247, 11.60
 - epidemiology of, 11.5
 - genetic contributions to, 11.41–42
 - indications for surgery and, 11.72
 - nuclear, 4.123, 4.124f, 11.43–45, 11.45f
 - nutritional deficiency and, 11.7, 11.63–64
 - posterior subcapsular, 11.46–48, 11.51f
- Age-related distance esotropia, 6.94
- Age-Related Eye Disease Study (AREDS), 2.285, 2.370, 11.7, 11.63, 12.64, 12.69–71, 12.70t
- Age-related macular degeneration/maculopathy (AMD), 3.315, 4.160–166, 4.161f, 4.162f, 4.163f, 4.164f, 4.165f
- adult-onset foveomacular vitelliform dystrophy versus, 12.272, 12.273f
- aging as cause of, 12.61
- antiangiogenic/anti-VEGF agents for, 2.372, 4.164
- blindness caused by, 12.61
- Bruch membrane calcification in, 12.19
- cataract surgery effects on, 12.71
- central blindness progression of, 12.86
- central serous chorioretinopathy versus, 12.67, 12.76, 12.79
- choroidal neovascularization in, 12.64. *See also* Choroidal neovascularization
- cigarette smoking and, 12.62
- clinical studies of, 1.12. *See also specific study*
- depression and, 1.182, 1.190
- drusen associated with, 4.160–163, 4.161f, 4.162f, 4.163f
- exudative, 12.79
- falls and, 1.185
- genetic factors/testing in, 4.160, 12.62–63, 12.63
- genome-wide association studies (GWAS) and, 2.165, 2.167f
- low vision therapies and rehabilitation, 12.86
- management of, 12.68–71, 12.79–86, 12.81f, 12.82t, 12.84t
- melanoma differentiated from, 4.269, 4.270f
- neovascular (“wet”/exudative), 4.154f, 4.164–166, 4.165f. *See also* Neovascular (“wet”/exudative)
- age-related macular degeneration
- aflibercept for, 12.82–83
- Amsler grid testing of, 12.71
- antiangiogenic therapies for, 12.79–80
- bevacizumab for, 12.83–85, 12.84t
- choroidal neovascularization associated with, 12.71–79. *See also* Choroidal neovascularization
- combination treatment for, 12.85
- differential diagnosis of, 12.76, 12.79
- intravitreal injections, 12.85
- laser photocoagulation for, 12.79
- low vision therapies for, 12.86
- macular translocation surgery for, 12.85
- management of, 12.79–86, 12.81f, 12.82t, 12.84t
- pegaptanib for, 12.80
- photodynamic therapy for, 12.79
- polypoidal choroidal vasculopathy, 12.75
- prevalence of, 12.61
- ranibizumab for, 12.80–82, 12.82t
- signs and symptoms of, 12.71
- submacular hemorrhage in, 12.85, 12.385
- surgical treatment for, 12.85–86
- treatment effect modifiers, 12.85
- verteporfin for, 12.79
- nonneovascular (“dry”/nonexudative), 4.164, 4.164f. *See also* Nonneovascular (“dry”/nonexudative)
- age-related macular degeneration
- Amsler grid testing for, 12.68–69

- differential diagnosis of, 12.67–68
- disproven treatment approaches for, 12.71
- drusen associated with. *See* Drusen
- education regarding, 12.68
- focal atrophy in, 12.66
- follow-up for, 12.68
- geographic atrophy in, 12.64, 12.66, 12.67*f*, 12.68
- hydrochloroquine toxicity versus, 12.68
- hyperacuity testing for, 12.69
- lifestyle changes for, 12.71
- management of, 12.68–71
- micronutrients for, 12.69–71
- preferential hyperacuity perimetry for, 12.69
- prevalence of, 12.61
- retinal pigment epithelium abnormalities in, 4.164, 4.164*f*, 12.66–67
- shape-discrimination hyperacuity for, 12.69
- nonsubfoveal, 12.69
- pharmacogenomic testing for, 12.63
- polypoidal choroidal vasculopathy and, 4.168
- prevalence of, 12.61
- race and, 12.62
- retinal pigment epithelium abnormalities associated with, 2.279
- risk factors for, 12.62, 12.70*t*
- statin drugs and, 1.89
- susceptibility genes for, 12.63
- Agensis
 - corpus callosum, 6.361
 - definition of, 6.183*t*
- Aggressive posterior retinopathy of prematurity (AP-ROP), 6.326, 6.327*t*, 6.330*f*, 6.333, 12.177, 12.178*t*
- Aging. *See* Age/aging
- AGIS (Advanced Glaucoma Intervention Study), 10.113–115
- AgKS. *See* Antigenic keratan sulfate
- Agnosia
 - in Alzheimer disease, 1.206
 - object, 5.179
 - parietal lobe lesions and, 5.156
- Agonist (drug), 2.304, 6.33
- Agraphia
 - alexia with, 5.179
 - alexia without, 5.179, 5.180*f*
- AGV. *See* Ahmed glaucoma valve/implant
- AHA. *See* American Heart Association
- AHC. *See* Acute hemorrhagic conjunctivitis
- Ahmed glaucoma valve/implant (AGV), 10.214, 10.214*t*
- AHP. *See* Abnormal head position
- AHT. *See* Abusive head trauma
- AIBSE. *See* Acute idiopathic blind-spot enlargement
- AICA. *See* Anterior inferior cerebellar artery
- Aicardi syndrome, 2.180–181, 6.338–339, 6.339*f*
- AIDS (acquired immunodeficiency syndrome), 1.262–272. *See also* HIV infection/AIDS
 - cytomegalovirus retinitis associated with, 12.235–236
 - progressive outer retinal necrosis syndrome associated with, 12.236–237, 12.237*f*
- AIDS dementia complex (HIV encephalopathy/HIV-associated neurocognitive disorder), 5.348. *See also* HIV infection/AIDS
- AIDS-related complex (ARC), 1.262, 1.264
- AIDS-related virus (ARV). *See* HIV; HIV infection/AIDS
- AIM. *See* Acute idiopathic maculopathy
- AION. *See* Anterior optic neuropathy, ischemic
- Air, refractive index of, 8.26
- Air cells, ethmoid (ethmoid sinuses), 2.10*f*, 2.10–11, 2.17*f*, 5.8, 5.10*f*, 7.8, 7.8*f*, 7.18, 7.19, 7.19*f*
- Air-puff (noncontact) tonometers, 10.26
- Air-tear-film interface, 2.38–39, 2.39*f*, 8.6, 8.26
 - optical power of eye and, 13.7–9
 - reflection at, 8.6
- AIRE (autoimmune regulator) deficiency, uveitis in mice and, 9.64
- Airway disease, in obstructive lung disease, 1.129, 1.130
- Airway management
 - in CPR, 1.295, 1.296, 1.298
 - in seizures, 1.303
- Airy disc, 3.106
- AJCC (American Joint Committee on Cancer), on staging of ocular tumors, 4.253–254
- AK. *See* Arcuate keratotomy; Astigmatic keratotomy/incision
- Ak-Cide, in combination preparations. *See* Prednisolone
- Ak-Con. *See* Naphazoline
- Ak-Dex. *See* Dexamethasone
- Ak-Dilate. *See* Phenylephrine
- Ak-Mycin. *See* Erythromycin
- Ak-Pentolate. *See* Cyclopentolate hydrochloride
- Ak-Poly-Bac. *See* Polymyxin B, in combination preparations
- Ak-Pred. *See* Prednisolone
- Ak-Spore. *See* Hydrocortisone, in combination preparations
- Ak-Sulf. *See* Sulfacetamide
- Ak-T-Caine. *See* Tetracaine
- Ak-Tob. *See* Tobramycin
- Ak-Tracin. *See* Bacitracin
- Ak-Trol. *See* Dexamethasone, in combination preparations
- Akarpine. *See* Pilocarpine
- AKC. *See* Atopic keratoconjunctivitis
- Akinetopsia, 5.179
 - in Alzheimer disease, 1.206
- AL. *See* Axial length
- Alagille syndrome (arteriohepatic dysplasia), 6.255, 8.97*t*, 8.102, 12.282*t*, 12.285
 - posterior embryotoxon and, 8.97*t*, 8.102
- Alamast. *See* Pemirolast
- Alaway. *See* Ketotifen
- Albalon. *See* Naphazoline
- Albendazole
 - for cysticercosis, 9.232
 - for diffuse unilateral subacute neuroretinitis, 9.234
 - for toxocariasis, 9.230
- Albinism, 2.174, 2.175*t*, 2.278, 4.142, 4.142*f*, 12.288
 - defective melanin synthesis and, 2.174, 2.278
 - definition of, 6.406
 - description of, 12.288
 - diagnosis of, 6.406–408
 - enzyme defect in, 2.175*t*
 - genetic heterogeneity and, 2.185
 - iris transillumination associated with, 4.142, 4.142*f*, 6.265, 6.406, 6.407*f*
 - ocular (OA), 4.142, 4.142*f*, 6.406–407

- ocular findings in carriers of, 2.198–200, 2.199*f*, 2.199*t*
- X-linked (Nettleship-Falls), ocular findings in carriers of, 2.198–200, 2.199*f*
- oculocutaneous (OCA), 2.185, 2.278, 4.142
 - racial and ethnic concentration of, 2.197
- pattern-appearance visual evoked potentials in, 12.53
- treatment of, 6.408
- types of, 6.408*t*
- tyrosinase activity/defect in, 2.175*t*, 2.185, 2.278
- X-linked, ocular findings in carriers of, 2.198–200, 2.199*f*
- Albinoidism, 12.288
- Albright syndrome/hereditary osteodystrophy, 7.84, 8.191*t*
- Albumin
 - in aqueous humor, 2.229, 2.233, 10.16
 - in vitreous, 2.251–252
- Albuminuria, in diabetes mellitus, 1.48
- Albuterol, 2.308*t*
- Alcaftadine, 2.338*t*, 2.339
- Alcaine. *See* Proparacaine
- Alcian blue stain, 4.31*t*
- Alcohol (ethanol)
 - retrobulbar injection of, for pain control, 7.128
 - as tissue fixative, 4.26, 4.26*t*
 - use/abuse of
 - cataract formation and, 11.63–64
 - esophageal cancer and, 1.213
 - intraocular pressure and, 10.22
 - maternal, malformations associated with, 1.192
 - moderation of, in hypertension management, 1.66, 1.67*t*
 - ophthalmic considerations and, 1.192
 - optic neuropathy caused by, 5.137, 5.138
 - vitamin A deficiency and, 8.196
- Aldehyde dehydrogenase, in cornea, 2.224
- Aldose reductase
 - in cataract formation, 2.247*f*, 2.247–248, 11.19
 - diabetes mellitus complications and, 1.48
 - in lens glucose/carbohydrate metabolism, 2.247*f*, 2.247–248, 11.18*f*, 11.19
- Aldose reductase inhibitors
 - cataract prevention/management and, 11.72
 - for diabetic neuropathy, 1.49
- Aldosterone-receptor blockers, for hypertension, 1.68*t*
- indications for, 1.69*t*
- Alemtuzumab, 1.175
 - for multiple sclerosis, 5.321*t*
- Alexander's law, 5.240, 5.242, 6.147
- Alexia
 - with agraphia, 5.179
 - without agraphia, 5.179, 5.180*f*
- Alfentanil, perioperative, 1.291
- Alfuzosin, intraoperative floppy iris syndrome and, 11.74, 11.136, 11.137*t*
- ALH. *See* Atypical lymphoid hyperplasia
- Alignment, ocular
 - disorders of/unsatisfactory, 5.184–185. *See also* Diplopia
 - nonorganic, 5.309–310
 - refractive surgery and, 13.41
 - tests of, 5.184*f*, 5.184–185, 5.185*f*. *See also specific type*
- Aliskiren, 1.68*t*, 1.74
- Alizarin red stain, 4.31*t*
- ALK. *See* Anterior lamellar keratoplasty
- Alkalis (alkaline solutions), 6.376
 - ocular injuries caused by, 8.375–380, 8.376*t*, 8.379*f*, 8.380*f*. *See also* Chemical injury
 - cataract and, 11.59
 - glaucoma and, 10.103–104
 - vitamin C in management of, 8.383
- Alkapton, corneal deposits of/pigmentation caused by, 8.118*t*, 8.184, 8.185*f*
- Alkaptonuria, 2.175*t*, 8.183*t*, 8.184–185, 8.185*f*
- Alkyl nitrites, 12.300, 12.300*f*
- Alkylating agents, 9.105–106
 - for Behçet disease, 1.169, 9.189
 - for cancer chemotherapy, 1.232*t*
 - for rheumatic disorders, 1.175
 - for uveitis, 9.105–106
- All-*trans*-retinol/all-*trans*-retinaldehyde, 2.259, 2.259*f*, 2.274–275, 2.275*f*
- Allele-specific marking (genetic imprinting), 2.138, 2.153–154
- Alleles, 2.131, 2.184–185
 - human leukocyte antigen, 9.65. *See also* Human leukocyte antigens
 - detection/classification of, 9.66
 - null, gene therapy and, 2.169
- Allelic, definition of, 2.131
- Allelic association. *See* Linkage disequilibrium
- Allelic heterogeneity, 2.132
- Allen figures, 6.7
- Allen symbols, 3.23
- Allergens, 9.51. *See also* Allergic reactions/allergies
 - avoidance of
 - in atopic dermatitis, 8.287
 - in atopic keratoconjunctivitis, 8.293
 - in contact dermatoblepharitis, 8.287
 - in hay fever conjunctivitis, 8.288
- Allergic aspergillosis sinusitis, 5.353, 7.51
- Allergic conjunctivitis, 6.246*f*, 6.246–248, 8.288–289, 9.51
 - cicatricial conjunctivitis differentiated from, 8.301*t*
 - drugs for, 2.337–339, 2.338*t*
 - perennial, 8.288–289
- Allergic fungal sinusitis, orbital involvement and, 4.228
- Allergic keratoconjunctivitis
 - atopic, 8.292–294, 8.293*f*, 9.51
 - vernal, 8.289–292, 8.290*f*, 8.291*f*
- Allergic reactions/allergies. *See also* Hypersensitivity reactions; *specific type*
 - to adrenergic agonists, 10.178*f*, 10.178–179
 - anaphylaxis, 1.301–303, 9.40, 9.41*t*, 9.52
 - to carbonic anhydrase inhibitors, 10.180
 - in children, 6.246*f*, 6.246–249, 6.247*t*, 6.248*t*
 - conjunctivitis, 8.288–289, 9.51
 - cicatricial conjunctivitis differentiated from, 8.301*t*
 - to contact lenses, 3.233–234
 - description of, 6.170, 6.171*f*
 - drugs for, 1.302. *See also* Antihistamines
 - corticosteroids, 2.329, 2.333*t*, 2.333–334, 2.337, 2.338, 2.339
 - mast-cell stabilizers and antihistamines, 2.337–339, 2.338*t*
 - ocular effects of, 1.307*t*

- dry eye and, 8.54, 8.54f, 8.55f
 in eyelid
 atopic dermatitis, 8.287
 contact dermatoblepharitis, 8.285–287, 8.286f
 to fluorescein, 1.302
 to insulin, 1.43
 keratoconjunctivitis
 atopic, 8.292–294, 8.293f, 9.51
 vernal, 8.289–292, 8.290f, 8.291f
 to latex, 1.288–289
 to local anesthetics, 1.304
 mast cells in, 9.10
 to penicillin/cephalosporin, 1.275, 2.343
 to topical medications, 8.285–287, 8.286f
- Allergic shiners, 6.246
- Allesthesia, visual, 5.180
- Allogeneic hematologic stem cell transplantation. *See* Stem cell transplantation
- Allografts/allogeneic transplantation
 corneal, 8.316, 8.411–451, 8.412t, 8.412–413t. *See also* Corneal grafts; Keratoplasty
 rejection of, 8.316–318, 8.428–431, 9.59, 9.60, 9.60f. *See also* Rejection
 immune privilege and, 8.316, 9.57
 limbal, 8.351t, 8.362–365. *See also* Limbal transplantation
 indications for, 8.351t
 retinal/retinal pigment epithelial, 9.62
 transplantation antigens and, 9.60
- Alloplastic material addition techniques, 13.28, 13.28f
 corneal effects of, 13.28, 13.28f
 corneal inlays, 13.28, 13.60–61, 13.61f
 intrastromal corneal ring segments, 13.28, 13.28f
- Alocril. *See* Nedocromil
- Alomide. *See* Lodoxamide
- Alpha (α)-actinin, in retinal pigment epithelium, 2.273
- Alpha (α)-adrenergic agents, 2.308t, 2.317–321, 2.318t, 2.320f
 agonists, 2.308t, 2.317–320, 2.318t, 2.320f
 direct-acting, 2.317–318
 for glaucoma, 2.318t, 2.318–319, 10.172t, 10.178f, 10.178–179
 in children, 10.165
 in elderly patients, 10.186
 suppression of aqueous formation and, 10.17, 10.165
 for hyphema, 8.395
 indirect-acting, 2.320, 2.320f
 for postoperative elevated intraocular pressure, 10.108
 antagonists, 1.308t, 2.308t, 2.321. *See also* Alpha (α)-blockers
 centrally acting, for hypertension, 1.68t, 1.69t, 1.73
- Alpha₂ (α_2)-adrenergic agonists, 6.289t, 6.290
- Alpha (α)-adrenergic receptors (adrenoceptors), 2.308t, 2.316t
 drugs affecting, 2.308t, 2.317–321, 2.318t, 2.320f.
 See also Alpha (α)-adrenergic agents
 effects mediated by, 2.316, 2.317f
 ocular decongestant mechanism of action and, 2.342
 signal transduction and, 2.316t
 in tear secretion, 2.218, 2.218f
- Alpha₁ (α_1)-antitrypsin, in aqueous humor, 2.234
- Alpha (α)-blockers, 1.308t, 2.308t, 2.321
 for heart failure, 1.110
 for hypertension, 1.68t, 1.73
 with β -blockers, 1.68t, 1.72, 1.73
 intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137t
 ocular effects of, 1.308t
- Alpha chemokines, 9.27t
- Alpha (α)-chymotrypsin, for ICCE, 11.195, 11.200
- Alpha (α)-crystallins, 2.64, 2.244, 11.15, 11.15f, 11.15–16
- Alpha (α)-galactosidase, defective/deficiency of, 2.175t
- Alpha (α)-galactosidase A, in Fabry disease, 2.175t
- Alpha (α)-glucosidase inhibitors, for diabetes mellitus, 1.45t, 1.46
- Alpha (α)-hemolytic bacteria
 endocarditis prophylaxis and, 1.243, 1.243t
 infectious pseudocrystalline/crystalline keratopathy caused by, 4.79, 8.268, 8.268f
- Alpha (α)-iduronidase, in mucopolysaccharidoses, 8.174, 8.175t
- Alpha (α)-iduronidase/ α -L-iduronidase defect/deficiency, in mucopolysaccharidoses, 2.175t, 2.184
- Alpha (α)-interferon (interferon- α), 9.28t
 for Behçet disease, 1.169, 9.189
 for delta hepatitis, 1.261
 for hepatitis C, 1.261
 for infantile (capillary) hemangiomas, 7.162
 for Mooren ulcer, 8.316
 for ocular surface tumors, 8.327, 8.330, 8.330f, 8.331, 8.331f
 conjunctival papilloma, 8.238–239, 8.239, 8.333
 optic neuropathy caused by, 5.137
 for uveitis, 9.108
- Alpha (α)-L-fucosidase defect/deficiency, in fucosidosis, 8.179
- Alpha₂ (α_2)-macroglobulin, in aqueous humor, 2.231, 2.233, 2.234
- Alpha (α)-mannosidase defect/deficiency, in mannosidosis, 2.175t, 8.179
- Alpha (α)-melanocyte-stimulating hormone (α -MSH), in tear secretion, 2.219
- Alpha (α)-thalassemia, 1.137
- Alpha (α)-toxins, in innate immune response, 9.16
- Alpha-tocopherol. *See* Vitamin E
- Alpha (α) zone peripapillary atrophy, 10.52
- Alphagan. *See* Brimonidine
- Alphavirus, 12.247
- Alport disease/syndrome, 4.118, 6.391
 lenticonus in, 4.118, 11.30
 pleiotropism in, 2.196
- Alprazolam, 1.307t
- Alrex. *See* Loteprednol
- Alström syndrome, 6.391, 12.285
- ALT (argon laser trabeculoplasty). *See* Argon laser therapy, for trabeculoplasty
- Altafrin. *See* Phenylephrine
- Alteplase. *See also* Tissue plasminogen activator
 for ST-segment elevation acute coronary syndrome, 1.104–105
- Alternaria, 8.251
- Alternate cover test
 description of, 6.65–66, 6.66f

- exodeviation evaluations, 6.100
- prism, 6.65–66, 6.66f
- Alternate occlusion, for binocular balance, 3.167–168
- Alternating fixation, 6.16
- Alternating heterotropia, 6.64
- Alternating nystagmus, periodic (PAN), 5.243t, 5.245–246, 6.149
- Alternating skew deviation, 5.216
- Alternating suppression, 6.49
- Alternating vision bifocal lenses, 3.224f, 3.224–225
- Alternative pathway activation (complement), 9.22, 9.23f
- Alternative splicing, 2.148, 2.152–153
- Altitudinal defect, 5.103, 5.105t, 5.106f
 - in glaucoma, 10.69, 10.70f
- ALTK. *See* Anterior lamellar keratoplasty (ALK), therapeutic
- Alu repeat sequence, 2.150
- Aluminum, in intraocular foreign body, 12.362
- Alveolar nerves
 - anterior superior, 7.17f
 - posterior, 5.49
 - superior, 7.17f
- Alveolar rhabdomyosarcoma, 4.236, 4.237f, 7.83
- Alzheimer disease (AD), 1.204–206
 - diagnosis of, 1.205
 - etiology of, 1.205
 - ophthalmic considerations and, 1.206
 - treatment of, 1.205–206
- Alzheimer's Association, 1.205
- Amacrine cells
 - description of, 2.71f, 2.257, 2.258f, 2.266, 2.267, 5.24, 12.15
 - illustration of, 12.15f
- Amalric triangles, 12.198
- Amantadine, 1.281
 - ophthalmic considerations and, 1.200
 - for Parkinson disease, 1.199
- Amaurosis
 - fugax, 5.164, 5.167, 5.168–169, 5.171. *See also* Monocular transient visual loss
 - in antiphospholipid antibody syndrome, 1.161
 - Horner syndrome and, 5.261
 - stroke and, 5.167, 5.168–169
- Leber congenital (LCA), 6.335–336, 6.337f. *See also* Leber congenital amaurosis
 - gene therapy for, 9.62
 - genetic heterogeneity in, 2.183, 2.183f
 - guanylate cyclase mutation causing, 2.263
 - infantile nystagmus syndrome and, 5.236
 - RPE65 gene defects causing, 2.264
- Amblyopia
 - in accommodative esotropia, 6.91
 - afferent pupillary defects in, 6.56
 - anisometropic, 3.175
 - clinical features of, 6.54–55
 - critical period for, 6.45
 - occlusion therapy for, 6.58
 - refractive surgery and, 13.185–187
 - strabismus amblyopia versus, 6.54–55
 - bilateral, 3.175
 - cataracts as cause of
 - congenital, 6.55
 - removal of, 6.57
 - causes of, 6.45–46
 - classification of, 6.54–56
 - in congenital ptosis, 7.211–212
 - contrast sensitivity curve affected by, 3.136
 - corneal opacities as cause of, 6.262
 - corneal transplantation and, 8.450
 - crowding phenomenon associated with, 6.56
 - definition of, 6.5, 6.53
 - deprivation. *See* Amblyopia, visual deprivation
 - detection of, 6.56
 - diagnosis of, 6.56–57
 - epidemiology of, 6.53
 - evaluation of, 6.56–57. *See also* Ocular motility, assessment of
 - extraocular muscle surgery in, 6.160
 - eyelid-sharing techniques in children and, 7.161, 7.195
 - fixation preference testing, 6.56–57
 - grating acuity associated with, 6.54, 6.56–57
 - infantile esotropia and, 6.87–89
 - in infantile (capillary) hemangioma, 7.68, 7.161
 - isoametropic, 6.55
 - meridional, 6.46
 - monofixation syndrome and, 6.52
 - near vision vs. distance vision in, 3.25
 - occlusion therapy for, 6.58, 6.96, 6.102
 - optical defocus caused by, 6.45
 - pathophysiology of, 6.53–54
 - in pediatric glaucoma, 10.166
 - post-cataract surgery management of, 6.304
 - prevalence of, 6.53
 - recurrence of, 6.61
 - refractive, 3.175, 6.54–55
 - refractive surgery and, 13.185–187
 - reverse, 6.55–56, 6.59–60
 - screening for, 6.56
 - severity assessments, 6.56–57
 - strabismic
 - anisometropic amblyopia versus, 6.54–55
 - clinical features of, 6.54
 - critical period for, 6.45
 - development of, 6.46–47
 - eccentric fixation in, 6.54
 - grating acuity associated with, 6.54, 6.56
 - occlusion therapy for, 6.58
 - pathophysiology of, 6.54
 - visual acuity in, 6.54
 - with third nerve palsy, 6.138
 - trauma as cause of, 6.375
 - in traumatic ptosis, 7.190
 - treatment of
 - atropine sulfate, 6.59
 - binocular, 6.59
 - cataract removal, 6.57
 - challenges associated with, 6.59–61
 - complications of, 6.59–61
 - cycloplegics, 6.59
 - lack of adherence to, 6.60
 - occlusion therapy, 6.58, 6.96
 - optical, 6.58–59
 - pharmacologic, 6.58–59
 - plus lenses, 6.59
 - recurrence of, 6.61

- refractive correction, 6.57–58
 - strabismus secondary to, 6.59–60
 - termination of, 6.61
 - unresponsiveness to, 6.60–61
 - uncorrected anisometropia as cause of, 3.139
 - unresponsiveness of, to treatment, 6.60–61
 - vision development and, 6.53
 - vision loss associated with, 6.53, 6.56
 - visual acuity assessments/testing in, 3.23, 6.56
 - visual deficits caused by, 6.53–54
 - visual deprivation
 - causes of, 6.55
 - congenital cataracts as cause of, 6.55
 - congenital nevocellular nevi as cause of, 6.200
 - corneal blood staining as cause of, 6.379
 - critical period for, 6.53
 - reverse amblyopia, 6.55–56
 - Amblyopia ex anopsia. *See* Deprivation amblyopia
 - Amblyoscope, major, 6.70, 6.70f
 - Amblyoscope testing
 - description of, 6.51
 - sensory adaptation assessments using, 6.79–80
 - Ambulatory blood pressure measurement (ABPM), 1.62
 - AMD. *See* Age-related macular degeneration/maculopathy
 - Amebic keratitis, 4.78–79, 4.79f, 8.208t, 8.252, 8.276–279, 8.277f, 8.278f
 - See also* *Acanthamoeba*, keratitis/ocular infection caused by
 - Amelanotic choroidal masses, 4.263, 4.264f, 4.306, 4.306f
 - differential diagnosis of, 4.272t
 - Amelanotic conjunctival nevus, 4.63, 8.340, 8.340f
 - Amelanotic melanoma, 4.68, 4.263, 4.264f, 4.272t, 8.343, 8.344f
 - Amelogenesis imperfecta, 12.286
 - American Academy of Ophthalmology (AAO), 1.89
 - on drug adverse effects, 1.306–307
 - on genetic testing, 2.171, 2.207–208
 - Initiative in Vision Rehabilitation page on the One Network, 4.254, 6.189, 9.292, 11.71, 12.68, 12.86, 12.260
 - on intravitreal medication sources, 2.306–307
 - IRIS (Intelligent Research in Sight) Registry of, 1.26
 - K-Card developed by, 13.194
 - on monitoring systems, 1.25, 1.26
 - on Preferred Practice Pattern guidelines, 1.25, 1.190, 3.311, 3.329
 - on preoperative assessment, 1.283
 - retinopathy of prematurity screening guidelines, 6.329
 - on vision loss and function (patient handout/website), 1.177
 - vision rehabilitation guidelines from, 6.189
 - American Academy of Pediatrics (AAP)
 - on eye examination in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.123, 9.124t
 - retinopathy of prematurity screening guidelines, 6.329
 - uveitis screening in juvenile idiopathic arthritis, 6.314
 - American Association for Pediatric Ophthalmology and Strabismus retinopathy of prematurity screening guidelines, 6.329
 - American Board of Ophthalmology, on Practice Improvement Modules, 1.25
 - American Cancer Society, cancer screening recommendations of, 1.210t, 1.211, 1.214
 - American College of Cardiology, 1.89
 - on hypercholesterolemia management, 1.84–85
 - American Diabetes Association (ADA), 1.34, 1.35
 - American Heart Association (AHA), 1.89
 - on advanced cardiac life support, 1.299
 - on cardiopulmonary resuscitation and emergency cardiovascular care, 1.296–298, 1.297f
 - on endocarditis prophylaxis, 1.287
 - on hypercholesterolemia management, 1.85
 - American Joint Committee on Cancer (AJCC), on ocular tumor staging, 4.253–254
 - American National Standards Institute (ANSI), intraocular lens standards, 3.263–264
 - American Red Cross, on basic life support, 1.295
 - American Society of Cataract and Refractive Surgery (ASCRS), on IOL power calculation, 11.85
 - online post-refractive calculator, 13.52, 13.195–197, 13.196f
 - American Society of Ocularists, 7.132
 - Amethocaine, 2.365
 - Ametropia. *See also* Refractive errors
 - axial, 3.137
 - correction of
 - in children, 3.174–175
 - spectacle
 - cylindrical correcting lenses for, 3.173
 - far point, 3.170, 3.170f
 - spherical correcting lenses, 3.170, 3.170f
 - vertex distance, 3.170–173, 3.171–172f
 - definition of, 3.136, 3.170
 - refractive, 3.137, 3.257
 - undercorrection in photoablation and, 13.102
- Amifampridine, for nystagmus, 5.245
- Amikacin, 1.278, 2.344t, 2.351, 12.300
 - for endophthalmitis, after cataract surgery, 11.163
 - for mycobacterial keratitis, 8.270t
- Amiloride
 - for heart failure, 1.109
 - for hypertension, 1.68t, 1.69t
- Amino acids
 - disorders of metabolism of. *See also* *specific disorder*
 - corneal changes and, 8.181f, 8.181–190, 8.182t, 8.183t, 8.184f, 8.185f, 8.186t, 8.187f, 8.188f, 8.189f
 - retinal manifestations of, 12.293
 - in tear film, 2.233
 - translation and, 2.151, 2.151f, 2.152
- Aminocaproic acid/ε-aminocaproic acid, 2.369, 2.370
 - for hyphema, 8.395, 10.105
- Aminoglycosides, 1.272, 1.278, 2.351–352, 12.300.
 - See also* *specific agent*
 - for *Acanthamoeba* keratitis, 8.278
 - ocular surface toxicity of, 8.90t, 8.91
 - ototoxicity of
 - mitochondrial DNA mutations and, 2.157
 - peripheral vestibular dysfunction and, 5.243
- Aminopenicillins, 1.275
- 4-Aminopyridine, for nystagmus, 5.245

- Amiodarone
 for arrhythmias, 1.113*t*
 for cardioversion, 1.115
 cornea verticillata caused by, 8.130
 for heart failure, 1.111
 lens changes caused by, 11.53
 for medical emergencies, 1.296*t*
 ocular effects of, 1.117, 1.308*t*
 optic neuropathy caused by, 1.117, 5.137
 refractive surgery in patient taking, 13.37, 13.77–78
 for ventricular fibrillation, 1.115
- Amlodipine
 for heart failure, 1.110
 for hypertension, 1.68*t*, 1.69*t*
- Ammonia (NH₃), ocular injury caused by, 8.376*t*
- AMN. *See* Acute macular neuroretinopathy
- Amniocentesis, 2.206–207
- Amniotic membrane transplantation (AMT)/graft, 8.351*t*
 for chemical injuries, 8.384
 for conjunctivochalasis, 8.86, 8.361
 for contracted socket, 7.134
 for corneal edema after cataract surgery, 11.129
 for descemetocoele, 8.369
 for eyelid repair, in burn injury, 7.190
 for herpetic eye disease, 8.224, 8.225
 indications for, 8.351*t*
 for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82, 8.224
 in pterygium surgery, 8.351, 8.355
 recurrence rate and, 8.353*t*
 for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.285, 8.297–298
 for superior limbic keratoconjunctivitis, 8.84
 for symblepharon, 7.208
 after tumor removal surgery, 8.329
- Amniotocoele (dacryocystocoele), 7.265–267, 7.266*f*
 in dacryocystitis, 7.285
- Amorphous corneal dystrophy, posterior (PACD), 8.135*t*, 8.136*t*, 8.154*f*, 8.154–155
- Amoxicillin, 1.275, 2.345
 with clavulanic acid, 1.276
 for endocarditis prophylaxis, 1.243*t*
 for Lyme disease, 9.247*t*
- Amphotericin B, 1.256, 1.270, 1.280–281, 2.354, 2.355*t*
 for fungal endogenous endophthalmitis, 12.239
 Aspergillus, 9.269
 Candida, 9.267
 coccidioidal, 9.272
 for fungal keratitis, 8.275
- Ampicillin, 1.275, 2.344*t*, 2.345
 for endocarditis prophylaxis, 1.243*t*
 Haemophilus influenzae resistance and, 1.245
 intravenous administration of, 2.301
 with sulbactam, 1.276
- Ampiginous choroiditis (relentless placoid chorioretinitis), 9.150–151, 9.151*f*
- Amplifying cells, transient, in corneal epithelium, 2.40
- Amplitude
 of accommodation, 11.23
 age-related changes in, 3.176, 3.176*t*, 11.23
 definition of, 3.147
 description of, 3.140
 measurement of, 3.178–179
 near point of accommodation for, 3.179
 Prince rule for measuring, 3.179, 3.179*f*
 spheres method for measuring, 3.179
 convergence, 5.226
 divergence, 5.226
 of visual evoked potential, 5.95
- AMPPPE (acute multifocal posterior placoid pigment epitheliopathy). *See* Acute posterior multifocal placoid pigment epitheliopathy
- Ampulla, 7.253
- Ampullectomy, 7.282
- Amsler grid testing, 3.315, 5.84
 in age-related macular degeneration, 12.68–69, 12.71
 in low vision evaluation, 5.84
 in optic neuropathy versus maculopathy, 5.100*t*
- Amsler sign, 10.101
- AMT. *See* Amniotic membrane transplantation/graft
- Amyloid AA, 4.58
- Amyloid AL, 4.58, 4.206
- Amyloid degeneration. *See also* Amyloidosis/amyloid deposits
 polymorphic, 8.122, 8.123*f*, 8.186*t*
- Amyloid plaques, in Alzheimer disease, 1.204
- Amyloidosis/amyloid deposits, 4.134*f*, 4.134–135, 4.206–207, 8.185–188, 8.186*t*, 8.187*f*, 8.188*f*, 12.348, 12.349*f*
 in Alzheimer disease, 1.204
 conjunctival, 4.58*f*, 4.58–59, 8.185, 8.186*t*, 8.187*f*
 corneal, 8.185–188, 8.186*t*, 8.188*f*
 in gelatinous droplike dystrophy, 8.141, 8.141*f*, 8.185–187, 8.186*t*
 in granular corneal dystrophy type 2, 8.148
 in lattice corneal dystrophy, 4.89*f*, 4.89–90, 8.145, 8.146, 8.147*f*, 8.185–187
 polymorphic amyloid degeneration and, 8.122, 8.123*f*, 8.186*t*
 in eyelid, 4.206–207, 4.207*f*, 4.207*t*, 8.186*t*, 8.187
 familial, 4.134, 4.134*f*, 4.206, 8.186*t*, 8.187
 familial amyloid polyneuropathy (FAP), 4.134, 4.134*f*, 4.206
 vitreous involvement/opacification and, 4.134, 4.134*f*
 Finnish/gelsolin type (Meretoja syndrome), 4.206, 8.186*t*, 8.187, 8.188*f*
 primary of cornea (subepithelial amyloidosis/gelatinous droplike dystrophy), 8.135*t*, 8.136*t*, 8.140–141, 8.141*f*, 8.185–187, 8.186*t*
 orbital, 4.228
 petechiae/purpura in, 1.143
 primary localized, 8.185–187, 8.186*t*
 primary systemic, 8.186*t*, 8.187
 secondary localized, 8.186*t*
 secondary systemic, 8.186*t*
 vitreous involvement in, 4.134*f*, 4.134–135
- ANA. *See* Antinuclear antibody
- Anabolism, glucose, 1.33
- Anaerobes
 as normal flora, 8.206*t*
 stains and culture media for identification of, 8.209*t*
- Anaerobic glycolysis, in glucose/carbohydrate metabolism
 in cornea, 2.224
 in lens, 2.246, 11.17–19, 11.18*f*

- Anakinra, 1.175, 9.108
for uveitis, 9.108
- Analgesics. *See also specific agent*
ocular effects of, 1.307*t*
perioperative, 1.289*t*
rebound headache and, 5.293
- Anamnestic immune response, 9.40
- Anaphase, 2.149, 2.149*f*
- Anaphylactic hypersensitivity (immediate/type I) reactions, 9.40, 9.41*t*, 9.52. *See also* Allergic reactions/allergies; Anaphylaxis
allergic conjunctivitis and, 9.51
atopic keratoconjunctivitis and, 8.292
contact dermatoblepharitis and, 8.285, 8.286*f*, 8.287
drugs in management of, 1.296*t*, 1.302–303
hay fever conjunctivitis and, 8.288
topical medications/substances and, 8.285, 8.286*f*, 8.287
- Anaphylactoid reactions, 1.301–302
drugs in management of, 1.296*t*, 1.302–303
penicillin/cephalosporin causing, 2.343
- Anaphylatoxins, 9.22, 9.23, 9.23*f*
- Anaphylaxis, 1.301–303, 9.40, 9.41*t*, 9.52. *See also*
Anaphylactic hypersensitivity (immediate/type I) reactions
drugs in management of, 1.296*t*, 1.302–303
local anesthetics causing, 1.304
penicillin/cephalosporin allergy causing, 2.343
topical medications/substances and, 8.285, 8.286*f*, 8.287
- Anaplasmosis, human granulocytic (human granulocytic ehrlichiosis), Lyme disease coinfection and, 1.250, 9.248
- Anaplastic carcinoma, of thyroid gland, 1.56
- Anatomical reattachment surgery, for retinal detachment. *See also* Retinal detachment, surgery for in CMV retinitis, 9.295
- ANCA (antineutrophil cytoplasmic autoantibody) in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), 1.168
in granulomatosis with polyangiitis (Wegener granulomatosis), 1.165*t*, 1.168, 7.33–34, 7.61–62, 9.138–139. *See also* Granulomatosis, with polyangiitis
eyelid manifestations of, 4.207*t*
optic neuritis and, 5.115
in microscopic polyangiitis, 1.168
vasculitis associated with, 1.165*t*, 1.167–168
- ANCHOR study, 12.80–81
- Ancobon. *See* Flucytosine/5-fluorocytosine
- Ancylostoma caninum* (dog hookworm), 12.246
diffuse unilateral subacute neuroretinitis caused by, 9.232
- Anderson-Kestenbaum procedure, for nystagmus, 5.236, 5.237*f*
- Anderson procedure, for nystagmus, 6.155
- Androgen antagonists, tear production affected by, 8.62*t*
- Androgens, in tear secretion, 2.219–220
- Anemia, 1.136–140
aplastic
carbonic anhydrase inhibitors causing, 2.326, 10.180
chloramphenicol causing, 1.279–280, 2.351
diabetic retinopathy and, 12.98
folic acid deficiency causing, 1.138
hemolytic, 1.138–140
autoimmune, 1.139–140
inflammatory, 1.137
iron deficiency differentiated from, 1.135
iron deficiency, 1.135, 1.136–137
megaloblastic, 1.138
pernicious, 1.138
sickle cell. *See* Sickle cell disease/sickle cell anemia (hemoglobin SS)
sideroblastic (SA), 1.137
in thalassemias, 1.137
vitamin B₁₂ deficiency causing, 1.137–138
- Anestacaine. *See* Lidocaine
- Anesthesia (anesthetics)
for cataract surgery, 11.91*f*, 11.91–92, 11.92*f*, 11.93*f*
retrobulbar hemorrhage and, 11.158, 11.171
for dacryocystorhinostomy, 7.279
examination under. *See* Examination, ophthalmic, under anesthesia
for extraocular muscle surgery, 6.174–175
general, 6.174
balanced, 1.290–291
for cataract surgery, 11.92
in arthritis, 11.171
in claustrophobia, 11.169
in patient unable to communicate, 11.170
for penetrating and perforating trauma repair, 8.403
for intraocular pressure measurement in infants and children, 10.158–159
for intravitreal injections, 12.403
for lacrimal probing, 7.260
local (topical/regional), 1.291–292, 2.362*t*, 2.362–366, 2.363*t*
abuse of, 8.89*f*, 8.89–90
adverse reactions to, 1.291, 1.303–304, 2.363, 8.90*t*
allergic, 1.304
toxic overdose, 1.292, 1.304–305
for anterior segment surgery, 2.365–366
for cataract surgery, 11.92
cholinesterase inhibitor use and, 2.312, 2.363
maximum safe dose of, 1.304, 1.304*t*
for penetrating and perforating trauma repair, 8.403–404
for phakic IOL insertion, 13.141
for photoablation, 13.82
malignant hyperthermia caused by, 1.292–293, 1.293*t*
for penetrating and perforating trauma repair, 8.403–404
peribulbar, 6.174
for cataract surgery, 11.91
for phakic IOL insertion, 13.141
for photoablation, 13.82
for photocoagulation, 12.375
preoperative evaluation and, 1.284
retrobulbar, 6.174
adverse reactions to, 1.291, 1.305
for cataract surgery, 11.91, 11.91*f*
hemorrhage and, 11.158, 11.171
systemic, 1.290–291
tear production affected by, 8.62*t*

Anesthesia/hypoesthesia

corneal

- congenital, 8.108
- herpes simplex keratitis and, 8.217–218, 8.226*t*
- herpes zoster and, 8.226*t*, 8.228
- keratoplasty and, 8.418, 8.424
- after LASIK, 13.172
- neurotrophic keratopathy/persistent corneal defects and, 8.80, 8.224
- in infraorbital nerve distribution
 - in orbital floor/blowout fracture, 7.19, 7.109
 - after orbital surgery, 7.125

Aneuploidy, 2.132, 2.189. *See also specific disorder*

of autosomes, 2.189–190

of sex chromosomes, 2.189

Aneurysmal bone cyst, 6.222

Aneurysmal telangiectasia, 12.161

Aneurysms

- basilar artery, 5.338, 5.339*f*
- berry (saccular), 1.126, 5.338
- cerebral, 5.338–342, 5.339*f*, 5.340*f*, 5.341*f*
 - neuroimaging in diagnosis of, 5.69–70, 5.72*t*, 5.194*f*, 5.194–195, 5.340, 5.341*f*
 - ruptured, 5.338–339, 5.340, 5.340*f*, 5.341
 - intracranial hemorrhage caused by, 1.126, 1.127
 - third nerve (oculomotor) palsy and, 5.20, 5.339
 - aberrant regeneration and, 5.198
 - divisional palsy and, 5.197
 - pupil-involving, 5.194*f*, 5.194–195, 5.265
 - pupil-sparing, 5.196
 - in younger patients, 5.197
- cranial nerve III (oculomotor) affected by, 2.94, 2.95
- giant, 5.338, 5.339
- internal carotid, 5.338, 5.339*f*
 - chiasmal syndromes caused by, 5.147, 5.150
 - third nerve (oculomotor) palsy and, 5.194, 5.194*f*, 5.196, 5.196*f*, 5.339
- intracavernous carotid, 5.339–340
- ophthalmic artery, 5.339
- retinal arterial, 12.147–148, 12.148*f*
 - microaneurysms, 4.154, 4.155*f*
 - in diabetes mellitus, 4.155*f*, 4.159
 - in diabetic retinopathy, 4.159
 - in retinal vein occlusion, 4.158, 4.159

Angelman syndrome, imprinting abnormalities causing, 2.138, 2.154

Angina pectoris, 1.93. *See also* Ischemic heart disease

- ECG changes in, 1.95
- exercise stress testing in, 1.97
- heart failure and, 1.105
- stable, 1.93
 - hypertension management and, 1.75
 - management of, 1.99–102, 1.100–101*t*
- unstable, 1.93
 - hypertension management and, 1.75
- variant (Prinzmetal), 1.93

Angiofibromas

- facial, 6.397
 - in tuberous sclerosis, 5.331*f*, 5.334*t*
- giant cell, of orbit, 4.235

Angiogenesis

- activators of, 12.80
- in cancer growth/spread, 1.235

in corneal transplant rejection, 8.317

definition of, 12.79

endothelial cells in, 12.79

inhibitors of. *See* Antiangiogenic agents

vitreous as inhibitor of, 2.253–254

Angiographic cystoid macular edema, after cataract surgery, 11.163–164, 11.164*f*

Angiography/arteriography

- in carotid-cavernous fistulas, 7.73
- in cerebral ischemia/stroke, 1.121–122, 1.122
- computed tomography (CTA), 5.58, 5.69–70, 5.72*t*
 - advantages/disadvantages of/contraindications for, 5.61*t*
 - in aneurysm detection/evaluation, 5.69–70, 5.194, 5.194*f*, 5.340
 - in arterial dissection, 5.342
 - in carotid artery evaluation, 5.167
 - in cerebral ischemia/stroke, 1.121–122
 - in ischemic heart disease, 1.98
 - in orbital evaluation, 7.32
 - in vertebrobasilar insufficiency, 5.338
- conventional/catheter/contrast, 5.68, 5.68*f*
 - in aneurysm detection/evaluation, 5.195, 5.340, 5.341*f*
 - in arteriovenous malformations, 5.292*f*, 5.344, 5.344*f*
 - in cerebral ischemia/stroke, 1.121–122, 1.122
 - in ischemic heart disease, 1.98
 - in reversible cerebral vasoconstriction syndrome, 5.347, 5.347*f*
 - in vertebrobasilar insufficiency, 5.337*f*, 5.338
- coronary, 1.94, 1.98
- digital subtraction (DSA), 5.68
 - in arterial dissection, 5.342
- dye injection in, 12.24
- fluorescein. *See* Fluorescein angiography (FA)
- indocyanine green. *See* Indocyanine green (ICG) angiography
- magnetic resonance (MRA), 5.58, 5.68–69, 5.69*f*, 5.72*t*
 - advantages/disadvantages of/contraindications for, 5.61*t*
 - in aneurysm detection/evaluation, 5.194, 5.340, 5.341*f*
 - in arterial dissection, 5.342
 - in carotid artery evaluation, 5.167, 5.167*f*
 - in carotid-cavernous fistulas, 7.73
 - in cerebral ischemia/stroke, 1.121–122
 - in orbital evaluation, 7.32
 - in reversible cerebral vasoconstriction syndrome, 5.347
 - in vertebrobasilar insufficiency, 5.338
- optical coherence tomographic
 - artifacts in, 12.29, 12.30*f*
 - choroidal circulation abnormalities, 12.198
 - choroidal neovascularization on, 12.75–76, 12.76–78*f*, 12.192
 - depth resolution using, 12.29
 - diabetic retinopathy on, 12.93, 12.94*f*
 - fluorescein angiography versus, 12.29
 - macular telangiectasia type 2 on, 12.163, 12.164*f*
 - motion artifacts in, 12.29

- projection artifacts in, 12.29, 12.30*f*
- pseudoxanthoma elasticum on, 12.199*f*
- retinal capillary layers on, 12.16
- retinal disease evaluations using, 12.28–29
- retinal vasculature on, 12.29, 12.30*f*
- severity of, 12.93, 12.94*f*
- in orbital evaluation, 7.32
- retinal. *See* Fluorescein angiography; Indocyanine green (ICG) angiography
- scanning laser ophthalmoscopy versus, 12.24
- in subarachnoid hemorrhage, 1.127
- Angioid streaks
 - choroidal neovascularization caused by, 12.87–89, 12.89*f*
 - definition of, 12.87
 - description of, 12.19
 - fluorescein angiography of, 12.87, 12.89*f*
 - in pseudoxanthoma elasticum, 1.143, 12.87, 12.89*f*
 - safety glasses for patients with, 12.88
 - in sickle cell disease, 12.154
 - visual disturbances caused by, 12.88
- Angiokeratoma corporis diffusum (Fabry disease), 2.175*t*, 8.176–178, 8.177*f*
 - enzyme replacement therapy for, 2.203
 - ocular findings in carriers of, 2.199*t*
- Angiomas (angiomatosis). *See also* Hemangiomas (hemangiomatosis)
 - cavernous. *See* Cavernous hemangioma
 - cerebrofacial/encephalotrigeminal/encephalofacial. *See* Cerebrofacial (encephalotrigeminal/encephalofacial) angiomatosis/Sturge Weber syndrome (SWS)
 - racemose (Wyburn-Mason syndrome/Bonnet-Dechaume-Blanc syndrome), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*
 - retinal (retinae). *See* Retinal angiomatosis
 - venous, 1.126
- Angiomatous tumors, 4.281–287. *See also* Angiomas; *specific tumor*
- Angioplasty, coronary. *See also* Percutaneous coronary intervention
 - for angina, 1.100–102
- Angiopoietin 1, nevus flammeus and, 8.346
- Angiosarcoma, conjunctival/ocular surface, 8.345*t*
- Angiotensin/angiotensinogen, in aqueous humor, 2.231, 2.234
- Angiotensin II receptor blockers (ARBs)
 - for heart failure, 1.110
 - for hypertension, 1.68, 1.68*t*, 1.69*t*, 1.71–72, 1.73
 - indications for, 1.69*t*
- Angiotensin-converting enzyme (ACE), 6.319
 - in sarcoidosis, 5.327
 - serum levels of, in sarcoidosis, 7.34, 7.63
- Angiotensin-converting enzyme (ACE) inhibitors
 - for heart failure, 1.109, 1.110
 - for hypertension, 1.68, 1.68*t*, 1.69*t*, 1.71, 1.73
 - indications for, 1.69*t*
 - for ischemic heart disease, 1.101*t*
 - non-ST-segment elevation acute coronary syndrome, 1.103
 - ocular effects of, 1.118
 - for systemic sclerosis, 1.162
- Angle
 - anterior chamber. *See* Anterior chamber angle
 - in uveitis, 9.80*t*
- Angle alpha (α), 3.123, 3.129, 3.129*f*
- Angle closure, 10.36, 10.117, 10.117*t*. *See also* Angle-closure glaucoma
 - acute, 10.123–125, 10.124*f*
 - management of, 10.184
 - anisocoria and, 5.263
 - chronic, 10.4*t*, 10.126–127
 - gonioscopic identification of/monitoring for, 10.36, 10.79
 - intermittent (subacute), 10.125–126
 - with iris bombé, 9.83, 9.285–286
 - lens-induced, 10.96, 10.119, 10.128–132
 - mechanisms of, 10.118–120, 10.119*t*
 - ocular inflammation and, 10.138*f*, 10.138–139, 10.139*f*
 - pathogenesis and pathophysiology of, 10.118–120, 10.119*t*
 - plateau iris and, 10.4*t*, 10.9, 10.32, 10.120, 10.127
 - primary (PAC), 10.4*t*, 10.117, 10.117*t*, 10.118, 10.120–122
 - acute, 10.123–125, 10.124*f*
 - management of, 10.184
 - chronic, 10.4*t*, 10.126–127
 - pupillary block causing, 10.118–119
 - secondary, 10.118
 - with pupillary block, 10.4*t*, 10.128–132
 - without pupillary block, 10.4*t*, 10.132–146
 - surgery for, 10.187. *See also* Glaucoma surgery
 - tumors causing, 10.99, 10.138
- Angle-closure glaucoma, 10.3, 10.4*t*, 10.6*t*, 10.117*t*, 10.117–146. *See also* Angle closure; Glaucoma
 - acute, 10.123–125, 10.124*f*
 - management of, 10.184
 - uveitic, 9.285
 - age and, 10.9
 - aniridia and, 10.120, 10.155
 - aphakic, 10.130–132
 - in children, 10.156
 - after cataract surgery, 11.136
 - ciliary block/malignant glaucoma (aqueous misdirection) and, 11.139
 - central retinal vein occlusion and, 10.143–144
 - neovascularization and, 10.134–135
 - in children and adolescents. *See* Angle-closure glaucoma, pediatric
 - chronic, 10.4*t*, 10.126–127
 - classification of, 10.4*t*, 10.6*t*
 - combined-mechanism glaucoma and, 10.7
 - cornea plana and, 8.96*t*, 8.100–101
 - creeping, 10.126
 - drug-induced, 10.122–123, 10.145*f*, 10.145–146
 - ectopia lentis and, 10.129–130, 10.130*f*, 10.130*t*, 10.131*f*
 - epithelial and fibrous ingrowth and, 10.141–142, 10.142*f*, 10.143*f*
 - family history and, 10.121
 - flat anterior chamber and, 10.121, 10.144–145
 - malignant/ciliary block glaucoma (aqueous misdirection) and, 10.32, 10.140, 10.140*f*
 - gender and, 10.9, 10.121
 - genetic/hereditary factors in, 10.9

- gonioscopic identification of, 10.36
inflammatory, 10.138*f*, 10.138–139, 10.139*f*
intermittent (subacute), 10.125–126
uveitic, 9.285–286
iridocorneal endothelial syndrome and, 4.101, 10.136*f*, 10.136–138, 10.137*f*
iris bombé and, 9.83, 9.285–286, 10.32, 10.129, 10.131*f*, 10.138, 10.139*f*
iris-induced, 10.120
lens-induced, 10.96, 10.119, 10.128–132
malignant (aqueous misdirection/ciliary block glaucoma), 10.32, 10.139–141, 10.140*f*
cataract surgery and, 10.139, 11.139
in children and adolescents, 10.149*t*
management of, surgical, 10.187. *See also* Glaucoma surgery
chamber deepening/goniosynechialysis, 10.220
incisional procedures. *See* Incisional surgery
laser gonioplasty/peripheral iridoplasty, 10.193–194
laser iridotomy, 10.124, 10.125, 10.126, 10.191–193, 10.192*f*
peripheral (surgical) iridectomy, 10.125, 10.220
microcornea and, 8.95–99
microspherophakia and, 10.130, 10.131*f*, 11.33
nanophthalmos and, 4.108, 4.109, 10.144
ocular biometrics and, 10.121
open-angle glaucoma differentiated from, 10.3, 10.5*f*
outflow obstruction mechanisms in, 10.5, 10.6*t*, 10.118–120, 10.119*t*
pain caused by, 5.295
pars planitis and, 9.131
pathogenesis and pathophysiology of, 10.118–120, 10.119*t*
pediatric (childhood/congenital/infantile/juvenile), 10.149*t*
persistent fetal vasculature and, 10.144
phacomorphic, 10.119, 10.128, 10.129*f*, 11.67, 11.68*f*
plateau iris and, 10.4*t*, 10.9, 10.32, 10.120, 10.127
posterior polymorphous corneal dystrophy and, 8.159
prevalence of, 10.117
primary (PACG), 10.4*t*, 10.117, 10.117*t*, 10.118, 10.120–122
acute, 10.123–125, 10.124*f*
management of, 10.184
epidemiology of, 10.9–10
prevalence of, 10.9, 10.117
with pupillary block, 10.119
iridotomy/iridectomy for, 10.124, 10.125, 10.191–193, 10.192*f*
without pupillary block (plateau iris), 10.4*t*, 10.9, 10.120, 10.127*f*, 10.127–128
risk factors for, 10.9, 10.120–122
subacute/intermittent, 10.125–126
pseudophakic, 10.130–132
with pupillary block, 10.4*t*, 10.6*t*, 10.118–119
iridotomy/iridectomy for, 10.124, 10.125, 10.191–193, 10.192*f*
without pupillary block, 10.4*t*, 10.6*t*, 10.119*t*, 10.119–120
race and, 10.9, 10.117, 10.120
refraction/refractive errors and, 10.9, 10.122
retinal detachment and, 10.141
retinal surgery and, 10.143
retinal vascular disease and, 10.143–144
in retinopathy of prematurity, 12.181. *See also* Glaucoma
risk factors for, 10.9, 10.120–122
in sarcoidosis, 9.169
secondary. *See also specific cause*
in children and adolescents, 10.149*t*
with pupillary block, 10.4*t*, 10.128–132
microspherophakia and, 11.33
phacomorphic glaucoma and, 11.67
without pupillary block, 10.4*t*, 10.132–146
uveitic, 9.83, 9.285–286
SSRIs causing, 1.196
subacute/intermittent, 10.125–126
uveitic, 9.285–286
topiramate causing, 1.187, 1.203, 10.145*f*, 10.145–146
transient visual loss and, 5.163*t*, 5.164
trauma and, 10.142
fibrous ingrowth and, 10.142, 10.143*f*
tumors causing, 10.99, 10.138
uveitic, 9.83, 9.285–286, 10.134, 10.139, 10.139*f*
Angle-closure suspect, primary, 10.4*t*, 10.117, 10.117*t*, 10.122–123
Angle kappa (κ), 3.123, 3.129, 3.129*f*, 3.267, 3.272
definition of, 6.67
description of, 8.33
negative, 6.67, 6.68*f*
pictorial representation of, 6.68*f*
positive, 6.67, 6.68*f*
Angle of deviation, 3.45, 3.46*f*
Angle of incidence
Brewster angle and, 3.99
definition of, 3.39
description of, 3.44*f*, 3.80
Angle of reflection, 3.80
Angle of refraction, 3.44*f*
Angle recession, 10.36, 10.107*f*
traumatic, 4.18, 4.19*f*, 4.103–104
glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
Angle-supported intraocular lenses, 13.137, 13.138, 13.139*t*, 13.144
complications of, 13.146–147
Angle surgery, in Sturge-Weber syndrome, 6.402
Angular artery, 5.12, 5.13*f*, 5.14*f*, 5.15*f*, 7.16*f*, 7.254
eyelids supplied by, 2.25, 2.26*f*, 7.16*f*, 7.154
orbit supplied by, 2.33*f*
Angular gyrus, 5.32*f*
Angular magnification, 3.84. *See also* Magnification
Angular vein, 2.35*f*, 5.21*f*, 5.22, 5.23, 7.254
eyelids drained by, 7.154
Anhedonia, 1.183, 1.189
Anhidrosis
congenital insensitivity to pain with (CIPA), congenital corneal anesthesia and, 8.108
in Horner syndrome, 5.257–258
Anidulafungin, 1.281
Animal bites, eyelid injuries caused by, 7.190
Aniridia, 2.193, 4.184, 6.266*f*, 6.266–267, 6.285, 10.150, 10.154–155, 11.33
cataract and, 11.33, 11.34*f*
surgery for, 11.184

- glaucoma and (iris-induced angle closure), 10.120, 10.155
 pediatric, 10.150, 10.155
 Axenfeld-Rieger syndrome differentiated from, 10.154*t*
 gonioscopic appearance of, 10.159
 pupil irregularity and, 5.255
 short arm 11 deletion syndrome/*PAX6* gene mutations and, 2.152, 2.177, 2.193, 4.184, 10.150, 10.155, 11.33
 Wilms tumor and, 4.184, 10.155, 11.33
- Aniseikonia
 definition of, 3.123, 3.139, 3.169, 3.255
 meridional (meridional magnification), 3.147, 3.173.
 See also Distortion
 spherical, 3.255
 symptoms of, 3.199
- Anisocoria, 5.253, 5.255–266, 6.275. *See also specific cause*
 cocaine in testing for, 5.256*f*
 equal in dim and bright light, 5.256*f*, 5.257
 evaluation of, 5.253–254, 5.256*f*
 eyelid disorders and, 5.271
 greater in bright light, 5.262–266, 5.263*f*, 5.264*f*, 5.265*f*
 greater in dim light, 5.256*f*, 5.257–262, 5.258*t*, 5.259*f*, 5.260*t*, 5.261*f*, 5.262*f*
 history in, 5.253
 Horner syndrome and, 5.256*f*, 5.257–262, 5.259*f*, 5.260*t*, 5.261*f*, 5.262*f*
 iris disorders and, 5.256*f*, 5.262–263
 mechanical, 5.258*t*
 pharmacologic, 5.258*t*, 5.263
 physiologic (simple/essential), 5.256*f*, 5.257
 pupillary light reflex and, 5.255–257
 third nerve (oculomotor) palsy/aberrant regeneration and, 5.256*f*, 5.265–266
 tonic pupil/Adie tonic pupil and, 5.256*f*, 5.263*f*, 5.263–265, 5.264*f*, 5.265*f*
- Anisometropia
 abnormal visual experience caused by, 6.44
 amblyopia caused by, 3.139
 refractive surgery and, 13.185–187
 anisophoria caused by correction of. *See* Anisophoria, induced
 anterior polar cataracts associated with, 6.295
 asymmetric lens-induced myopia causing, 11.70
 in children, 3.175
 contact lenses and, 3.206–208
 definition of, 3.139
 hyperopic, 3.140
 in infantile (capillary) hemangioma, 7.68, 7.161
 management of, 3.197, 3.198*t*
 after penetrating keratoplasty, 8.432
 refractive surgery for, 13.179
 second-eye cataract surgery for, 11.73
 spectacle correction of
 anisophoria induced by. *See* Anisophoria, induced
 description of, 3.139
- Anisometropic amblyopia, 3.175
 clinical features of, 6.54–55
 critical period for, 6.45
 epibulbar dermoids as cause of, 6.256
 occlusion therapy for, 6.58
 refractive surgery and, 13.185–187
 strabismus amblyopia versus, 6.54–55
- Anisometropic hyperopia, 3.185*f*
- Anisophoria
 definition of, 3.139
 induced
 compensating for, 3.186–190, 3.187*f*
 contact lenses for, 3.190
 dissimilar segments for, 3.189, 3.189*f*
 press-on prisms for, 3.188
 refractive surgery for, 3.190
 reverse slab-off for, 3.188–189
 single-vision reading glasses with lowered optical centers for, 3.189–190
 slab-off for, 3.188, 3.188*f*
 symptomatic, 3.187
- Ankyloblepharon, 6.193–194, 6.194*f*
 cataract surgery in patient with, 11.173
 in mucous membrane pemphigoid, 8.300, 8.302*t*
- Ankyloblepharon filiforme adnatum, 6.193–194, 6.194*f*, 7.158
- Ankyloblepharon–ectodermal dysplasia–clefting syndrome. *See* Hay-Wells syndrome
- Ankylosing spondylitis (AS), 1.153–154, 9.113*f*, 9.114–115
 cataract surgery in patient with, 11.171, 11.171*f*
 HLA in, 1.153, 9.114
 juvenile, 1.155
- ANNA-1 (anti-Hu) antibody, paraneoplastic-induced saccadic intrusions and, 5.249
- ANNA-2 (anti-Ri) antibody, paraneoplastic-induced saccadic intrusions and, 5.249
- Annular gap, 12.7
- Annular keratopathy, traumatic, 8.388
- Annular ring, 6.182
- Annular zones, multifocal intraocular lens with, 3.259, 3.259*f*
- Annulus of Zinn, 2.8, 2.9*f*, 2.13*f*, 2.14*f*, 2.16–17, 2.87, 5.8*f*, 5.26, 5.45, 7.11, 7.12–13, 7.13*f*, 7.14*f*, 7.15*f*, 7.16
 horizontal rectus muscles from, 6.20
 inferior rectus muscle from, 6.20
 superior oblique muscle from, 6.20
 superior rectus muscle from, 6.20
 vertical rectus muscles from, 6.20
- Anomalies, congenital. *See* Congenital anomalies; *specific type*
- Anomaloscope, 12.54
- Anomalous binocular vision, 6.50
- Anomalous retinal correspondence (ARC)
 afterimage test for, 6.79*f*
 definition of, 6.50
 diplopia and visual confusion eliminated with, 6.49*f*
 eccentric fixation versus, 6.51
 harmonious, 6.76
 Maddox rod testing in, 6.68
 major amblyoscope for, 6.70
 red-glass test findings in, 6.76*f*
 after strabismus surgery, 6.50
 testing for, 6.50–51
 unharmonious, 6.76
- Anomalous trichromatism, 12.249

- Anophthalmia/anophthalmos, 6.209, 6.210*f*, 6.263, 7.35, 7.127. *See also* Anophthalmic socket
- surgical, 7.127–137
- treatment of, 7.36
- Anophthalmic ectropion, 7.135
- Anophthalmic ptosis, 7.135
- Anophthalmic socket, 7.127–137. *See also specific aspect*
- complications and treatment of, 7.132–136, 7.133*f*, 7.134*f*, 7.135*f*
- contracted, 7.134–135, 7.135*f*
- enucleation and, 7.128–129, 7.130
- evisceration and, 7.129–130, 7.130
- exenteration and, 7.136–137, 7.137*f*
- goals for surgery of, 7.129
- implants and, 7.131*f*, 7.131–132
- in children, 7.129
- Anophthalmic surgery, 7.127–137. *See also*
- Anophthalmic socket
- Ansa subclavia, 5.54
- ANSI. *See* American National Standards Institute
- Antagonist (drug), 2.304
- Antagonist (muscle)
- contralateral, inhibitional palsy of, 6.120–121, 6.121*f*
- definition of, 6.33
- Antazoline, 2.337
- Antazoline/naphazoline, 2.338*t*
- Anterior banded zone, of Descemet membrane, 2.41, 2.42*f*
- Anterior basement membrane dystrophy. *See* Basement membrane dystrophy
- Anterior border, of iris, 2.54–55, 2.55, 2.56*f*, 4.181, 4.182*f*
- Anterior capsule
- description of, 6.302
- opacification of, cataract surgery and, 11.152, 11.153
- Anterior capsule fibrosis and phimosis, 11.153–154, 12.116
- Nd:YAG laser capsulotomy for, 11.154, 11.154*f*, 11.154–157, 11.156*f*
- See also* Nd:YAG laser therapy, capsulotomy
- Anterior capsulotomy. *See* Capsulotomy, anterior
- Anterior cerebral artery (ACA), 2.90, 2.107*f*, 5.16*f*, 5.18, 5.27*f*
- cranial nerve relationship and, 2.85*f*, 5.18–19, 5.42*f*
- Anterior chamber, 2.37, 2.37*f*, 2.45*f*, 2.45–48, 2.46*f*, 2.47*f*, 4.97–106. *See also* Anterior chamber angle; Anterior segment
- biomicroscopy in evaluation of, 10.31–32
- before refractive surgery, 13.43–44
- blunt trauma to, 10.39–40, 10.40, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*
- congenital anomalies of, 4.98–99, 4.99*f*, 4.100*f*
- See also* Anterior segment, dysgenesis of
- degenerations of, 4.100–105, 4.101*f*, 4.102*f*, 4.103*f*, 4.104*f*, 4.105*f*
- depth of (ACD), 2.45–46, 3.248–249, 4.97
- angle closure and, 10.9, 10.31–32, 10.121
- in IOL power determination/selection, 11.84, 11.86–87. *See also* Estimated lens position
- phakic IOL implantation and, 13.43, 13.141
- development of, 2.121*f*, 2.123*f*
- disorders of, 4.97–106. *See also specific type*
- double, after deep anterior lamellar keratoplasty, 8.435
- flat or shallow
- angle-closure glaucoma and, 10.9, 10.31–32, 10.121, 10.144–145
- malignant/ciliary block glaucoma (aqueous misdirection) and, 10.32, 10.140, 10.140*f*
- cataract surgery and, 11.134–136
- angle-closure glaucoma and, 10.144–145
- intraoperative complications and, 11.134–135
- posterior fluid misdirection syndrome and, 11.134–135
- postoperative complications and, 11.135–136
- preoperative considerations/IOL power determination and, 11.79, 11.84, 11.86–87
- iridotomy contraindicated in, 10.191
- after penetrating keratoplasty, 8.424
- refractive surgery and, 13.43
- after tube shunt surgery, 10.217, 10.218*t*
- gonioscopy/evaluation of, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
- assessment/documentation systems for, 10.36–40, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
- before cataract surgery, 11.79
- in glaucoma, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
- growth and development of, 6.181
- immune response/features/microenvironment of, 9.54*t*, 9.56–58
- corneal allograft immunity and, 9.60
- in leukemia, 4.315
- melanoma of, 4.105*f*, 4.106, 4.106*f*, 4.194, 4.195*f*
- glaucoma and, 4.105*f*, 4.106, 4.194
- Onchocerca volvulus* microfilariae in, 9.234–235
- phacoemulsification in, 11.112
- pigment dispersion affecting, 4.104–105, 4.105*f*
- topography of, 2.37, 2.37*f*, 4.97*f*, 4.97–98, 4.98*f*
- ultrasound biomicroscopy of, 12.40
- in uveitis, 9.72*t*, 9.79–83, 9.80*f*, 9.80*t*, 9.81*f*, 9.82*t*.
- See also* Anterior uveitis
- vitreous prolapse in, 11.143–144
- Anterior chamber angle, 2.37*f*, 2.45, 2.45*f*, 2.46*f*, 2.47*f*, 2.49*f*, 4.97*f*, 4.97–98, 4.98*f*. *See also* Anterior chamber
- blood vessels in, 10.38*f*, 10.38–39
- crowding of, retinopathy of prematurity as risk factor for, 6.334
- development of, 2.116*t*
- abnormalities of, glaucoma and, 4.98, 4.99*f*, 10.6*t*
- in glaucoma. *See* Angle closure; Angle-closure glaucoma
- gonioscopy of, 4.97–98, 4.98*f*, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
- in leukemia, 4.315
- neovascularization of, 10.32, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*.
- See also* Neovascular glaucoma
- in diabetes mellitus, 12.107
- normal, 10.34*f*
- in infants and children, 10.159
- occludable/narrow, 10.34*f*, 10.122
- OCT in evaluation of, 8.22, 8.22*f*
- pigmentation in, in pseudoexfoliation/exfoliation syndrome, 10.39, 10.92, 10.92*f*
- in rubella (congenital), 9.204

- topography of, 2.37f
 traumatic recession of, 4.18, 4.19f, 4.103–104
 glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40f, 10.41f, 10.106–108, 10.107f
 ultrasound biomicroscopy in evaluation of, 8.21
 in uveitis, 9.80t
- Anterior chamber–associated immune deviation (ACAID), 9.57–58
 corneal graft tolerance and, 8.316, 9.59, 9.60
 immune privilege and, 8.316, 9.57–58, 9.59, 9.60
- Anterior chamber cleavage syndrome. *See* Anterior segment, dysgenesis of
- Anterior chamber intraocular lenses (ACIOLs). *See* Intraocular lenses (IOLs), anterior chamber
- Anterior chamber/aqueous paracentesis, 6.414, 12.146
 in acute retinal necrosis, 9.196
 in coccidioidomycosis, 9.271
 in cysticercosis, 9.231
 in endogenous endophthalmitis, 9.264
 in uveitis, 9.91–92
- Anterior chamber phakic intraocular lenses, 13.8t.
 See also Phakic intraocular lenses
- Anterior choroidal artery (AChOA), 5.16f, 5.18, 5.18f
- Anterior ciliary artery, 2.17, 2.30, 2.32–35, 5.14f, 5.14–15, 6.23, 7.14f, 7.15f
- Anterior ciliary sclerotomy (ACS), for presbyopia, 13.162
- Anterior clinoid process, 2.8f, 2.84f, 2.105f, 5.6f, 5.7f, 5.9f, 5.16f, 5.43f, 7.7f
- Anterior communicating artery (ACoA), 2.90, 5.16f, 5.18, 5.27f
 aneurysm of, 5.339, 5.339f
 cranial nerve relationship and, 2.84f, 2.85f, 5.42f, 5.43f
- Anterior conjunctival artery, 2.30
- Anterior cortical gel, 12.7
- Anterior cranial fossa, 5.6f, 5.8, 5.10f, 7.7f
- Anterior crocodile shagreen (mosaic degeneration), 8.121
- Anterior cyclitis, 9.72t
- Anterior ethmoidal artery, 5.12, 5.13f, 5.14f, 5.16f
- Anterior ethmoidal foramen, 2.6f, 2.7, 5.11
- Anterior hyaloid, 12.8f
- Anterior inferior cerebellar artery (AICA), 5.19f, 5.20
 cranial nerve relationship and, 2.102, 5.42f
- Anterior lacrimal crest, 2.5, 2.6f
- Anterior lamellar deficiency, surgery for eyelid retraction and, 7.224
- Anterior lamellar keratoplasty (ALK), 8.412, 8.412t, 8.433, 8.433f. *See also* Keratoplasty, lamellar
 advantages of, 8.421–422t, 8.433
 complications of, 8.435
 intraoperative, 8.420t
 postoperative, 8.421t
 deep (DALK), 8.411, 8.412, 8.412t, 8.433, 8.434–435.
 See also Deep anterior lamellar keratoplasty
 disadvantages of, 8.422t, 8.433
 donor cornea contraindications and, 8.415t
 femtosecond/femtosecond laser–assisted (FALK/FLAK), 8.412t, 8.431, 8.434
 indications for, 8.412–413t, 8.420t, 8.433
 layer-based approach to use of, 8.417t
 preoperative evaluation/preparation and, 8.418
 therapeutic (ALTK), 8.412t
- Anterior lens opacities, 6.295
- Anterior lenticonus/lentiglobus, 4.118, 11.30
- Anterior optic neuropathy
 CMV infection causing, 5.349
 ischemic (AION), 5.107t, 5.119–124, 5.120t, 5.121f, 5.123t
 arteritic (AAION), 5.107t, 5.120, 5.120t, 5.120–122, 5.121f, 5.313
 nonarteritic (NAION), 5.107t, 5.120, 5.120t, 5.121f, 5.122–124, 5.123t
 OCT in evaluation of, 5.91f
 visual evoked potentials in, 12.52
 perioperative, 5.124–125
 with optic nerve/nerve head/disc edema, 5.104
- Anterior orbitotomy. *See also* Orbitotomy
 incisions for, 7.116f
- Anterior persistent fetal vasculature, 12.341–342
- Anterior pituitary hormones, 1.56, 1.56t
- Anterior polar cataracts (APCs), 6.55, 6.295, 6.295f, 11.35–36
- Anterior pole, 2.38, 2.65f, 2.242f, 11.9, 11.10f, 11.11f, 11.12f
- Anterior pupillary membrane, 11.29, 11.29f
- Anterior segment. *See also* Anterior chamber; Cornea;
 Iris; *specific structure*
 blood supply to
 description of, 6.172
 extraocular muscle blood supply and, 6.30
 blunt trauma to, 12.353
 in coccidioidomycosis, 9.271
 development of, 2.65f, 2.117–122, 2.120f, 2.121f
 disorders of
 cataract and, 11.68
 cataract surgery complications causing, 11.132–144, 11.137t. *See also specific type*
 characteristics of, 6.320t
 CMV-associated, 8.231–232, 8.232f
 cornea. *See* Cornea, disorders of
 description of, 6.253
 developmental anomalies, 8.95–109, 8.96–98t.
 See also Anterior segment, dysgenesis of
 globe anomalies, 6.263
 inflammation. *See* Anterior uveitis
 iris anomalies, 6.264–267, 267f
 pupil abnormalities, 6.267–268, 6.268f
 systemic disorders and, 8.173–203
 Th1-mediated delayed hypersensitivity and, 9.46t
 toxic, 8.375–409
 keratoconjunctivitis/keratopathy from medications, 8.80–81, 8.81t, 8.90t, 8.90–92, 8.91f
 traumatic, 8.375–409, 10.39–40, 10.40f, 10.41f, 10.103–108, 10.104f, 10.106f, 10.107f, 11.190.
 See also Anterior segment, trauma to
 dysgenesis of, 4.98–99, 4.99f, 4.100f, 8.95, 8.101–107.
 See also specific disorder
 Peters anomaly and, 11.31–32. *See also* Peters anomaly
 in Epstein-Barr virus infection, 9.202
 examination of. *See also* Slit-lamp biomicroscopy/
 examination
 in children, 6.10, 6.187
 in nystagmus evaluations, 6.154
 OCT in, 8.21–22, 8.22f
 in pediatric glaucoma, 10.158

- before refractive surgery, 13.41–44, 13.42*f*, 13.43*f*
- ultrasound biomicroscopy in, 2.47, 2.47*f*, 4.265, 8.20–21, 8.21*f*. *See also* Ultrasound biomicroscopy
- imaging of, 3.292–306, 3.293–303*f*
- immune response/features/microenvironment of, 9.54*t*, 9.56–58
- inflammation of, in uveitis, 6.320
- ischemia of, 6.172–173, 6.173*f*
- leukemic infiltration of, 4.315
- light wavelength transparency of, 3.118
- neovascularization of, 10.32, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*. *See also* Neovascular glaucoma
- in central retinal vein occlusion, 12.125
- in onchocerciasis, 9.234–235, 9.235*f*
- pigmentation in, in pseudoexfoliation/exfoliation syndrome, 10.39, 10.92, 10.92*f*
- in primary congenital glaucoma, 6.282, 6.282*f*
- surgery on
 - cystoid macular edema after, 12.393, 12.394*f*
 - endophthalmitis after. *See* Endophthalmitis, postoperative
 - posteriorly dislocated intraocular lenses after, 12.393
 - pupil irregularity and, 5.255
 - suprachoroidal hemorrhage after, 12.394–395, 12.395*f*
 - topical anesthetics for, 2.365–366
 - traumatic injury and, 10.108–109
 - vitrectomy for posterior segment complications of, 12.388–396
- in syphilis, 9.237, 9.238
- systemic disorders affecting, 8.173–203
- toxic injuries of, 8.375–409
- in toxocariasis, 9.228
- trauma to, 8.375–409, 10.39–40, 10.40*f*, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*, 11.190
- animal and plant substances causing, 8.386–387
- chemical injuries, 8.375–384, 8.376*t*. *See also* Chemical injury
- concussive (blunt), 8.387–396, 8.388*f*, 8.389*f*, 8.390*f*, 8.391*f*, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*. *See also* Concussive (blunt) trauma
- penetrating and perforating, 8.396–409. *See also* Penetrating and perforating ocular trauma; Trauma
- surgical, 10.108–109
- temperature and radiation causing, 8.384–386, 8.385*f*
- tumors of, 6.271–274
 - metastatic, 4.305
- ultraviolet irradiation injury to, 3.118–119
- in uveitis, 9.79–83, 9.80*f*, 9.81*f*, 9.82*t*. *See also* Anterior uveitis
- Anterior segment developmental anomalies (ASDA). *See* Anterior segment, dysgenesis of
- Anterior segment dysgenesis syndrome. *See also* Anterior segment, dysgenesis of
- Peters anomaly and, 11.31–32
- Anterior segment optical coherence tomography (OCT), 8.21–22, 8.22*f*. *See also* Optical coherence tomography
- in glaucoma, 10.77
- in keratoconus, 8.165–166
- Anterior stromal puncture, for recurrent corneal erosions, 8.79, 8.87
- Anterior subcapsular fibrous plaques, 4.120, 4.120*f*
- Anterior superior alveolar nerve, 7.17*f*
- Anterior synechiae
 - in glaucoma
 - angle closure and, 10.117, 10.121
 - inflammation and, 10.138, 10.139*f*
 - anterior segment/iris neovascularization and, 10.39, 10.39*f*, 10.133, 10.133*f*, 10.134*f*
 - chamber deepening/goniosynechialysis in management of, 10.220
 - flat anterior chamber and, 10.144
 - gonioscopy in identification of, 10.34*f*, 10.39, 10.39*f*
 - inflammation and, 9.286
 - iridocorneal endothelial syndrome and, 4.100–101, 4.101*f*, 10.136, 10.136*f*
 - plateau iris and, 10.128
 - uveitis and, 9.286
 - in sarcoidosis, 9.169
 - traumatic hyphema and, 8.394, 8.395*t*
 - in uveitis, 9.79, 9.82
 - glaucoma and, 9.286
- Anterior uvea. *See* Uvea
- Anterior uveitis, 9.72*t*, 9.72–73, 9.74*t*, 9.78–83, 9.80*f*, 9.81*f*, 9.82*t*, 9.112–127. *See also* Iridocyclitis; Iritis; Uveitis; *specific cause*
- acute, 9.78, 9.112–114, 9.113*f*
- in ankylosing spondylitis, 9.113*f*, 9.114–115
- in *Bartonella*-associated neuroretinitis, 9.256
- in Behçet disease, 9.182, 9.185
- in Chikungunya fever, 9.213–214
- in children with juvenile idiopathic (chronic/rheumatoid) arthritis, 9.122–126, 9.123*f*, 9.124*t*
- chronic, 9.78, 9.121–127
- CMV, 8.231–232, 8.232*f*, 9.201
- corticosteroids for, 9.113
 - route of administration of, 2.333*t*
- description of, 6.312
- differential diagnosis of, 6.312*t*
- drug-induced, 9.121
- in Epstein-Barr virus infection, 9.202
- fibrin in, 9.24
- flowchart for evaluation of, 9.74*t*
- Fuchs heterochromic (FHU/Fuchs heterochromic iridocyclitis/uveitis syndrome), 9.126*f*, 9.126–127
- glaucoma and, 10.100–102, 10.102*f*
- in glaucomatocyclitic crisis/Posner-Schlossman syndrome, 9.118
- herpetic disease and, 9.191–193, 9.192*f*
- in HIV infection/AIDS, 9.293
- HLA association and, 9.65–66, 9.67*t*, 9.113, 9.114–117
- in HTLV-1 infection, 9.212–213
- idiopathic, 6.316, 9.127
- incidence/prevalence of, 9.87*t*, 9.112
- in inflammatory bowel disease, 9.116
- juvenile idiopathic (chronic/rheumatoid) arthritis and, 6.312–315, 6.313–314*t*, 6.314*f*, 6.322, 9.122–126, 9.123*f*, 9.124*t*

- juvenile spondyloarthropathies as cause of, 6.315, 6.315*t*
- Kawasaki disease as cause of, 6.316
- keratic precipitates in, 9.82, 9.112–113
- laboratory tests for, 6.321*t*
- after laser trabeculoplasty, 10.190
- lens-associated, 9.118*f*, 9.118–119
- in leptospirosis, 9.249
- in Lyme disease, 9.245
- in nocardiosis, 9.249
- nongranulomatous, 9.112–114, 9.113*f*, 9.115
- noninfectious, 9.112–127
- in onchocerciasis, 9.235
- postoperative
- infectious endophthalmitis, 9.119. *See also* Postoperative endophthalmitis
 - IOL-associated, 9.119–121, 9.120*f*
 - in psoriasis/psoriatic arthritis, 9.116*f*, 9.116–117
 - in reactive arthritis syndrome, 9.115, 9.116*f*
 - in Rift Valley fever, 9.211, 9.212
 - in sarcoidosis, 9.90*f*, 9.167, 9.168
 - scleritis and, 8.323
 - screening for, 6.314–315
 - signs of, 9.79–83, 9.80*f*, 9.81*f*, 9.82*t*
 - in spondyloarthropathies/spondyloarthritis, 1.153, 9.114–117, 9.116*f*
- SUN Working Group classification/grading scheme for, 9.72*t*
- symptoms of, 9.78
- Th1-mediated delayed hypersensitivity and, 9.46*t*
- in toxoplasmosis, 9.222
- traumatic, 6.316, 8.389–390
- in tubulointerstitial nephritis and uveitis syndrome, 6.316, 9.117
- in uveal lymphoid proliferation, 9.276–277
- varicella-zoster infection and, 9.191–193, 9.192*f*
- in Vogt-Koyanagi-Harada syndrome, 9.176, 9.178
- West Nile virus infection and, 9.209
- in Whipple disease, 9.258
- Anterior vitreous, patellar fossa of, 12.7
- Anthracyclines, in cancer chemotherapy, 1.235
- Anti-acetylcholine receptor (AChR) antibodies, in myasthenia gravis, 5.323, 7.217
- testing for, 5.325–326, 7.217
- Anti-basement membrane antibody, in mucous membrane pemphigoid, 8.301–302
- Anti-CCP antibodies, in rheumatoid arthritis, 1.152
- Anti-cyclic citrullinated peptide (anti-CCP) antibodies, in rheumatoid arthritis, 1.152
- Anti-double-stranded DNA (anti-dsDNA) antibodies, in SLE, 1.158, 1.158*t*, 9.133
- Anti-elevation syndrome, 6.168–169
- Anti-GBM (anti-glomerular basement membrane) disease. *See* Anti-glomerular basement membrane (anti-GBM) disease
- Anti-glomerular basement membrane (anti-GBM) disease, 1.165*t*
- Anti-HCV, 1.261
- Anti-Hu (ANNA-1) antibody, paraneoplastic-induced saccadic intrusions and, 5.249
- Anti-idiotypic antibodies, 9.42
- Anti-inflammatory agents, 2.329–341, 2.330*t*, 2.333*t*, 2.335*t*, 2.338*t*. *See also* Corticosteroids; Nonsteroidal anti-inflammatory drugs; *specific agent*
- arachidonic acid release affected by, 2.238*f*, 2.239, 2.331, 2.336
- for asthma, 1.133*t*, 1.134
- in combination preparations with antibiotics, 2.348*t*
- for cystoid macular edema, after cataract surgery, 11.164
- for dry eye/keratoconjunctivitis sicca, 2.221*f*, 2.221–222, 8.61*t*
- for ocular allergies, 6.247*t*
- ocular effects of, 1.307*t*
- for superior limbic keratoconjunctivitis, 8.84
- Anti-La (SS-B) autoantibodies
- in Sjögren syndrome, 1.163, 8.56, 8.58*t*
 - in SLE, 1.159, 9.133
- Anti-MCV (anti-mutated citrullinated vimentin), in rheumatoid arthritis, 1.152
- Anti-muscle-specific kinase (MuSK) antibodies, testing for, in myasthenia gravis, 5.325–326
- Anti-mutated citrullinated vimentin (anti-MCV), in rheumatoid arthritis, 1.152
- Anti-neuronal nuclear antibodies, paraneoplastic-induced saccadic intrusions and, 5.249
- Anti-Parkinson agents, tear production affected by, 8.62*t*
- Anti-RA33 antibodies, in SLE, 1.159
- Anti-Ri (ANNA-2) antibody, paraneoplastic-induced saccadic intrusions and, 5.249
- Anti-RNA polymerase antibodies, in systemic sclerosis, 1.162
- Anti-RNP antibodies, in SLE, 1.159
- Anti-Ro (SS-A) autoantibodies
- in Sjögren syndrome, 1.163, 8.56, 8.58*t*
 - in SLE, 1.159, 9.133
- Anti-Scl-70, in systemic sclerosis, 1.162
- Anti-single-stranded DNA (anti-ssDNA) antibodies, in SLE, 9.133
- Anti-Smith (anti-Sm) antibodies, in SLE, 1.158, 1.158*t*, 9.133
- Anti-SS-A (anti-Ro) autoantibodies
- in Sjögren syndrome, 1.163, 8.56, 8.58*t*
 - in SLE, 1.159, 9.133
- Anti-SS-B (anti-La) autoantibodies
- in Sjögren syndrome, 1.163, 8.56, 8.58*t*
 - in SLE, 1.159, 9.133
- Anti-ssDNA antibodies, in SLE, 9.133
- Anti-TNF- α agents, 1.174
- adverse effects of, 9.102, 9.107, 9.121, 9.130, 9.132, 9.171
 - for ankylosing spondylitis, 9.115
 - for anterior uveitis, 9.113
 - anti-idiotypic antibodies and, 9.42
 - for Behçet disease, 9.188
 - multiple sclerosis and, 9.132
 - optic neuropathy caused by, 5.137
 - for pars planitis, 9.130
 - for rheumatic disorders, 1.151, 1.174
 - for sarcoidosis, 9.171
 - for scleritis, 8.324, 8.325*t*
 - for uveitis, 9.107, 9.113
 - uveitis caused by, 9.121
- Anti-topoisomerase I antibodies, in systemic sclerosis, 1.162
- Anti-Toxoplasma antibodies, 9.224

- Anti-vascular endothelial growth factor agents. *See* Anti-VEGF agents
- Anti-VEGF agents, 3.317
- adverse effects of, 12.113
 - for age-related macular degeneration/choroidal neovascularization, 2.372, 4.164
 - bevacizumab, 12.83–85, 12.84*t*
 - in cancer chemotherapy, 1.235
 - central retinal artery occlusion treated with, 12.146
 - choroidal neovascularization treated with, 12.87–88, 12.212, 12.355
 - clinical trials of, 12.81
 - Coats disease treated with, 12.161
 - complications of, 12.104
 - for corneal transplantation rejection, 8.317
 - diabetic macular edema treated with, 12.101, 12.110–113, 12.112*f*
 - diabetic retinopathy treated with
 - description of, 12.101–102
 - nonproliferative, 12.101–102
 - proliferative, 12.103–104, 12.386
 - follow-up after, 12.134
 - intraocular pressure affected by, 10.110
 - intravitreal administration of, 2.300*t*, 2.372, 12.404
 - low vision and, 12.86
 - for macular edema, 4.152–153, 4.153*f*
 - after cataract surgery, 11.165
 - in diabetes mellitus, 11.189
 - uveitic, 9.289
 - for multifocal choroiditis and panuveitis, 9.157
 - myopic choroidal neovascularization treated with, 12.212
 - neovascular age-related macular degeneration treated with, 12.80–81
 - for neovascular glaucoma, 10.135, 10.135*f*
 - nonproliferative diabetic retinopathy treated with, 12.101–102
 - for ocular histoplasmosis syndrome, 9.217
 - for ocular ischemic syndrome, 9.279
 - for pars planitis, 9.131
 - pathologic myopia treated with, 12.89
 - polypoidal choroidal vasculopathy treated with, 12.76
 - proliferative diabetic retinopathy treated with, 12.103–104
 - for radiation-related adverse effects, 4.276
 - radiation retinopathy treated with, 12.171
 - retinal arterial macroaneurysms treated with, 12.148
 - for retinal hemangioblastoma, 4.285
 - retinal vein occlusion treated with, 12.126
 - retinopathy of prematurity treated with, 6.333, 12.186–187
 - subretinal neovascularization treated with, 12.164
 - for uveitic neovascularization, 9.291, 9.292
 - uveitis caused by, 9.121
- Antiangiogenic agents. *See also* Anti-VEGF agents; *specific agent*
- for cancer chemotherapy, 1.234*t*, 1.235
 - complications of, 12.85
 - for corneal transplantation rejection, 8.317
 - neovascular age-related macular degeneration treated with, 12.79–80
- Antianxiety drugs, 1.194–198, 1.195*t*, 1.196*t*
- ocular effects of, 1.307*t*
 - perioperative, 1.290–291
- Antiarrhythmic drugs/therapy, 1.113*t*
- with implantable cardioverter-defibrillators, 1.115, 1.116
 - tear production affected by, 8.62*t*
 - for ventricular fibrillation, 1.115
- Antibacterial agents, 1.272–280, 1.273*t*, 2.343–354, 2.344*t*, 2.347*t*, 2.348*t*. *See also* Antibiotics; *specific agent*
- resistance to, 1.272–274
- Antibiotic-associated colitis, *Clostridium difficile* causing, 1.244
- Antibiotics, 1.272–282, 1.273*t*, 2.343–354, 2.344*t*, 2.347*t*, 2.348*t*. *See also specific type and agent*
- for *Acanthamoeba* keratitis, 2.361
 - for acute purulent conjunctivitis, 8.258
 - for bacterial keratitis, 8.269–271, 8.270*t*
 - β-lactam, 1.272, 1.275, 2.343–346, 2.344*t*
 - blepharitis treated with, 6.245
 - in cancer chemotherapy (antitumor), 1.233*t*, 1.235
 - for cat-scratch disease/bartonellosis, 9.258
 - in combination preparations, 2.347*t*
 - with anti-inflammatory agents, 2.348*t*
 - congenital nasolacrimal duct obstruction treated with, 6.231–232, 6.234
 - for corneal abrasion, 6.376, 8.398, 8.399
 - for endophthalmitis, after cataract surgery, 11.162–163
 - for gonococcal conjunctivitis, 8.259
 - intravenous administration of, 2.301
 - intravitreal injection of, 2.300*t*
 - after LASIK, 13.93, 13.94
 - for Lyme disease, 9.246–248, 9.247*t*
 - for meibomian gland dysfunction, 8.68
 - new/new classes of, 1.239, 1.273*t*, 1.280
 - ocular effects of, 1.307*t*
 - for penetrating and perforating ocular trauma, 8.402
 - postoperative, 8.409
 - preoperative, 8.403
 - perioperative, 1.287
 - photoablation and, 13.81
 - before photoablation, 13.81–82
 - prophylactic
 - cataract surgery and, 11.93–95, 11.94*f*
 - corneal melting and, 11.132
 - for endocarditis, 1.243, 1.243*t*
 - ocular surgery and, 1.287
 - for endophthalmitis, 11.93–95, 11.94*f*, 11.161–162
 - photoablation and, 13.81
 - for *Pneumocystis jirovecii* pneumonia, 1.267–268
 - pseudomembranous enterocolitis and, 1.1, 1.244
 - for recurrent corneal erosions, 8.87
 - resistance to, 1.272–274, 2.343, 2.346, 2.351, 2.352, 2.353. *See also specific agent and specific organism*
 - new drugs/drug classes and, 1.239, 1.280
 - for scleritis, 9.260
 - for staphylococcal blepharitis/blepharoconjunctivitis, 8.76
 - after surface ablation, 13.92, 13.108
 - for toxoplasmic retinochoroiditis, 12.243
 - for tuberculosis, 9.254–255

- Antibodies, 9.36*f*, 9.37–38, 9.39. *See also*
 Immunoglobulins
 local production of, 9.44
 monoclonal, 9.42. *See also* Monoclonal antibodies
 for uveitis, 9.107
 primary versus secondary immune response and,
 9.40
 structural and functional properties of, 9.41*f*, 9.41–42,
 9.43*t*
- Antibody class switching, 9.38, 9.39, 9.40
- Antibody-dependent cellular cytotoxicity (ADCC),
 9.50
- Antibody isotypes, 9.36*f*, 9.41
- Antibody-mediated immune effector responses, 9.41*f*,
 9.41–44, 9.43*t*
 B-cell tissue infiltration/local antibody production
 and, 9.42–44
 with cellular effector mechanisms, 9.50*f*, 9.50–52
 immunoglobulin structure and function and, 9.41*f*,
 9.41–42, 9.43*t*
 terminology associated with, 9.42
 in viral conjunctivitis, 9.56
- Anticardiolipin antibodies, in antiphospholipid
 antibody syndrome, 1.148, 1.159, 1.160
- Anticentromere antibodies, in systemic sclerosis, 1.162
- Anticholinergic agents, 2.308, 2.308*t*, 2.315, 2.315*t*.
See also Antimuscarinic agents
 Alzheimer disease and, 1.206
 angle closure caused by, 10.122
 for asthma, 1.133*t*, 1.134
 for extrapyramidal side effects of antipsychotics,
 1.193*t*
 mydriasis caused by, 5.263
 for Parkinson disease, 1.199
 ophthalmic considerations and, 1.200
- Anticholinesterase agents. *See* Cholinesterase/
 acetylcholinesterase inhibitors
- Anticipation (genetic), 2.132, 2.144, 2.195
- Anticoagulant therapy, 1.148–149, 12.346. *See also*
specific agent
 for antiphospholipid antibody syndrome, 1.161
 for atrial fibrillation, 1.114
 cataract surgery and, 11.74, 11.157, 11.171–172,
 11.172*t*
 for cerebral ischemia/stroke, 1.119, 1.123
 after coronary stenting, 1.91, 1.100
 in heart failure, 1.111
 in perioperative setting, 1.283, 1.286
 tailoring dosages and, 1.142
- Anticonvulsant drugs, 1.202*t*, 1.202–204
 as mood stabilizers, 1.197
 ophthalmic considerations and, 1.203, 1.307*t*
 in perioperative setting, 1.285
- Anticytokine therapy, 1.174–176
- Antidepressants, 1.195–197, 1.196*t*
 apraclonidine/brimonidine interactions and, 2.319,
 10.179
 ocular effects of, 1.196, 1.307*t*
 tear production and, 8.62*t*
- Antidiabetic agents. *See* Insulin therapy; Oral
 hypoglycemic agents
- Antidiuretic hormone (vasopressin), 1.56
 for medical emergencies, 1.296*t*
- Antiemetics
 oculogyric crisis caused by, 5.231
 perioperative, 1.289*t*, 1.290
- Antiepileptic drugs, 1.202*t*, 1.202–204
 in emergencies, 1.296*t*, 1.303–304
 as mood stabilizers, 1.197
 ophthalmic considerations and, 1.203, 1.307*t*
 in perioperative setting, 1.285
- Antifibrinolytic agents, 2.369–370
 for hyphema, 2.369–370, 8.395
- Antifibrotic agents, 2.340–341. *See also* Fluorouracil/5-
 Fluorouracil; Mitomycin/mitomycin C
 toxic keratoconjunctivitis caused by, 8.91
 in trabeculectomy, 10.205–207, 10.207*f*, 10.208*f*
 bleb-related endophthalmitis and, 10.163, 10.209
 tube shunt implantation after failure of, 10.215
- Antifungal agents, 1.280–281, 2.354–356, 2.355*t*.
See also specific type
 for coccidioidomycosis, 9.272
 for endophthalmitis, 9.263
Aspergillus, 9.269–270
Candida, 9.267–268
- Antigen-antibody complexes. *See* Immune (antigen-
 antibody) complexes
- Antigen-presenting cells (APCs), 9.11, 9.33–36, 9.34*f*,
 9.35*f*
 in conjunctiva, 8.13, 9.54*t*
 in cornea, 2.40, 8.13*f*, 8.13–14, 9.54*t*
 transplant tolerance and, 8.316, 8.317
 dendritic cells as, 9.11–12
 in external eye defense, 8.12–13*f*, 8.13, 8.13*f*, 8.13–14
 HLA-type and, 9.64
 locations of, 9.54*t*
- Antigen receptors
 in adaptive immune response/immune response arc,
 9.33*f*, 9.34, 9.34*f*, 9.35, 9.35*f*, 9.37, 9.38
 B-lymphocyte, 9.38
 in innate immune response, 9.12
 T-lymphocyte, 9.34, 9.34*f*, 9.35, 9.35*f*, 9.37
- Antigen-specific regulatory T (iTreg) cells, in external
 eye defense, 8.12–13*f*
- Antigenic keratan sulfate (AgKS), macular corneal
 dystrophy and, 8.150–151
- Antigenic surface variation, as microbial virulence
 factor, 1.240
- Antigens, 9.31, 9.33*f*
 transplantation, 9.60
- Antiglaucoma agents, 10.170–186, 10.171–174*t*. *See also*
 Glaucoma, management of
 administration of eyedrops and, 10.184–185
 adherence and, 10.186
 in children, 10.165
 adrenergic agonists, 10.172*t*, 10.177–179, 10.178*f*
 α-adrenergic agonists, 2.318*t*, 2.318–319, 10.165,
 10.172*t*, 10.178*f*, 10.178–179
 β-adrenergic agonists, 2.321
 for angle-recession glaucoma, 10.108
 β-blockers, 2.230, 2.318*t*, 2.321–323, 2.322*t*, 10.164–
 165, 10.171–172*t*, 10.176–177
 carbonic anhydrase inhibitors, 2.230, 2.323–326,
 2.324*f*, 2.325*t*, 10.165, 10.172–173*t*, 10.179–181
 cataracts and, 11.52
 in children, 10.153, 10.164–165

- ciliary body as target for, 2.237
- combined preparations, 2.328, 10.174*t*, 10.182
- conjunctiva affected by use of, 10.31
- cornea affected by use of, 10.31
- corneal graft failure and, 8.428
- cycloplegics, 2.313, 2.314*t*
- in elderly patients, 2.326, 10.186
- for elevated episcleral venous pressure, 10.103
- for Fuchs heterochromic iridocyclitis, 10.101–102
- general approach to use of, 10.183–186
- generic agents and, 10.186
- for hemolytic/ghost cell glaucoma, 10.106
- hyperosmotic/osmotic agents, 2.328–329, 2.329*t*, 10.174*t*
- for hyphema, 10.105
- for inflammatory glaucoma, 10.100
- interrelationship between medical and surgical treatment and, 10.111
- for iridocorneal endothelial syndrome, 10.137–138
- latanoprost, 2.237, 2.302, 2.327, 2.327*t*, 10.170–176, 10.171*t*
- for lens particle glaucoma, 10.98
- long-term therapy with, 10.183–184
- for malignant glaucoma (aqueous misdirection/ciliary block glaucoma), 10.140
- miotics, 2.311, 2.318*t*, 10.166, 10.173*t*, 10.181–182
- muscarinic drugs, 2.311
- for neovascular glaucoma, 10.135
- for normal-tension glaucoma, 10.88
- for ocular hypertension, 10.89–90, 10.112
- ocular surface toxicity of, 8.90*t*
- for open-angle glaucoma, 10.113
- parasympathomimetics, 10.173*t*, 10.181–182
- for pediatric glaucoma, 10.153, 10.164–165
- for phacoantigenic glaucoma, 10.98
- for pigmentary glaucoma, 10.96
- for postoperative elevated intraocular pressure, 10.108
- during pregnancy/lactation, 10.185–186
- preservative-free/alternatively preserved, 10.170–175, 10.175*t*
- as prodrugs, 2.302
- prostaglandins/prostaglandin analogues, 2.237–238, 2.318*t*, 2.327*t*, 2.327–328, 10.165–166, 10.170–176, 10.171*t*, 10.175*f*
- receptors in mode of action of, 2.318*t*
- after refractive surgery, 13.201
- for uveitic glaucoma, 9.287
- uveitis caused by, 9.121
- Antihelminthic therapy
 - for cysticercosis, 9.232
 - for diffuse unilateral subacute neuroretinitis, 9.233–234
 - for toxocariasis, 9.230
- Antihistamines, 2.337–338, 2.338*t*. *See also specific agent*
 - for allergic reactions, 1.302
 - for atopic dermatitis, 8.287
 - for ocular allergies, 6.247*t*
 - hay fever conjunctivitis, 8.288, 8.289
 - vernal keratoconjunctivitis, 8.291
 - ocular effects of, 1.307*t*
 - refractive surgery in patient taking, 13.37
 - tear production affected by, 8.62*t*
- Antihypertensive therapy, 1.61, 1.62, 1.67–75, 1.68*t*, 1.69*t*, 1.70*f*
 - agents used in, 1.68*t*, 1.69*t*, 1.70*f*, 1.70–75. *See also specific agent*
 - for children and adolescents, 1.78
 - combination therapy and, 1.61, 1.69*t*, 1.73
 - for hyphema, 8.395
 - initial drug choice/indications and, 1.68–69, 1.69*t*, 1.70*f*
 - new developments and, 1.61, 1.74–75
 - in older patients, 1.77
 - parenteral, 1.74, 1.79
 - in perioperative setting, 1.285
 - during pregnancy, 1.73, 1.74, 1.78
 - racial/ethnic variations and, 1.78–79
 - tear production affected by, 8.62*t*
 - withdrawal from, rebound hypertension and, 1.79, 1.285
- Antimalarial drugs, prophylactic use of, 1.225
- Antimetabolites, 2.340, 9.102–104
 - in cancer chemotherapy, 1.232*t*
 - for pars planitis, 9.130
 - for rheumatic disorders, 1.175
 - for scleritis, 8.324, 8.325*f*
 - for uveitis, 6.322, 9.102–104
- Antimicrobial polypeptides, in neutrophil granules, 9.30
- Antimicrobial prophylaxis
 - for cataract surgery, 11.93–95, 11.94*f*
 - corneal melting and, 11.132
 - infectious uveitis and, 9.282
 - for CMV retinitis, 9.201
 - for endocarditis, 1.243, 1.243*t*
 - ocular surgery and, 1.287
 - for endophthalmitis, 11.93–95, 11.94*f*, 11.161–162
 - for herpetic uveitis, 9.193
 - for malaria, 1.225
 - for photoablation, 13.81–82
 - for *Pneumocystis jirovecii* infections/pneumonia, 1.267–268, 9.102, 9.106
 - for toxoplasmic retinochoroiditis, 9.226–227
- Antimicrobial susceptibility testing, 1.274
- Antimicrobial therapy, 1.272–282, 1.273*t*, 2.343–361. *See also Antibiotics; specific agent*
- Antimicrosomal (thyroid microsomal) antibody (TMAb)
 - testing for, 1.52
 - in thyroid eye disease, 7.53
- Antimuscarinic agents, 2.308*t*, 2.313–314, 2.314*t*
 - adverse effects of, 2.313–314
- Antineoplastic drugs. *See Chemotherapy*
- Antineutrophil cytoplasmic autoantibody (ANCA)
 - in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), 1.168
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 1.165*t*, 1.168, 7.33–34, 7.61–62, 9.138–139. *See also Granulomatosis, with polyangiitis*
 - eyelid manifestations of, 4.207*t*
 - optic neuritis and, 5.115
 - in microscopic polyangiitis, 1.168
 - vasculitis associated with, 1.165*t*, 1.167–168
- Antinuclear antibody (ANA)
 - infliximab treatment and, 9.107

- in juvenile idiopathic (chronic/rheumatoid) arthritis, 1.156, 9.122
- in SLE, 1.156, 1.158, 1.158*t*, 1.159, 9.133, 9.134–135
- in systemic sclerosis, 1.162
- Antioncogenes. *See* Tumor suppressor genes
- Antioxidants
 - age-related macular degeneration and, 4.160, 12.69
 - cataract prevention and, 11.7, 11.20, 11.72
 - in lens, 2.284, 2.284*f*, 2.284–285
 - in retina and retinal pigment epithelium, 2.286–288, 2.289*f*
 - supplemental, 2.285, 2.370
- Antiphospholipid antibodies
 - SLE and, 1.157, 1.158, 9.133
 - retinal disease and, 9.134
 - testing for, 1.160
- Antiphospholipid antibody syndrome (APS), 1.148, 1.159–161
 - choroidal perfusion abnormalities and, 1.161
- Antiplatelet antibodies
 - in idiopathic thrombocytopenic purpura, 1.143
 - in SLE, 1.158, 1.158*t*
- Antiplatelet therapy. *See also* Aspirin
 - for carotid artery disease/stenosis, 1.125–126
 - cataract surgery and, 11.157, 11.171–172, 11.172*t*
 - for cerebral ischemia/stroke, 1.123
 - after coronary stenting, 1.91, 1.100
 - dual (DAT). *See* Dual antiplatelet therapy
 - for ischemic heart disease, 1.99
 - in perioperative setting, 1.286
- Antiproliferative agents, 2.340. *See also* Antimetabolites
- Antipsychotic drugs, 1.193*t*, 1.193–194
 - atypical, 1.193, 1.193*t*
 - intraoperative floppy iris syndrome and, 11.136, 11.137*t*
 - oculogyric crisis caused by, 5.231
 - ophthalmic considerations and, 1.198
 - tardive dyskinesia caused by
 - blepharospasm and, 5.281
 - facial movements and, 5.285
 - tear production affected by, 8.62*t*
 - typical, 1.193, 1.193*t*
- Antireflection coatings, 3.103, 3.104*f*
- Antiretinal antibody testing, in cancer-associated retinopathy, 5.102
- Antiretroviral therapy (ART), 1.266, 2.361
 - CMV retinitis and, 9.200–201
 - immune recovery uveitis and, 1.271, 9.201, 9.294–295
 - drug resistance and, 1.264
 - immune reconstitution syndromes and, 1.271, 9.294–295
 - during pregnancy, 1.265
 - for progressive outer retinal necrosis, 9.296
- Antiself-antibodies. *See* Autoantibodies
- Antisense (noncoding) DNA, 2.132, 2.148*f*, 2.150, 2.151
 - in gene therapy, 2.170
- Antisense oligonucleotides, in gene therapy, 2.169–170, 2.170*f*
- Antispasmodics, tear production affected by, 8.62*t*
- Antithrombin III (AT III), 1.141
 - deficiency of, 1.141, 1.147
- Antithrombin therapy, 1.148–149
 - for non-ST-segment elevation acute coronary syndrome, 1.103
- Antithrombotic agents, for cerebral ischemia/stroke, 1.122, 1.123
- Antithrombotic components, 1.141
- Antithyroid antibodies
 - in Hashimoto thyroiditis, 1.52
 - testing for, 1.52
 - in thyroid eye disease, 7.53
- Antithyroid drugs, for hyperthyroidism, 1.53, 7.58
- α_1 -Antitrypsin, in aqueous humor, 2.234
- Antitumor antibiotics, 1.233*t*, 1.235
- Antiulcer agents, tear production affected by, 8.62*t*
- Antiviral agents, 1.281–282, 2.356–361, 2.357–358*t*
 - acute retinal necrosis treated with, 12.236
 - for Bell palsy, 5.279
 - for herpetic eye disease, 2.356–361, 2.357–358*t*, 8.205, 8.215, 8.215*t*, 8.219, 8.222, 8.223*t*, 8.224, 9.193
 - acute retinal necrosis, 9.196–197
 - CMV retinitis, 9.201
 - epithelial keratitis, 8.219, 8.223*t*
 - epitheliopathy caused by, 8.224
 - graft survival after keratoplasty and, 8.225
 - herpes zoster ophthalmicus, 8.229–230
 - before refractive surgery, 13.174
 - stromal keratitis, 8.222, 8.223*t*, 8.224
 - uveitis, 9.193
 - for HIV infection/AIDS. *See* Antiretroviral therapy
 - for influenza, 1.220
 - interferons, 2.370–371
 - laser skin resurfacing and, 7.238
 - ocular surface toxicity of, 8.90*t*, 8.91
 - progressive outer retinal necrosis syndrome treated with, 12.236
 - resistance to, 2.358, 2.360
 - systemic, 2.357–358*t*, 2.358–361
 - topical, 2.356–358, 2.357–358*t*
- Anton syndrome, 5.158, 5.180–181, 5.337
- Antoni A pattern/Antoni B pattern, in neurilemmomas/schwannomas, 4.238, 4.239*f*, 7.82
- Anwar big-bubble technique, 4.834
- Anxiety disorders, 1.191
 - drugs for management of (anxiolytics), 1.194–198, 1.195*t*, 1.196*t*
 - ocular effects of, 1.307*t*
 - perioperative, 1.290–291
- Anxiolytics. *See* Antianxiety drugs
- Aortic arch, 5.13*f*, 5.19
 - emboli from atheroma of, transient visual loss and, 5.166
- Aortic arch (Takayasu) arteritis, 1.165*t*, 1.166
 - cataract caused by, 11.68
- Aortic coarctation, hypertension in, 1.64, 1.64*t*
- Aortitis syndrome (Takayasu arteritis), 1.165*t*, 1.166
 - cataract caused by, 11.68
- AOX. *See* Adult-onset xanthogranuloma
- AP-ROP. *See* Aggressive posterior retinopathy of prematurity
- APC. *See* Activated protein C
- APC gene, 12.286
- APCs. *See* Anterior polar cataracts; Antigen-presenting cells

- Apert syndrome (acrocephalosyndactyly), 6.206–207, 6.207*f*, 6.209*f*, 7.37, 7.38*f*, 8.191*t*
- Apertures
 diffraction created by, 3.105, 3.105*f*
 pinhole
 double, 3.285, 3.286*f*
 monocular diplopia and, 3.130
- Apex, corneal, 8.25, 8.26*f*
- Aphakia
 congenital, 4.117, 6.305, 11.30
 description of, 3.93, 3.119
 epikeratoplasty (epikeratophakia) for, 13.62
 glaucoma and. *See* Aphakic glaucoma
 homoplastic corneal inlays for, 13.60
 after ICCE, 11.201
 infantile, 3.225
 IOLs for, 11.118–122. *See also* Intraocular lenses
 monocular, 3.191
 post-cataract surgery management of, 6.304
 as refractive hyperopia, 3.137
 retinal detachment risks, 12.319
 unilateral, 3.140, 3.207
- Aphakic (pseudophakic) bullous keratopathy, after cataract surgery, 4.83–84, 4.84*f*, 11.129, 11.129*f*
 IOL design and, 11.149
- Aphakic glaucoma, 6.285, 10.130–132
 in children, 10.156–157
 tube shunt implantation for, 10.215
- Aphakic spectacles
 description of, 3.191*f*, 3.191–192
 image magnification caused by, 3.255
- Aphthous ulcers, oral, in Behçet disease, 9.184, 9.184*f*
- Apical alignment fit, of rigid gas-permeable contact lenses, 3.218–219, 3.219*f*
- Apical bearing, of rigid gas-permeable contact lenses, 3.218
- Apical clearance, of rigid gas-permeable contact lenses, 3.218
- Apical zone of cornea, 3.205, 3.215, 3.228, 8.25
- Apixaban, 1.148
 for heart failure, 1.111
 in perioperative setting, 1.286
- Aplastic anemia
 carbonic anhydrase inhibitors causing, 3.236, 10.180
 chloramphenicol causing, 1.279–280, 2.351
- APMPPE. *See* Acute posterior multifocal placoid pigment epitheliopathy
- Apnea
 local anesthetic administration causing, 1.291
 sleep. *See* Sleep apnea/sleep deprivation
- Apocrine glands, of eyelid, 2.19, 2.22*f*, 2.23*t*, 4.201, 4.202, 7.170, 8.4. *See also* Glands of Moll
 cyst arising in, 4.208, 4.208*f*
 tumors originating in, 7.171, 7.171*f*
- Apocrine hidrocystoma, 4.208, 4.208*f*, 7.171, 7.171*f*
- Apodization, 3.239, 3.260
- Apodized diffractive multifocal lenses, 13.166, 13.166*f*
- Apolipoprotein, 1.82
- Apolipoprotein D, in aqueous humor, 2.231, 2.233
- Apolipoprotein E, in Alzheimer disease, 1.205
- Apomorphine, for Parkinson disease, 1.199
- Aponeurosis, levator. *See* Levator aponeurosis
- Aponeurotic ptosis, 5.273, 5.273*t*, 7.214, 7.214*f*, 7.214*t*
- Apoplexy, pituitary (Sheehan syndrome), 1.58, 5.149, 5.150*f*
- Apoptosis, 2.132, 2.155
 by cytotoxic T lymphocytes, 9.48–49, 9.49*f*
 in DNA repair, 2.154, 2.155
 Fas ligand (CD95 ligand/FasL) in, 9.48–49, 9.49*f*, 9.58
 in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
 retinal ganglion cell, 6.44
- Apparent diffusion coefficient (ADC) technique/
 mapping, 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.75
 in cerebral ischemia/stroke, 1.122
- Applanation head/plate, of microkeratome, 13.85*f*, 13.85–86
- Applanation tonometry/tonometer, 3.282, 3.293–294, 3.294*f*, 10.22–25, 10.23*f*, 10.24*f*, 10.27
 corneal thickness affecting, 10.25, 10.81, 10.82, 10.86, 13.105, 13.181
 infection control and, 10.27
 in normal-tension glaucoma, 10.86
 portable electronic, 10.25
 after refractive surgery, 13.105, 13.181, 13.200–201
 LASIK, 13.105, 13.200–201
 surface ablation, 13.105, 13.200–201
 sources of error and, 10.23–24, 10.24*t*
- Applanation ultrasonography, 3.245, 3.245*f*
 for axial length measurement, in IOL power determination/selection, 11.83
- Appositional suprachoroidal hemorrhage, 12.394–395
- Appropriate Examination and Treatment Procedures, 1.283
- Approximations. *See specific type*
- Apraclonidine, 2.308*t*, 2.318*t*, 2.318–319, 2.319, 6.275, 6.289*t*, 6.290, 10.172*t*, 10.178–179
 anisocoria/Horner syndrome diagnosis and, 5.256*f*, 5.259, 5.259*f*
 in children, 10.165
- Apraxia
 of eyelid opening, 5.273*t*, 5.274
 ocular motor, 5.221, 5.222–223
 acquired, 5.223
 congenital, 5.223
 parietal lobe lesions and, 5.156, 5.223
- APS. *See* Antiphospholipid antibody syndrome
- aPTT. *See* Activated partial thromboplastin time
- AQP4-IgG (aquaporin-4 immunoglobulin G) antibody, in neuromyelitis optica spectrum disorder, 5.115, 5.117*t*, 5.118, 5.320, 5.322
- AquaLase liquefaction device, 11.125
- Aquaporin-4 immunoglobulin G (AQP4-IgG) antibody. *See* AQP4-IgG (aquaporin-4 immunoglobulin G) antibody
- Aquaporins (major intrinsic protein/MIP/water channels), 2.242, 2.245, 11.16, 11.20–21
- Aqueous cellular reaction, in uveitis, 9.79
- Aqueous drainage devices/shunts. *See* Tube shunts
- Aqueous flare, in uveitis, 9.79, 9.81*f*, 9.82, 9.82*t*, 9.113
- Aqueous humor, 2.46, 2.229–236
 biochemistry and metabolism of, 2.229–236
 carbohydrates in, 2.232
 carbon dioxide in, 2.236
 for CMV testing, 8.232

- composition of, 2.230–236, 2.231*t*
 dynamics of, 2.229–230, 2.323–324, 2.324*f*, 10.5*f*, 10.13–19
 formation of. *See* Aqueous humor, production/
 composition of
 functions of, 2.229
 glutathione in, 2.232–233
 growth modulatory factors in, 2.229, 2.234–235
 immunologic microenvironments and, 9.56–57
 immunosuppressive microenvironment of, corneal
 graft tolerance and, 8.316
 inorganic ions in, 2.232
 intraocular pressure and, 2.230, 10.5, 10.5*f*, 10.13, 10.14*f*
 organic anions in, 2.232
 outflow of, 10.5*f*, 10.17–19, 10.18*f*
 facility of, 10.19
 classification of glaucomas and, 10.3–5, 10.4*t*, 10.6*t*
 intraocular pressure and, 10.5, 10.5*f*, 10.13, 10.14*f*
 tonography in measurement of, 10.19
 laser trabeculoplasty affecting, 10.188
 prostaglandin analogues affecting, 10.165–166, 10.170
 trabecular, 10.5*f*, 10.13, 10.17–18, 10.18*f*
 uveoscleral, 10.5*f*, 10.13, 10.19
 oxygen in, 2.235–236
 production/composition of, 2.323–324, 2.324*f*, 10.5*f*, 10.13–17, 10.14–15*f*
 measurement of formation and, 10.17
 suppression of formation and, 2.318*t*, 10.16–17
 α_2 -agonists in, 10.17, 10.165
 β -blockers in, 10.16–17, 10.164, 10.176
 carbonic anhydrase inhibitors in, 2.230, 2.323–324, 10.16, 10.165, 10.179
 proteins in, 2.229, 2.233–234
 refractive index of, 3.127*t*, 8.26
 separation of, from blood. *See* Blood–aqueous barrier
 sodium transport and, 2.230–231, 2.323, 2.324*f*
 urea in, 2.233
 vascular endothelial growth factor (VEGF) in, 2.234, 2.235
- Aqueous layer (component), of tear film, 2.38, 2.213*f*, 2.215–217, 7.252
 deficiency of. *See* Aqueous tear deficiency
 secretion of, 2.216–217
 tests of, 8.38–39, 8.55–56
- Aqueous misdirection. *See* Malignant glaucoma
- Aqueous/anterior chamber paracentesis
 in acute retinal necrosis, 9.196
 in coccidioidomycosis, 9.271
 in cysticercosis, 9.231
 in endogenous endophthalmitis, 9.264
 in uveitis, 9.91–92
- Aqueous shunt implantation. *See* Tube shunts
- Aqueous tear deficiency (ATD), 2.220, 2.221*f*, 2.221–222, 8.45, 8.53, 8.54*f*, 8.55*f*, 8.55–58. *See also* Dry eye
 blepharitis and, 8.76
 clinical presentation of, 8.55*f*, 8.55–58
 non-Sjögren syndrome, 8.55*f*
 refractive surgery and, 13.173
 Sjögren syndrome, 8.39, 8.55*f*, 8.56–58, 8.58*t*
 superior limbic keratoconjunctivitis and, 8.84
 tests of, 8.38–39, 8.55–56
 treatment of
 medical, 8.61*t*, 8.61–64, 8.62*t*
 surgical, 8.64–65, 8.65*f*
- Aqueous veins, 2.51, 2.52*f*
- Arachidonic acid (AA/arachidonate)
 in eicosanoid synthesis, 2.237, 2.238, 2.238*f*, 9.24
 NSAID derivation and, 2.334–335
 NSAIDs affecting, 2.239
 release of, 2.237, 2.238, 2.238*f*
 anti-inflammatory drugs affecting, 2.238*f*, 2.239, 2.331, 2.336
 in retinal pigment epithelium, 2.274
- Arachnids, ocular injury caused by, 8.386–387
- Arachnodactyly, 6.307, 6.308*f*
 in Marfan syndrome, 11.40, 11.40*f*
- Arachnoid mater, optic nerve, 2.87–89, 2.88*f*, 2.89*f*, 4.241, 4.242*f*, 5.17*f*, 5.26
- Arachnoid villi, 5.22
- ARB. *See* Autosomal recessive bestrophinopathy
- ARBs. *See* Angiotensin II receptor blockers
- ARC. *See* AIDS-related complex; Anomalous retinal
 correspondence
- Arc of contact, 6.32
- Arc scanning, 8.35*t*
- ARC-T (Astigmatism Reduction Clinical Trial), 13.57
- Arcade retinal arteries, inferior/superior, 5.14
- Arcade retinal veins, 5.21
- Arcuate fibers, 5.103, 5.104*f*
 visual field defects and, 5.103, 5.106*f*
 glaucoma and, 10.42, 10.68, 10.68*f*
- Arcuate incisions, for keratorefractive surgery, 13.27, 13.27*f*, 13.53, 13.54–55
 coupling and, 13.27, 13.27*f*, 13.54, 13.54*f*, 13.55
- Arcuate keratotomy (AK), 13.8*t*, 13.53, 13.54–58
 complications of, 13.58
 instrumentation for, 13.55
 ocular surgery after, 13.58
 outcomes of, 13.57
 refractive lens exchange and, 13.149
 surgical technique for, 13.55–57
- Arcuate (Bjerrum) scotoma, 5.103, 5.105*t*, 5.106*f*
 in glaucoma, 10.68, 10.68*f*
- Arcus (corneal), 1.89, 8.120–121, 8.121*f*, 8.179
 in cornea plana, 8.100
 in dyslipoproteinemia/hyperlipoproteinemia, 8.120, 8.121, 8.179
 in hyperlipoproteinemia, 1.89
 juvenilis, 8.121
 in lecithin–cholesterol acyltransferase (LCAT)
 deficiency, 8.180, 8.180*f*
 lipoides, in Schnyder corneal dystrophy, 8.151, 8.152*f*
 senile furrow degeneration and, 8.122
 senilis, 8.120–121, 8.121*f*
- Arcus marginalis, 7.11
- Arden index/ratio, 12.50
- Area centralis, 2.75, 12.9, 12.9*f*. *See also* Macula/macula
 lutea
- Area of Martegiani, 12.7, 12.8*f*, 12.307
- Area postrema syndrome, 5.117*t*
- AREDS (Age-Related Eye Disease Study), 2.285, 2.370, 11.7, 11.63, 12.64, 12.69–71, 12.70*t*

- ArF laser. *See* Argon-fluoride (ArF) excimer laser
- Argon-fluoride (ArF) excimer laser, 13.29, 13.73–77, 13.74–75*f*. *See also* Excimer laser; Lasers
- for photoablation, 13.29, 13.73–77, 13.74–75*f*. *See also* Photoablation
- Argon laser therapy. *See also* Laser therapy;
- Photocoagulation
- for diabetic retinopathy/macular edema, 4.160, 4.161*f*
- for gonioplasty/iridoplasty, 10.194
- in plateau iris, 10.127*f*, 10.128, 10.193–194
- for iridotomy, 10.192, 10.193
- for iris bombé in uveitis, 9.286
- for trabeculoplasty (ALT), 10.88, 10.113–115, 10.188, 10.189, 10.190*f*
- for trichiasis, 7.208
- Argus II Retinal Prosthesis System, 12.264
- Argyll Robertson–like pupil, 5.267
- Argyll Robertson pupil, 5.267
- in syphilis, 9.240
- Argyria/argyriasis/argyrosis, 12.306
- ocular, 8.118*t*, 8.132
- silver causing, 4.120
- Argyrosis, ocular, 12.306
- Arlt line, 8.261, 8.261*f*
- Arlt triangle, keratic precipitates in viral infection
- in, 9.192
- ARMS2 gene, 12.63
- in age-related macular degeneration, 4.160
- ARN. *See* Acute retinal necrosis
- Arnold-Chiari malformation, nystagmus caused by, 5.244, 5.245*f*, 5.246
- ARPE. *See* Acute retinal pigment epitheliitis
- Arrestin, 2.260*f*, 2.261, 12.253
- in experimental autoimmune uveoretinitis, 9.63
- mutation in, 2.161, 2.263
- Arrhythmias, 1.112–118. *See also specific type*
- drugs for management of, 1.113*t*
- in emergency, 1.296*t*
- heart failure and, 1.111
- myocardial infarction and, 1.94, 1.96, 1.115
- sudden cardiac death and, 1.95, 1.113, 1.115
- ARRP. *See* Autosomal recessive pigmentosa
- ARS. *See* Axenfeld-Rieger syndrome
- ART. *See* Antiretroviral therapy
- Arterial circles, 2.34*f*, 2.35, 2.45*f*, 2.52*f*, 2.54*f*, 2.55, 2.55*f*, 5.15
- ciliary body, 2.58
- Arterial macroaneurysms, retinal, 12.147–148, 12.148*f*
- Arterial occlusive disease
- carotid artery. *See* Carotid occlusive disease
- retinal artery. *See also* Retinal artery occlusion
- branch retinal artery occlusion, 4.156
- central retinal artery occlusion, 4.156, 4.157*f*
- Arterial retrobulbar hemorrhage. *See also* Retrobulbar hemorrhage
- cataract surgery and, 11.158
- Arteries, 5.11–20, 5.13–14*f*, 5.15*f*, 5.16*f*, 5.17*f*, 5.18*f*, 5.20*f*. *See also specific artery*
- dissections in, 5.342–343
- Arteriography. *See* Angiography/arteriography
- Arteriohepatic dysplasia (Alagille syndrome), 6.255, 8.97*t*, 8.102, 12.282*t*, 12.285
- Arteriolitis
- in acute retinal necrosis, 9.194, 9.194*f*
- Kyrieleis, 9.222
- Arteriosclerotic retinopathy, 12.122
- Arteriovenous anastomoses, retinal, in Takayasu arteritis, 1.166
- Arteriovenous fistulas, 7.72*f*, 7.72–74, 7.73*f*
- glaucoma associated with, 10.30
- orbital, 7.72*f*, 7.72–74, 7.73*f*
- Arteriovenous malformations (AVMs), 5.343–345, 5.344*f*, 7.72
- cerebral ischemia caused by, 1.120
- congenital retinal, 4.286*f*, 4.286–287
- headache caused by, 5.291, 5.292*f*, 5.343
- intracranial hemorrhage caused by, 1.126, 1.127, 5.343
- neuro-ophthalmic signs of, 5.343–345, 5.344*f*
- neuroimaging in evaluation of, 5.292*f*
- occipital, 5.343
- binocular transient visual loss and, 5.172
- orbital, 6.222, 7.71
- in Wyburn-Mason syndrome, 5.333*f*, 5.334*t*
- Arteritic ischemic optic neuropathy
- anterior (AAION), 5.107*t*, 5.120, 5.120*t*, 5.120–122, 5.121*f*, 5.313
- posterior (PION), 5.107*t*, 5.119, 5.124
- Arteritis
- cerebral ischemia/stroke and, 1.120
- giant cell (GCA/temporal), 1.165*t*, 1.166, 5.89, 5.89*f*, 5.313–315, 7.61. *See also* Giant cell arteritis
- AAION and, 5.120, 5.313
- corticosteroid route of administration in, 2.333*t*
- diplopia in, 5.192, 5.313
- facial pain associated with, 5.288, 5.297
- headache in, 5.288, 5.313
- neuro-ophthalmic signs of, 5.313–315
- occult, 5.120, 5.170
- optic nerve affected in, 4.244*f*, 4.244–245, 5.120
- transient visual loss and, 5.120, 5.161, 5.162, 5.169–170, 5.313–314
- Takayasu (aortic arch arteritis/aortitis syndrome/pulseless disease), 1.165*t*, 1.166
- cataract caused by, 11.68
- Artery of Percheron, 5.20, 5.229–230
- Arthritis
- in ankylosing spondylitis, 1.153
- in Behçet disease, 1.169, 9.185
- cataract surgery in patient with, 11.171
- enteropathic, 1.155, 6.315*t*
- enthesitis-related, 6.315*t*
- in inflammatory bowel disease, 1.155
- juvenile idiopathic, 6.312–315, 6.313–314*t*, 6.314*f*, 6.322
- Lyme, 1.251, 9.244, 9.244*f*, 9.245
- mutilans, 1.155
- psoriatic, 1.155, 9.116*f*, 9.116–117
- reactive/Reiter syndrome, 1.154–155, 6.315*t*, 8.305–306, 9.115, 9.116*f*
- conjunctivitis/episcleritis associated with, 8.305–306
- HLA association in, 1.154, 9.65, 9.67*t*, 9.115
- rheumatoid (RA), 1.151–152
- cataract surgery in patient with, corneal melting/keratolysis and, 11.132

- juvenile. *See* Juvenile idiopathic (chronic/rheumatoid) arthritis
- peripheral ulcerative keratitis and, 8.311, 8.312, 8.312*f*
- refractive surgery contraindicated in, 13.191
- scleritis/scleromalacia perforans and, 8.321–322, 8.322*f*
- in SLE, 1.157, 9.133
- in Whipple disease, 9.258
- Arthro-ophthalmopathy (Stickler syndrome), 12.282*t*
- vitreous collapse in, 2.255
- Arthropods, 8.253, 8.254*f*
- Arthus reaction, chronic, 9.44
- Artifacts
- on automated perimetry, 10.66*f*, 10.66–67, 10.67*f*
- in optical coherence tomography angiography, 12.29, 12.30*f*
- projection, 12.29, 12.30*f*
- Artificial insemination, genetic counseling and, 2.206
- Artificial tears, 2.220, 2.221, 2.341, 2.342. *See also* Lubricants
- for corneal exposure in facial palsy, 5.280
- for dry eye, 2.220, 2.221, 2.341, 2.342, 8.61*t*, 8.62–63
- refractive surgery and, 13.173
- for exposure keratopathy, 8.80
- for hay fever conjunctivitis, 8.288
- for paralytic ectropion, 7.224–225
- for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.298
- for Thygeson superficial punctate keratitis, 8.307
- ARV (AIDS-related virus). *See* HIV infection/AIDS
- Arylsulfatase A, defective/deficiency of, in metachromatic leukodystrophy, 2.175*t*
- AS. *See* Ankylosing spondylitis
- ASA (advanced surface ablation). *See* Photorefractive keratectomy
- Ascending optic atrophy, 4.245–246
- Ascorbate. *See* Ascorbic acid
- Ascorbic acid (vitamin C)
- antioxidant effect of, 2.285, 2.288
- in lens, 2.283, 2.285
- in retina and retinal pigment epithelium, 2.288
- in aqueous humor, 2.231*t*, 2.232
- for chemical injuries, 8.383
- corneal wound healing and, 13.33
- deficiency of (scurvy), 1.142–143
- oral supplements and, 2.285
- in phototherapeutic keratectomy, 8.367
- in tear film, 2.214
- in vitreous, 2.231*t*, 12.9
- ASCRS (American Society of Cataract and Refractive Surgery), on IOL power calculation, 11.85
- online post-refractive calculator, 13.52, 13.195–197, 13.196*f*
- ASDA (anterior segment developmental anomalies). *See* Anterior segment, dysgenesis of
- Aseptic meningitis, in HIV infection/AIDS, 5.348
- Aseptic thrombosis
- cavernous sinus, 5.345
- lateral (transverse) sinus, 5.69*f*, 5.345
- Ash-leaf spot (hypopigmented macule), in tuberous sclerosis, 5.331*f*, 5.334*t*, 10.30
- ASI. *See* Anterior segment, ischemia of
- Asian eyelid, 2.19, 2.21*f*, 7.147, 7.147*f*
- epicanthus tarsalis and, 7.158, 7.159
- Asparaginase, 1.234*t*
- Aspergilloma (fungus ball), 5.353
- in endophthalmitis, 9.269*f*
- Aspergillus* (aspergillosis), 5.353–354, 5.354*f*, 7.50–51, 8.208*t*, 8.249*t*, 8.251
- allergic, 5.353, 7.51
- endophthalmitis caused by, 12.239
- endogenous, 9.265, 9.268–270, 9.269*f*
- postoperative, 9.262
- flavus*, 9.262, 9.268
- fumigatus*, 9.268, 9.269*f*
- invasive, 5.353, 5.354
- keratitis caused by, 4.78, 8.208*t*, 8.275
- neuro-ophthalmic signs of, 5.353–354, 5.354*f*
- ocular infection caused by, 8.208*t*
- orbital infection caused by, 4.227–228, 4.228*f*, 5.353, 5.354*f*, 7.50–51
- retinal infection caused by, 4.147
- sinus infection and, 5.353, 7.50–51
- Asphericity, corneal, 13.14
- Aspiration. *See also* Irrigation/aspiration
- in ECCE, 11.197
- in manual small-incision cataract surgery, 11.198, 11.199*f*
- in phacoemulsification, 11.102, 11.115
- pumps for, 11.103*f*, 11.103–104, 11.104*f*
- Aspiration biopsy. *See* Fine-needle aspiration biopsy
- Aspirin, 1.172, 2.335*t*, 2.335–336. *See also* Dual antiplatelet therapy
- for antiphospholipid antibody syndrome, 1.161
- for carotid occlusive disease, 1.124
- for carotid stenosis, 1.125–126
- for cerebral ischemia/stroke, 1.119, 1.123
- diabetic retinopathy and, 12.100
- for ischemic heart disease, 1.99, 1.100*t*
- ocular effects of, 1.307*t*
- perioperative discontinuation of, 1.286, 2.335
- platelet function affected by, 1.144, 1.172, 2.335, 2.336
- prostaglandin synthesis affected by, 2.239, 2.335
- Reye syndrome and, 2.335–336
- Aspirin-dipyridamole
- for carotid artery disease, 1.125–126
- for cerebral ischemia/stroke, 1.123
- for transient monocular visual loss, 1.168
- ASPPC. *See* Acute syphilitic posterior placoid chorioretinitis
- Assassination (cell), by cytotoxic T lymphocytes, 9.48, 9.49*f*
- Association (genetic), 6.183
- allelic. *See* Linkage disequilibrium
- Assortative mating, 2.132
- Asteroid bodies, 4.133, 4.133*f*
- in sarcoidosis, 4.187
- Asteroid hyalosis, 4.133, 4.133*f*, 12.346*f*, 12.346–347
- Asthenopia, 6.101
- Asthenoptic complaints
- definition of, 3.24
- development of, 3.196
- types of, 3.24

- Asthma, 1.130, 1.132
 adult-onset, with periocular xanthogranuloma (AAPOX), 7.90, 7.91
 drug treatment for, 1.133*t*, 1.133–134
 ocular effects of, 1.307*t*
 recent developments in, 1.129
 in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), 1.168
- Astigmatic dial technique, 3.148, 3.160–162, 3.161*f*, 3.166
- Astigmatic keratotomy (AK)/incision, 13.8*t*
 cataract surgery and, 11.123
 coupling and, 13.54, 13.54*f*, 13.55
 wound healing/repair and, 13.32
- Astigmatic refractive errors. *See* Astigmatism
- Astigmatism, 13.17–19
 against-the-rule, 3.123, 3.139, 3.250, 8.31, 8.32*t*, 8.33*f*
 autorefractor detection of, 3.273
 in cataract patient, 11.174
 corneal topography before surgery and, 11.84, 11.174
 modification during surgery and, 11.123–124
 toric IOLs for, 11.124, 13.151–153
 after cataract surgery, 11.131–132
 keratorefractive/refractive surgery and, 11.176, 11.177*f*, 13.53, 13.54–58
 manual small-incision surgery and, 11.198
 compound hyperopic, 3.138, 3.138*f*
 compound myopic, 3.138, 3.138*f*
 contact lenses for, 3.211–212
 corneal
 contact lens masking of, 3.225
 description of, 3.19
 spherical rigid contact lenses for, 3.211
 toric intraocular lenses for, 3.257
 in corneal ectasia, 8.32*t*
 corneal topography in detection/management of, 8.15, 8.31, 8.32, 8.32*t*, 13.17–19, 13.18*f*, 13.19*f*, 13.22–23, 13.44, 13.45, 13.45*f*
 after penetrating keratoplasty, 8.32, 8.431–432, 8.432*f*, 13.179–180
 correction of. *See also* Astigmatism, surgical
 correction of
 with contact lenses, 13.17
 after refractive surgery, 13.199
 contact lenses for, 3.211–212, 3.222–223, 3.223*t*
 minus cylinder lens for, 3.19, 3.20*f*
 quantities required for, 3.20
 toric soft contact lenses for, 3.222–223, 3.223*t*
 definition of, 3.3, 3.16, 3.39, 3.72, 3.123, 3.137
 description of, 3.15–19
 focal lines in, 3.137
 induced, cataract surgery and, 11.131–132
 irregular, 13.17–19, 13.18*f*, 13.19*f*. *See also* Wavefront aberrations
 after arcuate keratotomy, 13.58
 causes of, 3.277–278, 3.278*f*
 corneal topography in detection/management of, 8.15, 8.31, 8.32, 13.17–19, 13.18*f*, 13.19*f*, 13.22–23, 13.44, 13.45, 13.45*f*
 definition of, 3.124, 3.267
 description of, 3.130, 3.139
 epithelial basement membrane dystrophy and, 3.277, 3.278*f*
 keratorefractive/refractive surgery and, 13.18–19, 13.22–23, 13.44, 13.45
 cataract surgery outcome and, 11.176, 11.177*f*
 keratorefractive surgery and, 3.272–278, 3.274–276*f*
 after limbal relaxing incisions, 13.58
 after penetrating keratoplasty, 8.426
 quantification of, 3.273
 retinoscopy in detection/evaluation of, 8.163
 wavefront analysis of, 3.273–277, 3.274–276*f*.
 See also Wavefront analysis
 in keratoconus, 8.32*t*, 8.163, 8.164–165, 8.166
 keratometry in evaluation of, 8.27
 lenticular
 description of, 3.19
 refractive surgery and, 13.45, 13.149
 as “residual” astigmatism, 3.211
 in megalocornea, 8.100
 mixed, 3.138, 3.138*f*
 limbal relaxing incisions for, 13.57
 wavefront-optimized laser ablation for, 13.97
 after multifocal IOL implantation, 13.155
 oblique, 3.139, 3.147
 in pediatric glaucoma, 10.166
 after penetrating keratoplasty, 8.426, 13.178–180
 corneal keratoscopy in, 8.27
 management of, 8.431–432, 8.432*f*
 corneal topography in, 8.32, 8.431–432, 8.432*f*
 IOLs for, 8.432, 13.179
 refractive surgery in, 13.178–180
 suture removal/adjustment and, 8.419*f*, 8.431–432, 8.432*f*
 refractive surgery for, 13.178–180
 toric IOLs for, 8.432, 13.179
 phoropter detection of, 3.29
 pictorial representation of, 3.138*f*
 postoperative. *See specific procedure*
 principal axes of, 3.138–139
 pterygium and, 8.113
 after radial keratotomy, 13.51, 13.51*f*, 13.51–52
 refractive, 3.211
 after refractive lens exchange, 13.149
 regular, 3.124, 3.139, 3.276
 corneal topography in detection/management of, 13.17, 13.18*f*
 wavefront aberrations produced by, 13.11, 13.11*f*
 retinoscopy in detection/evaluation of, 8.163
 schematic diagram of, 3.72*f*
 simple hyperopic, 3.138, 3.138*f*
 simple myopic, 3.138, 3.138*f*
 surgical correction of. *See also specific procedure*
 arcuate keratotomy for, 13.8*t*, 13.53, 13.54–58
 bioptics for, 13.137, 13.157
 cataract surgery and, 11.123–124
 incisional corneal surgery for, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*, 13.57*f*
 light-adjustable IOLs for, 13.153–154, 13.154*f*
 limbal relaxing incisions for, 11.123–124, 13.8*t*, 13.53–54, 13.54*f*, 13.54–58, 13.55*f*, 13.56*f*, 13.56*t*, 13.57*f*
 nonlaser, 13.8*t*
 phakic IOLs for, 13.137, 13.140
 photoablation for, 13.75*f*

- preoperative patient preparation and, 13.82
 refractive lens exchange for, 13.148–149
 small-incision lenticule extraction for, 13.204
 thermokeratoplasty for, 13.127
 toric IOLs for, 11.124, 13.137, 13.148–149, 13.151–153
 after penetrating keratoplasty, 8.432, 13.179
 transverse keratotomy for, 13.53, 13.54, 13.54f
 wavefront-optimized/wavefront-guided laser ablation for, 13.31, 13.76–77
 results of, 13.31–32, 13.97
 tonometry accuracy and, 10.24
 after toric IOL implantation, 13.153
 toric lenses for, intraocular, 3.257, 11.124, 13.137, 13.148–149, 13.151–153
 after penetrating keratoplasty, 8.432, 13.179
 types of, 3.277
 wavefront analysis and, 13.11, 13.11f. *See also* Wavefront analysis
 with-the-rule, 8.31f
 definition of, 3.19, 3.125
 description of, 3.139
 minus cylinder lens correction of, 3.20f
 schematic diagram of, 3.19f
- Astigmatism Reduction Clinical Trial (ARC-T), 13.57
- Astrocytes
 optic nerve, 2.86, 2.87, 2.88f, 4.241, 4.242f
 retinal, 2.73, 2.268, 5.24
 in healing/repair, 4.17
- Astrocytoma (astrocytic hamartoma), 4.249, 4.249f, 5.108f, 6.353, 6.397, 6.399f
 juvenile pilocytic, 4.249
 optic. *See* Optic nerve (optic pathway/chiasm)
 gliomas
 pilocytic. *See* Optic nerve (optic pathway/chiasm)
 gliomas
 retinal, 4.295, 4.296f
 optic nerve/nerve head/disc drusen differentiated from, 5.108f, 5.143
 retinoblastoma differentiated from, 4.295, 4.296f
 in tuberous sclerosis, 4.295, 5.143, 5.331f, 5.334t
- Asymptomatic retinal breaks, 12.318
- AT. *See* Ataxia-telangiectasia
- AT III. *See* Antithrombin III
- Ataxia
 diplopia and, 5.191
 intermittent, 2.175t
 with neuropathy (neurogenic muscle weakness) and retinitis pigmentosa (NARP), 2.158–159
 mitochondrial DNA mutations and, 2.157, 2.158–159
 optic, 5.223
- Ataxia-telangiectasia (AT/Louis-Bar syndrome), 5.330, 5.332f, 5.334t, 6.393t, 6.403f, 6.403t, 6.403–404, 8.115t, 8.346
 ATM (ataxia-telangiectasia mutated) gene in, 2.154
- Ataxia-telangiectasia mutated (ATM) gene, 2.154
- Atazanavir, 1.266
- ATD. *See* Aqueous tear deficiency
- Atenolol, 1.68t, 1.69t, 2.317f
- Athens protocol, 13.134
- Atheroma
 cerebral ischemia and, 1.120
 intracranial bleeding risk and, 1.126
 transient visual loss and, 5.165–166, 5.167f
- Atherosclerosis, 1.82, 1.208–209
 carotid, 1.124–126
 cerebral ischemia and, 1.120
 coronary artery (coronary heart disease), 1.91–105.
 See also Ischemic heart disease
 assessment/screening/modification and, 1.82–83, 1.83t, 1.209
 diabetes mellitus and, 1.49, 1.83t
 heart failure and, 1.105, 1.108, 1.111
 hypercholesterolemia and, 1.81–89, 1.91–92, 1.92
 hypertension management and, 1.69t
 ophthalmic considerations and, 1.116–117
 prevention and, 1.81, 1.91
 risk factors for, 1.81–89, 1.91–92, 1.92
 hypercholesterolemia management and, 1.81
 hypertension and, 1.62
 ophthalmic considerations in hypercholesterolemia and, 1.88–89
 screening for, 1.208–209
 transient visual loss and, 5.165–166, 5.167f
- Atkinson nerve block, for cataract surgery, 11.92, 11.93f
- ATM (ataxia-telangiectasia mutated) gene, 2.154
- ATOH7 gene, 12.341
- Atopic dermatitis, 8.287
 atopic keratoconjunctivitis and, 8.292
 cataracts associated with, 11.66
 eyelid involvement and, 8.287
 vernal keratoconjunctivitis and, 8.289
- Atopic keratoconjunctivitis (AKC), 6.249, 8.292–294, 8.293f, 9.51
- Atopy. *See under* Atopic
- Atorvastatin, for hypercholesterolemia/heart disease prevention, 1.86t
- Atovaquone
 for *Pneumocystis jirovecii* pneumonia, 1.267–268
 for toxoplasmosis, 9.226, 9.297
- ATP-binding cassette (ABC) transporters/transporter protein, 2.261
 mutation in, 2.263
 in Stargardt disease, 2.263, 4.168–169
- ATP production
 in lens, 2.246
 in rod outer segments, 2.261
- ATP (Adult Treatment Panel) reports, 1.81–82, 1.84, 1.84t
- ATPase-6 gene, in neuropathy with ataxia and retinitis pigmentosa, 2.158–159
- ATP7B gene, 6.270
 in Wilson disease, 8.189
- Atracurium, 1.290
- Atrial complexes, premature (PACs), 1.112, 1.113
- Atrial fibrillation (AF), 1.114
 cerebral ischemia/stroke and, 1.120, 1.122
 heart failure and, 1.111, 1.114
- Atrial flutter, 1.114
- Atrial natriuretic peptide, in aqueous humor, 2.231
- Atrioventricular (AV) junction, 1.112
- Atrioventricular junctional tachycardia, 1.114
- Atrophy bulbi
 with shrinkage, 4.22
 without shrinkage, 4.22

- Atrophic retinal holes
 definition of, 12.315
 lattice degeneration and, 4.150, 12.310, 12.311*f*, 12.316*f*
 retinal detachment secondary to, 12.310
- Atrophy
 chorioretinal
 genes and loci associated with, 12.256*t*
 in pathologic myopia, 12.214*f*
 choroid, age-related, 12.200, 12.212
 geographic
 in Best vitelliform dystrophy, 12.271
 description of, 12.64, 12.66, 12.67*f*, 12.68
 in drusenoid retinal pigment epithelium detachment, 12.272
 gyrate, 12.268–269, 12.269*f*
 iris. *See* Iris, atrophy of
 macula, 12.265, 12.265*f*
 optic. *See* Optic atrophy
 retinal
 gyrate, 2.175*t*
 ischemic, 4.151, 4.151*f*, 4.156, 4.159
 of retinal pigment epithelium, 12.106*f*, 12.294*f*
 geographic/nongeographic, 4.164, 4.164*f*
 gyrate, 2.175*t*, 2.279
 ornithine aminotransferase defects causing, 2.175*t*, 2.265
- Atrophy creep, 12.89
- Atropine, 2.308*t*, 2.313, 2.314, 2.314*t*, 2.315*t*
 accommodation affected by, 11.23
 adverse effects of, 2.313
 amblyopia treated with, 6.59
 for asthma, 1.134
 in children, 6.11, 6.11*t*
 for cholinergic stimulation in toxic overdose, 1.305
 in Down syndrome, pharmacogenetics and, 2.201
 for edrophonium/neostigmine adverse effects, 2.315, 5.324, 5.325
 eyedrops, for refractive error prevention, 3.144
 for medical emergencies, 1.296*t*
 mydriasis caused by, 5.263
 systemic absorption of, 2.296
 for uveitis, 9.94
- Attachment, as microbial virulence factor, 1.240
- Atypia, cellular
 conjunctival melanocytic intraepithelial neoplasia and, 4.66–68, 4.67*f*
 primary acquired melanosis and, 4.65, 4.66, 4.67*f*, 8.342–343
- Atypical antipsychotic agents, 1.193, 1.193*t*
- Atypical granular corneal dystrophy. *See* Reis-Bücklers corneal dystrophy
- Atypical lymphoid hyperplasia (ALH), of orbit, 4.231, 4.232
- Atypical mole. *See also* Nevus/nevus, dysplastic melanoma arising from, 1.215
- Atypical mycobacteria, 1.254, 8.248, 8.272–273, 8.273*f*
 in HIV infection/AIDS, 1.254, 1.269
 keratitis caused by, after photoablation, 13.106, 13.119
 neuro-ophthalmic signs of infection with, 5.350
- Aubagio. *See* Teriflunomide
- Audio books, 3.323
- Auditory artery, internal, 5.20
- Auditory nerve. *See* Cranial nerve VIII
- Augmentin (oral amoxicillin and clavulanic acid), 1.276
- Aura
 without migraine headache (acephalgic migraine), 5.172, 5.177, 5.291
 migraine headache with, 5.171–172, 5.177, 5.290–291
 migraine headache without, 5.290
 seizures and, 1.201, 5.172, 5.177
- Auricular chondritis, in relapsing polychondritis, 1.164
- Auricular nerves, 7.144*f*, 7.145*f*
- Auriculotemporal nerve, 7.145*f*
- Auscultation, in orbital disorders, 7.26
- Autism, MMR vaccine and, 1.221
- Auto-oxidation, 2.282–283
 in lens, 2.283
 vitamin E affecting, 2.283
- Autoantibodies. *See also specific type*
 in antiphospholipid antibody syndrome, 1.160
 in autoimmune hemolytic anemia, 1.139–140
 in Cogan syndrome, 8.310
 in diabetes mellitus, 1.35–36
 in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), 1.168
 in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168, 7.33–34, 7.61–62, 9.138–139
 immunization and, 1.217
 in juvenile idiopathic (chronic/rheumatoid) arthritis, 1.156, 9.122
 in microscopic polyangiitis, 1.168
 in mucous membrane pemphigoid, 8.301–302
 in rheumatoid arthritis, 1.152
 in Sjögren syndrome, 1.163, 8.56, 8.58*t*
 in SLE, 1.156, 1.158–159, 9.133
 retinal vasculitis and, 9.134
 in systemic sclerosis, 1.162
 in thyroid eye disease, 7.53, 7.55
- Autocrine action, of cytokines, 9.26
- Autofluorescence (AF), 3.302–303. *See also*
 Hyperfluorescence
 central serous chorioretinopathy findings, 12.192*f*
 enhanced depth imaging optical coherence tomography and, 12.39
 fluorescein angiography, 12.35
- fundus (FAF), 5.89–90, 5.90*f*. *See also* Fundus autofluorescence
 in acute posterior multifocal placoid pigment epitheliopathy, 9.142*t*
 in acute zonal occult outer retinopathy, 5.90, 9.142*t*, 9.165, 9.165*f*
 in birdshot uveitis, 9.142*t*, 9.145, 9.146*f*
 in choroidal/ciliary body melanoma, 4.265, 4.266*f*
 in cone dystrophies, 5.102
 drusen demonstrating, 5.89, 5.90*f*, 5.141*f*, 5.142
 in inflammatory chorioretinopathies, 9.142*t*
 in low vision evaluation, 5.89–90, 5.90*f*
 in multifocal choroiditis and panuveitis syndrome, 9.142*t*, 9.156, 9.157*f*
 in multiple evanescent white dot syndrome, 9.142*t*, 9.162
 in punctate inner choroiditis, 9.142*t*
 in serpiginous choroiditis, 9.142*t*, 9.152–153, 9.153*f*

- in uveitis, 9.90
 - in Vogt-Koyanagi-Harada syndrome, 9.180
- retinitis pigmentosa findings, 12.261
- serpiginous choroidopathy findings, 12.223f
- Autogenous fascia lata. *See* Autologous/autogenous fascia lata
- Autografts/autologous transplantation
 - conjunctival, 8.351t, 8.353t, 8.353–355, 8.354f, 8.356
 - for chemical injuries, 8.384
 - indications for, 8.351t, 8.353
 - for limbal stem cell deficiency, 8.94
 - in pterygium surgery, 8.353t, 8.353–355, 8.354f
 - recurrence rate and, 8.353t
 - after tumor removal surgery, 8.329
 - conjunctival-limbal, in pterygium surgery, recurrence rate and, 8.353t
 - corneal, 8.411, 8.451–452. *See also* Corneal grafts; Keratoplasty
 - limbal, 8.351t, 8.362–365, 8.363–364f. *See also* Limbal transplantation
 - indications for, 8.351t
- Autoimmune diseases. *See also specific type*
 - Cogan syndrome as, 8.309, 8.310
 - conjunctivitis caused by, cicatricial conjunctivitis differentiated from, 8.301t
 - experimental uveoretinitis (EAU), 9.63
 - Graves hyperthyroidism as, 1.53
 - Mooren ulcer as, 8.314
 - mucous membrane pemphigoid as, 8.299, 8.301–302
 - multifocal choroiditis and panuveitis as, 9.156
 - peripheral ulcerative keratitis as, 8.51f, 8.311t, 8.311–313, 8.312f
 - refractive surgery in patient with, 13.191
 - retinopathy in, 5.103
 - scleritis in, 8.319, 8.323
 - SLE as, 9.133
 - type 1 diabetes mellitus and, 1.35–36
 - Vogt-Koyanagi-Harada syndrome as, 9.175, 9.176
- Autoimmune hemolytic anemia, 1.139–140
- Autoimmune regulator (AIRE) deficiency, uveitis in mice and, 9.64
- Autoimmune retinopathy, 5.103, 12.286
- Autoimmune uveitis. *See* Noninfectious ocular inflammatory diseases, uveitis/autoimmune uveitis
- Autologous/autogenous fascia lata, for frontalis suspension, 7.221
- Autologous serum drops
 - for dry eye, 2.342, 8.61t, 8.63
 - for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81, 8.224
 - for superior limbic keratoconjunctivitis, 8.84
- Autologous transplantation. *See* Autografts/autologous transplantation
- Automated external defibrillator (AED), 1.295, 1.298
- Automated optical biometers, 3.244
- Automated perimetry. *See also* Perimetry
 - short-wavelength (SWAP), 10.75
 - standard (SAP/achromatic), 10.59
 - static, 5.84, 5.85f, 5.85–88, 5.87f, 10.59, 10.60–62
 - artifacts seen on, 10.66f, 10.66–67, 10.67f
 - in glaucoma, 10.59, 10.60–62
 - high false-positive rate in, 10.67, 10.67f
 - incorrect corrective lens used in, 10.66
 - learning effect and, 10.71
 - in nonorganic disorder evaluation, 5.306–307, 5.307f, 5.308f
 - screening tests and, 10.62
 - threshold tests and, 10.61f, 10.61–62, 10.63f
- Automatic lensmeter, 3.285
- Automatisms, 1.201
- Autonomic cephalgias, trigeminal (TACs), 5.293–294
- Horner syndrome and, 5.260t, 5.261
- Autonomic dysfunction, in diabetes mellitus, 1.49
- Autonomic pathways, 5.52–56
 - cholinergic drug action and, 2.307, 2.307f
 - parasympathetic, 5.52, 5.54–56, 5.55f
 - sympathetic, 5.52–54, 5.53f
 - in tear secretion, 8.5, 8.5f
- Autorefractors. *See also* Retinoscope/retinoscopy
 - astigmatism detection using, 3.273
 - definition of, 3.147, 3.281
 - description of, 3.285–286
 - difficulties associated with, 3.286
 - function of, 3.285
 - initial estimate of refractive error obtained using, 3.28
 - ray-deflection, 3.289
- Autoregulation, vascular, disturbances of, in glaucoma, 10.85
- Autosomal dominant inheritance, 2.177–178, 2.178t
 - gene therapy for diseases related to, 2.169–170, 2.170f
 - of pigmentary retinopathies, retinitis pigmentosa, 2.177. *See also* Autosomal dominant retinitis pigmentosa
- Autosomal dominant optic atrophy (ADOA), 5.135, 5.136f
- Autosomal dominant retinitis pigmentosa (ADRP), 2.177
 - peripherin/RDS gene mutations causing, 2.161, 2.264
 - rhodopsin mutations causing, 2.161, 2.263
- Autosomal dominant vitreoretinopathies (ADVRC), 6.341
- Autosomal recessive bestrophinopathy (ARB)
 - description of, 12.271
 - electro-oculography of, 12.51
- Autosomal recessive inheritance
 - description of, 2.174–177, 2.175t, 2.177t
 - of pigmentary retinopathies, retinitis pigmentosa. *See* Autosomal recessive retinitis pigmentosa
- Autosomal recessive retinitis pigmentosa (ARRP)
 - retinal pigment epithelium defects in, 2.278
 - rhodopsin mutations causing, 2.263
 - rod cGMP-gated channel mutations causing, 2.161, 2.263
 - rod cGMP phosphodiesterase mutations causing, 2.161, 2.263
- Autosomes, 2.132, 2.184, 2.189f
 - aneuploidy of, 2.189–190. *See also specific disorder*
- Auxiliary lenses, for slit-lamp biomicroscope, 3.295–296, 3.296t
- AV junction. *See* Atrioventricular junction
- Avellino (granular type 2) corneal dystrophy, 4.90, 4.91f, 4.91t, 8.135t, 8.136t, 8.145t, 8.148–149, 8.149f
 - amyloid deposits in, 8.148, 8.186t
 - refractive surgery and, 13.43
- Average effect, 1.22
- AVMs. *See* Arteriovenous malformations

- Avonex. *See* Beta (β)-interferon
- Avulavirus, 8.240*t*
- Awareness of vision, disorders of, 5.178*t*, 5.180–181
- Axenfeld anomaly/syndrome, 4.100*f*, 8.102, 10.153.
See also Axenfeld-Rieger syndrome
- Axenfeld loop/Axenfeld nerve loop, 2.44, 4.108, 4.108*f*
- Axenfeld-Rieger syndrome (A-R syndrome /ARS), 4.98–99, 4.100*f*, 8.97*t*, 8.102, 8.103*f*, 10.31, 10.150, 10.153–154
 description of, 6.255, 6.255*f*, 6.264–265, 265*f*, 6.268*f*
 glaucoma associated with, 4.99, 6.285, 10.31, 10.153–154
 posterior embryotoxon in, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.102, 10.31, 10.153
- Axes
 optic/optical, 11.9, 11.10*f*
 visual, Nd:YAG laser capsulotomy location and, 11.155
- Axial ametropia, 3.137
- Axial curvature, 13.16, 13.16*f*, 13.17*f*
- Axial curvature/axial curvature map, 8.28, 8.29*f*
See also Cornea, topography of
- Axial displacement, of globe, in orbital disorders, 7.24
- “Axial distance,” 13.16
- Axial length (AL), 11.84–85
 age-related changes in, 3.141
 angle closure and, 10.121
 in biometric formula for intraocular lens power calculation, 3.244–248
 in children, 3.254
 definition of, 3.244
 extremes in, cataract surgery in patient with, 11.184–185
 in IOL power determination, 11.82–83, 11.83*f*, 11.85
 hypotony and, 11.185
 optical measurement of, 11.82, 11.85
 refractive surgery and, 13.193
 staphylomas affecting, 13.150
 ultrasound measurement of, 11.82–83, 11.83*f*, 11.85, 11.87
 unexpected refractive results after surgery and, 11.150, 11.176
 optical measurement of, 3.247, 3.247*f*
 in primary congenital glaucoma, 6.283, 10.160
 ultrasonic measurement of, 3.244–246, 3.245–246*f*
- Axial (longitudinal) magnification, 3.39, 3.63–64.
See also Magnification
- Axial power, 13.16, 13.16*f*
- Axial refractive errors, correction of, 3.12–13
- Axial resolution, of contact B-scan ultrasonography, 12.39
- Axonal transport system, of optic nerve, 5.26
- drusen and, 5.140
- AZA. *See* Azathioprine
- Azalides, 1.278
- Azathioprine (AZA), 1.175, 9.102–103
 for Behçet disease, 1.169, 9.188, 12.230
 for uveitis, 6.322, 9.102–103
- Azelaic acid, for rosacea, 8.71
- Azelastine, 2.337–338, 2.338*t*, 2.339
- Azithromycin, 1.278, 2.347*t*, 2.353
 for cat-scratch disease/bartonellosis, 9.258
 for chlamydial conjunctivitis, 8.263
 for endocarditis prophylaxis, 1.243*t*
 for meibomian gland dysfunction, 6.88–69
 for rosacea, 8.71
 for toxoplasmosis, 9.226, 9.297
 for trachoma, 8.262
- Azlocillin, 1.275, 2.345
- AZOOR (acute zonal occult outer retinopathy), 5.101, 9.141–143*t*, 9.164–166, 9.165*f*. *See also* Acute zonal occult outer retinopathy
 fundus autofluorescence in identification of, 5.90
 OCT in identification of, 5.92
- AZOOR (acute zonal occult outer retinopathy) complex, 9.166. *See also* White dot syndromes; *specific disorder*
- Aztreonam, 1.275–276
- ## B
- B&B stain (Brown and Brenn stain), 4.31*t*
- B&H stain (Brown and Hopps stain), 4.31*t*
- B-cell lymphomas. *See also* Lymphomas
 conjunctival/ocular surface, 4.70, 4.71*f*, 8.348, 8.349–350, 8.350*f*
 in HIV infection/AIDS, 1.270, 5.349
 orbital, 4.232, 4.233*f*, 7.86
 primary central nervous system/intraocular, 1.237, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 9.273–276, 9.274*f*, 9.275*f*. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
- B cells (B lymphocytes), 4.9, 9.12
 activation/priming of, 9.36, 9.36*f*, 9.37–38, 9.38
 in HIV infection/AIDS, 1.263
 in humoral immune system, 1.240
 in immune processing, 9.36, 9.36*f*, 9.37–38
 monoclonal proliferation of, crystalline corneal deposits and, 8.198, 8.198*f*
 primary versus secondary immune response and, 9.40
 receptors on, 9.38
 tissue infiltration by, in antibody-mediated immune response, 9.42–44
 in tuberculosis, 9.31
- B-lymphocyte antigen receptors, 9.38
- B-scan optical coherence tomography
 definition of, 12.26
 retinal pigment epithelium subretinal fluid on, 12.77*f*
 volume rendering versus, 12.27
- B-scan ultrasonography/echography. *See also* Ultrasonography/ultrasound (echography)
 anterior segment (ultrasound biomicroscopy/UBM), 2.47, 2.47*f*, 4.265, 8.20–21, 8.21*f*
 in choroidal melanoma/ciliary body melanoma, 4.265
 before corneal transplantation, 8.418
 in glaucoma, 10.77, 10.124*f*
 pediatric glaucoma and, 10.160
 uveitic glaucoma and, 9.285
 in pars planitis, 9.129
 before cataract surgery, 11.81
 in choroidal hemangioma, 4.281
 in choroidal melanoma/ciliary body melanoma, 4.265–267, 4.266*f*
 in cysticercosis, 9.231
 intraocular foreign body evaluations using, 12.352

- in metastatic eye disease, 4.307, 4.307f
- in optic nerve/nerve head/disc drusen, 5.95, 5.141f, 5.142
 - versus papilledema, 5.141f, 5.142
- orbital, 7.31
- in sympathetic ophthalmia, 9.174
- in toxocariasis, 9.229
- B-type natriuretic peptide (BNP)
 - in aqueous humor, 2.231
 - in heart failure, 1.105, 1.109
- b-waves, 12.5, 12.42–44, 12.43f, 12.47f, 12.50, 12.261
 - of ERG, 5.96. *See also* Electroretinography/electroretinogram
- BA. *See* Basilar artery
- Babesia*/babesiosis, Lyme disease coinfection and, 1.250, 9.248
- BAC (bacterial artificial chromosome), 2.145
- Bacampicillin, 2.345
- Bacille Calmette-Guérin (BCG) vaccination. *See* BCG vaccination
- Bacilli (bacteria), 8.243
- Bacillus*, 8.244t, 8.247
 - endogenous bacterial endophthalmitis caused by, 9.264
 - as normal flora, 8.206t
 - ocular infection caused by, 8.247, 9.16
 - after ocular trauma, 8.247, 8.403
 - traumatic endophthalmitis caused by, 8.247, 8.403
- Bacillus cereus*
 - description of, 8.247, 9.16
 - endophthalmitis caused by, 12.363
- Bacitracin, 2.344t, 2.347t, 2.353
 - in combination preparations, 2.347t, 2.348t, 2.353
- Background diabetic retinopathy. *See* Diabetic retinopathy, nonproliferative
- Background luminance, perimetry results affected by, 10.60
- Baclofen, for nystagmus, 5.245, 5.246
- Bacteria, 8.208t, 8.243–249, 8.244t. *See also specific bacteria or type of infection*
 - classification of, 8.243–244, 8.244t
 - conjunctivitis caused by, 4.52, 8.208t, 8.255–265
 - in children, 8.243, 8.255–256
 - classification of, 8.257t
 - in neonates, 8.257t, 8.263–265
 - corneal infection caused by, 4.75–76, 4.76f, 8.208t, 8.267–273, 8.268f, 8.269t, 8.270t, 8.273f
 - corneal opacity and, 8.16f
 - endophthalmitis caused by
 - endogenous, 9.263–265, 9.264f
 - lens affected in, 4.119, 4.119f
 - postoperative, 9.261–262, 9.262f
 - toxin production/severity and, 9.15
 - vitreous affected in, 4.127, 4.128f
 - eyelid margin and conjunctival infection caused by, 8.255–256
 - innate immunity triggered by, 9.13–16, 9.14t
 - keratitis caused by, 4.75–76, 4.76f, 8.208t, 8.267–273, 8.268f, 8.269t, 8.270t, 8.273f. *See also* Keratitis, bacterial
 - contact lens wear and, 8.266–267, 8.268, 8.269, 8.269t
 - in HIV infection/AIDS, 9.300
 - as normal flora, 8.205, 8.206t
 - ocular infection caused by, 8.208t, 8.243–249, 8.244t.
 - See also specific type or structure involved*
 - invasion and, 8.207
 - specimen collection/isolation techniques for
 - diagnosis of, 8.209t, 8.211
 - optic nerve infection caused by, 4.243–244
 - orbital infection caused by, 4.226
 - cellulitis, 7.44
 - necrotizing fasciitis, 7.48–49
 - scleral infection/scleritis caused by, 4.75–76, 4.76f, 8.282–283, 8.283f, 9.259–260
 - treatment of infection caused by. *See* Antibiotics
 - uveitis caused by, 9.236–259
- Bacterial artificial chromosome (BAC), 2.145
- Bacterial cell wall, 8.243–244
 - innate immune response and, 9.14, 9.14t
- Bacterial conjunctivitis, 6.240f, 6.240–241
- Bacterial endophthalmitis, endogenous, 12.237–239, 12.238f
- Bacterial orbital cellulitis, 6.213, 6.214f
- Bacteriology, 8.208t, 8.243–249, 8.244t. *See also* Bacteria
- Bacteriophage, λ , as vector, 2.145
- Bacteriophage endolysins, 1.280
- Baerveldt glaucoma implant (BGI), 10.214, 10.214t, 10.215
- Bagolini striated lenses
 - description of, 6.51–52
 - sensory adaptation testing using, 6.77f, 6.77–78
- Bailey-Lovie eyecharts, 3.133, 6.8
- BAK. *See* Benzalkonium
- BAL (British antilewisite), for Wilson disease, 2.203
- “Balance lens,” 3.198
- Balanced general anesthesia, 1.290–291
- “Balanced” orbital decompression, 7.122, 7.123f
- Balanced salt solution (BSS)
 - intracameral administration of, 2.300t
 - in phacoemulsification, 11.110, 11.118
 - in surface ablation, 13.92
 - in trabeculectomy, 10.201
 - vancomycin in, 2.352
- Balanitis, circinate, in reactive arthritis syndrome, 9.115
- Balint syndrome, 5.180, 5.223
 - in Alzheimer disease, 1.206
- Balloon angioplasty. *See* Percutaneous coronary intervention
- Balloon catheter dilation (BCD/balloon dacryoplasty)
 - for acquired nasolacrimal duct obstruction, 7.278
 - for canalicular obstruction, 7.275
 - for congenital nasolacrimal duct obstruction, 7.263–265
- Balloon cells
 - in choroidal/ciliary body melanoma, 4.192, 4.193f
 - in choroidal/ciliary body nevus, 4.191
- Balloon dacryoplasty, 6.234–235, 6.235f. *See also* Balloon catheter dilation
- Baltimore Eye Survey, 1.16f, 1.16–17, 1.17f, 10.81, 10.82, 10.83
- Bamboo spine, in ankylosing spondylitis, 1.153
- Band atrophy
 - in optic tract syndrome, 5.153
 - in pituitary adenoma, 5.92f

- Band keratopathy/calcific band keratopathy, 4.81–83, 4.82*f*, 6.322, 8.111, 8.117–120, 8.119*f*, 8.201
 “actinic,” 4.83
 in aqueous tear deficiency, 8.56
 EDTA for, 2.306, 9.281
 gelatinous droplike corneal dystrophy and, 8.141, 8.141*f*
 in gout, 8.119, 8.188
 in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.123*f*, 9.125
 parathyroid disorders and, 8.201
 in pars planitis, 9.129
 in sarcoidosis, 9.168–169
 in uveitis, 9.79, 9.281
- Band-shaped and whorled microcystic dystrophy of the corneal epithelium. *See* Lisch epithelial corneal dystrophy
- Bandage contact lenses, 3.227–228, 8.368
 for chemical injuries, 8.383
 contraindications to, in exposure keratopathy, 8.80
 for corneal abrasion, 8.398
 for dry eye, 8.61*t*, 8.63, 8.368
 for graft-vs-host disease, 8.304, 8.305*f*
 for involutional entropion, 7.203
 after LASIK, 13.93, 13.111, 13.200
 for epithelial ingrowth, 13.122
 for epithelial sloughing/defects, 13.112
 microkeratome complications and, 13.111
 for striae, 13.113
 for penetrating and perforating ocular trauma, 8.402
 for peripheral ulcerative keratitis, 8.313
 for recurrent corneal erosions, 8.87, 8.368
 for superior limbic keratoconjunctivitis, 8.84
 after surface ablation, 13.92, 13.107, 13.200
 sterile infiltrates and, 13.108, 13.108*f*
 for Thygeson superficial punctate keratitis, 8.307
- Banked fascia lata, for frontalis suspension, 7.221
- BAP1, in immunohistochemistry, 4.35
- BAP1 gene, in choroidal/ciliary body melanoma, 4.197, 4.262, 4.278
- Barbados Eye Study, 10.83, 11.6
- Barbiturates, 1.195*t*. *See also* Sedative-hypnotics/sedation
- Bardet-Biedl syndrome, 6.391, 6.391*f*
 clinical features of, 12.282*t*
 genes and loci associated with, 12.256*t*
 pleiotropism in, 2.196
 renal abnormalities associated with, 12.285
 retinal degeneration associated with, 12.281, 12.284, 12.284*f*
- Bare-metal stents (BMS), 1.91, 1.100
- Bare sclera, wound closure after pterygium excision and, 8.351, 8.353*t*, 8.353–355, 8.354*f*
 recurrence rate and, 8.353*t*
- Bariatric surgery
 in idiopathic intracranial hypertension, 5.112
 for obesity in diabetes mellitus, 1.40–41
- Barium enema, in cancer screening, 1.210*t*, 1.214
- Barkan membrane, 10.159
- Baroreceptors, phenylephrine affecting, 2.318
- Barr body, 2.132, 2.197. *See also* Lyonization
- Barrett esophagus, 1.213
- Barrett formula, for IOL power determination/selection, 11.85
- Barrier devices, for CPR, 1.298, 1.299
- Bartonella* (bartonellosis)
 cat-scratch disease caused by, 5.119, 8.248, 8.265–266, 9.255–258, 9.257*f*, 9.257*t*
henselae (*Rochalimaea henselae*), 5.119, 6.240–241, 6.369, 8.244*t*, 8.248, 8.265, 8.266, 9.255, 9.256, 12.243*f*
 neuroretinitis and, 5.115, 5.119, 9.256, 9.257*t*
 ocular infection caused by, 8.248, 8.265–266, 9.255–258, 9.257*f*, 9.257*t*
quintana, 5.119, 9.256
- Basal cell carcinoma (BCC), of eyelid, 4.212*f*, 4.212–213, 4.213*f*, 7.177–182, 7.178*f*, 7.179*f*
 intraocular extension of, 4.310
- Basal cell nevus syndrome (Gorlin syndrome), 7.178
 eyelid manifestations of, 4.210*t*, 7.178
- Basal ganglia, 5.30, 5.34
 in blepharospasm, 5.281
 in Parkinson disease, 1.198–199
- Basal lamina (basal cell layer)
 ciliary body, 2.57, 2.58*f*
 corneal, 2.39–40, 2.40*f*, 2.41, 2.42*f*, 2.223*f*. *See also*
 Descemet membrane/layer
 development of, 2.120–122, 2.121*f*
 drusen of (cuticular drusen), 4.162
 lens. *See* Lens capsule
 retinal blood vessel, 2.73
 retinal pigment epithelium, 2.68
- Basal laminar deposits, in age-related macular degeneration, 4.160, 4.162, 4.165, 4.165*f*
- Basal linear deposits, in age-related macular degeneration, 4.160, 4.162
- Basal (basic) secretors/basal (basic) tear secretion test, 2.217, 7.268, 8.38
- Base curve, of contact lens, 3.205, 3.215*f*, 3.216
- Base-down prism, 3.188
 in relative cycloptropia evaluation, 5.185
- Base-in prism, 3.211
 in fusional convergence evaluation, 5.226
- Base-out prisms, 3.46, 3.211
 convergence insufficiency and, 6.103
 convergence paralysis and, 6.106
 dissociated vertical deviation and, 6.129
 in fusional convergence evaluation, 5.226
 in nonorganic disorder evaluation, 5.302–303
 for nystagmus, 5.236, 5.245
 nystagmus treated with, 6.155
- Base pair (bp), 2.132
 mutation in, 2.155, 2.156
 conserved, 2.156
- Base-up prism, 3.46, 3.188
- Basedow disease. *See* Thyroid eye disease
- Baseline probability of the outcome, 1.21–22
- Basement membrane, corneal, 2.41, 2.120–121, 2.223*f*, 2.227, 4.73, 4.74*f*, 8.9. *See also* Descemet membrane/layer
- Basement membrane dystrophy, epithelial (EBMD/ map-dot-fingerprint/Cogan microcystic/anterior basement membrane), 4.87, 4.87*f*, 8.135*t*, 8.135–138, 8.136*t*, 8.137*f*, 8.138*f*
 cataract surgery in patient with, 11.174*f*, 11.174–175

- recurrent corneal erosion and, 8.86, 8.87, 8.133, 8.138
- reduced vision and, 5.99
- refractive surgery and, 13.42, 13.42*f*, 13.76, 13.78, 13.178
 - multifocal IOLs, 13.155
- Basement membrane zone (BMZ), in mucous membrane pemphigoid, 8.301*f*, 8.301–302
- Basic acquired nonaccommodative esotropia, 6.93
- Basic fibroblast growth factor (bFGF). *See also* Fibroblast growth factor
 - in aqueous humor, 2.234
- Basic intermittent exotropia, 6.101
- Basic life support (BLS), 1.295, 1.299
- Basic secretion test, 8.38
- Basic secretors/basic secretion test. *See* Basal (basic) secretors/basal (basic) tear secretion test
- Basilar artery (BA), 2.105–107, 2.107*f*, 5.12, 5.13*f*, 5.19, 5.19*f*, 5.20, 5.27*f*
 - aneurysm of, 5.338, 5.339*f*
 - cranial nerve relationship and, 2.84*f*, 5.42*f*
 - dissection of, 5.342
 - median perforators of, 5.20
 - stenosis of, 5.337*f*
 - transient visual loss caused by ischemia of, 5.162, 5.336–337
- Basilar laminar deposits
 - age-related changes in, 12.61
 - definition of, 12.64
 - illustration of, 12.62*f*
- Basilar linear deposits
 - definition of, 12.64
 - illustration of, 12.62*f*
- Basilar plexus, 5.23*f*
- Basilar-type migraine, 5.291. *See also* Migraine headache
- Basilar vein of Rosenthal, 5.22
- Basophils, 4.7, 4.8*f*, 9.10
- Bassen-Kornzweig syndrome, microsomal triglyceride transfer protein (MTP) defects causing, 2.265
- Bathopsis, 6.43
- Batson venous plexus, 2.102
- Batten, Spielmeier-Vogt disease, 6.389*t*
- Batten disease, 12.283*t*, 12.290*f*
- Battle sign, 5.280
- Bausch + Lomb keratometer, 3.287
- BAX expression, in adenoid cystic carcinoma, 4.231
- BAX gene, in DNA repair, 2.154
- Bayes theorem, 1.18
- Baylisascaris procyonis* (raccoon roundworm), 12.246
 - diffuse unilateral subacute neuroretinitis caused by, 9.232
- BCC. *See* Basal cell carcinoma
- BCD. *See* Balloon catheter dilation
- BCG treatment, for bladder cancer, purified protein derivative (tuberculin) test affected by, 9.254
- BCG vaccination
 - purified protein derivative (tuberculin) test affected by, 1.254, 9.254
 - uveitis associated with, 9.121
- Bcl-2 proteins
 - in adenoid cystic carcinoma, 4.231
 - apoptosis and, 2.154
- BCVA/BCSVA. *See* Best-corrected visual/Snellen visual acuity
- BD. *See* Behçet disease
- BDUMP. *See* Bilateral diffuse uveal melanocytic proliferation
- Beaded filaments, 2.245, 11.16
- Bear tracks (grouped pigmentation of retina), 4.269, 4.269*f*, 6.349
- BEAT-ROP. *See* Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity
- BEAT-ROP Cooperative Group study, 12.186–187
- Beaver Dam Eye Study, 1.12, 10.82, 10.83, 11.6
- BEB. *See* Benign essential blepharospasm
- Bee stings, ocular injury caused by, 8.386–387
- Behavioral/psychiatric disorders, 1.187–198. *See also specific type*
 - aging and, 1.182–183
 - cataract surgery in patient with, 11.169–170
 - hallucinations/illusions in, 5.174*t*
 - mental disorders due to general medical condition, 1.188
 - mood (affective) disorders, 1.189–190
 - nonadherence to therapy and, 1.188, 1.190
 - ophthalmic considerations and, 1.198
 - pharmacologic treatment of, 1.193*t*, 1.193–198, 1.195*t*, 1.196*t*
 - ophthalmic considerations and, 1.198
 - recent developments and, 1.187
 - recent developments in, 1.187
 - schizophrenia, 1.188–189
 - somatoform disorders, 1.190–191
 - substance abuse disorders, 1.192–193
 - visual symptoms and. *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
- Behçet disease (BD), 1.165*t*, 1.169–170, 4.187, 9.182–188, 9.183*f*, 9.183*t*, 9.184*t*, 9.184*f*, 9.185*f*, 9.186*f*, 9.187*f*, 12.230, 12.230*t*
 - azathioprine for, 1.169, 9.188
 - diagnosis/differential diagnosis of, 9.187*f*, 9.187–188
 - HLA association in, 1.169, 9.67*t*, 9.186
 - hypopyon in, 1.169, 9.185, 9.185*f*
 - nonocular systemic manifestations of, 9.184*f*, 9.184–185
 - ocular manifestations of, 1.169–170, 9.185*f*, 9.185–186, 9.186*f*
 - pathogenesis of, 9.186–187
 - prognosis for, 9.189
 - treatment of, 1.169, 9.188–189
- Behr optic atrophy, 6.368
- Belimumab, 1.175
- Bell palsy, 5.278*t*, 5.279
 - aberrant regeneration/facial nerve synkinesis and, 5.277, 5.279
- Bell phenomenon, 6.126*f*, 6.197
 - in ptosis evaluation, 7.211
- Benazepril, 1.68*t*, 1.69*t*
- Bence Jones protein, corneal deposition of, 8.198
- Bendroflumethiazide, for hypertension, 1.69*t*
- Benedikt syndrome, 5.191
- Benign episodic unilateral mydriasis, 5.267
- Benign essential blepharospasm (BEB), 5.281–283, 5.282*f*, 5.282*t*, 7.226–228, 7.227*f*. *See also* Blepharospasm

- Benign eyelid myokymia, 5.282*t*, 5.284
- Benign hereditary intraepithelial dyskeratosis, 8.332*t*
- Benign lymphoid folliculosis, 8.48, 8.49*f*
- Benign lymphoid hyperplasia, 4.70, 4.70*f*. *See also* Lymphoid hyperplasia
- Benign lymphoid pseudotumor/pseudolymphoma. *See* Lymphoid hyperplasia
- Benign mixed tumor (pleomorphic adenoma) of eyelid, 7.170
- of lacrimal gland, 4.229–230, 4.230*f*, 7.91, 7.92*f*, 7.92–93
- Benign monoclonal gammopathy, crystalline corneal deposits in, 8.198
- Benign paroxysmal positional vertigo (BPPV), nystagmus and, 5.242–243
- Benign prostatic hypertrophy, α -blockers for, intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137*t*
- Benign reactive lymphoid hyperplasia. *See* Lymphoid hyperplasia
- Benoxinate, with fluorescein, 2.363*t*, 2.365
- Benzalkonium (BAK)
- absorption affected by, 2.298
- in artificial tears, 2.341
- in irrigating solutions, 2.367
- toxic reactions to, 2.294, 2.341, 8.80, 8.90, 8.90*t*, 8.91, 10.184
- Benzodiazepines, 1.194–195, 1.195*t*
- ophthalmic considerations and, 1.195
- for seizures, 1.202*t*
- Benzotropine, for Parkinson disease, 1.199
- Bepotastine, 2.338*t*
- Berger space, 12.7, 12.8*f*
- Bergmeister papilla, 2.80, 4.126, 4.127*f*, 6.298, 6.366, 12.341. *See also* Hyaloid artery/system, persistence/remnants of
- Berlin edema (commotio retinae), 4.18–19
- Berlin nodules, in uveitis, 9.81*f*, 9.83
- Berry (saccular) aneurysm, 1.126, 5.338
- Besifloxacin, 1.277, 2.346, 2.347*t*, 2.347–349
- for bacterial keratitis, 8.270, 8.270*t*
- Besivance. *See* Besifloxacin
- Best-corrected visual/Snellen visual acuity (BCVA/BCSVA/corrected distance visual acuity/CDVA). *See also* Visual acuity
- blindness and, 3.311
- after Boston keratoprosthesis implantation, 8.452
- after cataract surgery, 11.126
- manual small-incision surgery and, 11.198–199
- multifocal IOLs and, 11.121–122
- corneal crosslinking and, 13.131
- after endothelial keratoplasty (DMEK/DSEK), 8.438–440
- flap folds/striae and, 13.112, 13.113, 13.114*t*, 13.115
- as gold standard, 3.21
- hard contact lens method for IOL power calculation and, 13.195
- hyperopia correction and, 13.94
- intrastromal corneal ring segment placement and, 13.67
- irregular astigmatism affecting, 13.17
- LASIK and, 13.95
- in amblyopia/anisometropic amblyopia, 13.185–186, 13.187
- in diabetes mellitus, 13.190
- after penetrating keratoplasty, 13.180
- after retinal detachment surgery, 13.185
- in low vision assessment, 5.78
- photostress testing and, 5.88
- multifocal intraocular lenses, 3.260
- myopia correction and, 13.95
- patient expectations/motivations for refractive surgery and, 13.36, 13.47
- phakic IOL implantation and, 13.144
- radial keratotomy and, 13.51–52
- small-incision lenticule extraction and, 13.205
- undercorrection after photoablation and, 13.102
- Best disease (Best vitelliform dystrophy/vitelliform macular dystrophy), 6.340–342, 6.342*f*
- bestrophin defect causing, 2.265
- characteristics of, 12.271, 12.272*f*
- definition of, 12.51
- electro-oculography of, 12.51, 12.271
- identification of carriers for, 2.178, 2.196
- retinal pigment epithelium in, 2.278
- BEST1* gene, 6.340–342, 12.271
- BEST1* (VMD2/vitelliform macular dystrophy) gene, 10.11*t*
- Bestrophin, 12.50
- mutation in, 2.265
- Bestrophinopathies, 6.341
- Beta (β)-adrenergic agents, 2.308*t*, 2.321–323, 2.322*t*
- agonists, 2.308*t*, 2.318*t*, 2.321
- for asthma, 1.133, 1.133*t*
- antagonists, 1.308*t*, 2.308*t*, 2.321–323, 2.322*t*. *See also* Beta (β)-blockers
- for glaucoma, 2.230, 2.318*t*, 2.321–323, 2.322*t*
- Beta (β)-adrenergic receptors (adrenoceptors), 2.308*t*, 2.316*t*
- drugs affecting, 2.308*t*, 2.321–323, 2.322*t*. *See also* Beta (β)-adrenergic agents
- effects mediated by, 2.316, 2.317*f*
- locations of, 2.321
- signal transduction and, 2.316*t*
- in tear secretion, 2.219, 2.219*f*
- Beta (β)-blockers, 2.230, 2.318*t*, 2.321–323, 2.322*t*, 10.164–165, 10.171–172*t*, 10.176–177
- aqueous humor suppression and, 2.230, 2.321, 2.323
- childhood glaucomas treated with, 6.288, 6.289*t*
- dry eye and, 8.61
- elevated intraocular pressure masked by, 10.86
- for glaucoma, 2.230, 2.318*t*, 2.321–323, 2.322*t*, 10.171–172*t*, 10.176–177
- in children, 10.164–165
- in combination preparations, 10.174*t*, 10.182
- in elderly patients, 10.186
- normal-tension glaucoma and, 10.88
- during pregnancy/lactation, 10.185
- side effects of, 10.171–172*t*, 10.177
- suppression of aqueous formation and, 10.16–17, 10.164, 10.176
- for heart failure, 1.110, 1.111
- hemangioma treated with, 6.220
- for hypertension, 1.68, 1.68*t*, 1.69*t*, 1.72, 1.73
- with α -blockers, 1.68*t*, 1.72, 1.73
- indications for, 1.69*t*
- for hyperthyroidism, 1.53
- for hyphema, 8.395

- for infantile (capillary) hemangioma, 7.68
- for ischemic heart disease, 1.101*t*
 - angina, 1.99
 - non-ST-segment elevation acute coronary syndrome, 1.103
- ocular effects of, 1.117, 1.308*t*. *See also* Beta (β)-blockers, for glaucoma
- for penetrating and perforating ocular trauma, 8.402
- in perioperative setting, 1.285
- for postoperative elevated intraocular pressure, 10.108
- for rate control in atrial fibrillation, 1.114
- for supraventricular tachycardias, 1.114
- Beta (β) carotene
 - antioxidant effect of, 2.285, 2.288
 - oral supplements and, 2.285
 - in retina, 2.288
- Beta (β) cells, pancreatic, in diabetes mellitus, 1.34
 - destruction of, 1.34, 1.35
- Beta chemokines, 9.27*t*
- Beta (β)-crystallins, 2.64, 2.244, 11.16
- Beta (β)-galactosidase, defective/deficiency of, in gangliosidoses, 2.175*t*
- Beta (β)-hemolytic group A streptococci (*Streptococcus pyogenes*), 1.242
 - orbital necrotizing fasciitis caused by, 7.48
- Beta (β)-interferon
 - for Kaposi sarcoma, 1.270
 - for multiple sclerosis, 5.321*t*
- Beta (β)-lactam antibiotics, 1.272, 1.275, 2.343–346, 2.344*t*. *See also* specific agent
- Beta (β)-lactam ring, 1.274, 1.275
- Beta (β)-lactamase (penicillinase), 1.275, 2.343, 2.345, 2.346
- Beta (β)-lactamase inhibitors, 1.276. *See also* specific antibiotic combination
- Beta (β_2)-microglobulin, 9.89*t*
- Beta (β)-thalassemia, 1.137
 - stem cell transplantation for, 1.135, 1.137
- Beta (β) zone peripapillary atrophy, 10.48, 10.52
- Betadine. *See* Povidone-iodine
- Betagamma (β , γ)-crystallins, 2.244, 11.15, 11.15*f*, 11.16
- Betagan. *See* Levobunolol
- Betaseron. *See* Beta (β)-interferon
- Betatrophin, for diabetes mellitus, 1.47
- Betaxolol, 1.68*t*, 2.308*t*, 2.321, 2.322*t*, 2.323, 6.288, 6.289*t*, 10.88, 10.113, 10.172*t*, 10.176–177
 - in children, 10.165
- Bethanechol, 2.309*f*
- Bevacizumab, 2.372
 - adverse effects of, 12.85
 - for age-related macular degeneration/choroidal neovascularization, 2.372
 - branch retinal vein occlusion treated with, 12.135
 - for cancer chemotherapy, 1.234*t*, 1.235
 - central retinal vein occlusion treated with, 12.135
 - choroidal neovascularization treated with, 12.73*f*, 12.213*f*
 - Coats disease treated with, 6.360
 - diabetic macular edema treated with, 12.113
 - endophthalmitis caused by, 12.404
 - intravitreal administration of, 2.300*t*
 - endophthalmitis and, 2.306
 - for macular edema, 4.152
 - neovascular age-related macular degeneration treated with, 12.83–85, 12.84*t*
 - for neovascular glaucoma, 10.135, 10.135*f*
 - off-label uses of, 2.306, 12.85
 - in pterygium excision, 8.356
 - ranibizumab and, comparison between, 12.83, 12.84*t*
 - retinal vein occlusion treated with, 12.135
 - retinopathy of prematurity treated with, 6.333, 12.186–187
- Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP), 6.333
- Bezafibrate, for hypercholesterolemia/heart disease prevention, 1.85*t*
- bFGF. *See* Basic fibroblast growth factor
- BGI. *See* Baerveldt glaucoma implant
- Biapenem, 1.276
- Bias (statistical)
 - investigator, 1.6
 - recall, 1.11
 - selection, 1.4
 - in case-control studies, 1.11
 - in case series, 1.9
- Biber-Haab-Dimmer (lattice type 1/LCD1/classic lattice) dystrophy, 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–147, 8.146*f*, 8.147*f*
- Bicanalicular intubation, 6.234
- Bicanalicular stents
 - for canalicular trauma, 7.283
 - after dacryocystorhinostomy, 7.279
- Bicarbonate (HCO_3)
 - in aqueous humor, 2.231*t*, 2.232
 - for malignant hyperthermia, 1.293*t*
 - for shock, 1.301
 - in tear film, 2.214*t*, 2.216
 - in vitreous, 2.231*t*
- Bicentric grinding, 3.188, 3.188*f*
- Bichrome (red-green/duochrome/Worth 4-dot) test
 - in nonorganic disorder evaluation
 - monocular no light perception and, 5.303, 5.304*f*
 - monocular reduced vision and, 5.305
 - before refractive surgery, 13.39
- Bick procedure, 7.199
- Biconvex design, for IOLs, 11.120
- Bielschowsky head-tilt test, 6.75, 6.122
- Bietti crystalline dystrophy, 12.258, 12.269, 12.282*t*
- Bietti nodular dystrophy (spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
- Bifocal add. *See* Add power; Bifocal lenses
- Bifocal lenses. *See also* Multifocal lenses
 - accommodative amplitude for, 3.178–179
 - add power of, 3.178–180
 - contact
 - alternating vision, 3.224*f*, 3.224–225
 - presbyopia correction using, 3.224–225
 - simultaneous vision, 3.225, 3.225*f*
 - fused, 3.180
 - for high AC/A ratio accommodative esotropia, 6.91–92
 - image displacement, 3.184, 3.186*f*
 - image jump, 3.184–186, 3.187*f*
 - induced anisophoria, compensating for, 3.186–190, 3.187*f*

- intraocular
 - description of, 3.258–259, 3.259f
 - modulation transfer function with, 3.262
- lens design of, 3.190
- plastic molded, 3.180
- Prentice rule and, 3.184–190, 3.185–189f
- prismatic effects of, 3.184, 3.185f
- round segment, 3.180, 3.181f
- types of, 3.180, 3.181f
- Bifocal segments. *See also* Bifocal lenses
 - decentration of, 3.190–191
 - dioptric power of, 3.190
 - occupation and, 3.190–191
 - shape of, 3.190
 - width of, 3.190
- Biguanides
 - for *Acanthamoeba* keratitis, 2.361, 8.278–279
 - for diabetes mellitus, 1.44f, 1.45t, 1.45–46
- Bilateral acoustic/central (type 2) neurofibromatosis, 5.330, 5.334t, 10.156
 - seventh nerve (facial) palsy and, 5.279, 5.279f
- Bilateral amblyopia, 3.175
- Bilateral diffuse uveal melanocytic proliferation (BDUMP), 9.278, 12.204–205, 12.205f, 12.287
- Bilateral fourth nerve (trochlear) palsy, 5.199
- Bilateral no light perception, testing, 5.301–302, 5.302f
- Bilateral ptosis. *See* Ptosis
- Bilateral vision/bilateral vision loss. *See* Binocular vision
- Bile acid sequestrants, for hypercholesterolemia/heart disease prevention, 1.85t
- Bimatoprost, 2.237, 2.302, 2.327, 2.327t, 10.170–176, 10.171t
 - in combination preparations, 2.327t, 10.174t
- Binocular balance
 - alternate occlusion for, 3.167–168
 - definition of, 3.34
 - Lancaster red-green test of, 3.35–36
 - in manifest refraction, 3.34–36
 - prism dissociation for, 3.168, 3.168f
 - in subjective refraction, 3.167–168, 3.168f
- Binocular blur, 5.183
- Binocular diplopia, 5.183
- Binocular eye movements. *See also specific type*
 - conjugate (versions), 5.34–35, 5.35f. *See also specific type*
 - in diplopia, 5.184
 - disconjugate (vergences), 5.212, 5.212t, 5.226–228. *See also* Vergences/vergence system
- Binocular function
 - field of single binocular vision assessment, 6.81–82, 6.82f
 - prism adaptation test, 6.82
- Binocular fusion, 6.60, 6.91
- Binocular indirect ophthalmoscopy/ophthalmoscopes (BIO). *See also* Ophthalmoscopy/ophthalmoscope
 - disadvantages of, 12.22
 - retinal disease evaluations using, 12.21–22
- Binocular states, of eye, 3.139–140
- Binocular transient visual loss, 5.161, 5.171–172
- Binocular treatment, for amblyopia, 6.59
- Binocular vision
 - abnormalities of. *See also specific type*
 - diplopia, 6.47–48
 - visual confusion, 6.47, 6.47f
 - anomalous, 6.50
 - assessment of
 - low vision evaluation and, 5.77
 - nonorganic disorder evaluation and, 5.301–302, 5.302f
 - in cyclic strabismus, 6.93
 - development of, 6.43
 - fusion, 6.42–43
 - monocular visual deprivation effects on, 6.45
 - no light perception, testing, 5.301–302, 5.302f
 - Panum's area of single, 6.42, 6.42f, 6.48
 - reduced, 5.77
 - nonorganic disorders and, 5.306–308, 5.307f, 5.308f, 5.309f
 - retinal correspondence, 6.41–42
 - single, 6.81–82, 6.82f
 - transient loss and, 5.161, 5.171–172
- Bioavailability, 2.293
- Biofilm, microbial, 8.207
 - keratitis and, 8.267
 - staphylococci forming, 8.244
 - virulence and, 1.240
- Biologic response modifiers (BRM/biological therapies), 1.175, 9.106–108. *See also* Immunomodulatory therapy/immunotherapy/immunosuppression
 - in cancer, 1.227, 1.235–237
 - for pars planitis, 9.130
 - in rheumatic disorders, 1.151, 1.152, 1.175
 - for scleritis, 8.324, 8.325f
 - for uveitis, 9.106–108
 - multiple sclerosis and, 9.132
- Biomarkers, cardiac. *See* Cardiac enzymes/biomarkers
- Biomechanics of cornea, 8.43, 13.13–14
 - measurement of, 8.43
- Biometry/biometrics
 - before cataract surgery, 11.82–83, 11.83f
 - hypotony and, 11.185
 - in IOL power determination/selection, 11.82–83, 11.83f, 11.84–85, 11.87
 - axial length, 11.82–83, 11.84–85, 11.87
 - hypotony affecting, 11.185
 - unexpected refractive results after surgery and, 11.150
 - hypotony and, 11.185
 - refractive surgery and, refractive lens exchange, 13.150
 - primary angle closure and, 10.121
- Biomicroscopy
 - slit-lamp. *See* Slit-lamp biomicroscopy/examination
 - ultrasound (UBM), 2.47, 2.47f, 4.265, 8.20–21, 8.21f
 - in choroidal/ciliary body melanoma, 4.265
 - before corneal transplantation, 8.418
 - in glaucoma, 10.77, 10.124f
 - pediatric glaucoma and, 10.160
 - uveitic glaucoma and, 9.285
 - in pars planitis, 9.129
- Bioptic telescope, 3.309
- Bioptics, 13.137, 13.157
- Bioterrorism, ocular complications of smallpox
 - vaccination and, 8.238
- Biotherapy. *See* Biologic response modifiers; Immunomodulatory therapy/immunotherapy/immunosuppression
- Bipedicle flap, 8.359f, 8.359–360

- Bipahalic eyes, axial length in, 3.245
- Bipolar cells, 2.71f, 2.257, 2.258f, 2.266, 5.24
 cone, 2.257, 2.266, 2.266f
 ganglion cells and, 12.13
 illustration of, 12.15f
 midget, 12.13
 rod, 2.257, 2.258f
- Bipolar disorder, 1.189
 lithium for, 1.197–198
- Birbeck granules, 9.11
- Birds, West Nile virus transmission and, 9.208
- Birdshot uveitis (birdshot retinochoroidopathy/birdshot chorioretinopathy/vitiliginous chorioretinitis), 9.141–143t, 9.144–147, 9.145f, 9.146f, 12.49
 characteristics of, 12.220t, 12.224–225, 12.225f
 ERG in, 9.143t, 9.147
 HLA association in, 9.67, 9.67t, 9.141t, 9.144
 uveal lymphoma and, 12.234
- Birth defects. *See* Congenital anomalies; *specific type*
- Birth trauma
 congenital facial palsy and, 5.280
 corneal edema and, 8.109
 Horner syndrome and, 5.260t, 5.261
- Birth weight, retinopathy and. *See* Retinopathy, of prematurity
- Bis-retinoids, 12.31
- Bisoprolol
 for heart failure, 1.110
 for hypertension, 1.68t, 1.69t, 1.72
- Bisphosphonates, 1.184
 ocular effects of, 1.184, 1.307t
 uveitis caused by, 1.184, 9.121
- Bistratified cells (koniocellular neurons), 10.42
- Bitemporal, definition of, 5.105t
- Bitemporal hemianopia, chiasmal lesions causing, 5.146, 5.147f, 5.152
- Bites, eyelid injuries caused by, 7.190
- Bitôt spot, 8.196–197, 8.197f
 Corynebacterium xerosis and, 8.196–197, 8.246
- Bivalirudin, for ischemic heart disease, 1.100t
 non-ST-segment elevation acute coronary syndrome, 1.103
- Bjerrum (arcuate) scotoma, 5.103, 5.105t, 5.106f
 in glaucoma, 10.68, 10.68f
- Blackbody radiometer, 3.107
- Bladder (Wedl) cells, 4.121, 4.121f, 11.48, 11.152
 in phakomatous choristoma, 4.202, 4.203f
- Blast injuries, corneal foreign bodies and, 8.400, 8.401f
- Blastocyst, 2.112f
- Blau syndrome (familial juvenile systemic granulomatosis), 6.319, 9.170
- Bleb, filtering. *See* Filtering bleb; Filtering procedures
- Bleb-associated endophthalmitis, 10.163, 10.209, 10.209t, 10.210f, 12.390–391, 12.391f
- Bleb leaks, after trabeculectomy, 10.209, 10.210, 10.211
- Bleb pattern
 Bron, in epithelial basement membrane dystrophy, 8.138
 in Meesmann epithelial corneal dystrophy, 8.139
- Blebitis, 12.390–391
 after filtering surgery, 10.163, 10.209, 10.209t, 10.210f
- Bleeding/blood loss. *See* Hemorrhages
- Bleeding disorders. *See also* Coagulation, disorders of; Hemostasis, disorders of
 cataract surgery in patient with, 11.171–172
 subconjunctival hemorrhages in, 8.388
- Bleeding time, 1.141
- Blend zone, 13.74f, 13.81
- Bleomycin, 1.233t, 1.235
- Bleph-10. *See* Sulfacetamide
- Blephamide. *See* Prednisolone, in combination preparations
- Blepharitis, 6.244–245, 245f, 8.72f, 8.72–76, 8.73t, 8.73f, 8.74f, 8.75f, 8.208t. *See also* Blepharoconjunctivitis
 α-agonists causing, 10.178, 10.178f
 cataract surgery in patient with, 11.172–173
 corticosteroid route of administration in, 2.333t
 dry eye and, 8.68, 8.72, 8.76
 keratitis and, 8.72, 8.73t, 8.74
 meibomian gland dysfunction and, 8.68, 8.72, 8.73t
 refractive surgery and, 13.42, 13.43f, 13.172, 13.173
 multifocal IOLs, 13.155
 in rosacea, 8.70, 8.73t
 seborrheic, 8.72, 8.72f, 8.73t
 staphylococcal, 8.72, 8.72f, 8.72–76, 8.73t, 8.73f, 8.74f, 8.75f, 8.208t, 8.254
 keratitis and, 8.73t, 8.74, 8.76
 marginal infiltrates in, 8.74, 8.74f
- Blepharochalasis, 7.230
- Blepharoconjunctivitis. *See also* Blepharitis; Conjunctivitis
 α-agonists causing, 10.178, 10.178f
 contact, 8.285–287, 8.286f
 herpes simplex virus causing, 8.213, 8.214f, 8.216
 marginal corneal infiltrates associated with, 8.74, 8.74f
 staphylococcal, 8.74, 8.75, 8.76, 8.256, 8.257t
- Blepharodermatitis, α-agonists causing, 10.178, 10.178f
- Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES/congenital eyelid/blepharophimosis syndrome), 6.197–198, 6.198f, 7.155–156, 7.156f, 7.158, 7.212
 with congenital ectropion, 7.155, 7.156
 with euryblepharon, 7.155, 7.156, 7.157
- Blepharophimosis syndrome. *See* Blepharophimosis-ptosis-epicanthus inversus syndrome
- Blepharoplasty, 7.230–234, 7.232f
 complications of, 7.233–234
 eyelid retraction, 7.223, 7.234
 cosmetic/functional indications and, 7.230–231
 exposure keratopathy and, 8.79
 infraciliary incision for, orbitotomy and, 7.118
 laser resurfacing as adjunct to, 7.237
 preoperative evaluation for, 7.231
 superior limbic keratoconjunctivitis and, 8.83
 techniques for, 7.232f, 7.232–233
- Blepharoptosis. *See* Ptosis
- Blepharospasm
 benign essential (BEB), 5.281–283, 5.282f, 5.282t, 7.226–228, 7.227f
 botulinum toxin for, 5.281–283, 7.227f, 7.227–228
 nonorganic, 5.310
 in primary congenital glaucoma, 10.151, 10.152, 10.158
 reflex, 5.281, 7.227
 superior limbic keratoconjunctivitis and, 8.84
 transient visual loss and, 5.164
- Blessig-Iwanoff cysts, 2.78, 2.79f

- Blind loop syndrome, 12.290
- Blind spot, 5.24
- cortical area corresponding to, 5.29f
 - enlargement of, 5.103, 5.106f
 - acute idiopathic (AIBSE), 5.100–101, 5.101f
 - fundus autofluorescence in identification of, 5.90
 - in multiple choroiditis and panuveitis, 9.156
 - in multiple evanescent white dot syndrome, 9.161, 9.163
- Blindness. *See also* Low vision; Vision loss/impairment
- age-related macular degeneration causing, 4.160
 - bilateral, testing, 5.301–302, 5.302f
 - after blepharoplasty, 7.233–234
 - cataract causing, 11.5
 - central, age-related macular degeneration progression to, 12.86
 - cerebral/cortical, 5.158, 5.336–337
 - blindsight and, 5.181
 - denial of (Anton syndrome), 5.158, 5.180–181, 5.337
 - color. *See* Color vision, defects in
 - congenital stationary night, spasmus nutans syndrome associated with, 6.151
 - cyclodestructive procedures for pain and, 10.195
 - cysticercosis causing, 9.232
 - day (hemeralopia), in cone/cone-rod dystrophies, 5.102
 - diabetes mellitus/diabetic retinopathy causing, 1.33, 4.159
 - functional. *See also* Nonorganic (functional/nonphysiologic) ophthalmic disorders
 - in benign essential blepharospasm, 7.226
 - in glaucoma, 10.7, 10.84
 - incisional surgery contraindicated in, 10.195, 10.198
 - primary congenital glaucoma and, 10.151, 10.152
 - race and, 10.82
 - herpetic stromal keratitis causing, 8.219
 - “hysterical.” *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
 - legal, 3.310–311, 3.329
 - aging and, 1.178
 - methanol toxicity as cause of, 12.301
 - monocular
 - testing, 5.302–305, 5.303f, 5.304f
 - transient. *See* Monocular transient visual loss
 - mucous membrane pemphigoid causing, 8.303
 - night. *See* Night blindness
 - nonorganic disorders and, 5.301–305, 5.302f, 5.303f, 5.304f. *See also* Nonorganic (functional/nonphysiologic) ophthalmic disorders
 - nystagmus after, 5.246
 - postmeasles, 8.239, 9.206
 - prevalence of, 3.311
 - rehabilitation devices for, 3.325
 - retinopathy of prematurity as cause of, 6.335, 12.182
 - river (onchocerciasis), 8.252–253, 9.234–235, 9.235f
 - snow, 8.385
 - trachoma causing, 8.260
 - transient. *See* Transient visual loss
 - traumatic injury causing, 4.22–23, 4.23f
 - in uveitis, 9.85–86, 9.292
 - vitamin A deficiency causing, 8.196
- Blindsight, 5.181
- Blinking (blink reflex), 5.52, 6.185
- abnormal, cranial nerve VII (facial) in, 5.49
 - excessive, 6.201–202
 - exposure keratopathy and, 8.79
 - medication absorption and, 2.296
 - protective/defensive function of, 8.3
 - tear secretion and, 2.220, 7.255, 7.256f, 8.3, 8.5
 - dry eye and, 8.55, 8.55f, 8.56
- Bloch-Sulzberger syndrome (incontinentia pigmenti/IP), 2.180, 12.283t, 12.286
- Blocked fluorescence, in fluorescein angiography, 12.35
- Blood. *See also* Hemorrhages
- clotting pathways of, 1.140, 1.140f. *See also* Coagulation
 - composition of, 1.135
 - cornea stained by, 4.86, 4.86f, 8.118t, 8.375, 8.394, 8.394f, 8.395, 8.395t, 10.104, 10.104f, 10.105
 - hyphema after cataract surgery and, 11.159
 - in LASIK interface, 13.122, 13.123f
- Blood–aqueous barrier, 2.229, 2.230, 2.233
- clinical implications of breakdown of, 2.236
- Blood–brain barrier, 12.16
- Blood cells, 1.135
- development of, 1.135–136
- Blood clotting/coagulation. *See* Coagulation
- Blood-derived macrophages, 9.11
- Blood glucose. *See* Glucose, plasma levels of
- Blood–ocular barriers, 2.229–230. *See also specific type*
- fluorescein passage affected by, 12.33
 - immune response and
 - of anterior chamber/anterior uvea/vitreous, 9.57
 - of retina/retinal pigment epithelium/choroid, 9.61
 - systemic drug administration and, 2.300, 2.301
- Blood oxygenation level–dependent (BOLD) imaging, 5.70, 5.75
- Blood-pool isotope scans, in ischemic heart disease, 1.97
- Blood pressure (BP). *See also* Hypertension
- ambulatory monitoring of, 1.62
 - cardiovascular risk and, 1.61, 1.62, 1.65, 1.65t, 1.66, 1.83t
 - classification of, 1.62t, 1.62–63
 - hypertension management goals and, 1.61, 1.66
 - normal, 1.61, 1.62t
 - phenylephrine affecting, 2.317, 2.318
 - screening, 1.66, 1.208
- Blood–retina barrier, 2.73, 2.229, 5.14
- breakdown of, in diabetic retinopathy, 4.159
 - fluorescein passage affected by, 12.33
 - hyperglycemia-induced breakdown of, 12.108
 - immune response and, 9.61, 9.62
 - ischemic damage to, hemorrhages and, 4.153–154, 4.155f
- Blood vessels. *See* Vascular system
- Blowout (indirect) fractures, 6.379
- of medial orbital wall, 7.8, 7.108
 - orbital cellulitis following, 7.47
 - of orbital floor, 7.108–112, 7.110f
 - diplopia after, 5.206, 7.108
 - infraorbital nerve and, 7.19
 - surgery for, 7.111–112
 - indications for, 7.110–111
 - of orbital roof, 7.106

- BLS. *See* Basic life support
- Blue-blocking intraocular lenses, 11.120
- Blue-cone (S-cone) monochromatism, 2.264, 6.337–338
description of, 12.250, 12.250*t*
electroretinography findings in, 12.46, 12.47*f*
ocular findings in carriers of, 2.199*t*
- Blue-dot (cerulean) cataract, 11.37, 11.38*f*
- Blue dyschromatopsia, 6.368
- Blue-light hazard, 2.286
- Blue nevus, 4.64, 7.175
- Blue sclera, 8.195*t*
in Ehlers-Danlos syndrome, 8.191*t*, 8.193
in keratoglobus, 8.171
in Marfan syndrome, 8.194
in osteogenesis imperfecta, 1.143, 8.194, 8.194*f*
- Blue-yellow color deficiency, 12.54
- Blue-yellow color vision defects
in optic atrophy, 5.135
tests for, 5.78–79
- Blunt (concussive) trauma, 6.378–379, 12.315, 12.353–358, 12.354–357*f*. *See also* Trauma
anisocoria caused by, 5.256*f*, 5.262–263
anterior segment, 8.387–396
anterior uveitis and, 8.389–390
corneal changes and, 8.388, 8.389*f*
cyclodialysis and, 8.391, 8.391*f*
hyphema and, 8.391–396, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*
iridodialysis and, 8.390*f*, 8.390–391, 8.391*f*, 8.409
mydriasis and miosis and, 8.388–389, 8.389*f*
subconjunctival hemorrhage and, 8.387–388, 8.388*f*
canalicular injury and, 7.282–283
in children, nonaccidental/abusive. *See* Abusive head trauma
commotio retinae and, 4.18–19
eyelid, 7.187
glaucoma and, 4.103–104, 10.39–40, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*
hyphema caused by, 8.391–396, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*
LASIK flap dislocation and, 13.115–116
lens injury/cataract caused by, 11.53–55, 11.54*f*
optic canal fracture caused by, 7.10
optic neuropathy caused by, 2.89
pupil irregularity caused by, 5.255
- Blur circles. *See also* Point spread function
definition of, 3.69
description of, 3.5, 3.5*f*
formation of, 3.130*f*
size of, 3.129
- Blurred vision/blurring. *See also* Vision loss/impairment
in corneal dystrophies, 8.133
multifocal IOLs and, 13.156
ocular misalignment and, 5.183
SSRIs causing, 1.196
in uveitis, 9.79
vergence system and, 5.226
vertebrobasilar insufficiency and, 5.336
in Vogt-Koyanagi-Harada syndrome, 9.176–177
- BMP. *See* Bone morphogenetic protein
- BMS. *See* Bare-metal stents
- BMZ. *See* Basement membrane zone
- BNP. *See* B-type natriuretic peptide
- Bobbing, ocular, 5.228
- Body dysmorphic disorder, 1.190
- Body lice, ocular infection caused by, 8.255. *See also* Lice
- BOLD (blood oxygenation level-dependent) imaging, 5.70, 5.75
- Bone, eosinophilic granuloma of, 7.90
- Bone cyst, aneurysmal, 6.222
- Bone density/bone mass
measurement of, 1.171
in osteoporosis, 1.184
- Bone disease, neuroimaging in evaluation of, 5.72*t*
- Bone growth disorders, nonsynostotic, 6.212
- Bone marrow derived stem cells, hyalocytes from, 12.7
- Bone marrow transplantation
graft-vs-host disease after, 8.304
for thalassemia, 1.135, 1.137
- Bone morphogenetic protein (BMP), lens placode formation and, 11.25
- Bonnet-Dechaume-Blanc syndrome (Wyburn-Mason syndrome/racemose angioma/hemangioma), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*, 6.222, 6.394*t*, 6.405*t*, 6.405–406, 12.168
- Bony orbit. *See* Orbit
- Bony tumors of orbit, 4.239, 4.240*f*
- Border tissue of Elschnig, 2.88*f*
- Borderline neoplastic proliferations, 4.10
- Borrelia* (borreliosis), 1.250–252, 5.279–280, 5.352–353, 5.353*f*, 8.249, 9.243. *See also* Lyme disease
afzelli, 9.243
burgdorferi, 1.250–252, 5.279, 8.249, 9.243, 12.245
garrinii, 9.243
- Bosentan, for systemic sclerosis, 1.162
- Boston keratoprosthesis, 8.452, 8.452*f*
- Botryoid rhabdomyosarcoma, 4.236, 7.83
- Botryoid tumors, 6.217
- Bottom-up acuity testing, in nonorganic disorder evaluation, 5.306. *See also* Visual acuity, testing of
- Botulinum toxin, 2.366, 7.227*f*, 7.227–228
for acute spastic entropion, 7.206
adverse effects of, 6.176
for blepharospasm, 2.366, 5.281–283, 7.227*f*, 7.227–228
chemodenervation using, 6.175–176
complications of, 6.176
for corneal exposure, in facial palsy, 5.281
cosmetic uses of, 2.366, 7.238–239
in extraocular muscle symmetric surgery, 6.160
in eyelids, 6.146
for hemifacial spasm, 2.366, 5.284, 7.229
indications for, 6.175–176
infantile esotropia treated with, 6.89
intramuscular administration of, 2.301
mechanism of action, 6.175
near reflex spasm treated with, 6.94
for nystagmus, 5.246
for paralytic ectropion, 7.225
periocular injection of, 2.299, 2.366
pharmacology of, 6.175
ptosis caused by, 7.216
results of, 6.175–176
for strabismus, 2.366, 6.175
techniques for, 6.175–176
for thyroid eye disease, 7.59
type A, as tarsorrhaphy alternative, 8.373

- Botulism poisoning
 ptosis/facial paralysis caused by, 5.273, 5.273*t*
 tonic pupils in, 5.265
- Bouin solution, as tissue fixative, 4.26*t*
- Bourneville disease/syndrome (tuberous sclerosis/TS),
 5.330, 5.331*f*, 5.334*t*, 6.393*t*, 6.397–399, 6.398*t*, 6.398*f*
 glaucoma associated with, 10.30
- Boutonnière deformity, 1.151–152
- Bovine spongiform encephalopathy (“mad cow”
 disease), 5.357
- Bow-tie optic atrophy, 5.25*f*, 5.153
- Bow-tie pattern
 keratoconus and, 13.175, 13.175*f*
 regular astigmatism and, 8.31, 8.31*f*, 13.17, 13.18*f*,
 13.22
- Bow zone/region, 2.242, 2.242*f*
- Bowen disease, 7.176
- Bowman layer/membrane, 2.40, 2.40*f*, 2.45*f*, 2.223*f*,
 2.225, 4.73, 4.74*f*, 8.7*f*, 8.8
 anatomy of, 2.40, 2.40*f*, 2.45*f*, 2.223*f*, 8.7*f*, 8.8
 biochemistry and metabolism of, 2.225
 development of, 2.120
 healing/repair and, 4.16
 in keratoconus, 8.162, 8.162*f*
 in keratoglobus, 8.171
 refractive surgery and, 2.225
 preparation of, 13.82–90
 epithelial debridement techniques for, 13.82–84,
 13.83*f*
 epithelial preservation techniques for, 13.84
 LASIK flap creation and, 13.84–90
 with femtosecond laser, 13.87–90, 13.88*f*,
 13.89*f*, 13.90*t*
 with microkeratome, 13.84–87, 13.85*f*, 13.86*f*,
 13.87*f*
- in Reis-Bücklers corneal dystrophy (corneal
 dystrophy of Bowman layer type 1), 8.142,
 8.142*f*, 8.143. *See also* Reis-Bücklers corneal
 dystrophy
- in Thiel-Behnke corneal dystrophy (corneal
 dystrophy of Bowman layer type 2), 8.143,
 8.144*f*. *See also* Thiel-Behnke corneal
 dystrophy
- Bowman probe, 7.261, 7.261*f*, 7.262*f*
- bp. *See* Base pair
- BP. *See* Blood pressure
- BP180. *See* Bullous pemphigoid antigen II
- BPD. *See* Butterfly-type pattern dystrophy
- BPES. *See* Blepharophimosis-ptosis-epicanthus
 inversus syndrome
- BPPV. *See* Benign paroxysmal positional vertigo
- Brachial plexus injury, Horner syndrome and, 5.260*t*,
 5.261
- Brachium conjunctivum, 5.18*f*, 5.39
- Brachycephaly, 6.205
- Brachytherapy, 1.229, 1.230
 for choroidal hemangioma, 4.283
 for choroidal melanoma/ciliary body melanoma,
 4.253, 4.275*f*, 4.275–276
 for iris melanoma, 4.261
 for medulloepithelioma, 4.296
 for metastatic eye disease, 4.310
 for retinal hemangioblastoma, 4.285
 for retinoblastoma, 4.301
- Bradyarrhythmias, 1.112
 heart failure and, 1.111
 in myocardial infarction, 1.96
- Bradykinesia, in Parkinson disease, 1.198, 1.199
- Bradykinetic movement disorders, 1.198. *See also*
 Parkinson disease/parkinsonism
- Bradyopsia, electroretinography findings in, 12.49
- Bragg peak effect, 4.276
- Brain. *See specific structure and under Cerebral*
- Brain injury, traumatic (TBI), falls in older patients
 and, 1.184
- Brain lesions, in tuberous sclerosis, 5.331*f*, 5.334*t*, 6.398*f*
- Brain natriuretic peptide (BNP)
 in aqueous humor, 2.231
 in heart failure, 1.105, 1.109
- Brain stones (calcified astrocytic hamartomas), in
 tuberous sclerosis, 5.331*f*, 5.334*t*
- Brain tumors, retinoblastoma and, 4.302
- Brainstem
 lesions of
 arteriovenous malformations, 5.343
 facial weakness/paralysis caused by, 5.278, 5.278*t*
 gaze palsy caused by, 5.228, 5.229*f*
 Horner syndrome and, 5.260*t*
 vestibular disorders and, 5.217
 in ocular motility, 5.33, 5.34–40, 5.35*f*, 5.36*f*, 5.37*f*, 5.39*f*
- Brainstem encephalitis, CMV infection causing, 5.349
- Brainstem neural network, 5.33, 5.34
- Brainstem saccade generators, 5.33
- Brainstem syndrome, acute, 5.117*t*
- Branch chain decarboxylase, defective/deficiency of,
 2.175*t*
- Branch retinal artery occlusion (BRAO), 4.156
 emboli that cause, 12.141, 12.142*f*
 hypertensive retinopathy and, 12.122
 imaging of, 12.141*f*
 management of, 12.142
 multiple, 12.152*f*
 in nonproliferative sickle cell retinopathy, 12.152*f*
 retinal infarction caused by, 12.141
 in Susac syndrome, 12.156
- Branch retinal vein occlusion (BRVO), 4.158–159
 aflibercept for, 12.135
 at arteriovenous crossing, 12.126
 bevacizumab for, 12.135
 clinical findings of, 12.125–127, 12.126*f*
 corticosteroids for, 12.137–138
 diabetes mellitus and, 12.128
 fluorescein angiography of, 12.129*f*
 glaucoma as risk factor for, 12.125
 hypercoagulable states and, 1.147
 hypertensive retinopathy and, 12.122
 intraretinal hemorrhages associated with, 12.125,
 12.126*f*
 macular laser surgery for, 12.128
 neovascularization in, 4.159, 12.125, 12.128, 12.129*f*
 pars plana vitrectomy for, 12.130
 pharmacologic management of, 12.135–138
 prognosis for, 12.128
 ranibizumab for, 12.135
 risk factors for, 12.127–128
 in sarcoidosis, 9.169–170
 scatter photocoagulation for, 12.128–130
 spontaneous resolution of, 12.125

- surgical management of, 12.128–130
- treatment of, 12.128–130
- triamcinolone for, 12.137
- vision loss caused by, 12.128
- Branchial arch syndromes, 6.210–211, 211*f*
- BRAO. *See* Branch retinal artery occlusion
- Brawny scleritis, 4.110, 4.110*f*
- BRCA1/BRCA2* genes, 1.211
- Breaks (retinal). *See* Retinal breaks
- Breast cancer, 1.211–212
 - eye involvement and, 1.237, 4.197, 4.304*t*, 4.305*f*, 4.307*f*, 4.308, 4.308*f*, 4.309–310, 7.100, 7.100*f*
 - paraneoplastic-induced saccadic intrusions and, 5.249
 - screening for, 1.207, 1.210*t*, 1.211–212
- Breast cancer genes, 1.211
- Breast Cancer Risk Assessment Tool, 1.211
- Breast examination, for cancer screening, 1.210*t*, 1.211
- Breastfeeding
 - glaucoma medication use during, 10.185–186
 - refractive surgery contraindicated during, 13.37
- Breathing exercises, 1.132
- Breslow thickness, 4.220
- Brewster angle, 3.99
- Brief psychotic disorder, 1.189
- Brightness. *See* Radiance
- Brightness sense testing, for relative afferent pupillary defect, 5.81
- Brimonidine, 2.318*t*, 2.319, 3.272, 6.289*t*, 6.290, 10.172*t*, 10.175*t*, 10.178–179
 - in children, 10.165
 - in combination preparations, 2.318*t*, 2.322*t*, 10.174*t*
 - during pregnancy/lactation, 10.185
- Brinzolamide, 2.324–325, 2.325*t*, 10.173*t*, 10.179–181
 - in children, 10.165
 - in combination preparations, 10.174*t*
- British antilewisite (BAL), for Wilson disease, 2.203
- Brittle cornea syndrome, 6.262
- Brivudine, 1.281
- BRM. *See* Biologic response modifiers
- Broad-beam illumination, for slit-lamp biomicroscopy, 8.17
- Broad-beam lasers, for photoablation, 13.30, 13.31
- Broad-spectrum penicillins, 2.345
- Brodmann area 8, 5.33
- Brodmann area 17 (striate cortex), 5.24*f*, 5.29*f*, 5.29–30, 5.30*f*, 5.32*f*, 5.34*f*. *See also* Visual (calcarine/occipital/striate) cortex
 - disorders of, 5.158, 5.178*t*, 5.178–181
 - illusions and, 5.175
- Brodmann area 18 (parastriate cortex), 5.20*f*, 5.30*f*, 5.30–31. *See also* Visual (calcarine/occipital/striate) cortex
- Broken heart syndrome (stress-induced/Takotsubo cardiomyopathy), 1.92
- Bromday. *See* Bromfenac
- Bromfenac, 2.330*t*
 - for cystoid macular edema, 9.94
- Bromocriptine, for Parkinson disease, 1.199
- Bron (bleb) pattern, in epithelial basement membrane dystrophy, 8.138
- Bronchial lavage, 1.131
- Bronchiectasis, 1.130
- Bronchitis, 1.130
- Bronchodilators, 1.133
- Bronchogenic carcinoma. *See also* Lung cancer
 - eye involvement and, 7.100
- Bronchoscopy, 1.131
 - in cancer screening, 1.212
- Brow- and forehead-lift, 7.241, 7.242*f*, 7.243*f*
- Brow ptosis, 7.234–235, 7.235*f*
 - dermatochalasis and, 7.229, 7.234, 7.235
- Brown and Brenn (B&B) stain, 4.31*t*
- Brown and Hopps (B&H) stain, 4.31*t*
- Brown-McLean syndrome, 11.128*t*, 11.130
- Brown syndrome, 5.208
 - acquired, 6.136
 - clinical features of, 6.136–137, 6.137*f*
 - congenital, 6.136
 - as congenital cranial dysinnervation disorder, 6.131
 - description of, 6.117
 - diagnosis of, 6.137
 - forced duction test for, 6.137
 - iatrogenic, 6.168
 - inferior oblique muscle palsy versus, 6.124, 6.125*t*, 6.137
 - management of, 6.137–138
 - primary position hypotropia with, 6.137
 - rheumatoid arthritis and, 6.137
 - superior oblique muscle weakening for, 6.138, 6.166
 - surgical treatment of, 6.138
- Brown tumor of bone, 6.222
- Browpexy, 7.235
- Bruch membrane, 2.60–61, 2.61*f*, 2.70*f*, 2.71*f*, 2.271–272, 2.272*f*, 4.141*f*
 - age-related macular degeneration/choroidal neovascularization and, 4.164, 4.165, 4.165*f*
- anatomy of, 12.210–211
- argyrosis effects on, 12.306
- basilar laminar deposits effect on, 12.62*f*, 12.64
- choroidal neovascularization after damage to, 12.355, 12.355*f*
- degeneration of, 12.19, 12.71
- development of, 2.116*t*, 2.122–124
- disorders that affect, 12.89
- embryologic development of, 12.210
- histology of, 12.18*f*
- layers of, 12.18*f*, 12.19
- ocular expansion effects on, 12.211
- outer lamella of, 12.211
- photocoagulation-related rupture of, 12.378
- remodeling of, 12.210
- in retinal healing/repair, 4.17
- rupture of, 4.22, 12.378
- supertraction crescent, 12.210
- tears in, 12.354
- type 1 choroidal neovascularization in, 12.72*f*
- Brückner test
 - in amblyopia screening, 6.56
 - description of, 6.9, 6.67–68
- Bruits
 - carotid, 1.122, 1.124, 5.166. *See also* Carotid occlusive disease
 - in orbital disorders, 7.26, 7.73
- Brunescent cataract, 4.123, 11.44. *See also* Cataract
 - lens proteins in, 11.17
 - surgery for, 11.180
 - hydrolinization in, 11.110, 11.180

- Bruns nystagmus, 5.243
 Brushfield spots, 6.272
 BRVO. *See* Branch retinal vein occlusion
 BSS. *See* Balanced salt solution
 Buccal fat pad, 7.142f
 Buccal mucous membrane graft. *See also* Mucous membrane grafting
 for contracted socket, 7.134
 for eyelid repair, 7.190
 for mucous membrane pemphigoid, 8.303, 8.366
 for symblepharon, 7.208
 Buccal nerve, 2.104, 5.51f, 5.52, 5.276–277f, 7.142f, 7.143, 7.144f, 7.145f
 Buccinator muscle, 7.141, 7.143f
 Budge-Waller, ciliospinal center/nucleus of, 5.53f, 7.16
 Buerger disease (thromboangiitis obliterans), cataract caused by, 11.68
 Bulbar conjunctiva, 2.25, 2.26f, 2.30, 4.47, 4.48f, 8.6.
 See also Conjunctiva
 fixation/plication of, for conjunctivochalasis, 8.86, 8.361
 lymphoid lesions involving, 4.69, 4.70f
 redundant. *See* Conjunctivochalasis
 resection of, for conjunctivochalasis, 8.86, 8.362
 in superior limbic keratoconjunctivitis, 8.83, 8.84
 Bulbar (limbal) vernal keratoconjunctivitis, 8.289–290, 8.290f
 Bulla
 conjunctival, in mucous membrane pemphigoid, 4.54, 4.54f, 8.299
 corneal, 8.46t
 in keratopathy, 4.84, 4.84f. *See also* Bullous keratopathy
 eyelid, 8.45t
 Bullous keratopathy, 4.83–84, 4.84, 4.84f, 4.85f
 after cataract surgery, 4.83–84, 4.84f, 11.129, 11.129f
 IOL design and, 11.149
 disciform keratitis and, 8.225
 DMET for, 8.449
 in Fuchs endothelial corneal dystrophy, 4.92, 8.156
 Bullous pemphigoid antigen II, in mucous membrane pemphigoid, 8.299
 Bullous retinoschisis, 12.326
 Bullous (reticular degenerative) retinoschisis, 4.148
 Bull's-eye maculopathy/depigmentation
 chloroquine/hydroxychloroquine causing, 1.173
 chloroquine toxicity as cause of, 12.295, 12.296f
 clofazimine as cause of, 12.298
 in cone dystrophies, 5.102
 in neuronal ceroid lipofuscinoses, 12.289
 Bull's-eye pattern
 in acute idiopathic maculopathy, 12.229
 in Bardet-Biedl syndrome, 12.284
 in Lyme disease, 12.245
 in macular atrophy, 12.265
 in Stargardt disease, 12.270
 Bull's-eye rash, 12.245, 12.265f
 Bumetanide
 for heart failure, 1.109, 1.110
 for hypertension, 1.68t
 Bundle of His, 1.112
 Buphthalmos, 6.283
 in megalocornea, 8.99, 8.100
 in primary congenital glaucoma, 8.100, 8.108, 10.151, 10.152f, 10.158, 10.166
 Bupivacaine, 2.362t, 2.364, 2.365
 maximum safe dose of, 1.304t
 toxic reaction to, 1.305
 Bupropion, 12.306
 Burkitt lymphoma, 6.218
 Epstein-Barr virus associated with, 1.228, 1.260
 Burns, 6.376
 chemical. *See* Chemical injury
 thermal
 anterior segment, 8.384–385, 8.385f
 cataract surgery incision, 11.131
 eyelid, 7.190
 Burst cells/neurons, 5.35, 5.219, 5.220f
 horizontal gaze and, 5.35, 5.37, 5.37f, 5.38
 saccadic system and, 5.219, 5.220f, 5.221
 vertical gaze and, 5.35, 5.36, 5.36f
 Burst-mode phacoemulsification, 11.101
 Busacca nodules
 in sarcoidosis, 4.187, 9.81f, 9.168, 9.168f
 in uveitis, 9.81f, 9.82
 Butenafine, 1.281
 Butoxamine, 2.308t
 Butterfly-type pattern dystrophy (BPD), 4.170, 12.276, 12.276f
 Buttonhole flap, 13.110, 13.110f
 N-butylcyanoacrylate tissue adhesive. *See* Cyanoacrylate glue/adhesive
 Butyrylcholinesterase, 2.312
 Bypass grafting, coronary artery (CABG), 1.102
- ## C
- C4 complement, in aqueous humor, 2.231, 2.233
 CH₃CO₂H. *See* Acetic acid
 C3a complement, 9.22, 9.23f
 C5a complement, 9.22, 9.23, 9.23f
 C (parafollicular) cells, 1.50
 medullary carcinoma arising in, 1.56
 C-MIN. *See* Conjunctival melanocytic intraepithelial neoplasia
 C-reactive protein (CRP)
 in AION
 giant cell arteritis/AAION, 5.120, 5.120t, 5.314
 nonarteritic (NAION), 5.120t
 in Behçet disease, 1.169
 in coronary artery disease, 1.91, 1.92
 in giant cell arteritis/AAION, 7.61
 C-scan, 12.26
 c-wave, of ERG, 5.96. *See also* Electroretinography/electroretinogram
 Ca(OH)₂. *See* Calcium hydroxide
 CA-MRSA. *See* Community-acquired methicillin-resistant *Staphylococcus aureus*
 Ca²⁺/protein kinase C–dependent pathway, in tear secretion, 2.218, 2.218f
 CAB mnemonic, 1.296
 CABG. *See* Coronary artery bypass graft
 CACD. *See* Central areolar choroidal dystrophy
 CACNA1S (calcium channel A1S) gene, in malignant hypertension, 1.292

- CAD (coronary artery disease). *See* Coronary heart disease; Ischemic heart disease
- CADASIL. *See* Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
- Café-au-lait spots, 6.392, 6.395*f*
in neurofibromatosis, 5.330*f*, 5.334*t*
in tuberous sclerosis, 5.331*f*, 5.334*t*
- CAFE (Conduit Artery Function Endpoint) study, 1.74
- CAIs. *See* Carbonic anhydrase inhibitors
- Cajal, interstitial nucleus of (INC), 5.35, 5.35*f*
saccadic eye movements and, 5.220–221
vertical gaze and, 5.36, 5.36*f*, 5.38
- Calcarine artery, 5.19*f*, 5.20
- Calcarine cortex. *See* Occipital (primary visual/ calcarine/striate) cortex
- Calcarine fissure, 5.29*f*, 5.29–30
- Calcific band keratopathy (band keratopathy), 4.81–83, 4.82*f*, 8.111, 8.117–120, 8.119*f*, 8.201
“actinic,” 4.83
in aqueous tear deficiency, 8.56
EDTA for, 2.306, 9.281
gelatinous droplike corneal dystrophy and, 8.141, 8.141*f*
in gout, 8.119, 8.188
in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.123*f*, 9.125
parathyroid disorders and, 8.201
in pars planitis, 9.129
in sarcoidosis, 9.168–169
in uveitis, 9.79
- Calcific drusen, 4.163, 12.66
- Calcific plaques, senile scleral, 4.111, 4.111*f*
- Calcified astrocytic hamartomas (brain stones), in tuberous sclerosis, 5.331*f*, 5.334*t*
- Calcinosis, in systemic sclerosis, 1.162
- Calcitonin, in calcium regulation, 8.200
- Calcitonin gene-related peptide (CGRP), 2.316*t*
outflow facility affected by, 2.48
in signal transduction, 2.316*t*
in tear secretion, 2.216
- Calcium
in aqueous humor, 2.232
in tear film, 2.214*t*
in tear secretion, 2.218, 2.218*f*
- Calcium antagonists. *See* Calcium channel blockers
- Calcium channel A1S (*CACNA1S*) gene, in malignant hypertension, 1.292
- Calcium channel blockers (CCBs)
for angina, 1.99
heart failure and, 1.110
for hypertension, 1.68, 1.68*t*, 1.69*t*, 1.72
indications for, 1.69*t*
ocular effects of, 1.308*t*
for systemic sclerosis, 1.162
- Calcium channels, L-type, mutation in, 2.264
- Calcium deposits, on IOLs, 11.151
- Calcium embolus, transient visual loss and, 5.165, 5.165*f*, 5.166*t*
- Calcium hydroxide ($\text{Ca}[\text{OH}]_2$), ocular injury caused by, 8.376*t*
- Calcium oxalate crystals, in nuclear cataract, 4.123, 4.124*f*
- Calcium (Ca^{2+})/protein kinase C–dependent pathway, in tear secretion, 2.218, 2.218*f*
- Caldwell-Luc procedure, for orbital decompression, 7.121
- Callender classification, of uveal melanomas, 4.194–196
iris melanoma and, 4.190
- Callosomarginal artery, 5.16*f*
- CALT. *See* Conjunctiva-associated lymphoid tissue
- Calvarium, 6.203
- CAM. *See* Complexion-associated melanosis
- Camera obscura, 3.3–7, 3.5–7*f*
- cAMP (cyclic adenosine monophosphate), 2.321
in α -agonist mechanism of action, 10.178
in β -blocker mechanism of action, 10.176
in signal transduction, 2.316*t*
in tear secretion, 2.218, 2.219*f*
- Campbell-Robson contrast sensitivity grating, 3.135*f*
- CAMs. *See* Cell-adhesion molecules
- Can-opener capsulotomy
for ECCE, 11.196
for phacoemulsification, 11.109–110
- Canagliflozin, for diabetes mellitus, 1.45*t*, 1.47
- Canakinumab, 1.175
- Canal of Dorello, 5.41, 5.42*f*
sixth nerve (abducens) injury/palsy and, 5.201
- Canalicular plugs, for dry eye, 7.281–282, 8.64. *See also* Lacrimal plugs
canalicular obstruction and, 7.274, 7.282
nasolacrimal duct obstruction and, 7.278, 7.282
- Canalicular stenting
for canalicular obstruction, 7.274, 7.275
for canalicular trauma, 7.283
for congenital lacrimal drainage obstruction, 7.262–263, 7.264*f*
- Canaliculi, lacrimal, 2.23*f*, 2.29, 2.30, 7.253, 7.253*f*, 7.254*f*
agenesis/dysgenesis of, 7.259–260
atresia of, 6.227–228, 6.228*f*, 7.259–260
development of, 7.255
duplication of, 7.257, 7.258*f*
infection of, 7.284–286, 7.285*f*. *See also* Canaliculitis
obstruction and, 7.274
obstruction of, 7.273–276, 7.276*f*
functional occlusion, 7.273
irrigation/probing in evaluation of, 7.270*f*, 7.271*f*, 7.271–272, 7.273
reconstruction/repair of, 7.275, 7.283
stenosis of, 7.271
trauma to, 7.282–284
obstruction caused by, 7.274
- Canaliculitis, 7.284–285, 7.285*f*, 8.208*t*
lacrimal plug migration causing, 7.282
obstruction and, 7.274
- Canaliculodacryocystorhinostomy, for canalicular obstruction, 7.275
- Canaliculoplasty, laser, for canalicular reconstruction, 7.275
- Canaliculorhinostomy, for canalicular obstruction, 7.275
- Canaliculotomy, for canaliculitis, 7.285
- Canaliculus, 6.378
- Canaloplasty, 10.217–219
cataract surgery and, 11.186

- Canals. *See also specific type*
in vitreous, 12.7
- Cancer, 1.227–237. *See also* Carcinoma; Intraocular tumors; Tumors; *specific type or organ or structure*
angiogenesis inhibitors and, 1.234*t*, 1.235
biologic therapies and, 1.227, 1.235–237
chemicals associated with, 1.228
chemotherapy and, 1.231–235, 1.232–234*t*
classification/growth patterns and, 4.10, 4.10*t*, 4.11*f*
etiology of, 1.227–229
genetic factors/profiling/familial factors and, 1.227, 1.236–237, 2.156–157
in HIV infection/AIDS, 1.270–271
hypercoagulability and, 1.148
incidence of, 1.227
infiltrative optic neuropathy and, 5.131–132
loss of telomeric DNA and, 2.150
ophthalmic considerations and, 1.237
orbital. *See* Orbit, tumors of
radiation/radiation therapy and, 1.228, 1.229–231
recent developments in, 1.227
retinopathy associated with (CAR), 5.102
ERG in identification of, 5.96, 5.102
screening for, 1.209–215, 1.210*t*
vaccines against, 1.236
viruses causing, 1.228
- Cancer checkup, 1.210*t*
- Cancer chemotherapy. *See* Chemotherapy
- Cancer-cluster families, 1.229
- Cancer genes, 2.156–157
- Candela (cd), 3.108
- Candesartan
diabetic retinopathy progression affected by, 1.48
for heart failure, 1.110
for hypertension, 1.68*t*, 1.69*t*
- Candida* (candidiasis), 1.255–256, 8.208*t*, 8.249*t*, 8.250*f*, 8.250–251, 9.265, 9.266, 9.267*f*
albicans, 1.255–256, 8.208*t*, 8.250, 8.250*f*, 9.265
adherence and, 8.206
chorioretinitis/retinitis caused by, 9.266, 9.266*f*, 9.267*f*
dacryolith formation and, 7.277
endophthalmitis caused by, 12.239–240, 12.240*f*
endogenous, 9.265–268, 9.266*f*, 9.267*f*
postoperative, 9.262
glabrata, 9.265
keratitis caused by, 4.78, 8.208*t*, 8.251, 8.273, 8.274–275
as normal flora, 8.206*t*, 8.250
ocular infection caused by, 8.208*t*, 8.250–251
parapsilosis, 9.262
retinal infection caused by, 4.147
- Candidate gene screening, 2.161
positional, 2.161
- “Candlewax drippings,” in sarcoidosis, 4.187, 5.327, 9.169
- Cannabis, intraocular pressure affected by, 1.192–193, 10.22
- Canthal reconstruction, 7.189, 7.195–196. *See also* Eyelids, surgery/reconstruction of
- Canthal soft tissues, trauma involving, 7.189
- Canthal tendons, 7.152*f*, 7.153
lateral, 2.17*f*, 7.7, 7.14*f*, 7.152*f*, 7.153
laxity in, in involutional ectropion, 7.199
medial, 2.17*f*, 7.152*f*, 7.153, 7.254
trauma involving, 7.189
- Canthaxanthine, 12.303
- Cantholysis
lateral
for orbital decompression, 7.122, 7.122*f*
for orbitotomy, 7.116*f*, 7.118, 7.119*f*
for orbital hemorrhage, 7.112
for traumatic vision loss, 7.113
- Canthotomy, lateral
for orbital decompression, 7.122, 7.122*f*
for orbital hemorrhage, 7.112
for orbitotomy, 7.116*f*, 7.118, 7.119*f*
for traumatic vision loss, 7.113
- Canthus, lateral/medial, 2.18*f*
- CAP. *See* Chromosome arm painting
- Capacitance, venous, increasing, for heart failure, 1.110
- Capillary-free zone (foveal avascular zone), 2.74*f*, 2.77, 2.78*f*
- Capillary hemangioblastoma, retinal, 4.283–285, 4.284*f*.
See also Retinal angiomas
- Capillary hemangioma
of conjunctiva/ocular surface, 8.345*t*
infantile. *See* Infantile (capillary) hemangioma
- Capillary malformations
eyelid involvement and, 7.161–162
orbital involvement and, 7.67*f*, 7.67–68
- Capillary nonperfusion. *See* Retinal capillaries, nonperfusion of
- Capillary plexus
of ciliary process, 2.57
deep, 12.16
intermediate, 12.16
- Capillary retinal arteriole obstruction. *See* Cotton-wool spots
- Capillary telangiectasias, intracranial bleeding risk and, 1.126
- Capsaicin cream, for postherpetic neuralgia, 8.230
- Capsid (viral), 8.211, 8.212
- Capsular block syndrome (CBS), 10.132, 11.148–149
- Capsular cataracts, 11.38
- Capsular fibrosis, 11.153–154
IOL decentration/dislocation and, 11.145
Nd:YAG laser capsulotomy for, 11.154, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser therapy, capsulotomy
- Capsular hooks, 11.182–183, 11.183*f*
- Capsular/capsule opacification, 11.152–157, 11.184
IOLs and, 11.153
multifocal IOLs, 13.156, 13.167
Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser therapy, capsulotomy
multifocal IOLs and, 13.156, 13.167
in uveitis, 9.284
- Capsular phimosis, 11.153–154
Nd:YAG laser capsulotomy for, 11.154, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser therapy, capsulotomy
in pseudoexfoliation/exfoliation syndrome, 11.184
- Capillary rupture, cataract surgery and, 11.142–143, 11.180–181

- Capsular tension rings (CTRs), for zonular incompetence, 11.180, 11.181*f*, 11.183
- Capsular theory (Helmholtz hypothesis) of accommodation, 11.22, 13.159–160, 13.160*f*
- Capsule, lens. *See* Lens capsule
- Capsule staining, for cataract surgery, 11.178–179, 11.179*f*
- Capsulopalpebral fascia, 7.151
- Capsulopalpebral head, 7.146*f*, 7.151
- Capsulopalpebral muscle, 2.20*f*
- Capsulopalpebral orbital septum complex, 7.149
- Capsulorrhexis, 6.302
- advanced cataract and, 11.180
- continuous curvilinear (CCC), 11.108–110, 11.109*f*
- capsule staining for, 11.178–179, 11.179*f*
- for ECCE, 11.196
- for phacoemulsification, 11.108–110, 11.109*f*
- in uveitis, 9.283
- for ECCE, 11.196, 11.197*f*
- for phacoemulsification, 11.108–110, 11.109*f*
- in zonular dehiscence with lens subluxation/dislocation, 11.182
- Capsulotomy
- anterior
- for ECCE, 11.196, 11.197*f*
- for phacoemulsification, 11.109–110
- can-opener, 11.109–110, 11.196, 11.197*f*
- lens particle glaucoma after, 10.98
- Nd:YAG laser, 11.154*f*, 11.154–157, 11.156*f*
- for anterior capsule fibrosis and phimosis, 11.154, 11.154*f*, 11.154–157, 11.156*f*
- for capsular block syndrome, 11.149
- for capsule opacification, 11.152, 11.153, 11.154, 11.154*f*, 11.154–157, 11.156*f*
- multifocal IOLs and, 13.156, 13.167
- in uveitis, 9.284
- complications of, 11.156–157
- contraindications for, 11.155
- indications for, 11.154–155
- lens particle glaucoma and, 11.67
- procedure for, 11.155–156, 11.156*f*
- retinal detachment and, 11.157, 11.166
- pupillary block after, 10.132
- Captopril
- for heart failure, 1.110
- for hypertension, 1.68*t*, 1.69*t*
- ocular effects of, 1.308*t*
- CAR. *See* Cancer, retinopathy associated with
- CAR antigen (recoverin), 2.260*f*, 2.261, 5.102
- Carbachol, 2.309*f*, 2.311, 2.311*t*
- intracameral administration of, 2.300*t*, 2.309, 2.310
- Carbamates, 2.312
- Carbamazepine, 1.202*t*
- as mood stabilizer, 1.197
- ophthalmic considerations and, 1.203
- Carbapenems, 1.276. *See also specific agent*
- Carbenicillin, 1.275, 2.344*t*, 2.345
- gentamicin incompatibility and, 2.351
- Carbidopa, for Parkinson disease, 1.199
- Carbocaine. *See* Mepivacaine
- Carbogen, for central retinal artery occlusion, 12.146
- Carbohydrate (“sugar”) cataracts, 2.246–248
- aldose reductase in development of, 2.247*f*, 2.247–248, 11.19
- Carbohydrate sulfotransferase 6 (*CHST6*) gene, in macular dystrophy, 4.91, 8.136*t*
- Carbohydrates
- in aqueous humor, 2.232
- metabolism of
- in cornea, 2.224
- in lens, 2.246, 11.17–19, 11.18*f*
- in retinal pigment epithelium, 2.273
- Carbon, corneal deposits of/ pigmentation caused by, 8.118*t*
- Carbon dioxide, in aqueous humor, 2.236
- Carbon dioxide (CO₂) laser. *See also* Laser therapy; Lasers
- for infantile (capillary) hemangioma, 7.162
- for skin resurfacing, 7.237
- Carbonic anhydrase
- aqueous humor dynamics and, 2.230, 2.323–324, 2.324*f*, 10.16, 10.179
- retinal pigment epithelial transport and, 2.277
- Carbonic anhydrase inhibitors (CAIs), 2.230, 2.323–326, 2.324*f*, 2.325*t*, 6.289*t*, 6.290
- for acute intraocular pressure elevation, 10.184
- adverse effects of, 2.326
- aspirin use and, 2.336
- for cystoid macular edema, after cataract surgery, 11.165
- for glaucoma, 2.230, 2.323–326, 2.324*f*, 2.325*t*, 10.172–173*t*, 10.179–181
- in children, 10.165
- for intraocular pressure control
- in chemical injuries, 8.383
- hyphema in sickle cell disease and, 8.396
- for postoperative elevated intraocular pressure, 10.108
- in sickle cell patients, 12.154–155
- in suppression of aqueous formation, 2.230, 2.323–324, 10.16, 10.165
- teratogenicity of, 2.326, 10.185
- Carboplatin, for retinoblastoma, 4.299
- Carboxymethylcellulose, in artificial tears, 2.341
- Carboxypenicillins, 1.275
- Carboxypeptidase E, in aqueous humor, 2.231
- Carcinogenesis, 1.227–229
- loss of telomeric DNA and, 2.150
- Carcinoid, metastatic, immunohistochemistry in
- identification of, 4.34, 4.35*f*
- Carcinoma, 4.10*t*, 4.11*f*. *See also* Adenocarcinoma; Cancer; Carcinoma in situ
- adenoid cystic (ACC/cylindroma)
- of eyelid, 7.171
- of lacrimal gland, 4.230–231, 4.231*f*, 7.91, 7.93
- basal cell. *See* Basal cell carcinoma
- of conjunctiva, intraocular extension and, 4.310
- of eyelid, 4.212*f*, 4.212–213, 4.213*f*, 4.214*f*, 7.177–182, 7.178*f*, 7.179*f*, 7.182, 7.182*f*, 7.183*f*, 7.183–184, 7.187
- intraocular extension of, 4.310
- metastatic, 4.197, 4.198*f*. *See also* Metastatic eye disease
- ocular surface
- mucoepidermoid, 8.332*t*, 8.336

- squamous cell, 8.336*f*, 8.336–337
 - management of, 8.330*f*, 8.336–337
- retinoblastoma associated with, 4.302*t*
- sebaceous, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*, 7.183*f*, 7.183–184, 8.327, 8.337*f*, 8.337–338
- squamous cell (SCC). *See* Squamous cell carcinoma
- thyroid, 1.55–56
 - retinoblastoma associated with, 4.302*t*
 - thyroid scanning in evaluation of, 1.52, 1.55
- Cardiac in situ
 - of conjunctiva, 4.61, 4.63*f*
 - of eyelid
 - keratoacanthoma, 4.209–210, 4.210*t*, 4.211*f*, 7.176–177, 7.177*f*
 - squamous cell (Bowen disease), 7.176
 - of ocular surface, 8.334. *See also* Conjunctival or corneal intraepithelial neoplasia
- sebaceous, 4.217*f*, 4.218
- CARD15 (NOD2) gene mutation, in familial juvenile systemic granulomatosis (Blau syndrome)/early-onset sarcoidosis, 6.319, 9.170
- Cardiac arrest. *See* Cardiopulmonary arrest
- Cardiac compressions, in CPR, 1.295, 1.297*f*, 1.298
- Cardiac disease. *See* Heart disease
- Cardiac emboli
 - cerebral ischemia/stroke and, 1.120, 1.122
 - transient visual loss and, 1.125, 5.165–166, 5.168
- Cardiac enzymes/biomarkers, in myocardial infarction, 1.93, 1.96–97
- Cardiac failure. *See* Congestive heart failure
- Cardiac glycosides. *See* Digitalis/digitoxin/digoxin
- Cardiac magnetic resonance imaging (MRI), in ischemic heart disease, 1.98
- Cardiac rhythm disorders, 1.112–118. *See also* Arrhythmias
- Cardiac-specific troponins (troponins T and I), in acute coronary syndrome, 1.93, 1.96
- Cardiac transplantation, for heart failure, 1.111
- Cardiff Acuity Test, 6.9, 6.187
- Cardinal positions of gaze, 6.31, 6.32*f*, 6.35, 6.64
- Cardiogenic shock, 1.300. *See also* Shock
- Cardiolite scintigraphy. *See* Technetium-99m sestamibi scintigraphy
- Cardiomyopathy
 - heart failure and, 1.108, 1.111
 - stress-induced (Takotsubo), 1.92
- Cardiopulmonary arrest, 1.295–299, 1.296*t*, 1.297*f*
- Cardiopulmonary resuscitation (CPR), 1.295–299, 1.296*t*, 1.297*f*
 - advance directives and, 1.181
 - guidelines for, 1.295, 1.296–298, 1.297*f*
 - medications used in, 1.296*t*
 - for ventricular fibrillation, 1.115
- Cardioselective β -blockers, 1.82
- CardioSource, 1.89
- Cardiovascular disease (CVD), 1.208–209. *See also specific type*
 - COX-2 inhibitors causing, 1.172, 9.94
 - in Lyme disease, 1.251, 9.246
 - risk factors for, 1.81–89, 1.91–92, 1.92
 - diabetes mellitus and, 1.38–39, 1.83*t*
 - hypertension/hypertension management and, 1.61, 1.62, 1.65, 1.65*t*, 1.66, 1.69*t*
 - smoking and, 1.65*t*, 1.66, 1.83*t*, 1.91
 - screening for, 1.208–209
 - in women, 1.92
- Cardiovascular drugs. *See also* Digitalis/digitoxin/digoxin
 - ocular effects of, 1.117–118, 1.308*t*
- Cardioversion
 - for atrial fibrillation, 1.114
 - for ventricular fibrillation, 1.115
 - for ventricular tachycardia, 1.115
- Cardioverter-defibrillators, implantable (ICDs). *See* Implantable cardioverter-defibrillators
- Carmustine, 1.234*t*
- Carney complex, eyelid manifestations of, 4.207*t*
- Carotenoids (xanthophylls)
 - antioxidant effects of, 2.284*f*, 2.288
 - in lens, 2.285
 - in macula, 4.140
 - in retina, 2.77, 2.286, 2.288, 2.289*f*
- Carotid arteries, 1.120, 5.27*f*
 - common, 5.12, 5.13*f*
 - disorders of, 1.119, 1.120. *See also* Carotid occlusive disease
 - dissection of, 5.342–343
 - Horner syndrome and, 5.162, 5.260*t*, 5.261, 5.262*f*, 5.297
 - neuroimaging in evaluation of, 5.72*t*, 5.342
 - external (ECA), 5.12, 5.13*f*, 5.15*f*, 7.13, 7.154
 - eyelids supplied by, 7.154
 - internal (ICA), 2.90, 5.10*f*, 5.12, 5.13*f*, 5.14, 5.15*f*, 5.16*f*, 5.18*f*, 5.27*f*, 7.13, 7.14*f*, 7.15*f*, 7.154
 - aneurysm of, 5.338, 5.339*f*
 - chiasmal syndromes caused by, 5.147, 5.150
 - third nerve (oculomotor) palsy and, 5.194, 5.194*f*, 5.196, 5.196*f*, 5.339
 - cranial nerve relationship and, 2.84*f*, 2.85*f*, 5.42*f*, 5.43*f*
 - dissection of, 5.342–343
 - Horner syndrome and, 5.162, 5.260*t*, 5.261, 5.262*f*, 5.297
 - pain caused by, 5.297, 5.342
 - optic nerve supplied by, 2.84*f*, 2.85*f*, 2.90, 2.91
 - neuroimaging in evaluation of, 5.72*t*, 5.167, 5.167*f*, 5.342
 - orbit supplied by, 7.13
 - stenosis of. *See* Carotid stenosis
 - stenting of (CAS), 1.124–125
 - ultrasonography in evaluation of, 5.70, 5.167
- Carotid bruits, 1.122, 1.124, 5.166. *See also* Carotid occlusive disease
- Carotid-cavernous sinus fistula, 5.203–206, 5.204*f*, 5.205*f*, 7.72*f*, 7.72–74, 7.73*f*, 12.198
 - direct, 7.72–73
 - dural (indirect), 7.72, 7.73
 - glaucoma associated with, 10.30
 - neuroimaging in evaluation of, 5.70, 5.72*t*, 5.204, 5.204*f*, 5.205*f*
 - sixth nerve (abducens) palsy and, 5.201, 5.205–206
- Carotid Doppler imaging, 5.70
- Carotid duplex ultrasonography, in cerebral ischemia/stroke, 1.122
- Carotid endarterectomy (CEA)
 - for carotid stenosis, 1.119, 1.124–125
 - for ocular ischemic syndrome, 9.279

- Carotid occlusive disease, 1.120, 1.124–126. *See also*
 Carotid stenosis
 clinical/laboratory evaluation of, 5.167, 5.167f
 neuroimaging in evaluation of, 5.167, 5.167f
 ocular ischemic syndrome and, 5.170, 9.278
 retinal hemorrhages in, 12.138
 retinopathy of, 12.138
 stroke/stroke risk and, 1.120, 5.167, 5.168, 5.169
 transient visual loss caused by, 5.162, 5.165–166, 5.167, 5.167f, 5.168
 treatment of, 5.169
- Carotid plexus, 2.102, 2.104
- Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), 1.125
- Carotid stenosis, 1.124–126. *See also* Carotid occlusive disease
 neuroimaging in evaluation of, 5.70, 5.72t, 5.167, 5.167f
 ocular ischemic syndrome and, 5.170
 stroke/stroke risk and, 5.167, 5.168, 5.169
 transient visual loss caused by, 5.162, 5.165–166, 5.167, 5.167f, 5.168
 treatment of, 5.169
- Carotid territory ischemia. *See* Carotid occlusive disease; Carotid stenosis
- Carpenter syndrome (acrocephalopolysyndactyly), 8.191t
- Carrier (genetic), 2.132, 2.176, 2.197–200. *See also specific disorder*
 identification of, 2.205, 2.206
 ocular findings in, 2.198–199f, 200, 2.199t
- Carrier (infection), in HIV infection/AIDS, 1.262
- Carteolol, 2.321, 2.322f, 2.323, 10.171t, 10.176–177
- Caruncle, 2.18f, 2.27, 4.47, 4.48f, 8.6
 edema of, in thyroid eye disease, 7.54
 glandular lesions involving, 4.71–72, 4.72f
 hypertrophied, punctal obstruction/malposition and, 7.273
 incision through. *See* Transcaruncular incision
 nevi in, 4.63
 squamous papilloma in, 4.59, 4.60f
- Carunclectomy, conjunctivodacryocystorhinostomy for canalicular obstruction and, 7.275
- Carvedilol
 for arrhythmias, 1.113t
 for heart failure, 1.110
 for hypertension, 1.68t, 1.72
- CAS. *See* Carotid arteries, stenting
- CAS (Clinical Activity Score), for thyroid eye disease, 7.57
- Cascade ionization, 3.115–116, 3.116f
- Case-control studies, 1.8f, 1.9–11, 1.10f
- Case reports, 1.8, 1.8f
- Case series, 1.8f, 1.9
- Casating granulomas, 4.7, 4.9f
- Casopfungin, 1.281
 for *Aspergillus* endophthalmitis, 9.269
 for *Candida* endophthalmitis, 9.267–268
- Cat-scratch disease (CSD), 5.119, 6.240, 6.369, 8.248, 8.265–266, 9.255–258, 9.257f, 12.242–243, 12.243f
 neuroretinitis and, 5.119, 9.256, 9.257f, 9.257t
- Parinaud oculoglandular syndrome and, 8.248, 8.265–266, 9.256
- Catabolism, glucose, 1.34
- Catalase, 2.282f, 2.284, 2.288
 in lens, 2.284, 11.20
 in retina and retinal pigment epithelium, 2.273, 2.288
- Cataract, 4.120f, 4.120–123, 4.121f, 4.122f, 4.123f, 11.43–68. *See also* Cataract surgery; *specific type*
 acquired, 6.293
 advanced, surgery for, 11.180
 age-related, 11.5, 11.43–48. *See also* Age-related cataracts
 epidemiology of, 11.5
 genetic contributions to, 11.41–42
 alcohol use/abuse and, 11.63–64
 amblyopia caused by, 6.55, 6.57
 anterior polar (APC), 6.55, 6.295, 6.295f, 11.35–36
 anterior subcapsular. *See* Cataract, subcapsular, anterior
 astigmatism caused by, 11.123
 atopic dermatitis and, 11.66
 autosomal dominant transmission of, 6.294
 bilateral, 6.293, 6.294t
 brunescant, 4.123, 11.44
 lens proteins in, 11.17
 surgery for, 11.180
 hydrodelineation in, 11.110, 11.180
 capsular, 11.38
 carbohydrate (“sugar”), 2.246–248
 aldose reductase in development of, 2.247f, 2.247–248, 11.19
 cerulean, 11.37, 11.38f
 chemical injuries causing, 11.59
 in children, 11.34–39, 11.35t, 11.36f, 11.37f, 11.38f, 11.39f. *See also* Cataract, congenital; Cataract, pediatric
 genetic contributions to, 11.41–42
 “Christmas tree,” in myotonic dystrophy, 5.330
 complete (total), 11.38
 congenital, 6.293, 11.34–39, 11.35t, 11.36f, 11.37f, 11.38f, 11.39f. *See also* Cataract, pediatric
 aniridia and, 11.33, 11.34f
 bilateral, 11.35t
 genetic/hereditary factors in, 11.41–42
 surgical management of. *See* Cataract surgery, in children
 unilateral, 11.35t
 contrast sensitivity affected by, 11.70
 contusion, 11.54, 11.54f
 coronary, 11.37
 cortical, 4.122, 4.122f, 11.45–46, 11.46f, 11.47f, 11.48f, 11.49f, 11.50f
 characteristics and effects of, 11.45, 11.70t
 genetic contributions to, 11.41
 race and, 11.6
 uveitis and, 11.64f, 11.64–66
 corticosteroid use and, 6.321, 9.98, 9.124, 11.51–52, 11.64, 11.188
 degenerative ocular disorders and, 11.68
 diabetic, 11.60f, 11.60–61
 carbohydrate (“sugar”), 2.246–248
 aldose reductase in development of, 2.247f, 2.247–248, 11.19

- surgery for, 11.170
 - preoperative evaluation and, 11.80–81
- drug-induced, 11.51–53, 11.52*f*
- duplication, 4.120, 4.120*f*
- electrical injury causing, 11.59, 11.59*f*
- after endothelial keratoplasty (DMEK/DSEK), 8.446–447
- epidemiology of, 11.5–7
- Epstein-Barr virus infection and, 9.202
- etiology of, 6.294, 6.294–295*t*, 11.35*t*
- evaluation of, 6.299*t*, 6.299–301, 11.69–88, 11.70*t*
- free radicals/antioxidants and, 2.284
- fundus evaluation in patient with, 11.80–81
- in galactosemia, 11.61, 11.61*f*
- general features of, 6.293–294
- glassblower's, 11.57
- glaucoma and, 4.103, 9.21, 9.118, 9.118*f*, 9.119, 10.97*f*, 10.97–98, 10.128, 10.211, 10.212, 11.67, 11.186*f*, 11.186–187
 - in children, 10.156
 - management of, 10.211–213, 10.213, 11.186–187
 - preoperative evaluation/care and, 11.186*f*, 11.186–187
- glaucoma surgery and, 10.187
- history in, 11.69–71, 11.70*t*
 - surgery evaluation and, 11.74–76
- history-taking for, 6.299*t*, 6.300
- hypermaturation, 11.46, 11.49*f*
 - phacolytic glaucoma/uveitis and, 4.103, 9.21, 9.118, 9.118*f*, 9.119, 10.97*f*, 10.97–98, 11.67
- hypocalcemic, 11.61–62
- illusions caused by, 5.174
- incidence/prevalence of, 11.5, 11.6
- infantile, 6.293, 11.34–39, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*. *See also* Cataract, congenital
- intraocular foreign body causing, 11.57
- intumescent, 11.46
 - surgery for, 11.179–180
- IOL implantation and. *See* Cataract surgery
- ischemia causing, 9.279, 11.68
- in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.123*f*, 9.124–125
- after keratoplasty, 11.176
- laboratory workup for, 6.299*t*, 6.301
- lamellar (zonular), 6.55, 6.296, 6.296*f*, 11.34–35, 11.36*f*
- lens proteins and, 11.17
- management of, 11.71–88. *See also* Cataract surgery
 - in glaucoma, 10.211–213, 10.213, 11.186*f*, 11.186–187
 - low vision aids in, 11.71
 - nonsurgical, 11.71–72
 - pharmacologic, 11.72
- in Marfan syndrome, 8.194
- mature, 11.46, 11.48*f*
 - phacolytic glaucoma/uveitis and, 9.21, 9.118, 9.118*f*, 9.119, 10.97*f*, 10.97–98, 11.67
- megalocornea and, 8.100
- membranous, 11.38, 11.39*f*
- metabolic, 11.60*f*, 11.60–62, 11.61*f*, 11.62*f*
- morgagnian, 4.122, 4.123*f*, 11.46, 11.50*f*
 - phacolytic glaucoma and, 10.97*f*, 10.97–98
- morphology of, 6.294–299, 6.295*t*, 6.295–298*f*
- muscarinic therapy and, 2.311
- in myotonic dystrophy, 11.62, 11.62*f*
- next-generation gene sequencing for, 6.301
- nuclear, 4.123, 4.124*f*, 11.43–45, 11.45*f*, 12.402, 12.402*t*
 - characteristics and effects of, 11.43, 11.44, 11.70, 11.70*t*
 - in children/congenital, 11.38, 11.39*f*
 - genetic contributions to, 11.42
 - hyperbaric oxygen therapy and, 11.20, 11.65
 - infantile, 6.295, 6.296*f*
 - race and, 11.6
 - in rubella, 6.410
 - vitrectomy and, 11.55, 11.190
- nutritional disease and, 11.7, 11.63–64
- ocular anomalies associated with, 6.293, 6.294*t*
- ocular examination of, 6.300
- oil droplet, 11.44, 11.61, 11.61*f*
- oxidative damage and, 11.19–20
- in pars planitis, 9.130, 9.131
- pediatric, 11.34–39, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*. *See also* Cataract, congenital
 - bilateral, 11.35*t*
 - persistent fetal vasculature and, 4.126, 11.42
 - surgery for. *See* Cataract surgery, in children
 - unilateral, 11.35*t*
- penetrating and perforating injuries causing, 11.55, 11.55*f*, 11.56*f*. *See also* Cataract, traumatic
- after penetrating keratoplasty, 8.432
- perimetry interpretation and, 10.71
- peripheral vacuolar, 6.298
- persistent fetal vasculature and, 4.126, 6.298*f*, 6.298–299, 11.42
- phacolytic glaucoma/uveitis and, 4.103, 9.21, 9.118, 9.118*f*, 9.119, 10.97*f*, 10.97–98, 11.67
- phacomorphic glaucoma and, 10.128, 11.67, 11.68*f*
- after phakic IOL insertion
 - iris-fixated lenses, 13.145
 - posterior chamber lenses, 13.138, 13.145–146, 13.146
- pinhole vision in patients with, 3.24
- polar, 6.55, 11.35–36, 11.37*f*
 - surgery for, 11.180–181
 - hydrodissection/nucleus rotation and, 11.111, 11.181
- posterior capsular, 6.387*f*
- posterior lenticonus/lentiglobus and, 6.296–297, 6.297*f*, 11.30
- posterior polar, 11.36
 - surgery for, 11.180–181
 - hydrodissection/nucleus rotation and, 11.111, 11.181
- posterior subcapsular (PSC). *See* Cataract, subcapsular, posterior
- postvitrectomy, 11.55, 11.190
- in pseudoexfoliation syndrome, 11.65
- quetiapine use and, 1.194
- race and, 11.6
- radiation-induced, 1.230, 11.57–58
- after refractive surgery, 11.176–177, 11.177*f*

- refractive surgery in patient with, 13.43–44
 removal of. *See* Cataract surgery
 retinoscopy evaluations, 6.299
 risk factors for development of, 11.6–7
 rosette, 11.54, 11.54f
 rubella, 6.410, 9.203, 9.204f, 11.38–39
 scleritis and, 8.323
 sectoral, 6.297–298
 in siderosis bulbi, 11.58f, 11.58–59
 silicone oil use and, 11.83, 11.120, 11.190
 slit-lamp examination of, 6.300
 smoking/tobacco use and, 11.6–7, 11.63–64
 “snowflake,” 11.60, 11.60f
 statin use and, 1.89, 11.53
 steroid-induced, 9.98, 9.124, 11.51–52, 11.64, 11.188
 subcapsular
 anterior (subcapsular fibrous plaques), 4.120, 4.120f
 posterior (PSC), 4.120f, 4.120–121, 4.121f, 6.297, 11.46–48, 11.51f
 characteristics and effects of, 11.47, 11.70t
 corticosteroids causing, 11.51–52
 ischemia causing, 11.68
 in myotonic dystrophy, 11.62
 race and, 11.6
 silicone oil use and, 11.190
 uveitis and, 11.64
 vitrectomy and, 11.55, 11.190
 subtypes of, distribution of, 11.6
 “sugar,” 2.246–248
 aldose reductase in development of, 2.247f, 2.247–248, 11.19
 “sunflower,” in chalcosis/Wilson disease, 8.189, 11.59, 11.62
 surgery for. *See* Cataract surgery
 sutural (stellate), 11.37, 11.37f
 tetanic, 11.61–62
 total (complete), 11.38
 traumatic, 4.18, 11.53–59, 11.54f, 11.55f, 11.56f, 11.59f, 11.190–193, 11.192f. *See also specific type*
 surgery for, 11.192
 treatment-induced. *See* Cataract, drug-induced
 types of, 6.293
 uveitis and, 9.73, 9.281–284, 11.64f, 11.64–65, 11.139–140
 visual acuity and, 11.69–70, 11.70t
 postoperative outcome and, 11.126
 preoperative evaluation and, 11.75–76
 visual deprivation amblyopia caused by, 6.55
 visual function affected by, 6.300
 vitrectomy and, 11.55, 11.190
 in Vogt-Koyanagi-Harada syndrome, 9.182
 in Wilson disease, 8.189, 11.62
 workup for, 6.299t, 6.301
 zonular (lamellar), 11.34–35, 11.36f
- Cataract surgery, 11.89–126. *See also* Lensectomy;
 Phacoemulsification; *specific procedure*
 in acne rosacea, 11.172–173
 age-related macular degeneration progression
 affected by, 12.71
 α-blocker use and, 11.74
 amblyopia managed with, 6.57, 6.304
 anesthesia for, 11.91f, 11.91–92, 11.92f, 11.93f
 anterior capsule fibrosis and phimosis and,
 11.153–154
 anterior capsule management in, 6.302
 anterior segment complications of, 11.132–144,
 11.137t
 anticoagulant use and, 11.74, 11.157, 11.171–172,
 11.172t
 antimicrobial prophylaxis for, 11.93–95, 11.94f
 corneal melting and, 11.132
 aphakia management after, 6.304
 aphakic glaucoma after, 10.156
 arcuate keratotomy with, 13.58
 astigmatism and
 arcuate keratotomy and, 13.53–54, 13.54–58
 induced, 11.131–132
 limbal relaxing incisions for, 13.8t, 13.27f,
 13.53–54, 13.54, 13.54f, 13.54–58, 13.55f,
 13.56f, 13.56t, 13.57f
 modification of preexisting, 11.123–124
 toric IOLs for, 11.124, 13.151–153
 axial length extremes and, 11.184–185
 biometry before, 11.82–83, 11.83f
 hypotony affecting, 11.185
 IOL power determination/selection and, 11.82–83,
 11.83f, 11.84–85, 11.87
 in bleeding diathesis, 11.171–172
 in blepharitis, 11.172–173
 Brown-McLean syndrome after, 11.128t, 11.130
 bullous keratopathy after, 4.83–84, 4.84f, 11.129,
 11.129f
 IOL design and, 11.149
 capsular block syndrome and, 10.132, 11.148–149
 capsular opacification and contraction and,
 11.152–157, 11.184
 Nd:YAG laser capsulotomy for, 11.152, 11.153,
 11.154, 11.154f, 11.154–157, 11.156f. *See also*
 Nd:YAG laser therapy, capsulotomy
 capsular rupture and, 11.142–143
 capsule staining and, 11.178–179, 11.179f
 capsulorrhexis in, 11.108–110, 11.109f
 capsule staining for, 11.178–179, 11.179f
 in children, 6.301–305
 glaucoma after, 10.149t
 juvenile idiopathic (chronic/rheumatoid) arthritis–
 associated uveitis and, 9.124–125
 choroidal hemorrhage and. *See* Cataract surgery,
 suprachoroidal hemorrhage/effusion and
 ciliary block (malignant) glaucoma and, 10.139,
 11.139
 in claustrophobia, 11.169
 clear corneal incision for, 11.106f, 11.106–107
 with trabeculectomy, 10.213
 in uveitis, 9.283
 communication with patient and, 11.169–170,
 11.170
 complications of, 6.304–305, 11.127–167. *See also*
 specific type
 anterior segment, 11.132–144, 11.137t
 antimicrobial prophylaxis in prevention of,
 11.93–95, 11.94f
 capsular opacification and contraction and,
 11.152–157
 corneal, 11.128t, 11.128–132, 11.129f

- endophthalmitis, 4.119, 4.119f, 9.119, 9.261–263, 9.262f, 11.127, 11.140, 11.160–163, 11.161f
- hemorrhage, 11.157–160
- intraoperative, 11.127
- IOL implantation and, 11.144f, 11.144–152, 11.146f, 11.147f, 11.148f
- retinal, 11.163–167, 11.164f
- in uveitis, 9.119–121, 9.120f, 9.284
- conjunctival evaluation before, 11.78
- corneal complications of, 11.128t, 11.128–132, 11.129f
- corneal conditions and, 11.174f, 11.174–177, 11.177f
- corneal decompensation after, 6.304
- corneal edema and, 11.128t, 11.128–130
- corneal evaluation before, 11.78–79
 - pachymetry, 11.84
 - topography, 11.84, 11.86, 11.174
- corneal melting/keratolysis after, 11.132
 - in patient with dry eye, 11.132
- cyclodialysis and, 11.139
- cystoid macular edema and, 11.163–165, 11.164f, 11.187, 12.157, 12.159, 12.260
 - in glaucoma, 11.164, 11.187
 - after Nd:YAG capsulotomy, 11.157
 - vitreous prolapse and, 11.143–144
- in dementia/mental disability, 11.169–170
- Descemet membrane detachment and, 11.131
- in diabetes mellitus, 11.170
 - preoperative evaluation and, 11.80–81
- diplopia after, 5.207
- donor cornea suitability and, 8.414
- elevated intraocular pressure after, 11.75, 11.128t, 11.129, 11.136. *See also* Elevated intraocular pressure
- endophthalmitis after, 4.119, 4.119f, 6.305, 9.119, 9.261–263, 9.262f, 11.127, 11.140, 11.160–163, 11.161f. *See also* Postoperative endophthalmitis
- prevention of, 11.93–95, 11.94f, 11.161–162
 - Propionibacterium acnes* causing, 4.119, 4.119f, 9.119, 9.261–262, 9.262f, 11.140, 11.162
- with endothelial keratoplasty (DMEK/DSEK), 8.446–447
- endothelial keratoplasty and, 11.175–176
- epithelial/fibrous ingrowth and, 11.128t, 11.132–133
- external eye examination before, 11.77–78
- external ocular abnormalities and, 11.172–174
- extracapsular cataract extraction (ECCE), 11.90, 11.90f, 11.196–198, 11.197f. *See also* Extracapsular cataract extraction
- femtosecond laser, 11.125–126
- filtering bleb (inadvertent) after, 11.130–131
- filtering surgery and
 - cataract surgery combined with, 10.211–213
 - cataract surgery following, 11.187
- flat or shallow anterior chamber and, 11.134–136
 - angle-closure glaucoma and, 10.144–145
 - intraoperative complications and, 11.134–135
 - posterior fluid misdirection syndrome and, 11.134–135
 - postoperative complications and, 11.135–136
 - preoperative considerations/IOL power determination and, 11.79, 11.84, 11.86–87
- fluid-based phacolysis, 11.125
- Fuchs heterochromic uveitis/iridocyclitis and, 9.127, 9.282, 11.64–65
- fundus evaluation before, 11.80–81
- for glaucoma, 10.213
 - phacomorphic glaucoma and, 10.128
 - trabeculectomy combined with, 10.211–213
- glaucoma and, 6.285, 6.304, 10.98, 10.128, 10.139, 10.156, 11.186f, 11.186–187
 - filtering surgery before, 11.187
 - filtering surgery combined with, 10.211–213
 - preoperative evaluation and, 11.186f, 11.186–187
- globe exposure for, 11.105, 11.105f, 11.199
- hemorrhage and, 11.157–160
- high hyperopia and, 11.185
- high myopia and, 11.184–185
- historical overview/key developments in, 11.89f, 11.89–91, 11.90f, 11.195
- hyphema after, 11.149, 11.158–159
- in hypotony, 11.185
- hypotony/flat anterior chamber after, 11.135
 - suprachoroidal effusion/hemorrhage and, 11.159, 11.160
- illusions caused by, 5.174
- incisions for. *See also* Incisions, for cataract surgery; *specific type of incision and type of surgery*
 - complications related to, 11.130–131, 11.134
 - for ECCE, 11.196
 - for ICCE, 11.199–200
 - leaking, 11.118, 11.130–131
 - flat anterior chamber and, 11.135
 - for phacoemulsification
 - clear corneal, 11.106f, 11.106–107
 - scleral tunnel, 11.107f, 11.107–108
- indications for, 11.72–74
- infectious scleritis after, 9.259, 9.260f
- informed consent for, 11.87–88
- intracapsular cataract extraction (ICCE), 11.90, 11.199–201, 11.200f. *See also* Intracapsular cataract extraction
- intraocular lens placement
 - description of, 6.301
 - issues associated with, 6.303–304
 - lensectomy with, 6.302–304
 - posterior capsulectomy/vitrectomy with, 6.303
 - power calculations, 6.303
- intraoperative floppy iris syndrome and, 11.74, 11.178
- IOLs and, 11.115–117, 11.118–122. *See also* Intraocular lenses
 - complications of, 11.144f, 11.144–152, 11.146f, 11.147f, 11.148f
- iridodialysis and, 11.138
- iris trauma and
 - in patient with preexisting iris trauma, 11.191, 11.192f
 - as surgical complication, 11.138
- juvenile idiopathic (chronic/rheumatoid) arthritis–associated uveitis and, 9.124–125
- in keratoconjunctivitis sicca, 11.173
- keratoplasty and, 11.175–176
 - with IOL insertion (triple procedure), 11.175–176
- key developments in, 11.195
- laser photolysis, 11.125

- lens anatomy alterations and, 11.179–184, 11.181*f*, 11.182*f*, 11.183*f*
- lens–iris diaphragm retropulsion syndrome and, 11.138, 11.184
- lens particle glaucoma after, 10.98
- lens visualization and, 11.177–179, 11.178*f*, 11.179*f*
 - trauma affecting, 11.191
- lensectomy, 6.302
- limbal relaxing incisions and, 11.123–124, 13.58
- macular edema after, 6.304–305
- macular function evaluation before, 11.82
 - retinal disease and, 11.189
- malignant glaucoma (aqueous misdirection/ciliary block glaucoma) and, 10.139, 11.139
- manifest refraction delays after, 3.26
- manual small-incision (MSICS), 11.198, 11.199*f*
- measurements taken before, 11.82–84, 11.83*f*
- medical status and, 11.72, 11.170–171
- medical therapy after, 6.304
 - in megalocornea, 8.100
 - in mucous membrane pemphigoid, 11.173
 - in nanophthalmos, 11.185
 - in neurocognitive/neurodevelopmental disorders, 11.169–170
- nucleus removal in
 - in ECCE, 11.196–197
 - in ICCE, 11.200, 11.200*f*
 - in phacoemulsification, 11.111, 11.112–114, 11.113*f*. *See also* Phacoemulsification
- ophthalmic viscosurgical devices (viscoelastic agents)
 - in, 11.95–97. *See also* Ophthalmic viscosurgical devices
- outcomes of, 11.126
 - improving, 11.87
- paracentesis for, 11.105
- in pars planitis, 9.131
- patient preparation for, 11.87–88
- in patient with communication obstacles, 11.169–170, 11.170
 - after penetrating keratoplasty, 8.432
 - with penetrating keratoplasty and IOL insertion (triple procedure), 11.175
- phacoemulsification, 11.98–118. *See also* Phacoemulsification
- photic retinopathy after, 12.368
- for plateau iris, 10.128
- posterior capsule opacification and, 11.152–153, 12.260
 - Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser therapy, capsulotomy
 - in uveitis, 9.284
- posterior capsule rupture and, 11.142–143
- posterior fluid misdirection syndrome and, 11.134–135
- postoperative care and, 6.304
 - after ECCE, 11.198
 - after ICCE, 11.201
- potential acuity estimation before, 11.81–82
- preoperative evaluation/preparation for, 11.74–76, 11.87–88
 - uveitis and, 9.281, 9.282
- primary posterior capsulectomy, 6.303
 - in pseudoexfoliation/exfoliation syndrome, 11.79, 11.184
- pseudophakic/aphakic bullous keratopathy after, 4.83–84, 4.84*f*, 11.129, 11.129*f*
 - IOL design and, 11.149
- psychosocial considerations in, 11.72, 11.76, 11.169–170
- pupil expansion and, 11.177–178, 11.178*f*
 - in uveitis, 11.191
- pupil irregularity caused by, 5.255
- pupillary capture and, 11.148, 11.148*f*
 - IOL decentration and, 11.145
- after radial keratotomy, 13.52–53
 - rate of, 11.5–6
- red reflex and, 11.178–179, 11.179*f*
- refraction before, 11.76
- refractive errors after, 11.86
 - after refractive surgery, 11.176–177, 11.177*f*
 - IOL power calculation and, 11.85–87, 11.176, 11.177*f*, 13.44, 13.194
- with refractive surgery, 11.123–124. *See also* Cataract surgery, astigmatism and
- retained foreign matter and, 11.191
- retained lens material and, 11.140–141
- retinal complications and, 11.163–167, 11.164*f*
- retinal detachment after, 6.304, 11.127, 12.319
 - family history as risk factor and, 11.75
 - Nd:YAG laser capsulotomy and, 11.157, 11.166
- in retinal disease, 11.189
- retinal light toxicity and, 11.166
- retrobulbar hemorrhage and, 11.158, 11.171
- same-day bilateral, 11.73
- scleral tunnel incisions for
 - ECCE and, 11.196
 - phacoemulsification and, 11.107*f*, 11.107–108
 - second-eye, 11.73
- shallow anterior chamber and. *See* Cataract surgery, flat or shallow anterior chamber and
- slit-lamp examination before, 11.78–80
- small pupil and, 11.177–178, 11.178*f*
- specular microscopy before, 11.84
- strabismus after, 6.304
- suprachoroidal hemorrhage/effusion and, 11.159, 11.171
 - delayed, 11.160
 - expulsive, 11.159–160
 - flat anterior chamber and, 11.134
- systemic conditions and, 11.170–172, 11.171*f*
- tamsulosin use and, 11.74, 11.136, 11.137, 11.137*t*
- timing of, 6.301
- toxic anterior segment syndrome and, 11.129, 11.133–134
 - after trauma, 11.190–193, 11.192*f*
 - in triple procedure, 11.175–176
- uveitis and, 6.323, 9.119–121, 9.120*f*, 9.281, 9.282–284, 11.64–65, 11.75, 11.139–140
 - juvenile idiopathic (chronic/rheumatoid) arthritis and, 9.124–125
- postoperative, 11.139–140
 - pupil expansion and, 11.191
- visual function evaluation after, 11.126
- visual function evaluation before, 11.71, 11.72, 11.76–77

- vitreal complications/vitreous abnormalities and
 - with ICCE, 11.200
 - posterior detachment, 11.166
 - prolapse, 11.142, 11.143–144
 - vitreocorneal adherence, 11.130
- vitreous abnormalities secondary to, 12.349
- vitreous loss during, 12.349
- wound closure for
 - complications associated with, 11.130–131
 - after ECCE, 11.197–198
 - after ICCE, 11.200–201
 - postoperative endophthalmitis and, 11.161
- wound dehiscence/rupture and, 11.131
- wound management in, 12.349
- zonular abnormalities and, 11.179–184
 - iris coloboma/corectopia and, 11.180
 - nucleus rotation and, 11.111
 - zonular dehiscence with lens subluxation or dislocation and, 11.181–183, 11.182f, 11.183f
 - zonular anatomy alterations and, 11.179–184
- Cataractous lens, B-scan ultrasonography of, 12.40f
- Catarrhal (marginal corneal) infiltrates, 8.310–311
 - staphylococcal blepharitis/blepharoconjunctivitis and, 8.74, 8.74f
- Catastrophic antiphospholipid antibody syndrome, 1.160
- Catatonic stupor, in schizophrenia, 1.189
- Caterpillar hairs, ocular inflammation caused by, 8.387
- Cathelicidins, in rosacea, 8.69
- Cathepsin, in Goldberg syndrome, 8.179
- Cathepsin D
 - in aqueous humor, 2.231, 2.233–234
 - macrophage priming and, 9.20
- Cathepsin E, macrophage priming and, 9.20
- Cathepsin O, in aqueous humor, 2.231, 2.233, 2.234
- Catheter/conventional/contrast angiography, 5.68, 5.68f
 - in aneurysm detection/evaluation, 5.195, 5.340, 5.341f
 - in arteriovenous malformations, 5.292f, 5.344, 5.344f
 - in reversible cerebral vasoconstriction syndrome, 5.347, 5.347f
 - in vertebrobasilar insufficiency, 5.337f, 5.338
- Catheter-based reperfusion. *See* Percutaneous coronary intervention
- Cation balance, in lens, maintenance of, 11.21, 11.22f
- Cats
 - Bartonella henselae* transmitted by, 8.248, 8.265, 9.256
 - toxocariasis transmitted by, 9.228
 - toxoplasmosis transmitted by, 1.256, 9.219, 9.220
- CATT clinical trial, 12.83, 12.84t
- Causal risk factor, 1.22. *See also* Risk factor
- Cause-and-effect diagram, 1.30, 1.30f
- Caustic chemicals, ocular injury caused by, 8.375–384, 8.376t. *See also* Chemical injury
- Caustic soda, ocular injury caused by, 8.376t
- Cautery, thermal
 - for conjunctivochalasis, 8.86, 8.361
 - for punctal occlusion, 7.282, 8.65
 - for superior limbic keratoconjunctivitis, 8.84
- Cavernous hemangioma, 1.126, 4.6. *See also* Vascular malformations
 - cerebrofacial. *See* Sturge-Weber syndrome
 - of conjunctiva/ocular surface, 8.345, 8.345t, 8.346
 - optic neuropathy caused by, 5.126
 - orbital, 4.6, 4.233, 4.234f, 7.68–69, 7.69f
 - retinal, 4.285f, 4.285–286, 12.168, 12.169f
- Cavernous optic atrophy of Schnabel, 4.246, 4.247f
- Cavernous sinus, 2.35f, 2.105, 2.105f, 2.106f, 5.6f, 5.11, 5.21f, 5.22, 5.23f, 7.14f, 7.15f
- carotid artery fistulas and, 5.203–206, 5.204f, 5.205f, 7.72f, 7.72–74, 7.73f
 - direct, 7.72–73
 - dural (indirect), 7.72, 7.73
 - neuroimaging in evaluation of, 5.70, 5.72t, 5.204, 5.204f, 5.205f
- cranial nerve IV (trochlear) in, 5.42f, 5.43, 5.43f
- cranial nerve V₁ (ophthalmic) in, 2.100
- cranial nerve VI (abducens) in, 5.41, 5.42f, 5.43f
- Horner syndrome caused by lesions of, 5.260t
- inflammation in (Tolosa-Hunt syndrome), 5.203
- multiple cranial nerve paresis caused by lesions of, 5.202
- ophthalmoplegia caused by lesions of, 5.202–206, 5.204f, 5.205f
- pain caused by lesions of, 5.296
- Cavernous sinus syndrome, 5.339
- Cavernous sinus thrombosis (CST), 5.345, 6.214
 - orbital infection/cellulitis and, 5.345, 7.48
- Cavitation, 11.99
- CBS. *See* Capsular block syndrome
- CCBs. *See* Calcium channel blockers
- CCC. *See* Continuous curvilinear capsulorrhexis
- CCD. *See* Charge-coupled device
- CCDDs. *See* Congenital cranial dysinnervation disorders
- CCL. *See* Corneal (collagen) crosslinking
- CCN1 gene, in neurofibromatosis, 4.238
- CCR5 defect, HIV infection/AIDS and, 1.266–267
- CCR5-*delta*32 gene, HIV infection/AIDS and, 1.267
- CCR5 receptor inhibitors, for HIV infection/AIDS, 1.267
- CCRS. *See* Co-contractive retraction with jaw-eyelid synkinesis syndrome
- CCT. *See* Central cornea, thickness of
- CCTA. *See* Coronary computed tomography angiography
- CCTVs, 3.323
- CD4, in HIV infection/AIDS, 1.263
- CD19, in lymphoma, 4.232
- CD20
 - in lymphoma, 4.232
 - in nonspecific orbital inflammation, 4.225
- CD20 receptor blockers, for thyroid eye disease, 7.58
- CD25, in nonspecific orbital inflammation, 4.225
- CD28, drugs blocking, 1.175
 - for rheumatic disorders, 1.151
- CD34, in orbital solitary fibrous tumors, 4.235
- CD40, orbital fibroblast, thyroid eye disease and, 7.55
- CD46, in immune privilege, 9.61
- CD95, ligand. *See* Fas ligand
- CD154, orbital fibroblast, thyroid eye disease and, 7.55
- CD340, in immunohistochemistry, 4.35
- CD antigens. *See also specific type*
 - in immunohistochemistry, 4.35
- CD4⁺ T cells. *See also* Helper T cells; T cells
 - in B-lymphocyte activation, 9.37–38

- class II MHC molecules as antigen-presenting platform for, 9.35*f*, 9.35–36
- in cytomegalovirus retinitis, 12.235
- cytotoxic T lymphocytes and, 9.48, 9.49*f*
- in delayed hypersensitivity (type IV) reactions, 9.38, 9.39*f*, 9.45, 9.45*f*, 9.46, 9.46*t*
- sympathetic ophthalmia and, 9.48
- differentiation of, 9.37
- epitope recognition and, 9.34
- in external eye defense, 8.12*f*
- in HIV infection/AIDS, 1.263, 8.241, 9.293, 9.294
- immune recovery uveitis and, 9.294
- in HTLV-1 infection, 9.212
- in immune processing, 9.36*f*, 9.37, 9.38
- regulatory, 9.37, 9.38, 9.45*f*
- CD8⁺ T cells. *See also* T cells
 - class I MHC molecules as antigen-presenting platform for, 9.34*f*, 9.34–35
 - cytotoxic, 9.38–39, 9.39*f*, 9.48–49, 9.49*f*
 - in viral conjunctivitis, 9.56
 - epitope recognition and, 9.34
 - in external eye defense, 8.12*f*
 - in immune processing, 9.36*f*, 9.38
 - regulatory (suppressor), 9.34, 9.38. *See also* Regulatory (Treg/suppressor) T cells
- CD25⁺ T cells, regulatory, 9.37, 9.38
- CDB1 (corneal dystrophy of Bowman layer type 1). *See* Reis-Bücklers corneal dystrophy
- CDB2 (corneal dystrophy of Bowman layer type 2). *See* Thiel-Behnke corneal dystrophy
- CDC (Centers for Disease Control and Prevention), 1.207, 1.217, 1.225
 - cataract epidemiology and, 11.5
- CD4⁺/CD8⁺ ratio, in HIV infection/AIDS, 1.263
- CDCR. *See* Conjunctivodacryocystorhinostomy
- CDKs. *See* Cyclin-dependent kinases
- cDNA, 2.133
 - sequencing, 2.161
- cDNA library, 2.138
- CDS (Cornea Donor Study), 8.416
- CDVA. *See* Corrected distance visual acuity
- CE (Conformité Européenne) marking, 13.3
 - for intrastromal corneal ring segments, 13.65
 - for small-incision lenticule extraction, 13.203
- CEA. *See* Carotid endarterectomy
- Cecentral scotoma, 5.103, 5.105*t*, 5.106*f*, 6.368
- Cefaclor, 1.273*t*
 - ocular effects of, 1.307*t*
- Cefadroxil, 2.345
- Cefamandole, 1.273*t*, 2.345
- Cefazolin, 1.273*t*, 2.344*t*, 2.345
 - for bacterial keratitis, 8.270*t*
 - for endocarditis prophylaxis, 1.243*t*
- Cefepime, 1.273*t*, 2.346
- Cefoperazone, 2.346
- Cefotaxime, 1.273*t*, 2.346
 - for Lyme disease, 9.247*t*
- Cefoxitin, 1.273*t*, 2.345
- Cefpirome, 1.273*t*, 2.346
- Ceftaroline, 1.273*t*
- Ceftazidime, 1.273*t*, 2.344*t*, 2.346
 - for bacterial keratitis, 8.270*t*
 - after corneoscleral laceration repair, 8.409
 - for endophthalmitis
 - after cataract surgery, 11.162
 - postoperative, 12.389
- Ceftizoxime, 2.346
- Ceftriaxone, 1.273*t*, 2.344*t*
 - for bacterial keratitis, 8.270*t*
 - for endocarditis prophylaxis, 1.243*t*
 - for gonococcal conjunctivitis, 8.259
 - in neonates, 8.264
 - for Lyme disease, 9.247*t*
 - for neurosyphilis in HIV coinfection, 1.250
 - for syphilis, 9.243
- Cefuroxime, 1.273*t*, 2.345
 - intracameral, during cataract surgery, 11.94, 11.162
 - for Lyme disease, 9.247*t*
 - ocular effects of, 1.307*t*
- “Ceiling effect,” 1.24
- Celecoxib, 1.172, 2.335*t*, 9.94
 - cardiovascular toxicity and, 2.239
- Cell-adhesion molecules (CAMs), 9.16, 9.37
 - in homing, 9.40
 - neural, in retinal pigment epithelium, 2.273
 - in neutrophil recruitment and activation, 9.16
- Cell cycle, 2.148–150, 2.149*f*
- Cell death, programmed (PCD/apoptosis), 2.132, 2.154, 2.155
 - by cytotoxic T lymphocytes, 9.48–49, 9.49*f*
 - in DNA repair, 2.154, 2.155
 - Fas ligand (CD95 ligand/FasL) in, 9.48–49, 9.49*f*, 9.58
- Cell lysis, by cytotoxic lymphocytes, 9.48, 9.49*f*
- Cell-marker studies, in orbital tumor evaluation, 7.33
- Cell-mediated immunity. *See* Cellular immunity
- Cell wall
 - bacterial, 8.243–244
 - innate immune response and, 9.14, 9.14*t*
 - fungal, 8.249
- Cellophane maculopathy, 12.335
- Cellular atypia
 - conjunctival melanocytic intraepithelial neoplasia and, 4.66–68, 4.67*f*
 - primary acquired melanosis and, 4.65, 4.66, 4.67*f*, 8.342–343
- Cellular immunity/immune system (cell-mediated immunity), 1.241. *See also* Lymphocyte-mediated immune effector responses
 - deficient, in HIV infection/AIDS, 1.263
 - in mucous membrane pemphigoid, 8.299
- Cellular retinaldehyde-binding protein/cytoplasmic retinal-binding protein (CRALBP)
 - in aqueous humor, 2.231
 - mutation in, 2.265
- Cellulitis, 4.204, 4.204*f*, 7.44–48, 7.46*f*, 7.46*t*, 7.47*f*
 - dacryocystitis and, 7.44, 7.285, 7.286*f*
 - orbital, 6.213–215, 6.214*f*, 7.46*f*, 7.46*t*, 7.46–48, 7.47*f*
 - in children, 7.47
 - pain in, 5.295, 7.45, 7.46
 - preseptal, 4.204, 4.204*f*, 6.170, 6.212–214, 7.44–46
 - in children, 7.44, 7.45
 - Haemophilus* causing, 7.44, 8.256
- Cellulose, in artificial tears, 2.341
- Cellulose sponge, in surface ablation, 13.92

- “CEMAS (The Classification of eye movement abnormalities and strabismus)”, 5.234
- Center-involved diabetic macular edema
description of, 12.92
imaging of, 12.109, 12.110f
- Centers for Disease Control and Prevention (CDC), 1.207, 1.217, 1.225
cataract epidemiology and, 11.5
- Centimorgan (cM), 2.132, 2.150
- Central, Steady, and Maintained (CSM) method, 6.6
- Central areolar choroidal dystrophy (CACD), 12.277
- Central blindness, age-related macular degeneration progression to, 12.86
- Central cornea, 2.38–39, 2.39f, 8.25, 8.25f
thickness of (CCT), 6.181, 6.281, 8.25, 8.41, 8.42.
See also Cornea, thickness/rigidity of
glaucoma and, 10.25, 10.31, 10.81, 10.82, 10.90
in infants and children, 10.159
normal-tension glaucoma and, 10.86–87
in infants and children
normal, 10.159
in primary congenital glaucoma, 10.159
ocular hypertension and, 8.41, 10.25, 10.90, 10.112
tonometry measurements affected by, 10.25, 10.81, 10.82, 10.86
transparency disorders, 6.257–258t, 6.257–263, 6.258f
- Central corneal power (K), 8.26. See also Cornea, refractive power of
description of, 3.243, 3.248
errors in, 3.252
in keratoconus/corneal ectasia, 8.32t
measurement of, 8.26–27, 8.27f, 13.7–9. See also Keratometry/keratometer
after refractive surgery, 13.193
simulation measurements (SIM K), 13.19
- Central dogma (of genetics), 2.151f, 2.151–154
- Central epithelial edema, 3.232
- Central fusion, 6.42
- Central fusion disruption, 6.48, 6.79, 6.104
- Central islands, after photoablation, 13.103–104, 13.104f
- Central macular atrophic lesions, 12.266
- Central nervous system (CNS)
Behçet disease involvement of, 12.230
cryptococcosis of, 5.356
disorders of. See Neurologic disorders
incontinentia pigmenti involvement of, 12.286
lymphoma/intraocular lymphoma of, 1.237, 4.135f, 4.135–137, 4.136f, 4.311f, 4.311–313, 4.313f, 5.349, 9.273–276, 9.274f, 9.275f. See also Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
metabolic abnormalities of
abetalipoproteinemia, 12.289–290
lysosomal, 12.291–292, 12.292f
mucopolysaccharidoses, 12.290–291
neuronoid ceroid lipofuscinoses, 12.289, 12.290f
peroxisomal disorders, 12.290
Refsum disease, 12.290
retinal degeneration caused by, 12.288–292
vitamin A deficiency, 12.289–290
metastatic lesions in, ocular metastases associated with, 4.304, 4.304f
primary vitreoretinal lymphoma involvement of, 12.234
zygomycosis of, 5.355
- Central (type 2) neurofibromatosis, 5.300, 5.334t, 10.156
seventh nerve (facial) palsy and, 5.279, 5.279f
- Central optical clear zone. See also Optical zone, corneal
arcuate keratotomy and, 13.54–55, 13.56
radial keratotomy and, 13.50, 13.50f, 13.51
IOL power calculations affected by, 13.193
- Central orbital fat pad, 7.149
- Central posterior keratoconus, 6.259
- Central posterior surface. See Base curve
- Central retinal artery (CRA), 2.73, 2.88f, 2.90, 2.91, 2.91f, 2.92f, 5.12, 5.13f, 5.14, 5.14f, 5.16f, 5.17f, 10.44–45, 10.45f
anatomy of, 12.16
occlusion of. See Central retinal artery occlusion
optic nerve supplied by, 5.17f, 5.26, 10.44–45, 10.45f
retinal inner layers supplied by, 12.140
- Central retinal artery occlusion (CRAO), 4.156, 4.157f
anti-VEGF therapy for, 12.146
causes of, 12.144
ciliary artery occlusion with, 12.144, 12.145f
electroretinography findings in, 12.50
emboli as cause of, 12.144
giant cell arteritis as cause of, 12.145
hyaluronic filler injection causing, 7.239, 7.240f
illustration of, 12.16f, 12.144f
iris neovascularization in, 12.146
management of, 12.146
retinal infarction caused by, 12.143
spectral-domain optical coherence tomography of, 12.144f
symptoms and signs of, 12.143
transient visual loss and, 5.161
vision loss caused by, 12.143–144
- Central retinal vein (CRV), 2.35f, 2.88f, 2.91f, 2.92f, 5.17f, 5.21, 5.21f, 10.44, 10.45f, 10.46
occlusion of. See Central retinal vein occlusion
optic nerve drained by, 5.17f, 10.45f, 10.46
- Central retinal vein occlusion (CRVO), 4.156–158, 4.158f
aflibercept for, 12.135
age and, 12.133
angle-closure glaucoma and, 10.143–144
neovascularization and, 10.134–135
bevacizumab for, 12.135
causes of, 12.133–134
chronic changes caused by, 12.127f
cilioretinal artery occlusion caused by, 12.143
clinical findings of, 12.127f, 12.130
complications of, 12.135
corticosteroids for, 12.137–138
cystoid macular edema caused by, 12.136f
differential diagnosis of, 12.134
diuretic and, 12.134
electroretinography findings in, 12.50
evaluation of, 12.134–135
follow-up for, 12.134
hypercoagulable states and, 1.147, 12.134
hypertensive retinopathy and, 12.122
hyperviscosity retinopathy versus, 12.134
intraocular pressure in, 12.133

- iris neovascularization in, 12.133, 12.135
- ischemic/complete/nonperfused, 4.156, 4.157–158, 4.158f, 12.132f
- macular laser surgery for, 12.135
- management of, 12.134–135
- neovascularization in, 12.125
- nonischemic, 12.130, 12.131f
- ocular ischemic syndrome versus, 12.134
- open-angle glaucoma and, 10.84, 12.133
- oral contraceptives and, 12.134
- panretinal photocoagulation for, 12.135
- papillophlebitis and, 5.125–126, 5.126f
- pars plana vitrectomy for, 12.135
- pharmacologic management of, 12.135–138
- progression of, follow-up for, 12.134
- ranibizumab for, 12.135
- retinal microvascular changes in, 12.125, 12.127f
- risk factors for, 12.133–134
- in sarcoidosis, 9.169–170
- spontaneous resolution of, 12.125
- transient visual loss and, 5.170
- treatment of, 12.135
- vision loss caused by, 12.130
- vitreous hemorrhage secondary to, 12.135
- Central scotomas, 5.103, 5.105t, 5.106f, 6.368, 12.86, 12.265
 - nonorganic disorders and, 5.306
- Central serous chorioretinopathy (CSC)
 - age and, 12.189
 - age-related macular degeneration versus, 12.67, 12.76, 12.79
 - autofluorescence abnormalities in, 12.192f
 - choroidal thickening in, 12.191
 - corticosteroids as cause of, 12.300
 - demographics of, 12.189–191, 12.190f
 - differential diagnosis of, 12.193–194
 - discovery of, 12.189
 - enhanced depth imaging optical coherence tomography findings, 12.67, 12.191, 12.193f
 - fluorescein angiography findings in, 12.190, 12.191f
 - fundus autofluorescence of, 12.32
 - historical descriptions of, 12.189
 - imaging of, 12.190–192, 12.191–193f
 - indocyanine green angiography of, 12.38, 12.192, 12.194f
 - neovascularization associated with, 12.194
 - nonneovascular age-related macular degeneration versus, 12.67, 12.76
 - optical coherence tomography of, 12.32
 - photodynamic therapy for, 12.194
 - polypoidal choroidal vasculopathy versus, 12.193
 - retinal detachment caused by, 12.189, 12.191
 - retinal pigment epithelium pigmentation in, 12.190, 12.190f
 - sildenafil as cause of, 12.299
 - stress and, 12.191
 - symptoms and signs of, 12.189–190
 - systemic conditions associated with, 12.191
 - systemic corticosteroids as risk factor for, 12.191
 - treatment of, 12.194
 - visual acuity in, 12.190
 - white dots with, 12.191, 12.191f
- Central stromal inflammation, 8.50–52
- Central supporting connective strand, 2.88f
- Central suppression, 6.48
- Central suppression scotoma, 4Δ base-out prism test for, 6.79
- Central surgical space (intraconal fat/surgical space), 7.11, 7.115f, 7.116
- Central toxic keratopathy, after photoablation, 13.105f, 13.105–106
- Central Vein Occlusion Study (CVOS), 4.157
- Central vestibular instability nystagmus, 6.149
- Central vestibular nystagmus, 5.216, 5.243t, 5.243–246, 5.245f
 - instability (periodic alternating/PAN), 5.243t, 5.245–246
- Central vision loss. *See also* Vision loss/impairment
 - in amblyopia, 6.54–55
 - in leukemia, 6.414
 - in optic atrophy, 6.384
- Central visual field, 3.315, 3.317
 - in low vision, 5.85, 5.85f
- Central vitreous, 12.7
- Central zone
 - of cornea, 8.25, 8.25f. *See also* Central cornea
 - of lens epithelium, 2.64, 2.242
- Centration, for photoablation, 13.91–92
 - decentered ablation and, 13.104
- Centromere, 2.132
- CEP290 gene, in Leber congenital amaurosis, 2.183f
- Cephalexin, 1.273t, 2.345
 - for endocarditis prophylaxis, 1.243t
- Cephalgias, trigeminal autonomic (TACs), 5.293–294
 - Horner syndrome and, 5.260t, 5.261
- Cephalosporins, 1.273t, 1.276, 2.343, 2.344t, 2.345–346.
 - See also specific agent*
 - allergic reaction to, 2.343
 - after penetrating and perforating trauma repair, 8.409
- Cephalothin, 2.345
- Cephadrine, 2.345
- Ceramide trihexosidase, defective/deficiency of, 2.175t
- Ceramide trihexoside, 12.291
 - in Fabry disease, 2.203, 8.176
- Cerebellar arteries
 - anterior inferior (AICA), 5.19f, 5.20
 - cranial nerve relationship and, 2.102, 5.42f
 - posterior inferior (PICA), 5.19, 5.19f, 5.20
 - superior (SCA), 5.18f, 5.19f, 5.20
 - cranial nerve relationship and, 2.94, 2.95f, 2.97, 5.42f
- Cerebellar hemangioblastoma, with retinal angiomatosis (von Hippel–Lindau disease), 4.284–285, 5.330, 5.331f, 5.334t
- Cerebellopontine angle, 2.101, 2.103
 - tumors of
 - Bruns nystagmus and, 5.243
 - seventh nerve (facial) palsy and, 5.276–277f, 5.278, 5.278t, 5.279
 - sixth nerve (abducens) palsy and, 5.200–201
- Cerebellum, 5.33, 5.39–40, 5.41f
 - dysfunction of, in multiple sclerosis, 5.317
 - saccadic eye movement control and, 5.221
- Cerebral achromatopsia, 5.179
- Cerebral akinetopsia, in Alzheimer disease, 1.206

- Cerebral aneurysm, 5.338–342, 5.339f, 5.340f, 5.341f
 neuroimaging in diagnosis of, 5.69–70, 5.72t, 5.194f, 5.194–195, 5.340, 5.341f
 ruptured, 1.126, 1.127, 5.338–339, 5.340, 5.341
 third nerve (oculomotor) palsy and, 5.20, 5.339
 aberrant regeneration and, 5.198
 divisional palsy and, 5.197
 pupil-involving, 5.194f, 5.194–195, 5.265
 pupil-sparing, 5.196
 in younger patients, 5.197
- Cerebral (intracerebral) angiography/arteriography. *See* Angiography/arteriography
- Cerebral aqueduct (Sylvius), 5.36f, 5.41f, 5.192
- Cerebral artery
 anterior (ACA), 2.90, 2.107f, 5.16f, 5.18, 5.27f
 cranial nerve relationship and, 2.85f, 5.18–19, 5.42f
 middle (MCA), 2.107f, 5.16f, 5.18, 5.18f, 5.19, 5.27f
 aneurysm of, 5.339f
 cranial nerve relationship and, 2.84f, 2.85f, 5.42f
 posterior (PCA), 2.93, 2.107f, 5.12, 5.18, 5.18f, 5.19f, 5.20
 aneurysm of, 5.339f
 cranial nerve relationship and, 2.84f, 5.42f
- Cerebral artery occlusion, stroke caused by, 1.123
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 5.295
 migrainelike headache in, 5.295
 stroke and, 1.120
- Cerebral/cortical blindness, 5.158, 5.336–337
 blindsight and, 5.181
 denial of (Anton syndrome), 5.158, 5.180–181, 5.337
- Cerebral diplopia, 5.185
- Cerebral edema, MRI in evaluation of, 5.64f, 5.65t, 5.66, 5.67f, 5.75
- Cerebral hemisphere abnormalities, 6.361
- Cerebral ischemia, 1.120–123. *See also* Stroke
 MRI in evaluation of, 5.64f, 5.65t, 5.66, 5.67f, 5.75, 5.167
- Cerebral palsy, hypoaccommodation in, 6.9
- Cerebral peduncles, 5.18f, 5.34f, 5.41f
- Cerebral ptosis, 5.273
- Cerebral vasculitis, 12.222
- Cerebral vasoconstriction syndrome, reversible (RCVS), 5.346–348, 5.347f
- Cerebral venography, in cerebral venous thrombosis, 5.346
- Cerebral venous thrombosis (CVT), 5.345–346
 in diabetes mellitus, 1.49
 in idiopathic intracranial hypertension, 5.111
 neuroimaging in, 5.69, 5.69f, 5.72t, 5.346
- Cerebral visual impairment (CVI), 6.186–187
- Cerebral (cortical/retrogeniculate) visual impairment (CVI). *See* Cerebral/cortical blindness
- Cerebrofacial (encephalotrigeminal/encephalofacial) angiomas/Sturge-Weber syndrome (SWS), 5.331, 5.332f, 5.334t, 10.30, 10.155
 choroidal hemangioma in, 4.197, 4.281, 5.332f, 5.334t
 glioma associated with, 5.332f, 5.334t, 10.30, 10.155
 in children, 5.332f, 10.155
 port-wine stain (port-wine nevus/nevus flammeus) in, 5.332f, 5.334t, 8.346, 10.30, 10.155
- Cerebroside α -galactosidase, defective/deficiency of, 2.175t
- Cerebrospinal fluid (CSF)
 in multiple sclerosis, 5.319
 in neuromyelitis optica, 5.322
 in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.274
 in syphilitic serology, 1.248, 9.241
 in uveitis, 9.89t
 in Vogt-Koyanagi-Harada syndrome, 9.176
- Cerebrotendinous xanthomatosis, 6.387f
- Cerebrovascular accident. *See* Stroke
- Cerebrovascular disease, 1.119–127. *See also* Ischemia; Stroke; *specific type*
 carotid occlusive disease, 1.124–126
 in diabetes mellitus, 1.49, 1.125
 fourth nerve (trochlear) palsy caused by, 5.199
 hypercholesterolemia and, 1.82
 hypertension management and, 1.69t, 1.76
 internuclear ophthalmoplegia caused by, 5.190
 intracranial hemorrhage, 1.126–127
 ischemic, 1.120–123
 neuro-ophthalmic signs of, 5.335–348
 neuroimaging in evaluation of, 5.60f, 5.67–71, 5.68f, 5.72t
 recent developments and, 1.119
 sixth nerve (abducens) palsy caused by, 5.200, 5.201, 5.345–346
 third nerve (oculomotor) palsy caused by, 5.195, 5.198
 transient visual loss caused by, 5.36, 5.161, 5.162, 5.164–165
- Cerivastatin, 1.87
- Certolizumab pegol, 1.174
- Cerulean cataract, 11.37, 11.38f
- Ceruloplasmin, in Wilson disease, 2.203, 8.189
- Cervarix, 1.224
- Cervical cancer, 1.209–210
 in HIV infection/AIDS, 1.266
 human papillomavirus and, 1.207, 1.209, 1.224, 1.228, 1.262
 screening for, 1.209–210, 1.210t
- Cervical fascia, deep and superficial, 7.143
- Cervical ganglia, 5.53f, 5.54
 Horner syndrome caused by lesions of, 5.260t
 superior, 2.11
 dilator muscle innervation and, 2.56
- Cervical nerve, 5.51f, 5.52, 5.276–277f, 7.143, 7.144f
- Cervicofacial division, of cranial nerve VII (facial), 2.104, 5.52
- Cetamide. *See* Sulfacetamide
- Cethromycin, 1.278
- Cevimeline, for dry eye, 8.64
- C₃F₈. *See* Perfluoropropane
- CFEOM. *See* Congenital fibrosis of the extraocular muscles
- CFH gene, 12.63
- CFH (complement factor H) gene, in age-related macular degeneration, 4.160
- CGH. *See* Comparative genomic hybridization
- cGMP (cyclic guanosine monophosphate)
 in cone phototransduction, 2.261
 mutation in, 2.161
 in rod phototransduction, 2.259, 2.260f, 2.261

- cGMP (cyclic guanosine monophosphate)-gated channel
 cone, 2.261
 mutation in, 2.264
 rod, 2.259, 2.260*f*, 2.261
 mutation in, 2.161, 2.263
- CGRP. *See* Calcitonin gene-related peptide
- CHADS2 risk calculator, 1.114
- Chair rotation fixation test, vestibular-ocular response suppression/smoot-pursuit deficits and, 5.225, 5.225*f*, 5.226
- Chalasis/conjunctivochalasis, 8.45*t*, 8.85*f*, 8.85–86, 8.114
 surgical management of, 8.86, 8.361–362
- Chalazion (chalazia), 4.204, 4.206*f*, 6.198–199, 6.199*f*, 6.244, 7.162–163, 7.163*f*, 8.77
 internal hordeolum and, 8.77
 in rosacea, 8.70
 sebaceous carcinoma misdiagnosed as, 7.183–184
- Chalcosis, 4.120, 11.59, 12.362
 corneal deposits/pigmentation in, 8.118*t*
 glaucoma and, 10.103
- Challenge testing
 in contact dermatophlepharitis, 8.287
 in hay fever conjunctivitis, 8.288
- Chamber angle. *See* Anterior chamber angle
- Chamber deepening. *See also* Anterior chamber, flat or shallow
 for angle-closure glaucoma, 10.220
- Chancre, syphilitic, 1.248, 9.237
- Chandler syndrome, 4.100, 8.111, 8.126, 10.136, 10.137*f*.
See also Iridocorneal endothelial (ICE) syndrome
- Charcot-Marie-Tooth disease, 12.282*t*
- Charge-coupled device (CCD), 3.289, 13.10*f*
- CHARGE syndrome, 6.364
- Charged-particle radiation
 for choroidal hemangioma, 4.283
 for choroidal melanoma/ciliary body melanoma, 4.276
- Charles Bonnet syndrome, 3.309, 3.312, 5.177–178, 12.86
- Chart review, monitoring systems and, 1.25–26
- Chatter, 11.99, 11.100
- Chavasse theory, of infantile esotropia, 6.87
- CHD. *See* Coronary heart disease
- Check ligament of lateral rectus muscle, 7.7
- Checklist (care system), 1.30
- CHED. *See* Congenital hereditary endothelial dystrophy
- CHED1. *See* Posterior polymorphous corneal dystrophy
- CHED/CHED2. *See* Congenital hereditary endothelial dystrophy
- Chédiak-Higashi syndrome (CHS), 6.407, 12.288
- Cheek advancement/rotation flap (Mustardé flap/procedure), for eyelid repair, 7.194*f*, 7.195
- Cheek elevation, in eyelid repair, 7.193
- Chelation therapy
 for band keratopathy, 8.119
 for Wilson disease, 2.203
- Chemical conjunctivitis, 6.239
- Chemical energy, 3.106
- Chemical exposure, cancer associated with, 1.228
- Chemical injury (burns), 6.376, 8.375–384, 8.376*t*
 acid burns, 8.376*t*, 8.380*f*, 8.380–381, 8.381*f*
 alkali burns, 8.375–380, 8.376*t*, 8.379*f*, 8.380*f*
 amniotic membrane transplantation for, 8.384
 during cataract surgery, corneal edema and, 11.128*t*
 cataracts caused by, 11.59
 classification/grading schemes for, 8.376*t*, 8.376–379, 8.377–378*t*, 8.379*f*
 clinical findings in, 8.376*t*, 8.376–379, 8.377–378*t*, 8.379*f*
 glaucoma and, 10.103–104
 limbal transplantation for, 8.380, 8.384
 management of, 8.381–384, 8.382*f*
 prognostic features of, 8.376*t*
- Chemodeneration. *See* Botulinum toxin
- Chemokines, 9.26
 in external eye defense, 8.12*f*
- Chemoreduction. *See* Chemotherapy (cancer)
- Chemosis, 8.46*t*
 insect/arachnid injuries causing, 8.386
 in nonspecific orbital inflammation, 7.64
 in thyroid eye disease, 7.52, 7.52*f*, 7.54
- Chemotaxis, in neutrophil recruitment and activation, 9.16, 9.17–18, 9.18*f*
- Chemotherapy (cancer), 1.231–235, 1.232–234*t*. *See also specific agent*
 canalicular obstruction caused by, 7.274
 for choroidal/ciliary body melanoma, 4.277
 for lacrimal gland tumors, 7.93
 for lymphoma, 4.312
 MEK inhibitors, 12.299
 for metastatic eye disease, 4.310
 for optic nerve glioma, 5.130, 7.77
 primary vitreoretinal lymphoma treated with, 12.234
 recent developments in, 1.227
 for retinoblastoma, 4.253, 4.299–300, 4.300*f*, 6.356–357
 for rhabdomyosarcoma, 7.83
 topical
 ocular surface toxicity of, 8.90*t*
 for ocular surface tumors, 8.330*f*, 8.330–332, 8.331*f*
- Cherry-red spot
 in central retinal artery occlusion, 4.156, 12.143
 in commotio retinae, 12.353
 in mucopolidoses, 8.178
 ophthalmic artery occlusion and, 12.146
 in Tay-Sachs disease, 12.291, 12.292*f*
- Cherry-red spot-myoclonus syndrome, 6.388*t*, 6.390
- Chest compressions, in CPR, 1.295, 1.297*f*, 1.298
- Chest pain, in angina pectoris/myocardial infarction, 1.93, 1.94
- Chest pain observation unit, 1.103
- Chest physiotherapy
 postoperative, 1.132
 preoperative, 1.288
- Chest radiograph
 in congestive heart failure, 1.105
 in pulmonary diseases, 1.131
- CHF. *See* Congestive heart failure
- Chi-square (χ^2) test, 1.7
- Chiasm (optic), 2.85*f*, 2.90, 2.92–93, 5.23*f*, 5.27*f*, 5.27–28, 5.28*f*
 gliomas involving, 5.129, 5.129*f*, 5.130, 6.396, 7.74–77, 7.75*f*
 lesions of, 5.146–152
 etiology of, 5.147–152

- extrinsic lesions, 5.147–151, 5.149*f*, 5.150*f*
- field loss patterns in, 5.146–147, 5.147*f*, 5.148*f*
- intrinsic lesions, 5.151–152, 152*f*
- in multiple sclerosis, 5.318
- neuroimaging in evaluation of, 5.72*t*, 5.91, 5.148*f*, 5.149*f*, 5.150*f*, 5.152*f*
- in neuromyelitis optica, 5.320
- parasellar lesions, 5.146, 5.150. *See also under Parasellar*
- Chiasmal neuritis, 5.151–152*f*
- Chibroxin. *See* Norfloxacin
- Chickenpox, 6.242–243. *See also* Varicella
- Chikungunya fever, 9.213–214
- Chikungunya virus retinitis, 12.247
- Child abuse
 - abusive head trauma, 6.381–384, 6.382–383*f*
 - ocular trauma caused by, 6.381, 6.384
- Childhood glaucoma, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147–167
 - algorithm for, 6.279*f*
 - aniridia and, 10.150, 10.155
 - gonioscopic appearance of, 10.159
 - anomalies associated with, 10.4*t*, 10.6*t*, 10.147, 10.148*t*, 10.151
 - anterior segment examination in, 10.158
 - aphakic, 6.285, 10.156–157
 - Axenveld-Rieger syndrome and, 4.99, 8.97*t*, 8.102, 10.31, 10.150, 10.153–154
 - axial length measurements in, 10.160
 - cataract surgery and, 10.149*t*, 10.156
 - central corneal thickness in, 10.159
 - classification of, 6.277, 6.278*t*, 6.279*f*, 10.4*t*, 10.6*t*, 10.147–150, 10.148*t*, 10.149–150*t*
 - corneal edema and, 8.108–109
 - corneal enlargement and, 8.95, 8.96*t*, 8.99–100, 8.108, 10.31, 10.147, 10.158
 - corneal opacities and, 8.108–109
 - corticosteroids as cause of, 6.284
 - definition of, 6.277
 - developmental, 10.153–156
 - diagnosis/differential diagnosis of, 10.151–152, 10.152*t*
 - examination/evaluation in, 10.151–152, 10.152*t*, 10.157*t*, 10.157–160
 - external examination in, 10.158
 - follow-up of, 6.290–291, 10.167
 - genetic/hereditary factors in, 10.11*t*, 10.150
 - genetics of, 6.277–278
 - gonioscopy in, 10.159
 - history in, 10.157
 - juvenile open-angle, 6.278, 6.284, 10.4*t*, 10.147, 10.148*t*, 10.153
 - medical therapy for, 10.153, 10.164–165
 - megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
 - neurofibromatosis and, 10.156
 - optic nerve/fundus evaluation in, 10.160
 - pachymetry in, 10.159
 - Peters anomaly and, 4.74, 10.150, 10.154
 - primary, 10.4*t*, 10.147–148, 10.148*t*
 - genetics of, 10.11*t*, 10.150
 - infantile, 10.151
 - juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153
 - primary congenital glaucoma, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*
 - anterior segment findings in, 6.282, 6.282*f*
 - axial length in, 6.283
 - central corneal thickness in, 6.281
 - clinical manifestations of, 6.279–280, 6.280*f*
 - corneal edema in, 6.279–280
 - corneal findings in, 6.280*f*, 6.280–281
 - definition of, 6.278
 - diagnostic examination for, 6.280–283, 6.282–283*f*
 - differential diagnosis of, 6.281*t*
 - genetics of, 6.277–278
 - gonioscopy for, 6.282, 6.282*f*
 - goniotomy for, 6.285, 6.286*f*
 - incidence of, 6.278
 - natural history of, 6.283–284
 - optic nerve findings in, 6.282–283, 6.283*f*
 - optical coherence tomography of, 6.283
 - pathophysiology of, 6.278
 - surgical treatment of, 6.285–287, 6.286*f*
 - tonometry in, 6.281–282
 - trabeculotomy, 6.286*f*, 6.286–287
 - prognosis for, 6.290–291, 10.166–167
 - secondary, 10.4*t*, 10.148, 10.149–150*t*, 10.156–157
 - acquired condition, 6.284
 - after cataract surgery, 6.285
 - classification of, 6.278*t*
 - nonacquired conditions associated with, 6.284*t*
 - Sturge-Weber syndrome and, 5.332*f*, 10.155
 - surgery for, 10.153, 10.164–165
 - strabismus and, 10.166–167
 - tonometry in, 10.158–159
 - treatment of, 10.153, 10.160–166
 - β -blockers, 6.288, 6.289*t*
 - cyclocryotherapy, 6.287
 - description of, 6.285
 - endoscopic photocoagulation, 6.287–288, 6.288*f*
 - goniotomy for, 6.285, 6.286*f*
 - medical/medications, 6.288–290, 6.289*t*, 10.153, 10.164–165
 - surgery, 6.285–288, 6.286*f*, 6.288*f*, 10.153, 10.160–164, 10.161*f*, 10.162*f*, 10.187
 - trabeculotomy, 6.286*f*, 6.286–287
 - tube shunt implantation surgery, 6.287
 - tumors causing, 10.149*t*
 - vision loss caused by, 6.290
 - visual acuity and, 10.158
- Children. *See also* Infants; *specific topic*
 - absence seizures in, 1.201
 - abuse of. *See* Child abuse
 - amblyopia in, 6.5
 - ametropia correction in, 3.174–175
 - anisometropia in
 - amblyopia caused by. *See* Anisometropic amblyopia
 - description of, 3.175
 - axial length measurements in, 3.254
 - bacterial conjunctivitis in, 6.240*f*, 6.240–241, 8.243, 8.255–256
 - cancer in, 1.237
 - cataract in, 11.34–39, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*. *See also* Cataract, congenital; Cataract, pediatric

- cataract surgery in, 6.301–305. *See also* Cataract surgery, in children
- clinical/cycloplegic refraction in. *See specific disorder*
- Coats disease in, 4.143, 4.143f, 4.295, 4.295f, 12.159
- retinoblastoma differentiated from, 4.295, 4.295f
- confrontation visual field testing in, 6.4, 6.10
- congenital toxoplasmosis in, 12.243
- conjunctivitis in, 6.240f, 6.240–241. *See also* Conjunctivitis, in children
- corneal transplantation in, 8.450–451
- decreased/low vision in. *See* Low vision, in infants
- difficult, eye examination in, 6.5
- drug toxicity and, 2.294
- muscarinic antagonists, 2.313
- electroretinography applications in, 12.50
- emmetropia in, 3.141
- enucleation in, 7.129
- eye examination in
- anterior segment examination, 6.10
 - Brückner test, 6.9
 - communication during, 6.4
 - cycloplegic refraction, 6.10–12
 - difficult child, 6.5
 - distance fixation targets, 6.3, 6.4f
 - dynamic retinoscopy, 6.9
 - fundus, 6.12
 - general consideration and strategies for, 6.3–5
 - glaucoma and, 10.157t, 10.157–160
 - intraocular pressure measurement, 6.10
 - 1 toy, 1 look rule, 6.3, 6.4f
 - in outpatient setting, 6.3, 6.4f
 - practitioner positioning during, 6.4
 - pupil testing, 6.10
 - red reflex, 6.9
 - “safe” environment for, 6.4
 - slit-lamp examination, 6.4–5
 - tonometry, 6.10
 - visual acuity assessment. *See* Children, visual acuity assessment in
 - visual field testing, 6.10
 - vocabulary during, 6.4
- eyedrop administration in, 6.11–12
- eyelid anomalies in, 7.155–162, 7.157f
- glaucoma in, 10.4t, 10.147–167. *See also* Glaucoma, pediatric
- hepatitis B immunization in, 1.219
- Hib vaccine in, 1.223
- history-taking in, 6.3–5
- Horner syndrome in, 5.259, 5.261–262
- hyperopia in, 3.141, 3.174–175
- hypertension in, 1.61, 1.78
- idiopathic intracranial hypertension in, 5.113
- infantile (capillary) hemangiomas in
- of eyelid, 7.161–162
 - of orbit, 7.67f, 7.67–68
- intraocular pressure in
- measurement of, 6.181
 - normal level of, 6.282
- iris heterochromia in, 6.274, 6.274f, 6.274t
- lateral orbitotomy in, 7.120
- low vision in, 3.327–328. *See also* Low vision, in infants
- medulloepithelioma in, 4.296
- meningococcal vaccine in, 1.224, 1.246
- myopia in, 3.142, 3.174
- nasolacrimal duct obstruction in, 6.235
- nystagmus in, 5.235–239, 5.237f, 6.147–157. *See also* Nystagmus
- ocular motor apraxia in, 5.222–223
- optic nerve gliomas in, 4.249, 5.129, 7.74, 7.75, 7.75f, 7.77
- optic nerve sheath meningioma in, 5.129
- optic neuritis in, 6.369, 6.369f
- orbital cellulitis in, 7.47
- orbital fractures in, 7.106
- orbital hemangiomas in, 7.67f, 7.67–68
- orbital inflammation in, 6.215–216, 7.65
- orbital metastatic disease in, 7.98f, 7.98–99
- orbital tuberculosis in, 7.49, 7.49f
- orbital tumors in, 4.228, 4.229. *See also* Orbit, tumors of overrefraction in, 3.169
- pars planitis in, 9.128, 9.129, 9.131
- preoperative assessment in, 1.284–285
- preseptal cellulitis in, 7.44, 7.45, 8.256
- preverbal, visual acuity assessment in, 6.8–9, 6.154
- ptosis in, 6.198
- refractive surgery in, 13.187–188
- slit-lamp examination in, 6.4–5
- staphylomas in, 4.112
- third nerve (oculomotor) palsy in, 5.197
- trauma in, 12.316–317, 12.365–366, 12.366f
- uveitis in. *See* Uveitis
- varicella-zoster infection in, 8.225, 8.227
- vision impairment in, 3.327
- vision rehabilitation in, 6.188–189, 6.189t, 9.292
- visual acuity assessment in, 3.38
- age-specific approaches, 6.5
 - alternative methods, 6.8–9
 - Central, Steady, and Maintained method of, 6.6
 - eye charts for, 6.6t, 6.6–8, 6.7f
 - fixation and following behavior for, 6.5
 - fixation behavior, 6.5–6
 - HOTV test, 6.6, 6.6t, 6.7f
 - induced tropia test, 6.6
 - in nystagmus, 6.8
 - occluders used in, 6.8
 - optotypes for, 6.6t, 6.6–8, 6.7f
 - preferential looking, 6.5, 6.8–9, 6.9f, 6.182, 6.300
 - preverbal children, 6.8–9, 6.154
 - sequence of, 6.8
 - symbol charts for, 6.7
 - visual evoked potential for, 6.9, 6.182, 6.300
- visual evoked potentials application in, 12.53
- visual impairment in, 6.186–187
- Children’s Oncology Group (COG), 4.301
- Chin-lift maneuver, for opening airway, 1.298
- Chip, in microarray, 4.41
- Chlamydia*, 1.154–155, 1.252–253, 8.248–249
- conjunctivitis caused by, 4.52, 4.54f, 8.208t, 8.257t, 8.260t, 8.260–263, 8.261f, 8.262f
 - in adults, 8.257t, 8.260, 8.263
 - in neonates, 8.257t, 8.265
- gonococcal coinfection and, 1.246, 8.259
- ocular infection/inflammation caused by, 8.208t, 8.257t, 8.260t, 8.260–263, 8.261f, 8.262f, 8.265
- HLA disease associations and, 9.65

- persistence/chronic infection and, 8.207
 specimen collection/isolation techniques for
 diagnosis of, 8.209t, 8.211
psittaci. *See Chlamydophila psittaci*
 trachoma caused by, 8.260–263, 8.261f, 8.262f
trachomatis, 1.154–155, 1.246, 1.252–253, 8.208t,
 8.257t, 8.260, 8.260t
 conjunctivitis caused by, 6.238–239, 6.239f, 6.241
 trachoma caused by, 6.241
Chlamydophila psittaci, 1.252, 8.260
 Chloasma, 7.173
 Chlorambucil, 1.175, 9.105, 9.106
 for Behçet disease, 1.169, 9.189
 in cancer chemotherapy, 1.232t
 for uveitis, 9.105, 9.106
 Chloramphenicol, 1.279–280, 2.347t, 2.350–351
 intravenous administration of, 2.301
 for syphilis, 9.243
 Chlorhexidine, for *Acanthamoeba* keratitis, 2.361, 8.278,
 8.279
 Chloride (Cl)
 in aqueous humor, 2.231t, 2.232
 in lens, 11.21
 in tear film, 2.214t, 2.216
 in vitreous, 2.231t, 2.252
 Chloroma (granulocytic sarcoma), 4.316, 6.218,
 7.98–99
 Chloroprocaine, maximum safe dose of, 1.304t
 Chloroquine, 1.173
 bull's-eye maculopathy caused by, 12.295, 12.296f
 indications for, 12.295
 retinal pigment epithelium abnormalities caused by,
 12.295–297, 12.296f
 toxicity of
 cornea verticillata and, 8.130
 retinopathy and, 1.173
 Chlorothiazide, 1.68t, 1.69t
 Chlorpromazine, 12.297
 corneal pigmentation/verticillata caused by, 8.130,
 8.132
 intraoperative floppy iris syndrome and, 11.136,
 11.137t
 lens changes caused by, 11.52
 Chlorpropamide, for diabetes mellitus, 1.45t
 Chlortetracycline, 2.350
 Chlorthalidone, 1.68t, 1.69t
 CHM gene, 12.268
 CHM (Rab escort protein 1/REP-1) gene mutation,
 2.265
 in choroideremia, 2.265
 C₂H₄O₂. *See Acetic acid*
 “Chocolate cyst,” 8.348
 Choking, 1.299
 Cholesterol, in lecithin–cholesterol acyltransferase
 deficiency, 8.180
 Cholesterol absorption inhibitor, for
 hypercholesterolemia/heart disease prevention, 1.85t
 Cholesterol crystals, vitreous hemorrhage and, 4.133
 Cholesterol emboli (Hollenhorst plaques)
 in branch retinal artery occlusion, 4.156
 transient visual loss and, 5.165, 5.165f, 5.166t
 Cholesterol intake/metabolism, cardiovascular disease
 and, 1.82, 1.91–92
 Cholesterol levels, 1.81–82
 drugs for modification of. *See Lipid-lowering therapy*
 elevated. *See Hypercholesterolemia*
 risk assessment/screening/modification and, 1.82–83,
 1.83t
 targets for, 1.81–82
 total, 1.81, 1.85
 Cholesterolosis, 12.348
 Cholestyramine, for hypercholesterolemia/heart disease
 prevention, 1.85t
 Cholinergic agents, 2.307f, 2.307–315, 2.308t, 2.309f,
 2.310f, 2.311t, 2.314t, 2.315t. *See also Muscarinic*
agents; Nicotinic agents; specific agent
 agonists, 2.308t, 2.309f
 direct-acting, 2.308–312, 2.309f, 2.310f, 2.311t
 for acute angle closure, 10.124
 for glaucoma, 10.173t, 10.181–182
 in children, 10.166
 for dry eye, 8.61t, 8.64
 indirect-acting, 2.308, 2.309f, 2.312–313,
 2.314–315
 antagonists, 2.308, 2.308t, 2.315, 2.315t
 ciliary muscle affected by, 2.59
 as miotics, 2.308t, 2.308–313, 2.311t
 Cholinergic receptors, 2.308, 2.308t
 drugs affecting, 2.307f, 2.307–315, 2.308t, 2.309f,
 2.310f, 2.311t, 2.314t, 2.315t. *See also Cholinergic*
agents
 signal transduction and, 2.316t
 Cholinesterase/acetylcholinesterase
 in acetylcholine degradation, 2.309, 2.309f, 2.310f
 defective, succinylcholine effects and, 2.201–202
 Cholinesterase/acetylcholinesterase inhibitors
 (anticholinesterase agents), 2.312–313
 angle closure caused by, 10.122
 cataracts caused by, 11.52
 for glaucoma, 10.173t, 10.181–182
 miotic action of, 2.311t, 2.312–313
 for myasthenia gravis diagnosis, 5.324–325
 for myasthenia gravis treatment, 5.326
 uveitis caused by, 9.121
 Chondritis, auricular or nasal, in relapsing
 polychondritis, 1.164
 Chondroitin sulfate
 in cornea, 2.226
 in mucopolysaccharidoses, 8.175t
 as viscoelastic, 2.368, 11.95
 Chondroitinase, for enzymatic vitreolysis, 2.255
 Chondrosarcoma, of orbit, 7.84
 Chopping techniques, in phacoemulsification, 11.114
 Chord diameter, of contact lens. *See Diameter*
 Chorda tympani, 2.101f, 2.103, 2.104, 5.51f, 5.276–277f
 seventh nerve lesions and, 5.276–277f
 Chordin-like 1 (CHRD1) gene, in megalocornea,
 6.254, 8.96t, 8.99
 Choriocapillaris, 2.59, 2.60f, 2.61f, 2.61–62, 2.62f, 2.70f,
 4.141f, 4.182–183, 9.61
 age-related changes in, 12.61
 anatomy of, 12.17, 12.19, 12.20f
 atrophy of, in choroideremia, 12.258
 blood flow abnormalities in, 12.198
 ghost vessels in, 12.198
 hypertensive choroidopathy findings, 12.123

- immune response/features/microenvironment of, 9.61
 optical coherence tomography angiography of, 12.30f
 in pseudoxanthoma elasticum, 12.199f
 in type 1 choroidal neovascularization, 12.71
- Choriomeningitis, lymphocytic, 9.205–206
- Chorionic villus sampling (CVS), 2.132, 2.206–207
- Chorioretinal atrophy
 genes and loci associated with, 12.256t
 in multifocal choroiditis and panuveitis, 9.156
 in pathologic myopia, 12.214f
 in relentless placoid chorioretinitis, 9.150, 9.151f
- Chorioretinal biopsy
 in primary central nervous system/intraocular/
 vitreoretinal/retinal lymphoma, 9.275
 in tuberculosis, 9.254
 in uveitis, 9.92
- Chorioretinal coloboma, 6.364
- Chorioretinal disruption, traumatic (sclopetaria), 4.22,
 12.357f, 12.357–358
- Chorioretinal edema, 12.379
- Chorioretinal folds, 12.200–201, 12.201f
- Chorioretinal inflammation. *See* Chorioretinitis;
 Chorioretinopathy; *specific disorder*
- Chorioretinal lacunae, 6.338, 6.339f
- Chorioretinal scarring
 in congenital toxoplasmosis, 12.243
 in ocular histoplasmosis syndrome, 9.215, 9.215f,
 9.216, 9.218f, 12.87
 in ocular toxoplasmosis/toxoplasmic chorioretinitis,
 4.147, 4.148f, 9.222, 9.222f, 9.223, 9.223f
- Chorioretinitis, 9.72t
 acute syphilitic posterior placoid, 12.241
Candida causing, 9.266, 9.266f, 9.267f
 in coccidioidomycosis, 9.271
Cryptococcus neoformans causing, 9.270
 in endogenous fungal endophthalmitis, 9.265
 focal, 12.238, 12.238f
 fungal, 4.147, 4.147f. *See also specific type*
 in neuroretinitis, 12.242
 in ocular histoplasmosis syndrome, 9.214–219,
 9.215f, 9.216f, 9.217f, 9.218f
 in onchocerciasis, 9.235, 9.235f
 relentless placoid (ampiginous choroiditis),
 9.150–151, 9.151f
 sclopetaria, 4.22
 in syphilis, 6.412, 9.237, 9.238f, 9.238–239, 9.239f,
 12.241–242, 12.242f
 HIV infection/AIDS and, 9.297–298
 posterior placoid, 9.239, 9.239f, 9.297–298
Toxoplasma, 6.409, 6.410f
 toxoplasmic, 1.257, 4.147–148, 4.148f
 with uveitis, 9.72t. *See also* Posterior uveitis
 vitiliginous (birdshot uveitis/retinochoroidopathy/
 chorioretinopathy), 9.141–143t, 9.144–147,
 9.145f, 9.146f
 ERG in, 9.143t, 9.147
 HLA association in, 9.67, 9.67t, 9.141t, 9.144
 with and without vitritis, flowchart for evaluation of,
 9.75–76t
 in West Nile virus infection, 9.209, 9.209f, 9.210,
 12.246, 12.247f
 in Whipple disease, 9.258
 Zika virus, 12.247
- Chorioretinopathy. *See also* Retinopathy; *specific type*
 birdshot (birdshot uveitis/retinochoroidopathy/
 vitiliginous chorioretinitis), 9.141–143t, 9.144–147,
 9.145f, 9.146f, 12.49
 ERG in, 9.143t, 9.147
 HLA association in, 9.67, 9.67t, 9.141t, 9.144
- central serous
 age and, 12.189
 age-related macular degeneration versus, 12.67,
 12.76, 12.79
 autofluorescence abnormalities in, 12.192f
 choroidal thickening in, 12.191
 corticosteroids as cause of, 12.300
 demographics of, 12.189–191, 12.190f
 differential diagnosis of, 12.193–194
 discovery of, 12.189
 enhanced depth imaging optical coherence
 tomography findings, 12.67, 12.191, 12.193f
 fluorescein angiography findings in, 12.190,
 12.191f
 fundus autofluorescence of, 12.32
 historical descriptions of, 12.189
 imaging of, 12.190–192, 12.191–193f
 indocyanine green angiography of, 12.38, 12.192,
 12.194f
 neovascularization associated with, 12.194
 nonneovascular age-related macular degeneration
 versus, 12.67, 12.76
 optical coherence tomography of, 12.32
 photodynamic therapy for, 12.194
 polypoidal choroidal vasculopathy versus, 12.193
 retinal detachment caused by, 12.189, 12.191
 retinal pigment epithelium pigmentation in,
 12.190, 12.190f
 sildenafil as cause of, 12.299
 stress and, 12.191
 symptoms and signs of, 12.189–190
 systemic conditions associated with, 12.191
 systemic corticosteroids as risk factor for, 12.191
 treatment of, 12.194
 visual acuity in, 12.190
 white dots with, 12.191, 12.191f
- inflammatory (white dot syndromes), 9.140–166,
 9.141–143t. *See also specific disorder*
- peripheral exudative hemorrhagic (PEHCR), 4.270f,
 4.271
- Choristomas, 4.6, 4.47, 4.49f, 5.332, 6.223, 6.256.
See also Dermoids
 complex, 4.48, 4.49f
 conjunctival, 4.47, 4.49f
 orbital, 7.39f, 7.39–41, 7.41f. *See also specific type*
 osseous, 4.48, 4.49f
 phakomatous (Zimmerman tumor), 4.202–203,
 4.203f
- Choristomatous tumors, 6.225–226
- Choroid, 2.37f, 2.59–62, 2.60f, 2.61f, 2.62f, 4.181, 4.181f,
 4.182–183, 4.183f, 5.17f. *See also* Uvea (uveal tract)
 age-related atrophy of, 12.200, 12.212
 amelanotic masses of, 4.263, 4.264f, 4.306, 4.306f
 differential diagnosis of, 4.272t
 anatomy of, 2.37f, 2.59–62, 2.60f, 2.61f, 2.62f, 4.181f,
 4.182–183, 4.183f, 5.17f, 12.19–20, 12.20f, 12.193f
 arterial supply to, 12.194, 12.195f

- autoimmune conditions of
 - Behçet disease, 12.230, 12.230t
 - inflammatory vasculitis, 12.230–231
 - intermediate uveitis, 12.231–232
 - intraocular lymphoma, 12.233–234, 12.234f
 - lupus vasculitis, 12.230–231, 12.231f
 - overview of, 12.229
 - sympathetic ophthalmia, 12.233
 - Vogt-Koyanagi-Harada disease, 12.232f, 12.232–233
- bilateral diffuse uveal melanocytic proliferation
 - effects on, 12.204
- in birdshot uveitis, 9.144–147, 9.145f, 9.146f
- blood circulation in, 12.19–20, 12.20f, 12.194, 12.195f
- blood flow abnormalities in, 12.198
- capillary arrangement in, 12.19
- in choroidal neovascularization, 12.36, 12.37f
- in coccidioidomycosis, 9.271, 9.271f
- coloboma of, 4.184, 4.184f
- cryptococcosis affecting, 9.270, 9.298–299
- detachment of, 4.270, 12.379, 12.379f
 - melanoma differentiated from, 4.270–271
- development of, 2.122
- diseases of. *See also* Chorioretinitis;
 - Chorioretinopathy; Choroiditis; Choroidopathy; *specific type*
- bilateral diffuse uveal melanocytic proliferation, 12.204–205, 12.205f
- central serous chorioretinopathy. *See* Central serous chorioretinopathy (CSC)
- hemangiomas, 12.202f, 12.202–203
- inflammatory, posttraumatic granulomatous, 4.22, 4.22f
- nonarteritic, 12.195–196, 12.197f
- perfusion abnormalities, 12.194, 12.195–197f, 12.199–200f
- Th1-mediated delayed hypersensitivity and, 9.46t
- in tuberculosis, 9.154, 9.251f, 9.251–252, 9.252f
- uveal effusion syndrome, 12.203, 12.204f
- in endogenous fungal endophthalmitis, 9.265
- enhanced depth imaging optical coherence tomography of, 12.25, 12.193f
- filling defects in, 12.198
- focal posttraumatic granulomatous inflammation of, 4.22, 4.22f
- folds in, 12.200–201, 12.201f
- functions of, 12.212
- gyrate atrophy of, 2.175t
- Haller layer, 12.19
- healing/repair and, 4.16
- as heat sink, 12.20
- hemangiomas of, 4.197, 4.198f, 4.281–283, 4.282f, 4.283f
 - in Sturge-Weber syndrome, 4.197, 4.281, 5.332f, 5.334t
- in HIV infection/AIDS, 9.298, 9.298f, 9.298–299
- immune response/features/microenvironment of, 9.61
- inflammation of
 - infectious causes, 12.235–247
 - noninfectious causes, 12.219–234
 - white dot syndromes as cause of. *See* White dot syndromes
- inner structure of, 12.193f
- ischemia of, illusions and, 5.175
- in leukemia, 4.315
- lymphoma of (uveal lymphoid proliferation/ hyperplasia/infiltration), 4.199, 4.199f, 4.313–314
- melanocytoma of, 4.192, 4.258
- melanoma of, 4.106, 4.106f, 4.192f, 4.192–197, 4.193f, 4.194f, 4.195f, 4.196f, 4.253, 4.262–279, 9.277. *See also* Choroidal melanoma/ciliary body melanoma
 - classification of, 4.194, 4.271–272, 4.272t
 - clinical characteristics of, 4.262–263, 4.264f
 - diagnosis of, 4.263f, 4.264f, 4.264–267, 4.266f, 4.267f
 - differential, 4.267–271, 4.269f, 4.270f
 - enucleation for, 4.196, 4.274–275, 7.128
 - glaucoma caused by, 4.105f, 4.106, 4.194, 10.99, 10.99f
 - metastatic, 4.196, 4.272–274, 4.273t, 4.306
 - prognosis/prognostic factors for, 4.194–197, 4.273t, 4.277–279
 - transpupillary thermotherapy for, 4.276
 - treatment of, 4.253, 4.274–277, 4.275f
- neovascularization of. *See* Choroidal neovascularization
- nevus of, 4.191, 4.192f, 4.256–258, 4.257f, 4.267–268
- melanoma differentiated from, 4.267–268
- in ocular histoplasmosis syndrome, 9.215, 9.216, 9.217f
- osteoma of, 4.198–199, 4.270f, 4.271
- melanoma differentiated from, 4.270f, 4.271
- in pathologic myopia, 12.212–216, 12.214–215f
- in polyarteritis nodosa, 1.167
- posttraumatic granulomatous inflammation of, focal, 4.22, 4.22f
- retinal metabolic needs supplied by, 12.20
- retinoblastoma invading, 4.177, 4.177f
- rupture of, 4.22, 4.22f, 12.88, 12.354–356f, 12.354–355
- Sattler layer, 12.19
- stroma of, 4.182
- in Sturge-Weber syndrome, 4.197, 4.281
- subfoveal thickness of, 12.19
- in sympathetic ophthalmia, 9.172, 9.173f
- thickness of
 - description of, 12.19
 - measurement of, 12.212
 - subfoveal, 12.212, 12.214f
- thinning of, 12.214
- topography of, 4.181f, 4.182–183, 4.183f
- trauma-related rupture of, 12.354–356f, 12.354–355
- tumors of, 4.191–197. *See also* Choroidal melanoma/ ciliary body melanoma; *specific type*
 - glaucoma caused by, 10.99, 10.99f
 - metastatic, 4.197, 4.198f, 4.303, 4.304t, 4.306f, 4.307f, 4.308f, 4.308t, 9.278
 - melanoma differentiated from, 4.270f, 4.271, 4.306
- in uveitis, 9.72t, 9.77, 9.80t, 9.84. *See also* Posterior uveitis
- vasculature of, 2.59–60, 2.60f, 2.61f, 2.61–62, 2.62f
- development of, 2.116t
- retina supplied by, 4.139–140
- ischemia and, 4.140, 4.151, 4.151f

- venous pressure increases in, 12.198
- in Vogt-Koyanagi-Harada syndrome, 9.176
- vortex veins in, 12.19
- Choroidal arteries, 2.62
 - anterior, 5.16*f*, 5.18, 5.18*f*
 - optic nerve supplied by, 2.91
 - posterior/posterior lateral, 5.18*f*, 5.19*f*
- Choroidal capillaries, 2.59, 2.60*f*, 2.61*f*, 2.61–62, 2.62*f*
- Choroidal detachment, 12.379, 12.379*f*
- Choroidal dystrophies
 - Bietti crystalline dystrophy, 12.258, 12.269, 12.282*t*
 - central areolar, 12.277
 - choroidemia, 12.267–268, 12.268*f*
 - classification of, 12.255
 - gyrate atrophy, 12.268–269, 12.269*f*
- Choroidal effusion
 - angle-closure glaucoma and, 10.141, 10.142*f*, 10.144, 10.145, 10.145*f*
 - bupropion as cause of, 12.306
 - in carotid-cavernous fistula, 5.205, 5.205*f*
 - contact B-scan ultrasonography of, 12.39*f*
 - after filtering surgery, 10.210–211
- Choroidal fissure. *See* Embryonic fissure
- Choroidal granuloma, 12.241*f*
- Choroidal hemangioma, 6.401
- Choroidal hemorrhage/suprachoroidal hemorrhage, 4.18, 4.19*f*
 - angle-closure glaucoma and, 10.141, 10.142*f*, 10.144, 10.145, 10.145*f*
 - cataract surgery and, 11.159, 11.171
 - delayed, 11.160
 - expulsive, 11.159–160
 - flat or shallow anterior chamber and, 11.134
 - expulsive, 4.18, 4.19*f*
 - cataract surgery and, 11.159–160
 - after filtering surgery, 10.210–211
- Choroidal lesions, 6.349–350
- Choroidal melanoma/ciliary body melanoma (posterior uveal melanoma), 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279, 9.277
 - age-related macular degeneration differentiated from, 4.269, 4.270*f*
 - chemotherapy for, 4.277
 - classification of, 4.194, 4.271–272, 4.272*t*
 - clinical characteristics of, 4.262–263, 4.263*f*, 4.264*f*
 - congenital hypertrophy of retinal pigment epithelium differentiated from, 4.144, 4.268–269, 4.269*f*
 - diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
 - differential, 4.267–271, 4.269*f*, 4.270*f*
 - enucleation for, 4.196, 4.274–275, 7.128
 - epithelioid cell, 4.192, 4.193*f*, 4.194, 4.195
 - exenteration for, 4.277
 - fine-needle aspiration biopsy in identification/evaluation of, 4.42, 4.43*f*, 4.253
 - glaucoma caused by, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*
 - immunotherapy for, 4.277
 - melanocytoma differentiated from, 4.268
 - metastatic, 4.196, 4.272–274, 4.273*t*, 4.306
 - mixed-cell type, 4.194, 4.195
 - nevus differentiated from, 4.267–268
 - observation in management of, 4.274
 - ocular surface/conjunctival involvement and, 4.68, 4.69*f*, 8.343
 - oculodermal melanocytosis and, 7.175
 - prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
 - risk factors for, 4.262, 4.268
 - spindle cell, 4.192*f*, 4.192–193, 4.194, 4.195
 - staging of, 4.271–272, 4.273*t*
 - surgical excision of, 4.277
 - transpupillary thermotherapy for, 4.276
 - treatment of, 4.253, 4.274–277, 4.275*f*
- Choroidal neovascular membranes (CNVMs), 6.342, 6.343*f*
- Choroidal neovascularization (CNV), 3.115. *See also* Neovascularization
 - in acute posterior multifocal placoid pigment epitheliopathy, 12.222
 - in age-related macular degeneration, 4.161*f*, 4.164–166, 4.165*f*, 12.64
 - anatomical classification of, 12.71–75
 - angioid streaks as cause of, 12.87–89, 12.89*f*
 - anti-VEGF therapy for, 12.87–88, 12.212, 12.355
 - bevacizumab for, 12.73*f*, 12.213*f*
 - after Bruch membrane damage, 12.355, 12.355*f*
 - classic, 12.72, 12.73*f*
 - conditions associated with, 12.90*t*
 - fluorescein angiography of, 12.36, 12.37*f*, 12.72–73, 12.73–74*f*
 - green laser for, 12.373
 - idiopathic, 12.89–90
 - indocyanine green angiography of, 12.73
 - laser photocoagulation for, 12.376
 - late leakage from an undetermined source, 12.72
 - miscellaneous causes of, 12.89–90
 - in multifocal choroiditis and panuveitis syndrome, 9.156, 9.157, 12.226, 12.226*f*
 - occult, 12.72–73
 - in ocular histoplasmosis syndrome, 9.215, 9.216, 9.217, 9.218*f*
 - management of, 9.217–218
 - ocular histoplasmosis syndrome as cause of, 12.86–87, 12.88*f*
 - optical coherence tomographic angiography of, 12.75–76, 12.76–78*f*, 12.192
 - optical coherence tomography of, 12.192, 12.194
 - in pathologic myopia, 12.89, 12.211*f*, 12.211–212
 - photocoagulation for, 12.376
 - photodynamic therapy for, 12.212, 12.213*f*, 12.380
 - polypoidal choroidal vasculopathy and, 4.166
 - in punctate inner choroiditis, 9.158, 9.159*f*
 - retinal pigment epithelium tears in, 12.31
 - scar tissue versus, 12.73
 - signs and symptoms of, 12.71
 - in SLE, 9.134
 - spectral-domain optical coherence tomography of, 12.73–75, 12.75*f*
 - subfoveal, 12.355, 12.380
 - subretinal hemorrhages versus, 12.211
 - susceptibility genes for, 12.63
 - in toxoplasmosis, 9.223, 9.223*f*
 - type 1, 4.165, 4.165*f*, 12.71–72, 12.72*f*, 12.76*f*
 - type 2, 4.165, 4.165*f*, 12.72, 12.75, 12.77*f*
 - type 3, 12.72–73, 12.75, 12.78*f*
 - in uveitis, 9.291–292

- vascular endothelial growth factor concentrations in, 12.80
- vitelliform exudative macular detachment versus, 12.272
- vitreous hemorrhage secondary to, 12.231*f*
- in Vogt-Koyanagi-Harada syndrome, 9.182
- Choroidal nevi
- description of, 6.349
- scanning laser ophthalmoscopy of, 12.24
- Choroidal osteoma, 6.349
- Choroidal vasculopathy, polypoidal (PCV/posterior uveal bleeding syndrome), 4.166*f*, 4.166–168, 4.167*f*.
See also Polypoidal choroidal vasculopathy
- Choroidal vein, 5.21
- Choroideremia, 12.267–268, 12.268*f*
- choriocapillaris atrophy in, 12.258
- electroretinography findings in, 12.50
- ocular findings in carriers of, 2.198*f*, 2.199*t*
- REP-1* (Rab escort protein 1/*CHM*) gene mutation in, 2.265
- retinal pigment epithelium in, 2.279
- Choroiditis, 9.77. *See also* Choroidopathy; Posterior uveitis
- ampiginous (relentless placoid chorioretinitis), 9.150–151, 9.151*f*
- birdshot uveitis on, 12.225, 12.225*f*
- diffuse, 9.72*t*
- focal, 9.72*t*
- geographic. *See* Choroiditis, serpiginous
- in HIV infection/AIDS
- Cryptococcus neoformans* causing, 9.298–299
- Pneumocystis jirovecii* causing, 9.298, 9.298*f*
- systemic dissemination and, 9.299
- multifocal (MFC), 6.319, 9.72*t*, 9.154–155, 12.220*t*, 12.225–226, 12.226*f*
- in HIV infection/AIDS
- Cryptococcus neoformans* causing, 9.298–299
- systemic dissemination and, 9.298–299
- in Lyme disease, 9.245
- with panuveitis (MCP/MFCPU), 9.141–143*t*, 9.154–158, 9.155*f*, 9.157*f*, 12.226*f*. *See also* Multifocal choroiditis
- serpiginoid/serpiginous-like choroiditis (tuberculosis-associated), 9.154, 9.252, 9.252*f*
- in SLE, 9.134, 9.134*f*
- in ocular histoplasmosis syndrome, 9.216, 9.217, 9.217*f*
- punctate inner (PIC), 9.141–143*t*, 9.158*f*, 9.158–160, 9.159*f*, 12.225. *See also* Multifocal choroiditis
- serpiginous (geographic/helicoid peripapillary choroidopathy), 9.141–143*t*, 9.151–154, 9.152*f*, 9.153*f*
- tuberculosis and (serpiginoid/serpiginous-like), 9.154, 9.252, 9.252*f*
- in sympathetic ophthalmia, 9.172, 9.173*f*
- tuberculous, 9.154, 9.251*f*, 9.251–252, 9.252*f*
- in Vogt-Koyanagi-Harada syndrome, 9.176
- Choroidopathy. *See also* Choroiditis
- central serous. *See* Chorioretinopathy, central serous
- geographic. *See* Choroidopathy, serpiginous
- helicoid peripapillary. *See* Choroidopathy, serpiginous
- hypertension, 12.123–124*f*
- lupus, 9.134, 9.134*f*
- punctate inner (PIC), 9.141–143*t*, 9.158*f*, 9.158–160, 9.159*f*, 12.225. *See also* Multifocal choroiditis
- serpiginous (geographic choroiditis/helicoid peripapillary choroidopathy), 9.141–143*t*, 9.151–154, 9.152*f*, 9.153*f*
- tuberculosis and (serpiginoid/serpiginous-like), 9.154, 9.252, 9.252*f*
- CHRD1* gene, in megalocornea, 6.254, 8.96*t*, 8.99
- “Christmas tree” cataracts, in myotonic dystrophy, 5.330
- Chromatic aberration, 3.40, 3.72, 3.166, 3.199
- Chromatid, 2.133
- Chromatin, 2.133
- Chromogens, in immunohistochemistry, 4.33, 4.35*f*
- Chromogranin, in immunohistochemistry, 4.34
- Chromophores, 3.115, 3.119
- ultraviolet-absorbing, IOLs with, 11.120
- Chromosomal aneuploidy, 2.132, 2.189. *See also specific disorder*
- autosome, 2.189–190
- sex chromosome, 2.189
- Chromosome arm painting (CAP), 2.188, 2.189*f*
- Chromosomes, 2.147, 2.148*f*, 2.184–187
- abnormalities of, 6.385, 6.386*t*. *See also specific type*
- identification of, 2.187–193, 2.189*f*, 2.191*t*
- incidence of, 2.188
- ocular manifestations of diseases due to. *See specific disease*
- ophthalmically important, 2.192–193
- analysis of, 2.187–193, 2.189*f*, 2.191*t*
- bacterial artificial (BAC), 2.145
- homologous, 2.137, 2.184
- sex, 2.147. *See also* X chromosome; Y chromosome
- aneuploidy of, 2.189
- mosaicism and, 2.191–192
- translocation of, 2.144
- Down syndrome caused by, 2.190
- variant (as genetic markers), 2.159
- yeast artificial (YAC), 2.145
- Chronic bronchitis, 1.130
- Chronic cyclitis. *See* Pars planitis
- Chronic kidney disease. *See* Renal disease
- Chronic lymphocytic lymphoma (CLL), of orbit, 7.86
- Chronic obstructive pulmonary disease (COPD), 1.130, 1.132
- corticosteroid use/pneumonia and, 1.129
- ocular surgery in patient with, 1.288
- cataract surgery, 11.170
- Chronic peripheral rhegmatogenous retinal detachment, 9.279
- Chronic (delayed-onset) postoperative endophthalmitis, 9.261–263, 9.262*f*
- Chronic progressive external ophthalmoplegia (CPEO), 2.158, 5.328–329, 5.329*f*, 6.141–142, 6.143*t*, 12.293–294
- mitochondrial DNA defects and, 2.157, 2.158
- ptosis in, 5.273, 5.273*t*, 5.328, 5.329*f*
- syndromes associated with, 2.158
- Chronic progressive external ophthalmoplegia (CPEO)—plus syndromes, 2.158
- Chronic relapsing inflammatory optic neuropathy (CRION), 5.116
- Chronic thyroiditis, 1.54
- CHRPE. *See* Congenital hypertrophy of retinal pigment epithelium
- Chrysiasis, corneal deposits/pigmentation in, 8.118*t*

- CHS. *See* Chédiak-Higashi syndrome
- CHSD. *See* Congenital hereditary stromal dystrophy
- CHST6* (carbohydrate sulfotransferase 6) gene, in macular dystrophy, 4.91, 8.136*t*
- Churg-Strauss syndrome. *See* Eosinophilic granulomatosis with polyangiitis
- Chylomicrons, 1.82
- Chymotrypsin (α -chymotrypsin), for ICCE, 11.195, 11.200
- CI. *See* Convergence insufficiency
- Ciancia syndrome, 6.88, 6.95
- Cicatricial ectropion, 7.198*f*
after blepharoplasty, 7.234
- Cicatricial entropion, 7.198*f*, 7.201, 7.202*f*, 7.206*f*, 7.206–207, 7.207*f*
trichiasis in, 7.208
- Cicatricial pemphigoid. *See* Mucous membrane (ocular cicatricial) pemphigoid
- Cicatricial retinal detachment, 12.286
- Cicatrizization, conjunctival, 8.47*t*. *See also* Conjunctivitis, cicatrizing; Mucous membrane (ocular cicatricial) pemphigoid
- CID. *See* Cytomegalic inclusion disease
- Cidofovir, 1.281, 2.357*t*, 2.360–361
for CMV retinitis, 1.260, 1.281, 2.357*t*, 2.360–361
for herpes simplex virus infection, 1.258
uveitis caused by, 9.121
- Cigarette burns, 6.376
- Cigarette smoking. *See* Smoking/smoking cessation
- CIGTS (Collaborative Initial Glaucoma Treatment Study), 10.81, 10.111, 10.187
- Cilia (eyelashes), 2.19, 2.22*f*, 2.24, 4.201, 7.153, 8.3, 8.4*f*
accessory. *See* Distichiasis
entropion/ptosis of. *See also* Trichiasis
in anophthalmic socket, 7.136
in epiblepharon, 7.157*f*, 7.159, 7.159*f*
follicles of, 7.154*f*
tumors arising in, 7.172, 7.172*f*, 7.173*f*
lice infestation of, 8.255
misdirection of. *See* Trichiasis
in staphylococcal blepharitis, 8.72*f*, 8.73*t*, 8.74, 8.254
in trichotillomania, 7.165
- Ciliary arteries, 2.17*f*, 2.32–35, 2.33*f*, 6.23. *See also* Cilioretinal artery
anterior, 2.17, 2.30, 2.32–35, 5.14*f*, 5.14–15, 7.14*f*, 7.15*f*
choroid supplied by, 2.60
conjunctiva supplied by, 2.30
extraocular muscles supplied by, 2.17
long, 5.13*f*, 5.14*f*, 5.15, 5.15*f*
occlusion of, 12.144, 12.145*f*
optic nerve supplied by, 10.44–46, 10.45*f*
posterior, 2.17*f*, 2.32, 2.33*f*, 2.34*f*, 2.90, 2.91, 2.91*f*, 2.92*f*, 5.15–17, 5.17*f*, 7.14*f*, 7.15*f*
short, 5.13*f*, 5.14*f*, 5.15–17, 5.17*f*
- Ciliary block, after cataract surgery, flat or shallow anterior chamber and, 11.135
- Ciliary block glaucoma (malignant glaucoma/aqueous misdirection), 10.32, 10.139–141, 10.140*f*
cataract surgery and, 10.139, 11.139
in children and adolescents, 10.149*t*
- Ciliary body, 2.17*f*, 2.37*f*, 2.46*f*, 2.57–59, 2.58*f*, 2.59*f*, 2.236–240, 4.97*f*, 4.98*f*, 4.181, 4.181*f*, 4.182, 4.183*f*, 12.40. *See also* Uvea (uveal tract)
anatomy of, 2.17*f*, 2.37*f*, 2.46*f*, 2.57–59, 2.58*f*, 2.59*f*, 4.97*f*, 4.98*f*, 4.181*f*, 4.182, 4.183*f*
biochemistry and metabolism of, 2.236–240
cyclodestruction of, 10.194–196, 10.195*f*
development of, 2.116*t*, 2.122
epithelium of. *See* Ciliary epithelium
healing/repair and, 4.16
hyalinization of, 4.189, 4.189*f*
immunologic microenvironment of, 9.57
medulloepithelioma arising in, 4.296, 4.296*f*
melanocytoma of, 4.192, 4.258, 4.268
melanoma of, 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279. *See also* Choroidal melanoma/ciliary body melanoma
classification of, 4.194, 4.271–272, 4.272*t*
clinical characteristics of, 4.262, 4.263*f*
diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
differential, 4.267–271, 4.269*f*, 4.270*f*
glaucoma caused by, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*, 10.138
metastatic, 4.196, 4.272–274, 4.273*t*
prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
treatment of, 4.253, 4.274–277, 4.275*f*
neoplastic disorders of, 4.191–197. *See also* Choroidal melanoma/ciliary body melanoma; *specific type*
glaucoma and, 10.99, 10.99*f*
metastatic, 4.303, 4.304
nevus of, 4.191, 4.256
smooth muscle in, 2.58–59, 2.59*f*, 2.237
stroma of, 2.57–58, 2.58*f*
tear in (angle recession), 4.18, 4.19*f*, 4.103–104
glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
topography of, 2.37*f*, 4.181*f*, 4.182, 4.183*f*
ultrasound biomicroscopy in evaluation of, 8.21
uveal portion of, 2.58
in uveitis, 9.72, 9.73, 9.83. *See also* Intermediate uveitis
hypotony and, 9.288
- Ciliary body band, 10.33*t*, 10.34*f*
- Ciliary body tumors, 6.273*f*, 6.273–274
- Ciliary epithelium, 2.57–58, 2.58*f*
aqueous humor formation/dynamics and, 2.229, 2.230, 2.231, 2.323, 2.324, 2.324*f*, 10.5*f*, 10.13–16, 10.14–15*f*
nonpigmented, 2.57, 2.58*f*, 2.229, 2.230
benign adenomas of, 4.279
pigmented, 2.57, 2.58*f*, 2.230
acquired hyperplasia of, 4.279, 4.280*f*
benign adenomas of, 4.279
- Ciliary flush
in herpetic epithelial keratitis, 8.217
in uveitis, 9.79, 9.82
- Ciliary ganglion, 2.11–12, 2.12*f*, 5.45, 5.48*f*, 5.55, 5.55*f*, 7.14*f*, 7.15*f*, 7.16, 7.17*f*, 8.5*f*
Adie tonic pupil and, 5.263, 5.264, 5.264*f*, 5.265
branches of, 2.11–12
- Ciliary margin, 7.153
- Ciliary muscle, 2.58–59, 2.59*f*, 6.20
in accommodation, 2.63, 11.22–23, 11.23*t*, 13.159, 13.160, 13.160*f*, 13.161*f*
innervation of, 2.94, 2.95

- miotic/muscarinic agents affecting, 2.308–309, 2.311–312, 10.181
- mydriatic/muscarinic agents affecting, 2.313
- Ciliary muscle spasm (spasm of accommodation), 3.176, 5.310, 6.94
- Ciliary nerves, 2.59
 - long, 2.12, 2.32, 2.100, 2.223–224, 5.53f, 7.14f, 7.15f, 7.16
 - dilator muscle supplied by, 2.100
 - lacrimal functional unit innervated by, 8.5f
 - posterior, 2.32, 2.223–224, 5.55
 - short, 2.12, 2.12f, 2.100, 5.55f, 7.12f, 7.14f, 7.15f, 7.16, 7.17f
 - Adie tonic pupil and, 5.263, 5.264, 5.264f, 5.265
 - ciliary muscle supplied by, 2.95
 - posterior, 2.32
 - sphincter muscle supplied by, 2.56
- Ciliary processes, 2.47f, 2.57, 2.59f, 10.13, 10.15f
 - in aqueous humor formation, 10.5f, 10.13–16, 10.14–15f
 - development of, 2.116t
 - plateau iris and, 10.120
- Ciliary sulcus, 2.47f
- Ciliochoroidal effusion, 6.284
- Ciliopathies, 6.336, 6.391–392, 392f
- Cilioretinal artery, 2.73, 2.91, 5.17
 - anatomy of, 12.16, 12.16f
 - occlusion of, 12.143
- Ciliospinal center of Budge-Waller, 5.53f, 7.16
- Cilium, photoreceptor, 2.69, 2.72f
- Ciloxan. *See* Ciprofloxacin
- Cimetidine, for conjunctival papillomas, 8.238, 8.239, 8.333
- CIN. *See* Conjunctival or corneal intraepithelial neoplasia
- Cingulate gyrus, 5.52
- CIPA. *See* Congenital insensitivity to pain with anhidrosis
- Ciprofibrate, for hypercholesterolemia/heart disease prevention, 1.85t
- Ciprofloxacin, 1.277, 2.346, 2.347t, 2.347–349
 - for bacterial keratitis, 8.269, 8.270t
 - for cat-scratch disease/bartonellosis, 9.258
 - corneal deposits caused by, 8.131, 8.131f
 - for gonococcal conjunctivitis, 8.259
 - ocular effects of, 1.307t
- Circadian variation, in intraocular pressure, 10.3, 10.8, 10.22, 10.80–81, 10.81t, 10.86, 10.87
- Circinate balanitis, in reactive arthritis syndrome, 9.115
- Circle of least confusion, 3.76, 3.76f
- Circle of Willis, 1.120, 2.90, 2.90f, 2.105–107, 2.107f, 5.18
 - aneurysms in, 1.126
- Circle of Zinn-Haller (circle of Haller and Zinn/circle of Zinn), 2.88f, 2.91, 5.17, 10.44, 10.46, 12.217
- Circular aperture, diffraction created by, 3.105, 3.105f
- Circular venous plexus, 5.23f
- Circularly polarized light, 3.98
- Circulation
 - choroid, 12.19–20
 - retinal, 12.16f, 12.16–17
- Circulatory failure
 - CPR for, 1.295–299, 1.296t, 1.297f
 - in shock, 1.300
- Circumscribed (localized) choroidal hemangioma, 4.197, 4.198f, 4.281, 4.282f
- Circumscribed iris nevus, 4.255, 4.256f
- Cirrhosis, hepatitis and, 1.261
- CIS. *See* Clinically isolated syndrome
- 11-*cis*-retinol dehydrogenase, 2.265, 12.252
- 11-*cis*-retinol/retinaldehyde, 2.274, 2.275, 2.275f, 12.17
- Cisapride, perioperative, 1.288
- Cisplatin, 1.234t
- Cisterns, in vitreous, 12.7
- Citrate, in tear film, 2.216
- Citric acid/sodium citrate, for chemical injuries, 8.383
- Citrobacter*, 8.247
- Citrullinated peptide antibodies, anti-cyclic (anti-CCP), in rheumatoid arthritis, 1.152
- Citrullinated vimentin, anti-mutated (anti-MCV), in rheumatoid arthritis, 1.152
- CJD. *See* Creutzfeldt-Jakob disease
- CK. *See* Conductive keratoplasty
- CK-MB (creatinine kinase MB), in acute coronary syndrome, 1.96
- Cl. *See* Chloride
- Clarithromycin, 1.278, 2.353
 - for bacterial keratitis, 8.270t
 - for endocarditis prophylaxis, 1.243t
- Clarity, optical, of ophthalmic viscosurgical device, 11.97
- Class I major histocompatibility complex molecules, 9.34f, 9.34–35, 9.64
- Class II major histocompatibility complex molecules, 9.35f, 9.35–36, 9.64
 - primed macrophages and, 9.20
- Class switching (immunoglobulin), 9.38, 9.39, 9.40
- Classic granular corneal dystrophy (granular corneal dystrophy type 1/GCD1), 4.90, 4.90f, 4.91t, 8.135t, 8.136t, 8.145t, 8.147–148, 8.148f
- Classic lattice corneal dystrophy (LCD1), 4.88–90, 4.89f, 4.91t, 8.135t, 8.136t, 8.145t, 8.145–147, 8.146f, 8.147f
- Classic pathway activation (complement), 9.22, 9.23f
- “The Classification of eye movement abnormalities and strabismus (CEMAS)”, 5.234
- Claude syndrome, 5.191
- Claudication, jaw/tongue, in giant cell arteritis, 5.313
- Claustrophobia, cataract surgery in patient with, 11.169
- Clavulanic acid, 1.276. *See also* specific antibiotic combination
- “Claw” haptics, for iris-fixed phakic IOL, 13.141
- Clear corneal incision
 - for cataract surgery, 11.106f, 11.106–107
 - in glaucoma, 11.186
 - after radial keratotomy, 11.177, 13.53
 - with trabeculectomy, 10.213
 - in uveitis, 9.283
 - for posterior chamber phakic IOL implantation, 13.142–143
- Cleft syndromes, 7.36–38, 7.37f, 7.38f. *See also* Craniofacial malformations
 - nasolacrimal duct obstruction and, 7.259
- Cleocin. *See* Clindamycin
- CLIA (Clinical Laboratory Improvement Amendments), 2.133
- CLIK. *See* Contact lens-induced keratoconjunctivitis

- Climatic droplet (actinic/Labrador) keratopathy (spheroidal degeneration), 4.83, 4.83f, 8.115–117, 8.116f
- Climatotherapy, for vernal keratoconjunctivitis, 8.291
- Clindamycin, 1.278, 2.344t
for endocarditis prophylaxis, 1.243t
for *Pneumocystis jirovecii* pneumonia, 1.267–268
for toxoplasmic retinochoroiditis, 12.243
for toxoplasmosis, 6.410, 9.225, 9.297
- Clinical Activity Score (CAS), for thyroid eye disease, 7.57
- Clinical breast examination, for cancer screening, 1.210t, 1.211
- Clinical heterogeneity, 2.133
- Clinical history method, for IOL power calculation after refractive surgery, 13.194. *See also* Historical methods
- Clinical Laboratory Improvement Amendments (CLIA), 2.133
- Clinical refraction. *See* Refraction, clinical
- Clinical research/studies, 1.2–31
design of, 1.7–14, 1.8f. *See also specific type of study*
case-control studies, 1.8f, 1.9–11, 1.10f
case reports, 1.8, 1.8f
case series, 1.8f, 1.9
clinical trials, 1.7, 1.8, 1.8f, 1.13f, 1.13–14
cohort study differences and, 1.13, 1.13f
systematic reviews/meta-analyses of, 1.8, 1.8f, 1.14
cohort studies, 1.8f, 1.10f, 1.11–12
clinical trial differences and, 1.13, 1.13f
cross-sectional studies, 1.11
diagnostic/screening test interpretation and, 1.14–21, 1.15t
clinical acceptance/ethics and, 1.20
combination strategies and, 1.19–20
complicating features in, 1.16f, 1.16–19, 1.17f, 1.18f, 1.19t
generalizability and, 1.20
evaluation of, 1.4–7
analysis and, 1.7
clinical relevance and, 1.6–7
clinical significance and, 1.7
follow-up and, 1.6
generalizability and, 1.4–5, 1.20, 1.22
outcome definition/reliability and, 1.5–6
reproducibility and, 1.5
sample size and, 1.5
interpreting results for patients and, 1.21–23
measurement/improvement of clinical practice and, 1.23–31
data presentation and, 1.27–30, 1.28f, 1.29f
measurement system design and, 1.23–25
monitoring system implementation and, 1.25–26
quality improvement and, 1.27–30, 1.28f, 1.29f, 1.30f
results analysis and, 1.26–27
research questions and, 1.3–7
- Clinical significance, 1.7, 1.26
- Clinical trials (experimental/interventional studies), 1.7, 1.8, 1.8f, 1.13f, 1.13–14. *See also* Clinical research/studies
cohort study differences and, 1.13, 1.13f
for new drug, 2.305
in retinoblastoma treatment, 4.301
systematic reviews/meta-analyses of, 1.8, 1.8f, 1.14
- Clinically isolated syndrome (CIS), 5.114. *See also* Optic neuritis
multiple sclerosis treatment and, 5.320
- Clinically significant diabetic macular edema (CSME), 12.92, 12.110, 12.114. *See also* Diabetic macular edema
- Clinically significant retinopathy of prematurity (CSROP), 12.184t. *See also* Retinopathy, of prematurity
- Clinoid process
anterior, 2.8f, 2.84f, 2.105f, 5.6f, 5.7f, 5.9f, 5.16f, 5.43f, 7.7f
posterior, 2.84f, 2.95, 2.102
- Clivus (umbo), 2.102, 5.5
anatomy of, 12.9, 12.9f
characteristics of, 12.10t
- CLK. *See* Contact lens–induced keratoconjunctivitis
- CLL. *See* Chronic lymphocytic lymphoma
- Clobetasol, for infantile (capillary) hemangioma, 7.162
- Clobetasone, for atopic dermatitis, 8.287
- Clofazimine, 12.298
corneal pigmentation caused by, 8.132
- Clofibrate, for hypercholesterolemia/heart disease prevention, 1.85t
- Clomiphene, 1.308t
- Clonality, 9.42
in orbital lymphoma, 7.88
in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.275
- Clonazepam
for benign essential blepharospasm, 7.228
for nystagmus, 5.245
- Clonidine
for heart failure, 1.110
for hypertension, 1.68t
in perioperative setting, 1.285
- Clopidogrel. *See also* Dual antiplatelet therapy
for carotid artery disease/stenosis, 1.126
for cerebral ischemia/stroke, 1.123
for ischemic heart disease, 1.99, 1.100, 1.100t
- Cloquet (hyaloid) canal, 2.80, 4.125
anatomy of, 12.7, 12.8f
formation of, 12.341
- Closed-circuit televisions, 3.310, 3.323
- Closed-loop intraocular lenses, pseudophakic bullous keratopathy and, 11.149
- Closed-loop speculum, for globe exposure, in cataract surgery, 11.105f
- Clostridium*
botulinum, toxin derived from, 2.366. *See also* Botulinum toxin
difficile, 1.244
- Clot removal, for stroke, 1.123
- Clotting. *See* Coagulation
- Cloverleaf visual field (artifact), in perimetry, 10.66, 10.66f
- Cloxacillin, 1.275, 2.344
- Clozapine, 1.194
- Clump cells, in iris, 4.181
- Cluster headache, 5.289t, 5.294
Horner syndrome and, 5.260t, 5.261, 5.294

- Clusters A, B, and C personality disorders, 1.191
- cM. *See* Centimorgan
- CME. *See* Cystoid macular edema
- CMN. *See* Congenital motor nystagmus
- CMV. *See* Cytomegalovirus
- CN. *See* Congenital nystagmus
- CNLDO. *See* Congenital nasolacrimal duct obstruction
- CNS. *See* Central nervous system
- CNs. *See* Cranial nerves
- CNTGS (Collaborative Normal-Tension Glaucoma Study), 10.87–88
- CNV. *See* Choroidal neovascularization
- CNVMs. *See* Choroidal neovascular membranes
- Co-contractive retraction with jaw–eyelid synkinesis syndrome (CCRS/Marcus Gunn jaw-winking syndrome/ptosis), 5.272, 5.272f, 7.211, 7.215, 7.216f
- synkinesis in, 7.211, 7.215, 7.216f
- CO₂ laser. *See* Carbon dioxide (CO₂) laser
- Coagulation, 1.140, 1.140f. *See also* Hemostasis disorders of, 1.144–147. *See also* Hemostasis, disorders of; Hypercoagulable states
- acquired, 1.145–146
- cataract surgery in patient with, 11.171–172
- hereditary, 1.144–145
- transient visual loss and, 5.171
- laboratory evaluation of, 1.141–142
- pathways of, 1.140, 1.140f
- Coagulation factors, 1.140, 1.140f
- laboratory evaluation of, 1.141
- liver disease and, 1.146
- vitamin K and, 1.145
- Coarctation of aorta, hypertension in, 1.64, 1.64t
- Coatability, of ophthalmic viscosurgical device, 11.97
- Coats disease, 4.143, 4.143f, 4.295, 4.295f, 12.159–161, 12.160f, 12.326
- clinical findings of, 6.358, 6.359f
- diagnosis of, 6.359–360
- differential diagnosis of, 6.360
- fluorescein angiography findings, 6.359, 6.359f
- gender predilection of, 6.358
- retinoblastoma differentiated from, 4.295, 4.295f, 6.352–353, 6.360
- treatment of, 6.360
- Coats reaction, 12.260
- Coats white ring, 8.115, 8.116f
- “Coaxial” illumination, 3.294
- Cobblestone (paving-stone) degeneration, 4.150, 4.150f, 12.313, 12.314f
- Cocaine, 2.320
- abuse of, during pregnancy, 1.192
- anisocoria/Horner syndrome diagnosis and, 5.256f, 5.258, 5.259
- norepinephrine uptake affected by, 2.320, 2.320f
- as topical anesthetic, 2.363t, 2.364, 2.365
- Cocci (bacteria), 8.243, 8.244t
- gram-negative, 8.244t, 8.245, 8.246f
- therapy for infection caused by, 8.270t
- gram positive, 8.243, 8.244t, 8.244–245, 8.245f
- therapy for infection caused by, 8.270t
- Coccidioides immitis* (coccidioidomycosis), 9.270–272, 9.271f
- endogenous endophthalmitis caused by, 9.265, 9.270–272, 9.271f
- optic nerve infection caused by, 4.243–244
- Cochet-Bonnet esthesiometer, 8.42–43
- Cochlear nerve, 5.38
- Cochrane Library, 1.3
- Cockayne syndrome (CS), 8.191t
- Codominance (codominant inheritance/alleles), 2.133, 2.173
- Codon, 2.133, 2.147
- stop/termination, 2.144
- frameshift mutation and, 2.135, 2.155
- Coefficient of variation, specular microscopy in evaluation of, 8.23
- COG (Children's Oncology Group), 4.301
- Cogan lid-twitch sign, 5.271, 5.324
- Cogan microcystic epithelial dystrophy. *See* Basement membrane dystrophy
- Cogan plaque, 8.128, 8.129f
- Cogan-Reese (iris nevus) syndrome/Cogan-Reese variant, 4.100, 4.101f, 4.259, 8.111, 8.127, 10.136.
- See also* Iridocorneal endothelial (ICE) syndrome
- Cogan syndrome, 1.165t, 1.170, 6.269, 8.285, 8.309–310
- Cogwheel (saccadic) pursuit, 5.219, 5.224, 5.225, 5.226
- Coherence
- definition of, 3.91, 3.99
- description of, 3.99–102
- pictorial representation of, 3.100f
- spatial, 3.101
- temporal, 3.100f, 3.101
- Coherence length
- description of, 3.101–102
- of laser light, 3.111
- spectral bandwidth and, 3.102, 3.103f
- Coherence time, description of, 3.101–102
- Coherence tomography, optical. *See* Optical coherence tomography
- Cohesive ophthalmic viscosurgical devices/viscoelastics, 2.368, 11.96. *See also* Ophthalmic viscosurgical devices
- Cohort studies (follow-up studies), 1.8f, 1.10f, 1.11–12
- clinical trial differences and, 1.13, 1.13f
- COL1A1/COL1A2* genes, in osteogenesis imperfecta, 8.194
- COL2A1* gene, 6.345, 12.343
- COL4A3–5* genes, in Alport syndrome, 4.118
- COL8A2* gene, in posterior polymorphous corneal dystrophy, 8.136t
- COL18A1* gene, 6.346–347
- COL25A1* gene, 6.133
- Colchicine, for Behçet disease, 9.188
- Cold (temperature), anterior segment injuries caused by, 8.385
- Cold remedies, tear production affected by, 8.62t
- Colesevelam, for hypercholesterolemia/heart disease prevention, 1.85t
- Colestipol, for hypercholesterolemia/heart disease prevention, 1.85t
- Colistimethate, 2.344t
- Colitis
- antibiotic-associated, 1.244
- granulomatous (Crohn disease), 1.155, 9.116
- ulcerative, 1.155, 9.116
- Collaborative Initial Glaucoma Treatment Study (CIGTS), 10.81, 10.111, 10.187
- Collaborative Normal-Tension Glaucoma Study (CNTGS), 10.87–88

- Collaborative Ocular Melanoma Study (COMS), 4.253, 4.271, 4.278–279
- Collagen
- in choroid, 2.62
 - in ciliary muscle, 2.59
 - corneal, 2.40–41, 2.225–226, 8.8, 8.9, 8.9f, 13.13
 - surgical procedures affecting character of, 13.127–135. *See also* Collagen shrinkage
 - as dermal filler for facial rejuvenation, 7.239
 - in Ehlers-Danlos syndrome, 8.193
 - in lens capsule, 2.64, 2.120, 2.241, 11.11
 - in megalocornea, 8.99
 - mutation in, in hereditary hyaloideoretinopathy, 2.255
 - in osteogenesis imperfecta, 8.194
 - scleral, 2.44, 4.107–108
 - stromal, 2.40–41, 2.225–226, 8.9, 8.9f
 - corneal haze after surface ablation and, 13.33, 13.109
 - in vitreous, 2.78–79, 2.79f, 2.249–250, 2.250f, 2.251f
 - liquefaction and, 2.253
- Collagen cornea shields, for drug administration, 2.303
- Collagen (corneal) crosslinking (CCL/CXL), 13.8t, 13.130–135, 13.131f, 13.133f, 13.133t. *See also* Corneal (collagen) crosslinking
- for *Acanthamoeba* keratitis, 8.279
 - accelerated, 13.134
 - for bacterial keratitis, 8.272
 - combined techniques for, 13.134–135
 - complications of, 13.135
 - for ectasia/postoperative ectasia, 13.124, 13.130, 13.131, 13.206
 - for fungal keratitis, 8.275
 - with intracorneal ring segment implantation, 13.134, 13.207
 - for keratoconus, 8.166
 - for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82
 - patient selection/indications/contraindications for, 13.131–132
 - with photorefractive or phototherapeutic keratectomy, 13.134, 13.206–207
 - with refractive procedures, 13.206–208
 - surgical technique for, 13.131f, 13.132–135, 13.133f, 13.133t
 - transepithelial, 13.132–134, 13.133f
- Collagen (corneal) crosslinking plus, 13.206
- Collagen fibers, in vitreous, 12.7, 12.344
- Collagen plugs, for dry eye, 7.281, 8.64. *See also* Lacrimal plugs
- Collagen shrinkage, 13.8t, 13.28, 13.28f, 13.127–129, 13.128f, 13.129f. *See also specific procedure*
- conductive keratoplasty for, 13.8t, 13.28, 13.28f, 13.128f, 13.128–129, 13.129f, 13.165
 - corneal effects of, 13.28, 13.28f
 - thermokeratoplasty for, 13.8t, 13.28, 13.28f, 13.127–128
- Collagen vascular diseases. *See also* Connective tissue disorders; *specific type*
- immune-related eye disorders and, 8.285
 - refractive surgery in patient with, 13.37, 13.171, 13.191
 - uveitis in, 9.132–139
- Collagenase inhibitors, for peripheral ulcerative keratitis, 8.313
- Collagenases, 8.207, 9.16, 9.30
 - for enzymatic vitreolysis, 2.255
 - in ocular infections, 8.207
- Collagenolysis, in conjunctivochalasis, 8.85
- Collagenous layer, posterior (retrocorneal fibrous membrane/RCFM), 2.227, 4.84, 4.85f
- Collamer, for posterior chamber phakic IOLs, 13.138, 13.139t, 13.142, 13.142f
- Collarette (iris), 2.54f, 2.55
- Collarettes (cilia), in blepharitis, 8.72f, 8.73
- Collateral vessels, retinochoroidal/retinociliary venous (optociliary shunt vessels), 5.22, 7.22, 7.22f
 - in optic nerve sheath meningioma, 5.127f, 5.128
 - in papilledema, 5.109
- Collector channels, 2.51, 2.52f, 10.5f, 10.13
- Colliculus
 - facial, 2.101, 2.103, 5.49
 - superior (SC), 5.18f, 5.33–34
 - saccadic control and, 5.219
- Collier sign
 - in convergence-retraction nystagmus, 5.250
 - in dorsal midbrain (Parinaud) syndrome, 5.229, 5.250, 5.267, 5.274
- Colloid bodies, optic disc/nerve. *See* Optic disc (optic nerve head/ONH), drusen of
- Colloidal iron stain, 4.31t
- Colobomas
 - chorioretinal, 6.364
 - as craniofacial malformation, 6.209
 - embryonic fissure closure and, 2.117, 2.119f
 - eyelid, 6.193, 6.193f, 7.160f, 7.160–161
 - in Treacher Collins syndrome (mandibulofacial dysostosis), 4.207t
 - globe, 6.263
 - inferonasal disc, 6.365f
 - iris, 4.184, 6.266, 6.266f
 - cataract surgery in patient with, 11.180
 - lens, 6.305f, 6.305–306, 11.30–31, 11.31f
 - optic nerve/nerve head/disc, 2.152, 4.242, 4.243f, 5.145, 6.364–365f
 - pupil irregularity and, 5.255
 - uveal, 4.184, 4.184f
- Colobomatous cyst (microphthalmia with cyst), 6.224, 7.36
- Colon cancer. *See* Colorectal cancer
- Colonography, computed tomography, 1.210t, 1.214
- Colonoscopy
 - in cancer screening, 1.210t, 1.214
 - computed tomography (CT colonography), 1.210t, 1.214
 - for polyp removal, 1.213
- Colony-stimulating factors
 - in cancer therapy, 1.236
 - in mucous membrane pemphigoid, 8.299
- Color blindness. *See* Color vision, defects in
- Color plate testing, pseudoisochromatic, in low vision evaluation, 5.78
- Color vision, 2.262–263
 - abnormalities of
 - achromatopsia, 12.250, 12.250t
 - acquired, 12.249, 12.250t
 - congenital, 12.249–251, 12.250t

- description of, 12.249
- drugs that cause, 12.304–305
- β -blockers affecting, 1.117
- blue-yellow deficiency, 12.54
- defects in, 2.262–263, 2.264. *See also specific type*
 - achromatopsia (monochromatism), S-cone (blue-cone), 2.264
 - cataract and, 11.44, 11.70
 - in cone dystrophies, 5.102
 - cortical lesions and, 5.30
 - genetic basis of, 2.262–263, 2.264
 - ocular findings in carriers of, 2.199*t*
 - in optic atrophy, 5.135, 5.146
 - in optic neuritis, 5.78, 5.114
 - in optic neuropathy versus maculopathy, 5.78–79, 5.99
 - retina as source of, 5.175
 - S-cone (blue-cone) monochromatism, 2.264
 - simultanagnosia and, 5.180
- description of, 12.54
- in NAION, 5.122
- red-green deficiency, 12.54
- testing, in low vision evaluation, 5.78–79
- trivariant, 2.262–263
- Color vision tests
 - Farnsworth-Munsell 100-hue test, 12.55
 - Farnsworth Panel D-15 test, 12.55*f*, 12.55–56
 - Hardy-Rand-Rittler plates, 12.54
 - Ishihara plates, 12.54, 12.55*f*
 - panel tests, 12.55
 - pseudoisochromatic plates, 12.54, 12.55*f*
- Colorectal cancer, 1.213–214
 - screening for, 1.207, 1.210*t*, 1.213–214
- Coma, 3.40, 3.72, 3.72*f*, 3.275*f*, 3.275–276
 - “myxedema,” 1.54
 - nonketotic hyperglycemic hyperosmolar, 1.47–48
- Coma (wavefront aberration), 13.9, 13.12, 13.12*f*
 - after LASIK, 13.103*f*
- Combigan. *See* Brimonidine, in combination preparations
- Combined hamartoma of retina and retinal pigment epithelium, 4.179, 4.180*f*, 4.280, 4.280*f*, 6.350
- Combined interrupted and continuous sutures
 - for penetrating keratoplasty, 8.419*f*
 - suture removal/adjustment and, 8.419*f*, 8.431–432, 8.432*f*
- Combined-mechanism glaucoma, 10.7
 - uveitic, 9.286
- Combined nevus, 4.218
- Comitance, spread of, 5.186
- Comitant (concomitant) deviations, 5.183, 5.184, 5.186.
 - See also specific type*
 - definition of, 6.16
 - in infantile esotropia, 6.88
- Comma sign, 12.154
- Commissure, posterior (PC), 5.35, 5.35*f*, 5.55*f*
 - vertical gaze and, 5.36, 5.36*f*
- Common carotid artery, 5.12, 5.13*f*
- Common cause factors, 1.29, 1.30
- Commotio retinae, 4.18–19, 12.353, 12.354*f*
- Communicating arteries
 - anterior (ACoA), 2.90, 5.16*f*, 5.18, 5.27*f*
 - aneurysm of, 5.339, 5.339*f*
 - cranial nerve relationship and, 2.84*f*, 2.85*f*, 5.42*f*, 5.43*f*
 - posterior (PCoA), 2.107*f*, 5.16*f*, 5.18, 5.18*f*, 5.19*f*, 5.20
 - aneurysm of, 5.339*f*
 - third nerve (oculomotor) palsy and, 5.20, 5.194, 5.194*f*, 5.339
 - cranial nerve relationship and, 2.84*f*, 2.85*f*, 5.42*f*
- Communication
 - between clinician and pathologist, 4.25–26
 - between clinician and patient, cataract surgery and, 11.169–170, 11.170
 - between clinician and radiologist, 5.57, 5.73
- Community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA)
 - dacryoadenitis caused by, 7.284
 - preseptal cellulitis caused by, 7.45
- Comparative genomic hybridization (CGH), 4.38*t*
- Compartment syndrome, 2.90, 7.125
 - vision loss after orbital trauma and, 7.109, 7.113
- Complement, 9.22–23, 9.23*f*
 - in aqueous humor, 2.231, 2.233
 - in conjunctiva, 9.53
 - in external eye defense, 8.11
 - in immune response, 9.22–23, 9.23*f*
 - in paroxysmal nocturnal hemoglobinuria, 1.138
 - receptors for, in phagocytosis, 9.19
- Complement C4, in aqueous humor, 2.231, 2.233
- Complement C3a, 9.22, 9.23*f*
- Complement C5a, 9.22, 9.23, 9.23*f*
- Complement factor H (CFH) gene, in age-related macular degeneration, 4.160
- Complementary DNA (cDNA), 2.133
 - sequencing, 2.161
- Complementary DNA library (cDNA library), 2.138
- Complete achromatopsia, 6.337–338
- Complete cataract, 11.38
- Complete third nerve (oculomotor) palsy, 5.195
- Completed stroke, 1.120
- CompleteMoisturePlus contact lens solution,
 - Acanthamoeba* keratitis and, 8.276
- Complex choristomas, 4.48, 4.49*f*
- Complex genetic disorder (multigene disorder), 2.133, 2.200–201
- Complex partial seizures, 1.201
- Complexion-associated melanosis (CAM/racial melanosis), 8.338*t*, 8.339*t*, 8.341, 8.341*f*
- Complexion-associated melanosis (primary conjunctival/hypermelanosis), 4.63*t*, 4.65, 4.66, 4.66*f*
- Compliance with therapy. *See* Adherence issues (therapy)
- Compound heterozygote, 2.133
- Compound hyperopic astigmatism
 - astigmatic dial technique applied to, 3.160, 3.161*f*
 - description of, 3.138, 3.138*f*
 - fogging to produce, 3.161*f*
- Compound myopic astigmatism, 3.138, 3.138*f*
- Compound nevi, 7.173
 - conjunctival/ocular surface, 4.64, 8.338*t*
 - of eyelid, 4.219, 4.219*f*, 7.173
- Compounding pharmaceuticals, 2.306
- Compression (dynamic) gonioscopy, 10.35, 10.35*f*, 10.36
 - in acute primary angle closure, 10.123

- Compressive optic neuropathy, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
 intraorbital/intracanalicular, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
 optic glioma causing, 5.126, 5.128*t*, 5.129*f*, 5.129–131
 optic nerve sheath meningioma causing, 5.126, 5.127*f*, 5.127–129, 5.128*t*
 orbital varices and, 7.71
 in pituitary apoplexy, 5.149, 5.150*f*
 in thyroid eye disease, 5.131, 5.132*f*, 7.52, 7.54, 7.56, 7.59
- Compromised host. *See also* Immunocompromised host
 refractive surgery in, 13.37, 13.171
- Computed tomography (CT/CT scan), 5.58, 5.58*f*, 5.60, 5.61*t*, 5.72*t*
 advantages/disadvantages of/contraindications for, 5.60, 5.61*t*
 in aneurysm detection/evaluation, 5.340
 in cerebral ischemia/stroke, 1.121–122
 in choroidal melanoma/ciliary body melanoma, 4.267
 corneal, 13.19–22, 13.20–21*f*, 13.194
 after refractive/keratorefractive surgery, 13.23
 IOL power determination/selection and, 13.194
 in cysticercosis, 9.231
 helical (spiral)
 chest, in cancer screening, 1.210*t*, 1.212
 in orbital evaluation, 7.27
 in intracranial hemorrhage, 1.127
 intraocular foreign body evaluations, 12.352
 in ischemic heart disease, 1.98
 in lacrimal drainage evaluation, 7.272
 in optic nerve/nerve head/disc drusen, 5.141*f*, 5.142
 in orbital cellulitis, 7.47, 7.47*f*
 in orbital evaluation, 5.58, 5.58*f*, 5.60, 5.61*t*, 5.72*t*, 5.73*f*, 7.26*f*, 7.26–27, 7.27*f*, 7.30*f*
 dermoid cysts and, 7.39*f*, 7.39–40
 MRI compared with, 7.29*t*, 7.29–31, 7.30*f*
 in preseptal cellulitis, 7.44–45
 in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.274
 in pulmonary diseases, 1.131
 in retinoblastoma, 4.293
 single-photon emission (SPECT), 5.70
 in toxocariasis, 9.229
 uveal lymphoma evaluations, 12.234
- Computed tomography angiography (CTA), 5.58, 5.69–70, 5.72*t*
 advantages/disadvantages of/contraindications for, 5.61*t*
 in aneurysm detection/evaluation, 5.69–70, 5.194, 5.194*f*, 5.340
 in arterial dissection, 5.342
 in carotid artery evaluation, 5.167
 in cerebral ischemia/stroke, 1.121–122
 in ischemic heart disease, 1.98
 in orbital evaluation, 7.32
 in vertebrobasilar insufficiency, 5.338
- Computed tomography (CT) colonography, 1.210*t*, 1.214
- Computed tomography perfusion imaging, in cerebral ischemia/stroke, 1.122
- Computed tomography venography (CTV), 5.58, 5.70, 5.72*t*, 5.75
 advantages/disadvantages of/contraindications for, 5.61*t*
 in cerebral venous thrombosis, 5.346
- Computerized corneal topography. *See* Cornea, topography of
- Computerized videokeratoscopy. *See* Videokeratoscopy
- COMS (Collaborative Ocular Melanoma Study), 4.253, 4.271, 4.278–279
- Concave (minus/negative) lenses
 anophthalmic socket camouflage and, 7.136
 combining of, 3.11
 description of, 3.11
 ray tracing for, 3.64, 3.65–66*f*
 spherical, description of, 3.11
- Concave mirrors
 ray tracing for, 3.82*f*, 3.83
 retinoscope setting, 3.150, 3.151*f*
- Concentric contact lenses, 3.225
- Conchae (turbينات), nasal, 7.18, 7.253*f*, 7.254*f*
 infraction of, for congenital nasolacrimal duct obstruction, 7.265
- Concomitant deviations. *See* Comitant (concomitant) deviations
- Concretions, conjunctival, 8.113–114
- Concussive (blunt) trauma, anterior segment, 8.387–396. *See also* Blunt (concussive) trauma
- Condensing lens, 3.298*f*, 3.299
- Conduction disturbances, 1.112
- Conductive keratoplasty (CK), 13.8*t*, 13.28, 13.28*f*, 13.128*f*, 13.128–129, 13.129*f*, 13.165
 corneal transplantation after, 13.198
 for presbyopia, 13.128, 13.128*f*, 13.165
- Conduit Artery Function Endpoint (CAFE) study, 1.74
- Cone dystrophies/degenerations, 5.102
 bull's-eye pattern associated with, 12.265, 12.265*f*
 description of, 12.264–265
 electroretinography findings in, 12.46, 12.47*f*, 12.265
 ERG in, 5.102
 genes and loci associated with, 12.256*t*
 in optic neuropathy versus maculopathy, 5.99
 with supernormal rod ERG, 12.49
- Cone inner segments, 2.70, 2.72*f*, 4.140*f*. *See also* Cones; Photoreceptor inner segments
- Cone outer segments, 2.69, 2.70, 2.72*f*, 4.140*f*. *See also* Cones; Photoreceptor outer segments
- shed, retinal pigment epithelium phagocytosis of, 2.276*f*, 2.276–277
- Cone response, 2.262, 2.269, 2.269*f*
 single-flash (photopic/light-adapted electroretinogram), in cone dystrophies, 5.102
- Cone-rod dystrophies. *See also* Retinitis pigmentosa
 ERG in, 5.96
 genes and loci associated with, 12.256*t*
 Jalili syndrome, 12.286
 retinitis punctata albescens, 12.258, 12.258*f*
 in Stargardt disease, 6.340
- Cones, 2.69, 2.71*f*, 2.72*f*, 2.77, 2.88*f*, 2.257, 2.258*f*, 4.140, 4.140*f*, 5.24. *See also* Cone outer segments
 abnormalities of. *See* Color vision, defects in
 amacrine cells for, 2.267

- bipolar cells for, 2.257, 2.266, 2.266f, 12.13
- development of, 2.116t
- electrophysiologic responses of, 2.269, 2.269f
- extrafoveal, 2.70
- foveal, 2.70, 2.77, 6.44, 12.11
- gene defects in, 2.264
- horizontal cells for, 2.258f, 2.262, 2.266f, 2.266–267
- inner segments of, 12.11–12, 12.12f
- L, 12.54
- light-sensitive molecules in, 12.12
- M, 12.54
- outer segments of, 12.11, 12.12f
- photoreceptors in, 12.13
- phototransduction in, 2.261–263
- retinoblastoma and, 4.172
- S, 12.54
- schematic diagram of, 12.14f
- types of, 12.54
- Confluent drusen, 12.65
- Confocal microscopy, 8.24, 8.24f
 - in *Acanthamoeba* keratitis diagnosis, 8.24, 8.277, 8.278f
 - in fungal keratitis diagnosis, 8.275
 - before phakic IOL insertion, 13.141
- Confocal scanning laser microscope, 3.302
- Confocal scanning laser ophthalmoscopy/ophthalmoscope (CSLO/SLO), 3.302, 3.302f
 - in optic nerve/nerve head/disc evaluation, 10.56
 - for retinal disease evaluations, 12.24
- Conformer
 - after anophthalmic surgery, 7.132
 - contracture of fornices and, 7.133
 - in congenital anophthalmia/microphthalmia management, 7.36
- Conformité Européene (CE) marking, 13.3
 - for intrastromal corneal ring segments, 13.65
 - for small-incision lenticule extraction, 13.203
- Confounding factor, 1.11
- Confrontation testing, 5.83–84, 6.4, 6.10
 - before cataract surgery, 11.82
 - in hemispatial neglect, 5.181
 - in nonorganic disorder evaluation, 5.307–308
 - before refractive surgery, 13.41
- Confusion (mental), postoperative, 1.204
 - in older patients, 1.181
- Confusion tests, in nonorganic disorder evaluation
 - monocular no light perception and, 5.303f, 5.303–305, 5.304f
 - monocular reduced vision and, 5.305
- Congenital. *See also* Genetics
 - definition of, 2.133, 2.181
- Congenital anomalies, 4.6, 4.7f, 4.12t. *See also specific type*
 - of anterior segment/chamber, 4.98–99, 4.99f, 4.100f, 8.95–109, 8.96–98t
 - of conjunctiva, 4.47–50, 4.49f
 - of cornea, 4.73–74, 4.74f, 4.75f, 8.95–109, 8.96–98t
 - secondary abnormalities and, 8.107–109
 - craniofacial malformations, 7.36–38, 7.37f, 7.38f
 - of eyelid, 4.202–203, 4.203f, 7.155–162, 7.157f
 - glaucoma associated with, 4.98, 4.99f, 10.4t, 10.6t, 10.147, 10.148t, 10.151. *See also* Glaucoma, pediatric
 - of lens, 4.117–118, 4.118f, 11.30f, 11.30–39, 11.31f, 11.32f, 11.33f, 11.34f, 11.35t, 11.36f, 11.37f, 11.38f, 11.39f. *See also* Cataract, congenital
 - of optic nerve/nerve head/disc, 4.241–242, 4.243f, 5.143f, 5.143–145, 5.144f
 - transient visual loss and, 5.164
 - of orbit, 4.223–224, 4.224f, 7.35–41, 7.37f, 7.38f, 7.39f, 7.41f
 - of retina and retinal pigment epithelium, 4.142f, 4.142–145, 4.143f, 4.144f, 4.145f
 - of sclera, 4.108–109, 8.95–109, 8.96–98t
 - of trabecular meshwork, 4.98–99, 4.99f, 4.100f
 - of uveal tract, 4.184, 4.184f
 - of vitreous, 4.125–127, 4.126f, 4.127f
- Congenital anterior staphyloma, 8.98t, 8.106f, 8.106–107
- Congenital aphakia, 4.117, 6.305, 11.30. *See also* Aphakia
- Congenital cataract, 11.34–39, 11.35t, 11.36f, 11.37f, 11.38f, 11.39f. *See also* Cataract, congenital; *specific type*
 - genetic/hereditary factors in, 11.41–42
- Congenital cranial dysinnervation disorders (CCDDs)
 - Brown syndrome as, 6.131
 - congenital fibrosis of the extraocular muscles, 6.134–135
 - definition of, 6.131
 - Duane retraction syndrome. *See* Duane retraction syndrome
 - Möbius syndrome, 6.97, 6.135–136, 6.136f
- Congenital cytomegalovirus (CMV) infection (cytomegalic inclusion disease/CID), 1.259, 9.198, 9.199, 9.200
- Congenital ectropion, 7.156, 7.157f
 - in blepharophimosis-ptosis-epicanthus inversus syndrome, 7.155, 7.156
- Congenital entropion, 7.159–160, 7.160f
- Congenital esotropia, 6.86t. *See also* Infantile esotropia
 - amblyopia associated with, 6.87–89
 - botulinum toxin injections for, 6.89
 - Chavasse theory of, 6.87
 - Ciancia syndrome, 6.88, 6.95
 - clinical features of, 6.87–88
 - cross-fixation associated with, 6.87–88, 6.88f
 - cyclopegic refraction for, 6.88
 - definition of, 6.87
 - evaluation of, 6.87–88
 - management of, 6.88–89
 - medial rectus muscle recession for, 6.89
 - mental illness and, 6.87
 - ocular alignment in, 6.88–89
 - pathogenesis of, 6.87
 - prematurity as risk factor for, 6.87
 - smooth-pursuit asymmetry associated with, 6.88
 - surgical treatment of, 6.89
 - Worth “sensory” concept of, 6.87
- Congenital Esotropia Observational Study, 6.89
- Congenital eyelid syndrome. *See* Blepharophimosis-ptosis-epicanthus inversus syndrome
- Congenital fibrosis of the extraocular muscles (CFEOM), 6.134–135
- Congenital fourth nerve (trochlear) palsy, 5.199, 5.199f
- Congenital glaucoma (primary congenital glaucoma/PCG), 4.98, 4.99f, 8.95, 8.108–109, 10.4t, 10.147,

- 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*. *See also* Glaucoma, pediatric; Primary congenital glaucoma
- corneal opacities and, 6.257*t*, 6.260, 6.261*f*, 8.108–109
- differential diagnosis of, 10.151–152, 10.152*t*
- genetics of, 10.11*t*, 10.150
- megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
- treatment of, 10.153
- medical, 10.153
- surgical, 10.153
- Congenital hereditary endothelial dystrophy (CHED/CHED2), 4.92–93, 4.94*f*, 6.257*t*, 6.258*f*, 6.258–259, 8.135*t*, 8.136*t*, 8.160, 8.161*f*
- Congenital hereditary stromal dystrophy (CHSD/CSCD), 6.257*t*, 6.259, 8.135*t*, 8.136*t*, 8.152, 8.153*f*
- Congenital hypertrophy of retinal pigment epithelium (CHRPE), 4.144–145, 4.145*f*, 4.268–269, 4.269*f*, 6.349, 6.349*f*
- melanoma differentiated from, 4.144, 4.268–269, 4.269*f*
- Congenital hypothyroidism/cretinism, 1.50
- Congenital infantile hemangioma
- of eyelid, 7.161–162
- of orbit, 7.67
- Congenital infection syndrome/TORCH (toxoplasmosis, other agents, rubella, cytomegalovirus, and herpesviruses). *See also specific disorder*
- lymphocytic choriomeningitis virus causing, 9.205
- Congenital insensitivity to pain with anhidrosis (CIPA), congenital corneal anesthesia and, 8.108
- Congenital iris ectropion syndrome, 6.267
- Congenital lacrimal/lacrimal–cutaneous fistula, 6.228, 6.229*f*, 7.257, 7.258*f*
- Congenital measles, 9.206, 9.207
- Congenital miosis, 6.267–268
- Congenital motor nystagmus (CMN), 6.148–149, 6.149*t*, 6.153–154
- Congenital mydriasis, 6.268
- Congenital myopia, 3.174
- Congenital nasolacrimal duct obstruction (CNLDO)
- antibiotics for, 6.231–232, 6.234
- balloon dacryoplasty for, 6.234–235, 6.235*f*
- bilateral, 6.232*f*
- clinical features of, 6.230, 6.232*f*
- complex, 6.230, 6.233–234
- description of, 6.227, 6.230
- examination of, 6.230
- infantile glaucoma versus, 6.230
- intubation for, 6.234–235
- massage for, 6.231–232
- nasolacrimal probing for, 6.232–235, 6.233*f*
- nonsurgical management of, 6.231–232
- prevalence of, 6.230
- recurrence of, 6.234
- simple, 6.230, 6.231*f*
- spontaneous resolution of, 6.231
- stents for, 6.234–235
- surgical management of, 6.232–233
- tearing caused by, 6.230
- Congenital nevocellular nevi, 6.200–201, 6.201*f*
- Congenital night blindness, stationary (CSNB), with myopia, ocular findings in carriers of, 2.199*t*
- Congenital nystagmus (CN), 5.234*f*, 5.235–237, 5.237*f*
- latent/manifest latent (LN/MLN/fusion/fusional maldevelopment nystagmus syndrome/FMN/FMNS), 5.237–238
- periodic alternating (PAN), 5.245
- pregeniculate visual impairment and, 5.235–236
- Congenital ocular motor apraxia, 5.223
- Congenital ptosis. *See* Ptosis
- Congenital retinal arteriovenous malformations, 4.286*f*, 4.286–287. *See also* Racemose angioma/hemangioma
- Congenital retinal disease. *See specific disorder and under Hereditary*
- Congenital rubella syndrome (CRS), 1.221, 8.240, 8.240*t*, 9.203–204, 9.204*f*, 9.205
- aphakia and, 4.117
- cataracts and, 9.203, 9.204*f*, 11.38–39
- glaucoma and, 10.150*t*
- Congenital sensory nystagmus, 6.149, 6.150*t*, 6.154
- Congenital sixth nerve (abducens) palsy, 5.201
- Congenital stationary night blindness (CSNB)
- Duchenne muscular dystrophy and, 12.285
- electroretinography findings in, 6.338, 12.46, 12.47*f*, 12.251, 12.252*f*
- genes and loci associated with, 12.256*t*
- retinitis pigmentosa versus, 12.251
- spasmus nutans syndrome associated with, 6.151
- subtypes of, 12.251
- X-linked, 12.252
- Congenital strabismus, 6.16. *See also* Strabismus
- Congenital superior oblique palsy, 6.69
- Congenital syphilis, 1.216, 1.248, 6.269, 6.412–413, 8.107, 8.308–309, 8.309*f*, 9.236–237, 9.237*f*
- corneal manifestations of/interstitial keratitis, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*, 9.237, 9.237*f*
- serodiagnosis of, 9.241
- treatment of, 9.242
- Congenital tarsal kink, 6.194–195
- Congenital tilted disc syndrome, 5.144, 5.144*f*
- Congenital toxoplasmosis, 1.256, 9.221, 9.222*f*, 9.226, 12.243
- Congenital West Nile infection, 9.210
- Congestive heart failure (CHF), 1.105–112, 1.106*f*
- at-risk patients and, 1.105, 1.106*f*
- atrial fibrillation and, 1.111, 1.114
- clinical course of, 1.108–109
- clinical signs of, 1.107
- compensated, 1.105
- decompensated, 1.105
- diagnosis of, 1.107
- epidemiology of, 1.105
- etiology of, 1.108
- high-output, 1.108
- hypertension management and, 1.69*t*, 1.72, 1.75, 1.109–110
- incidence of, 1.105
- ischemic heart disease and, 1.105, 1.108, 1.111
- management of, 1.106*f*
- invasive/surgical, 1.111–112
- medical/nonsurgical, 1.109–111
- myocardial infarction and, 1.94, 1.108
- pathophysiology of, 1.108–109
- refractory, 1.105

- stages of, 1.105, 1.106*f*
- symptoms of, 1.105
- ventricular tachycardia and, 1.115
- Congo red stain, 4.31*t*
- Congruous, definition of, 5.105*t*
- Congruous visual field defects, 5.29, 5.105*t*
 - retrochiasmal lesions producing, 5.153
 - occipital lobe lesions, 5.156, 5.157*f*
- Conidia, 8.249
- Conidiophores, 8.249
- Conjugacy, saccadic eye movement, 5.221
- Conjugate eye movements (versions), 5.34–35, 5.35*f*.
 - See also specific type*
 - in diplopia, 5.184
 - smooth-pursuit system and, 5.224
- Conjugate horizontal gaze, 6.182
- Conjugate planes, in indirect ophthalmoscope, 3.299*f*
- Conjugate points, 3.40, 3.64
- Conjunctiva, 2.20*f*, 2.25, 2.26*f*, 2.30–31, 4.47–72, 7.146*f*, 7.152, 7.154*f*, 8.4*f*. *See also under Conjunctival*
 - aging of/age-related changes in, 1.178, 8.112
 - anatomy of, 2.20*f*, 2.25, 2.26*f*, 2.30–31, 4.47, 4.48*f*, 8.4*f*, 8.6–7
 - biopsy of, 8.360–361
 - in granulomatous conjunctivitis, 4.52
 - in lymphoid lesions, 4.69, 4.70
 - in mucous membrane (cicatricial) pemphigoid, 4.54, 4.54*f*, 8.301*f*, 8.301–302
 - in neoplastic disorders, 8.329
 - in peripheral ulcerative keratitis, 8.311
 - in pseudopemphigoid (drug-induced pemphigoid), 8.301
 - in superior limbic keratoconjunctivitis, 8.84
 - blood supply of, 2.30
 - blood under, 8.387–388, 8.388*f*
 - bulbar, 2.25, 2.26*f*, 2.30, 4.47, 4.48*f*, 8.6
 - fixation/plication of, for conjunctivochalasis, 8.86, 8.361
 - lymphoid lesions involving, 4.69, 4.70*f*
 - resection of, for conjunctivochalasis, 8.86, 8.362
 - capillary hemangioma of, 4.50
 - carcinoma of. *See also Conjunctiva, tumors of*
 - intraocular extension and, 4.310
 - squamous cell, 8.336, 8.336*f*. *See also Ocular surface squamous neoplasia*
 - in situ, 4.61, 4.63*f*
 - invasive, 4.61, 4.62*f*, 4.63*f*
 - caruncular, 4.48*f*. *See also Caruncle*
 - cicatrizization of, 8.47*t*. *See also Conjunctivitis, cicatrizing; Mucous membrane (ocular cicatricial) pemphigoid*
 - concretions of, 8.113–114
 - congenital anomalies of, 4.47–50, 4.49*f*
 - cysts of, 4.59, 4.59*f*, 8.114, 8.114*f*. *See also Epithelial inclusion cysts*
 - nevi and, 4.64
 - degenerations of, 4.56*f*, 4.56–59, 4.57*f*, 4.58*f*, 4.59*f*, 8.111*t*, 8.111–114, 8.115*t*
 - deposits in
 - amyloid, 4.58*f*, 4.58–59, 8.185, 8.186*t*, 8.187*f*
 - in hematologic disorders, 8.198
 - discharge from, 8.46*t*
 - disorders of, 4.47–72, 8.45–46*t*, 8.47, 8.47*t*. *See also*
 - Conjunctivitis; Keratoconjunctivitis; *specific type*
 - common clinical findings in, 8.45–46*t*, 8.47, 8.47*t*
 - epithelial inclusion cysts, 6.250
 - in glaucoma, 10.31
 - immune-mediated, 8.288–306
 - ionizing radiation causing, 8.386
 - neoplastic, 4.59–72, 8.327–350. *See also*
 - Conjunctiva, tumors of
 - nevi, 6.250, 6.250*f*
 - ocular melanocytosis, 6.250–251, 6.251*f*
 - papillomas, 6.250
 - Stevens-Johnson syndrome, 6.251–252, 6.252*f*
 - Th1-mediated delayed hypersensitivity and, 9.46*t*
 - therapeutic/surgical interventions for, 8.352–366
 - toxic epidermal necrolysis, 6.251–252
 - drug absorption and, 2.297
 - dysplasia of (conjunctival intraepithelial neoplasia/ CIN), 4.61, 4.63*f*, 8.37, 8.38*f*, 8.332*t*, 8.334, 8.335*f*. *See also Conjunctival or corneal intraepithelial neoplasia; Ocular surface squamous neoplasia melanocytic*, 4.63*t*, 4.65, 4.66, 4.67*f*
 - epithelium of, 2.30–31, 2.215*f*, 2.216, 4.47, 4.48*f*, 8.7, 8.7*f*
 - cysts of, 4.59, 4.59*f*, 8.114, 8.114*f*. *See also Epithelial inclusion cysts*
 - nevi and, 4.64
 - dysplasia of (conjunctival intraepithelial neoplasia/ CIN), 4.61, 4.63*f*, 8.37, 8.38*f*, 8.332*t*, 8.334, 8.335*f*. *See also Conjunctival or corneal intraepithelial neoplasia; Ocular surface squamous neoplasia melanocytic*, 4.63*t*, 4.65, 4.66, 4.67*f*
 - evaluation of, in pseudoepiphora, 7.268
 - in external eye defense, 8.13
 - tear secretion and, 2.215*f*, 2.216, 2.217
 - tumors of, 8.332*t*, 8.332–337
 - erosions of, 8.47*t*
 - punctate epithelial, 8.46*t*
 - examination of
 - before cataract surgery, 11.78
 - in glaucoma, 10.31
 - before refractive surgery, 13.41–42
 - in external eye defense, 8.13
 - eyelid, 2.20*f*, 2.25, 2.26*f*, 2.30–31, 7.146*f*, 7.152, 7.154*f*
 - fixation/plication of
 - for conjunctivochalasis, 8.86, 8.361
 - for superior limbic keratoconjunctivitis, 8.84
 - follicles of, 8.46*t*, 8.47*t*, 8.48–49, 8.49*f*
 - in chlamydial conjunctivitis/trachoma, 8.261, 8.262, 8.263
 - foreign body on, 4.52, 4.53*f*, 8.397, 8.397*f*, 8.398*f*
 - insect stingers/hairs, 8.386–387
 - radioactive, 8.386
 - forniceal, 2.25, 2.26*f*, 2.30, 4.47, 4.48*f*, 8.6
 - lymphoid lesions involving, 4.69, 4.70*f*
 - glaucoma/glaucoma therapy affecting, 10.31
 - granuloma of, 8.46*t*, 8.47*t*
 - foreign-body, 4.52, 4.53*f*
 - in Parinaud oculoglandular syndrome, 4.51, 8.265
 - in sarcoidosis, 4.52, 4.52*f*, 8.347, 9.168, 9.168*f*
 - hemangiomas of, 4.50, 8.345*t*, 8.345–346
 - immune response/features/microenvironment of, 9.53–56, 9.54*t*

- inadequate, tube shunt implantation for, 10.215
incision through. *See* Transconjunctival incision
infection/inflammation of, 4.50f, 4.50–55, 4.51f, 4.52f, 4.53f, 4.54f, 4.55f. *See also* Conjunctivitis; Keratoconjunctivitis
canalicular obstruction and, 7.274
in graft-vs-host disease, 8.303, 8.304
inflammatory vascular lesions of, 8.346f, 8.346–347
innervation of, 2.30, 2.216
intraepithelial neoplasia of (CIN), 4.61, 4.63f, 8.37, 8.38f, 8.332t, 8.334, 8.335f. *See also* Conjunctival or corneal intraepithelial neoplasia; Ocular surface squamous neoplasia
melanocytic, 4.63t, 4.65, 4.66, 4.67f
laceration of, 8.396–397
lymphoid tissue associated with (CALT), 2.30, 4.47, 4.69, 8.7, 9.55
lymphoma arising in, 8.349–350, 8.350f
lymphoma of, 4.70f, 4.70–71, 4.71f, 8.349–350, 8.350f
mast cells in, 9.10
melanocytic/pigmented lesions of, 4.61–69, 4.63t, 4.64f, 4.65f, 4.66f, 4.67f, 4.68f, 4.69f
melanoma of, 4.68f, 4.68–69, 8.338t, 8.339t, 8.343–345, 8.344f
in situ, 4.65, 4.67f, 4.68
intraocular extension of, 4.310
ocular melanocytosis and, 8.349–350
primary acquired melanosis and, 4.66–68, 4.67f, 4.68, 4.68f, 8.327, 8.342, 8.343
membrane of, 8.46t, 8.47t
in epidemic keratoconjunctivitis, 8.234, 8.234f, 8.235
in gonococcal conjunctivitis, 8.258
in ligneous conjunctivitis, 8.294
nevus of, 4.61–64, 4.63t, 4.64f, 4.65f, 8.338t, 8.339t, 8.340f, 8.340–341
malignant transformation/melanoma and, 4.64, 4.68, 8.340, 8.341, 8.343
normal flora of, 8.205, 8.206t
palpebral, 2.25, 2.26f, 2.30, 4.47, 4.48f, 4.201, 4.201f, 4.202, 8.6
papillae of, 8.46t, 8.47f, 8.47t, 8.47–48, 8.48f. *See also* Papillae, conjunctival
papillomas of, 4.59–60, 4.60f, 8.238–239, 8.239f, 8.332t, 8.332–334, 8.333f
pH of, chemical injury management and, 8.382
pigmented lesions of, 8.338t, 8.338–345, 8.339t, 8.340f, 8.338t, 8.338–341, 8.339f, 8.339t, 8.340f, 8.341f, 8.338t, 8.339t, 8.343–345, 8.344f
preinvasive, 8.338t, 8.339t, 8.342f, 8.342–343
primary melanosis of, 4.63t, 4.65, 4.66–68, 4.67f
pseudomembrane of, 8.46t, 8.47t
in epidemic keratoconjunctivitis, 8.234
in ligneous conjunctivitis, 8.294
redundant. *See* Conjunctivochalasis
resection of, for conjunctivochalasis, 8.86, 8.362
scarring of, 6.146
scrapings/swabbings from, 8.210–211
specimen collection from, 8.209t, 8.209–210
stem cells of, 8.92, 8.362
stroma of (substantia propria), 4.47, 4.48f, 8.7, 9.53
age-related changes in, 8.112
in external eye defense, 8.13
immune and inflammatory cells in, 8.13, 9.53
in superior limbic keratoconjunctivitis, 8.83–84, 8.84f
tarsal, 8.6
telangiectasia of, in ataxia-telangiectasia, 5.332f, 5.334t
topography of, 4.47, 4.48f
transplantation of, 8.351, 8.351t, 8.353t, 8.353–355, 8.354f, 8.356
for chemical injuries, 8.384
indications for, 8.351t, 8.353, 8.356
for limbal stem cell deficiency, 8.94
in pterygium surgery, 8.351, 8.353t, 8.353–355, 8.354f, 8.356
recurrence rate and, 8.353t
after tumor removal surgery, 8.329
tumors of, 4.59–72, 8.327–350. *See also* Ocular surface, tumors of
approach to patient with, 8.328
epithelial, 8.332t, 8.332–337
glandular, 4.71–72, 4.72f, 8.337f, 8.337–338
human papillomavirus causing, 4.59–60, 4.60f, 8.238–239, 8.239f, 8.332t, 8.332–334, 8.333f
inflammatory, 8.346f, 8.346–347
Kaposi sarcoma, 8.239, 8.345t, 8.347f, 8.347–348, 9.299f
lymphoid/lymphatic/lymphocytic, 4.69–71, 4.70f, 4.71f, 8.348–350, 8.349f, 8.350f
malignant, 8.338t, 8.339t
management of, 8.328–332, 8.330f, 8.331f
surgical, 8.329–330, 8.330f
melanocytic/pigmented lesions, 4.61–69, 4.63t, 4.64f, 4.65f, 4.66f, 4.67f, 4.68f, 4.69f
metastatic, 8.350
neurogenic and smooth muscle, 8.345
pigmented, 8.338t, 8.338–345, 8.339t, 8.340f, 8.341f, 8.342f
preinvasive, 8.332t. *See also* Conjunctival or corneal intraepithelial neoplasia
pigmented, 8.338t, 8.339t, 8.342f, 8.342–343
squamous lesions, 4.59–61, 4.60f, 4.62f, 4.63f
topical chemotherapy for, 8.330f, 8.330–332, 8.331f
vascular and mesenchymal, 8.345t, 8.345–348, 8.346f, 8.347f
ulceration of, 8.47t
in uveitis, 9.80t
Conjunctiva-associated lymphoid tissue (CALT/ conjunctival MALT), 2.30, 4.47, 4.69, 8.7, 9.55
lymphoma arising in, 8.349–350, 8.350f
Conjunctival arteries, anterior and posterior, 2.30
Conjunctival autograft/autologous transplantation, 8.351t, 8.353t, 8.353–355, 8.354f, 8.356
for chemical injuries, 8.384
indications for, 8.351t, 8.353
for limbal stem cell deficiency, 8.94
in pterygium surgery, 8.353t, 8.353–355, 8.354f
recurrence rate and, 8.353t
after tumor removal surgery, 8.329
Conjunctival erythema, in thyroid eye disease, 7.52, 7.53f
Conjunctival filtering blebs, endophthalmitis associated with, 12.390–391, 12.391f
Conjunctival fixation sutures
for conjunctivochalasis, 8.86, 8.361
for superior limbic keratoconjunctivitis, 8.84

- Conjunctival flaps, 8.354f, 8.356–360, 8.357f, 8.358f, 8.359f
 for bare sclera after pterygium excision, 8.353, 8.354f
 cataract surgery and
 for ECCE, 11.196
 for ICCE, 11.199
 leak causing inadvertent filtering bleb and,
 11.130–131
 for postoperative corneal edema, 11.129–130
 for herpetic eye disease, 8.225
 for neurotrophic keratopathy/persistent corneal
 epithelial defects, 8.82, 8.357
 for peripheral ulcerative keratitis, 8.313
 removal of, 8.360
 for symblepharon, 7.208
 for trabeculectomy, 10.200, 10.201f, 10.202f
 closure of, 10.204, 10.206f
 in elderly patients, 10.221
 management of, 10.207–208
 for trabeculotomy, in children, 10.161–162
 Conjunctival hyperemia/congestion, 6.237, 6.238t, 8.45t,
 8.114, 8.115t
 in glaucoma, 10.31
 insect/arachnid injuries causing, 8.386
 in leptospirosis, 9.248–249
 prostaglandin analogues causing, 10.175
 Conjunctival inclusion cysts, 4.59, 4.59f, 8.114, 8.114f
 concretions and, 8.113–114
 nevi and, 4.64, 8.340
 Conjunctival-limbal autograft. *See also* Autografts/
 autologous transplantation
 for pterygium excision, recurrence rate and, 8.353t
 Conjunctival melanocytic intraepithelial neoplasia (C-
 MIN), 4.63t, 4.65, 4.66, 4.67f
 Conjunctival or corneal intraepithelial neoplasia (CIN),
 4.61, 4.63f, 8.37, 8.38f, 8.332t, 8.334–335, 8.335f.
 See also Ocular surface squamous neoplasia
 melanocytic, 4.63t, 4.65, 4.66, 4.67f
 Conjunctival sac, 2.213
 Conjunctival telangiectasia, 6.303f, 6.403
 Conjunctival vascular tortuosity, 8.114, 8.115t
 Conjunctivalization of cornea, 8.362
 Conjunctivitis, 4.50, 8.208t. *See also* Keratoconjunctivitis
 acute, 8.257t
 hemorrhagic (AHC), 8.240, 8.240t
 purulent, 8.256, 8.257t
 adenoviral, 4.52, 6.241–242, 8.208t, 8.233, 8.234f,
 8.234–236, 8.235f
 immune response to, 9.55–56
 adult inclusion, 6.241
 allergic, 6.246f, 6.246–248, 8.288–289, 9.51
 drugs for, 2.337–339, 2.338t
 perennial, 8.288–289
 seasonal, 8.288–289
 bacterial, 4.52, 6.240f, 6.240–241, 8.208t, 8.255–265
 in children, 8.243, 8.255–256
 classification of, 8.257t
 in neonates, 8.257t, 8.263–265
 blepharitis and, 6.244–245, 245f, 8.72, 8.73t, 8.74,
 8.75, 8.76. *See also* Blepharoconjunctivitis
 chemical, 6.239
 in children, 8.243, 8.255–256
 preseptal cellulitis caused by, 8.256
 Chlamydia trachomatis as cause of, 6.238–239, 6.239f
 chlamydial, 4.52, 4.54f, 8.208t, 8.257t, 8.260t,
 8.260–263, 8.261f, 8.262f
 in adults, 8.257t, 8.260, 8.263
 in neonates, 8.257t, 8.265
 cicatrizing, 4.53, 4.54f, 8.299, 8.300–301, 8.301t,
 8.303. *See also* Mucous membrane (ocular
 cicatrical) pemphigoid
 differential diagnosis of, 8.300–301, 8.301t
 corticosteroid route of administration in, 2.333t
 Corynebacterium causing, 8.245
 coxsackievirus, 8.240, 8.240t
 enterovirus, 8.240, 8.240t
 Epstein-Barr virus as cause of, 6.243, 8.230–231,
 9.202
 follicular, 4.50, 4.50f, 4.51, 4.51f, 6.241, 6.243, 8.47t,
 8.48–49, 8.49f
 in acute hemorrhagic conjunctivitis, 8.240
 adenoviral, 8.233, 8.234
 Epstein-Barr virus causing, 8.230–231
 in influenza, 8.240t
 in Lyme disease, 9.245
 in measles, 8.239, 8.240t
 in mumps, 8.240, 8.240t
 rhinovirus causing, 8.240t
 RNA viruses causing, 8.239
 toxic, 8.90t, 8.91, 8.91f
 varicella-zoster virus causing, 8.225, 8.226
 giant papillary (GPC), 3.231f, 3.234
 after penetrating keratoplasty, 8.426
 gonococcal/hyperacute gonococcal, 8.208t, 8.245,
 8.257t, 8.258–260, 8.259f, 8.260t
 in neonates, 8.257t, 8.258, 8.264
 in graft-vs-host disease, 8.303
 granulomatous, 4.51–52, 4.52f
 in HIV infection/AIDS, 9.300–301
 in Parinaud oculoglandular syndrome, 8.265–266
 Haemophilus causing, 4.52, 8.208t, 8.256, 8.257t
 hay fever, 8.288–289
 herpes simplex, 4.52, 6.239, 6.242, 8.208t, 8.213,
 8.214f, 8.216, 8.226t, 8.257t, 8.260t
 herpes zoster, 4.52, 8.225–230, 8.226t. *See also* Herpes
 zoster ophthalmicus
 in HIV infection/AIDS, 8.240t, 8.241, 8.260t,
 9.300–301
 hyperacute, 8.257t
 gonococcal, 8.208t, 8.245, 8.257t, 8.258–260,
 8.259f, 8.260t
 in infants, 8.257t, 8.263–265. *See also* Ophthalmia,
 neonatorum
 infectious, 4.52–53, 4.54f, 6.237–243. *See also specific
 type and causative agent*
 in infectious mononucleosis, 9.202
 ligneous, 6.249, 8.294f, 8.294–295
 Loa loa causing, 8.282, 8.282f
 in Lyme disease, 9.245
 measles virus causing, 8.239, 8.240t, 9.206
 medication toxicity causing, 8.80–81, 8.81t, 8.90t,
 8.90–91
 meningococcal, 8.257t
 microsporidial, 8.280f, 8.280–281
 molluscum contagiosum as cause of, 6.243, 6.244
 mumps virus causing, 8.240, 8.240t

- neonatal inclusion, 6.238
 in neonates, 8.257t, 8.263–265. *See also* Ophthalmia, neonatorum
 noninfectious, 4.52–55, 4.54f
 ophthalmia neonatorum
 Chlamydia trachomatis as cause of, 6.238–239, 6.239f
 definition of, 6.237
 epidemiology of, 6.237
 etiology of, 6.237
 herpes simplex virus as cause of, 6.239
 Neisseria gonorrhoeae as cause of, 6.238f, 6.238–239
 Neisseria meningitidis as cause of, 6.238
 prevalence of, 6.237
 prophylaxis for, 6.239
 papillary, 4.50, 4.50f, 4.51f, 8.47t, 8.48f, 8.426
 in Parinaud oculoglandular syndrome, 4.51, 8.265–266, 9.256
 perennial allergic, 6.246–248
 pneumococcal, 8.256, 8.257t
 in reactive arthritis/Reiter syndrome, 1.154–155, 8.305–306, 9.115
 RNA viruses causing, 8.239
 in rosacea, 8.70
 rubella, 9.205
 in sarcoidosis, 4.52, 4.52f
 seasonal allergic, 6.246f, 6.246–248, 8.288–289
 seroconversion, in HIV infection/AIDS, 8.240t, 8.241
 signs and symptoms of, 6.237
 staphylococcal/staphylococcal blepharitis and, 8.73t, 8.74, 8.75, 8.76, 8.254, 8.256, 8.257t
 in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296f, 8.296–297
 streptococcal, 8.208t, 8.256, 8.257t
 subacute, 8.257t
 toxic, 3.232
 medications causing, 8.80–81, 8.81t, 8.90t, 8.90–91
 varicella-zoster virus as cause of, 6.242–243, 8.225–230, 8.226t. *See also* Herpes zoster ophthalmicus
 viral, 4.52, 6.241–243, 6.243–244f, 8.208t. *See also specific virus*
 immune response to, 9.55–56
 Conjunctivochalasis, 8.45t, 8.85f, 8.85–86, 8.114
 punctal obstruction/malposition and, 7.273
 surgical management of, 8.86, 8.361–362
 Conjunctivodacryocystorhinostomy (CDCR), 6.227–228
 for canalicular obstruction, 7.275–276, 7.276f
 after canthal repair, 7.195
 for punctal/canalicular agenesis/dysgenesis, 7.260
 Conjunctivoplasty, 6.172
 Connective tissue
 eyelid, 2.21, 7.152–153
 pericanalicular, 2.49–50, 2.50f
 Connective tissue disorders. *See also* Collagen vascular diseases; *specific disorder*
 cataract surgery in patient with, 11.170–171, 11.171f
 corneal changes in, 8.190–196, 8.191–192t, 8.193f, 8.194f, 8.195f, 8.195t
 hemorrhage and, 1.142
 mixed (MCTD), 1.162
 peripheral ulcerative keratitis in, 8.312
 refractive surgery in patient with, 13.37, 13.171, 13.191
 scleritis in, 8.323, 8.325f
 tumors, 6.222
 uveitis in, 9.132–139
 Connective tissue mast cells, 9.10
 Connexins, in lens gap junctions, 2.246
 Conoid of Sturm, 3.40, 3.76, 3.76f, 3.160, 3.161f
 Conor Cornea, donor, for homoplasic corneal inlay, 13.60
 Consanguinity, 2.133, 2.172, 2.172f, 2.176, 2.205
 Consecutive anophthalmia, 7.35
 Consecutive esotropia, 6.95
 Consecutive exotropia, 6.16, 6.104
 Consecutive hyperopia, 13.101–102
 Consecutive myopia, 13.101–102
 Consecutive strabismus, 6.16
 Consensual response, in pupillary reaction to light, 5.254
 Consensus DNA sequence, 2.142
 Consent, informed, 1.284
 for cataract surgery, 11.87–88
 for facial rejuvenation surgery, 7.241
 older patients and, 1.181
 for refractive surgery, 13.36t, 13.46–48, 13.47t
 in patient with ocular or systemic disease, 13.171–172
 phakic IOL insertion and, 13.140–141
 refractive lens exchange and, 13.147–148
 Conservation (genetic), 2.133
 Conserved base-pair mutations, 2.156
 CONSORT (Consolidated Standards of Reporting Trials) Statement, 1.13
 Constant exotropia, 6.103–105, 6.104f
 Constant suppression, 6.49
 Constructive interference, 3.100, 3.119
 Contact applanation, for axial length measurement, in IOL power determination/selection, 11.83
 Contact B-scan ultrasonography, 12.39, 12.39f
 Contact dermatoblepharitis/dermatitis/conjunctivitis, 8.285–287, 8.286f
 Contact inhibition, in corneal wound repair, 4.13
 Contact lens drug-delivery systems, 2.303
 Contact lens–induced keratoconjunctivitis (CLIK), 3.233, 8.84
 Contact lens method, for IOL power calculation after refractive surgery, 13.195
 Contact lens solutions
 Acanthamoeba keratitis and, 8.276, 8.277
 Fusarium keratitis and, 8.273–274
 ocular surface toxicity and, 8.91
 Contact lenses. *See also* Rigid gas-permeable (RGP) contact lenses; Soft (flexible) contact lenses; *specific type*
 Acanthamoeba keratitis associated with, 2.361, 4.78–79, 8.276, 8.277
 accommodation and, 3.178, 3.208–211, 3.209f, 3.210t
 accommodative demand through, 3.210t
 amblyopia treated with, 6.304
 anisometropia and, 3.139, 3.206–208
 astigmatism correction and, 3.211–212, 3.222–223, 3.223t, 13.17
 after refractive surgery, 13.199

- bacterial keratitis associated with, 8.266–267
 - orthokeratology and, 13.71
- bandage, 3.227–228, 8.368
 - for chemical injuries, 8.383
 - contraindications to, in exposure keratopathy, 8.80
 - for corneal abrasion, 8.398
 - for dry eye, 8.61*t*, 8.63, 8.368
 - for graft-vs-host disease, 8.304, 8.305*f*
 - for involutional entropion, 7.203
 - after LASIK, 13.93, 13.111, 13.200
 - for epithelial ingrowth, 13.122
 - for epithelial sloughing/defects, 13.112
 - microkeratome complications and, 13.111
 - for striae, 13.113
 - for penetrating and perforating ocular trauma, 8.402
 - for peripheral ulcerative keratitis, 8.313
 - for recurrent corneal erosion, 8.87, 8.368
 - for superior limbic keratoconjunctivitis, 8.84
 - after surface ablation, 13.92, 13.107, 13.200
 - sterile infiltrates and, 13.108, 13.108*f*
 - for Thygeson superficial punctate keratitis, 8.307
- base curve of, 3.205, 3.215*f*, 3.216
- bifocal
 - alternating vision, 3.207*t*, 3.224*f*, 3.224–225
 - presbyopia correction using, 3.224–225
 - simultaneous vision, 3.207*t*, 3.225, 3.225*f*
- care of, 3.229–230
- complications/problems associated with
 - allergic reactions, 3.233–234
 - corneal abrasions, 3.233
 - corneal warpage, 3.232–233
 - dry eye, 3.234–235
 - giant pupillary conjunctivitis, 3.231*f*, 3.234
 - hypoxic/metabolic, 3.230–232, 3.231*t*
 - infections, 3.230, 3.231*f*, 3.231*t*
 - inflammation, 3.231*t*, 3.233–234
 - keratoconjunctivitis, 3.233
 - mechanical, 3.231*t*, 3.232–233
 - 9-o'clock staining, 3.233, 3.233*f*
 - ocular surface, 8.84, 8.266–267, 8.273–274, 8.276, 8.277
 - ptosis, 3.233
 - punctate keratitis, 3.232–233
 - risk factors for, 3.214
 - sterile corneal infiltrates, 3.231*f*, 3.234
 - 3-o'clock staining, 3.233, 3.233*f*
 - toxic, 3.231*t*, 3.232
 - toxic conjunctivitis, 3.232
- concentric, 3.225
- contraindications for, 3.214
- convergence affected by, 3.178
- corneal abnormalities corrected using, 3.225–226
- corneal abrasion caused by, 8.399
- custom, 3.228–229
- daily-wear, 3.214–215
- diameter of, 3.205, 3.215*f*, 3.216
- discontinuing use of before refractive surgery, 13.22–23, 13.38
- disinfection of, 3.229
- Dk, 3.213, 3.215
- Dk/*t*, 3.213
- drug delivery systems using, 2.303
- dry eye and, 8.54, 8.55*f*
- extended-wear
 - deep stromal neovascularization associated with, 3.232
 - description of, 3.215
- FAP-SAM rules for, 3.220, 3.220*f*
- Federal Fairness to Contact Lens Consumers Act, 3.235
- federal laws regarding, 3.235
- filtering bleb and, 10.211
- fitting of. *See also* Fitting (contact lens)
 - goals for, 3.215
 - LARS rule for, 3.223, 3.224*f*
 - rigid gas-permeable lens, 3.218–221*f*, 3.218–222, 3.220*t*
 - soft contact lens, 3.216–217, 3.217*f*, 3.217–218*t*
 - terminology associated with, 3.215*f*, 3.215–216
 - toric soft lens, 3.222–223, 3.224*f*
- flexible. *See* Soft (flexible) contact lenses
- fundus on, 12.22
- fungal keratitis associated with, 4.78, 8.273–274
- gas-permeable scleral, 3.226–227
- geometry of, 3.215*f*, 3.215–216
- history of use of, refractive surgery evaluation and, 13.38
- HIV transmission and, 1.271
- hybrid
 - description of, 3.226
 - indications for, 3.207*t*
- ideal characteristics of, 3.212–213
- image magnification by, 3.255
- image size and, 3.206–208
- induced anisophoria corrected using, 3.190
- keratitis/keratoconjunctivitis associated with use of, 4.78–79, 8.84, 8.266–267, 8.273–274, 8.276, 8.277
 - orthokeratology and, 13.71
- keratoconus correction using, 3.225–226, 8.166, 8.167*f*
- for keratoglobus, 8.171
- after LASIK, 13.199, 13.200
- lens dislocation treated with, 6.310
- materials used in, 3.212–214
- monovision and, 13.164
 - as trial for surgery, 13.39, 13.165, 13.198
- for myopia reduction (orthokeratology), 13.70–71
- optical zone of, 3.215*f*, 3.216
- optics of, 3.206–212
- for orthokeratology, 13.70–71
- over-the-counter, 3.235
- overrefraction of, 3.227
- overwear syndromes, 3.230
- oxygen permeability of, 3.213, 3.215
- parts of, 3.215*f*
- patient education about, 3.230
- patient history-taking for, 3.214
- for pellucid marginal degeneration, 8.169
- after penetrating keratoplasty, 8.432, 13.178
- peripheral curve of, 3.205, 3.215*f*, 3.216
- in photocoagulation delivery, 12.375
- physical examination before, 3.214
- piggyback, 3.226
- polymethylmethacrylate, 3.213
- power of, 3.220–221*f*, 3.220–222
- Prentice rule and, 3.206

- for presbyopia. *See* Contact lenses, bifocal
 presbyopia correction using, 3.223–225
 prevalence of, 3.206
 after radial keratotomy, 13.52, 13.199, 13.199f,
 13.199–200
 reading glasses over, 3.223
 rear vertex power of, 3.216, 3.216t
 after refractive/keratorefractive surgery, 13.198–200,
 13.199f
 rigid (hard). *See* Rigid gas-permeable (RGP) contact
 lenses
 rigid gas-permeable (RGP). *See also* Rigid
 gas-permeable (RGP) contact lenses
 advantages of, 3.214t, 3.215
 apical alignment fit of, 3.218–219, 3.219f
 apical bearing of, 3.218
 apical clearance of, 3.218
 base curve of, 3.218, 3.219f
 central fit of, 3.219
 characteristics of, 3.213–214
 corneal abnormalities corrected using, 3.226
 corneal reshaping uses of, 3.228
 disadvantages of, 3.215
 fitting of, 3.218–221f, 3.218–222, 3.220t
 fluorescein patterns for fitting evaluations, 3.219f,
 3.219–220
 indications for, 3.207t, 3.227
 interpalpebral fit of, 3.219
 keratoconus correction using, 3.226
 orthokeratology, 3.228
 pannus associated with, 3.232
 parameters of, 3.220t
 ptosis secondary to, 3.233
 scleral, 3.226–227
 soft lenses versus, 3.218
 tear layer created by, 3.221
 tear lens, 3.218, 3.218f
 sagittal depth or vault of, 3.205, 3.215f,
 3.216
 scleral
 description of, 3.226
 for dry eye, 8.61t, 8.63
 gas-permeable, 3.226–227
 for graft-vs-host disease, 8.304, 8.305f
 indications for, 3.207t
 for limbal stem cell deficiency, 8.94
 segmented, 3.224–225
 selection of, 3.214–215
 semi-scleral, 3.227
 soft
 adjusting of, 3.217t
 advantages of, 3.214, 3.214t
 daily-wear, 3.214–215
 duration of use, 3.214
 evaluation of, 3.217t
 extended-wear, 3.215
 fitting of, 3.216–217, 3.217f, 3.217–218t
 hydrogel, 3.213
 materials used in, 3.213
 overrefraction testing, 3.217
 parameters for, 3.217, 3.218t
 rigid gas-permeable lenses versus, 3.218
 selection of, 3.217t
 spherical, 3.207t
 toric, 3.207t, 3.222–223
 solutions for, 3.229t, 3.229–230
 spectacle lenses and, 3.206, 3.216
 after surface ablation, 13.200
 therapeutic, 3.227–228, 8.368. *See also* Contact lenses,
 bandage
 toric soft, 3.207t, 3.222–223, 3.224f
 discontinuing use of before refractive surgery, 13.38
 after radial keratotomy, 13.200
 for trial fitting, disinfection of, 1.271
 tube shunt implantation and, 10.215
 vault of. *See* Contact lenses, sagittal depth (vault) of
 wettability of, 3.213, 3.213f
 wetting angle of, 3.213
 Contact specular microscopy, 3.295, 8.23
 Contig map, 2.163f
 Contiguous gene deletion syndrome, 2.193
 Continuous blood glucose-monitoring systems, 1.39
 Continuous curvilinear capsulorrhexis (CCC), 11.108–
 110, 11.109f. *See also* Capsulorrhexis
 capsule staining for, 11.178–179, 11.179f
 for ECCE, 11.196
 for phacoemulsification, 11.108–110, 11.109f
 in uveitis, 9.283
 Continuous positive airway pressure (CPAP), 1.132
 dry eye and, 1.129, 1.132
 Continuous subcutaneous insulin infusion (CSII), 1.42
 Continuous sutures, for penetrating keratoplasty, 8.419f
 postoperative problems and, 8.419f, 8.426, 8.426f,
 8.431–432, 8.432f
 Continuous-wave lasers, 3.112
 Contour interaction bars, 6.7f, 6.8
 Contour stereopsis, 6.81
 Contraceptives, oral
 central retinal vein occlusion risks, 12.134
 hypercoagulability associated with, 1.148
 hypertension and, 1.77
 ocular effects/retinal toxicity of, 1.308t
 tetracycline use and, 2.350
 thyroxine levels affected by, 1.51
 uveitis caused by, 9.121
 Contracted fornices, anophthalmic socket and, 7.133
 socket contracture and, 7.135
 Contracted socket, 7.134–135, 7.135f
 Contractility, myocardial, 1.109
 enhancement of, in heart failure management, 1.110
 reduction of, in angina management, 1.99
 Contraction, wound, 4.13
 eyelid/orbit scarring and, 4.17
 Contralateral antagonist, inhibitional palsy of,
 6.120–121, 6.121f
 Contralateral corneal autograft, 8.451–452
 Contrast. *See also* Contrast sensitivity
 measurement of, 3.134
 Contrast/catheter/conventional angiography, 5.68, 5.68f,
 5.337f
 in aneurysm detection/evaluation, 5.195, 5.340, 5.341f
 in arteriovenous malformations, 5.292f, 5.344,
 5.344f
 in reversible cerebral vasoconstriction syndrome,
 5.347, 5.347f
 in vertebrobasilar insufficiency, 5.337f, 5.338

- Contrast dacryocystography, for lacrimal drainage evaluation, 7.272
- Contrast media
for angiography, 5.68, 5.68f
for CT studies, 5.60
for MRI studies, 5.60
- Contrast sensitivity, 12.56–57, 12.57f
cataracts and, 11.70, 11.77
definition of, 3.123
description of, 3.134–136, 3.136f
higher-order aberrations affecting, 13.12, 13.76
illumination requirements for, 3.318
low vision/vision rehabilitation and, 3.314–315, 5.88
with multifocal IOLs, 13.156
with phakic IOLs, 13.144
poor levels of, 3.314
posterior subcapsular lens opacity effects on, 3.67
sunglasses' effect on, 3.192
testing, 3.315, 3.316f, 5.88, 11.77
in low vision evaluation, 5.88
with wavefront-guided/optimized and topography-guided ablations, 13.77
- Contrast sensitivity function (CSF), 3.123, 3.134–136, 3.260
- Contrast sensitivity grating, Campbell-Robson, 3.135f
- Contrast threshold, 3.124, 3.135
- Contrecoup, 12.315
- Control charts, 1.27–29, 1.29f
- Control group, research study generalizability and, 1.4–5
- Contusion cataract, 11.54, 11.54f
- Contusion injury. *See also* Blunt (concussive) trauma; Trauma
lens damage caused by, 11.53–55, 11.54f
- Convergence, 5.226
accommodative, 6.39, 6.59
assessment of, 5.226–227, 6.71
contact lens correction effects on, 3.178, 3.212f
definition of, 6.39
dysfunction of, 5.227
fusional, 6.39, 6.43, 6.72
near point of, 6.71
near reflex and, 2.96
proximal (instrument), 6.39
spectacle lens correction effects on, 3.178
symmetric, 6.41
tonic, 6.40
voluntary, 6.40
- Convergence amplitude, 5.226
in convergence insufficiency, 5.227
- Convergence insufficiency (CI), 5.227, 6.103
- Convergence paralysis, 6.105–106
- Convergence-retraction nystagmus (CRN/induced convergence-retraction), 5.243t, 5.250, 6.152–153
- Convergence spasm, 5.227, 6.94
- Convergent rays. *See* Convergence
- Converging lens, for hyperopia correction, 3.170, 3.170f
- Conversion disorders, 1.190
- Convex (plus/positive) lenses
anophthalmic socket camouflage and, 7.136
description of, 3.8–9
image formation, 3.9f
ray tracing for, 3.62f
spherical lens combined with, 3.17
- Convex mirrors, ray tracing for, 3.82f
- Coombs and Gell hypersensitivity classification, 9.40–41, 9.41t. *See also* Hypersensitivity reactions
- Copaxone. *See* Glatiramer
- COPD. *See* Chronic obstructive pulmonary disease
- Copeland retinoscope, 3.150, 3.156
- Copeland streak projection system, 3.150
- Copper, 12.362
in aqueous humor, 2.232
corneal deposition of, 11.59
Kayser-Fleischer ring caused by, 11.62
corneal deposition of/Kayser-Fleischer ring and, 8.118t, 8.173, 8.189, 8.189f
foreign body of, 11.59
in free-radical formation, 2.282, 2.283
“sunflower” cataract and, 8.189, 11.59
in Wilson disease/chalcosis, 2.203, 8.189, 11.59, 11.62
- Copper deficiency, optic neuropathy caused by, 5.138
- Copy number variation (indels), 2.133–134, 2.148
- Core oligosaccharide, 9.13
- Core therapy, for glaucoma, indications for surgery and, 10.197
- Corectopia, 5.255, 6.268
cataract surgery in patient with, 11.180
in iridocorneal endothelial syndrome, 10.136, 10.137f
iridodialysis repair and, 8.375
- Cornea, 4.73–96, 4.74f. *See also under* Corneal
abrasions of, 3.233, 4.13–14, 6.376, 8.398–399
contact lenses causing, 8.399
in mucous membrane pemphigoid, 8.300
posttraumatic recurrent corneal erosion and, 8.86, 8.87, 8.398
age-related changes in, 1.178, 8.115
amyloid deposits in. *See* Cornea, deposits in
anatomy of, 2.37, 2.37f, 2.38–43, 2.39f, 2.40f, 2.42f, 2.43f, 3.268–271, 3.269–271f, 4.73, 4.74f, 8.7f, 8.7–10, 8.9f
anesthesia/hypoesthesia of
congenital, 8.108
herpes simplex epithelial keratitis and, 8.217–218, 8.226t
herpes zoster and, 8.226t, 8.228
keratoplasty and, 8.418, 8.424
after LASIK, 13.172
neurotrophic keratopathy/persistent corneal defects and, 8.80, 8.224
anterior surface of, 3.270
apex of, 8.25, 8.26f
apical zone of, 3.205, 3.215, 3.228, 8.25
aspheric, 3.269, 3.279, 13.14
axial map of, 3.269f
basal lamina of, 2.39–40, 2.40f, 2.41, 2.42f
biochemistry and metabolism of, 2.223f, 2.223–227
biomechanics of, 8.43, 13.13–14
measurement of, 8.43
biopsy of, 8.210, 8.211f, 8.366–367
blood staining of, 4.86, 4.86f, 8.118t, 8.375, 8.394, 8.394f, 8.395, 8.395t, 10.104, 10.104f, 10.105
hyphema after cataract surgery and, 11.159
Bowman layer/membrane of, 2.40, 2.40f, 2.45f, 2.223f, 2.225, 4.73, 4.74f, 8.7f, 8.8. *See also* Bowman layer/membrane
healing/repair of, 4.16
preparation for refractive surgery and, 13.82–90

- calcification of. *See* Band keratopathy/calcific band keratopathy
- central, 2.38–39, 2.39f, 8.25, 8.25f. *See also* Central cornea
- healing in, 4.14–16, 4.15f
- chemical injury of, 8.375–384, 8.376t. *See also* Chemical injury
- clouding of, 6.179, 6.385, 6.387f
- congenital/developmental anomalies of, 4.73–74, 4.74f, 4.75f; 8.95–109, 8.96–98t. *See also specific type*
- in hereditary syndromes and dystrophies, 8.107
- opacities, 8.16f, 8.107. *See also* Cornea, opacification of
- secondary abnormalities causing, 8.107–109
- of size and shape, 8.95–101, 8.96t, 8.99f
- structural, 8.101–107, 8.102f, 8.103f, 8.105f, 8.106f
- conjunctivalization of, 8.362
- curvature of, 8.25–26. *See also* Cornea, topography of
- axial, 8.28, 8.29f, 13.16, 13.16f, 13.17f
- in cornea plana, 8.96t, 8.100
- evaluation of, 8.25–36. *See also* Cornea, topography of; Keratometry/keratometer; Keratoscopy
- corneal zones and, 8.25, 8.25f, 8.26f
- keratometry for, 8.26–27, 8.27f
- keratoscopy for, 8.27–28, 8.28f
- Placido disk–based topography for, 8.27–28, 8.28, 8.35t
- shape/curvature/power and, 8.25–26
- tomography for, 8.33–36, 8.34f, 8.35f, 8.35t
- topography for, 8.28–36, 8.29f, 8.30f, 8.31f, 8.32f, 8.32t, 8.33f, 8.35t
- after keratorefractive surgery, 3.269
- mean, 8.28
- measurement of, 13.14–19, 13.15f, 13.16f, 13.17f, 13.18f, 13.19f, 13.44–45, 13.45f
- power and, 8.25–26, 13.7–9
- radius of, 8.8, 8.27
- in cornea plana, 8.100
- instantaneous (meridional/tangential power), 13.16–17, 13.17f
- keratometry in measurement of, 8.27
- in schematic eye, 3.127t
- refractive surgery affecting, 13.9, 13.26–28, 13.27f, 13.28f
- IOL power calculation and, 13.193–197, 13.196f
- in schematic eye, 3.127t
- defense mechanisms of, 8.11–14, 8.12–13f, 8.13f
- degenerations/dystrophies of, 4.81–94. *See also* Corneal degenerations; Corneal dystrophies; *specific type*
- degenerations, 4.81–86, 8.115–128
- dystrophies, 4.86–94, 8.133–160, 8.134t, 8.135t, 8.136t
- delle of, 6.172, 6.172f
- deposits in, 8.16f
- amyloid. *See also* Amyloidosis/amyloid deposits
- in gelatinous droplike corneal dystrophy, 8.141, 8.141f, 8.185–187, 8.186t
- in granular corneal dystrophy type 1 (GCD2/Avellino), 8.148, 8.186t
- in lattice corneal dystrophy, 4.89f, 4.89–90, 8.145, 8.146, 8.147f, 8.185–187
- in polymorphic amyloid degeneration, 8.122, 8.123f, 8.186t
- copper/Wilson disease causing, 8.118t, 8.173, 8.189, 8.189f, 11.59, 11.62
- crystalline, 8.182t
- in cystinosis, 8.181f, 8.181–182
- in hematologic disorders, 8.197–199, 8.198f, 8.199f
- in cystinosis, 8.181f, 8.181–182
- drug-induced, 8.129t, 8.129–132, 8.130f, 8.131f
- dystrophies and, 8.133
- pigment, 4.86, 8.118t
- drug-induced, 8.129t, 8.129–132, 8.130f, 8.131f
- Descemet membrane/layer of, 2.41, 2.42f, 2.223f, 2.227, 4.73, 4.74f, 8.7f, 8.9. *See also* Descemet membrane/layer
- development of, 2.118, 2.120–122, 2.121f
- diameter of, 6.179, 6.281, 8.7
- in infants and children, 10.158
- glaucoma and, 10.151, 10.156, 10.158
- disorders of, 4.73–96, 8.46t, 8.49–53, 8.50t. *See also* Keratitis; Keratoconjunctivitis; Keratopathy; *specific type*
- acquired, 6.269
- blunt trauma causing, 8.388, 8.389f
- as cataract surgery complication, 11.128t, 11.128–132, 11.129f
- cataract surgery in patient with, 11.174f, 11.174–177, 11.177f, 11.191–192
- central corneal transparency, 6.257–258t, 263, 6.258f
- clinical findings in, 8.46t, 8.49–53, 8.50f, 8.50t, 8.51f, 8.52f
- congenital hereditary endothelial dystrophy, 6.257t
- congenital hereditary stromal dystrophy, 6.257t, 6.259
- conjunctival flap for, 8.354f, 8.356–360, 8.357f, 8.358f, 8.359f
- contact lens–related, 8.84, 8.266–267, 8.273–274
- cornea plana, 6.255, 6.255f
- in cystinosis, 6.270, 6.387f
- decreased vision and, 5.99
- degenerations/dystrophies, 4.81–94. *See also* Corneal degenerations; Corneal dystrophies; *specific type*
- degenerations, 4.81–86, 8.115–128
- dystrophies, 4.86–94, 8.133–160, 8.134t, 8.135t, 8.136t
- dermatologic diseases and, 8.201–203
- dermolipoma, 6.256–257
- diffuse corneal transparency, 6.257–258t, 263, 6.258f
- ectatic, 4.95f, 4.95–96, 8.161–171. *See also* Ectatic disorders/ectasia
- endocrine diseases and, 8.199–201, 8.200t, 8.201f
- epibulbar dermoid, 6.256, 6.256f, 6.257t
- in Fabry disease, 6.270, 6.388t
- in familial dysautonomia, 6.270
- forceps injury, 6.257t
- hematologic disorders and, 8.197–199, 8.198f, 8.199f
- in herpetic infection, 9.191
- in HTLV-1 infection, 9.212
- illusions caused by, 5.174

- immune-mediated, 8.306–318
 - transplant rejection and, 8.316–318, 8.428–431
- infections, 6.257*t*
- ionizing radiation causing, 8.386
- keratitis, 6.269
- keratoconus, 6.254
- keratoglobus, 6.254
- keratoplasty for, 6.262–263
- medications causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
 - crystalline deposits, 8.182*t*
- megalocornea, 6.253*f*, 6.253–254
- metabolic disorders and, 8.174–190. *See also*
 - specific disorder*
 - amino acid/nucleic acid/protein/mineral
 - metabolism and, 8.181*f*, 8.181–190, 8.182*t*, 8.183*t*, 8.184*f*, 8.185*f*, 8.186*t*, 8.187*f*, 8.188*f*, 8.189*f*
 - lipoprotein metabolism and, 8.179–181, 8.180*f*
 - lysosomal storage diseases and, 8.174–179, 8.175*t*, 8.176*f*, 8.177*f*
 - microcornea, 6.254, 6.254*f*
 - in mucopolysaccharidoses, 6.257*t*, 6.270, 6.385, 6.387*f*, 6.388*t*
 - neoplastic, 4.96, 8.327–350. *See also* Cornea, tumors of; *specific tumor*
 - nutritional disorders and, 8.196–197, 8.197*f*
 - peripheral corneal transparency, 6.255–256*f*, 257
 - posterior corneal defect, 6.257*t*
 - posterior embryotoxon, 6.255, 6.255*f*
 - in rosacea, 8.70, 8.70*f*
 - in sarcoidosis, 9.168–169
 - in Schnyder corneal dystrophy, 6.270, 6.387*f*
 - sclerocornea, 6.257*t*
 - size- or shape-related, 6.253–254, 254*f*
 - skeletal/connective tissue disorders and, 8.190–196, 8.191–192*t*, 8.193*f*, 8.194*f*, 8.195*f*, 8.195*t*
 - systemic conditions that cause, 6.269–271
 - systemic disorders and, 8.173–203
 - Th1-mediated delayed hypersensitivity and, 9.46*t*
 - therapeutic/surgical interventions/transplantation
 - for, 8.366–373, 8.417*t*, 8.417–419. *See also* Cornea, transplantation of; Keratoplasty; *specific procedure*
 - layer-based approach to, 8.417, 8.417*t*
 - preoperative evaluation/preparation and, 8.418–419
 - thermal burns causing, 8.384–385, 8.385*f*
 - treatment of, 6.262–263
 - in tyrosinemia type II, 6.270
 - ulcers, 6.248, 6.249*f*, 6.262–263
 - ultraviolet radiation causing, 8.385–386
 - vitamin A deficiency and, 8.196–197, 8.197*f*
 - in Waardenburg syndrome, 6.270
 - in Wilson disease, 6.270
- donor. *See* Donor cornea
- drug absorption and, 2.296–297
- dysplasia of (corneal intraepithelial neoplasia/CIN), 4.96, 8.37, 8.38*f*, 8.332*t*, 8.335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
- dystrophies/degenerations of, 4.81–94. *See also* Corneal degenerations; Corneal dystrophies; *specific type*
- degenerations, 4.81–86, 8.115–128
- dystrophies, 4.86–94, 8.133–160, 8.134*t*, 8.135*t*, 8.136*t*
- ectasia of. *See* Ectatic disorders/ectasia
- ectatic, 4.95*f*, 4.95–96, 8.161–171. *See also* Ectatic disorders/ectasia
- edema of, 8.41–42
 - acute, 6.254, 8.41
 - biomechanics and, 13.13–14
 - birth trauma causing, 8.109
 - after cataract surgery, 11.128*t*, 11.128–130
 - ECCE, 11.198
 - ICCE, 11.201
 - persistent, with vitreocorneal adherence, 11.130
 - cataract surgery in patient with, 11.191–192
 - chronic, 8.41–42
 - cold-induced, 8.385
 - in congenital hereditary endothelial dystrophy, 8.160
 - in Fuchs endothelial dystrophy, 8.156, 8.157, 8.157*f*
 - illusions and, 5.174
 - intraocular surgery and, 8.42
 - in iridocorneal endothelial syndrome, 10.136
 - in keratoconus, 8.163–164, 8.164*f*, 8.167–168
 - in primary congenital glaucoma, 6.279–280, 8.108–109, 10.151, 10.158
 - refractive surgery contraindicated in, 13.43
 - tonometry accuracy and, 10.24
- endothelium of, 2.41–43, 2.42*f*, 2.43*f*, 2.223*f*, 2.227, 4.73, 4.74*f*, 8.7*f*, 8.10
 - anatomy of, 2.41–43, 2.42*f*, 2.43*f*, 2.223*f*, 8.7*f*, 8.10
 - biochemistry and metabolism of, 2.227
 - development of, 2.118, 2.120, 2.121*f*, 2.122
 - dysfunction of, 2.43, 8.52
 - keratoplasty for, 8.411, 8.436–450. *See also* Keratoplasty, endothelial
 - glucose metabolism in, 2.224
 - healing/repair of, 4.16
 - keratorefractive surgery and, 13.32–33
 - multifocal IOL implantation and, 13.155
 - phakic IOL implantation and, 13.141
 - angle-supported lenses, 13.146
 - iris-fixed lenses, 13.145
 - posterior chamber lenses, 13.146
 - pigmentation of/deposits in, 8.118*t*, 8.132
 - in uveitis, 9.80*t*
- enlargement of, 8.95, 8.96*t*, 8.99*f*, 8.99–100. *See also* Megalocornea
 - in pediatric/primary congenital glaucoma, 8.95, 8.96*t*, 8.99–100, 8.108, 10.31, 10.147, 10.158
- epithelium of, 2.39–40, 2.40*f*, 2.215*f*, 2.223*f*, 2.224–225, 4.73, 4.74*f*, 8.7*f*, 8.8
 - anatomy of, 2.39–40, 2.40*f*, 2.223*f*, 8.7*f*, 8.8
 - biochemistry and metabolism of, 2.224–225
 - cysts of, 8.130
 - debridement of
 - for epithelial defects
 - after LASIK, 13.112
 - after surface ablation, 13.108
 - for surface ablation, 13.82–84, 13.83*f*
 - defects/persistent defects of, 6.376, 8.46*t*, 8.80–82, 8.81*t*, 8.82*f*
 - acid burns causing, 8.380, 8.380*f*
 - after cataract surgery, 11.132, 11.173

- glaucoma medication toxicity and, 10.31
- after LASIK, 13.93, 13.112
 - in diabetes mellitus, 13.190
- management of, 8.368
- after penetrating/deep anterior lamellar keratoplasty, 8.80, 8.424
- after surface ablation, 13.107–108
- topical anesthetic use/abuse and, 8.80–81, 8.81*t*, 8.89, 8.89*f*
 - in toxic keratoconjunctivitis, 8.80–81, 8.81*t*
- development of, 2.118, 2.120, 2.121*f*
- drug-induced deposits in, 8.129*t*, 8.130*f*, 8.130–132, 8.131*f*
- dysplasia of (corneal intraepithelial dysplasia), 4.96, 8.37, 8.38*f*, 8.332*t*, 8.335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
- external eye defense and, 8.12*f*, 8.13*f*, 8.13–14, 8.207
- glucose metabolism in, 2.224
- healing/repair of, 4.13–14, 4.15*f*
 - keratorefractive surgery and, 13.32–33
 - delayed, 13.93–94, 13.108
- preparation of, for refractive surgery, 13.82–84, 13.83*f*
- preservation techniques for
 - in epi-LASIK, 13.84
 - in LASEK, 13.84
- in pseudoepiphora, 7.268
- tear secretion and, 2.215*f*, 2.217
- tumors of, 8.332*t*, 8.332–337
- erosions of
 - in epidemic keratoconjunctivitis, 8.234
 - punctate epithelial, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
 - in exposure keratopathy, 8.80
 - in herpetic eye disease/neurotrophic keratopathy, 8.224
 - in vernal keratoconjunctivitis, 8.290
- recurrent, 8.79, 8.86–88
 - dystrophic, 8.86, 8.87, 8.133, 8.135*t*
 - in epithelial basement membrane dystrophy, 8.86, 8.87, 8.133, 8.138
 - in lattice corneal dystrophy type 1, 8.147
 - in Reis-Bücklers corneal dystrophy, 8.143
- eye pain and, 5.295, 8.86, 8.87
 - management of, 8.368
 - posttraumatic, 8.86, 8.87
- examination of, 8.15–43. *See also* Examination, ophthalmic
 - before cataract surgery, 11.78–79, 11.84
 - in glaucoma, 10.31, 10.33*t*, 10.34*f*
 - in infants and children, 10.158
 - before refractive surgery, 13.42–43
- exposure of, in facial palsy, 5.280–281
- in external eye defense, 8.11–14, 8.12–13*f*, 8.13*f*
- farinata, 8.121–122, 8.122*f*
- fetal, secondary abnormalities affecting, 8.107–109
- flat (cornea plana), 8.96*t*, 8.100–101
 - flap creation and, 13.44–45, 13.79
 - microcornea and, 8.95, 8.96*t*, 8.100
 - in Peters anomaly, 4.74, 4.75*f*
 - posterior amorphous corneal dystrophy and, 8.154–155
- sclerocornea and, 8.96*t*, 8.98*t*, 8.100, 8.105
- foreign body in, 6.376, 8.399–400, 8.400*f*, 8.401*f*, 8.403
 - insect stingers/hairs, 8.386–387
 - plant/vegetation, 8.387, 8.399
 - radioactive, 8.386
 - removal of, 8.403
- glaucoma/glaucoma therapy affecting, 10.31
- growth and development of, 6.181
- guttae/guttata, 8.23*f*, 8.128
 - age-related, 8.115
 - Brown-McLean syndrome and, 11.130
- cataract surgery and, 11.79
- central, 2.41
 - in Fuchs endothelial corneal dystrophy, 2.43*f*, 4.92, 4.93*f*, 8.23*f*, 8.156, 8.157*f*
- in luetic keratitis, 4.80
- peripheral (Hassall-Henle bodies/warts), 2.41, 8.115, 8.128
 - refractive surgery and, 13.43
- healing/repair of, 4.13–16, 4.15*f*
 - keratorefractive surgery and, 13.32–33
 - delays in, 13.93–94, 13.108
- herpes simplex latency in, 8.215
- hydration of, 8.9, 8.41–42. *See also* Cornea, edema of
- pachymetry in measurement of, 8.41–42
- hypoesthesia of. *See* Cornea, anesthesia/hypoesthesia of
- imaging of. *See also* Cornea, topography of; *specific type*
 - for keratorefractive surgery, 13.14–26, 13.44–45, 13.45*f*. *See also* Cornea, topography of; *specific type*
 - indications for, 13.22–24, 13.23*f*, 13.24*f*
 - postoperative evaluation and, 13.23*f*, 13.23–24, 13.24*f*
 - preoperative evaluation and, 13.14–26, 13.44–45, 13.45*f*, 13.79–80
- immune response/features/microenvironment of, 9.54*t*, 9.58–60, 9.59*f*, 9.60*f*
- infection/inflammation of, 4.75–81, 4.76*f*, 4.77*f*, 4.78*f*, 4.79*f*, 4.80*f*, 4.81*f*, 8.266–283. *See also* Keratitis; Keratoconjunctivitis
 - contact lens wear and, 8.84, 8.266–267, 8.273–274
 - signs of, 8.49–53, 8.50*f*, 8.50*t*, 8.51*f*, 8.52*f*
- innervation of, 2.216, 2.223–224, 8.8. *See also* Corneal nerves
- intraepithelial neoplasia of (CIN), 4.96, 8.37, 8.38*f*, 8.332*t*, 8.335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
- irritation of, pseudoepiphora and, 7.268
- keloids of, 8.125
 - congenital, 8.107–108, 8.125
- keratitis-related scarring of, 6.245*f*
- lacerations of. *See* Corneoscleral lacerations
- layers of, 2.223, 2.223*f*, 4.73, 4.74*f*
- marginal (catarrhal) infiltrates of, 8.310–311
 - staphylococcal blepharitis/blepharoconjunctivitis and, 8.74, 8.74*f*
- melting of (keratolysis)
 - cataract surgery and, 11.132
 - in patient with dry eye, 11.132
 - management of, 8.369*f*, 8.369–370
 - neurotrophic keratopathy/persistent corneal epithelial defects and, 8.81, 8.82

- peripheral ulcerative keratitis and, 8.311, 8.312
- refractive surgery and, 13.94
- topical medication toxicity and, 4.80–81
- meridional map of, 3.269*f*
- neovascularization/vascularization of
 - in atopic keratoconjunctivitis, 8.292, 8.293*f*
 - corneal transplantation and, 8.317, 8.435
 - pediatric, 8.451
 - inflammation and, 8.52
 - after lamellar keratoplasty, 8.435
 - in rosacea, 8.70, 8.70*f*
 - in stem cell deficiency, 8.92, 8.93
 - in vernal keratoconjunctivitis, 8.290
- nonepithelial cells in, 2.40
- oblate shape of, 13.14, 13.26
 - after radial keratotomy, 13.50
- opacification of, 8.16*f*
 - acid burn causing, 8.381, 8.381*f*
 - in cornea farinata, 8.121–122, 8.122*f*
 - in Fleck corneal dystrophy, 8.153, 8.154*f*
 - flowchart for diagnosis of, 8.16*f*
 - in ichthyosis, 8.202
 - infantile/congenital, 8.16*f*
 - differential diagnosis/classification of, 8.16*f*
 - glaucoma and, 8.108–109
 - in hereditary syndromes, 8.107
 - inflammatory, 8.16*f*, 8.52
 - in keratectasia and congenital anterior staphyloma, 8.98*t*, 8.106*f*, 8.106–107
 - lamellar keratoplasty for, 8.434
 - noninflammatory, 8.16*f*
 - in Peters anomaly, 4.74, 4.75*f*, 8.97*t*, 8.102–103, 8.103*f*, 10.154, 11.31
 - polymorphic amyloid degeneration and, 8.122, 8.123*f*, 8.186*t*
 - in posterior amorphous corneal dystrophy, 8.154, 8.154*f*
 - in pre-Descemet corneal dystrophy, 8.155
 - in primary congenital glaucoma, 8.108–109, 10.151, 10.158
 - in Reis-Bücklers corneal dystrophy, 4.88, 4.88*f*, 8.143
 - in Schnyder corneal dystrophy, 8.151, 8.152*f*
 - in Thiel-Behnke corneal dystrophy, 4.88, 4.89*f*, 8.143
- optical zone of. *See* Optical zone, corneal
- pachymetry of, 13.21*f*, 13.45–46. *See also* Pachymetry/pachymeter
 - corneal thickness measurement and, 13.45–46, 13.125
 - forme fruste keratoconus and, 13.176, 13.177*f*
- paracentral zone of, 8.25, 8.25*f*
- penetrating injury to, 6.376
- perforation of. *See also* Corneoscleral lacerations; Penetrating and perforating ocular trauma; Trauma
 - foreign-body removal and, 8.403
 - in keratoconus, 8.163
 - LASIK and, 13.111
 - management of, 8.369*f*, 8.369–370, 8.370*f*, 8.402–403
 - nonsurgical, 8.402–403
 - surgical repair in, 8.403. *See also* Corneoscleral lacerations, repair of
 - radial keratotomy and, 13.52
 - Seidel test in identification of, 8.36, 8.38*f*
- peripheral, 2.38–39, 2.39*f*
- peripheral zone of, 8.25, 8.25*f*
- photoablation applications in, 3.115
- pigmentation/pigment deposits in, 4.86, 8.118*t*
 - drug-induced, 8.129*t*, 8.129–132, 8.130*f*, 8.131*f*
- plana (flat cornea), 8.96*t*, 8.100–101
 - flap creation and, 13.44–45, 13.79
- microcornea and, 8.95, 8.96*t*, 8.100
- in Peters anomaly, 4.74, 4.75*f*
- posterior amorphous corneal dystrophy and, 8.154–155
- sclerocornea and, 8.96*t*, 8.98*t*, 8.100, 8.105
- posterior surface of, 3.270
- power of, nominal value for, 3.12
- preparation of, for refractive surgery, 13.82–90, 13.83*f*, 13.85*f*, 13.86*f*, 13.87*f*, 13.88*f*, 13.89*f*, 13.90*t*
- in primary congenital glaucoma, 6.280*f*, 6.280–281
- prolate shape of, 3.268, 13.9, 13.14, 13.26
- Q value of, 13.14
- refractive index of, 3.127*t*, 8.8, 8.26
- refractive power of, 3.287, 8.25–26, 13.7–9
 - age-related changes in, 3.141
 - central
 - description of, 3.243, 3.248
 - errors in, 3.252
 - measurement of, 3.270, 8.26–27, 8.27*f*, 13.7–9. *See also* Keratometry/keratometer
 - after penetrating keratoplasty, 3.253
 - in schematic eye, 3.127*t*
- reshaping of
 - orthokeratology and, 13.70–71
 - using rigid gas-permeable contact lenses, 3.228
- in schematic eye, 3.127*t*
- sensation in, 8.8
 - measurement of (esthesiometry), 8.42–43
 - reduction/absence of
 - congenital, 8.108
 - in herpes simplex epithelial keratitis, 8.217–218, 8.226*t*
 - in herpes zoster, 8.226*t*, 8.228
 - keratoplasty and, 8.418, 8.424
 - after LASIK, 13.172
 - in neurotrophic keratopathy/persistent corneal epithelial defects, 8.80, 8.224
- shape of, 3.268–271, 3.269–271*f*, 8.25–26, 13.9
 - aspheric, 13.14
 - curvature and power and, 8.25–26, 13.7–9
 - disorders of, 8.96*t*, 8.100
 - orthokeratology and, 13.70–71
 - refractive surgery and, 13.9
 - tomography in evaluation of, 13.19–22, 13.20–21*f*
- shield ulcer of, 6.248, 6.249*f*
- size of, 2.38, 2.39, 8.7
 - disorders of, 8.95–101, 8.96*t*, 8.99*f*
- specimen collection from, 8.209*t*, 8.210, 8.210*f*
- staphyloma of, congenital anterior, 8.98*t*, 8.106*f*, 8.106–107
- steep, flap creation and, 13.79
- stem cells of, 8.8, 8.10–11, 8.92. *See also* Limbal stem cells
 - culture of, 8.365

- sterile infiltrates, 3.231f, 3.234
- stroma of, 2.40–41, 2.42f, 2.223f, 2.225–226, 4.73, 4.74f, 8.7f, 8.8–9, 8.9f
- anatomy of, 2.40–41, 2.42f, 2.223f, 8.7f, 8.8–9, 8.9f
- biochemistry and metabolism of, 2.225–226
- biomechanics and, 13.13–14
- degenerations of, 8.120–126
- development of, 2.118, 2.120, 2.121f
- dystrophies of. *See* Stromal corneal dystrophies
- healing/repair of, 4.14, 4.15f
- inflammation of, 8.50t, 8.50–52, 8.51f
- in systemic infections, 8.279
- neovascularization of, 8.52
- pigmentation of/deposits in, 8.118t
- drug-induced, 8.129t, 8.132
- refractive index of, 8.26
- subepithelial infiltrates of, 8.46t
- in epidemic keratoconjunctivitis, 8.234f, 8.234–235, 8.235f
- surgery on. *See* Keratorefractive surgery
- systemic disorders affecting, 8.173–203
- thermal injury to, 6.376
- thickness/rigidity of, 4.73, 4.74f, 8.7, 8.25, 8.41, 8.42
- corneal crosslinking and, 13.130, 13.132
- glaucoma and, 10.25, 10.31, 10.81, 10.82, 10.90
- in infants and children, 10.159
- normal-tension glaucoma and, 10.86–87
- in infants and children
- normal, 10.159
- in primary congenital glaucoma, 10.159
- intraocular pressure/pressure measurement and, 8.41, 10.25, 10.81, 10.82, 10.86–87, 10.90, 13.105, 13.181, 13.200
- in infants and children, 10.159
- measurement of, 8.41–42. *See also* Pachymetry/pachymeter
- before cataract surgery, 11.78–79
- in keratoconus screening, 13.24, 13.26
- minimum requirements for LASIK and, 13.45–46, 13.79–80
- corneal perforation and, 13.111
- ectasia and, 13.79
- pachymetry in, 13.45–46, 13.125
- before refractive surgery, 13.45–46
- topography in, 13.26, 13.79–80
- ocular hypertension and, 10.25, 10.90, 10.112
- tonometry measurements affected by, 10.25, 10.81, 10.82, 10.86, 13.105, 13.181
- thinning of
- in ectatic disorders, 8.133, 8.161, 8.170f
- in keratoconus, 8.161, 8.162, 8.163, 8.165, 8.165f, 8.166, 8.170f
- in keratoglobus, 8.170f, 8.171
- in macular dystrophy, 8.150, 8.150f
- management of, 8.368–369
- over intrastromal corneal ring segments/Intacs, 13.67, 13.68f
- in pellucid marginal degeneration, 8.168, 8.168f, 8.169, 8.169f, 8.170f
- in posterior amorphous corneal dystrophy, 8.154, 8.154f
- tomography of, 8.33–36, 8.34f, 8.35f, 8.35t, 13.19–22, 13.20–21f, 13.194
- in keratoconus, 8.35, 8.35f, 8.165f, 8.165–166
- after refractive/keratorefractive surgery, 13.23
- IOL power determination/selection and, 13.194
- topography of, 2.37, 2.37f, 2.38, 3.281, 3.288–289, 4.73, 8.15, 8.28–36, 8.29f, 8.30f, 8.31f, 8.32t, 8.32f, 8.33f, 8.35t, 13.14–19, 13.15f, 13.16f, 13.17f, 13.18f, 13.19f, 13.24–26, 13.25f, 13.44–45, 13.45f
- astigmatism detection/management and, 8.31, 8.32, 8.32t, 13.17–19, 13.18f, 13.19f, 13.22–23, 13.44, 13.45, 13.45f
- after penetrating keratoplasty, 8.32, 8.431–432, 8.432f, 13.179–180
- cataract surgery and, 11.84, 11.86, 11.174
- central islands after surface ablation and, 13.103–104, 13.104f
- computerized, 13.14–19, 13.15f, 13.16f, 13.17f, 13.18f, 13.19f, 13.44–45, 13.45f
- in decentered ablation, 13.104, 13.104f
- immunologic environments and, 9.59, 9.59f
- IOL power determination/selection and, 11.86
- after refractive surgery, 11.86, 13.193, 13.194
- in keratoconus, 8.29f, 8.30f, 8.31, 8.32f, 8.32t, 8.165f, 8.165–166, 13.23, 13.24, 13.25f, 13.44, 13.175, 13.175f, 13.176f, 13.177f
- keratorefractive surgery and. *See* Cornea, topography of, refractive/keratorefractive surgery and
- laser ablation guidance and, 13.32
- before LASIK, 13.79
- limitations of, 13.19
- maps generated by, 8.28–33, 8.29f, 8.30f, 8.31f, 8.32f, 8.33f, 13.14–19, 13.15f, 13.17f, 13.19f, 13.44–45, 13.45f. *See also* Corneal power maps
- postoperative, 13.23, 13.24f
- in pellucid marginal degeneration, 8.31, 8.33f, 8.169, 8.170f, 13.24, 13.44, 13.45f, 13.79, 13.176, 13.176f
- photoablation and, 13.32
- Placido-based, 13.7–9, 13.14–16, 13.15f, 13.17, 13.20–21f, 13.25f
- IOL power calculation after refractive surgery and, 13.193
- Placido disk-based, 8.27–28, 8.28, 8.35t
- in corneal biomechanics evaluation, 8.43
- after radial keratotomy, 13.50–51
- refractive/keratorefractive surgery and, 13.14–19, 13.15f, 13.16f, 13.17f, 13.18f, 13.19f, 13.24–26, 13.25f, 13.44–45, 13.45f, 13.79
- dry eye and, 13.173
- indications for, 13.22–23, 13.23f, 13.24f
- postoperative evaluation and, 13.23f, 13.23–24, 13.24f
- preoperative evaluation and, 13.14–19, 13.15f, 13.16f, 13.17f, 13.18f, 13.19f, 13.24–26, 13.25f, 13.44–45, 13.45f, 13.79–80
- refractive lens exchange and, 13.149
- toric IOLs and, 13.151–152
- transitional zone of, 8.25
- transparency of, 8.9
- transplantation of, 8.316, 8.411–452, 8.412t, 8.412–413t. *See also* Donor cornea; Keratoplasty; Keratoplasty, penetrating; *specific procedure*

- allografts/allogeneic transplantation, 8.316, 8.411–451, 8.412*t*, 8.412–413*t*
- arcuate keratotomy and, 13.56–57
- autografts/autologous transplantation, 8.411, 8.451–452
- cataract/cataract surgery and, 11.56, 11.175, 11.176
- for chemical injuries, 8.384
- for corneal edema after cataract surgery, 11.129
- definition of/terminology and, 8.411–412
- disease transmission and, 8.414, 8.415*t*, 8.416*t*
 - Creutzfeldt-Jakob disease, 8.254, 8.416*t*
 - rabies virus, 8.240, 8.240*t*, 8.416*t*
- donor selection and, 8.414, 8.415*t*, 8.416*t*
- eye banking and, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
- immune privilege and, 8.316, 9.60
- indications for, 8.412–413*t*
- intraocular lens implantation after, 3.253–254
- patient selection and, 8.418
- pediatric, 8.450–451
- preoperative evaluation/preparation and, 8.418–419
 - rabies virus, 8.240, 8.240*t*, 8.416*t*
- after refractive surgery, 13.197–198
- refractive surgery after, 13.37, 13.178–180
- rejection and, 4.84, 4.85*f*, 8.316–318, 8.428–431, 9.59, 9.60, 9.60*f*. *See also* Rejection
- in triple procedure, 11.175–176
- tumors of, 4.96, 6.271, 8.327–350. *See also* Ocular surface, tumors of; *specific type*
 - approach to patient with, 8.328
 - epithelial, 8.332*t*, 8.332–337
 - management of, 8.328–332, 8.330*f*, 8.331*f*
 - surgical, 8.329–330, 8.330*f*
 - topical chemotherapy for, 8.330*f*, 8.330–332, 8.331*f*
- in uveitis, 9.73, 9.80*t*
- vertex of, 8.25, 8.26*f*
- verticillata (hurricane/vortex keratopathy), 8.90, 8.129*t*, 8.130, 8.130*f*, 8.176, 8.177*f*
 - in chloroquine/hydroxychloroquine toxicity, 8.130
 - in Fabry disease, 8.176, 8.177*f*
- warp of
 - contact lens wear causing, refractive surgery and, 13.22, 13.38, 13.44, 13.79
 - topography in identification of, 13.44, 13.79
- zones of, 8.25, 8.25*f*, 8.26*f*
- Cornea Donor Study (CDS), 8.416
- Cornea plana, 6.255, 6.255*f*
- Cornea shields, collagen, for drug administration, 2.303
- Corneal alignment tool, 3.171*f*
- Corneal allografts. *See* Corneal grafts
- Corneal apex, 3.228
- Corneal arcus, 1.89, 8.120–121, 8.121*f*, 8.179
 - in cornea plana, 8.100
 - in dyslipoproteinemia/hyperlipoproteinemia, 8.120, 8.121, 8.179
 - in hyperlipoproteinemia, 1.89
 - juvenile, 8.121
 - in lecithin-cholesterol acyltransferase (LCAT) deficiency, 8.180, 8.180*f*
 - lipoides, in Schnyder corneal dystrophy, 8.151, 8.152*f*
 - senile furrow degeneration and, 8.122
 - senilis, 8.120–121, 8.121*f*
- Corneal astigmatism. *See also* Astigmatism
 - contact lens masking of, 3.225
 - description of, 3.19
 - spherical rigid contact lenses for, 3.211
 - toric intraocular lenses for, 3.257
- Corneal autografts. *See* Corneal grafts
- Corneal contact lenses. *See* Contact lenses
- Corneal (collagen) crosslinking (CCL/CXL), 13.8*t*, 13.130–135, 13.131*f*, 13.133*f*, 13.133*t*
 - for *Acanthamoeba* keratitis, 8.279
 - accelerated, 13.134
 - for bacterial keratitis, 8.272
 - combined techniques for, 13.134–135
 - complications of, 13.135
 - for ectasia/postoperative ectasia, 13.124, 13.130, 13.131, 13.206
 - for fungal keratitis, 8.275
 - with intracorneal ring segment implantation, 13.134, 13.207
 - for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82
 - patient selection/indications/contraindications for, 13.131–132
 - with photorefractive or phototherapeutic keratectomy, 13.134, 13.206–207
 - with refractive procedures, 13.206–208
 - surgical technique for, 13.131*f*, 13.132–135, 13.133*f*, 13.133*t*
 - transepithelial, 13.132–134, 13.133*f*
- Corneal (collagen) crosslinking plus, 13.206
- Corneal decompensation, after cataract surgery, 6.304
- Corneal degenerations, 4.81–86, 4.82*f*, 4.83*f*, 4.84*f*, 4.85*f*, 4.86*f*, 8.115–128. *See also* Keratopathy; *specific type*
 - age-related changes and, 8.115
 - dystrophies differentiated from, 8.111, 8.111*t*
 - endothelial, 8.126–128
 - age-related, 8.115
 - epithelial and subepithelial, 8.115–120
 - peripheral hypertrophic subepithelial, 8.124–125, 8.125*f*
 - stromal, 8.120–126
- Corneal depression, 3.245*f*
- Corneal dystrophies, 4.86–94, 8.133–160, 8.134*t*, 8.135*t*, 8.136*t*. *See also specific type*
 - cataract/cataract surgery in patient with, 11.84, 11.174*f*, 11.174–175
 - classification of, 8.133–134, 8.134*t*, 8.135*t*
 - degenerations differentiated from, 8.111, 8.111*t*
 - endothelial, 4.92–94, 4.93*f*, 4.94*f*, 8.135*t*. *See also* Endothelial dystrophies
 - cataract surgery in patient with, 11.84, 11.175
 - epithelial and subepithelial, 4.87, 4.87*f*, 8.135*t*, 8.135–141. *See also* Epithelial dystrophies, epithelial and subepithelial
 - epithelial–stromal *TGFBI*, 4.88*f*, 4.88–91, 4.89*f*, 4.90*f*, 4.91*t*, 4.91*f*, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149
 - genetic/hereditary factors and, 8.133, 8.134, 8.136*t*
 - macular (MCD), 4.91, 4.91*t*, 4.92*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.149–151, 8.150*f*
 - recurrence of after corneal transplantation, 8.425, 8.425*f*
 - recurrent erosion (EREDs), 8.86, 8.87, 8.133, 8.135*t*

- refractive surgery and, 13.42–43, 13.43*f*, 13.76, 13.78, 13.178
- multifocal IOLs, 13.155
- stromal, 4.91, 4.92*f*, 8.135*t*, 8.149–156. *See also* Stromal corneal dystrophies
- Corneal dystrophy of Bowman layer type 1 (CDB1). *See* Reis-Bücklers corneal dystrophy
- Corneal dystrophy of Bowman layer type 2 (CDB2). *See* Thiel-Behnke corneal dystrophy
- Corneal endothelial rings, traumatic, 8.388
- Corneal exposure, 6.207
- Corneal flap folds, after LASIK, 13.112–115, 13.114*t*, 13.115*f*. *See also* Striae
- Corneal grafts, 8.316. *See also* Cornea, transplantation of; Donor cornea; Keratoplasty
 - allografts (allogeneic transplantation), 8.316, 8.411–451, 8.412*t*, 8.412–413*t*
 - rejection of, 4.84, 4.85*f*, 8.316–318, 8.428–431, 9.59, 9.60, 9.60*f*. *See also* Rejection
 - arcuate keratotomies incisions in, 13.56–57
 - autografts (autologous transplantation), 8.411, 8.451–452
 - disease recurrence in, 8.225, 8.232
 - dislocation/decentration of, after endothelial keratoplasty, 8.440–444, 8.441*f*, 8.442*f*, 8.443*f*
 - DMEK, 8.442*f*, 8.442–443, 8.443*f*
 - DSEK, 8.441, 8.442*f*
 - endothelial failure of, 4.84, 4.85*f*
 - late non-immune-mediated, 8.427–428
 - primary
 - after endothelial keratoplasty (DMEK/DSEK), 8.447
 - after penetrating keratoplasty, 8.423, 8.423*f*
 - rejection of, 4.84, 4.85*f*, 8.316–318, 8.428–431, 9.59, 9.60, 9.60*f*. *See also* Rejection
- Corneal haze, 6.270. *See also* Haze formation
- Corneal hydrops, in keratoconus, 4.95*f*, 4.96, 8.163–164, 8.164*f*
 - management of, 8.167–168
- Corneal hysteresis, 8.43
- Corneal incision, clear, for cataract surgery, 11.106*f*, 11.106–107
 - in glaucoma, 11.186
 - with trabeculectomy, 10.213
 - in uveitis, 9.283
- Corneal inlays, 13.59–71, 13.169
 - alloplastic, 13.28, 13.60–61, 13.61*f*
 - homoplastic, 13.60
 - KAMRA, 3.175, 3.271
 - in keratophakia, 13.60–61, 13.61*f*
 - for presbyopia, 13.59–71, 13.169
- Corneal intraepithelial neoplasia (CIN), 4.96, 8.37, 8.38*f*, 8.332*t*, 8.335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
- Corneal intrastromal femtosecond laser treatment, for presbyopia, 13.168
- Corneal lacerations, 12.359
- Corneal light reflex
 - corneal vertex and, 8.25, 8.26*f*
 - eyelid margin distance to (margin-reflex distance), in ptosis, 7.209–210, 7.210*f*, 7.214*t*
- Corneal light reflex tests
 - Hirschberg test, 6.67, 6.68*f*
 - Krimsky test, 6.67, 6.68*f*, 6.104*f*
 - ocular alignment assessments using, 6.67–68, 6.68*f*
- Corneal light wedge (parallelepiped) technique, in gonioscopy, 10.36
- Corneal melting (keratolysis)
 - cataract surgery and, 11.132
 - in patient with dry eye, 11.132
 - management of, 8.369*f*, 8.369–370
 - neurotrophic keratopathy/persistent corneal epithelial defects and, 8.81, 8.82
 - peripheral ulcerative keratitis and, 8.311, 8.312
 - refractive surgery and, 13.94
 - topical medication toxicity and, 4.80–81
- Corneal neovascularization, 3.231*f*, 3.232
- Corneal nerves, 2.223–224, 8.8
 - confocal microscopy in evaluation of, 8.24, 8.24*f*
 - enlarged, in multiple endocrine neoplasia, 8.200, 8.200*t*
 - enlarged/prominent, 8.173, 8.200*t*
 - in multiple endocrine neoplasia, 1.59, 1.59*f*, 8.200, 8.200*t*
- Corneal nodules, Salzmann, 4.81, 4.82*f*, 8.124*f*, 8.124–125, 8.125*f*
- Corneal onlays, 13.59–71. *See also* Corneal inlays
- Corneal opacities
 - congenital hereditary endothelial dystrophy as cause of, 6.257*t*, 6.258*f*, 6.258–259
 - congenital hereditary stromal dystrophy as cause of, 6.259
 - differential diagnosis of, 6.257*t*
 - infantile glaucoma as cause of, 6.257*t*, 6.260, 6.261*f*
 - Peters anomaly, 6.259, 6.260*f*
 - posterior corneal depression, 6.259
 - primary, 6.258*t*
 - sclerocornea, 6.260, 6.261*f*
 - secondary, 6.258*t*
 - STUMPED mnemonic for, 6.257*t*, 6.257–258
 - total, 6.260, 6.261*f*
- Corneal optics, 13.7–9
- Corneal pachymetry. *See* Pachymetry/pachymeter
- Corneal power. *See* Cornea, refractive power of
- Corneal power maps, 8.28–33, 8.29*f*, 8.30*f*, 8.31*f*, 8.32*f*, 8.33*f*, 13.14–19, 13.15*f*, 13.17*f*, 13.19*f*, 13.19*f*, 13.44–45, 13.45*f*. *See also* Cornea, topography of
 - interpretation of, 8.28–31
 - in keratoconus, 8.165, 8.165*f*, 8.167*f*
 - in pellucid marginal degeneration, 8.31, 8.33*f*, 8.169, 8.170*f*
 - postoperative, 13.23, 13.24*f*
- Corneal power simulation measurements (SIM K), 13.19
 - astigmatism after penetrating keratoplasty and, 8.431, 8.432*f*
- Corneal refractive surgery, 13.7, 13.8*t*. *See also* Keratorefractive surgery
- Corneal refractive therapy, 13.70–71. *See also* Orthokeratology
- Corneal resistance factor (CRF), 8.43
- Corneal ring segments, intrastromal (ICRS), 13.8*t*, 13.28, 13.28*f*, 13.62*f*, 13.62–70, 13.63*f*, 13.64*f*, 13.65*f*, 13.67*f*, 13.68*f*, 13.69*f*
 - complications of, 13.67–70, 13.68*f*, 13.69*f*
 - contraindications for, 13.63
 - corneal crosslinking with, 13.134, 13.207
 - corneal transplantation after, 13.198

- instrumentation for, 13.63
- for keratoconus, 13.62, 13.65*f*, 13.65–66, 13.66, 13.69–70, 13.176
- after LASIK, 13.70
- limitations of, 13.47*t*
- number of segments used and, 13.66–67, 13.67*f*
- outcomes of, 13.64–65
- removal of, 13.63, 13.65
 - LASIK after, 13.70
 - surgical technique for, 13.64, 13.64*f*
- Corneal storage media, 8.414–417, 8.416*f*
- Corneal surgery, refractive. *See* Keratorefractive surgery
- Corneal tattoo, 8.118*t*, 8.371*f*, 8.371–372
- Corneal tomography, 13.19–22, 13.20–21*f*, 13.194
 - after refractive/keratorefractive surgery, 13.23
 - IOL power determination/selection and, 13.194
- Corneal topography. *See* Cornea, topography of
- Corneal transplant. *See* Cornea, transplantation of; Donor cornea; Keratoplasty
- Corneal ulcers, 8.46*t*, 8.82*f*. *See also* Keratitis
 - bacterial, 4.75–76, 4.76*f*
 - in gonococcal conjunctivitis, 8.258, 8.259*f*
 - in herpes simplex infection, 4.76–78, 4.77*f*. *See also* Herpes simplex virus (HSV), keratitis caused by
 - Mooren, 8.313–316, 8.315*f*
 - neurotrophic. *See* Neurotrophic keratopathy/ulcers
 - specimen collection from, 8.210, 8.211*f*
 - in vernal keratoconjunctivitis, 8.290, 8.291*f*
 - in vitamin A deficiency, 8.197
 - von Hippel internal, 4.74, 4.75*f*
- Corneal verticillata (hurricane/vortex keratopathy), 8.90, 8.129*t*, 8.130, 8.130*f*, 12.295
 - in chloroquine/hydroxychloroquine toxicity, 8.130
 - in Fabry disease, 8.176, 8.177*f*
- Corneal warpage, 3.232–233
- Corneoscleral junction, 2.44–45, 2.47*f*
- Corneoscleral lacerations, 6.377, 8.388. *See also* Anterior segment, trauma to; Penetrating and perforating ocular trauma; Trauma
 - repair of, 8.404*f*, 8.404–409, 8.405*f*, 8.407*f*, 8.408*f*
- Corneoscleral limbus, 8.10, 8.11*f*
- Corneoscleral meshwork, 2.48, 2.49, 2.50*f*, 10.17, 10.18*f*
- Corona, lymphoid follicle, 4.50*f*, 4.51*f*, 4.69, 4.70*f*
- Coronal incision, for orbitotomy, 7.117
- Coronal suture, 5.5
- Coronary angiography/arteriography, 1.94, 1.98. *See also* Angiography/arteriography
 - CT, 1.98
- Coronary angioplasty. *See also* Percutaneous coronary intervention
 - for angina, 1.100–102
- Coronary artery aneurysm, 6.316
- Coronary artery bypass graft (CABG), 1.102
- Coronary artery disease (CAD). *See* Coronary heart disease; Ischemic heart disease
- Coronary artery stenosis, 1.92
 - hemodynamically significant, 1.98
- Coronary cataract, 11.37
- Coronary computed tomography angiography (CCTA), 1.98
- Coronary heart disease (CHD/coronary artery disease [CAD]/atherosclerosis), 1.91–105. *See also* Ischemic heart disease
 - assessment/screening/modification and, 1.82–83, 1.83*t*, 1.209
 - in diabetes mellitus, 1.49, 1.83*t*
 - heart failure and, 1.105, 1.108, 1.111
 - hypercholesterolemia and, 1.81–89, 1.91–92, 1.92
 - hypertension management and, 1.69*t*
 - ophthalmic considerations and, 1.116–117
 - prevention of, 1.81, 1.91
 - risk factors for, 1.81–89, 1.91–92, 1.92
 - hypercholesterolemia management and, 1.81
- Coronary syndrome, acute. *See* Acute coronary syndrome; Myocardial infarction
- Coronary vasospasm, angina pectoris caused by, 1.93
- Coronary ventriculography, 1.98
- Corpus callosum agenesis, 6.361
- Corrected distance visual acuity (CDVA/best-corrected visual/Snellen visual acuity/BCVA/BCSVA). *See also* Visual acuity
 - after cataract surgery, 11.126
 - manual small-incision surgery and, 11.198–199
 - multifocal IOLs and, 11.121–122
 - corneal crosslinking and, 13.131
 - description of, 3.260
 - flap folds/striae and, 13.112, 13.113, 13.114*t*, 13.115
 - hard contact lens method for IOL power calculation and, 13.195
 - hyperopia correction and, 13.94
 - intrastromal corneal ring segment placement and, 13.67
 - irregular astigmatism affecting, 13.17
 - LASIK and, 13.95
 - in amblyopia/anisometropic amblyopia, 13.185–186, 13.187
 - in diabetes mellitus, 13.190
 - after penetrating keratoplasty, 13.180
 - after retinal detachment surgery, 13.185
 - in low vision assessment, 5.78
 - photostress testing and, 5.88
 - myopia correction and, 13.95
 - patient expectations/motivations for refractive surgery and, 13.36, 13.47
 - phakic IOL implantation and, 13.144
 - radial keratotomy and, 13.51–52
 - after small-incision lenticule extraction, 13.205
 - undercorrection after photoablation and, 13.102
- Correcting lens
 - retinal reflex neutralization with, 3.153, 3.154*f*
 - in retinoscopy, 3.153–155, 3.154*f*
- Correspondence. *See* Retinal correspondence
- Corrugator superciliaris muscle, 7.16
- Corrugator supercilii muscle, 7.141, 7.143*f*
- Cortex
 - lens, 2.64, 2.242*f*, 2.242–243, 4.116*f*, 4.117, 11.10*f*, 11.12*f*, 11.13
 - degenerations of, 4.121–122, 4.122*f*, 4.123*f*
 - topography of, 4.116*f*, 4.117
 - occipital/visual. *See* Occipital (primary visual/calcarine/striate) cortex
- Cortical/cerebral blindness, 5.158, 5.336–337, 6.186
 - blindsight and, 5.181
 - denial of (Anton syndrome), 5.158, 5.180–181, 5.337

- Cortical cataracts, 4.122, 4.122*f*, 11.45–46, 11.46*f*, 11.47*f*, 11.48*f*, 11.49*f*, 11.50*f*
 characteristics and effects of, 11.45, 11.70*t*
 genetic contributions to, 11.41
 race and, 11.6
 uveitis and, 11.64*f*, 11.64–65
- Cortical inattention, 6.186
- Cortical–nuclear barrier, in lens, 2.285
- Cortical pathways. *See* Supranuclear (cortical) pathways
- Cortical potential, visual evoked (visual evoked potential/response [VECP/VEP/VER]), 5.95. *See also* Visual evoked potential/cortical potential/response
 in low vision evaluation, 5.95
 in nonorganic disorder evaluation, 5.302
- Cortical spokes, 11.46, 11.47*f*
- Cortical spreading depression, 5.177
- Cortical syndromes, 5.178*t*, 5.178–181
 recognition disorders and, 5.178*t*, 5.179, 5.180*f*
 vision/visual deficit awareness disorders and, 5.178*t*, 5.180–181
 visual–spatial relationship disorders and, 5.178*t*, 5.180
- Cortical (cerebral/retrogeniculate) visual impairment.
See Cortical/cerebral blindness
- Corticobulbar tract, 5.50*f*
- Corticosteroid-sparing, in uveitis, 9.99, 9.100–105, 9.107, 9.113. *See also* Immunomodulatory therapy/immunotherapy/immunosuppression
- Corticosteroids (steroids), 1.170–172, 1.171*t*, 2.329–334, 2.330*t*, 2.333*t*, 9.95–100, 9.96*f*, 12.159, 12.393
Acanthamoeba keratitis treatment and, 8.279
 for acute posterior multifocal placoid pigment epitheliopathy, 9.150, 12.222
 for acute retinal necrosis, 9.196, 12.236
 for adenovirus infection, 8.236
 adverse effects of, 1.170–171, 2.331–333, 9.95, 9.100, 9.124
 for allergic eye disease, 2.329, 2.337, 2.338, 2.339, 8.289
 route of administration of, 2.329, 2.333*t*, 2.333–334
 for anaphylaxis, 1.302
 anti-inflammatory effects/potency of, 2.332, 2.333*t*
 for asthma, 1.133*t*, 1.134
 for atopic dermatitis, 8.287
 for bacterial keratitis, 8.271–272
 for Behçet disease, 1.169, 9.188
 for Bell palsy, 5.279
 for birdshot uveitis, 9.147
 branch retinal vein occlusion treated with, 12.137–138
 cataracts caused by, 6.321, 9.98, 9.124, 11.51–52, 11.64, 11.188
 central retinal vein occlusion treated with, 12.137–138
 central serous chorioretinopathy caused by, 12.300
 for chalazion, 8.77
 for chemical injuries, 8.383
 for Cogan syndrome, 8.310
 for contact dermatoblepharitis, 8.287
 for corneal graft rejection, 8.429–430, 8.447, 8.448
 for cysticercosis, 9.232
 for cystoid macular edema, 4.152
 after cataract surgery, 11.165
 in uveitis, 9.284
 cytomegalovirus retinitis and, 12.236
 for descemetocoele, 8.369
 diabetic macular edema treated with, 12.113–114
 for diffuse unilateral subacute neuroretinitis, 9.233
 for dry eye, 2.221, 8.61*t*
 for Epstein-Barr keratitis, 8.231
 fungal keratitis associated with use of, 4.78, 8.273
 for giant cell arteritis/AAION, 5.120*t*, 5.121–122, 5.314–315, 12.145
 glaucoma caused by, 2.334, 6.284, 6.321, 10.109–110
 in children and adolescents, 10.149*t*
 refractive surgery and, 13.41, 13.182, 13.201
 after glaucoma surgery, 10.208
 for granulomatosis with polyangiitis (Wegener granulomatosis), 1.168
 herpes simplex keratitis and, 8.217, 8.219, 8.223*t*
 for herpes zoster, 8.222, 8.229–230
 for hyphema, 8.394–395, 10.105
 in idiopathic intracranial hypertension, 5.112
 for infantile (capillary) hemangioma, 7.68, 7.161–162
 infectious pseudocrystalline keratopathy associated with use of, 4.79
 for insect/arachnid injuries, 8.387
 intraocular pressure affected by, 2.299, 2.332–333, 2.333*t*, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.100, 10.108, 10.109–110
 inflammatory glaucoma treatment and, 10.100
 optic nerve damage and, 10.110
 after refractive surgery, 13.41, 13.92, 13.104–105, 13.182, 13.201
 in uveitis, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.110
 intravitreal, 2.300*t*, 2.334, 6.321. *See also* Intravitreal injection, corticosteroid
 for juvenile idiopathic (chronic/rheumatoid) arthritis, 9.123–124
 for leptospirosis, 9.249
 for limbic stem cell deficiency, 8.94
 for Lyme disease, 9.246
 for meibomian gland dysfunction, 8.68
 for Mooren ulcer, 8.315
 for multifocal choroiditis and panuveitis syndrome, 9.156
 for multiple sclerosis, 5.319–320
 for neuromyelitis optica, 5.323
 for nonspecific orbital inflammation, 7.63, 7.64–65, 7.65
 for ocular allergies/inflammation, 2.329, 2.337, 2.338, 2.339, 6.247*t*, 6.248, 8.289
 route of administration of, 2.329, 2.333*t*, 2.333–334
 for ocular histoplasmosis syndrome, 9.216, 9.217*f*
 for ocular hypertension, 9.285
 ocular hypertension caused by, 9.95, 9.97, 9.98, 9.285, 9.286–288. *See also* Corticosteroids (steroids), intraocular pressure affected by
 ocular side effects of, 1.170–171, 1.307*t*
 for optic neuritis, 5.116, 6.369
 for orbital floor/blowout fracture, 7.109
 for pars planitis, 9.130
 after penetrating and perforating trauma repair, 8.409
 periocular administration of, 9.96*f*, 9.96–97, 9.97*f*
 in perioperative setting, 1.285–286
 for peripheral ulcerative keratitis, 8.313
 after photocoagulation, 13.92
 complications associated with, 13.104–105

- corneal haze reduction and, 13.33, 13.94, 13.108–109
 for diffuse lamellar keratitis, 13.117
 elevated intraocular pressure/glaucoma and, 13.41, 13.104–105, 13.182, 13.201
 fungal keratitis and, 13.106
 herpes simplex keratitis and, 13.174
 LASIK, 13.93, 13.94
 for transient light sensitivity, 13.123
 pressure-induced stromal keratopathy and, 13.119
 regression in overcorrection and, 13.101, 13.108–109
 regression in undercorrection and, 13.102
 surface ablation, 13.92, 13.94, 13.108–109
 progressive outer retinal necrosis syndrome treated with, 12.237
 after pterygium excision, 8.356
 ptosis caused by eyedrops containing, 5.273, 5.273t
 for punctate inner choroiditis, 9.160
 for recurrent corneal erosions, 8.87
 after refractive surgery, elevated intraocular pressure/
 glaucoma and, 13.41, 13.92, 13.104–105, 13.182, 13.201
 refractive surgery in patient taking, 13.37
 retinal vein occlusion treated with, 12.137–138
 for rheumatic disorders, 1.170–172, 1.171t
 for Rift Valley fever anterior uveitis, 9.212
 risks associated with long-term use of, 6.321
 for rosacea, 8.71
 for sarcoidosis, 9.171
 for scleritis, 8.324, 8.325f, 9.111, 9.260
 for serpiginous choroiditis, 9.153
 for staphylococcal blepharitis/blepharoconjunctivitis, 8.76
 for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.298
 for stromal keratitis, 8.222, 8.223t
 sub-Tenon injections of, 6.320
 supratarsal injection of, for vernal keratoconjunctivitis, 8.291
 for sympathetic ophthalmia, 9.175
 route of administration of, 2.333t
 systemic, 9.99–100
 in tear secretion, 2.219–220
 for thermal injuries, 8.385
 for Thygeson superficial punctate keratitis, 6.269, 8.307
 for thyroid eye disease, 5.131, 7.58, 7.59
 topical administration of, 9.95–96
 toxoplasmic retinochoroiditis treated with, 12.244
 for toxoplasmosis, 6.409–410, 9.223, 9.224f, 9.225–226, 9.297
 for traumatic anterior uveitis, 8.389–390
 for traumatic vision loss, 5.140, 7.114
 for tuberculous ocular disease, 9.255
 for uveitic glaucoma, 9.285, 9.286
 for uveitis, 6.320–321, 9.95–100, 9.96f, 9.113
 cataract surgery and, 9.282, 9.283–284
 cystoid macular edema and, 9.284, 9.289
 herpetic, 9.193
 intraocular pressure elevation and, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.100
 syphilitic, 9.243
 for vernal keratoconjunctivitis, 6.249, 8.291
 for Vogt-Koyanagi-Harada syndrome, 9.181–182
 withdrawal from, 1.171–172
 wound healing affected by, 13.33
 Corticotroph adenomas, 1.57
 Corticotropin-releasing hormone (CRH), 1.56t
 Cortisol deficiency, 1.58
 Cortisone, 1.171t
 Cortisporin. *See* Hydrocortisone, in combination preparations
Corynebacterium, 8.244t, 8.245–246
 diphtheriae, 8.207, 8.245
 invasive capability of, 8.207
 endophthalmitis caused by, 9.261
 as normal flora, 8.206t, 8.246
 ocular infection caused by, 8.245–246
 cicatrical conjunctivitis differentiated from, 8.301t
 xerosis, 8.196–197, 8.246
 Cosmetic facial surgery. *See* Facial surgery; *specific procedure*
 Cosmetic optics, for anophthalmic socket, 7.136
 Cosmid vector, 2.145
 Costimulatory molecules, 9.37
 Cotton-wool spots, 4.152
 in AAION/NAION, 5.120
 in branch retinal vein occlusion, 4.159
 in central retinal vein occlusion, 4.156, 4.157
 cytomegalovirus retinitis and, 12.235
 in diabetic retinopathy, 4.159, 12.140–141
 in HIV retinopathy, 9.293, 9.294f
 in hypertensive retinopathy, 12.122, 12.122f
 in leukemia, 4.315
 in Purtscher retinopathy, 12.171
 in SLE, 9.133, 9.133f
 in systemic lupus erythematosus, 12.230
 Couching, 11.89, 11.89f
 Cough, 1.129
 cataract surgery in patient with, 11.170
 in heart failure, 1.105
 Counseling. *See* Patient education
 genetic. *See* Genetic testing/counseling
 Coup, 12.315
 Coupling/coupling ratio, 13.27, 13.27f, 13.54, 13.54f, 13.55
 arcuate incisions/keratotomy and, 13.27, 13.27f, 13.54, 13.54f
 astigmatic keratotomy and, 11.123, 13.27, 13.27f, 13.54, 13.54f, 13.55
 limbal relaxing incisions and, 13.54, 13.54f, 13.55
 Cover tests
 alternate, 6.65–66, 6.66f
 before cataract surgery, 11.77–78
 cover-uncover test, 6.64, 6.65f
 ocular alignment assessments using, 6.64–67, 6.65–66f
 Cowden disease, eyelid manifestations of, 4.210t
 COX-1/COX-2. *See* Cyclooxygenase
 COX-2 (cyclooxygenase-2) inhibitors, 1.172, 2.239, 2.336, 9.94
 for cystoid macular edema, 9.25
 Coxsackieviruses, acute hemorrhagic conjunctivitis caused by, 8.240, 8.240t
 CPAP. *See* Continuous positive airway pressure

- CPC. *See* Cyclophotocoagulation/cycloablation
- CPEO. *See* Chronic progressive external ophthalmoplegia
- CPEO—plus syndromes. *See* Chronic progressive external ophthalmoplegia (CPEO)—plus syndromes
- CPR. *See* Cardiopulmonary resuscitation
- CR-39, 3.194–195
- CRA. *See* Central retinal artery
- “Crab claw” pattern
keratoconus and, 13.24, 13.176, 13.176f
in pellucid marginal degeneration, 8.31, 8.33f, 8.169, 8.170f
- Crab louse (*Phthirus pubis*), 8.253, 8.254f
ocular infection caused by, 8.208t, 8.253, 8.255
- Crack cocaine abuse, 1.192. *See also* Cocaine
- CRALBP. *See* Cellular retinaldehyde-binding protein/cytoplasmic retinal-binding protein
- Cranial dysinnervation disorders, congenital, 2.124.
See also specific disorder
- Cranial fossae
anterior, 5.6f, 5.8, 5.10f, 7.7f
middle, 5.6f, 5.10f, 5.11
neuroimaging in evaluation of, 5.72t
posterior, 5.6f
neuroimaging in evaluation of, 5.72t
- Cranial nerve I (olfactory nerve), 2.83, 2.84f, 2.85f
- Cranial nerve II (optic nerve). *See* Optic nerve
- Cranial nerve III (oculomotor nerve), 2.9f, 2.93–96, 2.94f, 2.95f, 5.8f, 5.35, 5.35f, 5.40, 5.40f, 5.41f, 5.42f, 5.43f, 5.44f, 5.44–45, 5.48f, 5.55f, 7.10f, 7.12, 7.12f, 7.13f, 7.14f, 7.15f
aberrant regeneration of, 5.197–198, 5.198f
anisocoria and, 5.265–266
light–near dissociation and, 5.266t, 5.267
synkinesis and, 7.211
in accommodation, 11.23
anatomy of, 2.9f, 2.93–96, 2.94f, 2.95f, 5.8f, 5.35, 5.35f, 5.40, 5.40f, 5.41f, 5.42f, 5.43f, 5.44f, 5.44–45, 5.48f, 5.55f
aneurysms affecting, 2.94, 2.95
divisions of, 6.19
extraocular muscles innervated by, 2.15f, 2.17, 2.93–96, 2.94f, 6.19–20, 7.12, 7.12f
eyelid disorders and, 5.271
gaze palsy caused by lesions of, 5.228
horizontal gaze and, 5.36, 5.37f
intra-axial lesions of, 5.191
levator muscle innervated by, 7.151
motor root of, 2.11, 2.12f
in ocular motility disorders, 5.188, 5.191, 5.193f, 5.193–198, 5.194f, 5.196f, 5.198f
cavernous sinus/superior orbital fissure lesions and, 5.202–206
palsy of. *See* Third nerve (oculomotor) palsy
superior division palsy of, 6.128
vertical gaze and, 5.36f, 5.36–37
- Cranial nerve IV (trochlear nerve), 2.9f, 2.96–97, 5.8f, 5.35, 5.35f, 5.40, 5.40f, 5.41f, 5.42f, 5.43f, 5.43–44, 5.48f, 7.10f, 7.12, 7.13f, 7.14f, 7.15f
anatomy of, 2.9f, 5.8f, 5.35, 5.35f, 5.40, 5.40f, 5.41f, 5.42f, 5.43f, 5.43–44, 5.48f
extraocular muscles innervated by, 2.17, 6.19, 7.12
- horizontal gaze and, 5.37f
- Horner syndrome in lesions of, 5.260t
- intra-axial lesions of, 5.191, 5.192
- in ocular motility disorders, 5.185, 5.186, 5.188–189, 5.198–200, 5.199, 5.199f
cavernous sinus/superior orbital fissure lesions and, 5.202–206
- palsy of, 6.140
- superior oblique myokymia and, 5.250
- vertical gaze and, 5.36f, 5.36–37
- Cranial nerve V (trigeminal nerve), 2.9f, 2.10, 2.97–101, 2.98f, 2.99f, 2.101f, 5.41f, 5.42f, 5.43f, 5.47f, 5.47–49, 5.48f, 5.55, 7.12, 7.17f, 7.144, 7.145f
anatomy of, 2.9f, 2.10, 2.97–101, 2.98f, 2.99f, 2.101f, 5.41f, 5.42f, 5.43f, 5.55
cold-induced anterior segment trauma and, 8.385
corneal sensation and, 8.42
divisions of, 2.98f, 2.99f, 2.100–101, 2.101f, 5.16f, 5.42f, 5.43f, 5.47f, 5.48–49
facial innervation and, 7.144, 7.145f
facial pain caused by lesions of, 5.297, 5.298, 5.298f
in herpes simplex infection, 8.213
in herpes zoster, 8.226, 8.227
lacrimal functional unit innervated by, 8.5f
in migraine, 5.291
neurotrophic keratopathy/persistent corneal epithelial defects caused by damage to, 8.42, 8.80, 8.81t
in ocular motility disorders, cavernous sinus/superior orbital fissure lesions and, 5.202–206
- V₁ (ophthalmic nerve), 2.9f, 2.98f, 2.99f, 2.100, 2.101f, 5.16f, 5.43f, 5.47f, 5.48, 7.14f, 7.15f, 7.16, 7.17f, 7.144, 7.145f
in reflex tear arc, 7.251
sensory root of, 2.11, 2.12f
- V₂ (maxillary nerve), 2.9f, 2.10, 2.98f, 2.99f, 2.100, 2.101f, 5.16f, 5.42f, 5.43f, 5.47f, 5.48f, 5.49, 7.14f, 7.15f, 7.16, 7.17f, 7.144, 7.145f
- V₃ (mandibular nerve), 2.98f, 2.99f, 2.101, 2.101f, 5.16f, 5.42f, 5.47f, 5.49, 7.14f, 7.15f, 7.17f, 7.144, 7.145f
- Cranial nerve VI (abducens nerve), 2.9f, 2.101–102, 2.102f, 5.8f, 5.35, 5.35f, 5.40, 5.40f, 5.40–41, 5.41f, 5.42f, 5.43f, 5.48f, 5.53f, 7.10f, 7.12, 7.13f, 7.14f, 7.15f
anatomy of, 2.9f, 5.8f, 5.35, 5.35f, 5.40, 5.40f, 5.40–41, 5.41f, 5.42f, 5.43f, 5.48f, 5.53f
extraocular muscles innervated by, 2.17, 6.19, 7.12
gaze palsy caused by lesions of, 5.228
horizontal gaze and, 5.36, 5.37, 5.37f, 5.38
in one-and-a-half syndrome, 5.191
intra-axial lesions of, 5.192
in ocular motility disorders, 5.189
cavernous sinus/superior orbital fissure lesions and, 5.202–206
palsy of. *See* Sixth nerve (abducens) palsy
pregnancy affecting, 5.333
pursuit system and, 5.34f, 5.224
- Cranial nerve VII (facial nerve), 2.101f, 2.102f, 2.102–104, 5.12, 5.41f, 5.42f, 5.49–52, 5.50–51f, 5.55, 5.56, 5.276–277f, 7.16, 7.142f, 7.143, 7.144f
aberrant regeneration of
Bell palsy and, 5.277, 5.279
synkinesis in, 5.271, 5.271f, 5.277, 7.211, 7.229

- anatomy of, 2.101*f*, 2.102–104, 5.41*f*, 5.42*f*, 5.49–52, 5.50–51*f*, 5.55, 5.56, 5.276–277*f*
- autonomic function of, testing, 5.275, 5.276–277*f*
- brainstem lesions involving, 5.278, 5.278*t*
- buccal branch of, 7.142*f*, 7.143, 7.144*f*
- cervical branch of, 7.143, 7.144*f*
- cervicofacial division of, 2.104, 5.52
- distribution of, 5.276–277*f*
- evaluation of, 5.275–277, 5.276–277*f*
- facial movement abnormalities caused by disorders of, 5.275–277, 5.276–277*f*, 5.277–285
- overactivity and, 5.281–285, 5.282*f*, 5.282*t*, 5.283*f*
- underactivity and, 5.275, 5.276–277*f*, 5.277–281, 5.278*t*, 5.279*f*. *See also* Facial paralysis/weakness
- horizontal gaze and, in one-and-a-half syndrome, 5.191
- intra-axial lesions of, 5.192
- labyrinthine segment of, 2.103
- mandibular branch of, 5.51*f*, 5.52, 5.276–277*f*
- marginal, 7.142*f*, 7.143, 7.144*f*
- mastoid segment of, 2.103
- palsy of. *See* Facial paralysis/weakness
- peripheral lesions involving, 5.278–280, 5.279*f*
- pregnancy affecting, 5.333
- in reflex tear arc, 7.251, 7.252*f*
- sarcoidosis involving, 5.280, 5.327
- supranuclear lesions involving, 5.276*f*, 5.277–278
- surgical ablation of, for benign essential blepharospasm, 7.228
- surgical decompression of, for hemifacial spasm, 5.284, 7.229
- synkinesis caused by disorders of, 5.271, 5.271*f*, 5.277
- temporal (frontal) branch of, 2.104, 5.51*f*, 5.52, 5.276–277*f*, 7.142*f*, 7.143, 7.144, 7.144*f*
- temporofacial division of, 2.104, 5.52
- terminal branches of, 5.51*f*, 5.52, 5.276–277*f*
- tympanic segment of, 2.103
- zygomatic branch of, 2.104, 5.51*f*, 5.52, 5.276–277*f*, 7.142*f*, 7.143, 7.144*f*
- Cranial nerve VIII (auditory nerve), 2.101*f*, 2.103, 5.35, 5.38
- anatomy of, 2.101*f*, 5.35, 5.38
- horizontal gaze and, 5.37*f*
- vertical gaze and, 5.36*f*
- vestibular imbalance caused by lesions of, 5.217
- in vestibulo-ocular reflex, 5.214, 5.217
- Cranial nerves (CNs), 2.11, 2.83–107, 2.84*f*, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*. *See also specific nerve*
- anatomy of, 2.11, 2.83–107, 2.84*f*, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*
- extraocular muscles supplied by, 2.15*f*, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*, 7.11, 7.14, 7.15*f*
- ocular motor, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*
- orbit supplied by, 7.16–18, 7.17*f*
- palsy of
- in cryptococcosis, 5.356
- diplopia caused by, 5.192, 5.193*f*, 5.193–201, 5.194*f*, 5.196*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.202
- multiple nerve involvement and, 5.202
- herpes infection and, 5.350
- isolated. *See also specific type*
- in multiple sclerosis, 5.318
- localization of lesions causing, 5.187*f*, 5.187–188
- in multiple sclerosis, 5.318
- neuroimaging in evaluation of, 5.70
- pain associated with, 5.192
- radiation therapy and, 5.358
- in sarcoidosis, 5.280, 5.327
- saccadic system and, 5.33
- Cranial neuropathy syndrome, idiopathic multiple, 5.202
- Cranial sutures, 6.203–204, 6.204*f*
- premature closure of, in craniosynostosis, 7.37
- Craniofacial bones, 5.6–7, 5.9*f*
- Craniofacial clefts, 7.36–38, 7.37*f*, 7.38*f*. *See also*
- Craniofacial malformations; *specific type*
- nasolacrimal duct obstruction and, 7.259
- Craniofacial dysostosis (Crouzon syndrome), 2.177, 7.37, 7.38*f*, 8.191*t*
- Craniofacial malformations, 7.36–38, 7.37*f*, 7.38*f*. *See also specific type*
- anophthalmia, 6.209, 6.210*f*, 7.35
- Apert syndrome (acrocephalosyndactyly), 6.206–207, 6.207*f*, 6.209*f*, 7.37, 7.38*f*, 8.191*t*
- branchial arch syndromes, 6.210–211, 211*f*
- craniosynostosis/syndromic craniosynostosis, 7.37–38, 7.38*f*
- Crouzon syndrome, 2.177, 6.206, 6.206*f*, 7.37, 7.38*f*, 8.191*t*
- fetal alcohol syndrome, 6.211–212, 6.212*f*
- Goldenhar syndrome/oculoauriculovertebral dysplasia, 7.37
- mandibulofacial dysostosis. *See* Craniofacial malformations, Treacher Collins/Treacher Collins–Franceschetti syndrome
- nonsynostotic, 6.209–212
- oculoauriculovertebral spectrum/sequence (OAVS), 8.191*t*, 8.195*f*, 8.195–196
- Pfeiffer syndrome, 6.207
- Pierre Robin sequence, 6.211, 8.192*t*
- Saethre–Chotzen syndrome, 6.207, 6.208*f*
- Treacher Collins/Treacher Collins–Franceschetti syndrome (mandibulofacial dysostosis), 6.211, 6.211*f*, 7.37, 7.37*f*, 8.192*t*
- eyelid manifestations of, 4.207*t*
- Craniometaphyseal dysplasia, 6.212
- Craniopharyngiomas, 5.147, 5.150
- nystagmus caused by, 5.247
- Craniosynostosis, 7.37–38, 7.38*f*
- anatomy of, 6.203–204
- Apert syndrome, 6.206–207, 6.207*f*, 6.209*f*
- brachycephaly, 6.205
- complications of
- corneal exposure, 6.207
- globe luxation, 6.207–208
- ocular adnexal abnormalities, 6.209
- optic nerve abnormalities, 6.208–209
- proptosis, 6.207
- strabismus, 6.208
- Crouzon syndrome, 6.206, 6.206*f*
- definition of, 6.203
- dolichocephaly, 6.205
- etiology of, 6.205–206
- Kleeblattschädel, 6.205
- Pfeiffer syndrome, 6.207
- plagiocephaly, 6.204–205

- Saethre-Chotzen syndrome, 6.207, 6.208*f*
 scaphocephaly, 6.205
 syndromes associated with, 6.206–207, 7.37–38, 7.38*f*
- Craniotomy, frontal, for orbital surgery, 7.124
- CRAO. *See* Central retinal artery occlusion
- CRAVE study, 12.135
- Crawford stent, for nasolacrimal intubation, 7.262, 7.264*f*
- CRB1* mutations, 12.258
- Creases (eyelid). *See* Eyelids, creases of
- Creatine kinase MB (CK-MB), in acute coronary syndrome, 1.96
- Creeping angle closure, 10.126. *See also* Angle-closure glaucoma
- “Crescent moon sign,” in internal carotid artery dissection, 5.262*f*, 5.342
- CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial), 1.125
- Crest cells. *See* Neural crest cells
- CREST syndrome, 1.162
- Cretinism, 1.50
- Creutzfeldt-Jakob disease (CJD), 5.357
 corneal transplant in transmission of, 8.254, 8.416*t*
- CRE. *See* Corneal resistance factor
- CRH. *See* Corticotropin-releasing hormone
- Cri-du-chat syndrome, 6.386*t*
- Cribiform plate, 2.10*f*, 2.11, 5.6*f*. *See also* Lamina cribrosa
- Cricothyrotomy, 1.299
 for anaphylaxis, 1.302
- Crigler-Najjar syndrome, 2.175*t*
- CRION. *See* Chronic relapsing inflammatory optic neuropathy
- Critical angle, 3.40, 3.50–51
- CRN. *See* Convergence-retraction nystagmus
- Crocodile shagreen, 8.121
- Crocodile tears, 5.277
- Crohn disease (granulomatous ileocolitis), 1.155, 9.116
- Crolom. *See* Cromolyn
- Cromolyn, 2.337, 2.338*t*
 for asthma, 1.134
 for hay fever conjunctivitis, 8.289
- Cross cylinder technique
 Jackson. *See* Jackson cross cylinder
 for refraction, 3.163–165, 3.164*f*, 3.165*t*
- Cross-fixation, in infantile esotropia, 6.87–88, 6.88*f*
- Cross-sectional studies, 1.11
- Crossed diplopia, 6.75
- Crossing over (genetic), 2.134, 2.150, 2.187
 unequal, 2.145
- Crosslinking. *See* Corneal (collagen) crosslinking
- Crouzon syndrome (craniofacial dysostosis), 2.177, 6.206, 6.206*f*, 7.37, 7.38*f*, 8.191*t*
- Crowding phenomenon
 in amblyopia, 6.56
 definition of, 6.54
- CRP. *See* C-reactive protein
- CRS. *See* Congenital rubella syndrome
- CRV. *See* Central retinal vein
- CRVO. *See* Central retinal vein occlusion
- Cryoablation, for retinopathy of prematurity, 12.185–186
- Cryoglobulin deposition, ophthalmic findings in, 8.198–199
- Cryoglobulinemic vasculitis, 1.165*t*
- Cryopexy
 transconjunctival, 12.398
 transscleral, 12.398
- Cryoprobe, for lens extraction, 11.195
 in ICCE, 11.200
- Cryotherapy
 for basal cell carcinoma of eyelid, 7.181
 for conjunctival papillomas, 8.239, 8.333
 for ligneous conjunctivitis, 8.295
 with ocular surface surgery for neoplasia, 8.329
 for pars planitis, 9.130
 retinal cavernous hemangioma treated with, 12.168
 for retinal hemangioblastoma/von Hippel-Lindau disease/syndrome, 4.285
 for retinoblastoma, 4.300
 for trichiasis/distichiasis, 7.160, 7.208, 8.88
 von Hippel-Lindau syndrome treated with, 12.167
- Cryotherapy for Retinopathy of Prematurity (CRYO-ROP), 6.326, 6.331
- Cryptococcus neoformans/gattii* (cryptococcosis), 5.356, 8.249*t*, 8.251, 9.270
 choroiditis caused by, 9.298–299
 endogenous endophthalmitis caused by, 9.270
 in HIV infection/AIDS, 5.356, 9.270, 9.298–299
 ocular infection caused by, 5.356
 optic nerve infection caused by, 4.243, 4.243*f*, 5.356
 retinal infection caused by, 4.147
- Cryptophthalmos, 6.191, 6.193, 6.193*f*, 7.161, 7.161*f*
- Cryptophthalmos-syndactyly (Fraser syndrome), eyelid manifestations of, 4.207*t*
- Cryptosporidium parvum* (cryptosporidiosis), in HIV infection/AIDS, 1.268–269
- Crystal deposition, corneal, 8.173, 8.182*t*
 in cystinosis, 8.181*f*, 8.181–182
 in hematologic disorders, 8.197–199, 8.198*f*, 8.199*f*
- Crystal violet stain, 4.31*t*
- Crystalline corneal/stromal dystrophy, Schnyder (SCD), 8.135*t*, 8.136*t*, 8.145*t*, 8.151–152, 8.152*f*. *See also* Schnyder corneal dystrophy
- hyperlipoproteinemia and, 8.151, 8.179
- Crystalline keratopathy, infectious, 8.268, 8.268*f*
 corneal deposits and, 8.182*t*
 after penetrating keratoplasty, 8.427, 8.427*f*
- Crystalline lens. *See* Lens
- Crystalline/pseudocrystalline keratopathy, infectious, 4.79–80, 4.80*f*
 after penetrating keratoplasty, 4.79
- Crystalline retinopathy
 cause of, 12.302–304, 12.303*t*
 drugs that cause, 12.302–304
 tamoxifen as cause of, 12.303, 12.304*f*
 West African, 12.303–304, 12.305*f*
- Crystallins, 2.64, 2.241, 2.243–244, 11.15*f*, 11.15–16.
See also Lens proteins
 α , 2.64, 2.244, 11.15, 11.15*f*, 11.15–16
 β , 2.64, 2.244, 11.16
 β , γ , 2.244, 11.15, 11.15*f*, 11.16
 γ , 2.64, 2.244, 11.16
 taxon-specific, 2.244
- Crystalloids, for shock, 1.301
- CS. *See* Cockayne syndrome
- CSC. *See* Central serous chorioretinopathy

- CSCD (congenital stromal corneal dystrophy). *See* Congenital hereditary stromal dystrophy
- CSD. *See* Cat-scratch disease
- CSF. *See* Cerebrospinal fluid; Contrast sensitivity function
- CSII. *See* Continuous subcutaneous insulin infusion
- CSLO. *See* Confocal scanning laser ophthalmoscopy/ophthalmoscope
- CSM method. *See* Central, Steady, and Maintained (CSM) method
- CSME. *See* Clinically significant diabetic macular edema
- CSNB. *See* Congenital stationary night blindness
- CSR (central serous retinopathy). *See* Central serous chorioretinopathy
- CSROP. *See* Clinically significant retinopathy of prematurity
- CST. *See* Cavernous sinus thrombosis
- CT/CT scan. *See* Computed tomography
- CTA. *See* Computed tomography angiography
- CTLs. *See* Cytotoxic T lymphocytes
- CTNS gene, 6.270
- in cystinosis, 8.181
- CTRs. *See* Capsular tension rings
- CTV. *See* Computed tomography venography
- Cu-Zn SOD (superoxide dismutase), 2.287
- Culex* mosquitoes, 12.246
- Cultured epithelial stem cells, for transplantation, 8.365.
- See also* Limbal transplantation
- Cuneiform opacities, 11.46, 11.47f
- Cup, optic. *See* Cupping of optic nerve/nerve head/disc; Optic cup
- Cup-disc ratio
- in AAION/NAION, 5.120, 5.121f
- in glaucoma evaluation, 10.48, 10.53
- in infants and children, 10.160
- Cupping of optic nerve/nerve head/disc, 2.86, 6.187, 6.402f
- asymmetry of, 10.48–49, 10.49f
- glaucomatous, 10.46, 10.47f; 10.48–49, 10.49t
- in infants and children, 10.46
- visual field changes correlated with, 10.74–75
- physiologic, 10.48
- vertical elongation and, 10.49, 10.50f
- Curly fibers, in Thiel-Behnke corneal dystrophy, 8.143, 8.144f. *See also* Thiel-Behnke corneal dystrophy
- Curvature
- corneal, 8.25–26. *See also* Cornea, topography of
- axial, 8.28, 8.29f; 13.16, 13.16f; 13.17f
- in cornea plana, 8.96t, 8.100
- evaluation of, 8.25–36
- corneal zones and, 8.25, 8.25f; 8.26f
- keratometry for, 8.26–27, 8.27f
- keratoscopy for, 8.27–28, 8.28f
- Placido disk-based topography for, 8.27–28, 8.28, 8.35t
- shape/curvature/power and, 8.25–26
- tomography for, 8.33–36, 8.34f; 8.35f; 8.35t
- topography for, 8.28–36, 8.29f; 8.30f; 8.31f; 8.32f; 8.32t; 8.33f; 8.35t
- after keratorefractive surgery, 3.269
- mean, 8.28
- measurement of, 13.14–19, 13.15f; 13.16f; 13.17f; 13.18f; 13.19f; 13.44–45, 13.45f
- power and, 8.25–26, 13.7–9
- radius of, 3.127t, 8.8, 8.27
- in cornea plana, 8.100
- instantaneous (meridional/tangential power), 13.16–17, 13.17f
- keratometry in measurement of, 8.27
- refractive surgery affecting, 13.9, 13.26–28, 13.27f; 13.28f
- IOL power calculation and, 13.193–197, 13.196f
- in schematic eye, 3.127t
- radius of, 3.127t
- Curvature maps, 8.28–33, 8.29f; 8.30f; 8.31f; 8.32f; 8.33f; 13.14–19, 13.15f; 13.17f; 13.19f; 13.44–45, 13.45f.
- See also* Cornea, topography of
- interpretation of, 8.28–31
- in keratoconus, 8.165, 8.165f; 8.167f
- in pellucid marginal degeneration, 8.31, 8.33f; 8.169, 8.170f
- postoperative, 13.23, 13.24f
- Curvature of field
- definition of, 3.72
- schematic diagram of, 3.72f
- Curvularia*, 8.249t, 8.251
- Cushing syndrome
- corticotroph adenoma causing, 1.57
- elevated intraocular pressure in, 10.110
- Custom (wavefront-guided) ablation, 13.31, 13.46, 13.76–77
- higher-order aberrations and, 13.13, 13.31–32, 13.76–77
- for LASIK re-treatment/enhancement, 13.99
- for mixed astigmatism, 13.97
- multifocal, 13.167, 13.168f
- outcomes of, 13.31–32, 13.97
- overcorrection and, 13.102
- patient selection/relative contraindications and, 13.80
- postoperative aberrations and, 13.13, 13.102
- preoperative planning/laser programming for, 13.31, 13.46, 13.81
- for presbyopia, 13.167, 13.168f
- wavefront analysis before, 13.31, 13.46, 13.80
- Cutaneous horn (exuberant hyperkeratosis), 4.211, 7.168
- Cutaneous leishmaniasis, 8.252
- Cuticular (basal laminar) drusen, 4.162, 12.274, 12.275f
- Cutler-Beard procedure, 7.192, 7.193f
- Cutting head, of microkeratome, 13.84, 13.85, 13.85f
- CVD. *See* Cardiovascular disease
- CVI. *See* Cerebral visual impairment
- CVOS (Central Vein Occlusion Study), 4.157
- CVS. *See* Chorionic villus sampling
- CVT. *See* Cerebral venous thrombosis
- CXL. *See* Corneal (collagen) crosslinking
- Cyanoacrylate glue/adhesive, 8.370–371
- for corneal perforation/corneoscleral laceration, 8.369, 8.369f; 8.370–371, 8.402, 8.406
- for descemetocoele, 8.369
- for peripheral ulcerative keratitis, 8.313
- as tarsorrhaphy alternative, 8.373
- Cyclic adenosine monophosphate (cAMP), 2.321
- in α -agonist mechanism of action, 10.178
- in β -blocker mechanism of action, 10.176
- in signal transduction, 2.316t
- in tear secretion, 2.218, 2.219f
- Cyclic esotropia, 6.93

- Cyclic guanosine monophosphate (cGMP)
 in cone phototransduction, 2.261
 mutation in, 2.161
 in rod phototransduction, 2.259, 2.260f, 2.261
- Cyclic guanosine monophosphate (cGMP)—gated channel
 cone, 2.261
 mutation in, 2.264
 rod, 2.259, 2.260f, 2.261
 mutation in, 2.161, 2.263
- Cyclic strabismus, 6.93
- Cyclin-dependent kinases (CDKs), in cancer, 1.228
- Cyclin-dependent phosphatases, in cancer, 1.228
- Cyclitis
 anterior, 9.72t
 chronic. *See* Intermediate uveitis; Pars planitis
 posterior, 9.72t
- Cycloablation. *See* Cyclophotocoagulation/cycloablation
- Cyclocryotherapy, 6.287, 10.194
 for pediatric glaucoma, 10.163–164
- Cyclodestructive procedures. *See*
 Cyclophotocoagulation/cycloablation
- Cyclodeviations
 double Maddox rod test for, 6.69, 6.69f
 fusion affected by, 6.79
- Cyclodialysis, 4.18, 4.19f, 4.103, 8.391, 8.391f
 after cataract surgery, 11.139
 gonioscopic appearance of, 10.40, 10.41f
 ultrasound biomicroscopy in evaluation of, 8.21,
 8.391, 8.391f
- Cyclogyl. *See* Cyclopentolate hydrochloride
- Cyclomydril. *See* Cyclopentolate hydrochloride, with
 phenylephrine
- Cyclooxygenase (COX-1/COX-2), 1.172, 2.239, 9.24
 aspirin affecting, 2.335
 in eicosanoid synthesis, 2.238f, 2.238–239, 9.24
 NSAIDs and, 1.172, 2.239, 2.334, 9.94. *See also*
 Cyclooxygenase-2 (COX-2) inhibitors
 in prostaglandin synthesis, 2.238f, 2.238–239, 2.334,
 9.24, 9.25f
- Cyclooxygenase-2 (COX-2) inhibitors, 1.172, 2.239,
 2.336, 9.94
 for cystoid macular edema, 9.25
- Cyclopentolate hydrochloride, 2.313, 2.314t, 6.11, 6.11t
 for cycloplegia/cycloplegic refraction, in uveitis, 9.94,
 9.113
 with phenylephrine, 2.314t
- Cyclophosphamide, 1.175, 9.105–106
 for Behçet disease, 1.169, 9.189
 in cancer chemotherapy, 1.232t
 for granulomatosis with polyangiitis (Wegener
 granulomatosis), 1.168
 for mucous membrane pemphigoid, 8.303
 for peripheral ulcerative keratitis, 8.313
 for uveitis, 9.105–106
- Cyclophotocoagulation/cycloablation (CPC/
 cyclodestruction), 10.194–196, 10.195f
 endoscopic, 10.194, 10.195, 10.196
 cataract surgery and, 11.186
 for neovascular glaucoma, 10.135
 for pediatric glaucoma, 10.161, 10.163–164
 uveitic glaucoma and, 9.287–288
- Cycloplegia/cycloplegics, 2.313, 2.314t, 11.23
 adverse effects of, 6.11–12
 amblyopia treated with, 6.59
 for chemical injuries, 8.383
 in children, 6.11–12
 for corneal abrasions, 6.376, 8.398
 for hyphema, 8.394, 10.105
 indications for, 3.38
 for insect/arachnid injuries, 8.387
 intraocular pressure affected by, 10.110
 near reflex spasm treated with, 6.94
 ocular surface toxicity and, 8.90t
 after penetrating and perforating trauma repair, 8.409
 for recurrent corneal erosions, 8.87
 refraction with. *See* Cycloplegic refraction
 for sarcoidosis, 9.171
 for scleritis pain management, 9.112
 for thermal injuries, 8.385
 for traumatic anterior uveitis, 8.389–390
 for uveitis, 9.94, 9.113, 9.114f
 for vegetative injuries, 8.387
- Cycloplegic refraction. *See also* Refraction; Refraction,
 clinical
 agents used in, 6.11–12
 in amblyopia treatment, 6.57
 in children, 3.174, 6.10–12
 description of, 3.168–169
 in infantile esotropia, 6.88
 before refractive surgery, 13.40
 laser programming and, 13.40, 13.81
 technique of, 6.11
- Cyclospora cayetanensis* (cyclosporiasis), in HIV
 infection/AIDS, 1.269
- Cyclosporine/cyclosporine A, 1.175–176, 2.337, 9.104–105
 for atopic keratoconjunctivitis, 8.294
 for Behçet disease, 1.169, 9.188, 12.230
 for birdshot uveitis, 9.147
 for corneal graft rejection prophylaxis, 8.430
 for dry eye, 2.221f, 2.221–222, 2.337, 2.342, 8.61t, 8.63
 before refractive surgery, 13.173
 for graft-vs-host disease, 8.304
 for hay fever conjunctivitis, 8.289
 for Mooren ulcer, 8.315, 8.316
 off-label use of, 2.306
 for peripheral ulcerative keratitis, 8.313
 for scleritis, 8.324
 for serpiginous choroiditis, 9.153
 for superior limbic keratoconjunctivitis, 8.84
 for Thygeson superficial punctate keratitis, 8.307
 topical, 2.337, 8.61t, 8.63
 for uveitis, 9.104
 for vernal keratoconjunctivitis, 6.249, 8.291, 8.292
- Cyclothymic disorder, 1.189
 treatment of, 1.197–198
- Cyclotropia, relative, 5.185
- Cyclovergence, fusional, 6.40
- Cyclovertical strabismus, 6.162
- Cylate. *See* Cyclopentolate hydrochloride
- Cylinder axis
 cross cylinder technique for determining, 3.163–166
 finding of, for regular astigmatism, 3.156–158,
 3.157–158f
 locating of, 3.156, 3.157f
 minus cylinder phoropter refinement of, 3.29–30, 3.30f
 plus cylinder phoropter refinement of, 3.30

- refinement of, 3.29–30, 3.30*f*, 3.163
straddling, 3.158, 3.158*f*
- Cylinder power
cross cylinder technique for determining, 3.163–166
finding of, for regular astigmatism, 3.158
lensmeter measurement of, 3.284, 3.284*f*
minus cylinder phoropter refinement of, 3.31
plus cylinder phoropter refinement of, 3.31–32
refinement of, 3.31–32, 3.163–165, 3.164*f*
- Cylindrical lenses
axis orientation in, 3.17–18
minus, 3.17*f*
plus, 3.17*f*
- Cylindroma (adenoid cystic carcinoma/ACC)
of eyelid, 7.171
of lacrimal gland, 4.230–231, 4.231*f*, 7.91, 7.93
- CYP1B1* gene, 6.259, 6.277
in glaucoma, 10.11*t*, 10.150
primary congenital, 8.108
in Peters anomaly, 8.97*t*, 8.103, 10.150
- CYP4V2*, 12.257*t*, 12.258, 12.269
- Cystadenoma (oncocytoma), 4.71–72, 4.72*f*, 8.337
- Cystathionine β -synthase, 6.308
- Cystathionine synthase/cystathionine β -synthase, abnormality of in homocystinuria, 2.175*t*
- Cysteamine, 6.270, 12.293
for cystinosis, 8.182
- Cysteine-rich proteins, in neurofibromatosis, 4.238
- Cystic carcinoma, adenoid (ACC/cylindroma)
of eyelid, 7.171
of lacrimal gland, 4.230–231, 4.231*f*, 7.91, 7.93
- Cystic fibrosis, 1.130
- Cysticercosis, 9.230–232, 9.231*f*
orbital involvement and, 4.228, 7.51
- Cystine accumulation/crystals, in cystinosis, 8.181*f*, 8.181–182
- Cystinosis, 6.270, 6.387*f*, 6.389*t*, 8.181–182, 8.183*t*, 12.293
corneal changes in, 8.181*f*, 8.181–182, 8.183*t*
cysteamine for, 8.182
in infants and children, 8.181
renal transplant for, 2.203
- Cystoid degeneration, peripheral, 4.148, 4.149*f*
reticular (RPCD), 4.148, 4.149*f*, 12.326
typical (TPCD), 4.148, 4.149*f*, 12.326
- Cystoid macular edema (CME), 4.140, 4.152–153, 4.153*f*, 4.154*f*. *See also* Macular edema
angiographic, after cataract surgery, 11.163–164, 11.164*f*
in birdshot uveitis, 9.144, 9.145*f*, 12.224
carbonic anhydrase inhibitors for, 2.324
cataract surgery as cause of, 12.157, 12.159, 12.260
central retinal vein occlusion as cause of, 12.136*f*
characteristics of, 12.156–157
corticosteroids for, 12.159, 12.393
after cataract surgery, 11.165
route of administration of, 2.333*t*
in cytomegalovirus retinitis, 12.235
differential diagnosis of, 12.157
drugs that cause, 12.301
edema sources in, 12.156–157
etiologies of, 12.157
fingolimod as cause of, 12.302
fluorescein angiography of, 12.36*f*, 12.157
in HTLV-1 infection, 9.212
incidence of, 12.157, 12.159
in Irvine-Gass syndrome, 12.157
in multifocal choroiditis and panuveitis syndrome, 9.156
nicotinic acid as cause of, 12.301
optical coherence tomography of, 12.132*f*, 12.157, 12.158*f*
in pars planitis, 9.128, 9.131
petaloid, 12.157
postoperative, cataract surgery and, 11.163–165, 11.164*f*, 11.187
in glaucoma, 11.164, 11.187
after Nd:YAG capsulotomy, 11.157
vitreous prolapse and, 11.143–144
predisposing factors for, 12.157, 12.159
prostaglandins and, 9.24–25
pseudophakic
definition of, 12.157
imaging of, 12.394*f*
optical coherence tomography of, 12.158*f*
pars plana vitrectomy for, 12.394*f*
in retinal dystrophies, 12.260, 12.260*f*
retinal vein occlusion as cause of, 12.135. *See also* Retinal vein occlusion (RVO)
in retinitis pigmentosa, 9.278, 12.260
in sarcoidosis, 9.170
spontaneous resolution of, 12.159
subretinal diseases that cause, 12.157
taxanes as cause of, 12.301
treatment of, 12.159
in uveal lymphoid proliferation, 9.276
in uveitis, 9.73, 9.90, 9.90*f*, 9.91, 9.91*f*, 9.289–290
cataract surgery and, 9.284
vision loss caused by, 12.225
vitrectomy for, 12.159, 12.393, 12.394*f*
- Cystotome, for ECCE, 11.196
- Cysts
colobomatous, 6.224
dermoid, 6.223–224, 224*f*
epithelial inclusion, 6.250
iris, 6.272*f*, 6.272–273
microphthalmia with, 6.224, 6.225*f*
- Cytarabine, 1.232*t*
epithelial cysts caused by, 8.130
- Cytobrush, 8.210
- Cytochrome oxidase complex, 2.281, 2.282*f*, 2.286
- Cytochrome P450, drug toxicity and, 2.294
- Cytogenetics, 2.187–193, 2.189*f*, 2.191*t*
indications for, 2.188, 2.189*f*
markers in, 2.159
- Cytoid bodies, 4.151–152, 4.152*f*
- Cytokeratins, in immunohistochemistry, 4.33
- Cytokines, 9.20*f*, 9.22*t*, 9.26–29, 9.27–28*t*. *See also* specific type
in cancer therapy, 1.236
cytotoxic, 9.39
in delayed hypersensitivity, 9.38, 9.45, 9.45*f*, 9.46
in external eye defense, 8.11–13, 8.12*f*
in immune processing, 9.36*f*, 9.37
inhibitors of. *See* Biologic response modifiers

- in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.274
 - in tear film, 2.217, 8.11–13, 8.12f
 - in uveitic cystoid macular edema, 9.289
 - Cytokinesis, 2.148, 2.149f
 - Cytology (ocular), 4.34t. *See also* Fine-needle aspiration biopsy
 - impression, in superior limbic keratoconjunctivitis, 8.84
 - Cytomegalic inclusion disease (CID/congenital CMV infection), 1.259, 9.198, 9.199, 9.200
 - Cytomegalovirus (CMV), 1.259–260, 6.411, 6.411f, 8.231, 9.198–202, 9.199f, 9.200f
 - anterior uveitis caused by, 8.231–233, 9.201
 - cancer association and, 1.229
 - congenital infection caused by, 1.259, 9.198, 9.199, 9.200
 - in HIV infection/AIDS, 1.259, 1.268, 5.349, 5.349f, 9.198, 9.200–201, 9.294–295
 - keratitis caused by, 8.231–232, 8.232f
 - ophthalmic considerations and, 1.260
 - retinitis caused by, 1.259, 1.260, 4.145, 4.146f, 5.349, 9.198–201, 9.199f, 9.200f, 12.235–236, 12.238t
 - acute retinal necrosis, 9.196
 - cidofovir for, 1.260, 1.281, 2.357t, 2.360–361
 - congenital (cytomegalic inclusion disease), 9.198, 9.199, 9.200
 - foscarnet for, 1.239, 1.260, 1.268, 1.281, 2.357t, 2.360, 9.201
 - ganciclovir for, 1.239, 1.260, 1.268, 1.281, 2.357t, 2.358t, 2.359–360, 9.201
 - in HIV infection/AIDS, 1.259, 1.268, 5.349, 5.349f, 9.198, 9.200–201, 9.294–295
 - immune recovery uveitis and, 1.271, 9.201, 9.294–295
 - recent developments in treatment of, 1.239
 - retinal detachment and, 9.201, 9.291, 9.295
 - valganciclovir for, 1.239, 1.260, 1.268, 1.281, 9.201
 - Cytoplasmic retinal-binding protein/cellular retinaldehyde-binding protein (CRALBP)
 - in aqueous humor, 2.231
 - mutation in, 2.265
 - Cytoskeletal (urea-soluble) lens proteins, 2.245, 11.15f, 11.16–17
 - Cytotoxic hypersensitivity (type II) reaction, 9.40, 9.41t. *See also* Cytotoxic T lymphocytes
 - in mucous membrane pemphigoid, 8.299
 - Cytotoxic T lymphocytes (CTLs), 9.38–39, 9.39f, 9.48–49, 9.49f
 - in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
 - in viral conjunctivitis, 9.56
 - Cytotoxicity, antibody-dependent, 9.50
 - Cytovene. *See* Ganciclovir
- D**
- D. *See* Diopter
 - D-15 test, in low vision evaluation, 5.79
 - D-penicillamine, for Wilson disease, 2.203, 8.189
 - Dabigatran
 - for heart failure, 1.111
 - in perioperative setting, 1.286
 - Daclizumab, for multiple sclerosis, 5.321t
 - Dacryoadenitis, 4.224, 7.284, 8.208t
 - Epstein-Barr virus causing, 7.284, 8.208t, 8.230–231
 - lacrimal gland masses and, 7.91
 - mumps virus causing, 8.208t, 8.240
 - nonspecific orbital inflammation and, 7.64
 - Dacryoceles/dacryocystoceles, 6.213, 6.225, 6.228–230, 6.229f, 7.265–267, 7.266f
 - in dacryocystitis, 7.285
 - Dacryocystectomy, for lacrimal sac tumors, 7.287
 - Dacryocystitis, 7.285–286, 7.286f, 8.208t
 - acute, 6.229, 7.285–286, 7.286f
 - cellulitis and, 7.44, 7.285, 7.286f
 - chronic, 7.286
 - dacryocystocele/dacryoceles and, 7.285
 - in nasolacrimal duct obstruction, 7.260, 7.285, 7.286
 - tumor associated with, 7.287
 - Dacryocystography
 - for lacrimal drainage evaluation, 7.272
 - for lacrimal sac tumor evaluation, 7.287
 - Dacryocystorhinostomy (DCR), 7.265, 7.278–281, 7.280f, 7.281
 - for acquired nasolacrimal duct obstruction, 7.278–281, 7.280f, 7.281
 - angular artery as landmark in, 2.25
 - for congenital nasolacrimal duct obstruction, 7.265
 - for dacryocystitis, 7.286
 - for nasolacrimal duct obstruction, 6.236
 - Dacryoliths, 7.277, 7.277f
 - Dacryoplasty, balloon (balloon catheter dilation/BCD)
 - for acquired nasolacrimal duct obstruction, 7.278
 - for canalicular obstruction, 7.275
 - for congenital nasolacrimal duct obstruction, 7.263–265
 - Dacryops, 4.208
 - Dacryoscintigraphy, for lacrimal drainage evaluation, 7.272
 - Dactinomycin, 1.233t, 1.235
 - Dactylitis, in spondyloarthropathies/spondyloarthritis, 1.153
 - DAG. *See* Diacylglycerol
 - DAISY digital format, of audio books, 3.323
 - Dalen-Fuchs nodules/spots, in sympathetic ophthalmia, 4.185, 4.186f, 9.172, 9.174, 9.174f
 - Dalfampridine, for nystagmus, 5.245
 - DALK. *See* Deep anterior lamellar keratoplasty
 - Danazol, ocular effects of, 1.308t
 - Dantrolene, for malignant hyperthermia, 1.293t
 - Dapagliflozin, for diabetes mellitus, 1.45t, 1.47
 - Dapiprazole, 2.308t, 2.321
 - Dapsone, for *Pneumocystis jirovecii* pneumonia, 1.267
 - Daptomycin, 1.273t
 - Daranide. *See* Dichlorophenamide
 - Daraprim. *See* Pyrimethamine
 - Dark adaptation
 - absorptive lenses for, 3.192
 - in congenital stationary night blindness, 6.338
 - in electro-oculography, 12.50
 - in full-field (Ganzfield) electroretinography, 12.42
 - in Oguchi disease, 12.253
 - spectral luminous efficiency function in, 3.109

- Dark adaptometry, 12.57–58
- Darkroom prone-position test, for primary angle-closure suspect, 10.122
- Darunavir, 1.266
- DASH (Dietary Approaches to Stop Hypertension) eating plan, 1.66, 1.67*t*
- DAT. *See* Dual antiplatelet therapy
- Data presentation, 1.27–30, 1.28*f*, 1.29*f*
- Database
- monitoring systems and, 1.25–26
 - searching, 1.3
- Database of Genotypes and Phenotypes (dbGaP), 2.134
- Dawn phenomenon, 1.42
- Dawson fingers, 5.67*f*
- Day blindness (hemeralopia), in cone/cone-rod dystrophies, 5.102
- dbGaP (Database of Genotypes and Phenotypes), 2.134
- DC cardioversion. *See* Direct-current (DC) cardioversion
- DCCT (Diabetes Control and Complications Trial), 1.38, 12.96
- DCN (decorin) gene
- in congenital stromal corneal dystrophy, 8.136*t*
 - in posterior amorphous corneal dystrophy, 8.136*t*
- DCR. *See* Dacryocystorhinostomy
- DCs. *See* Dendritic cells
- DDT. *See* Dye disappearance test
- de Morsier syndrome (septo-optic dysplasia), 5.143–144
- Deafness (hearing loss)
- cataract surgery in patient with, 11.170
 - congenital rubella and, 9.203
 - mitochondrial DNA mutations and, 2.157
 - pigmentary retinopathy and. *See* Usher syndrome
 - vestibular nystagmus and, 5.241, 5.241*t*, 5.242
 - Vogt-Koyanagi-Harada syndrome and, 9.176
- Death, sudden cardiac (SCD), 1.95
- premature ventricular complexes and, 1.113
 - ventricular fibrillation and, 1.115
- Debridement
- for *Acanthamoeba* keratitis, 8.278
 - for chemical injuries, 8.383
 - for epithelial defects
 - after LASIK, 13.112
 - after surface ablation, 13.108 - for fungal keratitis, 8.275
 - for herpes simplex epithelial keratitis, 8.219
 - layer-based approach to use of, 8.417*t*
 - for limbal stem cell deficiency, 8.94
 - for recurrent corneal erosions, 8.79, 8.87
 - for surface ablation, 13.82–84, 13.83*f*
 - for thermal injuries, 8.385
- Decadron. *See* Dexamethasone
- Decamethonium, 2.315
- Decentered ablation, 13.104, 13.104*f*
- Decentration/dislocation (IOL), 11.127, 11.144*f*, 11.144–147, 11.146*f*, 11.147*f*
- angle-supported lenses and, 13.146
 - bifocal segments, 3.190–191
 - iris-fixated lenses and, 13.145
 - laser application during photoablation and, 13.91
 - laser capsulotomy and, 11.156
 - multifocal lenses and, 3.258, 11.144, 11.145, 13.155
 - prism correction through, 3.197
- Decompression
- optic canal, for traumatic vision loss, 7.114
 - orbital, 7.121–123, 7.122*f*, 7.123*f*
 - complications of, 7.125
 - for orbital hemorrhage, 7.112
 - for thyroid eye disease, 7.52, 7.58, 7.59, 7.121
 - for traumatic vision loss, 7.113
 - for vision loss after blepharoplasty, 7.233
- Decongestants
- ocular, 2.342–343
 - tear production affected by, 8.62*t*
- Decorin, 8.9
- Decorin (DCN) gene
- in congenital stromal corneal dystrophy, 8.136*t*
 - in posterior amorphous corneal dystrophy, 8.136*t*
- Decreased vision. *See* Low vision; Vision loss/impairment
- Decussation
- cranial nerve III (oculomotor), 2.94
 - cranial nerve IV (trochlear), 2.96
 - optic nerve, 6.43
- Deep anterior lamellar keratoplasty (DALK), 6.263, 6.270, 8.411, 8.412, 8.412*t*, 8.433, 8.434–435
- advantages of, 8.421–422*t*
 - in children, 8.451
 - complications of, 8.435
 - intraoperative, 8.420*t*
 - postoperative, 8.421*t* - disadvantages of, 8.422*t*
 - for herpetic eye disease, 8.225
 - indications for, 8.420*t*
 - for keratoconus, 8.167
 - layer-based approach to use of, 8.417*t*
 - neurotrophic cornea after, 8.80
 - preoperative evaluation/preparation and, 8.418
 - rejection and, 8.411, 8.435, 8.435*f*
- Deep-brain stimulation, for Parkinson disease, 1.199–200
- Deep capillary plexus, 12.16
- Deep cervical fascia, 7.143
- Deep facial fascia, 7.141
- Deep lamellar endothelial keratoplasty (DLEK), 8.412*t*, 8.436, 8.437*t*
- Deep mimetic muscles, 7.141
- Deep petrosal nerve, 2.101*f*, 2.104
- Deep-plane rhytidectomy, 7.245
- Deep stromal neovascularization, 3.232
- Deep superior sulcus deformity, anophthalmic socket and, 7.132–133, 7.133*f*
- Deep temporal artery, 5.15*f*
- Deep temporal fascia, 7.141, 7.142*f*, 7.144
- Deep venous thrombosis, 5.345. *See also* Thrombosis/thrombotic disorders
- anticoagulation therapy in prevention of, 1.142
 - in antiphospholipid antibody syndrome, 1.148, 1.160
- Defense mechanisms
- of external eye, 8.11–14, 8.12–13*f*, 8.13*f*
 - impaired. *See* Immunocompromised host
- Defensins, in tear film, 2.216, 8.6*f*
- Deferoxamine, 12.298–299
- Defibrillation, 1.295, 1.296, 1.298
- Defibrillator-cardioverters, implantable (ICDs). *See* Implantable cardioverter-defibrillators

- Defibrillators
 implanted, laser surgery in patient with, 13.37
 portable, 1.295, 1.298
- Defocus, 3.40, 3.276, 3.276f
- Defocus aberrations, positive and negative, 13.11, 13.11f
- Deformable intraocular lenses, 13.170
- Deformational plagiocephaly, 6.204–205
- Degeneracy, of genetic code, 2.134
- Degenerations, 4.9–10, 4.12t. *See also specific type*
 anterior chamber/trabecular meshwork, 4.100–105,
 4.101f, 4.102f, 4.103f, 4.104f, 4.105f
 cataracts associated with, 11.68
 conjunctival, 4.56f, 4.56–59, 4.57f, 4.58f, 4.59f, 8.111t,
 8.111–114, 8.115t
 corneal, 4.81–86, 4.82f, 4.83f, 4.84f, 4.85f, 4.86f,
 8.115–128. *See also* Corneal degenerations
 dystrophies differentiated from, 8.111, 8.111t
 elastotic (elastosis)
 in pinguecula/pterygium, 4.56f, 4.56–58
 solar, of eyelid, 4.211–212, 4.212f
 eyelid, 4.206f, 4.206–207, 4.207f, 4.207t
 lens, 4.120f, 4.120–124, 4.121f, 4.122f, 4.123f, 4.124f.
See also Cataract
 macular. *See* Macular degeneration
 optic nerve, 4.245f, 4.245–247, 4.246f, 4.247f
 orbital, 4.228
 peripheral cystoid, 4.148, 4.149f
 reticular (RPCD), 4.148, 4.149f
 typical (TPCD), 4.148, 4.149f
 retinal, 4.148–170, 4.171f, 4.172f. *See also* Retinal
 degenerations; Retinal dystrophies
 gene defects causing, 2.265–266
 retinal pigment epithelium defects and, 2.278–279
 scleral, 4.111f, 4.111–112, 4.112f, 8.128, 8.129f
 uveal tract, 4.188, 4.189f
 vitreous, 4.128–135, 4.129f, 4.130f, 4.131f, 4.132f,
 4.133f, 4.134f
- Degenerative retinoschisis, reticular (bullous) and
 typical, 4.148
- Dehiscences, in lamina cribosa, 12.218, 12.218f
- Dehydration, preoperative fasting and, 1.288
- Delayed hypersensitivity (type IV) reaction, 9.40,
 9.41t, 9.44–48, 9.45f, 9.46t. *See also* Delayed
 hypersensitivity (DH) T lymphocytes
 contact dermatoblepharitis/dermatitis as, 8.286,
 8.286f, 8.287
 in graft rejection, 8.316, 8.317
 granulomatous form of, 9.47
 in sympathetic ophthalmia, 9.47–48
 topical medications/substances and, 8.286, 8.286f,
 8.287
 in *Toxocara* granuloma, 9.47
 tuberculin form of, 9.32
- Delayed hypersensitivity (DH) T lymphocytes, 9.38,
 9.39f, 9.45, 9.45f, 9.46t, 9.47–48. *See also* T cells
- Delayed-onset (chronic) postoperative endophthalmitis,
 9.261–263, 9.262f
- Delayed suprachoroidal hemorrhage, after cataract
 surgery, 11.160
- Delayed visual maturation (DVM), 6.186–187
- Deletion 4p, 6.386t
- Deletion 5p, 6.386t
- Deletion 18p, 6.386t
- Deletion 18q, 6.386t
- Deletions, 2.145, 2.148, 2.150, 2.153–154, 2.155, 2.159
 mitochondrial DNA, disorders caused by, 2.157
- Delirium, 1.204
 hallucinations and, 5.173
 postoperative, in older patient, 1.181
- Delivery (birth), difficult, corneal edema caused by,
 8.109
- Dellen, 8.79, 8.92, 8.368
 management of, 8.368
 after strabismus surgery, 6.172, 6.172f
- Delta hepatitis, 1.261
- DEM. *See* Diagnostic electron microscopy
- Demarcation lines
 pigmented, in rhegmatogenous retinal detachment,
 12.324
 in retinopathy of prematurity, 6.328f
 in retinoschisis, 12.328
- Demecarium, 2.312, 2.313
- Demeclocycline, 2.350
- Dementia, 1.204–206
 AIDS-associated (HIV encephalopathy/HIV-
 associated neurocognitive disorder), 1.264, 5.348.
See also HIV infection/AIDS
 Alzheimer (AD), 1.204–206
 cataract surgery in patient with, 11.169–170
 hallucinations and, 5.173
 hypertension and, 1.77
 Lewy body (LBD), 1.204
 surgery in older patients and, 1.181
 treatment of, 1.205–206
 recent developments in, 1.187
 vascular, 1.204
 vitamin B₁₂ deficiency and, 1.138
- Demodex, 6.245, 8.253, 8.254f, 8.254–255, 8.255f
 blepharitis/blepharoconjunctivitis and, 8.72, 8.72f,
 8.73f, 8.253, 8.255
brevis, 8.205, 8.253
folliculorum, 8.205, 8.253
 as normal flora, 8.205, 8.206t, 8.253
 ocular infection caused by, 8.208t, 8.253, 8.254–255,
 8.255f
 rosacea and, 8.69, 8.253
- Demodicosis, 6.245
- Demulcents, 2.341, 8.62–63
- Demyelination/demyelinating disease
 internuclear ophthalmoplegia and, 5.190
 multiple sclerosis, 5.315–320, 5.316f. *See also* Multiple
 sclerosis
 neuroimaging in evaluation of, 5.72t
 neuromyelitis optica and, 5.320–323
 optic nerve involvement/optic neuritis and, 4.244,
 4.244f, 5.114, 5.114f, 5.115, 5.317–318, 12.52
 illusions and, 5.175
 pain in, 5.295–296
- Denaturing gradient gel electrophoresis (DGGE), 2.162
- Dendrites/dendritic keratitis, 4.76, 4.77f, 8.46t
 herpes simplex, 4.76, 4.77f, 8.216–219, 8.218f, 8.226t
 herpes zoster, 8.226, 8.226t, 8.227
- Dendritic cells (DCs), 9.11–12
 in choroidal/ciliary body nevus, 4.191
 conjunctival, 8.13
 corneal, 8.13f, 8.13–14
 in external eye defense, 8.13, 8.13f, 8.13–14
- Denervation and extirpation, 6.164t

- Denervation anisocoria, 5.258t
- Dengue fever, 9.213
- Dense media
images in, 3.12
vergence equation for, 3.12
- Dental diseases, retinal degeneration associated with, 12.286
- Dental procedures, endocarditis prophylaxis and, 1.243t
- Dentate processes
definition of, 12.10
illustration of, 12.11f
- Deorsumduction, 6.33
- Deorsumduction/deorsumversion. *See* Depression of eye
- Deorsumversion, 6.37
- Deoxyribonucleic acid. *See* DNA
- Dependence (drug), 1.192
- Depigmentation, bull's-eye. *See also* Bull's-eye maculopathy/depigmentation
in cone dystrophy, 5.102
- Depo-Medrol. *See* Methylprednisolone
- Depolarizing neuromuscular blocking agents, 2.315
- Depot injections, corticosteroid
for pars planitis, 9.130
for uveitis, 9.96
- Depression (mood disorder), 1.189–190
drugs for (antidepressants), 1.195–197, 1.196t
ocular effects of, 1.307t
masked, 1.183
in older patients, 1.182–183, 1.190
screening for, 1.183, 1.190
in Parkinson disease, 1.199
- Depression (perimetry), generalized, in glaucoma, 10.69
- Depression of eye (downgaze), 6.33, 6.38
disorders/limitation of, 5.228–229
in newborn, 5.230–231
in orbital floor/blowout fracture, 7.108
surgery and, 7.110
extraocular muscles controlling, 5.36f, 5.49f
inferior rectus muscle, 5.36f, 5.46f
superior oblique muscle, 5.36f, 5.46f
ptosis exacerbation in, 7.209
ptotic eyelid position in, 7.211, 7.214t
- Depressor anguli oris muscle, 7.143, 7.143f
- Depressor labii inferioris muscle, 7.143, 7.143f
- Depressor septi muscle, 7.143f
- Deprivation amblyopia, 6.55, 6.379
- Depth of field
in camera obscura, 3.5, 3.5f
definition of, 3.40, 3.57, 3.58f
reduced, 3.8f
- Depth of focus, definition of, 3.40, 3.57, 3.58f
- Depth perception, stereopsis versus, 6.43
- Dermal appendages, of eyelid, neoplasms of, 4.214–218, 4.215f, 4.216f, 4.217f
- Dermal fillers, in facial rejuvenation, 7.239f, 7.239–240, 7.240f
- Dermal melanocytosis, 8.339
- Dermal/dermal orbital/oculodermal (nevus of Ota)
melanocytosis, 4.63t, 4.64, 7.175, 7.175f
glaucoma associated with, 10.30
of iris, 4.259
- Dermal (intradermal) nevus, 4.219, 4.220f, 7.173
- Dermal orbital melanocytosis. *See* Dermal/dermal orbital/oculodermal (nevus of Ota) melanocytosis
- Dermatan sulfate
in cornea, 2.226, 8.9
in mucopolysaccharidoses, 8.175t
- Dermatitis. *See also* Dermatoblepharitis
 α -agonists causing, 10.178, 10.178f
atopic, 8.287
atopic keratoconjunctivitis and, 8.292
cataracts associated with, 11.66
eyelid involvement and, 8.287
vernal keratoconjunctivitis and, 8.289
contact, eyelid involvement and, 8.285–287, 8.286f
zoster, 8.227, 8.229
- Dermatoblepharitis, 8.208t
contact, 8.285–287, 8.286f
herpes simplex virus causing, 8.208t, 8.213, 8.214f, 8.216
varicella-zoster virus causing, 8.208t, 8.225–230, 8.226t. *See also* Herpes zoster ophthalmicus
- Dermatochalasis, 7.218, 7.218f, 7.229f, 7.229–230
brow ptosis and, 7.229, 7.234, 7.235
pseudoptosis and, 7.218, 7.218f
ptosis and, 7.229, 7.229f
- Dermatologic disorders. *See* Skin, disorders of
- Dermatomyositis, 1.163–164, 1.164f
eyelid manifestations of, 4.207t
- Dermis, eyelid, 4.201, 4.201f
neoplasms of, 4.214, 4.215f
- Dermis-fat grafts, 7.132
in children, 7.129
in congenital anophthalmia/microphthalmia
management, 7.36
for exposure and extrusion of orbital implant, 7.134
for superior sulcus deformity, 7.132–133
- Dermoid cysts, 6.223–224, 224f
- Dermoids (dermoid cysts/tumors), 4.6, 4.47, 4.49f
congenital, 4.203
conjunctival, 4.47, 4.49f
corneal, 4.73, 8.196
epibulbar/limbal, 4.6, 4.47, 4.49f
of eyelid, congenital, 4.203
Goldenhar syndrome and, 4.47
limbal, Goldenhar-Gorlin syndrome and, 8.195, 8.195f
orbital, 4.223, 4.224f, 7.39f, 7.39–40
- Dermolipomas (lipodermoids), 4.47–48, 4.48f
in children, 6.210, 6.256–257
Goldenhar syndrome and, 4.48
of orbit, 7.40, 7.41f
- Dermopathy, infiltrative (pretibial myxedema),
hyperthyroidism/thyroid eye disease and, 1.53, 7.56
- Derry disease, 6.389t
- DES. *See* Drug-eluting stents
- Descemet membrane/layer, 2.41, 2.42f, 2.223f, 2.227, 4.73, 4.74f, 8.7f, 8.9
age-related changes in, 8.115
anatomy of, 2.41, 2.42f, 2.223f, 8.7f, 8.9
biochemistry and metabolism of, 2.227
breaks in
description of, 6.260
in primary congenital glaucoma, 6.280, 6.280f
traumatic, 6.262, 6.262f

- chalcosis findings in, 12.362
 in congenital hereditary endothelial dystrophy, 8.160
 in congenital stromal corneal dystrophy, 8.152
 copper deposits/Kayser-Fleischer ring and, 8.118*t*,
 8.173, 8.189, 8.189*f*
 deposits in/pigmentation of, 8.118*t*, 8.132
 in Wilson disease, 8.189, 8.189*f*
 detachment of
 after cataract surgery, 11.131
 after deep anterior lamellar keratoplasty, 8.435
 development of, 2.41, 2.116*t*, 2.120–121, 2.121*f*
 folds in, 8.41–42
 in Fuchs endothelial corneal dystrophy, 4.92, 4.93*f*,
 8.156, 8.157
 guttae in, 2.41
 in Fuchs dystrophy, 2.43*f*
 in luetic keratitis, 4.80
 healing/repair of, 4.16
 in macular dystrophy, 8.150
 in posterior amorphous corneal dystrophy, 8.154,
 8.154*f*, 8.155
 in posterior polymorphous corneal dystrophy, 4.93,
 4.94*f*, 8.158
 rupture of/tears in, 4.17, 4.18*f*
 birth trauma and, 8.109, 8.389*f*
 after deep anterior lamellar keratoplasty, 8.435
 infantile corneal opacities and, 6.254
 in keratoconus, 4.17, 4.18*f*, 4.95*f*, 4.96, 8.163–164,
 8.164*f*
 in keratoglobus, 8.171
 ocular trauma and, 4.17, 4.18*f*, 8.388, 8.389*f*
 Descemet membrane endothelial keratoplasty (DMEK),
 8.412, 8.412*t*, 8.436, 8.436*t*, 8.437*t*
 advantages of, 8.421–422*t*, 8.438
 cataract surgery and, 8.446–447
 complications of, 8.437*t*
 intraoperative, 8.420–421*t*, 8.440
 postoperative, 8.421*t*, 8.440–449
 disadvantages of, 8.422*t*, 8.438–440
 endothelial cell loss after, 8.448–449
 for Fuchs endothelial corneal dystrophy, 4.92, 4.93*f*
 graft dislocation/decentration after, 8.442*f*,
 8.442–443, 8.443*f*
 hemi, 8.449–450
 indications for, 8.420*t*
 primary graft failure and, 8.447
 pupillary block after, 8.444*f*, 8.444–445
 rejection and, 8.437*t*, 8.448
 results, 8.437*t*
 visual acuity after, 8.438–440
 Descemet membrane endothelial transfer (DMET), 8.449
 Descemet stripping/Descemet stripping automated
 endothelial keratoplasty (DSEK/DSAEK), 8.412,
 8.412*t*, 8.436, 8.436*t*, 8.437*t*
 advantages of, 8.421–422*t*, 8.438, 8.439*f*
 cataract formation and, 11.56
 cataract surgery and, 8.446–447
 complications of, 8.437*t*
 intraoperative, 8.420–421*t*, 8.440, 8.441*f*
 postoperative, 8.421*t*, 8.440–449
 disadvantages of, 8.422*t*, 8.438–440
 endothelial cell loss after, 8.448–449
 epithelial ingrowth after, 8.445, 8.445*f*
 graft dislocation/decentration and, 8.441, 8.442*f*
 graft failure and, 4.85*f*, 8.447
 indications for, 8.420*t*
 primary graft failure and, 8.447
 pupillary block after, 8.444*f*, 8.444–445
 rejection and, 8.437*t*, 8.447, 8.447*f*
 results of, 8.437*t*
 visual acuity after, 8.438–440
 Descemetocoele, management of, 8.369
 lamellar keratoplasty for, 8.433, 8.433*f*
 Descemetorrhexis
 in DMET, 8.449
 in DSEK, 8.436
 for Fuchs endothelial corneal dystrophy, 8.157–158,
 8.449
 Descending optic atrophy, 4.246
 Desmin, in immunohistochemistry, 4.33
 Desmoid tumors, 6.222
 Desmosomes, in corneal epithelium, 2.40
 Destructive interference, 3.100, 3.119
 Deutan red-green color deficiency, 12.54
 Deuteranopia (deutan defects), ocular findings in
 carriers of, 2.199*t*
 Deuteroanomalous dichromatism, 12.250*t*
 Deuteroanomalous trichromatism, 12.250*t*
 Developmental defects. *See also* Congenital anomalies;
 specific type
 of lens, 11.39–42, 11.40*f*
 of orbit, 7.35–41, 7.37*f*, 7.38*f*, 7.39*f*, 7.41*f*
 Developmental glaucomas, 10.153–156. *See also*
 Glaucoma, pediatric
 Developmental hyperopia, 3.143
 Developmental myopia, 3.142–143, 3.174
 Deviation maps, 10.65, 10.65*f*
 Deviations, 5.230–231. *See also* Esodeviations;
 Exodeviations; Horizontal deviations; Strabismus;
 Vertical deviations; *specific type*
 comitant (concomitant), 5.183, 5.184, 5.186
 definition of, 6.16
 in infantile esotropia, 6.88
 esodeviations
 accommodative, 6.90. *See also* Accommodative
 esotropia
 definition of, 6.85
 in divergence insufficiency, 6.94
 epidemiology of, 6.85
 extraocular muscle surgery amounts for, 6.160,
 6.160*t*
 risk factors for, 6.85
 types of, 6.86*t*
 exodeviations
 control of, 6.100
 convergence insufficiency, 6.103
 definition of, 6.99
 exotropia. *See* Exotropia
 extraocular muscle surgery amounts for, 6.160,
 6.161*t*
 latent, 6.99
 manifest, 6.99
 risk factors for, 6.99
 head tilt and, 5.185
 incomitant (noncomitant), 5.183, 5.184, 5.187, 6.16.
 See also specific type

- primary, 6.38
- secondary, 6.39
- seizure activity and, 1.203, 5.230
- skew. *See* Skew deviation
- strabismic amblyopia and, 6.46–47
- terminology used to describe, 6.15–16
- tonic, 5.230–231
 - in gaze preference, 5.228
- variations in size of, 6.16
- vertical. *See* Vertical deviations
- Devic disease (neuromyelitis optica/NMO), 5.107*t*, 5.116–118, 5.117*t*, 5.320–323
 - clinical presentation of, 5.320–322
 - diagnosis of, 5.322–323
 - treatment of, 5.323
- Dexacidin. *See* Dexamethasone, in combination preparations
- Dexamethasone, 1.171*t*, 2.300*t*, 2.302, 2.330*t*
 - anti-inflammatory potency of, 1.171*t*, 2.333*t*
 - in combination preparations, 2.348*t*
 - for corneal graft rejection
 - prophylaxis, 8.430
 - treatment, 8.430
 - elevated intraocular pressure after photoablation
 - associated with, 13.105
 - intravenous administration of, 2.301
 - for nonspecific orbital inflammation, 7.65
 - pressure-elevating potency of, 2.332, 2.333*t*
 - for toxoplasmosis, 6.410
 - for uveitis, 9.98
 - cystoid macular edema and, 9.289
 - for vernal keratoconjunctivitis, 8.291
- Dexamethasone implant, 2.300*t*, 2.302
 - complications of, 12.404
 - retinal vein occlusion treated with, 12.137
 - for uveitis, 9.98
- Dexasporin. *See* Dexamethasone, in combination preparations
- Dextran, in artificial tears, 2.341
- Dextrocycloversion, 6.38
- Dextroversion, 6.37
- DFP. *See* Diisopropyl phosphorofluoridate
- DGGE. *See* Denaturing gradient gel electrophoresis
- DH. *See* Delayed hypersensitivity (type IV) reaction
- DHA. *See* Docosahexaenoic acid
- DHD. *See* Dissociated horizontal deviation
- DI. *See* Divergence insufficiency/paralysis
- Diabetes Control and Complications Trial (DCCT), 1.38, 12.96
- Diabetes insipidus, diabetes mellitus, optic atrophy, and deafness (DIDMOAD/Wolfram) syndrome, 6.408–409
- pleiotropism in, 2.196
- Diabetes mellitus (DM), 1.33–50, 6.408–409. *See also* under *Diabetic*
 - antipsychotic drug use and, 1.187
 - aqueous humor glucose and, 2.232
 - asteroid hyalosis and, 12.346
 - cataract surgery in, 12.116, 12.117–120*t*
 - cataracts associated with, 2.232, 2.246–247, 11.19, 11.60*f*, 11.60–61
 - carbohydrate (“sugar”), 2.246–248
 - aldose reductase in development of, 2.247*f*, 2.247–248, 11.19
 - surgery for, 11.170
 - preoperative evaluation and, 11.80–81
 - classification of, 1.35–37
 - clinical presentation of, 1.37
 - complications of, 1.47–50
 - acute, 1.47–48
 - glucose control affecting, 1.38–39, 1.39*f*, 1.49. *See also* Diabetes mellitus (DM), glucose surveillance (glycemic control) and
 - long-term, 1.48–49
 - ophthalmic, 1.49–50. *See also* Diabetes mellitus (DM), cataracts associated with; Diabetic macular edema; Diabetic retinopathy
 - corneal changes in, 4.159, 8.173, 8.199–200
 - neurotrophic keratopathy/persistent corneal defects and, 8.81, 8.81*t*, 8.199
 - definition/diagnosis of/screening for, 1.34–35, 1.35*t*
 - Diabetes Control and Complications Trial, 12.96
 - diet/exercise in prevention/management of, 1.38, 1.40–41, 1.43, 1.44*f*
 - gestational, 1.36–37
 - glaucoma and, 10.83
 - glucose metabolism and, 1.33–34
 - glucose surveillance (glycemic control) and
 - importance of, 1.38–39, 1.39*f*, 1.49–50
 - management and, 1.39–40
 - prevention and, 1.38–39, 1.39*f*
 - retinopathy incidence and progression affected by, 1.38, 1.39*f*
 - Diabetes Control and Complications Trial, 1.38, 1.39*f*
 - United Kingdom Prospective Diabetes Study, 1.38
 - hypertension/hypertension management and, 1.48, 1.49, 1.66, 1.69*t*, 1.75
 - incidence/prevalence of, 1.33
 - insulin-dependent, 12.91
 - insulin therapy for, 1.41*t*, 1.41–43
 - latent autoimmune in adults (LADA), 1.36
 - management of, 1.39–47
 - recent developments in, 1.46–47
 - metabolic syndrome and, 1.37
 - non–insulin-dependent, 12.91
 - ophthalmic considerations and, 1.49–50. *See also* Diabetes mellitus (DM), cataracts associated with; Diabetic macular edema; Diabetic retinopathy
 - ophthalmic examinations for, 12.93–94, 12.95*t*
 - oral agents for, 1.43–46, 1.44*f*, 1.45*t*. *See also* Oral hypoglycemic agents
 - pancreatic transplantation for, 1.47
 - plasma glucose levels in, 1.34
 - prediabetic disorders and, 1.37
 - prevention of, 1.37–39, 1.39*f*
 - refractive surgery in patient with, 13.37, 13.190–191
 - retinal vein occlusion risks, 12.128
 - retinopathy of. *See* Diabetic retinopathy
 - surgical considerations in patient with, 1.287
 - type 1 (insulin-dependent/IDDM/juvenile-onset), 1.35–36, 12.91
 - insulin therapy for, 1.41*t*, 1.41–43
 - type 2 (non–insulin-dependent/NIDDM/adult-onset), 1.36–37, 12.91
 - insulin therapy for, 1.41, 1.42, 1.43, 1.44*f*

- mitochondrial DNA mutations and, 2.157
- oral agents for, 1.43–46, 1.44*f*, 1.45*t*
- United Kingdom Prospective Diabetes Study, 12.96–97
- Diabetes Prevention Program, 1.38
- Diabetic keratopathy, refractive surgery in patient with, 13.190
- Diabetic ketoacidosis (DKA), 1.34, 1.47–48
- infusion failure and, 1.42
- Diabetic macular edema (DME)
 - cataract surgery and, 11.80, 11.189, 12.116
 - center-involved, 12.92, 12.109, 12.110*f*
 - classification of, 12.109–110, 12.110*f*
 - clinically significant (CSME), 12.92, 12.110, 12.114
 - contrast sensitivity issues in, 12.56
 - definition of, 12.92
 - focal, 12.110
 - mechanism of, 12.108, 12.109*f*
 - non-center-involved, 12.109, 12.111*f*
 - optical coherence tomography of, 12.111*f*
 - spectral-domain optical coherence tomography of, 12.109*f*, 12.125
 - treatment of
 - afibercept, 12.113
 - anti-VEGF therapy, 12.101, 12.110, 12.111–113
 - bevacizumab, 12.113
 - corticosteroids, 12.113–114
 - Diabetic Retinopathy Clinical Research Network findings, 12.112*f*, 12.113
 - intravitreal steroids, 12.101
 - laser surgery, 12.114–115, 12.376
 - overview of, 12.110–111
 - pars plana vitrectomy, 12.115
 - pharmacologic treatment, corticosteroid route of administration in, 2.333*t*
 - ranibizumab, 12.111–112, 12.112*f*
 - surgery, 12.114–115, 12.388
 - vitrectomy, 12.388
 - vision loss caused by, 12.94
- Diabetic nephropathy, 1.48, 12.98
- glycemic control affecting, 1.38, 1.48
- Diabetic neuropathy, 1.48–49
- glycemic control affecting, 1.38
- neurotrophic keratopathy/persistent corneal defects and, 8.81, 8.81*t*, 8.199
- Diabetic papillopathy, 5.125, 5.125*f*
- Diabetic retinopathy, 4.155*f*, 4.159–160, 4.160*f*, 4.161*f*, 6.408–409
- anemia and, 12.98
- aspirin and, 12.100
- background. *See* Diabetic retinopathy, nonproliferative
- cataract surgery and, 11.80–81, 11.189
- cotton-wool spots associated with, 12.140–141
- description of, 12.91
- diabetic nephropathy associated with, 12.98
- epidemiology of, 12.92–93
- 4:2:1 rule for, 12.99
- glycemic control affecting, 1.38, 1.39*f*, 1.89, 12.96–98
 - Diabetes Control and Complications Trial, 1.38, 1.39*f*
 - United Kingdom Prospective Diabetes Study, 1.38
- hemoglobin A_{1c} levels in, 12.96, 12.98
- iris neovascularization and, 4.159, 4.160*f*
- ischemic heart disease and, 1.116
- medical management of, 12.96–98
- neurotrophic keratopathy/persistent corneal epithelial defect and, 8.81, 8.81*t*
- nonproliferative (NPDR/background). *See also* Diabetic macular edema
 - anti-VEGF therapy for, 12.101–102
 - clinical findings in, 12.99
 - definition of, 12.91
 - intraretinal hemorrhages associated with, 12.100*f*
 - intraretinal microvascular abnormalities in, 12.100*f*
 - microaneurysms associated with, 12.100*f*
 - optical coherence tomography angiography of, 12.94*f*
 - panretinal photocoagulation for, 12.101
 - posterior vitreous detachment creation for, 12.102
 - progression of, to proliferative diabetic retinopathy, 12.101
 - ranibizumab for, 12.102
 - scatter photocoagulation for, 12.116
 - severity of, 12.95*t*, 12.99
 - treatment of, 12.101–102
 - venous beading associated with, 12.100*f*
 - vision loss in, 12.101
- ophthalmic examinations for, 12.93–94, 12.95*t*
- papillopathy and, 5.125
- pathogenesis of, 12.93
- photocoagulation for, 4.160, 4.161*f*
- pregnancy-related progression of, 12.93–94
- progression of
 - fenofibrate effects on, 12.102
 - hypertension as risk factor for, 12.98
 - pregnancy-related, 12.93–94
- proliferative (PDR)
 - anti-VEGF therapy for, 12.103–104, 12.386
 - complications of, 12.103–108
 - definition of, 12.91–92
 - extraretinal fibrovascular proliferation associated with, 12.102
 - high-risk characteristics of, 12.103
 - laser surgery for, 12.104–107
 - management of, 12.103–108
 - neovascular proliferation associated with, 12.102
 - neovascularization in, 12.151
 - nonproliferative diabetic retinopathy progression to, 12.101
 - nonsurgical management of, 12.103–104
 - optical coherence tomography angiography of, 12.94*f*
 - panretinal photocoagulation for, 12.104, 12.106, 12.106*f*
 - photocoagulation for, 12.94
 - in pregnancy, 12.94
 - proangiogenic factors in, 12.102
 - proliferative sickle cell retinopathy versus, 12.151
 - ranibizumab for, 12.104
 - scatter photocoagulation for, 12.116
 - severe carotid artery occlusive disease associated with, 12.98
 - severity of, 12.95*t*
 - stages of, 12.102
 - steroids for, 12.103–104

- surgical management of, 12.104–107
- tractional retinal detachment caused by, 12.103, 12.108, 12.387–388
- vitreous hemorrhage caused by, 12.103, 12.103f, 12.107–108, 12.386–387
- refractive surgery in patient with, 13.190
- retinal capillary nonperfusion associated with, 12.101
- severity of, 12.95t, 12.101
- statin use affecting, 1.89
- studies of
 - Diabetes Control and Complications Trial, 12.96
 - Early Treatment Diabetic Retinopathy Study, 12.99–101
 - United Kingdom Prospective Diabetes Study, 12.96–97
- systemic medical management of, 12.96–98
- terminology associated with, 12.91–92
- vision loss from
 - abnormalities associated with, 12.98
 - lipid levels and, 12.98
 - mechanisms of, 12.101
- Diabetic Retinopathy Clinical Research Network
 - cataract surgery in diabetes mellitus studies, 12.116, 12.117–120t
 - diabetic macular edema treatment, 12.112f, 12.113
- Diabetic Retinopathy Study (DRS), 12.104–105
- Diacylglycerol (DAG), in tear secretion, 2.218, 2.218f
- Diagnostic agents, 2.367–368
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* (DSM-5), 1.182, 1.190, 1.191
- Diagnostic electron microscopy (DEM), 4.34t, 4.42
- Diagnostic positions of gaze, 6.64
- Diagnostic/screening tests. *See* Screening/diagnostic tests
- Diagnostic ultrasonography. *See* Ultrasonography/ultrasound (echography)
- Dialyses
 - anemia and, 1.137
 - description of, 4.19–20, 4.20f
- Diameter
 - of contact lenses, 3.205, 3.215f, 3.216
 - of pupil, 3.105
- Diamidines, for *Acanthamoeba* keratitis, 8.278
- 3,4-Diaminopyridine. *See* Amifampridine
- Diamox. *See* Acetazolamide
- “Diaphragm pattern,” 5.170
- Diaphragm pump, for phacoemulsification aspiration, 11.103, 11.104f
- Diarrhea
 - antibiotic-associated, 1.244
 - in HIV infection/AIDS, 1.269
- Diastole (diastolic phase), 1.108
- Diastolic dysfunction, 1.108
 - causes of, 1.109
 - management of, 1.110
- Diathermy, for hyphema, 8.396
- Diazepam, 1.195
 - for medical emergencies/seizures, 1.296t
 - perioperative, 1.290–291
- Diazoxide, for hypertensive emergency, 1.74
- Dibromopropamide, for *Acanthamoeba* keratitis, 2.361
- DIC. *See* Disseminated intravascular coagulation
- DICER1* gene mutation, in medulloepithelioma, 4.179
- Dichlorophenamide, 2.326
- Dichromacy, 12.250
- Diclofenac, 2.330t, 2.335t, 2.336, 9.94
- Dicloxacillin, 2.344
- Dideoxyinosine, 12.299
- DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness/Wolfram) syndrome, pleiotropism in, 2.196, 6.408–409
- Dieffenbachia* keratitis, 8.387
- Diencephalic syndrome, acute, 5.117t
- Diet/diet therapy
 - cancer and, 1.213
 - cardiovascular disease risk modification and, 1.83t, 1.85
 - in diabetes mellitus prevention/management, 1.38, 1.40–41, 1.43, 1.44f
 - for dry eye, 8.61t, 8.64, 8.68
 - in hypercholesterolemia management, 1.83t, 1.85
 - in hypertension management, 1.64t, 1.65, 1.66, 1.67t
 - in inborn errors of metabolism, 2.203
 - retinopathy of prematurity and, 12.184–185
 - in vitamin A deficiency, 8.196, 8.197
- Dietary Approaches to Stop Hypertension (DASH) eating plan, 1.66, 1.67t
- Diethylcarbamazine
 - for loiasis, 8.282
 - uveitis caused by, 9.121
- Difference map, after keratorefractive surgery, 13.23, 13.23f
- Diffraction of light, 3.91, 3.104–106, 3.105f
- Diffraction multifocal intraocular lenses, 3.259f, 3.259–260, 13.166, 13.166f
- Diffuse anterior scleritis, 8.320, 8.320f, 8.320t, 8.321f, 8.325f
- Diffuse choroidal hemangioma, 4.197, 4.198f, 4.281–283, 4.283f
- Diffuse corneal transparency disorders, 6.257–258t, 6.257–263, 6.258f
- Diffuse drusen, 4.160, 4.161f
- Diffuse illumination, for slit-lamp biomicroscopy, 8.16, 8.17f
- Diffuse infiltrative retinoblastoma, 6.353
- Diffuse injection (simple) episcleritis, 4.109, 8.318
- Diffuse iris nevus, 4.255, 4.256f
- Diffuse lamellar keratitis (DLK), after LASIK, 13.116f, 13.116–117, 13.117t
 - infectious keratitis differentiated from, 13.117–118, 13.118f, 13.118t
 - pressure-induced stromal keratopathy differentiated from, 13.119
- Diffuse macular edema, 12.110, 12.111f
- Diffuse neonatal hemangiomatosis, 6.220
- Diffuse photoreceptor dystrophies, 4.170, 4.172f. *See also* Cone dystrophies/degenerations; Cone-rod dystrophies/degenerations; Retinitis pigmentosa
- Diffuse soft-tissue histiocytosis, 6.219, 7.90
- Diffuse superficial keratitis, 6.242
- Diffuse toxic goiter, 1.53. *See also* Graves hyperthyroidism/ophthalmopathy/eye disease
- Diffuse unilateral subacute neuroretinitis (DUSN), 9.232–234, 9.233f, 12.246
- Diffuse uveitis. *See* Panuveitis

- Diffusion
 - in aqueous humor dynamics/formation, 2.230, 10.16
 - glucose transport into lens and, 11.17
- Diffusion-weighted magnetic resonance imaging (DWI), 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.72*t*, 5.75
 - in cerebral ischemia detection/evaluation, 5.167, 5.168
 - in cerebral ischemia/stroke, 1.122
- Diflucan. *See* Fluconazole
- Diflunisal, 2.335*t*
- Difluprednate, 2.330*t*
 - for corneal graft rejection prophylaxis, 8.430
 - for uveitis, 9.95
 - ocular hypertension/glaucoma and, 9.286
- Digenic inheritance, 2.134
- Digital eversion test, for cicatricial entropion, 7.206
- Digital polymerase chain reaction (dPCR), 2.141
- Digital pressure, for intraocular pressure estimation, 10.26
- Digital rectal exam, in cancer screening, 1.210*t*
- Digital resolution, of scanning laser ophthalmoscopy, 12.24
- Digital subtraction angiography (DSA), 5.68
 - in arterial dissection, 5.342
- Digitalis/digitoxin/digoxin
 - for heart failure, 1.110
 - ocular effects of, 1.117, 1.308*t*, 5.175
 - in perioperative setting, 1.285
 - for rate control in atrial fibrillation, 1.114
 - visual changes caused by, 5.175
 - xanthopsia caused by, 12.305
- Dihydropyridine calcium channel blockers, for hypertension, 1.68*t*, 1.72
- Diisopropyl phosphorofluoridate (DFP), 2.312, 2.313
- Diktyoma (medulloepithelioma), 4.178*f*, 4.178–179, 4.296*f*, 4.296–297
 - retinoblastoma differentiated from, 4.296*f*, 4.296–297
 - teratoid, 4.179
- Dilated fundus examination, before refractive surgery, 13.44
- Dilator muscle (iris), 2.53*f*, 2.55–56, 4.182
 - α -adrenergic agents affecting, 2.55, 2.317–318, 2.320
 - development of, 2.55, 2.116*t*, 2.122
 - in Horner syndrome, 5.258
 - innervation of, 5.53, 5.54
 - muscarinic agents affecting, 2.313
 - tadpole pupil caused by spasm of, 5.255
- Diltiazem
 - for arrhythmias, 1.113*t*
 - for hypertension, 1.68*t*
 - for non-ST-segment elevation acute coronary syndrome, 1.103
- Dimethyl fumarate, for multiple sclerosis, 5.321*t*
- Dimorphic fungi, 8.249
- Dinucleotide repeats, 2.139
- Diode laser. *See also* Lasers
 - for choroidal/ciliary body melanoma, 4.276
 - for cyclodestruction, 10.194, 10.195–196
 - in children, 10.163
 - for retinoblastoma, 4.300
 - for trabeculoplasty, 10.189–190
- Diopter (D), 8.3, 8.8, 8.26, 8.27, 13.7
 - definition of, 3.40, 3.51
 - prism, 3.46, 3.47*f*
 - values for, 3.52*t*
- Dioptric power, 8.3, 8.8. *See also* Diopter; Power (optical)
 - of bifocal segments, 3.190
- Dipeptidyl-peptidase IV (DPP-IV), 1.46
- Dipeptidyl-peptidase IV (DPP-IV) inhibitors, for diabetes mellitus, 1.45*t*, 1.46–47
- Diphenhydramine, for allergic reactions/medical emergencies, 1.296*t*, 1.302
- Diphtheria, immunization against, 1.218*t*
- Diphtheria and tetanus toxoid with acellular pertussis vaccine (DTaP), 1.222
- Diphtheria-tetanus-pertussis vaccine (DTP),
 - replacement of, with diphtheria and tetanus toxoid with acellular pertussis vaccine (DTaP), 1.222
- Diphtheroids, 8.246
 - as normal flora, 8.205, 8.206*t*, 8.246
- Dipivefrin (dipivalyl epinephrine/DPE), 2.318*t*
 - for glaucoma, 10.177
- Diploid/diploid number, 2.134, 2.149
- Diplopia, 5.183–209
 - binocular, 5.183
 - after blepharoplasty, 7.234
 - in Brown syndrome, 5.208
 - carotid-cavernous fistula causing, 5.203–206, 5.204*f*, 5.205*f*
 - after cataract surgery, 5.207
 - cavernous sinus/superior orbital fissure lesions causing, 5.202–206, 5.204*f*, 5.205*f*
 - cerebral, 5.185
 - comitant deviations and, 5.183, 5.184, 5.186
 - cranial nerve palsies causing, 5.192, 5.193*f*, 5.193–201, 5.194*f*, 5.196*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.202
 - multiple nerve involvement and, 5.202
 - crossed, 6.75
 - description of, 6.47–48
 - esotropia and, 6.102
 - extraocular muscle surgery as cause of, 6.168
 - fixation switch, 5.209
 - fourth nerve (trochlear) palsy causing, 5.185, 5.186, 5.188–189, 5.198–200, 5.199*f*
 - in foveal displacement syndrome, 5.209
 - in heavy eye syndrome, 5.208
 - heteronymous, 6.75
 - history in, 5.183
 - homonymous, 6.75
 - incomitant deviations and, 5.183, 5.184, 5.187
 - infranuclear causes of, 5.191–206, 5.193*f*, 5.194*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.204*f*
 - internuclear causes of, 5.189–191, 5.190*f*, 5.191*f*
 - after LASIK, 13.125
 - in amblyopia patient, 13.186
 - localization of lesions causing, 5.187*f*, 5.187–188
 - monocular, 5.174, 5.185
 - in cataracts, 11.43–44, 11.45, 11.47, 11.70–71
 - in multiple sclerosis, 5.318
 - in myasthenia gravis, 5.192, 5.206, 5.324
 - myopathic/restrictive/orbital causes of, 5.186, 5.206–209, 5.207*f*
 - neuroimaging in evaluation of, 5.73*f*

- neuromuscular junction causes of, 5.206
- neuromyotonia causing, 5.202
- nuclear causes of, 5.188–189
- one-and-a-half syndrome and, 5.191, 5.191f
- in orbital floor/blowout fracture, 5.206, 6.127–128, 7.108
 - surgery and, 7.110, 7.111
- orbital myositis causing, 5.207f, 5.207–208
- orbital neoplasia causing, 5.208
- in orbital roof fractures, 7.106
- paradoxical, 6.50, 6.50f
- paretic syndromes causing, 5.186
 - multiple cranial nerve involvement and, 5.202
 - restrictive syndromes differentiated from, 5.186, 5.186f
- physical examination in, 5.184f, 5.184–185, 5.185f
- physiologic, 6.48
- postoperative, 5.207, 5.209, 6.168
- posttraumatic, 5.186, 5.206
- press-on prisms for, 6.96
- prisms for, 6.72
- red-glass test for, 6.75
- refractive procedure–induced, 5.209
- restrictive syndromes causing, 5.186, 5.206–209, 5.207f
 - paretic syndromes differentiated from, 5.186, 5.186f
 - postsurgical, 5.207
 - posttraumatic, 5.186, 5.206
- in sagging eye syndrome, 5.209
- in sixth nerve palsy, 6.96
- sixth nerve (abducens) palsy causing, 5.200f, 5.200–201
- in superior oblique myokymia, 5.250, 5.251
- suppression of, 6.49f
- supranuclear causes of, 5.188, 5.188t
- testing for, 6.75
- third nerve (oculomotor) palsy causing, 5.188, 5.191, 5.193f, 5.193–198, 5.194f, 5.196f, 5.198f, 6.139
- in thyroid eye disease, 5.186, 5.206, 6.140–141, 7.56, 7.58, 7.59
- Tolosa-Hunt syndrome and, 5.203
- uncrossed, 6.75
- vergence dysfunction causing. *See* Vergences/vergence system
- vertebrobasilar insufficiency causing, 5.337, 5.337f
- Dipping pattern, blood pressure, 1.62, 1.77
- Dipyridamole
 - for carotid artery disease/stenosis, 1.126
 - for cerebral ischemia/stroke, 1.123
 - for transient monocular visual loss, 1.168
- Diquafosal, 2.342
- Direct carotid-cavernous fistula, 7.72–73
- Direct-current (DC) cardioversion
 - for atrial fibrillation, 1.114
 - for ventricular fibrillation, 1.115
- Direct illumination, 3.292
- Direct ophthalmoscope/ophthalmoscopy. *See also* Ophthalmoscope/ophthalmoscopy, direct
 - applications of, 3.297–298f, 3.297–298, 3.307
 - definition of, 3.281
 - limitations of, 12.21
 - retinal disease evaluations using, 12.21
- Direct renin inhibitors (DRIs), for hypertension, 1.68t, 1.74
- Direct response, in pupillary reaction to light, 5.254
- Direct sequencing, 2.161–162, 2.162f, 2.163f, 2.164f, 2.165f, 2.166f
- Direct thrombin inhibitors, 1.148
 - for cerebrovascular disease/atrial fibrillation, 1.119
 - for non–ST-segment elevation acute coronary syndrome, 1.103
- Direct-to-consumer genetic testing, 2.134
- Direct traumatic optic neuropathy, 5.139, 5.139f
- Direct visualization, in ophthalmic examination, 8.15–20, 8.16f, 8.17f, 8.18f, 8.19f, 8.20f. *See also* Slit-lamp biomicroscopy/examination
- Directly observed therapy (DOT), for tuberculosis, 9.255
- “Disc at risk,” 5.121f, 5.122
- Disc edema. *See* Optic nerve head (ONH/optic disc), edema of
- Disciform keratitis (endotheliitis), 8.51f
 - CMV causing, 8.232, 8.232f
 - herpes simplex virus causing, 4.77f, 4.78, 8.220, 8.221f, 8.222
 - persistent bullous keratopathy and, 8.225
- Discoid systemic lupus erythematosus, 1.157, 9.133
- Disconjugate eye movements (vergences), 5.212, 5.212t, 5.226–228. *See also* specific type
 - dysfunction of, 5.227–228
- Disconjugate (dissociated) nystagmus, 5.234, 5.247
- Disconnection syndromes, 5.178
- “Discontinuation syndrome,” with SSRIs, 1.197
- Discontinuity, lamellar/optic zones of, 2.64
- Disease-modifying antirheumatic drugs (DMARDs), for rheumatoid arthritis, 1.152
- Disease-modifying therapy (DMT), for multiple sclerosis, 5.320, 5.321t
 - neuromyelitis optica and, 5.323
- Disease severity, research study generalizability and, 1.4–5
- Disjunctive nystagmus, 5.234
- Disk-diffusion susceptibility testing, 1.274
- Dislocated lens, 11.40. *See also* Ectopia lentis
 - cataract surgery in patient with, 11.181–183, 11.182f, 11.183f
 - conditions associated with, 6.306t
 - description of, 6.306
 - ectopia lentis et pupillae, 6.267–268, 6.307, 6.307f
 - in homocystinuria, 6.308–309
 - illustration of, 6.306f
 - inborn errors of metabolism and, 6.306
 - iridodonesis with, 6.306
 - isolated/simple ectopia lentis, 6.307
 - in Marfan syndrome, 6.307–308, 6.308f
 - refractive error caused by, 6.310
 - in sulfite oxidase deficiency, 6.310
 - traumatic, 11.40, 11.54f, 11.54–55
 - treatment of, 6.310
 - in Weill-Marchesani syndrome, 6.309
- Dislocation (LASIK flap), 13.113, 13.115–116
 - striae and, 13.113
 - traumatic, 13.115–116
- Dislocation/decentration (IOL), 11.127, 11.144f, 11.144–147, 11.146f, 11.147f
 - angle-supported lenses and, 13.146

- iris-fixed lenses and, 13.145
- laser capsulotomy and, 11.156
- multifocal lenses and, 11.144, 11.145, 13.155
- Disodium ethylenediaminetetraacetic acid (EDTA). *See* Ethylenediaminetetraacetic acid
- Disomy, uniparental, 2.145, 2.154
- Disopyramide, 1.113*t*
- Dispace, for enzymatic vitreolysis, 2.255
- Dispersion, definition of, 3.45
- Dispersive ophthalmic viscosurgical devices/viscoelastics, 2.368, 11.96. *See also* Ophthalmic viscosurgical devices
- elevated intraocular pressure and, 10.108
- Dissection, gross, for pathologic examination, 4.28*f*, 4.28–30, 4.29*f*
- Dissections (arterial), 5.342–343. *See also specific type or artery affected*
- Disseminated intravascular coagulation (DIC), 1.146, 12.196
- pregnancy and, 1.148
- Dissimilar segments, induced anisophoria corrected using, 3.189, 3.189*f*
- Dissociated horizontal deviation (DHD), 6.17, 6.105, 6.129
- Dissociated (disconjugate) nystagmus, 5.234, 5.247
- Dissociated strabismus complex (DSC), 6.17, 6.105*f*, 6.129
- Dissociated torsional deviation (DTD), 6.17, 6.129
- Dissociated vertical deviation (DVD)
- age at onset, 6.129
- clinical features of, 6.129, 6.129*f*
- definition of, 6.129
- description of, 6.17, 6.105, 6.111, 6.115–116
- hyperopia and, 6.115
- inferior oblique anterior transposition for, 6.166
- inferior oblique muscle overaction versus, 6.129–130
- management of, 6.130
- Distance vision
- multifocal intraocular lenses for, 3.258
- near vision versus, in amblyopia, 3.25
- Distance visual acuity. *See also* Visual acuity
- corrected (best-corrected visual acuity). *See* Corrected distance visual acuity
- testing
- in low vision, 5.78
- before refractive surgery, 13.39
- Distance–near incomitance, 6.162
- Distant objects, principal planes and, 3.59
- Distichiasis, 2.24, 4.202, 6.195, 6.195*f*, 8.88
- acquired, 7.154*f*
- congenital, 4.202, 7.154*f*, 7.160, 7.160*f*
- Distometer, 3.171, 3.171*f*
- Distortion
- definition of, 3.40, 3.72
- schematic diagram of, 3.72*f*
- Distraction test, 7.199, 7.203
- Distribution, normal, clinical relevance of research and, 1.7
- Distributive shock, 1.300. *See also* Shock
- Disuse anopsia. *See* Deprivation amblyopia
- Diuretics, 12.134
- for heart failure, 1.109, 1.110
- for hypertension, 1.68, 1.68*t*, 1.70–71
- in combination, 1.69*t*, 1.73
- indications for, 1.69*t*
- ocular effects of, 1.308*t*
- in perioperative setting, 1.285
- Diurnal fluctuation of vision, after radial keratotomy, 13.51
- Diurnal variation
- in intraocular pressure, 10.3, 10.8, 10.22, 10.80–81, 10.81*t*, 10.86, 10.87
- in vision, after radial keratotomy, 13.51
- Divergence
- fusional, 6.40, 6.72
- fusional vertical, 6.40
- synergistic, 6.133
- Divergence amplitude, 5.226
- Divergence insufficiency/paralysis (DI), 5.227–228, 6.94
- Divergent strabismus, 6.15
- Diverging lens, for myopia correction, 3.170, 3.170*f*
- “Divide and conquer nucleofraxis,” 11.112–114, 11.113*f*
- Divisional third nerve (oculomotor) palsy, 5.197
- Dix–Hallpike maneuver, 5.242–243
- Dk, 3.213, 3.215
- Dk/t, 3.213
- DKA. *See* Diabetic ketoacidosis
- DLEK. *See* Deep lamellar endothelial keratoplasty
- DLK. *See* Diffuse lamellar keratitis
- DLPN. *See* Dorsolateral pontine nuclei
- DM. *See* Diabetes mellitus
- DMARDs. *See* Disease-modifying antirheumatic drugs
- DME. *See* Diabetic macular edema
- DMEK. *See* Descemet membrane endothelial keratoplasty
- DMET. *See* Descemet membrane endothelial transfer
- DMT. *See* Disease-modifying therapy
- DNA
- amplification of, in polymerase chain reaction, 2.141–142, 4.36–40, 4.38*t*, 4.39*t*, 4.40*f*
- antisense (noncoding), 2.132, 2.148*f*, 2.150, 2.151
- in gene therapy, 2.170
- complementary (cDNA), 2.133
- sequencing, 2.161
- damage to, 2.154
- encyclopedia of elements of (ENCODE), 2.135
- fecal, testing in cancer screening, 1.210*t*, 1.214
- methylation of, 2.139, 2.151, 2.153
- mitochondrial (mtDNA), 2.147, 2.148*f*
- diseases associated with deletions/mutations of, 2.157–159
- chronic progressive external ophthalmoplegia, 2.157, 2.158, 5.328–329, 5.329*f*
- Leber hereditary optic neuropathy, 2.157, 2.158, 5.133
- maternal inheritance/transmission and, 2.157, 2.181
- MELAS and MIDD, 2.159
- NARP (neuropathy [neurogenic muscle weakness]/ataxia/retinitis pigmentosa) syndrome, 2.157, 2.158–159
- replicative segregation and, 2.143, 2.157
- noncoding (antisense/junk), 2.132, 2.148*f*, 2.150, 2.151
- in gene therapy, 2.170
- plasmid, 8.243

- recombinant, 2.143
- repair of, 2.154. *See also* Mutation
- replication of, 2.143
 - segregation and, 2.143
 - slippage and, 2.143
- satellite, 2.150
- sequencing of, 2.161–162, 2.162*f*, 2.163*f*, 2.164*f*, 2.165*f*, 2.166*f*
 - next-generation (NGS/massively parallel), 2.140, 2.142, 2.161, 2.163*f*, 2.164*f*, 2.165*f*, 2.166*f*, 4.39*t*
- structure of, 2.147, 2.148*f*
- telomeric (telomeres), 2.144, 2.150
- virus, 8.211, 8.212. *See also* DNA viruses
- DNA code, 2.134
- DNA library, 2.138
 - cDNA, 2.138
 - genomic, 2.138
- DNA probes, 4.41
 - in infection diagnosis, 1.239
 - in microarray, 4.41
 - multiplex ligation-dependent amplification of (MLPA), 4.39*t*
- DNA viruses, 8.211, 8.212–239
 - adenoviruses (Adenoviridae), 8.233–236
 - cancer association of, 1.228
 - herpesviruses (Herpesviridae), 8.212–233
 - papovaviruses, 8.238–239
 - poxviruses (Poxviridae), 8.236–238
- Do-not-resuscitate orders, surgery in older patients and, 1.181
- Docetaxel, 12.301
- Docosahexaenoic acid (DHA), 12.70
 - in retina/retinal pigment epithelium, 2.274
 - oxidative damage and, 2.285
- Dofetilide, 1.113*t*
- Dog bites, eyelid injuries caused by, 7.190
- Dog hookworm (*Ancylostoma caninum*), diffuse unilateral subacute neuroretinitis caused by, 9.232
- Dog tapeworm (*Echinococcus granulosus*), orbital infection caused by, 4.228, 7.51
- Dogs, toxocariasis transmitted by, 9.228
- Dolichocephaly, 6.205
- Dolichoectasia, intracavernous carotid aneurysm as, 5.339
- Doll's head maneuver/phenomenon, 5.221, 5.228, 6.88
- Domains, immunoglobulin, 9.41*f*, 9.42
- Dominance, ocular, determining, 13.39
- Dominant inheritance (dominant gene/trait), 2.134, 2.173–174, 2.177
 - autosomal, 2.177–178, 2.178*t*
 - disorders associated with, 2.134
 - gene therapy for, 2.169–170, 2.170*f*
 - X-linked, 2.180–181
 - X-linked, 2.179–180, 2.181*t*
- Dominant-negative mutation/dominant-negative effect, 2.134
 - gene therapy for disorders caused by, 2.169
- Dominant optic atrophy, 5.135, 5.136*f*, 6.367–368, 6.368*f*
- Donder's law, 6.31
- Donepezil, for Alzheimer disease, 1.205
- Donor cornea, 8.411. *See also* Corneal grafts; Keratoplasty
 - contraindications to use of, 8.414, 8.415*t*, 8.416*t*
 - criteria for acceptability of, 8.414, 8.415*t*, 8.416*t*
 - disease transmission and, 8.414, 8.415*t*, 8.416*t*
 - Creutzfeldt-Jakob disease, 8.254, 8.416*t*
 - HIV, 1.271–272
 - rabies virus, 8.240, 8.240*t*, 8.416*t*
 - dislocation/decentration of, after endothelial keratoplasty, 8.440–444, 8.441*f*, 8.442*f*, 8.443*f*
 - DMEK, 8.442*f*, 8.442–443, 8.443*f*
 - DSEK, 8.441, 8.442*f*
 - endothelial failure of, 4.48, 4.85*f*
 - late non-immune-mediated, 8.427–428
 - primary
 - after endothelial keratoplasty (DMEK/DSEK), 8.447
 - after penetrating keratoplasty, 8.423, 8.423*f*
 - for epikeratoplasty (epikeratophakia), 13.62
 - eye banking and, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
 - for homoplastic corneal inlay, 13.60
 - prior LASIK affecting, 13.198
 - rejection of, 4.84, 4.85*f*, 8.316–318, 8.428–431, 9.59, 9.60, 9.60*f*. *See also* Rejection
 - selection/screening of, 8.414, 8.415*t*, 8.416*t*
 - HIV infection transmission and, 1.271–272
 - storage of, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
- L-Dopa, for Parkinson disease, 1.199
- Dopamine
 - antipsychotic mechanism of action and, 1.193
 - for medical emergencies, 1.296*t*
 - outer-segment disc shedding and, 2.277
 - in Parkinson disease, 1.198, 1.199
 - pituitary function affected by, 1.56*t*
- Dopamine-β-hydroxylase, defective/deficiency of, 2.175*t*
- Dopamine-norepinephrine reuptake inhibitors, 1.196*t*
- Doppler imaging, 5.70. *See also* Ultrasonography/ultrasound
 - carotid, 5.70
 - in cerebral ischemia/stroke, 1.122
 - in ischemic heart disease, 1.97
 - in ocular ischemic syndrome, 9.279
 - orbital, 5.70–71, 7.31
- Dorello canal, 2.102, 5.41, 5.42*f*
- sixth nerve (abducens) injury/palsy and, 5.201
- Doripenem, 1.276
- Dorsal midbrain (Parinaud) syndrome, 5.37, 5.229, 5.230*f*
 - in children, 5.231
 - convergence-retraction nystagmus in, 5.229, 5.250, 6.105
 - eyelid retraction in, 5.229, 5.250, 5.274, 5.275*t*, 7.223
 - light-near dissociation in, 5.229, 5.230*f*, 5.266*t*, 5.266–267
 - multiple sclerosis and, 5.319
- Dorsal nasal nerve, 7.17*f*
- Dorsal subnucleus, of cranial nerve VII (facial), 5.49
- Dorsal vermis, 5.33, 5.40
- Dorsal visual processing stream, 5.224
- Dorsolateral pontine nuclei (DLPN), 5.33, 5.34*f*, 5.35, 5.224
- Dorsum sella, 5.6*f*
- Dorzolamide, 2.324–325, 2.325*t*, 10.173*t*, 10.175*t*, 10.179–181
 - in children, 10.165
 - in combination preparations, 2.322*t*, 2.325, 2.325*t*, 10.174*t*

- DOT. *See* Directly observed therapy
- Dot-and-blot hemorrhages, ischemia causing, 4.153–154, 4.155f, 5.170, 5.171f
- Dots, in epithelial basement membrane dystrophy, 8.137–138, 8.138f
- Double anterior chamber, after deep anterior lamellar keratoplasty, 8.435
- Double-convexity deformity, 7.236, 7.241–242
- Double-elevator palsy (monocular elevation deficiency), 7.213
- Double freeze–thaw technique, for trichiasis, 7.208
- Double helix, DNA, 2.147, 2.148f
- Double heterozygotes, 2.185
- “Double hump” sign, in plateau iris, 10.127, 10.127f
- Double-K method, 3.252
- Double Maddox rod test, 5.184–185, 5.185f, 6.69, 6.69f, 6.120
- in fourth nerve (trochlear) palsy, 5.198
- Double pinhole apertures, 3.285, 3.286f
- Double-ring sign, 6.361, 6.362f
- in optic nerve hypoplasia, 5.143, 5.143f
- Double simultaneous stimulation, in confrontation testing, in hemispatial neglect, 5.181
- Double-slit experiments, 3.94, 3.101, 3.101f, 3.105
- Double vision. *See* Diplopia
- Down syndrome (trisomy 21), 2.189–190, 2.191t
- congenital ectropion and, 7.156
- hypoaccommodation in, 6.9
- idiopathic intracranial hypertension associated with, 6.372
- mosaicism in, 2.191
- ocular findings in, 6.386t
- pharmacogenetics and, 2.201
- pseudopapilledema associated with, 6.372
- Downbeat nystagmus, 5.243t, 5.244–245, 5.245f, 6.152
- Downgaze (depression of eye/deorsumversion/deorsumduction), 6.38
- disorders/limitation of, 5.228–229
- in newborn, 5.230–231
- in orbital floor/blowout fracture, 7.108
- surgery and, 7.110
- extraocular muscles controlling, 5.36f, 5.46f
- inferior rectus muscle, 5.36f, 5.46f
- superior oblique muscle, 5.36f, 5.46f
- ptosis exacerbation in, 7.209
- ptotic eyelid position in, 7.211, 7.214t
- Downward-slanting palpebral fissure
- description of, 6.196
- pattern strabismus and, 6.107, 6.108f
- syndromes with, 6.196
- Doxazosin
- for heart failure, 1.110
- for hypertension, 1.68t
- intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137t
- Doxorubicin, 1.233t, 1.235
- Doxycycline, 2.350
- for cat-scratch disease/bartonellosis, 9.258, 12.242–243
- for chlamydial conjunctivitis, 8.263
- for dry eye, 2.221
- for leptospirosis, 9.249
- for Lyme disease, 9.247t
- for meibomian gland dysfunction, 8.68
- ocular effects of, 1.307t
- off-label use of, 2.306
- for onchocerciasis, 9.235
- for recurrent corneal erosions, 8.87
- for rosacea, 2.306, 8.71
- for syphilis, 9.242t, 9.243
- Doyne honeycomb dystrophy, 12.275. *See also* Drusen
- EFEMP1 defects causing, 2.265
- dPCR. *See* Digital polymerase chain reaction
- DPE. *See* Dipivefrin
- DPP-IV. *See* Dipeptidyl-peptidase IV
- DPP-IV inhibitors. *See* Dipeptidyl-peptidase IV (DPP-IV) inhibitors
- Dragged-fovea diplopia syndrome, 6.145
- “Dresden protocol,” 13.130, 13.132, 13.133t. *See also*
- Corneal (collagen) crosslinking
- DRIs. *See* Direct renin inhibitors
- Dronedarone, 1.113t
- Drop attacks, 5.336
- DRS. *See* Diabetic Retinopathy Study
- Drug abuse, 1.192–193. *See also* Substance abuse disorders
- Drug addiction, 1.192
- Drug dependence, 1.192
- Drug-eluting stents (DES), 1.91, 1.100
- Drug-induced cicatricial pemphigoid (pseudopemphigoid), 8.91, 8.92, 8.299
- Drug-induced thrombocytopenia, 1.143–144
- Drug-induced uveitis, 9.121
- Drug resistance. *See also specific agent and specific organism*
- antibiotic, 1.272–274, 2.343, 2.346, 2.351, 2.352, 2.353
- new drugs/drug classes and, 1.239, 1.280
- antiretroviral, 1.264
- antiviral, 2.358, 2.360
- in tuberculosis, 1.255, 1.269, 9.254
- Drugs. *See also specific drug or drug group*
- allergic reaction to, 1.301–302, 1.306–308, 1.307–308t. *See also* Allergic reactions/allergies; *specific drug*
- antibiotic, 1.272–282, 1.273t, 2.343–354, 2.344t, 2.347t, 2.348t
- canalicular obstruction caused by, 7.274
- color-vision abnormalities caused by, 12.304–305
- crystalline retinopathy caused by, 12.302–304, 12.304t
- diabetes mellitus associated with, 1.187
- drug penetration and, 2.298
- dry eye caused by, 8.61–62, 8.62t
- fixed, dilated pupil caused by, 5.310
- ganglion cell toxicity caused by, 12.301
- genetics affecting (pharmacogenetics), 2.141, 2.201–202
- glaucoma caused by
- angle-closure, 10.122–123, 10.145f, 10.145–146
- open-angle, 10.109–111
- hallucinations/illusions caused by, 5.175
- hyaloidal separation effects on, 12.85
- lens changes caused by, 11.51–53, 11.52f
- macular edema caused by, 12.301–302, 12.302f
- medication use in older patients and, 2.295
- metabolism of
- age-related changes in, 2.294, 2.295
- toxicity and, 2.294, 2.295

- microvasculopathy caused by, 12.300–301
- occlusive retinopathy caused by, 12.300–301
- ocular. *See also specific agent*
 - absorption of, 2.294, 2.295–297, 2.296f
 - adrenergic, 2.316t, 2.316–323, 2.317f, 2.318t, 2.320f, 2.322t
 - age/aging and, 2.295
 - anti-inflammatory, 2.329–341, 2.330t, 2.333t, 2.335t, 2.338t
 - antibiotic, 2.343–354, 2.344t, 2.347t, 2.348t
 - antifibrinolytic, 2.369–370
 - antifungal, 2.354–356, 2.355t
 - antimicrobial, 2.343–361
 - antioxidant/vitamin supplements, 2.370
 - antiviral, 2.356–361, 2.357–358t
 - carbonic anhydrase inhibitors, 2.230, 2.323–326, 2.324f, 2.325t
 - cholinergic, 2.307f, 2.307–315, 2.308t, 2.309f, 2.310f, 2.311t, 2.314t, 2.315t
 - combined medications, 2.328
 - compounded, 2.306–307
 - concentration of, absorption affected by, 2.297
 - conjunctivitis/keratoconjunctivitis/keratopathy caused by, 8.80–81, 8.81t, 8.90t, 8.90–91
 - contact dermatophlepharitis caused by, 8.285–287, 8.286f
 - corneal deposits and pigmentation caused by, 8.129t, 8.129–132, 8.130f, 8.131f
 - crystalline deposits, 8.182t
 - decongestants, 2.342–343
 - diagnostic agents, 2.367–368
 - for dry eye, 2.221f, 2.221–222, 2.341–342
 - in eyedrops, 2.295–298, 2.296f
 - fibrinolytic, 2.369
 - growth factors and, 2.371–372
 - hyperosmolar, 2.366
 - interferons, 2.370–371
 - intraocular injection of, 2.299, 2.300t
 - intravenous administration of, 2.301
 - investigational, 2.305
 - for irrigation, 2.367
 - legal aspects of use of, 2.205–207
 - local administration of, 2.299, 2.300t
 - local anesthetics, 2.362t, 2.362–366, 2.363t
 - mechanisms of action of, 2.293, 2.304
 - methods of design and delivery of, 2.301–304
 - new technologies and, 2.303–304
 - mucous membrane (cicatricial) pemphigoid (pseudopemphigoid) caused by, 8.91, 8.92, 8.299
 - neurotrophic keratopathy/persistent corneal epithelial defects caused by, 8.80–81, 8.81t
 - new, clinical testing of, 2.305
 - off-label usage of, 2.305, 2.306
 - in ointments, 2.298–299
 - osmotic agents, 2.328–329, 2.329t
 - partition coefficients of, 2.298
 - periocular injection of, 2.299
 - pharmacodynamics of, 2.293, 2.304
 - age-related changes in, 2.295
 - pharmacokinetics of, 2.293, 2.295–304, 2.296f, 2.300t
 - age-related changes in, 2.295
 - pharmacologic principles and, 2.293–304
 - pharmacotherapeutics of, 2.293, 2.294
 - prostaglandin analogues, 2.302, 2.327t, 2.327–328
 - purified neurotoxin complex, 2.366
 - receptor interactions and, 2.304
 - refractive surgery and, 13.37
 - solubility of, absorption affected by, 2.297–298
 - sustained-release preparations
 - oral, 2.301
 - topical, 2.302
 - systemic absorption of, 2.294, 2.296
 - systemic administration and, 2.300–301
 - thrombin, 2.369
 - tissue binding of, 2.298
 - topical, 2.295–299, 2.296f. *See also* Eyedrops
 - sustained-release devices for, 2.302
 - toxic ulcerative keratopathy/keratoconjunctivitis caused by, 8.80–81, 8.81t, 8.90t, 8.90–91
 - toxicity of, 2.294, 8.80–81, 8.81t, 8.90t, 8.90–92, 8.91f, 8.129t. *See also specific disorder*
 - age/aging and, 2.294, 2.295
 - corneal crystalline deposition and, 8.182t
 - tissue binding and, 2.298
 - viscoelastics. *See* Ophthalmic viscosurgical devices
 - viscosity of, absorption affected by, 2.297
 - vitamin/antioxidant supplements, 2.370
 - ocular toxicities caused by, 1.306–308, 1.307–308t, 12.305–306
 - NAION and, 5.123
 - optic neuropathy caused by, 5.107t, 5.137–139
 - optic nerve toxicity caused by, 12.301
 - platelet destruction/dysfunction caused by, 1.143–144, 1.144
 - retinal toxicity caused by, 12.68
 - alkyl nitrites, 12.300, 12.300f
 - chloroquine derivatives, 12.295–297, 12.296f
 - clofazimine, 12.298
 - deferoxamine, 12.298–299
 - dideoxyinosine, 12.299
 - hydroxychloroquine, 12.295–297, 12.296f
 - MEK inhibitors, 12.299, 12.299f
 - nucleoside reverse transcriptase inhibitors, 12.299
 - phenothiazines, 12.297–298, 12.298f
 - scleral delivery of, 12.20
 - Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis) caused by, 8.295
 - uveitis caused by, 9.121

Drusen, 2.69

 - in age-related macular degeneration, 4.160–163, 4.161f, 4.162f, 4.163f
 - boundaries of, 12.65
 - calcific, 4.163, 12.66
 - categorization of, 12.64–65
 - choroidal nevi and, 4.256, 4.257f, 4.268
 - confluent, 12.65
 - cuticular (basal laminar), 4.162, 12.274, 12.275f
 - definition of, 12.63
 - diffuse, 4.160, 4.161f
 - early-onset, 12.273, 12.274f
 - fluorescein angiography of, 12.65
 - fundus camera imaging of, 12.23, 12.23f
 - geographic atrophy and, 12.66
 - giant, 4.295, 5.108f, 5.143
 - retinoblastoma differentiated from, 4.295
 - in tuberous sclerosis, 4.295

- hard (hyaline), 4.162, 4.162*f*, 12.65
 histologic appearance of, 12.63, 12.64*f*
 large colloid, 12.274
 optic nerve/nerve head/disc (ODD), 4.247, 4.247*f*,
 5.108*f*, 5.140–143, 5.141*f*, 6.373*f*, 6.373–374
 astrocytic hamartoma differentiated from,
 5.108*f*, 5.143
 autofluorescence in identification of, 5.89, 5.90*f*,
 5.141*f*, 5.142
 papilledema/pseudopapilledema and, 4.247, 5.107,
 5.108*f*, 5.141*f*, 5.142–143
 transient visual loss and, 5.141, 5.161, 5.164
 optical coherence tomography of, 12.65–66
 photoreceptors affected by, 12.64
 pigment epithelial detachment associated with, 12.64
 refractile, 12.23*f*
 soft, 4.162, 4.162*f*, 12.65, 12.68, 12.75, 12.200*f*, 12.272
 spectral-domain optical coherence tomography
 of, 12.64*f*
 Drusenoid deposits, subretinal (reticular pseudodrusen/
 RPD), 4.162, 4.163, 4.163*f*, 4.171*f*, 12.200
 Drusenoid pigment epithelial detachment, 12.64,
 12.272, 12.274*f*
 “Dry” age-related macular degeneration. *See*
 Nonneovascular (“dry”/nonexudative) age-related
 macular degeneration
 Dry eye (keratoconjunctivitis/keratitis sicca [KCS]),
 8.45, 8.53–69. *See also* Ocular surface, disorders of;
 specific causative factor
 aging and, 1.178
 aqueous tear deficiency causing, 2.220, 2.221*f*,
 2.221–222, 8.45, 8.53, 8.54*f*, 8.55*f*, 8.55–58, 8.61*t*,
 8.61–65, 8.62*t*, 8.65*f*. *See also* Aqueous tear
 deficiency
 β-blockers causing, 1.117
 blepharitis and, 8.68, 8.72, 8.76
 blepharoplasty and, 7.232
 in blepharospasm, 7.227
 cataract surgery in patient with, 11.173
 corneal melting/keratolysis and, 11.132
 clinical approach to, 8.53–69, 8.54*f*, 8.55*f*
 contact lens in patients with, 3.234–235
 decreased vision/transient visual loss and, 5.99, 5.164
 definition of, 8.53
 diagnostic classification of, 8.53–54, 8.55*f*
 evaporative, 8.45, 8.53–54, 8.54*f*, 8.55*f*, 8.58–60, 8.59*f*,
 8.60*f*, 8.66*t*, 8.66–67*t*, 8.66–69
 in graft-vs-host disease, 8.303
 illusions and, 5.174
 keratoprosthesis for, 8.452–453
 lacrimal lymphoepithelial lesions and, 7.94
 lacrimal plugs for, 7.281–282, 8.61*t*
 canalicular obstruction and, 7.274, 7.282
 extrusion/migration of, 7.282
 nasolacrimal duct obstruction and, 7.278, 7.282
 after LASIK, 13.78–79, 13.172
 LASIK in patient with, 13.78–79, 13.172–173
 mechanisms of, 8.53–55, 8.54*f*, 8.55*f*
 medications causing, 8.61–62, 8.62*t*
 in mucous membrane pemphigoid, 8.303
 mucus-fishing syndrome and, 8.89
 multifocal IOLs and, 13.155
 nasal continuous positive airway pressure and, 1.129,
 1.132
 non-Sjögren syndrome, 8.55*f*
 pain and, 5.295
 in peripheral ulcerative keratitis, 8.312–313
 after photoablation, 13.76, 13.78–79, 13.172
 after photorefractive keratectomy, 13.79
 radiation causing, 1.231
 refractive surgery and, 13.42, 13.78–79, 13.172–173
 sarcoidosis and, 9.168
 severity of, 8.57*t*
 Sjögren syndrome and, 1.163, 8.39, 8.55*f*, 8.56–58,
 8.58*t*
 in Stevens-Johnson syndrome (Stevens-Johnson
 syndrome/toxic epidermal necrolysis overlap and
 toxic epidermal necrolysis), 8.298
 after surface ablation, 13.76
 epithelial defect and, 13.107–108
 surface inflammation and, 2.221*f*, 2.221–222
 systemic diseases associated with, 8.59*t*
 tear film abnormalities and, 2.220, 2.221*f*, 2.221–222
 tear film evaluation in, 8.38–41, 8.40*f*, 8.55–56
 stains used in, 8.36–37, 8.37*f*, 8.38*f*, 8.56
 tear film osmolarity and, 8.39, 8.53
 treatment of, 8.61*t*, 8.61–69, 8.62*t*, 8.65*f*, 8.66*t*,
 8.66–67*t*
 medical management, 2.221*f*, 2.221–222,
 2.341–342
 of aqueous tear deficiency, 8.61*t*, 8.61–64, 8.62*t*
 of evaporative dry eye, 8.66*t*, 8.66–67*t*, 8.66–69
 surgical management, of aqueous tear deficiency,
 8.64–65, 8.65*f*
 “Dry”/nonexudative age-related macular degeneration.
 See Nonneovascular (“dry”/nonexudative) age-
 related macular degeneration
 DSA. *See* Digital subtraction angiography
 DSC. *See* Dissociated strabismus complex
 DSEK/DSAEK. *See* Descemet stripping/Descemet
 stripping automated endothelial keratoplasty
 DSM-5. *See* *Diagnostic and Statistical Manual of Mental*
 Disorders, Fifth Edition
 DTaP (diphtheria and tetanus toxoid with acellular
 pertussis) vaccine, 1.222
 DTD. *See* Dissociated torsional deviation
 DTP (diphtheria-tetanus-pertussis) vaccine,
 replacement of, with DTaP (diphtheria and tetanus
 toxoid with acellular pertussis) vaccine, 1.222
 Dual antiplatelet therapy (DAT), 1.100
 for heart failure, 1.111
 for ischemic heart disease
 non-ST-segment elevation acute coronary
 syndrome, 1.103
 after stenting, 1.91, 1.100
 Dual-optic intraocular lenses, 13.170, 13.170*f*
 Duane retraction syndrome
 bilateral, 6.132
 classification of, 6.132–133
 clinical features of, 6.132–133
 definition of, 6.131
 electromyographic studies of, 6.132
 esotropic, 6.95–97, 6.132*f*, 6.133
 exotropic, 6.105, 6.132, 6.132*f*
 genetics of, 6.132
 globe retraction in, 6.134
 incomitant hypertropia associated with, 6.125
 management of, 6.133–134

- “ocular splits,” 6.133
- overdepression in adduction caused by, 6.117
- overelevation in adduction caused by, 6.117
- prevalence of, 6.133
- surgical treatment of, 6.133–134
- synergistic divergence associated with, 6.133
- synkinesis in, 7.211, 7.215
- systemic/syndromic defects associated with, 6.131
- type 1, 6.132*f*, 6.132–133
- type 2, 6.132, 6.132*f*
- type 3, 6.132–134, 6.133*f*
- Dua’s (pre-Descemet) layer, 4.73, 4.74*f*, 8.9
- Duchenne muscular dystrophy, 12.285
- Ductal cysts of eyelid, 4.208, 4.208*f*
- Ductions, 5.184. *See also specific type*
 - description of, 6.33, 6.83
 - in diplopia, 5.184
 - forced, 5.186, 5.186*f*
 - forced. *See* Forced duction test
 - in infantile esotropia, 6.37
- Dulcitol (galactitol)
 - in cataract formation, 11.61
 - in lens glucose/carbohydrate metabolism, 2.247*f*
- Dumbbell dermoid cyst, 7.39–40
- Duochrome (red-green/bichrome/Worth 4-dot) test
 - basis of, 3.36
 - in nonorganic disorder evaluation
 - monocular no light perception and, 5.303, 5.304*f*
 - monocular reduced vision and, 5.305
 - pictorial representation of, 3.167*f*
 - before refractive surgery, 13.39
 - spherical endpoint verified using, 3.166, 3.167*f*
- DuoTrav. *See* Travoprost, in combination preparations
- Duplex ultrasonography. *See also* Ultrasonography/ultrasound (echography)
 - in carotid artery evaluation/disease, 1.125, 5.70, 5.167
 - in cerebral ischemia/stroke, 1.122
- Duplication (genetic), 2.145, 2.150, 2.155, 2.159
- Duplication cataract, 4.120, 4.120*f*
- Dura mater, optic nerve, 2.88*f*, 2.89, 2.89*f*, 4.241, 4.242*f*, 5.17*f*
- Dural arteriovenous/arterial malformations, 5.343, 12.198, 12.199*f*
- Dural (indirect) carotid-cavernous fistula, 7.72, 7.73
- Dural-cavernous fistula, glaucoma associated with, 10.30
- Dural rings, 5.14, 5.16*f*
- Dural sheath, optic nerve, 5.26
- Durezol. *See* Difluprednate
- DUSN. *See* Diffuse unilateral subacute neuroretinitis
- Duty cycle, in phacoemulsification, 11.100
- DVD. *See* Dissociated vertical deviation
- DVM. *See* Delayed visual maturation
- DWI. *See* Diffusion-weighted magnetic resonance imaging
- Dye disappearance test (DDT), 7.269, 7.269*f*, 8.36
- Dynamic contour tonometry/tonometer, 10.26
- Dynamic gonioscopy, 10.35, 10.35*f*, 10.36
 - in acute primary angle closure, 10.123
- Dynamic retinoscopy
 - accommodation measurements using, 6.9
 - in children, 6.9
- Dynamic skiascopy. *See* Retinoscope/retinoscopy
- Dynamic visual acuity, vestibular-ocular reflex
 - evaluation and, 5.216
- Dysacusia, Vogt-Koyanagi-Harada syndrome and, 9.176
- Dysautonomia, familial (FD/Riley-Day syndrome), 2.175*t*
 - congenital corneal anesthesia and, 8.108
 - racial and ethnic concentration of, 2.197
- Dyschromatopsia, 12.249, 12.265. *See also* Color vision, defects in
- Dysconjugate nystagmus, 6.151–152
- Dyscoria, 6.267
- Dysgeusia, Horner syndrome and, 5.261
- Dyskeratosis
 - in actinic keratosis, 4.211
 - benign hereditary intraepithelial, 8.332*t*
 - definition of, 4.202
- Dyskinesia, tardive
 - blepharospasm and, 5.281
 - facial movements and, 5.285
- Dyslexia, surface, in Alzheimer disease, 1.206
- Dysmetric saccades, 5.222
- Dysmorphic sialidosis (ML I), 8.178
- Dysphagia, local anesthetic administration causing, 1.292
- Dysphotopsias, 3.239, 3.255
 - IOLs and, 5.174, 11.150–151
- Dysplasia
 - ectodermal, 8.202
 - ocular surface (conjunctival or corneal intraepithelial neoplasia/CIN), 4.61, 4.63*f*, 4.96, 8.37, 8.38*f*, 8.332*t*, 8.334–335, 8.335*f*. *See also* Ocular surface squamous neoplasia
 - melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
 - of orbit
 - fibro-osseous, 4.239, 4.240*f*
 - fibrous, 4.239, 4.240*f*
- Dysplastic nevus, melanoma arising from, 1.215, 4.220, 4.262
- Dyspnea, 1.129
 - in heart failure, 1.105, 1.109
- Dysraphism, 6.183*t*
- Dysthymic disorder, 1.189
- Dysthyroid ophthalmopathy/orbitopathy. *See* Thyroid eye disease
- Dystonia, facial, 7.226–229, 7.227*f*
- Dystopia canthorum, 6.191, 6.192*f*
- Dystrophic lipidization, 12.66
- Dystrophies, 4.10, 4.12*t*. *See also specific type*
 - adult-onset foveomacular vitelliform, 4.170, 4.171*f*, 12.272, 12.276
 - butterfly-type pattern, 12.276, 12.276*f*
 - choroidal
 - Bietti crystalline dystrophy, 12.258, 12.269, 12.282*t*
 - central areolar, 12.277
 - choroideremia, 12.267–268, 12.268*f*
 - classification of, 12.255
 - gyrate atrophy, 12.268–269, 12.269*f*
 - cone
 - bull’s-eye pattern associated with, 12.265, 12.265*f*
 - description of, 12.264–265
 - electroretinography findings in, 12.46, 12.47*f*, 12.265
 - genes and loci associated with, 12.256*t*
 - with supernormal rod ERG, 12.49

- cone-rod
 genes and loci associated with, 12.256t
 Jalili syndrome, 12.286
 retinitis punctata albescens, 12.258, 12.258f
 corneal, 4.86–94, 8.133–160, 8.134t, 8.135t, 8.136t.
See also Corneal dystrophies; *specific type*
 cataract/cataract surgery in patient with, 11.84,
 11.174f, 11.174–175
 refractive surgery and, 13.42–43, 13.43f, 13.76,
 13.78, 13.178
 multifocal IOLs, 13.155
 degenerations differentiated from, 8.111, 8.111t
 hereditary. *See* Hereditary dystrophies
 macular, 4.168–169f, 170, 4.171f. *See also* Macular
 dystrophies
 adult-onset vitelliform lesions, 12.272, 12.273f
 atypical, 12.277
 Best disease, 12.271, 12.272f
 early-onset “drusenoid,” 12.273–276, 12.274–275f
 electroretinography findings in, 12.46, 12.47f
 North Carolina, 12.277, 12.278f
 occult, 12.277
 pattern dystrophies, 12.276f, 12.276–277
 Sorsby, 12.275f, 12.275–276
 Stargardt disease. *See* Macular dystrophies
 macular corneal (MCD), 4.91, 4.91t, 4.92f, 8.135t,
 8.136t, 8.145t, 8.149–151, 8.150f
 panretinal
 clinical findings of, 12.261, 12.263f
 Coats reaction associated with, 12.260
 nonsyndromic, 12.258–259
 syndromic, 12.259
 pattern, 4.170, 4.171f, 12.67, 12.272, 12.276f,
 12.276–277
 adult-onset foveomacular vitelliform, 4.170, 4.171f
 butterfly-type (BPD), 4.170
 photoreceptor (diffuse), 4.170, 4.172f
 retinal. *See* Retinal degenerations; Retinal dystrophies
 rod-cone. *See also* Retinitis pigmentosa
 in Bardet-Biedl syndrome, 12.284
 characteristics of, 12.261–264, 12.262–264f
 conventional testing of, 12.261
 electroretinography evaluations, 12.46, 12.47f,
 12.261
 imaging of, 12.262–264f
 macula-spared, 12.46, 12.47f
 stromal, 4.91, 4.91t, 4.92f
 Dystrophin, 2.153, 12.285
- E**
- E_g . *See* Irradiance
 E_v . *See* Illuminance
E. coli. *See* *Escherichia/Escherichia coli*
 E-selectin, in neutrophil rolling, 9.17, 9.18f
 Eagle Vision glaucoma implant, 10.214t
 Eales disease, 9.253, 9.253f, 9.291, 12.156, 12.241
 Ear cartilage graft
 for cicatricial entropion, 7.207
 for eyelid retraction, 7.224
 for paralytic ectropion, 7.226
 Early latent syphilis, 1.216, 1.248, 9.238, 9.242t
 Early macular telangiectasia, 12.277
 Early Manifest Glaucoma Trial (EMGT), 10.88, 10.113
 Early-onset Alzheimer disease, 1.205
 Early-onset “drusenoid” macular dystrophies, 12.273–
 276, 12.274–275f
 Early-onset (childhood) nystagmus, 5.235–239. *See also*
 Nystagmus
 Early Treatment Diabetic Retinopathy Study (ETDRS),
 12.99–101, 12.110
 Early Treatment Diabetic Retinopathy Study (ETDRS)
 visual acuity chart
 in branch retinal vein occlusion, 12.128
 in central retinal vein occlusion, 12.136–137
 description of, 3.23f, 3.133, 3.133f, 6.8
 in diabetic retinopathy/macular edema, 12.101, 12.114
 in low vision, 3.313, 3.313f
 Early Treatment for Retinopathy of Prematurity
 (ETROP), 3.133, 3.133f, 6.326, 6.331t, 6.332, 12.179,
 12.185
 EAU. *See* Experimental autoimmune uveoretinitis
 EB. *See* Elementary body
 EBAA. *See* Eye Bank Association of America
 EBAA (Eye Bank Association of America), 8.414
 EBMD. *See* Epithelial dystrophies, epithelial and
 subepithelial, basement membrane
 Ebola virus (EBOV) panuveitis, 12.247
 EBRT. *See* External-beam radiotherapy
 EBV. *See* Epstein-Barr virus
 EBV-associated hemophagocytic lymphohistiocytosis
 (EBV-HLH/EBV-associated hemophagocytic
 syndrome), 1.260
 ECA. *See* External carotid artery
 ECCE. *See* Extracapsular cataract extraction
 Eccentric fixation, 3.310
 anomalous retinal correspondence versus, 6.51
 definition of, 6.54
 in strabismic amblyopia, 6.54
 Eccentric gaze, 5.38
 gaze-evoked nystagmus and, 5.222, 5.240
 rebound, 5.240–241
 saccadic dysfunction and, 5.222
 Ecchymoses, 1.142. *See also* Purpura
 periorbital, 7.22, 7.22f
 in neuroblastoma, 7.98, 7.98f
 in orbital floor/blowout fracture, 7.108
 in orbital roof fracture, 7.106
 Eccrine hidrocystoma, 4.208, 7.170
 Eccrine sweat glands, of eyelid, 4.201, 4.202, 7.170, 8.4
 cyst arising in, 4.208
 syringoma associated with malformation of, 4.214,
 4.215f
 tumors originating in, 7.170, 7.171f
 ECD. *See* Erdheim-Chester disease
 ECDC. *See* European Centre for Disease Prevention and
 Control
 ECG. *See* Electrocardiography
 Echinocandins, 1.281
 for *Candida* endophthalmitis, 9.267–268
Echinococcus granulosus (echinococcosis), orbital
 infection caused by, 4.228, 7.51
 Echocardiography
 cardiac emboli identification and, 1.125, 5.168
 in carotid occlusive disease, 1.125

- in cerebral ischemia/stroke, 1.122, 5.168
- in congestive heart failure, 1.105
- exercise (stress), 1.97
- in ischemic heart disease, 1.97
- Echography. *See* Ultrasonography/ultrasound (echography)
- Echothiophate, 2.311*t*, 2.312, 2.313, 10.173*t*
 - cataract and, 11.52
 - in Down syndrome, pharmacogenetics and, 2.201
 - for glaucoma, 10.173*t*
 - local anesthetic use and, 2.312
 - succinylcholine and, 1.286
- Eclampsia, 1.77, 1.78, 12.196. *See also* Preeclampsia
 - neuro-ophthalmic signs of, 5.333
 - transient visual loss and, 5.161
- Eclipse retinopathy. *See* Solar retinopathy
- Econopred. *See* Prednisolone
- ECP. *See* Endoscopic cyclophotocoagulation
- Ectatic disorders/ectasia. *See also specific type*
 - corneal, 4.95*f*, 4.95–96, 8.161–171. *See also*
 - Keratoconus; Pellucid marginal degeneration
 - corneal crosslinking for, 13.124, 13.130, 13.131, 13.176, 13.206
 - intrastromal corneal ring segments for, 13.63
 - after LASIK, 8.166, 13.124–125
 - corneal crosslinking for, 13.124, 13.130, 13.131
 - intrastromal corneal ring segments for, 13.70
 - opacities in, 8.16*f*
 - refractive lens exchange and, 13.149
 - refractive surgery contraindicated in, 13.23, 13.24–25, 13.25*f*, 13.78
 - corneal topography and, 13.23, 13.24, 13.25*f*, 13.78
 - topography in evaluation of, 8.31, 8.32*t*, 8.33*f*
 - retinal. *See* Coats disease
- Ectoderm, 2.111, 2.112*f*, 2.113*f*, 2.114*f*
 - in lens development, 11.25, 11.26*f*
 - ocular structures derived from, 2.115*t*
 - cornea, 2.120–121, 2.121*f*
 - lens, 2.117–122, 2.120*f*, 11.25, 11.26*f*
- Ectodermal dysplasia, 6.194, 8.202
- Ectopia lentis, 10.129–130, 10.130*f*, 10.130*t*, 10.131*f*, 11.39–41, 11.40*f*
 - angle-closure glaucoma and, 10.129–130, 10.130*f*, 10.130*t*, 10.131*f*
 - cataract surgery in patient with, 11.181–183, 11.182*f*, 11.183*f*
- et pupillae, 6.267–268, 6.307, 6.307*f*, 11.42
 - Axenveld-Rieger syndrome differentiated from, 10.154*t*
 - in homocystinuria, 11.41
 - in hyperlysinemia, 11.41
 - isolated/simple, 6.307, 11.40
 - in Marfan syndrome, 1.143, 8.193, 8.193*f*, 8.194, 11.40*f*, 11.40–41
 - traumatic, 11.40
- Ectopic lacrimal gland, 6.226
- Ectopic tissue masses, 6.223–225*f*, 223–226
- Ectropion, 2.55, 7.197–201, 7.198*f*, 7.200*f*
 - anophthalmic, 7.135
 - cicatricial, 7.198*f*, 7.201, 7.202*f*
 - after blepharoplasty, 7.234
 - congenital, 7.156, 7.157*f*
 - in blepharophimosis-ptosis-epicanthus inversus syndrome, 7.155, 7.156
 - of eyelid, 6.194
 - of iris, 6.267
 - involutional, 7.198*f*, 7.199–201, 7.200*f*
 - mechanical, 7.198*f*, 7.201
 - paralytic, 7.198*f*, 7.224–226, 7.225*f*
 - tarsal, 7.200
 - uveae, 2.55, 4.188, 4.189*f*, 4.255, 4.256*f*, 4.259, 4.259*f*, 10.137*f*
- Ectropion uveae, 6.267
- Eculizumab, for paroxysmal nocturnal hemoglobinuria, 1.138–139
- Eczema, of eyelid, 8.45*t*
- ED (epithelial debridement). *See* Debridement
- Edema
 - corneal. *See* Cornea, edema of
 - epithelial, 8.42, 8.46*t*
 - cataract surgery and, 11.128*t*, 11.128–130
 - intraocular surgery and, 8.42
 - eyelid, 7.164
 - in blepharochalasis, 7.230
 - in orbital floor/blowout fracture, 7.108
 - in rhabdomyosarcoma, 7.82
 - in heart failure, 1.105
 - macular. *See* Macular edema
 - optic nerve/nerve head/disc. *See* Optic nerve head (ONH/optic disc), edema of
 - pulmonary, in heart failure, 1.105, 1.109
 - retinal, 4.152–153, 4.153*f*, 4.154*f*
 - stromal, 8.42
 - cataract surgery and, 11.128*t*, 11.128–130
- Edetate disodium
 - for band keratopathy, 8.119
 - salt of (EDTA)
 - in artificial tears, 2.341
 - for band keratopathy, 2.306, 8.119, 9.281
 - in irrigating solutions, 2.367
 - off-label use of, 2.306
- EDI/EDI-OCT. *See* Enhanced depth imaging optical coherence tomography
- Edinger-Westphal (EW) nucleus, 2.56, 2.94, 2.94*f*, 2.96, 5.44*f*, 5.54, 5.55*f*
- EDOF. *See* Extended-depth-of-focus
- Edrophonium, 2.309*f*, 2.312, 2.314–315
 - intravenous administration of, 2.301
 - in myasthenia gravis diagnosis, 1.305, 2.301, 2.315, 5.324–325, 7.217
 - toxic reaction to/side effects of, 1.305, 5.324–325
- EDS. *See* Ehlers-Danlos syndrome
- EDTA (Ethylenediaminetetraacetic acid)
 - in artificial tears, 2.341
 - for band keratopathy, 2.306, 8.119, 9.281
 - in irrigating solutions, 2.367
 - off-label use of, 2.306
- Edwards syndrome, 6.386*t*
- EEG. *See* Electroencephalography
- EF. *See* Ejection fraction
- Efavirenz, 1.266
- EFEMP1 (epidermal growth factor-containing fibulin/fibrillin-like extracellular matrix protein 1) gene
 - mutations, 2.265, 12.275
- Effectivity of lenses, 3.40, 3.60

- Effector blockade, 9.58, 9.59
- Effector cells, 9.38–39, 9.39f
 basophils and mast cells as, 9.10
 dendritic cells and Langerhans cells as, 9.11–12
 eosinophils as, 9.10
 locations of, 9.54t
 lymphocytes as, 9.12, 9.38–39, 9.39f, 9.44–49, 9.45f, 9.46t
 monocytes and macrophages as, 9.10–11
 neutrophils as, 9.9–10
- Effector phase of immune response arc, 9.33f, 9.38–39, 9.39f
 adaptive immunity and, 9.9, 9.40–52
 in anterior chamber–associated immune deviation, 9.58
 antibody-mediated, 9.41f, 9.41–44, 9.43t
 cells in. *See* Effector cells
 combined antibody and cellular, 9.50f, 9.50–52
 innate immunity and, 9.13–21, 9.14t
 lymphocyte-mediated, 9.38–39, 9.39f, 9.44–49, 9.45f, 9.46t
 mediator systems and, 9.22t, 9.22–30, 9.23f, 9.25f, 9.27–28t
 response to tuberculosis and, 9.31–32
 in viral conjunctivitis, 9.55–56
- Effector T (Teff) cells, in external eye defense, 8.12–13f
- Efference copy information, 5.40
- Efferent fibers, visceral, 2.103
- Efferent pupillary pathway, 2.96
- Efferent visual pathways/efferent visual system, 5.31–46, 5.211. *See also* Ocular motility, control of; Ocular motor pathways
- Effusion
 suprachoroidal
 angle-closure glaucoma and, 10.141, 10.142f, 10.144, 10.145, 10.145f
 cataract surgery and, 11.159
 flat or shallow anterior chamber and, 11.134
 after filtering surgery, 10.210–211
 uveal, angle-closure glaucoma and, 10.138–139
- Eflone. *See* Fluorometholone
- EGF. *See* Epidermal growth factor
- EGF-containing fibulin/fibrillin-like extracellular matrix protein 1 (*EFEMP1*) gene mutations, 2.265
- EGFR inhibitors. *See* Epidermal growth factor receptor (EGFR) inhibitors
- “Egg yolk” stage, of Best disease, 6.341, 6.342f
- EGPA. *See* Eosinophilic granulomatosis with polyangiitis
- Ehlers-Danlos syndrome (EDS), 1.142, 1.143, 2.175t, 8.190–193, 8.191t
 blue sclera in, 8.191t, 8.193
 corneal changes in, 8.191t, 8.193
 keratoglobus in, 8.171, 8.191t, 8.193
- Ehrlichiosis, human granulocytic (human granulocytic anaplasmosis), Lyme disease coinfection and, 1.250, 9.248
- Eicosanoids, 2.237–240, 2.238f, 9.20f, 9.24–25, 9.25f
 synthesis of, 2.238f, 2.238–239
- Eicosapentaenoic acid (EPA), 12.70
- EIF1AX* gene, in choroidal/ciliary body melanoma, 4.197, 4.278
- Eight-and-a-half syndrome, 5.191
- Eight-ball (total) hyphema, 8.393, 8.393f
- Eighth cranial nerve. *See* Cranial nerve VIII
- Eighth nerve tumors, in neurofibromatosis, 10.156.
 See also Acoustic neuromas/neurofibromas
- Einstein, Albert, 3.95
- EIU. *See* Endotoxin-induced (experimental immune) uveitis
- Ejection fraction (EF), in congestive heart failure, 1.105
- EK (endothelial keratoplasty). *See* Keratoplasty, endothelial
- EKC. *See* Epidemic keratoconjunctivitis
- Elastases, in ocular infections, 8.207
- Elastin, in pseudoexfoliation/exfoliation syndrome, 10.91, 10.93
- Elastotic degeneration/elastosis
 in pinguecula/pterygium, 4.56, 4.56f
 solar, of eyelid, 4.211–212, 4.212f
- Elder abuse, 1.179–180
- Elderly patients. *See* Age/aging; Geriatrics
- Electrical injuries
 corneal injury caused by, 8.385
 lens damage/cataracts caused by, 11.59, 11.59f
 macular hole caused by, 12.357
- Electro-oculography/electro-oculogram (EOG). *See also specific disorder*
 in acute pigment epitheliitis, 9.143t, 9.164
 in acute zonal occult outer retinopathy, 9.164–165, 12.51
 autosomal recessive bestrophinopathy evaluations, 12.51
 Best disease evaluations, 6.342, 12.51, 12.271
 bestrophin mutation evaluations, 12.51
 hereditary retinal disease evaluations using, 6.335
 illustration of, 12.52f
 in inflammatory chorioretinopathies, 9.143t
 in multiple evanescent white dot syndrome, 9.162
 purpose of, 12.50
 technique of, 12.50
 trans-RPE potential as basis for, 2.277
 vitelliform macular dystrophy evaluations, 12.51
- Electroablation, 10.213
- Electrocardiography (ECG)
 in congestive heart failure, 1.105
 exercise, 1.97
 in ischemic heart disease, 1.93, 1.94, 1.95–96
 in stroke evaluation, 1.122
- Electroencephalography (EEG), in epilepsy diagnosis, 1.201
- Electrolysis, for trichiasis/distichiasis, 7.160, 7.208, 8.88
- Electrolytes
 in lens, maintenance of balance of, 11.21, 11.22f
 in tear film, 2.214t, 2.216
- Electromagnetic spectrum, 3.93, 3.93f
- Electromagnetism theory, 3.94
- Electromyography/electromyogram (EMG)
 definition of, 6.32
 motor units on, 6.32
 in myasthenia gravis, 5.326, 7.217
 in myotonic dystrophy, 5.330
- Electron beam computed tomography, in ischemic heart disease, 1.98
- Electron microscopy
 diagnostic, 4.34t, 4.42
 in orbital tumor evaluation, 7.33
- Electrons, quantum theory of, 3.110
- Electrophoresis, denaturing gradient gel (DGGE), 2.162

- Electrophysiologic testing
 cardiac, in ventricular tachycardia, 1.115
 International Society for Clinical Electrophysiology of Vision standards for, 12.41
 purpose of, 12.41
 of retina, 2.268–269, 2.269*f*. *See also specific test*
 in inflammatory chorioretinopathies, 9.143*t*
 in low vision evaluation, 5.95–97, 5.96*f*
 in nonorganic disorder evaluation, 5.302
 retinal, 12.41–42
- Electroretinography/electroretinogram (ERG), 2.269, 5.96*f*, 5.96–97. *See also specific type*
 a-waves, 12.46, 12.251, 12.261
 ABCA4 retinopathy findings, 12.48*f*
 achromatopsia findings, 6.337, 12.250
 in acute zonal occult outer retinopathy, 9.143*t*, 9.164, 9.165
 acute zonal occult outer retinopathy findings, 12.227
 b-waves, 12.5, 12.42–44, 12.43*f*, 12.47*f*, 12.50, 12.261
 Best disease findings, 12.271
 birdshot chorioretinopathy findings, 12.49
 in birdshot uveitis, 9.143*t*, 9.147
 bradyopsia findings, 12.49
 central retinal artery occlusion findings, 12.50
 central retinal vein occlusion findings, 12.50
 in children, 12.50
 choroideremia findings, 12.50
 clinical considerations for, 12.46, 12.49–50
 cone dystrophies, 5.102
 findings associated with, 12.46, 12.47*f*, 12.265
 with supernormal rod ERG findings, 12.49
 cone–rod dystrophy phenotype in, 12.44
 congenital stationary night blindness findings, 6.338, 12.46, 12.47*f*, 12.251, 12.252*f*
 dark adaptometry and, 12.58
 drugs that cause abnormalities in, 12.304–305
 electrodes used in, 12.42
 enhanced S-cone disease/syndrome findings, 12.49, 12.266, 12.267*f*
 full-field (Ganzfeld). *See* Full-field (Ganzfeld)
 electroretinography
 functions of, 12.42
 fundus albipunctatus findings, 12.252
 hereditary retinal disease evaluations, 6.335
 hydrochloroquine toxicity findings, 12.45, 12.49*f*
 in inflammatory chorioretinopathies, 9.143*t*
 inherent noise in, 12.44
 Knobloch syndrome findings, 6.347
 Leber congenital amaurosis findings, 6.336, 12.266
 in low vision evaluation, 5.96*f*, 5.96–97
 macular dystrophy findings, 12.44, 12.46, 12.47*f*
 in measles retinopathy, 9.206
 melanoma-associated retinopathy findings, 12.286
 multifocal (mfERG), 5.96*f*, 5.96–97, 12.45, 12.48–49*f*
 in melanoma-associated retinopathy, 5.102–103
 in multiple evanescent white dot syndrome, 5.101
 multiple evanescent white dot syndrome on, 5.101, 9.143*t*, 9.162, 12.224
 in newborn, 12.44
 night blindness findings, 12.46
 in nonparaneoplastic autoimmune retinopathy, 5.103
 ocular ischemic syndrome findings, 12.138, 12.139*f*
 pattern, 12.45–46, 12.46–49*f*
 peak-time shift in, 12.44
 photophobia findings, 12.46
 in retinitis pigmentosa, 9.278
 rod monochromatism findings, 12.250
 S-cone monochromatism findings, 12.250
 siderosis bulbi findings, 12.362
 in uveitis, 9.90
 vigabatrin-related abnormalities of, 12.305
 X-linked retinitis pigmentosa findings, 12.50
- Elementary body (EB), 8.248–249
- Elestat. *See* Epinastine
- Elevated episcleral venous pressure, 10.102*t*, 10.102–103, 10.103*f*
 adnexal signs of, 10.31
 in children and adolescents, 10.150*t*
 intraocular pressure and, 10.20, 10.102
 open-angle glaucoma caused by, 10.102*t*, 10.102–103, 10.103*f*
 Sturge-Weber syndrome and, 10.30, 10.155
- Elevated intraocular pressure, 10.3, 10.89–90. *See also* Intraocular pressure
 in angle closure/angle-closure glaucoma, 10.117, 10.118
 acute, 10.123–124, 10.124–125
 management of, 10.184
 chronic, 10.126
 subacute/intermittent, 10.125
 in angle-recession glaucoma, 10.106, 10.107, 10.108
 aqueous humor dynamics and, 10.5, 10.5*f*, 10.13–19, 10.14*f*
 cataract surgery and, 10.211, 10.213, 11.75, 11.128*t*, 11.129, 11.136
 corneal edema and, 11.129
 ECCE, 11.198
 epithelial ingrowth and, 11.133
 expulsive suprachoroidal hemorrhage and, 11.159, 11.160
 flat or shallow anterior chamber and, 11.134, 11.135–136
 in glaucoma, 11.67, 11.75, 11.187
 postoperative hyphema and, 11.159
 retained lens material and, 11.141
 retrobulbar hemorrhage and, 11.158
 stromal/epithelial corneal edema and, 11.129
 in central retinal artery occlusion, 12.146
 in central retinal vein occlusion, 10.84, 12.133
 in chemical injury, management and, 8.383
 in children, 10.158–159
 circadian/diurnal variation and, 10.3, 10.8, 10.22, 10.80–81, 10.81*t*, 10.86, 10.87
 in combined-mechanism glaucoma, 10.7
 conjunctiva affected by, 10.31
 corneal blood staining and, 4.86
 corticosteroids causing, 2.299, 2.332–333, 2.333*t*, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.100, 10.108, 10.109–110
 optic nerve damage and, 10.110
 refractive surgery and, 13.41, 13.92, 13.104–105, 13.182, 13.201
 uveitis and, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.110
 cycloplegics causing, 2.313

- drugs for. *See* Antiglaucoma agents; Glaucoma, management of; *specific agent*
- episcleral venous pressure and, 10.20, 10.102
- factors causing, 10.21*t*, 10.21–22
- frequency of, 10.20*f*, 10.20–21
- in glaucoma, 10.3, 10.79, 10.80–81, 10.81*t*
- angle closure/angle-closure glaucoma, 10.117, 10.118
- acute, 10.123–124
- management of, 10.184
- chronic, 10.126
- subacute/intermittent, 10.125
- angle-recession glaucoma, 10.106, 10.107, 10.108
- cataract surgery and, 11.75
- combined-mechanism glaucoma, 10.7
- uveitic, 9.286
- corticosteroids after refractive surgery and, 13.41, 13.182, 13.201
- ghost cell glaucoma, 10.106
- glaucoma risk and, 10.3, 10.8, 10.79, 10.80–81, 10.81*t*
- glaucomatocyclitic crisis (Posner-Schlossman syndrome) and, 10.101
- hemolytic glaucoma, 10.106
- indications for surgery and, 10.197
- open-angle glaucoma, 10.79, 10.80–81, 10.81*t*
- optic neuropathy and, 10.46–47
- pediatric glaucoma, 10.147, 10.166
- phacolytic glaucoma/uveitis, 9.119, 11.67
- pigmentary glaucoma, 10.95
- postoperative, 10.108
- refractive surgery and, 13.41, 13.180–183, 13.182*f*, 13.200–201
- uveitis and, 9.119, 9.284–285, 9.285, 9.286, 10.100
- glaucoma risk and, 10.3, 10.8, 10.79, 10.80–81, 10.81*t*
- glaucoma without, 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*. *See also* Glaucoma, normal-tension
- in glaucomatocyclitic crisis (Posner-Schlossman syndrome), 10.101
- in hyphema, 8.394, 8.395, 10.104, 10.105
- sickle cell disease and, 8.395, 8.395*t*, 8.396
- surgery and, 8.395, 8.395*t*, 8.396
- indications for surgery and, 10.197
- after intravitreal injection of anti-VEGF drugs, 12.404
- after LASIK, 13.181, 13.182, 13.200–201
- pressure-induced stromal keratopathy and, 13.119, 13.120*f*
- LASIK flap creation and, 13.181, 13.201
- lens epithelium affected by, 4.120
- nasal continuous positive airway pressure and, 1.132
- Nd:YAG laser capsulotomy and, 11.156
- in ocular ischemic syndrome, 9.279
- optic neuropathy and, 10.46–47
- after penetrating keratoplasty, 8.424–425, 8.426
- phacoemulsification lowering, 11.186
- after photoablation, 13.104–105, 13.200–201
- postoperative, 10.108–109
- after combined cataract surgery and trabeculectomy, 10.212
- after laser trabeculectomy, 10.108, 10.190, 10.191
- after trabeculectomy, 10.208–209
- after tube shunt implantation, 10.217
- in pseudoexfoliation/exfoliation syndrome, 10.93
- refractive surgery and, 13.41, 13.181, 13.200–201
- retinal detachment and, 10.109, 10.141
- sickle cell hemoglobinopathies/retinopathy and, 10.104, 10.105
- after surface ablation, 13.104–105, 13.181, 13.200–201
- trauma and, 7.113, 10.103–108
- in uveal lymphoid proliferation, 9.277
- in uveitis, 9.83, 9.113, 9.284–285, 9.285
- corticosteroid-induced, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.110
- glaucoma and, 9.119, 9.284–285, 9.285, 10.100–102, 10.102*f*
- herpetic infection and, 9.192
- Elevation-based tomography, 13.22, 13.22*f*
- Elevation of eye (upgaze), 6.33, 6.37–38
- disorders/limitation of, 5.228–229
- in Brown syndrome, 5.208
- in dorsal midbrain (Parinaud) syndrome, 5.229, 5.230*f*
- in monocular elevation deficiency (double-elevator palsy), 7.213
- in newborns, 5.230
- in orbital floor/blowout fracture, 7.108
- surgery and, 7.110
- saccadic dysfunction and, 5.222
- extraocular muscles controlling, 5.36*f*, 5.46*f*
- inferior oblique muscle, 5.36*f*, 5.46*f*
- superior rectus muscle, 5.36*f*, 5.46*f*
- 11p13 syndrome (short arm 11 deletion syndrome/ PAX6 gene mutation), 2.193
- in aniridia, 2.152, 2.177, 2.193, 4.184, 10.150, 11.33
- ELISA. *See* Enzyme-linked immunosorbent assay
- Ellipsoid, 12.12
- of cone, 2.70, 2.72*f*
- photoreceptor
- of cone, 2.70, 2.72*f*
- of rod, 2.69, 2.72*f*
- of rod, 2.69, 2.72*f*
- Ellipsoid zone, 4.141*f*
- Ellipsoidal mirror, scanning laser ophthalmoscopy use of, 12.24
- Elliptical phacoemulsification, 11.101
- Elliptically polarized light, 3.98
- ELM. *See* External limiting membrane
- ELOVL4 gene, in Stargardt disease, 4.168
- ELP. *See* Estimated lens position
- Elschnig, border tissue of, 2.88*f*
- Elschnig pearls, 4.121, 4.121*f*, 11.152
- Elschnig ring, 10.43
- Elschnig spots, 12.123, 12.123*f*, 12.196
- in polyarteritis nodosa, 9.136
- Eltrombopag, for idiopathic thrombocytopenic purpura, 1.143
- Emadine. *See* Emedastine
- Emanation theory of vision, 11.3
- Emboli
- in atrial fibrillation, 1.114
- cholesterol (Hollenhorst plaques)
- in branch retinal artery occlusion, 4.156
- transient visual loss and, 5.165, 5.165*f*, 5.166*t*
- retinal vasculitis versus, 12.156
- stroke caused by, 1.120

- transient visual loss caused by, 5.161, 5.162, 5.163*t*, 5.165, 5.165*f*, 5.165–169, 5.166*t*
 clinical/laboratory evaluation in, 5.166–168
 prognosis/treatment and, 5.168–169
- Embryogenesis, 2.111, 2.112*f*. *See also* Eye, development of
- Embryology. *See* Congenital anomalies; Eye, development of
- Embryonal rhabdomyosarcoma, 4.236, 7.83
- Embryonic fissure, 2.117*f*, 2.118*f*
 closure of, 2.116*t*, 2.118*f*, 2.119*f*
 colobomas and, 2.117, 2.119*f*
- Embryonic lens nucleus, 2.65*f*, 4.117, 11.13, 11.27*f*
 opacification of (congenital nuclear cataract), 11.38, 11.39*f*
- Embryotoxon, posterior, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.101–102, 8.102*f*. *See also* Anterior segment, dysgenesis of
 in Axenfeld-Rieger syndrome, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.102, 10.31, 10.153
 isolated, Axenfeld-Rieger syndrome differentiated from, 10.154*t*
- Emedastine, 2.337, 2.338*t*
- Emergencies, 1.295–305. *See also specific type*
 cardiopulmonary arrest, 1.295–299, 1.296*t*, 1.297*f*
 medications used in, 1.296*t*
 recent developments and, 1.295
 seizures/status epilepticus, 1.303–304
 shock, 1.300–303
 syncope, 1.300
 toxic medication reactions, 1.304*t*, 1.304–305
- Emergency kit, personal, 1.302
- Emergency Medical Service (EMS) system, 1.297
- EMG. *See* Electromyography/electromyogram
- EMGT (Early Manifest Glaucoma Trial), 10.88, 10.113
- Emissary channels, scleral, 2.44, 4.107*f*, 4.108, 4.108*f*
 melanoma spread via, 4.194, 4.195*f*
- Emmetropia
 accommodative demand, 3.208
 in children, 3.141
 definition of, 3.124, 3.136, 3.137*f*
 model of, 3.12, 3.13*f*
 pictorial representation of, 3.140*f*
 retinal reflex in, 3.152
- Emmetropization, 3.141, 6.180
- Emollients, ocular, 2.341
- Emphysema, 1.130
- Emphysema (ocular), of orbit and eyelids, in orbital floor/blowout fracture, 7.109
- Empirical horopter, 6.41, 6.42*f*
- EMS (Emergency Medical Service) system, 1.297
- Emtricitabine, 1.266, 1.267
- Emulsification. *See also* Phacoemulsification
 locations of, 11.111–112
- En face scan
 definition of, 12.26
 retinal disease evaluations, 12.26, 12.29
- En grappe nerve endings, for tonic (slow twitch) fibers, 2.18
- En plaque nerve endings
 for fast twitch fibers, 2.18
 neuromuscular blocking agents affecting, 2.315
- Enalapril
 for heart failure, 1.110
 for hypertension/hypertensive emergencies, 1.68*t*, 1.69*t*, 1.74
 ocular effects of, 1.308*t*
- Encapsulated-cell technology, for drug delivery, 2.303
- Encapsulation, polysaccharide, as microbial virulence factor, 1.240
- Encephalitis
 brainstem, CMV infection causing, 5.349
 herpes, 1.258, 5.350, 5.350*f*
 acute retinal necrosis and, 9.196
 West Nile virus causing, 9.209
- Encephalitozoon, 8.252
 keratoconjunctivitis caused by, 8.280
- Encephaloceles, 6.225, 7.37
 orbital region, 7.37
- Encephalofacial angiomatosis/encephalofacial cavernous hemangiomatosis. *See* Encephalotrigeminal/encephalofacial angiomatosis/hemangiomatosis (Sturge-Weber syndrome/SWS)
- Encephalomyelitis
 acute disseminated, optic nerve involvement and, 4.244, 4.244*f*
 in Lyme disease, 1.251
- Encephalopathy
 HIV (AIDS dementia complex/HIV-associated neurocognitive disorder), 1.264, 5.348
 inherited, migrainelike headache and, 5.294–295
 Leigh necrotizing (Leigh syndrome), 2.159, 2.175*t*
 mitochondrial DNA mutations and, 2.159
 posterior reversible (PRES) syndrome, 5.333–335, 5.335*f*
 transmissible spongiform, 5.357
- Encephalotrigeminal/encephalofacial angiomatosis/hemangiomatosis (Sturge-Weber syndrome/SWS), 5.331, 5.332*f*, 5.334*t*, 10.30, 10.155
 choroidal hemangioma in, 4.197, 4.281, 5.332*f*, 5.334*t*
 glaucoma associated with, 5.332*f*, 5.334*t*, 10.30, 10.155
 in children, 5.332*f*, 10.155
 port-wine stain (port-wine nevus/nevus flammeus) in, 5.332*f*, 5.334*t*, 10.30, 10.155
- Enclavation, 13.141
- ENCODE (ENCyclopedia Of DNA Elements), 2.135
- End-stage renal disease, in diabetes mellitus, 1.48
- Endarterectomy, carotid (CEA)
 for carotid stenosis, 1.119, 1.124–125
 for ocular ischemic syndrome, 9.279
- Endemic Kaposi sarcoma, 9.299
- Endobrow incision, 7.243
- Endocarditis/endocarditis prophylaxis, 1.243, 1.243*t*
 ocular surgery and, 1.287
- Endocrine action, of cytokines, 9.26
- Endocrine diseases, corneal changes in, 8.199–201, 8.200*t*, 8.201*f*
- Endocrine disorders, 1.33–59. *See also specific type*
 diabetes mellitus, 1.33–50
 hypothalamic-pituitary axis and, 1.56*t*, 1.56–58
 multiple endocrine neoplasia syndromes, 1.58–59, 1.59*f*, 8.200
 recent developments in, 1.33
 thyroid disease, 1.50–56
- Endoderm, 2.111, 2.112*f*, 2.113*f*, 2.114*f*

- Endogenous bacterial endophthalmitis, 12.237–239, 12.238f
- Endogenous endophthalmitis. *See* Endophthalmitis, endogenous
- Endogenous infection, uveal, 4.185
- Endolysins, bacteriophage, 1.280
- Endometrial tissue sampling, for cancer screening, 1.210t
- Endonasal (internal) dacryocystorhinostomy (DCR), 7.279, 7.280, 7.281f
endoscopic, 7.280
- Endonucleases, 2.135
- Endophthalmitis, 9.261–272
Bacillus causing, 8.247, 8.403, 12.363
bacterial
 endogenous, 9.263–265, 9.264f
 postoperative, 9.261–262, 9.262f
 toxins affecting severity of, 9.15
 vitreous affected in, 4.127, 4.128f
bevacizumab and, 12.85
bleb-associated, 10.163, 10.209, 10.209t, 10.210f, 12.390–391, 12.391f
after cataract surgery, 6.305
compounded bevacizumab causing, 2.306
corticosteroid route of administration in, 2.333t
endogenous, 9.261, 9.263–272, 9.264f, 9.266f, 9.267f, 9.269f, 9.271f
 Aspergillus causing, 9.265, 9.268–270, 9.269f
 bacterial, 9.263–265, 9.264f
 Candida causing, 9.265–268, 9.266f, 9.267f
 in coccidioidomycosis, 9.265, 9.270–272, 9.271f
 in cryptococcosis, 9.270
 fungal, 9.265–272, 9.266f, 9.267f, 9.269f, 9.271f
evisceration for, 7.130
fungal, 12.239, 12.239f
 endogenous, 9.265–272, 9.266f, 9.267f, 9.269f, 9.271f
 postoperative, 9.262
infectious, 4.119, 4.119f, 4.127, 4.128f, 9.119. *See also*
 specific type and causative agent
 after cataract surgery, 11.127, 11.140, 11.160–163, 11.161f
 intravitreal corticosteroids and, 9.98
intraocular specimens for diagnosis of, 9.262–263, 9.264–265
after intravitreal injections, 12.404
after penetrating and perforating ocular trauma, 8.247, 8.403
phacoanaphylactic/lens-induced granulomatous (phacoantigenic/lens-associated uveitis), 4.118–119, 4.119f, 9.118, 9.119, 11.66
sympathetic ophthalmia and, 9.174
postoperative, 9.119
 acute-onset, 9.261, 11.162, 12.388–390, 12.390f
 bleb-associated, 10.163, 10.209, 10.209t, 10.210f, 12.390–391, 12.391f
 after cataract surgery, 4.119, 4.119f, 9.261–263, 9.262f, 11.127, 11.140, 11.160–163, 11.161f
 prevention of, 11.93–95, 11.94f, 11.161–162
 chronic (delayed-onset), 9.261–263, 9.262f, 11.162, 11.163, 12.390, 12.391f
 bacterial, 9.261–262, 9.262f
 fungal, 9.262
 after penetrating keratoplasty, 8.424
 prophylaxis of, 11.93–95, 11.94f, 11.161–162
 Propionibacterium acnes causing, 4.119, 4.119f, 8.246, 9.119, 9.261–262, 9.262f, 11.140, 11.162
 posttraumatic, 12.362–363
 Propionibacterium acnes causing, 4.119, 4.119f, 8.246, 9.119, 9.261–262, 9.262f, 11.140, 11.162
 sterile, 9.261
 intravitreal corticosteroids and, 9.98
 Streptococcus viridans as cause of, 12.404
 in toxocariasis, 9.228, 9.229t
 yeast, 12.239–240, 12.240f
- Endophthalmitis Study Group of the European Society of Cataract and Refractive Surgeons (ESCRS), on postoperative endophthalmitis, 11.94, 11.162
- Endophthalmitis Vitrectomy Study (EVS), 11.161, 11.162, 12.389–390
- Endophytic retinoblastoma, 6.352, 6.352f
- Endoscopic brow- and forehead-lift, 7.241, 7.242f
- Endoscopic cyclophotocoagulation (ECP)/endoscopic laser delivery, 10.194, 10.195, 10.196. *See also* Cyclophotocoagulation/cycloablation
- cataract surgery and, 11.186
for pediatric glaucoma, 10.163–164
- Endoscopic dacryocystorhinostomy (DCR), 7.280
- Endoscopic photocoagulation (ECP), for childhood glaucomas, 6.287–288, 6.288f
- Endoscopic subperiosteal midface lift, 7.243, 7.244f
- Endoscopy, nasal
 for lacrimal drainage evaluation/obstruction, 7.272
 for orbital decompression, 7.122
- Endothelial cells
 in angiogenesis, 12.79
 density of, 8.10
 age-related decrease in, 8.10, 8.23
 reduction of after endothelial keratoplasty (DMEK/DSEK), 8.448–449
 specular microscopy in evaluation of, 8.23
 migration of, DMEK and, 8.449
- Endothelial degenerations, 8.126–128
 age-related, 8.115
- Endothelial dystrophies, 4.92–94, 4.93f, 4.94f, 8.135t
 cataract surgery in patient with, 11.175
 congenital hereditary (CHED/CHED2), 4.92–93, 4.94f, 8.135t, 8.136t, 8.160, 8.161f
 Fuchs (FECD), 2.43f, 4.92, 4.93f, 8.23f, 8.135t, 8.136t, 8.156–158, 8.157f
 descemetorhexis/DMET for, 8.157–158, 8.449
 IOL implantation and, 11.149, 13.155
 refractive surgery and, 13.43, 13.178
 multifocal IOL implantation, 13.155
 posterior polymorphous (PPCD/PPMD/CHED1), 4.93–94, 4.94f, 8.135t, 8.136t, 8.158–160, 8.159f, 8.160f
 glaucoma and, 8.159, 10.31
- Endothelial failure. *See also* Endothelial graft rejection
 after endothelial keratoplasty (DMEK/DSEK), 8.447
 after penetrating keratoplasty, 4.84, 4.85f
 late non-immune-mediated, 8.427–428
 primary, 8.423, 8.423f
- Endothelial graft rejection. *See also* Endothelial failure; Rejection
 after endothelial keratoplasty (DMEK/DSEK), 8.437t, 8.447f, 8.447–448
 after penetrating keratoplasty, 8.429, 8.430f, 9.59, 9.60, 9.60f

- Endothelial keratoplasty (EK). *See* Keratoplasty, endothelial
- Endothelial meshwork, 2.49–50
- Endothelial pump, corneal hydration and, 8.9
- pachymetry in evaluation of, 8.41–42
- Endothelial rings, corneal, traumatic, 8.388
- Endotheliitis (disciform keratitis), 8.51f
- CMV causing, 8.232, 8.232f
- herpes simplex virus causing, 4.77f, 4.78, 8.220, 8.221f, 8.222
- persistent bullous keratopathy and, 8.225
- Endothelin (ET)
- in aqueous humor, 2.234
- receptors for, 2.316t
- in signal transduction, 2.316t
- Endothelium, corneal, 2.41–43, 2.42f, 2.43f, 2.223f, 2.227, 4.73, 4.74f, 8.7f, 8.10. *See also under Endothelial*
- anatomy of, 2.41–43, 2.42f, 2.43f, 2.223f, 8.7f, 8.10
- biochemistry and metabolism of, 2.227
- deposits in, 8.118t, 8.132
- development of, 2.118, 2.120, 2.121f, 2.122
- dysfunction of, 2.43, 8.52
- keratoplasty for, 8.411, 8.436–450. *See also* Keratoplasty, endothelial
- novel methods for treatment of, 8.449–450
- glucose metabolism in, 2.224
- healing/repair of, 4.16
- keratorefractive surgery and, 13.32–33
- multifocal IOL implantation and, 13.155
- phakic IOL implantation and, 13.141
- angle-supported lenses, 13.146
- iris-fixated lenses, 13.145
- posterior chamber lenses, 13.146
- pigmentation of/deposits in, 8.118t
- drug-induced, 8.132
- in uveitis, 9.80t
- Endotoxin-induced (experimental immune) uveitis (EIU), 9.14–15, 9.63
- Endotoxins, microbial, 8.244
- endophthalmitis severity and, 9.15
- in innate immune response, 9.13–14, 9.14t
- virulence and, 1.240
- Energy
- definition of, 3.106
- kinetic, 3.106
- phaco, 11.99. *See also* Power
- potential, 3.106
- transfer of, 3.106
- Energy production
- in lens, 2.246
- in retinal pigment epithelium, 2.273, 2.274
- Energix-B (hepatitis B vaccine), 1.219
- Enhanced depth imaging optical coherence tomography (EDI/EDI-OCT)
- autofluorescence imaging and, 12.39
- central serous chorioretinopathy findings, 12.67, 12.191, 12.193f
- in choroidal/ciliary body melanoma, 4.265, 4.268
- choroidal layer on, 12.79, 12.193f
- choroidal-scleral interface on, 12.66
- description of, 12.25
- in metastatic eye disease, 4.307
- in optic nerve/nerve head/disc drusen, 5.142
- pachychoroid on, 12.76
- Enhanced S-cone disease (ESCD), 12.266, 12.267f
- Enhanced S-cone syndrome, 12.49
- Enhancer (of transcription rate), 2.135
- Enophthalmos, 5.271, 7.23–24
- breast carcinoma metastasis to orbit and, 7.100, 7.100f
- cataract surgery in patient with, 11.77
- in medial orbital wall/blowout fracture, 7.108
- in orbital floor/blowout fracture, 7.109
- surgery and, 7.110–111, 7.111
- orbital varices and, 7.71
- Enoxacin, 1.277
- Enoxaparin, for non-ST-segment elevation acute coronary syndrome, 1.103
- Entacapone, for Parkinson disease, 1.199
- Enteritis, regional (Crohn disease), 1.155, 9.116
- Enterobacter*/*Enterobacteriaceae*, 8.244t, 8.247
- conjunctivitis caused by, 8.257t
- Enterococcus*, 8.244t, 8.245
- faecalis*, 8.245
- postoperative endophthalmitis caused by, 11.161
- vancomycin-resistant, 1.239, 1.241, 1.277, 8.245
- Enterocolitis, pseudomembranous, *Clostridium difficile* causing, 1.244
- Enterocytozoon*, 8.252
- Enteropancreatic tumors, in multiple endocrine neoplasia, 1.58
- Enteropathic arthritis, 1.155, 6.315t
- Enteroviruses, 8.240t
- acute hemorrhagic conjunctivitis caused by, 8.240, 8.240t
- Enthesitis
- in juvenile idiopathic (chronic/rheumatoid) arthritis, 1.155
- in spondyloarthropathies/spondyloarthritis, 1.153, 1.155
- Enthesitis-related arthritis, 6.315t
- Entrance pupil, 3.124, 3.130–131
- Entropion, 7.202–207, 7.203f, 7.204f, 7.205f, 7.206f, 7.207f
- cicatricial, 7.198f, 7.201, 7.202f, 7.206f, 7.206–207, 7.207f
- congenital, 6.194, 7.159–160, 7.160f
- involutional, 7.202–204, 7.203f, 7.204f, 7.205f
- lash margin
- in anophthalmic socket, 7.136
- tarsal fracture operation for, 7.207, 7.207f
- trichiasis in, 7.208
- spastic/acute spastic, 7.203, 7.204f
- Eucleation, 7.127, 7.128–129
- in childhood, 7.129
- congenital anophthalmia/microphthalmia treatment and, 7.36
- goals of, 7.129
- intraoperative complications of, 7.130
- for medulloepithelioma, 4.296
- for melanoma, 4.196, 4.274–275, 7.128
- ocular prostheses after, 7.132
- orbital implants after, 7.129

- for penetrating and perforating ocular trauma, 8.404, 12.233
- ptosis/extraocular muscle damage and, 7.130
- for retinoblastoma, 4.299, 7.128
- rubeosis iridis and, 4.188, 4.189*f*
- for sympathetic ophthalmia prevention, 7.128, 8.404, 9.175
- for uveal lymphoid proliferation/infiltration, 4.314
- wrong-eye removal and, 7.130
- Envelope (virus)/enveloped viruses, 8.212
- Environment/environmental factors
 - in dry eye, 8.54*f*, 8.55, 8.55*f*, 8.61
 - in glaucoma, 10.10
- Enzymatic cleaners, for contact lens, 3.229, 3.229*t*
- Enzymatic (Sanger) method, for DNA sequencing, 2.143, 2.161, 2.162, 2.162*f*
- Enzymatic vitreolysis, 2.255
- Enzyme defects, disorders associated with, 2.174, 2.175*t*
 - inheritance of, 2.174, 2.175*t*
 - management of, 2.203–204
 - ocular findings in, 2.175*t*
- Enzyme-linked immunosorbent assay (ELISA)
 - in CMV infection, 9.201
 - in cysticercosis, 9.231
 - in leptospirosis, 9.249
 - in Lyme disease, 1.251, 5.353, 9.246, 12.246
 - in syphilis, 9.241–242
 - in toxocarasis, 9.229, 12.245
 - in toxoplasmosis, 9.224
 - in tuberculosis, 9.254
- Enzymes, in aqueous humor, 2.229, 2.234
- EOG. *See* Electro-oculography/electro-oculogram
- EOMs. *See* Extraocular muscles
- Eosinophilic granuloma. *See also* Histiocytosis
 - of bone, 6.219, 6.219*f*
 - orbital, 7.90
- Eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss syndrome), 1.165*t*, 1.168
- Eosinophils, 4.7, 4.8*f*, 9.10
- EPA. *See* Eicosapentaenoic acid
- Eperezolid, 1.273*t*
- EPHA2* gene, in age-related cataracts, 11.41–42
- Ephelis, 4.219. *See also* Freckle
 - of eyelid, 7.174
- Epi-LASIK. *See* Epipolis laser in situ keratomileusis
- “Epi-off” (“epithelium-off”) corneal crosslinking, 13.130, 13.132, 13.133*t*. *See also* Corneal (collagen) crosslinking
- “Epi-on” (“epithelium-on”) corneal crosslinking, 13.133*f*. *See also* Transepithelial corneal crosslinking
- Epiblast, 2.112*f*
- Epiblepharon, 6.194, 6.195*f*, 7.157*f*, 7.159, 7.159*f*
- Epibulbar (limbal) dermoids, 4.6, 4.47, 4.49*f*, 6.210, 6.256, 6.256*f*, 6.257*t*
 - Goldenhar syndrome and, 8.195, 8.195*f*
- Epicanthus, 6.196, 6.196*f*, 7.157*f*, 7.158*f*, 7.158–159
 - inversus, 7.158, 7.159
 - in blepharophimosis-ptosis-epicanthus inversus syndrome, 7.155, 7.158
 - palpebralis, 7.158
 - supraciliaris, 7.158
 - tarsalis, 7.158, 7.159
- Epicanthus inversus, 6.196
- Epicanthus palpebralis, 6.196, 6.196*f*
- Epicanthus supraciliaris, 6.196
- Epicanthus tarsalis, 6.196, 6.196*f*
- Epicapsular star, 11.31, 11.32*f*
- Epidemic Kaposi sarcoma, 9.299*f*, 9.299–300
- Epidemic keratoconjunctivitis (EKC), 6.213, 6.242, 8.233, 8.234*f*, 8.234–236, 8.235*f*
- Epidermal/epidermoid cysts
 - of eyelid, 4.208, 4.208*f*, 7.168*f*, 7.168–169, 7.169*f*
 - of orbit, 4.223–224, 7.39
- Epidermal growth factor (EGF), 2.371–372
 - in tear film, 2.217, 8.6*f*
- Epidermal growth factor (EGF)—containing fibulin/fibrillin-like extracellular matrix protein 1 (*EFEMP1*) gene mutations, 2.265
- Epidermal growth factor receptor (EGFR) inhibitors, for squamous cell carcinoma, 7.182
- Epidermal inclusion cysts, of eyelid, 7.168, 7.168*f*
- Epidermal necrolysis, toxic (Stevens-Johnson syndrome and Stevens-Johnson syndrome/toxic epidermal necrolysis overlap/SJS-TEN), 8.285, 8.295–298, 8.296*f*, 8.297*f*
- Epidermis, eyelid, 4.201, 4.201*f*, 8.3–4
 - neoplasms of, 4.209*f*, 4.209–213, 4.210*f*, 4.210*t*, 4.211*f*, 4.212*f*, 4.213*f*, 4.214*f*, 7.155, 7.168*f*, 7.168–169, 7.169*f*, 7.175–176, 7.176*f*. *See also* Eyelids, tumors of
 - benign, 7.168*f*, 7.168–169, 7.169*f*
 - pre-malignant (actinic keratosis), 4.210–212, 4.211*f*, 4.212*f*, 7.175–176, 7.176*f*
- Epidermoid/epidermal cysts
 - of eyelid, 4.208, 4.208*f*, 7.168*f*, 7.168–169, 7.169*f*
 - of orbit, 4.223–224, 6.223, 7.39
- Epifrin. *See* Epinephrine
- Epigastric thrusts, 1.299
- Epigenetics/epigenomics, 2.135, 2.151
- Epikeratoplasty (epikeratophakia), 13.8*t*, 13.27, 13.59, 13.62
- Epilation, for trichiasis/distichiasis, 7.160, 7.208, 8.88
- Epilepsy, 1.200–204. *See also* Seizures
 - diagnosis of, 1.201–202
 - etiology of, 1.201
 - hallucinations and, 5.177
 - ophthalmic considerations and, 1.203–204
 - status epilepticus and, 1.303–304
 - transient visual loss and, 5.161, 5.162, 5.172
 - treatment of (antiepileptic drugs), 1.202*t*, 1.202–204
 - ophthalmic considerations and, 1.203, 1.307*t*
- Epimerase deficiency, galactosemia/cataract formation and, 11.61
- Epimyoepithelial islands, 7.94
- Epinastine, 2.338*t*, 2.339
- Epinephrine, 2.318*t*, 2.321
 - adrenergic receptor response and, 2.316, 2.321
 - adrenochrome deposition caused by, 8.118*t*, 8.131
 - for anaphylaxis, 1.302
 - for asthma, 1.134
 - dipivalyl. *See* Dipivefrin
 - for glaucoma, 10.177
 - intracameral administration of, 2.300*t*
 - for intraoperative floppy iris syndrome, 11.138
 - with local anesthetic, 1.305, 2.363–364
 - for dacryocystorhinostomy, 7.279

- maximum safe dosage and, 1.304*t*
 - toxic reaction to, 1.305, 2.364
 - for medical emergencies, 1.296*t*, 1.302–303
 - in personal emergency kits, 1.302–303
- Epinephrine auto-injectors, 1.302–303
- Epipapillary vessels, 10.45
- Epiphora, 7.267, 8.46*t*. *See also* Tearing/epiphora
 - in primary congenital glaucoma, 10.151, 10.152, 10.152*t*, 10.158
 - differential diagnosis and, 10.151, 10.152*t*
- Epiphygan (*EPYC*) gene, in posterior amorphous corneal dystrophy, 8.136*t*
- Epipolis laser in situ keratomileusis (epi-LASIK), 13.8*t*, 13.73. *See also* Surface ablation
 - corneal preparation for, 13.83, 13.83*f*, 13.84
 - epithelial debridement, 13.83, 13.83*f*
 - epithelial preservation, 13.84
 - glaucoma/ocular hypertension and, 13.181, 13.182
 - immediate postablation measures for, 13.92–93
 - outcomes of, 13.84
- Epiretinal membranes (ERMs)
 - asymptomatic, 12.336
 - causes of, 12.332
 - contracture of, 12.335
 - definition of, 12.332
 - fluorescein angiography findings, 12.335
 - in idiopathic macular holes, 4.132
 - incidence of, 12.333
 - optical coherence tomography of, 12.335, 12.383*f*
 - prevalence of, 12.333
 - “pseudohole” appearance with, 12.334
 - retinal distortion caused by, 6.145
 - scanning laser ophthalmoscopy of, 12.334*f*
 - secondary, 12.333
 - signs and symptoms of, 12.334–335*f*, 12.334–336
 - spectral-domain optical coherence tomography of, 12.335*f*
 - treatment of, 12.336, 12.382, 12.383*f*
 - vitrectomy for, 12.382, 12.383*f*
 - vitreomacular traction syndrome versus, 12.382–383
- Episclera, 2.44, 4.107, 4.107*f*. *See also* Episcleritis
 - in glaucoma, 10.31, 10.102*t*, 10.102–103, 10.103*f*
 - healing/repair of, 4.16
 - immune-mediated disorders of, 8.318–326
 - melanosis of, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
 - nodular fasciitis causing tumor of, 4.112
- Episcleral plexus, 2.51, 2.52*f*, 5.21, 10.5*f*
- Episcleral (sub-Tenon) surgical space, 7.115, 7.115*f*
- Episcleral venous pressure (EVP), 10.19–20
 - elevated, 10.102*t*, 10.102–103, 10.103*f*
 - adnexal signs of, 10.31
 - in children and adolescents, 10.150*t*
 - intraocular pressure and, 10.20, 10.102
 - open-angle glaucoma caused by, 10.102*t*, 10.102–103, 10.103*f*
 - Sturge-Weber syndrome and, 10.30, 10.155
 - normal, 10.20, 10.102
- Episcleritis, 4.109, 8.46*t*, 8.318*f*, 8.318–319
 - in Chikungunya fever, 9.213–214
 - corticosteroid route of administration in, 2.333*t*
 - in herpes zoster, 8.227
 - immune-mediated, 8.318*f*, 8.318–319
 - in Lyme disease, 9.245, 9.246
 - nodular, 4.109, 8.318, 8.318*f*
 - in reactive arthritis/Reiter syndrome, 8.305–306
 - in rosacea, 8.70, 8.70*f*
 - simple (diffuse injection), 4.109, 8.318
 - in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296–297
- Epithelial basement membrane dystrophy, 3.277, 3.278*f*
- Epithelial cells. *See also* Epithelium
 - keratinization of (keratinized/degenerated)
 - in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297
 - in superior limbic keratoconjunctivitis, 8.84
 - in vitamin A deficiency, 8.196
- Epithelial cysts. *See also* Epithelial inclusion cysts
 - of cornea, drug-induced, 8.130
 - of eyelids, benign, 7.168*f*, 7.168–169, 7.169*f*
 - of orbit, 4.223–224, 6.170–171, 7.39
- Epithelial debridement (ED). *See* Debridement
- Epithelial defects
 - conjunctival, 8.46*t*
 - corneal/persistent corneal, 8.46*t*, 8.80–82, 8.81*t*, 8.82*f*
 - acid burns causing, 8.380, 8.380*f*
 - after cataract surgery, 11.132, 11.173
 - glaucoma medication toxicity and, 10.31
 - after LASIK, 13.93, 13.112
 - in diabetes mellitus, 13.190
 - management of, 8.368
 - after penetrating/deep anterior lamellar keratoplasty, 8.80, 8.424
 - after small-incision lenticule extraction, 13.205
 - after surface ablation, 13.107–108
 - topical anesthetic use/abuses and, 8.80–81, 8.81*t*, 8.89, 8.89*f*
 - in toxic keratoconjunctivitis, 8.80–81, 8.81*t*
- Epithelial degenerations, 8.115–120, 8.116*f*, 8.117*f*, 8.118*t*, 8.119*f*
- Epithelial downgrowth. *See* Epithelial ingrowth
- Epithelial dystrophies
 - epithelial and subepithelial, 4.87, 4.87*f*, 8.135*t*, 8.135–141
 - basement membrane (EBMD/map-dot-fingerprint/Cogan microcystic/anterior basement membrane), 4.87, 4.87*f*, 8.135*t*, 8.135–138, 8.136*t*, 8.137*f*, 8.138*f*
 - cataract surgery in patient with, 11.174*f*, 11.174–175
 - recurrent corneal erosion and, 8.86, 8.87, 8.133, 8.138
 - reduced vision and, 5.99
 - refractive surgery and, 13.42, 13.42*f*, 13.76, 13.78, 13.178
 - multifocal IOLs, 13.155
 - gelatinous droplike (GDLD), 8.135*t*, 8.140–141, 8.141*f*
 - Lisch (LECD), 8.135*t*, 8.136*t*, 8.140, 8.140*f*
 - Meesmann/Stocker-Holt variant, 8.135*t*, 8.136*t*, 8.139, 8.139*f*
 - mucinous (SMCD), 8.135*t*
 - recurrent erosion (EREDs), 8.86, 8.87, 8.133, 8.135*t*

- epithelial–stromal *TGFBI*, 4.88*f*, 4.88–91, 4.89*f*, 4.90*f*, 4.91*t*, 4.91*f*, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149
 granular, 8.135*t*
 type 1 (GCD1/classic), 4.90, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.147–148, 8.148*f*
 type 2 (GCD2/Avellino), 4.90, 4.91*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.148–149, 8.149*f*
 amyloid deposits in, 8.148, 8.186*t*
 refractive surgery and, 13.43
 lattice, 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–147, 8.146*f*, 8.147*f*
 recurrence of after corneal transplantation, 8.425
 Reis–Bücklers (RBCD/CDB1/atypical granular), 4.88, 4.88*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.142*f*, 8.142–143
 Thiel–Behnke (TBCD/CDB2), 4.88, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.143–144, 8.144*f*
- Epithelial edema, 8.42, 8.46*t*. *See also* Cornea, edema of
 after cataract surgery, 11.128*t*, 11.128–130
- Epithelial erosions, punctate (PEE)
 of conjunctiva, 8.46*t*
 of cornea, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
 in exposure keratopathy, 8.80
 in herpetic eye disease/neurotrophic keratopathy, 8.224
 refractive surgery and, 13.42, 13.42*f*
 vernal keratoconjunctivitis and, 8.290
- Epithelial graft rejection, 8.428, 8.428*f*. *See also* Rejection
- Epithelial hyperplasias, of eyelids, 7.166*f*, 7.166–168, 7.167*f*
- Epithelial inclusion cysts, 6.250
 conjunctival, 4.59, 4.59*f*, 8.114, 8.114*f*
 concretions and, 8.113–114
 nevi and, 4.64, 8.340
- Epithelial ingrowth (downgrowth)
 angle-closure glaucoma and, 10.141–142, 10.142*f*, 10.143*f*
 cataract surgery and, 11.128*t*, 11.132–133
 corneal graft failure and, 4.84, 4.85*f*
 after DSEK, 8.445, 8.445*f*
 after LASIK, 13.120–122, 13.121*f*
 in diabetes mellitus, 13.190
 pannus and, 8.52, 8.52*f*
- Epithelial keratitis/keratopathy
 adenovirus causing, 8.234, 8.235, 8.235*f*
 CMV causing, 8.232
 dry eye and, 8.56
 in epidemic keratoconjunctivitis, 8.235, 8.235*f*
 herpes simplex virus causing, 8.213, 8.214*f*, 8.216*f*, 8.216–219, 8.217*f*, 8.218*f*, 8.223*t*, 8.226*t*
 measles virus causing, 8.239
 punctate (PEK), 8.46*t*, 8.50, 8.50*f*, 8.50*t*
 adenoviruses causing, 8.234
 blepharitis/blepharoconjunctivitis and, 8.72, 8.73*t*, 8.74
 exposure causing, 8.80
 herpes simplex virus causing, 8.216, 8.216*f*
 in herpes zoster, 8.227, 8.228
 microsporidial, 8.280, 8.280*f*
 superficial Thygeson (SPK), 8.306–307, 8.307*f*
 varicella-zoster virus causing, 8.226, 8.226*t*
- Epithelial slough, LASIK and, 13.112
- Epithelial–stromal *TGFBI* dystrophies, 4.88*f*, 4.88–91, 4.89*f*, 4.90*f*, 4.91*t*, 4.91*f*, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149
 granular, 8.135*t*
 type 1 (GCD1/classic), 4.90, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.147–148, 8.148*f*
 type 2 (GCD2/Avellino), 4.90, 4.91*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.148–149, 8.149*f*
 amyloid deposits in, 8.148, 8.186*t*
 refractive surgery and, 13.43
 lattice, 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–147, 8.146*f*, 8.147*f*
 recurrence of after corneal transplantation, 8.425
 Reis–Bücklers (RBCD/CDB1/atypical granular), 4.88, 4.88*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.142*f*, 8.142–143
 Thiel–Behnke (TBCD/CDB2), 4.88, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.143–144, 8.144*f*
- Epithelial tumors, 4.10*t*, 4.11*f*
 of eyelids
 benign lesions, 7.168*f*, 7.168–169, 7.169*f*
 hyperplasias, 7.166*f*, 7.166–168, 7.167*f*
 in situ carcinoma, 7.176–177, 7.177*f*
 of lacrimal gland, 7.91–94, 7.92*f*
 exenteration for, 7.93, 7.136
 ocular surface, 8.332*t*, 8.332–337
 benign, 8.322*t*, 8.322–324, 8.333*f*
 malignant, 8.334–337, 8.335*f*, 8.336*f*
 preinvasive, 8.332*t*. *See also* Conjunctival or corneal intraepithelial neoplasia
 pigmented, of uvea and retina, 4.279–280, 4.280*f*
- Epithelial ulcer, geographic, in herpes simplex keratitis, 8.217, 8.217*f*, 8.218*f*
- Epitheliitis, acute retinal pigment (ARPE/Krill disease), 9.141–143*t*, 9.164, 9.164*f*
- Epithelioid (Leber) cells, 9.11, 9.21. *See also* Macrophages
 in choroidal/ciliary body melanoma, 4.192, 4.193*f*, 4.194, 4.195
 in sarcoidosis, 9.11
- Epithelioid histiocytes, 4.7, 4.8*f*
- Epithelioid melanoma, 4.192, 4.193*f*, 4.194, 4.195
- Epitheliopathy
 acute posterior multifocal placoid pigment (APMPPE/AMPPPE), 9.141–143*t*, 9.148*f*, 9.148–151, 9.149*f*, 9.150*f*, 9.151*f*
 in herpetic keratitis, 8.224
 in microsporidiosis, 8.280, 8.280*f*
 in toxic keratoconjunctivitis, 8.90
- Epithelium. *See also* Epithelial; Ocular surface
 ciliary, 2.57–58, 2.58*f*
 aqueous humor formation/dynamics and, 2.229, 2.230, 2.231, 2.232, 2.324, 2.324*f*
 nonpigmented, 2.57, 2.58*f*, 2.229, 2.230
 benign adenomas of, 4.279
 pigmented, 2.57, 2.58*f*, 2.230
 acquired hyperplasia of, 4.279, 4.280*f*
 benign adenomas of, 4.279
 conjunctival, 2.30–31, 2.215*f*, 2.216, 4.47, 4.48*f*, 8.7, 8.7*f*
 corneal resurfacing by (conjunctivalization), 8.362
 cysts of, 4.59, 4.59*f*, 8.114, 8.114*f*. *See also* Epithelial inclusion cysts
 nevi and, 4.64

- dysplasia of (conjunctival intraepithelial neoplasia/ CIN), 4.61, 4.63*f*, 8.37, 8.38*f*, 8.332*t*, 8.334, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia; Ocular surface squamous neoplasia
 melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
 in external eye defense, 8.13
 in pseudoeptiphora, 7.268
 tear secretion and, 2.215*f*, 2.216, 2.217
 tumors of, 8.332*t*, 8.332–337
 corneal. *See* Cornea, epithelium of
 debridement of
 for epithelial defects
 after LASIK, 13.112
 after surface ablation, 13.108
 for surface ablation, 13.82–84, 13.83*f*
 in external eye defense, 8.12*f*, 8.13, 8.13*f*, 8.13–14, 8.207
 eyelid
 benign lesions of, 7.168*f*, 7.168–169, 7.169*f*
 hyperplasia of, 7.166*f*, 7.166–168, 7.167*f*
 in situ carcinoma of, 7.176–177, 7.177*f*
 healing of, keratorefractive surgery and, 13.32–33
 delayed, 13.93–94, 13.108
 iris pigment. *See* Iris pigment epithelium
 lens, 2.63*f*, 2.64, 2.65*f*, 2.120, 2.242, 2.242*f*, 4.116*f*, 4.117, 11.10*f*, 11.12*f*, 11.12–13
 active transport and, 11.21
 degenerations of, 4.120*f*, 4.120–121, 4.121*f*, 4.122*f*.
 See also Cataract
 development of, 11.27, 11.27*f*
 opacification of (capsular cataract), 11.38
 topography of, 4.116*f*, 4.117
 preparation of, for refractive surgery, 13.82–84, 13.83*f*
 preservation techniques for
 in epi-LASIK, 13.84
 in LASEK, 13.84
 retinal pigment. *See* Retinal pigment epithelium
 tumors of. *See* Epithelial tumors
 “Epithelium-off” (“epi-off”) corneal crosslinking, 13.130, 13.132, 13.133*t*. *See also* Corneal (collagen) crosslinking
 “Epithelium-on” (“epi-on”) corneal crosslinking, 13.133*f*. *See also* Transepithelial corneal crosslinking
 Epitopes, 9.31, 9.34, 9.42
 in adaptive immunity, 1.240
 Eplerenone, 1.68*t*
 Epley procedure, for benign paroxysmal positional vertigo, 5.243
 Eprosartan, 1.68*t*, 1.69*t*
 Epstein-Barr virus (EBV), 1.260, 6.243, 8.230, 9.202, 9.203*f*
 cancer association and, 1.228, 1.260
 dacryoadenitis caused by, 7.284, 8.208*t*, 8.230–231
 in multifocal choroiditis and panuveitis syndrome, 9.156
 ocular infection caused by, 8.208*t*, 8.230–231, 8.231*f*, 9.202, 9.203, 9.203*f*
 Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH/EBV-associated hemophagocytic syndrome), 1.260
 Eptifibatide, for ischemic heart disease, 1.101*t*
 non-ST-segment elevation acute coronary syndrome, 1.103–104
 EPYC gene, in posterior amorphous corneal dystrophy, 8.136*t*
 Equator (lens), 2.63, 2.63*f*, 2.65*f*, 2.242, 2.242*f*, 4.116*f*, 4.117, 11.9, 11.10*f*, 11.12*f*
 Equatorial lens bow, 4.116*f*, 4.117
 Equatorial retina, 12.9–10
 Equatorial streaks, in ocular histoplasmosis syndrome, 9.215, 9.216*f*
 Equine recurrent uveitis, 9.63
 Equivalent optical system, 3.67–68, 3.68–69*f*
 Erbium:YAG laser, for skin resurfacing, 7.237
 Erdheim-Chester disease (ECD), 7.90, 7.91
 eyelid manifestations of, 4.207*t*
 Erectile dysfunction, ocular effects of drugs for, 1.308*t*
 EREDs. *See* Recurrent erosion corneal dystrophies
 ERG. *See* Electroretinography/electroretinogram
 Ergot alkaloids, 12.300
 ERMs. *See* Epiretinal membranes
 Erosions
 conjunctival, 8.47*t*
 punctate epithelial, 8.46*t*
 corneal
 in epidemic keratoconjunctivitis, 8.234
 epithelial, punctate, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
 in exposure keratopathy, 8.80
 in herpetic eye disease/neurotrophic keratopathy, 8.224
 refractive surgery and, 13.42, 13.42*f*
 vernal keratoconjunctivitis and, 8.290
 recurrent, 8.79, 8.86–88
 dystrophic, 8.86, 8.87, 8.133, 8.135*t*
 in epithelial basement membrane dystrophy, 8.86, 8.87, 8.133, 8.138
 in lattice corneal dystrophy type 1, 8.147
 in Reis-Bücklers corneal dystrophy, 8.143
 eye pain in, 5.295, 8.86, 8.87
 management of, 8.368
 posttraumatic, 8.86, 8.87
 eyelid, 8.45*t*
 Ertapenem, 1.276
 Erysiphakes, 11.195
 Erythema
 nodosum, in coccidioidomycosis, 9.271
 in nonspecific orbital inflammation, 7.64
 in thyroid eye disease, 7.52, 7.53*f*, 7.54
 Erythema migrans/erythema chronicum migrans, in Lyme disease, 1.250, 5.352, 5.353*f*, 9.244, 9.244*f*, 12.245
 Erythema multiforme, in coccidioidomycosis, 9.271
 Erythrocyte sedimentation rate (ESR)
 in Behçet disease, 1.169
 in giant cell arteritis/AAION, 5.120, 5.120*t*, 5.314
 in NAION, 5.120*t*
 in optic neuritis, 5.115
 Erythrocytes (red blood cells/RBCs), 1.135
 in anemia, 1.136
 hemolytic anemia, 1.138
 development of, 1.135–136
 Erythromycin, 1.278, 2.344*t*, 2.347*t*, 2.352–353
 for chlamydial conjunctivitis, 8.263
 in neonates, 8.265
 for chlamydial infections, 6.239
 intravenous administration of, 2.301
 for meibomian gland dysfunction, 8.68

- for rosacea, 8.71
- for trachoma, 8.262–263, 8.263
- Erythropeiosis, 1.135–136
- Erythropeiosis-stimulating agents (ESAs), 1.137
- Erythropoietin, 1.135
- ESAs. *See* Erythropeiosis-stimulating agents
- ESC. *See* European Society of Cardiology
- ESCD. *See* Enhanced S-cone disease (ESCD)
- Escherichia/Escherichia coli (E coli)*, 8.247
 - endogenous endophthalmitis caused by, 9.264
 - as normal flora, 8.205
 - ocular infection caused by, 8.247, 9.264
 - urinary tract infections caused by, 12.238
- ESCRS (Endophthalmitis Study Group of the European Society of Cataract and Refractive Surgeons), on postoperative endophthalmitis, 11.94, 11.162
- Eserine. *See* Physostigmine
- Eslicarbazepine, 1.202*t*
- Esmolol
 - for arrhythmias, 1.113*t*
 - for hypertensive emergency, 1.74
- Eso- (prefix), 6.15
- Esodeviations. *See also* Esotropia; *specific type*
 - accommodative, 6.90. *See also* Accommodative esotropia
 - definition of, 6.85
 - in divergence insufficiency, 6.94
 - epidemiology of, 6.85
 - extraocular muscle surgery amounts for, 6.160, 6.160*t*
 - risk factors for, 6.85
 - types of, 6.86*t*
- Esophageal cancer, screening for, 1.213
- Esophageal dysmotility, in systemic sclerosis, 1.162
- Esophoria, 3.142
- Esotropia. *See also* Esodeviations
 - accommodative, 5.227
 - amblyopia associated with, 6.91
 - definition of, 6.90
 - description of, 6.57
 - evaluation of, 6.91
 - high AC/A ratio, 5.227, 6.90–92
 - management of, 6.91–92
 - muscarinic antagonists for management of, 2.313
 - nonrefractive, 6.90
 - partially, 6.90–92
 - pathogenesis of, 6.90–91
 - refractive, 6.90–92
 - refractive surgery and, 13.188
 - types of, 6.86*t*, 6.90–91
 - acquired nonaccommodative
 - basic, 6.93
 - consecutive esotropia, 6.95
 - cyclic esotropia, 6.93
 - description of, 6.92
 - divergence insufficiency, 6.94
 - near reflex spasm, 6.94
 - sensory esotropia, 6.93–94
 - types of, 6.86*t*
 - age-related distance, 6.94
 - botulinum toxin injection for, 6.97
 - congenital. *See* Esotropia, infantile
 - in congenital fibrosis of the extraocular muscles (CFEOM), 6.135
 - consecutive, 6.16, 6.95
 - contact lens trial before refractive surgery and, 13.199
 - cyclic, 6.93
 - diplopia and, 6.102
 - in Duane retraction syndrome, 6.95–97, 6.132*f*, 6.133
 - exotropia following, 6.16
 - high myopia and, 6.97, 6.143–144
 - Hirschberg test for, 6.67, 6.68*f*
 - hyperopia and, 3.175
 - incomitant, 6.95–97, 6.96*f*
 - infantile, 6.86*t*
 - amblyopia associated with, 6.87–89
 - botulinum toxin injections for, 6.89
 - Chavasse theory of, 6.87
 - Ciancia syndrome, 6.88, 6.95
 - clinical features of, 6.87–88
 - cross-fixation associated with, 6.87–88, 6.88*f*
 - cyclopegic refraction for, 6.88
 - definition of, 6.87
 - evaluation of, 6.87–88
 - management of, 6.88–89
 - medial rectus muscle recession for, 6.89
 - mental illness and, 6.87
 - ocular alignment in, 6.88–89
 - pathogenesis of, 6.87
 - prematurity as risk factor for, 6.87
 - smooth-pursuit asymmetry associated with, 6.88
 - surgical treatment of, 6.89
 - V-pattern strabismus associated with, 6.109, 6.112*t*
 - Worth “sensory” concept of, 6.87
 - large-angle, 6.87
 - negative angle kappa and, 6.67, 6.68*f*
 - nystagmus and, 6.86*t*, 6.95. *See also* Nystagmus latent, 5.238
 - nystagmus blockage syndrome as cause of, 6.155
 - postoperative, 6.102
 - postsurgical, 6.102
 - postsurgical consecutive, 6.95
 - prevalence of, 6.85
 - primary inferior oblique muscle overaction associated with, 6.117
 - pseudoesotropia, 6.85–87, 6.86*f*
 - risk factors for, 6.85
 - sensory, 6.93–94
 - small-angle, 6.102
 - spontaneous consecutive, 6.95
 - strabismus surgery for, 6.91
 - types of, 6.86*t*
 - V-pattern strabismus associated with, 6.109, 6.112*t*
- ESR. *See* Erythrocyte sedimentation rate
- Essential (physiologic/simple) anisocoria, 5.256*f*, 5.257
- Essential blepharospasm, benign (BEB), 5.281–283, 5.282*f*, 5.282*t*, 7.226–228, 7.227*f*
- Essential (primary) hypertension, 1.63, 1.63*f*
 - in children and adolescents, 1.78
- Essential/progressive iris atrophy, 4.100, 4.101*f*, 8.111, 8.126, 8.127*f*, 10.136, 10.137*f*. *See also* Iridocorneal endothelial (ICE) syndrome
 - cataract and, 11.68
- Esterase D, retinoblastoma and, 2.159
- Esthesiometry, 8.42–43
- Estimated lens position (ELP), 3.239, 3.243, 3.248–250, 3.249*f*, 3.252–253
- Estradiol, 1.308*t*

- Estrogen/hormone replacement therapy (HRT)
 breast cancer and, 1.211
 refractive surgery in patient taking, 13.37
 tear production affected by, 8.62*t*
- Estrogen receptors, in immunohistochemistry, 4.35
- ESTs. *See* Expressed sequence tags
- Eszopiclone, 1.194
- ET. *See* Endothelin
- Etanercept, 1.174, 6.322, 9.107
 sarcoidlike syndrome caused by, 9.171
 for uveitis, 9.107
 uveitis caused by, 1.151, 1.175, 9.121
- ETDRS. *See* Early Treatment Diabetic Retinopathy Study
- ETDRS visual acuity chart. *See* Early Treatment Diabetic Retinopathy Study visual acuity chart
- Ethambutol, 1.255
- Ethanol. *See also* Alcohol
 retrobulbar injection of, for pain control, 7.128
 as tissue fixative, 4.26, 4.26*t*
- Ethics, of clinical testing, 1.20
- Ethmoid air cells/sinuses, 2.10*f*, 2.10–11, 2.17*f*, 5.8, 5.10*f*, 7.8, 7.8*f*, 7.18, 7.19, 7.19*f*
- Ethmoid/ethmoidal arteries, 2.33*f*, 2.34*f*, 5.12, 5.13*f*, 5.14*f*, 5.16*f*
 anterior/posterior, 7.14*f*, 7.15*f*
- Ethmoid/ethmoidal bone, 2.6, 2.6*f*, 5.7*f*, 5.8, 5.9*f*, 7.6*f*, 7.7*f*, 7.8, 7.8*f*
- Ethmoid nerves, anterior/posterior, 7.14*f*, 7.15*f*, 7.17*f*
- Ethmoidal complex, 5.8
- Ethmoidal foramina, anterior/posterior, 2.6*f*, 2.7–8, 5.11, 7.6*f*, 7.7*f*, 7.9
- Ethmoidal suture, frontal, 5.8
- Ethnic background. *See also* Race
 Behçet disease and, 9.182–183
 fall rates in elderly patients and, 1.184
 genetic disorders and, 2.196–197
 hypertension and, 1.62, 1.78–79
 multiple sclerosis and, 5.315
 oculopharyngeal dystrophy and, 5.329
 sarcoidosis and, 5.327, 9.167
 spasmus nutans and, 5.239
 Vogt-Koyanagi-Harada syndrome and, 4.186, 9.175–176, 9.177–178
- Ethosuximide, 1.202*t*
- Ethylene glycol, 12.303
 optic neuropathy caused by, 5.137
- Ethylenediaminetetraacetic acid (EDTA)
 in artificial tears, 2.341
 for band keratopathy, 2.306, 8.119, 9.281
 in irrigating solutions, 2.367
 off-label use of, 2.306
- Etodolac, 2.335*t*
- Etoposide, 1.231, 1.233*t*
 for retinoblastoma, 4.299
- Etoricoxib, 1.172
- ETROP. *See* Early Treatment for Retinopathy of Prematurity
- Euchromatin, 2.133
- Eukaryotes, 2.135, 2.147
- European Centre for Disease Prevention and Control (ECDC), on immunization schedules, 1.217, 1.218*t*
- European Council, on colorectal cancer screening, 1.214
- European Glaucoma Prevention Study, 10.89
- European Glaucoma Society, angle closure definitions and, 10.117
- European Society of Cardiology (ESC), 1.81, 1.89
 on endocarditis prophylaxis, 1.287
- EUROSCREEN, 1.211
- Euryblepharon, 6.195, 7.156–158, 7.157*f*, 7.158*f*
- Evaporative dry eye, 8.45, 8.53–54, 8.54*f*, 8.55*f*, 8.58–60, 8.59*f*, 8.60*f*. *See also* Dry eye
 blepharitis and, 8.68, 8.72
 meibomian gland dysfunction and, 8.40–41, 8.53–54, 8.54*f*, 8.55*f*, 8.58–59, 8.60*f*, 8.66*t*, 8.66–67*t*, 69
 rosacea and, 8.60, 8.70
 treatment of, 8.66*t*, 8.66–67*t*, 69
- Event-based analysis, of visual field progression, 10.71
- Evisceration, 7.127, 7.129–130
 goals of, 7.129
 intraoperative complications of, 7.130
 ocular prostheses after, 7.132
 for penetrating ocular injury, 12.233
 sympathetic ophthalmia and, 7.130, 9.175
 wrong-eye removal and, 7.130
- Evoked cortical potential, visual. *See* Visual evoked potential/cortical potential/response
- Evolving stroke, 1.121
- EVP. *See* Episcleral venous pressure
- EVR1 gene, 12.346*t*
- EVR2 gene, 12.346*t*
- EVR3 gene, 12.346*t*
- EVR4 gene, 12.346*t*
- EVR5 gene, 12.346*t*
- EVS (Endophthalmitis Vitrectomy Study), 11.161, 11.162
- EW. *See* Edinger-Westphal (EW) nucleus; Extended-wear (EW) contact lenses
- Ewing sarcoma, 6.218
 retinoblastoma associated with, 4.302*t*
- Exact ray tracing. *See* Ray tracing
- Examination, ophthalmic, 8.15–43. *See also* Refraction, clinical; *specific method used*
 amiodarone use and, 1.117
 under anesthesia
 for infants and children, 10.157, 10.157*t*
 for pediatric glaucoma, 10.157, 10.157*t*
 gonioscopy and, 10.159
 for retinoblastoma, 4.292, 4.292*f*
 before cataract surgery, 11.77–78, 11.78–80
 in children
 anterior segment examination, 6.10
 Brückner test, 6.9
 communication during, 6.4
 cycloplegic refraction, 6.10–12
 difficult child, 6.5
 distance fixation targets, 6.3, 6.4*f*
 dynamic retinoscopy, 6.9
 fundus, 6.12
 general considerations and strategies for, 6.3–5
 intraocular pressure measurement, 6.10
 1 toy, 1 look rule, 6.3, 6.4*f*
 in outpatient setting, 6.3, 6.4*f*
 practitioner positioning during, 6.4
 pupil testing, 6.10
 red reflex, 6.9
 “safe” environment for, 6.4

- slit-lamp examination, 6.4–5
- tonometry, 6.10
- visual acuity assessment. *See* Children, visual acuity assessment
- visual field testing, 6.10
- vocabulary during, 6.4
- confocal microscopy in, 8.24, 8.24f
- corneal biomechanics measurement in, 8.43
- corneal curvature evaluation in, 8.25–36, 13.14–19, 13.15f, 13.16f, 13.17f, 13.18f, 13.19f, 13.44–45, 13.45f. *See also* Cornea, curvature of; evaluation of
- corneal pachymetry in, 8.41–42. *See also* Pachymetry/pachymeter
- before corneal transplantation, 8.418
- diabetes mellitus–related, 12.93–94, 12.95t
- in diplopia, 5.184f, 5.184–185, 5.185f
- direct visualization in, 8.15–20, 8.16f, 8.17f, 8.18f, 8.19f, 8.20f
- esthesiometry in, 8.42–43
- in glaucoma, 10.48, 10.49t, 10.157t, 10.157–160
- in infants and children, 10.157t, 10.157–160
- HIV infection precautions/transmission and, 1.271, 9.301
- in inflammatory chorioretinopathies, 9.141t
- in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.123, 9.124t
- in low vision evaluation, 5.78–97. *See also* Low vision, assessment of
- in nonorganic disorders, 5.301–311, 5.302f, 5.303f, 5.304f, 5.305t, 5.307f, 5.308f, 5.309f
- OCT in, 8.21–22, 8.22f
- in ocular surface neoplasia, 8.328
- in penetrating and perforating ocular trauma, 8.401–402, 8.402t
- periocular malpositions/involucional changes and, 7.197
- in primary congenital glaucoma, 10.151–152, 10.152t, 10.157t, 10.157–160
- in ptosis evaluation, 7.209–212, 7.210f, 7.211f
- before refractive surgery, 13.36t, 13.39–44, 13.42f, 13.43f
- ancillary tests and, 13.44–46, 13.45f
- in retinoblastoma, 4.292, 4.292f
- scanning in, 8.20–24, 8.21f, 8.22f, 8.23f, 8.24f
- slit-lamp biomicroscopy in, 8.15–20, 8.16f, 8.17f, 8.18f, 8.19f, 8.20f
- specular microscopy in, 8.23, 8.23f
- stains used in, 8.36–37, 8.37f, 8.38f, 8.56
- tear film/tear production evaluation and, 8.38–41, 8.40f
- stains used in, 8.36–37, 8.37f, 8.38f, 8.56
- in transient visual loss evaluation, 5.163
- ultrasound biomicroscopy in, 8.20–21, 8.21f
- Excavated optic nerve/nerve head/disc, 5.137f
- congenital, 5.145
- in glaucoma, 5.136, 5.137f
- Excessive blinking, 6.201–202
- Excimer laser, 13.8t, 13.29, 13.73–77, 13.74–75f. *See also* Lasers
- for photoablation, 13.8t, 13.29, 13.73–77, 13.74–75f. *See also* Photoablation; specific procedure
- aberrations and, 13.13, 13.102–103, 13.103f
- application of treatment and, 13.91f, 13.91–93
- calibration of, 13.80
- complications/adverse effects of, 13.101–126
- corneal preparation for, 13.82–90, 13.83f, 13.85f, 13.86f, 13.87f, 13.88f, 13.89f, 13.90t
- corneal transplantation after, 13.198
- elevated intraocular pressure after, 13.104–105, 13.180–183, 13.182f, 13.200–201
- herpes simplex virus keratitis and, 13.173–174
- outcomes of, 13.95–97
- preoperative programming of, 13.31, 13.40, 13.81
- for presbyopia, 13.167, 13.168f
- tracking/centration/ablation and, 13.91f, 13.91–92
- for phototherapeutic keratectomy, 8.367
- for recurrent corneal erosions, 8.87
- Excision repair, 2.154
- Excisional biopsy, 7.179f, 7.180
- in conjunctival nevi, 8.341
- in primary acquired melanosis, 8.342
- Exciting eye, 4.185, 9.171, 9.172, 9.174, 9.175. *See also* Sympathetic ophthalmia
- Exclusion criteria, 1.4, 1.13, 1.24
- Excretory lacrimal system, 2.29f, 2.29–30, 7.252–255, 7.253f, 7.254f. *See also* Lacrimal drainage system
- anatomy of, 7.252–255, 7.253f, 7.254f
- development of, 7.255
- abnormalities of, 7.257–259, 7.258f
- disorders of
- acquired, 7.267–281
- congenital, 7.259–267
- therapeutic closure of, 7.281–282
- tumors of, 7.287
- Excyclo- (prefix), 6.16
- Excycloduction, 6.33. *See also* Extorsion
- Executive function deficit, 1.188
- Exenatide, for diabetes mellitus, 1.45t, 1.46
- Exenteration, 7.127, 7.136–137, 7.137f
- for basal cell carcinoma, 7.180
- for lacrimal gland tumors, 7.93, 7.136
- for lacrimal sac tumors, 7.287
- for melanoma, 4.277, 7.136, 8.344
- ocular prosthesis after, 7.137
- for sebaceous adenocarcinoma, 7.184
- for squamous cell carcinoma, 7.182
- for teratoma, 7.41
- Exercise/activity
- cardiovascular disease risk modification and, 1.83t, 1.85
- diabetes mellitus prevention/management and, 1.38, 1.40–41, 1.43, 1.44f
- hypercholesterolemia management and, 1.83t, 1.85
- hypertension management and, 1.66, 1.67t
- Exercise stress tests, in ischemic heart disease, 1.97
- Exfoliation. *See also* Exfoliation/pseudoexfoliation syndrome
- true, infrared radiation/heat causing, 4.102, 11.57
- Exfoliation/pseudoexfoliation syndrome, 4.101–103, 4.102f, 4.124, 10.11t, 10.31, 10.91f, 10.91–93, 10.92f, 10.130, 10.131f, 11.65f, 11.65–66
- cataract surgery in patient with, 11.79, 11.184
- glaucoma and (pseudoexfoliation glaucoma), 10.11t, 10.31, 10.91, 10.93, 10.130, 10.131f
- IOL decentration/dislocation and, 11.144
- postoperative hyphema and, 11.158
- zonular incompetence and, 10.92, 10.93, 10.130, 10.131f, 11.65–66, 11.181, 11.182f, 11.184

- Exo- (prefix), 6.15
- Exodeviations. *See also* Exotropia; *specific type*
- control of, 6.100
 - convergence insufficiency, 6.103
 - definition of, 6.99
 - exotropia. *See* Exotropia
 - extraocular muscle surgery amounts for, 6.160, 6.161*t*
 - latent, 6.99
 - manifest, 6.99
 - risk factors for, 6.99
- Exogenous infection, uveal, 4.185
- Exogenous inoculation, 8.206
- Exome sequencing, 2.135
- Exon, 2.135, 2.147, 2.148, 2.148*f*, 2.151, 2.152
- Exon shuffling, 2.148
- Exophoria
- definition of, 6.99
 - diagnosis of, 6.99
- Exophthalmometry, 7.24, 7.24*f*
- Exophthalmos, 5.271, 7.23. *See also* Proptosis
- in orbital roof fractures, 7.106
 - thyrotoxic. *See* Thyroid eye disease
- Exophytic retinoblastoma, 6.352–353, 6.353*f*
- Exorbitism, 6.203, 7.23. *See also* Proptosis
- Exotoxins, microbial
- in innate immune response, 9.14*t*, 9.16
 - virulence and, 1.240, 8.207
- Exotropia
- A-pattern strabismus associated with, 6.109
 - alternate cover test for, 6.66*f*, 6.99
 - angle kappa and, 6.67
 - consecutive, 6.16, 6.104
 - constant, 6.103–105, 6.104*f*
 - contact lens trial before refractive surgery and, 13.199
 - in craniosynostosis, 6.208
 - in Duane retraction syndrome, 6.105, 6.132, 6.132*f*
 - esotropia after, 6.95
 - high myopia and, 6.143–144
 - hypertropias associated with, 6.100
 - infantile, 6.103–104, 6.104*f*
 - intermittent
 - age at onset, 6.99
 - basic, 6.101
 - characteristics of, 6.99–100
 - control of, 6.100
 - course of, 6.99
 - dissociated horizontal deviation and, 6.105
 - evaluation of, 6.100–101
 - nonsurgical management of, 6.101–102
 - normal retinal correspondence in, 6.99
 - occlusion therapy for, 6.102
 - patch test for, 6.101
 - postoperative alignment, 6.102
 - prisms for, 6.102
 - recurrence of, 6.103
 - refractive errors in, 6.101
 - surgical treatment of, 6.102–103
 - tenacious proximal fusion in, 6.71
 - treatment of, 6.101–103
 - Krimsky test, 6.67, 6.68*f*, 6.104*f*
 - large-angle, 6.116
 - neuromuscular abnormalities as cause of, 6.105
 - postsurgical, 6.104
 - primary inferior oblique muscle overaction associated with, 6.117
 - pseudoexotropia, 6.99
 - risk factors for, 6.99
 - sensory, 6.104
 - V-pattern strabismus with, 6.108*f*, 6.112
- Experimental autoimmune uveoretinitis (EAU), 9.63
- Experimental immune (endotoxin-induced) uveitis (EIU), 9.14–15, 9.63
- Experimental (interventional) studies (clinical trials), 1.7, 1.8, 1.8*f*, 1.13*f*, 1.13–14. *See also* Clinical research/studies
- cohort study differences and, 1.13, 1.13*f*
 - for new drug, 2.305
 - systematic reviews/meta-analyses of, 1.8, 1.8*f*, 1.14
- Exposure keratitis/keratopathy, 8.79–80
- cataract surgery in patient with, 11.174
 - tarsorrhaphy for, 8.80
- Exposure staining, 8.56
- Expressed sequence tags (ESTs), 2.135
- Expressivity (genetic), 2.135, 2.196. *See also* Transcription (gene)
- Expulsive choroidal/suprachoroidal hemorrhage, 4.18, 4.19*f*
- cataract surgery and, 11.159–160
- Extavia. *See* Beta (β)-interferon
- Extend plug, for dry eye, 8.64
- Extended-depth-of-focus (EDOF)
- intraocular lenses, 3.262–263, 3.263*f*
 - for multifocal IOLs, 13.166
- Extended-wear (EW) contact lenses, deep stromal neovascularization associated with, 3.232
- External adnexa. *See* Ocular adnexa
- External-beam radiotherapy (EBRT), 1.229
- for choroidal hemangioma, 4.283
 - for choroidal melanoma/ciliary body melanoma, 4.276
 - for lymphoma, 4.312
 - for metastatic eye disease, 4.310
 - for retinoblastoma, 4.301
 - secondary tumors and, 4.302, 4.302*t*
 - for uveal lymphoid proliferation/infiltration, 4.314
- External carotid artery (ECA), 5.12, 5.13*f*, 5.15*f*, 7.13, 7.154
- External dacryocystorhinostomy (DCR), 7.279, 7.280*f*
- External (outer) eye. *See also specific structure*
- anatomy of, 8.3–14
 - cataract surgery in patient with abnormalities of, 11.172–174
 - common clinical findings in disorders of, 8.45–46*t*
 - defense mechanisms of, 8.11–14, 8.12–13*f*, 8.13*f*
 - examination of, 8.15–43. *See also* Examination; Examination, ophthalmic
 - before cataract surgery, 11.77–78
 - in primary congenital glaucoma, 10.158
 - HIV infection/AIDS affecting, 9.299*f*, 9.299–301, 9.300*f*
 - immune-related disorders of, 8.285–326. *See also* Immune response (immunity), ocular, disorders of infections of. *See* Infection (ocular)
 - pediatric disorders of. *See specific disorder*
- External hordeolum (stye), 4.203–204, 7.163–164, 8.76, 8.76*f*

- External jugular vein, 5.23
- External (transcutaneous) levator advancement surgery, for ptosis, 7.219, 7.219f
- External limiting membrane (ELM/XLM), 2.71f, 2.72f, 2.74, 2.76f, 2.88f, 2.258f, 4.140f, 4.141f
- anatomy of, 12.15
- histology of, 12.11, 12.12f
- Extinction, 5.84
- Extorsion (excycloduction)
- definition of, 6.33
- extraocular muscles in, 5.46f
- oblique muscles, 5.46f
- rectus muscles, 5.46f
- V-pattern strabismus caused by, 6.107, 6.110
- Extra-areal periphery, 12.9
- Extracapsular cataract extraction (ECCE), 11.90, 11.90f, 11.196–198, 11.197f. *See also* Cataract surgery
- for advanced cataract, 11.180
- anterior capsulotomy in, 11.196, 11.197f
- complications of, 11.135–136, 11.195, 11.198
- flat or shallow anterior chamber and, 11.134, 11.135
- intraoperative complications and, 11.134–135
- posterior fluid misdirection syndrome and, 11.134–135
- postoperative complications and, 11.135–136
- historical overview/key developments in, 11.90, 11.90f, 11.119, 11.195
- incisions for, 11.196
- IOLs for, 11.197
- lens particle glaucoma and, 11.67
- manual small-incision cataract surgery and, 11.198, 11.199f
- nucleus removal in, 11.196–197
- ocular trauma affecting visualization and, 11.191
- patient preparation for, 11.196
- posterior capsule opacification and, 11.152–153
- Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154f, 11.154–157, 11.156f. *See also* Nd:YAG laser therapy, capsulotomy
- postoperative course and, 11.198
- retained lens fragments after, 11.141
- retinal detachment and, 11.166
- suture-induced astigmatism after, 11.132
- wound closure and, 11.197–198
- in zonular dehiscence with lens subluxation or dislocation, 11.182
- Extracapsular IOL dislocation, 11.144, 11.144f, 11.145
- Extraconal fat pads, 6.28
- Extraconal fat/surgical space (peripheral surgical space), 7.11, 7.115, 7.115f
- Extracranial to intracranial bypass surgery, for ocular ischemic syndrome, 12.140
- Extracranial trunk, of cranial nerve VII (facial), 5.52
- Extrafoveal cones, 2.70
- Extranodal marginal zone lymphoma (MALToma)
- of conjunctiva, 4.70, 4.71f, 8.349–350, 8.350f
- of orbit, 4.232, 4.233f, 7.86
- Extraocular muscle surgery. *See also specific type or disorder*
- adjustable sutures used in, 6.165
- in amblyopia, 6.160
- anesthesia for, 6.174–175
- in awake patients, 6.165
- complications of, 6.168–174
- adherence syndrome, 6.172
- alignment issues, 6.168
- allergic reactions, 6.170, 6.171f
- anterior segment ischemia, 6.172–173, 6.173f
- anti-elevation syndrome, 6.168–169
- conjunctival scarring, 6.171–172, 6.172f
- delle, 6.172, 6.172f
- diplopia, 6.168
- epithelial cyst, 6.170–171
- eyelid position changes, 6.173, 6.173f
- foreign-body granuloma, 6.170
- iatrogenic Brown syndrome, 6.168
- infections, 6.170, 6.170f
- lost muscles, 6.169
- orbital cellulitis, 6.170, 6.170f
- pulled-in-two syndrome, 6.169–170
- pyogenic granuloma, 6.170, 6.171f
- refractive changes, 6.173–174
- scleral perforation, 6.170
- slipped muscles, 6.169, 6.169f
- unsatisfactory alignment, 6.168
- cyclovertical strabismus, 6.162
- distance–near incomitance and, 6.162
- for esodeviations, 6.160, 6.160t
- esotropia correction with, 6.159
- evaluation before, 6.159
- for exodeviations, 6.160, 6.161t
- exotropia after, 6.17
- formulas for, 6.160–161t
- fornix incision for, 6.162–163
- hangback recession, 6.163
- horizontal deviations, 6.161
- horizontal incomitance and, 6.161
- hypertropia treated with, 6.164–165
- hypotropia treated with, 6.164–165
- incisions for, 6.162–163
- incomitance and, 6.161–162
- indications for, 6.159–160
- limbal incision for, 6.163
- malignant hyperthermia secondary to, 6.174–175
- monocular horizontal recession–resection
- procedures, 6.161
- for nystagmus, 5.236
- nystagmus treated with, 6.155–157, 6.156f
- oblique muscles
- inferior, 6.164t, 6.165–166
- tightening procedures, 6.164t, 6.166–167
- weakening procedures, 6.164t, 6.165–166
- oculocardiac reflex, 6.174
- planning of, 6.160–162
- posterior fixation, 6.167
- postoperative nausea and vomiting secondary to, 6.174
- prior surgery and, 6.162
- reasons for, 6.159
- rectus muscles
- hypertropia, 6.164–165
- hypotropia, 6.164–165
- slipped, 6.169, 6.169f
- tightening procedures, 6.163–164, 6.164t
- weakening procedures, 6.163, 6.164t
- stay sutures used in, 6.167

- for superior oblique myokymia, 5.251
 - sutures used in
 - adjustable, 6.165
 - posterior fixation, 6.167
 - stay, 6.167
 - symmetric, 6.160–161*t*
 - techniques for, 6.164*t*
 - tightening procedures
 - for inferior oblique muscle, 6.166
 - for oblique muscles, 6.164*t*, 6.166–167
 - for rectus muscles, 6.163–164, 6.164*t*
 - for superior oblique muscle, 6.167
 - transposition procedures, 6.167
 - vertical incomitance and, 6.161
 - weakening procedures
 - for inferior oblique muscle
 - bilateral, 6.165
 - indications for, 6.118
 - for superior oblique muscle palsy, 6.123, 6.123*t*
 - surgical procedures for, 6.164*t*, 6.165–166
 - for V-pattern strabismus, 6.111
 - for oblique muscles, 6.164*t*, 6.165–166
 - for rectus muscles, 6.163, 6.164*t*
 - weakening procedures in. *See* Weakening procedures
- Extraocular muscles (EOMs), 2.13*f*, 2.13–18, 2.14*f*, 2.15*t*, 2.16*f*, 2.17*f*, 5.45–46, 5.46*f*, 7.11–12, 7.12*f*. *See also* Ocular motility; *specific muscle*
- action of
- description of, 6.31–32
 - gaze position and, 6.34–37, 6.35–37*f*
 - primary, 6.34
 - secondary, 6.34
 - tertiary, 6.34
- anatomy of, 2.13*f*, 2.13–18, 2.14*f*, 2.15*t*, 2.16*f*, 2.17*f*, 5.45–46, 5.46*f*
- arc of contact, 6.32
- arterial system of, 6.23
- blood supply/arterial system of, 2.15*t*, 2.17, 6.23–24, 6.30
- congenital fibrosis of, 6.134–135
- in convergence-retraction nystagmus, 5.250
- course of, 6.19–22
- damage to
- during blepharoplasty, 7.234
 - during enucleation/evisceration, 7.130
 - in orbital floor/blowout fracture, 7.108, 7.109–110
 - in orbital roof fractures, 7.106
- development of, 2.124–125
- fascial relationships of, 6.25–28, 6.26–27*f*
- fiber types in, 2.18, 6.24
- fibrosis of
- congenital, 6.134–135
 - in thyroid eye disease, 6.140
- fine structure of, 2.18
- global layer of, 6.24
- growth and development of, 6.181–182
- inflammation of. *See* Myositis
- inherited conditions affecting, 5.328–330, 5.329*f*
- innervation of, 2.12*f*, 2.17, 2.93–96, 2.94*f*, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*, 6.19–22, 7.12, 7.14*f*, 7.15*f*. *See also* Cranial nerves
- insertions of, 2.13–15, 2.14*f*, 2.15*t*, 6.19–22, 6.31
- lost, 6.162, 6.169
- metastatic disease of, 7.99
- myasthenia gravis effects on, 6.142
- nonspecific orbital inflammation involving, 7.63–64
- ophthalmic artery supply of, 6.23
- orbital implants and, 7.131, 7.132
- orbital layer of, 6.24
- orbital relationships of, 2.14*f*, 2.15–16, 2.16*f*, 2.17*f*, 6.25–28, 6.26–27*f*
- origins of, 2.15*t*, 2.16–17, 6.19–22
- in ptosis, 7.212
- pulley system of, 6.28, 6.32
- retrobulbar injection–related damage to, 6.146
- slipped, 6.162, 6.169, 6.169*f*
- structure of, 2.18, 6.24, 6.25*f*
- surgery of. *See* Extraocular muscle surgery;
- Strabismus surgery
- 3-step test of, 6.73–75, 6.74*f*
- in thyroid eye disease, 4.226, 4.227*f*, 5.131, 5.206, 6.140, 7.25, 7.52, 7.54, 7.54*f*, 7.56
- optic neuropathy and, 5.131, 5.132*f*
- venous system of, 6.23–24
- yoke muscles, 6.38
- Extraocular myopathy. *See also specific disorder*
- inherited conditions causing, 5.328–330, 5.329*f*
- in thyroid eye disease, 4.226, 4.227*f*, 5.206, 7.25, 7.52, 7.54, 7.54*f*, 7.56
- Extrapulmonary tuberculosis, 9.250, 9.255
- Extrastriate cortex, 5.34*f*
- Extrinsic pathway (coagulation), 1.140, 1.140*f*
- Exuberant granulation tissue (pyogenic granuloma), 4.55, 4.55*f*
- Exuberant hyperkeratosis (cutaneous horn), 4.211, 7.168
- Exudates
- hard, 4.140, 4.152, 4.153*f*, 12.122, 12.160
 - in leukemia, 4.315
 - macular, 12.124*f*
 - soft, 12.122. *See also* Cotton-wool spots
- Exudative hemorrhagic chorioretinopathy, peripheral (PEHCR), 4.270*f*, 4.271
- Exudative retinal detachment. *See* Retinal detachment
- Exudative/“wet” age-related macular degeneration. *See* Neovascular (“wet”) exudative age-related macular degeneration
- Eye
- aging affecting, 1.177, 1.178
 - anatomy of, 2.37–81. *See also specific structure*
 - early conceptions of, 11.3, 11.3*f*, 11.4*f*
 - antipsychotic drugs affecting, 1.198
 - axes of, 3.128–129, 3.129*f*
 - axial length of
 - angle closure and, 10.121
 - extremes of, cataract surgery in patient with, 11.184–185
 - in infants and children, in primary congenital glaucoma, 10.160
 - in IOL power determination, 11.82–83, 11.83*f*, 11.85
 - hypotony affecting, 11.185
 - unexpected refractive results after surgery and, 11.150, 11.176
 - in primary congenital glaucoma, 10.160

- congenital anomalies of, 4.6, 4.7f, 4.12t, 6.182–183, 6.183t. *See also* Congenital anomalies; *specific type*
 - glaucoma associated with, 10.4t, 10.6t, 10.147, 10.148t, 10.151. *See also* Glaucoma, pediatric
 - curvature of, 3.268
 - depression of (downgaze). *See* Depression of eye
 - development of, 2.115–126. *See also specific structure*
 - abnormalities of, 4.6, 4.7f, 4.12t. *See also*
 - Congenital anomalies; *specific type*
 - glaucoma associated with, 10.4t, 10.6t, 10.153–156. *See also* Glaucoma, pediatric
 - chronology of, 2.115–117, 2.116t, 2.117f, 2.118f, 2.119f
 - general principles and, 2.111, 2.112f, 2.113f, 2.114f, 2.115t
 - genetic cascades and morphogenic gradients and, 2.111, 2.126–128
 - homeobox genes and, 2.126
 - neural crest cells and, 2.111, 2.113f, 2.114f, 2.115t
 - dimensions of, 2.37, 6.179t, 6.179–180
 - dry. *See* Dry eye
 - elevation of (upgaze). *See* Elevation of eye
 - examination of, 8.15–43. *See also* Examination
 - before refractive surgery, 13.36t, 13.39–44, 13.42f, 13.43f
 - ancillary tests and, 13.44–46, 13.45f
 - external. *See* External (outer) eye
 - fellow. *See* Fellow eye
 - glands of, 2.23t
 - growth and development of
 - abnormal, 6.182–183, 6.183t
 - normal, 6.179–182
 - Gullstrand mathematical model of, 3.59, 3.124, 3.125, 3.126f, 3.127t, 3.243, 3.270
 - hereditary diseases of. *See* Hereditary dystrophies
 - infection of. *See* Infection (ocular)
 - information about position of (efference copy information), 5.40
 - injury to. *See* Trauma
 - malformation of, 6.182–183
 - normal flora of, 8.205–206, 8.206t
 - optics of
 - accommodation, 3.140–141
 - axes, 3.128–129, 3.129f
 - binocular states, 3.139–140
 - contrast sensitivity, 3.134–136, 3.135–136f
 - contrast sensitivity function, 3.134–136
 - developmental hyperopia, 3.143
 - developmental myopia, 3.142–143
 - mathematical models of, 3.125, 3.126f
 - pupil size effects on visual resolution, 3.129–131
 - refractive errors, 3.141f, 3.141–142
 - refractive states, 3.136–139, 3.137–138f
 - schematic eye and, 3.125–128, 3.126f, 3.127t, 3.128f. *See also* Schematic eye
 - visual acuity, 3.131–134, 3.132–133f
 - phthisical (phthisis bulbi), 4.22, 4.23, 4.23f
 - retinoblastoma regression and, 4.301
 - sympathetic ophthalmia and, 9.175
 - physical examination of. *See* Examination
 - radiation affecting, 1.230–231
 - refractive states of, 6.180f, 6.180–181. *See also* Eye, optics of, refractive states and
 - removal of. *See also* Anophthalmic socket;
 - Enucleation; Evisceration; Exenteration
 - prevention of removing wrong eye and, 7.130
 - schematic, 3.127t
 - systemic drugs affecting, 1.306–308, 1.307–308t
 - in systemic malignancies, 1.237, 4.197, 4.303–316
 - traumatic injury of. *See* Trauma
 - tumors of. *See* Intraocular tumors
- Eye Bank Association of America (EBAA), 8.414
- Eye banking, 8.413–417, 8.415t, 8.416f, 8.416t. *See also*
- Cornea, transplantation of; Donor cornea
 - screening for prior LASIK and, 13.198
- Eye drops. *See* Eyedrops
- Eye fields
 - frontal (FEFs), 5.32f, 5.33, 5.34f, 5.37f
 - saccadic control and, 5.219, 5.220
 - seizures/tonic deviations and, 5.230
- parietal, 5.32f
- supplementary (SEFs), 5.32f, 5.33
- Eye marking, before phacoemulsification, 11.104
- Eye movements. *See also* Ocular motility
- abnormalities of
 - National Eye Institute classification of, 6.147
 - nystagmus. *See* Nystagmus
 - active force generation test, 6.73
 - binocular
 - vergences, 6.37, 6.39–40
 - versions, 6.37–39
 - electromyography of, 6.32–33
 - forced duction test, 6.73
 - monocular
 - ductions, 6.33
 - field of action, 6.33–34
 - gaze position effects on extraocular muscle action, 6.34–37, 6.35–37f
 - primary action, 6.34
 - secondary action, 6.34
 - terminology associated with, 6.33
 - tertiary action, 6.34
 - motor units, 6.32–33
 - optokinetic system of, 6.40
 - saccadic system of, 6.40
 - saccadic velocity, 6.73
 - smooth-pursuit system of, 6.40
 - supranuclear control systems for, 6.40
 - tracking of, optical coherence tomography with, 12.27
 - vergence system of, 6.40
 - vestibular-ocular system of, 6.40
- Eye muscles. *See* Extraocular muscles
- Eye pain. *See* Pain
- Eye patches. *See* Patching
- Eye-popping reflex, 5.274
- Eye socket. *See* Socket
- “Eye strain,” pain and, 5.295
- Eyeball. *See* Globe
- Eyebrows
 - direct elevation of, 7.235
 - drooping of (brow ptosis), 7.234–235, 7.235f
 - dermatochalasis and, 7.229, 7.234, 7.235
 - follicles of, tumors arising in, 7.172, 7.172f, 7.173f
 - in trichotillomania, 7.165

- Eyecharts**
 Bailey-Lovie, 3.133, 6.8
 for children, 3.38
 contrast sensitivity testing, 3.315, 3.316f
 distance from patient to, 3.149
Early Treatment Diabetic Retinopathy Study (ETDRS), 3.23f, 3.133, 3.133f, 3.313f, 6.8
 pictorial representation of, 3.23f
Snellen
 disadvantages of, 3.132–133
 letters on, 3.131–134, 3.132f
 visual acuity testing using, 3.22, 3.23f
- Eyedrops (topical medications)**, 2.295–298, 2.296f
 administration of, 10.184–185
 adherence and, 10.186
 in children, 10.165
anesthetic
 abuse of, 8.89f, 8.89–90
 for cataract surgery, 11.92
antibiotic, after cataract surgery, 11.95
 corneal melting and, 11.132
 corneal melting and, 4.80–81, 11.132
corticosteroid. *See also* Corticosteroids
 ptosis caused by, 5.273, 5.273t
 for uveitis, 9.95–96
examination/diagnosis and, 2.367–368
for glaucoma. *See also* Antiglaucoma agents
 administration of, 10.184–185
 adherence and, 10.186
 in children, 10.165
ocular allergies treated with, 6.247t
ocular toxicity of, 8.80–81, 8.81t, 8.90t, 8.90–91
 contact dermatoblepharitis, 8.285–287, 8.286f
pediatric administration of, 6.11–12
sustained-release devices for, 2.302
- Eyeglasses**. *See* Spectacle lenses (spectacles)
- Eyelashes (cilia)**, 2.19, 2.22f, 2.24, 4.201, 7.153, 8.3, 8.4f
accessory. *See* Distichiasis
entropion/ptosis of. *See also* Trichiasis
 in anophthalmic socket, 7.136
 in epiblepharon, 7.157f, 7.159, 7.159f
 follicles of, 7.154f
 tumors arising in, 7.172, 7.172f, 7.173f
 lice infestation of, 8.255
 misdirection of. *See* Trichiasis
 in staphylococcal blepharitis, 8.72f, 8.73t, 8.74, 8.254
 in trichotillomania, 7.165
- Eyelid artifact**, in perimetry, 10.66
- Eyelid crutches**, for benign essential blepharospasm, 7.227
- Eyelid droop**. *See* Ptosis
- Eyelid–globe incongruity**, in tear deficiency, 2.220
- Eyelid hygiene**
 in blepharitis/meibomian gland dysfunction, 8.66–68, 8.72, 8.76
 for canaliculitis, 7.284–285
 for chalazia and hordeola, 7.162, 7.163
 in chalazion/hordeolum, 8.77
- Eyelid imbrication syndrome**, 7.164
- Eyelid myokymia**, 5.282t, 5.284
- Eyelid retractor/speculum**
 for examination in conjunctival foreign body, 8.397
 for examination/management in chemical injury, 8.381, 8.382f
 for globe exposure, in cataract surgery, 11.105, 11.105f
- Eyelid-sharing techniques**, in eyelid repair, 7.161, 7.195
- Eyelid splitting**
 for distichiasis, 7.160
 for orbitotomy, 7.116f, 7.117–118
- Eyelid springs**, for paralytic lagophthalmos/upper eyelid paralysis, 7.226
- Eyelid taping**
 for exposure keratopathy, 8.80
 for floppy eyelid syndrome, 8.83
 as tarsorrhaphy alternative, 8.373
- Eyelid weights**
 for corneal exposure in facial palsy, 5.281
 for exposure keratopathy, 8.80
 for paralytic ectropion, 7.225–226
 for paralytic lagophthalmos/upper eyelid paralysis, 7.226
- Eyelids**, 2.18f, 2.18–27, 4.201–221, 5.52, 7.145–154, 7.146f, 7.147f, 7.148f, 7.150f, 7.152f, 7.154f, 8.3–4, 8.4f. *See also* Lower eyelid; Upper eyelid
accessory structures of, 2.18f, 2.27
aging effects on, 1.178
 orbital septum changes and, 7.149
 suborbicularis oculi fat (SOOF) and, 7.152
amyloid deposits in, 4.206–207, 4.207f, 4.207t, 8.186t, 8.187
anatomy of, 2.18f, 2.19–25, 2.20f, 2.21f, 2.22f, 2.23t, 2.23f, 2.25f, 2.26f, 4.201f, 4.201–202, 5.52, 7.145–154, 7.146f, 7.147f, 7.148f, 7.150f, 7.152f, 7.154f, 8.3–4, 8.4f
 racial variations in, 2.19, 2.21f
apraxia of opening of, 5.273t, 5.274
in atopic dermatitis, 8.287
basal cell carcinoma of, 4.212f, 4.212–213, 4.213f, 7.177–182, 7.178f, 7.179f
 intraocular extension of, 4.310
biopsy of, 7.179f, 7.179–180
 for basal cell carcinoma, 7.179f, 7.179–180
 for melanoma, 7.185–186
 for sebaceous carcinoma, 7.184
botulinum toxin injection into, 6.146
canthal tendons and, 7.152f, 7.153
coloboma of, 7.160f, 7.160–161
 in Treacher Collins syndrome (mandibulofacial dysostosis), 4.207t
congenital anomalies/disorders of, 4.202–203, 4.203f, 7.155–162, 7.157f
conjunctiva of, 2.20f, 2.25, 2.26f, 7.146f, 7.152.
See also Conjunctiva
connective tissue structures of, 2.21, 7.152–153
in contact dermatoblepharitis, 8.285–287, 8.286f
creases of, 5.52, 6.197, 7.146f, 7.147, 8.4f
 for orbitotomy incision, 7.116f, 7.116–117, 7.117f, 7.119, 7.121
 in ptosis, 7.210, 7.210f, 7.214t
cysts of, 4.208, 4.208f
 congenital dermoid, 4.203
 ductal, 4.208, 4.282f
 epidermoid/epidermal, 4.208, 4.208f, 7.168f, 7.168–169, 7.169f
 inclusion/sebaceous, 4.208, 4.208f, 7.168, 7.168f
 degenerations of, 4.206f, 4.206–207, 4.207f, 4.207t
 in dermatomyositis, 1.164, 1.164f

- development of, 2.116*t*, 2.125, 2.125*f*
 disorders of, 4.201–221, 5.269–275, 7.155–196, 8.45*t*.
See also specific disorder
 ablepharon, 6.193
 acquired, 7.162–165
 ankyloblepharon, 6.193–194, 6.194*f*
 cataract surgery in patient with, 11.174
 chalazia, 6.198–199, 6.199*f*
 coloboma, 6.193, 6.193*f*
 common clinical findings in, 8.45*t*
 congenital, 4.202–203, 4.203*f*, 6.191–198, 7.155–162, 7.157*f*
 congenital tarsal kink, 6.194–195
 cryptophthalmos, 6.191, 6.193, 6.193*f*
 distichiasis, 6.195, 6.195*f*
 dystopia canthorum, 6.191, 6.192*f*
 ectropion, 6.194
 entropion, 6.194
 epiblepharon, 6.194, 6.195*f*
 epicanthus, 6.196, 6.196*f*
 epithelial lesions, 6.200
 euryblepharon, 6.195
 evaluation of, 5.169*f*, 5.269–272, 5.270*f*, 5.271*f*
 excessive blinking, 6.201–202
 hemangiomas, 6.199
 hordeola, 6.198–199
 infectious, 6.198–199
 inflammatory, 6.198–199
 immune-mediated, 8.285–287, 8.286*f*
 lice infestation, 8.255
 Marcus Gunn jaw-winking syndrome, 6.198
 in myasthenia gravis, 5.324
 neoplasms, 4.209–221, 4.210*t*, 6.199–200, 7.165–187. *See also* Eyelids, tumors of
 nevi, 6.200–201, 6.201*f*
 noninflammatory, 6.199–201
 nonorganic, 5.310–311
 palpebral fissure slants, 6.196
 pilomatricoma, 6.200, 6.200*f*
 port-wine stain, 6.199
 ptosis, 6.196–198, 6.197*t*, 6.198*f*
 pyogenic granuloma, 6.199, 6.199*f*
 in thyroid eye disease, 4.226, 4.227*f*, 7.25, 7.52, 7.52*f*, 7.54, 7.56, 7.59. *See also* Thyroid eye disease
 traumatic, 7.187–190, 7.188*f*. *See also* Eyelids, trauma to
 trichotillomania, 6.201, 6.201*f*
 vascular, 6.199
 drooping. *See* Ptosis
 ectropion of, 7.197–201, 7.198*f*, 7.200*f*. *See also* Ectropion
 congenital, 7.156, 7.157*f*
 edema of, 7.164
 in blepharochalasis, 7.230
 in orbital floor/blowout fracture, 7.108
 in thyroid eye disease, 7.54
 emphysema of, in orbital floor/blowout fracture, 7.109
 entropion of, 7.202–207, 7.203*f*, 7.204*f*, 7.205*f*, 7.206*f*, 7.207*f*. *See also* Entropion
 congenital, 7.159–160, 7.160*f*
 epithelium of
 benign lesions of, 7.168*f*, 7.168–169, 7.169*f*
 hyperplasias of, 7.166*f*, 7.166–168, 7.167*f*
 in situ carcinoma of, 7.176–177, 7.177*f*
 in evaporative dry eye, 8.55*f*, 8.58
 eversion of. *See* Ectropion
 examination of, 5.269*f*, 5.269–271, 5.270*f*
 before refractive surgery, 13.41, 13.42, 13.43*f*
 floppy, 7.164, 7.164*f*, 8.79, 8.82–83, 8.83*f*
 folds of, 7.147
 function of, 8.3
 fusion of (ankyloblepharon), 7.157*f*, 7.158
 in mucous membrane pemphigoid, 8.300, 8.302*t*
 glands of, 4.202, 8.4. *See also specific type*
 healing/repair of, 4.17
 in herpes simplex blepharoconjunctivitis/dermatoblepharitis, 8.213, 8.214*f*, 8.216
 in herpes zoster ophthalmicus, 8.227, 8.227*f*
 horizontal laxity of
 in involutional ectropion, 7.199
 in involutional entropion, 7.202, 7.203
 horizontal shortening/tightening of
 for cicatricial ectropion, 7.201
 for exposure keratopathy, 8.80
 for involutional ectropion, 7.199, 7.200*f*
 for involutional entropion, 7.204
 infection/inflammation of, 4.203–204, 4.204*f*, 4.205*f*, 4.206*f*, 8.254–255, 8.255*f*. *See also* Blepharitis
 fungal and parasitic, 8.254–255, 8.255*f*
 staphylococcal, 8.72, 8.72*f*, 8.72–76, 8.73*t*, 8.73*f*, 8.74*f*, 8.75*f*, 8.208*t*, 8.254
 inversion of, 7.202–207, 7.203*f*, 7.204*f*, 7.205*f*, 7.206*f*, 7.207*f*. *See also* Entropion
 keratosis of, 8.46*t*
 actinic, 4.210–212, 4.211*f*, 4.212*f*, 7.175–176, 7.176*f*
 squamous cell carcinoma and, 7.176, 7.182
 seborrheic, 4.209, 4.209*f*, 4.210*f*, 7.167, 7.167*f*
 lacerations of, 6.378
 canthal tissue involved in, 7.189
 lid margin involved in, 7.188*f*, 7.188–189, 7.192–195, 7.193*f*, 7.194*f*
 lid margin not involved in, 7.187–188, 7.191–192
 ptosis caused by, 7.218
 repair of, 7.188, 7.188*f*, 7.188–189, 7.189. *See also* Eyelids, surgery/reconstruction of
 secondary, 7.189–190
 lower
 anatomy of, 2.20*f*, 2.21, 2.22*f*, 2.25*f*
 blepharoplasty on, 7.230–231, 7.231, 7.232*f*, 7.232–233
 laser resurfacing as adjunct to, 7.237
 vision loss after, 7.233
 crease of, 7.147
 for orbitotomy incision, 7.118
 development of, 2.125, 2.125*f*
 inferior rectus muscle attachment to, 6.30*f*
 involutional entropion in, 7.202–204, 7.203*f*, 7.204*f*, 7.205*f*
 reconstruction of, 7.192–195, 7.194*f*
 retractors of, 7.146*f*, 7.151
 in involutional ectropion, repair of, 7.200–201
 in involutional entropion, 7.202–203
 repair of, 7.204, 7.205*f*
 reverse ptosis of, 7.212, 7.215
 tarsal plate of, 7.152
 vertical elevation of, for paralytic ectropion, 7.226
 lymphatics of, 2.27, 2.27*f*
 malformations of, 6.191

- malpositions of, 7.197–224. *See also specific type*
 nonorganic disorders and, 5.310–311
- margin of, 2.19, 2.22f, 2.23t, 2.25f, 4.201f, 7.153, 8.3
 disease of, 8.45
 distance from corneal reflex and, in ptosis,
 7.209–210, 7.210f, 7.214t
 in evaporative dry eye, 8.55f, 8.58
 eversion of, 7.197–201, 7.198f, 7.200f. *See also*
 Ectropion
 infections of, 8.254–255, 8.255f
 inversion of, 7.202–207, 7.203f, 7.204f, 7.205f,
 7.206f, 7.207f. *See also Entropion*
 lacerations of, 7.188f, 7.188–189
 nevus involving, 7.173, 7.174f
 repair of, 7.188f, 7.188–189, 7.192–195, 7.193f, 7.194f
 in rosacea, 8.70
 sebaceous carcinoma arising in, 7.184
 vascular and mesenchymal tumors of, 8.345t,
 8.345–348
- melanoma of, 4.220, 4.221f, 7.184–186, 7.185f
 in molluscum contagiosum, 8.236–237, 8.237f, 8.238f
 morphologic measurements of, 6.191, 6.192f
 movement of, in tear film renewal and distribution,
 2.220
 muscles of, 5.52
 nevi involving, 4.218f, 4.218–220, 4.219f, 7.173–174,
 7.174f
 in nonspecific orbital inflammation, 7.64
 normal flora of, 8.205, 8.206t
 orbital fat and, 2.20f, 2.23, 7.146f, 7.149
 orbital septum and, 2.20f, 2.22–23, 7.146f, 7.149
 orbital tumors/inflammation originating in, 7.94–95
 in Parkinson disease, 1.200
 perforating injury of, 6.377f
 plexiform neurofibroma involving, 5.269f, 7.77f, 7.78,
 7.78f
 positional changes in, 6.173, 6.173f
 protractors of, 7.147–149, 7.148f
 spasm of (benign essential blepharospasm/BEB),
 7.226–227, 7.227f. *See also Blepharospasm*
 racial variations in, 7.147, 7.147f
 reconstruction of. *See* Eyelids, surgery/reconstruction of
 redundancy of. *See* Dermatochalasis
 retraction of, 5.274, 5.275f, 5.275t, 7.222f, 7.222–224
 after blepharoplasty, 7.223, 7.234
 in dorsal midbrain (Parinaud) syndrome, 5.229,
 5.250, 5.274, 5.275t, 7.223
 pseudoptosis/ptosis and, 5.274, 5.275t
 seizures causing, 1.203
 in thyroid eye disease, 4.226, 4.227f, 5.131, 5.274,
 5.275f, 5.275t, 7.52, 7.52f, 7.54, 7.56, 7.59,
 7.222–223, 7.223, 7.224
 treatment of, 7.223–224
 retractors of, 7.149–151, 7.150f
 in involutional ectropion, repair of, 7.200–201
 in involutional entropion, 7.202–203
 repair of, 7.204, 7.205f
 rhabdomyosarcoma involving, 7.82
 in rosacea, 8.70
 in scleroderma, 4.207t
 sebaceous adenocarcinoma/sebaceous gland
 carcinoma of, 4.210t, 4.215–218, 4.216f, 4.217f,
 7.183f, 7.183–184, 8.327, 8.337f, 8.337–338
- skin of, 2.19, 2.20f, 2.21f, 4.201, 4.210, 7.146f,
 7.146–147, 8.3–4
 amyloid deposits in, 4.206–207, 4.207f, 4.207t,
 8.186t, 8.187
 excessive removal of, in blepharoplasty, 7.234
 healing/repair of, 4.17
 melanoma arising in, 4.220, 4.221f
 tumors of, 7.165. *See also* Eyelids, tumors of
 medial canthal/lacrimal drainage involvement
 and, 7.180
 melanoma, 4.220, 4.221f, 7.184–186, 7.185f
 in SLE, 1.159, 4.207t, 9.133
 specimen collection from, 8.208–209, 8.209t
 splitting of. *See* Eyelid splitting
 squamous cell carcinoma of, 4.213, 4.214f, 7.182,
 7.182f
 actinic keratosis and, 4.211, 7.176, 7.182
 in situ (Bowen disease), 7.176
 well-differentiated (keratoacanthoma), 4.209–210,
 4.210t, 4.211f, 7.176–177, 7.177f
- in Stevens-Johnson syndrome (Stevens-Johnson
 syndrome/toxic epidermal necrolysis overlap and
 toxic epidermal necrolysis), 8.297, 8.297f, 8.298
 subcutaneous tissue of, 2.20f, 2.21, 7.146f, 7.146–147
 suborbicularis fat pads/suborbicularis oculi fat
 (SOOF) and, 7.146f, 7.152–153
 midface rejuvenation surgery (SOOF lift) and,
 7.242, 7.243f
 surgery/reconstruction of, 7.191–196, 7.193f, 7.194f
 for basal cell carcinoma, 7.180–181
 for blepharophimosis-ptosis-epicanthus inversus
 syndrome, 7.159
 blepharoplasty, 7.230–234, 7.232f
 for coloboma, 7.161
 for defects involving eyelid margin, 7.188f,
 7.188–189, 7.192–195, 7.193f, 7.194f
 for defects not involving eyelid margin, 7.187–188,
 7.191–192
 for epicanthus, 7.159
 for euryblepharon, 7.157–158
 for eyelid retraction, 7.224
 history and examination in patient considering,
 7.197
 laceration/trauma repair and, 7.188, 7.188f,
 7.188–189, 7.189
 secondary, 7.189–190
 for lateral canthal defects, 7.195
 for medial canthal defects, 7.195–196
 after Mohs micrographic surgery, 7.181
 for mucous membrane pemphigoid, 8.303
 principles of, 7.191
 priorities in, 7.191
 for ptosis repair, 7.218–222, 7.219f, 7.220f, 7.221f
 in blepharophimosis-ptosis-epicanthus inversus
 syndrome, 7.159
 for thyroid eye disease, 7.58, 7.59
 symblepharon and, 7.208
 systemic diseases manifesting in, 4.206–207, 4.207t
 in systemic sclerosis, 1.163, 4.207t
 tarsus of, 2.20f, 2.24, 2.25f, 7.146f, 7.151–152, 7.152f
 in thyroid eye disease, 4.226, 4.227f, 5.131, 5.274,
 5.275f, 5.275t. *See also* Thyroid eye disease
 topography of, 4.201f, 4.201–202

trauma to, 7.187–190, 7.188f
 bite wounds (dog and human), 7.190
 blunt, 7.187
 burns, 7.190
 penetrating, 7.187–189, 7.188f
 ptosis caused by, 7.190, 7.218
 repair of, 7.188, 7.188f, 7.188–189, 7.189. *See also*
 Eyelids, surgery/reconstruction of
 secondary, 7.189–190
 tumors of, 4.209–221, 4.210t, 7.165–187, 8.327
 basal cell carcinoma, 4.212f, 4.212–213, 4.213f,
 7.177–182, 7.178f, 7.179f
 intraocular extension of, 4.310
 benign, 4.209f, 4.209–210, 4.210f, 4.214–215,
 4.215f, 4.216f, 4.218f, 4.218–220, 4.219f, 4.221f,
 7.166f, 7.166–169, 7.167f, 7.168f, 8.327
 adnexal lesions, 7.169–172, 7.171f, 7.172f, 7.173f
 epithelial hyperplasias, 7.166f, 7.166–168, 7.167f
 epithelial lesions, 7.168f, 7.168–169, 7.169f
 melanocytic, 4.218f, 4.218–220, 4.219f, 7.172–
 175, 7.174f, 7.175f
 biopsy in evaluation of, 7.179f, 7.179–180
 clinical evaluation of, 7.165–166
 dermal, 4.214, 4.215f
 dermal appendage, 4.214–218, 4.215f, 4.216f, 4.217f
 epidermal, 4.209f, 4.209–213, 4.210f, 4.210t, 4.211f,
 4.212f, 4.213f, 4.214f, 7.165
 benign, 7.168f, 7.168–169, 7.169f
 premalignant (actinic keratosis), 4.210–212,
 4.211f, 4.212f, 7.175–176, 7.176f
 epithelial
 benign lesions, 7.168f, 7.168–169, 7.169f
 hyperplasias, 7.166f, 7.166–168, 7.167f
 in situ malignancies, 7.176–177, 7.177f
 frozen section/Mohs surgery for, 4.44f, 4.44–45
 keratoacanthoma, 4.209–210, 4.210t, 4.211f,
 7.176–177, 7.177f
 malignant, 4.210t, 4.212f, 4.212–213, 4.213f,
 4.215–218, 4.216f, 4.217f, 4.220, 4.221f,
 7.177–187, 8.327
 basal cell carcinoma, 4.212f, 4.212–213, 4.213f,
 7.177–182, 7.178f, 7.179f
 intraocular extension of, 4.310
 in situ epithelial, 7.176–177, 7.177f
 intraocular extension of, 4.310
 Kaposi sarcoma, 5.349, 7.186, 7.186f, 8.345t,
 8.347–348
 melanocytic (melanoma), 4.220, 4.221f,
 7.184–186, 7.185f
 Merkel cell carcinoma, 7.187
 predisposing factors and, 7.165
 sebaceous adenocarcinoma/sebaceous gland
 carcinoma, 4.210t, 4.215–218, 4.216f, 4.217f,
 7.183f, 7.183–184, 8.327, 8.337f, 8.337–338
 signs suggesting, 7.165
 squamous cell carcinoma, 4.213, 4.214f, 7.182,
 7.182f
 actinic keratosis and, 4.211, 7.176, 7.182
 in situ (Bowen disease), 7.176
 well-differentiated (keratoacanthoma),
 4.209–210, 4.210t, 4.211f, 7.176–177,
 7.177f
 mechanical ptosis caused by, 7.217–218

melanocytic
 benign, 4.218f, 4.218–220, 4.219f, 4.221f,
 7.172–175, 7.174f, 7.175f
 malignant (melanoma), 4.220, 4.221f, 7.184–186,
 7.185f
 premalignant, 7.177
 in multiple endocrine neoplasia, 1.59, 1.59f
 orbital involvement and, 7.94–95
 premalignant
 epidermal (actinic keratosis), 4.210–212, 4.211f,
 4.212f, 7.175–176, 7.176f
 melanocytic, 7.177
 sebaceous gland carcinoma, 8.327, 8.337f, 8.337–338
 squamous cell carcinoma, 4.213, 4.214f
 actinic keratosis and, 4.211
 well-differentiated (keratoacanthoma), 4.209–
 210, 4.210t, 4.211f, 7.176–177, 7.177f
 systemic malignancies and, 4.209, 4.210t
 vascular and mesenchymal, 8.345t, 8.345–348
 upper
 anatomy of, 2.18–19, 2.19–25, 2.20f, 2.21f, 2.22f,
 2.23f, 2.25f
 blepharoplasty on, 7.230, 7.231, 7.232, 7.232f
 crease of, 7.150
 for orbitotomy incision, 7.116f, 7.116–117,
 7.117f, 7.119, 7.121
 in ptosis, 7.210, 7.210f, 7.214t
 development of, 2.125, 2.125f
 drooping of. *See* Ptosis
 excursion of, in ptosis, 7.210, 7.211f
 fold of, 7.147, 7.150
 hematoma of, in orbital roof fractures, 6.380, 6.380f
 paralysis of, 7.226
 in plexiform neurofibromas, 6.395–396
 ptosis of, in third nerve palsy, 6.138, 6.139f
 reconstruction of, 7.192, 7.193f
 retraction of, in thyroid eye disease, 6.140, 6.141f
 retractors of, 7.149–151, 7.150f
 tarsal plates of, 7.151–152, 7.152f
 in uveitis, 9.80t
 vascular supply of, 2.25–26, 2.26f, 5.12, 5.13f, 5.14f,
 5.17, 7.154
 venous drainage of, 2.26, 5.21f, 5.23
 vertical rectus muscle attachment of, 6.30f
 Ezetimibe, for hypercholesterolemia/heart disease
 prevention, 1.85t

F

F₃. *See* Trifluridine
 FA. *See* Facial artery; Fluorescein angiography
 Fab region (antibody molecule), 9.41f, 9.42
 Fabry disease (angiokeratoma corporis diffusum),
 2.175t, 6.270, 6.388t, 8.176–178, 8.177f, 12.291–292
 enzyme replacement therapy for, 2.203
 ocular findings in carriers of, 2.199t
 Face. *See also under* Facial
 aging affecting
 pathogenesis of, 7.236
 physical examination and, 7.197, 7.236–237
 rejuvenation and, 7.235–247. *See also* Facial
 rejuvenation

- anatomy of, 7.141–144, 7.142f, 7.143f, 7.144f, 7.145f
 sensory and motor components and, 5.47–52
- Face-lift. *See also* Facial rejuvenation
 elevation of superficial musculoaponeurotic system (SMAS) and, 7.141, 7.142f, 7.245
- Facia paralysis/weakness, 6.136f
- Facial angiofibromas, 6.397
 in tuberous sclerosis, 5.331f, 5.334t
- Facial angioma. *See* Nevi/nevus, flammeus
- Facial artery (FA), 5.12, 5.13f, 5.14f, 5.15f, 7.16f
 eyelids supplied by, 2.25, 2.26f
 orbit supplied by, 2.33f
- Facial asymmetry, torticollis and, 6.82
- Facial bones, aging and, 2.7
- Facial clefts, 7.36–38, 7.37f, 7.38f. *See also* Craniofacial malformations
 nasolacrimal duct obstruction and, 7.259
- Facial colliculus, 2.101, 2.103, 5.49
- Facial colliculus syndrome, 5.189
- Facial contracture, spastic paretic, 5.284
- Facial defects. *See* Craniofacial malformations
- Facial description, in confrontation testing, 5.83
- Facial diplegia
 in Guillain-Barré syndrome, 5.280
 in pontine lesions, 5.278
- Facial dystonia, 7.226–229, 7.227f
- Facial fasciae
 deep, 7.141
 superficial, 7.141
- Facial genu, 5.40, 5.41f, 5.49, 5.192
- Facial grimacing, blepharospasm associated with, 5.281, 5.282f
- Facial hemiatrophy, progressive (Parry-Romberg syndrome), 8.192t
- Facial motor pathways, 5.49–52, 5.50–51f. *See also* Cranial nerve VII
 disorders of, 5.275–285. *See also* Facial movement abnormalities
- Facial movement abnormalities, 5.269, 5.275–285
 cranial nerve VII (facial) disorders causing, 5.275–277, 5.276–277f, 5.277–285
 overactivity and, 5.281–285, 5.282f, 5.282t, 5.283f
 underactivity and, 5.275, 5.276–277f, 5.277–281, 5.278t, 5.279f. *See also* Facial paralysis/weakness
 evaluation of, 5.269, 5.271f, 5.271–272
- Facial muscles, 7.16, 7.141–143, 7.143f
 innervation of, 5.49–52, 5.50–51f. *See also* Cranial nerve VII
- Facial myokymia, 5.282t, 5.284
- Facial nerve. *See* Cranial nerve VII
- Facial nerve block, for cataract surgery, 11.92, 11.93f
- Facial nerve palsy. *See* Facial paralysis/weakness
- Facial neurectomy, for benign essential blepharospasm, 7.228
- Facial numbness, pain associated with, 5.298
- Facial pain, 5.289t, 5.296–298. *See also* Headache; Neuralgia; Pain
- Facial paralysis/weakness, 5.275, 5.276–277f, 5.277–281, 5.278t, 5.279f, 7.224–226
 bilateral, 5.280
 brainstem lesions causing, 5.278, 5.278t
 cataract surgery in patient with, 11.174
 ectropion and, 7.198f, 7.224–226, 7.225f
 after facial nerve ablation for benign essential blepharospasm, 7.228
 hemifacial paralysis and, 7.229
 in HIV infection/AIDS, 5.280
 in Lyme disease, 1.251
 nuclear lesions causing, 5.276f
 peripheral lesions causing, 5.278–280, 5.279f
 progressive, 5.280
 recurrent, 5.280
 in sarcoidosis, 5.280, 5.327
 seventh nerve lesions causing, 5.275, 5.276–277f
 supranuclear lesions causing, 5.276f, 5.277–278
 treatment of, 5.280–281
 upper eyelid paralysis and, 7.226
- Facial rejuvenation, 7.235–247
 botulinum toxin (cosmetic) for, 7.238–239
 laser skin resurfacing for, 7.237–238
 nonsurgical, 7.237–240, 7.239f, 7.240f
 pathogenesis of aging face and, 7.236
 physical examination of aging face and, 7.236–237
 soft tissue dermal fillers for, 7.239f, 7.239–240, 7.240f
 surgical, 7.241–247, 7.242f, 7.243f, 7.244f, 7.245f, 7.246f. *See also* Facial surgery
- Facial surgery. *See also* Eyelids, surgery/reconstruction of; *specific procedure*
 anatomy and, 7.141–144, 7.142f, 7.143f, 7.144f, 7.145f
 history and examination in patient considering, 7.197, 7.236–237
 preoperative considerations and, 7.236, 7.241, 7.245
 rejuvenation procedures, 7.241–247, 7.242f, 7.243f, 7.244f, 7.245f, 7.246f
 brow- and forehead-lift, endoscopic/pretrichial, 7.241, 7.242f, 7.243f
 forehead rejuvenation, 7.241, 7.242f, 7.243f
 lower face and neck rejuvenation, 7.245f, 7.245–247, 7.246f
 midface rejuvenation, 7.241–245, 7.243f, 7.244f
 neck liposuction, 7.246
 platysmaplasty, 7.246f, 7.246–247
 rhytidectomy, 7.245f, 7.245–246
- Facial synkinesis, 5.271, 5.271f
- Facial tic (habit spasm), 5.285
- Facial vein, 2.35f, 5.21f, 5.22, 5.23
 eyelids drained by, 5.21f, 5.23, 7.154
- Facial venous system, 5.23
- Facilitated diffusion, glucose transport into lens and, 11.17
- Factitious disorders, 1.190
 ocular surface, 8.88–90, 8.89f
- Factor V Leiden, 1.147
- Factor VIII deficiency (hemophilia A/classic hemophilia), 1.144–145
- Factor VIII transfusions, 1.145
- Factor Xa inhibitors, 1.148
- Facultative suppression, 6.49
- Fadenoperation, 6.128, 6.164t
- FAF. *See* Fundus autofluorescence
- Falciform ligament, 5.26
- FALK. *See* Femtosecond anterior lamellar keratoplasty
- Fallopian canal, 2.103, 5.52, 5.56
 seventh nerve lesions and, 5.276–277f
- Falls, in older patients, 1.184–185
- False-negative responses, in perimetry, 5.86, 10.62

- False-positive responses
 in confrontation testing, 5.84
 in perimetry, 5.86, 10.62, 10.67, 10.67f
- Famciclovir, 1.281, 2.302, 2.357t, 2.359, 8.215t
 for acute retinal necrosis/herpetic retinitis, 9.196
 for herpes simplex virus infections, 1.258, 1.281, 8.215t, 9.193, 9.196
 for herpes zoster virus infections, 1.258, 1.281, 2.357t, 2.359, 8.229, 9.193, 9.196
 for herpetic uveitis, 9.193
- FAME. *See* Fingolimod-associated macular edema
- Familial adenomatous polyposis (FAP/Gardner syndrome), 12.285–286
 retinal manifestations of, 4.144–145, 4.269
- Familial Alzheimer disease, 1.205
- Familial amyloid polyneuropathy (FAP), 4.134, 4.134f, 4.206
 vitreous involvement/opacification and, 4.134, 4.134f
- Familial amyloidosis, 4.134, 4.134f, 4.206, 8.186t, 8.187
 Finnish/gelsolin type (Meretoja syndrome), 4.206, 8.186t, 8.187, 8.188f
 with lattice corneal changes, 8.146, 8.185–187
 primary of cornea (subepithelial amyloidosis/gelatinous droplike dystrophy), 8.135t, 8.136t, 8.140–141, 8.141f, 8.185–187, 8.186t
- Familial cerebello retinal angiomatosis. *See* von Hippel-Lindau (VHL) disease/syndrome
- Familial Creutzfeldt-Jakob disease (fCJD), 5.357
- Familial dysautonomia (FD/Riley-Day syndrome), 2.175t, 6.271
 congenital corneal anesthesia and, 8.108
 racial and ethnic concentration of, 2.197
- Familial exudative vitreoretinopathy (FEVR), 6.347–348, 6.348f, 12.343–344, 12.345f
- Familial, definition of, 2.181. *See also* Family history/familial factors; Genetics
- Familial glaucoma iridogoniodyplasia. *See* Axenfeld-Rieger syndrome
- Familial hemiplegic migraine, 5.291
- Familial juvenile nephronophthisis, 12.285
- Familial juvenile systemic granulomatosis (Blau syndrome), 6.319, 9.170
- Familial oculorenal syndromes, 6.391–392, 6.391–392f
- Family history/familial factors, 2.171. *See also under Genetic*
 in cancer, 1.229
 genetic counseling and, 2.204
 in glaucoma, 10.10, 10.82, 10.121
 angle closure/angle-closure glaucoma and, 10.121
 open-angle glaucoma and, 10.82
 in ocular hypertension, 10.90
 pedigree analysis and, 2.171, 2.172f, 2.172–173
 in ptosis evaluation, 7.209
 in uveitis, 9.303
- Family planning, genetic counseling and, 2.206
- Famotidine, preoperative, 1.288
- Famvir. *See* Famciclovir
- Fanconi syndrome, tetracyclines causing, 2.350
- FAP. *See* Familial adenomatous polyposis; Familial amyloid polyneuropathy
- Far point
 ametropia correction using spectacles, 3.170, 3.170f
 cylindrical correcting lenses and, 3.173
 refractive states and, 3.136
 spherical correcting lenses and, 3.170, 3.170f
- Farkas canthal index, 6.191
- Farnsworth-Munsell 100-hue test, 12.55
 in low vision evaluation, 5.79
- Farnsworth Panel D-15 test, 12.55f, 12.55–56
 in low vision evaluation, 5.79
- Faropenem, 1.276
- FAS. *See* Fetal alcohol syndrome
- Fas ligand (CD95 ligand/FasL), 9.48, 9.49f
 in apoptosis (programmed cell death), 9.48–49, 9.49f, 9.58
 in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
 corneal transplant tolerance and, 8.316, 9.60
 in effector blockade, 9.58
- Fasanella-Servat ptosis repair procedure, 7.220
- Fascia, orbital, 6.27
- Fascia bulbi, 6.26. *See also* Tenon capsule
- Fascia lata, autologous/autogenous/banked, for frontalis suspension, 7.221
- Fascia lata sling, for paralytic ectropion, 7.226
- Fascia solitarius, 5.51f
- Fascial cutaneous ligaments, 7.141
- Fascicles
 cranial nerve III (oculomotor), 5.44–45
 cranial nerve IV (trochlear), 2.96, 5.43
 cranial nerve V (trigeminal), 5.48
 cranial nerve VI (abducens), 5.41
 cranial nerve VII (facial), 5.49
 optic nerve, 2.86, 2.88f
- Fascicular ocular motor nerve palsies, 5.191
- Fasciitis
 necrotizing, of orbit, 7.48–49
 nodular, 4.112, 4.113f, 8.347
 episcleral tumor caused by, 4.112
- FasL. *See* Fas ligand
- Fast twitch fibers, 2.18
- Fastigial nucleus, 5.40
- Fasting, preoperative, 1.288
- Fasting plasma glucose (FPG)
 in diabetes mellitus diagnosis/screening, 1.34
 impaired (IFG), 1.37
- Fat
 orbital, 2.20f, 2.23, 7.11, 7.146f, 7.149
 dermatochalasis and, 7.229
 eyelid lacerations and, 7.149, 7.187, 7.188
 retro-orbicularis oculi (ROOF), 7.146f, 7.152, 7.153
 suborbicularis oculi (SOOF/suborbicularis fat pads), 7.146f, 7.152–153
 midface rejuvenation surgery (SOOF lift) and, 7.242, 7.243f
 Fat emboli/embolism, 12.141, 12.173
 transient visual loss caused by, 5.165
 Fat-suppression/saturation techniques, in MRI, 5.58, 5.58f, 5.62–65, 5.65f, 5.66f, 5.67f, 7.28f, 7.29
 Fatal insomnia, 5.357
 Fatty acid supplements, for dry eye, 8.61, 8.61t, 8.64, 8.68
 Fatty acids
 oxidation of, 2.281, 2.282–283
 in retina, 2.285
 in retinal pigment epithelium, 2.274

- Fatty streak, 1.91–92
- FAZ. *See* Foveal avascular zone
- FBN1* gene, 6.307
- in Marfan syndrome, 8.194
- Fc portion (immunoglobulin)/Fc receptors, 9.41*f*, 9.42
- in antibody-dependent cellular cytotoxicity, 9.50
- mast cells and, 9.10
- phagocytosis and, 9.19
- FCD. *See* Fleck corneal dystrophy
- fCJD. *See* Familial Creutzfeldt-Jakob disease
- FD. *See* Familial dysautonomia
- FD-OCT. *See* Fourier-domain optical coherence tomography (FD-OCT); Frequency-domain optical coherence tomography
- FDA. *See* Food and Drug Administration
- FDF perimetry. *See* Flicker-defined form (FDF) perimetry
- FDG-PET (fluorodeoxyglucose positron emission tomography) in sarcoidosis, 5.328
- FDT perimetry. *See* Frequency-doubling technology (FDT) perimetry
- Fecal DNA testing, in cancer screening, 1.210*t*, 1.214
- Fecal immunochemical testing (FIT), in cancer screening, 1.207, 1.210*t*, 1.214
- Fecal occult blood test (FOBT), in cancer screening, 1.207, 1.214
- FECD. *See* Fuchs endothelial corneal dystrophy
- Federal Fairness to Contact Lens Consumers Act, 3.235
- FEFs. *See* Frontal eye fields
- Feiz and Mannis formula, for IOL power determination/selection, 11.86
- Felbamate, 1.202*t*
- Fellow eye. *See also* Sympathetic ophthalmia
- macular hole risks, 12.339
- in patient with AAION, 5.120, 5.120*t*, 5.121–122
- in patient with acute angle closure, 10.123, 10.125
- in patient with exfoliation syndrome, 10.91
- in patient with malignant optic glioma of adulthood, 5.130
- in patient with NAION, 5.120*t*, 5.123
- in patient with optic neuritis, 5.115
- in patient with traumatic/angle-recession glaucoma, 10.108
- retinal detachment in, 12.319
- sympathetic ophthalmia and. *See* Sympathetic ophthalmia
- Fells modification of Harada-Ito procedure, 6.167
- Felodipine, 1.68*t*, 1.69*t*
- Felty syndrome, 1.152
- Femto-LASIK. *See* Femtosecond laser in situ keratomileusis
- Femtosecond anterior lamellar keratoplasty (FALK), 8.412*t*, 8.434
- Femtosecond laser, 13.29
- for anterior/deep anterior lamellar keratoplasty, 8.412*t*, 8.431, 8.434
- for arcuate keratotomy incisions, 13.54, 13.55
- for cataract extraction, 11.125–126
- for corneal inlay insertion, 13.61, 13.169
- for corneal intrastromal treatment, 13.168
- for intrastromal corneal ring segment incisions/channels, 13.64
- for LASIK flap creation, 13.8*t*, 13.87–90, 13.88*f*, 13.89*f*, 13.90*t*
- aberrations and, 13.102–103
- advantages/disadvantages/complications of, 13.88, 13.90*t*, 13.122–124, 13.123*f*
- re-treatment/enhancements and, 13.98
- steep or flat corneas and, 13.44–45, 13.79
- for lenticule extraction, 13.8*t*, 13.27–28, 13.203
- for photodisruption, 13.29
- for presbyopia treatment, 13.168
- for relaxing incisions after penetrating keratoplasty, 8.432
- for small-incision lenticule extraction, 13.204
- Femtosecond laser-assisted keratoplasty (FLAK), 8.412*t*, 8.431
- Femtosecond laser in situ keratomileusis (Femto-LASIK), 13.8*t*. *See also* Femtosecond laser, for LASIK flap creation
- Femtosecond lenticule extraction (FLEX), 13.8*t*, 13.27–28, 13.203
- Fenofibrate
- diabetic retinopathy progression affected by, 1.48, 1.89, 12.102
- for hypercholesterolemia/heart disease prevention, 1.85*t*
- Fenopropfen, 2.335*t*
- Fenoterol, 1.133
- Fentanyl, perioperative, 1.290
- Fermat principle
- definition of, 3.40, 3.70
- description of, 3.86–88, 3.274
- point spread function and, 3.275
- wavefront analysis based on, 3.274
- Ferrara rings, 13.62–63. *See also* Intrastromal corneal ring segments
- Ferritin levels, in iron deficiency anemia, 1.135, 1.136
- Ferrous sulfate, for iron deficiency anemia, 1.136–137
- Ferry lines, 8.118*t*
- Fetal alcohol syndrome (FAS), 1.192, 6.183, 6.211–212, 6.212*f*, 6.361
- Fetal fissure. *See* Embryonic fissure
- Fetal hydantoin syndrome (FHS), 1.203
- Fetal lens nucleus, 4.117, 11.13, 11.27*f*, 11.28, 11.28*f*, 11.28–29
- opacification of (congenital nuclear cataract), 11.38, 11.39*f*
- Fetal radiation, effects/ocular manifestations of, 1.230
- Fetal vasculature, persistent. *See* Persistent fetal vasculature
- Fetus
- HIV transmission to, 1.265
- maternal antiglaucoma agents affecting, 10.185–186
- FEV₁ (forced expiratory volume over 1 second), 1.131
- FEVR. *See* Familial exudative vitreoretinopathy
- Feynman, Richard, 3.96
- FGF. *See* Fibroblast growth factor
- FGFR2* gene, in Crouzon syndrome, 2.177
- FGFR* genes, in Crouzon syndrome, 2.177
- FHS. *See* Fetal hydantoin syndrome
- FHU. *See* Fuchs heterochromic uveitis
- Fiber layer of Henle (HFL), 2.74, 2.74*f*, 4.140, 4.141*f*, 5.24. *See also* Nerve fiber layer
- Fibric acid derivatives, for hypercholesterolemia/heart disease prevention, 1.85*t*

- Fibril-associated proteins, in vitreous, 2.251–252
- Fibrillar opacities, 2.253
- Fibrillation
- atrial (AF), 1.114
 - heart failure and, 1.111
 - stroke and, 1.120
 - ventricular (VF), 1.114, 1.115
 - emergency management of, 1.115
 - myocardial infarction and, 1.96, 1.115
- Fibrillin, 2.66, 2.252
- defects in, in Marfan syndrome, 2.66, 2.252, 8.193–194, 11.40
- Fibrillin-1, 6.307
- Fibrin, 9.23–24
- in uveitis, 9.24, 9.79, 9.113
- Fibrin clots, 6.377
- Fibrin glue/sealant/tissue adhesive, 2.369, 8.355
- for conjunctivochalasis, 8.86
 - for corneal autograft fixation, 8.351, 8.355
 - in pterygium excision, 8.355
 - recurrence rate and, 8.353*t*
 - off-label use of, 2.306, 2.369, 8.355
- Fibrinogen, 9.23
- Fibrinolytic agents (thrombolysis/thrombolytic therapy), 1.149, 2.369
- for cerebral ischemia/stroke, 1.122–123
 - emergency transport and, 1.295, 1.299
 - for myocardial infarction/STEMI, 1.94, 1.104–105
- Fibrinolytic system, 1.141
- Fibro-osseous dysplasia (juvenile ossifying fibroma), of orbit, 4.239, 4.240*f*
- Fibroblast growth factor (FGF), 2.371–372
- in aqueous humor, 2.234
 - gene expression/ocular development and, 2.127
 - in tear film, 2.217
- Fibroblast growth factor receptor (*FGFR*) genes, 2.177, 6.206
- Fibroblasts
- keratocytes as, 8.8, 8.9*f*. *See also* Keratocytes
 - orbital, in thyroid eye disease, 4.226, 7.55
- Fibrocellular proliferation, intraocular, 4.20–22, 4.21*f*
- Fibrocytes (stromal keratocytes), 4.73
- corneal haze after surface ablation and, 13.33, 13.109
 - in wound healing/repair, 4.14–15, 4.15*f*, 4.16
- Fibroepithelial polyp (acrochordon/skin tag), 7.166, 7.166*f*
- Fibroma/fibromatosis
- juvenile, of orbit, 4.239, 4.240*f*
 - juvenile ossifying, of orbit, 4.239, 4.240*f*
 - molluscum, 5.334*t*
- Fibronectin, 12.7
- in vitreous, 2.249, 2.250, 2.251*f*
- Fibroplasia, retrolental. *See* Retinopathy, of prematurity
- Fibrosarcoma
- of orbit, 7.84
 - retinoblastoma associated with, 4.302*t*
- Fibrotic pulmonary disease, 1.130–131
- Fibrous astrocytes, 2.73
- Fibrous downgrowth. *See* Fibrous ingrowth (downgrowth)
- Fibrous dysplasia, 6.222
- of orbit, 4.239, 4.240*f*, 7.84, 7.85*f*
 - secondary, 7.97
- Fibrous histiocytoma (fibroxanthoma), 8.347
- malignant, 4.112
 - orbital, 4.235, 7.84
 - scleral, 4.112, 4.113*f*
- Fibrous ingrowth (downgrowth)
- angle-closure glaucoma and, 10.141–142, 10.143*f*
 - corneal edema after cataract surgery and, 11.128*t*, 11.133
 - corneal graft failure and, 4.84, 4.85*f*
- Fibrous tumor, solitary, of orbit, 4.235*f*, 4.235–236, 7.84
- Fibrovascular pigment epithelial detachment, 12.72–73
- Fibrovascular plaque, anterior, in persistent fetal vasculature, 4.125, 4.126*f*
- Fibroxanthoma. *See* Fibrous histiocytoma
- Fibulin-1, in vitreous, 2.249
- Field defects. *See* Visual field defects
- Field loss, vision rehabilitation for, 3.325–326
- Field of vision. *See* Visual field
- Fifth cranial nerve. *See* Cranial nerve V
- Filamentary keratopathy, 8.56, 8.56*f*
- in graft-vs-host disease, 8.304
 - treatment of, 8.63
- Filamentous fungi, 8.249, 8.249*t*, 8.250*f*, 8.251
- keratitis caused by, 8.251, 8.273, 8.274*f*, 8.275
 - as normal flora, 8.206*t*
 - ocular infection caused by, 8.251
- Filaments, corneal, 8.46*t*
- in aqueous tear deficiency, 8.56, 8.56*f*
- Filaments (bacteria), gram-positive, 8.244*t*, 8.248–249
- Filariae
- Loa loa*, 8.282
 - orbital involvement and, 4.228
 - onchocercal, 8.252–253
 - in anterior chamber, 9.234–235
- Filensin, 2.245, 11.16
- Filtering bleb
- cataract surgery in eye with, 11.187
 - endophthalmitis associated with, 10.163, 10.209, 10.209*t*, 10.210*f*
 - evaluation for, before glaucoma surgery, 10.31
 - inadvertent, after cataract surgery, 11.130–131
 - LASIK and, 13.182
 - in trabeculectomy, 10.200, 10.206, 10.206*f*, 10.207, 10.207*f*, 10.208*f*
 - postoperative complications and, 10.209, 10.209*t*, 10.210, 10.210*f*, 10.211
- Filtering procedures, 10.197–211. *See also* Trabeculectomy
- cataract surgery after, 11.186, 11.187
 - cataract surgery combined with, 10.211–213
 - conjunctival evaluation before, 10.31
 - flat or shallow anterior chamber/angle-closure glaucoma and, 10.144–145
 - LASIK and, 13.182
 - for neovascular glaucoma, 10.135
 - for pigmentary glaucoma, 10.96
 - for uveitic glaucoma, 9.287
- Fimbriae, bacterial, 8.244
- Fine-needle aspiration biopsy (FNAB), 4.34*t*, 4.42–43, 4.43*f*, 4.253
- in lymphoma, 4.42, 7.88
 - in metastatic eye disease, 4.253, 4.307

- of orbit, 4.43, 7.124
 - in tumor evaluation, 7.33, 7.88, 7.99
- of thyroid gland, 1.52
- in uveal lymphoid proliferation/infiltration, 4.314
- Finger comparison test, in confrontation testing, 5.83–84
- Finger counting, in confrontation testing, 5.83
- Finger-touching test, nonorganic disorder evaluation and, 5.301, 5.302f
- Fingerprint lines, in epithelial basement membrane dystrophy, 8.137
- Fingolimod, 12.301
 - for multiple sclerosis, 5.320, 5.321t
 - macular edema and, 5.320, 5.322f
 - uveitis and, 9.132
- Fingolimod-associated macular edema (FAME), 5.320, 5.322f
- Finnish Twin Cohort Study, 10.10
- Finnish (gelsolin) type amyloidosis (Meretoja syndrome), 4.206, 8.186t, 8.187, 8.188f
- Finoff transilluminator, 3.33
- FIPs. *See* Focal intraretinal periarteriolar transudates
- First cranial nerve. *See* Cranial nerve I
- First-degree relatives, 2.143
- First nodal point, 3.66
- First-order aberrations, 13.11
- First-order approximation. *See* Paraxial rays
- First-order neuron, 5.52, 5.53, 5.53f
 - dilator muscle innervation and, 2.56
 - Horner syndrome caused by lesions of, 5.257, 5.259, 5.260t
- First-order optics, ophthalmic lenses and. *See* Ophthalmic lenses
- First principal plane, 3.56, 3.58
- FISH. *See* Fluorescence in situ hybridization
- Fish eye disease, 8.180
- Fishbone diagram, 1.30, 1.30f
- Fissures
 - calcarine, 5.29f, 5.29–30
 - embryonic, 2.117f, 2.118f
 - closure of, 2.116t, 2.118f, 2.119f
 - colobomas and, 2.117, 2.119f
 - orbital, 2.6f, 2.8f, 2.8–10, 2.9f, 5.6f, 5.7f, 5.9f, 5.11, 7.6f, 7.7, 7.7f, 7.8f, 7.9, 7.10f
 - inferior, 2.6f, 2.8–10, 5.7f, 5.9f, 5.11, 7.6f, 7.7f, 7.8f, 7.9
 - superior, 2.6f, 2.8, 2.8f, 2.9f, 2.14f, 5.6f, 5.7f, 5.9f, 5.11, 7.6f, 7.7, 7.7f, 7.9, 7.10f
 - ophthalmoplegia caused by lesions of, 5.203
 - palpebral, 2.18f, 2.18–19, 2.25f, 7.153
 - in euryblepharon, 7.157
 - vertical height of, in ptosis, 7.210, 7.210f
- Fistulas
 - arteriovenous
 - glaucoma associated with, 10.30
 - of orbit, 7.72f, 7.72–74, 7.73f
 - carotid-cavernous sinus, 5.203–206, 5.204f, 5.205f, 7.72f, 7.72–73, 7.73f
 - direct, 7.72–73
 - dural (indirect), 7.72, 7.73
 - neuroimaging in evaluation of, 5.70, 5.72t, 5.204, 5.204f, 5.205f
 - congenital lacrimal, 6.228, 6.229f
 - lacrimal/lacrimal–cutaneous, 7.257, 7.258f
- Fistulizing procedures, 10.197–211. *See also* Filtering procedures
- FIT. *See* Fecal immunochemical testing
- Fite-Faraco stain, 4.31t
- Fitting (contact lens)
 - disinfection of trial lenses and, 1.271
 - after refractive surgery, 13.199, 13.200
- Fitzpatrick skin type, 7.236–237
- 5-FU. *See* Fluorouracil/5-Fluorouracil
- 5′ untranslated region, 2.145
- Fixation (visual), 5.212, 5.212t, 5.213–214
 - alternating, 6.16
 - amblyopia evaluations, 6.56–57
 - assessments of, in preverbal children, 6.300
 - dysfunction of, 5.214
 - eccentric
 - anomalous retinal correspondence versus, 6.51
 - definition of, 6.54
 - maintained, 6.6
 - monocular, 6.16
 - near, 6.64
 - in normal vision, 3.313–314
 - nystagmus and, 5.215, 5.240, 5.241t
 - for retinoscopy, 3.152
 - spasm of. *See* Ocular motor apraxia
 - steady, 6.6
 - uncentral, 6.6
 - unsteady, and unmaintained, 6.6
 - vestibular-ocular reflex suppression and, 5.225, 5.225f
 - in visual acuity assessment in children, 6.5–6
- Fixation loss, in perimetry, 5.86
- Fixation reflex, 6.300
- Fixation switch diplopia, 5.209
- Fixatives, for tissue preservation, 4.26, 4.26t
- Fixed, dilated pupil, nonorganic causes of, 5.310
- FKHL7* gene. *See* *FOXC1* (*FKHL7*) gene
- Flagella, bacterial, 8.244
- FLAIR (fluid-attenuated inversion recovery) images, 5.62, 5.63t, 5.65, 5.66f, 5.67f, 5.72t, 5.75
 - in multiple sclerosis, 5.65, 5.66f, 5.316f, 5.319
- FLAIR (fluid-attenuated inversion recovery) technique, 7.29
- FLAK. *See* Femtosecond laser-assisted keratoplasty
- Flame hemorrhages, ischemia causing, 4.153, 4.155f
- Flap folds, after LASIK, 13.112–115, 13.114t, 13.115f. *See also* Striae
- Flap tears, of retina, 12.315, 12.318–319
- Flaps
 - advancement, 8.359, 8.359f
 - bipedicle, 8.359f, 8.359–360
 - for canthal repair, 7.195, 7.196
 - conjunctival, 8.354f, 8.356–360, 8.357f, 8.358f, 8.359f
 - for bare sclera after pterygium excision, 8.353, 8.354f
 - cataract surgery and
 - for ECCE, 11.196
 - for ICCE, 11.199
 - leak causing inadvertent filtering bleb and, 11.130–131
 - for postoperative corneal edema, 11.129–130
 - for herpetic eye disease, 8.225
 - for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82, 8.357
 - for peripheral ulcerative keratitis, 8.313

- removal of, 8.360
- for symblepharon, 7.208
- for trabeculectomy, 10.200, 10.201*f*, 10.202*f*
 - closure of, 10.204, 10.206*f*
 - management of, 10.207–208
- for trabeculectomy, in children, 10.161–162
- epi-LASIK, 13.84
- after exenteration, 7.137
- for eyelid repair, 7.190, 7.191, 7.192, 7.193*f*, 7.194, 7.194*f*, 7.195
 - in burn injury, 7.190
- Gundersen, 8.357*f*, 8.357–358, 8.358*f*, 11.129
- LASIK, 13.30, 13.73, 13.75*f*, 13.79, 13.82, 13.84–90
 - aberrations associated with creation of, 13.102–103, 13.103*f*
 - buttonhole, 13.110, 13.110*f*
 - corneal inlay insertion and, 13.60, 13.169
 - corneal transplantation and, 13.198
 - dislocation of, 13.113, 13.115–116
 - striae and, 13.113
 - traumatic, 13.115–116
 - femtosecond, 13.8*t*, 13.87–90, 13.88*f*, 13.89*f*, 13.90*t*
 - aberrations and, 13.102–103
 - advantages/disadvantages/complications of, 13.88, 13.90*t*, 13.122–124, 13.123*f*
 - re-treatment/enhancements and, 13.98
 - steep or flat corneas and, 13.44–45, 13.79
 - glaucoma/elevated intraocular pressure and, 13.181, 13.201
 - haze formation and, 13.33
 - immediate postablation care of, 13.92–93
 - infected, 13.107, 13.107*f*, 13.117–119
 - diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
 - microkeratome, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
 - aberrations and, 13.102
 - complications associated with, 13.110*f*, 13.110–112, 13.111*f*
 - re-treatment/enhancements and, 13.98
 - penetrating keratoplasty and, 13.180
 - re-treatment/enhancements and, 13.98–99, 13.99*f*
 - retinal detachment repair and, 13.185, 13.197
 - steep or flat corneas and, 13.44–45, 13.79
 - striae in, 13.112–115, 13.114*t*, 13.115*f*
 - scleral, for trabeculectomy, 10.200–201, 10.203*f*
 - closure of, 10.202–204, 10.205*f*
 - management of, 10.207–208
 - single pedicle, 8.359*f*, 8.359–360
 - for symblepharon, 7.208
- Flarex. *See* Fluorometholone
- Flash visual evoked potential, 5.95
 - in nonorganic disorder evaluation, 5.302
- Flashing lights. *See* Photopsias
- Flat anterior chamber. *See* Anterior chamber, flat or shallow
- Flat refracting surface, optics of, 3.44–45
- Flattening
 - in myopia surgery, 13.26, 13.80
 - progressive, after radial keratotomy, 13.51
- Flaviviridae, 12.247
- Flecainide, 1.113*t*
 - ocular effects of, 1.308*t*
- Fleck corneal dystrophy (FCD), 8.135*t*, 8.136*t*, 8.153, 8.154*f*
- Fleischer ring, 4.95*f*, 4.96, 6.254, 8.117, 8.118*t*, 8.163, 8.163*f*
- Fleurettes
 - in retinoblastoma, 4.175, 4.175*f*
 - in retinocytoma, 4.178
- FLEX. *See* Femtosecond lenticule extraction
- Flexible contact lenses. *See* Soft (flexible) contact lenses
- Flexible-loop anterior chamber intraocular lenses, 11.119, 11.120*f*
- Flexivue Microlens, 13.169
- Flexner-Wintersteiner rosettes, 6.353
 - in medulloepithelioma, 4.178*f*, 4.179
 - in primary intracranial pinealoblastoma, 4.298
 - in retinoblastoma, 4.174–175, 4.175*f*
- FlexOptic intraocular lens, 13.170
- Flicker-defined form (FDF) perimetry, 10.75, 10.76*f*
- Flicker fusion frequency, 2.262
- Floater
 - description of, 12.344
 - in posterior vitreous detachment, 12.308–309
 - in retinal tears, 5.175
 - in rhegmatogenous retinal detachment, 12.320
 - in toxocariasis, 12.244
 - in toxoplasmic retinochoroiditis, 12.243
 - in uveitis/pars planitis, 9.73, 9.78
 - vitrectomy for, 12.386
- Flocculus, 5.34*f*
- “Floor effect,” 1.24
- Floppy eyelid syndrome, 7.164, 7.164*f*, 8.79, 8.82–83, 8.83*f*
- Floppy iris syndrome, intraoperative (IFIS), 11.74, 11.136–138, 11.137*t*
 - pupil expansion devices for, 11.178
- Flow cytometry, 4.34*t*, 4.36, 4.37*f*, 7.124
 - in orbital lymphoma, 7.88
 - in paroxysmal nocturnal hemoglobinuria screening, 1.135, 1.138
- Flow rate, in phacoemulsification, 11.102
 - vacuum rise time and, 11.102
- Flowchart (care system), 1.30, 1.30*f*
- Floxacin, 2.344
- Flu. *See* Influenza
- Flublok, 1.220
- Fluaine. *See* Fluorescein, with proparacaine
- Flucelvac, 1.220
- Fluconazole, 1.270, 1.280, 2.355*t*, 2.356
 - for *Candida* endophthalmitis, 9.267
 - for coccidioidomycosis, 9.272
 - for fungal keratitis, 8.275
 - for yeast endophthalmitis, 12.240
- Flucytosine/5-fluorocytosine, 2.355*t*, 2.356
 - for *Candida* endophthalmitis, 9.267
- Fluence, 3.107*t*
- Fluid-attenuated inversion recovery (FLAIR) images, 5.62, 5.63*t*, 5.65, 5.66*f*, 5.67*f*, 5.72*t*, 5.75
 - in multiple sclerosis, 5.65, 5.66*f*, 5.316*f*, 5.319
- Fluid-attenuated inversion recovery (FLAIR)
 - technique, 7.29
- Fluid-based phacolysis, 11.125
- Fluid resuscitation
 - for anaphylaxis, 1.302
 - for shock, 1.301
- Fluidics, terminology used in, 11.102–103
- FLuidVision intraocular lens, 13.170

- Flumazenil, for benzodiazepine reversal, 1.291
- FluMist, 1.220
- Fluocinolone implant, 2.300*t*, 2.302, 2.334, 9.98
- for birdshot uveitis, 9.147
 - for multifocal choroiditis and panuveitis syndrome, 9.157
 - ocular hypertension/glaucoma and, 9.286
 - for sarcoidosis, 9.171
 - for serpiginous choroiditis, 9.153
 - for sympathetic ophthalmia, 9.175
 - for uveitic cystoid macular edema, 9.289
 - for uveitis, 9.98
 - for Vogt-Koyanagi-Harada syndrome, 9.181
- Fluor-Op. *See* Fluorometholone
- Fluoracaine. *See* Fluorescein, with proparacaine
- Fluorescein, 2.367, 8.36
- absorption properties of, 3.301
 - allergic reactions to, 1.302
 - angiography with. *See* Fluorescein angiography
 - for applanation tonometry, 10.22–23
 - accuracy and, 10.23–24
 - for aqueous deficiency diagnosis, 8.56
 - with benoxinate, 2.363*t*, 2.365
 - characteristics of, 12.33
 - for dye disappearance test, 7.269, 8.36
 - for fluorophotometry, 10.17
 - intravenous administration of, 2.301, 2.367. *See also* Fluorescein angiography
 - for Jones I and Jones II tests, 7.269
 - leakage of, 12.35
 - in ocular surface evaluation, 8.36–37, 8.37*f*, 8.38*f*
 - pooling of, 12.35, 12.36*f*
 - with proparacaine, 2.363*t*
 - punctate staining patterns and, 8.36, 8.37*f*
 - rigid gas-permeable contact lens fitting evaluations using, 3.219*f*, 3.219–220
 - for tear breakup time testing, 7.267, 8.36, 8.57*t*, 8.60
- Fluorescein angiography (FA), 2.367, 5.89, 5.89*f*
- in AAION, 5.120, 5.120*t*
 - acute idiopathic maculopathy on, 12.228
 - in acute posterior multifocal placoid pigment epitheliopathy, 9.142*t*, 9.148–149, 9.149*f*, 12.221*f*, 12.222
 - in acute retinal pigment epitheliitis, 9.142*t*, 9.164, 9.164*f*
 - in acute zonal occult outer retinopathy, 9.142*t*, 9.165, 12.227
 - adult-onset vitelliform maculopathy on, 12.68
 - adverse effects of, 12.36
 - in age-related macular edema/melanoma
 - differentiation, 4.269, 4.270*f*
 - allergic reactions and, 1.302
 - angioid streaks on, 12.87, 12.89*f*
 - asteroid hyalosis on, 12.347
 - autofluorescence, 12.35
 - in Behçet disease, 9.187, 9.187*f*
 - Best disease on, 6.342, 6.343*f*
 - bilateral diffuse uveal melanocytic proliferation on, 12.205*f*
 - in birdshot uveitis, 9.142*t*, 9.144–145, 9.145*f*, 12.224–225, 12.225*f*
 - blocked fluorescence in, 12.35
 - branch retinal artery occlusions on, 12.152*f*
 - in cataract surgery evaluation, 11.82, 11.188, 11.189
 - central retinal artery occlusion on, 12.144*f*
 - central retinal vein occlusion on, 12.130, 12.131*f*
 - central serous chorioretinopathy on, 12.190, 12.191*f*
 - in choroidal hemangioma, 4.281, 4.282*f*
 - in choroidal melanoma/ciliary body melanoma, 4.265
 - choroidal neovascularization on, 12.36, 12.37*f*, 12.72–73, 12.73–74*f*
 - in choroidal nevus, 4.257
 - choroidemia on, 12.268
 - in Coats disease, 4.295, 4.295*f*, 6.359, 6.359*f*, 12.160*f*
 - in cystoid macular edema
 - description of, 12.36*f*, 12.157
 - in uveitis, 9.289
 - in dengue fever, 9.213
 - description of, 3.303
 - drusen on, 12.65
 - epiretinal membranes on, 12.335
 - familial exudative vitreoretinopathy on, 12.345*f*
 - fluorescein dye used in, 12.33
 - fovea in, 12.34
 - foveal avascular zone in, 12.9
 - fundus camera for, 3.301, 12.23, 12.36
 - in HTLV-1-associated uveitis, 9.212
 - hyperfluorescence in, 12.35
 - hypertensive choroidopathy findings, 12.123, 12.124*f*
 - illustration of, 12.34*f*
 - in inflammatory chorioretinopathies, 9.142*t*
 - in iris melanoma, 4.260–261
 - ischemic central retinal vein occlusion on, 12.132*f*
 - laser therapy for diabetic macular edema guided using, 12.115
 - in low vision evaluation, 5.89, 5.89*f*
 - lupus vasculitis on, 12.231*f*
 - in lymphoma, 4.311, 9.274
 - macular telangiectasia type 2 on, 12.163, 12.163*f*
 - in metastatic eye disease, 4.306
 - in multifocal choroiditis and panuveitis syndrome, 9.142*t*, 9.155–156, 9.156*f*
 - in multiple evanescent white dot syndrome, 5.101, 9.142*t*, 9.162, 9.162*f*, 12.223–224
 - in NAION, 5.120*t*, 5.123*t*
 - narrow-band interference filters in, 3.103
 - nonischemic central retinal vein occlusion on, 12.130, 12.131*f*
 - in ocular histoplasmosis syndrome, 9.216–217, 9.218*f*
 - in ocular ischemic syndrome, 9.279, 12.138, 12.139*f*
 - in optic nerve/nerve head/disc drusen versus papilledema, 5.142
 - in optic neuritis, 5.123*t*
 - optical coherence tomography angiography versus, 12.29
 - in pars planitis, 9.129
 - in pregnancy, 12.36
 - prepapillary vascular loops on, 12.341
 - in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.274
 - in punctate inner choroiditis, 9.142*t*, 9.158, 9.159*f*
 - radiation retinopathy on, 12.170, 12.170*f*
 - recirculation phase of, 12.34
 - retinal cavernous hemangioma on, 12.169*f*

- in retinal disease, 12.33–38, 12.34*f*, 12.36–37*f*. *See also specific disease*
 - cavernous hemangioma, 4.286
 - hemangioblastoma, 4.284, 4.284*f*
- retinal pigment epithelium cells on, 12.34
- in Rift Valley fever, 9.211
- in serpiginous choroiditis, 9.142*t*, 9.152*f*, 9.152–153, 9.153*f*
- skin yellowing caused by, 12.36
- Stargardt disease on, 12.269–270, 12.270*f*
- in subretinal fibrosis and uveitis syndrome, 9.142*t*, 9.161
- in Susac (SICRET) syndrome, 9.139*f*, 9.139–140
- in sympathetic ophthalmia, 9.173*f*, 9.173–174
- in syphilitic chorioretinitis, 9.239, 9.239*f*
- technique for, 12.33–34, 12.34*f*
- in tuberculous uveitis, 9.251*f*, 9.252
- uveal effusion syndrome on, 12.204*f*
- in uveitis, 9.90, 9.90*f*
 - cystoid macular edema and, 9.289
- vascular filling defects in, 12.35
- vitreoretinal traction syndrome on, 12.337
- in Vogt-Koyanagi-Harada syndrome, 9.180, 9.180*f*, 9.181*f*, 12.232
- in West Nile virus chorioretinitis, 9.209, 9.209*f*
- wide-angle, 12.36, 12.37*f*
- Fluorescence, 3.111
- Fluorescence in situ hybridization (FISH), 2.188, 4.38*t*
- Fluorescent bronchoscopy, in cancer screening, 1.212
- Fluorescent treponemal antibody absorption (FTA-ABS) test, 1.249, 9.241, 12.241
- Fluorexon, 8.36
- 5-Fluorocytosine. *See* Flucytosine/5-fluorocytosine
- Fluorodeoxyglucose positron emission tomography (FDG-PET), in sarcoidosis, 5.328
- Fluorometholone (FML), 2.330*t*
 - anti-inflammatory/pressure-elevating potency of, 2.333*t*
 - in combination preparations, 2.348*t*
 - elevated intraocular pressure after photocoagulation associated with, 13.182
 - for Thygeson superficial punctate keratitis, 8.307
 - for uveitis, 9.95
 - ocular hypertension/glaucoma and, 9.286
- Fluorophores, in fundus autofluorescence, 12.29
- Fluorophotometry, 10.17
- Fluoroquinolones, 1.277, 2.346–349, 2.347*t*
 - for bacterial conjunctivitis, 6.240
 - for bacterial keratitis, 8.269, 8.270*t*, 8.271
 - corneal deposits caused by, 8.131
 - for gonococcal conjunctivitis, 8.259
 - in neonates, 8.264
 - uveitis caused by, 9.121
- Fluorouracil/5-fluorouracil (5-FU), 1.232*t*, 2.339
 - bleb-associated endophthalmitis and, 10.209
 - for ocular surface tumors, 8.327, 8.330*f*, 8.331
 - off-label use of, 2.306
 - in trabeculectomy, 10.205, 10.206–207
- Fluoxetine, ocular effects of, 1.307*t*
- Fluphenazine, oculogyric crisis caused by, 5.231
- Flurbiprofen, 1.111, 2.330*t*, 2.335*t*, 2.336
- Fluress. *See* Fluorescein, with benoxinate
- Fluorox. *See* Fluorescein, with benoxinate
- Flutamide, 1.234*t*
- Flutter
 - atrial, 1.114
 - ocular, 5.243*t*, 5.248, 5.248*f*, 5.249
 - ventricular, 1.114
 - voluntary, 5.249–250, 5.309
- Fluvastatin, for hypercholesterolemia/heart disease prevention, 1.86*t*
- Fluzone high dose, 1.220
- “Flying spot” excimer lasers, 3.277
 - for photocoagulation, 13.31
- FML. *See* Fluorometholone
- FMN/FMNS. *See* Fusion/fusional maldevelopment
- nystagmus syndrome
- fMRI. *See* Functional magnetic resonance imaging
- FNAB. *See* Fine-needle aspiration biopsy
- Foam cells, 1.92
- FOBT. *See* Fecal occult blood test
- Focal chorioretinitis, 12.238, 12.238*f*
- Focal illumination, for slit-lamp biomicroscopy, 8.17, 8.18*f*
- Focal intraretinal peripapillary transudates (FIPTs), 12.121–122, 12.122*f*
- Focal length, 3.3, 3.8
- Focal line, 3.76*f*
 - in astigmatism, 3.137, 3.160
- Focal macular edema, 12.110, 12.111*f*
- Focal point
 - posterior, 3.140
 - refractive states and, 3.136
 - secondary, 3.170
 - “virtual,” 3.11, 3.11*f*
- Focal stromal infiltrates, 8.50
- Focimeter. *See* Lensmeters
- Fodrin, in retinal pigment epithelium, 2.273
- Fogging
 - description of, 3.286
 - for nonorganic disorder evaluation
 - monocular no light perception and, 5.303, 5.304*f*
 - monocular reduced vision and, 5.305
 - for retinoscopy, 3.152, 3.160–161
- Folate/folic acid
 - antagonists of, in cancer chemotherapy, 1.232*t*
 - deficiency of, 1.138
 - optic neuropathy caused by, 5.138
 - supplemental
 - for folic acid deficiency, 1.138
 - for hemolytic anemia, 1.138
 - in methotrexate therapy, 6.322
- Foldable intraocular lenses, 11.116, 11.120, 11.120*f*, 11.121*f*
 - insertion of, 11.116
 - posterior chamber phakic, 13.138
 - in uveitis, 9.121
- Folic acid. *See* Folate/folic acid
- Folinic acid, 2.349
- Follicle-stimulating hormone, pituitary adenoma producing, 1.57
- Follicles
 - conjunctival, 8.46*t*, 8.47*t*, 8.48–49, 8.49*f*
 - in chlamydial conjunctivitis/trachoma, 8.261, 8.262, 8.263
 - hair
 - of eyelash, 7.154*f*
 - tumors originating in, 7.172, 7.172*f*, 7.173*f*
 - thyroid, 1.50
- Follicular carcinoma, of thyroid gland, 1.55

- Follicular conjunctivitis, 4.50, 4.50*f*, 4.51, 4.51*f*, 6.241, 6.243, 8.47*t*, 8.48–49, 8.49*f*
 in acute hemorrhagic conjunctivitis, 8.240
 adenoviral, 4.52, 8.233, 8.234
 Epstein-Barr virus causing, 8.230–231
 in influenza, 8.240*t*
 in Lyme disease, 9.245
 in measles, 8.239, 8.240*t*
 in mumps, 8.240, 8.240*t*
 rhinovirus causing, 8.240*t*
 RNA viruses causing, 8.239
 toxic, 8.90*t*, 8.90*f*, 8.91
 varicella-zoster virus causing, 8.225, 8.226
- Follicular keratosis, inverted, 4.209, 4.210*f*
- Follicular lymphoma/follicular center lymphoma, of orbit, 7.86
- Folliculosis, benign lymphoid, 8.48, 8.49*f*
- Follow-up, in clinical research/studies, 1.6
 case series, 1.9
- Follow-up studies (cohort studies), 1.8*f*, 1.10*f*, 1.11–12
 clinical trial differences and, 1.13, 1.13*f*
- Followability, in phacoemulsification, 11.102
- Fondaparinux, 1.148–149
 for ischemic heart disease, 1.100*t*
 non-ST-segment elevation acute coronary syndrome, 1.103
- Fontanelles, 6.204*f*
- Food and Drug Administration (FDA), 2.305
- Foot-pedal controls, phaco machine, 11.99
- Footplates of Müller cells, 12.15, 12.15*f*
- Foramen (foramina)
 ethmoidal, anterior/posterior, 2.6*f*, 2.7–8, 5.11, 7.6*f*, 7.7*f*, 7.9
 infraorbital, 2.7, 7.6*f*
 lacerum, 5.6*f*
 magnum, 5.5
 oculomotor, 7.12
 optic, 2.7, 5.7*f*, 7.10
 orbital, 2.7–8
 ovale, 5.6*f*
 rotundum, 2.100, 5.6*f*, 5.11, 7.6*f*, 7.8*f*
 spinosum, 5.6*f*
 supraorbital, 2.5, 2.7, 5.9*f*, 7.6, 7.6*f*
 zygomatic, 2.8
 zygomaticofacial, 7.6*f*, 7.8*f*
 zygomaticotemporal, 5.11, 7.6*f*
- Forced duction test (traction test)
 for Brown syndrome, 6.137
 for consecutive esotropia, 6.95
 description of, 6.73
 in diplopia, 5.186, 5.186*f*
 in orbital floor/blowout fracture, 7.109
 surgery and, 7.110
 for orbital floor/blowout fractures, 6.379
- Forced expiratory volume over 1 second (FEV₁), 1.131
- Forced vital capacity (FVC), 1.131
- Forehead
 drooping of (brow ptosis), 7.234–235, 7.235*f*
 dermatochalasis and, 7.229, 7.234, 7.235
 surgical rejuvenation of, 7.241, 7.242*f*, 7.243*f*
- Forehead flap
 for canthal repair, 7.196
 for eyelid repair, 7.193*f*
- Foreheadplasty, 7.241, 7.242*f*
- Foreign bodies
 corneal, 6.376
 intralenticular, 11.57
 intraocular (IOFBs), 9.279–280
 aluminum, 12.362
 chalcosis secondary to, 12.362
 composition of, 12.362
 conjunctival, 4.52, 4.53*f*, 8.397, 8.397*f*, 8.398*f*
 insect stingers/hairs, 8.386–387
 radioactive, 8.386
 copper, 12.362
 corneal, 8.399–400, 8.400*f*, 8.401*f*, 8.403
 insect stingers/hairs, 8.386–387
 iron, 8.118*t*, 8.399
 plant/vegetation, 8.387, 8.399
 radioactive, 8.386
 removal of, 8.403
 evaluation of, 12.351
 imaging of, 12.352–353, 12.360, 12.361*f*
 of iris, 4.259
 iron, 12.362
 magnetic resonance imaging of, 12.353
 migration of, 12.362
 ocular reaction to, 12.362
 penetrating and perforating trauma and, 8.396, 8.397, 8.397*f*, 8.398*f*, 8.399–400, 8.400*f*, 8.401*f*, 8.403. *See also* Penetrating and perforating ocular trauma
 removal and, 8.408
 plain-film x-ray studies of, 12.352–353
 retained, 9.279–280, 12.362
 cataract surgery and, 11.191
 glaucoma and, 10.32, 10.103
 siderosis and, 4.120, 11.58*f*, 11.58–59
 siderosis bulbi secondary to, 12.362, 12.363*t*
 surgical removal of, 12.360–362
 zinc as, 12.362
 intraorbital, 7.112
 MRI and, 7.30–31, 7.112
 neuroimaging in evaluation of, 5.72*t*
- Foreign body giant cells, 4.7, 4.9*f*
- Foreign-body granuloma, 6.170
- Foreign-body sensation, in corneal abrasion, 8.398
- Forkhead genes/forkhead transcription factor
 Axenfeld-Rieger syndrome and, 8.97*t*, 8.102, 10.150
 glaucoma and, 10.150
 in Peters anomaly, 8.97*t*, 8.103
- Form-deprivation errors, 12.216
- Form-vision deprivation amblyopia, 6.55. *See also* Visual deprivation amblyopia
- Formalin, as tissue fixative, 4.26, 4.26*t*
- Forme fruste (subclinical keratoconus), 8.166, 13.124.
See also Keratoconus
 refractive surgery contraindicated in, 13.23, 13.25–26, 13.79, 13.124
 LASIK, 13.79, 13.124, 13.175*f*, 13.175–176, 13.177*f*
 topography in detection and, 8.31, 8.166, 13.23, 13.25–26, 13.79, 13.175*f*, 13.175–176, 13.177*f*
- Formed elements, 1.135. *See also* Blood cells
- Formed hallucinations, 5.158, 5.175, 5.176. *See also* Hallucinations

- Formoterol, 1.133
- Forniceal conjunctiva, 2.25, 2.26*f*, 2.30, 4.47, 4.48*f*, 8.6.
See also Conjunctiva; Fornices
 lymphoid lesions involving, 4.69, 4.70*f*
- Fornices, 2.25, 2.26*f*, 2.30, 4.47, 4.48*f*, 8.6, 8.7
 contracture of, anophthalmic socket and, 7.133
 socket contracture and, 7.135
 depth of, in “giant fornix syndrome,” 7.133
 lymphoid lesions involving, 4.69, 4.70*f*
 in mucous membrane pemphigoid, 8.285, 8.299–300, 8.300*f*, 8.302, 8.302*t*, 8.303
 reconstruction of, for mucous membrane pemphigoid, 8.303
 sterilization of, during cataract surgery, 11.94
- Fornix-based conjunctival flap, for trabeculectomy, 10.200, 10.201*f*
 closure of, 10.204, 10.206*f*
 in elderly patients, 10.221
- Fornix incision, 6.162–163
- Fortification spectrum, in migraine, 5.162
- Foscarnet, 1.281, 2.357*t*, 2.360
 for acute retinal necrosis, 9.196–197, 12.236
 for CMV retinitis, 1.239, 1.260, 1.268, 1.281, 2.357*t*, 2.360, 9.201, 12.235, 12.238*t*
 for progressive outer retinal necrosis, 9.296, 12.236
- Foscavir. *See* Foscarnet
- Fosinopril, 1.68*t*
- Fosphenytoin, 1.202*t*
- Fossae
 anterior cranial, 5.6*f*, 5.8, 5.10*f*, 7.7*f*
 lacrimal/lacrimal gland, 2.5–6, 2.6, 2.6*f*, 5.7*f*, 5.9*f*, 7.6, 7.6*f*, 7.254, 7.254*f*
 middle cranial, 5.6*f*, 5.10*f*, 5.11
 neuroimaging in evaluation of, 5.72*t*
 nasal, 7.18
 pituitary, 5.6*f*
 posterior cranial, 5.6*f*
 neuroimaging in evaluation of, 5.72*t*
 pterygopalatine, 5.12, 7.7*f*
 temporal, 5.8, 5.10*f*
 trochlear/for trochlea of superior oblique tendon, 2.6, 7.6
- Foster-Kennedy/pseudo-Foster-Kennedy syndrome, 5.122
- Foster modification, 6.167
- Foster staging system, for mucous membrane pemphigoid, 8.299–300, 8.300*f*, 8.302, 8.302*t*
- 4Δ base-out prism test, 6.78*f*, 6.78–79
- Four-E Model of Health Care Communication, 3.326*f*
- 454 next-generation sequencing method, 2.164*f*. *See also* Next-generation sequencing
- 4:2:1 rule, for diabetic retinopathy, 12.99
- Fourier analysis, 13.10
- Fourier-domain optical coherence tomography (FD-OCT), 3.304–305, 8.22, 10.54
- Fourth nerve (trochlear) palsy, 5.185, 5.186, 5.188–189, 5.198–200, 5.199*f*, 6.140
 diplopia and, 5.185, 5.186, 5.188–189, 5.198–200, 5.199*f*
 isolated, 5.199, 5.200
 in multiple sclerosis, 5.318
 skew deviation differentiated from, 5.198–199, 5.216
- Fourth-order aberrations, 13.12, 13.12*f*
- Fourth-order wavefront aberrations, 3.276*f*
- Fovea (fovea centralis), 2.67, 2.70*f*, 2.74*f*, 2.75, 2.77, 3.314*f*, 4.140, 5.24, 12.9, 12.9*f*
 anatomy of, 12.9, 12.9*f*
 characteristics of, 12.10*t*
 cone density in, 6.44
 cones in, 12.11
 development of, 2.116*t*, 6.44
 fluorescein angiography of, 12.34
 hypoplasia of, 6.154, 6.338, 6.406
 nystagmus associated with, 5.236
 inner cellular layers in, 12.12*f*
 in metabolic disorders. *See* Cherry-red spot
 photocoagulation-related burns of, 12.378
 retinoschisis, 6.344
- Fovea ethmoidalis, 2.10*f*, 2.11
- Fovea externa, 2.77
- Foveal avascular zone (FAZ), 2.74*f*, 2.77, 2.78*f*
 definition of, 12.9
 optical coherence tomography angiography of, 12.77*f*
- Foveal center, rods in, 12.11
- Foveal cones, 2.70, 2.77
- Foveal displacement syndrome, diplopia caused by, 5.209
- Foveal fibers, 2.86
- Foveal-sparing scotomas, 3.314, 3.315*f*
- Foveation periods, 5.234
- Foveola, 2.68, 2.75, 2.77, 4.140, 4.141*f*
 anatomy of, 12.9, 12.9*f*, 12.11
 characteristics of, 12.10*t*
- Foveomacular retinitis. *See* Solar retinopathy
- Foveomacular vitelliform dystrophy, adult-onset (AFMVD), 4.170, 4.171*f*
- Foville syndrome, 5.192
- FOXO1 (FKHL7) gene, 6.265
 in Axenfeld-Rieger syndrome, 8.97*t*, 8.102, 10.150
 in glaucoma, 10.11*t*
 in Peters anomaly, 8.97*t*, 8.103, 10.150, 11.32
- FOXO3 gene
 in congenital aphakia, 4.117
 in Peters anomaly, 8.97*t*, 8.103
- FOXO2 gene, 6.197
 in blepharophimosis-ptosis-epicanthus inversus syndrome, 7.155
- FOXO1 gene, in orbital rhabdomyosarcoma, 4.236
- FOXO1A gene, in Axenfeld-Rieger syndrome, 8.97*t*
- Foxp3⁺ T cells, regulatory, 9.37, 9.38
- FPG. *See* Fasting plasma glucose
- Fractures. *See also* specific type or structure affected
 blowout, 6.379
 orbital floor, 6.127–128, 6.128*f*, 6.379–380, 6.380*f*
 orbital roof, 6.380, 6.380*f*
 osteoporosis-related, 1.184
- Fragile sites, in chromatids, 2.135
- Fragile X syndrome, 2.135
- Frames (spectacle), anophthalmic socket camouflage and, 7.136
- Frameshift mutation (framing error/frameshift), 2.135, 2.155
- Framingham Global Risk and Pooled Cohort Equations, 1.83
- Francisella tularensis, 6.240
- François-Neetens speckled corneal dystrophy (Fleck corneal dystrophy/FCD), 8.135*t*, 8.136*t*, 8.153, 8.154*f*

- Fraser syndrome, 6.193
 eyelid manifestations of, 4.207*t*
- Freckle, 4.219
 of eyelid, 7.174
 Hutchinson melanotic (lentigo maligna/precancerous melanosis), 7.177
 iris, 4.259, 4.260*f*
 ocular surface, 8.338*t*
- Free, 1.51, *T*₄
- Free cap formation, in LASIK, 13.111, 13.111*f*
- Free radicals (oxygen radicals), 2.281–286, 9.20*f*, 9.22*t*, 9.29
 cellular sources of, 2.281–282, 2.282*f*
 detoxification of, 2.281–282, 2.282*f*
 lens damage and, 2.283–285, 2.284*f*, 11.19–20
 lipid peroxidation and, 2.281, 2.282–283
 retinal damage and, 2.285–286
- Freezing, anterior segment injuries caused by, 8.385
- Frenzel goggles, in nystagmus assessment, 5.234
- Frequency
 of light, 3.93
 in phacoemulsification, 11.99
- Frequency-domain optical coherence tomography (FD-OCT), 3.304, 8.22
- Frequency-doubling technology (FDT) perimetry, 10.75
 in glaucoma suspect screening, 10.89
- Fresnel prisms. *See also* Prisms
 advantages of, 3.197
 description of, 3.49, 3.49*f*
 induced anisophoria correction using, 3.188
 Press-On, 3.49
- Frisby Davis Distance Stereotest, 6.81
- FRMD7* gene, 6.149, 6.153
- Frontal artery, 5.14
- Frontal bone, 2.5, 2.6, 2.6*f*, 5.5, 5.7, 5.7*f*, 5.9*f*, 7.6, 7.6*f*, 7.7*f*
- Frontal branch of facial nerve. *See* Temporal nerve
- Frontal craniotomy, for orbital surgery, 7.124
- Frontal ethmoidal suture, 5.8
- Frontal eye fields (FEFs), 5.32*f*, 5.33, 5.34*f*, 5.37*f*
 saccadic control and, 5.219, 5.220
 seizures/tonic deviations and, 5.230
- Frontal gyri, 5.32*f*
- Frontal lobe, 5.24*f*
- Frontal nerve, 2.9*f*, 2.100, 2.101*f*, 2.104, 5.8*f*, 5.43*f*, 5.48, 5.48*f*, 7.10*f*, 7.13*f*, 7.14*f*, 7.15*f*, 7.16, 7.17*f*
 lacrimal functional unit innervated by, 8.5*f*
- Frontal pontine pathway, 5.34*f*
- Frontal sinuses, 2.10*f*, 2.10–11, 5.8, 5.10*f*, 7.7*f*, 7.18–19, 7.19*f*
- Frontalis muscle, 2.20*f*, 7.16, 7.141, 7.142*f*, 7.143*f*, 7.146*f*, 7.148*f*
- Frontalis suspension
 for eyelid ptosis, 6.197
 for ptosis correction/repair, 7.220–221, 7.221*f*
 anophthalmic socket and, 7.135
 in blepharophimosis-ptosis-epicanthus inversus syndrome, 7.155
- Frontoethmoidal (Lynch) incision, for orbitotomy, 7.116*f*, 7.119
- Frontoethmoidal suture, 2.6, 2.6*f*, 5.9*f*, 7.8, 7.9
- Frontosphenoid suture, 5.9*f*
- Frontotemporal-orbitozygomatic approach, for orbital surgery, 7.124
- Frontozygomatic suture, 5.7, 5.9*f*, 7.6*f*, 7.7
- Frost suture, 8.372, 8.372*f*
- Frozen section, for pathologic examination, 4.34*t*, 4.43–45, 4.44*f*
 in orbital tumor evaluation, 7.33
- FTA-ABS (fluorescent treponemal antibody absorption) test, 1.249, 9.241
- 5-FU. *See* Fluorouracil/5-fluorouracil
- FUCA1* gene, in fucosidosis, 8.179
- Fuchs adenoma (pseudoadenomatous hyperplasia), 4.179, 4.279
- Fuchs crypts, 2.54*f*, 2.54–55
- Fuchs endothelial corneal dystrophy (FECD), 2.43*f*, 4.92, 4.93*f*, 8.23*f*, 8.135*t*, 8.136*t*, 8.156–158, 8.157*f*
 descemetorhexis/DMET for, 8.157–158, 8.449
 IOL implantation and, 11.149, 13.155
 refractive surgery and, 13.43, 13.178
 multifocal IOL implantation, 13.155
- Fuchs heterochromic uveitis (FHU/Fuchs heterochromic iridocyclitis/Fuchs uveitis syndrome), 9.126*f*, 9.126–127
 cataracts/cataract surgery and, 9.127, 9.282, 11.64*f*, 11.64–65
 glaucoma and, 9.127, 10.101–102, 10.102*f*
 rubella reactivation and, 9.44, 9.127, 9.205
- Fuchs superficial marginal keratitis, 8.123
- α -L-Fucosidase, defective/deficiency of, in fucosidosis, 8.179
- Fucosidosis, 6.388*t*, 8.179
- Full-field (Ganzfeld) electroretinography, 5.96
 ABCA4 retinopathy findings, 12.48*f*
 in cone dystrophies, 5.102, 12.265
 cone-rod dystrophies, 12.265
 description of, 12.42–45, 12.43*f*
 in melanoma-associated retinopathy, 5.102–103
 mixed rod-cone, 12.43
 in multiple evanescent white dot syndrome, 5.101
 normal response in, 12.43*f*, 12.44
 photopic flicker, 12.44
 photopic single-flash, 12.44
 quinine toxicity on, 12.302*f*
 rod-specific, 12.42
- Full-thickness eyelid biopsy, 7.179*f*
- Full-thickness pentagonal resection, for trichiasis, 7.208
- Full-time occlusion
 amblyopia treated with, 6.58
 reverse amblyopia caused by, 6.60
- Fumagillin, for microsporidial keratoconjunctivitis, 8.280
- Functional disorders/vision loss, 1.190, 1.198.
See also Nonorganic (functional/nonphysiologic) ophthalmic disorders
- Functional imaging, 5.70
- Functional magnetic resonance imaging (fMRI), 5.70, 5.75
- Functional vision loss. *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
- Fundus
 in acute posterior multifocal placoid pigment epitheliopathy, 9.142*t*, 9.148, 9.148*f*

- in acute zonal occult outer retinopathy, 9.142*t*, 9.165, 9.165*f*
- albipunctatus, 11-*cis*-retinol dehydrogenase defects causing, 2.265
- arteriolar narrowing of, 12.261
- autofluorescence imaging of, 12.23*f*
- in Behçet disease, 9.186, 9.186*f*
- in birdshot uveitis, 9.142*t*, 9.144, 9.145*f*, 9.146*f*
- color photograph of, 12.23, 12.23*f*
- evaluation of, 8.19. *See also* Fundus autofluorescence; Fundus photography; Ophthalmoscopy/ophthalmoscopy; Slit-lamp biomicroscopy/examination
- before cataract surgery, 11.80–81
- in children, 6.12
- in choroidal melanoma/ciliary body melanoma, 4.263*f*, 4.265
- in conjunctival neoplasia, 8.328
- in glaucoma, 10.32
- in infants and children, 10.160
- in ischemic optic neuropathy, 5.120, 5.121*f*
- in low vision evaluation, 5.81–82, 5.82*f*, 5.83*f*
- in ocular ischemic syndrome, 5.170, 5.171*f*
- in optic neuropathy versus maculopathy, 5.100, 5.100*t*
- before refractive surgery, 13.44
- flavimaculatus (Stargardt disease/juvenile macular degeneration), 4.168–169*f*, 4.168–170
- ATP-binding cassette (ABC) transporter protein mutations causing, 2.263, 4.168–169
- retinal pigment epithelium in, 2.279, 4.168–169*f*, 4.169–170
- Leber congenital amaurosis findings, 6.336, 6.337*f*
- in Leber hereditary optic neuropathy, 5.133, 5.134*f*
- in multiple evanescent white dot syndrome, 9.142*t*, 9.162
- in multiple sclerosis, 5.318
- ocular, 3.296
- in ocular histoplasmosis syndrome, 9.215*f*, 9.215–216
- ocular torticollis findings, 6.84
- oculi, 2.67
- optic disc drusen evaluations, 6.374
- primary congenital glaucoma–related findings, 6.284
- relative depth of, 3.64
- retinitis pigmentosa findings, 12.261, 12.262*f*
- salt-and-pepper
 - in rubella, 9.203, 9.204*f*
 - in syphilis, 9.237
- in serpiginous choroiditis, 9.142*t*, 9.151, 9.152*f*
- sunset-glow, in Vogt-Koyanagi-Harada syndrome, 9.176, 9.177, 9.177*f*, 9.178, 9.178*f*, 12.232*f*, 12.232–233
- in sympathetic ophthalmia, 9.172, 9.173*f*
- tomato ketchup, 4.281, 4.283*f*
- Fundus albipunctatus, 12.252, 12.253*f*
- Fundus autofluorescence (FAF), 5.89–90, 5.90*f*
 - in acute posterior multifocal placoid pigment epitheliopathy, 9.142*t*
 - in acute zonal occult outer retinopathy, 5.90, 9.142*t*, 9.165, 9.165*f*
 - Best disease on, 6.343*f*
 - in birdshot uveitis, 9.142*t*, 9.145, 9.146*f*
 - in choroidal melanoma/ciliary body melanoma, 4.265, 4.266*f*
 - in cone dystrophies, 5.102
 - definition of, 12.29
 - drusen demonstrating, 5.89, 5.90*f*, 5.141*f*, 5.142
 - fluorophores, 12.29
 - Gardner syndrome on, 6.350*f*
 - hyperspectral, 12.33
 - in inflammatory chorioretinopathies, 9.142*t*
 - in low vision evaluation, 5.89–90, 5.90*f*
 - in multifocal choroiditis and panuveitis syndrome, 9.142*t*, 9.156, 9.157*f*
 - in multiple evanescent white dot syndrome, 9.142*t*, 9.162
 - near-infrared, 12.32–33
 - optic disc drusen on, 6.373*f*, 6.374
 - in punctate inner choroiditis, 9.142*t*
 - retinal disease evaluations, 12.29, 12.31–33
 - retinal pigment epithelium tears on, 12.31, 12.32*f*
 - in serpiginous choroiditis, 9.142*t*, 9.152–153, 9.153*f*
 - Stargardt disease on, 6.340, 12.270
 - in uveitis, 9.90
 - in Vogt-Koyanagi-Harada syndrome, 9.180
- Fundus biomicroscopy. *See* Slit-lamp biomicroscopy/examination
- Fundus camera, 3.301
 - disadvantages of, 12.23
 - flash illumination used by, 12.23
 - for fluorescein angiography, 12.23, 12.36
 - for indocyanine green angiography, 12.23
 - operating principles of, 12.22–23
 - retinal disease evaluations using, 12.22–23, 12.23*f*
- Fundus flavimaculatus, 6.339, 12.269
 - description of, 12.44
 - electroretinography findings in, 12.48*f*
- Fundus photograph
 - in choroidal melanoma/ciliary body melanoma, 4.263*f*, 4.265
 - exudative retinal detachment on, 12.325*f*
 - lattice degeneration on, 12.310–311*f*
 - retinopathy of prematurity screening uses of, 12.184
- Fundus pulverulentus, 12.276–277
- Fundus-related perimetry, 3.317
- Fungal cell wall, 8.249
- Fungal endophthalmitis, 12.239, 12.239*f*
- Fungal orbital cellulitis, 6.215
- Fungemia, 12.239
- Fungi, 1.255–256, 8.208*t*, 8.249*t*, 8.249–251. *See also specific organism or type of infection*
 - allergic sinusitis caused by, orbital involvement and, 4.228
 - chorioretinitis caused by, 4.147, 4.147*f*
 - disseminated infection and, 1.255–256, 1.270
 - drugs for infection caused by (antifungal agents), 1.280–281, 2.354–356, 2.355*t*
 - endophthalmitis caused by
 - endogenous, 9.265–272, 9.266*f*, 9.267*f*, 9.269*f*, 9.271*f*
 - postoperative, 9.262
 - eyelid infections caused by, 8.254–255, 8.255*f*
 - isolation techniques for identification of, 8.211
 - keratitis caused by, 4.78, 4.78*f*, 8.208*t*, 8.273–276, 8.274*f*
 - after photoablation, 13.106–107
 - plant/vegetable materials and, 4.78, 8.273, 8.387, 8.399

- as normal flora, 8.206*t*
- ocular infection caused by, 8.208*t*, 8.249–251, 8.254–255, 8.255*f*, 8.282–283
- corneal opacity and, 8.16*f*
- neuro-ophthalmic signs of, 5.353–356, 5.354*f*, 5.355*f*
- optic nerve infection caused by, 4.243*f*, 4.243–244
- orbital infection caused by, 4.226–228, 4.228*f*
- aspergillosis, 4.227–228, 4.228*f*, 7.50–51
- exenteration in management of, 7.50, 7.136
- mucormycosis/zygomycosis/phycomycosis, 4.226–227, 4.228*f*, 7.50
- exenteration in management of, 7.50, 7.136
- retinal infection caused by, 4.146–147, 4.147*f*
- scleritis caused by, 8.282–283
- stains and culture media for identification of, 8.209*t*, 8.275
- uveitis caused by, 9.214–219
- Fungizone. *See* Amphotericin B
- Fungus ball (aspergilloma), 5.353
- in endophthalmitis, 9.269*f*
- Furazolidone, 1.273*t*
- Furosemide
 - for heart failure, 1.109, 1.110
 - for hypertension, 1.68*t*
 - for idiopathic intracranial hypertension, 5.112
- Furrow degeneration, senile, 8.122
- Fusarium*, 8.207, 8.208*t*, 8.249*t*, 8.251
- endophthalmitis, 12.239
- keratitis caused by, 4.78, 4.78*f*, 8.208*t*, 8.251, 8.273–274, 8.274*f*, 8.275
- oxysporum*, 8.251
- solani*, 8.251, 8.274*f*, 8.275
- Fusiform dendritic cells, in choroidal/ciliary body nevus, 4.191
- Fusion
 - binocular, 6.60, 6.91
 - central, 6.42
 - in cyclic strabismus, 6.93
 - definition of, 6.42
 - motor, 6.43
 - peripheral, 6.51–52
 - sensory, 6.43
 - stereopsis, 6.43
- Fusion/fusional maldevelopment nystagmus syndrome (FMN/FMNS/latent/manifest latent nystagmus/LN/MLN), 5.237–238, 6.83, 6.88, 6.95, 6.148, 6.150–151, 6.151*f*, 6.154
- Fusional convergence, 5.226, 6.39, 6.43, 6.72
- Fusional cyclovergence, 6.40
- Fusional divergence, 6.40, 6.72
- Fusional vergence, 5.226, 6.72, 6.72*t*
- Fusional vertical divergence, 6.40
- FVC (forced vital capacity), 1.131

G

- G₀ phase, cell cycle, 2.148, 2.149*f*
- G₁ phase, cell cycle, 2.148, 2.149, 2.149*f*
- G₂ phase, cell cycle, 2.148, 2.149*f*
- G38D mutation, 2.263
- G6P. *See* Glucose-6-phosphate

- G6PD deficiency. *See* Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- G protein α -subunit (*GNAQ/GNA11*) genes
 - in nevus of Ota, 4.64
 - in uveal melanoma, 4.197
- G-protein-linked/coupled receptors
 - prostaglandin, 2.239–240, 2.316*t*
 - in tear secretion, 2.217–218, 2.218*f*, 2.219, 2.219*f*
- G proteins, in tear secretion, 2.217–218, 2.218*f*, 2.219, 2.219*f*
- GA. *See* Geographic atrophy
- GABA (gamma [γ]-aminobutyric acid), horizontal cell release/cone phototransduction and, 2.262, 2.266, 2.267
- GABA (gamma [γ]-aminobutyric acid) agonists, for nystagmus, 5.245, 5.246
- Gabapentin, 1.202*t*
 - for nystagmus, 5.236, 5.245, 5.246
 - for postherpetic neuralgia, 8.230
- GAD. *See* Generalized anxiety disorder; Glutamic acid decarboxylase
- Gadolinium, 5.60, 5.75, 7.29
 - in MR angiography, 5.68
 - in multiple sclerosis imaging, 5.316*f*, 5.319
- GAGs. *See* Glycosaminoglycans
- Gain/gain adjustment (eye movement), 5.39–40
 - pursuit system and, 5.224, 5.225
 - vestibular-ocular reflex (VOR), 5.215–216
 - in toxic vestibular dysfunction, 5.243
- Gain of function mutations, 2.156
- Gal-1-PO₄ uridyltransferase, defective/deficiency of, in galactosemia, 2.175*t*
- Gal-1-PUT (galactose-1-phosphate uridyltransferase), defective/deficiency of, in galactosemia, 2.175*t*, 11.61
- Galactitol (dulcitol)
 - in cataract formation, 11.61
 - in lens glucose/carbohydrate metabolism, 2.247*f*
- Galactokinase, defective/deficiency of, 2.175*t*
 - galactosemia/ataract formation and, 2.247, 11.61
- Galactose
 - in cataract formation, 2.247, 11.61
 - in lens glucose/carbohydrate metabolism, 2.247, 2.247*f*
- Galactose-6-sulfatase deficiency, in Morquio syndrome, 8.175*t*
- Galactose-free diet, 2.203
- Galactose-1-phosphate uridyltransferase (Gal-1-PUT), defective/deficiency of, in galactosemia, 2.175*t*, 11.61
- Galactosemia, 2.175*t*, 6.389*t*, 11.61
 - cataracts in, 2.246, 2.247, 11.61, 11.61*f*
 - dietary therapy for, 2.203, 11.61
- Galactosialidoses, 6.389*t*, 8.179
- α -Galactosidase, defective/deficiency of, 2.175*t*
- α -Galactosidase A, in Fabry disease, 2.175*t*, 8.176, 8.177, 8.178
- β -Galactosidase, defective/deficiency of, 2.175*t*
 - in gangliosidoses, 2.175*t*, 8.176
 - in lysosomal storage diseases, 8.179
 - in Morquio syndrome, 8.175*t*
 - in sphingolipidoses, 8.176
- Galanin, in aqueous humor, 2.231
- Galea aponeurotica, 7.141, 7.143*f*
- Galen, vein of, 5.22

- Galilean telescopes, 3.40, 3.83–84, 3.84*f*, 3.140, 3.166, 3.255, 3.292, 3.298, 3.322
- Galilei system, 3.248
- Gallamine, 2.315, 2.315*t*
- Gallium scanning, in sarcoidosis, 5.328
- Gametes, 2.186
- Gamma (γ)-aminobutyric acid (GABA), horizontal cell release/cone phototransduction and, 2.262, 2.266, 2.267
- Gamma (γ)-aminobutyric acid (GABA) agonists, for nystagmus, 5.245, 5.246
- Gamma (γ)-crystallins, 2.64, 2.244, 11.16
- Gamma (γ)-interferon, 9.28*t*
- blood test for tuberculosis and, 1.215, 1.254, 9.32, 9.253
- in delayed hypersensitivity, 9.38, 9.46
- in helper T-lymphocyte differentiation, 9.37
- Gamma knife technique, 5.357
- Gammopathy, benign monoclonal, crystalline corneal deposits in, 8.198
- Ganciclovir, 1.281, 2.300*t*, 2.302, 2.357*t*, 2.358, 2.358*t*, 2.359–360, 8.215*t*
- for acute retinal necrosis/herpetic retinitis, 9.196–197, 12.236
- for CMV infection
- anterior segment, 8.232
- retinitis, 1.239, 1.260, 1.268, 1.281, 2.357*t*, 2.358*t*, 2.359–360, 9.201, 12.235, 12.238*t*
- for herpes simplex virus infections, 8.215*t*, 8.219, 9.196–197
- for progressive outer retinal necrosis, 9.296, 12.236
- Ganciclovir intraocular device/implant, 2.300*t*, 2.302, 2.357*t*, 2.360
- Ganfort. *See* Bimatoprost, in combination preparations
- Ganglion-blocking drugs, 2.315
- Ganglion cell complex (GCC), OCT in evaluation of, 5.92, 10.54
- Ganglion cell layer with the inner plexiform layer (GCPL), spectral domain-OCT in evaluation of, 10.54
- Ganglion cells/ganglion cell layer (GCL)
- anatomy of, 12.15
- bipolar cells and, 12.13
- drug toxicity affecting, 12.301
- histology of, 12.11, 12.12*f*
- quinine effects on, 12.301
- retinal, 2.70, 2.70*f*, 2.71*f*, 2.74, 2.74*f*, 2.76*f*, 2.88*f*, 2.257, 2.258*f*, 2.267, 2.267*f*, 2.268*f*, 4.140*f*, 4.141*f*, 5.24, 5.25*f*, 5.26
- development/differentiation of, 2.116*t*, 2.119*f*, 2.122
- in optic nerve, 5.103, 5.104*f*, 10.41–42
- in optic neuropathy, glaucomatous, 10.46–47
- in optic nerve head pallor, 5.81
- ratio of, to photoreceptors, 5.24
- spectral domain-OCT in evaluation of, 10.54–56, 10.55*f*, 10.56*f*
- superficial vascular plexus in, 12.16
- Ganglioneuromas, in multiple endocrine neoplasia, 1.59
- Ganglionic neurons, dilator muscle innervation and, 2.56
- Gangliosidosis, 6.388–389*t*, 8.176–178. *See also specific type under GM*
- Ganzfeld bowl, 12.42
- Ganzfeld (full-field) electroretinogram, 5.96. *See also*
- Full-field (Ganzfeld) electroretinography
- in cone dystrophies, 5.102
- in melanoma-associated retinopathy, 5.102–103
- in multiple evanescent white dot syndrome, 5.101
- Gap junctions, in lens, 2.246, 11.20
- Garamycin. *See* Gentamicin
- Gardasil, 1.224
- Gardner syndrome (familial adenomatous polyposis/FAP)
- in children, 6.349, 6.350*f*
- retinal manifestations of, 4.144–145, 4.269
- Gas-permeable contact lenses. *See* Rigid gas-permeable (RGP) contact lenses; Scleral contact lenses; Soft (flexible) contact lenses
- Gas-permeable scleral contact lenses, 3.226–227
- Gases, intraocular, 2.300*t*
- Gasserian ganglion (semilunar/trigeminal ganglion), 2.9*f*, 2.98*f*, 2.99, 2.99*f*, 2.101*f*, 5.42*f*, 5.48, 5.48*f*, 7.14*f*, 7.15*f*, 7.16, 7.17*f*
- herpes simplex/varicella zoster virus latency and, 8.205, 8.207, 8.212, 8.213, 8.226
- Gastric bypass surgery
- in diabetes mellitus, 1.40–41
- for weight loss, in idiopathic intracranial hypertension, 5.112
- Gastric cancer, 1.213
- Gastrinomas, in multiple endocrine neoplasia, 1.58
- Gastroesophageal reflux disease (GERD)
- aspiration during surgery and, 1.288
- cancer and, 1.213
- systemic sclerosis and, 1.162
- Gastrointestinal carcinoma, metastatic eye disease and, 4.304*t*
- Gastrointestinal disease
- in Behçet disease, 9.185
- cancer screening and, 1.213
- in HIV infection/AIDS, 1.268–269
- NSAID use and, 1.172
- in polyarteritis nodosa, 9.136
- retinal degeneration associated with, 12.285–286
- in SLE, 1.157
- in systemic sclerosis, 1.162
- in Whipple disease, 9.258
- Gastrulation, 2.111, 2.112*f*, 2.113*f*
- GAT. *See* Goldmann applanation tonometry
- Gatifloxacin, 2.346, 2.347*t*, 2.347–349
- for bacterial keratitis, 8.269, 8.270*t*
- Gaucher disease, 6.388*t*, 12.291
- racial and ethnic concentration of, 2.197
- Gaussian optics, 3.40, 3.60, 3.66
- Gaussian reduction formulas, 3.243
- Gaze. *See also* Ocular motility
- cardinal positions of, 6.31, 6.32*f*, 6.35, 6.64
- direction of, 6.147
- downgaze, 6.38
- horizontal, 5.37*f*, 5.37–38
- left, 6.37
- positions of, 6.31
- cardinal, 6.31, 6.32*f*, 6.35, 6.64
- definition of, 6.64
- diagnostic, 6.64
- extraocular muscle action and, 5.46, 5.46*f*, 6.34–37

- field of action, 6.33
- nystagmus affected by, 5.240–241
- ocular alignment assessment using, 6.64
- primary, 6.31, 6.64
- secondary diagnostic, 6.31
- for strabismus, 6.64
- tertiary diagnostic, 6.31
- for vertical strabismus, 6.64
- right, 6.37
- upgaze, 6.37
- vertical, 5.36, 5.36f, 5.36–37
- Gaze deviation, seizure activity and, 1.203, 5.230
- Gaze-evoked nystagmus, 5.38, 5.222, 5.234f, 5.240–241.
 - See also* Nystagmus
 - in internuclear ophthalmoplegia, 5.189, 5.190f
 - rebound, 5.240–241
 - substance use/abuse and, 1.192
- Gaze-evoked transient visual loss, 5.164
- Gaze palsy, 5.228–230, 5.229f, 5.230f
 - in ataxia-telangiectasia, 5.334f
 - horizontal, 5.228
 - in one-and-a-half syndrome, 5.191
 - in sixth nerve palsy, 5.189, 5.200, 5.200f
 - ipsilateral, 5.41, 5.200, 5.200f
 - in multiple sclerosis, 5.318
 - nonorganic, 5.309
 - in sarcoidosis, 5.327
 - vertical, 5.228
- Gaze preference, 5.228
- GB virus C, 1.261
- GCA. *See* Giant cell arteritis
- GCAPs. *See* Guanylate cyclase–assisting proteins
- GCC. *See* Ganglion cell complex
- GCD1. *See* Granular corneal dystrophy, type 1
- GCD2. *See* Granular corneal dystrophy, type 2
- GCPL. *See* Ganglion cell layer with the inner plexiform layer
- GCL. *See* Ganglion cells/ganglion cell layer
- GDLD. *See* Gelatinous droplike corneal dystrophy
- GDx. *See* Scanning laser polarimetry/polarimeter
- Gel electrophoresis, denaturing gradient (DGGE), 2.162
- Gelatinase (MMP-2/MMP-9), in vitreous, 2.249
- Gelatinous droplike corneal dystrophy (GDLD/primary familial amyloidosis), 8.135t, 8.136t, 8.140–141, 8.141f, 8.185–187, 8.186t
- Gelsolin gene mutation
 - amyloidosis/amyloid deposits (Meretoja syndrome) and, 4.206, 8.186t, 8.187, 8.188f
 - lattice corneal dystrophy and, 4.206
- Gelsolin (Finnish) type familial amyloidosis (Meretoja syndrome), 4.206, 8.186t, 8.187, 8.188f
- Gemfibrozil, for hypercholesterolemia/heart disease prevention, 1.85t
- Gemifloxacin, 1.277
- Gender, in glaucoma, 10.9, 10.121
- Gene, 2.136, 2.184–187
 - cancer, 2.156–157
 - candidate, 2.161
 - defective copy of (pseudogene), 2.142
 - expression of. *See* Gene transcription; Genetic/hereditary factors; Genetics
 - structure of, 2.147–148, 2.148f
- Gene assignments, 2.160
- Gene dosage, 2.159
- Gene duplication. *See* DNA, replication of
- Gene expression profile, 4.40
 - in choroidal/ciliary body melanoma, 4.197
- Gene linkage, 2.138, 2.150, 2.160, 2.184, 2.187
- Gene mapping, 2.160, 2.184
- Gene replacement therapy, 2.169
- Gene therapy, 2.169–170, 2.170f, 2.204
 - for choroidemia, 12.268
 - for hemophilia, 1.145
 - for HIV infection/AIDS, 1.267
 - for Leber congenital amaurosis, 6.337, 9.62, 12.266
 - retinal, 9.62
 - for retinal dystrophies, 12.260, 12.266
 - Stargardt disease treated with, 6.340
- Gene transcription, 2.144, 2.147, 2.151, 2.151f, 2.152
 - embryogenesis and, 2.111
 - reverse, 2.143
- Gene translation, 2.144, 2.147, 2.151, 2.151f, 2.152
 - gene product changes/modification after (posttranslational modification), 2.142
 - of lens proteins, 2.245
- General anesthesia, 6.174, 12.50. *See also* Anesthesia
 - balanced, 1.290–291
 - for cataract surgery, 11.92
 - in arthritis, 11.171
 - in claustrophobia, 11.169
 - in patient unable to communicate, 11.170
 - for penetrating and perforating trauma repair, 8.403
- Generalizability
 - of clinical research study, 1.4–5, 1.20, 1.22
 - of screening/diagnostic test, 1.20
- Generalized anxiety disorder (GAD), 1.191. *See also* Anxiety
 - benzodiazepines for, 1.194
- Generalized gangliosidosis (GM₁ gangliosidosis type I), 2.175t, 8.176
- Generalized seizures, 1.201
- Generic drugs, antiglaucoma, 10.186
- Genetic, definition of, 2.181
- Genetic cascades, 2.111, 2.126
 - in neural retinal development, 2.122
- Genetic code, degeneracy of, 2.134
- Genetic counseling. *See* Genetic testing/counseling
- Genetic/hereditary factors. *See also* Family history/familial factors; Genetics, clinical; Inborn errors of metabolism
 - in age-related cataracts, 11.41–42
 - in Alzheimer disease, 1.205
 - in cancer, 1.229
 - in choroidal melanoma, 4.253
 - in corneal dystrophies, 8.133, 8.134, 8.136t
 - in diabetes mellitus, 1.36
 - in glaucoma, 10.10, 10.11, 10.11t
 - in children and adolescents, 10.150
 - in multiple sclerosis, 5.315
 - in Parkinson disease, 1.199
 - in retinoblastoma, 2.192, 4.172–173, 4.253, 4.289–291, 4.290f
- Genetic heterogeneity, 2.137, 2.183, 2.183f, 2.185, 12.255
- Genetic imprinting, 2.138, 2.153–154

- Genetic Information Nondiscrimination Act (GINA), 2.136
- Genetic map, 2.160, 2.184
- Genetic markers, 2.159. *See also specific type*
- Genetic profiling, of tumors, 1.227, 1.236–237
- Genetic testing/counseling, 2.171, 2.204–208
- accurate diagnosis and, 2.202, 2.204
 - for age-related macular degeneration, 12.63
 - autosomal dominant disorders and, 2.178
 - direct-to-consumer, 2.134
 - disease process explanation and, 2.202
 - family history/pedigree analysis and, 2.171, 2.204
 - in glaucoma, 10.11
 - issues in, 2.205
 - in multiple endocrine neoplasia, 1.59
 - polygenic and multifactorial inheritance and, 2.140, 2.141, 2.200
 - prenatal diagnosis and, 2.188, 2.206–207
 - recommendations for, 2.207–208
 - reproductive issues and, 2.206–207
 - in retinoblastoma, 4.289–291, 4.290f
 - in sickle cell disease, 1.135, 1.139
 - support group referral and, 2.207
 - in von Hippel–Lindau syndrome, 4.285
 - warfarin dosage determination and, 1.142
- Genetic therapy. *See* Gene therapy
- Genetics
- clinical, 2.171–208. *See also* Family history/familial factors; Genetic/hereditary factors; *specific disorder*
 - chromosomal analysis and, 2.187–193, 2.189f, 2.191t
 - disease management and, 2.202–204
 - genes and chromosomes and, 2.184–187, 2.186f
 - genetic counseling and, 2.202, 2.204–208. *See also* Genetic testing/counseling
 - importance of accurate diagnosis and, 2.202, 2.204
 - inheritance patterns and, 2.173–181. *See also specific type*
 - lyonization (X-chromosome inactivation) and, 2.132, 2.139, 2.197–200, 2.198–199f, 2.199t
 - mutations and, 2.193–196
 - pedigree analysis and, 2.172f, 2.172–173
 - pharmacogenetics and, 2.141, 2.201–202
 - polygenic and multifactorial inheritance and, 2.140, 2.141, 2.200–201
 - racial and ethnic concentration of disorders and, 2.196–197
 - terminology used in, 2.181–183, 2.182f, 2.183f
 - introduction to, 2.131–145
 - molecular, 2.147–170
 - cell cycle and, 2.148–150, 2.149f
 - correlation of genes with specific diseases and, 2.159–161
 - DNA damage/repair and, 2.154–155
 - gene structure and, 2.147–148, 2.148f
 - gene therapy and, 2.169–170, 2.170f
 - independent assortment and, 2.150
 - linkage and, 2.138, 2.150, 2.160
 - lyonization (X-chromosome inactivation) and, 2.132, 2.139, 2.153
 - mitochondrial disease and, 2.157–159
 - mutations/disease and, 2.140, 2.155–157
 - screening and, 2.161–167, 2.162f, 2.163f, 2.164f, 2.165f, 2.166f, 2.167f, 2.168f
 - noncoding (junk) DNA and, 2.150, 2.151
 - transcription and translation (central dogma) and, 2.151f, 2.151–154
 - myopia and, 3.143
 - personalized, 2.141
 - terms used in, 2.131–145
- Geniculate body/nucleus/ganglion, 2.101f, 2.103, 5.51f, 5.56, 5.276–277f
- lateral (LGB/LGN), 2.90, 2.90f, 2.93, 2.267, 5.18, 5.18f, 5.24f, 5.28–29, 5.55f, 5.154
- lesions of, 5.154, 5.154f
- medial, 5.18f
- Geniculate ganglion, 8.5f
- Geniculate ganglionitis, facial paralysis/weakness caused by, 5.276–277f
- Geniculocalcarine pathways (optic radiations), 2.90, 2.90f, 2.93, 5.18f, 5.19, 5.24f, 5.29, 5.30
- lesions of, 5.153, 5.155
- in multiple sclerosis, 5.318
- Genital ulcers, in Behçet disease, 1.169, 9.184
- Genome, 2.136, 2.181, 2.194
- reference, 2.143
- Genome-wide association studies (GWAS), 2.136, 2.163–167, 2.166f, 2.167f, 2.168f
- in age-related macular degeneration, 2.165, 2.167f
- Genomic DNA library, 2.138
- Genomics, 2.136
- Genoptic. *See* Gentamicin
- Genotype, 2.136, 2.194
- database of, 2.134
- Gentak. *See* Gentamicin
- Gentamicin, 1.278, 2.344t, 2.347t, 2.351, 12.300
- in combination preparations, 2.348t
- Gentasol. *See* Gentamicin
- Geographic atrophy (GA), of retinal pigment epithelium, 4.164, 4.164f
- in Best vitelliform dystrophy, 12.271
- description of, 12.64, 12.66, 12.67f, 12.68
- in drusenoid retinal pigment epithelium detachment, 12.272
- Geographic choroiditis/choroidopathy (serpiginous/helicoid peripapillary), 9.141–143t, 9.151–154, 9.152f, 9.153f
- tuberculosis and (serpiginoid/serpiginous-like), 9.154, 9.252, 9.252f
- Geographic epithelial ulcer, in herpes simplex keratitis, 8.217, 8.217f, 8.218f
- Geographic map lines, in epithelial basement membrane dystrophy, 8.137, 8.137f
- Geometric optics, 3.43–89. *See also specific aspect*
- aberrations. *See* Aberrations
 - axial (longitudinal) magnification, 3.63–64
 - basic rules of, 3.86
 - conjugate points, 3.64
 - conoid of Sturm, 3.76, 3.76f
 - critical angle, 3.50–51
 - definition of, 3.43
 - depth of field, 3.57, 3.58f
 - depth of focus, 3.57, 3.58f

- description of, 3.54–57
- general refracting system, 3.58–67
- IOLs and, 11.120, 11.121f
- Jackson cross cylinder. *See* Jackson cross cylinder mirrors. *See* Mirrors
- nodal points, 3.66–67, 3.67f
- physical optics and, 3.119
- power cross, 3.16, 3.17f, 3.77, 3.77–78f
- power-versus-meridian graph, 3.79f, 3.79–80
- principal planes, 3.56–57, 3.57f
- principles of, 3.43
- prisms. *See* Prisms
- ray tracing. *See* Ray tracing
- real objects, 3.61
- reduced optical system, 3.67–68, 3.68–69f
- refraction by single curved surface, 3.51–54
- refractive index, 3.43–44
- spherical equivalent, 3.76
- telescopes. *See* Telescopes
- “thick-lens formula,” 3.54–55
- total internal reflection, 3.50, 3.50f
- transverse magnification, 3.62
- two-sided lenses. *See* Two-sided lenses
- virtual objects, 3.61
- Geometric scattering, 3.91, 3.97–98
- Geometric wavefront, 3.70–71, 3.274
- Geranylgeranyl transferase Rab escort protein (*CHM*)
 - gene mutation, 2.265
 - in choroideremia, 2.265
- GERD. *See* Gastroesophageal reflux disease
- Geriatrics, 1.177–185. *See also* Age/aging
 - elder abuse and, 1.179–180
 - falls and, 1.184–185
 - medication use and, 2.295
 - carbonic anhydrase inhibitor use and, 2.326
 - corticosteroid use and, 2.332
 - pharmacologic principles and, 2.295
 - osteoporosis and, 1.184
 - outpatient visits and, 1.179
 - physiologic/pathologic eye changes and, 1.178
 - psychology/psychopathology of aging and, 1.181–183
 - surgical considerations and, 1.180–181
- Germ layers, formation of, 2.111
- German measles. *See* Rubella
- Germinal center, lymphoid follicle, 4.50f, 4.51, 4.51f, 4.69, 4.70, 4.70f, 4.71f
- Germinal mosaicism, 2.136
- Germinative zone, 11.12, 11.12f
 - of lens epithelium, 2.64, 2.242, 2.242f
- Germline mutations, 6.358
- Gerstmann syndrome, 5.156, 5.179
- Gerstmann-Sträussler-Scheinker syndrome, 5.357
- Gestational age, retinopathy and. *See* Retinopathy, of prematurity
- Gestational diabetes mellitus, 1.36–37
- GH. *See* Growth hormone
- Ghost cells/ghost cell glaucoma, 4.103, 4.104f, 10.105–106, 10.106f, 12.347
 - vitreous hemorrhage and, 4.133, 10.105, 10.106
- Ghost dendrites, in herpes simplex keratitis, 8.217, 8.218f
- Ghost images
 - with multifocal IOLs, 13.156
 - after photoablation, 13.102
 - after small-incision lenticule extraction, 13.205
- GHRH. *See* Growth hormone–releasing hormone
- GHT. *See* Glaucoma Hemifield Test
- Giant aneurysm, 5.338, 5.339
- Giant cell arteritis (GCA/temporal arteritis), 1.165t, 1.166, 5.89, 5.89f, 5.313–315, 7.61
 - AAION and, 5.120, 5.313
 - central retinal artery occlusion caused by, 12.145
 - corticosteroid route of administration in, 2.333t
 - description of, 12.195
 - diplopia in, 5.192, 5.313
 - facial pain associated with, 5.288, 5.297
 - headache in, 5.288, 5.313
 - indocyanine green angiography of, 12.196f
 - neuro-ophthalmic signs of, 5.313–315
 - occult, 5.120, 5.170
 - optic nerve affected in, 4.244f, 4.244–245, 5.120
 - transient visual loss and, 5.120, 5.161, 5.162, 5.169–170, 5.313–314
- Giant cells, 9.11, 9.21
 - foreign body, 4.7, 4.9f
 - Langhans, 4.7, 4.9f
 - multinucleated, 4.7, 4.9f
 - in focal posttraumatic choroidal granulomatous inflammation, 4.22f
 - in granulomatous conjunctivitis, 4.52, 4.52f
 - in sarcoidosis, 4.187, 4.187f
 - Touton, 4.7, 4.9f
 - in juvenile xanthogranuloma, 4.187, 4.188f, 9.277
- Giant congenital melanocytic nevi, 4.218
- Giant drusen, 4.295, 5.108f, 5.143
 - retinoblastoma differentiated from, 4.295
 - in tuberous sclerosis, 4.295
- “Giant fornix syndrome,” 7.133
- Giant papillae, conjunctival, 8.48, 8.48f
- Giant papillary conjunctivitis (GPC), 3.231f, 3.234
 - after penetrating keratoplasty, 8.426
- Giant tears, of retina, 12.315
- Giant vacuoles, in Schlemm canal, 2.50f, 2.50–51, 2.51f
- Giemsa stain, 4.31t
- Gigantism, 1.57
- Gilenya. *See* Fingolimod
- Gillespie syndrome (OMIM 206700), aniridia in, 2.193, 10.155
- GINA (Genetic Information Nondiscrimination Act), 2.136
- Glabellar flap, for canthal repair, 7.196
- Glands of Krause, 2.20f, 2.22f, 2.23t, 2.29, 2.216, 4.202, 7.146f, 7.152, 7.252
- Glands of Moll, 2.19, 2.22f, 2.23t, 4.201, 7.154f, 7.170, 8.4, 8.4f
 - hidrocystoma arising in, 7.171, 7.171f
- Glands of Wolfring, 2.20f, 2.22f, 2.23t, 2.29, 2.216, 4.202, 7.146f, 7.152, 7.252, 8.4f
- Glands of Zeis, 2.19, 2.22f, 2.23t, 2.215, 4.201, 7.170, 8.4, 8.4f
 - chalazion and, 4.204, 4.206f, 8.76, 8.77
 - hordeolum caused by infection of, 4.203–204, 7.163, 8.76, 8.77

- sebaceous adenocarcinoma arising in, 4.215, 7.183
in tear film lipids/tear production, 2.215
- Glare
assessment of, 3.318
cataracts and, 11.45, 11.47, 11.70, 11.70*t*, 11.77
definition of, 3.318
with IOLs, 11.144, 11.150–152
angle-supported lenses, 13.146
iris-fixed lenses, 13.145
multifocal lenses, 13.156
in optic neuropathy versus maculopathy, 5.100*t*
after photoablation, 13.102
polarized sunglasses for reduction of, 3.99, 3.192–193
as positive dysphotopsia, 11.150
pupil size and, 13.40
after radial keratotomy, 13.51
rainbow, after LASIK with femtosecond laser flap
creation, 13.123–124
before refractive surgery, 13.41
- Glare testing, in cataract evaluation, 11.77
- Glass foreign body, 8.399, 8.400*f*
- Glass lenses
high-index, 3.195
standard, 3.195
tempering of, 3.195
- Glass prisms in Prentice position, 3.45, 3.46*f*
- Glassblower's cataract, 11.57
- Glasses. *See also* Spectacle lenses
anisometropia correction with, 3.139
in bright light, 3.130
existing initial estimate of refractive error from, 3.27
- Glatiramer, for multiple sclerosis, 5.321*t*
- Glaucoma, 10.3–11, 10.10. *See also* Angle-closure glaucoma;
Elevated intraocular pressure; Open-angle glaucoma;
Uveitis-glaucoma-hyphema (UGH) syndrome
age affecting development of
angle-closure glaucoma and, 10.9
open-angle glaucoma and, 10.7, 10.81–82
angle-closure. *See* Angle-closure glaucoma
angle-recession, 4.18, 4.103–104
posttraumatic, 10.39–40, 10.40*f*, 10.41*f*, 10.106–
108, 10.107*f*
aniridia and, 10.120, 10.150, 10.154–155
anterior chamber evaluation in, 10.32–40, 10.33*t*,
10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*.
See also Gonioscopy
aphakic, 10.130–132, 10.156–157
tube shunt implantation for, 10.215
aqueous misdirection and. *See* Glaucoma, malignant
Axenfeld-Rieger syndrome and, 4.99, 8.97*t*, 8.102,
10.31, 10.150, 10.153–154
biomicroscopy in evaluation of
slit-lamp, 10.30–32
ultrasound, 10.77, 10.124*f*
pediatric glaucoma and, 10.160
after cataract surgery, 6.304
cataracts and, 4.103, 9.21, 9.118, 9.118*f*, 9.119, 10.97*f*,
10.97–98, 10.128, 10.211, 10.212, 11.52, 11.56,
11.186*f*, 11.186–187
management of, 10.211–213, 10.213, 11.186*f*, 11.186–
187. *See also* Cataract surgery, glaucoma and
preoperative evaluation/care and, 11.75
childhood. *See* Childhood glaucoma; Glaucoma,
pediatric
ciliary block. *See* Glaucoma, malignant
classification of, 10.3–5, 10.4*t*, 10.6*t*
in children, 10.4*t*, 10.6*t*, 10.147–150, 10.148*t*,
10.149–150*t*
clinical evaluation of, 1.16*f*, 1.16–18, 1.17*f*, 1.18*f*,
10.29–77. *See also specific type*
gonioscopy in, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*,
10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
history and general examination in, 10.29–32
in infants and children, 10.157
in infants and children, 10.151–152, 10.152*t*,
10.157*t*, 10.157–160
optic nerve and, 10.41–46, 10.43*f*, 10.44*f*, 10.45*f*
in infants and children, 10.160
optic neuropathy and, 10.46–59, 10.47*f*,
10.49*f*, 10.50*f*, 10.51*f*, 10.55*f*, 10.56*f*,
10.57*f*, 10.58*f*
visual field examination in, 10.59–77. *See also*
Perimetry; Visual field testing, in glaucoma
combined-mechanism, 10.7
uveitic, 9.286
congenital, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147,
10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*.
See also Glaucoma, pediatric; Primary congenital
glaucoma
conjunctiva affected in, 10.31
cornea affected in, 10.31
cornea plana and, 8.96*t*, 8.100–101
enlargement/megalocornea and, 8.95, 8.96*t*,
8.99–100, 8.108, 10.31, 10.147, 10.158
opacities and, 8.108–109
corneal thickness and, 10.25, 10.31, 10.81, 10.82,
10.86–87, 10.90, 10.159
corticosteroid-induced, 2.334, 9.124, 9.286–288,
10.109–110
refractive surgery and, 13.41, 13.182, 13.201
corticosteroids as cause of, 6.321
definitions and, 10.3
developmental, 10.153–156. *See also* Glaucoma,
pediatric
diabetes mellitus and, 10.83
drug-induced
angle-closure glaucoma and, 10.122–123, 10.145*f*,
10.145–146
open-angle glaucoma and, 10.109–111
drugs for, 10.170–186, 10.171–174*t*. *See also*
Antiglaucoma agents
environmental factors in, 10.10
epidemiology of, 10.7–10, 10.9*t*
episclera affected in, 10.31, 10.102*t*, 10.102–103,
10.103*f*
external adnexae affected in, 10.29–30
Fuchs heterochromic uveitis/iridocyclitis and, 9.127,
10.101–102, 10.102*f*
fundus examination in, 10.32
gender affecting risk of, 10.9, 10.121
genetic/hereditary factors in, 2.200, 8.108, 10.10,
10.11, 10.11*t*
genome-wide association studies (GWAS) and,
2.164, 2.166*f*, 2.168*f*

- ghost cell, 4.103, 4.104f, 10.105–106, 10.106f, 12.347
- hemolytic, 4.103, 4.104f, 10.105, 10.106
- hemorrhage/hyphema and, 4.103, 4.104f, 8.394, 10.50, 10.51f, 10.85f, 10.85–86. *See also* Uveitis-glaucoma-hyphema (UGH) syndrome
- hemosiderin in, 4.103, 4.104f
- incidence of, 10.7, 10.8
- infantile, 6.230, 10.4t, 10.147, 10.148t. *See also* Glaucoma, pediatric
- inflammatory
- angle-closure glaucoma and, 10.138f, 10.138–139, 10.139f
 - open-angle glaucoma and, 10.100–102, 10.102f
- intraocular pressure in, 10.3, 10.20–21, 10.46–47, 10.79, 10.80–81, 10.81t. *See also* Elevated intraocular pressure
- uveitis and, 9.284–285, 9.285
- IOL implantation and, 11.149
- iridocorneal endothelial syndrome and, 4.101, 8.127, 10.136f, 10.136–138, 10.137f
- iris bombé and, 9.285–286, 10.32, 10.129, 10.131f, 10.138, 10.139f
- juvenile idiopathic (chronic/rheumatoid) arthritis and, 9.125
- juvenile open-angle, 10.4t, 10.147, 10.148t, 10.153. *See also* Glaucoma, pediatric
- lens evaluation in, 10.32
- lens-induced, 4.103, 4.103f, 4.122, 9.21, 9.118, 9.118f, 9.119, 10.96–98, 10.97f, 10.119, 11.67–68, 11.68f
- angle-closure glaucoma and, 10.96, 10.119, 10.128–132
 - in children and adolescents, 10.149t
 - open-angle glaucoma and, 10.96–98, 10.97f
- lens particle, 10.98, 11.67
- leukemia and, 4.315
- low-tension, 10.3, 10.4t, 10.85f, 10.85–88, 10.86t. *See also* Glaucoma, normal-tension
- malignant (aqueous misdirection/ciliary block glaucoma), 10.32, 10.139–141, 10.140f
- cataract surgery and, 10.139, 11.139
 - in children and adolescents, 10.149t
 - after penetrating keratoplasty, 8.424
- management of
- in children, 10.160–166
 - clinical trials in evaluation of, 10.111–115
 - interrelationship between medical and surgical treatment and, 10.111
- medical, 10.169–186. *See also* Antiglaucoma agents
- adherence and, 10.186
 - agents used in, 10.170–186, 10.171–174t. *See also* Antiglaucoma agents; *specific drug*
 - in children, 10.153
 - combined medications in, 10.182
 - in elderly patients, 10.186
 - general approach to, 10.183–186
 - long-term therapy and, 10.183–184
 - during pregnancy/lactation, 10.185–186
- prognosis and, 10.84
- after refractive surgery, 13.201
- surgical, 10.187–212. *See also* Glaucoma surgery; *specific procedure*
- cataract surgery and, 10.211–213, 10.213, 11.186f, 11.186–187
 - in children, 10.160–164, 10.161f, 10.162f
 - in elderly patients, 10.221
- in Marfan syndrome, 8.194
- megalocornea and, 8.95, 8.96t, 8.99–100, 8.108
- melanocytoma and, 4.106, 4.258
- melanomalytic, 4.105f, 4.106, 4.194
- microcornea and, 8.95–99
- microspherophakia and, 10.130, 10.131f, 11.33
- nanophthalmos and, 4.108, 4.109, 10.144
- neovascular, 4.188, 10.38f, 10.38–39, 10.132t, 10.132–135, 10.133f, 10.134f, 10.135f
- iris examination in, 10.32, 10.39, 10.135f
 - rubeosis iridis and, 4.188
 - tube shunt implantation for, 10.215
- nerve damage caused by, 12.328
- nerve fibers/nerve fiber layer in, 10.48, 10.49t
- diffuse/focal loss and, 10.50–52, 10.51f
 - patterns of loss and, 10.67–69, 10.68f, 10.69f, 10.70f
- neurofibromatosis and, 10.156
- in children, 10.156
- neuroretinal rim changes in, 10.48–50, 10.49t, 10.50f
- normal-tension (NTG), 10.3, 10.4t, 10.85f, 10.85–88, 10.86t
- diagnostic evaluation of, 10.87
 - differential diagnosis of, 10.86t, 10.86–87
 - disc hemorrhages in, 10.85f, 10.85–86
 - genetic/hereditary factors in, 10.11t
 - prognosis/therapy of, 10.87–88
 - risk factors/clinical features of, 10.85f, 10.85–86
- ocular receptors and, 2.318t
- open-angle. *See* Open-angle glaucoma
- ophthalmoscopic signs of, 10.48, 10.49t
- optic neuropathy/optic nerve changes in, 5.107t, 5.136, 5.137f, 10.3, 10.46–59, 10.47f, 10.49f, 10.50f, 10.51f, 10.55f, 10.56f, 10.57f, 10.58f
- imaging in evaluation of, 10.53–59, 10.55f, 10.56f, 10.57f, 10.58f
 - optic nerve/nerve head/disc evaluation and, 10.32, 10.41–46, 10.43f, 10.44f, 10.45f, 10.48–59, 10.49t, 10.49f, 10.50f, 10.51f, 10.55f, 10.56f, 10.57f, 10.58f
 - normal-tension glaucoma and, 10.86
 - perimetry changes correlated with, 10.74–75
 - recording findings and, 10.53
 - patterns of nerve loss and, 10.67–69, 10.68f, 10.69f, 10.70f
- outflow facility in, 10.19
- classification of glaucomas and, 10.3–5, 10.4t, 10.6t
 - intraocular pressure and, 10.5, 10.5f, 10.13, 10.14f, 10.19
 - laser trabeculoplasty affecting, 10.188
 - tonography in measurement of, 10.19
- outflow obstruction mechanisms in, 10.5, 10.6t
- pain caused by, 5.295
- pars planitis and, 9.131
- in pathologic myopia, 12.218, 12.218f
- pediatric, 4.98, 4.99f, 8.95, 8.108–109, 10.4t, 10.147–167
- algorithm for, 6.279f
 - aniridia and, 10.150, 10.155
 - gonioscopic appearance of, 10.159
 - anomalies associated with, 10.4t, 10.6t, 10.147, 10.148t, 10.151

- anterior segment examination in, 10.158
 aphakic, 6.285, 10.156–157
 Axenfeld-Rieger syndrome and, 4.99, 8.97*t*, 8.102, 10.31, 10.150, 10.153–154
 axial length measurements in, 10.160
 cataract surgery and, 10.149*t*, 10.156
 central corneal thickness in, 10.159
 classification of, 6.277, 6.278*t*, 6.279*f*, 10.4*t*, 10.6*t*, 10.147–150, 10.148*t*, 10.149–150*t*
 corneal edema and, 8.108–109
 corneal enlargement and, 8.95, 8.96*t*, 8.99–100, 8.108, 10.31, 10.147, 10.158
 corneal opacities and, 8.108–109
 corticosteroids as cause of, 6.284
 definition of, 6.277
 developmental, 10.153–156
 diagnosis/differential diagnosis of, 10.151–152, 10.152*t*
 examination/evaluation in, 10.151–152, 10.152*t*, 10.157*t*, 10.157–160
 external examination in, 10.158
 follow-up of, 6.290–291, 10.167
 genetic/hereditary factors in, 10.11*t*, 10.150
 genetics of, 6.277–278
 gonioscopy in, 10.159
 history in, 10.157
 juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153
 juvenile open-angle glaucoma, 6.278, 6.284
 medical therapy for, 10.153, 10.164–165
 megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
 neurofibromatosis and, 10.156
 optic nerve/fundus evaluation in, 10.160
 pachymetry in, 10.159
 Peters anomaly and, 4.74, 10.150, 10.154
 primary, 10.4*t*, 10.147–148, 10.148*t*
 genetics of, 10.11*t*, 10.150
 infantile, 10.151
 juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153
 primary congenital glaucoma, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*
 anterior segment findings in, 6.282, 6.282*f*
 axial length in, 6.283
 central corneal thickness in, 6.281
 clinical manifestations of, 6.279–280, 6.280*f*
 corneal edema in, 6.279–280
 corneal findings in, 6.280*f*, 6.280–281
 definition of, 6.278
 diagnostic examination for, 6.280–283, 6.282–283*f*
 differential diagnosis of, 6.281*t*
 genetics of, 6.277–278
 gonioscopy for, 6.282, 6.282*f*
 goniotomy for, 6.285, 6.286*f*
 incidence of, 6.278
 natural history of, 6.283–284
 optic nerve findings in, 6.282–283, 6.283*f*
 optical coherence tomography of, 6.283
 pathophysiology of, 6.278
 surgical treatment of, 6.285–287, 6.286*f*
 tonometry in, 6.281–282
 trabeculotomy, 6.286*f*, 6.286–287
 prognosis for, 6.290–291, 10.166–167
 secondary, 10.4*t*, 10.148, 10.149–150*t*, 10.156–157
 acquired condition, 6.284
 after cataract surgery, 6.285
 classification of, 6.278*t*
 nonacquired conditions associated with, 6.284*t*
 Sturge-Weber syndrome and, 5.332*f*, 10.155
 surgery for, 10.153, 10.164–165
 strabismus and, 10.166–167
 tonometry in, 10.158–159
 treatment of, 10.153, 10.160–166
 β -blockers, 6.288, 6.289*t*
 cryotherapy, 6.287
 description of, 6.285
 endoscopic photocoagulation, 6.287–288, 6.288*f*
 goniotomy for, 6.285, 6.286*f*
 medical/medications, 6.288–290, 6.289*t*, 10.153, 10.164–165
 surgical, 6.285–288, 6.286*f*, 6.288*f*, 10.153, 10.160–164, 10.161*f*, 10.162*f*, 10.187
 trabeculotomy, 6.286*f*, 6.286–287
 tube shunt implantation surgery, 6.287
 tumors causing, 10.149*t*
 vision loss caused by, 6.290
 visual acuity and, 10.158
 pediatric (childhood/congenital/infantile/juvenile), 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147–167
 aniridia and, 10.150, 10.155
 gonioscopic appearance of, 10.159
 anomalies associated with, 10.4*t*, 10.6*t*, 10.147, 10.148*t*, 10.151
 anterior segment examination in, 10.158
 aphakic, 10.156–157
 Axenfeld-Rieger syndrome and, 4.99, 8.97*t*, 8.102, 10.31, 10.150, 10.153–154
 axial length measurements in, 10.160
 cataract surgery and, 10.149*t*, 10.156
 central corneal thickness in, 10.159
 classification of, 10.4*t*, 10.6*t*, 10.147–150, 10.148*t*, 10.149–150*t*
 corneal edema and, 8.108–109
 corneal enlargement and, 8.95, 8.96*t*, 8.99–100, 8.108, 10.31, 10.147, 10.158
 corneal opacities and, 8.108–109
 developmental, 10.153–156
 diagnosis/differential diagnosis of, 10.151–152, 10.152*t*
 examination/evaluation in, 10.151–152, 10.152*t*, 10.157*t*, 10.157–160
 external examination in, 10.158
 follow-up care and, 10.167
 genetic/hereditary factors in, 10.11*t*, 10.150
 gonioscopy in, 10.159
 history in, 10.157
 juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153
 medical therapy for, 10.153, 10.164–165
 megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
 neurofibromatosis and, 10.156
 optic nerve/fundus evaluation in, 10.160
 pachymetry in, 10.159
 Peters anomaly and, 4.74, 10.150, 10.154

- primary, 10.4*t*, 10.147–148, 10.148*t*
 - congenital, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*. *See also* Primary congenital glaucoma
 - genetics of, 10.11*t*, 10.150
 - infantile, 10.151
 - juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153
 - prognosis for, 10.166–167
 - secondary, 10.4*t*, 10.148, 10.149–150*t*, 10.156–157
 - Sturge-Weber syndrome and, 5.332*f*, 10.155
 - surgery for, 10.153, 10.164–165
 - strabismus and, 10.166–167
 - tonometry in, 10.158–159
 - treatment of, 10.153, 10.160–166
 - medical, 10.153, 10.164–165
 - surgical, 10.153, 10.160–164, 10.161*f*, 10.162*f*, 10.187
 - tumors causing, 10.149*t*
 - visual acuity and, 10.158
- penetrating keratoplasty and, 8.424–425, 10.109
 - graft failure and, 8.428
- peripapillary atrophy in, 10.48, 10.52
- persistent fetal vasculature and, 10.144
- Peters anomaly and, 4.74, 10.150, 10.154
- phacoantigenic, 10.98
- phacolytic (phacolytic uveitis), 4.103, 4.103*f*, 4.122, 9.21, 9.118, 9.118*f*, 9.119, 10.97*f*, 10.97–98, 11.67
- phacomorphic, 10.119, 10.128, 10.129*f*, 11.67, 11.68*f*
- pigmentary/pigment dispersion syndrome and, 4.105, 4.105*f*, 10.93–96, 10.94*f*, 10.95*f*, 10.96*f*
- port-wine stain and, 6.199
- posterior polymorphous corneal dystrophy and, 8.159
- preperimetric, 10.3
- prevalence of, 10.7–8, 10.9
- primary, 10.3–5. *See also* Angle-closure glaucoma, primary; Open-angle glaucoma, primary
 - congenital, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*. *See also* Primary congenital glaucoma
 - juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153
 - management of. *See* Antiglaucoma agents;
 - Glaucoma surgery
- pseudoexfoliation/exfoliation syndrome and (pseudoexfoliation glaucoma), 4.101–103, 4.102*f*, 10.11*t*, 10.31, 10.91, 10.93, 10.130, 10.131*f*
- pseudophakic, 10.130–132
- pupillary-block, in retinopathy of prematurity, 12.181
- pupils affected in, 10.30, 10.33*t*
- race affecting risk of, 10.7–8, 10.9, 10.81, 10.82, 10.120
 - in angle-closure glaucoma, 10.9, 10.117, 10.120
 - in open-angle glaucoma, 10.7–8, 10.81, 10.82
- radiation-related, 4.276
- refraction/refractive errors in, 10.9, 10.29, 10.122
- refractive surgery and, 13.41, 13.180–183, 13.182*f*, 13.200–201
- retinal vein occlusion risks secondary to, 12.125
- retinoblastoma and, 4.292
- retinopathy of prematurity as risk factor for, 6.334
- risk factors for
 - in angle-closure glaucoma, 10.9, 10.120–122
 - in open-angle glaucoma, 10.8, 10.9*t*, 10.80–83
- rubella (congenital) and, 9.203
- rubeosis iridis and, 4.188
- sarcoidosis and, 9.169
- scleral involvement/scleritis and, 8.323, 10.31
- screening perimetry in, 10.62
- secondary, 4.101–106, 4.102*f*, 4.103*f*, 4.104*f*, 4.105*f*, 4.106, 10.5. *See also* Angle-closure glaucoma, secondary; Open-angle glaucoma, secondary
 - in infants and children, 10.4*t*, 10.148, 10.149–150*t*
 - management of. *See* Antiglaucoma agents;
 - Glaucoma surgery
 - rubeosis iridis and, 4.188
 - uveitis and, 9.83, 9.285–286
- slit-lamp biomicroscopy in evaluation of, 10.30–32
- spatial frequencies affected by, 3.136
- SSRIs causing, 1.196
- statin use and, 1.89
- Sturge-Weber syndrome and, 5.332*f*, 5.334*t*, 6.401–402, 10.30, 10.155
- surgery for, 10.187–221. *See also* Glaucoma surgery; *specific procedure*
- sympathetic ophthalmia and, 9.285
- tests for, 1.16*f*, 1.16–18, 1.17*f*, 1.18*f*, 10.29–77. *See also* Glaucoma, clinical evaluation of
- threshold perimetry in, 10.61*f*, 10.61–62, 10.63*f*
- topiramate causing, 1.187, 1.203, 10.145*f*, 10.145–146
- transient visual loss and, 5.163*t*, 5.164
- trauma and, 4.103–104, 4.104*f*, 10.39–40, 10.40*f*, 10.41*f*, 10.98, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*
 - in children and adolescents, 10.149*t*
- tube shunt implantation for, 10.213–217, 10.214*t*, 10.218*t*
- tumors causing, 4.105*f*, 4.106, 10.98–100, 10.99*f*, 10.138
 - in children and adolescents, 10.149*t*
- ultrasound biomicroscopy in evaluation of, 10.77, 10.124*f*
- pediatric glaucoma and, 10.160
- uveal lymphoid proliferation/infiltration and, 4.314, 9.277
- uveitis and, 9.284, 9.285–286, 10.100–102, 10.102*f*, 10.134, 10.139, 10.139*f*. *See also* Uveitis-glaucoma-hyphema (UGH) syndrome
 - in children and adolescents, 10.149*t*
- visual field changes in, 10.59–77. *See also* Visual field defects, in glaucoma
 - evaluation of. *See also* Perimetry; Visual field testing, in glaucoma
 - patterns of field loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
 - serial fields/progression and, 10.71–75, 10.72*f*, 10.73*f*, 10.74*f*
 - single field and, 10.62–67, 10.64*f*, 10.65*f*, 10.66*f*, 10.67*f*
- vitrectomy and, 10.143
- Vogt-Koyanagi-Harada syndrome and, 9.182, 9.285
- Glaucoma diagnosis (GDx) test. *See* Scanning laser polarimetry/polarimeter
- Glaucoma drainage devices (tube shunts), 10.196–197, 10.213–217, 10.214*t*, 10.218*t*
- cataract extraction combined with, 10.213
- complications associated with, 10.217, 10.218*t*
- corneal graft failure and, 8.428

- in iridocorneal endothelial syndrome, 8.127
- LASIK and, 13.182
- neovascular glaucoma and, 10.135
- pediatric glaucoma and, 10.161, 10.163
- strabismus and, 10.166–167
- uveitis/uveitic glaucoma and, 9.287, 10.214
- Glaucoma genes, 10.10, 10.11, 10.11*t*
- Glaucoma Hemifield Test (GHT), 10.65, 10.65*f*
- Glaucoma Laser Trial (GLT), 10.188
- Glaucoma surgery, 10.187–221. *See also specific procedure*
 - for angle-closure glaucoma, 10.220
 - cataract development after, 11.56
 - cataract surgery and, 10.211–213, 10.213, 11.186–187, 11.187
 - chamber deepening/goniosynechialysis, 10.220
 - in children, 10.160–164, 10.161*f*, 10.162*f*
 - strabismus and, 10.166–167
 - corneal graft failure and, 8.428
 - deep sclerectomy, 10.217–219
 - in elderly patients, 10.221
 - electroablation, 10.219
 - filtering procedures, 10.197–211. *See also* Filtering procedures; Trabeculectomy
 - goniotomy, 10.160, 10.161, 10.161*f*, 10.163
 - incisional surgery, 10.196–220. *See also* Trabeculectomy
 - for angle-closure glaucoma, 10.220
 - cataract surgery, 10.213
 - with trabeculectomy, 10.211–213
 - complications of, 10.187
 - for open-angle glaucoma, 10.113–115
 - trabeculectomy, 10.197–211
 - with cataract surgery, 10.211–213
 - tube shunt implantation, 10.213–217, 10.214*t*, 10.218*t*
- interrelationship between medical and surgical treatment and, 10.111
- laser surgery, 10.188–196
 - cyclodestruction, 10.194–196, 10.195*f*
 - gonioplasty/iridoplasty, 10.193–194
 - iridotomy, 10.191–193, 10.192*f*
 - trabeculoplasty, 10.88, 10.113–115, 10.188–191, 10.190*f*
- LASIK and, 13.182, 13.201
- microshunts, 10.219–220
- minimally invasive, 10.219–220
- nonpenetrating, 10.217–219
- peripheral (surgical) iridectomy, 10.125, 10.220
- peripheral iridoplasty, 10.193–194
- after refractive surgery, 13.201
- shunting surgeries, 10.213–217, 10.214*t*, 10.218*t*, 10.219–220. *See also* Microshunts; Tube shunts
- trabeculectomy, 10.160, 10.161–162, 10.162*f*, 10.219
- in uveitis, 6.323
- viscocanalostomy, 10.217–219
- Glaucoma suspect, 10.4*t*, 10.89
 - angle-closure, 10.4*t*, 10.117, 10.117*t*, 10.122–123
 - open-angle, 10.4*t*, 10.89
 - screening tests for, 1.19, 10.62
- Glaucoma tube shunts. *See* Tube shunts
- Glaucomatocyclitic crisis (Posner-Schlossman syndrome), 9.118, 10.100–101
- Glaucomatous cupping. *See* Cupping of optic nerve/nerve head/disc, glaucomatous
- Glaucomas. *See* Methazolamide
- Glaukomflecken, 4.120, 10.124, 11.68
- GLC1A gene, 10.10, 10.11*t*
- GLC1A myocilin gene, 10.150
- GLC3A gene, 10.11*t*
- GLC1B gene, 10.11*t*
- GLC3B gene, 10.11*t*
- GLC1C gene, 10.11*t*
- GLC3C gene, 10.11*t*
- GLC1D gene, 10.11*t*
- GLC3D gene, 10.11*t*
- GLC1E gene, 10.11*t*
- GLC1F gene, 10.11*t*
- GLC1G gene, 10.11*t*
- GLC1H gene, 10.11*t*
- GLC1J gene, 10.11*t*
- GLC1K gene, 10.11*t*
- Glial cells
 - optic nerve, 2.86, 2.88*f*, 4.241, 4.242*f*
 - retinal, 2.73, 2.266, 5.24
 - in healing/repair, 4.17
 - ischemia and, 4.152
- Glimepiride, for diabetes mellitus, 1.45, 1.45*t*
- Glioblastoma/glioblastoma multiforme, optic nerve (malignant optic glioma of adulthood/MOGA), 4.249, 5.130–131, 7.76
- Gliomas, optic nerve/pathway/chiasm (OPGs), 4.249, 4.249*f*, 5.126, 5.128*t*, 5.129*f*, 5.129–131, 7.74–77, 7.75*f*
 - in children (juvenile), 4.249
 - malignant (malignant optic gliomas of childhood/MOGAs/glioblastomas), 4.249, 5.130–131, 7.76
 - in neurofibromatosis, 5.130, 5.334*t*, 7.74, 7.76, 7.78
 - orbital involvement and, 7.74–77, 7.75*f*
- Gliosis, retinal, 4.157, 4.158, 4.158*f*
 - of peripapillary nerve fiber layer, 5.109
- Gliotic (sclerotic) lesions, in multiple sclerosis, 5.316, 5.316*f*
- Glipizide, for diabetes mellitus, 1.45, 1.45*t*
 - with metformin, 1.46
- Glistenings, IOL, 11.151
- Glitazones, 1.44*f*
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 1.130
- Global layer, of extraocular muscles, 6.24, 6.27
- Globe
 - atrophy/disorganization of (atrophia/phthisis bulbi), 4.22–23, 4.23*f*
 - retinoblastoma regression and, 4.301
 - congenital and developmental anomalies of, 6.263
 - displacement of, 4.223
 - in orbital disorders, 7.11–12, 7.23–24, 7.95, 7.95*f*
 - exposure of
 - for ICCE, 11.199
 - for phacoemulsification, 11.105, 11.105*f*
 - gross dissection of, for pathologic examination, 4.28*f*, 4.28–30, 4.29*f*
 - injuries to
 - lacerating, 12.358
 - needle perforation/penetration, 12.358, 12.395*f*, 12.395–396

- penetrating, 6.376, 12.358
- perforating, 12.358
- primary repair of, 12.359
- scleral rupture, 12.352, 12.358
- surgical management of, 12.359–360
- vitreotomy for, 12.359–360
- wound closure of, 12.359
- luxation of, 6.207–208
- orbital tumors/inflammation originating in, 7.94–95
- orientation of, pathologic examination and, 4.27, 4.27*f*
- penetrating injuries of, 6.376, 12.358
 - needle penetration/perforation and, 12.358.
 - See also* Penetrating and perforating ocular trauma; Trauma
- ptosis of, in orbital floor/blowout fracture, 7.109
- retraction of
 - in Duane retraction syndrome, 6.134
 - in induced convergence-retraction, 6.153
- rupture/traumatic injury of, surgical repair of, 8.403–409, 8.404*f*, 8.405*f*, 8.407*f*, 8.408*f*. *See also* Corneoscleral lacerations, repair of
- stabilization of, for clear corneal incision, 11.106
- suspensory ligament of. *See* Lockwood ligament
- topographic features of, 2.37*f*, 2.37–38
- Globe-conserving therapy, for retinoblastoma, 4.299
- Globus pallidus, in Parkinson disease, 1.198, 1.199
- Glomerulonephritis, in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137
- Glomus tumor, 8.345*t*
- GLP-1 (glucagon-like peptide-1) agonists, for diabetes mellitus, 1.45*t*, 1.46
- GLT (Glaucoma Laser Trial), 10.188
- Glucagon-like peptide-1 (GLP-1) agonists, for diabetes mellitus, 1.45*t*, 1.46
- Glucocorticoids, 1.170–172, 1.171*t*, 2.329–334, 2.330*t*, 2.333*t*. *See also* Corticosteroids
- Glucose
 - in aqueous humor, 2.231*t*, 2.232
 - in cataract formation, 2.247, 11.19, 11.60. *See also* Diabetes mellitus
 - for medical emergencies, 1.296*t*
 - metabolism of, 1.33–34
 - in cornea, 2.224
 - in lens, 2.246, 2.247, 2.247*f*, 11.17–19, 11.18*f*
 - in retinal pigment epithelium, 2.273
 - plasma levels of
 - in diabetes mellitus
 - diagnosis/screening and, 1.34
 - self-monitoring of, 1.40–41
 - surgery and, 1.287
 - surveillance of (glycemic control). *See also* Glycemic control
 - importance of, 1.38–39, 1.39*f*, 1.49–50
 - management and, 1.40–41
 - prevention and, 1.38–39, 1.39*f*
 - hormones affecting, 1.33–34
 - insulin-induced hypoglycemia and, 1.43
 - in metabolic syndrome, 1.37, 1.88
 - in prediabetes, 1.37
 - in tear film, 2.216
 - in vitreous, 2.231*t*
- Glucose control. *See* Glycemic control
- Glucose-6-phosphate (G6P), in lens glucose/carbohydrate metabolism, 2.246, 11.17, 11.18*f*
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency, 1.139
 - pharmacogenetics and, 2.201
- Glucose surveillance. *See* Glycemic control
- Glucose tolerance/intolerance, 1.34
 - in gestational diabetes mellitus, 1.36
 - impaired (IGT), 1.37
 - in metabolic syndrome, 1.37, 1.88
 - in prediabetes, 1.37
- Glucose tolerance test, 1.34
 - in prediabetes, 1.37
- Glucose toxicity, 1.36
- Glucose transport inhibitors, for diabetes mellitus, 1.45*t*, 1.47
- α -Glucosidase inhibitors, for diabetes mellitus, 1.45*t*, 1.46
- β -Glucuronidase deficiency, in Sly syndrome, 8.175*t*
- Glucuronide transferase, defective/deficiency of, 2.175*t*
- Glutamate
 - in cone phototransduction, 2.266, 2.267
 - in rod phototransduction, 2.259, 2.261
- Glutamic acid decarboxylase (GAD), downbeat nystagmus and, 5.244
- Glutaraldehyde, as tissue fixative, 4.26, 4.26*t*
- Glutathione (GSH)
 - in aqueous humor, 2.232–233
 - in lens, 2.246, 2.284–285
 - oxidative changes and, 2.283, 2.284–285, 11.17, 11.20
 - in retina and retinal pigment epithelium, 2.251, 2.273, 2.287
- Glutathione disulfide (GSSG), 2.283, 2.284
- Glutathione peroxidase (GSH-Px)
 - in aqueous humor, 2.231
 - in lens, 2.284, 11.20
 - in retina and retinal pigment epithelium, 2.287
 - selenium-dependent, 2.287
- Glutathione redox cycle, 2.284, 2.285
- Glutathione-S-transferase (GSH-S-Ts), in retina and retinal pigment epithelium, 2.287
- Glyburide, for diabetes mellitus, 1.45, 1.45*t*
 - with metformin, 1.46
- Glycation cross-link breakers, for hypertension, 1.74–75
- Glycemic control (glucose surveillance)
 - for diabetic retinopathy, 12.96–98
 - importance of, 1.38–39, 1.39*f*, 1.49–50, 1.89
 - management and, 1.40–41
 - prevention and, 1.38–39, 1.39*f*
 - retinopathy incidence and progression affected by, 1.38, 1.39*f*
 - Diabetes Control and Complications Trial, 1.38, 1.39*f*
 - United Kingdom Prospective Diabetes Study, 1.38
 - surgery and, 1.287
- Glycerin, 2.329, 2.329*t*
 - in artificial tears, 2.341
- Glycerol, 10.174*t*, 10.182–183
- Glycine cell transport, defective, 2.175*t*
- Glycocalyx, corneal epithelium, 2.224
- Glycolysis, in glucose/carbohydrate metabolism
 - in cornea, 2.224

- in lens, 2.246, 11.17–19, 11.18f
- in rod outer segments, 2.261
- Glycopeptide antibiotics, 1.272, 1.276–277
- Glycopeptide-intermediate *Staphylococcus aureus*, 1.241
- Glycoprotein IIb/IIIa inhibitors
 - for ischemic heart disease, 1.100t, 1.101t
 - non-ST-segment elevation acute coronary syndrome, 1.103–104
 - after stent placement, 1.100, 1.100t
- Glycoprotein IIb/IIIa receptor, 1.103–104
- Glycoproteinosis, 6.388t. *See also* Sialidoses
- Glycoproteins
 - corneal, 2.224–225
 - in lipid keratopathy, 8.125
 - viral, 8.207, 8.212
 - in vitreous, 2.252
- Glycosaminoglycans (GAGs)
 - corneal haze after surface ablation and, 13.109
 - corneal hydration and, 8.9
 - in Fleck corneal dystrophy, 8.153
 - in macular corneal dystrophy, 8.149–150
 - in mucopolidoses, 8.178
 - in mucopolysaccharidoses, 8.174
 - stromal, 2.41, 2.226
 - in thyroid eye disease, 4.226, 7.55
- Glycosylated hemoglobin (HbA_{1c})
 - in diabetes mellitus screening, 1.34
 - in glucose control/surveillance, 1.38, 1.39, 1.39f, 1.40
 - in prediabetes, 1.37
- Glycylcysteine antibiotics, 1.280
- Glyrol. *See* Glycerin
- GM₁ gangliosidoses, 6.389t
- GM₁ gangliosidosis type I (generalized), 2.175t, 8.176
- GM₂ gangliosidosis type I (Tay-Sachs disease), 2.175t, 6.389t, 8.176–178, 12.291
 - racial and ethnic concentration of, 2.197
- GM₂ gangliosidosis type II (Sandhoff disease), 2.175t
- GMS (Gomori or Grocott methenamine silver) stain, 4.31t
- GNA11 gene
 - in nevus of Ota, 4.64
 - in uveal melanoma, 4.197
- GNAQ gene
 - in nevus of Ota, 4.64
 - in uveal melanoma, 4.197
- GnRH. *See* Gonadotropin-releasing hormone
- Goblet cells, 2.22f, 2.23t, 2.30, 2.215f, 4.47, 4.48f, 7.152, 8.5, 8.6f
 - mucin tear secretion by, 2.22f, 2.215f, 2.217, 7.252
 - in mucous membrane pemphigoid, 8.299, 8.300
- Goiter. *See also* Hyperthyroidism; Thyroid eye disease
 - diffuse toxic, 1.53
 - nodular toxic, 1.53, 1.54
- Gold compounds/salts, 1.174
 - corneal deposits of/pigmentation caused by, 8.118t, 8.132
 - for rheumatoid arthritis, 1.152
- Gold eyelid weights
 - for corneal exposure in facial palsy, 5.281
 - for exposure keratopathy, 8.80
 - for paralytic ectropion, 7.225–226
 - for paralytic lagophthalmos/upper eyelid paralysis, 7.226
- GOLD (Global Initiative for Chronic Obstructive Lung Disease), 1.130
- Goldberg syndrome, 8.179
- Goldberg theory of reciprocal zonular action, 13.162
- “Golden ring” sign, 11.110
- Goldenhar-Gorlin syndrome (oculoauriculovertebral (OAV) syndrome), 8.191t, 8.195f, 8.195–196
- Goldenhar syndrome/oculoauriculovertebral dysplasia, 4.47, 7.37
 - craniofacial malformations associated with, 6.210f, 6.210–211
 - dermoids/dermolipomas/lipodermoids and, 4.47, 4.48, 6.256
 - description of, 6.131
 - epibulbar dermoids associated with, 6.256, 6.256f
- Goldman (kinetic) perimetry, 5.84, 5.85f. *See also* Perimetry
 - in nonorganic disorder evaluation, 5.308, 5.308f
- Goldmann 3-mirror contact gonioscopy lens, 3.295–296, 3.296f
- Goldmann applanation, 6.281
- Goldmann applanation tonometry (GAT), 3.282, 3.293, 10.22–23, 10.23f, 10.24f. *See also* Applanation tonometry/tonometer
 - corneal thickness affecting, 13.105, 13.181
 - infection control and, 10.27
 - after refractive surgery, 13.105, 13.181, 13.200–201
 - LASIK, 13.105, 13.200–201
 - surface ablation, 13.105, 13.200–201
- Goldmann equation, 10.13
- Goldmann-Favre syndrome. *See* Enhanced S-cone disease (ESCD)
- Goldmann lenses, for gonioscopy, 10.33, 10.34f, 10.35
- Goldmann perimetry, 3.315
- Goldmann-Weekers (G-W) adaptometer, 12.57–58
- Goldmann-Witmer (GW) coefficient, 9.44
 - in acute retinal necrosis, 9.195–196
 - in toxocariasis, 9.229
 - in toxoplasmosis, 9.91, 9.196, 9.224
- Golimumab, 1.174
- Gomori methenamine silver (GMS) stain, 4.31t
- Gonadotroph adenomas, 1.57
- Gonadotropin-releasing hormone (GnRH), 1.56t
- Gonadotropins, pituitary adenoma producing, 1.57
- Goniolenses, 10.33–35, 10.35f. *See also* Gonioscopy
 - in children and adolescents, 10.159
- Gonioplasty, laser, 10.193–194
- Gonioscopy, 10.32–40, 10.33t, 10.34f, 10.35f, 10.37f, 10.38f, 10.39f, 10.40f, 10.41f
 - assessment/documentation systems for, 10.36–40, 10.37f, 10.38f, 10.39f, 10.40f, 10.41f
 - before cataract surgery, 11.79
 - chamber angle, 4.97–98, 4.98f, 10.32–40, 10.33t, 10.34f, 10.35f, 10.37f, 10.38f, 10.39f, 10.40f, 10.41f
 - in traumatic/angle-recession glaucoma, 10.39–40, 10.40f, 10.41f, 10.107, 10.107f
 - in choroidal/ciliary body melanoma, 4.262, 4.263f, 4.265
 - direct, 10.33, 10.35f
 - dynamic (compression/indentation), 10.35, 10.35f, 10.36
 - in elevated episcleral venous pressure, 10.102

- in Fuchs heterochromic uveitis/iridocyclitis, 10.101, 10.102*f*
 - in glaucoma, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
 - angle-closure, 10.123, 10.124*f*, 10.125
 - in infants and children, 6.282, 6.282*f*, 10.159
 - inflammatory, 10.100
 - lens particle, 11.67
 - neovascular, 10.38*f*, 10.38–39, 10.134
 - normal-tension, 10.87
 - primary open-angle, 10.79
 - traumatic/angle-recession, 10.39–40, 10.40*f*, 10.41*f*, 10.107, 10.107*f*
 - indirect, 10.33–36, 10.35*f*
 - in pediatric glaucoma, 10.159
 - in iris nevus, 4.255
 - Koepe-type lenses in, 10.33
 - normal angle landmarks in, 10.34*f*
 - in pigment dispersion syndrome, 10.94, 10.94*f*
 - trabecular meshwork, 4.97–98, 4.98*f*, 10.33*t*, 10.34*f*
 - in trauma evaluation, 10.39–40, 10.40*f*, 10.41*f*, 11.190
 - Goniosynechialysis
 - for angle-closure glaucoma, 10.220
 - with cataract extraction, 10.213
 - for subacute/intermittent angle closure, 10.126
 - Goniotomy, 10.160, 10.161, 10.161*f*, 10.163
 - primary congenital glaucoma treated with, 6.285, 6.286*f*
 - uveitis and, 6.323, 9.287
 - Gonococcus (*Neisseria gonorrhoeae*/gonorrhea), 1.246–247, 8.207, 8.208*t*, 8.245, 8.246*f*
 - conjunctivitis/hyperacute conjunctivitis caused by, 8.208*t*, 8.245, 8.257*t*, 8.258–260, 8.259*f*, 8.260*t*
 - in neonates, 8.257*t*, 8.258, 8.264
 - invasive capability of, 8.207
 - resistant strains of, 1.246–247, 8.259, 8.264
 - Gorlin syndrome (basal cell nevus syndrome), 7.178
 - eyelid manifestations of, 4.210*t*, 7.178
 - Gottron sign, in dermatomyositis, 1.163
 - Gout, 8.188
 - corneal changes in, 8.119, 8.188
 - GPA. *See* Granulomatosis, with polyangiitis; Guided Progression Analysis
 - GPC. *See* Giant papillary conjunctivitis
 - GPDS1 genes, 10.11*t*
 - GPR143 gene, 6.407
 - GRACE risk calculator, 1.103, 1.104
 - Graded-density sunglasses, 3.192–193
 - Gradenigo syndrome, 5.201, 5.345
 - Gradient echo MR sequences, 7.29
 - Gradient method, for accommodative convergence/accommodation ratio, 3.177–178, 6.71
 - Graft–host interface
 - arcuate keratotomy incisions in, 13.56–57
 - pathology in
 - after DSEK, 8.445–446, 8.446*f*
 - after lamellar keratoplasty, 8.435
 - Graft-vs-host disease (GVHD), 8.303–305, 8.305*f*
 - superior limbic keratoconjunctivitis and, 8.83
 - Grafts
 - for canthal repair, 7.195
 - for cicatricial ectropion, 7.201, 7.202*f*
 - for cicatricial entropion, 7.207
 - conjunctival, 8.351*t*
 - for chemical injuries, 8.384
 - indications for, 8.351*t*, 8.353, 8.356
 - for limbal stem cell deficiency, 8.94
 - in pterygium surgery, 8.351, 8.353*t*, 8.353–355, 8.354*f*, 8.356
 - recurrence rate and, 8.353*t*
 - after tumor removal surgery, 8.329
 - conjunctival-limbal, for pterygium, recurrence rate and, 8.353*t*
 - corneal, 8.316. *See also* Cornea, transplantation of; Donor cornea; Keratoplasty
 - allografts (allogeneic transplantation), 8.316, 8.411–451, 8.412*t*, 8.412–413*t*
 - arcuate keratotomy incisions in, 13.56–57
 - autografts (autologous transplantation), 8.411, 8.451–452
 - disease recurrence in, 8.225, 8.232
 - dislocation/decentration of, after endothelial keratoplasty, 8.440–444, 8.441*f*, 8.442*f*, 8.443*f*
 - DMEK, 8.442*f*, 8.442–443, 8.443*f*
 - DSEK, 8.441, 8.442*f*
 - endothelial failure of, 4.84, 4.85*f*
 - late non-immune-mediated, 8.427–428
 - primary
 - after endothelial keratoplasty (DMEK/DSEK), 8.447
 - after penetrating keratoplasty, 8.423, 8.423*f*
 - rejection of, 4.84, 4.85*f*, 8.316–318, 8.428–431, 9.59, 9.60, 9.60*f*. *See also* Rejection
- dermis-fat, 7.132
 - in children, 7.129
 - in congenital anophthalmia/microphthalmia management, 7.36
 - for exposure and extrusion of orbital implant, 7.134
 - for superior sulcus deformity, 7.132–133
- after exenteration, 7.137
- for eyelid repair, 7.190, 7.191, 7.193, 7.193*f*, 7.194, 7.194*f*
 - in burn injury, 7.190
 - in burn patients, 8.385
- for eyelid retraction, 7.223, 7.224
- immune privilege and, 8.316, 9.57
- limbal, 8.351*t*. *See also* Limbal transplantation
 - for chemical injuries, 8.380, 8.384
 - indications for, 8.351*t*
- mucous membrane, 8.351*t*, 8.365–366
 - for cicatricial entropion, 7.207
 - for contracted socket, 7.134
 - for eyelid retraction, 7.224
 - indications for, 8.351*t*, 8.366
 - for mucous membrane pemphigoid, 8.303, 8.366
 - for symblepharon, 7.208
- for paralytic ectropion, 7.226
- rejection of. *See* Rejection
- retinal/retinal pigment epithelium, 9.62
- scleral patch, for exposure and extrusion of orbital implant, 7.133
- for symblepharon, 7.208
- tarsconjunctival
 - for cicatricial entropion, 7.207
 - for eyelid repair, 7.190
- transplantation antigens and, 9.60

- Gram-negative bacteria, 8.243, 8.244t
 cocci, 8.244t, 8.245, 8.246f
 therapy for infection caused by, 8.270t
 as normal flora, 8.206t
 rods, 8.244t, 8.247f, 8.247–248
 therapy for infection caused by, 8.270t
- Gram-positive bacteria, 8.243, 8.244t
 cocci, 8.243, 8.244t, 8.244–245, 8.245f
 therapy for infection caused by, 8.270t
 filaments, 8.244t, 8.248–249
 rods, 8.244t, 8.245–247, 8.246f
- Gram stain, 4.31t, 8.243–244, 8.244t
- Gramicidin, with polymyxin B and neomycin, 2.347t
 for *Acanthamoeba* keratitis, 2.361
- “Grand mal” (tonic-clonic) seizures, 1.201
- Granular corneal dystrophy, 8.135t, 8.145t. *See also*
specific type
 atypical. *See* Reis-Bücklers corneal dystrophy
 genetics of, 8.136t
 recurrence of after corneal transplantation, 8.425, 8.425f
 refractive surgery and, 13.43
 type 1 (GCD1/classic), 4.90, 4.90f, 4.91t, 8.135t,
 8.136t, 8.145t, 8.147–148, 8.148f
 type 2 (GCD2/Avellino), 4.90, 4.91f, 4.91t, 8.135t,
 8.136t, 8.145t, 8.148–149, 8.149f
 amyloid deposits in, 8.148, 8.186t
 refractive surgery and, 13.43
- Granular-lattice corneal dystrophy. *See* Granular corneal
 dystrophy, type 2
- Granulocyte colony-stimulating factor, 1.136
- Granulocytes
 basophils and mast cells, 9.10
 eosinophils, 9.10
 neutrophils, 9.9–10
- Granulocytic sarcoma (chloroma), 4.316, 6.218, 7.98–99
- Granulomas, 4.7, 4.8f, 4.9f. *See also* Granulomatosis;
 Granulomatous disease/inflammation
 chalazia, 8.77
 choroidal, 12.241f
 in coccidioidomycosis, 9.271, 9.271f
 conjunctival/ocular surface, 8.46t, 8.47t
 foreign-body, 4.52, 4.53f
 in Parinaud oculoglandular syndrome, 4.51, 8.265
 pyogenic, 4.55, 4.55f, 8.345t, 8.346, 8.346f
 after pterygium excision, 8.356
 in sarcoidosis, 4.52, 4.52f, 8.347, 9.168, 9.168f
 eosinophilic
 orbital, 7.90
 unifocal, 6.219, 6.219f
 foreign-body, 6.170
 macular, 6.317f
 necrobiotic
 in episcleritis, 4.109
 in scleritis, 4.110, 4.110f
 posterior pole, 12.245
 pyogenic, 4.55, 4.55f, 6.170, 6.171f, 8.345t, 8.346,
 8.346f
 after pterygium excision, 8.356
 in sarcoidosis, 4.52, 4.52f, 4.187, 4.187f, 5.126f, 5.327,
 8.347, 9.166, 9.168, 9.169
 in toxocariasis, 9.47, 9.228, 9.229f, 9.229t, 12.244,
 12.245f
 zonal, 4.119, 4.119f
- Granulomatosis. *See also* Granulomas; Granulomatous
 disease/inflammation
 eosinophilic, with polyangiitis (EGPA/Churg-Strauss
 syndrome), 1.165t, 1.168
 familial juvenile systemic (Blau syndrome), 9.170
 with polyangiitis (GPA/Wegener granulomatosis),
 1.165t, 1.167–168, 7.61–62, 7.62f, 9.137–139,
 9.138f, 12.195, 12.196f
 eyelid manifestations of, 4.207t
 optic neuritis and, 5.115
 scleritis/retinal vasculitis and, 7.61, 9.138
 screening/diagnostic tests for, 7.33–34
- Granulomatous arthritis, pediatric, 6.318
- Granulomatous conjunctivitis, 4.51–52, 4.52f
 in Parinaud oculoglandular syndrome, 8.265–266
- Granulomatous delayed hypersensitivity, 9.47
- Granulomatous disease/inflammation, 4.7. *See also*
 Granulomas; Granulomatosis
 colitis/ileocolitis (Crohn disease), 1.155, 9.116
 conjunctivitis, 4.51–52, 4.52f
 in HIV infection/AIDS, 9.300–301
 in Parinaud oculoglandular syndrome, 8.265
 focal posttraumatic choroidal, 4.22, 4.22f
 pulmonary, 1.131
 subacute thyroiditis, 1.55
 uveitis, 9.78
 lens-associated, 9.119
 tuberculous, 9.250–255, 9.251f, 9.252f, 9.253f
- Granulomatous inflammatory infiltrate, necrobiotic, in
 episcleritis, 4.109
- Granulysin, in Stevens-Johnson syndrome (Stevens-
 Johnson syndrome/toxic epidermal necrolysis
 overlap and toxic epidermal necrolysis), 8.296
- Grating acuity
 contrast sensitivity and, 5.88
 definition of, 6.54
 in strabismic amblyopia, 6.54
 testing for, 6.8, 6.9f, 6.56–57
- Graves hyperthyroidism/ophthalmopathy/eye disease,
 1.52, 1.53–54, 7.51, 7.52, 7.53, 7.55, 7.56. *See also*
 Thyroid eye disease
 thyroid antibodies in, 1.52
- Graves ophthalmopathy. *See* Thyroid eye disease
- Gray (Gy), radiation dose measurement, 1.229
- Gray line (intermarginal sulcus), 2.19, 2.22f, 2.215,
 7.149, 7.153, 7.154f
- Grayscale map, 5.86, 5.87f
- Greater (major) arterial circle, 2.34f, 2.35, 2.45f, 2.55, 5.15
 ciliary body, 2.58
- Greater superficial petrosal nerve, 2.101f, 2.103, 2.104,
 5.276–277f, 5.277
- Green cones. *See* M cones
- Green laser, 12.373
- GRK1 gene, 12.253
- Grocott methenamine silver (GMS) stain, 4.31t
- Groenouw dystrophy type I (granular corneal
 dystrophy, type 1/GCD1/classic), 4.90, 4.90f, 4.91t,
 8.135t, 8.136t, 8.145t, 8.147–148, 8.148f
- Groenouw dystrophy type II (macular corneal
 dystrophy/MCD), 8.135t, 8.136t, 8.145t, 8.149–151,
 8.150f
- Grönblad-Strandberg syndrome. *See* Pseudoxanthoma
 elasticum

Gross dissection, for pathologic examination, 4.28f, 4.28–30, 4.29f

Ground-in prisms, for nystagmus, 6.155

Ground substance, of cornea, 2.41

Group A β -hemolytic streptococci (*Streptococcus pyogenes*), 1.242

orbital necrotizing fasciitis caused by, 7.48

Grouped pigmentation of retina (bear tracks), 4.269, 4.269f

Growth factors, 2.127, 2.371–372, 9.26, 9.28t

in aqueous humor, 2.229, 2.234–235

in ocular development, 2.111, 2.127

in tear film, 2.217

Growth hormone (GH)

dawn phenomenon and, 1.42

pituitary adenoma producing, 1.57

Growth hormone–releasing hormone (GHRH), 1.56t

Gruber (petroclinoid) ligament, 2.102, 5.41

GSH. *See* Glutathione

GSH-Px. *See* Glutathione peroxidase

GSH-S-Ts. *See* Glutathione-S-transferase

GSSG. *See* Glutathione disulfide

Guaiac stool test, in cancer screening, 1.207, 1.214

Guanfacine, 1.68t

Guanylate cyclase

mutation in, 2.263

in rod phototransduction, 2.260f, 2.261

Guanylate cyclase activators, for hypertension, 1.74

Guanylate cyclase–assisting proteins (GCAPs), 2.260f, 2.261

Guérin (Le Fort I) fracture, 7.103, 7.104f

Guided Progression Analysis (GPA), in visual field

progression identification, 10.71–72, 10.72f, 10.73f

Guillain-Barré syndrome

facial diplegia in, 5.280

immunization and, 1.217

Miller Fisher variant of, 5.273, 5.273t, 5.280

Guillain-Mollaret triangle lesion, oculopalatal myoclonus and, 5.247

Gullstrand mathematical model, of human eye, 3.59, 3.124, 3.125, 3.126f, 3.127t, 3.243, 3.270

Gummata, syphilitic, 1.248, 9.238

Gundersen flap, 8.357f, 8.357–358, 8.358f, 11.129

Gustatory nucleus, 2.103

“Guttering,” 12.79

GVHD. *See* Graft-vs-host disease

GW coefficient. *See* Goldmann-Witmer (GW) coefficient

GWAS (genome-wide association studies), 2.136, 2.163–167, 2.166f, 2.167f, 2.168f

in age-related macular degeneration, 2.167f

Gy (gray), radiation dose measurement, 1.229

Gyrate atrophy, 2.175t, 12.268–269, 12.269f

ornithine aminotransferase defects causing, 2.175t, 2.265

retinal pigment epithelium in, 2.279

Gyrus

angular, 5.32f

cingulate, 5.52

frontal, 5.32f

postcentral, 5.47f

precentral, 5.49

facial weakness/paralysis caused by lesion of, 5.277

rectus, 2.83, 2.85f, 5.26

supramarginal, 5.32f

H

H_{ce} . *See* Fluence

H_2SO_3 . *See* Sulfurous acid

H_2SO_4 . *See* Sulfuric acid

H&E (hematoxylin-eosin) stain, 4.31t

H_1 -receptor blockers, for ocular allergy. *See* Antihistamines

H_2 -receptor blockers

corticosteroid treatment in uveitis and, 9.100

preoperative, 1.288

Haab striae, 6.260, 6.261f, 6.280f, 6.280–281, 8.109, 10.31, 10.147, 10.151, 10.152f, 10.158, 10.166

HAART (highly active antiretroviral therapy). *See* Antiretroviral therapy

Habit spasm, 5.285

HAcetate. *See* Acetic acid

Haemophilus/Haemophilus influenzae, 1.245, 8.208t, 8.244t, 8.248

biotype III (*H aegyptius*), 8.207

conjunctivitis caused by, 8.208t, 8.256, 8.257t

invasive capability of, 8.207

bleb-associated endophthalmitis caused by, 8.248, 12.391

conjunctivitis caused by, 4.52, 8.208t, 8.256, 8.257t

endogenous endophthalmitis caused by, 9.264

immunization against, 1.223, 1.245

as normal flora, 8.206t

orbital cellulitis caused by, 7.47

preseptal cellulitis caused by, 7.44, 8.256

resistant strains of, 1.245

type b (Hib), 1.245, 8.248

Haemophilus influenzae type b (Hib) vaccine, 1.223, 1.245

cellulitis prevention and, 7.44

Hagberg-Santavuori disease, infantile, 6.389t

Haigis formula, 3.249f, 3.249–250

for IOL power determination/selection, 11.85

Hair cells, 5.38, 5.39f, 5.214

Hair follicles, of eyelid, 7.154f

tumors arising in, 7.172, 7.172f, 7.173f

Haldol. *See* Haloperidol

Haller and Zinn, circle of (circle of Zinn), 2.88f, 2.91, 5.17, 10.44, 10.46

Haller layer, 12.19

Hallermann-Streiff-François syndrome (oculomandibulodyscephaly), 8.191t

Hallucinations, 5.158, 5.173, 5.175–178

cortical origin of, 5.158, 5.176–178

hypnagogic, 5.177

hypnopompic, 5.177

nonvisual causes of, 5.174t

occipital lobe lesions causing, 5.158, 5.176–178

ocular origin of, 5.175

optic nerve origin of, 5.176

parietal lobe lesions causing, 5.175, 5.177

sleep-associated, 5.177

temporal lobe lesions causing, 5.155, 5.176–177

in visually impaired patient (Charles Bonnet syndrome), 5.177–178

Hallucinosis, peduncular, 5.176

Haloperidol, oculogyric crisis caused by, 5.231

- Halos
 with IOLs
 angle-supported lenses, 13.146
 iris-fixed lenses, 13.145
 multifocal lenses, 13.156
 after photoablation, 13.102
 pupil size and, 13.40
 after radial keratotomy, 13.51
 spherical aberrations causing, 13.12, 13.102
 with transient monocular visual loss, 5.164
- Hamartin, 5.334*t*
- Hamartomas, 4.6, 4.50, 5.331–332
 astrocytic (astrocytomas), 4.249, 4.249*f*, 5.108*f*
 juvenile pilocytic, 4.249
 optic. *See* Optic nerve (optic pathway/chiasm)
 gliomas
 pilocytic. *See* Optic nerve (optic pathway/chiasm)
 gliomas
 retinal, 4.295, 4.296*f*
 optic nerve/nerve head/disc drusen
 differentiated from, 5.108*f*, 5.143
 retinoblastoma differentiated from, 4.295, 4.296*f*
 in tuberous sclerosis, 4.295, 5.143, 5.331*f*, 5.334*t*
 combined, of retina and retinal pigment epithelium,
 4.179, 4.180*f*, 4.280, 4.280*f*
 of conjunctiva/eyelid/ocular surface, 4.50, 8.345*t*
 of orbit, 7.39
 of retinal pigment epithelium
 combined, 4.179, 4.180*f*, 4.280, 4.280*f*
 in Gardner syndrome, 4.145
 simple, 4.279, 4.280*f*
- Hamartomatous angiofibromas. *See also* Adenoma,
 sebaceous (sebaceum)
 in tuberous sclerosis, 5.331*f*, 5.334*t*
- Hand-Schüller-Christian disease, orbital involvement
 and, 7.90
- Hand washing, HIV transmission prevention and,
 1.271
- Handheld esthesiometer, 8.42–43
- Handheld laser-pointer injury, 12.369
- Handheld magnifiers, 3.321, 3.321*f*
- Handpiece, phaco, 11.98, 11.98*f*
- Hangback recession, 6.163
- Haploid/haploid number, 2.136, 2.149, 2.186
- Haploid insufficiency (haploinsufficiency), 2.136
 in aniridia/*PAX6* gene disorders, 2.136, 2.193
 gene therapy for disorders caused by, 2.169
- Haplotype, 2.136, 9.65
- HapMap, 2.136, 2.163
- Haptic, of IOL, insertion of lens and, 11.116, 11.117,
 11.119, 11.119*f*
- Harada-Ito procedure
 description of, 6.124
 Fells modification of, 6.167
- HARBOR study, 12.82
- Harboyan syndrome, 6.259
- Hard contact lens method, for IOL power calculation
 after refractive surgery, 13.195
- Hard contact lenses. *See* Rigid gas-permeable (RGP)
 contact lenses
- Hard-design progressive addition lenses, 3.182, 3.183*f*
- Hard (hyaline) drusen, 4.162, 4.162*f*, 12.65
- Hard exudates, 4.140, 4.152, 4.153*f*, 12.122, 12.160
 in leukemia, 4.315
- Hard palate composite grafts
 for cicatricial entropion, 7.207
 for eyelid repair, 7.190
 for eyelid retraction, 7.224
 for paralytic ectropion, 7.226
- “Hard” tubercles, 4.7, 4.8*f*. *See also* Tubercles
- Hardy-Rand-Rittler (HRR) plates
 for color vision testing, 12.54
 in low vision evaluation, 5.78–79
- Harlequin syndrome, 5.257
- Harmonious anomalous retinal correspondence, 6.76
- Hartmann screen, 3.286
- Hartmann-Shack wavefront sensor/aberrometry, 3.277,
 3.289, 3.290*f*, 13.9, 13.10*f*
- Hashimoto thyroiditis, 1.54, 1.55
 hypothyroidism caused by, 1.54, 1.55
 thyroid antibodies in, 1.52, 1.55
 thyroid eye disease and, 7.52, 7.53, 7.56
- Hasner, valve of, 7.253*f*, 7.254*f*
 nasolacrimal duct obstruction and, 7.255, 7.260
- Hassall-Henle bodies/warts (peripheral corneal guttae),
 2.41, 8.115, 8.128
- “Hatchet face,” in myotonic dystrophy, 5.329
- HATTS (hemagglutination treponemal test for syphilis),
 1.249
- HAV. *See* Hepatitis, type A
- Havrix (hepatitis A vaccine), 1.219
- Hay fever conjunctivitis, 8.288–289
- Hay-Wells syndrome, 6.194
- Haze formation
 after corneal crosslinking, 13.135
 after LASIK, 13.33
 diffuse lamellar keratitis and, 13.116
 pressure-induced stromal keratopathy and, 13.119
 surface ablation re-treatment/enhancements and,
 13.98
 late-onset, 13.109
 regression after surgery and, 13.109
 after small-incision lenticule extraction, 13.205
 after surface ablation, 13.33, 13.52, 13.92, 13.108–110,
 13.109*f*
 corticosteroids in reduction of, 13.33, 13.94,
 13.108–109
 mitomycin C in reduction of, 13.33, 13.92, 13.109
 undercorrection and, 13.102, 13.108–109
 wound healing and, 13.33
- Hb. *See* Hemoglobin
- HbA_{1c}. *See* Hemoglobin A_{1c}
- HBV. *See* Hepatitis, type B
- HCl. *See* Hydrochloric acid
- HCO₃. *See* Bicarbonate
- HCV. *See* Hepatitis, type C
- HDE. *See* Humanitarian device exemption
- HDL cholesterol. *See* High-density-lipoprotein (HDL)
 cholesterol
- Head
 abnormal position of. *See* Torticollis
 bony anatomy of, 5.5–11, 5.6*f*, 5.7–8*f*, 5.9*f*, 5.10*f*
 vascular anatomy of, 5.11–23
 arterial, 5.11–20, 5.13–14*f*, 5.15*f*, 5.16*f*, 5.17*f*, 5.18*f*,
 5.20*f*
 venous, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*
- Head lice. *See also* Lice
 ocular infection caused by, 8.255

- Head movements
 abnormal, spasmus nutans and, 5.239
 vestibular-ocular reflex and, 5.214, 5.215
- Head thrust maneuver, vestibular-ocular reflex gain evaluation and, 5.215–216
- Head thrusts, in ocular motor apraxia patients, 5.223
- Head-tilt, chin-lift maneuver, for opening airway, 1.298
- Head trauma. *See also* Trauma
 abusive, 6.381–384, 6.382–383*f*
 anisocoria caused by, 5.256*f*, 5.262–263
 chiasmal injury caused by, 5.152
 convergence insufficiency caused by, 5.227
 fourth nerve (trochlear) palsy caused by, 5.199, 5.200
 optic nerve damage caused by, 5.139*f*, 5.139–140
 pupil irregularity caused by, 5.255
 restrictive syndromes caused by, 5.186, 5.206
 seventh nerve (facial) palsy caused by, 5.280
 sixth nerve (abducens) palsy caused by, 5.201
- Headache, 5.287–295, 5.288*t*
 analgesic rebound, 5.293
 in arteriovenous malformations, 5.291, 5.292*f*, 5.343
 in carotid dissection, 5.342
 classification of, 5.287
 cluster, 5.289*t*, 5.294
 Horner syndrome and, 5.260*t*, 5.261, 5.294
 evaluation of, 5.287–288, 5.288*t*
 in giant cell (temporal) arteritis, 5.288, 5.313
 in hemicrania continua, 5.289*t*, 5.294
 history in, 5.287, 5.288*t*
 ice pick, 5.294
 idiopathic stabbing, 5.294
 intracranial hemorrhage causing, 1.126, 1.127, 5.288
 intracranial hypertension causing, 5.107, 5.288
 idiopathic, 5.110, 5.112, 5.113, 5.288
 migraine. *See* Migraine headache
 primary, 5.287
 in recurrent painful oculomotor neuropathy, 5.197
 refractive errors and, 3.25
 ruptured aneurysm causing, 5.340
 secondary, 5.287
 tension-type, 5.292–293
 “thunderclap,” 5.346
 transient visual loss and, 5.161, 5.162, 5.171–172, 5.177, 5.287. *See also* Migraine headache
 treatment of, 5.292–293
 trigeminal autonomic cephalgias, 5.289*t*, 5.293–294
 trochlear (trochleitis), 5.296
- Healing, ophthalmic wound. *See* Wound healing/repair
- Healon/Healon-GV/Healon5, 2.368, 11.96, 11.97
- Health counseling, in cancer prevention, 1.210*t*
- Hearing loss (deafness)
 cataract surgery in patient with, 11.170
 congenital rubella and, 9.203
 mitochondrial DNA mutations and, 2.157
 pigmentary retinopathy and, 12.284. *See also* Usher syndrome
 retinitis pigmentosa and, 12.284
 vestibular nystagmus and, 5.241, 5.241*t*, 5.242
 Vogt-Koyanagi-Harada syndrome and, 9.176
- Heart block, 1.96, 1.111
- Heart disease, 1.91–118
 assessment/screening/modification and, 1.82–83, 1.83*t*, 1.209
 in children, Kawasaki disease and, 1.167
 congestive failure, 1.105–112, 1.106*f*. *See also* Congestive heart failure
 in diabetes mellitus, 1.49, 1.83*t*
 endocarditis prophylaxis recommendations and, 1.243, 1.243*t*, 1.287
 hypertension/hypertension management and, 1.61, 1.62, 1.65, 1.65*t*, 1.66, 1.69*t*, 1.75, 1.83*t*
 ischemic, 1.91–105
 in Lyme disease, 1.251
 ophthalmic considerations and, 1.116–118
 prevention and, 1.91
 recent developments in, 1.91
 rhythm disturbances, 1.112–118
 risk factors for, 1.81–89, 1.91–92, 1.92
 in SLE, 1.157
 in systemic sclerosis, 1.162
- Heart failure. *See* Congestive heart failure
- Heart transplantation, for heart failure, 1.111
- HeartSCORE, 1.83
- Heat, anterior segment injuries caused by, 8.384–385, 8.385*f*
- Heavy-chain disease, crystalline corneal deposits and, 8.198
- Heavy chains, immunoglobulin, 9.42
 isotype classification and, 9.42
 overproduction of, crystalline corneal deposits and, 8.198
- Heavy eye syndrome (strabismus fixus), 5.208
- Hedgehog family, gene expression/ocular development and, 2.127
- Hedgehog pathway inhibitors, for squamous cell carcinoma, 7.182
- HEDS (Herpetic Eye Disease Study), 8.216, 8.222, 8.223*t*, 11.175
- Heerfordt syndrome, 9.167
- Heidenhain variant of Creutzfeldt-Jakob disease, 5.357
- Height maps, 13.22, 13.22*f*
- Heimann-Bielschowsky phenomenon, 5.238–239, 6.152
- Heimlich maneuver, 1.299
- Heinz bodies, 1.139
- Helical (spiral) computed tomography
 chest, in cancer screening, 1.210*t*, 1.212
 in orbital evaluation, 7.27
- Helicases, 2.154
- Helicobacter pylori* infection, cancer screening and, 1.213
- Helicoid (geographic/peripapillary) choroidopathy (serpiginous choroiditis), 9.141–143*t*, 9.151–154, 9.152*f*, 9.153*f*
 tuberculosis and (serpiginoid/serpiginous-like), 9.154, 9.252, 9.252*f*
- Helicoid peripapillary choroidopathy. *See* Serpiginous choroiditis/choroidopathy
- Heliotope rash, in dermatomyositis, 1.163, 1.164, 1.164*f*
- HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, 12.197*f*
- Helmholtz hypothesis (capsular theory) of accommodation, 11.22, 13.159–160, 13.160*f*
- Helmholtz type keratometer, 8.27
- Helminths, 8.252–253
 uveitis caused by, 9.228–235
- Helper T cells, 9.36. *See also* CD4⁺ T cells; T cells; *specific T helper cell*
 in B-lymphocyte activation, 9.37–38
 class II MHC molecules as antigen-presenting platform for, 9.35*f*, 9.35–36
 cytotoxic T lymphocytes and, 9.48, 9.49*f*

- in delayed hypersensitivity (type IV) reactions, 9.38, 9.39*f*, 9.45, 9.45*f*, 9.46, 9.46*t*
- sympathetic ophthalmia and, 9.48
- Toxocara granuloma* and, 9.47
- differentiation of, 9.37
- in HIV infection/AIDS, 1.263, 9.293, 9.294
- in immune processing, 9.36*f*, 9.37, 9.38
- Hemagglutination treponemal test for syphilis (HATTS), 1.249
- Hemangioblastomas, 6.353, 6.400, 6.400*t*
 - cerebellar, with retinal angiomatosis (von Hippel–Lindau disease), 4.284–285, 5.330, 5.331*f*, 5.334*t*
 - retinal, 4.144, 4.144*f*, 4.283–285, 4.284*f*. *See also* Retinal angiomatosis
 - in von Hippel–Lindau disease, 5.330, 5.331*f*, 5.334*t*, 12.165–166, 12.166*f*, 12.168
- Hemangiomas (hemangiomatosis), 4.281–286. *See also* Angiomas (angiomatosis)
 - capillary, 8.345*t*, 8.345–346. *See also* Infantile (capillary) hemangioma
 - cavernous, 1.126, 4.6, 8.345, 8.345*t*, 8.346, 12.168, 12.169*f*. *See also* Cavernous hemangioma
 - of choroid, 4.197, 4.198*f*, 4.281–283, 4.282*f*, 4.283*f*, 12.202*f*, 12.202–203
 - in Sturge–Weber syndrome, 4.197, 4.281, 5.332*f*, 5.334*t*
 - of conjunctiva, 4.50, 8.345*t*, 8.345–346
 - definition of, 6.219
 - of eyelid, 4.214, 4.215*f*, 6.199, 7.161–162, 8.345*t*, 8.345–346
 - eyelid involvement/ptosis and, 5.271
 - infantile (capillary). *See* Infantile (capillary) hemangioma
 - of orbit, 4.6, 4.233, 4.234*f*, 6.219–221
 - cavernous, 4.6, 4.233, 4.234*f*, 7.68–69, 7.69*f*
 - in children, 7.67*f*, 7.67–68
 - infantile (capillary), 4.233, 7.67*f*, 7.67–68
 - transient visual loss and, 5.164
 - plaque, 6.220, 6.220*f*
 - propranolol for, 6.220, 6.221*f*
 - racemose (Wyburn–Mason syndrome/Bonnet–Dechaume–Blanc syndrome), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*
 - of retina, 4.283–286, 4.284*f*, 4.285*f*
 - capillary (retinal capillary hemangioblastoma/angiomatosis retinae). *See* Capillary hemangioblastoma; Retinal angiomatosis
 - cavernous, 4.285*f*, 4.285–286
 - systemic disease associated with, 6.220
 - treatment of, 6.220–221
- Hemangiopericytoma, of orbit, 4.235, 4.235*f*, 7.69
- Hematic cyst, orbital, 7.112
- Hematogenous seeding, 8.206
- Hematologic disorders, 1.135–149. *See also specific type*
 - anemia, 1.136–140
 - blood composition and, 1.135
 - corneal changes in, 8.197–199, 8.198*f*, 8.199*f*
 - erythropoiesis and, 1.135–136
 - hemostasis disorders, 1.140*f*, 1.140–149
 - recent developments in, 1.135
 - in SLE, 1.157
 - Hematologic tests, in uveitis, 9.88*t*
 - Hematopoietic growth factors, in cancer therapy, 1.236
 - Hematopoietic stem cells, 1.135
 - Hematopoietic tissue, tumors arising in, 4.10*t*, 4.11*f*
 - Hematoxylin–eosin (H&E) stain, 4.31*t*
 - Hemeralopia (day blindness), 12.264
 - in cone/cone–rod dystrophies, 5.102
 - Hemi–Descemet membrane endothelial keratoplasty (hemi–DMEK), 8.449–450
 - Hemiachromatopsia, 5.179
 - Hemianopia, 5.105*t*
 - chiasmal lesions causing, 5.146, 5.147*f*, 5.151*f*, 5.152
 - homonymous
 - arteriovenous malformations causing, 5.343, 5.344*f*
 - cortical injury causing, 5.29
 - hallucinations within, 5.177
 - lateral geniculate body lesions causing, 5.154, 5.154*f*
 - in migraine headache, 5.171–172
 - in neuromyelitis optica, 5.320
 - occipital lobe lesions causing, 5.156–158, 5.157*f*, 5.158*f*, 5.159*f*
 - optic tract lesions causing, 5.147*f*, 5.153
 - optokinetic nystagmus (OKN) testing in evaluation of, 5.219
 - in palinopsia, 5.176
 - parietal lobe lesions causing, 5.156
 - retrochiasmal lesions causing, 5.153
 - temporal lobe lesions causing, 5.155, 5.155*f*
 - in vertebrobasilar disease, 5.336
 - Hemiatrophy, progressive facial (Parry–Romberg syndrome), 8.192*t*
 - Hemicrania
 - continua, 5.289*t*, 5.294
 - paroxysmal, 5.289*t*, 5.294
 - Hemidesmosomes, 2.39, 2.40*f*
 - Hemifacial microsomia, 6.210, 6.210*f*, 7.37
 - in Goldenhar–Gorlin syndrome, 8.191*t*, 8.195–196
 - Hemifacial paralysis, after facial nerve ablation for benign essential blepharospasm, 7.228
 - Hemifacial spasm (HFS), 5.282*t*, 5.283*f*, 5.283–284, 6.202, 7.228–229
 - Hemiretinal vein occlusion (HRVO), 12.130, 12.133*f*
 - Hemispatial neglect (hemineglect), 5.181
 - Hemispheric transient ischemic attack (HTIA), stroke and, 5.168–169
 - Hemizygote/hemizygous alleles, 2.137
 - X-linked recessive inheritance and, 2.179
 - Hemocult slides. *See* Stool guaiac slide test
 - Hemoglobin, 12.373, 12.374*f*
 - Hemoglobin (Hb), in thalassemia, 1.137
 - Hemoglobin A_{1c} (HbA_{1c})
 - in diabetes mellitus screening, 1.34
 - diabetic retinopathy and, 12.96, 12.98
 - in glucose control/surveillance, 1.38, 1.39, 1.39*f*, 1.40
 - in prediabetes, 1.37
 - Hemoglobin S, 1.139, 12.149
 - Hemoglobin SC (sickle cell), 1.139, 2.184
 - Hemoglobinopathies, sickle cell. *See* Sickle cell disease/sickle cell anemia (hemoglobin SS); Sickle cell retinopathy
 - Hemoglobinuria, paroxysmal nocturnal (PNH), 1.138–139
 - hypercoagulability and, 1.148
 - screening test for, 1.135, 1.138
 - Hemolysins, in innate immune response, 9.16

- Hemolytic anemia, 1.138–140
 autoimmune, 1.139–140
 in sickle cell disease, 1.139
- Hemolytic glaucoma, 4.103, 4.104*f*, 10.105, 10.106
- Hemophagocytic syndrome, Epstein-Barr virus-associated (EBV-HLH/EBV-associated hemophagocytic lymphohistiocytosis), 1.260
- Hemophilia A (classic hemophilia/factor VIII deficiency), 1.144–145
- Hemorrhages. *See also* Hyphema
 cataract surgery and, 11.157–160
 flat anterior chamber and, 11.134
 patient receiving anticoagulation therapy and, 11.74, 11.157, 11.171–172
 choroidal. *See* Hemorrhages, suprachoroidal/choroidal
 coagulation disorders and, 1.144–147
 conjunctival
 in acute hemorrhagic conjunctivitis, 8.240
 in dengue fever, 9.213
 dot-and-blot, ischemia causing, 4.153–154, 4.155*f*, 5.170, 5.171*f*
 flame, ischemia causing, 4.153, 4.155*f*
 glaucoma and, 4.103, 4.104*f*, 10.50, 10.51*f*, 10.85*f*, 10.85–86
 hemophilia and, 1.144–145
 hemostatic derangement and, 1.142
 histologic sequelae of, 4.22
 intracranial, 1.126–127
 arteriovenous malformations causing, 1.126, 1.127, 5.343
 headache caused by, 1.126, 1.127, 5.288
 ruptured aneurysm causing, 1.126, 1.127, 5.340
 intralesional, 6.221, 6.221*f*
 iron deficiency anemia and, 1.136
 nerve fiber layer, in glaucoma, 10.50, 10.51*f*
 neuroimaging in evaluation of, 5.72*t*
 ocular, ruptured aneurysm causing, 5.340, 5.340*f*
 orbital, 7.74, 7.112
 after blepharoplasty, vision loss and, 7.233–234
 in orbital floor/blowout fracture, 7.108, 7.109
 from orbital lymphatic malformation, 7.70, 7.70*f*, 7.71
 postoperative, 7.121, 7.125
 peripapillary, 6.373
 platelet disorders and, 1.143–144
 retinal. *See also specific type*
 in abusive head trauma, 6.382–383, 383*f*, 12.366, 12.366*f*
 in *Aspergillus* endophthalmitis, 9.269
 in branch retinal vein occlusion, 4.159
 in carotid occlusive disease, 12.138
 in central retinal vein occlusion, 4.156, 4.158*f*
 in dengue fever, 9.213
 in glaucoma, 10.50, 10.51*f*
 ischemia causing, 4.153–154, 4.155*f*
 in leukemia, 4.315, 4.315*f*, 6.414
 in ocular histoplasmosis syndrome, 9.216
 in ocular ischemic syndrome, 5.170, 5.171*f*
 in Rift Valley fever, 9.211
 in SLE, 9.133
 retrobulbar
 after blepharoplasty, vision loss and, 7.233
 cataract surgery and, 11.158, 11.171
 salmon-patch
 description of, 12.150, 12.150*f*
 syphilitic keratitis and, 8.107, 8.308, 8.309*f*
 subarachnoid, 1.126, 6.382
 arteriovenous malformations causing, 5.343
 with ocular hemorrhage, 5.340, 5.340*f*
 ruptured aneurysm causing, 5.340
 subconjunctival, 8.115*t*, 8.387–388, 8.388*f*
 submacular
 in neovascular age-related macular degeneration, 12.85, 12.385
 posttraumatic, 12.354*f*
 vitrectomy for, 12.385, 12.386*f*
 subretinal, 6.373
 choroidal neovascularization versus, 12.211
 in polypoidal choroidal vasculopathy, 12.76
 suprachoroidal/choroidal, 4.18, 4.19*f*, 12.394–395, 12.395*f*
 angle-closure glaucoma and, 10.141
 cataract surgery and, 11.159, 11.171
 delayed, 11.160
 expulsive, 11.159–160
 flat anterior chamber and, 11.134
 expulsive, 4.18, 4.19*f*
 cataract surgery and, 11.159–160
 after filtering surgery, 10.210–211
 vascular disorders and, 1.142–143
 vitreous, 2.254, 4.132–133
 in central retinal vein occlusion, 12.135
 echography for, 12.347
 hemolytic/ghost cell glaucoma and, 4.133, 10.105, 10.106
 peripheral neovascularization, 12.232
 photocoagulation as cause of, 12.379
 in polypoidal choroidal vasculopathy, 12.75
 posterior vitreous detachment and, 12.309
 in proliferative diabetic retinopathy, 12.103, 12.103*f*, 12.107–108
 in SLE, 9.134
 trauma-related, 12.357
 treatment of, 12.309
 in Valsalva retinopathy, 12.171
 vision loss caused by, 12.346
- Hemorrhagic chorioretinopathy, peripheral exudative (PEHCR), 4.270*f*, 4.271
- Hemorrhagic choroidal detachment, melanoma differentiated from, 4.170–171
- Hemorrhagic conjunctivitis, acute (AHC), 8.240, 8.240*t*
- Hemorrhagic disease of newborn, 1.145
- Hemorrhagic occlusive retinal vasculitis (HORV), 12.300–301
- Hemorrhagic stroke, 1.120. *See also* Stroke
- Hemorrhagic telangiectasia, hereditary (Rendu-Osler-Weber disease), 1.142, 1.143
- Hemosiderin
 corneal blood staining and, 4.86, 4.86*f*
 in glaucoma, 4.103, 4.104*f*
- Hemosiderosis/siderosis bulbi, 4.103, 4.120, 11.58*f*, 11.58–59
 glaucoma and, 4.103, 10.103
- Hemostasis, 1.140*f*, 1.140–141
 disorders of, 1.140–149

- cataract surgery in patient with, 11.171–172
- clinical manifestations of/hemorrhage, 1.142
- coagulation disorders and, 1.144–147
- hypercoagulable states and, 1.146, 1.147–149
- ophthalmic considerations and, 1.143, 1.147
- platelet disorders and, 1.143–144
- vascular disorders and, 1.142–143
- laboratory evaluation of, 1.141–142
- Henderson-Patterson bodies, 8.237
- Henle, lacrimal gland of, 2.215f, 2.217
- Henle fiber layer/Henle layer (HFL), 2.74, 2.74f, 4.140, 4.141f, 5.24. *See also* Nerve fiber layer
- definition of, 12.9
- histology of, 12.11, 12.12f
- myopia macular schisis of, 12.209
- Henoch-Schönlein purpura, 1.165t
- HEP. *See* Hepatoerythropoietic porphyria
- Heparan sulfate
 - in microbial adherence, 8.207
 - in mucopolysaccharidoses, 8.175t
- Heparan sulfate sulfatase, defective/deficiency of, 2.175t
- Heparin, in mast cells, 9.10
- Heparin therapy, 1.148
 - for antiphospholipid antibody syndrome, 1.161
 - for cerebral ischemia/stroke, 1.123
 - for ischemic heart disease, 1.100t
 - non-ST-segment elevation acute coronary syndrome, 1.103
 - in perioperative setting, 1.286
- Hepatic disease. *See* Hepatitis; Liver disease
- Hepatitis, 1.207, 1.219–220, 1.260–262
 - delta (type D), 1.261
 - HIV coinfection and, 1.270
 - transfusion-transmitted virus causing, 1.261–262
- type A (HAV), 1.219
 - immunization against, 1.207, 1.219
 - travel and, 1.224
- type B (HBV), 1.219
 - cancer and, 1.228
 - in HIV infection/AIDS, 1.270
 - immunization against, 1.207, 1.219
 - travel and, 1.224
 - in polyarteritis nodosa, 1.166, 9.135
- type C (HCV), 1.207, 1.220, 1.261–262
 - in HIV infection/AIDS, 1.270
- type E, 1.261
- type G, 1.261
- vaccine against, 1.207, 1.219
- Hepatitis A vaccine, 1.207, 1.219
 - travel and, 1.224
- Hepatitis B immunoglobulin, 1.219
- Hepatitis B vaccine, 1.207, 1.219
 - travel and, 1.224
- Hepatocellular carcinoma, 1.213, 1.219, 1.228
- Hepatoerythropoietic porphyria (HEP), 8.190
- Hepatolenticular degeneration (Wilson disease), 2.203, 8.189f, 8.189–190, 11.62
 - cataracts associated with, 8.189, 11.62
 - oculogyric crisis in, 5.231
 - penicillamine for, 2.203, 8.189
- Hepcidin levels, in iron deficiency anemia, 1.136
- Herbal supplements, perioperative discontinuation of, 1.286
- Herbert pits, 8.261, 8.261f
- Hereditary benign intraepithelial dyskeratosis, 8.332t
- Hereditary dystrophies. *See also specific type*
 - choroidal
 - Bietti crystalline dystrophy, 12.258, 12.269, 12.282t
 - choroidemia, 12.267–268, 12.268f
 - classification of, 12.255
 - gyrate atrophy, 12.268–269, 12.269f
 - endothelial, congenital (CHED/CHED2), 4.92–93, 4.94f, 8.135t, 8.136t, 8.160, 8.161f
 - photoreceptor (diffuse), 4.170, 4.172f
 - retinal
 - bilateral symmetric involvement of, 12.258
 - blindness concerns of patients with, 12.260
 - cystoid macular edema in, 12.260, 12.260f
 - diagnostic considerations for, 12.258–259
 - enhanced S-cone disease, 12.266, 12.267f
 - gene therapy for, 12.260, 12.266
 - genes and loci associated with, 12.256–257t
 - genetic considerations for, 12.259
 - inheritance patterns for, 12.259
 - Leber congenital amaurosis, 12.265–266
 - management of, 12.259–260, 12.260f
 - molecular genetic testing for, 12.259
 - photoreceptor, 4.170, 4.172f
 - rod-cone dystrophies, 12.261–264, 12.262–264f
 - stem cell therapy for, 12.260
 - stromal, congenital (CHSD/CSCD), 8.135t, 8.136t, 8.152, 8.153f
- Hereditary factors. *See* Genetic/hereditary factors
- Hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease), 1.142, 1.143
- Hereditary. *See also* Genetics
 - definition of, 2.137, 2.181
- Hereditary hyaloideoretinopathies with optically empty vitreous, 12.342–343, 12.343f
- Hereditary macular dystrophies
 - Best disease, 6.340–342, 6.342f
 - Stargardt disease, 6.339–340, 6.340–341f
- Hereditary optic neuropathy, 5.107t, 5.133–135, 5.134f, 5.136f
 - Leber (LHON), 2.158, 5.133–135, 5.134f
 - mitochondrial DNA mutations and, 2.157, 5.133
 - optic neuritis and, 5.115, 5.133
- Hereditary sensory and autonomic neuropathy, type III. *See* Familial dysautonomia
- Hereditary spherocytosis, 1.138
- Hereditary vitreoretinopathies, familial exudative, 6.347–348, 6.348f
- Hering's law of equal innervation/motor correspondence
 - eyelid retraction and, 5.274, 7.222, 7.223
 - horizontal gaze and, 5.36f
 - nystagmus and, 5.247
 - ptosis enhancement and, 5.270f, 5.310
- Hering's law of motor correspondence, 6.38, 6.115–116, 6.121
- Heritable/heritability, definition of, 2.137, 2.182, 2.182f
- Hermansky-Pudlak syndrome (HPS), 1.144, 6.407, 12.288
 - racial and ethnic concentration of, 2.197
- Her2Neu, in immunohistochemistry, 4.35

- Herpes simplex virus (HSV), 1.257–258, 8.212–225, 9.191–202
- acute retinal necrosis/progressive outer retinal necrosis/nonnecrotizing retinitis caused by, 4.145, 5.350, 9.193–198, 9.194*f*, 9.194*f*, 9.195*f*, 9.197*f*, 9.295–296, 9.296*f*. *See also* Herpes simplex virus (HSV), retinitis caused by
 - acyclovir for infection caused by, 1.258, 1.281, 2.357*t*, 2.358, 8.215*t*, 8.219, 8.222, 8.223*t*
 - anterior uveitis caused by, 9.191–192
 - antiviral agents for, 2.356–361, 2.357–358*t*, 8.205, 8.215, 8.215*t*, 8.219, 8.222, 8.223*t*, 8.224, 8.225
 - blepharitis/blepharoconjunctivitis/conjunctivitis caused by, 8.208*t*, 8.213, 8.214*f*, 8.216, 8.226*t*, 8.257*t*, 8.260*t*
 - cancer association and, 1.229
 - conjunctivitis caused by, 4.52, 6.239, 6.242, 8.208*t*, 8.213, 8.214*f*, 8.216, 8.226*t*, 8.257*t*, 8.260*t*
 - dermatoblepharitis caused by, 8.208*t*, 8.213, 8.214*f*, 8.216
 - famciclovir for infection caused by, 1.258, 1.281, 8.215*t*, 9.193, 9.196
 - in HIV infection/AIDS, 9.295–296, 9.296*f*
 - iridocyclitis caused by, 8.222–224
 - keratitis caused by, 4.76–78, 4.77*f*, 4.80, 6.269, 8.208*t*, 8.213, 8.214*f*, 8.216*f*, 8.216–222, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 9.191, 9.192
 - Acanthamoeba* keratitis differentiated from, 8.278
 - antiviral agents for, 2.356–361, 2.357–358*t*
 - disciform, 4.77*f*, 4.78, 8.220, 8.221*f*, 8.222
 - persistent bullous keratopathy and, 8.225
 - epithelial, 8.213, 8.214*f*, 8.216*f*, 8.216–219, 8.217*f*, 8.218*f*, 8.226*t*
 - in HIV infection/AIDS, 9.300
 - interstitial, 4.77*f*, 4.78, 4.80, 8.219–220, 8.220*f*, 8.222
 - necrotizing, 8.219, 8.220–221, 8.221*f*, 8.222, 8.223*t*
 - neurotrophic keratopathy/ulcers/persistent corneal epithelial defects and, 4.77*f*, 8.80, 8.81*t*, 8.217–218, 8.224, 8.225
 - nonnecrotizing, 8.219, 8.220*f*, 8.221*f*, 8.223*t*
 - after penetrating keratoplasty, 8.424, 8.425*f*
 - penetrating keratoplasty for, 8.225
 - recurrence of in graft, 8.225
 - recurrent corneal erosion and, 8.86
 - refractive surgery and, 13.173–174
 - stromal, 4.77*f*, 4.78, 8.219–222, 8.220*f*, 8.221*f*
 - treatment of, 8.219, 8.222
 - latency/recurrent infection and, 8.205, 8.207, 8.212, 8.213, 8.215–224, 8.216*f*, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 8.223*t*, 8.226*t*
 - in multifocal choroiditis and panuveitis syndrome, 9.156
 - neonatal, 6.412
 - ocular infection/inflammation caused by, 1.258, 8.208*t*, 8.212–225
 - adenovirus infection differentiated from, 8.213–214
 - cataract surgery and, 11.175
 - complications of, 8.224–225
 - iridocorneal endothelial syndrome and, 8.127
 - neuro-ophthalmic signs of, 5.350, 5.350*f*
 - pathogenesis of, 8.213
 - primary infection, 8.213–215, 8.214*f*
 - recurrent infection, 8.215–224, 8.216*f*, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 8.223*t*, 8.226*t*. *See also* Herpes simplex virus (HSV), latency/recurrent infection and
 - excimer laser exposure and, 13.173–174
 - refractive surgery and, 13.37, 13.173–174
 - treatment of, 8.205, 8.215, 8.215*t*, 8.219, 8.222, 8.223*t*
 - surgical, 8.225
 - varicella-zoster virus infection differentiated from, 8.225, 8.226*t*
 - ocular manifestations of, 6.412
 - ophthalmia neonatorum caused by, 6.239
 - perinatal infection caused by, 1.258, 8.213
 - retinitis caused by, 4.145, 5.350, 9.193–198, 9.194*t*, 9.194*f*, 9.195*f*, 9.197*f*, 9.295–296, 9.296*f*
 - necrotizing, 4.145, 9.193–198, 9.194*f*, 9.194*t*, 9.195*f*, 9.295–296, 9.296*f*, 12.236–237*f*, 12.236–237, 12.238*t*
 - nonnecrotizing (nonnecrotizing posterior uveitis), 9.198
 - skin infection after laser resurfacing caused by, 7.238
 - transmission of, 8.213
 - type 1, 1.229, 1.257, 1.258, 8.213
 - type 2, 1.229, 1.257, 1.258, 8.213
 - valacyclovir for infection caused by, 1.258, 1.281, 8.215*t*, 8.219, 8.222, 9.193, 9.196
- Herpes zoster, 1.258–259, 6.243, 6.243*f*, 8.225, 8.226–227. *See also* Herpes zoster ophthalmicus; Varicella-zoster virus
- acute retinal necrosis/progressive outer retinal necrosis/nonnecrotizing retinitis caused by, 5.350. *See also* Herpes zoster, retinitis caused by
 - acyclovir for, 1.258, 1.281, 2.357*t*, 2.359, 8.229
 - conjunctivitis and, 4.52, 8.225–230, 8.226*t*
 - cranial nerve VII (facial) involvement and, 5.280
 - famciclovir for, 1.258, 1.281, 2.357*t*, 2.359, 8.229, 9.193, 9.196
 - in HIV infection/AIDS, 9.300
 - immunization against, 1.218*t*
 - ophthalmic manifestations in, 5.298, 5.298*f*, 5.350, 8.226*t*, 8.226–230, 8.227*f*, 8.228*f*
 - retinitis caused by
 - necrotizing, 4.145, 5.350, 9.193–198, 9.194*t*, 9.194*f*, 9.195*f*, 9.197*f*, 9.295–296, 9.296*f*
 - nonnecrotizing (nonnecrotizing posterior uveitis), 9.198
 - scleritis/episcleritis and, 8.227, 8.282, 9.259
 - vaccine in prevention of, 5.298, 8.229
 - valacyclovir for, 1.258, 1.281, 2.357*t*, 2.359, 8.229
 - without vesicles (zoster sine herpete), 5.298, 9.191
- Herpes zoster ophthalmicus (HZO), 5.298, 5.298*f*, 5.350, 8.226*t*, 8.226–230, 8.227*f*, 8.228*f*
- acyclovir for, 1.281, 8.229
 - lipid keratopathy and, 8.125, 8.228, 8.228*f*
 - neurotrophic keratopathy/persistent corneal epithelial defects and, 8.80, 8.81*t*, 8.227
 - refractive surgery and, 13.174
- Herpesviruses (Herpesviridae)/herpesvirus infection, 1.257–260, 8.212–233. *See also specific virus*
- cancer association and, 1.228–229
 - neuro-ophthalmic signs of, 5.350, 5.350*f*

- refractive surgery and, 13.37, 13.173–174
- uveitis, 9.191–202
- Herpetetic Eye Disease Study (HEDS), 8.216, 8.222, 8.223*f*, 11.175
- Herpex. *See* Idoxuridine
- Hertel exophthalmometer, 7.24, 7.24*f*
- Hess screen, 6.120
- Heterochromatin, 2.133
- Heterochromia (heterochromia iridis)
 - in Fuchs heterochromic uveitis/iridocyclitis, 9.126*f*, 9.127, 10.101
 - in Horner syndrome, 5.258
 - pediatric iris, 6.274, 6.274*f*, 6.274*t*
 - in siderosis bulbi, 11.58*f*
- Heterocyclic antidepressants, 1.197
- Heterogeneity, 2.137
 - allelic, 2.132
 - clinical, 2.133
 - genetic, 2.137, 2.183, 2.183*f*, 2.185
 - locus, 2.138
- Heteronymous diplopia, 6.75
- Heterophoria method
 - for accommodative convergence/accommodation ratio, 3.177, 6.71
 - for accommodative convergence measurement, 5.226, 5.227
- Heterophorias/phorias
 - bifocal segment decentration and, 3.191
 - definition of, 6.15
 - heterotropia versus, 6.64
 - horizontal, 3.196–197
 - refractive surgery and, 13.41
 - vertical, 3.197
- Heteroplasmy, 2.137, 2.147
 - in Leber hereditary optic neuropathy, 5.133
 - mitochondrial disease and, 2.157
- Heterotopy, 6.28
- Heterotropias/tropias
 - alternating, 6.64
 - definition of, 6.15
 - heterophoria versus, 6.64
 - in monofixation syndrome, 6.51
 - refractive surgery and, 13.41
- Heterozygosity, loss of, 2.157
- Heterozygote/heterozygous alleles, 2.137, 2.184
 - carrier, 2.176. *See also* Carrier (genetic)
 - compound, 2.133
 - double, 2.185
 - X-linked recessive inheritance and, 2.179
- Hex K. *See* Hexagonal keratotomy
- Hexagonal cells, specular microscopy in evaluation of
 - percentage of, 8.23
- Hexagonal keratotomy (Hex K), 13.8*t*
- Hexokinase, in lens glucose/carbohydrate metabolism, 2.246, 11.17, 11.18*f*, 11.19
- Hexosaminidase, defective/deficiency of, in
 - gangliosidoses, 2.175*t*, 8.176
- Hexosaminidase activator deficiency, 6.389*t*
- Hexose monophosphate (HMP) shunt, in glucose/carbohydrate metabolism
 - in cornea, 2.224
 - in lens, 2.246, 11.17, 11.18*f*, 11.19
 - in rod outer segments, 2.261
- Hexosidase, defective, 2.175*t*
- HF. *See* Hydrofluoric acid
- HFAs. *See* Humphrey perimeters/Humphrey Field Analyzers
- HFL. *See* Henle fiber layer/Henle layer
- HFS. *See* Hemifacial spasm
- HGD gene, in alkaptonuria, 8.184
- HGP. *See* Human Genome Project
- Hiatus semilunaris, 2.10*f*
- Hib (*Haemophilus influenzae* type b), 1.245, 8.248
- Hib (*Haemophilus influenzae* type b) vaccine, 1.223, 1.245
- Hidrocystoma
 - apocrine, 4.208, 4.208*f*, 7.171, 7.171*f*
 - eccrine, 4.208, 7.170
- High accommodative convergence/accommodation (AC/A) ratio
 - in accommodative esotropia, 6.90–92
 - bifocal glasses for, 6.102
 - in intermittent exotropia, 6.100
- High-density-lipoprotein (HDL) cholesterol, 1.82. *See also* Cholesterol
 - drugs affecting metabolism of, 1.85*t*
 - ischemic heart disease risk/risk assessment and, 1.82
 - target level for, 1.82
- High-grade lymphoma, of orbit, 7.86
- High hyperopia, cataract surgery in patient with, 11.185
- High-index glass, 3.195
- High-index lens, 3.196
- High (pathologic) myopia
 - cataract surgery in patient with, 11.184–185
 - chorioretinal atrophy in, 12.214*f*
 - choroid in, 12.212–216, 12.214–215*f*
 - choroidal neovascularization caused by, 12.89, 12.90*f*, 12.211*f*, 12.211–212
 - criteria for, 3.143
 - definition of, 12.207
 - esotropia associated with, 6.97, 6.143–144
 - exotropia associated with, 6.143–144
 - factors associated with, 12.207
 - glaucoma in, 10.82, 10.122, 12.218, 12.218*f*
 - global prevalence of, 12.207
 - macular holes in, 12.209
 - ocular expansion related to, 12.216
 - optic nerve in, 12.217–218, 12.218*f*
 - prevalence of, 12.207
 - prevention of, 12.207–208
 - retina in, 12.207–216, 12.209–215*f*
 - sclera in, 12.216–217, 12.217*f*
 - surgical correction of
 - bioptics for, 13.157
 - phakic IOLs for, 13.140
 - refractive lens exchange for, 13.148, 13.150
 - retinal detachment and, 13.44, 13.183–184, 13.184, 13.197
 - swept-source optical coherence tomography of, 12.209*f*
 - traction effects on retinal vessels in, 12.209
- High-output failure, 1.108
- High-plus-power lenses, 12.375
- High-power intraocular lenses, 3.264

- Higher-order aberrations, 13.11–13, 13.12*f*, 13.13*f*.
 See also Aberrations; Irregular astigmatism;
 Wavefront aberrations; *specific type*
 keratorefractive surgery and, 3.276–277
 after LASIK, 13.11, 13.12, 13.102–103, 13.103*f*
 point spread function and, 3.305
 pupil size and, 3.106
 after radial keratotomy, 13.11, 13.12
 after surface ablation, 13.11, 13.12, 13.13, 13.102
 topography-guided laser ablation and, 13.32, 13.77
 wavefront-guided/wavefront-optimized ablation and,
 13.13, 13.31–32, 13.76–77
 Zernike polynomials and, 3.139
- Highly active antiretroviral therapy (HAART). *See*
 Antiretroviral therapy
- Hip fracture, osteoporosis-related, 1.184
- Hippus, 5.254
- Hirschberg test, 6.67, 6.68*f*
- Hirudin, for non-ST-segment elevation acute coronary
 syndrome, 1.103
- His bundle, 1.112
- Histamine, 2.337, 9.10, 9.24
 hay fever conjunctivitis and, 8.288
 in tear film, 2.216
- Histiocytes, 4.7
 epithelioid, 4.7, 4.8*f*
- Histiocytic lymphoma, 1.237. *See also* Primary
 central nervous system/intraocular/vitreoretinal/
 retinal lymphoma; Primary vitreoretinal
 lymphoma
- Histiocytoma, fibrous (fibroxanthoma), 8.347
 malignant, 4.112
 orbital, 4.235, 7.84
 scleral, 4.112, 4.113*f*
- Histiocytosis (Langerhans cell histiocytosis/LCH/
 histiocytosis X)
 diffuse soft tissue histiocytosis and, 7.90
 orbital involvement and, 7.90
- “Histo spots,” 9.215, 9.215*f*, 9.216
- Histocompatibility antigens. *See* Human leukocyte
 antigens
- Histocryl. *See* Cyanoacrylate glue/adhesive
- Histogram, 1.27, 1.28*f*
 for flow cytometry results, 4.36, 4.37*f*
- Histones, 2.148*f*, 2.151
- Histoplasma capsulatum* (histoplasmosis), 12.86–87
 ocular/presumed ocular (OHS/POHS), 9.214–219,
 9.215*f*, 9.216*f*, 9.217*f*, 9.218*f*, 12.86–87
 choroidal neovascularization in, 9.215, 9.216,
 9.217, 9.218*f*
 management of, 9.217–218
 management of, 9.217–218
- Histoplasmin skin test, 9.213
- Historical methods, for IOL power calculation after
 refractive surgery, 11.86–87, 13.194
- History
 in cataract, 11.69–71, 11.70*t*
 evaluation for surgery and, 11.74–76
 before corneal transplantation, 8.418
 in diplopia, 5.183
 family, 2.171. *See also under Genetic*
 cancer and, 1.229
 genetic counseling and, 2.204
 in glaucoma, 10.10, 10.82, 10.121
 angle-closure glaucoma and, 10.121
 open-angle glaucoma and, 10.82
 in ocular hypertension, 10.90
 pedigree analysis and, 2.171, 2.172*f*, 2.172–173
 in uveitis, 9.303
 glaucoma evaluation and, 10.29–32
 in infants/children/adolescents, 10.157
 in headache, 5.287, 5.288*t*
 in low vision assessment, 5.78–79
 in ocular surface neoplasia, 8.328
 orbital evaluation and, 7.21–22, 7.22*f*, 7.23*t*
 in penetrating and perforating ocular trauma, 8.401
 in periocular malpositions/involucional changes, 7.197
 preoperative assessment and, 1.283
 in ptosis evaluation, 7.209
 in refractive surgery evaluation, 13.35–39, 13.36*t*
 in trauma, 8.401
 in uveitis, 9.84*t*, 9.84–85, 9.303–306
 family, 9.303
 personal medical, 9.84*t*, 9.303–306
 social, 9.84*t*, 9.303
- HIV (human immunodeficiency virus), 1.262, 1.263,
 8.240*t*, 8.241, 9.293. *See also* HIV infection/AIDS
 conjunctivitis caused by, 8.240*t*, 8.241, 8.260*t*,
 9.300–301
 cytomegalovirus retinitis and, 12.235
 drug resistance and, 1.264
 intraocular lymphoma risks, 12.234
 isolation of from retina, 9.293
 superinfection and, 1.266
 testing for, 1.239, 1.264–265
 in syphilis, 9.241
 toxoplasmic retinochoroiditis and, 12.243
 transmission of, 1.265
 contact lens care/trial lens disinfection and, 1.271
 excimer laser ablation and, 13.189
 vaccine development and, 1.267
- HIV-1, 1.263. *See also* HIV infection/AIDS
 superinfection and, 1.266
- HIV-2, 1.263. *See also* HIV infection/AIDS
- HIV-associated neurocognitive disorder (HIV
 encephalopathy/AIDS dementia complex), 1.263,
 5.348
- HIV-associated neuroretinal disorder (HIV-RND), 5.348
- HIV infection/AIDS, 1.262–272, 5.348–350, 8.240*t*,
 8.241, 9.293–301
 acute retinal necrosis in, 9.193
 atypical mycobacterial infections and, 1.254, 1.269
 choroiditis in
 Cryptococcus neoformans, 9.298–299
 multifocal
 Cryptococcus neoformans, 9.298–299
 systemic dissemination and, 9.299
 Pneumocystis jirovecii, 9.298, 9.298*f*
 clinical syndromes and, 1.264
 CMV infection in, 1.259, 1.268, 5.349, 5.349*f*
 retinitis, 5.349, 9.198, 9.200–201, 9.294–295
 conjunctivitis in, 8.240*t*, 8.241, 8.260*t*, 9.300–301
 cryptococcosis in, 5.356, 9.270, 9.298–299
 diagnosis of, 1.264–265
 encephalopathy in (AIDS dementia complex/HIV-
 associated neurocognitive disorder), 1.264, 5.348

- endophthalmitis in, 9.263
- etiology of, 1.263–264
- herpes simplex keratitis in, 8.222, 9.300
- herpes zoster in, 9.300
- herpesvirus infection in, 8.222, 9.295–296, 9.296f, 9.300
- immunizations in patient with, 1.219, 1.220, 1.266
- incidence of, 1.262–263, 9.301
- Kaposi sarcoma in, 1.262, 1.270, 5.349, 7.186, 7.186f, 8.347, 9.299f, 9.299–300
- lymphoma in, 1.270, 5.349, 9.301
- malignancies associated with, 1.270–271
- management of, 1.265–267
 - CMV retinitis and, 9.200–201
 - drug resistance and, 1.264
 - immune reconstitution syndromes/immune recovery uveitis and, 1.271, 9.201, 9.294–295
 - recent developments in, 1.239
- microsporidiosis in, 1.269, 8.280, 8.280f, 9.300, 9.300f
- molluscum contagiosum in, 7.169, 8.237, 8.238f, 9.300
- natural immunity to, 1.266
- neuro-ophthalmic signs of, 5.348–350, 5.349f
- neuroretinal disorder in, 5.348
- occupational exposure to, precautions in health care setting and, 9.301
- ocular infection/manifestations and, 1.271–272, 5.348, 8.240t, 8.241, 8.260t, 9.293–301
 - external eye manifestations, 9.299f, 9.299–301, 9.300f
 - ophthalmic manifestations, 9.293–298, 9.294f, 9.296f, 9.297f, 9.298f
- ocular surface squamous neoplasia in, 4.61
- opportunistic infections associated with, 1.267–272, 1.268t, 9.293, 9.301
- pathogenesis of, 1.263–264
- Pneumocystis jirovecii* infections and, 1.262, 1.267–268, 9.298, 9.298f
- primary, 1.264
- prognosis for, 1.265–267
- progressive multifocal leukoencephalopathy in, 5.351
- progressive outer retinal necrosis in, 9.197–198, 9.295–296, 9.296f
- refractive surgery in patient with, 13.188–190
- resource limitations and, 9.301
- retinitis in, 4.145, 9.193, 9.198, 9.200–201, 9.206f, 9.293, 9.294–295, 9.295–296
- retinopathy associated with, 9.293, 9.294f
- screening for, 1.239, 1.264–265
- seventh nerve (facial) palsy in, 5.280
- spore-forming intestinal protozoal infection and, 1.268–269
- superinfection and, 1.266
- syphilis/syphilitic chorioretinitis in, 1.249–250, 9.240, 9.297–298
- Toxoplasma* retinochoroiditis/toxoplasmosis in, 5.352, 9.223, 9.225, 9.226, 9.227f, 9.296–297, 9.297f
- transmission of, 1.265
 - contact lens care/trial lens disinfection and, 1.271
 - ophthalmic considerations and, 1.271–272
 - perinatal, 1.265
 - tuberculosis and, 1.255, 1.269, 9.250, 9.253
 - uveitis in, 9.293
 - vaccine development and, 1.267
- HIV RNA levels, 1.264, 1.266
- HIV-RND. *See* HIV-associated neuroretinal disorder
- Hives, fluorescein angiography as cause of, 12.36
- HLA-B5, 12.230
- HLAs. *See* Human leukocyte antigens
- HMB-45, in immunohistochemistry, 4.34
- melanoma diagnosis and, 4.68
- HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme-A) reductase inhibitors. *See also* Statins
 - cataracts and, 1.89, 11.53
 - hypercholesterolemia/heart disease prevention and, 1.85t, 1.86t, 1.86–88
- HMP shunt. *See* Hexose monophosphate (HMP) shunt
- HMS. *See* Medrysone
- Hodgkin disease
 - in HIV infection/AIDS, 1.270
 - orbital, 7.86
 - transfusion-transmitted virus (TTV) associated with, 1.262
- Hoffer Q formula, 3.249f, 3.249–250
 - for IOL power determination/selection, 11.85, 11.86
- Holes
 - macular, 4.131–132, 4.132f
 - contusion injury as cause of, 12.315
 - fellow-eye risk for development of, 12.339
 - formation of, 12.339, 12.340f
 - idiopathic
 - description of, 12.337–339, 12.338f
 - vitrectomy for, 12.384–385, 12.385f
 - International Vitreomacular Traction Study Classification System for, 12.336t
 - lamellar, 12.28f
 - management of, 12.339–340
 - optical coherence tomography of, 12.27f
 - in pathologic myopia, 12.209
 - posttraumatic, 12.355–357, 12.356f
 - rhegmatogenous retinal detachment caused by, 12.330, 12.330f
 - spontaneous resolution of, 12.340
 - stage 0, 12.339
 - stage 1, 12.339–340
 - stage 2, 12.339
 - stage 3, 12.339
 - stage 4, 12.339
 - surgical management of, 12.339–340
 - vitreous in formation of, 2.254–255
 - optic (optic pits, optic nerve/disc pits, optic pit maculopathy), 5.145
 - acquired, 10.49–50
 - outer-schisis-layer, 12.327, 12.327f
 - retinal
 - atrophic
 - definition of, 12.315
 - lattice degeneration and, 4.150, 12.310, 12.311f, 12.316f
 - retinal detachment secondary to, 12.310
 - description of, 12.378
 - lattice degeneration and, 4.150
 - operculated, 12.315–316
- Holladay formulas
 - description of, 3.249f, 3.250
 - for IOL power determination/selection, 11.85, 11.87

- Hollenhorst plaques (cholesterol emboli)
 in branch retinal artery occlusion, 4.156, 12.141, 12.142f
 in central retinal artery occlusion, 12.144
 transient visual loss and, 5.165, 5.165f, 5.166t
- Holmes-Adie syndrome, 5.264. *See also* Adie tonic pupil
- Holmium:yttrium-aluminum-garnet (Ho:YAG) laser
 photothermal effects of, 13.29
 for thermokeratoplasty, 13.127–128
- Holocrine glands, of eyelid, 8.4
- Homatropaire. *See* Homatropine
- Homatropine, 2.313, 2.314t
- Homeobox, 2.137. *See also* Homeobox genes/homeotic selector genes
- Homeobox gene program, 2.126
- Homeobox genes/homeotic selector genes, 2.126, 2.137, 2.152
 in Axenfeld-Rieger syndrome, 8.97t, 8.102
 in ocular development, 2.126
 in Peters anomaly, 8.97t, 8.103
- Homeodomain, 2.126
- Homeotic genes/homeotic selector genes. *See* Homeobox genes/homeotic selector genes
- Homer Wright rosettes, 6.353
 in medulloepithelioma, 4.179
 in retinoblastoma, 4.175, 4.175f
- Homing, 9.40
 mucosa-associated lymphoid tissue and, 9.55
- Homocysteine, hypercoagulability and, 1.147
- Homocystinuria, 2.175t, 6.308–309, 6.389t, 11.41, 12.282t
 ectopia lentis in, 11.41
 lens disorders in, 11.41
 vitamin B₆ replacement therapy for, 2.203, 11.41
- Homogentisate 1,2-dioxygenase, in alkaptonuria, 8.184
- Homogentisic acid/homogentisic acid oxidase, alkaptonuria and, 2.175t, 8.184
- Homologous chromosomes, 2.137, 2.184
- Homonymous, definition of, 5.105t
- Homonymous diplopia, 6.75
- Homonymous hemianopia, 6.83
 arteriovenous malformations causing, 5.343, 5.344f
 cortical injury causing, 5.29
 hallucinations within, 5.177
 lateral geniculate body lesions causing, 5.154, 5.154f
 in migraine headache, 5.171–172
 in neuromyelitis optica, 5.320
 occipital lobe lesions causing, 5.156–158, 5.157f, 5.158f, 5.159f
 optic tract lesions causing, 5.147f, 5.153
 optokinetic nystagmus (OKN) testing in evaluation of, 5.219
 in palinopsia, 5.176
 parietal lobe lesions causing, 5.156
 retrochiasmal lesions causing, 5.153
 temporal lobe lesions causing, 5.155, 5.155f
 in vertebrobasilar disease, 5.336
- Homoplasmy, 2.137
 replicative segregation and, 2.143, 2.157
- Homoplastic corneal inlays, 13.60
- Homoplastic lenticule, in epikeratoplasty, 13.62
- Homozygote/homozygous alleles, 2.137, 2.184
- Honeycomb-shaped corneal dystrophy. *See* Thiel-Behnke corneal dystrophy
- Hookworm, dog (*Ancylostoma caninum*), diffuse unilateral subacute neuroretinitis caused by, 9.232
- Hordeolum (hordeola), 7.163–164, 8.76f, 8.76–77
 in children, 6.198–199
 external (stye), 4.203–204, 7.163–164, 8.76, 8.76f
 internal, 7.162, 7.163, 8.76, 8.77. *See also* Chalazion
- HORIZON study, 12.81–82
- Horizontal cells, 2.71f, 2.257, 2.258f, 2.266, 2.266f, 2.266–267, 5.24
 in cone phototransduction, 2.262
- Horizontal deviations. *See also* A-pattern strabismus; V-pattern strabismus
 in craniosynostosis, 6.208
 dissociated, 6.17, 6.105, 6.105f, 6.129
 extraocular muscle surgery for, 6.161
 Maddox rod test for, 6.69
- Horizontal eyelid shortening/tightening
 for cicatricial ectropion, 7.201
 for exposure keratopathy, 8.80
 for involutional ectropion, 7.199, 7.200f
 for involutional entropion, 7.204
- Horizontal gaze, 5.37f, 5.37–38
- Horizontal gaze palsy, 5.228, 5.229f
 in one-and-a-half syndrome, 5.191
 in sixth nerve palsy, 5.189, 5.200, 5.200f
- Horizontal heterophorias, 3.196–197
- Horizontal phaco chop technique, 11.114
- Horizontal rectus muscles. *See also* Lateral rectus (LR) muscle; Medial rectus (MR) muscle
 anatomy of, 6.20, 6.35f
 inferior zone of, 6.24
 innervation of, 6.34
 in pattern strabismus, 6.109–110
 primary position of, 6.35, 6.35f
 recession/resection of
 description of, 6.139
 for esodeviations, 6.160
 monocular, 6.161
 for nystagmus correction, 6.157
 superior zone of, 6.24
 transposition of, 6.110, 6.112
- Horizontal rotations, 6.31
- Horizontal strabismus. *See* Horizontal deviations
- Hormone replacement therapy (HRT)
 breast cancer and, 1.211
 refractive surgery in patient taking, 13.37
 tear production affected by, 8.62t
- Hormones
 in cancer chemotherapy, 1.234t
 metastatic eye disease and, 4.310, 7.100
 cytokines as, 9.26
 in glucose metabolism, 1.33–34
 ocular effects of, 1.308t
 pituitary adenoma producing, 1.57–58
- Horner muscle, 2.21, 7.148
- Horner syndrome, 5.256f, 5.257–262, 5.259f, 5.260t, 5.261f, 5.262f, 6.274–275, 6.415f, 7.18
 carotid artery dissection causing, 5.162, 5.260t, 5.261, 5.262f, 5.297
 cluster headache and, 5.260t, 5.261, 5.294
 congenital, 5.261–262, 7.215
 dilator muscle and, 2.56
 in neuroblastoma, 7.98
 pharmacologic testing for, 5.258–259, 5.259f, 7.212

- ptosis and, 5.257, 5.259*f*, 5.272, 5.273*t*, 7.212
vertebrobasilar insufficiency and, 5.337
- Horner-Trantas dots, 6.248, 6.249*f*, 8.289–290, 8.290*f*
- Horopter
definition of, 6.41
empirical, 6.41, 6.42*f*
- Horror fusionis, 6.48
- Horseshoe-shaped retinal tears, 12.316, 12.323*f*
- HORV. *See* Hemorrhagic occlusive retinal vasculitis
- Host defenses, 8.11–14, 8.12–13*f*, 8.13*f*, 8.206
impaired. *See* Immunocompromised host
- “HOTV” character set, 3.23
- HOTV optotypes, 3.133*f*
- HOTV test, 6.6, 6.6*t*, 6.7*f*
- Houseplants, ocular injuries caused by, 8.387
- Hox (homeobox) gene program, in ocular development, 2.126
- HOX genes, 2.126, 2.137
- Ho:YAG laser (holmium:yttrium-aluminum-garnet laser)
photothermal effects of, 13.29
for thermokeratoplasty, 13.127–128
- HPMC. *See* Hydroxypropyl methylcellulose
- HPMPC. *See* Cidofovir
- HPS. *See* Hermansky-Pudlak syndrome
- HPV. *See* Human papillomavirus
- HRR plates. *See* Hardy-Rand-Rittler (HRR) plates
- HRT. *See* Hormone replacement therapy
- HRVO. *See* Hemiretinal vein occlusion
- HSV. *See* Herpes simplex virus
- HTIA. *See* Hemispheric transient ischemic attack
- HTLV-1 (human T-lymphotropic virus/retrovirus type 1), 1.263, 9.212–213
- HTLV-1 (human T-lymphotropic virus/retrovirus type 1)
uveitis (HU), 9.212–213
- HTLV-1 (human T-lymphotropic virus/retrovirus type 1)—related keratopathy (HTLV-1-related chronic interstitial keratitis), 9.212
- HTLV-2 (human T-lymphotropic virus/retrovirus type 2), 1.263
- HTLV-3 (human T-lymphotropic virus/retrovirus virus type 3). *See* Human immunodeficiency virus
- HTRA1 gene, in age-related macular degeneration, 4.160
- HU. *See* HTLV-1 (human T-lymphotropic virus/retrovirus type 1)
- Hudson-Stähli line, 8.117, 8.118*t*
- Hughes classification, for chemical injury of eye, 8.376, 8.376*t*
- Hughes/modified Hughes procedure, in eyelid repair, 7.194*f*, 7.194–195, 7.195
- Human bites, eyelid injuries caused by, 7.190
- Human gene mapping, 2.160, 2.184
- Human Genome Project (HGP), 2.137, 2.160
- Human granulocytic anaplasmosis/ehrlichiosis, Lyme disease coinfection and, 1.250, 9.248
- Human herpesvirus 4. *See* Epstein-Barr virus
- Human herpesvirus 8, Kaposi sarcoma caused by, 1.257, 8.239, 8.347, 9.299
- Human herpesviruses, 1.257–260, 8.212–233. *See also* Herpesviruses; *specific type*
- Human hyperimmunoglobulin, 1.225
- Human immunodeficiency virus (HIV), 1.262, 1.263, 8.240*t*, 8.241, 9.293. *See also* HIV infection/AIDS in children, 6.348
- conjunctivitis caused by, 8.240*t*, 8.241, 8.260*t*, 9.300–301
- drug resistance and, 1.264
- isolation of from retina, 9.293
- superinfection and, 1.266
- testing for, 1.239, 1.264–265
in syphilis, 9.241
- transmission of, 1.265
contact lens care/trial lens disinfection and, 1.171
excimer laser ablation and, 13.189
vaccine development and, 1.267
- Human insulin, 1.41, 1.41*t*
- Human leukocyte antigens (HLAs), 9.34, 9.64–67, 9.67*t*.
See also Major histocompatibility complex
- in acute posterior multifocal placoid pigment epitheliopathy, 9.148
- allelic variations and, 9.34, 9.65
- in ankylosing spondylitis, 1.153, 9.114
- in anterior uveitis, 9.65–66, 9.67*t*, 9.113, 9.114–117
- in Behçet disease, 1.169, 9.67*t*, 9.186
- in birdshot uveitis, 9.67, 9.67*t*, 9.141*t*, 9.144
- detection and classification of, 9.66
- in diabetes mellitus, 1.36
- disease associations of, 9.66–67, 9.67*t*, 9.114–117
- in inflammatory bowel disease, 1.155, 9.116
- in intermediate uveitis/pars planitis, 9.67*t*
- in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.67*t*, 9.122
- in Lyme disease, 1.251, 9.245
- in Mooren ulcer, 8.314
- in mucous membrane pemphigoid, 8.299
- in multiple sclerosis, 5.315, 9.67*t*, 9.132
- normal function of, 9.64
- in ocular histoplasmosis syndrome, 9.216
- in psoriatic arthritis, 1.155, 9.117
- in reactive arthritis syndrome/Reiter syndrome, 1.154, 8.305–306, 9.65, 9.67*t*, 9.115
- in retinal vasculitis, 9.67*t*
- in rheumatoid arthritis, 1.152
- in sarcoidosis, 9.67*t*
- in serpiginous choroiditis, 9.141*t*
- in SLE, 1.156
- in spondyloarthropathies/spondyloarthritis, 1.153, 9.114–117
- in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
- in sympathetic ophthalmia, 9.67*t*, 9.174
- in tubulointerstitial nephritis and uveitis, 9.67*t*, 9.117
- in Vogt-Koyanagi-Harada syndrome, 9.67*t*, 9.176
- “Human optical bench,” 3.14*f*
- Human papillomavirus (HPV), 1.262, 8.238
- cancer association of, 1.207, 1.209, 1.224, 1.228, 1.262
- conjunctival intraepithelial neoplasia, 8.238
- conjunctival papillomas caused by, 4.59–60, 4.60*f*, 8.238–239, 8.239*f*, 8.332*t*, 8.332–334, 8.333*f*
- eyelid infection/wart caused by, 4.204, 4.205*f*, 7.167
- ocular infection/papillomas caused by, 4.59–60, 4.60*f*, 4.204, 4.205*f*, 8.238–239, 8.239*f*, 8.332*t*, 8.332–334, 8.333*f*
- ocular surface squamous neoplasia and, 4.61
- screening for, 1.209–210
- vaccine against, 1.207, 1.210, 1.218*t*, 1.224, 1.228, 1.262

- Human T-lymphotropic virus/retrovirus type 1 (HTLV-1), 1.263, 9.212–213
- Human T-lymphotropic virus/retrovirus type 1 (HTLV-1) uveitis (HU), 9.212–213
- Human T-lymphotropic virus/retrovirus type 1 (HTLV-1)—related keratopathy (HTLV-1—related chronic interstitial keratitis), 9.212
- Human T-lymphotropic virus/retrovirus type 2 (HTLV-2), 1.263
- Human T-lymphotropic virus/retrovirus type 3 (HTLV-3). *See* Human immunodeficiency virus
- Humanitarian device exemption (HDE), for Intacs use in keratoconus, 13.65–66
- Humoral immune system/humoral immunity, 1.240–241. *See also* Antibody-mediated immune effector responses
- Humorsol. *See* Demecarium
- Humphrey perimeters/Humphrey Field Analyzers (HFAs), 5.87*f*, 10.60, 10.61, 10.61*f*, 10.64*f*, 10.64–65
visual field progression evaluation with, 10.71–74, 10.72*f*, 10.73*f*, 10.74*f*
- Humphrey perimetry, 3.315
- Humphrey Visual Field Index, 10.72–74, 10.74*f*
- Hunter syndrome (MPS II), 2.175*t*, 6.388*t*, 8.174, 8.175*t*, 12.283*t*, 12.291
- Hurler-Scheie syndrome (MPS IH/S), 2.185, 8.174, 8.175*t*
- Hurler syndrome (MPS IH/MPS1-H), 2.175*t*, 2.184–185, 6.270, 6.388*t*, 8.174, 8.175*t*, 8.176*f*, 12.282*t*, 12.290
- Hurricane (vortex) keratopathy (cornea verticillata), 8.90, 8.129*t*, 8.130, 8.130*f*, 8.176, 8.177*f*
in chloroquine/hydroxychloroquine toxicity, 8.130
in Fabry disease, 8.176, 8.177*f*
- Hutchinson melanotic freckle (lentigo maligna/precancerous melanosis), 7.177
- Hutchinson sign, 5.49, 9.191, 9.192*f*
- Hutchinson teeth, 9.237
- Hutchinson triad, 6.412, 8.308, 9.237
- Huygens, Christiaan, wave theory of light, 3.94–95, 3.95*f*
- Hyaline bodies, optic disc/nerve. *See* Optic disc (optic nerve head/ONH), drusen of
- Hyaline deposits
in granular corneal dystrophy type 1, 8.147
in granular corneal dystrophy type 2, 8.148
- Hyaline (hard) drusen, 4.162, 4.162*f*
- Hyalitis, 9.72*t*
- Hyalocytes, 2.78–79, 4.125
oxygen consumption by, 12.7
in vitreous, 12.7
- Hyaloid artery/system
development/regression of, 2.116*t*, 2.118*f*, 2.119*f*, 2.122, 2.123*f*
persistence/remnants of, 4.125–126, 4.126*f*, 6.366, 12.340–341. *See also* Persistent fetal vasculature
optic nerve/nerve head/disc edema differentiated from, 5.107
tunica vasculosa lentis development and, 11.29, 11.29*f*
- Hyaloid (Cloquet) canal, 2.80, 4.125
- Hyaloid corpuscle (Mittendorf dot), 2.80, 2.81*f*, 4.126, 11.29, 11.31, 11.32*f*
- Hyaloidoretinopathies, hereditary, collagen chain mutations and, 2.255
- Hyalosis, asteroid, 4.133, 4.133*f*
- Hyaluronan/hyaluronic acid, 12.331
as dermal filler for facial rejuvenation, 7.239, 7.240*f*, 7.241*f*
off-label use of, 2.306
in thyroid eye disease, 4.226, 7.55
in vitreous, 2.79, 2.79*f*, 2.249, 2.250–251
- Hyaluronate/sodium hyaluronate, as viscoelastic, 2.306, 11.95
elevated intraocular pressure and, 10.108
- Hyaluronidase
for enzymatic vitreolysis, 2.255
with local anesthetics, 2.364–365
in Natowicz syndrome, 8.175*t*
in vitreous, 2.249
- Hybrid contact lenses, after radial keratotomy, 13.200
- Hybridization, 2.137–138
comparative genomic (CGH), 4.38*t*
fluorescence in situ (FISH), 2.188, 4.38*t*
in orbital lymphoma, 7.88
- Hybridomas, 1.236
- Hydatid cyst, orbital infection associated with, 4.228, 7.51
- Hydralazine
for heart failure, 1.110
for hypertension, 1.68*t*, 1.73, 1.74
- Hydrochloric acid (HCl), ocular injuries caused by, 8.376*t*
- Hydrochlorothiazide, 1.68*t*, 1.69*t*
- Hydrocortisone, 1.171*t*
anti-inflammatory/pressure-elevating potency of, 2.333*t*
in combination preparations, 2.348*t*
for medical emergencies, 1.296*t*
perioperative, 1.286
- Hydrodelineation, in phacoemulsification, 11.110
for advanced cataract, 11.180
for posterior polar cataract, 11.181
for zonular dehiscence with lens subluxation or dislocation, 11.182
- Hydrodissection, in phacoemulsification, 11.110
for advanced cataract, 11.180
for posterior polar cataract, 11.111, 11.181
for traumatic cataract, 11.192
for zonular dehiscence with lens subluxation or dislocation, 11.182
- Hydrofluoric acid (HF), ocular injuries caused by, 8.376*t*, 8.380
- Hydrogel contact lenses, 3.213
- Hydrogel polymers
for IOLs, capsular opacification and, 11.153
in material addition techniques, 13.28
corneal inlays, 13.59, 13.60
- Hydrogen peroxide, 2.281–282, 2.282, 2.282*f*, 2.287, 2.288, 9.29. *See also* Free radicals
in contact lens solution, 3.229, 3.229*t*
as inflammatory mediator, 9.29
- Hydroperoxides (ROOH), 2.283
- Hydrops, in keratoconus, 4.95*f*, 4.96, 8.163–164, 8.164*f*
management of, 8.167–168
- 3-Hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors. *See also* Statins
cataracts and, 1.89, 11.53

- hypercholesterolemia/heart disease prevention and, 1.85*t*, 1.86*t*, 1.86–88
 - Hydroxyamphetamine, 2.314*t*, 2.320
 - in Horner syndrome diagnosis, 5.259–260, 5.261*f*
 - with tropicamide, 2.314*t*
 - Hydroxyapatite orbital implant, 7.131, 7.131*f*. *See also* Orbital implant
 - Hydroxychloroquine, 1.173
 - cornea verticillata caused by, 8.130
 - ocular effects/retinal toxicity of, 1.173, 1.307*t*
 - description of, 12.295–297
 - multifocal electroretinography findings in, 12.45, 12.49*f*
 - nonneovascular age-related macular degeneration versus, 12.68
 - for SLE, 1.159
 - Hydroxyethylcellulose, in artificial tears, 2.341
 - Hydroxyl/hydroxy radicals, 2.281, 2.282, 2.282*f*, 2.283, 9.29. *See also* Free radicals
 - 9-2-Hydroxypropoxymethylguanine. *See* Ganciclovir
 - Hydroxypropyl cellulose inserts, for dry eye, 8.63
 - Hydroxypropyl methylcellulose (HPMC)
 - in artificial tears, 2.341
 - as viscoelastic, 2.368, 11.95
 - Hydroxyurea, for sickle cell disease, 1.139
 - Hyfrecator, for punctal occlusion, 8.65
 - Hyper- (prefix), 6.15
 - Hyperacuity testing, in age-related macular degeneration, 12.69
 - Hyperaldosteronism, hypertension in, 1.64, 1.64*t*
 - Hyperautofluorescence, in chloroquine toxicity, 12.297
 - Hyperbaric oxygen therapy, oxidative lens damage/ cataracts and, 11.20, 11.65
 - Hypercalcemia
 - corneal changes in, 8.118, 8.198. *See also* Band keratopathy/calcific band keratopathy
 - in sarcoidosis, 5.327
 - Hypercalciuria, in sarcoidosis, 5.327
 - Hypercholesterolemia, 1.81–89. *See also*
 - Hyperlipoproteinemias
 - cardiovascular risk/coronary heart disease and, 1.81–89, 1.91–92, 1.92
 - cholesterol target levels and, 1.81–82
 - corneal arcus and, 8.120, 8.121, 8.179
 - management of, 1.83*t*, 1.84*t*, 1.84–89, 1.85*t*, 1.86*t*. *See also* Lipid-lowering therapy
 - metabolic syndrome and, 1.88
 - ophthalmic considerations and, 1.88–89
 - recent developments in, 1.81
 - risk assessment/screening/modification and, 1.82–83, 1.83*t*
 - in Schnyder corneal dystrophy, 8.151, 8.179
 - xanthelasma associated with, 7.169
 - Hyperchromic heterochromia, 6.274*t*
 - Hypercoagulable states (hypercoagulability), 1.146, 1.147–149. *See also* Thrombophilia; Thrombosis/ thrombotic disorders
 - antithrombotic component deficiencies and, 1.141
 - in Behçet disease, 1.169
 - cerebral venous thrombosis and, 5.346
 - fetal loss/preeclampsia and, 1.135, 1.148
 - NAION and, 5.123
 - ophthalmic considerations and, 1.147
 - in pregnancy, 1.135, 1.148
 - primary, 1.146, 1.147
 - secondary, 1.146, 1.148–149
 - transient visual loss and, 5.171
 - Hyperemia
 - conjunctival, 6.237, 6.238*t*, 8.45*t*, 8.114, 8.115*t*
 - in glaucoma, 10.31
 - in leptospirosis, 9.248–249
 - prostaglandin analogues causing, 10.175
 - insect/arachnid injuries causing, 8.386
 - Hyperfluorescence
 - angiographic
 - in acute zonal occult outer retinopathy, 9.165
 - in multifocal choroiditis and panuveitis, 9.155, 9.156*f*
 - in multiple evanescent white dot syndrome, 9.142*t*, 9.162, 9.162*f*
 - in ocular histoplasmosis syndrome, 9.217
 - in primary central nervous system/intraocular/ vitreoretinal/retinal lymphoma, 9.274
 - in punctate inner choroiditis, 9.158, 9.159*f*
 - in Rift Valley fever, 9.211
 - in serpiginous choroiditis/choroidopathy, 9.152
 - in sympathetic ophthalmia, 9.173, 9.173*f*
 - in Vogt-Koyanagi-Harada syndrome, 9.180, 9.180*f*
 - in West Nile chorioretinitis, 9.209, 9.209*f*
 - in fluorescein angiography, 12.35
 - Hyperglobus, 7.23
 - Hyperglycemia, 1.34. *See also* Diabetes mellitus;
 - Glycemic control
 - acute diabetes mellitus complications and, 1.47–48
 - blood–retina barrier breakdown caused by, 12.108
 - cataract formation and. *See* Diabetes mellitus (DM), cataracts associated with
 - control of. *See* Glycemic control
 - dawn phenomenon and, 1.42
 - diabetic retinopathy incidence and progression and, 1.38, 1.39*f*
 - Diabetes Control and Complications Trial, 1.38, 1.39*f*
 - United Kingdom Prospective Diabetes Study, 1.38
 - infusion failure and, 1.42
 - long-term diabetes mellitus complications and, 1.48–49
 - obesity and, 1.34
 - rebound, 1.42
 - Somogyi phenomenon and, 1.42
 - surgery and, 1.287
- Hyperglycinemia, 2.175*t*
- Hyperhomocysteinemia, 1.147, 12.134
- Hyperimmunoglobulin, 1.225
- Hyperkeratosis
 - in actinic keratosis, 4.211
 - definition of, 4.202
 - exuberant (cutaneous horn), 4.211, 7.168
- Hyperlipoproteinemias, 8.179. *See also*
 - Hypercholesterolemia
- corneal changes in, 8.179
 - arcus and, 8.120, 8.121, 8.179
 - Schnyder corneal dystrophy and, 8.151, 8.179
 - xanthelasma associated with, 4.206, 4.207*t*, 7.169
- Hyperlysinemia, 11.41

- Hypermetropic cataract, 11.46, 11.49f
 phacolytic glaucoma/uveitis and, 4.103, 9.21, 9.118, 9.118f, 9.119, 10.97f, 10.97–98, 11.67
- Hypermelanosis (complexion-associated melanosis), 4.63t, 4.65, 4.66, 4.66f
- Hypermetabolism, in hyperthyroidism, 1.52–53
- Hypermetric saccades, 5.221, 5.222, 5.248, 5.248f
- Hyperopia, 6.180, 12.201
 age-related increases in, 3.143
 angle closure/angle-closure glaucoma and, 10.29, 10.122
 anisometric, 3.185f
 after cataract surgery, prior refractive surgery and, 11.177
 cataract surgery in patient with, 11.185
 in children, 3.141, 3.174–175
 consecutive, 13.101–102
 converging lens for, 3.170, 3.170f
 cornea plana and, 8.96t, 8.100
 definition of, 3.3, 3.13, 3.124
 developmental, 3.143
 esotropia and, 3.175
 glaucoma and, 10.29, 10.122
 high, cataract surgery in patient with, 11.185
 high accommodative convergence/accommodative (AC/A) esotropia and, refractive surgery and, 13.188
 in infants, 3.141
 isometric, 3.185f
 laser in situ keratomileusis for, 3.271, 3.271f
 latent, refraction at near to detect, 3.36–38
 microcornea and, 8.96t, 8.99
 model of, 3.13, 3.13f
 myopia overcorrection and, 13.101–102
 conductive keratoplasty for, 13.129
 after phototherapeutic keratectomy, 8.367
 pictorial representation of, 3.138f
 prismatic effects of bifocal lenses in, 3.185f
 after radial keratotom, 13.51, 13.52
 correction of, 13.52
 retinal reflex in, 3.152
 spectacle lenses for, 3.211, 3.212f
 surgical correction of, 13.30
 bioptics for, 13.137, 13.157
 conductive keratoplasty for, 13.128, 13.129f, 13.165
 corneal curvature steepening and, 13.26, 13.80, 13.96
 homoplastic corneal inlays and, 13.60
 keratophakia for, 13.59–62, 13.62f
 LASIK for, 13.96, 13.97
 light-adjustable IOLs for, 13.153–154, 13.154f
 monovision for, 13.165
 myopia after (consecutive myopia), 13.101–102
 nonlaser, 13.8t
 overcorrection and, 13.101–102
 phakic IOLs for, 13.137, 13.138–140, 13.140
 photoablation for, 13.74f
 outcomes of, 13.96
 photorefractive keratectomy for, 13.94, 13.96
 photothermal therapy for, 13.29
 refractive lens exchange for, 13.148, 13.150
 thermokeratoplasty for, 13.127
 wavefront-optimized/wavefront-guided laser ablation for, 13.31
 outcomes of, 13.31–32, 13.97
 wavefront aberration produced by (negative defocus), 13.11
- Hyperopic anisometropia, 3.140
- Hyperopic astigmatism, 3.138, 3.138f
 outcomes of photoablation for, 13.96
- Hyperosmolar agents, 2.366
- Hyperosmolarity, tear film, dry eye and, 8.39, 8.53
- Hyperosmotic/osmotic agents, 2.328–329, 2.329t, 10.174t, 10.182–183
 for acute angle closure, 10.124–125, 10.184
- Hyperparathyroidism
 corneal changes and, 8.200–201
 in multiple endocrine neoplasia, 1.58
- Hyperpigmentation, after laser skin resurfacing, 7.238
- Hyperplasia, 4.10t, 6.183t
 epithelial
 ciliary pigmented, 4.279, 4.280f
 of eyelid, 7.166f, 7.166–168, 7.167f
 intravascular papillary endothelial, 8.345t
 lymphoid/reactive lymphoid (RLH)
 of conjunctiva/ocular surface, 4.69–70, 4.70f, 8.327, 8.348–349, 8.349f
 lymphoma and, 8.327, 8.348, 8.349
 of orbit, 4.231, 4.232, 7.86–88, 7.88. *See also* Lymphomas, orbital; Lymphoproliferative disorders
 of uveal tract (primary choroidal lymphoma/uveal lymphoid proliferation/infiltration/lymphoma), 4.199, 4.199f, 4.313–314
 masquerade syndromes secondary to, 9.276–277
 pseudoadenomatous (Fuchs adenoma), 4.179, 4.279
 pseudoepitheliomatous, 7.167, 8.332t
 sebaceous, 4.215, 4.216f, 7.170
- Hyperprolactinemia, pituitary adenoma causing, 1.57
- Hypersensitivity reactions, 9.40–41, 9.41t. *See also*
 Allergic reactions/allergies
 anaphylactic (immediate/type I), 9.40, 9.41t, 9.52
 allergic conjunctivitis and, 9.51
 atopic keratoconjunctivitis and, 8.292, 9.51
 contact dermatoblepharitis and, 8.285, 8.286f, 8.287
 hay fever conjunctivitis and, 8.288
 topical medications/substances and, 8.285, 8.286f, 8.287
 cytotoxic (type II), 9.40, 9.41t
 in mucous membrane pemphigoid, 8.299
 delayed (type IV), 9.40, 9.41t, 9.44–48, 9.45f, 9.46t
 contact dermatoblepharitis and, 8.286, 8.286f, 8.287
 in graft rejection, 8.316, 8.317
 in sympathetic ophthalmia, 9.47–48
 topical medications/substances and, 8.286, 8.286f, 8.287
 in *Toxocara* granuloma, 9.47
 tuberculin form of, 9.32
 granulomatous, 9.47
 immediate (type I/anaphylactic). *See* Hypersensitivity reactions, anaphylactic (immediate/type I)
 immune-complex (type III), 9.40, 9.41t. *See also* Immune (antigen–antibody) complexes
 stimulatory (type V), 9.41, 9.41t

- Hypertelorism (telorbitism), 6.191, 7.23
 in craniosynostosis, 7.37
 with midline clefts, 7.37
- Hypertension, 1.61–80, 1.208
 arteriosclerotic vascular disease and, 12.122
 asteroid hyalosis and, 12.346
 cardiovascular risk and, 1.61, 1.62, 1.65, 1.65*t*, 1.66, 1.83*t*
 in children and adolescents, 1.61, 1.78
 choroidopathy caused by, 12.123, 12.123–124*f*
 classification of, 12.121
 in diabetes mellitus, 1.48, 1.49, 1.75
 diabetic retinopathy progression associated with, 12.98
 diagnosis/definition of, 1.62*t*, 1.62–63
 etiology and pathogenesis of, 1.63*f*, 1.63–65, 1.64*t*
 evaluation of, 1.65*t*, 1.65–66
 focal intraretinal periarteriolar transudates caused by, 12.121–122, 12.122*f*
 glaucoma and, 10.83
 incidence/prevalence of, 1.61–62, 1.208
 intracranial. *See* Intracranial hypertension
 intracranial hemorrhage and, 1.126–127
 left ventricular hypertrophy and, 1.76
 malignant, 12.196
 masked, 1.61, 1.62
 metabolic syndrome and, 1.37, 1.76, 1.88
 monoamine oxidase inhibitor interactions and, 1.79
 obesity and, 1.37, 1.76
 children and adolescents and, 1.78
 ocular (OHT), 10.4*t*, 10.89–90. *See also* Elevated intraocular pressure; Ocular hypertension
 refractive surgery and, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
 in older patients, 1.77
 ophthalmic considerations and, 1.77, 1.79, 1.80*t*
 optic neuropathy caused by, 12.123, 12.125
 orthostatic hypotension and, 1.77
 peripheral arterial disease and, 1.76
 phenylephrine causing, 2.317, 2.318
 in polyarteritis nodosa, 9.136
 during pregnancy, 1.77–78
 management and, 1.73, 1.74, 1.78
 prevalence of, 12.121
 primary (essential), 1.63, 1.63*f*
 in children and adolescents, 1.78
 racial and ethnic variations in, 1.62, 1.78–79
 rebound, 1.79, 1.285
 recent developments in, 1.61
 resistant, 1.64*t*, 1.64–65, 1.75
 retinal disease associated with, 1.79, 1.80*t*, 12.121–125, 12.122–124*f*
 retinopathy caused by, 12.121–123, 12.122*f*, 12.124*f*
 screening tests for, 1.66, 1.208
 secondary, 1.64, 1.64*t*
 in children and adolescents, 1.78
 sleep disorders and, 1.67*t*, 1.76
 special considerations in, 1.75–80
 stroke and, 1.69*t*, 1.76, 1.123
 treatment of, 1.66–75, 1.68*t*, 1.69*t*, 1.70*f*
 cardiovascular/ischemic heart disease and, 1.75, 1.83*t*
 cerebrovascular disease and, 1.69*t*, 1.76
 chronic renal disease and, 1.66, 1.69*t*, 1.76
 diabetes mellitus and, 1.48, 1.49, 1.75
 future therapies/targets and, 1.74–75
 goals for, 1.61, 1.66
 heart failure and, 1.69*t*, 1.72, 1.75, 1.109–110
 lifestyle modifications and, 1.66–67, 1.67*t*, 1.70*f*
 obesity/metabolic syndrome and, 1.76
 pharmacologic, 1.67–75, 1.68*t*, 1.69*t*, 1.70*f*. *See also* Antihypertensive therapy
 racial/ethnic variations and, 1.78–79
 in special situations, 1.75–80
 “white coat,” 1.62
 withdrawal syndromes and, 1.79
 in women, 1.77–78
- Hypertensive crisis/emergencies, 1.79
 monoamine oxidase inhibitor interactions and, 1.79
 parenteral antihypertensive agents for, 1.74, 1.79
- Hypertensive retinopathy, 1.79, 1.80*t*
 in polyarteritis nodosa, 1.167, 9.136
- Hyperthermia, malignant (MH), 1.283, 1.292–293, 1.293*t*
- Hyperthyroidism, 1.52–54
 Graves, 1.53–54, 7.51, 7.52. *See also* Thyroid eye disease
 orbitopathy/ophthalmopathy and. *See* Thyroid eye disease
 pituitary adenoma causing, 1.57
 toxic nodular goiter, 1.53, 1.54
 treatment of, 7.58
- Hypertonic medications, for recurrent corneal erosions, 8.87
- Hypertrichosis, prostaglandin analogues/latanoprost causing, 10.175, 10.175*f*
- Hypertrophic subepithelial corneal degeneration, peripheral, 8.124–125, 8.125*f*
- Hypertropia
 dissociated vertical deviation and, 6.115
 exotropia associated with, 6.100
 extraocular muscle surgery for, 6.164–165
 incomitant, 6.125
 inferior rectus muscle weakness as cause of, 6.128
 rectus muscle surgery for, 6.164–165
 superior oblique muscle palsy associated with, 6.123
- Hypertyrosinemia/tyrosinemia, 8.183*t*, 8.183–184, 8.184*f*
 alkaptonuria and, 8.184
 corneal changes in, 8.183–184, 8.184*f*
- Hyperuricemia, 8.188
 band keratopathy and, 8.119, 8.188
- Hypervariable region, immunoglobulin, 9.42
- Hyperviscosity
 cerebral ischemia/stroke and, 1.120–121
 transient visual loss and, 5.171
- Hyperviscosity retinopathy, central retinal vein occlusion versus, 12.134
- Hyphae, 8.249, 8.250*f*
- Hyphema, 6.378*f*, 6.378–379
 after cataract surgery, 11.149, 11.158–159
 corneal blood staining and, 4.86
 after cataract surgery, 11.159
 glaucoma/elevated intraocular pressure and, 4.103, 4.104*f*, 8.395, 10.104*f*, 10.104–105. *See also* Uveitis-glaucoma-hyphema (UGH) syndrome
 normal-tension glaucoma and, 10.85*f*, 10.85–86

- iris-fixed phakic IOL insertion and, 13.145
- in juvenile xanthogranuloma, 9.277
- layered, 8.392, 8.393*f*
- microscopic, 8.392, 8.392*f*
- sickle cell disease/retinopathy/elevated intraocular pressure and, 8.395, 8.395*t*, 8.396, 10.104, 10.105
- spontaneous, 8.393
- total/eight-ball, 8.393, 8.393*f*
- transient visual loss and, 5.164
- traumatic, 8.391–396, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*, 12.154
 - glaucoma/elevated intraocular pressure and, 8.395, 10.104*f*, 10.104–105
 - medical management of, 8.394–395
 - rebleeding after, 8.394, 8.394*f*, 10.104, 10.105
 - sickle cell disease/retinopathy/elevated intraocular pressure and, 8.395, 8.395*t*, 8.396, 10.104, 10.105
 - surgery for, 8.395*t*, 8.395–396, 8.396, 10.105
- Hypnagogic hallucinations, 5.177
- Hypnopompic hallucinations, 5.177
- Hypnotic drugs, 1.194–198, 1.195*t*, 1.196*t*
- Hypo- (prefix), 6.16
- Hypoaccommodation, 6.9
- Hypoautofluorescence, in chloroquine toxicity, 12.297
- Hypoblast, 2.112*f*
- Hypocalcemia, cataracts associated with, 11.61–62
- Hypochondriasis. *See* Illness anxiety disorder
- Hypochromic heterochromia, 6.274*t*
- Hypoesthesia/anesthesia
 - corneal
 - congenital, 8.108
 - herpes simplex keratitis and, 8.217–218, 8.226*t*
 - herpes zoster and, 8.226*t*, 8.228
 - keratoplasty and, 8.418, 8.424
 - after LASIK, 13.172
 - in neurotrophic keratopathy/persistent corneal epithelial defects, 8.80, 8.224
 - in infraorbital nerve distribution
 - in orbital floor/blowout fracture, 7.19, 7.109
 - after orbital surgery, 7.125
- Hypofluorescence, angiographic
 - in acute posterior multifocal placoid pigment epitheliopathy, 9.148, 9.149*f*
 - in acute zonal occult outer retinopathy, 9.165
 - in birdshot uveitis, 9.144, 9.145, 9.146*f*
 - in multifocal choroiditis and panuveitis, 9.155, 9.156, 9.157*f*
 - in multiple evanescent white dot syndrome, 9.142*t*, 9.162, 9.162*f*
 - in ocular histoplasmosis syndrome, 9.217
 - in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.274
 - in punctate inner choroiditis, 9.158, 9.159*f*
 - in Rift Valley fever, 9.211
 - in serpiginous choroiditis/choroidopathy, 9.142*t*, 9.152, 9.153*f*
 - in sympathetic ophthalmia, 9.173–174, 9.174*f*
 - in syphilitic chorioretinitis, 9.239, 9.239*f*
 - in tuberculous uveitis, 9.252
 - in uveitis, 9.90
 - in Vogt-Koyanagi-Harada syndrome, 9.180
 - in West Nile chorioretinitis, 9.209, 9.209*f*
- Hypoglobus, 7.23
- Hypoglycemia
 - insulin-induced, 1.38, 1.43
 - sulfonylurea-induced, 1.44–45
 - surgery and, 1.287
- Hypoglycemia unawareness, 1.39, 1.43
- Hypoglycemic agents. *See* Insulin therapy; Oral hypoglycemic agents
- Hypogonadism, pituitary adenoma causing, 1.57
- Hypoinsulinemia, infusion failure and, 1.42
- Hypokalemia, carbonic anhydrase inhibitors causing, 2.326, 10.180–181
- Hypolipoproteinemias, corneal changes in, 8.180*f*, 8.180–181
- Hypomania, 1.189
- Hypometabolism, in hypothyroidism, 1.54
- Hypometric saccades, 5.221, 5.222
- Hypoperfusion. *See also* Ischemia
 - scotomata caused by, 5.157–158, 5.159*f*
 - transient visual loss caused by, 5.161, 5.162, 5.170, 5.171*f*
- Hypophosphatasia, 8.192*t*
- Hypophysitis, lymphocytic, 5.335
- Hypopigmented macule (ash-leaf spot), in tuberous sclerosis, 5.331*f*, 5.334*t*, 10.30
- Hypoplasia, 6.183*t*. *See also* specific structure affected
- Hypoplasminogenemia, in ligneous conjunctivitis, 8.294
- Hypopyon, 12.390
 - in Behçet disease, 1.169, 9.185, 9.185*f*
 - after cataract surgery, 11.140
 - in endophthalmitis
 - Aspergillus*, 9.268, 9.269*f*
 - bacterial, 9.264, 9.264*f*
 - in uveitis, 9.79, 9.113, 9.113*f*
- Hypotelorism
 - ocular, 6.191
 - orbital, 6.203
- Hypotension
 - glaucoma and, 1.77, 10.87
 - ocular. *See* Hypotony
 - orthostatic, 1.77
- Hypotensive lipids. *See* Prostaglandin (PG) analogues
- Hypothalamic hormones, 1.56, 1.56*t*
- Hypothalamic-pituitary axis, 1.56
 - disorders of, 1.56*t*, 1.56–58
- Hypothalamus, 1.56, 5.52, 5.53*f*
- Hypothyroidism, 1.54
 - congenital/cretinism, 1.50
 - pituitary adenoma causing, 1.57
 - thyroid eye disease and, 7.52, 7.56. *See also* Thyroid eye disease
- Hypotony
 - cataract/cataract surgery in patient with, 11.68, 11.185
 - during/after surgery
 - filtering surgery and, 10.210
 - flat anterior chamber and, 11.135
 - angle-closure glaucoma and, 10.144
 - suprachoroidal effusion/hemorrhage and, 11.159, 11.160
 - tube shunt implantation and, 10.216–217, 10.217, 10.218*t*
 - in uveitis, 9.288
- Hypotony maculopathy, 10.210, 12.201
- antifibrotic use and, 10.205

Hypotropia
 extraocular muscle surgery for, 6.164–165
 high myopia associated with, 6.143–144
 in monocular elevation deficiency, 6.126, 6.126f
 primary position, with Brown syndrome, 6.137
 pseudoptosis/superior rectus muscle anatomy and, 5.270, 5.270f, 5.274, 6.30
 rectus muscle surgery for, 6.164–165
 Hypovolemic shock, 1.300. *See also* Shock
 Hypoxemia, stroke and, 1.121
 Hysteresis, corneal, 8.43
 Hysteria, 5.299
 “Hysterical blindness.” *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
 HZO. *See* Herpes zoster ophthalmicus

I

I_e . *See* Radiant intensity
 I_v . *See* Luminous intensity
 I-cell (inclusion-cell) disease (ML II), 6.388t, 8.178
 I–S (inferior–superior) values, 8.31, 13.4
 after intrastromal corneal ring segment implantation, 13.66
 in keratoconus/corneal ectasia, 8.32t, 8.165, 8.165f
 IA. *See* Irrigation/aspiration
 IADL. *See* Instrumental activities of daily living
 IAPB (International Agency for the Prevention of Blindness), 11.6
 Iatrogenic Brown syndrome, 6.168
 IBD. *See* Inflammatory bowel disease
 Ibuprofen, 1.172, 2.335t
 ocular effects of, 1.307t
 perioperative use of, 1.286
 for scleritis, 8.324
 Ibutilide, 1.113t
 for cardioversion, 1.114
 ICA. *See* Internal carotid artery
 ICAM-1 (intercellular adhesion molecule 1), in neutrophil rolling, 9.17
 ICAM-2 (intercellular adhesion molecule 2), in neutrophil rolling, 9.17
 Icare tonometer, 6.10, 6.281
 ICCE. *See* Intracapsular cataract extraction
 IC3D (International Committee for the Classification of Corneal Dystrophies), 8.133–134, 8.134t, 8.135t
 ICDs. *See* Implantable cardioverter-defibrillators
 “ICE” cells, 8.127
 Ice-pack test, for myasthenia gravis, 5.324, 5.325, 5.325f, 7.217
 Ice pick headache, 5.294
 ICE syndrome. *See* Iridocorneal endothelial (ICE) syndrome
 ICG. *See* Indocyanine green
 ICG angiography. *See* Indocyanine green (ICG) angiography
 Ichthyosis, 8.201–202
 congenital ectropion and, 7.156
 pre-Descemet corneal dystrophy and, 8.155
 vulgaris, 8.201–202
 Iclaprim, 1.280
 ICP (increased intracranial pressure). *See* Intracranial hypertension

ICRB. *See* International Classification of Retinoblastoma
 ICROP. *See* International Classification of Retinopathy of Prematurity
 ICRS. *See* Intrastromal corneal ring segments
 ICSI. *See* Intracytoplasmic sperm injection
 IDDM (insulin-dependent diabetes mellitus). *See* Diabetes mellitus (DM), type 1
 Idebenone, for Leber hereditary optic neuropathy, 5.135
 Idiopathic anterior uveitis, 9.127
 Idiopathic autoantibody, 1.217
 Idiopathic enlargement of blind spot syndrome, acute (AIBSE), 5.100–101, 5.101f
 fundus autofluorescence in identification of, 5.90
 Idiopathic intracranial hypertension (IIH/pseudotumor cerebri/PTC), 5.110–113, 5.111t, 6.370f, 6.370–371
 in children, 5.113
 headache and, 5.110, 5.112, 5.113, 5.288
 Idiopathic macular holes, 4.131–132, 4.132f
 description of, 12.337–339, 12.338f
 vitrectomy for, 12.384–385, 12.385f
 Idiopathic multifocal choroiditis. *See* Multifocal choroiditis
 Idiopathic multiple cranial neuropathy syndrome, 5.202
 Idiopathic orbital inflammation/inflammatory syndrome. *See* Nonspecific orbital inflammation
 Idiopathic polypoidal choroidal vasculopathy. *See* Polypoidal choroidal vasculopathy
 Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN), 12.156
 Idiopathic stabbing headache, 5.294
 Idiopathic stellate maculopathy. *See* Leber idiopathic stellate neuroretinitis
 Idiopathic thrombocytopenic purpura (ITP), 1.143
 Idiotypes, 9.42
 Idiotypes, 9.42
 Idoxuridine, 2.356, 2.357t
 Iduronate-2-sulfatase, in Hunter syndrome, 8.175t
 α -L-Iduronidase
 defective/deficiency of, in mucopolysaccharidoses, 2.175t, 2.184
 in mucopolysaccharidoses, 8.174, 8.175t
 IEP. *See* Individualized Education Plan
 IFG. *See* Impaired fasting glucose
 IFIS. *See* Intraoperative floppy iris syndrome
 IFNs. *See* Interferons
 Ifosfamide, 1.232t
 Ig. *See* Immunoglobulins; *specific Immunoglobulin entries*
 IGA. *See* Indocyanine green angiography
 IgA dermatosis, linear, 8.301
 IGFbps. *See* Insulin-like growth factor binding proteins
 IgG4 disease, 7.60
 IGT. *See* Impaired glucose tolerance
 IHD. *See* Ischemic heart disease
 Ihh factor, gene expression/ocular development and, 2.127
 IIH. *See* Idiopathic intracranial hypertension
 IIVs. *See* Inactivated influenza vaccines
 IK. *See* Interstitial keratitis
 IKBKAP gene, 6.271
 IL-1RA. *See* Interleukin-1 receptor antagonist
 Ileocolitis, granulomatous (Crohn disease), 1.155, 9.116
 Illness anxiety disorder, 1.190
 Illuminance (E_v), 3.109, 3.109t

- Illumination
 in indirect ophthalmoscope/ophthalmoscopy, 12.21
 for slit-lamp biomicroscope
 direct, 8.16–18, 8.17f, 8.18f, 8.19f
 indirect, 8.17f, 8.18–19, 8.20f
- Illusions, 5.173–175, 5.174t
 cortical origin of, 5.175
 nonvisual causes of, 5.174t
 ocular origin of, 5.174–175
 optic nerve origin of, 5.175
- ILM. *See* Internal limiting membrane
- Ilotycin. *See* Erythromycin
- IM. *See* Infectious mononucleosis
- Image displacement
 definition of, 3.147
 through bifocal lenses, 3.184, 3.186f
- Image distance, definition of, 3.3, 3.10
- Image jump
 definition of, 3.147
 through bifocal lenses, 3.184–186, 3.187f
- Image magnification
 contact lenses, 3.255
 intraocular lenses, 3.255
- Image size, contact lenses and, 3.206–208
- Image vergence, 3.51
- Images. *See also specific type*
 in dense media, 3.12
 magnification of. *See* Magnification
 paraxial theory of, 3.69
 real, 3.41, 3.60–61
 relocation of, 3.62
 virtual. *See* Virtual images
- Imaging
 of nearby objects, 3.9–10, 3.10f
 radiographic. *See* Neuroimaging; *specific modality*
- Imbert-Fick principle, 10.22
- Imbibition pressure (IOP-SP), 8.9
- Imidazoles, 1.256, 1.270, 1.280, 2.355t, 2.356
 for *Acanthamoeba* keratitis, 2.361, 8.278
- Imipenem-cilastin, 1.276, 2.344t
- Imipramine, ocular effects of, 1.307t
- Immediate hypersensitivity (type I) reaction, 9.40, 9.41t, 9.52. *See also* Allergic reactions/allergies
 allergic conjunctivitis and, 9.51
 atopic keratoconjunctivitis and, 8.292
 contact dermatophlepharitis and, 8.285, 8.286f, 8.287
 hay fever conjunctivitis and, 8.288
 topical medications/substances and, 8.285, 8.286f, 8.287
- Immersion ultrasonography, 3.245, 3.246f
 for axial length measurement, in IOL power
 determination/selection, 11.83, 11.83f
- Immune-complex hypersensitivity (type III) reaction, 9.40, 9.41t. *See also* Immune (antigen–antibody) complexes
- Immune complex vasculitis, 1.165t
- Immune (antigen–antibody) complexes, 9.22, 9.23f
 in Behçet disease, 1.169
 in SLE, 1.156
 in type III hypersensitivity reaction, 9.40, 9.41t
 in vasculitis, 1.165t
- Immune deficiency, in HIV infection/AIDS, 1.263.
See also HIV infection/AIDS
- Immune hypersensitivity reactions. *See* Hypersensitivity reactions
- Immune privilege, 9.57–58
 in anterior chamber/anterior uvea/vitreous, 9.57–58
 corneal allograft immunity and, 8.316, 9.60
 corneal, 8.316, 9.59, 9.60
 in retina/retinal pigment epithelium/choriocapillaris/choroid, 9.61, 9.62
- Immune processing, 9.33f, 9.36f, 9.36–38
 in primary versus secondary immune response, 9.40
 response to tuberculosis and, 9.31
- Immune reconstitution syndromes (IRs), 1.271
- Immune recovery uveitis (IRU), 1.271, 9.201, 9.294–295
- Immune-related disorders. *See* Immune response (immunity), disorders of
- Immune response (immunity). *See also* Immune response arc
 adaptive, 1.240, 9.9, 9.31–52. *See also* Adaptive immune response/adaptive immunity
 cellular, 1.241. *See also* Lymphocyte-mediated immune effector responses
 definitions for, 9.9
 disorders of. *See also specific type and specific structure affected*
 in HIV infection/AIDS, 1.263. *See also* HIV infection/AIDS
 neuro-ophthalmic signs of, 5.313–318
 ocular disease and, 8.285–326, 9.53–62
 glucocorticoids affecting, 2.331
 humoral, 1.240–241. *See also* Antibody-mediated immune effector responses
 inflammation and, 9.12–13
 innate, 1.239–240, 9.9, 9.12–13, 9.13–21, 9.14t.
 See also Innate immune response/innate immunity
 mediator systems in, 9.22t, 9.22–30, 9.23f, 9.25f, 9.27–28t. *See also* Mediators
 ocular, 9.53–62
 of anterior chamber/anterior uvea/vitreous, 9.54t, 9.56–58
 corneal allograft immunity and, 9.60
 of conjunctiva, 9.53–56, 9.54t
 of cornea/sclera, 9.54t, 9.58–60, 9.59f, 9.60f
 disorders of, 8.285–326. *See also specific structure affected and specific type*
 conjunctival involvement and, 8.288–306
 corneal involvement and, 8.306–318
 transplant rejection and, 8.316–318, 8.428–431
 episcleral/scleral involvement and, 8.318–326
 eyelid involvement and, 8.285–287, 8.286f
 graft-vs-host disease and, 8.303–305
 hypersensitivity reactions and, 9.40–41, 9.41t
 mediators of, 9.22t, 9.22–30, 9.23f, 9.25f, 9.27–28t.
 See also Mediators
 ocular surface immunoregulation and, 8.11–13, 8.12–13f
 of retina/retinal pigment epithelium/choriocapillaris/choroid, 9.54t, 9.61–62
 population-wide, 9.65
 primary, 9.39–40
 regional, 9.53, 9.54t. *See also* Immunologic microenvironments
 secondary, 9.39–40

- Immune response arc, 9.32–40, 9.33*f*. *See also* Immune response
 overview of, 9.32, 9.33*f*
 phases of, 9.33*f*, 9.33–39
 afferent, 9.33*f*, 9.33–36, 9.34*f*, 9.35*f*
 response to tuberculosis and, 9.31, 9.32
 effector, 9.33*f*, 9.38–39, 9.39*f*. *See also* Effector
 phase of immune response arc
 response to tuberculosis and, 9.31–32
 processing, 9.33*f*, 9.36*f*, 9.36–38
 response to tuberculosis and, 9.31
 primary or secondary responses and, 9.39–40
 regional immunity and, 9.53, 9.54*t*
- Immune ring, corneal, 8.51*f*
- Immune system, 1.239–241. *See also* Immune response;
 Immune response arc
 components of, 9.9–12
- Immunization, 1.216–225. *See also specific disease*
 active, 1.216–217
 adaptive immunity and, 9.31–52. *See also* Immune
 response arc
 in immunocompromised host/HIV infection/AIDS,
 1.216, 1.220, 1.266
 new developments in, 1.225
 passive, 1.217, 1.225
 recommended schedules for, 1.217, 1.218*t*
 for travel, 1.224–225
- Immunocompromised host. *See also* HIV infection/AIDS
 acute retinal necrosis in, 9.193
 CMV infection in, 1.259, 4.145, 4.146*f*, 9.198,
 9.200–201
 cryptococcosis in, 9.270
 endophthalmitis in, 9.263
 fungal infection in, disseminated, 1.256
 herpes zoster in, 8.225, 8.226–227
 immunization in, 1.216
 nocardiosis in, 9.249
 ocular infection in
 microsporidia causing, 8.280, 8.280*f*
 yeasts causing, 8.250
 ocular surface squamous cell carcinoma in, 8.336
 progressive outer retinal necrosis in, 9.197, 9.295–
 296, 9.296*f*
 refractive surgery and, 13.37, 13.171
 syphilis in, 9.240
 toxoplasmosis in, 9.223, 9.225
 tuberculosis in, 9.250, 9.253
- Immunofluorescence assay
 in Lyme disease, 1.251
 in mucous membrane pemphigoid, 4.55
- Immunoglobulin A (IgA), 9.41, 9.42
 secretory (sIgA), in tear film, 2.216
 structural and functional properties of, 9.42, 9.43*t*
 in tear film, 2.216, 8.6*f*, 9.53
 viral conjunctivitis and, 9.56
 in toxoplasmosis, 9.224
- Immunoglobulin A (IgA) dermatosis, linear, 8.301
- Immunoglobulin A (IgA) protease, as microbial
 virulence factor, 1.240
- Immunoglobulin class switching, 9.38, 9.39, 9.40
- Immunoglobulin D (IgD), 9.38, 9.41
 structural and functional properties of, 9.43*t*
 in tear film, 2.216
- Immunoglobulin E (IgE), 9.41
 Fc receptors for
 on mast cells, 9.10
 in phagocytosis, 9.19
 mast-cell degranulation mediated by, 9.10, 9.50*f*,
 9.50–52
 structural and functional properties of, 9.43*t*
 in tear film, 2.216, 8.39
 in type I hypersensitivity/anaphylactic reactions,
 1.301, 8.285, 9.10, 9.51
- Immunoglobulin G (IgG), 9.40, 9.41, 9.42
 IgG4 disease and, 7.60
 in multiple sclerosis, 5.319
 in neuromyelitis optica/neuromyelitis optica
 spectrum disorder, 5.117*f*, 5.118, 5.320, 5.322
 structural and functional properties of, 9.43*t*
 in tear film, 2.216
 in thyroid eye disease, 7.55
 in toxoplasmosis, 9.224
- Immunoglobulin G (IgG) κ -chain deposition, corneal,
 8.198
- Immunoglobulin G4 (IgG4)-positive plasmacytic
 infiltrates, in nonspecific orbital inflammation, 4.225
- Immunoglobulin M (IgM), 9.38, 9.39, 9.40, 9.41, 9.42
 structural and functional properties of, 9.42, 9.43*t*
 in tear film, 2.216
 in toxoplasmosis, 9.224
 in viral conjunctivitis, 9.56
- Immunoglobulin superfamily molecules, in neutrophil
 rolling, 9.17
- Immunoglobulin (IgE) vasculitis (Henoch-Schönlein
 purpura), 1.165*t*
- Immunoglobulins, 9.39. *See also* Antibodies; *specific*
type
 classes of, 9.41
 disorders of, corneal crystal deposition and, 8.182*t*,
 8.197–199, 8.198*f*, 8.199*f*
 intravenous (IVIg)
 for neuromyelitis optica, 5.323
 for uveitis, 9.108
 isotypes of, 9.36*f*, 9.41
 structural and functional properties of, 9.41*f*, 9.41–42,
 9.43*t*
- Immunohistochemistry, 4.33–35, 4.35*f*
 in melanoma diagnosis, 4.68
 in primary central nervous system/intraocular/
 vitreoretinal/retinal lymphoma diagnosis, 4.136,
 4.312
- Immunologic memory, 9.39–40
 response to tuberculosis and, 9.32
- Immunologic microenvironments, 9.53, 9.54*t*
 of anterior chamber/anterior uvea/vitreous, 9.54*t*,
 9.56–57
 of conjunctiva, 9.53–55, 9.54*t*
 of cornea/sclera, 9.54*t*, 9.58–59, 9.59*f*, 9.60*f*
 of retina/retinal pigment epithelium/chorioid/choroid,
 9.54*t*, 9.61
- “Immunologic privilege.” *See also* Immune privilege
 corneal, 8.316
- Immunologic tolerance
 AIRE (autoimmune regulator) and, 9.64
 corneal transplantation and, 8.316
 T regulatory cells in, 9.37, 9.38

- Immunology (ocular), 9.5–67. *See also* Immune response; Immune response arc
 basic concepts in, 9.9–30
- Immunomodulatory therapy/immunotherapy/
 immunosuppression (IMT), 1.174–176, 2.333
 adverse effects of, 1.174–175
 for asthma, 1.133*t*, 1.134
 for atopic keratoconjunctivitis, 8.294
 for Behçet disease, 1.169, 9.188–189
 for birdshot uveitis, 9.147
 for cancer, 1.227, 1.235–237
 cataract surgery/IOLs in uveitis and, 9.283
 juvenile idiopathic (chronic/rheumatoid) arthritis
 and, 9.124–125
 for choroidal/ciliary body melanoma, 4.277
 complications of, 9.101–102
 for corneal graft rejection prophylaxis, 8.430
 diabetes mellitus affected by, 1.36
 for graft-vs-host disease, 8.304
 for granulomatosis with polyangiitis (Wegener
 granulomatosis), 1.168
 for hay fever conjunctivitis, 8.289
 infectious pseudocrystalline keratopathy associated
 with, 4.79
 for juvenile idiopathic (chronic/rheumatoid)
 arthritis, 9.124
 for Mooren ulcer, 8.316
 for mucous membrane pemphigoid, 8.303
 for multifocal choroiditis and panuveitis syndrome,
 9.156–157
 for multiple sclerosis, 5.116
 for neuromyelitis optica, 5.323
 for pars planitis, 9.130
 for peripheral ulcerative keratitis, 8.313
 for rheumatic disorders, 1.174–176
 for sarcoidosis, 9.171
 for scleritis, 8.324, 8.325*f*, 9.112
 for serpiginous choroiditis, 9.153
 for Stevens-Johnson syndrome (Stevens-Johnson
 syndrome/toxic epidermal necrolysis overlap and
 toxic epidermal necrolysis), 8.297
 for sympathetic ophthalmia, 9.175
 for systemic sclerosis, 1.162
 for uveitis, 9.100–109
 cataracts/cataract surgery and, 9.283
 corticosteroid therapy and, 9.99, 9.100–101, 9.101,
 9.102, 9.103, 9.104, 9.105, 9.107
 for Vogt-Koyanagi-Harada syndrome, 9.182
- Immunophenotyping, flow cytometry for, 4.36
- Immunoregulation/immunoregulatory systems, 9.54*t*
 for anterior chamber/anterior uvea/vitreous, 9.54*t*,
 9.57–58
 corneal allograft immunity and, 9.60
 for conjunctiva, 9.54*t*, 9.55
 for cornea/sclera, 9.54*t*, 9.59–60
 for retina/retinal pigment epithelium/
 choriocapillaris/choroid, 9.54*t*, 9.61
- Immunosuppression. *See* Immunomodulatory therapy/
 immunotherapy/immunosuppression
- Immunotherapy. *See* Immunomodulatory therapy/
 immunotherapy/immunosuppression
- Impact resistance, of spectacle lenses, 3.195
- Impaired fasting glucose (IFG), 1.37
- Impaired glucose tolerance (IGT), 1.37
- Implant, orbital, 7.131*f*, 7.131–132
 in children, 7.129
 after evisceration, 7.130
 exposure and extrusion of, 7.130, 7.131, 7.133–134,
 7.134*f*
 contracted socket and, 7.134
 migration of, 7.130, 7.131
 for orbital floor/blowout fracture, 7.111
 for superior sulcus deformity, 7.132
- Implant (intrastromal corneal ring segment/Intacs)
 extrusion, 13.67, 13.68*f*
- Implantable cardioverter-defibrillators (ICDs), 1.91,
 1.95, 1.115–116
 for heart failure, 1.111
 laser surgery in patient with, 13.37
 after myocardial infarction, 1.91, 1.95, 1.116
 perioperative disabling of, 1.117, 1.284
 for tachyarrhythmias, 1.91, 1.95, 1.115–116
- Implantable insulin pumps, 1.42
- Impotence, ocular effects of drugs for, 1.308*t*
- Impression cytology, in superior limbic
 keratoconjunctivitis, 8.84
- Imprinting (genetic), 2.138, 2.153–154
- IMT. *See* Immunomodulatory therapy/immunotherapy/
 immunosuppression
- In situ hybridization, fluorescence (FISH), 2.188, 4.38*t*
- In vitro fertilization (IVF), genetic counseling and,
 2.206, 2.207
- Inactivated influenza vaccines (IIVs), 1.220
- Inactivated poliovirus vaccine (IPV/Salk vaccine), 1.222
- Inborn errors of metabolism
 dietary therapy in, 2.203
 enzyme defect in, 2.174, 2.175*t*
 lens dislocation and, 6.306
 ocular findings in, 2.175*t*, 6.385, 6.387*f*, 6.388–389*t*,
 6.390*f*
 prevalence of, 6.385
- INC. *See* Interstitial nucleus of Cajal
- Incest, pedigree analysis and, 2.172, 2.172*f*, 2.205
- Incision leaks, after cataract surgery, 11.118, 11.130–131
 flat anterior chamber and, 11.135
 angle-closure glaucoma and, 10.144–145
- Incisional biopsy, 7.179*f*, 7.180
- Incisional surgery
 corneal (keratorefractive), 13.8*t*, 13.26–27, 13.27*f*,
 13.49–58. *See also specific procedure*
 for astigmatism, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*,
 13.57*f*
 corneal effects of, 13.26–27, 13.27*f*
 for myopia, 13.49–53, 13.50*f*, 13.51*f*
 for glaucoma, 10.187, 10.196–220. *See also*
 Trabeculectomy
 angle-closure glaucoma and, 10.220
 cataract surgery, with trabeculectomy, 10.211–213
 complications of, 10.187
 open-angle glaucoma and, 10.113–115
 trabeculectomy, 10.197–211
 with cataract surgery, 10.211–213
 tube shunt implantation, 10.213–217, 10.214*t*,
 10.218*t*
- Incisions. *See also* Incisional surgery
 for arcuate keratotomies, 13.27, 13.27*f*, 13.53, 13.54–55
 for cataract surgery. *See also specific type of incision*
 and type of surgery

- clear corneal, 11.106*f*, 11.106–107
- closure of
- complications associated with, 11.130–131
 - after ECCE, 11.197–198
 - postoperative endophthalmitis and, 11.161
- complications associated with, 11.130–131
- flat or shallow anterior chamber, 11.134
- dehiscence/rupture of, 11.131
- for ECCE, 11.196
- wound closure and, 11.197–198
- for ICCE, 11.199–200
- induced astigmatism and, 11.131–132
- for manual small-incision surgery, 11.198
- modification of preexisting astigmatism and, 11.123–124
- for phacoemulsification
- clear corneal, 11.106*f*, 11.106–107
 - scleral tunnel, 11.107*f*, 11.107–108
- postoperative leaking and, 11.118, 11.130–131
- flat anterior chamber and, 11.135
 - angle-closure glaucoma and, 10.144–145
- after radial keratotomy, 13.53
- for radial keratotomy, 13.50, 13.50*f*
- traumatic rupture of, 13.52
- scleral tunnel
- for ECCE, 11.196
 - for phacoemulsification, 11.107*f*, 11.107–108
- self-sealing, beveled/biplanar, clear corneal
- incisions and, 11.106*f*, 11.106–107
- thermal wounds of, 11.131
- fornix, 6.162–163
- for intrastromal corneal ring segment placement, 13.64
- for keratorefractive surgery, 13.26–27, 13.27*f*
- limbal relaxing (LRIs), 6.163, 13.8*t*, 13.27*f*, 13.53–54, 13.54*f*, 13.54–58, 13.55*f*, 13.56*f*, 13.56*t*, 13.57*f*
- for orbital surgery, 7.116*f*, 7.116–121
- for trabeculectomy, 10.200, 10.201*f*, 10.202*f*
- Inciting eye. *See* Exciting eye
- Inclusion-cell disease (ML II), 8.178
- Inclusion conjunctivitis, chlamydial, 8.260, 8.263, 8.265
- in adults, 8.260, 8.263
 - in neonates, 8.260, 8.265
- Inclusion criteria, 1.4, 1.13, 1.24
- clinical trial interpretation and, 1.22
- Inclusion cysts, 6.250
- epidermal, of eyelid, 4.208, 4.208*f*, 7.168, 7.168*f*
 - epithelial, conjunctival, 4.59, 4.59*f*, 8.114, 8.114*f*
 - concretions and, 8.113–114
 - nevi and, 4.64, 8.340
- IncobotulinumtoxinA, 5.281, 7.238. *See also* Botulinum toxin
- Incomitant (noncomitant) deviations, 5.183, 5.184, 5.187, 6.16. *See also specific type*
- Incomitant esotropia, 6.95–97, 6.96*f*
- Incomitant strabismus
- abnormal head position caused by, 6.83
 - prism alternate cover test for, 6.66
- Incomplete achromatopsia, 6.337
- Incomplete penetrance (skipped generation), 2.177
- Incongruous visual field defects, 5.29
- retrochiasmal lesions producing, 5.153
- Incontinentia pigmenti (IP/Bloch-Sulzberger syndrome), 2.180, 6.393*t*, 6.404*t*, 6.404–405, 405*f*, 12.283*t*, 12.286
- Incorrect corrective lens artifact, in perimetry, 10.66
- Increased intraocular pressure. *See* Elevated intraocular pressure; Ocular hypertension
- Incretin mimetics, for diabetes mellitus, 1.46
- Incretins, 1.46
- Incyclo- (prefix), 6.16
- Incyclodiplopia, 6.119
- Incycloduction, 6.33. *See also* Intorsion
- Indapamide, 1.68*t*
- Indels, 2.133–134, 2.148
- Indentation (dynamic) gonioscopy, 10.35, 10.35*f*, 10.36
- in acute primary angle closure, 10.123
- Indentation (Schiotz) tonometry, 10.19, 10.26
- Independent assortment, 2.150, 2.187
- Indeterminate neoplastic proliferations, 4.10
- Index case (proband), 2.142, 2.172
- Index features, in diagnosis, 4.11
- Index of refraction. *See* Refractive index
- Indinavir, 1.270
- Indirect (dural) carotid-cavernous fistula, 7.72, 7.73
- Indirect (blowout) fractures
- of medial orbital wall, 7.8, 7.108
 - orbital cellulitis following, 7.47
 - of orbital floor, 7.108–112, 7.110*f*
 - diplopia after, 5.206, 7.108
 - infraorbital nerve and, 7.19
 - surgery for, 7.111–112
 - indications for, 7.110–111
 - of orbital roof, 7.106
- Indirect illumination, 3.292
- Indirect ophthalmoscope/ophthalmoscopy
- definition of, 3.281
 - description of, 3.298–300*f*, 3.298–301, 3.307
 - illumination in, 12.21
 - posterior vitreous detachment diagnosed using, 12.309, 12.331
 - retinal disease evaluations using, 12.21–22
 - transverse magnification of, 3.63
- Indirect traumatic optic neuropathy, 2.89, 5.139
- Individual effect, 1.22
- Individualized Education Plan (IEP), 6.188
- Indocyanine green (ICG), 2.367–368
- intravenous administration of, 2.301, 2.367. *See also* Indocyanine green (ICG) angiography
- Indocyanine green (ICG) angiography, 2.367, 5.89
- acute idiopathic maculopathy on, 12.228
 - acute posterior multifocal placoid pigment epitheliopathy on, 9.142*t*, 9.149, 9.149*f*, 12.222
 - acute retinal pigment epitheliitis on, 9.142*t*
 - acute zonal occult outer retinopathy on, 9.142*t*, 12.227
 - adverse effects of, 12.39
 - applications of, 12.38–39
 - birdshot uveitis on, 9.142*t*, 9.145, 9.146*f*
 - central serous chorioretinopathy on, 12.38, 12.192, 12.194*f*
 - choroidal hemangioma on, 4.281, 4.282*f*, 12.202*f*
 - choroidal melanoma/ciliary body melanoma on, 4.265
 - choroidal neovascularization on, 12.73
 - definition of, 12.38
 - dengue fever on, 9.213
 - description of, 3.303

- fundus camera for, 12.23
 giant cell arteritis findings, 12.196f
 HTLV-1 infection on, 9.212
 inflammatory chorioretinopathies on, 9.142t
 in low vision evaluation, 5.89
 multifocal choroiditis and panuveitis syndrome on, 9.142t, 9.156
 multiple evanescent white dot syndrome on, 5.101, 9.142t, 9.162, 9.162f, 9.163f, 12.223–224
 narrow-band interference filters in, 3.103
 polypoidal choroidal vasculopathy on, 12.38, 12.38f
 punctate inner choroiditis on, 9.142t, 9.158, 9.159f
 serpiginous choroiditis on, 9.142t
 subretinal fibrosis and uveitis syndrome on, 9.142t
 sympathetic ophthalmia on, 9.174, 9.174f
 syphilitic chorioretinitis on, 9.239
 tuberculous uveitis on, 9.252
 uveitis on, 9.90
 Vogt-Koyanagi-Harada syndrome on, 9.180
 West Nile virus chorioretinitis on, 9.209–210
- Indomethacin, 1.111, 2.335t, 2.336
 cornea verticillata caused by, 8.130
 prostaglandin synthesis affected by, 2.239
 for scleritis, 8.324
- Induced anisophoria
 compensating for, 3.186–190, 3.187f
 contact lenses for, 3.190
 dissimilar segments for, 3.189, 3.189f
 press-on prisms for, 3.188
 refractive surgery for, 3.190
 reverse slab-off for, 3.188–189
 single-vision reading glasses with lowered optical centers for, 3.189–190
 slab-off for, 3.188, 3.188f
- Induced convergence-retraction (convergence-retraction nystagmus/CRN), 5.243t, 5.250, 6.152–153
- Induced tropia test, 6.6
- Inert orbital implant, 7.131. *See also* Orbital implant
- Infantile, definition of, 2.181
- Infantile cataract, 11.34–39, 11.35t, 11.36f, 11.37f, 11.38f, 11.39f. *See also* Cataract, congenital
- Infantile esotropia, 6.86t
 amblyopia associated with, 6.87–89
 botulinum toxin injections for, 6.89
 Chavasse theory of, 6.87
 Ciancia syndrome, 6.88, 6.95
 clinical features of, 6.87–88
 cross-fixation associated with, 6.87–88, 6.88f
 cyclopegic refraction for, 6.88
 definition of, 6.87
 evaluation of, 6.87–88
 management of, 6.88–89
 medial rectus muscle recession for, 6.89
 mental illness and, 6.87
 ocular alignment in, 6.88–89
 pathogenesis of, 6.87
 prematurity as risk factor for, 6.87
 smooth-pursuit asymmetry associated with, 6.88
 surgical treatment of, 6.89
 V-pattern strabismus associated with, 6.109, 6.112t
 Worth “sensory” concept of, 6.87
- Infantile exotropia, 6.103–104, 6.104f
- Infantile glaucoma, 4.98, 4.99f, 10.4t, 10.147, 10.148t, 10.151. *See also* Glaucoma, pediatric; Primary congenital glaucoma
 corneal opacities associated with, 6.257t, 6.260, 6.261f
 description of, 6.230
- Infantile Hagberg-Santavuori disease, 6.389t
- Infantile (capillary) hemangioma. *See also* Hemangiomas
 amblyopia and, 7.68, 7.161
 of conjunctiva/ocular surface, 4.50, 8.345t, 8.345–346
 of eyelid, 4.214, 4.215f, 7.161–162, 8.345t, 8.345–346
 of orbit, 4.233, 7.67f, 7.67–68
 of retina. *See* Capillary hemangioblastoma; Retinal angiomatosis
 and thrombocytopenia (Kasabach-Merritt syndrome), 7.67–68
- Infantile malignant osteopetrosis, 6.212
- Infantile nystagmus syndrome (INS), 5.235–237, 5.237f, 6.83, 6.148–149, 6.149t, 6.156f, 6.187, 6.335. *See also* Congenital nystagmus
- Infantile primary congenital glaucoma. *See* Infantile glaucoma; Primary congenital glaucoma
- Infantile Refsum disease, 2.175t
 gene defects causing, 2.265, 2.266
- Infantile strabismus. *See also* Strabismus
 description of, 6.16
 dissociated vertical deviation associated with, 6.129
 fusion maldevelopment nystagmus syndrome associated with, 6.151, 6.154
 primary inferior oblique muscle overaction associated with, 6.117
- Infants. *See also* Children; Newborns; *specific Infantile entries*
 abusive head trauma in, 6.381–384, 6.382–383f, 12.365–366, 12.366f
 aphakia in, 3.225
 cataracts in, 6.293
 chlamydial infection in, 6.239
 congenital toxoplasmosis in, 12.243
 conjunctivitis in, 8.257t, 8.263–265. *See also* Ophthalmia, neonatorum
 corneal transplantation in, 8.450–451
 cystinosis in, 8.181
 cytomegalovirus infection in, 6.411, 6.411f
 decreased/low vision in. *See* Low vision, in infants
 delayed visual maturation in, 6.186–187
 extraocular muscles in, 6.181–182
 eye examination in, glaucoma and, 10.157, 10.157t
 eyelid retraction in, 5.274
 hemorrhagic disease of newborn in, 1.145
 hepatitis B immunization in, 1.219
 herpes simplex infection in, 1.258, 8.213
 Horner syndrome in, 5.261–262
 hyperopia in, 3.141
 intraocular pressure in
 measurement of, 6.181
 normal level of, 6.282
 Leber congenital amaurosis in, 12.265–266
 low vision in, 3.327–328
 neuronoid ceroid lipofuscinoses in, 12.289
 normal flora in, 8.205
 nystagmus in, 5.235–237, 5.237f

- ocular infections in, 8.257t, 8.263–265. *See also specific type*
- ophthalmia neonatorum in, 8.257t, 8.263–265.
See also Ophthalmia, neonatorum
- Refsum disease in, 12.290
- retinal hemorrhage in, 6.382–383, 383f
- retinopathy of prematurity in, 12.175
- trauma in, 12.316–317, 12.365–366, 12.366f
- vision in
decreased, 6.187–188
development of, 6.185
impairments in, 6.186–187
- visual evoked cortical potential in, 5.95
decreased vision and, 5.95
- visual evoked potentials application in, 12.53
- Infarction. *See also specific type/tissue or organ involved*
neuroimaging in evaluation of, 5.64f, 5.65t, 5.66, 5.67f, 5.75
- Infection (ocular), 8.208t. *See also specific type, structure affected, causative agent and under Infectious*
Acanthamoeba causing, 8.208t, 8.252, 8.276–279, 8.277f, 8.278f
- bacterial/bacteriology, 8.208t, 8.243–249, 8.244t.
See also Bacteria
corneal and scleral involvement and, 8.208t, 8.267–273, 8.268f, 8.269t, 8.270t, 8.273f, 8.282–283, 8.283f
eyelid margin and conjunctival involvement and, 8.255–266
- basic concepts and, 8.205–211, 8.208t, 8.209t, 8.211f
- canalicular obstruction caused by, 7.274
- contact lens–related, 3.230, 3.231f, 8.84, 8.266–267, 8.273–274, 8.276, 8.277
- corneal and scleral involvement and, 6.257t, 8.266–283. *See also Keratitis; Scleritis*
- corneal opacity and, 8.16f
- defense mechanisms and, 8.11–14, 8.12–13f, 8.13f, 8.206
- diagnostic laboratory techniques in, 8.208–211, 8.209t, 8.211f
- eyelid disorders caused by, 6.198–199
- eyelid margin and conjunctival involvement and, 8.254–266. *See also Conjunctivitis; Eyelids*
- fungal/mycology, 8.208t, 8.249–251
corneal and scleral involvement and, 8.282–283
eyelid margin involvement and, 8.254–255, 8.255f
- in infants and children
intrauterine and perinatal, corneal anomalies and, 8.107
ophthalmia neonatorum, 8.257t, 8.263–265
- Loa loa* causing, 4.228, 8.253, 8.282, 8.282f
- microbiology of, 8.207–211, 8.208t, 8.209t, 8.211f.
See also specific causative factor
- microsporidia causing, 8.280f, 8.280–281, 8.281f
- mycobacterial, 8.248
atypical organisms and, 8.248, 8.272–273, 8.273f
- neuroimaging in evaluation of, 5.72t
- normal flora and, 8.205–206, 8.206t
- parasitic/parasitology, 8.208t, 8.252–253
corneal and scleral involvement and, 8.208t, 8.266–283
eyelid margin involvement and, 8.254–255, 8.255f
- pathogenesis of, 8.206–207
- pediatric glaucoma and, 10.150t
after penetrating keratoplasty, 8.426, 8.426f
- postoperative, 6.170, 6.170f
- preseptal cellulitis caused by, 6.212–213
- prions causing, 8.254
- Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis) and, 8.295
- viral/virology, 8.208t, 8.211–241
- Infection control, in clinical tonometry, 10.27
- Infectious conjunctivitis, 4.52–53, 4.54f. *See also specific type and causative agent*
- Infectious crystalline keratopathy, 8.268, 8.268f
corneal deposits and, 8.182t
after penetrating keratoplasty, 8.427, 8.427f
- Infectious disease, 1.239–282. *See also Infection; specific organism and disorder*
antibiotic therapy and, 1.272–282, 1.273t
- external eye, 8.208t. *See also Infection; specific causative agent*
bacterial, 8.208t, 8.243–249, 8.244t, 8.255–266
basic concepts and, 8.205–211, 8.208t, 8.209t, 8.211f
corneal and scleral involvement and, 8.266–283.
See also Keratitis; Scleritis
diagnostic laboratory techniques in, 8.208–211, 8.209t, 8.211f
eyelid margin and conjunctival involvement and, 8.254–266. *See also Conjunctivitis; Eyelids*
fungal, 8.208t, 8.249–251, 8.254–255, 8.255f, 8.282–283
microbiology of, 8.207–211, 8.208t, 8.209t, 8.211f.
See also specific causative factor
normal flora and, 8.205–206, 8.206t
parasitic, 8.208t, 8.252–253, 8.254–255, 8.255f, 8.266–283
pathogenesis of, 8.206–207
prions causing, 8.254
viral, 8.208t, 8.211–241
- immunization in prevention of, 1.216–225
- microbiologic principles and, 1.239–241
- neuro-ophthalmic signs of, 5.348–357
- ocular inflammatory. *See Infectious ocular inflammatory disease*
- recent developments in, 1.239
- screening for, 1.215–216
- seventh nerve pathology caused by, 5.278t, 5.279–280
- Infectious endophthalmitis, 4.119, 4.119f, 4.127, 4.128f
- Infectious/microbial keratitis, 4.75–80, 4.76f, 4.77f, 4.78f, 4.79f, 4.80f, 4.81f, 8.208t, 8.266–279, 8.307–309, 8.309f. *See also specific type and causative agent*
clinical presentation of, 8.267–268, 8.268f, 8.274f, 8.274–275, 8.276–277, 8.277f
- contact lens wear and, 8.266–267, 8.273–274
for orthokeratology, 13.71
- interstitial disease and, 8.307–309, 8.309f
- intrauterine, 8.107
syphilitic, 4.80, 4.81f, 8.107, 8.308–309, 8.309f
- laboratory evaluation/causes of, 8.268–269, 8.269t, 8.275, 8.277, 8.278f
- after LASIK, 13.106f, 13.106–107, 13.107f, 13.117–119, 13.118f, 13.118t
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118f, 13.119t

- management of, 8.269–272, 8.270*t*, 8.275–276, 8.277–279
- orthokeratology and, 13.71
- pathogenesis of, 8.267, 8.273–274, 8.276
- after penetrating keratoplasty, 8.427
- after photoablation, 13.106*f*, 13.106–107, 13.107*f*
- recurrence of in graft, 8.225, 8.232
- specimen collection in evaluation of, 8.210, 8.211*f*
- stains and culture in identification of, 8.209*t*, 8.269, 8.273, 8.275
- Infectious mononucleosis (IM)
 - Epstein-Barr virus causing, 1.260, 9.202
 - ocular involvement in, 8.230–231, 8.231*f*, 9.202, 9.203*f*
- Infectious ocular inflammatory disease, 9.191–260.
 - See also specific type and causative agent*
 - bacterial uveitis, 9.236–259
 - endophthalmitis, 4.119, 4.119*f*, 4.127, 4.128*f*, 9.119, 9.271–272
 - intravitreal corticosteroids and, 9.98
 - fungal uveitis, 9.214–219
 - helminthic uveitis, 9.228–235
 - as masquerade syndrome, 9.280
 - protozoal, 4.147–148, 4.148*f*, 8.252, 9.219–227
 - Acanthamoeba* keratitis, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*
 - corneal opacity and, 8.16*f*
 - retinitis, 4.147–148, 4.148*f*
 - uveitis, 9.219–227
 - scleritis, 9.259–260
 - viral uveitis, 9.191–214
- Infectious pseudocrystalline/crystalline keratopathy, 4.79–80, 4.80*f*
 - after penetrating keratoplasty, 4.79
- Inferior infraorbital vein, 7.13*f*
- Inferior meatus, 2.6, 2.8, 5.11, 7.10, 7.18, 7.255. *See also* Inferior turbinate/concha
- Inferior muscular artery, 5.14–15
- Inferior oblique (IO) muscle, 2.7, 2.13, 2.13*f*, 2.14*f*, 2.15*t*, 2.20*f*, 5.36*f*, 5.46, 5.46*f*, 7.11, 7.14*f*, 7.146*f*
 - action of, 6.34*t*, 6.38*f*
 - advancement of, 6.166
 - anatomy of, 2.7, 2.13*f*, 2.14*f*, 2.20*f*, 5.36*f*, 5.46, 5.46*f*, 6.19*f*
 - anteriorization/anterior transposition of
 - anti-elevation syndrome caused by, 6.168
 - description of, 6.166
 - blood supply of, 2.15*t*, 2.33*f*, 2.34*f*
 - characteristics of, 6.21*t*
 - elevator function of, 6.73
 - field of action for, 6.33
 - innervation of, 2.17, 2.94*f*, 2.95, 5.40, 5.44, 5.44*f*, 7.12, 7.14*f*, 7.15*f*
 - description of, 6.19
 - surgical considerations and, 6.29
 - insertions of, 2.14*f*, 2.15, 2.15*t*
 - origins of, 2.15*t*, 2.17, 6.20, 6.21*t*, 6.28
 - overaction of
 - bilateral, 6.117
 - clinical features of, 6.117–118
 - in craniosynostosis, 6.208
 - description of, 6.17
 - latent dissociated vertical deviation versus, 6.129–130
 - management of, 6.118
 - overelevation in adduction caused by, 6.117*f*, 6.117–118
 - primary, 6.117
 - secondary, 6.117
 - in superior oblique muscle paralysis, 6.166
 - V-pattern strabismus caused by, 6.107
 - Y-pattern strabismus caused by, 6.113
 - palsy of
 - Brown syndrome versus, 6.124, 6.125*t*, 6.137
 - clinical features of, 6.124, 6.124*f*, 6.125*t*
 - management of, 6.124–125
 - pseudo-overaction of, 6.109, 6.113
 - pulley system, 6.28
 - tightening of, 6.166
 - transposition of, anterior, 6.166
 - underaction of, 6.17
 - weakening of
 - bilateral, 6.165
 - indications for, 6.118
 - for superior oblique muscle palsy, 6.123, 6.123*t*
 - surgical procedures for, 6.164*t*, 6.165–166
 - for V-pattern strabismus, 6.111
- Inferior oblique tendon, 2.14*f*
- Inferior ophthalmic vein, 5.8*f*, 5.21*f*, 5.22, 5.22*f*, 5.23*f*, 7.14*f*
- Inferior orbital fissure, 2.6*f*, 2.8–10, 5.7*f*, 5.9*f*, 5.11, 7.6*f*, 7.7*f*, 7.8*f*, 7.9
- Inferior orbital groove, 5.9*f*
- Inferior orbital vein, 6.23
- Inferior palpebral artery, 5.13*f*
- Inferior palpebral vein, 5.21*f*
- Inferior petrosal nerve, 2.103
- Inferior petrosal sinus, 2.106*f*, 5.22, 5.23*f*
- Inferior punctum, 2.29
- Inferior rectus (IR) muscle, 2.9*f*, 2.13, 2.13*f*, 2.14*f*, 2.15*t*, 2.16*f*, 2.20*f*, 5.8*f*, 5.36*f*, 5.45, 5.46*f*, 7.11, 7.13*f*, 7.14*f*, 7.15*f*, 7.146*f*
 - action of, 6.34*t*, 6.36*f*
 - anatomy of, 2.9*f*, 2.13*f*, 2.14*f*, 2.16*f*, 2.20*f*, 5.8*f*, 5.36*f*, 5.45, 5.46*f*
 - blood supply of, 2.15*t*, 2.17, 2.33*f*, 2.34*f*
 - depressor function of, 6.73
 - flap tears of, 6.127–128
 - injury of, in orbital floor/blowout fracture, 7.108, 7.109–110
 - innervation of, 2.17, 2.94*f*, 2.95, 5.44, 5.44*f*, 6.19, 7.12, 7.14*f*, 7.15*f*
 - insertions of, 2.13–15, 2.14*f*, 2.15*t*
 - lateral border of, 6.29
 - neurofibrovascular bundle, 6.29
 - origins of, 2.15*t*, 2.17, 6.20, 6.22*f*
 - recession/resection of
 - description of, 6.29
 - eyelid position affected by, 6.173
 - surgery of
 - considerations for, 6.29
 - for orbital floor/blowout fracture, 7.109–110
 - weakening of
 - for nystagmus, 6.156
 - procedures for, 6.163, 6.164*t*
- Inferior rectus tendon, 2.13*f*, 2.14*f*, 6.19*f*

- Inferior retinal arcade, 5.14
 Inferior sagittal sinus, 5.22f
 Inferior staphyloma syndrome, 12.217, 12.217f
 Inferior–superior (I–S) values, 8.31, 13.4
 after intrastromal corneal ring segment implantation, 13.66
 in keratoconus/corneal ectasia, 8.32t, 8.165, 8.165f
 Inferior tarsal muscle, 7.151
 Inferior turbinate/concha, 7.18, 7.253f, 7.254f
 infracture of, for congenital nasolacrimal duct obstruction, 7.265
 Inferolateral displacement of globe, in orbital disorders, 7.24
 Inferolateral trunk, 5.12
 Inferomedial displacement of globe, in orbital disorders, 7.24
 Inferonasal disc coloboma, 6.365f
 Infiltrative dermopathy (pretibial myxedema), hyperthyroidism/thyroid eye disease and, 1.53, 7.56
 Infiltrative lesions, orbital, 5.126f, 5.126–127
 Infiltrative optic neuropathy, 5.107t, 5.126f, 5.126–127, 5.131–133
 Inflamase Forte. *See* Prednisolone
 Inflammation (ocular), 3.231t, 3.233–234, 4.6–9, 4.8f, 4.9f, 4.12t, 9.12–13, 9.69–301. *See also* Endophthalmitis; Uveitis; *specific type or structure affected*
 acute, 4.6, 4.13
 angle-closure glaucoma and, 10.138f, 10.138–139, 10.139f
 anisocoria and, 5.258t
 canalicular obstruction caused by, 7.274
 lacrimal gland tumors causing, 7.94, 7.274
 cataracts/cataract surgery and, 11.64f, 11.64–66, 11.139–140, 11.170–171
 postoperative, 11.139–140
 retained lens material and, 11.141
 trauma and, 11.191
 in chemical injury, management and, 8.382–384
 choroidal. *See also* Chorioretinitis;
 Chorioretinopathy; Choroidopathy
 posttraumatic, 4.22, 4.22f
 chronic, 4.6–7
 local antibody production and, 9.44
 conjunctival, 4.50f, 4.50–55, 4.51f, 4.52f, 4.53f, 4.54f, 4.55f
 corneal, 4.75–81, 4.76f, 4.77f, 4.78f, 4.79f, 4.80f, 4.81f
 eyelid, 4.203–204, 4.204f, 4.205f, 4.206f, 6.198–199
 glaucoma and, 10.100–102, 10.102f, 10.138f, 10.138–139, 10.139f
 granulomatous, 4.7
 focal posttraumatic choroidal, 4.22, 4.22f
 immunity and, 9.12–13
 infectious diseases and, 9.191–260
 bacterial uveitis, 9.236–259
 endophthalmitis, 9.119, 9.271–272
 intravitreal corticosteroids and, 9.98
 fungal uveitis, 9.214–219
 helminthic uveitis, 9.228–235
 as masquerade syndrome, 9.280
 protozoal, 4.147–148, 4.148f, 8.252, 9.219–227
 Acanthamoeba keratitis, 8.208t, 8.252, 8.276–279, 8.277f, 8.278f
 corneal opacity and, 8.16f
 retinitis, 4.147–148, 4.148f
 uveitis, 9.219–227
 scleritis, 9.259–260
 viral uveitis, 9.191–214
 lens-related, 4.118–119, 4.119f
 mediators of, 9.22t, 9.22–30, 9.23f, 9.25f, 9.27–28t.
 See also Mediators
 nasolacrimal duct obstruction caused by, 7.278
 nongranulomatous, 4.7
 noninfectious, 9.111–189. *See also* Noninfectious
 ocular inflammatory diseases
 nonspecific orbital, 6.215–216, 6.216f
 NSAIDs for, 1.172
 open-angle glaucoma and, 10.100–102, 10.102f
 optic nerve, 4.243f, 4.243–245, 4.244f, 4.245f
 orbital, 4.224–226, 4.225f, 6.215–216, 7.43t, 7.43–66.
 See also Nonspecific orbital inflammation
 autoimmune, 7.43t
 granulomatous, 7.43t
 in histiocytic disorders, 7.90
 infectious, 7.43t, 7.44–51
 noninfectious, 7.51–66
 pain in, 5.295
 vasculitic, 7.43t, 7.60–63, 7.62f
 pupil irregularity and, 5.255
 retinal, 4.145–148, 4.146f, 4.147f, 4.148f
 in retinoblastoma, 4.291, 4.291t, 9.277
 scleral, 4.109–110, 4.110f, 4.111f
 treatment of. *See* Anti-inflammatory agents
 uveal tract, 4.185–187, 4.186f, 4.187f, 4.188f. *See also* Uveitis
 in uveitis, 6.320–322
 vitreal, 2.254, 4.127, 4.128f. *See also* Endophthalmitis;
 Vitritis
 in wound healing/repair, 4.13
 Inflammatory anemia, 1.137
 iron deficiency differentiated from, 1.135
 Inflammatory anisocoria, 5.258t
 Inflammatory bowel disease (IBD), 1.155, 9.116
 Inflammatory infiltrate, necrobiotic granulomatous, in episcleritis, 4.109
 Inflammatory (stimulated/reparative) macrophages, 9.19, 9.20f, 9.21
 Inflammatory mediators, 9.22t, 9.22–30, 9.23f, 9.25f, 9.27–28t. *See also* Mediators
 Inflammatory optic neuropathy, 5.113–118, 5.114f, 5.117t. *See also* Optic neuritis
 chronic relapsing, 5.116
 pain in, 5.295–296
 Inflammatory pseudoguttae, 8.52
 Inflammatory pseudotumor. *See* Nonspecific orbital inflammation
 Inflammatory response, 9.12–13, 9.69–301. *See also* Endophthalmitis; Inflammation (ocular); Uveitis; *specific type or structure*
 immunity and, 9.12–13
 local antibody production and, 9.44
 Inflammatory vascular tumors, conjunctival/ocular surface, 8.346f, 8.346–347
 Inflammatory vasculitis, 12.230, 12.230t. *See also* Vasculitis
 Infliximab, 1.174, 1.175, 6.322, 9.42, 9.106–107, 9.107
 for Behçet disease, 1.169, 9.188
 for Mooren ulcer, 8.316

- for peripheral ulcerative keratitis, 8.313
- for sarcoidosis, 9.171
- for scleritis, 8.324
- for uveitis, 9.106–107, 9.107
- Influenza virus, 8.239, 8.240*t*
 - antiviral agents for infection with, 1.220, 1.281
 - immunization against, 1.218*t*, 1.220
 - uveitis associated with, 9.121
- Informed consent, 1.284
 - for cataract surgery, 11.87–88
 - for facial rejuvenation surgery, 7.241
 - older patients and, 1.181
 - for refractive surgery, 13.36*t*, 13.46–48, 13.47*t*
 - in patient with ocular or systemic disease, 13.171–172
 - phakic IOL insertion and, 13.140–141
 - refractive lens exchange and, 13.147–148
- Infraciliary blepharoplasty incision, for orbitotomy, 7.118
- Infracture of turbinates, for congenital nasolacrimal duct obstruction, 7.265
- Infraduction, 6.33. *See also* Depression of eye
- Infranuclear pathways, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*, 5.211
 - disorders of, 5.191–206, 5.193*f*, 5.194*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.204*f*. *See also* Diplopia
- Infraorbital artery, 5.12, 5.13*f*, 5.14*f*, 5.15*f*, 6.23
 - extraocular muscles supplied by, 2.17
 - orbit supplied by, 2.33*f*
- Infraorbital canal, 2.6*f*, 2.8, 2.16*f*, 5.11, 7.9
- Infraorbital foramen, 2.7, 5.9*f*, 7.6*f*
- Infraorbital groove, 2.7, 7.9
- Infraorbital nerve, 2.8, 2.100, 5.48*f*, 5.49, 7.12*f*, 7.17*f*, 7.145*f*
 - hypoesthesia in distribution of
 - in orbital floor/blowout fracture, 7.19, 7.109
 - after orbital surgery, 7.125
 - lacrimal functional unit innervated by, 8.5*f*
- Infraorbital vein, 2.9*f*, 2.35*f*, 5.21*f*
 - inferior, 7.13*f*
- Infrared laser, 12.374. *See also* Lasers
- Infrared meibography, 8.40, 8.40*f*
- Infrared (IR) radiation. *See also* Radiation
 - lens affected by, 11.57
- Infratrochlear artery, 5.12
- Infratrochlear nerve, 7.14*f*, 7.15*f*, 7.145*f*
- Inhaled insulin, 1.46
- Inhalers, metered-dose, β_2 -adrenergics for pulmonary disease and, 1.133
- Inheritance. *See also* Genetics; *specific disorder*
 - codominant, 2.133
 - digenic, 2.134
 - dominant, 2.134, 2.173–174, 2.177
 - autosomal, 2.177–178, 2.178*t*
 - disorders associated with, 2.134
 - gene therapy for, 2.169–170, 2.170*f*
 - X-linked, 2.180–181
 - X-linked, 2.179–180, 2.181*t*
 - maternal, 2.157, 2.181
 - multifactorial/polygenic, 2.140, 2.141, 2.200–201
 - patterns of, 2.173–181
 - recessive, 2.142, 2.173–174
 - autosomal, 2.174–177, 2.175*t*, 2.177*t*
 - disorders associated with, 2.142, 2.174–177, 2.175*t*
 - gene therapy for, 2.169
 - X-linked, 2.179, 2.180*t*
 - sex-linked, 2.143
 - X-linked, 2.145, 2.178–181
 - disorders associated with, 2.180–181
 - gene therapy for, 2.169
 - Y-linked, 2.145
- Inherited disorders
 - metabolic. *See* Metabolic disorders
 - migrainelike headache and, 5.294–295
 - neuro-ophthalmic signs of, 5.328–333, 5.334*t*.
See also specific disorder
- Inhibitors (drug), 2.304
- Injection drug use. *See* Substance abuse disorders
- INL. *See* Inner nuclear layer
- Inlays, corneal, 13.59–71, 13.169
 - alloplastic, 13.28, 13.60–61, 13.61*f*
 - homoplastic, 13.60
 - in keratophakia, 13.60–61, 13.61*f*
 - for presbyopia, 13.59–71, 13.169
- Innate immune response/innate immunity, 1.239–240, 9.9, 9.12–13, 9.13–21, 9.14*t*
 - bacteria-derived molecules in, 9.13–16, 9.14*t*
 - complement and, 9.22–23, 9.23*f*
 - effector reactivities of, 9.13–21, 9.14*t*
 - inflammation and, 9.12–13
 - macrophage recruitment and activation and, 9.14*t*, 9.19–21, 9.20*f*
 - mediator systems in, 9.22*t*, 9.22–30, 9.23*f*, 9.25*f*, 9.27–28*t*. *See also* Mediators
 - neutrophil recruitment and activation and, 9.14*t*, 9.16–19, 9.18*f*
 - overview of, 9.12–13
 - receptors in, 9.12
 - triggers of, 9.13–21, 9.14*t*
 - in viral conjunctivitis, 9.55
- Inner ischemic retinal atrophy, 4.151, 4.151*f*
 - in diabetic retinopathy, 4.159
 - in retinal arterial and venous occlusions, 4.156, 4.159
- Inner nuclear layer (INL), 2.70*f*, 2.71*f*, 2.74, 2.74*f*, 2.76*f*, 2.88*f*, 2.258*f*, 2.266*f*, 2.266–268, 2.267*f*, 2.268*f*, 4.140*f*, 4.141*f*
 - histology of, 12.11, 12.12*f*, 12.15*f*
 - paracentral acute middle maculopathy of, 12.143
- Inner-outer segment (IS/OS) junction, 12.12
- Inner plexiform layer (IPL), 2.70*f*, 2.71*f*, 2.74, 2.74*f*, 2.88*f*, 4.140*f*, 4.141*f*, 12.11, 12.12*f*
- Inner segments (IS), 2.69, 2.70, 2.70*f*, 2.72*f*, 2.74*f*, 4.140*f*.
See also Cone inner segments; Rod inner segments
 - of cones, 12.11, 12.12*f*
 - ellipsoid, 12.12
 - free-radical leakage from, 2.285
 - of rods, 12.11, 12.12*f*
- Innominate artery, 5.12, 5.13*f*, 5.19
- INO. *See* Internuclear ophthalmoplegia
- Inoculum, 8.206
- Inositol, in aqueous humor, 2.232
- Inositol-1,4,5-triphosphate (IP₃), in tear secretion, 2.218, 2.218*f*
- Inotropic agents, for heart failure, 1.110
- INR. *See* International normalized ratio
- INS. *See* Infantile nystagmus syndrome
- Insect hairs/stings, ocular injury/infection caused by, 8.386–387
- Insertions, mitochondrial DNA, disorders caused by, 2.157

- Insomnia
 benzodiazepines for, 1.194
 fatal, 5.357
 Inspection, in orbital disorders, 7.23–25, 7.24f, 7.25f
 Instantaneous radius of curvature (meridional/tangential power), 13.16–17, 13.17f
 Instrument myopia, 3.282, 3.286
 Instrumental activities of daily living (IADL). *See also*
 Activities of daily living
 preoperative assessment of, 1.180
 Instrumentation. *See* Ophthalmic instruments; Surgical instruments
 Insulin. *See also* Insulin therapy
 in glucose metabolism/diabetes mellitus, 1.33, 1.34
 Insulin aspart, 1.41t
 Insulin degludec, 1.41t
 Insulin-dependent diabetes mellitus, 6.408, 12.91.
 See also Diabetes mellitus (DM), type 1
 Insulin detemir, 1.41t
 Insulin glargine, 1.41t
 Insulin glulisine, 1.41t
 Insulin growth factor-1 (IGF-1), retinopathy of
 prematurity screening and, 12.182
 Insulin isophane suspension, 1.41t
 Insulin-like growth factor 1 (IGF-1), 2.371–372
 in aqueous humor, 2.234, 2.235
 in retinopathy of prematurity pathophysiology, 6.325, 6.326t
 in thyroid eye disease, 7.55
 Insulin-like growth factor binding proteins (IGFBPs),
 in aqueous humor, 2.234, 2.235
 Insulin lispro, 1.41t
 Insulin-neutralizing antibodies, 1.43
 Insulin pumps, 1.42
 surgery and, 1.287
 Insulin resistance
 immunologic, insulin therapy and, 1.43
 obesity/metabolic syndrome/glucose toxicity and,
 1.34, 1.36, 1.88
 Insulin therapy, 1.41t, 1.41–43
 allergic reactions and, 1.43
 complications of, 1.43
 inhaled, 1.46
 intensive (tight control). *See also* Glycemic control
 management and, 1.40–41, 1.41–42
 prevention and, 1.38–39, 1.39f
 recent developments in, 1.46
 surgery and, 1.287
 in type 2 diabetes mellitus, 1.41, 1.42, 1.43, 1.44f
 types of insulin for, 1.41t
 Insulinoma, in multiple endocrine neoplasia, 1.59
 Intacs, 13.63. *See also* Intrastromal corneal ring
 segments
 corneal crosslinking with, 13.207
 Integrase strand transfer inhibitors, for HIV infection/
 AIDS, 1.266
 Integrins
 Candida virulence and, 8.206
 in external eye defense, 8.12–13f
 in neutrophil rolling, 9.17
 Intelligent Research in Sight (IRIS) Registry, 1.26
 Intense pulsed-light (IPL) therapy
 for meibomian gland dysfunction, 8.69
 for rosacea, 8.71
 Intention-to-treat analysis, 1.14
 Intercavernous sinus, 2.106f
 Intercellular adhesion molecules (ICAMs). *See also*
 Cell-adhesion molecules
 in neutrophil rolling, 9.17
 Interdigitation zone, 4.141f
 Interface. *See* Graft–host interface
 Interface debris, after LASIK, 13.122, 13.123f
 Interference, 3.99–103
 applications of, 3.103
 constructive, 3.100, 3.119
 definition of, 3.91
 destructive, 3.100, 3.119
 pictorial representation of, 3.101f
 subtractive, 3.100
 Interference filters, narrow-band, 3.103, 3.104f
 Interferogram, 12.25
 Interferometry
 coherence length and, 3.101–102
 coherence time and, 3.101–102
 concept of, 3.102f
 description of, 3.303
 low-coherence, 3.102, 3.304, 8.21
 in meibomian gland dysfunction, 8.40, 8.40f
 Interferon- α . *See* Interferons (IFNs),
 α (interferon- α)
 Interferon α -2a, 12.300
 Interferon- γ release assay, for tuberculosis, 1.215,
 1.254, 9.32, 9.253
 Interferons (IFNs), 2.370–371, 9.26, 9.28t
 α (interferon- α), 9.28t
 for Behçet disease, 1.169, 9.189
 for delta hepatitis, 1.261
 for hepatitis C, 1.262
 for infantile (capillary) hemangioma, 7.162
 for Mooren ulcer, 8.316
 for ocular surface tumors, 8.327, 8.330, 8.330f,
 8.331, 8.331f
 conjunctival papilloma, 8.238–239, 8.239,
 8.333
 optic neuropathy caused by, 5.137
 for uveitis, 9.108
 β
 for Kaposi sarcoma, 1.270
 for multiple sclerosis, 5.321t
 for cystoid macular edema, 9.289
 γ , 9.28t
 blood test for tuberculosis and, 1.215, 1.254, 9.32,
 9.253
 in delayed hypersensitivity, 9.38, 9.46
 in helper T-lymphocyte differentiation, 9.37
 for hepatitis B, 1.219–220, 1.261
 for Mooren ulcer, 8.316
 ocular effects of, 1.307t
 for ocular surface tumors, 8.327, 8.330, 8.330f, 8.331,
 8.331f
 conjunctival papilloma, 8.238–239, 8.239, 8.333
 in tear film, 2.216–217
 Intergroup Rhabdomyosarcoma Study Group
 (IRSG), 7.83
 INTERHEART study, 1.82
 Interlenticular membranes, piggyback IOLs and,
 13.150
 Interlenticular opacifications, IOL, 11.151

- Interleukin-1
 drugs inhibiting, 1.175
 in dry eye, 8.53
 in external eye defense, 8.11–13, 8.12f
 for rheumatic disorders, 1.151
 in tear film, 8.11–13, 8.12f
- Interleukin-1 receptor antagonist (IL-1RA), in external eye defense, 8.6f, 8.12f
- Interleukin-1 α , 9.27t
 in tear film, 2.217
- Interleukin-1 β , in tear film, 2.217
- Interleukin-2, 9.27t
 for cancer chemotherapy, 1.236
 in immune processing, 9.36f, 9.37
- Interleukin-4, 9.27t
 in delayed hypersensitivity, 9.46
 in helper T-lymphocyte differentiation, 9.37
- Interleukin-5, 9.27t
 in delayed hypersensitivity, 9.46
 in eosinophil activation, 9.10
- Interleukin-6, 9.27t
 drugs affecting, 1.175
 in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.274
 for rheumatic disorders, 1.151
 thyroid eye disease and, 7.55
 in uveitic cystoid macular edema, 9.289
- Interleukin-8, 9.27t
 thyroid eye disease and, 7.55
- Interleukin-10, in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.274
- Interleukins, 9.26, 9.27t
 for cancer therapy, 1.236
 in delayed hypersensitivity, 9.46
 in external eye defense, 8.6f, 8.11–13, 8.12f
 for rheumatic disorders, 1.151
 thyroid eye disease and, 7.55
- Intermarginal sulcus (gray line), 2.19, 2.22f, 2.215, 7.149, 7.153, 7.154f
- Intermediate-acting insulin, 1.41t
- Intermediate capillary plexus, 12.16
- Intermediate uveitis (IU), 6.312t, 6.316, 6.316f, 6.320, 6.321t, 9.72t, 9.73, 9.74–75t, 9.78, 9.83, 9.127–132, 12.231–232. *See also* Pars planitis; Uveitis; *specific cause*
 flowchart for evaluation of, 9.74–75t
 in HIV infection/AIDS, 9.293
 HLA association in, 9.67t
 HTLV-1 causing, 9.212
 incidence/prevalence of, 9.87t
 in inflammatory bowel disease, 9.116
 in Lyme disease, 9.245
 multiple sclerosis and, 5.318, 9.129, 9.132
 noninfectious, 9.127–132
 signs of, 9.83
 symptoms of, 9.78
- Intermediate zone, of lens epithelium, 2.64, 2.65f
- Intermediated filaments, 2.245
- Intermittent ataxia, 2.175t
- Intermittent exotropia
 age at onset, 6.99
 basic, 6.101
 characteristics of, 6.99–100
 control of, 6.100
 course of, 6.99
 dissociated horizontal deviation and, 6.105
 evaluation of, 6.100–101
 nonsurgical management of, 6.101–102
 normal retinal correspondence in, 6.99
 occlusion therapy for, 6.102
 patch test for, 6.101
 postoperative alignment, 6.102
 prisms for, 6.102
 recurrence of, 6.103
 refractive errors in, 6.101
 surgical treatment of, 6.102–103
 tenacious proximal fusion in, 6.71
 treatment of, 6.101–103
- Intermittent strabismus, 6.182
- Intermuscular septum, 2.31, 6.28–29, 7.11
- Internal (transconjunctival) approach, in ptosis repair, 7.220, 7.220f
- Internal auditory artery, 5.20
- Internal carotid artery (ICA), 2.90, 2.105, 5.10f, 5.12, 5.13f, 5.14, 5.15f, 5.16f, 5.18f, 5.27f, 7.13, 7.14f, 7.15f, 7.154
 aneurysm of, 5.338, 5.339f
 chiasmal syndromes caused by, 5.147, 5.150
 third nerve (oculomotor) palsy and, 5.194, 5.194f, 5.196, 5.196f, 5.339
 atherosclerosis of, stroke/transient ischemia attack and, 1.124
 cranial nerve relationship and, 2.84f, 2.85f, 5.42f, 5.43f
 dissection of, 5.342–343
 Horner syndrome and, 5.162, 5.260t, 5.261, 5.262f, 5.297
 pain caused by, 5.297, 5.342
 optic nerve supplied by, 2.84f, 2.85f, 2.90, 2.91
- Internal (endonasal) dacryocystorhinostomy (DCR), 7.279, 7.280f, 7.281f
 endoscopic, 7.280
- Internal hordeolum, 7.162, 7.163, 8.77. *See also* Chalazion
- Internal jugular vein, 5.22, 5.22f, 5.23
 lesions of, Horner syndrome and, 5.260t
- Internal limiting membrane (ILM), 2.70f, 2.71f, 2.75, 2.88f, 2.258f, 4.140f
 amacrine cells in, 12.15
 anatomy of, 12.15
 epiretinal membranes, 12.332
 hemorrhagic detachment of, 12.171
 histology of, 12.11, 12.12f
 nonproliferative sickle cell retinopathy findings, 12.150
 optic nerve/nerve head/disc, 2.86, 2.88f
 peeling of, 12.209
 in retinal healing/repair, 4.17
 vitreous detachment and, 2.253, 4.129
 vitreous remnants on, 12.332
- Internal medullary lamina, 5.34
- Internal radiation therapy. *See* Brachytherapy
- Internal scleral sulcus, 2.48, 4.98
- Internal ulcer of von Hippel, 4.74, 4.75f
- International Agency for the Prevention of Blindness (IAPB), 11.6

- International Classification of Retinoblastoma (ICRB), 6.354, 6.356*t*
- International Classification of Retinopathy of Prematurity (ICROP), 6.325, 6.327*t*
- International Classification System for Intraocular Retinoblastoma (ABC System), 4.297, 4.297*t*
- International Committee for the Classification of Corneal Dystrophies (IC3D), 8.133–134, 8.134*t*, 8.135*t*
- International Diabetes Federation, metabolic syndrome defined by, 1.88
- International Federation for Clinical Neurophysiology electrophysiologic testing standards, 12.41
- International normalized ratio (INR), 1.142
- International Reading Speed Texts (iReST), 3.318
- International Society for Clinical Electrophysiology of Vision (ISCEV)
electrophysiologic testing standards of, 12.41
full-field electroretinography standards, 12.42, 12.43*f*
- International Society of Refractive Surgery (ISRS), K-Card developed by, 13.194
- International Standards Organization (ISO), intraocular lens standards of, 3.263–264
- International Vitreomacular Traction Study Classification System, 12.336*t*
- Internuclear lesions, diplopia caused by, 5.189–191, 5.190*f*, 5.191*f*
- Internuclear ophthalmoplegia (INO), 5.38, 5.189–190, 5.190*f*, 5.247, 6.144
bilateral/wall-eyed bilateral (WEBINO), 5.189, 5.190*f*
in multiple sclerosis, 5.318
in multiple sclerosis, 5.318
in neuromyelitis optica, 5.322
nystagmus in, 5.189, 5.190*f*, 5.247
pursuit dysfunction in, 5.226
- Interpalpebral fissure, vertical, height of, in ptosis, 7.210, 7.210*f*
- Interphase, 2.149
- Interphotoreceptor matrix (IPM), 2.273, 2.275*f*
retinal pigment epithelium in maintenance of, 2.273
- Interphotoreceptor retinoid-binding protein (IRBP), 2.275, 2.275*f*, 4.172
in AIRE (autoimmune regulator)-deficient mice, 9.64
in experimental autoimmune uveoretinitis, 9.63
transgenic mice/specific T-cell receptor and, 9.64
- Interphotoreceptor retinoid-binding protein (IRBP)—derived peptides, in experimental autoimmune uveoretinitis, 9.63
- Interphotoreceptor retinoid-binding protein (IRBP)-specific T-cell receptor transgenic mice, 9.64
- Interplexiform cells, 5.24
- Interpulse time (TI), 5.75
- Interpupillary distance, 6.203
bifocal segment decentration and, 3.191
in spectacle lens prescription, 3.198
- Interrater reliability, 1.24
- Interrupted sutures, for penetrating keratoplasty, 8.419*f*
removal/adjustment of, 8.419*f*, 8.431–432, 8.432*f*
- Intersaccadic interval, 5.213
saccadic intrusions/oscillations and
normal, 5.247–248, 5.248*f*
not normal, 5.248*f*, 5.248–249
- Intersexes, 2.192
- Interstitial keratitis (IK), 4.80, 4.81*f*, 8.46*t*. *See also* Keratitis
- Epstein-Barr, 8.230, 8.231*f*
glaucoma and, 10.139
herpetic, 4.77*f*, 4.78, 4.80, 8.219–220, 8.220*f*, 8.222
HTLV-1-related (HTLV-1-associated keratopathy), 9.212
in infectious disease, 8.307–309, 8.309*f*
syphilitic, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*, 9.237, 9.237*f*
intrauterine infection and, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
- Interstitial nucleus of Cajal (INC), 5.35, 5.35*f*
saccadic eye movements and, 5.220–221
vertical gaze and, 5.36, 5.36*f*, 5.38
- Interstitial nucleus of medial longitudinal fasciculus, rostral (riMLF), 5.33, 5.35, 5.35*f*, 5.220
saccadic eye movements and, 5.220
vertical gaze and, 5.36, 5.36*f*, 5.220
- Intervening sequence. *See* Intron
- Interventional (experimental) studies (clinical trials), 1.7, 1.8, 1.8*f*, 1.13*f*, 1.13–14. *See also* Clinical research/studies
cohort study differences and, 1.13, 1.13*f*
for new drug, 2.305
systematic reviews/meta-analyses of, 1.8, 1.8*f*, 1.14
- Intorsion (incycloduction)
A-pattern strabismus caused by, 6.107, 6.110
definition of, 6.33
extraocular muscles in, 5.46*f*
oblique muscles, 5.46*f*
rectus muscles, 5.46*f*
- Intra-arterial chemotherapy, for retinoblastoma, 4.299–300, 4.300*f*
- Intra-arterial thrombolysis/therapy, for ischemic stroke, 1.119, 1.123
- Intra-axial ocular motor nerve course, 5.41*f*
- Intra-axial ocular motor nerve palsies, 5.191
- Intracameral injections, 2.299, 2.300*t*
acetylcholine, 2.300*t*, 2.309, 2.310
carbachol, 2.300*t*, 2.309, 2.310
cefuroxime, during cataract surgery, 11.94, 11.162
lidocaine, 2.300*t*, 2.365–366
during cataract surgery, 11.92, 11.137
- Intracanalicular plugs, for dry eye, 8.64
- Intracanalicular region of optic nerve, 2.83, 2.85*t*, 2.89–90, 4.241
blood supply of, 2.85*t*, 2.89, 2.91
compressive lesions of, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*. *See also specific lesion*
one-and-a-half syndrome and, 5.191
- Intracapsular cataract extraction (ICCE), 3.240, 11.90, 11.199–201, 11.200*f*. *See also* Cataract surgery
globe exposure for, 11.199
historical overview/key developments in, 11.90, 11.119, 11.120*f*, 11.195
incision for, 11.199–200
IOLs for, 11.200
iridectomy/lens delivery in, 11.200, 11.200*f*
patient preparation for, 11.199
postoperative course for, 11.201
postoperative flat or shallow anterior chamber and, 11.135

- retinal detachment and, 11.166
- suture-induced astigmatism after, 11.131–132
- wound closure and, 11.200–201
- in zonular dehiscence with lens subluxation or dislocation, 11.182
- Intracapsular IOL dislocation, 11.144, 11.144f, 11.145
- Intracavernous carotid aneurysms, 5.339–340
- Intracavernous ocular motor nerve course, 5.43f
- Intracerebral hemorrhage, 1.126. *See also* Intracranial hemorrhage
- Intraconal fat pads, 6.28
- Intraconal fat/surgical space (central surgical space), 7.11, 7.115f, 7.116
- Intraconal orbital abscesses, 6.214
- IntraCor (corneal intrastromal femtosecond laser treatment), 13.168
- Intracorneal inlays. *See* Corneal inlays
- Intracranial aspergilloma, 5.353–354
- Intracranial hemorrhage, 1.126–127
 - arteriovenous malformations causing, 1.126, 1.127, 5.343
 - headache caused by, 1.126, 1.127, 5.288
 - neuroimaging in evaluation of, 5.72t
 - ruptured aneurysm causing, 1.126, 1.127, 5.340
- Intracranial hypertension (increased intracranial pressure/ICP)
 - headache caused by, 5.107, 5.110, 5.112, 5.113, 5.288
 - idiopathic (IIH/pseudotumor cerebri/PTC), 5.110–113, 5.111t
 - in children, 5.113
 - headache and, 5.110, 5.112, 5.113, 5.288
 - optic nerve/nerve head/disc edema and. *See* Papilledema
 - ruptured aneurysms causing, 5.340
 - symptoms associated with, 5.107, 5.110–111, 5.111t
- Intracranial pinealoblastoma, primary, retinoblastoma and, 4.298, 4.302
- Intracranial pressure (ICP), 6.209, 6.370
- Intracranial region of optic nerve, 2.83, 2.85t, 2.90, 2.90f, 4.241, 5.26–27
 - blood supply of, 2.85t, 2.90, 2.91, 2.92f
 - meningioma involving, 5.127–129, 5.128f
- Intracranial retinoblastoma, ectopic, 4.298
- Intracytoplasmic sperm injection (ICSI), 2.207
- Intradermal (dermal) nevus, 4.219, 4.220f, 7.173
- Intraepithelial dyskeratosis, benign hereditary, 8.332t
- Intraepithelial melanosis, 4.65–68, 4.66f, 4.67f
- Intraepithelial neoplasia
 - conjunctival (CIN), 4.61, 4.63f, 4.96, 8.37, 8.38f, 8.332t, 8.334–335, 8.335f. *See also* Ocular surface squamous neoplasia
 - melanocytic, 4.63t, 4.65, 4.66, 4.67f
 - corneal, 4.61, 4.63f, 4.96, 8.37, 8.38f, 8.332t, 8.334–335, 8.335f
- Intraepithelial (junctional) nevus, 8.338t, 8.340
- Intralenticular fibrosis, 3.241
- Intralenticular foreign bodies, 11.57
- Intralesional hemorrhage, 6.221, 6.221f
- Intramuscular circle of iris, 2.34f, 2.35
- Intramuscular drugs, in ocular pharmacology, 2.301
- Intramuscular plexus, ciliary body, 2.58
- Intranasal cysts, 6.229
- Intranasal examination, for lacrimal drainage evaluation, 7.272
- Intranasal influenza vaccine, 1.220
- Intraocular chemotherapy, for lymphoma, 4.312
- Intraocular culture
 - in endogenous endophthalmitis, 9.264–265
 - in postoperative endophthalmitis, 9.262–263
- Intraocular drug injection. *See* Intraocular medications
- Intraocular fine-needle aspiration biopsy (FNAB), 4.34t, 4.42–43, 4.43f, 4.253. *See also* Fine-needle aspiration biopsy
- Intraocular fluid analysis, in uveitis, 9.89t
- Intraocular foreign bodies (IOFBs). *See* Foreign bodies, intraocular
- Intraocular inflammation. *See* Endophthalmitis; Inflammation (ocular); Uveitis; *specific type or structure*
- Intraocular lenses (IOLs), 11.115–117, 11.118–122. *See also* Cataract surgery
 - accommodating, 3.261, 11.122, 11.122f, 13.8t, 13.154, 13.163–164, 13.164f
 - complications of, 11.151
 - acrylic, 3.256
 - American National Standards Institute standards for, 3.263–264
 - angle kappa in evaluation of, 8.33
 - angle-supported, 13.137, 13.138, 13.139t, 13.144
 - complications of, 13.146–147
 - anterior chamber (ACIOLs), 11.117, 11.119, 11.120f
 - after capsular rupture, 11.142–143
 - closed-loop, pseudophakic bullous keratopathy and, 11.149
 - complications of, 11.146
 - flexible-loop, 11.119, 11.120f
 - history of development of, 11.119, 11.120f
 - after ICCE, 11.200
 - insertion of, 11.117
 - phakic, 13.8t. *See also* Phakic intraocular lenses
 - pictorial representation of, 3.241f
 - pupillary block and, 10.131–132
 - in uveitis, 9.120, 9.120f
- apodized diffractive, 13.166, 13.166f
- biconvex, 3.241f
- bifocal
 - description of, 3.258–259, 3.259f
 - modulation transfer function with, 3.262
- biometry in power calculation/selection of, 11.82–83, 11.83f, 11.84–85, 11.87
 - axial length, 11.82–83, 11.83f, 11.84–85, 11.87
 - hypotony affecting, 11.185
 - unexpected refractive results after surgery and, 11.150
 - refractive lens exchange and, 13.150
- blue-blocking, 11.120
- capsular block syndrome and, 10.132, 11.148–149
- capsular opacification and, 11.153, 13.156, 13.167
- after capsular rupture, 11.142–143
- in children. *See* Intraocular lenses (IOLs), in infants and children
- closed-loop, pseudophakic bullous keratopathy and, 11.149

- complications of, 11.144f, 11.144–152, 11.146f, 11.147f, 11.148f
 - induced-astigmatism, 11.132
- corneal disease and, 11.128t
- cystoid macular edema and, 11.165
- decentration and dislocation of, 11.127, 11.144f, 11.144–147, 11.146f, 11.147f
 - angle-supported lenses and, 13.146
 - iris-fixated lenses and, 13.145
 - laser capsulotomy and, 11.156
 - multifocal IOLs and, 11.144, 11.145, 13.155
- deformable, 13.170
- description of, 6.301
- designs of
 - innovations in, 13.170, 13.170f
 - modifications of, 11.119–122, 11.120f, 11.121f, 11.122f
- diffraction multifocal, 13.166, 13.166f
- dual-optic, 13.170, 13.170f
- dysphotopsias caused by, 3.255
- endophthalmitis and, 9.261, 9.262f, 9.263
- estimated lens position for, 3.239, 3.243, 3.248–250, 3.249f, 3.252–253
- extended-depth-of-focus, 3.262–263, 3.263f
- flexible-loop, 11.119, 11.120f
- foldable, 11.116, 11.120, 11.120f, 11.121f. *See also* Foldable intraocular lenses
 - insertion of, 11.116
 - in uveitis, 9.121
- Fuchs heterochromic uveitis/iridocyclitis and, 9.127
- glare and, 11.144, 11.150–152
- glaucoma and, 10.108
- high-power, 3.264
- history of, 11.118f, 11.118–119
- hyphema after cataract surgery and, 11.159
- illusions caused by, 5.174
- image magnification, 3.255
- in infants and children, 13.187
- innovations in, 13.170, 13.170f
- insertion of, 11.115–117
 - anterior chamber, 11.117
 - after capsular rupture, 11.142–143
 - complications of, 11.144f, 11.144–152, 11.146f, 11.147f, 11.148f
 - after ECCE, 11.197
 - after ICCE, 11.200
 - posterior chamber, 11.116–117
 - procedures after, 11.117–118
- International Standards Organization standards for, 3.263–264
- iris-fixated/supported, 11.116–117, 11.119, 11.119f, 13.8t, 13.137, 13.138, 13.139t, 13.141–142, 13.142f
 - after ICCE, 11.200
 - insertion of, 11.116–117, 11.119f
 - after keratoplasty, 11.176
 - pseudophakic bullous keratopathy and, 11.149
 - uveitis and, 11.188
- issues associated with, 6.303–304
- juvenile idiopathic (chronic/rheumatoid) arthritis–associated uveitis and, 9.125, 9.283
- after keratoplasty, 11.176
- with keratoplasty and cataract surgery (triple procedure), 11.175–176
- laser capsulotomy affecting, 11.155–156, 11.156
- lens dislocation treated with, 6.310
- lensectomy with, 6.302–304
- light-adjustable, 13.153–154, 13.154f
- for manual small-incision cataract surgery, 11.198
- materials for, 3.240
- megalocornea and, 8.100
- meniscus, 3.240, 3.241f
- minus-power, 3.240
- modulation transfer function, 3.261–263, 3.262–263f
- monofocal, 3.257, 3.260, 13.151
- multifocal (MFIOLs), 11.121f, 11.121–122, 13.8t, 13.155–156, 13.165–167, 13.166f
 - annular zones, 3.259, 3.259f
 - best-corrected visual acuity with, 3.260
 - bifocal, 3.258–259, 3.259f
 - capsular decentration and, 11.183
 - clinical results of, 3.260–261
 - complications of, 11.151
 - decentration effects on, 3.258
 - description of, 3.257–258
 - diffraction, 3.259f, 3.259–260
 - disadvantages of, 3.258
 - dry eye therapy before use of, 11.173
 - extended-depth-of-focus lenses versus, 3.262–263, 3.263f
 - indications for, 3.258
 - multiple-zone, 3.259, 3.259f
 - patient selection for, 3.260
 - power calculation for, 3.258
 - for presbyopia, 13.165–167, 13.166f
 - three-zone, 3.259, 3.259f
 - types of, 3.258–260
- in myopia, 11.184–185
- nonspherical optics with, 3.257
- after ocular trauma, 11.193
- opacification of, 11.151
- optical performance standards for, 3.264
- overview of, 3.240–241
- in pars planitis, 9.131
- partial-ridge, 3.240
- after penetrating keratoplasty, 8.432, 13.179
- with penetrating or endothelial keratoplasty and cataract surgery (triple procedure), 11.175–176
- phakic (PIOLs), 13.8t, 13.47t, 13.137, 13.138–147, 13.139t, 13.142f, 13.143f. *See also* Phakic intraocular lenses
 - advantages/disadvantages/limitations of, 13.47t, 13.138–140
 - for amblyopia/anisometropic amblyopia/strabismus, 13.185–186, 13.187
 - in children, 13.187
 - corneal crosslinking with, 13.134, 13.207–208
 - retinal detachment and, 13.138, 13.145, 13.146
- piggyback
 - definition of, 3.240
 - intralenticular fibrosis after placement of, 3.241
 - power calculations for, 3.251
 - refractive lens exchange and, 13.150
- planoconvex, 3.241f
- plus-power, 3.250
- posterior capsule opacification and, 3.240
- posterior capsulectomy/vitrectomy with, 6.303

- posterior chamber (PCIOLs), 11.116–117, 11.118f, 11.119f, 11.119–122, 11.120f, 11.121f
 anterior chamber depth prediction formula for, 3.249
 capsular block syndrome and, 10.132
 after capsular rupture, 11.143
 decentration/dislocation of, 11.145, 12.393
 after ECCE, 11.197
 history of development of, 11.118–119, 11.119f
 image magnification with, 3.255
 insertion of, 11.116–117
 after keratoplasty, 11.176
 light-adjustable, 13.153–154, 13.154f
 near-addition power for, 3.259
 after ocular trauma, 11.193
 pachymetry studies of, 3.249
 phakic, 13.8t, 13.138, 13.142f, 13.142–144, 13.143f.
 See also Phakic intraocular lenses
 complications with, 13.145–146
 corneal crosslinking with, 13.207–208
 sizing, 13.144
 pictorial representation of, 3.241f
 pupillary capture of, 11.148, 11.148f
 in retinal disease, 11.189
 scleral/iris-fixated (sutured), 11.116–117, 11.119, 11.119f, 13.8t, 13.137, 13.138, 13.139t, 13.141–142, 13.142f
 after ICCE, 11.200
 insertion of, 11.116–117, 11.119f
 after keratoplasty, 11.176
 pseudophakic bullous keratopathy and, 11.149
 uveitis and, 11.188
 uveitis and, 9.281–282, 9.283, 11.188
 posteriorly dislocated, 12.393
 power determination for, 11.84–87
 axial length, 3.243–248
 biometry in, 11.82–83, 11.83f, 11.84–85, 11.87, 13.150. *See also* Intraocular lenses (IOLs),
 biometry in power calculation/selection of
 hypotony affecting, 11.185
 central corneal power, 3.243, 3.248
 in children, 3.254–255, 6.303
 contact lens method for, 13.195
 in corneal transplant eyes, 3.253–254
 double-*K* method, 3.252
 formulas for, 11.84, 11.85–87
 biometric, 3.244–250
 errors in, 3.252
 for post-keratorefractive procedure eye, 3.252–253
 prediction, 3.243–244
 regression formulas, 11.85–87
 theoretical, 3.243
 geometric optics and, 3.243
 historical methods for, 11.86–87, 13.194
 improving outcomes of surgery and, 11.87
 incorrect, 11.85
 multifocal lenses, 3.258
 in myopia, 11.184
 online post-refractive calculator for (ASCRS), 13.52, 13.195–197, 13.196f
 piggyback lenses, 3.251
 preventing errors in, 11.87
 after radial keratotomy, 13.51, 13.52–53, 13.193
 refraction and, 11.76
 refractive lens exchange and, 13.150
 refractive surgery and, 3.251–253, 11.85–87, 11.176, 11.177f, 13.44, 13.193–197, 13.196f
 in silicone oil-filled eyes, 3.254
 sulcus placement adjustments, 3.250t
 topographical method for, after refractive surgery, 13.193, 13.194
 triple procedure and, 11.175
 unexpected refractive results after surgery and, 11.86, 11.149–150
 in uveitis, 9.283
 power labeling of, 3.263–264
 for presbyopia, 13.8t, 13.154, 13.163–164, 13.164f, 13.170, 13.170f
 pressure on, 3.242f
 pseudoaccommodating, 11.122
 complications of, 11.151
 for pseudophakia, 13.163–164, 13.164f
 pseudophakic bullous keratopathy and, 11.149
 pupil evaluation and, 11.78
 pupillary block and, 10.131–132
 pupillary capture of, 11.148, 11.148f
 for refractive errors. *See also specific type*
 accommodating, 13.8t, 13.154, 13.163–164, 13.164f
 deformable, 13.170
 dual-optic, 13.170, 13.170f
 innovations in, 13.170, 13.170f
 light-adjustable, 13.153–154, 13.154f
 monocular, 13.151
 multifocal (MFIOLs), 13.155–156, 13.165–167, 13.166f
 complications of, 13.156, 13.167
 for presbyopia, 13.165–167, 13.166f
 phakic, 13.137, 13.138–147, 13.139t, 13.142f, 13.143f. *See also* Phakic intraocular lenses
 advantages/disadvantages/limitations of, 13.47t, 13.138–140
 retinal detachment and, 13.138, 13.145, 13.146
 power determination of
 refractive lens exchange and, 13.150
 refractive surgery and, 13.44, 13.193–197, 13.196f
 after radial keratotomy, 13.51, 13.52–53
 with refractive lens exchange, 13.8t, 13.150. *See also*
 Refractive lens exchange
 piggybacking and, 13.150
 toric, 13.8t, 13.137, 13.148–149, 13.151–153
 with refractive lens exchange, 13.8t, 13.150. *See also*
 Refractive lens exchange
 piggybacking and, 13.150
 in retinal disease, 11.189
 silicone oil use and, 3.254, 11.83, 11.120, 11.190
 split bifocal, 3.258, 3.259f
 square edge design of, 3.242f
 standards for, 3.263–264
 sulcus-supported, 13.137, 13.139t
 supplemental, power calculations for, 3.251
 sutured-in, 3.250
 TECNIS Symfony, 3.263
 tilt of, 3.250
 toric, 11.124, 13.8t, 13.137, 13.148–149, 13.151–153.
 See also Toric intraocular lenses
 astigmatism correction using, 3.257

- complications of, 11.151
- contraindication for, capsular decentration and, 11.183
- corneal crosslinking with, 13.134, 13.207–208
- dry eye therapy before use of, 11.173
- after penetrating keratoplasty, 8.432, 13.179
- traumatic cataract and, 11.193
- types of, 3.240, 3.241*f*
- with UV-absorbing chromophores, 11.120
- in uveitis, 9.120–121, 9.281–282, 9.283, 11.188
 - explantation and, 9.284
 - postoperative inflammation and, 9.119–121, 9.120*f*, 9.284, 11.140
- uveitis-glaucoma-hyphema (UGH) syndrome and, 9.17, 9.120, 10.108–109, 11.149
 - decentration and, 11.145
- vision disturbances related to, 3.255–256, 3.256*f*
- zonal refractive, 13.166, 13.166*f*
- Intraocular lymphoma, 1.237, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 9.273–276, 9.274*f*, 9.275*f*, 12.233–234, 12.234*f*. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
- Intraocular medications, 2.299, 2.300*t*. *See also specific drug*
 - lidocaine, 2.300*t*, 2.365–366
- Intraocular pressure (IOP), 10.3, 10.20*f*, 10.20–27
 - age affecting, 10.81–82
 - applanation tonometry of, 3.293
 - aqueous humor dynamics and, 2.230, 10.5, 10.5*f*, 10.13, 10.14*f*
 - in chemical injury, management and, 8.383
 - in childhood glaucoma, 6.277, 6.279, 6.290–291
 - circadian/diurnal variation in, 10.3, 10.8, 10.22, 10.80–81, 10.81*t*, 10.86, 10.87
 - corneal thickness/rigidity and, 8.41, 10.25, 10.81, 10.82, 10.86–87, 10.90, 13.105, 13.181, 13.200
 - in infants and children, 10.159
 - corticosteroids affecting, 2.299, 2.332–333, 2.333*t*, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.100, 10.108, 10.109–110
 - optic nerve damage and, 10.110
 - after refractive surgery, 13.41, 13.92, 13.201
 - in uveitis, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.110
- cycloplegics affecting, 2.313
- decreased
 - after cataract surgery, flat anterior chamber and, 11.135
 - factors causing, 10.21*t*, 10.22
- digital palpation of, 6.10
- digital pressure in estimation of, 10.26
- distribution in population and, 10.20*f*, 10.20–21
- drugs for lowering, 3.144. *See also* Antiglaucoma agents
- elevated/increased. *See* Elevated intraocular pressure
- episcleral venous pressure and, 10.20, 10.102
- factors affecting, 10.21*t*, 10.21–22
- flap creation affected by, 13.181
- follow-up for, 6.290–291
- in glaucoma, 10.3, 10.20–21, 10.46–47, 10.79, 10.80–81, 10.81*t*
 - See also* Elevated intraocular pressure; Glaucoma, normal-tension
- uveitis and, 9.119, 9.284–285, 9.285
- in hyphema, 6.378, 8.394, 8.395, 10.104, 10.105
- sickle cell disease and, 8.395, 8.395*t*, 8.396
- surgery and, 8.395, 8.395*t*, 8.396
- lens epithelium affected by, 4.120
- lowering of, in glaucoma management. *See also* Antiglaucoma agents
 - clinical trials in study of, 10.111–115
 - normal-tension glaucoma and, 10.87–88
 - target range for, 10.169, 10.183
- measurement of, 10.22–27, 10.23*f*, 10.24*f*. *See also* Tonometry
 - artifact in, normal-tension glaucoma and, 10.86
 - in children
 - description of, 6.10, 6.181
 - tonometry for, 6.281
 - in infants and children, 10.158–159
 - after refractive surgery, 13.105, 13.181, 13.200–201
 - pressure-induced stromal keratopathy after LASIK and, 13.119
 - before refractive surgery, 13.41
 - during refractive surgery, suction ring placement and, 13.86
 - as screening tool, 1.16*f*, 1.16–17, 1.17*f*
 - medications for reducing, 6.288, 6.289*t*
- nasal continuous positive airway pressure affecting, 1.132
- normal range for, 6.282, 10.20–21, 10.80, 10.85
 - in infants and children, 10.159
- in ocular ischemic syndrome, 9.278–279
- pregnancy affecting, 10.185
- in rhegmatogenous retinal detachment, 12.320
- scleral buckling effects on, 12.399
- in sickle cell retinopathy, 12.154
- swelling pressure and, 8.9
- target, in glaucoma treatment, 10.169, 10.183
- in trauma patients, 12.352
- in uveitis, 9.80*t*, 9.83, 9.113, 9.284–285, 9.285
 - corticosteroids affecting, 9.95, 9.97, 9.98, 9.285, 9.286–288, 10.110
 - herpetic infection and, 9.192
- Intraocular region of optic nerve, 2.83, 2.85, 2.85*t*, 2.86–87, 2.88*f*, 4.241
- blood supply of, 2.85*t*
- Intraocular specimens, for endophthalmitis diagnosis, 9.262–263, 9.264–265
- Intraocular (ocular) surgery. *See* Ocular (intraocular) surgery
- Intraocular tumors. *See also specific type of tumor and structure affected*
 - angiomatous, 4.281–287
 - canalicular obstruction and, 7.274
 - enucleation for, 7.128
 - exenteration for, 7.136
 - glaucoma caused by, 4.105*f*, 4.106, 10.98–100, 10.99*f*, 10.138
 - in children and adolescents, 10.149*t*
 - gross dissection in identification of, 4.29*f*, 4.29–30
 - leukemia and, 4.315*f*, 4.315–316, 4.316*f*
 - lymphoma, 1.237, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 9.273–276, 9.274*f*, 9.275*f*. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
 - melanocytic, 4.255–280

- metastatic, 1.237, 4.197, 4.303–316, 9.278. *See also* Metastatic eye disease
- molecular pathology in identification/evaluation of, 4.34*t*, 4.36–42, 4.38–39*t*, 4.40*f*, 4.41*f*
- nasolacrimal duct obstruction and, 7.278
- retinoblastoma, 4.172–177, 4.253, 4.289–302, 9.277. *See also* Retinoblastoma
- in systemic malignancies, 4.197, 4.303–316. *See also* Metastatic eye disease
- direct extension from extraocular tumors and, 4.310
- leukemia and, 4.315*f*, 4.315–316, 4.316*f*
- lymphomatous, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–314, 4.313*f*
- secondary, 4.303–310
- transillumination in identification of, 4.28*f*, 4.28–29
- Intraoperative considerations, in ocular surgery, 1.290–293, 1.293*t*
- Intraoperative floppy iris syndrome (IFIS), 11.74, 11.136–138, 11.137*t*
- pupil expansion devices for, 11.178
- Intraoperative optical coherence tomography (OCT), 8.22
- Intraoral trauma/tumor, Horner syndrome caused by, 5.260*t*
- Intraorbital foreign bodies, 7.112
- MRI and, 7.30–31, 7.112
- Intraorbital region of optic nerve, 2.83, 2.85, 2.85*t*, 2.87–89, 4.241, 5.26, 7.5, 7.11, 10.42
- blood supply of, 2.85*t*, 2.91, 2.91*f*
- compressive lesions of, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*. *See also specific lesion*
- length of, 7.5*t*, 7.11
- Intraorbital tissue expanders, in congenital anophthalmia/microphthalmia management, 7.36
- Intrapapillary drusen, 6.373*f*, 6.373–374
- Intraretinal hemorrhage
- in branch retinal vein occlusion, 12.125, 12.126*f*
- in nonproliferative diabetic retinopathy, 12.100*f*
- in systemic lupus erythematosus, 12.230–231
- Intraretinal microvascular abnormalities (IRMAs), 4.153*f*, 4.154, 4.155*f*
- in diabetic retinopathy, 4.159
- in nonproliferative diabetic retinopathy, 12.100*f*
- Intrascleral fixation, 12.393
- Intrastromal corneal femtosecond laser treatment, for presbyopia, 13.168
- Intrastromal corneal ring segments (ICRS), 13.8*t*, 13.28, 13.28*f*, 13.62*f*, 13.62–70, 13.63*f*, 13.64*f*, 13.65*f*, 13.67*f*, 13.68*f*, 13.69*f*
- complications of, 13.67–70, 13.68*f*, 13.69*f*
- contraindications for, 13.63
- corneal crosslinking with, 13.134, 13.207
- corneal transplantation after, 13.198
- instrumentation for, 13.63
- for keratoconus, 13.62, 13.65*f*, 13.65–66, 13.66, 13.69–70, 13.176
- after LASIK, 13.70
- limitations of, 13.47*t*
- number of segments used and, 13.66–67, 13.67*f*
- outcomes of, 13.64–65
- removal of, 13.63, 13.65
- LASIK after, 13.70
- surgical technique for, 13.64, 13.64*f*
- Intrauterine ocular infection. *See also specific type*
- corneal anomalies and, 8.107
- keratectasia, 8.107
- cytomegalovirus, 6.411, 6.411*f*
- description of, 6.409
- herpes simplex virus, 6.412
- lymphocytic choriomeningitis, 6.413
- rubella, 6.410*f*, 6.410–411
- syphilitic, 4.80, 4.81*f*, 6.412–413, 8.107, 8.308–309, 8.309*f*, 9.237, 9.237*f*
- toxoplasmosis, 6.409–410, 6.410*f*
- Zika virus, 6.413
- Intravascular papillary endothelial hyperplasia, 8.345*t*
- Intravascular ultrasound, in ischemic heart disease, 1.98
- Intravenous drug administration, in ocular pharmacology, 2.301. *See also* Substance abuse disorders
- Intravenous immunoglobulin (IVIg)
- for neuromyelitis optica, 5.323
- for uveitis, 9.108
- Intraventricular hemorrhage, 1.126. *See also* Intracranial hemorrhage
- Intravitreal injection, 2.299, 2.300*t*
- for acute retinal necrosis, 9.196–197
- for age-related macular degeneration, 4.164
- anesthesia for, 12.403
- anti-VEGF drugs, 12.404
- aseptic technique for, 12.403–404
- for birdshot uveitis, 9.147
- cataract formation and, 11.56
- chemotherapy for retinoblastoma and, 4.299, 4.300
- for CMV retinitis, 1.239, 1.260, 9.201
- complications of, 12.404
- compounded, 2.306–307
- corticosteroid, 2.300*t*, 2.334
- after cataract surgery, 11.163
- for cystoid macular edema, 4.152, 11.165
- in uveitis, 9.289
- diabetic macular edema treated with, 12.101
- elevated intraocular pressure and, 10.110
- for pars planitis, 9.130
- proliferative diabetic retinopathy treated with, 12.104
- retinopathy of prematurity treated with, 12.187
- for sarcoidosis, 9.171
- for sympathetic ophthalmia, 9.175
- for uveitis, 9.98, 9.289
- for endophthalmitis
- endogenous *Aspergillus*, 9.269
- endogenous bacterial, 9.264
- endogenous *Candida*, 9.267
- postoperative, 9.263, 11.162
- endophthalmitis after, 12.404
- indications for, 12.403
- for multifocal choroiditis and panuveitis, 9.157
- for ocular histoplasmosis syndrome, 9.217
- for pars planitis, 9.130, 9.131
- prevalence of, 12.403
- for primary central nervous system/intraocular/vitreoretinal lymphoma, 9.275
- for serpiginous choroiditis, 9.153
- technique for, 12.403, 12.403*f*
- for uveitic cystoid macular edema, 9.289

- for uveitic neovascularization, 9.292
- for Vogt-Koyanagi-Harada syndrome, 9.181
- Intravitreal triamcinolone acetonide (IVTA). *See* Triamcinolone
- Intrinsic factor/intrinsic factor deficiency, vitamin B₁₂ absorption and, 1.138
- Intrinsic pathway (coagulation), 1.140, 1.140f
- Intrinsic sympathomimetic activity (ISA), β -blockers with, 1.68t, 1.72
- Intrinsically photosensitive retinal ganglion cells (ipRGCs), 5.24, 5.28. *See also* Ganglion cells/ganglion cell layer (GCL), retinal
- Intron, 2.138, 2.147, 2.148, 2.148f, 2.151
- excision of, 2.152. *See also* Splicing
- Intrusions, saccadic. *See* Saccadic intrusions/oscillations
- Intubation, lacrimal
 - for acquired nasolacrimal obstruction, 7.278
 - for canaliculal obstruction, 7.275
 - for canaliculal trauma, 7.283
 - for congenital lacrimal drainage obstruction, 7.262–263, 7.264f
 - for punctal/canaliculal agenesis/dysgenesis, 7.259, 7.260
- Intumescent cortical cataract, 11.46
 - surgery for, 11.179–180
- Invasion, as microbial virulence factor, 8.207
- Invasive aspergillosis, 5.353, 5.354
- Inverse Knapp procedure, 6.128
- Inversion recovery (IR) imaging, 5.75
- Inverted follicular keratosis, 4.209, 4.210f
- Investigator bias, 1.6
- Involuntary ectropion, 7.198f, 7.199–201, 7.200f
- Involuntary entropion, 7.202–204, 7.203f, 7.204f, 7.205f
- Involuntary stenosis, nasolacrimal obstruction caused by, 7.277
- IO. *See* Inferior oblique (IO) muscle
- Iodine, 2.354
 - radioactive (RAI)
 - for block and replace therapy in thyroid eye disease, 7.58
 - for hyperthyroidism, 1.53–54
 - nasolacrimal duct obstruction and, 7.278
 - for retinoblastoma, 4.301
 - for thyroid scanning, 1.52
 - thyroid uptake of, 1.52
 - for uveal melanoma, 4.275
- Iodine 123, for thyroid scanning, 1.52
- Iodine 125
 - for retinoblastoma, 4.301
 - for uveal melanoma, 4.275
- Iodine 131
 - for block and replace therapy in thyroid eye disease, 7.58
 - for hyperthyroidism, 1.53–54
- IOFBs (intraocular foreign bodies). *See* Foreign bodies, intraocular
- IOL power calculator, online post-refractive (ASCRS), 13.52, 13.195–197, 13.196f
- IOLs. *See* Intraocular lenses
- Ionic charge, of ocular medication, absorption affected by, 2.298
- Ionizing radiation. *See also* Radiation
 - anterior segment injury caused by, 8.386
 - cataracts caused by, 11.57
 - DNA repair after, 2.154
 - in free-radical generation, 2.282, 2.283
 - retinopathy caused by exposure to, 12.170f, 12.170–171
- Iontophoresis, for drug delivery, 2.304
- IOP. *See* Intraocular pressure
- IOP–SP. *See* Imbibition pressure
- Iopidine. *See* Apraclonidine
- IP. *See* Incontinentia pigmenti
- IP₃. *See* Inositol-1,4,5-triphosphate
- IPL. *See* Inner plexiform layer; Intense pulsed-light (IPL) therapy
- IPM. *See* Interphotoreceptor matrix
- Ipratropium, 1.134
 - in combination agents, 1.133t
- ipRGCs. *See* Intrinsically photosensitive retinal ganglion cells
- Ipsilateral gaze palsy, 5.41, 5.200, 5.200f
- IPV (inactivated poliovirus vaccine/Salk vaccine), 1.222
- IR. *See* Inferior rectus (IR) muscle
- IR (index of refraction). *See* Refractive index
- IR (inversion recovery) imaging, 5.75
- IR radiation. *See* Infrared radiation
- Irbesartan, 1.68t, 1.69t
- IRBP. *See* Interphotoreceptor retinoid-binding protein
- iReST. *See* International Reading Speed Texts (iReST)
- IRID1 gene, 10.11t
- Iridectomy
 - for angle-closure glaucoma, 10.125, 10.220
 - acute angle closure and, 10.125
 - for anterior chamber IOL insertion, 11.117, 11.136
 - in ICCE, 11.200
 - for iris bombe in uveitis, 9.285, 9.286
 - for phakic IOL insertion, 13.141
 - in trabeculectomy, 10.202, 10.204f
- Irides. *See* Iris
- Iridocorneal adhesions (Peters anomaly), 4.74, 4.75f, 4.98, 8.97t, 8.102–104, 8.103f, 10.150, 10.154, 11.31–32. *See also* Axenfeld-Rieger syndrome
- Axenfeld-Rieger syndrome differentiated from, 10.154t
- glaucoma and, 4.74, 10.150, 10.154
- pediatric keratoplasty for, 8.450
- Iridocorneal endothelial (ICE) syndrome, 4.100–101, 4.101f, 4.259, 6.268, 8.111, 8.126–128, 8.127f, 10.31, 10.136f, 10.136–138, 10.137f
- Axenfeld-Rieger syndrome differentiated from, 10.154t
- glaucoma and, 4.101, 10.31, 10.136f, 10.136–138, 10.137f
- posterior polymorphous corneal dystrophy differentiated from, 8.159
- Iridocyclitis, 3.176, 6.412, 9.72t, 9.73. *See also* Anterior uveitis; Iritis; *specific cause*
- in ankylosing spondylitis, 1.154
- in Behçet disease, 1.169
- Fuchs heterochromic (Fuchs heterochromic uveitis [FHU])/uveitis syndrome), 9.126f, 9.126–127
- cataracts/cataract surgery and, 9.127, 9.282, 11.64f, 11.64–65
- glaucoma and, 9.127, 10.101–102, 10.102f
- rubella reactivation and, 9.44, 9.127, 9.205

- herpetic, 8.222–224, 8.223*t*
 in inflammatory bowel disease, 1.155
 in juvenile idiopathic arthritis, 1.156
 muscarinic antagonists for, 2.313
 in reactive arthritis/Reiter syndrome, 1.154, 8.305–306
 in rosacea, 8.70, 8.70*f*
- Iridodialysis, 4.18, 4.20*f*, 4.103, 5.255, 8.390*f*, 8.390–391, 8.391*f*, 10.41*f*
 during cataract surgery, 11.138
 cataract surgery in patient with, 11.191
 pupil irregularity and, 5.255
 repair of, 8.375, 8.390*f*, 8.390–391, 8.391*f*, 8.409
- Iridodonesis, 6.306, 6.308
 cataract surgery and, 11.79, 11.181–182
 in pseudoexfoliation/exfoliation syndrome, 10.92
- Iridogoniodysgenesis, gene for, 10.11*t*
- Iridogoniodysgenesis anomaly/syndrome. *See* Axenfeld-Rieger syndrome
- Iridogoniodysplasia, familial glaucoma. *See* Axenfeld-Rieger syndrome
- Iridoplasty
 for angle-closure glaucoma, 10.193–194
 for plateau iris, 10.127*f*, 10.128, 10.193–194
- Iridoschisis, 4.98
 Axenfeld-Rieger syndrome differentiated from, 10.154*t*
- Iridotomy
 for acute angle closure, 10.124, 10.125, 10.191–193, 10.192*f*
 for angle-closure glaucoma, 10.124, 10.125, 10.126, 10.191–193, 10.192*f*
 cataract extraction after, 10.213
 for chronic angle closure, 10.126
 for ectopia lentis, 10.129–130
 for iris bombé in uveitis, 9.285
 laser, 10.191–193, 10.192*f*
 for malignant/ciliary block glaucoma (aqueous misdirection), 10.140
 for phacomorphic glaucoma, 10.128
 for phakic IOL insertion, 13.141
 for pigmentary glaucoma, 10.96, 10.96*f*
 for plateau iris, 10.128, 10.191
 for primary angle-closure suspect, 10.122, 10.191
 for subacute/intermittent angle closure, 10.126
- Iris, 2.37*f*, 2.46*f*, 2.47*f*, 2.53*f*, 2.53–56, 2.54*f*, 2.56*f*, 2.236–240, 4.97*f*, 4.98*f*, 4.181, 4.181*f*, 4.181–182, 4.182*f*. *See also* Uvea (uveal tract)
 abnormalities of, 6.264–267, 267*f*
 anisocoria and, 5.256*f*, 5.262–263
 pupil irregularity caused by, 5.255
 absence of/rudimentary (aniridia), 2.193, 4.184, 10.150, 10.154–155, 11.33
 cataract and, 11.33, 11.34*f*
 surgery for, 11.184
 glaucoma and (iris-induced angle closure), 10.120, 10.155
 pediatric, 10.150, 10.155
 Axenfeld-Rieger syndrome differentiated from, 10.154*t*
 gonioscopic appearance of, 10.159
 pupil irregularity and, 5.255
 short arm 11 deletion syndrome/PAX6 gene mutations and, 2.152, 2.177, 2.193, 4.184, 10.150, 10.155, 11.33
 Wilms tumor and, 4.184, 10.155, 11.33
 anatomy of, 2.37*f*, 2.46*f*, 2.47*f*, 2.53*f*, 2.53–56, 2.54*f*, 2.56*f*, 4.97*f*, 4.98*f*, 4.181*f*, 4.181–182, 4.182*f*
 angle closure and, 10.120
 aniridia, 6.266*f*, 6.266–267
 anterior border of, 2.54–55, 2.55, 2.56*f*, 4.181, 4.182*f*
 atrophy of, 4.100, 4.101*f*, 8.111, 8.126, 8.127*f*, 10.136, 10.137*f*. *See also* Iridocorneal endothelial (ICE) syndrome
 in acute angle closure, 10.123–124
 cataract and, 11.68
 in Fuchs heterochromic uveitis/iridocyclitis, 9.126, 9.126*f*, 9.127
 in herpetic eye disease, 8.226*t*, 8.227
 in herpetic inflammation, 9.192*f*, 9.193
 in Axenfeld-Rieger syndrome, 6.264–265, 265*f*
 biochemistry and metabolism of, 2.236–240
 bowing of
 with pupillary block, 10.119
 with reverse pupillary block, in pigment dispersion syndrome/pigmentary glaucoma, 10.93, 10.96*f*
 Brushfield spots of, 6.272
 collarette of, 2.54*f*, 2.55
 coloboma of, 4.184, 6.266, 6.266*f*
 cataract surgery in patient with, 11.180
 congenital ectropion of, 6.267
 cysts of, 4.259, 4.260*f*, 6.272*f*, 6.272–273
 muscarinic therapy and, 2.311
 development of, 2.116*t*, 2.122
 evaluation of
 before cataract surgery, 11.79
 in glaucoma, 10.32, 10.33*t*, 10.34*f*
 in pupillary examination, 5.254
 in familial dysautonomia, 6.270
 growth and development of, 6.181
 healing/repair of, 4.16
 heterochromia of (heterochromia iridis)
 in Fuchs heterochromic uveitis/iridocyclitis, 9.126*f*, 9.127, 10.101
 in Horner syndrome, 5.258
 pediatric, 6.274, 6.274*f*, 6.274*t*
 in siderosis bulbi, 11.58*f*
 hypoplasia of, 6.264–267, 267*f*
 Axenfeld-Rieger syndrome and. *See* Axenfeld-Rieger syndrome
 immune response/features/microenvironment of, 9.57, 9.58
 incarceration of, after penetrating keratoplasty, 8.424
 innervation of, 2.55
 intramuscular circle of, 2.34*f*, 2.35
 juvenile xanthogranuloma of, 4.187, 4.260, 6.271, 9.277
 laceration of, repair of, 8.406, 8.408*f*, 8.409
 in leukemia, 4.315
 Lisch nodules of, 6.271–272, 6.272*f*, 6.392, 6.395*f*, 6.397
 malformation of, pupil irregularity and, 5.255
 mammillations of, 6.271–272, 6.272*f*
 melanocytoma of, 4.192, 4.258
 melanoma of, 4.106, 4.190, 4.191*f*, 4.258–261, 4.259*f*, 4.260*f*, 4.261*f*
 glaucoma caused by, 4.106, 4.194

- neoplastic disorders of, 4.189–190, 4.190*f*, 4.191*f*
 fine-needle aspiration biopsy in identification/
 evaluation of, 4.42
 metastatic, 4.260, 4.260*f*, 4.303, 4.304, 4.305*f*
 neovascularization of (rubeosis iridis), 4.188, 4.189*f*
 in branch retinal vein occlusion, 12.128–129, 12.129*f*
 in central retinal artery occlusion, 12.146
 in central retinal vein occlusion, 12.133, 12.135
 in diabetes mellitus, 4.159, 4.160*f*, 12.107
 glaucoma and, 4.188, 10.32, 10.39, 10.132*t*, 10.133,
 10.133*f*, 10.135*f*. *See also* Neovascular glaucoma
 in children and adolescents, 10.149*t*
 incisional surgery contraindicated in, 10.198
 laser iridotomy contraindicated in, 10.191
 in radiation retinopathy, 12.170
 in retinoblastoma, 4.174, 4.174*f*, 4.292
 persistent pupillary membrane, 6.264, 6.264*f*, 6.266*f*
 pigment epithelium of. *See* Iris pigment epithelium
 pigmentation of, 2.53, 2.54, 2.55, 2.56*f*, 2.236
 prostaglandin analogues/latanoprost affecting,
 2.327, 10.175
 pseudoexfoliation syndrome/glaucoma and, 10.39,
 10.92
 plateau, 10.4*t*, 10.9, 10.32, 10.120, 10.127*f*, 10.127–128
 laser iridotomy for, 10.128, 10.191
 posterior pigmented layer of, 2.53*f*, 2.55, 2.56*f*
 prolapse of, after DSEK, 8.439*f*
 pupillary abnormalities and, 5.254
 rubella (congenital) and, 9.204
 in sarcoidosis, 9.81*f*, 9.168, 9.168*f*, 9.169
 sectoral palsy of, 5.254
 anisocoria/Adie tonic pupil and, 5.256*f*, 5.263,
 5.263*f*
 smooth muscle in, 2.237, 4.182
 stroma of, 2.54–55, 2.56*f*, 4.181
 development of, 2.122
 systemic conditions that affect, 6.269–270
 topography of, 2.37*f*, 4.181*f*, 4.181–182, 4.182*f*
 transillumination of, 6.265, 6.406, 6.407*f*
 in albinism, 4.142, 4.142*f*
 in pigment dispersion syndrome, 10.94, 10.94*f*
 traumatic damage to
 anisocoria and, 5.256*f*, 5.262–263
 during cataract surgery, 11.138
 cataract surgery in patient with, 11.191
 iridodialysis, 4.18, 4.20*f*, 4.103, 8.390*f*, 8.390–391,
 8.391*f*
 cataract surgery and, 11.138, 11.191
 repair of, 8.375, 8.390*f*, 8.390–391, 8.391*f*, 8.409
 laceration, 8.406, 8.408*f*, 8.409
 mydriasis and miosis, 8.388–389, 8.389*f*
 pupil irregularity and, 5.255
 repair of, 4.16, 8.406, 8.408*f*, 8.409
 tumors of, 4.189–190, 4.190*f*, 4.191*f*, 6.271–273,
 6.272*f*
 fine-needle aspiration biopsy in identification/
 evaluation of, 4.42
 metastatic, 4.260, 4.260*f*, 4.303, 4.304, 4.305*f*
 in uveitis, 9.72, 9.73, 9.80*t*, 9.82–83. *See also*
 Iridocyclitis; Iritis
 vessels of, 2.35, 2.54*f*, 2.55
 vitreous adhesions to, 12.159
 in Waardenburg syndrome, 6.270
- Iris bombé, 6.285
 after endothelial keratoplasty (DMEK/DSEK), 8.444*f*,
 8.444–445
 glaucoma and, 10.32, 10.129, 10.131*f*, 10.138, 10.139*f*
 in uveitis, 9.83, 9.285–286
- Iris-claw lenses, 6.310
- Iris-clip intraocular lenses, pseudophakic bullous
 keratopathy and, 11.149
- Iris diaphragm, 2.53
- Iris dilator. *See* Dilator muscle (iris)
- Iris-fixated/supported posterior chamber intraocular
 lenses, 11.116–117, 11.119, 11.119*f*, 13.8*t*, 13.137,
 13.138, 13.139*t*, 13.141–142, 13.142*f*
 after ICCE, 11.200
 insertion of, 11.116–117, 11.119*f*
 after keratoplasty, 11.176
 phakic, 13.8*t*, 13.137, 13.138, 13.139*t*, 13.141–142,
 13.142*f*. *See also* Phakic intraocular lenses
 complications of, 13.145
 sizing, 13.142, 13.142*f*
 pseudophakic bullous keratopathy and, 11.149
 uveitis and, 11.188
- Iris fixation, 12.393
- Iris freckle, 4.259, 4.260*f*
- Iris granuloma, in coccidioidomycosis, 9.271, 9.271*f*
- Iris hooks
 for pupil expansion, 11.177, 11.178*f*
 for zonular incompetence, 11.180
- Iris hypoplasia, Axenfeld-Rieger syndrome and. *See*
 Axenfeld-Rieger syndrome
- Iris-induced angle closure, 10.120
- Iris nevus, 4.106, 4.189–190, 4.190*f*, 4.255, 4.256*f*, 4.259
- Iris nevus syndrome (Cogan-Reese syndrome/variant),
 4.100, 4.101*f*, 4.259, 8.111, 8.127, 10.136. *See also*
 Iridocorneal endothelial (ICE) syndrome
- Iris nodosa, in syphilis, 9.238
- Iris nodules, 6.271–272, 6.272*f*. *See also* Lisch nodules
 in leukemia, 4.315
 in neurofibromatosis, 5.330*f*, 5.334*t*
 in sarcoidosis, 4.187, 9.81*f*, 9.168, 9.168*f*
 in syphilis, 9.238
 in uveitis, 9.79, 9.81*f*, 9.82–83
 in Vogt-Koyanagi-Harada syndrome, 9.177, 9.178
- Iris papulosa, in syphilis, 9.238
- Iris pigment epithelium, 2.53*f*, 2.55, 2.56*f*, 4.181
 cysts of, 4.259, 4.260*f*, 6.272, 6.272*f*
 in diabetic retinopathy, 4.159, 4.160*f*
 in healing/repair, 4.16
 in pigment dispersion syndrome, 10.94, 10.94*f*
 proliferation of, 4.259
- Iris plane, phacoemulsification at, 11.112
- Iris processes, 2.46*f*
- IRIS (Intelligent Research in Sight) Registry, 1.26
- Iris roseola, in syphilis, 9.238
- Iris sphincter. *See* Sphincter muscle (iris)
- Iris suture fixation, peripheral, for IOL decentration,
 11.145, 11.146*f*
- Iritis, 6.412, 9.72*t*, 9.73. *See also* Anterior uveitis;
 Iridocyclitis; *specific cause*
 CMV, 8.232
 herpetic, 8.222–224, 8.223*t*
 after iris-fixated phakic IOL insertion, 13.145
 mydriatic/muscarinic antagonists for, 2.313

- IRMAs. *See* Intraretinal microvascular abnormalities
- Iron
- in aqueous humor, 2.232
 - colloidal, for tissue staining, 4.31*t*
 - corneal deposits of, 8.117, 8.117*f*, 8.118*t*
 - in keratoconus, 4.95*f*, 4.96, 8.117, 8.162, 8.163, 8.163*f*
 - foreign body of, 8.118*t*, 8.399
 - siderosis caused by, 4.120, 11.58*f*, 11.58–59
 - in free-radical formation, 2.281–282, 2.283
 - in hemosiderosis bulbi, glaucoma and, 4.103
- Iron deficiency anemia, 1.135, 1.136–137
- inflammatory anemia differentiated from, 1.135
- Iron lines, 8.117, 8.117*f*, 8.118*t*
 - in keratoconus, 8.117, 8.162, 8.163, 8.163*f*
 - in pterygium, 8.113
- Irradiance, 3.107*t*, 3.108
- Irregular astigmatism, 13.17–19, 13.18*f*, 13.19*f*. *See also* Astigmatism
- after arcuate keratotomy, 13.58
 - after cataract surgery, keratorefractive/refractive surgery and, 13.53
 - causes of, 3.277–278, 3.278*f*
 - corneal topography in detection/management of, 8.15, 8.31, 8.32, 13.17–19, 13.18*f*, 13.19*f*, 13.22–23, 13.44, 13.45, 13.45*f*
 - after penetrating keratoplasty, 8.431–432, 8.432*f*
 - definition of, 3.124, 3.267
 - description of, 3.139
 - epithelial basement membrane dystrophy and, 3.277, 3.278*f*
 - keratorefractive/keratorefractive surgery and, 3.272–278, 3.274–276*f*, 13.18–19, 13.22–23, 13.44, 13.45
 - cataract surgery outcome and, 11.176, 11.177*f*
 - after limbal relaxing incisions, 13.58
 - after penetrating keratoplasty, 8.426, 8.431–432, 8.432*f*
 - quantification of, 3.273
 - retinoscopy in evaluation of, 8.163
 - wavefront analysis of, 3.273–277, 3.274–276*f*. *See also* Wavefront analysis
- Irreversible cholinesterase inhibitors, 2.312
- Irrigation. *See also* Irrigation/aspiration; Ophthalmic irrigants
- for chemical injuries, 8.381–382
 - for conjunctival foreign body, 8.397
 - in ECCE, 11.197
 - for hyphema, 8.395
 - of lacrimal drainage system
 - for acquired obstruction, 7.270*f*, 7.271
 - for canalicular obstruction evaluation, 7.270*f*, 7.271, 7.271*f*
 - for canalicular trauma, 7.283
 - for congenital obstruction, 7.261*f*, 7.261–262, 7.262*f*, 7.263*f*
 - in phacoemulsification, 11.101–102, 11.115
 - posterior fluid misdirection and, 11.134–135
 - toxic solutions exposure and, corneal edema caused by, 11.129, 11.133–134
 - for plant materials, 8.387
 - solutions for, 2.367
- Irrigation/aspiration (IA). *See also* Aspiration; Irrigation in ECCE, 11.197
- in manual small-incision cataract surgery, 11.198
 - in phacoemulsification, 11.115
 - posterior fluid misdirection and, 11.134–135
- IRSG (Intergroup Rhabdomyosarcoma Study Group), 7.83
- IRSS. *See* Immune reconstitution syndromes
- IRU. *See* Immune recovery uveitis
- IRVAN. *See* Idiopathic retinal vasculitis, aneurysms, neuroretinitis
- Irvine-Gass syndrome, 11.163–165, 11.164*f*, 12.157, 12.349. *See also* Cystoid macular edema
- IS. *See* Inner segments
- IS/OS junction. *See* Inner-outer segment (IS/OS) junction
- ISA. *See* Intrinsic sympathomimetic activity
- ISCEV. *See* International Society for Clinical Electrophysiology of Vision
- Ischemia, 1.92. *See also* Cerebrovascular disease; Stroke; *specific territory affected*
- cardiac. *See* Ischemic heart disease
 - carotid territory. *See also* Carotid occlusive disease
 - transient visual loss and, 5.162, 5.165–166, 5.167, 5.167*f*, 5.168
 - cataracts caused by, 11.68
 - cerebral, 1.120–123. *See also* Stroke
 - choroidal, 12.196, 12.196*f*
 - diplopia caused by, 5.192
 - fourth nerve (trochlear) palsy and, 5.199
 - intraocular pressure-induced, in acute angle closure, 10.123–124
 - macular, 12.98, 12.101, 12.115
 - MRI in evaluation of, 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.75
 - occipital, transient visual loss caused by, 5.162, 5.172
 - ocular (ocular ischemic syndrome/OIS), 5.170, 5.171*f*, 9.278–279
 - posterior circulation. *See* Vertebrobasilar system, disorders of
 - retinal, 4.140, 4.150–160. *See also* Retinal ischemia
 - stroke and, 5.167, 5.168–169
 - transient visual loss and, 5.161, 5.164, 5.167, 5.168–169
 - sixth nerve (abducens) palsy and, 5.200, 5.201
 - third nerve (oculomotor) palsy and, 5.195, 5.198
 - time course of vision loss and, 5.77
- Ischemic/complete/nonperfused central retinal vein occlusion, 4.156, 4.157–158, 4.158*f*
- Ischemic heart disease (IHD), 1.91–105. *See also* Acute coronary syndrome; Angina pectoris; Heart disease
- asymptomatic, 1.95
 - clinical syndromes in, 1.92–95
 - in diabetes mellitus, 1.49, 1.83*t*
 - retinopathy and, 1.116
 - diagnosis of
 - invasive procedures for, 1.98
 - noninvasive procedures for, 1.95–98
 - heart failure and, 1.105, 1.108, 1.111
 - hypertension management in, 1.75
 - management of, 1.98–105, 1.100–101*t*
 - ophthalmic considerations and, 1.116–117
 - pathophysiology of, 1.91–92
 - risk factors for, 1.81–89, 1.91–92, 1.92

- Ischemic optic neuropathy, 5.107*t*, 5.119–125, 5.120*t*, 5.121*f*, 5.123*t*
 anterior (AION), 5.107*t*, 5.119–124, 5.120*t*, 5.121*f*, 5.123*t*
 arteritic (AAION), 5.107*t*, 5.120, 5.120*t*, 5.120–122, 5.121*f*, 5.313
 giant cell arteritis and, 5.120, 5.313
 nonarteritic (NAION), 5.107*t*, 5.120, 5.120*t*, 5.121*f*, 5.122–124, 5.123*t*
 OCT in evaluation of, 5.91*f*
 in granulomatosis with polyangiitis (Wegener granulomatosis), 9.138
 perioperative, 5.124–125
 posterior (PION), 5.107*t*, 5.119, 5.124
 Ischemic stroke, 1.120–123. *See also* Stroke
 emergency transport and, 1.295, 1.299
 Ischemic uveitis, 5.170
 Ishihara plates
 for color vision testing, 12.54, 12.55*f*
 in low vision evaluation, 5.78
 in simultanagnosia, 5.180
 Island of vision, in perimetry, 5.84
 Islet cell injection/transplantation, for diabetes mellitus, 1.47
 Ismotic. *See* Isosorbide
 ISNT rule, 10.49
 ISO. *See* International Standards Organization (ISO)
 Isoametropic amblyopia, 6.55
 Isochrone, 3.71
 Isoetharine, 1.133
 Isoflurophate, 2.309*f*
 Isoforms, 2.152
 Isolated (simplex) case/genetic disease, 2.143, 2.182
 Isolated optic neuritis, 5.113–115, 5.114*f*
 Isolated/simple ectopia lentis, 6.307
 Isolated stromal rejection, 8.429. *See also* Rejection
 Isolation techniques, in ocular microbiology, 8.211
 Isometropic hyperopia, 3.185*f*
 Isoniazid, 1.254–255
 pharmacogenetics of, 2.201
 Isoproterenol, 2.308*t*
 Isopter, 5.84
 Isopto Atropine. *See* Atropine
 Isopto Carbachol. *See* Carbachol
 Isopto Carpine. *See* Pilocarpine
 Isopto Cetamide. *See* Sulfacetamide
 Isopto Eserine. *See* Physostigmine
 Isopto Homatropine. *See* Homatropine
 Isopto Hyoscine. *See* Scopolamine
 Isosorbide, 2.329
Isospora belli (isosporiasis), in HIV infection/AIDS, 1.269
 Isotretinoin, 12.305
 corneal pigmentation caused by, 8.132
 laser skin resurfacing contraindicated in patient taking, 7.238
 ocular effects of, 1.307*t*
 refractive surgery in patient taking, 13.37, 13.77–78
 Isotypes, 9.36*f*, 9.41
 Isradipine, 1.68*t*
 ISRS. *See* International Society of Refractive Surgery
 ITP. *See* Idiopathic thrombocytopenic purpura
 Itraconazole, 1.270, 1.280, 2.355*t*, 2.356
 for coccidioidomycosis, 9.272
 for fungal keratitis, 8.275
 iTreg cells. *See* Antigen-specific regulatory T (iTreg) cells
 IU. *See* Intermediate uveitis
 Ivermectin
 for loiasis, 8.282
 for onchocerciasis, 9.235
 IVF. *See* In vitro fertilization
 IVIg. *See* Intravenous immunoglobulin
 IVTA (intravitreal triamcinolone acetate). *See* Triamcinolone
 Ixodes ticks, Lyme disease transmitted by, 1.250, 9.243
- ## J
- “Jabs and jolts” syndrome, 5.294
 “Jack-in-the-box” phenomenon, 3.191
 Jackson cross cylinder
 definition of, 3.40, 3.80, 3.147
 hand-held, 3.32, 3.32*f*
 minus cylinder phoropter with
 cylinder axis refinement using, 3.29, 3.30*f*
 cylinder power refinement using, 3.31, 3.31*f*
 for refraction, 3.163–165, 3.164*f*
 for regular astigmatism, 3.163–165, 3.164*f*
 Jalili syndrome, 12.286
 Japanese encephalitis vaccine, 1.224
 Jarisch-Herxheimer reaction
 in Lyme disease treatment, 1.252, 9.246–248
 in syphilis treatment, 9.243
 Javal-Schiötz-style keratometer, 3.287, 8.27
 Jaw claudication, in giant cell arteritis, 5.313
 Jaw thrust/modified jaw thrust, for opening airway, 1.298
 Jaw-winking syndrome/ptosis, Marcus Gunn, 5.272, 5.272*f*, 7.211, 7.215, 7.216*f*
 synkinesis in, 7.211, 7.215, 7.216*f*
 JC virus, in progressive multifocal leukoencephalopathy, 5.351
 Jerk nystagmus, 5.214, 5.233, 5.234, 6.147. *See also* Nystagmus
 in multiple sclerosis, 5.319
 JIA. *See* Juvenile idiopathic (chronic/rheumatoid) arthritis
 JNC7/JNC8. *See* Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
 JOAG. *See* Juvenile open-angle glaucoma
 Joint Commission on Accreditation of Healthcare Organizations, Universal Protocol of, 1.289–290
 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7/JNC8)
 blood pressure classification/hypertension diagnosis and, 1.61, 1.62, 1.62*t*
 hypertension treatment and, 1.61, 1.68, 1.69*t*, 1.70*f*, 1.80
 Jones I (primary dye) test, 7.269
 Jones II test, 7.269
 Jones tubes, 7.195, 7.260, 7.275–276, 7.276*f*

Joubert syndrome, 6.144, 6.392, 6.392*f*, 12.285
 Joules, 3.106
 JRA (juvenile rheumatoid arthritis). *See* Juvenile idiopathic (chronic/rheumatoid) arthritis
 Jugular bulb, 5.22
 Jugular veins
 external, 5.23
 internal, 5.22, 5.22*f*, 5.23
 lesions of, Horner syndrome and, 5.260*t*
 Junctional complexes (cardiac arrhythmia)
 in corneal endothelium, 2.43, 2.227
 premature (PJC)s, 1.112, 1.113
 in retinal pigment epithelium, 2.68, 2.272
 Junctional (intraepithelial) nevus, 7.173
 of conjunctiva, 4.64
 conjunctival/ocular surface, 8.338*t*, 8.340
 of eyelid, 4.219, 4.219*f*, 7.173
 “Junctional scotomas,” 5.146–147, 5.148*f*, 5.151*f*
 Junctional tachycardia, atrioventricular, 1.114
 Junk (noncoding/antisense) DNA, 2.132, 2.148*f*, 2.150, 2.151
 in gene therapy, 2.170
 Juvenile ankylosing spondylitis, 1.155, 6.315*t*
 Juvenile chronic arthritis. *See* Juvenile idiopathic (chronic/rheumatoid) arthritis
 Juvenile fibromatosis, 6.222
 Juvenile glaucoma. *See* Glaucoma, pediatric; Juvenile open-angle glaucoma
 Juvenile idiopathic (chronic/rheumatoid) arthritis (JIA/JRA), 1.156, 6.312–315, 6.313–314*t*, 6.314*f*, 6.322, 9.122–126, 9.123*f*, 9.124*t*
 cataract/cataract surgery and, 9.123*f*, 9.124–125
 classification of, 1.156, 9.122
 eye examination schedule for children with, 9.123, 9.124*t*
 glaucoma and, 9.125
 HLA association in, 9.67*t*, 9.122
 management of, 9.123–125
 pauciarticular (oligoarticular/oligoarthritis), 1.156, 9.122
 polyarticular (polyarthritis), 1.156, 9.122
 prognosis for, 9.123
 systemic-onset (Still disease), 1.156, 9.122
 uveitis in, 9.122–126, 9.123*f*, 9.124*t*
 cataracts and, 9.123*f*, 9.124–125
 Juvenile macular degeneration (Stargardt disease/fundus flavimaculatus), 4.168–169*f*, 170
 ATP-binding cassette (ABC) transporter protein mutations causing, 2.263, 4.168–169
 retinal pigment epithelium in, 2.279, 4.168–169*f*, 4.169–170
 Juvenile-onset diabetes mellitus. *See* Diabetes mellitus (DM), type 1
 Juvenile-onset myopia, 3.142
 Juvenile-onset vitelliform macular dystrophy. *See* Best disease
 Juvenile open-angle glaucoma (JOAG), 6.278, 6.284, 10.4*t*, 10.147, 10.148*t*, 10.153. *See also* Glaucoma, pediatric
 genetics of, 10.11*t*, 10.150
 Juvenile ossifying fibroma (fibro-osseous dysplasia), 6.222
 of orbit, 4.239, 4.240*f*

Juvenile pilocytic astrocytoma, 4.249
 Juvenile psoriatic arthritis, 6.315*t*
 Juvenile retinal dystrophy, 6.390*f*
 Juvenile retinoschisis
 abusive head trauma as cause of, 6.383
 description of, 6.342–343
 diagnosis of, 6.344–345*f*
 treatment of, 6.344
 Juvenile rheumatoid arthritis (JRA). *See* Juvenile idiopathic (chronic/rheumatoid) arthritis
 Juvenile spondyloarthropathy, 1.155, 6.315, 6.315*t*
 Juvenile systemic granulomatosis, familial (Blau syndrome), 9.170
 Juvenile xanthogranuloma (JXG), 6.271, 7.91, 8.347, 9.277
 glaucoma associated with, 10.30
 of iris, 4.187, 4.260
 uveal tract/uveitis and, 4.187, 4.188*f*
 Juxtacanalicular meshwork/tissue, 2.48, 10.17, 10.18*f*
 Juxtafoveal telangiectasia, 12.161
 JXG. *See* Juvenile xanthogranuloma

K

K. *See* Potassium
 K. *See* Central corneal power
 K-Card, 13.194
 K_m (Michaelis/affinity constant), sorbitol in cataract development and, 11.19
 K (keratometry) reading. *See* Keratometry/keratometer
 K system (koniocellular system/neurons/bistratified cells), 10.42
 Kabuki syndrome, 6.195
 KAMRA corneal inlay, 3.175, 3.271, 13.28, 13.61, 13.61*f*, 13.169
 Kanamycin, 1.278, 2.344*t*, 2.351
 Kaposi sarcoma, 1.262, 1.270, 7.186, 7.186*f*, 8.239, 8.345*t*, 8.347*f*, 8.347–348
 human herpesvirus 8 causing, 1.257, 8.239, 8.347, 9.299
 ocular adnexal, 5.349, 7.186, 7.186*f*, 9.299*f*, 9.299–300
 Kaposi sarcoma–associated herpesvirus (KSHV)/human herpesvirus 8, 1.257, 8.239, 8.347, 9.299
 Kappa (κ) statistic, 1.24
 Kartagener syndrome, 1.130
 Karyotype/karyotyping, 2.138, 2.188, 2.189*f*
 Kasabach-Merritt syndrome, 6.220, 7.67–68
 Kawasaki disease (mucocutaneous lymph node syndrome), 1.165*t*, 1.167, 6.316
 Kayser-Fleischer ring, 6.270, 8.118*t*, 8.173, 8.189, 8.189*f*, 11.62, 12.362
 kb. *See* Kilobase
 KC. *See* Keratoconus
 KCS (keratoconjunctivitis sicca). *See* Aqueous tear deficiency; Dry eye
 Kearns-Sayre syndrome, 2.158, 5.329, 6.142, 12.283*t*, 12.294
 mitochondrial DNA defects and, 2.157, 2.158
 Kelman phaco tip, 11.101
 Keloids
 corneal, 8.125
 congenital, 8.107–108, 8.125
 refractive surgery in patient with history of, 13.77

- Kenalog. *See* Triamcinolone
- Keplerian telescopes, 3.40, 3.83–84, 3.84f
- KERA gene, 6.255
- in cornea plana, 8.96t, 8.100
 - posterior amorphous corneal dystrophy and, 8.136t, 8.155
- Keratan sulfate
- antigenic (AgKS), macular corneal dystrophy and, 8.150–151
 - in cornea, 2.41, 2.226, 8.9
 - cornea plana and, 8.96t, 8.100
 - mucopolysaccharidoses and, 8.175t
- Keratectasia, 8.98t, 8.106–107
- Keratotomy, 8.366–367, 8.412t, 13.30f
- for corneal haze after surface ablation, 13.109
 - lamellar, for keratophakia, 13.59, 13.60
 - mechanical, 8.367
 - multizone, 13.30, 13.30f
 - photorefractive (PRK). *See* Photorefractive keratectomy
 - phototherapeutic (PTK). *See* Phototherapeutic keratectomy
 - superficial (SK), 8.366–367, 8.412t
 - layer-based approach to use of, 8.417t
 - in trabeculectomy, 10.201–202, 10.204f
- Keratic precipitates (KPs), 8.52, 9.59, 9.79, 9.82
- in CMV infection, 8.232
 - in Fuchs heterochromic uveitis/iridocyclitis, 9.126, 9.126f, 9.127
 - in glaucomatocyclitic crisis (Posner-Schlossman syndrome), 10.101
 - in herpetic ocular infection, 9.192
 - in inflammatory glaucoma, 10.100
 - in phacoantigenic glaucoma, 10.98
 - in sarcoidosis, 9.80f, 9.168, 9.168f
 - in sympathetic ophthalmia, 4.185, 9.172
 - in uveitic glaucoma, 10.31
 - in uveitis, 9.79, 9.80f, 9.82, 9.112–113
 - in Vogt-Koyanagi-Harada syndrome, 9.177, 9.178
- Keratin
- in adenoid cystic carcinoma, 4.231
 - in squamous cell carcinoma, 4.213, 4.214f
- Keratin gene mutation, in Meesmann corneal dystrophy, 8.136t
- Keratinization (keratinized/degenerated epithelial cells)
- in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297
 - in superior limbic keratoconjunctivitis, 8.84
 - in vitamin A deficiency, 8.196
- Keratitis, 8.46t, 8.49–53, 8.50f, 8.50t, 8.51f, 8.52f, 8.208t
- Acanthamoeba*, 4.78–79, 4.79f, 8.208t, 8.252, 8.276–279, 8.277f, 8.278f
 - contact lens wear and, 4.78–79, 8.276, 8.277
 - herpes simplex keratitis differentiated from, 8.278
 - isolation techniques for diagnosis of, 4.79, 8.211
 - stains and culture media for identification of, 4.79, 8.209t, 8.277
 - treatment of, 2.361, 8.277–279
 - adenovirus caused by, 6.269
 - bacterial, 4.75–76, 4.76f, 8.208t, 8.267–273, 8.268f, 8.269t, 8.270t, 8.273f. *See also* Keratitis, infectious/microbial
 - clinical presentation of, 8.267–268, 8.268f
 - contact lens wear and, 8.266–267, 8.268, 8.269, 8.269t
 - for orthokeratology, 13.71
 - intrauterine, 8.107
 - syphilitic, 4.80, 4.81f, 8.107, 8.308–309, 8.309f
 - laboratory evaluation/causes of, 8.268–269, 8.269t
 - management of, 8.269–272, 8.270t
 - pathogenesis of, 8.267
 - stains and culture media for identification of, 8.209t, 8.269
 - blepharitis and, 8.72, 8.73t, 8.74
 - Candida* causing, 8.208t, 8.251, 8.273, 8.274–275
 - chlamydial infection and, 8.263
 - CMV, 8.231–232, 8.232f
 - in Cogan syndrome, 8.309–310
 - congenital syphilis as cause of, 6.269
 - contact lens wear and, 4.78–79, 8.84, 8.266–267, 8.273–274
 - for orthokeratology, 13.71
 - corneal involvement, 6.269
 - corneal scarring caused by, 6.245f
 - corticosteroid route of administration in, 2.333t
 - dendritic, 4.76, 4.77f
 - herpes simplex virus causing, 4.76, 4.77f, 8.216–219, 8.218f, 8.226t
 - herpes zoster, 8.226, 8.226t, 8.227
 - Dieffenbachia*, 8.387
 - diffuse lamellar (DLK), after LASIK, 13.116f, 13.116–117, 13.117t
 - infectious keratitis differentiated from, 13.117–118, 13.118f, 13.118t
 - pressure-induced stromal keratopathy differentiated from, 13.119
 - diffuse superficial, 6.242
 - disciform (endotheliitis), 8.51f
 - CMV causing, 8.232, 8.232f
 - herpes simplex virus causing, 4.77f, 4.78, 8.220, 8.221f, 8.222
 - persistent bullous keratopathy and, 8.225
 - Enterobacteriaceae causing, 8.247
 - epithelial. *See also* Epithelial keratitis/keratopathy
 - adenovirus causing, 8.234, 8.235, 8.235f
 - CMV causing, 8.232
 - in epidemic keratoconjunctivitis, 8.235, 8.235f
 - herpes simplex virus causing, 8.213, 8.214f, 8.216f, 8.216–219, 8.217f, 8.218f, 8.223t, 8.226t
 - measles virus causing, 8.239
 - varicella-zoster virus causing, 8.226, 8.226t
 - Epstein-Barr virus, 8.230–231, 8.231f
 - exposure, 8.79–80
 - cataract surgery in patient with, 11.174
 - Fuchs superficial marginal, 8.123
 - fungal, 4.78, 4.78f, 8.208t, 8.273–276, 8.274f, 12.239
 - plant/vegetable materials and, 4.78, 8.273, 8.387, 8.399
 - gonococcal conjunctivitis and, 8.258
 - herpes simplex, 4.76–78, 4.77f, 6.269, 6.412, 8.208t, 8.213, 8.214f, 8.216f, 8.216–222, 8.217f, 8.218f, 8.220f, 8.221f, 8.226t, 9.191, 9.192. *See also* Herpes simplex virus (HSV), keratitis caused by
 - Acanthamoeba* keratitis differentiated from, 8.278
 - antiviral agents for, 2.356–361, 2.357–358t

- in HIV infection/AIDS, 9.300
 neurotrophic keratopathy/ulcers/persistent corneal epithelial defects caused by, 4.77f, 8.80, 8.81t, 8.217–218, 8.224, 8.225
 after penetrating keratoplasty, 8.424, 8.425f
 refractive surgery and, 13.173–174
 herpes zoster, 8.226, 8.226t. *See also* Herpes zoster ophthalmicus
 in HIV infection/AIDS, 9.300, 9.300f
 after LASIK, 13.189
 immune-mediated corneal disease and, 8.306–318
 infectious/microbial, 4.75–80, 4.76f, 4.77f, 4.78f, 4.79f, 4.80f, 4.81f, 6.269, 8.208t, 8.266–279, 8.307–309, 8.309f. *See also specific infectious agent*
 clinical presentation of, 8.267–268, 8.268f, 8.274f, 8.274–275, 8.276–277, 8.277f
 contact lens wear and, 8.266–267, 8.273–274, 13.71
 for orthokeratology, 13.71
 interstitial disease and, 8.307–309, 8.309f
 intrauterine, 8.107
 syphilitic, 4.80, 4.81f, 8.107, 8.308–309, 8.309f
 laboratory evaluation/causes of, 8.268–269, 8.269t, 8.275, 8.277, 8.278f
 after LASIK, 13.106f, 13.106–107, 13.107f, 13.117–119, 13.118f, 13.118t
 diffuse lamellar keratitis differentiated from, 13.117–118, 13.118f, 13.118t
 management of, 8.269–272, 8.270t, 8.275–276, 8.277–279
 orthokeratology and, 13.71
 pathogenesis of, 8.267, 8.273–274, 8.276
 after penetrating keratoplasty, 8.427
 after photoablation, 13.106f, 13.106–107
 recurrence of, in graft, 8.225, 8.232
 specimen collection in evaluation of, 8.210, 8.211f
 stains and culture in identification of, 8.209t, 8.269, 8.273, 8.275
 interstitial (IK), 4.80, 4.81f, 6.269, 8.46t
 Epstein-Barr, 8.230, 8.231f
 glaucoma and, 10.139
 herpetic, 4.77f, 4.78, 4.80, 8.219–220, 8.220f, 8.222
 HTLV-1-related (HTLV-1-associated keratopathy), 9.212
 in infectious disease, 8.307–309, 8.309f
 syphilitic, 4.80, 4.81f, 8.308–309, 8.309f, 9.237, 9.237f
 intrauterine infection and, 4.80, 4.81f, 8.107, 8.308–309, 8.309f
 intrauterine, 8.107
 keratectasia caused by, 8.107
 syphilitic, 4.80, 4.81f, 8.107, 8.308–309, 8.309f
 lipid keratopathy and, 8.125
 in Lyme disease, 9.246
 measles virus causing, 8.239, 9.206
 microsporidial, 8.280–281, 9.300, 9.300f
 mycobacterial, 8.248
 noninfectious, 4.80–81, 6.269
 nummular, 6.243
 herpes zoster, 8.228, 8.228f
 in onchocerciasis, 8.253
 pain caused by, 5.295
 peripheral, 8.50t
 in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168
 scleritis and, 8.323
 ulcerative (PUK), 8.51f, 8.311t, 8.311–313, 8.312f.
 See also Keratitis, ulcerative/peripheral ulcerative
Propionibacterium acnes causing, 8.246
 punctate, 8.46t, 8.50, 8.50f, 8.50t. *See also* Punctate epithelial keratitis/keratopathy
 adenoviruses causing, 8.234
 blepharitis/blepharoconjunctivitis and, 8.72, 8.73t, 8.74
 exposure causing, 8.80
 herpes simplex causing, 8.216, 8.216f
 in herpes zoster, 8.227, 8.228
 microsporidial, 8.280
 superficial Thygeson (SPK), 8.306–307, 8.307f
 topical anesthetic abuse causing, 8.89
 punctate epithelial, 6.269
Pythium insidiosum causing, 8.251, 8.275
 in reactive arthritis syndrome/Reiter syndrome, 8.305–306, 9.115
 in rosacea, 8.70, 8.70f
 rubella, 9.205
 Salzmann nodular degeneration and, 8.124f, 8.124–125, 8.125f
 scleritis and, 8.323
 sicca. *See* Dry eye
 staphylococcal, 8.73t, 8.74, 8.76
 stromal, 8.46t, 8.50t, 8.50–52, 8.51f
 CMV causing, 8.232
 in Cogan syndrome, 8.309–310
 Epstein-Barr virus, 8.230–231, 8.231f
 herpes simplex virus causing, 4.77f, 4.78, 8.219–222, 8.220f, 8.221f, 8.223t
 penetrating keratoplasty for, 8.225
 recurrence of, in graft, 8.225
 in herpes zoster ophthalmicus, 8.228, 8.228f
 microsporidial, 8.280–281
 necrotizing, 8.52, 8.219, 8.220–221, 8.221f, 8.222, 8.223t
 necrotizing, 8.51f, 8.219, 8.220f, 8.221f, 8.223t
 nonsuppurative, 8.46t, 8.50, 8.50t, 8.51f, 8.52
 in rosacea, 8.70, 8.70f
 suppurative, 8.46t, 8.50, 8.50t, 8.51f, 8.52
 syphilitic, 8.308–309, 8.309f
 syphilitic, 4.80, 4.81f, 8.308–309, 8.309f, 9.237, 9.237f
 intrauterine, 4.80, 4.81f, 8.107, 8.308–309, 8.309f
 Thygeson superficial punctate (SPK), 6.269, 8.306–307, 8.307f
 toxic, 8.91. *See also* Keratoconjunctivitis, toxic
 ulcerative/peripheral ulcerative (PUK), 8.51f, 8.311t, 8.311–313, 8.312f
 differential diagnosis of, 8.311, 8.311t
 in microscopic polyangiitis, 1.168
 in polyarteritis nodosa, 9.136
 in rosacea, 8.71
 in systemic immune-mediated diseases, 8.51f, 8.311t, 8.311–313, 8.312f
 varicella-zoster virus, 8.225–230, 8.226t. *See also* Herpes zoster ophthalmicus
 yeast, 8.208t, 8.251, 8.273, 8.274–275

- Kerato-irido-lenticular dysgenesis. *See* Peters anomaly
- Keratoacanthoma, eyelid, 4.209–210, 4.210*t*, 4.211*f*, 7.176–177, 7.177*f*
- Keratocan, mutation in gene for, in cornea plana, 8.96*t*, 8.100
- posterior amorphous corneal dystrophy and, 8.136*t*
- Keratoconjunctivitis. *See also* Conjunctivitis
- adenoviral, 8.233, 8.234*f*, 8.234–236, 8.235*f*
- atopic (AKC), 6.249, 8.292–294, 8.293*f*, 9.51
- chlamydial, 8.260
- contact lens–induced (CLIK/CLK), 3.233, 8.84
- epidemic (EKC), 8.233, 8.234*f*, 8.234–236, 8.235*f*
- microsporidial, 8.280–281
- plants causing, 8.387
- sicca (KCS). *See* Aqueous tear deficiency; Dry eye
- superior limbic (SLK), 8.83–85, 8.84*f*
- toxic, medications causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
- vernal (VKC), 6.248–249, 249*f*, 8.289–292, 8.290*f*, 8.291*f*
- atopic keratoconjunctivitis differentiated from, 8.292–293, 8.293*f*
- Keratoconus (KC), 4.95*f*, 4.95–96, 6.254, 6.259, 8.161*f*, 8.161–168, 8.162*f*, 8.163*f*, 8.164*f*, 8.165*f*, 8.167*f*, 8.170*f*, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*
- contact lenses for, 3.225–226, 8.166, 8.167*f*
- corneal (collagen) crosslinking for, 8.166, 13.130–131, 13.131, 13.176, 13.206–208
- corneal opacity caused by, 8.16*f*
- Descemet membrane rupture and, 4.17, 4.18*f*, 4.95*f*, 4.96
- ectasia after LASIK and, 13.124, 13.175
- intrastromal corneal ring segments for, 13.70, 13.124
- Fleischer ring in, 4.95*f*, 4.96, 8.117, 8.118*t*, 8.163, 8.163*f*
- in floppy eyelid syndrome, 8.79, 8.82
- illusions and, 5.174
- intrastromal corneal ring segments for, 13.62, 13.65*f*, 13.65–66, 13.66, 13.69–70, 13.176
- keratotomy in, 8.28, 8.167*f*
- Marfan syndrome and, 8.194
- posterior, 4.98, 8.97*t*, 8.104, 8.105*f*
- refractive lens exchange and, 13.149
- refractive surgery contraindicated in, 8.31, 8.166, 13.23, 13.24, 13.25*f*, 13.38, 13.42–43, 13.44, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*
- corneal topography and, 8.31, 8.166, 13.23, 13.24, 13.25*f*, 13.44, 13.175, 13.175*f*, 13.176*f*, 13.177*f*
- subclinical (*forme fruste*), 8.166, 13.124
- refractive surgery contraindicated in, 13.23, 13.25–26, 13.79, 13.124, 13.175*f*, 13.175–176, 13.177*f*
- LASIK, 13.79, 13.124, 13.175*f*, 13.175–176, 13.177*f*
- topography in detection and, 8.31, 8.166, 13.23, 13.25–26, 13.79, 13.175*f*, 13.175–176, 13.177*f*
- thermokeratoplasty for, 13.127–128
- tomography in, 8.35, 8.35*f*, 8.165*f*, 8.165–166
- topography in, 8.29*f*, 8.30*f*, 8.31, 8.32*f*, 8.32*t*, 8.165*f*, 8.165–166, 13.23, 13.24, 13.25*f*, 13.44, 13.175, 13.175*f*, 13.176*f*, 13.177*f*
- Keratocytes, 2.41, 2.225, 8.8–9, 8.9*f*
- apoptosis of, in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.295–296
- in Fleck corneal dystrophy, 8.153
- glucose/carbohydrate metabolism in, 2.224
- stromal (fibrocytes), 4.73
- corneal haze after surface ablation and, 13.33, 13.109
- in wound healing/repair, 4.14–15, 4.15*f*, 4.16, 13.33
- Keratoderma blennorrhagicum, 1.154
- in reactive arthritis syndrome, 9.115, 9.116*f*
- Keratoectasias, corneal, 4.95*f*, 4.95–96
- Keratoepithelin, gene for, in corneal dystrophies, 4.88, 8.133, 8.134, 8.136*t*. *See also* TGFBI dystrophies
- Reis-Bücklers, 8.142
- Thiel-Behnke, 8.143
- Keratoglobus, 4.95, 6.254, 8.169–171, 8.170*f*
- in Ehlers-Danlos syndrome, 8.171, 8.191*t*, 8.193
- Keratolenticular adhesions (Peters anomaly), 4.74, 4.75*f*, 4.98, 8.97*t*, 8.102–104, 8.103*f*, 10.150, 10.154, 11.31–32. *See also* Axenfeld-Rieger syndrome
- Axenfeld-Rieger syndrome differentiated from, 10.154*t*
- glaucoma and, 4.74, 10.150, 10.154
- pediatric keratoplasty for, 8.450
- Keratolimbal allograft, 8.362–365. *See also* Limbal transplantation
- Keratolysis (corneal melting)
- cataract surgery and, 11.132
- in patient with dry eye, 11.132
- management of, 8.369*f*, 8.369–370
- neurotrophic keratopathy/persistent corneal epithelial defects and, 8.81, 8.82
- peripheral ulcerative keratitis and, 8.311, 8.312
- refractive surgery and, 13.94
- topical medication toxicity and, 4.80–81
- Keratomalacia, in vitamin A deficiency, 8.197
- Keratometry/keratometer, 3.282, 3.286–288, 3.287*f*, 3.307, 8.26–27, 8.27*f*, 13.7–9
- astigmatism after penetrating keratoplasty and, 8.431
- in IOL power determination/selection, 11.84, 11.174
- corneal irregularities and, 11.174
- refractive surgery and, 11.86, 13.193
- unexpected refractive results after surgery and, 11.150
- in keratoconus, 8.164–165
- refractive surgery and, 13.44, 13.45
- IOL power calculation and, 11.86, 13.193
- postoperative, 13.193
- radial keratotomies, 13.50–51, 13.52
- toric IOLs, 13.152
- Keratometry (K) reading. *See* Keratometry/keratometer
- Keratomileusis, 13.27, 13.76. *See also* LASEK; LASIK
- Keratoneuritis/perineuritis, radial, in *Acanthamoeba* keratitis, 4.79, 8.277
- Keratopathy
- actinic (Labrador/climatic droplet/spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
- annular, traumatic, 8.388
- band/calcific band, 4.81–83, 4.82*f*, 8.111, 8.117–120, 8.119*f*, 8.201
- “actinic,” 4.83

- in aqueous tear deficiency, 8.56
- EDTA for, 9.281
- gelatinous droplike corneal dystrophy and, 8.141, 8.141*f*
- in gout, 8.119, 8.188
- in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.123*f*, 9.125
- parathyroid disorders and, 8.201
- in pars planitis, 9.129
- in sarcoidosis, 9.168–169
- in uveitis, 9.79
- bullous, 8.83–84, 4.84, 4.84*f*, 4.85*f*
 - after cataract surgery, 4.83–84, 4.84*f*, 11.129, 11.129*f*
 - IOL design and, 11.149
 - disciform keratitis and, 8.225
 - DMET for, 8.449
 - in Fuchs endothelial corneal dystrophy, 4.92, 8.156
- central toxic, after photoablation, 13.105*f*, 13.105–106
- climatic droplet. *See* Spheroidal degeneration
- diabetic, refractive surgery in patient with, 13.190
- exposure, 8.79–80
 - tarsorrhaphy for, 8.80
- filamentary, 8.56, 8.56*f*
 - in graft-vs-host disease, 8.304
 - treatment of, 8.63
- in herpetic disease, 9.192
- HTLV-1-associated (HTLV-1-related chronic interstitial keratitis), 9.212
- infectious crystalline/pseudocrystalline, 4.79–80, 4.80*f*, 8.268, 8.268*f*
 - corneal deposits and, 8.182*t*
 - after penetrating keratoplasty, 4.79, 8.427, 8.427*f*
- Labrador (actinic/climatic droplet/spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
- lipid, 8.125–126, 8.126*f*
 - corneal crystal deposition and, 8.182*t*
 - in herpes zoster, 8.125, 8.228, 8.228*f*
- measles, 8.239, 8.240*t*
- medications causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
- neurotrophic, 8.42, 8.80–82, 8.81*t*, 8.82*f*
 - diabetic neuropathy and, 8.81, 8.81*t*, 8.199
 - esthesiometry in evaluation of, 8.42
 - herpetic/postherpetic eye disease and, 4.77*f*, 4.78, 8.80, 8.81*t*, 8.217–218, 8.224, 8.225, 8.227
 - after penetrating/deep anterior lamellar keratoplasty, 8.80
- pressure-induced stromal (PISK), after LASIK, 13.119, 13.120*f*
- punctate epithelial, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
 - adenoviruses causing, 8.234
 - blepharitis/blepharoconjunctivitis and, 8.72, 8.73*t*, 8.74
 - exposure causing, 8.80
 - herpes simplex causing, 8.216, 8.216*f*
 - in herpes zoster, 8.227
 - microsporidial, 8.280, 8.280*f*
 - superficial Thygeson (SPK), 8.306–307, 8.307*f*
 - topical anesthetic abuse causing, 8.89
- toxic
 - central, after photoablation, 13.105*f*, 13.105–106
 - ulcerative, 8.80–81, 8.81*t*. *See also* Keratoconjunctivitis, toxic
- urate, 8.119, 8.188
- vortex (hurricane/cornea verticillata), 8.90, 8.129*t*, 8.130, 8.130*f*, 8.176, 8.177*f*
 - in chloroquine/hydroxychloroquine toxicity, 8.130
 - in Fabry disease, 8.176, 8.177*f*
- Keratophakia, 13.27, 13.59–62, 13.61*f*
- Keratoplasty, 8.411–412, 8.412*t*, 8.412–413*t*
 - cataract formation after, 11.176
 - cataract surgery and IOL implantation combined with (triple procedure), 11.175–176
 - in children, 8.450–451
 - conductive (CK), 13.8*t*, 13.28, 13.28*f*, 13.128*f*, 13.128–129, 13.129*f*, 13.165
 - corneal transplantation after, 13.198
 - for presbyopia, 13.128, 13.128*f*, 13.165
 - corneal disorders treated with, 6.262–263
 - for corneal edema after cataract surgery, 11.129
 - donor cornea contraindications and, 8.414, 8.415*t*, 8.416*t*
 - endothelial (EK), 8.411, 8.412, 8.412*t*, 8.436*t*, 8.436–450, 8.437*t*, 8.439*f*, 8.441*f*, 8.442*f*, 8.443*f*, 8.444*f*, 8.445*f*, 8.446*f*, 8.447*f*
 - advantages of, 8.421–422*t*, 8.438, 8.439*f*
 - cataract surgery and, 8.446–447, 11.175–176
 - in children, 8.451
 - complications of, 8.437*t*
 - intraoperative, 8.420–421*t*, 8.440, 8.441*f*
 - postoperative, 8.421*t*, 8.440–449
 - for corneal edema after cataract surgery, 11.129
 - Descemet membrane (DMEK), 8.412, 8.412*t*, 8.436, 8.436*t*, 8.437*t*
 - advantages of, 8.421–422*t*, 8.438
 - cataract surgery and, 8.446–447
 - complications of, 8.437*t*
 - intraoperative, 8.420–421*t*, 8.440
 - postoperative, 8.421*t*, 8.440–449
 - disadvantages of, 8.422*t*, 8.438–440
 - endothelial cell loss after, 8.448–449
 - for Fuchs endothelial corneal dystrophy, 4.92, 4.93*f*
 - graft dislocation/decentration after, 8.442*f*, 8.442–443, 8.443*f*
 - hemi, 8.449–450
 - indications for, 8.420*t*
 - primary graft failure and, 8.447
 - pupillary block after, 8.444*f*, 8.444–445
 - rejection and, 8.437*t*, 8.438
 - results of, 8.437*t*
 - visual acuity after, 8.438–440
 - Descemet stripping/Descemet stripping automated (DSEK/DSAEK), 8.412, 8.412*t*, 8.436, 8.436*t*, 8.437*t*
 - advantages of, 8.421–422*t*, 8.438, 8.439*f*
 - cataract surgery and, 8.446–447
 - complications of, 8.437*t*
 - intraoperative, 8.420–421*t*, 8.440, 8.441*f*
 - postoperative, 8.421*t*, 8.440–449
 - disadvantages of, 8.422*t*, 8.438–440
 - endothelial cell loss after, 8.448–449
 - epithelial ingrowth after, 8.445, 8.445*f*
 - graft dislocation/decentration after, 8.441, 8.442*f*
 - graft failure and, 4.85*f*
 - indications for, 8.420*t*

- primary graft failure and, 8.447
- pupillary block after, 8.444f, 8.444–445
- rejection and, 8.437t, 8.447, 8.447f
- results of, 8.437t
- visual acuity after, 8.438–440
- disadvantages of, 8.422t, 8.438–440
- donor cornea contraindications and, 8.415t
- endothelial cell loss after, 8.448–449
- epithelial ingrowth after, 8.445, 8.445f
- for Fuchs endothelial corneal dystrophy, 8.157
- graft dislocation/decentration after, 8.440–444, 8.441f, 8.442f, 8.443f
- graft rejection and, 4.84, 4.85f
- indications for, 8.412–413t, 8.420t, 8.436
- layer-based approach to use of, 8.417t
- preoperative evaluation/preparation and, 8.418
- primary graft failure and, 8.447
- pupillary block after, 8.444f, 8.444–445
- rejection and, 8.437t, 8.447f, 8.447–448
- short-term results of, 8.437t
- in triple procedure, 11.175–176
- visual acuity after, 8.438–440
- eye banking and, 8.413–417, 8.415t, 8.416f, 8.416t
- indications for, 8.412–413t
- lamellar (LK), 8.411, 8.433f, 8.433–436, 8.435f
 - for *Acanthamoeba* keratitis, 8.279
 - anterior (ALK), 8.412, 8.412t, 8.433, 8.433f
 - advantages of, 8.421–422t, 8.433
 - complications of, 8.435
 - intraoperative, 8.420t
 - postoperative, 8.421t
 - disadvantages of, 8.422t, 8.433
 - donor cornea contraindications and, 8.415t
 - femtosecond/femtosecond laser–assisted (FALK/FLAK), 8.412t, 8.431, 8.434
 - indications for, 8.412–413t, 8.420t, 8.433
 - layer-based approach to use of, 8.417t
 - preoperative evaluation/preparation and, 8.418
 - therapeutic (ALTK), 8.412t
- complications of, 8.420t, 8.421t, 8.435–436
- conjunctival flap removal and, 8.360
- for corneoscleral lacerations, 8.406
- deep (DLEK), 8.412t, 8.436, 8.437t
- deep anterior (DALK), 8.411, 8.412, 8.412t, 8.433, 8.434–435
 - advantages of, 8.421–422t
 - in children, 8.451
 - complications of, 8.435
 - intraoperative, 8.420t
 - postoperative, 8.421t
 - for corneal changes in mucopolysaccharidoses, 8.174–176
 - disadvantages of, 8.422t
 - for herpetic eye disease, 8.225
 - indications for, 8.420t, 8.434
 - for keratoconus, 8.167
 - layer-based approach to use of, 8.417t
 - neurotrophic cornea after, 8.80
 - preoperative evaluation/preparation and, 8.418
 - rejection and, 8.411, 8.435, 8.435f
- graft rejection and, 4.84
- rejection and, 8.411, 8.435, 8.435f
- wound healing/repair and, 13.32–33
- patient selection and, 8.418
- penetrating (PK/PPK), 8.411, 8.412, 8.419–432, 8.437t
 - for *Acanthamoeba* keratitis, 8.279
 - advantages of, 8.421t
 - arcuate keratotomy and, 13.56–57, 13.58
 - astigmatism after
 - control of, 8.431–432, 8.432f
 - refractive surgery for, 13.178–180
 - suture removal/adjustment and, 8.419f, 8.431–432, 8.432f
 - corneal keratotomy and, 8.28
 - corneal topography and, 8.32, 8.431–432, 8.432f
 - for bacterial keratitis, 8.272
 - bullous keratopathy after, 4.83–84, 4.84, 4.84f, 4.85f
 - cataract/cataract surgery and, 11.56, 11.175, 11.176
 - for chemical injuries, 8.379–380
 - in children, 8.450–451
 - CMV recurrence after, 8.232
 - complications of, 8.437t
 - intraoperative, 8.419, 8.420–421t
 - postoperative, 8.421t, 8.423–430
 - conjunctival flap removal and, 8.360
 - for corneal changes in mucopolysaccharidoses, 8.174–176
 - for corneal edema after cataract surgery, 11.129
 - corneal topography after, 13.179–180
 - disadvantages of, 8.422t
 - disease recurrence in graft and, 8.225, 8.232, 8.425, 8.425f
 - donor cornea contraindications and, 8.415t
 - endophthalmitis after, 8.424
 - for Fuchs endothelial dystrophy, 8.157
 - for fungal keratitis, 8.276
 - glaucoma after, 8.424–425, 10.109
 - graft rejection and, 4.84, 4.85f, 8.316–318, 8.428–431, 8.437t, 9.59, 9.60, 9.60f. *See also* Rejection
 - prevention of, 8.430–431
 - treatment of, 8.429–430
 - for herpetic eye disease, 8.225
 - recurrence of, in graft, 8.225
 - indications for, 8.412–413t, 8.419, 8.420t
 - infectious/microbial keratitis after, 8.427
 - infectious pseudocrystalline/crystalline keratopathy after, 4.79
 - for keratoconus, 8.167
 - for keratoglobus, 8.171
 - layer-based approach to use of, 8.417t
 - for microsporidial stromal thinning, 8.281
 - for mucous membrane pemphigoid, 8.303
 - neurotrophic cornea after, 8.80
 - for peripheral ulcerative keratitis, 8.313
 - postoperative care and, 8.423–430
 - preoperative evaluation/preparation and, 8.418
 - after radial keratotomy, 13.52
 - refractive error after, control of, 8.431–432, 8.432f
 - after refractive surgery, 13.197–198
 - refractive surgery after, 13.37, 13.178–180
 - results of, 8.423–429, 8.437t
 - in rosacea patients, 8.71
 - in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298

- sutures for, 8.419*f*
 - corneoscleral laceration repair and, 8.406, 8.407*f*, 8.408*f*
 - postoperative problems and, 8.426*f*, 8.426–427, 8.431–432, 8.432*f*
 - removal/adjustment and, for astigmatism control, 8.419*f*, 8.431–432, 8.432*f*
- tectonic
 - for herpetic eye disease, 8.225
 - keratoglobus, 8.171
 - for peripheral ulcerative keratitis, 8.313
- in triple procedure, 11.175
- preoperative evaluation/preparation and, 8.418–419
- Keratoprostheses, 8.452*f*, 8.452–453, 8.453*t*
 - for chemical injuries, 8.380, 8.384
 - complications of, 8.452–453, 8.453*t*
 - for graft-vs-host disease, 8.304
 - for herpetic eye disease, 8.225
 - for limbal stem cell deficiency, 8.94
 - for mucous membrane pemphigoid, 8.303, 8.453*t*
 - for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298, 8.452
- Keratorefractive surgery (KRS), 13.7, 13.8*t*. *See also*
 - Refractive surgery; *specific procedure*
 - abbreviations and acronyms used in, 13.3–5
 - ablation zones used in, 3.272
 - amblyopia/anisometropic amblyopia and, 13.185–187
 - angle kappa, 3.272
 - astigmatism and
 - corneal topography in detection/management of, 8.32, 13.18–19, 13.22–23, 13.44, 13.45, 13.45*f*
 - penetrating keratoplasty and, 13.178–180
 - in autoimmune disease, 13.191
 - cataract/cataract surgery and, 11.123–124, 11.176–177, 11.177*f*, 13.43–44
 - IOL power calculation and, 11.85–87, 11.176, 11.177*f*, 13.44, 13.194
 - preoperative evaluation/planning and, 11.76, 11.79
 - in children, 13.187–188
 - collagen shrinkage, 13.8*t*, 13.28, 13.28*f*, 13.127–129, 13.128*f*, 13.129*f*
 - in collagen vascular/connective tissue diseases, 13.37, 13.171, 13.191
 - contact lens use after, 13.198–200, 13.199*f*
 - contraindications to
 - corneal topography in identification of, 13.23, 13.24–26, 13.25*f*
 - in ocular and systemic disease, 13.171
 - corneal biomechanics affected by, 13.13–14
 - corneal crosslinking, 13.8*t*, 13.130–135, 13.131*f*, 13.133*f*, 13.133*t*
 - corneal effects of, 13.9, 13.26–28, 13.27*f*, 13.28*f*
 - corneal imaging/evaluation and, 13.14–26, 13.44–45, 13.45*f*. *See also* Cornea, topography of; *specific type*
 - indications for, 13.22–24, 13.23*f*, 13.24*f*
 - postoperative, 13.23*f*, 13.23–24, 13.24*f*
 - preoperative, 13.14–26, 13.44–45, 13.45*f*, 13.79–80
 - dry eye and, 13.173
 - corneal optics and, 13.7–9
 - corneal shape and, 3.268–271, 3.269–271*f*, 13.9
 - corneal topography and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79. *See also* Cornea, topography of
 - dry eye and, 13.173
 - indications for, 13.22–23, 13.23*f*, 13.24*f*
 - postoperative evaluation and, 13.23*f*, 13.23–24, 13.24*f*
 - preoperative evaluation and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79–80
 - refractive lens exchange and, 13.149
 - toric IOLs and, 13.151–152
 - after corneal transplant, 13.37, 13.178–180
 - corneal transplant after, 13.197–198
 - corneal wound healing and, 13.32–33
 - in diabetes mellitus, 13.37, 13.190–191
 - donor cornea suitability and, 8.414
 - emerging technologies in, 13.203–208
 - excimer laser, 13.8*t*, 13.29, 13.73–77, 13.74–75*f*
 - glaucoma/ocular hypertension and, 13.41, 13.180–183, 13.182*f*, 13.200–201
 - herpes simplex virus infection and, 13.173–174
 - higher-order aberrations from, 3.276–277
 - in HIV infection/AIDS, 13.188–190
 - incisional, 13.8*t*, 13.26–27, 13.27*f*, 13.49–58
 - for astigmatism, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*, 13.57*f*
 - corneal effects of, 13.26–27, 13.27*f*
 - for myopia, 13.49–53, 13.50*f*, 13.51*f*
 - informed consent for, 13.36*t*, 13.46–48, 13.47*t*
 - inlays/onlays, 13.59–71, 13.169
 - with intraocular refractive surgery (bioptics), 13.137, 13.157
 - IOL power calculations after, 13.44, 13.193–197, 13.196*f*
 - iron lines associated with, 8.117
 - irregular astigmatism and, 3.272–278, 3.274–276*f*, 13.18–19, 13.22–23, 13.44, 13.45
 - keratoconus and, 13.23, 13.24, 13.25*f*, 13.38, 13.42–43, 13.44, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*. *See also* Keratoconus
 - keratometric power measurements affected by, 13.193
 - in large-pupil patients, 3.272
 - laser biophysics and, 13.29–32, 13.30*f*
 - laser–tissue interactions and, 13.29
 - limitations of, 13.47*t*
 - medical history and, 13.36*t*, 13.37
 - monovision and, 13.39, 13.164–165
 - myopia treated with, 3.275
 - night vision problems after, 3.272
 - nonlaser lamellar, 13.8*t*
 - in ocular and systemic disease, 13.171–191. *See also specific disorder*
 - ocular history and, 13.36*t*, 13.37–38
 - optical considerations/principles and, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*
 - overview of, 3.268
 - overview of procedures used in, 13.7, 13.8*t*
 - patient age and, 13.38–39
 - patient evaluation for, 13.35–48, 13.36*t*. *See also* Keratorefractive surgery (KRS), preoperative evaluation for
 - after penetrating keratoplasty, 8.432, 13.37, 13.178–180
 - penetrating keratoplasty after, 13.197–198

- photoablation, 13.29–32, 13.30*f*, 13.73–74, 13.74–75*f*, 13.101–126. *See also* Photoablation
- postoperative considerations and, 13.193–201
- contact lens use and, 13.198–200, 13.199*f*
- corneal imaging and, 13.23*f*, 13.23–24, 13.24*f*
- corneal transplantation and, 13.197–198
- glaucoma and, 13.200–201
- IOL power calculations and, 13.193–197, 13.196*f*
- retinal detachment repair and, 13.197
- preoperative evaluation for, 13.35–48, 13.36*t*
- corneal imaging/ancillary tests and, 13.14–26, 13.44–46, 13.45*f*, 13.79–80. *See also* Cornea, topography of; *specific type*
- discussion of findings/informed consent and, 13.36*t*, 13.46–48, 13.47*t*
- history and, 13.35–39, 13.36*t*
- ocular examination and, 13.36*t*, 13.39–44, 13.42*f*, 13.43*f*
- patient expectations/motivations and, 13.35–36, 13.36*t*, 13.47
- in presbyopia, 13.38–39, 13.159–170
- pupil size and, 3.272–273
- after radial keratotomy, 13.52
- retinal disease/detachment and, 13.44, 13.183–185, 13.197
- social/occupational history and, 13.36*t*, 13.36–37
- spherical aberrations in, 3.272
- strabismus and, 13.41, 13.185–187
- techniques used in, 3.268
- topography-guided, 13.32, 13.77, 13.97
- wavefront aberrations/analysis and, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*, 13.46, 13.102–103, 13.103*f*
- wavefront-guided/wavefront-optimized, 13.31–32, 13.76–77, 13.97. *See also* Wavefront-guided (custom) laser ablation; Wavefront-optimized laser ablation
- Keratotomy, 8.27–28, 8.28*f*, 8.35*t*. *See also* Videokeratotomy
- in keratoconus, 8.28, 8.167*f*
- Keratitis, 8.45*t*
- actinic, 4.210–212, 4.211*f*, 4.212*f*, 7.175–176, 7.176*f*
- squamous cell carcinoma and, 4.211, 7.176, 7.182
- inverted follicular, 4.209, 4.210*f*
- sebhorheic, 4.209, 4.209*f*, 4.210*f*, 7.167, 7.167*f*
- Keratotomy
- arcuate (AK), 13.8*t*, 13.53, 13.54–58
- complications of, 13.58
- instrumentation for, 13.55
- ocular surgery after, 13.58
- outcomes of, 13.57
- refractive lens exchange and, 13.149
- surgical technique for, 13.55–57
- astigmatic (AK), 13.8*t*
- cataract surgery and, 11.123
- wound healing/repair and, 13.32
- hexagonal (Hex K), 13.8*t*
- incisional, 13.49. *See also* Radial keratotomy
- radial (RK). *See* Radial keratotomy
- transverse (tangential/straight), 13.53, 13.54, 13.54*f*
- Keratouveitis, 9.73
- in herpetic disease, 9.191
- syphilitic, 9.237
- varicella, 8.226, 8.229
- Kerlone. *See* Betaxolol
- Kestenbaum-Anderson procedure, for nystagmus, 5.236, 5.237*f*
- Kestenbaum procedure, 6.155, 6.156*t*, 6.156*f*
- Kestenbaum rule, 3.320
- Ketoacidosis, diabetic (DKA), 1.34, 1.47–48
- infusion failure and, 1.42
- Ketoconazole, 1.280, 2.355*t*, 2.356
- for fungal keratitis, 8.275
- Ketolides, 1.273*t*, 1.278
- Ketoprofen, 2.335*t*
- Ketorolac, 2.330*t*, 2.335*t*, 2.336, 2.338*t*
- for cystoid macular edema, 9.94
- after cataract surgery, 11.165
- for intraoperative floppy iris syndrome, 11.138
- perioperative, 1.290
- Ketotifen, 2.238, 2.338*t*, 2.339
- Keywords, in online searching, 1.3
- Khodadoust line, 8.429, 8.430*f*, 9.50, 9.60*f*
- Ki-67
- in orbital solitary fibrous tumors, 4.236
- in pingueculae/pterygia, 4.57
- Kidney cancer, metastatic eye disease and, 4.304*t*
- Kidney transplantation, for cystinosis, 2.203
- Kidneys. *See specific Renal entries*
- KIF21A gene mutation, congenital extraocular muscle disorders and, 2.124
- Killer cells, 9.39, 9.50
- in antibody-dependent cellular cytotoxicity, 9.50
- natural, in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
- natural (NK), 9.34, 9.39, 9.49
- in viral conjunctivitis, 9.56
- Kilobase (kb), 2.138
- Kinetic energy, 3.106
- Kinetic perimetry, 5.84, 5.85*f*, 10.59. *See also* Visual field testing
- in nonorganic disorder evaluation, 5.308, 5.308*f*
- Kinetic red target test, in confrontation testing, 5.83
- “Kissing” nevus, 4.218, 4.218*f*
- Klebsiella, 8.247
- endogenous endophthalmitis caused by, 9.264
- endophthalmitis caused by, 12.238
- Kleebattschädel, 6.205
- Klippel-Trénaunay syndrome (KTS), 6.406
- Klippel-Trénaunay-Weber syndrome (KTWS)
- description of, 6.199, 6.251, 6.394*t*, 6.406
- glaucoma associated with, 10.30
- K_m (Michaelis/affinity constant), sorbitol in cataract development and, 11.19
- Knapp procedure, 6.127
- inverse, 6.128
- Knobloch syndrome, 6.346*f*, 6.346–347
- Koeppel lens/Koeppel-type lenses, for gonioscopy/funduscopy, 10.33
- in children and adolescents, 6.282, 6.282*f*, 10.159
- Koeppel nodules
- in sarcoidosis, 4.187, 9.81*f*, 9.168, 9.168*f*
- in uveitis, 9.81*f*, 9.82
- Koganei, clump cells of, 4.181
- KOH. *See* Potassium hydroxide

- Kohn shell, 3.246f
 Koilocytosis, in human papillomavirus infection, 4.204, 4.205f
 Koniocellular (K) system/neurons/bistratified cells, 10.42
 KPro. *See* Boston keratoprosthesis
 KPs. *See* Keratic precipitates
 Krabbe disease/leukodystrophy, 2.175t, 6.388t
 Krause, glands of, 2.20f, 2.22f, 2.23t, 2.29, 2.216, 4.202, 7.146f, 7.152, 7.252
 Krill disease (acute retinal pigment epitheliitis/ARPE), 9.141–143t, 9.164, 9.164f
 Krimsky test, 6.67, 6.68f, 6.104f
 KRS. *See* Keratorefractive surgery
 KRT3/KRT12 mutation, in Meesmann corneal dystrophy, 8.136t
 Krusenbergs spindles, 4.105, 8.118t, 8.128, 10.31, 10.92, 10.94, 10.94f. *See also* Pigment/pigmentary dispersion syndrome
 KSHV. *See* Kaposi sarcoma–associated herpesvirus
 KTS. *See* Klippel-Trénaunay syndrome
 KTWs. *See* Klippel-Trénaunay-Weber syndrome
 Kuglen hook, for pupil expansion, 11.177
 Kuru, 5.357
 Kyrieleis arteriolitis, 9.222
 Kyrieleis plaques, 12.244f
- L**
- L_e . *See* Radiance
 L_v . *See* Luminance
 L-cone opsin genes, 2.262
 mutation in, 2.262, 2.264
 L cones, 2.262, 12.54
 bipolar cells for, 2.266
 horizontal cells for, 2.266
 retinal ganglion cells for, 2.267, 2.267f, 2.268f
 L-Dopa, for Parkinson disease, 1.199
 L-selectin, in neutrophil rolling, 9.17
 L-type calcium channels, mutation in, 2.264
 LA. *See* Lacrimal artery
 “La belle indifference,” 5.299
 LA 3.0 (photopic single-flash) electroretinogram, in cone dystrophies, 5.102
 Labbé, vein of, 5.22
 Labetalol, 1.68t, 1.72
 for hypertensive emergency, 1.74
 intraoperative floppy iris syndrome and, 11.137, 11.137t
 Labrador (actinic/climatic droplet) keratopathy (spheroidal degeneration), 4.83, 4.83f, 8.115–117, 8.116f
 Labyrinth, 5.38, 5.39f, 6.40
 in vestibular-ocular reflex, 5.214
 Labyrinthine segment, of cranial nerve VII (facial), 2.103, 5.52
 Lacerations. *See also* Trauma
 canalicular, 7.282–283
 conjunctival, 8.396–397
 corneal, 12.359
 corneoscleral, 6.377, 8.388. *See also* Anterior segment, trauma to; Penetrating and perforating ocular trauma; Trauma
 repair of, 8.404f, 8.404–409, 8.405f, 8.407f, 8.408f
 eyelid, 6.378
 lid margin involved in, 7.188f, 7.188–189, 7.192–195, 7.193f, 7.194f
 lid margin not involved in, 7.187–188, 7.191–192
 ptosis caused by, 7.218
 repair of, 7.188, 7.188f, 7.188–189, 7.189. *See also* Eyelids, surgery/reconstruction of
 secondary, 7.189–190
 globe, 12.358
 iris, repair of, 8.406, 8.408f, 8.409
 lacrimal sac/nasolacrimal duct, 7.284
 medial rectus muscle, 6.146
 scleral, 12.359
 Lacosamide, 1.202t
 Lacquer cracks, 12.211, 12.211f
 Lacrimal artery (LA), 2.28–29, 2.33f, 2.34f, 5.13f, 5.14, 5.14f, 5.15f, 6.23, 7.12f, 7.14f, 7.15f
 extraocular muscles supplied by, 2.17, 7.12f
 eyelids supplied by, 7.154
 Lacrimal bone, 2.5, 2.6, 2.6f, 5.7f, 5.8, 5.9f, 7.6f, 7.7f, 7.8, 7.8f, 7.254
 Lacrimal canaliculi. *See* Canaliculi
 Lacrimal crests, 5.9f
 anterior and posterior, 2.5, 2.6f
 Lacrimal drainage system, 2.29f, 2.29–30, 7.252–255, 7.253f, 7.254f. *See also* Nasolacrimal duct
 anatomy of, 2.29f, 2.29–30, 7.252–255, 7.253f, 7.254f
 development of, 7.255
 abnormalities of, 7.257–259, 7.258f
 diagnostic tests for evaluation of, 7.269f, 7.269–272, 7.270f, 7.271f
 disorders of. *See also* Tearing/epiphora
 acquired, 7.267–281
 congenital, 6.227–230, 7.255, 7.259–267
 congenital lacrimal fistula, 6.228, 6.229f
 dacryocystocele, 6.213, 6.225, 6.228–230, 6.229f
 infectious, 7.284–286, 7.285f, 7.286f
 lacrimal puncta or canaliculi atresia, 6.227–228, 6.228f
 neoplastic, 7.287
 canalicular obstruction and, 7.274
 nasolacrimal duct obstruction and, 7.278
 obstruction. *See* Nasolacrimal duct, obstruction of
 traumatic, 7.282–284
 duplications in, 7.257–258, 7.258f
 irrigation of
 for canalicular obstruction evaluation, 7.270f, 7.271, 7.271f
 for canalicular trauma, 7.283
 for congenital lacrimal drainage management, 7.261f, 7.261–262, 7.262f, 7.263f
 for lacrimal drainage evaluation, 7.269–271, 7.270f, 7.271f
 obstruction of. *See also* Tearing/epiphora
 acquired, 7.267–281
 evaluation of, 7.267–272, 7.269f, 7.270f, 7.271f
 neoplastic causes of, 7.274
 in canalicular disorders
 acquired, 7.273–276, 7.276f
 congenital, 7.259–260
 congenital, 7.255, 7.259–267
 evaluation of, 7.259

- dacryocystocele and, 7.265–267, 7.266f
 diagnostic tests for evaluation of, 7.269f, 7.269–272, 7.270f, 7.271f
 examination in patient with, 7.259, 7.267–268
 history in patient with, 7.267
 lacrimal outflow evaluation in patient with, 7.268–269
 nasolacrimal duct obstruction
 acquired, 7.276–281, 7.277f, 7.280f, 7.281f
 congenital, 7.255, 7.259, 7.260–265, 7.261f, 7.262f, 7.263f, 7.264f
 pseudoepiphora evaluation and, 7.267–268
 in punctal disorders
 acquired, 7.272–273
 congenital, 7.259–260
 reconstruction of, 7.275, 7.283
 after medial canthal basal cell carcinoma removal, 7.180
 therapeutic closure of, 7.281–282
 Lacrimal ducts, 2.22f, 2.28, 7.251. *See also* Lacrimal drainage system
 cyst arising from, 4.208
 Lacrimal/lacrimal–cutaneous fistula, congenital, 6.228, 6.229f, 7.257, 7.258f
 Lacrimal fossa/lacrimal gland fossa, 2.5–6, 2.6, 2.6f, 5.7f, 5.9f, 6.181, 7.6, 7.6f, 7.254, 7.254f
 lymphoproliferative lesions/lymphomas arising in, 7.88, 7.91
 Lacrimal functional unit (LFU), 8.4–5, 8.5f
 disturbance of
 dry eye caused by, 8.53, 8.54f. *See also* Dry eye
 immunoregulation in reduction of, 8.12f
 Lacrimal gland, 2.9f, 2.22f, 2.23t, 2.28f, 2.28–29, 2.101f, 2.215f, 2.216, 4.202, 4.223, 5.51f, 7.14f, 7.15f, 7.18, 7.251–252, 7.252f, 8.5, 8.6f
 accessory glands and, 2.22f, 2.23t, 2.29, 2.215f, 2.216, 4.202, 7.146f, 7.152, 7.252
 agenesis of, 7.257
 anatomy of, 2.9f, 2.22f, 2.28f, 2.28–29, 7.14f, 7.15f, 7.18, 7.251–252, 7.252f
 aqueous component/tears produced by, 2.22f, 2.215f, 2.216, 2.217–220, 2.218f, 2.219f
 congenital abnormalities of, 7.257
 cyst arising from duct of, 4.208
 development of, 2.125–126, 7.251, 7.255
 abnormalities of, 7.257
 dysfunction of
 in Sjögren syndrome, 8.57
 tests of, 8.38–41, 8.40f
 ectopic, 6.226, 7.257
 Epstein-Barr virus infection and, 8.230–231
 in external eye defense, 8.11
 of Henle and Manz, 2.215f, 2.217
 hypoplasia of, 7.257
 infection of. *See* Dacryoadenitis; Lacrimal system
 innervation of, 5.52, 5.55, 5.276–277f, 8.5, 8.5f
 ionizing radiation damaging, 8.386
 nonspecific orbital inflammation involving, 7.64, 7.94
 oncocytoma arising in, 4.71–72, 4.72f, 8.337
 orbital, 2.28, 2.216
 palpebral, 2.28, 2.216
 parasympathetic innervation of, 2.100, 2.101f, 2.104, 2.216, 7.16, 7.251
 prolapse of, 7.257
 sarcoidosis involving, 7.63
 tumors of, 4.229–231, 4.230f, 4.231f, 7.91–94, 7.92f
 epithelial, 4.229–231, 4.230f, 4.231f, 7.91–94, 7.92f
 exenteration for, 7.93, 7.136
 nonepithelial, 7.94
 Lacrimal intubation
 for acquired nasolacrimal obstruction, 7.278
 for canalicular obstruction, 7.275
 for canalicular trauma, 7.283
 for congenital lacrimal drainage obstruction, 7.262–263, 7.264f
 for punctal/canalicular agenesis/dysgenesis, 7.259, 7.260
 Lacrimal nerve, 2.9f, 2.100, 2.101f, 5.8f, 5.43f, 5.48, 5.48f, 7.10f, 7.13f, 7.14f, 7.15f, 7.16, 7.17f, 7.145f, 8.5f
 in reflex tear arc, 7.251–252
 Lacrimal nucleus, 2.103, 2.104
 Lacrimal outflow evaluation, 7.268–269
 dye disappearance test and, 7.269, 7.269f
 Jones I and Jones II tests in, 7.269
 Lacrimal papillae, 2.29
 Lacrimal plugs, for dry eye, 7.281–282, 8.61t, 8.64–65, 8.65f
 canalicular obstruction and, 7.274, 7.282
 extrusion/migration of, 7.282
 nasolacrimal duct obstruction and, 7.278, 7.282
 Lacrimal probing
 for acquired nasolacrimal duct/canalicular obstruction, 7.271–272, 7.273
 for canalicular trauma, 7.283
 for congenital dacryocystocele/dacryoceles, 7.265
 for congenital nasolacrimal duct obstruction, 7.260, 7.261f, 7.261–262, 7.262f, 7.263f
 Lacrimal pump, 7.147, 7.255, 7.256f
 large puncta affecting, 7.273
 ocular medication absorption affected by, 2.296
 Lacrimal puncta, atresia of, 6.227–228, 6.228f
 Lacrimal reflex arc, 2.101f
 Lacrimal sac (tear sac), 2.29, 7.253, 7.253f, 7.254, 7.254f
 cast formation in (dacryoliths), 7.277, 7.277f
 development of, 7.255
 distension of
 in dacryocystitis, 7.285
 in dacryocystocele, 7.265–267, 7.266f
 dacryolith causing, 7.277
 in nasolacrimal duct obstruction, 7.249, 7.271
 neoplasm causing, 7.278
 evaluation of, 7.268
 inflammation of, 7.285–286, 7.286f. *See also* Dacryocystitis
 trauma to, 7.284
 tumors of, 4.229, 7.287
 Lacrimal scintigraphy, for lacrimal drainage evaluation, 7.272
 Lacrimal system. *See also specific structure*
 anatomy of, 7.251–255, 7.252f, 7.253f, 7.254f
 biopsy of, in dacryocystorhinostomy, 7.279
 development of, 7.255
 abnormalities of, 7.257–259, 7.258f

- disorders of, 7.257–287. *See also* Tearing/epiphora
 acquired, 7.267–281
 congenital, 7.259–267
 developmental abnormalities, 7.257–259, 7.258f
 infection, 7.284–286, 7.285f, 7.286f
 neoplastic, 7.91–94, 7.92f, 7.286–287
 therapeutic closure of drainage system for, 7.281–282
 traumatic, 7.282–284
- excretory apparatus of, 2.29f, 2.29–30, 7.252–255, 7.253f, 7.254f. *See also* Excretory lacrimal system;
 Lacrimal drainage system
- healing/repair of, 4.17
- intubation of
 for acquired nasolacrimal obstruction, 7.278
 for canalicular obstruction, 7.275
 for canalicular trauma, 7.283
 for congenital lacrimal drainage obstruction, 7.262–263, 7.264f
 for punctal/canalicular agenesis/dysgenesis, 7.259, 7.260
- physiology of, 7.255, 7.256f
- secretory apparatus/function of, 2.22f, 2.28f, 2.28–29, 2.217–220, 2.218f, 2.219f, 7.251–252, 7.252f, 7.255. *See also* Lacrimal gland; Secretory lacrimal apparatus
- tumors of, 7.91–94, 7.92f, 7.286–287
 canalicular obstruction and, 7.274
 nasolacrimal duct obstruction and, 7.278
- Lacrimal vein, 5.21f, 7.12f
- Lacrimation, 7.267. *See also* Tearing/epiphora
 in thyroid eye disease, 7.56
- Lactate/lactic acid
 in aqueous humor, 2.232
 in cornea, glucose metabolism and, 2.224
 in tear film, 2.216
- Lactation
 glaucoma medication use during, 10.185–186
 refractive surgery contraindicated during, 13.63
- Lactoferrin, in tear film, 2.216, 8.6f, 8.39
- Lactotroph adenomas (prolactinomas), 1.57
- Lacus lacrimalis, 8.6
- LADA. *See* Latent autoimmune diabetes in adults
- Lagophthalmos
 assessment for, 5.271
 after blepharoplasty, 7.234
 causes of, 8.79
 exposure keratopathy and, 8.79
 paralytic, 7.226
 in paralytic ectropion, 7.224, 7.226
 in ptosis, 7.210, 7.210f
 after repair, 7.222
- LAIV. *See* Live, attenuated influenza vaccine
- LAL. *See* Light Adjustable Lens
- Lambda (λ)-bacteriophage, as vector, 2.145
- Lambda (λ)-pattern strabismus
 clinical features of, 6.110
 surgical treatment of, 6.113
- Lambdoid suture, 5.5
- Lamellae
 corneal, 2.40–41, 2.225–226, 8.8, 8.9f
 zonular, 11.11
- Lamellar (zonular) cataracts, 6.55, 6.296, 6.296f, 11.34–35, 11.36f
- Lamellar channels, for intrastromal corneal ring
 segment placement, 13.62, 13.62f, 13.63f, 13.64
 deposits in, 13.69, 13.69f
- Lamellar deficiency, surgery for eyelid retraction and, 7.224
- Lamellar flaps, LASIK, 13.73, 13.79, 13.82, 13.84–90.
See also Flaps, LASIK
 after penetrating keratoplasty, 13.180
- Lamellar macular hole, 12.28f
- Lamellar surgery, 13.8t. *See also* LASIK
 corneal wound healing and, 13.32–33
 keratectomy, for keratophakia, 13.59, 13.60
 keratoplasty. *See* Keratoplasty; Keratoplasty, lamellar
 nonlaser, 13.8t
- Lamina cribrosa, 2.87, 2.88f, 4.107, 4.242f, 5.17f, 6.364, 10.43–44, 10.44f, 10.45f, 10.46
 blood supply of, 2.91, 2.91f, 2.92f
 dehiscences in, 12.218, 12.218f
 development of, 2.116t
- Lamina fusca, 2.44, 4.107, 4.107f, 4.108, 4.182
- Lamina papyracea, 2.6, 2.6f, 5.7f, 5.8, 7.6f, 7.7f, 7.8, 7.8f, 7.254
- Lamina terminalis, 5.27f
- Laminar area of optic nerve, 2.85t, 2.86, 2.87, 10.42, 10.43, 10.46
 blood supply of, 2.91
- Laminar deposits, basal, in age-related macular degeneration, 4.160, 4.162, 4.165, 4.165f
- Laminin, 2.64, 2.250, 2.251f, 8.8, 12.7
- Lamivudine
 for delta hepatitis, 1.261
 for hepatitis B, 1.219–220
 for HIV infection/AIDS, 1.266
- Lamotrigine, 1.202t
 as mood stabilizer, 1.197
- Lampalizumab, 12.71
- Lancaster red-green test, 3.35–36, 6.69, 6.120
- Lancefield groups, 8.244–245
- Landolt C optotypes, 3.133f, 3.134
- Lang stereopsis tests, 6.81
- Langerhans cell histiocytosis (LCH/histiocytosis X), 6.218–219
 diffuse soft-tissue histiocytosis and, 7.90
 orbital involvement and, 7.90
- Langerhans cells (LCs), 2.40, 9.11–12
 conjunctival, 8.13
 corneal, 8.13f, 8.13–14
 in external eye defense, 8.13, 8.13f, 8.13–14
- Langhans giant cells, 4.7, 4.9f
- Large-angle esotropias, 6.87
- Large cell (primary central nervous system/intraocular) lymphoma, 1.237, 4.135f, 4.135–137, 4.136f, 4.311f, 4.311–313, 4.313f, 5.349, 9.273–276, 9.274f, 9.275f. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
- Large colloid drusen, 12.274
- Larval/larvae migrans. *See also* *Toxocara* (toxocariasis)
 neural, 9.233
 ocular, 8.253
 visceral, 8.253, 9.228
- LASEK (laser subepithelial keratomileusis), 13.8t, 13.73.
See also Keratorefractive surgery; Photorefractive keratectomy; Surface ablation
 Bowman layer and, 2.225

- in children, 13.187
- corneal preparation/epithelial preservation for, 13.84
- glaucoma/ocular hypertension and, 13.182
- immediate postablation measures for, 13.92–93
- LASER (Light Amplification by Stimulated Emission of Radiation). *See* Lasers
- Laser capsulotomy (Nd:YAG), 11.154*f*, 11.154–157, 11.156*f*
 - for anterior capsule fibrosis and phimosis, 11.154, 11.154*f*, 11.154–157, 11.156*f*
 - for capsular block syndrome, 11.149
 - for capsule opacification, 11.152, 11.153, 11.154, 11.154*f*, 11.154–157, 11.156*f*
 - multifocal IOLs and, 13.156, 13.167
 - in uveitis, 9.284
 - complications of, 11.156–157
 - contraindications for, 11.155
 - indications for, 11.154–155
 - lens particle glaucoma and, 11.67
 - procedure for, 11.155–156, 11.156*f*
 - retinal detachment and, 11.157, 11.166
- Laser goniotomy, 10.193–194
- Laser in situ keratomileusis. *See* LASIK
- Laser iridotomy, 3.115. *See also* Iridotomy
 - for acute angle closure, 10.124, 10.125, 10.191–193, 10.192*f*
 - for angle-closure glaucoma, 10.124, 10.125, 10.126, 10.191–193, 10.192*f*
 - cataract extraction after, 10.213
 - for angle-closure suspect, 10.122, 10.191
 - for ectopia lentis, 10.129–130
 - for malignant/ciliary block glaucoma (aqueous misdirection), 10.140
 - for phacomorphic glaucoma, 10.128
 - for phakic IOL insertion, 13.141
 - for pigmentary glaucoma, 10.96, 10.96*f*
 - for subacute/intermittent angle closure, 10.126
- Laser ophthalmoscopy/ophthalmoscope, in optic nerve/nerve head/disc evaluation, 10.56
- Laser photoablation. *See* Photoablation
- Laser photolysis, 11.125
- Laser-pointer injury, 12.369
- Laser pupilloplasty
 - for cataracts, 11.71–72
 - for IOL decentration/dislocation, 11.145
- Laser retinopexy, 12.376–377
- Laser scanning confocal microscope, 8.24. *See also* Confocal microscopy
- Laser subepithelial keratomileusis. *See* LASEK
- Laser suture lysis (LSL), scleral flap closure/management and, 10.202–203, 10.207–208
- Laser therapy (laser surgery). *See also* Photocoagulation;
 - Photodynamic therapy; *specific procedure*
 - adverse effects of, 12.114
 - branch retinal vein occlusion treated with, 12.128
 - canaliculoplasty, for canalicular reconstruction, 7.275
 - central retinal vein occlusion treated with, 12.135
 - for choroidal hemangioma, 4.283
 - for choroidal melanoma/ciliary body melanoma, 4.276
 - diabetic macular edema treated with, 12.114–115
 - for diabetic retinopathy, 4.160, 4.161*f*
 - for glaucoma, 10.188–196. *See also specific procedure*
 - malignant/ciliary block glaucoma (aqueous misdirection) and, 10.139
 - trabeculoplasty and, 10.88, 10.93, 10.96, 10.96*f*, 10.113–115, 10.188–191, 10.190*f*
 - uveitic glaucoma and, 9.287
 - for infantile (capillary) hemangioma, 7.68, 7.162
 - for iris bombé in uveitis, 9.286
 - light–tissue interactions and, 13.29
 - for multifocal choroiditis and panuveitis syndrome, 9.157
 - for pars planitis, 9.130–131
 - proliferative diabetic retinopathy treated with, 12.104–107
 - for punctal occlusion, 7.282
 - for retinoblastoma, 4.300
 - retinopathy of prematurity treated with, 12.185–186
 - for skin resurfacing, 7.237–238
 - for trichiasis, 7.208
- Laser thermokeratoplasty (LTK). *See also* Thermokeratoplasty
 - corneal transplantation after, 13.198
 - description of, 13.8*t*, 13.127–128
 - hyperopia treated with, 3.115
- Laser–tissue interactions
 - overview of, 3.112–113, 13.29
 - photoablation, 3.113, 3.113*t*, 3.113*f*, 3.115
 - photochemical, 3.113*t*, 3.113–114
 - photodisruption, 3.113, 3.113*t*, 3.113*f*, 3.116–117, 3.117*f*
 - plasma-induced ablation, 3.113, 3.113*t*, 3.113*f*, 3.115–116, 3.116–117*f*
 - thermal, 3.113–114*t*, 3.113–114*f*, 3.113–115
 - types of, 3.113, 3.113*t*, 3.113*f*
- Laser trabeculoplasty (LTP), 3.115, 10.113–115, 10.188–191, 10.190*f*
 - for normal-tension glaucoma, 10.88
 - for open-angle glaucoma, 10.113–115, 10.188–191
 - for pigmentary glaucoma, 10.96, 10.96*f*
 - for pseudoexfoliation glaucoma, 10.93
 - selective (SLT), 10.188, 10.189, 10.190, 10.190*f*
- LaserACE procedure, 13.162
- Lasers, 13.73–74. *See also* Laser therapy; *specific type*
 - active medium used by, 3.111–112, 3.112*f*
 - biophysics of, 13.29–32, 13.30*f*
 - coagulation uses of, 3.115
 - continuous-wave, 3.112
 - definition of, 3.92
 - description of, 3.110
 - excimer, 13.8*t*, 13.29, 13.73–77, 13.74–75*f*
 - fundamentals of, 3.110–112
 - green, 12.373
 - infrared, 12.374
 - light produced by, 3.111
 - mode-locking, 3.112
 - Nd:YAG, 3.112, 3.115
 - photochemical effect caused by, 12.374
 - photocoagulation using. *See* Photocoagulation
 - Q-switching, 3.112
 - red, 12.374
 - stimulated emission, 3.111, 3.111*f*
 - tissue interactions and, 13.29
 - topography-guided, 13.32, 13.77
 - transpupillary thermotherapy using, 12.380

- ultrashort laser pulses, 3.117–118
- vaporization caused by, 12.374–375
- wavefront-guided/wavefront-optimized, 13.31–32, 13.76–77. *See also* Wavefront-guided (custom) laser ablation; Wavefront-optimized laser ablation programming, 13.31, 13.81
- wavelength of
 - description of, 3.115
 - for photocoagulation, 12.373–375
 - yellow, 12.374
- Lash follicles, 7.154f
 - tumors arising in, 7.172, 7.172f, 7.173f
- Lash margin entropion
 - in anophthalmic socket, 7.136
 - tarsal fracture operation for, 7.207, 7.207f
 - trichiasis in, 7.208
- Lashes. *See* Eyelashes
- LASIK (laser in situ keratomileusis), 13.8t, 13.73, 13.74, 13.75f, 13.76. *See also* Keratorefractive surgery; Photoablation
 - aberrations after, 13.11, 13.12, 13.102–103, 13.103f
 - for accommodative esotropia, 13.188
 - for amblyopia/anisometropic amblyopia, 13.186, 13.187
 - application of laser treatment and, 13.30, 13.91f, 13.91–93
 - arcuate keratotomy and, 13.54, 13.58
 - in astigmatism, 13.97
 - after penetrating keratoplasty, 8.432, 13.179, 13.180
 - bandage contact lenses after, 13.93, 13.111, 13.200
 - for epithelial ingrowth, 13.122
 - for epithelial sloughing/defects, 13.112
 - for microkeratome complications, 13.111
 - for striae, 13.113
 - bioptics with, 13.157
 - Bowman layer and, 2.225
 - calibration of excimer laser for, 13.80
 - cataract surgery after, 11.177
 - IOL power calculation and, 11.86
 - central toxic keratopathy after, 13.105f, 13.105–106
 - in children, 13.187
 - complications/adverse effects of, 13.110–124. *See also specific type*
 - in diabetes mellitus, 13.190
 - rare, 13.125–126
 - in connective tissue/autoimmune diseases, 13.191
 - contact lens use after, 13.199, 13.200
 - contraindications/relative contraindications to, 13.78–80
 - forme fruste/keratoconus and, 13.79, 13.124, 13.175f, 13.175–176, 13.177f
 - ocular and systemic disease and, 13.171
 - “pellucid suspect” pattern and, 13.176, 13.176f
 - residual stromal bed thickness and, 13.30, 13.45–46, 13.79–80. *See also* LASIK (laser in situ keratomileusis), residual stromal bed thickness and
 - corneal biomechanics affected by, 13.14
 - corneal perforation and, 13.111
 - corneal preparation for, 13.84–90, 13.85f, 13.86f, 13.87f, 13.88f, 13.89f
 - corneal thickness and, 13.45–46, 13.79–80
 - corneal transplantation after, 13.198
 - corneal wound healing/repair and, 13.33
 - corticosteroids after, 13.93, 13.94
 - complications associated with, 13.105
 - in diabetes mellitus, 13.190
 - diffuse lamellar keratitis after, 13.116f, 13.116–117, 13.117t
 - infectious keratitis differentiated from, 13.117–118, 13.118f, 13.118t
 - pressure-induced stromal keratopathy differentiated from, 13.119
 - drugs affecting success of, 13.37
 - dry eye after, 13.78–79, 13.172
 - in dry eye disorders, 13.78–79, 13.172–173
 - ectasia/keratoconus and, 13.124–125, 13.175f, 13.175–178, 13.176f, 13.177f
 - corneal crosslinking and, 13.124, 13.130, 13.131, 13.176
 - intrastromal corneal ring segment placement and, 13.70
 - ectatic disorders after, 8.166
 - elevated intraocular pressure after, 13.105, 13.119, 13.181, 13.182, 13.200–201
 - epipolis. *See* Epipolis laser in situ keratomileusis
 - epithelial ingrowth after, 13.120–122, 13.121f
 - epithelial sloughing/defects after, 13.112
 - filtering surgery and, 13.182
 - flap creation for, 13.30, 13.73, 13.75f, 13.79, 13.82, 13.84–90. *See also* Flaps, LASIK
 - aberrations and, 13.102–103, 13.103f
 - corneal inlay insertion and, 13.60, 13.169
 - femtosecond, 13.8t, 13.87–90, 13.88f, 13.89f, 13.90t
 - aberrations and, 13.102–103
 - advantages/disadvantages/complications of, 13.88, 13.90t, 13.122–124, 13.123f
 - re-treatment/enhancements and, 13.98
 - steep or flat corneas and, 13.44–45, 13.79
 - glaucoma/elevated intraocular pressure and, 13.181, 13.201
 - infection and, 13.107, 13.107f, 13.117–119
 - diffuse lamellar keratitis differentiated from, 13.117–118, 13.118f, 13.118t
 - microkeratome, 13.84–87, 13.85f, 13.86f, 13.87f
 - aberrations and, 13.102
 - complications associated with, 13.110f, 13.110–112, 13.111f
 - re-treatment/enhancements and, 13.98
 - after penetrating keratoplasty, 13.180
 - retinal detachment surgery and, 13.185, 13.197
 - steep or flat corneas and, 13.44–45, 13.79, 13.80
 - flap dislocation and, 13.113, 13.115–116
 - striae and, 13.113
 - traumatic, 13.115–116
 - flap folds and, 13.112–115, 13.114t, 13.115f
 - glaucoma/ocular hypertension and, 13.105, 13.181, 13.182, 13.200–201
 - haze formation and, 13.33
 - herpes simplex virus keratitis and, 13.174
 - herpes zoster ophthalmicus and, 13.174
 - in HIV infection/AIDS, 13.189
 - for hyperopia, 13.96, 13.97
 - hyperopia correction using, 3.271, 3.271f

- infectious keratitis after, 13.106*f*, 13.106–107, 13.107*f*, 13.117–119, 13.118*f*, 13.118*t*
 diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
 interface complications and, 13.116–122
 interface debris after, 13.122, 13.123*f*
 intraocular pressure elevation/measurement after, 10.25, 13.105, 13.119, 13.181, 13.200–201
 after intrastromal corneal ring segment removal, 13.70
 keratitis after
 atypical mycobacteria causing, 8.272–273, 8.273*f*, 13.106, 13.119
 diffuse lamellar, 13.116*f*, 13.116–117, 13.117*t*
 infectious keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
 pressure-induced stromal keratopathy differentiated from, 13.119
 herpes simplex, 13.174
 infectious, 13.106*f*, 13.106–107, 13.107*f*, 13.117–119, 13.118*f*, 13.118*t*
 diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
 keratopathy after
 central toxic, 13.105*f*, 13.105–106
 pressure-induced stromal, 13.119, 13.120*f*
 limbal relaxing incisions and, 13.54, 13.58
 limitations of, 13.47*t*
 microkeratome for, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
 aberrations and, 13.102
 complications associated with, 13.110*f*, 13.110–112, 13.111*f*
 re-treatment/enhancements and, 13.98
 for mixed astigmatism, 13.97
 for myopia, 13.95, 13.97
 intraocular pressure measurements and, 13.181, 13.182*f*
 spherical aberrations after, 13.11, 13.12, 13.102
 OCT in evaluation and, 8.22
 outcomes of, 13.95
 for hyperopia correction, 13.96, 13.97
 for myopia correction, 13.95, 13.97
 small-incision lenticule extraction compared with, 13.204, 13.205
 for wavefront-guided/wavefront-optimized/topography-guided treatment, 13.31–32, 13.97
 overcorrection and, 13.101–102
 conductive keratoplasty for, 13.129
 patient selection and, 13.78–80
 after penetrating keratoplasty, 13.179, 13.180
 postoperative care for, 13.94–95
 immediate postablation measures and, 13.93
 preoperative care for
 patient preparation and, 13.81–82
 patient selection/relative contraindications and, 13.78–80
 planning/laser programming and, 13.81
 pressure-induced stromal keratopathy after, 13.119, 13.120*f*
 after radial keratotomy, 13.52
 re-treatment/enhancements and, 13.97–100, 13.99*f*
 refractive lens exchange and, 13.149
 residual myopia after, intrastromal corneal ring segments for, 13.70
 residual stromal bed thickness and, 13.30, 13.45–46, 13.79–80
 calculation of, 13.46, 13.79
 corneal perforation and, 13.111
 ectasia and, 13.79
 retinal detachment/retinal detachment repair and, 13.183, 13.184, 13.185, 13.197
 small-incision lenticule extraction compared with, 13.205, 13.206
 striae and, 13.112–115, 13.114*t*, 13.115*f*
 stromal bed preparation for, 13.84–90. *See also* LASIK (laser in situ keratomileusis), flap creation for surface ablation for enhancement of, 13.98–99
 surgical technique for, 13.80–95
 tracking/centration/ablation and, 13.91*f*, 13.91–92
 undercorrection and, 13.102
 wavefront aberrations after, 13.11, 13.12, 13.102–103, 13.103*f*
 wavefront analysis before, 13.80
 wavefront-guided. *See* Wavefront-guided (custom) laser ablation
 LASIK-interface complications, 13.116–122
 diffuse lamellar keratitis, 13.116*f*, 13.116–117, 13.117*t*
 epithelial ingrowth, 13.120–122, 13.121*f*
 infectious keratitis, 13.117–119, 13.118*f*, 13.118*t*
 interface debris, 13.122, 13.123*f*
 pressure-induced stromal keratopathy, 13.119, 13.120*f*
 LASIK line, 8.118*t*
 Lastacraft. *See* Alcaftadine
 Latanoprost, 2.237, 2.302, 2.327, 2.327*t*, 10.170–176, 10.171*t*
 in combination preparations, 2.327*t*, 10.174*t*
 Late-diagnosed primary congenital glaucoma, 10.147, 10.148*t*. *See also* Glaucoma, pediatric
 Late latent syphilis, 1.216, 1.248, 9.238, 9.242*t*
 Late non-immune-mediated endothelial failure, 8.427–428
 Late-onset Alzheimer disease, 1.205
 Late-onset corneal haze, 13.109
 Latency (saccadic), 5.219, 5.221, 5.222
 Latency (viral), herpesvirus/recurrent infection and, 1.257–258, 8.205, 8.207, 8.212, 8.213, 8.215–224, 8.216*f*, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 8.223*t*, 8.226*t*
 Latency (visual evoked potential), 5.95
 Latent autoimmune diabetes in adults (LADA), 1.36
 Latent exodeviations, 6.99
 Latent/manifest latent nystagmus (LN/MLN) (fusion/fusional maldevelopment nystagmus syndrome/FMN/FMNS), 5.237–238, 6.88, 6.95, 6.129, 6.150–151, 6.154
 Latent strabismus, 6.15
 Latent syphilis, 1.216, 1.248, 9.238, 9.242*t*
 Latent transforming growth factor beta-binding protein 2 (LTBP-2), 6.306
 Lateral canthal defects, repair of, 7.195
 Lateral canthal tendon, 2.17*f*, 7.7, 7.14*f*, 7.152*f*, 7.153
 laxity in, in involutional ectropion, 7.199
 trauma involving, 7.189
 Lateral canthotomy. *See* Canthotomy
 Lateral flare, in thyroid-related eyelid retraction, 7.223
 Lateral geniculate body/nucleus (LGB/LGN), 2.90, 2.90*f*, 2.93, 2.267, 5.18, 5.18*f*, 5.24*f*, 5.28–29, 5.55*f*, 5.154
 description of, 6.43
 lesions of, 5.154, 5.154*f*
 neurons of, 6.44

- Lateral lenticulostriate artery, 5.16f
 Lateral long posterior ciliary arteries, 5.15
 Lateral magnification, 3.62. *See also* Transverse magnification
 Lateral medullary syndrome of Wallenberg (Wallenberg syndrome), 5.20, 5.180, 5.217, 5.337
 Horner syndrome and, 5.260t, 5.337
 MRI in, 5.64f
 Lateral orbital tubercle of Whitnall, 2.7, 7.6f, 7.7, 7.7f
 Lateral orbital wall, 2.7, 5.9f, 7.7–8
 Lateral orbitotomy, 7.120–121. *See also* Orbitotomy incisions for, 7.116f, 7.120–121
 Lateral pontine cistern, 2.103
 Lateral rectus (LR) muscle, 2.9f, 2.13, 2.14f, 2.15t, 2.16f, 2.17f, 5.8f, 5.45, 5.46f, 7.11, 7.12f, 7.13f, 7.14f, 7.15f
 abduction of, 6.35f
 action of, 6.34t, 6.35f
 anatomy of, 2.9f, 2.13f, 2.14f, 2.16f, 2.17f, 5.8f, 5.45, 5.46f
 anomalous innervation of, 6.109
 blood supply of, 2.15t, 2.17, 2.34f
 characteristics of, 6.21t
 contracture of, 6.109
 field of action, 6.33
 horizontal gaze and, 5.37f, 5.38
 innervation of, 2.17, 5.38, 6.19, 7.12
 insertions of, 2.13–15, 2.14f, 2.15t
 lost, 6.95
 origins of, 2.15t, 2.17, 6.20, 6.21t
 recession/resection of
 for Duane retraction syndrome, 6.134
 for exodeviations, 6.160
 for high myopia, 6.143
 for intermittent exotropia, 6.102
 for third nerve palsy, 6.139
 for X-pattern strabismus, 6.113
 slipped, 6.95
 superior transposition of, 6.113
 Lateral rectus tendon, 2.13f, 2.14f, 6.19f
 Lateral (transverse) sinus thrombosis, 5.69f, 5.345–346
 Lateral subnucleus
 of cranial nerve III (oculomotor), 5.44, 5.44f
 of cranial nerve VII (facial), 5.49
 Lateral tarsal strip procedure
 for cicatricial ectropion, 7.201
 for involutional ectropion, 7.199, 7.200f
 for involutional entropion, 7.204
 Lateropulsion/ocular lateropulsion, in Wallenberg syndrome, 5.217
 Latex allergy, 1.288–289
 Lattice corneal dystrophy (LCD), 4.88–90, 4.89f, 4.91t, 8.135t
 classic (LCD1/type 1), 4.88–90, 4.89f, 4.91t, 8.135t, 8.136t, 8.145t, 8.145–147, 8.146f, 8.147f
 recurrence of, after corneal transplantation, 8.425
 variant, 8.135t, 8.146–147, 8.147f
 Lattice degeneration, 4.148–150, 4.149f
 prophylactic treatment of, 12.319
 radial perivascular, 4.150
 retinal detachment and, 12.309–311, 12.310–311f, 12.316f, 12.319
 Lattice lines, 8.145, 8.146, 8.146f, 8.147f
 in amyloidosis, 8.187–188, 8.188f
 LAV (lymphadenopathy-associated virus). *See* Human immunodeficiency virus
 Lavage, bronchial, 1.131
 Law of equal innervation/motor correspondence, Hering's
 eyelid retraction and, 5.274, 7.222, 7.223
 horizontal gaze and, 5.36f
 nystagmus and, 5.247
 ptosis enhancement and, 5.270f, 5.310
 Law of reflection
 definition of, 3.40
 description of, 3.80–81
 vergence equation for mirrors derived from, 3.88–89, 3.89f
 Law of refraction (Snell's law), 8.26
 Law of specular reflection, 3.80
 Layered hyphema, 8.392, 8.393f
 LBD. *See* Lewy body dementia
 LCA. *See* Leber congenital amaurosis
 LCAT deficiency. *See* Lecithin–cholesterol acyltransferase (LCAT) deficiency
 LCD. *See* Lattice corneal dystrophy
 LCD1. *See* Lattice corneal dystrophy, classic/type 1 (LCD/type 1)
 LCH. *See* Langerhans cell histiocytosis
 LCMV. *See* Lymphocytic choriomeningitis virus
 LCPUFAs. *See* Long-chain polyunsaturated fatty acids
 LCs. *See* Langerhans cells
 LD. *See* Lyme disease
 LDL cholesterol (LDL-C). *See* Low-density-lipoprotein (LDL) cholesterol
 Le Fort (midfacial) fractures, 7.103, 7.104f
 LEA Grating Acuity Test, 6.8
 LEA symbols, 3.23, 3.133f, 3.134, 6.6, 6.7f
 Lead ingestion, optic neuropathy caused by, 5.137
 Leakage, hyperfluorescence and, 12.35
 Learning effect, in automated perimetry, 10.71
 Leber (epithelioid) cells, 9.11, 9.21. *See also* Macrophages
 in choroidal/ciliary body melanoma, 4.192, 4.193f, 4.194, 4.195
 in sarcoidosis, 9.11
 Leber congenital amaurosis (LCA), 6.335–336, 6.337f
 characteristics of, 12.265–266
 gene therapy for, 9.62
 genes and loci associated with, 12.256t
 genetic heterogeneity in, 2.183, 2.183f
 guanylate cyclase mutation causing, 2.263
 infantile nystagmus syndrome and, 5.236
 retinal degeneration associated with, 12.281
 RPE65 gene defects causing, 2.264
 Leber hereditary optic neuropathy (LHON), 2.158, 5.133–135, 5.134f, 6.368
 mitochondrial DNA mutations and, 2.157, 2.158, 5.133
 optic neuritis and, 5.115, 5.133
 Leber idiopathic stellate neuroretinitis, 9.256
 Leber stellate neuroretinitis, 12.242
 LECD. *See* Lisch epithelial corneal dystrophy
 Lecithin–cholesterol acyltransferase (LCAT) deficiency, 8.180f, 8.180–181
 LED bulb, 3.108
 Leflunomide, 1.173
 for rheumatoid arthritis, 1.152

- Left hypotropia (LHoT), 6.17
- Left jerk nystagmus, 6.148f, 6.150
- Left ventricular hypertrophy
heart failure and, 1.108
hypertension and, 1.76
- Legal blindness, 3.310–311, 3.329
- Leigh syndrome (Leigh necrotizing encephalopathy),
2.159, 2.175t
mitochondrial DNA mutations and, 2.159
- Leiomyoma
of ciliary body, 4.199
of iris, 4.260
mesectodermal, 4.199
of orbit, 4.236–237
- Leiomyosarcoma
ocular surface, 8.338t, 8.345
of orbit, 4.237
- Leishmania* (leishmaniasis), 8.252
- Lemtrada. *See* Alemtuzumab
- Lens (crystalline), 2.17f, 2.37f, 2.63f, 2.63–67, 2.65f,
2.77f, 2.241–248, 4.114f, 4.115–124, 4.116f
absence of, 4.117. *See also* Aphakia
age-related changes in, 11.43–48. *See also* Age-related
cataracts
alcohol use/abuse and, 11.63–64
anatomy of, 2.17f, 2.37f, 2.63f, 2.63–67, 2.65f, 2.77f,
2.241–243, 2.242f, 4.115f, 4.115–117, 4.116f, 11.9f,
11.9–13, 11.10f, 11.11f, 11.12f
altered, cataract surgery and, 11.179–184, 11.181f,
11.182f, 11.183f
early conceptions of, 11.3, 11.3f, 11.4f
antioxidants in, 2.284f
biochemistry and metabolism of, 2.241–248, 11.11,
11.14–23
carbohydrate (“sugar”) cataracts and, 2.246–248
capsule of. *See* Lens capsule
carbohydrate metabolism in, 2.246, 11.17–19, 11.18f
changing shape of. *See* Accommodation
chemical composition of, 2.243–245
chemical injuries affecting, 11.59
colobomas of, 6.305f, 6.305–306, 11.30–31, 11.31f
coloration change in, 4.121–122, 11.43, 11.44f
congenital anomalies and abnormalities of,
4.117–118, 4.118f, 11.30f, 11.30–39, 11.31f, 11.32f,
11.33f, 11.34f, 11.35t, 11.36f, 11.37f, 11.38f,
11.39f
congenital aphakia of, 6.305
cortex of, 2.64, 2.242f, 2.242–243, 4.116f, 4.117,
11.10f, 11.12f, 11.13
degenerations of, 4.121–122, 4.122f, 4.123f
topography of, 4.116f, 4.117
degenerations/degenerative ocular disorders and,
4.120f, 4.120–124, 4.121f, 4.122f, 4.123f, 4.124f,
11.68. *See also* Cataract
development/embryology of, 2.65f, 2.117–122, 2.120f,
11.25–42
cataract development and. *See* Cataract, congenital
congenital anomalies and abnormalities and,
4.117–118, 4.118f, 11.30f, 11.30–39, 11.31f,
11.32f, 11.33f, 11.34f, 11.35t, 11.36f, 11.37f,
11.38f, 11.39f
developmental defects and, 11.39–42, 11.40f
normal, 11.25–29, 11.26–27f, 11.28f, 11.29f
diabetes mellitus affecting, 11.60f, 11.60–61. *See also*
Cataract, diabetic
dislocation of, 11.39–40. *See also* Ectopia lentis
cataract surgery in patient with, 11.181–183,
11.182f, 11.183f
conditions associated with, 6.306t
description of, 6.306
ectopia lentis et pupillae, 6.267–268, 6.307, 6.307f
in homocystinuria, 6.308–309
illustration of, 6.306f
inborn errors of metabolism and, 6.306
iridodonesis with, 6.306
isolated/simple ectopia lentis, 6.307
in Marfan syndrome, 6.307–308, 6.308f
refractive error caused by, 6.310
in sulfite oxidase deficiency, 6.310
traumatic, 11.40, 11.54f, 11.54–55
treatment of, 6.310
in Weill-Marchesani syndrome, 6.309
disorders of, 4.115–124, 11.43–68. *See also* Cataract;
specific disorder
illusions caused by, 5.174
systemic disorders and, 4.124
drug-induced changes in, 11.51–53, 11.52f
ectopic. *See* Ectopia lentis
electrical injury of, 11.59, 11.59f
energy production in, 2.246
epithelium of, 2.63f, 2.64, 2.65f, 2.242, 2.242f, 4.116f,
4.117, 11.10f, 11.12–13
active transport and, 11.21
degenerations of, 4.120f, 4.120–121, 4.121f, 4.122f
development of, 11.27, 11.27f
opacification (capsular cataract), 11.38
topography of, 4.116f, 4.117
evaluation of
before cataract surgery, 11.79–80
in glaucoma, 10.32. *See also* Lens-induced
glaucoma; Lens particle glaucoma
before refractive surgery, 13.43–44
focal opacifications and, 4.121, 4.122, 4.122f, 4.123f
foreign body in, 11.57
free radicals affecting, 2.283–285, 2.284f, 11.19–20
generalized discoloration with loss of transparency
and, 4.121–122
glaucoma and. *See* Lens-induced glaucoma; Lens
particle glaucoma
healing/repair of, 4.17
in homocystinuria, 11.41
hyperbaric oxygen therapy associated with changes
in, 11.20, 11.65
in hyperlysinemia, 11.41
infection/inflammation of, 4.118–119, 4.119f. *See also*
Lens (crystalline), uveitis and
iris-claw, 6.310
ischemic damage to, 11.68
luxed/luxated, 6.268, 6.306, 6.390f, 11.40. *See also*
Ectopia lentis
cataract surgery in patient with, 11.181–183,
11.182f, 11.183f
traumatic, 11.40, 11.54f, 11.54–55
in Marfan syndrome, 2.66, 8.193, 8.193f, 8.194, 11.40f,
11.40–41
in megalocornea, 8.100

- membranes of, 2.243
 - metabolic diseases affecting, 11.60f, 11.60–62, 11.61f, 11.62f
 - molecular biology of, 11.15f, 11.15–17
 - nucleus of, 2.64, 2.242f, 2.242–243, 4.116f, 4.117, 11.10f, 11.12f, 11.13
 - congenital cataract of, 11.38, 11.39f
 - degenerations of, 4.123, 4.123f, 4.124f
 - embryonic, 2.64, 2.65f, 11.13, 11.27f
 - opacification of (congenital nuclear cataract), 11.38, 11.39f
 - emulsification of. *See* Phacoemulsification
 - fetal, 11.13, 11.27f, 11.28, 11.28f, 11.28–29
 - opacification of (congenital nuclear cataract), 11.38, 11.39f
 - opacification of. *See* Nuclear cataracts
 - removal/disassembly of, 11.111, 11.112–114, 11.113f. *See also* Cataract surgery; Lensectomy; Phacoemulsification
 - in ECCE, 11.196–197
 - in ICCE, 11.200f, 11.200–201
 - in manual small-incision cataract surgery, 11.198, 11.199f
 - in phacoemulsification, 11.111, 11.112–114, 11.113f
 - chopping techniques for, 11.114
 - phaco fracture for, 11.112–114, 11.113f
 - rotation of, in phacoemulsification, 11.111
 - topography of, 4.116f, 4.117
 - nutritional diseases affecting, 11.63–64
 - opacification of. *See* Cataract
 - oxidative damage to, 2.283–285, 2.284f, 11.19–20
 - performing and penetrating injury of, 11.55, 11.55f, 11.56f
 - glaucoma and, 11.67
 - physiology of, 2.245–246, 11.20–23
 - pseudoexfoliation/exfoliation syndrome and, 11.65f, 11.65–66
 - radiation affecting, 1.230, 11.57–58
 - removal of. *See* Cataract surgery; Lensectomy; Phacoemulsification; Refractive lens exchange
 - retained, cataract surgery and, 11.140–141
 - rubella (congenital) and, 9.204
 - ruptured, removal of, 8.408–409
 - in schematic eye, 3.127t
 - size of, 2.63, 11.11
 - smoking/tobacco use and, 11.63–64
 - spherophakia of, 6.305
 - subluxed/subluxated, 11.39–40, 11.40f. *See also*
 - Ectopia lentis
 - angle closure/pupillary block and, 10.119, 10.129–130, 10.130f, 10.130t
 - cataract surgery in patient with, 11.181–183, 11.182f, 11.183f
 - description of, 6.268, 6.306
 - in homocystinuria, 6.309
 - in Marfan syndrome, 6.308f
 - surgery for, 6.310
 - traumatic, 11.40, 11.54f, 11.54–55
 - sutures of, 2.64, 2.65f, 11.13
 - development of, 11.27f, 11.28–29
 - opacification of (sutural/stellate cataract), 11.37, 11.37f
 - topography of, 2.37f, 4.115f, 4.115–117, 4.116f
 - transport functions in, 11.21, 11.22f
 - traumatic damage to, 11.53–59, 11.54f, 11.55f, 11.56f, 11.58f, 11.59f
 - glaucoma and, 10.98
 - phacoantigenic uveitis and, 4.118–119, 4.119f, 11.66, 11.191
 - surgery and, 11.190–193, 11.192f
 - uveitis and, 4.118–119, 4.119f, 9.118f, 9.118–119, 11.64f, 11.64–65, 11.66. *See also* Phacoantigenic (lens-associated) uveitis
 - water and cation balance in, maintenance of, 11.21, 11.22f
 - zonular fibers/zonules of, 2.37f, 2.46f, 2.63f, 2.65f, 2.66–67, 2.241, 4.115, 4.117, 11.9, 11.10f, 11.12
 - absent/abnormal
 - cataract surgery and, 11.179–184
 - iris coloboma/corectopia and, 11.180
 - nucleus rotation and, 11.111
 - in glaucoma, 10.33t, 10.119
 - in accommodation, 2.64f, 2.66, 13.159, 13.160, 13.160f, 13.161, 13.161f
 - degenerations of, 4.124
 - development of, 2.120, 2.120f, 11.29
 - evaluation of
 - before cataract surgery, 11.80
 - in glaucoma, 10.33t
 - pigment deposits on, in pigment dispersion syndrome, 10.94, 10.95f
 - in pseudoxfoliation/exfoliation syndrome, 10.92, 10.93, 10.130, 10.131f, 11.65–66, 11.181, 11.182f, 11.184
 - as tertiary vitreous, 2.123f, 4.125
 - topography of, 2.37f, 4.115, 4.117
- Lens-associated (phacoantigenic/phacolytic) uveitis (lens-induced granulomatous/phacoanaphylactic endophthalmitis), 4.103, 4.103f, 4.118–119, 4.119f, 4.122, 9.21, 9.118f, 9.118–119, 11.66. *See also* Phacolytic glaucoma
- sympathetic ophthalmia and, 9.174
- Lens block, 10.119
- Lens capsule, 2.37f, 2.63, 2.63f, 2.64, 2.65f, 2.241, 2.242f, 4.115, 4.116f, 11.10f, 11.11, 11.11f, 11.12f. *See also* Capsulorrhexis; Capsulotomy
- anatomy of, 2.37f, 2.63, 2.63f, 2.64, 2.65f, 2.241, 2.242f, 4.115, 4.116f
- degenerations of, 4.120
- development of, 2.118–120, 2.119f, 11.27, 11.27f
- exfoliation of, infrared radiation/heat causing, 11.57
- healing/repair of, 4.17
- pigment deposits in, in pigment dispersion syndrome, 10.94, 10.95f
- rupture of
 - cataract formation and, 4.18. *See also* Cataract, traumatic
 - cataract surgery and, 11.142–143
 - staining, in cataract surgery, 11.178–179, 11.179f
 - topography of, 4.115, 4.116f
- Lens clips. *See* Trial lens
- Lens crystallins, 2.64, 2.241, 2.243–244, 11.15f, 11.15–16. *See also* Crystallins
- Lens-extraction procedures. *See* Refractive lens exchange

- Lens-fiber plasma membranes, 2.243, 2.245
- Lens fibers, 2.63f, 2.64, 2.65f, 2.66f, 2.242f, 2.242–243, 4.117
- accommodation and, 11.22
 - development of, 2.120f, 11.12f, 11.12–13
 - primary fibers, 11.26–27, 11.27f
 - secondary fibers, 11.27f, 11.27–28
 - microspherophakia and, 11.33
 - opacities of, 4.122, 4.122f
 - zonular (zonules of Zinn), 2.37f, 2.46f, 2.63f, 2.65f, 2.66–67, 2.241, 4.115, 4.117, 11.9, 11.10f, 11.12
 - absent/abnormal
 - cataract surgery and, 11.179–184
 - iris coloboma/corectopia and, 11.180
 - nucleus rotation and, 11.111
 - in glaucoma, 10.33f, 10.119
 - in accommodation, 2.64f, 2.66, 13.159, 13.160, 13.160f, 13.161, 13.161f
 - degenerations of, 4.124
 - development of, 2.120, 2.120f, 11.29
 - evaluation of
 - before cataract surgery, 11.80
 - in glaucoma, 10.33t
 - pigment deposits on, in pigment dispersion syndrome, 10.94, 10.95f
 - in pseudoexfoliation/exfoliation syndrome, 10.92, 10.93, 10.130, 10.131f, 11.65–66, 11.181, 11.182f, 11.184
 - as tertiary vitreous, 2.123f, 4.125
 - topography of, 2.37f, 4.115, 4.117
- Lens gradient method, for accommodative convergence measurement, 5.226–227
- Lens-induced glaucoma, 4.103, 4.103f, 4.122, 9.21, 9.118, 9.118f, 9.119, 10.96–98, 10.97f, 10.119, 11.67–68, 11.68f
- angle-closure glaucoma and, 10.96, 10.119, 10.128–132
 - in children and adolescents, 10.149t
 - open-angle glaucoma and, 10.96–98, 10.97f
- Lens-induced granulomatous (phacoanaphylactic) endophthalmitis (phacoantigenic uveitis), 4.103, 4.103f, 4.118–119, 4.119f, 4.122, 9.21, 9.118f, 9.118–119, 11.66. *See also* Phacolytic glaucoma
- sympathetic ophthalmia and, 9.174
- Lens-iris diaphragm retropulsion syndrome (LIDRS), 11.138, 11.184
- Lens-iris interface, angle closure/angle-closure glaucoma and, 10.118–119
- Lens particle glaucoma, 10.98, 11.67
- Lens pit, 2.117f, 2.117–118, 11.25, 11.26f
- Lens placode, 2.115, 2.116t, 2.117f, 11.25, 11.26f
- Lens plate, 2.117
- Lens power, bifocal segment decentration and, 3.191
- Lens proteins, 2.243–245, 11.15f, 11.15–17. *See also specific type*
- aging affecting, 11.17
 - crystallins, 2.64, 2.241, 2.243–244, 11.15f, 11.15–16. *See also* Crystallins
 - cytoskeletal and membrane, 2.245, 11.15f, 11.16–17
 - in phacoantigenic glaucoma, 10.98
 - in phacoantigenic uveitis/endophthalmitis, 10.98, 11.66, 11.191
 - in phacolytic glaucoma/uveitis, 4.103, 4.103f, 4.122, 9.21, 9.118, 9.118f, 9.119, 10.96, 11.67
 - posttranslational modification of, 2.245
 - traumatic cataract and, 11.66, 11.192
 - urea-insoluble (membrane structural), 2.245, 11.15f, 11.16–17
 - urea-soluble (cytoskeletal), 2.245, 11.15f, 11.16–17
 - in uveitis, 4.103, 4.103f, 4.122, 11.67
 - water-insoluble, 11.15, 11.15f
 - age affecting, 11.17
 - water-soluble, 11.15, 11.15f. *See also* Crystallins
 - conversion of, to water-insoluble, 11.17
- Lens rim artifact, in perimetry, 10.60, 10.66, 10.66f
- Lens vesicle, 2.117f, 2.118, 2.120f
- formation of, 11.25, 11.26f
- Lensectomy, 6.302, 6.410. *See also* Cataract surgery
- for acute angle closure, 10.125
 - for chronic angle closure, 10.126
 - for ectopia lentis, 10.130
 - in Marfan syndrome, 11.41
 - pars plana, for uveitis, 9.283
 - juvenile idiopathic (chronic/rheumatoid) arthritis and, 9.124
 - for plateau iris, 10.128
 - for subacute/intermittent angle closure, 10.126
- Lenses. *See also* Bifocal lenses; Contact lenses; Intraocular lenses; Ophthalmic lenses
- absorptive, 3.192–194, 3.193f
 - anophthalmic socket camouflage and, 7.136
 - aphakic. *See* Aphakic spectacles
 - balance, 3.198
 - combining of, 3.9, 3.11
 - concave (minus/negative), anophthalmic socket camouflage and, 7.136
 - convex (plus/positive), anophthalmic socket camouflage and, 7.136
 - effectivity of, 3.40, 3.60
 - high-plus-power, 12.375
 - intraocular. *See* Intraocular lenses
 - materials used in
 - glass, 3.195
 - high-index, 3.196
 - polycarbonate, 3.195–196
 - standard plastic, 3.195
 - Trivex, 3.196
 - multifocal. *See* Multifocal lenses
 - photochromic, 3.193, 3.193f
 - for photocoagulation, 12.375, 12.376f
 - spectacle. *See* Spectacle lenses
 - ultraviolet-absorbing, 3.193–194
- Lensmaker's equation
- definition of, 3.41
 - derivation of, from Snell's law, 3.85–86
 - description of, 3.51–52
 - power comparisons using, 3.52
 - thin-lens approximation and, 3.54
- Lensmeters, 3.169
- automatic, 3.285
 - cylinder power measurements, 3.284, 3.284f
 - definition of, 3.282
 - manual, 3.283–284f, 3.283–285
 - pictorial representation of, 3.283f
 - prism detection using, 3.285

- Lensometers. *See* Lensmeters
- Lenticonus/lentiglobus, 6.296, 11.30, 11.30f
 anterior, 4.118, 11.30
 posterior, 4.118, 4.118f, 11.30, 11.30f
- Lenticular astigmatism. *See also* Astigmatism
 description of, 3.19
 refractive surgery and, 13.45, 13.149
 toric IOLs and, 13.152
 as “residual” astigmatism, 3.211
- Lenticular irregularities, decreased vision and, 5.99
- Lenticular myopia (myopic shift), 11.43, 11.70
- Lenticular optics, 3.8f
- Lenticular refractive procedures. *See* Intraocular lenses (IOLs), for refractive errors; *specific procedure*
- Lenticules, 13.59
 in epikeratoplasty, 13.62
 femtosecond extraction of (FLEX), 13.8t, 13.27–28, 13.203
 graft failure and, 4.84, 4.85f
 in keratophakia, 13.59, 13.60
 refractive extraction of (ReLEX), 13.8t, 13.27, 13.203–206
 complications of, 13.205
 indications and preoperative evaluation for, 13.204
 LASIK compared with, 13.206
 outcomes of, 13.205
 re-treatment and, 13.206
 surgical technique for, 13.204–205
 small-incision extraction of (SMILE), 13.8t, 13.28, 13.203–206. *See also* Lenticules, refractive extraction of
- Lenticulostriate artery, lateral, 5.16f
- Lentiglobus. *See* Lenticonus/lentiglobus
- Lentigo (lentigines)
 senile, 7.174
 simplex (simple lentigines), 7.174
 solar, 7.174
- Lentigo maligna (Hutchinson melanotic freckle/precancerous melanosis), 7.177
- Lentigo maligna melanoma, 4.220, 4.221f, 7.177, 7.185
- LENTIS Mplus intraocular lens, 3.258, 13.166, 13.166f
- Leopard spot fluorescence pattern, in primary central nervous system/intraocular/vitreoretinal lymphoma, 9.274
- “Leopard spots,” 4.306, 4.308f
- Leptochoroid, 12.19
- Leptomeningeal vascular malformation, 6.401t
- Leptospirosis (*Leptospira interrogans*), 9.248–249
- Leser-Trélat sign, 4.209
- Lesionectomy, for seizures, 1.202
- Lesser (minor) arterial circle, 2.54f, 2.55, 5.15
- Lester hooks, for pupil expansion, 11.177
- Letter chart visual acuity. *See* Visual acuity
- Letter tests, of contrast sensitivity, 5.88
- Letterer-Siwe disease, orbital involvement and, 7.90
- Leucine zipper, neural retinal (Nrl), in retinal development, 2.122
- Leukemia, 4.10, 4.10t, 4.11f, 6.218, 6.413–414
 neoplastic masquerade syndromes secondary to, 9.276
 ocular involvement in, 1.237, 4.315f, 4.315–316, 4.316f
 choroid, 4.315
 iris, 4.315
 optic nerve/nerve head/disc, 4.316, 4.316f
 orbit, 4.316, 7.98–99
 retina, 4.315, 4.315f
 uvea, 4.315
 vitreous, 4.315
- Leukemic retinopathy, 4.315, 4.315f
- Leukocoria, 6.299, 6.351, 6.351f, 6.351t, 12.342. *See also specific cause*
 in Coats disease, 4.143f
 in retinoblastoma, 4.291, 4.291f
 in toxocariasis, 9.228
- Leukocyte common antigen, in immunohistochemistry, 4.34
- Leukocyte function–associated antigen 1 (LFA-1), in neutrophil rolling, 9.17
- Leukocytes (white blood cells), 1.135, 9.9–12. *See also specific type*
 immunophenotyping of, flow cytometry for, 4.36
 in inflammation, 4.7, 4.8f
- Leukodystrophy
 Krabbe, 2.175t
 metachromatic, 2.175t
- Leukoencephalopathy
 with cerebral autosomal dominant arteriopathy and subcortical infarcts (CADASIL), 5.295
 migrainelike headache in, 5.295
 stroke and, 1.20
 progressive multifocal (PML), 5.351f, 5.351–352
 natalizumab causing, 5.318, 5.351
- Leukomas, in Peters anomaly, 10.154, 11.31
- Leukotriene inhibitors, for asthma, 1.133t, 1.134
- Leukotrienes, 2.237, 2.334, 9.25
 synthesis of, 2.238f
 by mast cells, 9.10
- Leuprolide, ocular effects of, 1.308t
- Levator anguli oris muscle, 7.141, 7.143f
- Levator aponeurosis, 2.20f, 2.24, 2.216, 5.52, 7.7, 7.14f, 7.15f, 7.146f, 7.149, 7.150, 7.150f, 8.4f
 horns of, 7.150, 7.150f
 laceration of, 7.188
 ptosis and, 5.273, 5.273t, 7.214, 7.214f, 7.214t, 7.218
 repair of, for ptosis correction, 7.219, 7.219f
- Levator labii superioris alaeque nasi muscle, 7.143, 7.143f
- Levator labii superioris muscle, 7.143, 7.143f
- Levator muscle (levator palpebrae superioris/LPS), 2.9f, 2.13, 2.13f, 2.14f, 2.16f, 2.20f, 2.23–24, 4.202, 5.8f, 5.52, 7.11, 7.13f, 7.14f, 7.15f, 7.146f, 7.149–151, 7.150f
 action of, 6.34t, 8.3
 anatomy of, 5.8f, 6.19f, 6.26f, 8.4f, 8.8
 characteristics of, 6.21t, 6.22
 congenital ptosis caused by dystrophic development of, 5.272
 damage to, in enucleation/evisceration, 7.130
 evaluation of function of, in ptosis, 7.210, 7.210f, 7.211f, 7.214t
 external (transcutaneous) advancement of, for ptosis correction, 7.219, 7.219f
 innervation of, 2.17, 2.94f, 2.95, 5.44, 5.44f, 6.19, 7.12, 7.151
 laceration of, 7.188
 in myasthenia gravis/myogenic ptosis, 7.213, 7.213f
 origins of, 2.17, 6.21t, 6.22

- superior rectus muscle attachment to, 6.29
 - in traumatic ptosis, 7.218
- Levator palpebrae muscle, 8.3, 8.4f
- Levetiracetam, 1.202t
- Levobunolol, 2.321, 2.322t, 2.323, 10.171t, 10.176–177
 - in children, 10.165
- Levocabastine, 2.337, 2.338t
- Levocycloversion, 6.38
- Levodopa/carbidopa, for Parkinson disease, 1.199
- Levodopa (L-dopa), for Parkinson disease, 1.199
- Levofloxacin, 1.277, 2.346, 2.347t, 2.347–349
 - for bacterial keratitis, 8.269, 8.270t
- Levothyroxine, for hypothyroidism, 1.54
- Levoversion, 6.37
- Lewy body dementia (LBD), 1.204
- LFA-1. *See* Leukocyte function–associated antigen 1
- LFU. *See* Lacrimal functional unit
- LGB. *See* Lateral geniculate body/nucleus
- LGN. *See* Lateral geniculate body/nucleus
- Lhermitte sign, in multiple sclerosis, 5.317
- LHON. *See* Leber hereditary optic neuropathy
- LHoT. *See* Left hypotropia
- Library, DNA, 2.138
 - cDNA, 2.138
 - genomic, 2.138
- Lice, ocular infection caused by, 8.255
- Lid lag, in thyroid eye disease, 5.131, 5.271, 7.25, 7.52, 7.56
- Lid margin. *See* Eyelids, margin of
- Lid-twitch sign, Cogan, 5.271, 5.324
- Lidocaine, 1.113t, 2.362t, 2.363t, 2.364, 2.365–366
 - for cardioversion, 1.115
 - for cataract surgery, 11.92
 - for dacryocystorhinostomy, 7.280
 - intracameral administration of, 2.300t, 2.364, 2.365–366
 - for intraoperative floppy iris syndrome, 11.137
 - maximum safe dose of, 1.304t
 - toxic reaction to, 1.292
- LIDRS. *See* Lens–iris diaphragm retropulsion syndrome
- Lids. *See* Eyelids
- Lieberman speculum, for globe exposure, in cataract surgery, 11.105f
- Lifestyle modification/therapeutic lifestyle changes (TLCs)
 - for age-related macular degeneration, 12.71
 - in coronary artery disease prevention, 1.81, 1.84t, 1.85
 - in diabetes mellitus prevention/management, 1.37–38, 1.40–41, 1.43, 1.44f
 - in hypercholesterolemia management, 1.81, 1.84t, 1.85
 - in hypertension management, 1.66–67, 1.67t, 1.70f
- Lifitegrast, 2.342, 8.63
- Ligament of Wieger, 12.7, 12.8f
- Ligaments. *See specific ligament*
- Ligands, 2.111, 2.127
 - optic nerve development and, 2.124
- Light. *See also specific aspect*
 - coherence of, 3.99–102
 - cone opsin changes caused by, 2.261
 - corneal reflex to
 - corneal vertex and, 8.25, 8.26f
 - eyelid margin distance to (margin–reflex distance), in ptosis, 7.209–210, 7.210f, 7.214t
 - definition of, 3.93
 - diffraction of, 3.104–106, 3.105f
 - eye injury caused by, 2.283, 2.286. *See also* Light toxicity/photoc damage/phototoxicity
 - frequency of, 3.93
 - hazards of, 3.118–119
 - interference, 3.99–102
 - from lasers. *See* Lasers
 - measurement of. *See also* Photometry; Radiometry
 - candela as unit for, 3.108
 - overview of, 3.106–107
 - photometry, 3.108–110, 3.109t
 - radiometry, 3.107t, 3.107–108, 3.110
 - particle theory of, 3.94
 - paths for, 3.119
 - phenomena of, 3.98–106
 - photo-oxidative processes triggered by, 2.283
 - in retina, 2.286
 - polarization of, 3.98–99
 - propagation of, 3.119
 - properties of, 3.106
 - pupillary response to. *See* Pupillary light reflex
 - reflection of, 3.96. *See also* Reflection
 - refraction of, 3.96
 - retinal changes caused by, 2.283, 2.286
 - retinal pigment epithelial transport systems affected by, 2.277
 - rhodopsin changes caused by, 2.258, 2.259, 2.259f
 - scattering of
 - age-related increase in, 3.98
 - definition of, 3.96–97
 - geometric, 3.97–98
 - Mie, 3.92, 3.97–98
 - Rayleigh, 3.92, 3.97
 - Tyndall effect and, 3.97
 - spectral bandwidth of, 3.102
 - transmission of. *See* Transmission
 - unpolarized, 3.98
 - visible, 3.93, 3.94t
 - wave nature of, 3.71
 - wave–particle duality of, 3.94
 - wave theory of, 3.94–95, 3.95f
 - wavelength of, 3.93, 3.94t
- Light adaptation, 2.262
 - in electro-oculography, 12.50
 - in full-field (Ganzfield) electroretinography, 12.42
 - spectral luminous efficiency function in, 3.109
- Light-adjustable intraocular lenses, 13.153–154, 13.154f
- Light Adjustable Lens (LAL), 13.170
- Light Amplification by Stimulated Emission of Radiation (LASER). *See* Lasers
- Light chains, immunoglobulin, 9.41, 9.41f
 - overproduction of, crystalline corneal deposits and, 8.198
- Light-gathering power. *See* Transverse magnification
- Light–near dissociation, 2.96, 5.254, 5.266t, 5.266–267
 - Adie tonic pupil and, 5.263, 5.264f, 5.266t
 - in dorsal midbrain (Parinaud) syndrome, 5.229, 5.230f, 5.266t, 5.266–267
- Light reflex. *See* Pupillary light reflex

- Light sensitivity. *See also* Photophobia
after LASIK with femtosecond laser flap creation, 13.123
- Light toxicity/phototoxicity
cataract surgery and, 11.166
free-radical damage and, 2.283, 2.286
ophthalmic instrumentation causing, cataract surgery and, 11.166
retinal, 2.286
- Light waves
frequency of. *See* Frequency
measurement of. *See* Photometry; Radiometry
- Lighthouse chart, 6.7
- Lightning injuries, 12.357
- Lightning streaks of Moore, 5.175
- Ligneous conjunctivitis, 6.249, 8.294f, 8.294–295
- Lignocaine. *See* Lidocaine
- Likelihood ratio, 1.18–19, 2.160
combining screening tests and, 1.20
logarithm of (LOD score), 2.138–139, 2.160
- Limbal dermoids, Goldenhar-Gorlin syndrome and, 8.195, 8.195f
- Limbal (epibulbar) dermoids, 4.6, 4.47, 4.49f
- Limbal groove, for ECCE, 11.196
- Limbal relaxing incisions (LRIs), 6.163, 13.8t, 13.27f, 13.53–54, 13.54f, 13.54–58, 13.55f, 13.56f, 13.56t, 13.57f
cataract surgery and, 11.123–124
complications of, 13.58
instrumentation for, 13.55, 13.56f
ocular surgery after, 13.58
outcomes of, 13.57
refractive lens exchange and, 13.149
technique for, 13.55–57, 13.56t, 13.57f
- Limbal stem cells, 8.8, 8.10–11, 8.92. *See also* Limbal transplantation
in aniridia, 10.155
in corneal epithelium maintenance, 8.8, 8.362
deficiency of, 2.40, 8.92–94, 8.93t, 8.94f, 8.362
in graft-vs-host disease, 8.304
repopulation and. *See* Limbal transplantation
toxic insults/toxic keratoconjunctivitis from medications and, 8.91, 8.224
transplantation of. *See* Limbal transplantation
- Limbal transplantation (limbal autograft/allograft/stem cell transplantation), 8.94, 8.351t, 8.362–365, 8.363–364f
for chemical injuries, 8.380, 8.384
indications for, 8.351t
simple epithelial (SLET), 8.365
for chemical injury, 8.384
for pterygium, 8.355
- Limbal (bulbar) vernal keratoconjunctivitis, 6.248, 6.249f, 8.289–290, 8.290f
- Limbal zone, corneal, 8.25, 8.25f. *See also* Limbus
- Limbic system (cingulate gyrus), 5.52
- Limbitis, in onchocerciasis, 9.235
- Limbus, 2.44–45, 2.45f, 8.10–11, 8.11f, 8.25, 8.25f.
See also under Limbal
alkali burns affecting, 8.379, 8.379f, 8.380f
immune response/features/microenvironment of, 9.59, 9.59f
marginal corneal infiltrates and, 8.310–311
blepharoconjunctivitis and, 8.74, 8.74f
squamous cell carcinoma of, 8.336, 8.336f
- Limbus-based conjunctival flap, for trabeculectomy, 10.200, 10.202f
closure of, 10.204, 10.206f
in elderly patients, 10.221
- Lime, ocular injury caused by, 8.376t
- Limiting membranes
external (ELM/XLM), 2.71f, 2.72f, 2.74, 2.76f, 2.88f, 2.258f, 4.140f, 4.141f
anatomy of, 12.15
histology of, 12.11, 12.12f
- internal (ILM), 2.70f, 2.71f, 2.75, 2.88f, 2.258f, 4.140f
amacrine cells in, 12.15
anatomy of, 12.15
epiretinal membranes, 12.332
hemorrhagic detachment of, 12.171
histology of, 12.11, 12.12f
nonproliferative sickle cell retinopathy findings, 12.150
optic nerve/nerve head/disc, 2.86, 2.88f
peeling of, 12.209
in retinal healing/repair, 4.17
vitreous detachment and, 2.253, 4.129
vitreous remnants on, 12.332
- middle (MLM), 2.258f
anatomy of, 12.15
definition of, 12.16
histology of, 12.11, 12.12f
- Linagliptin, for diabetes mellitus, 1.45t, 1.46–47
- Lincoff rules, 12.320, 12.322f
- Linear deposits, basal, in age-related macular degeneration, 4.160, 4.162
- Linear IgA dermatosis, 8.301
- Linear incisions, for keratorefractive surgery, 13.27
- Linear magnification, 3.62. *See also* Transverse magnification
- Linear nevus sebaceous syndrome, 4.47, 4.48
- Linearly polarized light, 3.95f, 3.98
- LINEs. *See* Long interspersed elements
- Linezolid, 1.273t
- Lingua plicata, in Melkersson-Rosenthal syndrome, 5.280
- Lingual nerve, 2.101f, 5.276–277f
- Link protein, in vitreous, 2.249
- Linkage (gene), 2.138, 2.150, 2.160, 2.184, 2.187
- Linkage disequilibrium (allelic association), 2.138, 2.150
HLA-associated diseases and, 9.66
- Lipid A, 9.13
- Lipid keratopathy, 8.125–126, 8.126f
corneal crystal deposition in, 8.182t
in herpes zoster, 8.125, 8.228, 8.228f
- Lipid layer of tear film, 2.38, 2.213f, 2.214–215, 2.215f, 8.5, 8.6f
interferometry in evaluation of, 8.40, 8.40f
- Lipid-lowering therapy, 1.83t, 1.84t, 1.84–89, 1.85t, 1.86t. *See also specific agent*
for ischemic heart disease, 1.99, 1.101t
pharmacologic, 1.85t, 1.85–88, 1.86t
statins in, 1.81, 1.85t, 1.86t, 1.86–88
- Lipid peroxidation, 2.281, 2.283
in lens opacification, 11.19
mechanisms of, 2.282–283
retinal vulnerability and, 2.285

- Lipid strip, 2.214
- Lipidoses. *See* Lipids, metabolism and storage of
- Lipids
- disorders of
 - cerebral ischemia/stroke and, 1.123
 - metabolic syndrome/diabetes mellitus and, 1.37, 1.88
 - screening for, 1.82–83, 1.83*t*
 - xanthelasma associated with, 4.206, 7.169
 - in Fleck corneal dystrophy, 8.153
 - as inflammatory mediators, 9.22*t*, 9.24–26, 9.25*f*
 - metabolism and storage of, disorders of (lipidoses), 6.388*t*, 8.179–181, 8.180*f*
 - corneal changes in, 8.179–181, 8.180*f*
 - arcus and, 8.120, 8.121, 8.179
 - in Schnyder corneal dystrophy, 8.151, 8.179
 - muco-lipidoses and, 8.178
 - xanthelasma associated with, 7.169
 - as ocular hypotensive agents. *See* Prostaglandin (PG) analogues
 - in retinal pigment epithelium, 2.274
 - solubility of, medication absorption affected by, 2.297–298, 2.300
 - in tear film. *See* Lipid layer of tear film
- Lipoatrophy, at insulin injection site, 1.43
- Lipocalins, in tear film, 2.216
- Lipodermoids (dermolipomas), 4.47–48, 4.48*f*, 6.210
- Goldenhar syndrome and, 4.48
 - of orbit, 7.40, 7.41*f*
- Lipofuscin, 2.69, 6.340
- accumulation of, in cornea farinata, 8.122
 - fundus autofluorescence and, 5.89–90
 - in lysosomes, 12.31
 - in retinal pigment epithelium, 4.141, 12.32
 - phagocytosis and, 2.276, 2.276*f*
- Lipofuscin-like material/lipoprotein, in pre-Descemet corneal dystrophy, 8.155
- Lipohypertrophy, at insulin injection site, 1.43
- Lipomas, of orbit, 4.238
- Lipopeptide antibiotics, 1.273*t*
- Lipopolysaccharide (LPS), bacterial, 8.244. *See also* Endotoxins
- endophthalmitis severity and, 9.15
 - in innate immune response, 9.13–14, 9.14*t*
 - uveitis caused by, 9.14–15
 - animal model of (endotoxin-induced uveitis), 9.14–15, 9.63
 - HLA association and, 9.65
- Lipoproteins, 1.82
- corneal arcus and, 8.120, 8.121, 8.179
 - corneal changes in disorders of metabolism of, 8.179–181, 8.180*f*
 - drugs affecting metabolism of, 1.85, 1.85*t*. *See also* Lipid-lowering therapy
 - risk assessment and (lipoprotein analysis), 1.82–83, 1.83*t*
- Liposarcomas, of orbit, 4.238, 7.84
- Liposomes, for drug delivery, 2.303–304
- Liposuction, neck, 7.246
- Lipoxin, 9.25
- Lipoxygenase, in eicosanoid synthesis, 2.238*f*, 2.238–239, 2.334, 9.24, 9.25, 9.25*f*
- Liraglutide, for diabetes mellitus, 1.45*t*, 1.46
- Lisch epithelial corneal dystrophy (LECD), 8.135*t*, 8.136*t*, 8.140, 8.140*f*
- Lisch nodules, 4.259, 4.260*f*, 5.330*f*, 5.334*t*, 6.271–272, 6.272*f*, 6.392, 6.395*f*, 6.397
- Lisinopril
 - for heart failure, 1.110
 - for hypertension, 1.68*t*, 1.69*t*
- Lissajous figures, 3.98
- Lissamine green, 2.367, 8.37, 8.38*f*
 - in ocular surface evaluation, 8.37, 8.38*f*
 - in tear film/dry eye evaluation, 8.37, 8.56
- Listeria monocytogenes*, invasive capability of, 8.207
- Listing's law, 6.31
- Listing's plane, 6.31
- Lithium, 1.197–198
- Live attenuated influenza vaccine (LAIV), 1.220
 - Live attenuated vaccine, 1.216. *See also* specific type
- Liver abscesses, endogenous bacterial endophthalmitis and, 12.238
- Liver disease. *See also* Hepatitis
- cancer, 1.213
 - hemostatic abnormalities and, 1.146
 - metastatic uveal melanoma causing, 4.196, 4.272, 4.273
 - retinal degeneration associated with, 12.285
 - Living will, surgery in older patients and, 1.181
- Livostin. *See* Levocabastine
- Lixisenatide, for diabetes mellitus, 1.45*t*, 1.46
- LK (lamellar keratoplasty). *See* Keratoplasty, lamellar
- LME. *See* Lensmaker's equation
- LMs. *See* Lymphatic malformations
- LMW heparins/LMWHs (low-molecular-weight heparins). *See* Heparin therapy
- LMX1B* gene, 10.11*t*
- LN. *See* Latent/manifest latent nystagmus (LN/MLN)
- Loa loa* (loiasis), 8.253, 8.282, 8.282*f*
 - orbital involvement and, 4.228
- Lobectomy, for seizures, 1.202
- Lobular capillary hemangioma. *See* Pyogenic granuloma
- LOC387715* gene, in age-related macular degeneration, 4.160
- Local anesthesia. *See* Anesthesia (anesthetics), local
- Localized (circumscribed) choroidal hemangioma, 4.197, 4.198*f*, 4.281, 4.282*f*
- Lockwood ligament (suspensory ligament of Lockwood), 2.32, 2.32*f*, 6.28, 7.7, 7.150, 7.151
- Locus (gene), 2.138, 2.184. *See also* Gene
- Locus heterogeneity, 2.138
- Locus vacuus, 11.3, 11.3*f*
- LOD score, 2.138–139, 2.160
- Lodoxamide, 2.337, 2.338*t*
 - for hay fever conjunctivitis, 8.289
- Löfgren syndrome, 9.167
- Logarithm of odds/logarithm of the likelihood ratio (LOD score), 2.138–139, 2.160
- LogMAR, 3.132, 6.7*f*, 6.8
 - cystoid macular edema after cataract surgery and, 11.164
- LoGTS (Low-Pressure Glaucoma Treatment Study), 10.88
- Lomefloxacin, 1.277
- Lomustine, 1.234*t*
- Long-acting insulin, 1.41, 1.41*t*

- Long (q) arm, 2.142, 2.148f
 Long arm 13 deletion (13q14) syndrome, 2.192
 Long-chain polyunsaturated fatty acids (LCPUFAs), 12.70
 Long ciliary arteries, 5.13f, 5.14f, 5.15, 5.15f
 Long ciliary nerve, 2.12, 2.32, 2.100, 2.223–224, 5.53f, 7.14f, 7.15f, 7.16
 lacrimal functional unit innervated by, 8.5f
 Long interspersed elements (LINEs), 2.150
 Long-wavelength sensitive cones. *See* L cones
 Longitudinal fasciculus, medial (MLF), 2.101–102, 2.102f, 5.35, 5.35f, 5.38
 diplopia caused by disruption of, 5.189–191, 5.190f
 dissociated nystagmus caused by lesions of, 5.247
 horizontal gaze and, 5.37, 5.38
 rostral interstitial nucleus of (riMLF), 5.33, 5.35, 5.35f, 5.220
 saccadic eye movements and, 5.220
 vertical gaze and, 5.36, 5.36f
 vertical gaze and, 5.36, 5.36f
 Longitudinal (axial) magnification, 3.63–64. *See also* Magnification
 Longitudinal (spin-lattice) relaxation time (T1), 5.62, 5.63t, 5.76, 7.28
 Loop diuretics
 for heart failure, 1.109, 1.110
 for hypertension, 1.68t, 1.70–71, 1.71
 Loop of Meyer, 2.90f, 2.93, 5.24f, 5.29, 5.155
 lesions affecting, 5.155, 5.155f
 Loracarbef, 1.276
 Lorazepam
 for benign essential blepharospasm, 7.228
 for medical emergencies/seizures, 1.296t
 Losartan, 1.68t, 1.69t
 Loss, as issue for older patient, 1.181–182
 Loss of function mutations, 2.156
 Loss of heterozygosity, 2.157
 Lotemax. *See* Loteprednol
 Loteprednol, 2.330t, 2.334, 2.338t, 2.339
 with tobramycin, 2.334, 2.348t
 for uveitis, 9.95
 ocular hypertension/glaucoma and, 9.286
 Louis-Bar syndrome (ataxia-telangiectasia/AT), 5.330, 5.332f, 5.334t, 6.393t, 6.403f, 6.403t, 6.403–404, 8.115t, 8.346
 ATM (ataxia-telangiectasia mutated) gene in, 2.154
 Loupes, 3.322
 Louse. *See* Lice
 Lovastatin, for hypercholesterolemia/heart disease prevention, 1.86t
 Low birth weight, retinopathy and. *See* Retinopathy, of prematurity
 Low-coherence interferometry, 3.102, 3.304, 8.21
 Low-coherence light, in optical coherence tomography, 12.25
 Low-density DNA microarray, 4.41
 Low-density-lipoprotein (LDL) cholesterol, 1.81, 1.82.
 See also Cholesterol
 corneal arcus and, 8.121, 8.179
 drugs affecting metabolism of, 1.85, 1.85t
 ischemic heart disease and, 1.82–83
 reducing levels of, 1.81, 1.85, 1.85t, 1.86–87. *See also*
 Lipid-lowering therapy
 goals for, hypercholesterolemia management and, 1.84t
 risk assessment/screening/modification and, 1.82–83, 1.83t
 target level for, 1.81, 1.82, 1.84t
 Low-dose helical chest CT, in cancer screening, 1.210t, 1.212
 Low-molecular-weight heparins (LMW heparins/LMWHS). *See* Heparin therapy
 Low-molecular-weight solutes, in vitreous, 2.252
 Low-order Zernike polynomials, 3.73, 3.73f
 Low-Pressure Glaucoma Treatment Study (LoGTS), 10.88
 Low-tension glaucoma, 10.3, 10.4t, 10.85f, 10.85–88, 10.86t. *See also* Glaucoma, normal-tension
 Low vision, 3.311–325. *See also* Blindness; Vision loss/impairment; Vision rehabilitation
 approach to patient with. *See* Low vision, assessment of; Low vision, management of
 assessment of, 5.77–97
 adjunct testing in, 5.88–97
 Amsler grid testing in, 5.84
 associated symptoms and, 5.78
 color vision and, 5.78–79
 confrontation testing in, 5.83–84
 contrast sensitivity and, 5.88
 electrophysiologic testing in, 5.95–97, 5.96f
 electroretinography in, 5.96f, 5.96–97
 fluorescein angiography in, 5.89, 5.89f
 fundus examination in, 5.81–82, 5.82f, 5.83f
 history in, 5.78–79
 neuroimaging in, 5.71
 nonorganic disorders and, 5.301–311, 5.302f, 5.303f, 5.304f, 5.305t, 5.307f, 5.308f, 5.309f
 OCT in, 5.90–94, 5.91f, 5.92f, 5.93f, 5.93–94f
 perimetry in, 5.84–88, 5.85f, 5.87f
 photostress recovery testing in, 5.88
 potential acuity meter testing in, 5.88–89
 pupillary testing in, 5.79f, 5.79–81
 refraction in, 5.78
 time course and, 5.77–78
 ultrasonography in, 5.95
 visual acuity testing in, 5.78
 visual evoked potential testing in, 5.95
 visual field testing in, 5.83–88, 5.85f, 5.87f. *See also*
 Visual field testing
 central visual field and, 5.85, 5.85f
 bilateral/binocular, 5.77
 nonorganic disorders and, 5.306–308, 5.307f, 5.308f, 5.309f
 central visual field and, 5.85, 5.85f
 chiasmal lesions causing, 5.146–152. *See also specific disorder*
 in children, 3.327–328
 classification of, 5.99–159. *See also specific causative factor*
 communication with patients with, 3.326f, 3.326–327
 definition of, 3.310
 evaluation of
 central visual field, 3.315, 3.317
 Charles Bonnet syndrome, 3.312
 contrast sensitivity, 3.314–315, 3.316f
 elements of, 3.311–312

- fixation, 3.313, 3.314*f*
- glare assessments, 3.318
- history-taking in, 3.312
- ocular history, 3.312
- ophthalmic evaluation versus, 3.311–312
- peripheral visual field, 3.318
- refraction, 3.314, 3.315*f*
- visual function assessments, 3.313–318*f*, 3.313–318
- visual task performance, 3.318–319
- fundus autofluorescence in, 5.89–90, 5.90*f*
- in infants, 3.327–328
- information sources on, 6.189*t*
- interventions for
 - devices, 3.318–325, 3.321–322*f*
 - electronic devices, 3.323, 3.324*f*
 - higher adds, 3.320
 - magnifiers, 3.320–322, 3.321*f*
 - nonoptical aids, 3.323
 - telescopes, 3.322*t*, 3.322*f*, 3.322–323
 - video magnifiers, 3.323, 3.324*f*
- management of, 5.99–159. *See also* Low vision aids; Vision rehabilitation; *specific causative factor*
- nonorganic disorders causing, 5.299*t*, 5.299–312
 - afferent visual pathways and, 5.301–305, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*
 - clinical profile of patient with, 5.300
 - examination techniques in, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
 - eyelid position/function and, 5.310–311
 - malingered and, 5.299
 - management of, 5.311
 - ocular motility/alignment and, 5.309–310
 - organic disorders misdiagnosed as, 5.299, 5.299*t*
 - pupils/accommodation and, 5.310
- optic neuropathy causing, 5.103–146. *See also* Optic neuropathy
- overview of, 3.311
- rehabilitation for, 6.188–189, 6.189*t*, 12.86, 12.260
- retrochiasmal lesions causing, 5.152–158
- therapies for, 12.86
- unilateral/monocular, 5.77
 - nonorganic disorders and, 5.302–305, 5.303*f*, 5.304*f*, 5.305*t*
- Low vision aids. *See also* Vision rehabilitation
 - for cataract, 11.71
 - in nonorganic disorder evaluation, 5.306
- Lowe disease/syndrome (oculocerebrorenal syndrome), 4.118, 6.391
 - congenital corneal keloids in, 8.107, 8.125
 - ocular findings in carriers of, 2.199*t*, 2.200
- Lower eyelid. *See* Eyelids, lower
- Lower eyelid reverse ptosis, 7.212, 7.215
- Lower face and neck rejuvenation, 7.245*f*, 7.245–247, 7.246*f*
- Lower-order aberrations, 13.11, 13.11*f*
- LOXL1 (lysyl oxidase–like) gene, in pseudoexfoliation/exfoliation syndrome, 2.167, 2.168*f*, 4.102, 10.11*t*, 10.91
- LPS. *See* Lipopolysaccharide
- LPS (levator palpebrae superioris). *See* Levator muscle
- LR. *See* Lateral rectus (LR) muscle
- LRIs. *See* Limbal relaxing incisions
- LRP5 gene, 12.345*f*
- LSL. *See* Laser suture lysis
- LTBP2. *See* Latent transforming growth factor beta-binding protein 2
- LTBP2 gene, 6.277
 - in glaucoma, 10.150
- LTK. *See* Laser thermokeratoplasty
- LTP. *See* Laser trabeculoplasty
- Lubricants. *See also* Artificial tears
 - for chemical injuries, 8.383
 - for conjunctivochalasis, 8.86
 - for dellen, 8.79, 8.92
 - for graft-vs-host disease, 8.304
 - for involutional entropion, 7.203
 - for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81, 8.224, 8.230
 - for paralytic ectropion, 7.224–225
 - for peripheral ulcerative keratitis, 8.312–313
 - for recurrent corneal erosions, 8.87
 - for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.298
 - for thermal injuries, 8.385
- Lucentis. *See* Ranibizumab
- Luetic keratitis/interstitial keratitis, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*, 9.237, 9.237*f*. *See also* Syphilis
- LUM (lumican) gene
 - in cornea plana, 8.100
 - in posterior amorphous corneal dystrophy, 8.136*t*
- Lumbar puncture
 - in aneurysm evaluation, 5.195, 5.340–341
 - in cerebral ischemia/stroke, 1.122
 - in subarachnoid hemorrhage, 1.127
 - in syphilis, 9.241
 - in Vogt-Koyanagi-Harada syndrome, 9.181
- Lumboperitoneal shunting, for idiopathic intracranial hypertension, 5.112, 5.113
- Lumen (lm), 3.108
- Lumican, 8.9
 - mutation in gene for
 - in cornea plana, 8.100
 - in posterior amorphous corneal dystrophy, 8.136*t*
- Lumigan. *See* Bimatoprost
- Luminance (L_v), 3.109, 3.109*t*
 - perimetry results affected by, 10.60
- Luminous exitance, 3.108
- Luminous flux, 3.108
- Luminous intensity, 3.108
- Lung cancer, 1.212–213
 - cancer-associated retinopathy and, 5.102
 - eye involvement and, 1.237, 4.197, 4.198*f*, 4.304, 4.304*t*, 4.308–309, 4.309*f*, 7.100
 - paraneoplastic-induced saccadic intrusions and, 5.249
 - screening for, 1.210*t*, 1.212–213
- Lung diseases. *See* Pulmonary diseases
- Lupus anticoagulant
 - in antiphospholipid antibody syndrome, 1.148, 1.159, 1.160
 - coagulation system effects and, 1.160–161
- Lupus choroidopathy, 9.134, 9.134*f*
- Lupus erythematosus, systemic (SLE), 1.156–159, 1.157*f*, 1.158*t*, 9.132–135, 9.133*f*, 9.134*f*
- eyelid manifestations of, 1.169, 4.207*t*

- HLA association in, 1.156
 optic neuritis and, 5.115
 refractive surgery contraindicated in, 13.191
 retinal manifestations of, 1.159, 9.133f, 9.133–134, 9.134f
- Lupus nephritis, 1.157, 1.158
 Lupus retinopathy, 9.133f, 9.133–134, 9.134f
 Lupus vasculitis, 9.134, 9.134f, 12.230–231, 12.231f
 Lutein, 2.77
 age-related macular degeneration managed with, 12.70t
 antioxidant effect of, 2.286, 2.288
 cataract risk affected by, 11.7
 description of, 12.367
 in retina, 2.267, 2.288
- Luteinizing hormone, pituitary adenoma producing, 1.57
- Luxed/luxated lens, 11.40. *See also* Ectopia lentis
 cataract surgery in patient with, 11.181–183, 11.182f, 11.183f
 traumatic, 11.40, 11.54f, 11.54–55
- Lye, ocular injury caused by, 8.376t
- Lyme disease (LD)/Lyme borreliosis, 1.250–252, 5.352–353, 5.353f, 8.249, 9.243–248, 9.244f, 9.245f, 9.247t, 12.245–246
 facial palsies and, 5.279–280
 ocular manifestations of, 5.115, 5.352, 9.245f, 9.245–246
 optic neuritis and, 5.115
- Lymecycline, 1.279
- Lymph node biopsy
 in conjunctival/ocular surface melanoma, 8.344
 in eyelid melanoma, 7.185
 in sebaceous adenocarcinoma, 7.184
- Lymphadenopathy
 in HIV infection/AIDS, 1.264
 in ocular surface neoplasia, 8.328
- Lymphadenopathy-associated virus (LAV). *See* Human immunodeficiency virus
- Lymphangiectasia, conjunctival/ocular surface, 8.348
- Lymphangiogenesis, in corneal transplant rejection, 8.317
- Lymphangioma, 6.221. *See also* Lymphatic malformations
 conjunctival/ocular surface, 8.348
- Lymphatic malformations (LMs/lymphangiomas). *See also* Vascular malformations
 conjunctival/ocular surface, 8.348
 orbital, 4.233, 4.234f, 6.221–222, 7.69–71, 7.70f
- Lymphatic/lymphocytic/lymphoid tumors. *See also* Lymphoproliferative disorders; *specific type*
 conjunctival/ocular surface, 4.69–71, 4.70f, 4.71f, 8.348–350, 8.349f, 8.350f
- Lymphatics (afferent lymphatic channels), 9.21, 9.33
 eyelid, 2.27, 2.27f, 7.154
- Lymphedema, eyelid, 7.164
- Lymphocyte-mediated immune effector responses, 9.38–39, 9.39f, 9.44–49, 9.45f, 9.46t
 with antibody effector mechanisms, 9.50f, 9.50–52
 cytotoxic lymphocytes and, 9.48–49, 9.49f
 delayed hypersensitivity T lymphocytes and, 9.44–48, 9.45f, 9.46t
- Lymphocytes, 4.8f, 4.9, 9.12. *See also* B cells; T cells
 activation/sensitization/priming of, 9.36f, 9.36–38, 9.38
 effector, 9.12, 9.38–39, 9.39f
 homing and, 9.40
- Lymphocytic choriomeningitis virus (LCMV), 6.413, 9.205–206
- Lymphocytic hypophysitis, 5.335
- Lymphocytic thyroiditis, subacute (“painless”), 1.55
- Lymphogranuloma venereum, 8.260
- Lymphohistiocytosis, Epstein-Barr virus–associated hemophagocytic (EBV-HLH/EBV-associated hemophagocytic syndrome), 1.260
- Lymphoid follicle, conjunctival, 4.47, 4.50f, 4.51, 4.51f, 4.69, 4.70, 4.70f
- Lymphoid folliculosis, benign, 8.48, 8.49f
- Lymphoid hyperplasia (lymphoid infiltration/reactive lymphoid hyperplasia [RLH]/benign lymphoid pseudotumor/pseudolymphoma). *See also* Lymphoproliferative disorders
 of conjunctiva/ocular surface, 4.69–70, 4.70f, 8.327, 8.348–349, 8.349f
 lymphoma and, 8.327, 8.348, 8.349
 of orbit, 4.231, 4.232, 7.86–88, 7.88. *See also* Lymphomas, orbital
 atypical, 4.231, 4.232
 of uveal tract (primary choroidal lymphoma/uveal lymphoid proliferation/infiltration/lymphoma), 4.199, 4.199f, 4.313–314
 masquerade syndromes secondary to, 9.276–277
- Lymphoid proliferation, uveal, 4.199, 4.199f, 4.313–314
 masquerade syndromes secondary to, 9.276–277
- Lymphoid pseudotumor/pseudolymphoma, benign. *See* Lymphoid hyperplasia
- Lymphoid stem cells, 1.135
- Lymphoid tissues
 immunoregulation in, 8.12–13f
 mucosa-associated (MALT), 4.47, 4.69, 9.55
 in allergic reactions, 9.51
 of conjunctiva (conjunctiva-associated/CALT), 2.30, 4.47, 4.69, 8.7, 9.55
 lymphoma of (extranodal marginal zone lymphoma/MALToma)
 of conjunctiva, 4.70, 4.71f, 8.349–350, 8.350f
 of orbit, 4.232, 4.233f, 7.86
 in viral conjunctivitis, 9.56
- Lymphoid/lymphocytic/lymphatic tumors. *See also* Lymphoproliferative disorders; *specific type*
 conjunctival/ocular surface, 4.69–71, 4.70f, 4.71f, 8.348–350, 8.349f, 8.350f
- Lymphokine-activated T cells, 9.39
- Lymphokines, 9.26
- Lymphomas, 4.10, 4.10t, 4.11f, 4.231
 adnexal, 4.231, 4.232, 4.233f, 7.85–89, 7.87f
 Burkitt, 6.218
 Epstein-Barr virus associated with, 1.228
 Chlamydia psittaci and, 1.252
 choroidal (uveal lymphoid hyperplasia/proliferation/infiltration), 4.199, 4.199f, 4.313–314
 conjunctival/ocular surface, 4.70f, 4.70–71, 4.71f, 8.349–350, 8.350f
 lymphoid hyperplasia and, 8.327, 8.348, 8.349

- extranodal marginal zone (mucosa-associated/MALToma)
 of conjunctiva, 4.70, 4.71f, 8.349–350, 8.350f
 of orbit, 4.232, 4.233f, 7.86
 in HIV infection/AIDS, 1.270, 5.349, 9.301
 intraocular, 12.233–234, 12.234f. *See also*
 Lymphomas, primary central nervous system/
 intraocular/vitreoretinal/retinal
 mucosa-associated (MALToma/extranodal marginal
 zone)
 of conjunctiva, 4.70, 4.71f, 8.349–350, 8.350f
 of orbit, 4.232, 4.233f, 7.86
 ocular adnexal, 4.231, 4.232, 4.233f, 7.85–89, 7.87f
 orbital, 4.231, 4.232, 4.233f, 6.218, 7.85–89, 7.87f
 in HIV infection/AIDS, 9.301
 lacrimal gland origin and, 7.87f, 7.88, 7.91
 orbital inflammatory syndrome differentiated
 from, 4.225
 primary central nervous system/intraocular/
 vitreoretinal/retinal, 1.237, 4.135f, 4.135–137,
 4.136f, 4.311f, 4.311–313, 4.313f, 5.349,
 9.273–276, 9.274f, 9.275f. *See also* Primary central
 nervous system/intraocular/vitreoretinal/retinal
 lymphoma
 primary vitreoretinal, 12.233–234
 systemic
 neoplastic masquerade syndromes secondary to,
 9.276
 secondary eye involvement and, 4.135f, 4.135–137,
 4.136f, 4.314
 transfusion-transmitted virus (TTV) associated with,
 1.262
 uveal, 4.199, 4.199f, 4.313–314, 12.234, 12.235f
 of vitreous, 4.135f, 4.135–137, 4.136f
- Lymphoproliferative disorders. *See also* Lymphoid
 hyperplasia; Lymphomas; *specific type*
 of choroid, 4.199, 4.199f, 4.313–314
 Epstein-Barr virus and, 1.260
 of lacrimal gland, 7.94
 of orbit, 4.231–232, 4.233f, 7.85–91
 histiocytic disorders, 7.90
 lymphoid hyperplasia/lymphomas, 4.231–232,
 4.233f, 7.85–89, 7.87f
 plasma cell tumors, 7.89–90
 xanthogranuloma, 7.90–91
 uveal, 4.199, 4.199f, 4.313–314
- Lynch (frontoethmoidal) incision, for orbitotomy,
 7.116f, 7.119
- Lyonization (X-chromosome inactivation/Barr body),
 2.132, 2.139, 2.153, 2.197–200
 ocular findings in carrier states and, 2.197–200,
 2.198f, 2.199t
- Lysis, cell, by cytotoxic lymphocytes, 9.48, 9.49f
- Lysosomal acid hydrolase, in mucopolidoses, 8.178
- Lysosomal fusion, blocking, as microbial virulence
 factor, 1.240
- Lysosomal metabolic diseases, 12.291–292, 12.292f
- Lysosomal storage disorders, 8.174–179. *See also*
 Mucopolysaccharidoses
 corneal changes in, 8.174–179, 8.175t, 8.176f, 8.177f
- Lysosomes
 lipofuscin in, 12.31
 outer segment digestion by, 12.17
- Lysozyme
 serum levels of, in sarcoidosis, 5.327, 7.34, 7.63
 in tear film, 2.216
- Lysyl hydroxylase, in Ehlers-Danlos syndrome, 2.175t,
 8.193
- Lysyl oxidase-like (*LOXL1*) gene, in pseudoexfoliation/
 exfoliation syndrome, 2.167, 2.168f, 4.102, 10.11t,
 10.91
- ## M
- M cells (magnocellular neurons/system), 5.28, 5.32,
 10.42
 smooth-pursuit system and, 5.224
- M-cone opsin genes, 2.262
 mutation in, 2.262, 2.264
- M cones, 2.262, 12.54
 bipolar cells for, 2.266
 horizontal cells for, 2.266
 retinal ganglion cells for, 2.267, 2.267f, 2.268f
- M-flex T intraocular lens, 13.166
- M phase, cell cycle, 2.148–149, 2.149f
- M proteins, plasma cell overproduction of, 8.198
- mAbs. *See* Monoclonal antibodies
- MAC. *See* Membrane attack complex; Microphthalmia,
 anophthalmia, coloboma
- Mac-1. *See* Macrophage-1 antigen
- MAC (*Mycobacterium avium* complex) infections
 in HIV infection/AIDS, 1.269
 neuro-ophthalmic signs of, 5.350
- Mackay-Marg type tonometer/tonometry, 10.25
- Macroadenoma, pituitary, 1.57
- Macroalbuminuria, in diabetes mellitus, 1.48
- Macroaneurysms, retinal arterial, 12.147–148, 12.148f
- Macrocytic anemia, 1.136
- Macroglia, retinal, 2.268
- α_2 -Macroglobulin, in aqueous humor, 2.231, 2.233, 2.234
- Macroglobulinemia, Waldenström, crystalline corneal
 deposits in, 8.198, 8.199f
- Macrolides, 1.272, 1.278, 2.352–353. *See also specific*
agent
 for blepharitis, 6.245
 for Lyme disease, 9.247t
 polyene, 2.354, 2.355t
- Macrophage-1 antigen (Mac-1), in neutrophil rolling,
 9.17
- Macrophage-activating factor, in delayed
 hypersensitivity, 9.46
- Macrophage chemotactic protein-1 (MCP-1), 9.27t
- Macrophage colony-stimulating factor, in mucous
 membrane pemphigoid, 8.299
- Macrophages, 4.7, 4.13, 9.10–11
 activation and recruitment of, 9.14t, 9.19–21, 9.20f
 in wound healing/repair, 4.13
- Macropsia, 5.175
 migraine and, 5.177
- Macrosaccadic oscillations, 5.248, 5.248f
 in multiple sclerosis, 5.319
- Macrosquare-wave jerks, 5.248f
- Macrostromiae, in LASIK flaps, 13.113, 13.114t, 13.115f.
See also Striae
- Macugen. *See* Pegaptanib

- Macula/macula lutea, 2.67, 2.68*f*, 2.75*f*, 2.75–77, 2.76*f*, 4.140, 4.141*f*
 adaptive optics scanning laser ophthalmoscope of, 12.13*f*
 age-related changes in. *See* Age-related macular degeneration/maculopathy
 aminoglycoside effects on, 12.300
 anatomy of, 2.67, 2.68*f*, 12.9
 atrophy of
 in cone dystrophies, 5.102
 description of, 12.265, 12.265*f*
 characteristics of, 12.10*t*
 detachment of. *See* Macular detachment
 diseases of, 5.99–103, 5.100*t*. *See also* Retinopathy;
 specific type
 fingolimod and, 5.320, 5.322*f*
 illusions and, 5.174–175
 transient visual loss and, 5.164
 evaluation of function of. *See* Macular function tests
 in glaucoma, imaging in evaluation of, 10.54
 length of, 12.9
 photic lesions of, 12.369
 photocoagulation applications, 12.375–376
 puckering of, 12.335
 retinal pigment epithelium in, 4.141
 schisis of, 12.328
 superior, rods in, 12.12
 Macula acoustica, 5.38, 5.39*f*
 Macula-sparing homonymous hemianopia, 5.157
 Macular colobomas, 12.266
 Macular corneal dystrophy (MCD). *See* Macular dystrophies
 Macular cube optical coherence tomography (OCT), 5.92, 5.93*f*
 Macular degeneration. *See also* Macular dystrophies
 age-related. *See* Age-related macular degeneration/maculopathy
 cataract surgery in patient with, 11.80
 exudative, 12.68
 genes and loci associated with, 12.256*t*
 juvenile (Stargardt disease/fundus flavimaculatus), 4.168–169*f*, 170
 ATP-binding cassette (ABC) transporter protein mutation causing, 2.263, 4.168–169
 retinal pigment epithelium in, 2.279, 4.168–169*f*, 4.169–170
 pinhole vision in patients with, 3.24
 vitelliform. *See* Macular dystrophies, vitelliform
 Macular detachment
 optic nerve pit with, 12.329*f*
 optic pits and, 5.145
 vitelliform exudative, 12.272, 12.274*f*
 Macular dragging, in retinopathy of prematurity, 6.334, 6.334*f*
 Macular dystrophies, 4.168–169*f*, 4.168–170, 4.171*f*.
 See also specific type
 adult-onset vitelliform lesions, 12.272, 12.273*f*
 atypical, 12.277
 Best disease
 bestrophin defect causing, 2.265
 description of, 6.340–342, 6.342*f*, 12.271, 12.272*f*
 identification of carriers for, 2.178, 2.196
 retinal pigment epithelium in, 2.278
 corneal (MCD), 4.91, 4.91*t*, 4.92*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.149–151, 8.150*f*
 early-onset “drusenoid,” 12.273–276, 12.274–275*f*
 electroretinography findings in, 12.46, 12.47*f*
 hereditary. *See specific type*
 North Carolina, 12.277, 12.278*f*
 occult, 12.277
 pattern, 4.170, 4.171*f*, 12.276*f*, 12.276–277
 Sorsby, 12.275*f*, 12.275–276
 retinal pigment epithelium in, 2.278
 TIMP3 defects causing, 2.161, 2.265
 Stargardt disease, 4.168–170, 6.339–340, 6.340–341*f*.
 See also Stargardt disease
 vitelliform, adult-onset, 4.170, 4.171*f*
 Macular edema, 4.140, 4.152–153, 4.153*f*, 4.154*f*
 after cataract surgery, 6.304–305
 cystoid (CME)
 angiographic, after cataract surgery, 11.163–164, 11.164*f*
 in birdshot uveitis, 9.144, 9.145*f*, 12.224
 carbonic anhydrase inhibitors for, 2.324
 cataract surgery as cause of, 12.157, 12.159, 12.260
 central retinal vein occlusion as cause of, 12.136*f*
 characteristics of, 12.156–157
 corticosteroids for, 12.159, 12.393
 after cataract surgery, 11.165
 route of administration of, 2.333*t*
 in cytomegalovirus retinitis, 12.235
 differential diagnosis of, 12.157
 drugs that cause, 12.301
 edema sources in, 12.156–157
 etiologies of, 12.157
 fingolimod as cause of, 12.302
 fluorescein angiography of, 12.36*f*, 12.157
 in HTLV-1 infection, 9.212
 incidence of, 12.157, 12.159
 in Irvine-Gass syndrome, 12.157
 in multifocal choroiditis and panuveitis syndrome, 9.156
 nicotinic acid as cause of, 12.301
 optical coherence tomography of, 12.132*f*, 12.157, 12.158*f*
 in pars planitis, 9.128, 9.131
 petaloid, 12.157
 postoperative, cataract surgery and, 11.163–165, 11.164*f*, 11.187
 in glaucoma, 11.164, 11.187
 after Nd:YAG capsulotomy, 11.157
 vitreous prolapse and, 11.143–144
 predisposing factors for, 12.157, 12.159
 prostaglandins and, 9.24–25
 pseudophakic
 definition of, 12.157
 imaging of, 12.394*f*
 optical coherence tomography of, 12.158*f*
 pars plana vitrectomy for, 12.394*f*
 in retinal dystrophies, 12.260, 12.260*f*
 retinal vein occlusion as cause of, 12.135. *See also* Retinal vein occlusion (RVO)
 in retinitis pigmentosa, 9.278, 12.260
 in sarcoidosis, 9.170
 spontaneous resolution of, 12.159

- subretinal diseases that cause, 12.157
 - taxanes as cause of, 12.301
 - treatment of, 12.159
 - in uveal lymphoid proliferation, 9.276
 - in uveitis, 9.73, 9.90, 9.90f, 9.91, 9.91f, 9.289–290
 - cataract surgery and, 9.284
 - vision loss caused by, 12.225
 - vitrectomy for, 12.159, 12.393, 12.394f
 - diabetic (DME)
 - cataract surgery and, 11.80, 11.189, 12.116
 - center-involved, 12.92, 12.109, 12.110f
 - classification of, 12.109–110, 12.110f
 - clinically significant, 12.92, 12.110, 12.114
 - contrast sensitivity issues in, 12.56
 - definition of, 12.92
 - focal, 12.110
 - mechanism of, 12.108, 12.109f
 - non-center-involved, 12.109, 12.111f
 - optical coherence tomography of, 12.111f
 - spectral-domain optical coherence tomography of, 12.109f, 12.125
 - treatment of
 - aflibercept, 12.113
 - anti-VEGF therapy, 12.101, 12.110, 12.111–113
 - bevacizumab, 12.113
 - corticosteroids, 12.113–114
 - Diabetic Retinopathy Clinical Research Network findings, 12.112f, 12.113
 - intravitreal steroids, 12.101
 - laser surgery, 12.114–115, 12.376
 - overview of, 12.110–111
 - pars plana vitrectomy, 12.115
 - pharmacologic treatment, corticosteroid route of administration and, 2.333t
 - ranibizumab, 12.111–112, 12.112f
 - surgery, 12.114–115, 12.388
 - vitrectomy, 12.388
 - vision loss caused by, 12.94
 - diffuse, 12.110, 12.111f
 - drugs that cause, 12.301–302, 12.302f
 - Early Treatment Diabetic Retinopathy Study findings for, 12.99–100
 - focal, 12.110, 12.111f
 - in gyrate atrophy, 12.268
 - panretinal photocoagulation effects on, 12.106, 12.379
 - Macular epiretinal membranes. *See* Epiretinal membranes
 - Macular exudates, 12.124f
 - Macular fibers/projections, 2.92–93
 - Macular function tests
 - before cataract surgery, 11.82
 - retinal disease and, 11.189
 - before multifocal IOL implantation, 13.155, 13.166–167
 - Macular granuloma, 6.317f
 - Macular halo, 12.292f
 - Macular holes, 4.131–132, 4.132f
 - contusion injury as cause of, 12.315
 - fellow-eye risk for development of, 12.339
 - formation of, 12.339, 12.340f
 - idiopathic
 - description of, 12.337–339, 12.338f
 - vitrectomy for, 12.384–385, 12.385f
 - International Vitreomacular Traction Study
 - Classification System for, 12.336t
 - lamellar, 12.28f
 - management of, 12.339–340
 - optical coherence tomography of, 12.27f
 - in pathologic myopia, 12.209
 - posttraumatic, 12.355–357, 12.356f
 - rhegmatogenous retinal detachment caused by, 12.330, 12.330f
 - spontaneous resolution of, 12.340
 - stage 0, 12.339
 - stage 1, 12.339–340
 - stage 2, 12.339
 - stage 3, 12.339
 - stage 4, 12.339
 - surgical management of, 12.339–340
 - vitreous in formation of, 2.254–255
- Macular laser surgery. *See* Photocoagulation
- Macular line scans, 5.92, 5.93f
- Macular microperimetry, 3.310, 3.317, 3.317f
- Macular neuroretinopathy, acute (AMN), 9.163
- fundus autofluorescence in identification of, 5.90
- OCT in identification of, 5.92, 5.93f
- Macular pits, 12.356
- Macular star
 - in neuroretinitis, 5.118, 5.118f, 5.119, 9.256, 9.257f
 - in toxoplasmic optic neuritis, 5.352
 - in tuberculous uveitis, 9.252, 9.252f
- Macular telangiectasia
 - early, 12.277
 - type 1, 12.161
 - type 2, 12.161–164, 12.162–164f
 - type 3, 12.164–165
 - volume rendering of, 12.31
- Macular translocation surgery, 12.85
- Macule
 - of eyelid, 8.45t
 - hypopigmented (ash-leaf spot), in tuberous sclerosis, 5.331f, 5.334t, 10.30
- Maculopathies, 5.99–103, 5.100t. *See also* Retinopathy; *specific type*
- acute exudative polymorphous vitelliform, 12.287
 - acute idiopathic (AIM), 12.228–229
 - adult-onset vitelliform
 - fluorescein angiography of, 12.68
 - spectral-domain optical coherence tomography of, 12.67–68, 12.68f
 - age-related. *See* Age-related macular degeneration/maculopathy
 - bull's-eye
 - chloroquine/hydroxychloroquine causing, 1.173, 12.295, 12.296f
 - clofazimine as cause of, 12.298
 - in cone dystrophies, 5.102
 - in neuronal ceroid lipofuscinoses, 12.289
 - cellophane, 12.335
 - color vision testing in, 5.78–79, 5.99
 - in dengue fever, 9.213
 - hypotony, 10.210, 12.201
 - antifibrotic use and, 10.205
 - idiopathic stellate. *See* Leber idiopathic stellate neuroretinitis
 - in ocular histoplasmosis syndrome, 9.215–216, 9.217f

- optic neuropathy differentiated from, 5.78–79, 5.99–100, 5.100*t*
- optic pit, 12.328–329, 12.329*f*
- paracentral acute middle (PAMM), 12.143
- in subacute sclerosing panencephalitis, 9.207, 9.208*f*
- MAD. *See* Minimum deviation position
- “Mad cow” disease (bovine spongiform encephalopathy), 5.357
- Madarosis
- basal cell carcinoma associated with, 7.179
 - in staphylococcal blepharitis, 8.74
- Maddox rod/Maddox rod test, 3.75, 3.75*f*, 5.184, 5.184*f*
- double, 5.184–185, 5.185*f*, 6.69, 6.69*f*, 6.120
 - in fourth nerve (trochlear) palsy, 5.198
 - in fourth nerve (trochlear) palsy, 5.198
 - in myasthenia gravis, 5.325
 - ocular alignment assessments using, 6.68–69, 6.69*f*
- Magnesium
- in aqueous humor, 2.232
 - in tear film, 2.214*t*
- Magnesium hydroxide (Mg[OH]₂), ocular injury caused by, 8.376*t*
- Magnetic resonance angiography (MRA), 5.58, 5.68–69, 5.69*f*, 5.72*t*
- advantages/disadvantages of/contraindications for, 5.61*t*
 - in aneurysm detection/evaluation, 5.194, 5.340, 5.341*f*
 - in arterial dissection, 5.342
 - in carotid artery evaluation, 5.167, 5.167*f*
 - in carotid-cavernous fistulas, 7.73
 - in cerebral ischemia/stroke, 1.121–122
 - in orbital evaluation, 7.32
 - in reversible cerebral vasoconstriction syndrome, 5.347
 - in vertebrobasilar insufficiency, 5.338
- Magnetic resonance imaging (MRI), 5.58–59*f*, 5.60–67, 5.61*t*, 5.62*f*, 5.63*t*, 5.63*f*, 5.64*f*, 5.65*f*, 5.65*t*, 5.66*f*, 5.67*f*, 5.72*t*
- advantages/disadvantages of/contraindications for, 5.61*t*
 - in aneurysm detection/evaluation, 5.194–195, 5.340, 5.341*f*
 - in arterial dissections, 5.342
 - in arteriovenous malformations, 5.292*f*, 5.343–344, 5.344*f*
 - of breast, 1.211
 - in carotid artery evaluation, 5.167, 5.167*f*
 - in cerebral ischemia detection/evaluation, 5.167, 5.168
 - in cerebral ischemia/stroke, 1.121–122
 - in choroidal melanoma/ciliary body melanoma, 4.267
 - functional (fMRI), 5.70, 5.75
 - in idiopathic intracranial hypertension, 5.111
 - in infiltrative optic neuropathy, 5.132
 - in intraocular foreign bodies, 12.353
 - in ischemic heart disease, 1.98
 - in lacrimal drainage evaluation, 7.272
 - in multiple sclerosis, 5.65, 5.114*f*, 5.316*f*, 5.319
 - in NAION, 5.123, 5.123*t*
 - in optic atrophy, 5.146
 - optic nerve on, 6.363*f*
 - in optic neuritis/neuromyelitis optica, 5.66*f*, 5.115, 5.116, 5.123*t*, 5.322–323
 - in orbital evaluation, 5.58–59*f*, 5.60–67, 5.61*t*, 5.62*f*, 5.63*f*, 5.63*t*, 5.65*t*, 5.65*f*, 5.66*f*, 5.67*f*, 5.72*t*, 7.28*f*, 7.28–29, 7.30*f*
 - CT compared with, 7.29*t*, 7.29–31, 7.30*f*
 - dermoid cysts and, 7.40
 - in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.274
 - primary vitreoretinal lymphoma evaluations, 12.234
 - in progressive multifocal leukoencephalopathy, 5.351, 5.351*f*
 - in retinoblastoma, 4.293
 - in reversible cerebral vasoconstriction syndrome, 5.347*f*
 - in sarcoidosis, 5.327
 - Sturge-Weber syndrome findings, 6.402*f*
 - in Susac (SICRET) syndrome, 9.140
 - T1- and T2-weighted images in, 5.58*f*, 5.62, 5.62*f*, 5.63*f*, 7.28*f*, 7.28–29
- Magnetic resonance spectroscopy (MRS), 5.70
- Magnetic resonance venography (MRV), 5.58, 5.69, 5.69*f*, 5.72*t*, 5.75
- advantages/disadvantages of/contraindications for, 5.61*t*
 - in cerebral venous thrombosis, 5.69, 5.69*f*, 5.346
 - in idiopathic intracranial hypertension, 5.111
- Magnification
- angular, 3.84
 - axial (longitudinal), 3.39, 3.63–64
 - devices for, 3.319–320
 - in indirect ophthalmoscope/ophthalmoscopy, 12.21
 - meridional (meridional aniseikonia). *See* Distortion
 - trade, 3.321–322
 - transverse, 3.42, 3.62, 3.300
 - video magnifiers for, 3.323, 3.324*f*
- Magnifiers, 3.320–322, 3.321*f*. *See also* Vision rehabilitation
- Magnocellular neurons (M cells/system), 5.28, 5.32, 10.42
- smooth-pursuit system and, 5.224
- Magnocellular nevus. *See* Melanocytoma
- MAI (*Mycobacterium avium-intracellulare* complex)
- infections, neuro-ophthalmic signs of, 5.350
- Main sensory nucleus, of cranial nerve V (trigeminal), 2.97, 2.98*f*, 2.101*f*, 5.47, 5.47*f*
- Main sequence, 5.219
- Maintained fixation, 6.6
- Major amblyoscope, 6.70, 6.70*f*
- Major (greater) arterial circle, 2.34*f*, 2.35, 2.45*f*, 2.55, 5.15
- ciliary body, 2.58
- Major depressive disorder, 1.189. *See also* Depression
- drugs for (antidepressants), 1.195–197, 1.196*t*
 - ocular effects of, 1.196, 1.307*t*
 - in older patients, 1.182
- Major histocompatibility complex (MHC), 9.64. *See also* Human leukocyte antigens
- class I molecules of, 9.34*f*, 9.34–35, 9.64
 - class II molecules of, 9.35*f*, 9.35–36, 9.64
 - primed macrophages and, 9.20
- Major intrinsic protein (MIP/aquaporin), 2.242, 2.245, 11.16, 11.20–21
- MAK-associated retinitis pigmentosa, racial and ethnic concentration of, 2.197

- Malar rash, in SLE, 1.157, 9.133
- Malaria prevention, 1.225
- Malassezia furfur*
as normal flora, 8.206*t*
ocular infection caused by, 8.255
- Malattia leventinese, 12.275. *See also* Drusen
EFEMP1 defects causing, 2.265
retinal pigment epithelium in, 2.279
- Malformation. *See* Congenital anomalies; *specific type*
- Malherbe calcifying epitheliomas. *See* Pilomatricoma
- Malignancy. *See* Cancer
- Malignant fibrous histiocytoma, 4.112
- Malignant glaucoma (aqueous misdirection/ciliary block glaucoma), 10.32, 10.139–141, 10.140*f*
cataract surgery and, 10.139, 11.139
in children and adolescents, 10.149*t*
after penetrating keratoplasty, 8.424
- Malignant hypertension, 12.196
- Malignant hyperthermia (MH), 1.283, 1.292–293, 1.293*t*, 6.174–175
- Malignant Hyperthermia Association of the United States (MHAUS), 1.293
- Malignant lymphomas. *See* Lymphomas
- Malignant melanoma. *See* Melanoma
- Malignant mixed tumor, of lacrimal gland, 7.91, 7.93
- Malignant optic gliomas of adulthood (MOGAs/glioblastomas), 5.130–131
- Malignant osteopetrosis, infantile, 6.212
- Malignant scleroderma, 1.162
- Maltingering, 1.190–191, 1.198, 5.299
- Malnutrition. *See also* Nutritional deficiency
corneal changes in, 8.196–197, 8.197*f*
- MALT. *See* Mucosa-associated lymphoid tissue
- MALT lymphoma/MALToma. *See* Mucosa-associated lymphoid tissue (MALT) lymphoma
- Malyugin ring, for pupil expansion, 11.178*f*
- Mamillations, iris, 6.271–272, 6.272*f*
- Mammography, for cancer screening, 1.207, 1.210*t*, 1.211
- Mandibular branch of cranial nerve VII (facial), 5.51*f*, 5.52, 5.276–277*f*
- Mandibular division of cranial nerve V (trigeminal). *See* Cranial nerve V (trigeminal nerve)
- Mandibular ligament, 7.141
- Mandibulofacial dysostosis (Treacher Collins/Treacher Collins–Franceschetti syndrome), 6.196, 6.211, 6.211*f*, 7.37, 7.37*f*, 8.192*t*
eyelid manifestations of, 4.207*t*
- Manhattan plot, 2.139, 2.164, 2.166*f*, 2.167*f*
- Mania, 1.189
treatment of, 1.197–198
- Manic depression. *See* Bipolar disorder
- Manifest exodeviations, 6.99
- Manifest latent nystagmus (MLN), 5.238, 6.88, 6.95, 6.151
- Manifest (noncycloplegic) refraction. *See also* Refraction
after cataract surgery, 3.26
definition of, 3.21
indications for, 3.25–26
IOL power calculation and, 13.194, 13.195
pacing of, 3.38
after penetrating keratoplasty, 8.431–432, 8.432*f*
before refractive surgery, 13.39, 13.40
laser programming and, 13.40, 13.81
steps involved in, 3.21–38
accommodative control, 3.34–36
binocular balance, 3.34–36
cylinder axis refinements, 3.29–30, 3.30*f*
cylinder power refinements, 3.30–33, 3.32*f*
initial estimate of refractive error, 3.27*f*, 3.27–29
occluding of left eye and refracting of right eye, 3.26–27
occluding of right eye and refracting of left eye, 3.33–34
overview of, 3.21–22
preliminary, 3.22–26
refinements, 3.33
visual acuity testing, 3.22–25, 3.23–24*f*
visual history, 3.25
summary of, 3.38
- Manifest strabismus, 6.15
- Mannitol, 2.233, 2.328–329, 2.329*t*, 10.174*t*, 10.182–183
- Mannose-binding lectin pathway (complement activation), 9.22, 9.23*f*
- Mannose-induced protein (MIP-133), *Acanthamoeba* keratitis and, 8.276
- α -Mannosidase, defective/deficiency of, in
mannosidosis, 2.175*t*, 8.179
- Mannosidosis, 2.175*t*, 6.389*t*, 8.179, 12.282*t*
- Mantle zone, 4.51, 4.51*f*, 4.69
- Manual lensmeter, 3.283–284*f*, 3.283–285
- Manual small-incision cataract surgery (MSICS), 11.198, 11.199*f*
in eye with functioning filter, 11.187
in glaucoma, 11.186, 11.187
- Manz, lacrimal gland of, 2.215*f*, 2.217
- MAO inhibitors. *See* Monoamine oxidase (MAO) inhibitors
- Map biopsy, conjunctival, pagetoid spread of sebaceous adenocarcinoma and, 7.184
- Map-dot-fingerprint dystrophy. *See* Basement membrane dystrophy
- Map lines, in epithelial basement membrane dystrophy, 8.137, 8.137*f*
- Maple syrup urine disease, 2.175*t*
- MAR. *See* Melanoma-associated retinopathy
- MAR (minimum angle of resolution), logarithm of (logMAR), cystoid macular edema after cataract surgery and, 11.164
- Marcarine. *See* Bupivacaine
- Marcus Gunn jaw-winking syndrome/ptosis, 5.272, 5.272*f*, 6.198, 7.211, 7.215, 7.216*f*
synkinesis in, 7.211, 7.215, 7.216*f*
- Marcus Gunn pupil (relative afferent pupillary defect/RAPD), 5.253
in acute idiopathic blind-spot enlargement/
acute zonal occult outer retinopathy/multiple
evanescent white dot syndrome, 5.101
cataract surgery on patient with, 11.78
in NAION, 5.122
in ocular trauma, 8.401
in optic neuropathy versus maculopathy, 5.81, 5.99, 5.100*t*
in optic tract syndrome, 5.153
testing for, 5.79*f*, 5.79–81
in glaucoma evaluation, 10.30
nonorganic disorders and, 5.302

- Marfan syndrome, 1.142, 8.192*t*, 8.193*f*, 8.193–194, 11.40*f*, 11.40–41
 cardiovascular abnormalities associated with, 6.307–308
 clinical features of, 6.307, 6.308*f*
 corneal changes in, 8.192*t*, 8.193*f*, 8.194
 fibrillin defects in, 2.66, 2.252, 8.193–194, 11.40
 lens defects/ectopia lentis and, 1.143, 2.66, 8.193, 8.193*f*, 8.194, 10.130, 11.40*f*, 11.40–41
 lens dislocation associated with, 6.307–308, 6.308*f*
 megalocornea and, 8.96*t*, 8.194
 ocular abnormalities associated with, 6.308, 6.308*f*
 pleiotropism and, 2.196
- Margin
 ciliary, 7.153
 lid. *See* Eyelids, margin of
- Margin–reflex distance (MRD₁ and MRD₂), in ptosis, 6.197, 7.209–210, 7.210*f*, 7.214*t*
- Marginal arterial arcades, 5.13*f*
 conjunctiva supplied by, 2.30
 eyelids supplied by, 2.25, 2.26*f*, 7.16*f*, 7.146*f*, 7.154, 8.4*f*
- Marginal corneal (catarrhal) infiltrates, 8.310–311
 staphylococcal blepharitis/blepharoconjunctivitis and, 8.74, 8.74*f*
- Marginal degeneration
 pellucid (PMD), 4.95, 8.16*f*, 8.168*f*, 8.168–169, 8.169*f*, 8.170*f*
 corneal topography in evaluation of, 8.31, 8.33*f*, 8.169, 8.170*f*
 refractive lens exchange and, 13.149
 refractive surgery contraindicated in, 13.24, 13.44, 13.79, 13.176, 13.176*f*
 corneal topography and, 13.24, 13.44, 13.45*f*, 13.79, 13.176, 13.176*f*
 Terrien, 8.122–124, 8.123*f*
- Marginal entropion
 in anophthalmic socket, 7.136
 tarsal fracture operation for, 7.207, 7.207*f*
 trichiasis in, 7.208
- Marginal keratitis
 Fuchs superficial, 8.123
 in rosacea, 8.70, 8.70*f*
- Marginal mandibular nerve, 2.104, 7.142*f*, 7.143, 7.144*f*
- Marginal myotomy, 6.164*t*
- Marginal tear strip (tear meniscus), 2.213
 inspection of, 8.56
 in pseudoepiphora evaluation, 7.267
- Marginal zone, 4.69
 extranodal lymphoma (MALToma) involving
 of conjunctiva, 4.70, 4.71*f*, 8.349–350, 8.350*f*
 of orbit, 4.232, 4.233*f*
 of orbit, 7.86
- Marijuana, intraocular pressure affected by, 1.192–193, 10.22
- MARINA study, 12.80–81
- Markers (gene), 2.159. *See also specific type*
- Maroteaux-Lamy syndrome (MPS VI), 6.388*t*, 8.175*t*
- Marshall syndrome, vitreous collapse in, 2.255
- MART-1 (Melan-A), in immunohistochemistry, 4.34
 melanoma diagnosis and, 4.67*f*, 4.68
- Masked bilateral superior oblique muscle palsy, 6.122
- Masked depression, in older patients, 1.183
- Masked hypertension, 1.61, 1.62
- Masquerade syndromes, 9.273–280
 neoplastic, 9.273–278, 9.274*f*, 9.275*f*
 nonneoplastic, 9.278–280
 endogenous fungal endophthalmitis as, 9.265, 9.280
- Masseter muscle, 7.142*f*, 7.143
- Masseteric ligament, 7.141
- Massively parallel DNA sequencing (next-generation sequencing/NGS), 2.140, 2.142, 2.161, 2.163*f*, 2.164*f*, 2.165*f*, 2.166*f*, 4.39*t*
- Masson trichrome stain, 4.31*t*
- Mast-cell stabilizers, 2.337, 2.338, 2.338*t*. *See also specific agent*
 for asthma, 1.133*t*, 1.134
 for atopic dermatitis, 8.287
 for hay fever conjunctivitis, 8.288–289
 for ocular allergy, 6.247*t*, 6.248, 8.287
 for vernal keratoconjunctivitis, 8.291
- Mast cells, 2.337, 4.7, 9.10
 degranulation of, 9.10, 9.50*f*, 9.50–52
- Mastoid segment, of cranial nerve VII (facial), 2.103, 5.52
- Maternal age, Down syndrome incidence and, 2.190
- Maternal drug/alcohol use, malformations associated with, 1.192
- Maternal infection transmission. *See specific infection*
- Maternal inheritance, 2.157, 2.181. *See also*
 Mitochondrial DNA
- Maternally inherited diabetes and deafness (MIDD), 12.283*t*, 12.294, 12.294*f*
 mitochondrial DNA mutations and, 2.159
- Mating, assortative, 2.132
- Matrix metalloproteinases (MMPs). *See also specific MMP*
 in cornea, 2.226
 for dry eye, 2.221, 2.221*f*
 in ligneous conjunctivitis, 8.294
 in neurotrophic keratopathy/persistent corneal epithelial defects, 8.81
 in recurrent corneal erosion, 8.87
 in tear film, 8.6*f*, 8.39
 in vitreous, 2.249
- Mature cataract, 11.46, 11.48*f*
 phacolytic glaucoma/uveitis and, 9.21, 9.118, 9.118*f*, 9.119, 10.97*f*, 10.97–98, 11.67
- Maxindex. *See* Dexamethasone
- Maxilla/maxillary bone, 2.5, 2.6, 2.6*f*, 5.5, 5.6*f*, 5.8, 5.9*f*, 7.6*f*, 7.7*f*, 7.8, 7.8*f*
 fracture of, 7.103, 7.104*f*
- Maxillary artery, 2.33*f*, 5.12, 5.15*f*
- Maxillary division of cranial nerve V (trigeminal). *See* Cranial nerve V (trigeminal nerve)
- Maxillary sinuses, 2.10*f*, 2.10–11, 5.8, 5.9*f*, 5.10*f*, 7.7*f*, 7.9, 7.18, 7.19, 7.19*f*
- Maxilloethmoidal suture, 5.9*f*
- Maxitrol. *See* Dexamethasone, in combination preparations
- Maxwell, James Clerk
 electromagnetism theory by, 3.94
 equations created by, 3.94, 3.96
- Maze procedure, for atrial fibrillation/flutter, 1.114
- Mazzocco foldable intraocular lens, 11.120, 11.120*f*

- MCA. *See* Middle cerebral artery
- McCannel sutures/technique
for IOL decentration, 11.145
for iris laceration/iridodialysis repair, 8.406, 8.408f
- McCarey-Kaufman (MK) medium, for donor corneas, 8.414
- MCD. *See* Macular dystrophies, corneal
- McDonald criteria, for multiple sclerosis, 5.319
- MCP-1. *See* Macrophage chemotactic protein-1
- MCP (multifocal choroiditis and panuveitis syndrome).
See Multifocal choroiditis (MFC), with panuveitis
- MCTD. *See* Mixed connective tissue disease
- MCV. *See* Mean corpuscular volume
- MCV4 vaccine, 1.224
- MD index. *See* Mean Deviation (MD) index
- MDRTB. *See* Multidrug-resistant tuberculosis
- M_c . *See* Radiant exitance
- Mean corpuscular volume (MCV), in anemia, 1.136
- Mean curvature/mean curvature map, 8.28, 8.30f.
See also Cornea, topography of
- Mean Deviation (MD) index, 10.65
in visual field progression identification, 10.71
- Mean of the ten largest melanoma cell nuclei (MLN), 4.196, 4.196f
- Mean performance, 1.26
- Measles-mumps-rubella (MMR) vaccine, 1.218t, 1.221
travel and, 1.224
- Measles retinopathy, 9.206–207
- Measles (rubeola) virus, 8.239, 8.240t, 9.206
immunization against, 1.218t, 1.221
travel and, 1.224
ocular infection caused by, 8.239, 8.240t, 9.206–208, 9.208f
- Measurement system, designing, 1.23–25
- Mecamylamine, 2.315t
- MECD. *See* Meesmann epithelial corneal dystrophy
- Mechanical anisocoria, 5.258t
- Mechanical ectropion, 7.198f, 7.201
- Mechanical ptosis/blepharoptosis, 7.217–218
- Mechanical ventilation
for pulmonary diseases, 1.132
for shock, 1.300–301, 1.301
- Mechlorethamine (nitrogen mustard), 1.232t
- Meckel cave, 2.99, 5.48
- Media
ocular. *See* Optical (ocular) medium/media
refractive indices of, 3.43, 3.44t
- Medial canthal defects, repair of, 7.195–196
- Medial canthal tendon, 2.17f, 7.152f, 7.153, 7.254
laxity in, in involutional ectropion, 7.199
trauma involving, 7.189
- Medial canthal tumors
basal cell carcinoma, 7.180
canalicular obstruction and, 7.274
reconstructive surgery after removal of, 7.195–196
- Medial geniculate nucleus, 5.18f
- Medial lemniscus, 5.41f
- Medial long posterior ciliary arteries, 5.15
- Medial longitudinal fasciculus (MLF), 2.101–102, 2.102f, 5.35, 5.35f, 5.38, 6.144
diplopia caused by disruption of, 5.189–191, 5.190f
dissociated nystagmus caused by lesions of, 5.247
horizontal gaze and, 5.37, 5.38
rostral interstitial nucleus of (riMLF), 5.33, 5.35, 5.35f, 5.220
saccadic eye movements and, 5.220
vertical gaze and, 5.36, 5.36f
vertical gaze and, 5.36, 5.36f
- Medial orbital fractures, 7.8, 7.106–108, 7.107f
- Medial orbital wall, 2.6, 5.7, 5.9f, 7.5, 7.5t, 7.8
fracture of, 7.8, 7.106–108, 7.107f
- Medial rectus (MR) muscle, 2.9f, 2.13, 2.14f, 2.15t, 2.16f, 2.17f, 5.8f, 5.45, 5.46, 5.46f, 7.11, 7.12f, 7.13f, 7.14f, 7.15f
action of, 6.31, 6.34t, 6.35f
adduction of, 6.35f
anatomy of, 2.9f, 2.13f, 2.14f, 2.16f, 2.17f, 5.8f, 5.45, 5.46, 5.46f
blood supply of, 2.15t, 2.17, 2.33f, 2.34f
botulinum toxin injection of, 6.97
characteristics of, 6.21t
in convergence-retraction nystagmus, 5.250
displacement of, for A-pattern strabismus, 6.110, 6.111f
excision of, 6.146
field of action, 6.33
horizontal gaze and, 5.37f, 5.38
inadvertent excision of, 6.146
innervation of, 2.17, 2.94, 2.94f, 2.95, 5.38, 5.44, 5.44f, 6.19, 7.12, 7.14f, 7.15f
insertions of, 2.13–15, 2.14f, 2.15t
laceration of, 6.146
optic nerve and, 2.87
origins of, 2.15t, 2.17, 6.20, 6.21t
recession/resection of
for convergence insufficiency, 6.103
for Duane retraction syndrome, 6.133
for esotropia from nystagmus blockage syndrome, 6.155
for infantile esotropia, 6.89
for internuclear ophthalmoplegia, 6.144
for Möbius syndrome, 6.136
restriction of, 6.97
slipped, 6.169, 6.169f
surgery considerations for, 6.29
- Medial rectus tendon, 2.13f, 2.14f, 6.19f
- Medial spindle procedure, for involutional ectropion, 7.199, 7.200f
- Medial superior temporal (MST) area, 5.32f, 5.33, 5.34f, 5.224
- Medial temporal (MT) area, 5.30f, 5.32f, 5.33, 5.34f, 5.224
- Median forehead flap, for eyelid repair, 7.193f
- Median perforators, of basilar artery, 5.20
- Mediators, 2.337, 9.22t, 9.22–30, 9.23f, 9.25f, 9.27–28t.
See also specific type
cytokines, 9.20f, 9.22t, 9.26–29, 9.27–28t
in delayed hypersensitivity, 9.45, 9.45f
hay fever conjunctivitis and, 8.288
lipid, 9.22t, 9.24–26, 9.25f
macrophage synthesis of, 9.21
neutrophil-derived granule products, 9.22t, 9.30
plasma-derived enzyme systems, 9.22t, 9.22–24, 9.23f
reactive nitrogen products, 9.22t, 9.29–30
reactive oxygen intermediates, 9.22t, 9.29
- Medical emergencies. *See* Emergencies

- Medical history. *See also* History
 cataract surgery evaluation and, 11.72, 11.170–171
 glaucoma evaluation and, 10.29
 refractive surgery evaluation and, 13.36*t*, 13.37
 Medical records, monitoring systems and, 1.25–26
 Medicare, 3.325
 Medicare Improvement for Patients and Providers Act, 1.187
 Medications. *See* Drugs
 Medium. *See* Optical (ocular) medium/media
 Medium-wavelength sensitive cones. *See* M cones
 Medroxyprogesterone, for chemical injuries, 8.383
 Medrysone, 2.330*t*
 anti-inflammatory/pressure-elevating potency of, 2.333*t*
 Medullary epithelium, medulloepithelioma arising from, 4.178, 4.296
 Medullary lamina, internal, 5.34
 Medullary thyroid carcinoma (MTC), 1.55–56
 multiple endocrine neoplasia and, 1.56, 1.58
 Medulloepithelioma (diktyoma), 4.178*f*, 4.178–179, 4.296*f*, 4.296–297, 6.273*f*, 6.273–274
 retinoblastoma differentiated from, 4.296*f*, 4.296–297
 teratoid, 4.179
 Meesmann epithelial corneal dystrophy (MECD), 8.135*t*, 8.136*t*, 8.139, 8.139*f*
 Megaloblastic anemia, 1.138
 Megalocornea, 6.253*f*, 6.253–254, 8.95, 8.96*t*, 8.99*f*, 8.99–100
 congenital glaucoma and, 8.95, 8.96*t*, 8.99–100, 8.108
 Marfan syndrome and, 8.96*t*, 8.194
 Megalopapilla, 6.366
 Meglitinides, for diabetes mellitus, 1.45*t*, 1.46
 Meibography, infrared, 8.40, 8.40*f*
 Meibomian (tarsal) glands, 2.20*f*, 2.22*f*, 2.23*t*, 2.24, 2.25*f*, 2.214–215, 2.215*f*, 4.201*f*, 4.202, 7.146*f*, 7.154, 7.154*f*, 7.162, 7.170, 8.4, 8.4*f*, 8.5
 atrophy of, 8.60
 blepharitis with dysfunction of, 6.244, 6.244*f*
 chalazion/hordeolum and, 4.203–204, 4.204, 4.206*f*, 7.162, 7.163, 8.76, 8.77
 distichiasis of, 6.195, 6.195*f*
 dysfunction of (MGD), 2.220, 8.40*f*, 8.40–41, 8.53–54, 8.54*f*, 8.55*f*, 8.58–59, 8.60*f*
 blepharitis in, 8.68, 8.72, 8.73*t*
 cataract surgery and, 11.172–173
 dry eye and, 8.40–41, 8.53–54, 8.54*f*, 8.55*f*, 8.58–59, 8.60*f*
 refractive surgery and, 13.42, 13.173
 rosacea and, 8.70
 staging of, 8.67*t*
 treatment of, 8.66*t*, 8.66–67*t*, 8.66–69
 sebaceous adenocarcinoma arising in, 4.215, 7.183
 in tear film lipids/tear production, 2.24, 2.214*f*, 2.214–215, 2.217, 7.252, 8.5
 Meibomitis. *See also* Meibomian (tarsal) glands, dysfunction of
 refractive surgery and, 13.42, 13.173
 Meige syndrome, 5.281, 5.282*f*, 7.228
 Meiosis, 2.139, 2.149–150, 2.186, 2.186*f*
 nondisjunction during, 2.186*f*, 2.189. *See also* Nondisjunction
 MEK inhibitors, 12.299, 12.299*f*
 Melan-A (MART-1), in immunohistochemistry, 4.34
 melanoma diagnosis and, 4.67*f*, 4.68
 Melanin, 12.32–33, 12.367, 12.373, 12.374*f*
 corneal deposits of/pigmentation caused by, 8.118*t*, 8.128
 defective synthesis of, in albinism, 2.174, 2.278
 photoprotective function of, 2.278, 2.286
 in retinal pigment epithelium, 2.272, 2.277–278
 albinism and, 4.142
 hypertrophy and, 4.144, 4.145*f*
 Melanin-like pigment, corneal deposits of/pigmentation caused by, 8.118*t*, 8.131*f*, 8.131–132
 α-Melanocyte-stimulating hormone (α-MSH), in tear secretion, 2.219
 Melanocytes, 7.172, 7.173
 choroidal, 2.60*f*, 2.62
 in iris stroma, 2.54
 tumors arising from, 8.338*t*, 8.338–345, 8.339*t*.
See also Melanocytic tumors; Pigmented (melanocytic) lesions
 Melanocytic lesions, 6.392, 6.395*f*
 Melanocytic nevus
 of anterior chamber/trabecular meshwork, 4.106
 congenital, 4.218, 4.218*f*
 conjunctival, 4.61–64, 4.64*f*, 4.65*f*
 malignant transformation of, 4.64, 4.68
 of eyelid, 4.218*f*, 4.218–220, 4.219*f*, 7.173–174, 7.174*f*
 glaucoma and, 4.106
 malignant transformation/melanoma risk and, 4.64, 4.68, 4.218, 4.263, 4.267–268
 Melanocytic proliferation, bilateral diffuse uveal (BDUMP), 9.278
 Melanocytic tumors, 4.255–280. *See also* Nevus; *specific type*
 of anterior chamber/trabecular meshwork, 4.106, 4.106*f*
 of conjunctival/ocular surface, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*, 8.338*t*, 8.338–345
 benign, 8.338*t*, 8.338–341, 8.339*f*, 8.339*t*, 8.340*f*, 8.341*f*
 malignant, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
 preinvasive, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
 of eyelid
 benign, 4.218*f*, 4.218–220, 4.219*f*, 4.221*f*, 7.172–175, 7.174*f*, 7.175*f*
 malignant (melanoma), 4.220, 4.221*f*, 7.184–186, 7.185*f*
 nevi, 7.173–174, 7.174*f*
 premalignant, 7.177
 melanoma risk and, 4.262, 4.268
 of ocular surface, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*
 Melanocytoma
 glaucoma and, 4.106, 4.258, 10.99, 10.99*f*
 of iris/ciliary body/choroid, 4.192, 4.258, 4.268
 melanoma differentiated from, 4.268
 ocular surface, 8.338*t*
 of optic nerve/nerve head/disc, 4.248, 4.248*f*, 4.257*f*, 4.258, 4.268, 6.367, 6.367*f*
 Melanocytosis
 dermal/dermal orbital/oculodermal (nevus of Ota), 4.63*t*, 4.64, 7.175, 7.175*f*, 8.339
 glaucoma associated with, 10.30
 of iris, 4.259

- ocular (melanosis oculi), 4.63*t*, 4.64, 4.65*f*, 6.250–251, 6.251*f*, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
 choroidal nevus resembling, 4.257, 4.257*f*
 congenital, 8.338–340, 8.339*f*
 of iris, 4.259, 4.260*f*
 oculodermal (nevus of Ota), 8.339, 8.339*t*
 Melanogenesis, 2.277–278
 latanoprost and, 2.327
 Melanokeratosis, striate, 4.65, 8.341
 Melanolipofuscin, 12.33
 Melanolysosomes, 12.32
 Melanoma, 1.214–215, 7.184–186, 7.185*f*
 acral-lentiginous/acrolentiginous, 7.185
 amelanotic, 4.68, 4.263, 4.264*f*, 4.272*t*
 of anterior chamber/trabecular meshwork, 4.106, 4.106*f*, 4.195*f*
 chemotherapy for, 4.277
 choroidal/ciliary body (uveal), 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279, 9.277
 age-related macular degeneration differentiated from, 4.269, 4.270*f*
 chemotherapy for, 4.277
 classification of, 4.194, 4.271–272, 4.272*t*
 clinical characteristics of, 4.262–263, 4.264*f*
 congenital hypertrophy of retinal pigment epithelium differentiated from, 4.144, 4.268–269, 4.269*f*
 diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
 differential, 4.267–271, 4.269*f*, 4.270*f*
 enucleation for, 4.196, 4.274–275, 7.128
 epithelioid cell, 4.192, 4.193*f*, 4.194, 4.195
 exenteration for, 4.277
 fine-needle aspiration biopsy in identification/evaluation of, 4.42, 4.43*f*, 4.253
 glaucoma caused by, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*
 immunotherapy for, 4.277
 melanocytoma differentiated from, 4.268
 metastatic, 4.196, 4.197, 4.272–274, 4.273*t*, 4.306
 mixed-cell type, 4.194, 4.195
 nevus differentiated from, 4.267–268
 observation in management of, 4.274
 ocular surface/conjunctival involvement and, 4.68, 4.69*f*, 8.343
 oculodermal melanocytosis and, 7.175
 prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
 risk factors for, 4.262, 4.268
 spindle cell, 4.192*f*, 4.192–193, 4.194, 4.195
 staging of, 4.271–272, 4.273*t*
 surgical excision of, 4.277
 transpupillary thermotherapy for, 4.276
 treatment of, 4.253, 4.274–277, 4.275*f*
 congenital hypertrophy of retinal pigment epithelium differentiated from, 4.144, 4.268–269, 4.269*f*
 conjunctival/ocular surface, 4.68*f*, 4.68–69, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
 in situ, 4.65, 4.67*f*, 4.68
 intraocular extension of, 4.310
 ocular melanocytosis and, 8.349–350
 primary acquired melanosis and, 4.66–68, 4.67*f*, 4.68, 4.68*f*, 8.327, 8.342, 8.343
 enucleation for, 4.196, 4.274–275, 7.128
 exenteration for, 4.277, 7.136, 8.344
 of eyelid, 4.220, 4.221*f*, 7.184–186, 7.185*f*
 glaucoma and, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*, 10.138
 immunotherapy for, 4.277
 of iris, 4.106, 4.190, 4.191*f*, 4.258–261, 4.259*f*, 4.260*f*, 4.261*f*
 melanomalytic glaucoma caused by, 4.106, 4.194
 lentigo maligna, 4.220, 4.221*f*, 7.177, 7.185
 metastatic, 4.196, 4.197, 4.272–274, 4.273*t*, 4.306, 9.278
 nevi and, 4.64, 4.68, 4.218, 4.262, 4.263, 4.267–268
 nodular, 4.220, 4.221*f*, 7.185, 7.185*f*
 oculodermal melanocytosis and, 7.175
 retinoblastoma and, 4.302, 4.302*t*
 retinopathy and, 5.102–103
 ERG in identification of, 5.96, 5.102–103
 ring, 4.193, 4.194*f*, 4.262, 4.263*f*
 screening for, 1.214–215
 superficial spreading, 4.220, 4.221*f*, 7.185
 uveal, 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279. *See also* Melanoma, choroidal/ciliary body
 Melanoma-associated retinopathy (MAR), 5.102–103, 12.286
 ERG in identification of, 5.96, 5.102–103
 Melanomalytic glaucoma, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*
 Melanopsin, in intrinsically photosensitive retinal ganglion cells, 5.24
 Melanosis, 8.338
 acquired
 primary (PAM), 8.327, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
 melanoma and, 8.327, 8.342, 8.343
 secondary, 8.342
 complexion-associated (CAM/racial melanosis/primary conjunctival/hypermelanosis), 4.63*t*, 4.65, 4.66, 4.66*f*, 8.338*t*, 8.339*t*, 8.341, 8.341*f*
 congenital episcleral, 8.338, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
 intraepithelial, 4.65–68, 4.66*f*, 4.67*f*
 ocular (ocular melanocytosis/melanosis oculi), 4.63*t*, 4.64, 4.65*f*, 6.250–251, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
 choroidal nevus resembling, 4.257, 4.257*f*
 of iris, 4.259, 4.260*f*
 precancerous (lentigo maligna/Hutchinson melanotic freckle), 7.177
 primary acquired (PAM), 4.63*t*, 4.65, 4.66–68, 4.67*f*
 secondary acquired, 4.65–66
 Melanosomes
 in choroid, 2.62
 in ciliary body epithelium, 2.57
 in iris dilator muscle, 2.55
 in retinal pigment epithelium, 2.68–69
 MELAS (mitochondrial myopathy and encephalomyopathy, lactic acidosis, and strokelike episodes), 5.294–295
 migrainelike headache and, 5.294–295
 mitochondrial DNA mutations and, 2.157, 2.159
 Melasma, 7.173

- Melkersson-Rosenthal syndrome, 5.280
- Melles technique, 8.434
- Meloxicam, 2.335*t*
- Melphalan, 1.232*t*, 6.357
for retinoblastoma, 4.300
- Memantine
for Alzheimer disease, 1.205
for nystagmus, 5.236, 5.245, 5.246
- Membrane attack complex (MAC), 9.22, 9.23*f*
- Membrane lens proteins, 2.245
- Membrane sacs, in rods, 2.257
- Membrane structural (urea-insoluble) lens proteins, 11.15*f*, 11.16–17
- Membrane-type frizzled protein (*MFRP*) gene
in glaucoma, 10.11*t*
in nanophthalmos, 4.108, 10.11*t*
- Membranes. *See also specific type*
Bowman, 2.40, 2.40*f*, 2.223*f*, 2.225, 4.73, 4.74*f*.
See also Bowman layer/membrane
- Bruch, 2.60–61, 2.61*f*, 2.70*f*, 2.71*f*, 2.271–272, 2.272*f*.
See also Bruch membrane
- conjunctival, 8.46*t*, 8.47*t*
in epidemic keratoconjunctivitis, 8.234, 8.234*f*, 8.235
in gonococcal conjunctivitis, 8.258
in ligneous conjunctivitis, 8.294
- Descemet, 2.41, 2.42*f*, 2.223*f*, 2.227, 4.73, 4.74*f*.
See also Descemet membrane/layer
- limiting
external (ELM/XLM), 2.71*f*, 2.72*f*, 2.74, 2.76*f*, 2.88*f*, 2.258*f*, 4.140*f*, 4.141*f*
internal (ILM), 2.70*f*, 2.71*f*, 2.75, 2.88*f*, 2.258*f*, 4.140*f*
optic nerve/nerve head/disc, 2.86, 2.88*f*
in retinal healing/repair, 4.17
vitreous detachment and, 2.253, 4.129
- middle (MLM), 2.258*f*
- neovascular. *See also* Choroidal neovascularization; Neovascularization
in age-related macular degeneration, 4.165*f*, 4.165–166
in ocular histoplasmosis syndrome, 9.215, 9.217–219, 9.218*f*
in toxoplasmosis, 9.223, 9.223*f*
- retrocorneal fibrous (RCFM/posterior collagenous layer), 2.227, 4.84, 4.85*f*
- Membranous cataract, 11.38, 11.39*f*
- Membranous conjunctivitis, 6.251
- Memory, immunologic, 9.39–40
response to tuberculosis and, 9.32
- Memory cells, 9.40
- MEN. *See* Multiple endocrine neoplasia
- Mendelian disorder (single-gene disorder), 2.139, 2.194
- Mendelian Inheritance in Man, Online (OMIM), 2.140, 2.160
for corneal dystrophies, 8.191–192*t*
- Ménière disease, 5.242
- Meningeal artery
middle (MMA), 5.12, 5.14*f*, 5.15*f*
recurrent, 5.14, 5.14*f*, 5.15*f*
- Meningeal nerve, middle, 5.49
- Meninges
neuroimaging in evaluation of, 5.72*t*
optic nerve, 2.87–89, 2.89*f*, 4.241, 4.242*f*
- Meningiomas, 7.78–82, 7.79*f*, 7.80*f*
cerebellopontine angle
Bruns nystagmus and, 5.243
seventh nerve (facial) palsy and, 5.279
intracranial, 5.127*f*, 5.127–129, 5.128*t*
malignant, 7.81
MRI of, 5.65*f*, 5.66*f*, 5.127*f*
optic nerve sheath (ONSM), 4.250, 4.250*f*, 5.65*f*, 5.66*f*, 5.126, 5.127*f*, 5.127–129, 5.128*t*, 7.79, 7.80*f*, 7.81
orbital, 4.250, 5.127, 6.223, 7.78–82, 7.79*f*, 7.80*f*
transient visual loss and, 5.164
parasellar, 5.147, 5.150
sphenoid wing, 7.79, 7.79*f*, 7.81
- Meningitis
acute retinal necrosis and, 9.196
cryptococcal, 5.356, 9.270
facial palsies and, 5.279
Haemophilus influenzae causing, 1.245
immunization against, 1.223, 1.245
headache and, 5.288
in HIV infection/AIDS, 5.348
meningococcal, 1.246
immunization against, 1.224, 1.246
tuberculous, 5.350
neuro-ophthalmic signs of, 5.350
West Nile virus causing, 9.209
- Meningoceles, 6.225, 7.37
orbital, 7.37
- Meningococcal vaccine, 1.224, 1.246
- Meningococcus (*Neisseria meningitidis*), 1.245–246, 8.207, 8.245
conjunctivitis caused by, 8.257*t*
endogenous endophthalmitis caused by, 9.264
immunization against, 1.224, 1.246
invasive capability of, 8.207
- Meningoencephalitis, in HIV infection/AIDS, 5.348
- Meningoencephaloceles, 7.37
- Meningohypophyseal trunk, 5.12–14
- Meningothelial optic meningioma, 4.250, 4.250*f*
- Meniscus lenses, principal planes for, 3.56
- Mental acuity disturbances, in multiple sclerosis, 5.317
- Mental disorders due to general medical condition (organic mental syndromes), 1.188. *See also* Alzheimer disease; Behavioral/psychiatric disorders
- Mental Health Parity and Addiction Equity Act of 2008, 1.187, 1.188
- Mental nerve, 7.145*f*
- Mentalis muscle, 7.141, 7.143*f*
- Mepivacaine, 2.362*t*, 2.364
maximum safe dose of, 1.304*t*
- 6-Mercaptopurine (6-MP), 1.232*t*
- Merci Retriever, for cerebral ischemia/stroke, 1.123
- Meretoja syndrome (Finnish/gelsolin type familial amyloidosis), 4.206, 8.186*t*, 8.187, 8.188*f*
- Meridian, 11.9
definition of, 3.4, 3.15
notation symbol for, 3.18
power-cross, 3.77
principal
definition of, 3.4, 3.16
in irregular astigmatism, 3.139
refractive powers of, 3.16
toric surface curvature variation along, 3.16*f*

- Meridional complex
 definition of, 12.10
 illustration of, 12.10f
- Meridional folds
 definition of, 12.10, 12.312
 retinal detachment and, 12.312
- Meridional magnification (meridional aniseikonia), 3.147, 3.173. *See also* Distortion
- Meridional power (instantaneous radius of curvature), 13.16–17, 13.17f
- Merkel cells/Merkel cell carcinoma, 7.187
- Merlin (neurofibromin 2), 5.334t
- Meroopenem, 1.276
- MERRF. *See* Myoclonic epilepsy with ragged red fibers
- MESA (Multi-Ethnic Study of Atherosclerosis), 12.62
- Mesectodermal dysgenesis. *See* Anterior segment, dysgenesis of
- Mesectodermal leiomyoma, 4.199
- Mesencephalic nucleus, of cranial nerve V (trigeminal), 2.97, 2.98f, 2.101f, 5.47, 5.47f
- Mesencephalic reticular formation (MRF), 5.35f
- Mesencephalon, cranial nerve III (oculomotor) arising from, 2.94
- Mesenchymal dysgenesis. *See* Anterior segment, dysgenesis of
- Mesenchymal tumors
 of eyelid and conjunctiva, 8.345t, 8.345–348
 orbital, 7.82f, 7.82–85, 7.85f
 malignant, 7.84
- Mesoderm, 2.111, 2.112f, 2.113f, 2.114f
 ocular structures derived from, 2.115t
- Mesodermal dysgenesis, Peters anomaly and, 11.31–32
- Messenger RNA (mRNA), 2.147, 2.151, 2.151f, 2.152
 precursor, 2.148, 2.151f, 2.152
- Meta-analyses, of clinical trials, 1.8, 1.8f, 1.14
- Metabolic acidosis, carbonic anhydrase inhibitors
 causing, 2.325–326
 aspirin interactions and, 2.336
- Metabolic disorders. *See also* Inborn errors of metabolism; *specific disorder*
 cataracts and, 11.60f, 11.60–62, 11.61f, 11.62f
 corneal changes and, 8.174–190
 amino acid/nucleic acid/protein/mineral metabolism and, 8.181f, 8.181–190, 8.182t, 8.183t, 8.184f, 8.185f, 8.186t, 8.187f, 8.188f, 8.189f
 lipoprotein metabolism and, 8.179–181, 8.180f
 lysosomal storage diseases, 8.174–179, 8.175t, 8.176f, 8.177f
 enzyme defects/ocular signs in, 2.175t
- Metabolic imaging, 5.70
- Metabolic syndrome, 1.37, 1.76, 1.88
- Metabolism, thyroid hormone in regulation of, 1.50
- Metabolomics, 2.136
- Metachromatic leukodystrophy, 2.175t, 6.388t
- Metahepetic ulcer, 8.224
- Metalloproteinases, matrix (MMPs). *See also specific type under MMP*
 in cornea, 2.226
 for dry eye, 2.221, 2.221f
 in ligeneous conjunctivitis, 8.294
 in neurotrophic keratopathy/persistent corneal epithelial defects, 8.81
 in recurrent corneal erosion, 8.87
 in tear film, 8.6f, 8.39
 in vitreous, 2.249
- Metallosis, lens damage/cataracts caused by, 11.58f, 11.58–59
- Metamorphopsia, 5.174–175
 in optic neuropathy versus maculopathy, 5.100, 5.100t
 in uveitis, 9.78
- Metaphase, 2.149, 2.149f
- Metarhodopsin II, 2.259
- Metastases
 orbital neuroblastoma, 6.414, 6.415f
 orbital tumors, 6.218
- Metastatic eye disease, 1.237, 4.197, 4.303–310, 9.278.
See also specific type and structure affected
 carcinoma, 4.303–310
 ancillary tests in evaluation of, 4.306–308, 4.309f
 clinical features of, 4.304–306, 4.305f, 4.306f, 4.307f, 4.308f, 4.308t
 diagnostic factors in, 4.308–309
 direct intraocular extension and, 4.310
 mechanisms of intraocular metastasis and, 4.303–304, 4.304f
 primary sites and, 4.303, 4.304t
 prognosis for, 4.309–310
 treatment of, 4.310
 of choroid, 4.197, 4.198f, 4.303, 4.304t, 4.306f, 4.307f, 4.308f, 4.308t, 9.278
 melanoma differentiated from, 4.270f, 4.271, 4.306
 of conjunctiva/ocular surface, 8.350
 of iris, 4.260, 4.260f, 4.303, 4.304, 4.305f
 of optic nerve/nerve head/disc, 4.303, 4.307–308
 of orbit, 4.228, 4.240, 7.98f, 7.98–101, 7.99f, 7.100f
 in adults, 7.99f, 7.99–101, 7.100f
 in children, 7.98f, 7.98–99
 management of, 7.101
 of retina, 4.303, 4.308, 4.309f, 9.278
 retinoblastoma and, 4.177, 4.177f, 4.293–294
 of uvea, 4.197, 4.198f, 4.303, 4.304–306, 4.305f, 4.306f, 4.307f, 4.308f, 4.309t, 9.278
 prognosis for, 4.309–310
- Metered-dose inhalers, β_2 -adrenergics for pulmonary disease and, 1.133
- Metformin, for diabetes mellitus, 1.43, 1.44f, 1.45t, 1.45–46
 in combination agents, 1.46
- Methanol, as tissue fixative, 4.26t
- Methanol toxicity, 12.301
 optic neuropathy caused by, 5.137
- Methazolamide (MZM), 2.324, 2.325, 2.325t, 2.326, 10.173t, 10.180
 in children, 10.165
- Methenamine silver stain, Gomori or Grocott (GMS), 4.31t
- Methicillin, 1.275, 2.344, 2.344t
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 1.241, 6.213, 6.240, 8.244, 8.271
 dacryoadenitis caused by, 7.284
 keratitis caused by, after photoablation, 13.106
 preseptal cellulitis caused by, 7.45
- Methimazole
 for block and replace therapy in thyroid eye disease, 7.58
 for hyperthyroidism, 1.53

- Methionine, in homocystinuria, 11.41
 dietary restriction in management of, 11.41
- Methohexital, perioperative, 1.291
- Methotrexate (MTX), 1.172–173, 9.103
 in cancer chemotherapy, 1.232*t*
 for granulomatosis with polyangiitis (Wegener granulomatosis), 1.168
 for intraocular (primary central nervous system) lymphoma, 4.312, 9.275
 for juvenile idiopathic (chronic/rheumatoid) arthritis, 9.124
 for primary vitreoretinal lymphoma, 12.234
 for rheumatoid arthritis, 1.152
 for scleritis, 8.324
 for uveitis, 6.322, 9.103
 cystoid macular edema and, 9.289
- Methoxyflurane, 12.303
- Methylation, DNA, 2.139, 2.151, 2.153
- Methylcellulose, 2.297
 in artificial tears, 2.341
 hydroxypropyl (HPMC)
 in artificial tears, 2.341
 as viscoelastic, 2.368, 11.95
 as viscoelastic, 11.95
- Methyldopa, 1.68*t*, 1.69*t*, 1.73
- Methylene blue, intracameral administration of, 2.300*t*
- Methylprednisolone, 1.171*t*, 2.329
 for anaphylaxis, 1.302
 for corneal graft rejection, 8.430
 for giant cell arteritis/AAION, 5.121, 5.314
 for neuromyelitis optica, 5.323
 for optic neuritis, 5.116
 for pars planitis, 9.130
 for thyroid eye disease, 7.59
 for uveitis, 9.95–96, 9.99
 for Vogt-Koyanagi-Harada syndrome, 9.181
- Metipranolol, 2.321, 2.322*t*, 2.323, 10.171*t*, 10.176–177
 uveitis caused by, 9.121
- Metoclopramide
 oculogyric crisis caused by, 5.231
 perioperative, 1.288, 1.290
- Metolazone, 1.68*t*
- Metoprolol, 2.317*f*
 for arrhythmias, 1.113*t*
 for heart failure, 1.110
 for hypertension, 1.68*t*, 1.69*t*, 1.72
- Metronidazole
 for *Clostridium difficile* colitis, 1.244
 for rosacea, 8.71
- MEWDS. *See* Multiple evanescent white dot syndrome
- Mexiletine, 1.113*t*
- Meyer loop, 2.90*f*, 2.93, 5.24*f*, 5.29, 5.155
 lesions affecting, 5.155, 5.155*f*
- Mezlocillin, 1.275, 2.345
- MFC. *See* Multifocal choroiditis
- MFCPU (multifocal choroiditis with panuveitis).
See Multifocal choroiditis
- mfERG. *See* Multifocal electroretinogram
- MFIOLs. *See* Multifocal lenses, intraocular
- MFRP (membrane-type frizzled protein) gene, 6.263
 in glaucoma, 10.11*t*
 in nanophthalmos, 4.108, 10.11*t*
- MG. *See* Myasthenia gravis
- Mg(OH)₂. *See* Magnesium hydroxide
- MGD. *See* Meibomian (tarsal) glands, dysfunction of
- MGDA. *See* Morning glory disc anomaly
- mGY (milligray), radiation dose measurement, 5.60, 5.75
- MH. *See* Malignant hyperthermia
- MHA-TP (microhemagglutination assay–*T pallidum*), 1.249, 9.241
- MHAUS (Malignant Hyperthermia Association of the United States), 1.293
- MHC. *See* Major histocompatibility complex
- MI. *See* Myocardial infarction
- MIC. *See* Minimal inhibitory concentration
- Micafungin, 1.281
 for *Candida* endophthalmitis, 9.268
- Michaelis constant (*K_m*), sorbitol in cataract development and, 11.19
- Michel medium, as tissue fixative, 4.26, 4.26*t*
- Miconazole, 2.355*t*, 2.356
 for *Acanthamoeba* keratitis, 2.361
- Micro-lenslet array, 3.291*f*
- Microadenoma, pituitary, 1.57
- Microalbuminuria, in diabetes mellitus, 1.48
- Microaneurysms
 in nonproliferative diabetic retinopathy, 12.100*f*
 retinal, 4.154, 4.155*f*
 in diabetes mellitus, 4.155*f*, 4.159
 in diabetic retinopathy, 4.159
 in retinal vein occlusion, 4.158, 4.159
- Microarrays, 4.40–41, 4.41*f*
 clinical use of, 4.41–42
 SNP oligonucleotide (SOMA), 4.39*t*
 tissue (TMAs), 4.40, 4.41*f*
- Microbial keratitis. *See* Infectious/microbial keratitis
- Microbiology, 8.207–211, 8.208*t*, 8.209*t*, 8.211*f*. *See also*
 Infection; Infectious disease; *specific organism*
- bacteriology, 8.208*t*, 8.243–249, 8.244*t*
 diagnostic laboratory techniques in, 8.208–211, 8.209*t*, 8.211*f*
 mycology (fungal infection), 8.208*t*, 8.249–251
 parasitology, 8.208*t*, 8.252–253
 principles of, 1.239–241
 prions, 8.254
 virology, 8.208*t*, 8.211–241
- Microcirculatory failure, in shock, 1.300
- Micrococcus*, as normal flora, 8.206*t*
- Microcornea, 6.254, 6.254*f*, 8.95–99, 8.96*t*
 cornea plana and, 8.95, 8.96*t*, 8.100
- Microcystic dystrophy
 band-shaped and whorled. *See* Lisch epithelial corneal dystrophy
 Cogan (epithelial basement membrane).
 See Basement membrane dystrophy
- Microcystic epitheliopathy, 3.232
- Microcysts
 in bullous keratopathy, 4.84
 in Lisch epithelial corneal dystrophy, 8.140, 8.140*f*
- Microcytic anemia, 1.136
- Microelectromechanical systems, in swept-source optical coherence tomography, 12.25–26
- Microenvironments, immunologic. *See* Immunologic microenvironments
- Microexplosions, 12.375

- Microfilariae
Loa loa, 8.282
 onchocercal, 8.253
 in anterior chamber, 9.234–235
- Microglia/microglial cells
 optic nerve, 4.241, 4.242*f*
 retinal, 2.73, 2.88*f*, 2.268
 ischemia and, 4.152
- Micrographic surgery, Mohs
 for canthal tumors, 7.195–196
 for eyelid tumors, 4.44*f*, 4.44–45
 basal cell carcinoma, 4.213, 7.180–181
 sebaceous adenocarcinoma, 4.218, 7.184
 squamous cell carcinoma, 4.213, 7.182
- Microhemagglutination assay–*T pallidum* (MHA-TP), 1.249, 9.241, 12.241
- Microinvasive glaucoma surgery (MIGS), cataract surgery and, 11.186
- Microkeratomes, for LASIK, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
 aberrations and, 13.102
 complications associated with, 13.110*f*, 13.110–112, 13.111*f*
 re-treatment/enhancements and, 13.98
- Micronutrients. *See also specific type*
 for age-related macular degeneration, 12.69–71
- Micropannus. *See* Pannus/micropannus
- Microperoxisomes, in retinal pigment epithelium, 2.273
- Microphthalmia, anophthalmia, coloboma (MAC), 6.263
- Microphthalmia/microphthalmos, 4.109, 7.35–36, 7.127
 with cyst, 6.224, 6.225*f*
 with cyst (colobomatous cyst), 7.36
 description of, 6.209
 persistent fetal vasculature associated with, 4.126
 treatment of, 7.36
- Microplacae, in corneal epithelium, 2.39–40, 2.40*f*, 2.224
- Micropsia, 5.175
 migraine and, 5.177
- MicroRNA (miRNA), 2.139
- Microsaccadic refixation movements, 5.213
- Microsatellites (variable/variable number of tandem repeats [VNTRs/VTRs]), 2.139, 2.150
- Microscope
 confocal, 3.302, 8.24, 8.24*f*
 in *Acanthamoeba* keratitis diagnosis, 8.24, 8.277, 8.278*f*
 examination before phakic IOL insertion and, 13.141
 slit-lamp. *See* Slit-lamp biomicroscopy/examination
 specular, 3.295, 8.23, 8.23*f*
 examination before cataract surgery and, 11.84
 examination before phakic IOL insertion and, 13.141
 examination in iridocorneal endothelial syndrome and, 10.137
 in Fuchs endothelial corneal dystrophy, 8.23*f*, 8.158
 surgical/operating, 3.294, 3.295*f*
 for intraorbital surgery, 7.121
 for manual small-incision cataract surgery, 11.198
 phototoxicity and, 11.166
- Microscopic hyphema, 8.392, 8.392*f*
- Microscopic polyangiitis (MPA), 1.165*t*, 1.168, 9.137
- Microshunts, 10.219–220
- Microsomal triglyceride transfer protein (MTP)
 mutation, 2.265
- Microsomia, hemifacial, in Goldenhar-Gorlin syndrome, 8.191*t*, 8.195–196
- Microspherophakia, 6.307, 11.32–33, 11.33*f*
 pupillary block/angle-closure glaucoma caused by, 10.130, 10.131*f*, 11.33
 in Weill-Marchesani syndrome, 11.33
- Microsporidia (microsporidiosis), 8.252, 8.280*f*, 8.280–281, 8.281*f*
 conjunctivitis/keratitis/keratoconjunctivitis caused by, 8.280–281, 9.300, 9.300*f*
 in HIV infection/AIDS, 1.269, 8.280, 8.280*f*, 9.300, 9.300*f*
- Microstriae, in LASIK flaps, 13.113, 13.114*t*, 13.115*f*.
See also Striae
- Microtrauma, ocular infection and, fungal keratitis, 4.78
- Microtropia, 6.51
- Microtubules, 2.245
- Microvascular abnormalities, intraretinal (IRMAs), 4.153*f*, 4.154, 4.155*f*
 in diabetic retinopathy, 4.159
- Microvascular decompression surgery, for hemifacial spasm, 5.284, 7.229
- Microvasculopathy, in diabetes mellitus. *See* Diabetic retinopathy
- Microvilli, in corneal epithelium, 2.39–40, 2.40*f*, 2.224
- Midazolam, 1.195
 perioperative, 1.290–291
- Midbrain, 5.27*f*, 5.30
 cranial nerve III (oculomotor) arising from, 2.94
 lesions of
 convergence insufficiency caused by, 5.227
 corectopia caused by, 5.255
 eyelid retraction in, 5.229, 5.250, 5.274, 5.275*t*, 7.223
 gaze palsies caused by, 5.228–229
 light–near dissociation and, 5.229, 5.230*f*, 5.266*t*, 5.266–267
 vertical eye movements and, 5.36, 5.36*f*, 5.36–37
- Midbrain corectopia, 5.255
- MIDD (maternally inherited diabetes and deafness), mitochondrial DNA mutations and, 2.159
- Middle cerebral artery (MCA), 2.107*f*, 5.16*f*, 5.18, 5.18*f*, 5.19, 5.27*f*
 aneurysm of, 5.339*f*
 cranial nerve relationship and, 2.84*f*, 2.85*f*, 5.42*f*
- Middle cervical ganglion, 5.54
- Middle cranial fossa, 5.6*f*, 5.10*f*, 5.11
 neuroimaging in evaluation of, 5.72*t*
- Middle lamellar deficiency, surgery for eyelid retraction and, 7.224
- Middle limiting membrane (MLM), 2.258*f*, 4.140*f*
 anatomy of, 12.15
 definition of, 12.16
 histology of, 12.11, 12.12*f*
- Middle meatus, 7.18, 7.254
- Middle meningeal artery (MMA), 5.12, 5.14*f*, 5.15*f*
- Middle meningeal nerve, 5.49
- Middle turbinate/concha, 7.18, 7.253*f*
- Midface rejuvenation/elevation, 7.241–245, 7.243*f*, 7.244*f*, 7.245*f*

- Midfacial (Le Fort) fractures, 7.103, 7.104f
- Midget bipolar cell, 12.13
- Mie scattering, 3.92, 3.97–98
- Miglitol, for diabetes mellitus, 1.45t, 1.46
- Migraine attacks, stroke-like, after radiation therapy (SMART), 5.358
- Migraine headache, 5.171–172, 5.177, 5.288–292, 5.290f, 5.292f
 with aura, 5.171–172, 5.177, 5.290–291
 without aura, 5.290
 aura without (acephalgic migraine), 5.172, 5.177, 5.291
 basilar-type, 5.291
 evaluation of, 5.291–292, 5.292f
 familial hemiplegic, 5.291
 hallucinations and, 5.177
 inherited encephalopathies resembling, 5.294–295
 ophthalmoplegic, 5.197
 persistent positive visual phenomena and, 5.177, 5.201, 5.290
 prophylaxis for, 5.293
 transient visual loss and, 5.161, 5.162, 5.171–172, 5.177, 5.291
 treatment of, 5.292–293
 visual phenomena of, 5.177, 5.290–291
- Migration inhibitory factor, in mucous membrane pemphigoid, 8.299
- MIGS. *See* Microinvasive glaucoma surgery
- Mikulicz syndrome, 7.94
- Milia, 7.168
- Miliary tuberculosis, 9.250
- Milk-alkali syndrome, corneal changes in, 8.201
- “Milky Way” sign, in Vogt-Koyanagi-Harada disease, 12.232
- Millard-Gubler syndrome, 5.192
- Miller Fisher syndrome, 5.273, 5.273t, 5.280
- Milligray (mGy), radiation dose measurement, 5.60, 5.75
- Mimecan, mutation in gene for, in cornea plana, 8.96t, 8.100
- Mimetic muscles, 7.141–143, 7.143f
 facial nerve supplying, 7.16, 7.143–144, 7.144f
- Mimicry, molecular, HLA disease associations and, 9.65, 9.67
- Mineral metabolism, disorders of, corneal changes in, 8.181f, 8.181–190, 8.182t, 8.183t, 8.184f, 8.185f, 8.186t, 8.187f, 8.188f, 8.189f
- Mini- (modified) monovision, 13.39, 13.164–165
 accommodating IOLs and, 13.154
- Minimal inhibitory concentration (MIC), 1.274
- Minimal lethal concentration (MLC), 1.274
- Minimum angle of resolution (MAR), logarithm of (logMAR), cystoid macular edema after cataract surgery and, 11.164
- Minimum deviation position (MAD), 3.45, 3.46f
- Minimum legible threshold, 3.131
- Minimum separable threshold, 3.131
- Minimum visible threshold, 3.131
- Miniplates
 for canthal repair, 7.195
 for orbital fracture, 7.108
- Minnesota Low-Vision Reading Test (MNREAD), 3.318, 3.319f
- Minocycline, 2.350
 adrenochrome deposition caused by, 8.118t, 8.131
 for meibomian gland dysfunction, 8.68
 ocular effects of, 1.307t
 for rosacea, 8.71
- Minor (lesser) arterial circle, 2.54f, 2.55, 5.15
- Minoxidil, 1.68t, 1.73
- Minus cylinder lens
 description of, 3.148–149
 for against movement, 3.155
 pictorial representation of, 3.17f
 plus cylinder conversion to, 3.149
 “with-the-rule” astigmatism correction using, 3.19, 3.20f
- Minus cylinder phoropter
 advantages of, 3.148
 astigmatism detection using, 3.29
 cylinder axis refinement using, 3.29–30, 3.30f
 with Jackson cross cylinder, 3.29, 3.30–31f
- Minus lenses. *See also* Concave (minus/negative) lenses
 anophthalmic socket camouflage and, 7.136
- Miochol. *See* Acetylcholine
- Miosis/miotic agents, 2.308, 2.308t, 2.309, 2.310, 2.311, 2.311t
 for acute angle closure, 10.124
 adrenergic antagonists, 2.321
 angle closure caused by, 10.124, 10.182
 contrast sensitivity affected by, 3.136
 direct-acting muscarinic agonists, 2.308t, 2.308–312, 2.311t
 for glaucoma, 2.311, 2.318t, 10.173t, 10.181–182
 anterior uveitis and, 10.100
 cataract/cataract surgery and, 11.52
 in children, 10.166
 in Horner syndrome, 5.257, 5.258, 5.258t, 5.259f, 5.261f
 indirect-acting muscarinic agonists (cholinesterase inhibitors), 2.311t, 2.312–313
 pharmacologic, 5.259f, 5.261f, 5.265f
 toxic keratoconjunctivitis and, 8.90t, 8.91
 traumatic injury and, 5.262, 8.389
- Miostat. *See* Carbachol
- MIP. *See* Major intrinsic protein
- MIP-133 (mannose-induced protein), *Acanthamoeba* keratitis and, 8.276
- Mires
 in applanation tonometry, 10.23, 10.24f
 astigmatism evaluation and, 8.15
 in keratometry, 8.27, 8.27f
 in keratoscopy, 8.27, 8.28, 8.28f
 in topography, 8.28, 13.14, 13.16, 13.25f
- miRNA. *See* MicroRNA
- Mirror test, nonorganic disorders and, 5.302
- Mirrors
 description of, 3.80–83
 examination room use of, 3.149–150
 plane, 3.81
 ray tracings and, 3.81, 3.82f, 3.83
 vergence equation for, 3.81, 3.88–89, 3.89f
- Misdirection, in nonorganic disorder evaluation, 5.300
- Mismatch repair, 2.154
- Missense mutation, 2.140, 2.155
 of mitochondrial DNA, 2.157

- “Missing half” field defect, in nonorganic disorder, 5.307, 5.307f
- Mitochondria, 2.147, 2.148f
- Mitochondrial disorders, 12.293–294
- Mitochondrial DNA (mtDNA), 2.147, 2.148f
- diseases associated with deletions/mutations of, 2.157–159
- chronic progressive external ophthalmoplegia, 5.328–329, 5.329f
- Leber hereditary optic neuropathy, 2.157, 2.158, 5.133
- maternal inheritance/transmission and, 2.157, 2.181
- MELAS and MIDD, 2.159
- NARP (neuropathy [neurogenic muscle weakness]/ataxia/retinitis pigmentosa) syndrome, 2.157, 2.158–159
- replicative segregation and, 2.143, 2.157
- Mitochondrial myopathy, 12.293f, 12.293–294
- with encephalopathy, lactic acidosis, and strokelike episodes (MELAS), 5.294–295, 12.283t, 12.294
- migrainelike headache and, 5.294–295
- mitochondrial DNA mutations and, 2.157, 2.159
- neuro-ophthalmic signs of, 5.328–330, 5.329f
- Mitomycin/mitomycin C (MMC), 1.233t, 1.235, 2.339
- in dacryocystorhinostomy, 7.281
- for ocular surface tumors, 8.327, 8.330, 8.330f, 8.331
- off-label use of, 2.306
- in phototherapeutic keratectomy, 8.367
- in pterygium surgery, 8.355
- recurrence rate and, 8.353t, 8.355
- after radial keratotomy, 13.52
- in surface ablation, 13.92
- corneal haze prevention/corneal wound healing and, 13.33, 13.92, 13.109
- for undercorrection, 13.102
- toxic reactions to, 8.91
- in trabeculectomy, 10.205, 10.207
- bleb-associated endophthalmitis and, 10.163, 10.209
- in children, 10.163
- scleral flap closure and, 10.203, 10.205f
- for uveitic glaucoma, 9.287
- Mitosis, 2.140, 2.148, 2.149f, 2.185
- nondisjunction during, 2.191. *See also* Nondisjunction
- Mitten deformity, 6.206, 6.207f
- Mittendorf dot, 2.80, 2.81f, 4.126, 6.298, 11.29, 11.31, 11.32f, 12.340
- Mivacurium, 1.290
- Mixed astigmatism, 3.138, 3.138f
- limbal relaxing incisions for, 13.57
- wavefront-optimized laser ablation for, 13.97
- Mixed-cell type melanoma, 4.194, 4.195
- Mixed connective tissue disease (MCTD), 1.162
- Mixed tumor
- benign (pleomorphic adenoma)
- of eyelid, 7.170
- of lacrimal gland, 4.229–230, 4.230f, 7.91, 7.92f, 7.92–93
- malignant, of lacrimal gland, 7.91, 7.93
- Mizuo-Nakamura phenomenon, 12.253, 12.253f
- MK medium. *See* McCarey-Kaufman (MK) medium
- ML I. *See* Dysmorphic sialidosis
- ML II. *See* Inclusion-cell disease
- ML III. *See* Pseudo-Hurler polydystrophy
- ML IV, 8.178
- MLC. *See* Minimal lethal concentration
- MLF. *See* Medial longitudinal fasciculus
- MLM. *See* Middle limiting membrane
- MLN. *See* Manifest latent nystagmus; Mean of the ten largest melanoma cell nuclei
- MLPA. *See* Multiplex ligation-dependent probe amplification
- MLS. *See* Microphthalmia/microphthalmos
- MLs. *See* Mucopolidoses
- MMA. *See* Middle meningeal artery
- MMC. *See* Mitomycin/mitomycin C
- MMCRs. *See* Müller muscle–conjunctival resections
- MMP. *See* Mucous membrane (ocular cicatricial) pemphigoid
- MMP-2, in vitreous, 2.249
- MMP-2 proenzyme, in cornea, 2.226
- MMP-9
- in ligneous conjunctivitis, 8.294
- in tear film, 8.6f, 8.39
- MMPs. *See* Matrix metalloproteinases
- MMR (measles-mumps-rubella) vaccine, 1.218t, 1.221
- travel and, 1.224
- Mn SOD (superoxide dismutase), 2.287
- MNREAD. *See* Minnesota Low-Vision Reading Test
- MOABs. *See* Monoclonal antibodies
- Möbius syndrome/sequence, 5.228, 5.278, 6.97, 6.135–136, 6.136f
- Mode-locking, 3.112
- Modified (mini-) monovision, 13.39, 13.164–165
- accommodating IOLs and, 13.154
- Modulation transfer function (MTF)
- definition of, 3.124, 3.239, 3.261
- description of, 3.135
- intraocular lenses, 3.261–263, 3.262–263f
- Moebius syndrome. *See* Möbius syndrome/sequence
- Moexipril, 1.68t, 1.69f
- MOGAs. *See* Malignant optic gliomas of adulthood
- Mohs micrographic surgery
- for canthal tumors, 7.195–196
- for eyelid tumors, 4.44f, 4.44–45
- basal cell carcinoma, 4.213, 7.180–181
- sebaceous adenocarcinoma, 4.218, 7.184
- squamous cell carcinoma, 4.213, 7.182
- Moisture-retaining eyewear (moisture chambers/shields), 8.61t, 8.63–64
- “Molar tooth” sign, 6.392f
- Molds, 5.353, 8.249, 8.249t, 8.251
- endogenous endophthalmitis caused by, 9.265, 9.268–270, 9.269f
- Molecular biologic techniques. *See* Genetics, molecular
- Molecular genetics. *See* Genetics, molecular
- Molecular mimicry, HLA disease associations and, 9.65, 9.67
- Molecular motifs, in innate immune response, 9.12
- Molecular pathology, 4.34t, 4.36–42, 4.38–39t, 4.40f, 4.41f
- Moles. *See also* Nevi/nevus
- atypical, melanoma arising from, 1.215

- Moll, glands of, 2.19, 2.22f, 2.23t, 4.201, 7.154f, 7.170, 8.4, 8.4f
 hidrocystoma arising in, 7.171, 7.171f
- Molluscum contagiosum/molluscum nodule, 6.199, 6.243, 6.244, 8.208t, 8.236–237, 8.237f, 8.238f
 of eyelid, 4.204, 4.205f, 7.169, 7.169f, 8.236–237, 8.237f, 8.238f
 in HIV infection/AIDS, 9.300
- Molteno implant, 10.214, 10.214t
- Molybdenum cofactor (sulfite oxidase) deficiency, 2.175t
- Mondino and Brown staging system, for mucous membrane pemphigoid, 8.302, 8.302t
- Monitoring system, implementation of, 1.25–26
- Monoamine oxidase (MAO) inhibitors, 1.196t, 1.197
 drug interactions and, 1.197
 apraclonidine/brimonidine interactions, 2.319, 10.179
 hypertension and, 1.79
 perioperative discontinuation of, 1.286
- Monobactams, 1.275–276
- Monocanicular stents, 6.234
 for lacrimal trauma, 7.283
 for nasolacrimal intubation, 7.263, 7.264f
- Monochromatism/achromatopsia, 12.250t
 blue-cone. *See* Monochromatism/achromatopsia, S-cone
 cerebral, 5.179
 infantile nystagmus syndrome and, 5.236
 rod, 2.264, 6.337
 S-cone (blue-cone), 2.264, 6.337–338
 ocular findings in carriers of, 2.199t
- Monoclonal antibodies (mAbs/MOABs), 6.322, 9.42
 in cancer therapy, 1.235, 1.236
 for rheumatic disorders, 1.175
 for uveitis, 9.107
- Monoclonal gammopathy, benign, crystalline corneal deposits in, 8.198
- Monocular aphakia, 3.191
- Monocular cover-uncover test, 6.64, 6.65f
- Monocular diplopia, 5.174, 5.185
 in cataracts, 11.43–44, 11.45, 11.47, 11.70–71
 multifocal intraocular lenses as cause of, 3.258
 pinhole aperture testing for, 3.130
- Monocular distortion. *See* Distortion
- Monocular elevation deficiency (double-elevator palsy), 6.125–127, 6.126f, 7.213
- Monocular eye movements, 5.184. *See also* Ductions;
 Forced duction test; *specific type*
 ductions, 6.33
 field of action, 6.33–34
 gaze position effects on extraocular muscle action, 6.34–37, 6.35–37f
 primary action, 6.34
 secondary action, 6.34
 terminology associated with, 6.33
 tertiary action, 6.34
- Monocular fixation, 6.16
- Monocular nystagmus, 6.152
 in Heimann-Bielschowsky phenomenon, 5.238–239
- Monocular transient visual loss (transient monocular visual loss/TMVL), 5.161, 5.163t, 5.163–171.
See also Transient visual loss
 carotid artery disease and, 1.125, 5.162, 5.165–166, 5.167, 5.167f, 5.168
 embolic causes of, 1.125, 5.161, 5.162, 5.163t, 5.165, 5.165f, 5.165–169, 5.166t
 clinical/laboratory evaluation in, 5.166–168
 prognosis/treatment and, 5.168–169
 hypoperfusion causing, 5.161, 5.162, 5.170, 5.171f
 ocular causes of, 5.163t, 5.163–164
 ocular ischemic syndrome causing, 5.170, 5.171f
 optic nerve disorders causing, 5.161, 5.164
 orbital causes of, 5.164
 postural changes causing, 5.161, 5.164, 5.170
 systemic causes of, 5.169–171, 5.171f
 vascular disease causing, 5.163t, 5.164–171
 vasospasm/hyperviscosity/hypercoagulability causing, 5.161, 5.162, 5.171
- Monocular vision
 no light perception, testing, 5.302–305, 5.303f, 5.304f
 reduced, 5.161, 5.163t, 5.163–171. *See also* Monocular transient visual loss; Unilateral vision loss
 in low vision evaluation, 5.77
 in nonorganic disorders, 5.305, 5.305t
- Monocular visual deprivation
 binocularity affected by, 6.45
 description of, 6.44
 visual cortex affected by, 6.45
- Monocytes, 4.7, 4.8f, 9.10–11. *See also* Macrophages
- Monofixation syndrome
 amblyopia and, 6.52
 definition of, 6.51
 diagnosis of, 6.51–52
 management of, 6.52
 Worth 4-dot test for, 6.81
- Monofocal intraocular lenses, 13.151
- Monogenic (mendelian) disorder, 2.139
- Monokines, 9.26
- Mononeuritis multiplex
 in diabetes mellitus, 1.49
 in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), 1.168
 in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137
 in polyarteritis nodosa, 1.166, 9.135–136
- Mononucleosis, infectious (IM)
 Epstein-Barr virus causing, 1.260, 9.202
 ocular involvement in, 8.230–231, 8.231f, 9.202, 9.203f
- Monosomy, 2.189
- Monosomy 3, in choroidal/ciliary body melanoma, 4.197, 4.253, 4.268, 4.278
- Monosomy X, 6.386t
- Monovision, 3.224, 3.240, 3.258, 13.39, 13.164–165
 with contact lenses, 13.164
 as trial before surgery, 13.39, 13.165, 13.198
 modified (mini), 13.39, 13.164–165
 accommodating IOLs and, 13.154
- Mood disorders (affective disorders), 1.189–190
 drugs for treatment of (mood stabilizers), 1.197–198
- Moore, lightning streaks of, 5.175
- Mooren ulcer, 8.313–316, 8.315f

- Moraxella*
 blepharitis/blepharoconjunctivitis caused by, 8.74, 8.208*t*
 conjunctivitis caused by, 8.208*t*, 8.257*t*
 keratitis caused by, 8.208*t*
lacunata, 8.257*t*
 as normal flora, 8.206*t*
 orbital cellulitis caused by, 7.47
- Morgagnian cataract, 4.122, 4.123*f*, 11.46, 11.50*f*
 phacolytic glaucoma and, 10.97*f*, 10.97–98
- Morgagnian globules, 4.122, 4.122*f*, 4.123*f*, 4.124*f*, 11.46
- Morning glory disc anomaly (MGDA), 6.362–363, 6.364*f*, 7.37
- Morning glory optic nerve head anomaly, 5.145
- Morpheaform (sclerosing) basal cell carcinoma, 4.212–213, 4.213*f*, 7.178*f*, 7.178–179, 7.180. *See also* Basal cell carcinoma
- Morphine, for heart failure, 1.110
- Morphogenic gradients, 2.127
- Morphogens, 2.127
- Morquio syndrome (MPS IV), 6.270, 8.175*t*
- Morula, 2.112*f*
- Mosaic degeneration (anterior crocodile shagreen), 8.121
- Mosaicism (mosaic), 2.140, 2.190–192
 germinal, 2.136
 sex chromosome, 2.191–192
 trisomy 21, 2.191
- Mosquito-borne diseases, 12.246–247
- Mossy fiber input, 5.40
- Motifs, in innate immune response, 9.12
- Motility, ocular. *See* Ocular motility
- Motility disorders. *See* Ocular motility, disorders of
- Motility examination. *See* Ocular motility, assessment of
- Motion artifacts, in optical coherence tomography angiography, 12.29
- Motion contrast, 12.28
- Motor apraxia, ocular. *See* Ocular motor apraxia
- Motor correspondence, Hering's law of (Hering's law of equal innervation), 6.38, 6.115–116, 6.121
 eyelid retraction and, 5.274, 7.222, 7.223
 horizontal gaze and, 5.36*f*
 nystagmus and, 5.247
 ptosis enhancement and, 5.270*f*, 5.310
- Motor fusion, 6.43
- Motor nucleus
 of cranial nerve III (oculomotor), 2.94, 2.94*f*
 of cranial nerve IV (trochlear), 2.96
 of cranial nerve V (trigeminal), 2.97, 2.98*f*, 2.99, 5.47–48
 of cranial nerve VI (abducens), 2.101, 2.102*f*, 5.51*f*
 of cranial nerve VII (facial), 2.102*f*, 2.103, 5.49, 5.50*f*, 5.51*f*, 5.276–277*f*
- Motor pathways, facial, 5.49–52, 5.50–51*f*. *See also* Cranial nerve VII
- Motor physiology
 eye movements. *See* Eye movements
 gaze positions, 6.31
 ocular rotations, 6.31
 principles of, 6.31–32
 terminology associated with, 6.31–32
- Motor root
 of cranial nerve III (oculomotor), 2.11, 2.12*f*
 of cranial nerve V (trigeminal), 2.99
 of cranial nerve VII (facial), 2.102
- Motor system disorders. *See* Movement disorders;
 Parkinson disease/parkinsonism
- Motor tracking systems, ocular, 5.212*t*, 5.212–213
- Motor units
 description of, 6.32–33
 recruitment of, during fixation or following movement, 6.33
- Movement disorders
 bradykinetic, 1.198. *See also* Parkinson disease/parkinsonism
 in schizophrenia, 1.188–189
- Moxeza. *See* Moxifloxacin
- Moxifloxacin, 1.277, 2.346, 2.347*t*, 2.347–349
 for bacterial keratitis, 8.269, 8.270*t*
 ocular effects of, 1.307*t*
 after penetrating and perforating trauma repair, 8.409
 uveitis caused by, 9.121
- Moxisylyte. *See* Thymoxamine
- Moyamoya disease, 6.363
- 6-MP. *See* 6-Mercaptopurine
- MPA. *See* Microscopic polyangiitis
- MPO-ANCA. *See* Myeloperoxidase autoantibodies
- MPS. *See* Mucopolysaccharidoses
- MPS I H. *See* Hurler syndrome
- MPS I HS. *See* Hurler-Scheie syndrome
- MPS I S. *See* Scheie syndrome
- MPS IH/MPS1-H. *See* Hurler syndrome
- MPS IH/S. *See* Hurler-Scheie syndrome
- MPS IS/MPS1-S. *See* Scheie syndrome
- MPS II. *See* Hunter syndrome
- MPS III. *See* Sanfilippo syndrome
- MPS III A–D. *See* Sanfilippo syndrome
- MPS IV. *See* Morquio syndrome
- MPS IV A–B. *See* Morquio syndrome
- MPS VI. *See* Maroteaux-Lamy syndrome
- MPS VII. *See* Sly syndrome
- MPS IX. *See* Natowicz syndrome
- MPSs. *See* Mucopolysaccharidoses
- MPSV4 vaccine, 1.224
- MR. *See* Medial rectus (MR) muscle
- MRA. *See* Magnetic resonance angiography
- MRD. *See* Margin–reflex distance
- MRD₁/MRD₂. *See* Margin–reflex distance
- MRF. *See* Mesencephalic reticular formation
- MRI. *See* Magnetic resonance imaging
- mRNA. *See* Messenger RNA
- mRNA precursor. *See* Messenger RNA (mRNA), precursor
- MRS. *See* Magnetic resonance spectroscopy
- MRSA. *See* Methicillin-resistant *Staphylococcus aureus*
- MRV. *See* Magnetic resonance venography
- MS. *See* Multiple sclerosis
- α-MSH (α-melanocyte-stimulating hormone), in tear secretion, 2.219
- MSICS. *See* Manual small-incision cataract surgery
- MST area. *See* Medial superior temporal (MST) area
- MT area. *See* Medial temporal (MT) area
- MTC. *See* Medullary thyroid carcinoma
- mtDNA. *See* Mitochondrial DNA
- MTF. *See* Modulation transfer function
- MTP (microsomal triglyceride transfer protein)
 mutation, 2.265
- MTX. *See* Methotrexate

- Mucinous corneal dystrophy, subepithelial (SMCD), 8.135t
- Mucins, tear film, 2.38, 2.213f, 2.217, 2.224, 7.252, 8.5, 8.6f
 deficiency/dysfunction and, 2.217, 2.220
 dry eye and, 8.54, 8.54f
 secretion of, 2.217, 8.5, 8.6f
- Mucocele, 2.10, 6.224
 lacrimal (dacryocystocele), 7.265–267, 7.266f
 dacryocystitis and, 7.286
 orbital invasion by, 7.95, 7.95f
- Mucocutaneous junction, eyelid, 7.153, 7.154f
- Mucocutaneous lymph node syndrome (Kawasaki disease), 1.165t, 1.167
- Mucoepidermoid carcinoma, 4.61
 ocular surface, 8.332t, 8.336
- Mucopolidoses (MLs), 6.388t, 8.178
 corneal changes in, 8.178
 congenital/infantile opacities and, 8.107
- Mucomyst. *See* Acetylcysteine
- Mucopolysaccharide deposits. *See also* Glycosaminoglycans
 in macular dystrophy, 8.149
- Mucopolysaccharidoses (MPSs), 2.175t, 2.184–185, 8.174–176, 8.175t, 8.176f, 12.282–283t, 12.290–291.
See also specific type
 corneal changes in, 8.174–176, 8.175t, 8.176f
 congenital/infantile opacities and, 8.107
 corneal disorders in, 6.257t, 6.270, 6.385, 6.387f, 6.388t
- Mucopyoceles, orbital invasion by, 7.95
- Mucor infection (mucormycosis/zygomycosis/phycomycosis), 5.355f, 5.355–356, 6.215, 6.215f, 8.249t, 8.251
 cornea involved in (keratitis), 4.78
 optic nerve involved in, 4.243
 orbit involved in, 4.226–227, 4.228f, 5.355, 7.50
 exenteration in management of, 7.50, 7.136
- Mucosa-associated lymphoid tissue (MALT), 4.47, 4.69, 9.55
 in allergic reactions, 9.51
 of conjunctiva (conjunctiva-associated/CALT), 2.30, 4.47, 4.69, 8.7, 9.55
 lymphoma arising in, 8.349–350, 8.350f
 in viral conjunctivitis, 9.56
- Mucosa-associated lymphoid tissue (MALT) lymphoma (MALToma/extranodal marginal zone lymphoma)
 of conjunctiva, 4.70, 4.71f, 8.349–350, 8.350f
 of orbit, 4.232, 4.233f, 7.86
- Mucosal mast cells, 9.10
- Mucous membrane grafting (transplantation), 8.351t, 8.365–366
 for cicatricial entropion, 7.207
 for contracted socket, 7.134
 for eyelid retraction, 7.224
 indications for, 8.351t, 8.366
 for mucous membrane pemphigoid, 8.303, 8.366
 for symblepharon, 7.208
- Mucous membrane (ocular cicatricial) pemphigoid (MMP), 4.53–55, 4.54f, 8.285, 8.299–303, 8.300f, 8.301f, 8.301t, 8.302t
 cataract surgery in patient with, 11.173
 drug-induced (pseudopemphigoid), 8.91, 8.92, 8.299
 mucous membrane grafting for, 8.303, 8.366
 staging of, 8.299–300, 8.300f, 8.302, 8.302t
- Mucus, tear film, 8.5
- Mucus excess, conjunctival, 8.46t
- Mucus-fishing syndrome, 8.89
- MUGA. *See* Multiple gated acquisition
- Muir-Torre syndrome, 7.170
 eyelid manifestations of, 4.210t, 4.215, 4.216f
- Mulberry lesions (astrocytic hamartomas), 4.295, 4.296f, 5.108f, 5.143
- Müller cells/fibers
 defect of, 12.162
 footplates of, 12.15, 12.15f, 12.326
 optic nerve, 2.86, 2.88f
 outer extent of, 12.15
 retinal, 2.71f, 2.73, 2.258f, 2.266, 2.268, 5.24
 in healing/repair, 4.17
 retinoschisis and, 12.279
- Müller muscle (superior tarsal muscle), 2.20f, 2.24, 4.202, 7.146f, 7.149, 7.151, 8.3, 8.4f
 eyelid control and, 8.3, 8.4f
 in Horner syndrome, 5.257, 7.215
 innervation of, 5.53, 5.53f, 5.54
 internal (transconjunctival) resection of, for ptosis correction, 7.220, 7.220f
 anophthalmic socket and, 7.135
- Müller muscle–conjunctival resections (MMCRs), for ptosis repair, 7.220, 7.220f
- Multi-Ethnic Study of Atherosclerosis (MESA), 12.62
- Multi-lenslet array, 3.291f
- Multicentric basal cell carcinoma, 7.179. *See also* Basal cell carcinoma
- Multidrug-resistant tuberculosis (MDRTB), 1.255, 1.269, 9.254
- Multifactorial/polygenic inheritance, 2.140, 2.141, 2.200–201
- Multifocal ablation, for presbyopia, 13.167, 13.168f
- Multifocal choroiditis (MFC), 6.319, 9.72t, 9.154–155, 12.220t, 12.225–226, 12.226f
 in HIV infection/AIDS
Cryptococcus neoformans causing, 9.298–299
 systemic dissemination and, 9.298–299
 in Lyme disease, 9.245
 with panuveitis (MCP/MFCPU), 9.141–143t, 9.154–158, 9.155f, 9.157f
 serpiginoid/serpiginous-like (tuberculosis-associated), 9.154, 9.252, 9.252f
 in SLE, 9.134, 9.134f
- Multifocal electroretinogram (mfERG), 5.96f, 5.96–97, 12.45, 12.48–49f
 in acute zonal occult outer retinopathy, 9.165
 in melanoma-associated retinopathy, 5.102–103
 in multiple evanescent white dot syndrome, 5.101, 9.162
- Multifocal eosinophilic granuloma, 6.219, 7.90
- Multifocal lenses
 bifocal
 accommodative amplitude for, 3.178–179
 add power of, 3.178–180
 fused, 3.180
 image displacement, 3.184, 3.186f
 image jump, 3.184–186, 3.187f

- induced anisophoria, compensating for, 3.186–190, 3.187*f*
- lens design of, 3.190
- plastic molded, 3.180
- Prentice rule and, 3.184–190, 3.185–189*f*
- prismatic effects of, 3.184, 3.185*f*
- round segment, 3.180, 3.181*f*
- types of, 3.180, 3.181*f*
- definition of, 3.178
- intraocular (MFIOLs), 11.121*f*, 11.121–122, 13.8*t*, 13.155–156, 13.165–167, 13.166*f*
 - adverse effects of/complications/patient dissatisfaction and, 11.151, 13.156, 13.167
 - annular zones, 3.259, 3.259*f*
 - apodized diffractive, 13.166, 13.166*f*
 - best-corrected visual acuity with, 3.260
 - bifocal, 3.258–259, 3.259*f*
 - bilateral implantation of, 13.155
 - capsular decentration and, 11.183
 - clinical results of, 3.260–261
 - decentration effects on, 3.258
 - description of, 3.257–258
 - diffractive, 3.259*f*, 3.259–260, 13.166, 13.166*f*
 - disadvantages of, 3.258
 - dry eye therapy before use of, 11.173
 - extended-depth-of-focus lenses versus, 3.262–263, 3.263*f*
 - indications for, 3.258
 - multiple-zone, 3.259, 3.259*f*
 - outcomes of, 13.155–156
 - patient selection for, 3.260, 13.155, 13.166–167
 - power calculation for, 3.258
 - for presbyopia, 13.165–167, 13.166*f*
 - refractive, 13.166, 13.166*f*
 - surgical technique for insertion of, 13.155
 - three-zone, 3.259, 3.259*f*
 - types of, 3.258–260
 - zonal refractive, 13.166, 13.166*f*
- progressive addition, 3.182–184, 3.183*f*
- trifocal, 3.180–182
- Multifocal stromal infiltrates, 8.50
- Multigene disorder (complex genetic disorder), 2.133, 2.200–201
- Multinucleated giant cells, 4.7, 4.9*f*
 - in focal posttraumatic choroidal granulomatous inflammation, 4.22*f*
 - in granulomatous conjunctivitis, 4.52, 4.52*f*
 - in sarcoidosis, 4.187, 4.187*f*
- Multiplanar incisions, clear corneal, 11.106, 11.106*f*
- Multiple endocrine neoplasia (MEN), 1.56, 1.58–59, 1.59*f*, 1.229, 8.200
 - conjunctival neurogenic/smooth muscle tumors in, 8.345
 - corneal nerve enlargement in, 8.200, 8.200*t*
- Multiple evanescent white dot syndrome (MEWDS), 5.101, 9.140, 9.141–143*t*, 9.161*f*, 9.161–163, 9.162*f*, 9.163*f*, 12.220*t*, 12.223–224, 12.224*f*
 - fundus autofluorescence in identification of, 5.90
 - OCT in identification of, 5.92, 5.101
- Multiple gated acquisition (MUGA), in ischemic heart disease, 1.98
- Multiple myeloma, crystalline corneal deposits and, 8.198, 8.198*f*
- Multiple sclerosis (MS), 5.315–320, 5.316*f*
 - chiasmal/retrochiasmal abnormalities in, 5.318
 - course and prognosis of, 5.315
 - diagnosis of, 5.319
 - epidemiology and genetics of, 5.315
 - fundusoscopic abnormalities in, 5.318
 - HLA association in, 5.315, 9.67*t*, 9.132
 - intermediate uveitis associated with, 12.231
 - laboratory evaluation of, 5.319
 - neuro-ophthalmic signs of, 5.315–320, 5.316*f*
 - neuroimaging in, 5.65, 5.72*t*, 5.92, 5.316*f*, 5.319
 - nonocular symptoms of, 5.317
 - ocular motility disturbances in, 5.246, 5.248, 5.249, 5.318–319
 - optic nerve conduction delay in, 12.52
 - optic nerve involvement and, 5.107*t*, 5.114, 5.114*f*, 5.115, 5.116, 5.317–318
 - pathology in, 5.315–316, 5.316*f*
 - presentation of, 5.316–317
 - progressive, 5.315
 - relapsing-remitting course of, 5.315
 - treatment of, 5.319–320, 5.321*t*
 - uveitis in, 5.318, 9.129, 9.132
- Multiple sulfatase deficiency, 8.177
- Multiple-zone multifocal intraocular lens, 3.259, 3.259*f*
- Multiplex ligation-dependent probe amplification (MLPA), 4.39*t*
- Multipurpose solutions, for contact lens, 3.229*t*, 3.230
- Multizone keratectomies, 13.30, 13.30*f*
- Mumps virus, 8.239, 8.240*t*
 - immunization against, 1.218*t*, 1.221
 - ocular infection caused by, 8.208*t*, 8.239, 8.240, 8.240*t*
- Münchhausen syndrome, 5.299
- Munnerlyn formula, 3.279, 13.29
- Munson sign, 8.163, 8.163*f*
- Mural cells, retinal blood vessel, 2.73
- Muro 128. *See* Sodium chloride
- Muscarine, 2.308, 2.308*t*
- Muscarinic agents, 2.308*t*, 2.311*t*
 - adverse effects of, 2.311, 2.313–314
 - agonists, 2.308*t*
 - direct-acting, 2.308–312, 2.310*f*, 2.311*t*
 - indirect-acting, 2.312–313
 - antagonists, 2.308*t*, 2.313–314, 2.314*t*, 2.315*t*
 - adverse effects of, 2.313–314
- Muscarinic receptors, 2.308, 2.308*t*
 - drugs affecting, 2.308*t*, 2.311*t*, 2.315*t*. *See also* Muscarinic agents
 - signal transduction and, 2.316*t*
 - in tear secretion, 2.218, 2.218*f*
- Muscle cone, 6.26, 6.26*f*
- Muscle of Riolan, 2.21, 7.149, 7.153, 7.154*f*
- Muscle relaxants, for benign essential blepharospasm, 7.228
- Muscle-specific kinase (MuSK) antibodies, in myasthenia gravis, 5.325–326
- Muscle-weakening procedures. *See* Weakening procedures
- Muscles. *See* Extraocular muscles; *specific muscle*
- Muscular arteries, inferior/superior, 5.14–15, 5.15*f*
- MuSK antibodies. *See* Muscle-specific kinase (MuSK) antibodies

- Mustardé flap/procedure, for eyelid repair, 7.194f, 7.195
- Mutagens, 2.194
- Mutamycin. *See* Mitomycin/mitomycin C
- Mutation, 2.140, 2.155–157, 2.193–196. *See also specific type*
- base pair, 2.155, 2.156
 - conserved, 2.156
 - cancer and, 1.227–228
 - carrier of, 2.132, 2.176, 2.197–200
 - identification of, 2.205, 2.206
 - ocular findings in, 2.198–199f, 2.198–200, 2.199t
 - dominant negative, 2.134
 - frameshift (framing error/frameshift), 2.135, 2.155
 - gain/loss of function, 2.156
 - missense, 2.140, 2.155
 - of mitochondrial DNA, 2.157
 - nonsense, 2.140, 2.155
 - of mitochondrial DNA, 2.157
 - null, 2.155
 - point, 2.193
 - mitochondrial DNA, 2.157
 - screening for, 2.161, 2.163f, 2.164f, 2.165f, 2.166f
 - polymorphism and, 2.155, 2.156, 2.194
 - repair and, 2.154
 - screening for, 2.161–167, 2.162f, 2.163f, 2.164f, 2.165f, 2.166f, 2.167f, 2.168f
- Mutton-fat keratic precipitates, 8.52, 9.80f, 9.82. *See also*
- Keratic precipitates
 - in sarcoidosis, 9.80f, 9.168, 9.168f
 - in sympathetic ophthalmia, 4.185, 9.172
 - in uveitis, 9.80f, 9.82
 - in Vogt-Koyanagi-Harada syndrome, 9.177
- Myasthenia gravis (MG), 2.315, 5.323–326, 5.325f, 6.142f, 6.142–143, 6.143t, 7.216–217
- clinical presentation of, 5.324
 - diagnosis of, 2.301, 2.315, 5.324–326, 5.325f
 - edrophonium in, 1.305, 2.301, 2.315, 5.324–325, 7.217
 - extraocular motor dysfunction/diplopia in, 5.192, 5.206, 5.324
 - neuro-ophthalmic signs of, 5.323–326, 5.325f
 - pseudo-internuclear ophthalmoplegia caused by, 5.190, 5.324
 - ptosis in, 5.206, 5.270f, 5.271, 5.273, 5.273t, 5.324, 7.209, 7.212, 7.216–217
 - saccadic dysfunction in, 5.221–222
 - thyroid eye disease and, 7.56
 - treatment of, 5.326
- Mycelium, 8.249
- MYCN oncogene, in retinoblastoma, 4.173, 4.290
- Mycobacterium* (mycobacteria), 1.253–255, 8.244t, 8.248, 8.272–273, 8.273f
- avium/avium-intracellulare*, 1.269, 5.350
 - chelonei*, 8.248, 8.272
 - fortuitum*, 8.248, 8.272
 - in HIV infection/AIDS, 1.269
 - kansasii*, 1.269
 - keratitis caused by, after photoablation, 13.106, 13.119
 - leprae*, 6.240, 8.248
 - neuro-ophthalmic signs of infection with, 5.350
 - nontuberculous (atypical) infection caused by, 1.254, 1.269, 8.248, 8.272–273, 8.273f
 - ocular infection/inflammation caused by, 8.248, 8.272–273, 8.273f
 - therapy for, 8.270t
 - stains and culture media for identification of, 8.209t, 8.273
 - tuberculosis*, 1.215, 1.253–254, 1.254–255, 1.269, 5.350, 6.240, 8.248, 9.250, 12.240. *See also* Tuberculosis
 - immune response to, 9.31–32
 - phlyctenulosis associated with, 8.75
 - screening/testing for, 1.215–216, 9.32, 9.253–254
- Mycology, 8.208t, 8.249–251. *See also* Fungi
- Mycophenolate mofetil, 1.176, 9.103–104
- for Behçet disease, 9.188–189
 - for corneal graft rejection prophylaxis, 8.430
 - for uveitis, 6.322, 9.103–104
- Mycoplasma pneumoniae*, 1.253
- Mycotic (fungal) keratitis, 4.78, 4.78f, 8.208t, 8.273–276, 8.274f
- after photoablation, 13.106–107
 - plant/vegetable materials and, 4.78, 8.273, 8.387, 8.399
- Mydfrin. *See* Phenylephrine
- Mydral. *See* Tropicamide
- Mydriacyl. *See* Tropicamide
- Mydriasis/mydriatics, 2.314t
- adrenergic agents, 2.314t, 2.317–318
 - angle closure caused by, 10.122, 10.123
 - benign episodic, 5.267
 - after cataract surgery, 11.138
 - congenital, 6.268
 - in Horner syndrome, 5.259
 - for Lyme disease, 9.246
 - multifocal IOLs and, 13.156
 - muscarinic antagonists, 2.313–314, 2.314t
 - pharmacologic, 5.263
 - seizures and, 1.203
 - SSRIs and, 1.196
 - traumatic, 5.262
 - traumatic injury and, 8.388, 8.389f
 - for uveitis, 9.94
- Myectomy, 6.164t
- for benign essential blepharospasm, 5.283, 7.228
- Myelin sheaths, 6.44
- Myelinated retinal nerve fibers, 4.143, 6.365, 6.365f
- Myelination
- of nerve fiber layer, optic nerve/nerve head/disc
 - edema differentiated from, 5.107–109, 5.108f
 - of optic nerve, 5.26
- Myelitis, with optic neuritis (neuromyelitis optica/NMO/Devic disease), 5.107t, 5.116–118, 5.117t, 5.320–323
- Myelogenous leukemia, orbital involvement and, 7.99
- Myelohyoid muscle, 7.143
- Myeloid stem cells, 1.135
- Myeloma, crystalline corneal deposits and, 8.198, 8.198f
- Myeloperoxidase autoantibodies (MPO-ANCA)
- in granulomatosis with polyangiitis (Wegener granulomatosis), 7.62
 - in microscopic polyangiitis, 1.168
- Myeloproliferative disorders, hypercoagulability and, 1.148

- MYOC* (*TIGR/myocilin* [*TIGR/MYOC*]) gene, 2.200, 10.10, 10.11*t*, 10.150
 in pediatric glaucoma, 8.108
- Myocardial contractility, 1.109
 enhancement of, in heart failure management, 1.110
 reduction of, in angina management, 1.99
- Myocardial infarction (MI), 1.93, 1.94–95. *See also*
 Acute coronary syndrome; Ischemic heart disease
 definition of, 1.93
 in diabetes mellitus, 1.49
 ECG changes in, 1.93, 1.94, 1.96
 heart failure and, 1.94, 1.108
 hypertension management and, 1.69*t*, 1.75
 management of, 1.100*t*
 cardiac-specific troponins and, 1.93, 1.96
 percutaneous coronary intervention for, 1.91
 painless/asymptomatic, 1.94, 1.95
 pericarditis after (post-MI pericarditis), 1.94
 stroke and, 1.120
 ventricular fibrillation and, 1.96, 1.115
- Myocardial oxygen demand
 in high-output failure, 1.108
 reduction of
 for angina, 1.99
 for non–ST-segment elevation acute coronary syndrome, 1.103
- Myocardial scintigraphy, thallium-201, 1.97–98
- Myocarditis, heart failure and, 1.108
- Myocilin gene (*TIGR/myocilin*/*TIGR/MYOC*) gene, 2.200, 10.10, 10.11*t*, 10.150
 in pediatric glaucoma, 8.108
- Myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial DNA mutations and, 2.157
- Myoclonus
 oculopalatal, pendular nystagmus and, 5.246–247
 opsoclonus and, 5.249
 voluntary nystagmus and, 5.250
- Myoepithelial cells, 5.54
 iris, 2.55, 2.56*f*
 lacrimal gland, 2.28, 2.28*f*
- Myofibromas, 6.222
- Myogenic ptosis, 5.273*t*, 7.213*f*, 7.213–214, 7.214*t*
- Myoglobin
 in immunohistochemistry, 4.33
 serum, in acute coronary syndrome, 1.96–97
- Myoid, 12.12
 photoreceptor
 of cone, 2.70, 2.72*f*
 of rod, 2.69, 2.72*f*
- Myoid zone, 4.141*f*
- Myokymia
 eyelid, 5.282*t*, 5.284
 facial, 5.282*t*, 5.284
 superior oblique (SOM), 5.250–251, 6.145
- Myopathies
 diplopia caused by, 5.206–209, 5.207*f*
 extraocular
 inherited conditions causing, 5.328–330, 5.329*f*
 in thyroid eye disease, 4.226, 4.227*f*, 5.206, 7.25, 7.52, 7.54, 7.54*f*, 7.56
 mitochondrial, with encephalopathy, lactic acidosis, and strokelike episodes (MELAS), 5.294–295
 migrainelike headache and, 5.294–295
 mitochondrial DNA mutations and, 2.157, 2.159
- Myopia
 accommodative demand, 3.208
 with achromatopsia, racial and ethnic concentration of, 2.197
 in adolescents, 3.142
 adult-onset, 3.143
 Bruch membrane affected in, 2.61
 cataract causing, 11.43, 11.70, 11.70*t*
 cataract surgery in patient with, 11.184–185
 retinal detachment and, 11.166
 in children, 3.142, 3.174
 congenital, 3.174
 congenital stationary night blindness with, ocular findings in carriers of, 2.199*t*
 consecutive, 13.101–102
 contact lenses for, orthokeratology and, 13.70–71
 definition of, 3.4, 3.124
 description of, 3.12–13, 3.137
 developmental, 3.142–143, 3.174
 diverging lens for, 3.170, 3.170*f*
 educational achievement and, 3.143
 etiology of, 3.143
 genetic factors, 3.143
 glaucoma and, 10.9, 10.29, 10.82, 10.87, 10.122
 high. *See* High (pathologic) myopia
 historical treatments for, 12.208
 hyperopia overcorrection and, 13.101–102
 conductive keratoplasty for, 13.129
 instrument, 3.282, 3.286
 juvenile-onset, 3.142
 keratorefractive surgery for, 3.275
 lenticular (myopic shift), 11.43, 11.70
 megalocornea and, 8.100
 model of, 3.12–13, 3.13*f*
 muscarinic agents causing, 2.311
 night, spherical aberrations and, 13.12, 13.102
 orthokeratology for correction of, 13.70–71
 pathologic. *See* High (pathologic) myopia
 photorefractive keratectomy for, 3.271, 3.271*f*
 pictorial representation of, 3.137*f*
 positive defocus caused by, 3.276
 prevalence of, 6.180
 prismatic effects of bifocal lenses in, 3.185*f*
 progression of, methods for reducing, 3.144
 residual
 after intrastromal corneal ring segment placement, 13.65
 after LASIK, intrastromal corneal ring segments for, 13.70
 retinal detachment and, 13.44, 13.183–184, 13.184, 13.197
 retinal reflex in, 3.152, 3.152*f*
 in retinopathy of prematurity, 6.334
 spectacle lenses for, 3.211, 3.212*f*
 squinting by persons with, 3.130
 surgical correction of, 13.30, 13.30*f*. *See also specific procedure*
 aberrations after, 13.11, 13.12
 bioptics for, 13.137, 13.157
 corneal curvature flattening and, 13.26, 13.51, 13.80
 examination before, 13.40

- hyperopia after (consecutive hyperopia), 13.101–102
 incisional corneal surgery for, 13.49–53, 13.50f, 13.51f
 intraocular pressure measurement and, 13.181, 13.182f
 intrastromal corneal ring segments for, 13.62, 13.62f, 13.63, 13.63f, 13.64–65
 LASIK for, 13.95, 13.97. *See also* LASIK
 light-adjustable IOLs for, 13.153–154, 13.154f
 monovision for, 13.164, 13.165
 nonlaser, 13.8t
 overcorrection and, 13.101–102
 phakic IOLs for, 13.137, 13.138, 13.140
 photoablation for, 13.74f
 outcomes of, 13.95–96
 photorefractive keratectomy for, 13.95
 radial keratotomy for, 13.49–53, 13.50f, 13.51f
 See also Radial keratotomy
 refractive lens exchange for, 13.148, 13.150
 retinal detachment/retinal detachment repair and, 13.44, 13.183–184, 13.184, 13.197
 small-incision lenticule extraction for, 13.204
 wavefront-optimized/wavefront-guided laser ablation for, 13.31
 outcomes of, 13.31–32, 13.97
 topiramate as cause of, 12.305
 vitreous changes and, 2.252, 2.253
 wavefront aberration produced by (positive defocus), 13.11, 13.11f
 wavefronts in, 3.73, 3.73f
 Myopic astigmatism, 3.138, 3.138f
 Myopic keratomileusis, 13.8t. *See also* LASIK
 Myopic macular schisis, 12.209, 12.210f
 Myopic shift, in cataracts (lenticular myopia), 11.43, 11.70
 Myorhythmia, oculomastatory, 5.251
 Myosin, in retinal pigment epithelium, 2.273
 Myosin/*myosin VIIA* gene mutation, 2.264
 Myositis, orbital, 4.224, 4.225f, 5.207f, 5.207–208
 nonspecific orbital inflammation and, 4.225, 4.225f, 7.63–64
 Myotomy, 6.164t
 Myotonic dystrophy, 5.329–330, 12.282t
 lens disorders/cataracts in, 11.62, 11.62f
 ptosis in, 5.273, 5.273t, 5.329, 5.330
 Myxedema, 1.54
 pretibial (infiltrative dermatopathy), hyperthyroidism/thyroid eye disease and, 1.53, 7.56
 “Myxedema coma,” 1.54
 “Myxedema psychosis,” 1.54
 MZM. *See* Methazolamide
- N**
- N95, 12.45
N-MYC gene, in retinoblastoma, 4.173, 4.290
 Na. *See* Sodium
 Na⁺,K⁺-ATPase (sodium-potassium pump)
 in aqueous humor secretion/suppression, 2.230, 2.323, 10.16–17
 cold affecting, 8.385
 corneal hydration and, 8.9
 in Fuchs endothelial corneal dystrophy, 8.156
 in lens active transport, 11.21
 pump-leak theory and, 11.21, 11.22f
 in lens ionic balance, 2.246
 in retinal pigment epithelium, 2.273, 2.277
 in rods, 2.259
 Na⁺,K⁺-Ca exchanger (sodium-potassium-calcium exchanger), in rods, 2.259
 Nabumetone, 2.335t
 Nadbath block, 1.292
 Nadbath-Ellis block, for cataract surgery, 11.93f
 NADH dehydrogenase, mutation in gene for, in Leber hereditary optic neuropathy, 2.158
 Nadifloxacin, 1.277
 Nadolol, 1.68t, 1.69t
 NADP, in lens glucose/carbohydrate metabolism, 11.18f, 11.19
 NADPH
 in free-radical generation, 2.282
 in lens glucose/carbohydrate metabolism, 2.246, 11.18f, 11.19
 glutathione redox cycle and, 2.284, 2.284f
 Nafcillin, 1.275, 2.344
 Nail-patella syndrome (onycho-osteodysplasia), 8.192t
 gene for, 10.11t
 NAION. *See* Nonarteritic ischemic optic neuropathy, anterior
 Nalidixic acid, 2.346
 Naloxone, for narcotic reversal, 1.291
 Naming-meshing system, for uveitis differential diagnosis, 9.85
 Nanophthalmos, 4.108–109, 6.263
 angle-closure glaucoma and, 4.108, 4.109, 10.144
 cataract surgery in patient with, 11.185
 genetic/hereditary factors in, 10.11t
 Nanopore sequencing technology, in next-generation sequencing, 2.166f. *See also* Next-generation sequencing
 Nanotechnology, for drug delivery, 2.304
 NaOH. *See* Sodium hydroxide
 Naphazoline, 2.337, 2.338t, 2.342
 Naphazoline/antazoline, 2.338t
 Naphazoline/pheniramine, 2.337, 2.338t
 Naphcon-A. *See* Naphazoline/pheniramine
 Naproxen, 1.111, 2.335t
 ocular effects of, 1.307t
 Narcolepsy, in neuromyelitis optica spectrum disorder, 5.117t
 NARP (neuropathy [neurogenic muscle weakness]/ataxia/retinitis pigmentosa) syndrome, 2.158–159
 mitochondrial DNA mutations and, 2.157, 2.158–159
 Narrow-band interference filters, 3.103, 3.104f
 Narrow complex tachycardias, 1.113
 Nasal artery, 2.26f, 2.33f, 7.16f
 Nasal bone, 7.6f
 Nasal cavity, 7.18
 Nasal chondritis, in relapsing polychondritis, 1.164
 Nasal conchae (turbinates), 7.18, 7.253f, 7.254f
 fracture of, for congenital nasolacrimal duct obstruction, 7.265
 Nasal continuous positive airway pressure (nasal CPAP), 1.132
 ophthalmic considerations and, 1.132

- Nasal endoscopy
 - for lacrimal drainage evaluation/obstruction, 7.272
 - for nasolacrimal duct obstruction, 6.235
 - for orbital decompression, 7.122
- Nasal/nasal radiating fibers, 5.25, 5.25f, 5.103, 5.104f
 - visual field defects and, 5.103, 5.106f
- Nasal fossae, 7.18
- Nasal nerve
 - dorsal, 7.17f
 - external, 7.145f
- Nasal orbital fat pad, 7.149
- Nasal retina, 5.24f, 5.25, 5.27
- Nasal septum, 7.18
- Nasal step, 5.103, 5.106f
 - in glaucoma, 10.68, 10.69f
- Nasal vein, 2.35f
- Nasalis muscles, compressor and dilator, 7.143f
- Naso-orbital/naso-orbital-ethmoidal (NOE) fractures, 7.106–107, 7.107f
 - nasolacrimal duct obstruction and, 7.278
- Nasociliary nerve, 2.9f, 2.100, 5.8f, 5.43f, 5.48, 5.48f, 5.54, 7.10f, 7.12f, 7.13f, 7.14f, 7.15f, 7.16, 7.17f
 - lacrimal functional unit innervated by, 8.5f
- Nasofrontal vein, 2.35f
- Nasolacrimal canal, 2.6, 7.8f, 7.10, 7.19
 - balloon catheter dilation of
 - for acquired nasolacrimal duct obstruction, 7.278
 - for congenital nasolacrimal duct obstruction, 7.263–265
- Nasolacrimal duct (NLD), 2.8, 2.29–30, 5.9f, 5.11, 7.10, 7.18, 7.253f, 7.254f, 7.254–255. *See also* Lacrimal drainage system
 - development of, 7.255
 - irrigation of
 - for acquired obstruction evaluation, 7.270f, 7.271
 - for congenital obstruction management, 7.261f, 7.261–262, 7.262f, 7.263f
 - obstruction of (NLDO). *See also* Tearing/epiphora
 - acquired, 7.276–281, 7.277f, 7.280f, 7.281f
 - balloon catheter dilation for, 7.278
 - dacryocystorhinostomy for, 7.278–281, 7.280f, 7.281
 - etiology of, 7.277f, 7.277–278
 - intubation and stenting for, 7.278
 - irrigation in evaluation of, 7.270f, 7.271
 - probing in evaluation of, 7.271–272
 - congenital, 7.255, 7.259, 7.260–265, 7.261f, 7.262f, 7.263f, 7.264f
 - antibiotics for, 6.231–232, 6.234
 - balloon catheter dilation (balloon dacryoplasty) for, 6.234–235, 6.235f, 7.263–265
 - bilateral, 6.232f
 - clinical features of, 6.230, 6.232f
 - complex, 6.230, 6.233–234
 - dacryocystorhinostomy for, 7.265
 - description of, 6.227, 6.230
 - examination of, 6.230
 - infantile glaucoma versus, 6.230
 - intubation for, 6.234–235, 7.262–263, 7.264f
 - irrigation for, 7.261f, 7.261–262, 7.262f, 7.263f
 - lacrimal/lacrimal–cutaneous fistula and, 7.258
 - massage for, 6.231–232
 - nasolacrimal probing for, 6.232–235, 6.233f
 - nonsurgical management of, 6.231–232
 - prevalence of, 6.230
 - probing for, 7.260, 7.261f, 7.261–262, 7.262f, 7.263f
 - recurrence of, 6.234
 - simple, 6.230, 6.231f
 - spontaneous resolution of, 6.231
 - stents for, 6.234–235
 - surgical management of, 6.232–233
 - tearing caused by, 6.230
 - turbinate infraction for, 7.265
 - dacryocystitis and, 7.260, 7.285, 7.286
 - dacryocystorhinostomy for, 6.236
 - functional, 7.271
 - management of, 7.259, 7.278–281, 7.280f, 7.281f
 - nasal endoscopy for, 6.235
 - in older children, 6.235
 - primary congenital glaucoma differentiated from, 10.152, 10.152f
 - recurrent, 6.234
- occlusion of, ocular medication absorption and, 2.296, 2.296f, 10.184–185
 - in children, 10.165
- stenosis of, 7.271
 - involutional, 7.277
 - trauma to, 7.278, 7.284
- Nasolacrimal probing, for congenital nasolacrimal duct obstruction, 6.232–235, 6.233f
- Nasolacrimal procedures, endocarditis prophylaxis and, 1.243t
- Nasopharyngeal carcinoma, Epstein-Barr virus
 - associated with, 1.228, 1.260
- Natacyn. *See* Natamycin
- Natalizumab, for multiple sclerosis, 5.318, 5.321t
 - progressive multifocal leukoencephalopathy caused by, 5.318, 5.351
- Natamycin, 2.354, 2.355t
 - for *Acanthamoeba* keratitis, 2.361
 - for fungal keratitis, 8.275
- Nateglinide, for diabetes mellitus, 1.45t, 1.46
- National Cholesterol Education Program (NCEP), 1.81
- National Elder Abuse Incidence Study, 1.179
- National Eye Institute (NEI) classification of eye movement abnormalities, 6.147
- National Eye Institute Visual Function Questionnaire (NEI-VFQ), 11.71
- National Institutes of Health Stroke Scale, 1.121
- National Registry of Drug-Induced Ocular Side Effects, 1.306
- Natowicz syndrome (MPS IX), 8.175t
- Natriuretic peptides
 - in aqueous humor, 2.231, 2.234
 - in heart failure, 1.105, 1.109
- Natural (innate) immunity, 9.9, 9.12–13, 9.13–21, 9.14t. *See also* Innate immune response/innate immunity
- Natural killer (NK) cells, 9.34, 9.39, 9.49
 - in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
 - in viral conjunctivitis, 9.56
- Natural regulatory T (nTreg) cells, in external eye defense, 8.12–13f

- Nausea and vomiting
 fluorescein angiography as cause of, 12.36
 postoperative, management of, 1.290
- NBX. *See* Necrobiotic xanthogranuloma
- NCAM-140, in retinal pigment epithelium, 2.273
- NCEP (US National Cholesterol Education Program), 1.81
- NCLs. *See* Neuronal ceroid lipofuscinoses
- ND-1/ND-4/ND-6 genes, in Leber hereditary optic neuropathy, 2.158
- NDP gene
 description of, 6.347
 in Norrie disease/familial exudative vitreoretinopathy, 2.183
- Nd:YAG laser therapy, 3.112, 3.115. *See also* Lasers
 capsulotomy, 6.302, 11.154f, 11.154–157, 11.156f
 for anterior capsule fibrosis and phimosis, 11.154, 11.154f, 11.154–157, 11.156f
 for capsular block syndrome, 11.149
 for capsule opacification, 11.152, 11.153, 11.154, 11.154f, 11.154–157, 11.156f
 multifocal IOLs and, 13.156, 13.167
 in uveitis, 9.284
 complications of, 11.156–157
 contraindications for, 11.155
 indications for, 11.154–155
 lens particle glaucoma and, 11.67
 procedure for, 11.155–156, 11.156f
 retinal detachment and, 11.157, 11.166
- for cyclodestruction, 10.194, 10.195
 in children, 10.163, 10.164
- cystoid macular edema treated with, 12.159
- endophthalmitis caused by, 9.262
- for iridotomy, 10.192, 10.193
- for iris bombé in uveitis, 9.286
- mechanism of, 12.367
- ocular injury caused by, 12.367
- photolysis, 11.125
- for trabeculoplasty (selective), 10.188, 10.189, 10.190, 10.190f
- vitreolysis
 for cystoid macular edema, after cataract surgery, 11.165
 for vitreous prolapse in anterior chamber, 11.143
- “Near clear” incision, for cataract surgery, 11.107
- Near fixation, 6.64
- Near-infrared fundus autofluorescence, 12.32–33
- Near periphery, 12.9
- Near-point chart, phoropter with, 3.37f
- Near point of accommodation
 definition of, 3.140
 measurement of, 3.179
 pupil size effects on, 3.130
- Near point of convergence (NPC), 5.226, 6.71
 in convergence insufficiency, 5.227
- Near reflex, 2.96
 convergence and, 2.96
 pathways for, 2.96
 spasm of, 5.227, 5.309–310, 6.94
- Near response, in pupillary examination, 5.254
 light–near dissociation and, 5.254, 5.266f, 5.266–267
- Near synkinesis, 6.39
- Near triad, 6.39
- Near vision
 distance vision versus, in amblyopia, 3.25
 multifocal intraocular lenses for, 3.258
 refraction at, 3.36–38
- Near visual acuity. *See also* Visual acuity
 age-related loss of, 11.23. *See also* Presbyopia
 testing
 indications for, 3.24
 in low vision, 5.78
 before refractive surgery, 13.39
- Nebivolol, 1.68t, 1.72
- Neck
 anatomy of, 7.143
 rejuvenation surgery on, 7.245f, 7.245–247, 7.246f
 liposuction, 7.246
 platysmaplasty, 7.246f, 7.246–247
- Necrobiotic granuloma
 in episcleritis, 4.109
 in scleritis, 4.110, 4.110f
- Necrobiotic granulomatous inflammatory infiltrate, in episcleritis, 4.109
- Necrobiotic xanthogranuloma (NBX), 7.90, 7.91, 8.347
- Necrotizing encephalopathy, Leigh (Leigh syndrome), 2.159, 2.175t
 mitochondrial DNA mutations and, 2.159
- Necrotizing fasciitis, of orbit, 7.48–49
- Necrotizing retinitis/retinopathy, herpetic, 4.145, 9.193–198, 9.194f, 9.194t, 9.195f, 9.295–296, 9.296f, 12.236–237f, 12.236–237, 12.238t
- Necrotizing retinochoroiditis, 12.243
- Necrotizing scleritis, 4.110, 4.110f, 8.46t, 8.320t, 8.320–322, 8.321f, 8.322f, 8.325f, 9.111, 9.259, 9.260, 9.260f
 with inflammation, 8.320t, 8.320–321, 8.321f
 without inflammation (scleromalacia perforans), 4.110, 8.320t, 8.321–322, 8.322f
 surgically induced (SINS), 8.282
- Necrotizing stromal keratitis, 8.52
 herpes simplex causing, 8.219, 8.220–221, 8.221f, 8.222, 8.223t
- Nedocromil, 2.338t, 2.339
- Needle perforation/penetration injuries, of globe, 12.358, 12.395f, 12.395–396
- Needle sticks, HIV transmission by, 1.265
- Negative angle kappa, 6.67, 6.68f
- Negative defocus, 3.276, 13.11
- Negative dysphotopsias, 3.255–256
 IOLs and, 5.174, 11.150–151
- Negative lenses. *See* Concave (minus/negative) lenses
- Negative numbers, in vergence equation, 3.10
- Negative predictive value (NPV), of screening/
 diagnostic test, 1.15, 1.16
 pretest probability of disease and, 1.19t
- Negative staining (fluorescein), 8.36
- Neglect, elder, 1.179–180
- NEI classification of eye movement abnormalities, 6.147
- NEI-VFQ (National Eye Institute Visual Function Questionnaire), 11.71
- Neisseria*, 1.245–247, 8.244t, 8.245
gonorrhoeae (gonococcus), 1.246–247, 6.238f, 6.238–239, 8.207, 8.208t, 8.245, 8.246f
 conjunctivitis/hyperacute conjunctivitis caused by, 8.208t, 8.245, 8.257t, 8.258–260, 8.259f, 8.260t
 in neonates, 8.257t, 8.258, 8.264

- invasive capability of, 8.207
- resistant strains of, 1.246–247, 8.259, 8.264
- meningitidis* (meningococcus), 1.245–246, 6.238, 8.207, 8.245
- conjunctivitis caused by, 8.257*t*
- endogenous endophthalmitis caused by, 9.264
- immunization against, 1.224, 1.246
- invasive capability of, 8.207
- Nematodes, diffuse unilateral subacute neuroretinitis caused by, 9.232, 9.233*f*
- Neo-Synephrine. *See* Phenylephrine
- Neodymium:yttrium-aluminum-garnet laser. *See* Nd:YAG laser
- Neofrin. *See* Phenylephrine
- Neomycin, 2.351
 - for *Acanthamoeba* keratitis, 2.361
 - in combination preparations, 2.347*t*, 2.348*t*
- Neonatal adrenoleukodystrophy, 12.283*t*, 12.290, 12.291*f*
- Neonatal inclusion conjunctivitis, 6.238
- Neonates. *See also* Infants
 - CMV retinitis in, 9.198, 9.199, 9.200
 - conjunctivitis in, 8.257*t*, 8.263–265. *See also* Ophthalmia, neonatorum
 - corneal transplantation in, 8.450–451
 - drug toxicity in, 2.294
 - hemorrhagic disease of newborn in, 1.145
 - herpes simplex infection in, 1.258, 8.213
 - normal ocular flora in, 8.205
 - ocular deviations in, 5.230–231
 - ocular infections in, 8.257*t*, 8.263–265. *See also specific type*
 - ophthalmia neonatorum in, 8.257*t*, 8.263–265. *See also* Ophthalmia, neonatorum
- Neoplasia, 4.10, 4.10*t*, 4.11*f*, 4.12*t*. *See also* Cancer; Intraocular tumors; Tumors; *specific type or structure*
 - classification of, 4.10*t*, 4.11*f*
 - diplopia caused by, 5.208
 - facial pain associated with, 5.298
 - masquerade syndromes and, 9.273–278, 9.274*f*, 9.275*f*
 - neuroimaging in evaluation of, 5.64*f*, 5.65*f*, 5.72*t*
 - ocular flutter/opsochonus caused by, 5.249
 - ocular surface. *See* Ocular surface, tumors of
- Neoplasms, orbital. *See also* Tumors
 - benign, 6.219–223
 - differential diagnosis of, 6.216–217
 - eyelid, 6.199–200
 - hemangiomas, 6.219–221
 - hematopoietic, 6.218–219
 - histiocytic, 6.218–219
 - Langerhans cell histiocytosis, 6.218–219
 - leukemia, 6.218
 - lymphoma, 6.218
 - lymphoproliferative, 6.218–219
 - metastatic, 6.218
 - neuroblastoma, 6.218
 - primary malignant, 6.217–218
 - rhabdomyosarcoma, 6.217*f*, 6.217–218
 - sarcomas, 6.218
 - vascular, 6.219–221, 6.220–221*f*
- Neosporin. *See* Gramacidin, with polymyxin B and neomycin
- Neostigmine, 2.309*f*, 2.312
 - myasthenia gravis applications of, 2.301, 2.315, 5.325, 5.326
- Neovascular (“wet”) exudative age-related macular degeneration, 4.154*f*, 4.164–166, 4.165*f*
 - afibercept for, 12.82–83
 - Amsler grid testing of, 12.71
 - antiangiogenic therapies for, 12.79–80
 - bevacizumab for, 12.83–85, 12.84*t*
 - choroidal neovascularization associated with, 12.71–79. *See also* Choroidal neovascularization
 - combination treatment for, 12.85
 - differential diagnosis of, 12.76, 12.79
 - intravitreal injections, 12.85
 - laser photocoagulation for, 12.79
 - low vision therapies for, 12.86
 - macular translocation surgery for, 12.85
 - management of, 12.79–86, 12.81*f*, 12.82*t*, 12.84*t*
 - pegaptanib for, 12.80
 - photodynamic therapy for, 12.79
 - polypoidal choroidal vasculopathy, 12.75
 - prevalence of, 12.61
 - ranibizumab for, 12.80–82, 12.82*t*
 - signs and symptoms of, 12.71
 - submacular hemorrhage in, 12.85, 12.385
 - surgical treatment for, 12.85–86
 - treatment effect modifiers, 12.85
 - verteporfin for, 12.79
- Neovascular glaucoma, 4.188, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*
 - iris examination in, 10.32, 10.39, 10.135*f*
 - tube shunt implantation for, 10.215
- Neovascular membrane. *See also* Choroidal neovascularization; Neovascularization
 - in age-related macular degeneration, 4.165*f*, 4.165–166
 - in ocular histoplasmosis syndrome, 9.215, 9.217–219, 9.218*f*
 - in toxoplasmosis, 9.223, 9.223*f*
- Neovascular proliferation, in proliferative diabetic retinopathy, 12.102
- Neovascularization
 - of anterior chamber angle, in glaucoma, 10.32, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*. *See also* Neovascular glaucoma
 - in Behçet disease, 9.186
 - in branch retinal vein occlusion, 4.159, 12.125, 12.128, 12.129*f*
 - in central retinal vein occlusion, 4.158, 12.125
 - in central serous chorioretinopathy, 12.194
 - choroidal. *See* Choroidal neovascularization
 - corneal
 - in atopic keratoconjunctivitis, 8.292, 8.293*f*
 - corneal transplantation and, 8.317
 - pediatric, 8.451
 - inflammation and, 8.52
 - after lamellar keratoplasty, 8.435
 - in rosacea, 8.70, 8.70*f*
 - stem cell deficiency and, 8.92, 8.93
 - in vernal keratoconjunctivitis, 8.290
 - in diabetes mellitus, 4.159, 4.160*f*. *See also* Diabetic retinopathy, proliferative
 - in Eales disease/tuberculosis, 9.253, 9.253*f*

- in glaucoma, 4.188, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*. *See also* Neovascular glaucoma
 - incisional surgery contraindicated in, 10.198
 - laser iridotomy contraindicated in, 10.191
 - tube shunt implantation and, 10.215
 - of iris (rubeosis iridis), 4.188, 4.189*f*
 - in branch retinal vein occlusion, 12.128–129, 12.129*f*
 - in central retinal artery occlusion, 12.146
 - in central retinal vein occlusion, 12.133, 12.135
 - in diabetes mellitus, 4.159, 4.160*f*, 12.107
 - glaucoma and, 4.188, 10.32, 10.39, 10.132*t*, 10.133, 10.133*f*, 10.135*f*. *See also* Neovascular glaucoma
 - in children and adolescents, 10.149*t*
 - incisional surgery contraindicated in, 10.198
 - laser iridotomy contraindicated in, 10.191
 - in radiation retinopathy, 12.170
 - in retinoblastoma, 4.174, 4.174*f*, 4.292
 - in multifocal choroiditis and panuveitis syndrome, 9.156, 9.157
 - in ocular histoplasmosis syndrome, 9.215, 9.216, 9.217, 9.218*f*
 - management of, 9.217–218
 - in ocular ischemic syndrome, 9.278, 9.279
 - optic nerve/nerve head/disc (NVD), 12.128, 12.129*f*
 - in diabetic retinopathy, papillopathy and, 5.125
 - in pars planitis, 9.128–129, 9.130, 9.131
 - peripheral, 12.232
 - peripheral retinal, 12.154*t*
 - in proliferative sickle cell retinopathy, 12.151, 12.153*f*
 - in punctate inner choroiditis, 9.158, 9.159*f*
 - pupillary reactivity disorders and, 5.255
 - retinal. *See also* Retinal disease, vascular
 - in age-related macular degeneration, 4.161*f*, 4.164–166, 4.165*f*
 - ischemia causing, 4.154, 4.156*f*
 - in retinopathy of prematurity, 12.180–181
 - sea fan, 12.151, 12.153*f*
 - in SLE, 9.134, 9.134*f*
 - stromal, inflammation and, 8.52
 - subretinal, 12.162
 - in toxoplasmosis, 9.223, 9.223*f*
 - in uveitis, 9.291–292
 - in Vogt-Koyanagi-Harada syndrome, 9.182
- Nepafenac, 2.330*t*, 2.336
- for cystoid macular edema, 9.94
- Nephritis
- lupus, 1.157, 1.158
 - tubulointerstitial, uveitis and, 9.67*t*, 9.117
- Nephroblastoma. *See* Wilms tumor
- Nephrogenic systemic fibrosis (NSF), gadolinium causing, 5.60
- Nephropathic cystinosis, 8.181
- Nephropathy, diabetic, 1.48
 - glycemic control affecting, 1.38, 1.48
- Nephrotic syndrome, diabetes mellitus and, 1.48
- Nephrotoxicity, of aminoglycosides, 1.278, 2.352
- Neptazane. *See* Methazolamide
- Nerve block
 - facial, for cataract surgery, 11.92, 11.93*f*
 - local anesthetics for, 2.363, 2.365
- Nerve endings
 - en grappe, 2.18
 - en plaque, 2.18
 - neuromuscular blocking agents affecting, 2.315
 - in scleral spur, 2.48
- Nerve fiber layer (NFL/RNFL), 2.70*f*, 2.71*f*, 2.74*f*, 2.74–75, 2.88*f*, 4.139, 4.140*f*, 4.141*f*, 5.17*f*, 5.25, 5.25*f*, 5.103, 5.104*f*, 10.42–43, 10.43*f*, 10.45*f*
 - anatomy of, 12.15
 - atrophy of, in glaucoma, 10.48, 10.52
 - cotton-wool spots, 12.122, 12.122*f*, 12.140, 12.140*f*
 - development of, 2.117*f*
 - in glaucoma, 10.48, 10.49*t*
 - diffuse/focal loss and, 10.50–52, 10.51*f*
 - hemorrhages in, 10.50, 10.51*f*
 - patterns of loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
 - gliosis of, 5.109
 - of Henle (HFL), 2.74, 2.74*f*, 4.140, 4.141*f*, 5.24
 - histology of, 12.11, 12.12*f*
 - imaging in evaluation of, 10.53–59, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
 - infarction of, 12.140. *See also* Cotton-wool spots
 - measurement of, 12.26
 - in multiple sclerosis, 5.318
 - myelination of, optic nerve/nerve head/disc edema
 - differentiated from, 5.107–109, 5.108*f*
 - optic nerve/nerve head/disc, 2.86, 2.88*f*, 10.42–43, 10.43*f*, 10.45*f*
 - blood supply of, 2.91, 2.91*f*, 2.92*f*
 - edema and, 5.82, 5.82*f*, 5.83*f*, 5.105
 - pallor of, 5.82, 5.82*f*, 5.91*f*
 - optical coherence tomography applications
 - assessment, 5.91, 5.91*f*, 5.92, 5.92*f*, 5.94, 5.94*f*
 - measurement, 12.218
- Nerve fibers, 4.140. *See also* Nerve fiber layer
 - distribution of, 10.42–43, 10.43*f*
 - myelinated, 4.143
- Nerve head sign of sickling, 12.154
- Nerve loop (Axenfeld loop), 2.44, 4.108, 4.108*f*
- Nerve of pterygoid canal, 2.101*f*, 2.104
- Nerve (neural) sheath tumors
 - conjunctival/ocular surface, 8.345
 - of orbit, 4.237–238, 4.238*f*, 4.239*f*
 - of uveal tract, 4.199, 4.200*f*
- Nerves, cranial. *See* Cranial nerves; *specific nerve*
- Nervus intermedius, 2.101*f*, 2.102*f*, 2.102–103, 2.103, 5.49, 5.51*f*, 5.55–56, 5.276–277*f*
- Netilmicin, 1.278
- Nettleship-Falls X-linked ocular albinism, 6.407
 - ocular findings in carriers of, 2.198–200, 2.199*f*
- Neural cell adhesion molecules, in retinal pigment epithelium, 2.273
- Neural crest cells, 2.111, 2.113*f*, 2.114*f*, 2.116*t*, 2.119*f*
 - ocular structures derived from, 2.111, 2.115*t*, 2.119*f*
 - cornea, 2.41, 2.120, 2.121*f*
 - optic nerve, 2.124
 - orbit and extraocular muscles, 2.124–126
 - sclera, 2.124
 - uvea, 2.122
- Neural folds, 2.113*f*
- Neural integrator/integration, 5.36, 5.37*f*, 5.38, 5.220
 - in gaze-evoked nystagmus, 5.38, 5.240
 - in saccadic eye movement, 5.220, 5.220*f*, 5.222

- Neural larvae migrans, 9.233
- Neural network, brainstem, 5.33, 5.34
- Neural/neurogenic tumors, 6.223. *See also specific type*
 conjunctival/ocular surface, 8.345
 orbital, 7.74–82
- Neural plate, 2.112f, 2.113f, 2.114f
- Neural reflex arc, immune response arc compared with, 9.32, 9.33f
- Neural retinal leucine zipper (Nrl), in retinal development, 2.122
- Neural (neuroretinal) rim, 10.48
 changes in, in glaucoma, 10.48–50, 10.49t, 10.50f
- Neural sheath tumors
 conjunctival/ocular surface, 8.345
 of orbit, 4.237–238, 4.238f, 4.239f
 of uveal tract, 4.199, 4.200f
- Neural tube, 2.111, 2.112f, 2.113f, 2.114f, 2.118f
- Neuralgia
 occipital, 5.296, 5.297
 postherpetic (PHN), 1.258, 5.280, 5.298, 8.226t, 8.227, 8.229, 8.230
 trigeminal (tic douloureux), 5.289t, 5.297
- Neuraminidase inhibitors, 1.281
- Neurectomy, facial, for benign essential blepharospasm, 7.228
- Neurilemoma (neurinoma/schwannoma)
 conjunctival/ocular surface, 7.82, 8.345
 of orbit, 4.238, 4.239f, 7.82
 of uveal tract, 4.199
 vestibular, Bruns nystagmus and, 5.243
- Neuritis
 chiasmal, 5.151–152f
 optic. *See* Optic neuritis
- Neuro-oculocutaneous syndromes. *See also* Phakoma/
 phakomatoses
 ataxia-telangiectasia, 6.393t, 6.403t, 6.403f, 6.403–404
 characteristics of, 6.392
 clinical features of, 6.393–394t
 incontinentia pigmenti, 6.393t, 6.404t, 6.404–405, 405f
 Klippel-Trénaunay syndrome (KTS), 6.406
 neurofibromatosis type 1. *See* Neurofibromatosis 1
 neurofibromatosis type 2, 6.393t, 6.397
 tuberous sclerosis, 6.393t, 6.397–399, 6.398t, 6.398f
 von Hippel-Lindau syndrome, 6.393t, 6.399–401, 6.400t, 6.400f
 Wyburn-Mason syndrome, 6.222, 6.394t, 6.405t, 6.405–406
- Neuro-ophthalmology
 anatomy in, 5.5–56
 afferent visual pathways, 5.23–31, 5.24f
 autonomic pathways, 5.52–56
 bony anatomy, 5.5–11
 efferent visual system (ocular motor pathways), 5.31–46, 5.211
 sensory and facial motor pathways, 5.47–52
 vascular anatomy, 5.11–23
 neuroimaging in, 5.57–76, 5.72t. *See also* Neuroimaging
 pregnancy and, 5.333–335
 radiation therapy complications and, 5.357–358, 5.358f
- systemic conditions and, 5.313–358
 cerebrovascular disorders, 5.335–348
 immunologic disorders, 5.313–318
 infectious disorders, 5.348–357
 inherited disorders, 5.328–333, 5.334t
- Neuroblastoma, 6.218, 6.414–415, 6.415f
 Horner syndrome and, 5.261–262, 7.98
 of orbit, 7.98, 7.98f
 paraneoplastic-induced saccadic intrusions caused by, 5.249
- Neurocognitive/neurodevelopmental disorders, cataract surgery in patient with, 11.169–170
- Neurocrisoptopathy, 4.98–99, 4.99f, 4.100f. *See also*
 Anterior segment, dysgenesis of; Axenfeld-Rieger syndrome
 Peters anomaly and, 11.31–32
- Neurocutaneous syndromes (phakomatoses), 5.330f, 5.330–333, 5.331f, 5.332f, 5.333f, 5.334t. *See also*
 Neurofibromatosis; Phakoma/phakomatoses;
specific type
- Neuroectoderm (neural ectoderm), 2.111, 2.112f
 ocular structures derived from, 2.115t
 tumors arising in, 8.338t, 8.338–345, 8.339t
- Neuroectodermal tumor, primitive (PNET),
 retinoblastoma associated with, 4.298, 4.302, 4.302t
- Neuroendocrine peptides, in aqueous humor, 2.231, 2.234
- Neurofibrillary tangles, in Alzheimer disease, 1.204–205
- Neurofibromas, 7.77f, 7.77–78, 7.78f. *See also*
 Neurofibromatosis
 acoustic, 5.330, 5.334t, 10.156
 seventh nerve (facial) palsy and, 5.279, 5.279f
 cutaneous, 5.330f
 discrete, 7.77–78
 eyelid involvement/ptosis and, 5.269, 5.269f, 5.271, 7.77f, 7.78, 7.78f
 ocular surface, 8.338t, 8.345
 of orbit, 4.237–238, 4.238f, 7.77f, 7.77–78, 7.78f
 plexiform, 7.77, 7.77f, 7.78, 7.78f, 10.30, 10.156
 eyelid involvement/ptosis and, 5.269f, 7.77f, 7.78, 7.78f
 glaucoma and, 10.30, 10.156
 of orbit, 4.238, 4.238f, 7.77, 7.77f, 7.78, 7.78f
 of uveal tract, 4.199, 4.200f
- Neurofibromatosis (NF). *See also* Neurofibromas;
 Neurofibromatosis 1; Neurofibromatosis 2
 eyelid abnormalities/ptosis caused by, 5.269f
- Neurofibromatosis 1 (NF1/von Recklinghausen), 5.330, 5.330f, 5.334t, 7.77f, 7.78, 7.78f, 10.156
 clinical features of, 6.393t
 conjunctival neurofibroma and, 8.345
 expressivity in, 2.196
 eyelid involvement/ptosis and, 5.269f, 7.77f, 7.78, 7.78f
 glaucoma and, 10.30, 10.156
 Lisch nodules associated with, 4.259, 4.260f
 manifestations of, 6.396–397
 melanocytic lesions in, 6.392, 6.395f
 neuroglial lesions in, 6.395f, 6.395–396
 optic nerve meningiomas and, 4.250
 optic pathway/optic nerve gliomas and, 4.249, 5.130, 5.334t, 7.74, 7.76, 7.78
 orbital involvement and, 4.238, 4.238f, 7.77f, 7.78, 7.78f

- plexiform neurofibromas in, 5.334*t*, 6.395*f*, 6.395–396, 7.77, 7.77*f*, 7.78, 7.78*f*, 10.30, 10.156
 eyelid involvement/ptosis and, 5.269*t*, 7.77*f*, 7.78, 7.78*f*
 sphenoid dysplasia associated with, 6.397
 uveal/choroidal involvement and, 4.199, 4.200*f*
 Neurofibromatosis 2 (NF2/bilateral acoustic/central), 5.330, 5.334*t*, 6.393*t*, 6.397, 10.156
 seventh nerve (facial) palsy and, 5.279, 5.279*f*
 Neurofibromin/neurofibromin 1, 5.334*t*
 Neurofibromin 2 (merlin), 5.334*t*
 Neurofibrovascular bundle, 6.29
 Neurogenic muscle weakness/ataxia/retinitis pigmentosa (NARP) syndrome, 2.158–159, 12.294
 mitochondrial DNA mutations and, 2.157, 2.158–159
 Neurogenic ptosis, 5.273, 5.273*t*, 7.215–217, 7.216*f*
 congenital, 5.272–273
 Neurogenic/neural tumors. *See also specific type*
 conjunctival/ocular surface, 8.345
 orbital, 7.74–82
 Neuroglia, 2.268
 Neuroglial lesions, 6.395*f*, 6.395–396
 Neuroimaging, 5.57–76, 5.72*t*. *See also specific modality*
 in aneurysm detection/evaluation, 5.69–70, 5.194*f*, 5.194–195, 5.340, 5.341*f*
 in arteriovenous malformations, 5.292*f*
 in cerebral venous thrombosis, 5.69, 5.69*f*, 5.72*t*, 5.346
 cerebral visual impairment evaluations, 6.188
 clinical principles and, 5.57–59, 5.71–73, 5.72*t*
 how to order studies and, 5.73
 interpretive errors and, 5.57
 modality selection and, 5.57, 5.71–73, 5.72*t*
 prescriptive errors and, 5.57
 what studies to order and, 5.57, 5.71–73, 5.72*t*
 when to order studies and, 5.57, 5.71
 in cranial nerve palsy, 5.70
 CT, 5.58, 5.58*f*, 5.60, 5.61*t*, 5.72*t*
 in headache evaluation, 5.287
 migraine headache and, 5.291, 5.292*f*
 metabolic and functional, 5.70
 MRI, 5.58–59*f*, 5.60–67, 5.61*t*, 5.62*f*, 5.63*t*, 5.63*f*, 5.64*f*, 5.65*f*, 5.65*t*, 5.66*f*, 5.67*f*, 5.72*t*
 in multiple sclerosis, 5.65, 5.72*t*, 5.92, 5.316*f*, 5.319
 negative studies and, 5.73–75, 5.74*f*
 in optic atrophy, 5.146
 in optic nerve glioma, 5.128*t*, 5.130
 in optic nerve/nerve head/disc drusen, 5.89, 5.90*f*, 5.141*f*, 5.142
 in optic nerve sheath meningioma, 5.128*t*
 in optic neuritis/neuromyelitis optica, 5.66*f*, 5.72*t*, 5.115, 5.322–323
 in papilledema, 5.109
 in retinoblastoma, 4.292–293
 in reversible cerebral vasoconstriction syndrome, 5.347, 5.347*f*
 in sarcoidosis, 5.327
 superior oblique muscle palsy evaluations, 6.119
 terminology used in, 5.75–76
 in traumatic optic neuropathy, 5.139*f*, 5.140
 vascular, 5.60*f*, 5.67–71, 5.68*f*, 5.72*t*
 in vertebrobasilar insufficiency, 5.337*f*, 5.338
 Neuroleptic malignant syndrome (NMS), 1.193–194
 Neuroleptics (antipsychotic drugs), 1.193*t*, 1.193–194
 atypical, 1.193, 1.193*t*
 oculogyric crisis caused by, 5.231
 ophthalmic considerations and, 1.198
 tardive dyskinesia caused by
 blepharospasm and, 5.281
 facial movements and, 5.285
 typical, 1.193, 1.193*t*
 Neurologic disorders, 1.198–206. *See also specific type*
 Alzheimer disease/dementia, 1.204–206
 in antiphospholipid antibody syndrome, 1.160
 in Behçet disease, 1.169, 9.185
 cataract surgery in patient with, 11.169–170
 cerebrovascular disease, 1.119–127
 epilepsy, 1.200–204, 1.202*t*
 in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137, 9.138
 hallucinations/illusions caused by, 5.174*t*
 in Lyme disease, 1.251, 1.252, 9.244–245, 9.246
 Parkinson disease, 1.198–200
 in polyarteritis nodosa, 1.166, 9.135–136
 in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.312, 9.273–276
 recent developments in, 1.187
 in SLE, 1.157–158, 9.133
 stroke. *See* Stroke
 in syphilis. *See* Neurosyphilis
 in Vogt-Koyanagi-Harada syndrome, 9.176
 in Whipple disease, 9.258
 Neuromas. *See also* Neurofibromas
 acoustic, 5.330, 5.334*t*, 10.156
 seventh nerve (facial) palsy and, 5.279, 5.279*f*
 conjunctival/ocular surface, 8.345
 Neuromuscular blocking agents, 1.290, 2.315, 6.174
 Neuromuscular disorders. *See also specific type*
 retinal degeneration associated with, 12.285
 Neuromuscular junction disease
 diplopia in, 5.206
 ptosis in, 5.206, 5.273*t*
 Neuromyelitis optica (NMO/Devic disease), 5.107*t*, 5.116–118, 5.117*t*, 5.320–323
 clinical presentation of, 5.320–322
 diagnosis of, 5.322–323
 treatment of, 5.323
 Neuromyelitis optica (NMO)-IgG (AQP4-IgG) antibody, 5.115, 5.117*t*, 5.118, 5.320, 5.322
 Neuromyelitis optica spectrum disorder (NMOSD), 5.115, 5.116–118, 5.117*t*, 5.322, 5.323
 Neuromyotonia, 5.202, 5.358
 Neuronal ceroid lipofuscinoses (NCLs), 6.389*t*, 12.283*t*, 12.289, 12.290*f*
 Neuritis, vestibular, peripheral vestibular dysfunction and, 5.242
 Neurons, retinal, 2.69–73, 2.72*f*, 2.73*f*
 ischemia affecting, 4.151*f*, 4.151–152, 4.152*f*
 Neuropathy
 with ataxia and retinitis pigmentosa (NARP), 2.158–159
 mitochondrial DNA mutations and, 2.157, 2.158–159
 diabetic, 1.48–49
 glycemic control affecting, 1.38

- neurotrophic keratopathy/persistent corneal defects and, 8.81, 8.81t, 8.199
- in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137, 9.138
- hereditary sensory and autonomic. *See* Familial dysautonomia
- optic. *See* Optic neuropathy
- in polyarteritis nodosa, 9.135–136
- in rheumatoid arthritis, 1.152
- Neuropeptide-processing enzymes, in aqueous humor, 2.231
- Neuropeptide Y (NPY), in tear secretion, 2.214, 2.216
- Neuropeptides, 9.28t
- Neuroretinal disorder, HIV-associated (HIV-RND), 5.348
- Neuroretinal (neural) rim, 10.48
 - changes in, in glaucoma, 10.48–50, 10.49t, 10.50f
- Neuroretinitis, 5.118f, 5.118–119, 6.369, 6.369f, 9.72t
 - cat-scratch disease causing (*Bartonella*-associated), 5.119, 9.256, 9.257f, 9.257t
 - causes of, 9.257t
 - diffuse unilateral subacute (DUSN), 9.232–234, 9.233f
 - Leber idiopathic stellate, 9.256
 - in sarcoidosis, 5.327
 - in syphilis, 9.240
 - in toxoplasmosis, 5.352, 9.223
- Neuroretinopathy, acute macular (AMN), 9.163
 - fundus autofluorescence in identification of, 5.90
 - OCT in identification of, 5.92, 5.93f
- Neurosarcoidosis, 5.327–328. *See also* Sarcoidosis
- Neurosensory retina, 2.69–75, 2.70–71f, 2.72f, 2.73f, 2.74f, 2.257–266, 2.258f, 4.139–140, 4.140f, 4.141f.
 - See also* Retina
 - anatomy of, 2.69–75, 2.70–71f, 2.72f, 2.73f, 2.74f, 2.258f, 4.139–140, 4.140f, 4.141f
 - biochemistry and metabolism of, 2.257
 - development of, 2.115, 2.116t, 2.117f, 2.119f, 2.122
 - glial elements of, 2.73
 - melanoma invading, 4.194, 4.195f
 - neuronal elements of, 2.69–73, 2.72f, 2.73f
 - ischemia affecting, 4.151f, 4.151–152, 4.152f
 - stratification of, 2.70–71f, 2.74f, 2.74–75
 - vascular elements of, 2.73–74. *See also* Retinal blood vessels
 - development of, 2.116t
- Neurosyphilis, 9.238
 - tests for, 1.248, 9.241
 - treatment of, 1.249, 9.242, 9.242t
- Neurotensin, in aqueous humor, 2.231, 2.234
- Neurotoxicity, of antiepileptic drugs, 1.202
- Neurotoxin complex, purified, 2.366
- Neurotransmitters
 - cholinergic action and, 2.307, 2.307f, 2.309f, 2.310f
 - pituitary function and, 1.56t
 - in tear secretion, 2.216, 2.217–218
- Neurotrophic keratopathy/ulcers, 8.42, 8.80–82, 8.81t, 8.82f
 - diabetic neuropathy and, 8.81, 8.81t, 8.199
 - esthesiometry in evaluation of, 8.42
 - herpetic/postherpetic eye disease and, 4.77f, 4.78, 8.80, 8.81t, 8.217–218, 8.224, 8.225, 8.227
 - after penetrating/deep anterior lamellar keratoplasty, 8.80
- Neurotrophic proteins, in aqueous humor, 2.234
- Neutral density filter effect, 6.54
- Neutrality, retinoscopy, 3.152, 3.153–154f, 3.155
- Neutrophil-derived granule products, 9.22t, 9.30
- Neutrophil elastase inhibitor, in vitreous, 2.252
- Neutrophil rolling, 9.17, 9.18f
- Neutrophils, 4.7, 9.9–10
 - in chemical injuries, 8.383
 - in external eye defense, 8.13
 - in inflammation, 4.7, 9.9–10
 - granule products of, 9.22t, 9.30
 - recruitment and activation of, 9.14t, 9.16–19, 9.18f
 - in wound healing/repair, 4.14, 4.15f
- Nevanac. *See* Nepafenac
- Nevi/nevus, 7.173–174, 7.174f
 - anterior chamber/trabecular meshwork affected by, 4.106
 - blue, 4.64, 7.175
 - of choroid, 4.191, 4.192f, 4.256–258, 4.257f, 4.267–268
 - melanoma differentiated from, 4.267–268
 - of ciliary body, 4.191, 4.256
 - compound, 7.173, 8.338t
 - of conjunctiva, 4.64
 - of eyelid, 4.219, 4.219f, 7.173
 - congenital, 4.218, 4.218f
 - conjunctival/ocular surface, 4.61–64, 4.63t, 4.64f, 4.65f, 6.250, 6.250f, 8.338t, 8.339t, 8.340f, 8.340–341
 - malignant transformation and, 4.64, 4.68
 - melanomas and, 4.64, 4.68, 8.340, 8.341, 8.343
 - dermal (intra-dermal), 4.219, 4.220f, 7.173
 - dysplastic, melanoma arising from, 1.215, 4.220, 4.262
 - of eyelid, 4.218f, 4.218–220, 4.219f, 6.200–201, 6.201f, 7.173–174, 7.174f
 - flammeus (port-wine nevus/stain/PWS), 8.345t, 8.346. *See also* Vascular malformations
 - increased episcleral venous pressure and, 10.30
 - in Sturge-Weber syndrome, 5.332f, 5.334t, 8.346, 10.30, 10.155
 - intra-dermal (dermal), 4.219, 4.220f, 7.173
 - intraepithelial (junctional), 8.338t, 8.340
 - iris, 4.106, 4.189–190, 4.190f, 4.255, 4.256f, 4.259
 - junctional, 7.173
 - of conjunctiva, 4.64
 - of eyelid, 4.219, 4.219f
 - “kissing,” 4.218, 4.218f
 - magnocellular. *See* Melanocytoma
 - melanocytic
 - of anterior chamber/trabecular meshwork, 4.106
 - congenital, 4.218, 4.218f
 - conjunctival, 4.61–64, 4.63t, 4.64f, 4.65f
 - malignant transformation of, 4.64, 4.68
 - of eyelid, 4.218f, 4.218–220, 4.219f, 7.173–174, 7.174f
 - glaucoma and, 4.106
 - malignant transformation/melanoma risk and, 4.64, 4.68, 4.218, 4.263, 4.267–268
 - of Ota (dermal/oculodermal melanocytosis), 4.63t, 4.64, 6.251, 7.175, 7.175f, 8.339, 8.339t
 - glaucoma associated with, 10.30
 - of iris, 4.259

- port-wine. *See* Nevus/nevus, flammeus
- stromal, 4.64, 8.340
- subepithelial, 4.64, 8.338*t*, 8.340
- uveal tract, 4.191, 4.192*f*
- Nervus cells, 4.218, 4.219*f*, 4.219–220, 4.220*f*, 7.172, 7.173
- tumors arising from, 4.218, 7.173–174, 7.174*f*, 8.338*t*, 8.338–345, 8.339*t*. *See also* Melanocytic tumors; Nevus/nevus; Pigmented (melanocytic) lesions
- Newborns. *See also* Infants
- CMV retinitis in, 9.198, 9.199, 9.200
- conjunctivitis in, 8.257*t*, 8.263–265. *See also* Ophthalmia, neonatorum
- corneal transplantation in, 8.450–451
- dysconjugate eye movements in, 6.185
- ectropion in, 7.156, 7.157*f*
- extraocular muscles in, 6.182
- glaucoma in, 10.147, 10.148*t*, 10.151. *See also* Glaucoma, pediatric; Primary congenital glaucoma
- hemorrhagic disease of, 1.145
- herpes simplex infection in, 1.258, 8.213
- maternal antiglaucoma agents affecting, 10.185–186
- milia in, 7.168
- normal ocular flora in, 8.205
- ocular deviations in, 5.230–231
- ocular infections in, 8.257*t*, 8.263–265. *See also specific type*
- ophthalmia neonatorum in, 8.257*t*, 8.263–265
- primary congenital glaucoma in, 10.147, 10.148*t*, 10.151. *See also* Glaucoma, pediatric; Primary congenital glaucoma
- pupils in, 6.10
- skew deviation in, 6.185
- sunsetting in, 6.185
- toxoplasmosis in, 9.221, 9.222*f*, 9.226
- visual acuity of, 6.44
- visual development in, 6.185
- Newcastle Control Score for Intermittent Exotropia, 6.100
- Newcastle disease, 8.240*t*
- Newton, Isaac
- description of, 3.94
- third law of motion, 3.293
- Next-generation gene sequencing, 6.301
- Next-generation sequencing (NGS/massively parallel DNA sequencing), 2.140, 2.142, 2.161, 2.163*f*, 2.164*f*, 2.165*f*, 2.166*f*, 4.39*t*
- NF. *See* Neurofibromatosis
- NF1. *See* Neurofibromatosis 1
- NF1 gene, 5.334*t*
- NF2. *See* Neurofibromatosis 2
- NF2 gene, 5.334*t*
- NFL. *See* Nerve fiber layer
- NGS. *See* Next-generation sequencing
- NH₃. *See* Ammonia
- NIA imaging. *See* Near-infrared fundus autofluorescence
- Nicardipine, for hypertension, 1.68*t*, 1.74
- Nicotinamide adenine dinucleotide phosphate (NADPH)
- in free-radical generation, 2.282
- in lens glucose/carbohydrate metabolism, 2.246, 11.18*f*, 11.19
- glutathione redox cycle and, 2.284, 2.284*f*
- Nicotine, 2.308, 2.308*t*, 2.315*t*. *See also* Nicotinic agents
- Nicotinic acid, 12.301
- for hypercholesterolemia/heart disease prevention, 1.85*t*, 1.87
- perioperative discontinuation of, 1.286
- Nicotinic agents, 2.308*t*, 2.314–315
- antagonists, 2.315, 2.315*t*
- indirect-acting agonists, 2.314–315
- Nicotinic receptors, 2.308, 2.308*t*
- drugs affecting, 2.308*t*, 2.314–315. *See also* Nicotinic agents
- NIDDM (non–insulin-dependent diabetes mellitus). *See* Diabetes mellitus (DM), type 2
- Nidogen-1, in vitreous, 2.249
- Niemann-Pick disease, 2.175*t*, 6.388*t*, 12.291
- racial and ethnic concentration of, 2.197
- Nifedipine, for hypertension, 1.68*t*
- Night blindness
- in choroideremia, 12.267
- congenital stationary (CSNB). *See also* Congenital stationary night blindness
- electroretinography findings in, 12.46, 12.47*f*, 12.251, 12.252*f*
- with myopia, ocular findings in carriers of, 2.199*t*
- retinitis pigmentosa versus, 12.251
- subtypes of, 12.251
- dark adaptometry evaluations, 12.58
- electroretinography evaluations, 12.46
- fundus albipunctatus, 12.252, 12.253*f*
- in gyrate atrophy, 12.268
- in vitamin A deficiency, 8.196
- Night myopia, spherical aberrations and, 13.12, 13.102
- Night vision, 3.272
- Night-vision abnormalities, 12.251–253*f*, 12.251–253. *See also* Night blindness
- after refractive/keratorefractive surgery
- contact lens use for, 13.199
- phakic IOLs
- angle-supported lenses, 13.146
- iris-fixated lenses, 13.145
- multifocal lenses, 13.156
- posterior chamber lenses, 13.146
- photoablation, 13.102
- radial keratotomy, 13.51
- spherical aberrations and, 13.12, 13.102
- 9-o'clock staining, 3.233, 3.233*f*
- Nisin, 1.280
- Nisoldipine, 1.68*t*
- Nitrates, for angina, 1.99
- Nitric oxide (NO), 9.29–30
- Nitric oxide synthase (NOS), 9.29–30
- Nitrogen mustard (mechlorethamine), 1.232*t*
- Nitrogen radicals, 9.22*t*, 9.29–30
- Nitroglycerin
- for angina, 1.99
- for hypertensive emergency, 1.74
- for non–ST-segment elevation acute coronary syndrome, 1.103

- Nitroprusside, for hypertensive emergency, 1.74
 Nitrosoureas, in cancer chemotherapy, 1.234*t*
 Nizoral. *See* Ketoconazole
 NK cells. *See* Natural killer (NK) cells
 NLD. *See* Nasolacrimal duct
 NLDO. *See* Nasolacrimal duct (NLD), obstruction of
 NLP. *See* No light perception
 NMO (neuromyelitis optica)-IgG (AQP4-IgG) antibody, 5.115, 5.117*t*, 5.118, 5.320, 5.322
 NMOSD. *See* Neuromyelitis optica spectrum disorder
 NMS. *See* Neuroleptic malignant syndrome
NNO1 gene, 10.11*t*
 NNRTIs. *See* Nonnucleoside reverse transcriptase inhibitors
 NO. *See* Nitric oxide
 No light perception (NLP) testing. *See also* Blindness
 bilateral, 5.301–302, 5.302*f*
 monocular, 5.302–305, 5.303*f*, 5.304*f*
 NO SPECS scoring system, for thyroid eye disease, 7.57
Nocardia/Nocardia asteroides (nocardiosis), 8.244*t*, 8.248, 9.249–250
 keratitis caused by
 corticosteroid treatment and, 8.271
 after photoablation, 13.106
 scleritis caused by, 9.259, 9.260*f*
 Nociceptors, in lacrimal functional unit/tear secretion, 8.5
 Nocturnal hypotension, systemic, glaucoma and, 1.77
NOD2 (CARD15) gene mutation, in familial juvenile systemic granulomatosis (Blau syndrome)/early-onset sarcoidosis, 6.319, 9.170
 Nodal points, 3.41, 3.66–67, 3.67*f*
 Nodular anterior scleritis, 8.320, 8.320*t*, 8.321*f*, 8.325*f*
 Nodular basal cell carcinoma, 4.212, 4.212*f*, 7.178, 7.178*f*. *See also* Basal cell carcinoma
 Nodular episcleritis, 4.109, 8.318, 8.318*f*
 Nodular fasciitis, 4.112, 4.113*f*, 8.347
 episcleral tumor caused by, 4.112
 Nodular melanoma, 4.220, 4.221*f*, 7.185, 7.185*f*. *See also* Melanoma
 Nodules. *See specific type*
 Nodulus, 5.39
 NOE fractures. *See* Naso-orbital/naso-orbital-ethmoidal (NOE) fractures
 Non-A, non-B hepatitis, 1.261–262
 Non-center-involved diabetic macular edema, 12.109, 12.111*f*
 Non-contact lens, indirect ophthalmoscopy using, 12.22
 Non-Hodgkin lymphoma of the central nervous system. *See* Primary vitreoretinal lymphoma
 Non-Hodgkin lymphomas. *See also* Lymphomas
 conjunctival, 8.349
 orbital, 4.232, 4.233*f*, 7.85–89, 7.87*f*
 primary central nervous system/intraocular, 1.237, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 9.273–276, 9.274*f*, 9.275*f*. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
 Non-insulin-dependent diabetes mellitus. *See* Diabetes mellitus (DM), type 2
 Non-Sjögren syndrome dry eye, 8.55*f*
 Non-ST-segment elevation myocardial infarction (NSTEMI), 1.93, 1.94. *See also* Acute coronary syndrome
 management of, 1.103–104
 Non-T, non-B lymphocytes, 9.12, 9.39, 9.49, 9.50
 Nonaccidental trauma
 abusive head trauma, 6.381–384, 6.382–383*f*
 ocular injury secondary to, 6.384
 Nonadherence to therapy
 behavioral/psychiatric disorders and, 1.188, 1.190, 1.198
 in older patients, 10.186
 resistant hypertension and, 1.64
 Nonallelic, 2.131
 Nonalternating suppression, 6.49
 Nonarteritic ischemic optic neuropathy
 anterior (NAION), 5.107*t*, 5.120, 5.120*t*, 5.121*f*, 5.122–124, 5.123*t*
 OCT in evaluation of, 5.91*f*
 visual evoked potentials in, 12.52
 posterior (PION), 5.107*t*, 5.124
 Nonaxial displacement of globe, in orbital disorders, 7.24
 Noncaseating granulomas, 4.8*f*
 in granulomatous conjunctivitis, 4.52, 4.52*f*
 in sarcoidosis, 4.187, 4.187*f*, 9.166
 Noncoding (junk/antisense) DNA, 2.132, 2.148*f*, 2.150, 2.151
 in gene therapy, 2.170
 Noncomitant deviations. *See* Incomitant (noncomitant) deviations
 Noncontact specular microscopy, 8.23
 Noncontact (air-puff) tonometers, 10.26
 Noncycloplegic (manifest) refraction, 3.168–169.
 See also Refraction, clinical
 IOL power calculation and, 13.194, 13.195
 after penetrating keratoplasty, 8.431–432, 8.432*f*
 before refractive surgery, 13.39, 13.40
 laser programming and, 13.40, 13.81
 Nondepolarizing neuromuscular blocking agents, 2.315
 Nondihydropyridine calcium channel blockers, for hypertension, 1.68*t*, 1.72
 Nondipping pattern, blood pressure, 1.62
 Nondisjunction, 2.140
 aneuploidy and, 2.189
 in Down syndrome, 2.190
 meiotic, 2.186*f*, 2.189
 mitotic, 2.191
 in mosaicism, 2.191
 Nonenveloped viruses, 8.212
 Nonepithelial tumors, 7.94
 orbital invasion by, 7.97, 7.97*f*
 Nonexperimental (observational) studies, 1.7, 1.8
 Nongranulomatous inflammation, 4.7
 Nongranulomatous uveitis, 9.78, 9.112–114, 9.113*f*, 9.115
 Nonhomologous chromosomes, independent assortment and, 2.187
 Noninfectious ocular inflammatory diseases, 9.111–189.
 See also specific type and specific cause
 conjunctivitis, 4.52–55, 4.54*f*
 sarcoidosis and, 4.52, 4.52*f*
 endophthalmitis, 9.261

- keratitis, 4.80–81
 optic nerve involvement and, 4.244f, 4.244–245, 4.245f
 orbital, 4.224–226, 4.225f, 7.51–66
 scleritis, 9.111–112
 uveitis/autoimmune uveitis, 4.127, 4.128f. *See also specific cause*
 anterior uveitis, 9.112–127
 intermediate uveitis, 9.127–132
 panuveitis, 9.166–189
 posterior uveitis, 9.132–166
 vitreous infiltrate in, 4.127, 4.128f
- Noninvasive pressure support ventilation, 1.132
- Nonketotic hyperglycemic hyperosmolar coma, 1.47–48
- Nonlaser lamellar keratorefractive surgery, 13.8t
- Nonnecrotizing herpetic retinitis (nonnecrotizing posterior uveitis), 9.198
- Nonnecrotizing scleritis, 4.110, 8.46t, 8.320t, 8.320–322, 8.321f, 8.322f, 9.111
- Nonnecrotizing stromal keratitis, 8.51f
 herpes simplex causing, 8.219, 8.220f, 8.221f, 8.223t
- Nonneovascular (“dry”/nonexudative) age-related macular degeneration, 4.164, 4.164f
 Amsler grid testing for, 12.68–69
 contrast sensitivity issues in, 12.56
 differential diagnosis of, 12.67–68
 disproven treatment approaches for, 12.71
 drusen in, 4.160–163, 4.161f, 4.162f, 4.163f
 education regarding, 12.68
 focal atrophy in, 12.66
 follow-up for, 12.68
 geographic atrophy in, 12.64, 12.66, 12.67f, 12.68
 hydrochloroquine toxicity versus, 12.68
 hyperacuity testing for, 12.69
 lifestyle changes for, 12.71
 management of, 12.68–71
 micronutrients for, 12.69–71
 preferential hyperacuity perimetry for, 12.69
 prevalence of, 12.61
 retinal pigment epithelium abnormalities in, 4.164, 4.164f, 12.66–67
 shape-discrimination hyperacuity for, 12.69
- Nonnephropathic cystinosis, 8.181, 8.181f
- Nonnucleoside reverse transcriptase inhibitors (NNRTIs), 1.266
- Nonorganic (functional/nonphysiologic) ophthalmic disorders, 1.190, 1.198, 5.299t, 5.299–312
 afferent visual pathways and, 5.301–305, 5.302f, 5.303f, 5.304f, 5.305t
 clinical profile of patient with, 5.300
 examination techniques in, 5.301–311, 5.302f, 5.303f, 5.304f, 5.305t, 5.307f, 5.308f, 5.309f
 eyelid position/function and, 5.310–311
 malingering and, 5.299
 management of, 5.311
 ocular motility/alignment and, 5.309–310
 organic disorders misdiagnosed as, 5.299, 5.299t
 pupils/accommodation and, 5.310
- Nonorganic overlay, 5.299, 5.311
- Nonparaneoplastic autoimmune retinopathy (NpAIR), 5.103
- Nonparaneoplastic autoimmune retinopathy (NpAIR)-associated antibody, 5.103
- Nonpenetrance/nonpenetrant gene, 2.141, 2.195, 2.205
- Nonpenetrating glaucoma surgery, 10.217–219
- Nonperfused/complete/ischemic central retinal vein occlusion, 4.156, 4.157–158, 4.158f
- Nonperfusion, capillary. *See* Retinal capillaries, nonperfusion of
- Nonphysiologic ophthalmic disorders. *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
- Nonpigmented ciliary epithelium (NPE), 2.57, 2.58f
 in aqueous dynamics, 2.229, 2.230, 2.231, 2.323, 2.324, 2.324f
- Nonproliferative diabetic retinopathy (NPDR/background). *See also* Diabetic macular edema; Diabetic retinopathy
 anti-VEGF therapy for, 12.101–102
 clinical findings in, 12.99
 definition of, 12.91
 intraretinal hemorrhages associated with, 12.100f
 intraretinal microvascular abnormalities in, 12.100f
 microaneurysms associated with, 12.100f
 optical coherence tomography angiography of, 12.94f
 panretinal photocoagulation for, 12.101
 posterior vitreous detachment creation for, 12.102
 progression of, to proliferative diabetic retinopathy, 12.101
 ranibizumab for, 12.102
 scatter photocoagulation for, 12.116
 severity of, 12.95t, 12.99
 treatment of, 12.101–102
 venous beading associated with, 12.100f
 vision loss in, 12.101
- Nonproliferative sickle cell retinopathy (NPSR). *See also* Sickle cell retinopathy
 branch retinal artery occlusions in, 12.152f
 characteristics of, 12.149–150
 imaging of, 12.150–152f
 retinal arteriolar occlusions in, 12.151f
 salmon-patch hemorrhage in, 12.150f
- Nonrefractive accommodative esotropia, 6.90
- Nonrhegmatogenous retinal detachment. *See* Retinal detachment
- Nonsense mutation, 2.140, 2.155
 of mitochondrial DNA, 2.157
- Nonseptate filamentous fungi, 8.249t, 8.251. *See also* Filamentous fungi; Fungi
- Nonspecific orbital inflammation (NSOI/orbital pseudotumor/idiopathic orbital inflammation/orbital inflammatory syndrome [OIS]), 4.224–226, 4.225f, 6.215–216, 6.216f, 7.43, 7.43t, 7.63–66, 7.64f
 in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168
 lacrimal gland masses and, 7.64, 7.94
 orbital lymphoma differentiated from, 4.225
 pain in, 5.295
 plasma cell-rich, 7.89
- Nonspherical optics, 3.257
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 1.172, 2.330t, 2.334–337, 2.335t, 9.94–95
 for ankylosing spondylitis, 9.115
 for corneal abrasion, 8.398–399

- corneal melting after cataract surgery associated with, 11.132, 11.173
- COX-1/COX-2 inhibition by, 1.172, 2.239, 2.335, 9.94
- for cystoid macular edema
- after cataract surgery, 11.165
 - in uveitis, 9.289
- hypertension and, 1.64*t*, 1.64–65
- for ischemic heart disease, 1.101*t*
- after LASIK, 13.93
- for diffuse lamellar keratitis, 13.117
- for ocular allergy
- description of, 6.247*t*
 - hay fever conjunctivitis, 8.289
- ocular side effects of, 1.307*t*, 2.336–337
- perioperative use of, 1.286
- platelet function affected by, 1.144, 1.172
- prostaglandins affected by, 2.239
- for rheumatic disorders, 1.172
- for rheumatoid arthritis, 1.152
- for scleritis, 8.324, 8.325*f*, 9.111
- after surface ablation, 13.92, 13.93–94, 13.108
- delayed re-epithelialization and, 13.93–94, 13.108
 - sterile infiltrates and, 13.108
- for uveitis, 9.94–95
- cystoid macular edema and, 9.289
- Nonsyndromic panretinal dystrophies, 12.258–259
- Nontreponemal tests, for syphilis, 1.216, 1.248–249, 9.241
- Nontuberculous (atypical) mycobacteria, 1.254, 8.248, 8.272–273, 8.273*f*
- in HIV infection/AIDS, 1.254, 1.269
 - neuro-ophthalmic signs of infection with, 5.350
- Nonvalved tube shunts, 10.214, 10.214*t*
- Norepinephrine, 2.308*t*
- adrenergic receptor response and, 2.316, 2.317*f*.
 - See also* Adrenergic agents
 - for shock, 1.301
 - synthesis and release of, 2.320, 2.320*f*
 - in tear secretion, 2.216, 2.218, 2.218*f*, 2.219, 2.219*f*
- Norfloxacin, 1.277, 2.349
- Normal distribution, 1.27, 1.28*f*
- clinical relevance of research and, 1.7
- Normal flora, 1.239
- ocular, 8.205–206, 8.206*t*
- Normal retinal correspondence (NRC)
- afterimage test for, 6.79*f*
 - in intermittent exotropia, 6.100
 - strabismus and, 6.48, 6.49*f*
 - testing for, 6.51
- Normal-tension glaucoma (NTG), 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*. *See also* Glaucoma, normal-tension
- Normocytic anemia, 1.136
- Norrie disease, 6.347
- Norrie disease (NDP) gene, 2.183
- North Carolina macular dystrophy, 12.277, 12.278*f*
- NOS. *See* Nitric oxide synthase
- Nose, 7.18. *See also* under *Nasal*
- inferior meatus of, 2.6, 2.8, 5.11, 7.10, 7.18, 7.19, 7.255
 - middle meatus of, 7.18, 7.254
 - orbital tumors originating in, 7.95*f*, 7.95–98, 7.96*f*, 7.97*f*
 - superior meatus of, 7.19
- Nosema, 8.252
- stromal keratitis caused by, 8.280
- NOTCH3* gene mutation, in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, 5.295
- Nothnagel syndrome, 5.191
- Notochord, 2.112*f*, 2.114*f*
- Nougaret disease, rod transducin mutation causing, 2.263
- Novocain. *See* Procaine
- Nozik technique, for periocular corticosteroid injection, 9.96*f*, 9.96–97
- NpAIR. *See* Nonparaneoplastic autoimmune retinopathy
- NPC. *See* Near point of convergence
- NPDR. *See* Nonproliferative diabetic retinopathy
- NPE. *See* Nonpigmented ciliary epithelium
- NPH. *See* Nucleus prepositus hypoglossi
- NPS gene, 10.11*t*
- NPSR. *See* Nonproliferative sickle cell retinopathy
- NPV. *See* Negative predictive value
- NPY. *See* Neuropeptide Y
- NRC. *See* Normal retinal correspondence
- NR2E3 gene, 12.49, 12.266
- Nrl (neural retinal leucine zipper), in retinal development, 2.122
- NRTIs. *See* Nucleoside reverse transcriptase inhibitors
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
- NSF. *See* Nephrogenic systemic fibrosis
- NSOI. *See* Nonspecific orbital inflammation
- NSSDE. *See* Non-Sjögren syndrome dry eye
- NSTEMI. *See* Non-ST-segment elevation myocardial infarction
- NTG. *See* Normal-tension glaucoma. *See also* Glaucoma, normal-tension
- nTreg cells. *See* Natural regulatory T (nTreg) cells
- NTRK1* gene, in congenital insensitivity to pain with anhidrosis, 8.108
- Nuclear cataracts, 4.123, 4.124*f*, 11.43–45, 11.45*f*
- characteristics and effects of, 11.43, 11.44, 11.70, 11.70*t*
 - in children/congenital, 11.38, 11.39*f*
 - genetic contributions to, 11.42
 - hyperbaric oxygen therapy and, 11.20, 11.65
 - infantile, 6.295, 6.296*f*
 - after posterior chamber phakic IOL insertion, 13.146
 - race and, 11.6
 - in rubella, 6.410
 - vitrectomy and, 11.55, 11.190
- Nuclear disassembly/removal, 11.111, 11.112–114, 11.113*f*. *See also* Cataract surgery; Lensectomy; Phacoemulsification
- in ECCE, 11.196–197
 - in ICCE, 11.200*f*, 11.200–201
 - in manual small-incision cataract surgery, 11.198, 11.199*f*
 - in phacoemulsification, 11.111, 11.112–114, 11.113*f*
 - chopping techniques for, 11.114
 - phaco fracture for, 11.112–114, 11.113*f*
- Nuclear facial palsy, 5.276*f*
- Nuclear layer
- inner (INL), 2.70*f*, 2.71*f*, 2.74, 2.74*f*, 2.76*f*, 2.88*f*, 2.258*f*, 2.266*f*, 2.266–268, 2.267*f*, 2.268*f*, 4.140*f*, 4.141*f*
 - outer (ONL), 2.70*f*, 2.71*f*, 2.72*f*, 2.74*f*, 2.76*f*, 2.88*f*, 4.140*f*, 4.141*f*

- Nuclear lesions, diplopia caused by, 5.188–189. *See also specific nerve*
- Nuclear sclerosis, 11.43, 11.45f, 11.48f, 11.50f. *See also*
 Nuclear cataracts
 myopic shift associated with, 3.143
 refractive surgery and, 13.44
 smoking and, 11.6–7
- Nuclear sclerotic cataract, 12.402, 12.402t
- Nucleic acids. *See also* DNA; RNA
 disorders of metabolism of, corneal changes and,
 8.181f, 8.181–190, 8.182t, 8.183t, 8.184f, 8.185f,
 8.186t, 8.187f, 8.188f, 8.189f
 in retinal pigment epithelium, 2.274
 viral, 8.211
- Nucleofraxis, “divide and conquer,” 11.112–114, 11.113f
- Nucleoside, 2.140
- Nucleoside reverse transcriptase inhibitors (NRTIs),
 1.266, 12.299
- Nucleosome, 2.140
- Nucleotides, 2.140, 2.147, 2.148f. *See also* Nucleic acids
- Nucleus (lens). *See* Lens (crystalline), nucleus of
- Nucleus prepositus hypoglossi (NPH), 5.35, 5.35f, 5.220
 horizontal gaze and, 5.37f, 5.38
- NuLens accommodating intraocular lens, 13.170
- Null allele, gene therapy and, 2.169
- Null-cell adenomas, 1.58
- Null hypothesis, 1.5
- Null mutations, 2.155
- Null point/zone, 5.234
 in congenital motor nystagmus, 6.148, 6.156
 in jerk nystagmus, 6.147
 surgical adjustment of, for nystagmus, 5.236, 5.237f
- Numbness, facial pain and, 5.298
- Nummular keratitis, 6.243
 herpes zoster, 8.228, 8.228f
- Nursing (breastfeeding)
 glaucoma medication use during, 10.185–186
 refractive surgery contraindicated during, 13.37
- Nutritional deficiency
 cataract formation and, 11.7, 11.63–64
 corneal changes in, 8.196–197, 8.197f
 optic neuropathy and, 5.107t, 5.137–139, 5.138f
- Nutritional supplements. *See also specific type*
 for dry eye, 8.61t, 8.64, 8.68
 perioperative discontinuation of, 1.286
- NVD. *See* Neovascularization, optic nerve/nerve head/
 disc
- Nyctalopia, 12.290. *See also* Night blindness
 rod-specific mutations causing, 2.263, 2.264
 in uveitis, 9.78
 in vitamin A deficiency, 8.196
- Nystagmus, 5.214, 5.215, 5.233–251, 5.234f
 acquired, 5.233, 6.151–152
 pendular, 5.246–247
 Alexander's law and, 5.240, 5.242
 amplitude of, gaze position affecting, 5.234
 Anderson procedure for, 6.155
 antiepileptic drugs causing, 1.203
 assessment of, 5.215, 5.233–235, 5.234f
 Bruns, 5.243
 central vestibular instability, 6.149
 childhood (early-onset), 5.235–239
 chin-down position, 6.156
 chin-up position, 6.156
 congenital (CN), 5.234f, 5.235–237, 5.237f
 congenital motor, 6.148–149, 6.149t, 6.153–154
 congenital sensory, 6.149, 6.150t, 6.154
 convergence-retraction (CRN/induced convergence-
 retraction), 5.243t, 5.250, 6.152–153
 definition of, 6.147
 diagnosis of, 6.84
 dissociated (disconjugate/dysconjugate), 5.234, 5.247,
 6.151–152
 downbeat, 5.243t, 5.244–245, 5.245f, 6.152
 esotropia and, 6.86t, 6.95
 evaluation of, 6.153–154
 features of, 6.147
 fixation and, 5.240, 5.241t
 fusion maldevelopment nystagmus syndrome, 6.83,
 6.88, 6.95, 6.148, 6.150–151, 6.151f, 6.154
 gaze direction and, 6.147
 gaze-evoked, 5.38, 5.222, 5.234f, 5.240–241
 in internuclear ophthalmoplegia, 5.189, 5.190f
 rebound, 5.240–241
 gaze positions affecting, 5.240
 head-tilt correction in, 6.156
 in hereditary retinal disease, 6.335
 history-taking for, 6.153
 horizontal rectus muscle surgery for, 6.157
 induced convergence-retraction, 6.152–153
 infantile nystagmus syndrome, 6.83, 6.148–149,
 6.149t, 6.156f, 6.187, 6.335
 inheritance patterns, 6.153
 in internuclear ophthalmoplegia, 5.189, 5.190f, 5.247
 jerk, 5.214, 5.233, 5.234, 6.147
 in multiple sclerosis, 5.319
 Kestenbaum procedure for, 6.155, 6.156t, 6.156f
 latent/manifest latent (LN/MLN/fusion/fusional
 maldevelopment nystagmus syndrome/FMN/
 FMNS), 5.237–238, 6.88, 6.95, 6.129, 6.150–151,
 6.154
 monocular, 6.152
 in Heimann-Bielschowsky phenomenon, 5.238–239
 monocular occlusion effects on intensity of, 6.154
 in multiple sclerosis, 5.246, 5.319
 in neuromyelitis optica, 5.320–322
 nomenclature for, 6.147
 occluding of one eye as cause of, 3.27
 ocular examination for, 6.153–154
 oculopalatal myoclonus/tremor and, 5.246–247
 optic nerve gliomas causing, 5.130
 optokinetic (OKN/optokinetic system), 5.212, 5.212t,
 5.218–219, 6.40
 dysfunction of, 5.218–219
 in congenital nystagmus, 5.235
 parietal lobe lesions and, 5.156, 5.219
 nonorganic disorders and, 5.301–302
 pendular, 5.214, 5.233, 5.234f, 5.246–247, 6.147
 acquired, 5.246–247
 in multiple sclerosis, 5.246, 5.319
 periodic alternating (PAN), 5.243t, 5.245–246, 6.149
 prevalence of, 6.147
 prisms for, 6.155
 pupil responses in, 6.154
 rebound, 5.240–241
 retinal dystrophy and, 6.391f

- saccadic intrusions, 5.233, 5.247–250, 5.248f
 see-saw (vision loss), 5.243t, 5.247, 6.152
 seizures causing, 1.203
 sensory, 6.187
 spasmus nutans syndrome, 5.239, 6.151–152
 strabismus associated with, 6.154, 6.156–157
 substance use/abuse and, 1.192
 surgery for, 6.155–157, 6.156t, 6.156f
 torsional, 5.245
 treatment of, 6.155–157
 upbeat, 5.243t, 5.245
 vertical, 6.152
 vestibular, 5.215, 5.234f, 5.241t, 5.241–246, 5.243t, 5.245f
 central, 5.216, 5.243t, 5.243–246, 5.245f
 peripheral, 5.216, 5.241t, 5.241–243
 visual acuity assessments in, 6.8, 6.153–154
 visual evoked potentials in, 12.53
 voluntary, 5.249–250, 5.309
 wandering, 12.266
 Nystagmus blockage syndrome, 6.95, 6.148, 6.155
 Nystagmus-like disorders, 6.152–153
 Nystatin, 1.281
- O**
- O polysaccharide, 9.13
 OA. *See* Ocular albinism
 OA1 (albinism). *See* Ocular albinism
 OAT gene, 12.269
 OAT (ornithine aminotransferase) gene mutations/
 defects, in gyrate atrophy, 2.175t, 2.265
 OAVS. *See* Oculoauriculovertebral spectrum/sequence
 Obesity
 diabetes mellitus/hyperglycemia and, 1.33, 1.34, 1.36
 weight reduction and, 1.36, 1.38, 1.40
 floppy eyelid syndrome and, 8.82
 hypertension and, 1.76
 in children and adolescents, 1.78
 in idiopathic intracranial hypertension, 5.111, 5.112
 insulin secretion affected by, 1.34
 metabolic syndrome and, 1.37, 1.88
 Object agnosia, 5.179
 Object distance, 3.4, 3.10
 Object vergence, 3.51
 Objective refraction. *See* Retinoscope/retinoscopy
 OBL. *See* Opaque bubble layer
 Oblate, 3.267
 Oblate cornea, 13.14, 13.26
 Q value and, 13.14
 after radial keratotomy, 13.50
 Oblique astigmatism, 3.139, 3.147
 Oblique muscles, 2.7, 2.9f, 2.13, 2.13f, 2.14f, 2.15t, 2.16f, 2.20f, 5.8f, 5.45, 5.46, 5.46f, 7.11, 7.12f, 7.13f, 7.14f, 7.15f, 7.146f. *See also* Inferior oblique (IO) muscle; Superior oblique (SO) muscle
 anatomy of, 2.7, 2.9f, 2.13, 2.13f, 2.14f, 2.15t, 2.16f, 2.20f, 5.8f, 5.45, 5.46, 5.46f, 6.20–22, 6.21t
 blood supply of, 2.15t, 2.33f, 2.34f
 inferior. *See* Inferior oblique muscle
 innervation of, 2.17, 2.94f, 2.95, 5.40, 5.44, 5.44f, 7.12, 7.14f, 7.15f
 insertions of, 2.14f, 2.15, 2.15t
 myokymia affecting, 5.250–251
 origins of, 2.15t, 2.17
 overactions of, 6.17, 6.117
 pseudo-overactions, 6.116
 superior. *See* Superior oblique muscle
 tightening procedures for, 6.164t, 6.166–167
 weakening procedures for, 6.164t, 6.165–166
 O'Brien nerve block, for cataract surgery, 11.92, 11.93f
 Observation
 in choroidal/ciliary body melanoma management, 4.274
 in epicanthus management, 7.159
 in medulloepithelioma management, 4.296
 in ocular surface tumor management, 8.328–329
 in optic nerve glioma management, 7.76
 in orbital lymphoma management, 7.89
 in traumatic vision loss management, 7.114
 Observational studies, 1.7, 1.8
 Obstructive pulmonary disease, 1.129–130
 ocular surgery in patient with, 1.288
 Obstructive shock, 1.300. *See also* Shock
 Obstructive sleep apnea syndrome (OSAS)
 floppy eyelids and, 8.79, 8.82
 hypertension and, 1.67t, 1.76
 nasal continuous positive airway pressure for, 1.129, 1.132
 ocular conditions associated with, 1.129, 1.132
 OCA. *See* Oculocutaneous albinism
 OCA1 (albinism), 2.278
 OCA2 (albinism), 2.278
 OCA2 gene (*P* gene), in albinism, 2.185
 Occipital artery, 5.12
 Occipital association cortex, near reflex initiated in, 2.96
 Occipital bone, 5.5
 Occipital (primary visual/calcarine/striate) cortex, 2.90, 2.93, 5.24f, 5.29f, 5.29–31, 5.30f, 5.32f, 5.34f
 disorders of, 5.158, 5.178t, 5.178–181
 hallucinations and, 5.158, 5.176–178
 illusions and, 5.175
 recognition disorders and, 5.178t, 5.179, 5.180f
 vision/visual deficit awareness disorders and, 5.178t, 5.180–181
 visual-spatial relationship disorders and, 5.178t, 5.180
 ocular motor control and, 5.32f, 5.32–33, 5.34f
 vascular supply of
 arterial supply, 5.20, 5.20f
 venous drainage, 5.22f, 5.22–23, 5.23f
 Occipital ischemia, transient visual loss and, 5.162, 5.172
 Occipital lobe, 5.24f
 lesions of, 5.147f, 5.156–158, 5.157f, 5.158f, 5.159f.
 See also Occipital (primary visual/calcarine/striate) cortex, disorders of
 hallucinations and, 5.158, 5.177
 transient visual loss/seizures and, 5.161, 5.162, 5.172
 Occipital nerves, 7.145f
 facial pain and, 5.296
 Occipital neuralgia, 5.296, 5.297
 Occipital seizures, transient visual loss and, 5.161, 5.162, 5.172
 Occipital sinus, 2.106f
 Occipitoparietal pathway, 5.30f

- Occipitotemporal pathway, 5.30f
- Occlusion therapy. *See also* Patching
- adherence to, 6.60
 - amblyopia treated with, 6.58, 6.96, 6.102
 - basic acquired nonaccommodative esotropia
 - secondary to, 6.93
 - full-time, 6.58, 6.60
 - intermittent exotropia treated with, 6.102
 - part-time, 6.58
 - in phacoemulsification, 11.102
 - reverse amblyopia caused by, 6.60
- Occlusive arterial disease
- branch retinal artery
 - emboli that cause, 12.141, 12.142f
 - hypertensive retinopathy and, 12.122
 - imaging of, 12.141f
 - management of, 12.142
 - multiple, 12.152f
 - in nonproliferative sickle cell retinopathy, 12.152f
 - retinal infarction caused by, 12.141
 - in Susac syndrome, 12.156
 - branch retinal vein
 - aflibercept for, 12.135
 - at arteriovenous crossing, 12.126
 - bevacizumab for, 12.135
 - clinical findings in, 12.125–127, 12.126f
 - corticosteroids for, 12.137–138
 - diabetes mellitus and, 12.128
 - fluorescein angiography of, 12.129f
 - glaucoma as risk factor for, 12.125
 - hypertensive retinopathy and, 12.122
 - intra retinal hemorrhages associated with, 12.125, 12.126f
 - macular laser surgery for, 12.128
 - neovascularization in, 12.125, 12.128, 12.129f
 - pars plana vitrectomy for, 12.130
 - pharmacologic management of, 12.135–138
 - prognosis for, 12.128
 - ranibizumab for, 12.135
 - risk factors for, 12.127–128
 - scatter photocoagulation for, 12.128–130
 - spontaneous resolution of, 12.125
 - surgical management of, 12.128–130
 - treatment of, 12.128–130
 - triamcinolone for, 12.137
 - vision loss caused by, 12.128
 - central retinal artery
 - anti-VEGF therapy for, 12.146
 - causes of, 12.144
 - ciliary artery occlusion with, 12.144, 12.145f
 - electroretinography findings in, 12.50
 - emboli as cause of, 12.144
 - giant cell arteritis as cause of, 12.145
 - illustration of, 12.16f, 12.144f
 - iris neovascularization in, 12.146
 - management of, 12.146
 - retinal infarction caused by, 12.143
 - spectral-domain optical coherence tomography of, 12.144f
 - symptoms and signs of, 12.143
 - vision loss caused by, 12.143–144
 - central retinal vein occlusion. *See* Central retinal vein occlusion (CRVO)
- Occlusive retinal disease
- arterial. *See also* Retinal artery occlusion
 - branch retinal artery occlusion, 4.156
 - central retinal artery occlusion, 4.156, 4.157f
 - in SLE, 9.134
 - venous. *See also* Retinal vein occlusion
 - branch retinal vein occlusion, 4.158–159
 - central retinal vein occlusion, 4.156–158, 4.158f
 - angle-closure glaucoma and, 10.143–144
 - neovascularization and, 10.134–135
 - open-angle glaucoma and, 10.84
 - hypercoagulability states and, 1.147
 - in sarcoidosis, 9.169–170
 - in SLE, 9.134
- Occlusive retinopathy, 12.300–301
- Occult choroidal neovascularization, 12.72–73
- Occult giant cell arteritis, 5.120, 5.170
- Occult macular dystrophies, 12.277
- Occupation, refractive surgery selection and, 13.36–37
- Occupational light toxicity, 12.369
- Occupational therapists, 3.325
- Ochronosis, 8.118t, 8.184, 8.185f
- Ocriplasmin, 12.337, 12.340
- for enzymatic vitreolysis, 2.255
- OCRL gene, in oculocerebrorenal (Lowe) syndrome, 4.118, 6.391
- OCT. *See* Optical coherence tomography
- OCTA. *See* Optical coherence tomographic angiography
- Octopus perimeters, 10.61
- visual field progression evaluation with, 10.74
- Ocucoat, 2.368
- Ocufen. *See* Flurbiprofen
- Ocuflox. *See* Ofloxacin
- Ocular adnexa, 7.169–170. *See also specific structure*
- abnormalities of, in craniosynostosis, 6.209
 - anatomy of, 2.5–11, 2.6f, 2.8f, 2.9f, 2.10f
 - arterial supply of, 5.13–14f
 - benign lesions of, 7.169–172, 7.171f, 7.172f, 7.173f
 - in cryptophthalmos, 6.191
 - description of, 6.181
 - in external eye defense, 8.11
 - glands of, 2.23t
 - in glaucoma evaluation, 10.29–30
 - Kaposi sarcoma of, 5.349, 9.299f, 9.299–300
 - lymphoma/lymphoproliferative lesions of, 4.231, 4.232, 4.233f, 7.85–91. *See also* Lymphomas
 - radiation affecting, 1.230–231
 - in systemic malignancies, 1.237
- Ocular albinism (OA), 4.142, 4.142f, 6.406–407. *See also* Albinism
- characteristics of, 12.288
 - ocular findings in carriers of, 2.198–200, 2.199f, 2.199t
 - pattern-appearance visual evoked potentials in, 12.53
 - X-linked (Nethleship-Falls), ocular findings in carriers of, 2.198–200, 2.199f
- Ocular alignment
- assessment of
 - alternate cover test, 6.65–66, 6.66f
 - corneal light reflex tests, 6.67–68, 6.68f

- cover tests, 6.64–67, 6.65–66*f*
- diagnostic positions of gaze, 6.64
- Lancaster red-green test for, 6.69
- Maddox rod test, 6.68–69, 6.69*f*
- major amblyoscope for, 6.70, 6.70*f*
- monocular cover test, 6.64, 6.65*f*
- prism alternate cover test, 6.65–66, 6.66*f*
- red reflex tests, 6.67–68
- simultaneous prism and cover test, 6.66–67
- subjective tests for, 6.68–70
- disorders of/unsatisfactory, 5.184–185. *See also*
 - Diplopia
 - nonorganic, 5.309–310
 - after extraocular muscle surgery, 6.168
 - in infantile esotropia, 6.88–89
 - refractive surgery and, 13.41
 - tests of, 5.184*f*, 5.184–185, 5.185*f*. *See also specific type*
- Ocular allergy, 6.246*f*, 6.246–249, 6.247*t*, 6.248*t*. *See also*
 - Allergic reactions/allergies
- Ocular argyrosis/argyria/argyriasis, 12.306
- silver causing, 4.120
- Ocular autonomic pathways, 5.52–56
 - parasympathetic, 5.52, 5.54–56, 5.55*f*
 - sympathetic, 5.52–54, 5.53*f*
- Ocular biometrics. *See* Biometry/biometrics
- Ocular bobbing, 5.228
- Ocular cicatricial pemphigoid. *See* Mucous membrane (ocular cicatricial) pemphigoid
- Ocular cysticercosis. *See* Cysticercosis
- Ocular cytology. *See* Cytology
- Ocular development, 2.111–128. *See also* Eye,
 - development of
 - general principles and, 2.111, 2.112*f*, 2.113*f*, 2.114*f*, 2.115*t*
 - genetic cascades and morphogenic gradients and, 2.111, 2.126–128
- Ocular deviations. *See* Deviations
- Ocular dominance, determining, 13.39
- Ocular examination. *See* Examination
- Ocular expansion, pathologic myopia as cause of, 12.216
- Ocular fixation system, 5.212, 5.212*t*, 5.213–214.
 - See also* Fixation
 - dysfunction of, 5.214
- Ocular flutter, 5.243*t*, 5.248, 5.248*f*, 5.249
- Ocular fundus, 3.296
- Ocular graft-vs-host disease (GVHD), 8.303–305, 8.305*f*
 - superior limbic keratoconjunctivitis and, 8.83
- Ocular hemorrhage. *See also* Hemorrhages
 - ruptured aneurysm causing, 5.340, 5.340*f*
- Ocular histoplasmosis syndrome (OHS), choroidal neovascularization caused by, 12.86–87, 12.88*f*
- Ocular histoplasmosis syndrome/presumed ocular histoplasmosis syndrome (OHS/POHS), 9.214–219, 9.215*f*, 9.216*f*, 9.217*f*, 9.218*f*
 - choroidal neovascularization in, 9.215, 9.216, 9.217, 9.218*f*
 - management of, 9.217–218
 - management of, 9.217–218
- Ocular history. *See also* History
 - in cataract, 11.69–71, 11.70*t*
 - evaluation for surgery and, 11.75–76
 - diabetes mellitus and, 10.83
 - glaucoma evaluation and, 10.29
 - in low vision evaluation, 3.312
 - refractive surgery evaluation and, 13.36*t*, 13.37–38
- Ocular hypertelorism, 6.191
- Ocular hypertension (OHT), 10.4*t*, 10.89–90, 10.112.
 - See also* Elevated intraocular pressure
 - age/aging and, 10.81
 - corneal thickness and, 10.25, 10.90, 10.112
 - glaucoma risk and, 10.8, 10.81, 10.89, 10.90, 10.112
 - glaucoma suspect and, 10.89–90
 - nasal continuous positive airway pressure affecting, 1.132
 - race and, 10.82
 - refractive surgery and, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
 - uveitis, 9.284–285, 9.285
 - herpetic infection and, 9.192–193
- Ocular Hypertension Treatment Study (OHTS), 1.21, 1.22, 10.65, 10.81, 10.82, 10.83, 10.89–90, 10.112
- Ocular hypotelorism, 6.191
- Ocular hypotension. *See* Hypotony
- Ocular immunology, 9.5–67. *See also* Immune response;
 - Immune response arc
 - basic concepts in, 9.9–30
- Ocular infection. *See* Infection; Infectious disease
- Ocular inflammation. *See* Endophthalmitis;
 - Inflammation (ocular); Uveitis; *specific organ or structure affected*
- Ocular injury. *See* Penetrating and perforating ocular trauma; Trauma
- Ocular instability of infancy, 6.87
- Ocular ischemic syndrome (OIS), 5.170, 5.171*f*, 9.278–279
 - central retinal vein occlusion versus, 12.134
 - course of, 12.139
 - definition of, 12.138
 - etiology of, 12.139
 - ischemic cardiovascular disease associated with, 12.139
 - retinopathy caused by, 12.138
 - stroke rate in, 12.139
 - symptoms and signs of, 12.138–139
 - treatment of, 12.140
- Ocular larval migrans, 8.253. *See also* *Toxocara* (toxocariasis)
- Ocular lateropulsion, in Wallenberg syndrome, 5.217
- Ocular (optical) media
 - abnormalities of, 5.99
 - diplopia and, 5.185
 - fundus examination in evaluation of, 5.81
 - perimetry affected by, 5.86
 - transient visual loss and, 5.164
 - clear, traumatic vision loss with, 7.112–114
 - opaque. *See* Cataract; Opacities
 - refractive index of. *See* Refractive index
- Ocular melanocytosis (melanosis oculi), 4.63*t*, 4.64, 4.65*f*, 6.250–251, 6.251*f*, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
 - choroidal nevus resembling, 4.257, 4.257*f*
 - congenital, 8.338–340, 8.339*f*
 - of iris, 4.259, 4.260*f*
- Ocular microbiology. *See* Microbiology

- Ocular motility. *See also specific type of eye movement*
 abnormal, 5.183–209. *See also* Ocular motility, disorders of
 assessment of, 5.233–235, 5.234f
 before cataract surgery, 11.77–78
 in nonorganic disorders, 5.309–310
 before refractive surgery, 13.41
 binocular eye movements and. *See also specific type*
 conjugate (versions), 5.34–35, 5.35f
 in diplopia, 5.184
 disconjugate (vergences), 5.212, 5.212t, 5.226–228.
See also Vergences/vergence system
 contact lens trial before refractive surgery and, 13.199
 control of, 5.31–46, 5.211, 5.212t, 5.212–213. *See also*
 Ocular motor pathways
 brainstem in, 5.34–40, 5.35f, 5.36f, 5.37f, 5.39f
 cerebellum in, 5.39–40
 cortical/supranuclear pathways in, 5.32f, 5.32–33,
 5.34f. *See also* Supranuclear (cortical) pathways
 disorders of, 5.188, 5.188t, 5.211–231
 cranial nerves/infranuclear pathways in, 5.40f,
 5.40–45, 5.41f, 5.42–43f, 5.44f, 5.211
 disorders of, 5.191–206, 5.193f, 5.194f, 5.198f,
 5.199f, 5.200f, 5.204f. *See also* Diplopia
 extraocular muscles in, 2.18, 5.45–46, 5.46f,
 7.11–12, 7.12f
 ocular fixation system in, 5.212, 5.212t, 5.213–214
 optokinetic system/nystagmus in, 5.212, 5.212t,
 5.218–219
 saccades/saccadic system in, 5.32–33, 5.38, 5.212,
 5.212t, 5.219–223, 5.220f
 smooth-pursuit system in, 5.32, 5.33, 5.34f, 5.212,
 5.212t
 subcortical structures in, 5.33–34
 vergence system in, 5.212, 5.212t, 5.226–228
 vestibular-ocular system in, 5.38–39, 5.39f, 5.212,
 5.212t
 disorders of, 5.183–209, 5.211–231, 7.25. *See also*
specific disorder
 in carotid-cavernous fistulas, 7.73
 chronic progressive external ophthalmoplegia
 (CPEO), 6.141–142, 6.143t
 diplopia, 5.183–209. *See also* Diplopia
 esotropia and hypotropia associated with high
 myopia, 6.143–144
 gaze palsy/preference and, 5.228–230, 5.229f,
 5.230f
 infranuclear, 5.191–206, 5.193f, 5.194f, 5.198f,
 5.199f, 5.200f, 5.204f
 internuclear ophthalmoplegia, 6.144
 localization of lesions causing, 5.187f, 5.187–188
 in multiple sclerosis, 5.246, 5.248, 5.249, 5.318–319
 myasthenia gravis, 6.142f, 6.142–143, 6.143t
 nonorganic, 5.309–310
 nystagmus/spontaneous, 5.233–251, 5.234f.
See also Nystagmus
 ocular fixation system dysfunction and, 5.214
 ocular motor apraxia, 6.144–145
 optokinetic nystagmus dysfunction and, 5.218–219
 in orbital floor/blowout fracture, 7.108–109
 surgery and, 7.110
 orbital mass causing, 7.25
 after orbital surgery, 7.125
 in Parkinson disease, 1.200
 saccadic dysfunction and, 5.221–223, 5.233,
 5.247–250, 5.248f
 intrusions, 5.233, 5.247–250, 5.248f
 ocular motor apraxia and, 5.221, 5.222–223
 seizure activity and, 1.203, 5.230
 smooth-pursuit system dysfunction and, 5.224,
 5.225–226
 superior oblique myokymia, 6.145
 supranuclear, 5.188, 5.188t, 5.211–231
See also Supranuclear (cortical) pathways,
 disorders of
 thyroid eye disease, 6.140–141, 6.141f, 6.143t, 6.215
 in thyroid eye disease, 4.226, 7.25, 7.52, 7.54, 7.56
 tonic deviations and, 5.230–231
 vergence dysfunction and, 5.227–228
 in vertebrobasilar insufficiency, 5.337, 5.337f
 vestibular/vestibular-ocular dysfunction and,
 5.216f, 5.216–218, 5.234f, 5.241t, 5.241–246,
 5.243t, 5.245f
 ductions and, 5.184
 efferent visual system and, 5.31–46, 5.211. *See also*
 Ocular motility, control of; Ocular motor
 pathways
 evisceration and, 7.129, 7.130
 fundamental principles of, 5.212t, 5.212–213
 ocular prostheses and, 7.132
 orbital implants and, 7.131, 7.132
 in ptosis, 7.212
 vergences and, 5.212, 5.212t, 5.226–228. *See also*
 Vergences/vergence system
 versions and, 5.34–35, 5.35f
 in diplopia, 5.184
 Ocular motor pathways, 5.31–46, 5.211, 5.212t, 5.212–
 213. *See also* Ocular motility; *specific nerve*
 brainstem and, 5.34–40, 5.35f, 5.36f, 5.37f, 5.39f
 cerebellum and, 5.39–40
 cortical input and, 5.32f, 5.32–33, 5.34f
 cranial nerves and, 5.40f, 5.40–45, 5.41f, 5.42–43f,
 5.44f. *See also specific nerve*
 diplopia and, 5.187f, 5.187–206
 extraocular muscles and, 5.45–46, 5.46f
 ocular fixation system and, 5.212t, 5.213–214
 optokinetic system/nystagmus and, 5.212, 5.212t,
 5.218–219
 saccades/saccadic system and, 5.32–33, 5.38, 5.212,
 5.212t, 5.219–223, 5.220f
 smooth-pursuit system and, 5.32, 5.33, 5.34f, 5.212,
 5.212t
 subcortical structures in, 5.33–34
 supranuclear, 5.212t, 5.213–231
 vergence system and, 5.212, 5.212t, 5.226–228
 vestibular-ocular system and, 5.38–39, 5.39f, 5.212,
 5.212t
 Ocular motor tracking systems, 5.212t, 5.212–213
 Ocular myasthenia gravis, 7.217. *See also* Myasthenia
 gravis
 Ocular neuromyotonia, 5.202, 5.358
 Ocular nocardiosis. *See* Nocardia/Nocardia asteroides
 (nocardiosis)

- Ocular pain, 5.295–296. *See also* Pain
 in ocular ischemic syndrome, 5.170
- Ocular perfusion pressure (OPP), glaucoma and, 10.83
- Ocular pharmacology. *See also* Drugs, ocular; *specific agent*
 age/aging and, 2.295
 legal aspects of, 2.205–207
 principles of, 2.293–304
- Ocular prostheses, 7.36, 7.132
 anophthalmic ectropion and, 7.135, 7.137
 for graft-vs-host disease, 8.304
 for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
- Ocular receptors. *See* Receptors
- Ocular Response Analyzer (ORA), 10.26
- Ocular-retinal developmental disease, genes and loci associated with, 12.256*t*
- Ocular rotations
 assessment of, 6.71
 definition of, 6.31
 horizontal, 6.31
 torsional, 6.31
 tube shunt effects on, 6.146
 vertical, 6.31
- Ocular-scoliotic type Ehlers-Danlos syndrome, 8.193
- Ocular sensory pathways, 5.47*f*, 5.47–49, 5.48*f*. *See also*
 Cranial nerve V
 “Ocular splits,” 6.133
- Ocular surface. *See also* Conjunctiva; Cornea;
 Epithelium
 disorders of. *See also specific structure affected and specific type*
 clinical approach to, 8.45–77. *See also specific structure and disorder*
 common clinical findings and, 8.45–46*t*, 53
 contact lens wear and, 8.84, 8.266–267, 8.273–274, 8.276, 8.277
 corneal transplantation success and, 8.418
 dry eye, 8.45, 8.53–69. *See also* Dry eye
 aqueous tear deficiency, 8.45, 8.53, 8.54*f*, 8.55*f*, 8.55–58, 8.61*t*, 8.61–65, 8.62*t*, 8.65*f*
 evaporative, 8.45, 8.53–54, 8.54*f*, 8.55*f*, 8.58–60, 8.59*f*, 8.60*f*, 8.66*t*, 8.66–67*t*, 69
 eyelid disease associated with, 8.69–77
 factitious, 8.88–90, 8.89*f*
 immune-mediated, 8.285–326. *See also* Immune response (immunity), disorders of
 limbal stem cell deficiency and, 8.92–94, 8.93*t*, 8.94*f*, 8.362. *See also* Limbal transplantation
 neoplastic, 8.327–350. *See also* Ocular surface, tumors of
 refractive surgery and, 13.172–173
 structural/exogenous, 8.79–94
 systemic conditions associated with, 8.173–203
 tear film/tear production evaluation and, 8.38–41, 8.40*f*
 therapeutic/surgical interventions for, 8.351*t*, 8.352–373. *See also specific procedure*
 conjunctival interventions, 8.352–366
 corneal interventions, 8.366–373
 indications for, 8.351*t*
 toxic, 8.90*t*, 8.90–92, 8.91*f*
 evaluation of, 8.36–41
 staining in, 8.36–37, 8.37*f*, 8.38*f*, 8.56
 tear production and, 8.38–39
 qualitative tests of, 8.40*f*, 8.40–41
 quantitative tests of, 8.39
 immunoregulation of, 8.11–13, 8.12–13*f*
 infectious. *See* Infection
 trauma to, 8.375–409. *See also* Anterior segment, trauma to
 tumors of, 8.327–350
 approach to patient with, 8.328
 epithelial origin of, 8.332*t*, 8.332–337
 glandular origin of, 8.337*f*, 8.337–338
 incidence of, 8.327
 lymphoid/lymphatic/lymphocytic, 4.69–71, 4.70*f*, 4.71*f*, 8.348–350, 8.349*f*, 8.350*f*
 management of, 8.328–332, 8.330*f*, 8.331*f*
 surgical, 8.329–330, 8.330*f*
 topical chemotherapy, 8.330*f*, 8.330–332, 8.331*f*
 melanocytic, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*
 metastatic, 8.350
 neuroectodermal origin of, 8.338*t*, 8.338–345, 8.339*t*
 pigmented, 8.338*t*, 8.338–345
 benign, 8.338*t*, 8.338–341, 8.339*f*, 8.339*t*, 8.340*f*, 8.341*f*
 malignant, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
 preinvasive, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
 squamous neoplasia, 4.60–61, 4.62*f*, 4.63*f*, 8.334–337, 8.335*f*, 8.336*f*
 invasive, 8.336, 8.336*f*. *See also* Squamous cell carcinoma
 management of, 8.330*f*, 8.336–337
 noninvasive, 8.334–335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
 vascular and mesenchymal, 8.345*t*, 8.345–348, 8.346*f*, 8.347*f*
- Ocular surface prosthesis
 for graft-vs-host disease, 8.304
 for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
- Ocular surface squamous neoplasia (OSSN), 4.60–61, 4.62*f*, 4.63*f*, 8.334–337, 8.335*f*, 8.336*f*. *See also under* Squamous
 invasive, 8.336, 8.336*f*. *See also* Squamous cell carcinoma
 management of, 8.330*f*, 8.336–337
 noninvasive, 8.334–335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
- Ocular (intraocular) surgery. *See also specific procedure*
 after arcuate keratotomy, 13.58
 bullous keratopathy after, 4.83–84, 4.84, 4.84*f*, 4.85*f*
 cardiac complications and, 1.116–117
 cataract and, 11.55–57
 for choroidal/ciliary body melanoma, 4.275*f*, 4.277
 with corneal surgery (bioptics), 13.137, 13.157
 after corneal transplantation, 8.432
 after corneoscleral laceration repair, 8.407–408
 diplopia after, 5.207

- endophthalmitis after, 9.119. *See also* Postoperative endophthalmitis
- acute-onset, 9.261
- chronic (delayed-onset), 9.261–263, 9.262*f*
- bacterial, 9.261–262, 9.262*f*
- fungal, 9.262
- Propionibacterium acnes* causing, 4.119, 4.119*f*, 8.246, 9.119, 9.261–262, 9.262*f*, 11.140, 11.162
- epithelial and fibrous ingrowth after, 10.141–142, 10.142*f*
- implantable cardioverter-defibrillators and, 1.117, 1.284
- infectious scleritis and, 9.259
- lens particle glaucoma and, 11.67
- after limbal relaxing incisions, 13.58
- malignant/ciliary block glaucoma (aqueous misdirection) and, 10.139
- ocular surface, 8.351*t*
- for ocular surface tumors, 8.329–330, 8.330*f*
- in older patients, 1.180–181
- perioperative management for, 1.283–293, 1.289*t*
- intraoperative considerations and, 1.290–293, 1.293*t*
- medication management and, 1.285–287
- in older patients, 1.180–181
- preoperative assessment/management and, 1.283–290, 1.289*t*. *See also* Preoperative assessment/preparation for surgery
- recent developments and, 1.283
- after radial keratotomy, 13.52–53
- refractive, 13.7, 13.8*t*, 13.137–157. *See also*
- Keratorefractive surgery; Refractive surgery; *specific procedure*
- accommodating IOLs, 13.8*t*, 13.154, 13.163–164, 13.164*f*
- bioptics, 13.137, 13.157
- light-adjustable IOLs, 13.153–154, 13.154*f*
- limitations of, 13.47*t*
- monofocal IOLs, 13.151
- multifocal IOLs, 13.8*t*, 13.155–156, 13.165–167, 13.166*f*
- phakic/phakic IOLs, 13.8*t*, 13.137, 13.138–147, 13.139*t*, 13.142*f*, 13.143*f*. *See also specific procedure*
- pseudophakic, 13.8*t*. *See also specific procedure*
- refractive lens exchange, 13.8*t*, 13.137, 13.147–151
- toric IOLs, 13.8*t*, 13.137, 13.148–149, 13.151–153
- suprachoroidal hemorrhage and, 11.159–160, 11.171
- sympathetic ophthalmia secondary to, 4.185, 9.171, 9.172, 9.174, 12.233. *See also* Surgery
- for uveitis, 9.109
- Ocular tics, 6.201–202
- Ocular tilt reaction, 5.216*f*, 5.216–217
- torsional nystagmus in, 5.245
- Ocular torsion, 6.107
- Ocular torticollis, 6.82–84, 6.83*t*
- Ocular toxocariasis (OT). *See* *Toxocara* (toxocariasis)
- Ocular toxoplasmosis. *See* *Toxoplasma* (toxoplasmosis)
- Ocular trauma. *See* Trauma
- Ocular Trauma Score, 12.364, 12.364*t*
- Ocular tumors. *See* Intraocular tumors; Tumors
- Oculoauriculovertebral spectrum/sequence (OAVS), 6.210, 7.37, 7.37*f*
- Oculoauriculovertebral syndrome (OAV/Goldenhar-Gorlin syndrome), 8.191*t*, 8.195*f*, 8.195–196
- Oculocardiac reflex, 2.99, 6.174
- atropine affecting, 2.314
- Oculocerebrorenal syndrome (Lowe disease/syndrome), 4.118, 6.391
- congenital corneal keloids in, 8.107, 8.125
- ocular findings in carriers of, 2.199*t*, 2.200
- Oculocutaneous albinism (OCA), 2.185, 2.278, 4.142. *See also* Albinism
- racial and ethnic concentration of, 2.197
- Oculodento-osseous dysplasia, 8.192*t*
- Oculodentodigital dysplasia
- Axenfeld-Rieger syndrome differentiated from, 10.154*t*
- description of, 12.282*t*
- Oculodermal/dermal/dermal orbital melanocytosis (nevus of Ota), 4.63*t*, 4.64, 6.251, 7.175, 7.175*f*, 8.339, 8.339*t*
- glaucoma associated with, 10.30
- of iris, 4.259
- Oculodigital reflex, 6.185, 12.266
- Oculoglandular syndrome, Parinaud (POS), 4.51, 8.265–266, 9.256. *See also* Cat-scratch disease
- Oculogyric crisis, 5.231
- Oculomandibulodyscephaly (Hallermann-Streiff-François syndrome), 8.191*t*
- Oculomasticatory myorhythmia, 5.251
- Oculomotor foramen, 7.12
- Oculomotor neuropathy, recurrent painful, 5.197
- Oculomycosis, 8.249–251. *See also* Fungi
- trauma and, 8.251
- Oculopalatal myoclonus/tremor, pendular nystagmus and, 5.246–247
- Oculopharyngeal dystrophy, 5.329
- ptosis in, 5.273, 5.273*t*, 5.329
- Ocupress. *See* Carteolol
- Ocusert delivery system, 2.302. *See also* Pilocarpine
- ODAd. *See* Overdepression in adduction
- ODD. *See* Optic disc (optic nerve head/ONH), drusen of
- Odds ratio (OR), 1.22
- OEAd. *See* Overelevation in adduction
- Off-axis object point, 3.72
- Off-bipolar cells, 2.257, 2.266, 2.266*f*
- Off-label uses
- for conductive keratoplasty, 13.129
- of drug, 2.305, 2.306
- refractive surgery in ocular and systemic disease and, 13.171
- Off retinal ganglion cells, 2.267, 2.267*f*, 2.268*f*
- “Off-the-pump bypass surgery,” 1.102
- Ofloxacin, 1.277, 2.346, 2.347*t*, 2.347–349
- for bacterial keratitis, 8.269, 8.270*t*
- for gonococcal conjunctivitis, 8.259
- OGTT. *See* Oral glucose tolerance test
- Oguchi disease, 12.253
- arrestin mutation causing, 2.161, 2.263
- racial and ethnic concentration of, 2.197
- rhodopsin kinase mutation causing, 2.263
- “Ohno” sign, 12.233
- OHS. *See* Ocular histoplasmosis syndrome
- OHT. *See* Ocular hypertension

- OHTS (Ocular Hypertension Treatment Study), 1.21, 1.22, 10.65, 10.81, 10.82, 10.83, 10.89–90, 10.112
- Oil droplet appearance/cataract, 11.44
in galactosemia, 11.61, 11.61f
in lenticonus/lentiglobus, 11.30
- Oil glands, of eyelid, 7.170
lesions originating in, 7.170. *See also under Sebaceous*
- Ointments, ocular, 2.298–299. *See also Lubricants*
for dry eye, 2.341
- OIS. *See* Ocular ischemic syndrome
- OIS (orbital inflammatory syndrome). *See* Nonspecific orbital inflammation
- OKN. *See* Optokinetic system/nystagmus
- Olanzapine, 1.194
- Older patients. *See* Age/aging; Geriatrics
- Oleic acid, in pigment retinal epithelium, 2.276
- Olfactory bulb, 2.83, 2.85f, 2.106f
- Olfactory nerve. *See* Cranial nerve I
- Olfactory tract, 2.83, 2.85f
- Oligemic shock, 1.300. *See also Shock*
- Oligoarticular (pauciarticular)-onset juvenile idiopathic (chronic/rheumatoid) arthritis (oligoarthritis), 1.156, 9.122. *See also Juvenile idiopathic (chronic/rheumatoid) arthritis*
eye examination schedule for children with, 9.124t
uveitis in, 9.122
- Oligodendrocytes, 2.88f, 4.241, 4.242f
- Oligodendroglia
optic nerve, 2.87
retinal, 2.257, 2.268
- Oligonucleotide microarray analysis, SNP (SOMA), 4.39t
- Oligonucleotides, in gene therapy, 2.169–170, 2.170f
- Oligosaccharide, core, 9.13
- Olivopontocerebellar atrophy, 12.282t
- Olmesartan, 1.68t
- Olopatadine, 2.238, 2.338t, 2.339
- Omalizumab, for asthma, 1.129
- Omega-3 fatty acid supplements
for dry eye, 8.61, 8.61t, 8.64, 8.68
dry eye management and, 2.370
- Omega-3 long-chain polyunsaturated fatty acids, 12.70
- OMIM (Online Mendelian Inheritance in Man), 2.140, 2.160, 6.294, 12.255
for corneal dystrophies, 8.191–192t
- Omnipause cells/neurons, 5.38, 5.219, 5.220f
saccadic intrusions and, 5.248, 5.249
saccadic system and, 5.219, 5.220f
- Omnipred. *See* Prednisolone
- On-bipolar cells, 2.257, 2.266, 2.266f
- On retinal ganglion cells, 2.267, 2.267f, 2.268f
- OnabotulinumtoxinA, 5.281, 7.238. *See also Botulinum toxin*
as tarsorrhaphy alternative, 8.373
- Onchocerca*/*Onchocerca volvulus* (onchocerciasis), 8.252–253, 9.234–235, 9.235f
- Oncocytoma, 4.71–72, 4.72f, 8.337
- Oncogenes, 1.227, 2.140
- Oncologist, ophthalmic, 4.42
- Ondansetron, perioperative, 1.290
- One-and-a-half syndrome, 5.191, 5.191f
- 100-hue test (Farnsworth-Munsell), in low vision evaluation, 5.79
- 1-piece foldable intraocular lens, insertion of, 11.116
- 1000 Genomes Project, 2.144
- 1 toy, 1 look rule, for pediatric eye examination, 6.3, 6.4f
- ONH. *See* Optic nerve (cranial nerve II), hypoplasia of;
Optic nerve head
- ONL. *See* Outer nuclear layer
- Onlays, corneal, 13.59–71. *See also Inlays, corneal*
- Online Mendelian Inheritance in Man (OMIM), 2.140, 2.160, 6.294, 12.255
for corneal dystrophies, 8.191–192t
- Online post-refractive intraocular lens power calculator (ASCRS), 13.52, 13.195–197, 13.196f
- Online search, 1.3
- ONSF. *See* Optic nerve sheath fenestration
- ONSM. *See* Optic nerve sheath meningioma
- Onycho-osteodysplasia (nail-patella syndrome), 8.192t
gene for, 10.11t
- OPA1* gene, 6.367
in optic atrophy, 5.135
- Opacities
corneal. *See* Cornea, opacification of
fundus evaluation with, 11.81
IOL, 11.151
lens. *See* Cataract
lens fiber, 4.122, 4.122f
vitreous
in amyloidosis, 4.134 12.348, 12.349f
asteroid hyalosis, 12.346f, 12.346–347
bilateral, 12.348
cholesterolosis, 12.348
fibrillar, 2.253
pigment granules, 12.348
in uveitis, 9.290
vitrectomy for, 12.386
vitreous degeneration and detachment associated, 12.344
vitreous hemorrhage, 12.347
- Opaque bubble layer (OBL), femtosecond laser flap creation and, 13.88, 13.122–123
- Opcon-A. *See* Naphazoline/pheniramine
- Open-angle glaucoma, 10.3–5, 10.4t, 10.6t, 10.79–115.
See also Glaucoma
age and, 10.7
angle-closure glaucoma differentiated from, 10.3, 10.5f
aphakic, 6.285
in central retinal vein occlusion, 12.133
central retinal vein occlusion and, 10.84
childhood. *See* Open-angle glaucoma, pediatric
classification of, 10.3–5, 10.4t, 10.6t
combined-mechanism, 10.7
cornea plana and, 8.101
corneal thickness and, 10.81, 10.82, 10.86–87, 10.90
corticosteroids causing, 10.109–110
cycloplegic use in, 2.313, 2.314t
diabetes mellitus and, 10.83
drug-induced, 10.109–111
without elevated intraocular pressure, 10.3, 10.4t, 10.85f, 10.85–88, 10.86t. *See also Glaucoma, normal-tension*
episcleral venous pressure elevation and, 10.102t, 10.102–103, 10.103f
family history and, 10.82

- Fuchs heterochromic iridocyclitis/uveitis and, 10.101–102, 10.102f
- genetic/hereditary factors in, 2.200, 10.10, 10.11t
- glaucoma suspect and, 10.4t, 10.89
- glaucomatocyclitic crisis (Posner-Schlossman syndrome) and, 10.100–101
- hemorrhage/hyphema and, 10.85f, 10.85–86
- intraocular pressure in, 10.79, 10.80–81, 10.81t
- intraocular tumors and, 10.98–100, 10.99f
- juvenile, 6.278, 6.284
- lens-induced, 10.96–98, 10.97f
- management of
- clinical trials in evaluation of, 10.111–115
 - medical, 10.183–184. *See also* Antiglaucoma agents; *specific drug*
 - surgical, 10.187. *See also* Glaucoma surgery; *specific procedure*
 - incisional, 10.113–115. *See also* Filtering procedures
 - laser trabeculoplasty, 10.113–115, 10.188–191, 10.190f
 - minimally invasive procedures/microshunts, 10.219–220
 - nonpenetrating procedures and, 10.217–219
 - microcornea and, 8.95–99
 - myopia and, 10.82, 10.87
 - normal-tension (NTG). *See* Glaucoma, normal-tension
 - ocular hypertension and, 10.89–90, 10.112
 - ocular inflammation and, 10.100–102, 10.102f
 - optic nerve/nerve head/disc appearance in, 5.136, 5.137f, 10.79–80
 - outflow obstruction mechanisms in, 10.5, 10.6t
 - pars planitis and, 9.131
 - pediatric (childhood/congenital/infantile/juvenile), 10.4t, 10.147, 10.148t
 - genetics of, 10.11t, 10.150
 - primary
 - congenital, 4.98, 4.99f, 10.4t, 10.147, 10.148t, 10.151f, 10.151–153, 10.152f, 10.152t. *See also* Primary congenital glaucoma
 - genetics of, 10.11t, 10.150
 - juvenile, 10.4t, 10.148t, 10.153
 - penetrating keratoplasty and, 10.109
 - pigmentary/pigment dispersion syndrome and, 4.105, 4.105f, 10.93–96, 10.94f, 10.95f, 10.96f
 - posterior polymorphous corneal dystrophy and, 8.159
 - primary (POAG), 10.3–5, 10.4t, 10.79–84, 10.81t
 - clinical features of, 10.79–80
 - clinical trials in, 10.111–115. *See also specific study*
 - congenital, 4.98, 4.99f
 - disorders associated with, 10.83–84
 - without elevated intraocular pressure, 10.3, 10.4t, 10.85f, 10.85–88, 10.86t. *See also* Glaucoma, normal-tension
 - epidemiology of, 10.7–8, 10.9t
 - genetic/hereditary factors in, 10.10, 10.11t
 - incidence of, 10.7, 10.8
 - intraocular pressure–lowering drugs for, 2.311
 - juvenile, 10.4t, 10.148t, 10.153
 - management of. *See* Antiglaucoma agents; Glaucoma surgery
 - prevalence of, 10.7–8
 - prognosis/therapy for, 10.84
 - refractive surgery and, 13.180–183, 13.182f, 13.200–201
 - risk factors for, 10.8, 10.9t, 10.80–83
 - pseudoexfoliation/exfoliation syndrome and (pseudoexfoliation glaucoma), 10.91f, 10.91–93, 10.92f
 - race and, 10.7–8, 10.81, 10.82
 - refractive surgery and, 13.180–183, 13.182f, 13.200–201
 - retinal detachment and, 9.279
 - risk factors for, 10.8, 10.9t, 10.80–83
 - Schwartz (Schwartz-Matsuo) syndrome and, 10.109
 - secondary, 10.4t, 10.5, 10.79, 10.91–111. *See also specific cause*
 - trauma causing, 4.103–104, 4.104f, 10.39–40, 10.40f, 10.41f, 10.106–108, 10.107f
 - traumatic, 4.103–104, 4.104f, 10.39–40, 10.40f, 10.41f, 10.106–108, 10.107f
 - uveitic, 9.286
 - visual field loss in, 10.79–80
 - vitrectomy as risk factor for, 12.402
- Open-loop speculum, for globe exposure, in cataract surgery, 11.105f
- Open-loop trackers, 13.91
- Open reading frame (ORF), 2.141, 2.147
- Operating/surgical microscope
 - for intraorbital surgery, 7.121
 - for manual small-incision cataract surgery, 11.198
 - phototoxicity and, 11.166
- Operculated retinal holes, 12.315–316
- OPGs. *See* Optic nerve (optic pathway/chiasm) gliomas
- OphA. *See* Ophthalmic artery
- Ophthacet. *See* Sulfacetamide
- Ophthalmia
 - neonatorum, 8.257t, 8.263–265
 - Chlamydia trachomatis* as cause of, 6.238–239, 6.239f
 - chlamydial, 8.257t, 8.265
 - definition of, 6.237
 - epidemiology of, 6.237
 - etiology of, 6.237
 - gonococcal, 8.257t, 8.258, 8.264
 - herpes simplex. *See* Conjunctivitis, herpes simplex
 - herpes simplex virus as cause of, 6.239
 - Neisseria gonorrhoeae* as cause of, 6.238f, 6.238–239
 - Neisseria meningitidis* as cause of, 6.238
 - prevalence of, 6.237
 - prophylaxis for, 6.239
 - nodosum, 8.387
 - sympathetic (SO), 4.185, 4.186f, 9.47–48, 9.171–175, 9.172f, 9.173f, 9.174f
 - corticosteroids for, 9.175
 - route of administration of, 2.333t
 - enucleation in prevention of, 7.128, 8.404, 9.175
 - evisceration and, 7.130, 9.175
 - glaucoma/glaucoma surgery and, 9.285, 10.195, 10.196, 10.198
 - histologic/histopathologic features of, 4.185, 4.186f, 9.174
 - HLA association in, 9.67t, 9.174
 - incidence of, 7.128
 - surgical procedures/injuries leading to, 4.185, 9.171, 9.172, 9.174

- Ophthalmic artery (OphA), 2.9f, 2.16f, 2.17f, 2.33f, 2.34f, 2.90, 5.8f, 5.12, 5.13f, 5.14f, 5.14–17, 5.15f, 6.23, 7.10f, 7.12f, 7.13, 7.13f, 7.14f, 7.15f
aneurysm of, 5.339
extraocular muscles supplied by, 2.17
eyelids supplied by, 2.25, 7.154
occlusion of, 12.146, 12.147f
optic nerve supplied by, 2.84f, 2.89, 2.90, 2.91, 5.17f, 5.26, 10.44
orbit supplied by, 2.33f, 2.34f, 5.12, 5.13f, 5.14f, 5.14–17, 5.15f, 7.12f, 7.13
terminal, 5.15
Ophthalmic division of cranial nerve V (trigeminal). *See* Cranial nerve V (trigeminal nerve), V₁
Ophthalmic echography. *See* Ultrasonography/
ultrasound (echography)
Ophthalmic examination. *See also* Examination, ophthalmic
in children
 anterior segment examination, 6.10
 Brückner test, 6.9
 communication during, 6.4
 cycloplegic refraction, 6.10–12
 difficult child, 6.5
 distance fixation targets, 6.3, 6.4f
 dynamic retinoscopy, 6.9
 fundus, 6.12
 general considerations and strategies for, 6.3–5
 intraocular pressure measurement, 6.10
 1 toy, 1 look rule, 6.3, 6.4f
 in outpatient setting, 6.3, 6.4f
 practitioner positioning during, 6.4
 pupil testing, 6.10
 red reflex, 6.9
 “safe” environment for, 6.4
 slit-lamp examination, 6.4–5
 tonometry, 6.10
 visual acuity assessment. *See* Children, visual
 acuity assessment
 visual field testing, 6.10
 vocabulary during, 6.4
 diabetes mellitus–related, 12.93–94, 12.95t
Ophthalmic instruments. *See also specific instrument; specific type*
 errors in, after refractive surgery, 3.251–252
 phototoxicity from, 12.368–369
 cataract surgery and, 11.166
 polarized light applications in, 3.99
Ophthalmic irrigants, 2.367. *See also* Irrigation
Ophthalmic lenses. *See also* Lenses; *specific type*
 anophthalmic socket camouflage and, 7.136
 concave (minus/negative), anophthalmic socket
 camouflage and, 7.136
 convex (plus/positive), anophthalmic socket
 camouflage and, 7.136
Ophthalmic oncologist, 4.42
Ophthalmic pathology. *See also specific structure and specific disorder*
 of anterior chamber/trabecular meshwork, 4.97–106
 checklist for requesting, 4.25, 4.33, 4.34t
 communication among health care team members
 and, 4.25–26
 congenital anomalies and, 4.6, 4.7f, 4.12t
 of conjunctiva, 4.47–72
 of cornea, 4.73–96
 cytology for, 4.34t
 degeneration and dystrophy and, 4.9–10, 4.12t
 diagnosis/differential diagnosis and, 4.11–12, 4.12t
 electron microscopy in, 4.34t, 4.42
 of eyelids, 4.201–221
 fine-needle aspiration biopsy in, 4.34t, 4.42–43, 4.43f
 flow cytometry in, 4.34t, 4.36, 4.37f
 frozen section for, 4.34t, 4.43–45, 4.44f
 immunohistochemistry in, 4.33–35, 4.35f
 inflammation and, 4.6–9, 4.8f, 4.9f, 4.12t
 of lens, 4.115–124
 molecular pathology in, 4.34t, 4.36–42, 4.38–39t, 4.40f, 4.41f
 neoplasia and, 4.10, 4.10t, 4.11f, 4.12t
 of optic nerve, 4.241–250
 of orbit, 4.223–240, 7.32–33
 organizational paradigm for, 4.5–12, 4.12t
 of retina/retinal pigment epithelium, 4.139–180
 of sclera, 4.107–112, 4.113f
 special procedures in, 4.33–45
 specimen collection/handling for, 4.25–30, 4.31t
 topography and, 4.6, 4.12t
 of uveal tract, 4.181–199, 4.200f
 of vitreous, 4.125–137
 wound repair and, 4.13–23, 4.14f
Ophthalmic prisms. *See* Prisms
Ophthalmic surgery. *See* Ocular (intraocular) surgery
Ophthalmic ultrasonography. *See* Ultrasonography/
ultrasound (echography)
Ophthalmic vein, 2.9f, 2.16f, 2.35f, 5.8f, 5.21f, 5.22f, 5.23f, 7.10f, 7.12f, 7.13f, 7.13–14, 7.14f, 7.15f
 inferior, 5.8f, 5.21f, 5.22, 5.22f, 5.23f
 orbit drained by, 5.21f, 7.13–14, 7.14f, 7.15f
 superior, 5.8f, 5.21, 5.21f, 5.22f, 5.23, 5.23f
Ophthalmic viscosurgical devices (OVDs/viscoelastic agents), 2.368, 11.95–97
 for cataract surgery, 11.95–97
 advanced cataract and, 11.180
 aniridia and, 11.184
 capsular block syndrome and, 11.148
 capsular rupture during surgery and, 11.142–143
 ECCE, 11.197
 high hyperopia and, 11.185
 ICCE, 11.200
 inflamed eye and, 11.191
 intumescent cataract and, 11.179–180
 IOL implantation and, 11.116, 11.117–118
 in keratoconjunctivitis sicca, dry eye therapy before
 use of, 11.173
 phacoemulsification, 11.105, 11.109, 11.110, 11.112, 11.115, 11.116, 11.117–118
 posterior polar cataract and, 11.181
 pupil expansion and, 11.178
 selection of, 11.97
 traumatic cataract and, 11.191, 11.192
 uveitis and, 11.191
 zonular dehiscence with lens subluxation or
 dislocation and, 11.182
 in corneoscleral laceration repair, 8.405f, 8.406
 elevated intraocular pressure and, 10.108, 11.136
 for goniotomy and trabeculotomy, in children,
 10.162–163

- intracameral administration of, 2.300*t*
- phakic IOL implantation and, 13.141
 - posterior chamber lenses, 13.143
- physical properties of, 11.96
- toric IOL implantation and, 13.152
- Ophthalmic wound healing/repair. *See* Wound healing/repair
- Ophthalmology examination, 3.23
- Ophthalmometry/ophthalmometer. *See* Keratometry/keratometer
- Ophthalmopathy, thyroid (Graves/dysthyroid). *See* Thyroid eye disease
- Ophthalmoplegia
 - cavernous sinus lesion causing, 5.202–206, 5.204*f*, 5.205*f*
 - in gaze palsy, 5.228
 - herpes infection and, 5.350
 - internuclear (INO), 5.38, 5.189–190, 5.190*f*, 5.247
 - bilateral/wall-eyed bilateral (WEBINO), 5.189, 5.190*f*
 - in multiple sclerosis, 5.318
 - in multiple sclerosis, 5.318
 - myasthenia gravis and, 5.190, 5.324
 - in neuromyelitis optica, 5.322
 - nystagmus in, 5.189, 5.190*f*, 5.247
 - one-and-a-half syndrome and, 5.191
 - pursuit dysfunction in, 5.226
 - in myotonic dystrophy, 5.329
 - in oculopharyngeal dystrophy, 5.329
 - in optic neuropathy, 5.126
 - progressive (chronic progressive) external (CPEO), 2.158, 5.328–329, 5.329*f*
 - mitochondrial DNA defects and, 2.157, 2.158
 - ptosis in, 5.273, 5.273*t*, 5.328, 5.329*f*
 - syndromes associated with, 2.158
 - in third nerve palsy (recurrent painful oculomotor neuropathy), 5.197
- Ophthalmoplegic migraine, 5.197. *See also* Migraine headache
- Ophthalmoscopy/ophthalmoscope
 - before cataract surgery, 11.80–81
 - confocal scanning laser, 3.302, 3.302*f*
 - definition of, 3.296
 - direct, 3.281, 3.297–298*f*, 3.297–298, 3.307
 - limitations of, 12.21
 - in low vision evaluation, 5.81
 - in optic nerve/nerve head/disc evaluation, 10.48, 10.56
 - retinal disease evaluations using, 12.21
 - fundus camera, 3.301
 - in glaucoma evaluation, 10.48, 10.49*t*, 10.56
 - in infants and children, 10.160
 - indirect, 3.281, 3.298–300*f*, 3.298–301, 3.307
 - in choroidal/ciliary body melanoma, 4.265
 - illumination in, 12.21
 - in optic nerve/nerve head/disc evaluation, 10.48
 - posterior vitreous detachment diagnosed using, 12.309, 12.331
 - retinal disease evaluations using, 12.21–22
 - laser, in optic nerve/nerve head/disc evaluation, 10.56
 - retinal disease evaluations using, 12.21–22
- Ophthalmic. *See* Proparacaine
- OPL. *See* Outer plexiform layer
- OPP. *See* Ocular perfusion pressure
- Opportunistic infections, 12.235–236. *See also*
 - Immunocompromised host; *specific type*
 - CMV retinitis, 4.145, 4.146*f*, 9.198, 9.294–295
 - cryptococcosis, 9.270
 - in HIV infection/AIDS, 1.267–272, 1.268*t*, 9.293, 9.301. *See also specific type*
- Opsins
 - cone, 2.261
 - genes for, 2.262, 2.264
 - rod. *See* Rhodopsin
- Opsoclonus (saccadomania), 5.248–249, 6.153, 6.415
 - in neuromyelitis optica, 5.322
- Opsonization, complement, 9.22, 9.23*f*
- Optic ataxia, 5.223
- Optic atrophy, 4.245*f*, 4.245–246, 4.246*f*, 4.247*f*, 5.81–82, 5.82*f*, 5.145–146
 - ascending, 4.245–246
 - autosomal dominant (ADOA), 5.135, 5.136*f*
 - in Behçet disease, 9.186
 - Behr, 6.368
 - bow-tie, 5.25*f*, 5.153
 - causes of, 6.367, 6.367*t*
 - cavernous, of Schnabel, 4.246, 4.247*f*
 - descending, 4.246
 - dominant, 5.135, 5.136*f*, 6.367–368, 6.368*f*
 - genes and loci associated with, 12.256*t*
 - Leber hereditary optic neuropathy, 6.368
 - in onchocerciasis, 9.235
 - in optic tract syndrome, 5.153
 - recessive, 6.368
 - in Rift Valley fever, 9.211
 - traumatic hyphema and, 8.393, 8.394, 8.395*t*
- Optic (optical) axis, 3.51, 3.124, 3.129, 3.129*f*, 11.9, 11.10*f*
- Optic canal, 2.6*f*, 2.17*f*, 2.87, 2.88*f*, 5.5, 5.6*f*, 5.7*f*, 5.10*f*, 5.11, 5.26, 7.6*f*, 7.7*f*, 7.8, 7.10, 7.19. *See also*
 - Intracranial region of optic nerve
 - decompression of, for traumatic vision loss, 5.140, 7.114
- Optic cap (apical zone), 8.25
- Optic chiasm. *See* Chiasm
- Optic cup, 2.86, 10.48
 - in AAIION/NAION, 5.120, 5.121*f*, 5.122
 - asymmetry of, 10.48–49, 10.49*f*
 - development of, 2.115, 2.117, 2.117*f*, 2.118*f*, 2.119*f*, 11.25
 - enlargement of, 2.86, 10.47*f*, 10.48, 10.49*f*, 10.49*t*. *See also* Cupping of optic nerve/nerve head/disc
 - extraocular muscle development and, 2.124
 - ratio of, to optic disc (cup–disc ratio), in glaucoma evaluation, 10.48, 10.53
 - in infants and children, 10.160
 - retinal development and, 2.117*f*
 - vertical elongation of, 10.49, 10.50*f*
- Optic disc (optic nerve head/ONH), 2.37*f*, 2.67, 2.85, 2.85*t*, 2.86–87, 2.88*f*, 5.17*f*, 5.24–25, 5.25*f*. *See also*
 - Optic nerve
 - anatomy of, 2.37*f*, 2.67, 2.85, 2.85*t*, 2.86–87, 2.88*f*, 5.17*f*, 5.24–25, 5.25*f*
 - atrophy of. *See* Optic atrophy
 - blood supply of, 2.85*t*, 2.89, 2.90–91, 2.91*f*, 2.92*f*, 5.17*f*
 - coloboma of, 2.152, 4.242, 4.243*f*, 6.339*f*

- congenital/developmental abnormalities of, 4.241–242, 4.243f, 5.143f, 5.143–145, 5.144f
transient visual loss and, 5.164
- cupping of. *See* Cupping of optic nerve/nerve head/disc
- drusen of (ODD), 4.247, 4.247f, 5.108f, 5.140–143, 5.141f, 6.373f, 6.373–374
astrocytic hamartoma differentiated from, 5.108f, 5.143
autofluorescence in identification of, 5.89, 5.90f, 5.141f, 5.142
papilledema/pseudopapilledema and, 4.247, 5.107, 5.108f, 5.141f, 5.142–143
transient visual loss and, 5.141, 5.161, 5.164
ultrasonography in identification of, 5.95, 5.141f, 5.142
- dysplastic, 5.145
- edema of, 5.82, 5.83f, 5.105–113, 5.107t, 5.108f, 5.109f, 5.110f, 5.111t. *See also* Papilledema; Pseudopapilledema
in anterior optic neuropathy, 5.104
AAION, 5.120, 5.120t, 5.121f
NAION, 5.120, 5.120t, 5.121f, 5.122, 5.123t
in diabetic papillopathy, 5.125, 5.125f
fluorescein angiography in evaluation of, 5.89
neuroimaging in evaluation of, 5.71, 5.109
in neuroretinitis, 5.118, 5.118f, 5.118–119, 9.256
in optic atrophy, 4.245, 4.245f
in papillitis, 5.113
in papillophlebitis, 5.125, 5.126f
in syphilis, 9.238
in Whipple disease, 9.258
- examination of
in glaucoma evaluation, 10.32, 10.48–59. *See also*
Optic disc (optic nerve head/ONH), in glaucoma
in low vision evaluation, 5.81–82, 5.82f, 5.83f
- excavation of, 5.137f
congenital, 5.145
in glaucoma, 5.136, 5.137f
- in Foster-Kennedy/pseudo-Foster-Kennedy syndrome, 5.122
- in glaucoma, 5.136, 5.137f, 10.3, 10.48
evaluation of, 10.32, 10.48–59, 10.49f, 10.49t, 10.50f, 10.51f, 10.55f, 10.56f, 10.57f, 10.58f
imaging and, 10.53–59, 10.55f, 10.56f, 10.57f, 10.58f
normal-tension glaucoma and, 10.86
perimetry changes correlated with, 10.74–75
recording findings and, 10.53
hemorrhage of, 10.50, 10.51f, 10.85f, 10.85–86
open-angle glaucoma and, 10.79–80
visual field changes and, 10.74–75
- hemangioblastoma of, 4.284, 4.284f, 4.285
- in HTLV-1 infection, 9.212
- hypoplasia of, 5.143f, 5.143–144
- imaging in evaluation of, 10.53–59, 10.55f, 10.56f, 10.57f, 10.58f
- in Leber hereditary optic neuropathy, 5.133, 5.134f
- megalopapilla, 6.366
- melanocytoma (magnocellular nevus) of, 4.248, 4.248f, 4.257f, 4.258, 4.268, 6.367, 6.367f
melanoma differentiated from, 4.268
- morning glory, 5.145
- neovascularization of (NVD), in diabetic retinopathy, papillopathy and, 5.125
- nerve fibers entering, 10.42–43, 10.43f, 10.45f
- neuroimaging in evaluation of, 5.71
- pallor of, 5.81–82, 5.82f. *See also* Optic atrophy
OCT in evaluation of, 5.91f
- papilledema of
definition of, 6.370
idiopathic intracranial hypertension and, 6.370f, 6.370–371
peripapillary staphyloma of, 6.366
pseudopapilledema of, 6.372–373f, 374
sarcoid granuloma involving, 5.126f, 5.327
swelling of, 6.371t
tilted, 5.144, 5.144f, 6.365–366, 6.366f
topography, 2.37f, 10.53
tumors of, 4.248f, 4.248–250, 4.249f, 4.250f
metastatic, 4.303, 4.307–308
- Optic disc cup, 6.282, 6.283f
- Optic disc pits. *See* Optic pits
- Optic foramen, 2.7, 5.7f, 7.10
- Optic gliomas. *See* Optic nerve (optic pathway/chiasm) gliomas
- Optic holes. *See* Holes
- Optic nerve (cranial nerve II), 4.241–250, 7.12f, 7.13f, 7.14f, 7.15f. *See also* Optic nerve head
in acute retinal necrosis, 9.194
anatomy of, 2.9f, 2.16f, 2.37f, 2.70–71, 2.83–93, 2.84f, 2.85t, 2.85f, 2.88f, 2.89f, 2.90f, 2.91f, 2.92f, 4.241, 4.242f, 5.8f, 5.16f, 5.17f, 5.18f, 5.23f, 5.25f, 5.26–27, 5.27f, 5.43f, 5.48f, 5.55f, 10.41–46, 10.43f, 10.44f, 10.45f
anterior/anterior zone of, 10.42
aplasia of, 6.366
atrophy of. *See* Optic atrophy
in Behçet disease, 9.186
blood supply of, 2.85t, 2.89, 2.90–91, 2.91f, 2.92f, 5.17f, 5.18f, 10.44–46, 10.45f
coloboma of, 2.152, 4.242, 4.243f, 6.364–365f
conduction delay, visual evoked potentials of, 12.52
congenital/developmental abnormalities of, 4.241–242, 4.243f, 5.143f, 5.143–145, 5.144f
transient visual loss and, 5.164
craniosynostosis-related abnormalities of, 6.208–209
decussation of, 6.43
degenerations of, 4.245f, 4.245–247, 4.246f, 4.247f
development of
anomalies of, 6.361–367, 6.362–367f
description of, 2.119f, 2.124
disorders of, 4.241–250. *See also* Optic neuropathy; *specific type*
color vision affected in, 5.78
hallucinations and, 5.176
illusions and, 5.175
neoplastic, 4.248f, 4.248–250, 4.249f, 4.250f, 4.303, 4.307–308
radiation causing, 1.231, 5.358, 5.358f
relative afferent pupillary defect in, 5.81
- dysplastic, 5.145
- evaluation of
before cataract surgery, 11.81
electrophysiologic testing in, 5.95–97, 5.96f

- in glaucoma, 10.41–46, 10.43*f*, 10.44*f*, 10.45*f*
 - in infants and children, 10.160
 - normal-tension glaucoma and, 10.86
 - before refractive surgery, 13.44
- in glaucoma, 10.3, 10.46–59, 10.47*f*, 10.49*f*, 10.50*f*, 10.51*f*, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*. *See also* Optic neuropathy
 - examination of, 10.41–46, 10.43*f*, 10.44*f*, 10.45*f*
 - in infants and children, 10.160
 - normal-tension glaucoma and, 10.86
- glioma of. *See* Optic nerve (optic pathway/chiasm) gliomas
- in granulomatosis with polyangiitis (Wegener granulomatosis), 5.115, 9.138
- hypoplasia of, 5.143*f*, 5.143–144, 6.154, 6.361–362, 6.362*f*
 - nystagmus in, 5.236
- infection of, 4.243*f*, 4.243–244, 4.244*f*
- infiltrative lesions of, 5.126*f*, 5.126–127, 5.131–133
- inflammation of, 4.243*f*, 4.243–245, 4.244*f*, 4.245*f*, 5.113–118, 5.114*f*, 5.117*t*. *See also* Optic neuritis
- intracanalicular region of, 2.83, 2.85*t*, 2.89–90, 4.241
 - blood supply of, 2.85*t*, 2.89, 2.91
 - compressive lesions of, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
 - transient visual loss and, 5.164
- intracranial region of, 2.83, 2.85*t*, 2.90, 2.90*f*, 4.241, 5.26–27
 - blood supply of, 2.85*t*, 2.90, 2.91, 2.92*f*
- intraocular region of, 2.83, 2.85, 2.85*t*, 2.86–89, 2.88*f*, 2.89*f*, 4.241
 - blood supply of, 2.85*t*
- intraorbital region of, 2.83, 2.85, 2.85*t*, 2.87–89, 4.241, 5.26, 7.5, 7.11, 10.42
 - blood supply of, 2.85*t*, 2.91, 2.91*f*
 - compressive lesions of, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
 - length of, 7.5*t*, 7.11
- laminar area of, 2.85*t*, 2.86, 2.87, 10.42, 10.43, 10.46
 - blood supply of, 2.91
- in leukemia, 4.316, 4.316*f*
- leukemic infiltration of, 6.414, 6.414*f*
- in Lyme disease, 9.246
- magnetic resonance imaging of, 6.363*f*
- meningiomas of, 5.65*f*, 5.66*f*, 5.126, 5.127*f*, 5.127–129, 5.128*t*
- morning glory disc anomaly of, 6.362–363, 6.364*f*
- myelination of, 6.365, 6.365*f*
- orbital varices affecting, 7.71
- in pathologic myopia, 12.217–218, 12.218*f*
- peripapillary intrachoroidal cavitations, 12.215, 12.215*f*
- posterior, 10.42
- prelaminar area of, 2.85*t*, 2.86, 10.42, 10.43, 10.45*f*, 10.45–46. *See also* Optic nerve head
 - blood supply of, 2.85*t*, 2.91, 2.91*f*, 2.92*f*
- in primary congenital glaucoma, 6.282–283, 6.283*f*
- regional differences in, 2.83–85, 2.85*t*
- retinal ganglion cells in, 10.41–42
 - degeneration of, in glaucomatous optic neuropathy, 10.46–47
- retinoblastoma involving, 4.176*f*, 4.176–177, 4.177*f*, 4.293
- retrolaminar area of, 2.86, 2.87, 10.42, 10.43, 10.45*f*, 10.46
 - blood supply of, 2.90–91, 2.92*f*
- in Rift Valley fever, 9.211
- sarcoidosis involving, 5.115, 5.126*f*, 5.327
- in syphilis, 9.240
- in thyroid eye disease, 4.226, 5.131, 5.132*f*, 7.52, 7.54, 7.56, 7.59
- topography of, 2.37*f*, 4.241, 4.242*f*
- trauma to, 5.139*f*, 5.139–140, 7.10, 7.113
- tumors of, 4.248*f*, 4.248–250, 4.249*f*, 4.250*f*. *See also specific type*
 - meningioma, 5.127–129, 5.128*f*
 - metastatic, 4.303, 4.307–308
- in uveitis, 9.80*t*
- in Vogt-Koyanagi-Harada syndrome, 9.176, 9.177*f*
- Optic nerve glioblastomas (malignant optic gliomas of adulthood/MOGAs), 4.249, 5.130–131, 7.76
- Optic nerve (optic pathway/chiasm) gliomas (OPGs/pilocytic astrocytomas), 4.249, 4.249*f*, 4.295, 5.126, 5.128*t*, 5.129*f*, 5.129–131, 7.74–77, 7.75*f*. *See also* Optic pathway glioma
 - in children (juvenile), 4.249
 - malignant (malignant optic gliomas of adulthood/MOGAs/glioblastomas), 4.249, 5.130–131, 7.76
 - in neurofibromatosis, 5.130, 5.334*t*, 7.74, 7.76, 7.78
 - orbital involvement and, 7.74–77, 7.75*f*
- Optic nerve head (ONH/optic disc), 2.37*f*, 2.67, 2.85, 2.85*t*, 2.86–87, 2.88*f*, 5.17*f*, 5.24–25, 5.25*f*. *See also* Optic disc; Optic nerve
 - anatomy of, 5.17*f*, 5.24–25, 5.25*f*
 - angiomatous lesion of, 12.242
 - atrophy of. *See* Optic atrophy
 - avulsion of, 12.365, 12.365*f*
 - blood supply of, 2.85*t*, 2.89, 2.90–91, 2.91*f*, 2.92*f*, 5.17*f*
 - coloboma of, 2.152, 4.242, 4.243*f*
 - congenital/developmental abnormalities of, 4.241–242, 4.243*f*, 5.143*f*, 5.143–145, 5.144*f*
 - transient visual loss and, 5.164
 - cupping of. *See* Cupping of optic nerve/nerve head/disc
 - drusen of (ODD), 4.247, 4.247*f*, 5.108*f*, 5.140–143, 5.141*f*, 12.260
 - astrocytic hamartoma differentiated from, 5.108*f*, 5.143
 - autofluorescence in identification of, 5.89, 5.90*f*, 5.141*f*, 5.142
 - papilledema/pseudopapilledema and, 4.247, 5.107, 5.108*f*, 5.141*f*, 5.142–143
 - transient visual loss and, 5.141, 5.161, 5.164
 - ultrasonography in identification of, 5.95, 5.141*f*, 5.142
 - dysplastic, 5.145
 - edema of, 5.82, 5.83*f*, 5.105–113, 5.107*t*, 5.108*f*, 5.109*f*, 5.110*f*, 5.111*t*, 12.234, 12.349. *See also* Papilledema; Pseudopapilledema
 - in anterior optic neuropathy, 5.104
 - AAION, 5.120, 5.120*t*, 5.121*f*
 - NAION, 5.120, 5.120*t*, 5.121*f*, 5.122, 5.123*t*
 - in diabetic papillopathy, 5.125, 5.125*f*
 - fluorescein angiography in evaluation of, 5.89

- neuroimaging in evaluation of, 5.71, 5.109
- in neuroretinitis, 5.118, 5.118f, 5.118–119, 9.256
- in optic atrophy, 4.245, 4.245f
- in papillitis, 5.113
- in papillophlebitis, 5.125, 5.126f
- in syphilis, 9.238
- in Whipple disease, 9.258
- examination of
 - in glaucoma evaluation, 10.32, 10.48–59. *See also* Optic nerve head (ONH/optic disc), in glaucoma
 - in low vision evaluation, 5.81–82, 5.82f, 5.83f
- excavation of, 5.137f
- congenital, 5.145
- in glaucoma, 5.136, 5.137f
- in Foster-Kennedy/pseudo-Foster-Kennedy syndrome, 5.122
- in glaucoma, 5.136, 5.137f, 10.3, 10.48
 - evaluation of, 10.32, 10.48–59, 10.49f, 10.49t, 10.50f, 10.51f, 10.55f, 10.56f, 10.57f, 10.58f
 - imaging and, 10.53–59, 10.55f, 10.56f, 10.57f, 10.58f
 - normal-tension glaucoma and, 10.86
 - perimetry changes correlated with, 10.74–75
 - recording findings and, 10.53
- hemorrhage of, 10.50, 10.51f, 10.85f, 10.85–86
- open-angle glaucoma and, 10.79–80
- visual field changes and, 10.74–75
- hemangioblastoma of, 4.284, 4.284f, 4.285
- in HTLV-1 infection, 9.212
- hyperemia of, 12.232
- hypoplasia of, 5.143f, 5.143–144
- imaging in evaluation of, 10.53–59, 10.55f, 10.56f, 10.57f, 10.58f
- in Leber hereditary optic neuropathy, 5.133, 5.134f
- melanocytoma (magnocellular nevus) of, 4.248, 4.248f, 4.257f, 4.258, 4.268
- melanoma differentiated from, 4.268
- morning glory, 5.145
- neovascularization of (NVD)
 - description of, 12.128, 12.129f, 12.170
- in diabetic retinopathy, papillopathy and, 5.125
- nerve fibers entering, 10.42–43, 10.43f, 10.45f
- neuroimaging in evaluation of, 5.71
- pallor of, 5.81–82, 5.82f. *See also* Optic atrophy
- OCT in evaluation of, 5.91f
- in pathologic myopia, 12.217–218, 12.218f
- sarcoid granuloma involving, 5.126f, 5.327
- subretinal hemorrhage, 12.355f
- tilted, 5.144, 5.144f
- topography of, 2.37f, 10.53
- tumors of, 4.248f, 4.248–250, 4.249f, 4.250f
- metastatic, 4.303, 4.307–308
- Optic nerve head (ONH/optic disc) pallor, 5.81–82, 5.82f. *See also* Optic atrophy
- OCT in evaluation of, 5.91f
- Optic nerve sheath, 5.8f
 - inflammation of, 5.119. *See also* Optic perineuritis
- Optic nerve sheath fenestration (ONSF), for idiopathic intracranial hypertension, 5.112
- Optic nerve sheath meningioma (ONSM), 4.250, 4.250f, 5.65f, 5.66f, 5.126, 5.127f, 5.127–129, 5.128t, 7.79, 7.80f, 7.81
- Optic neuritis, 5.107t, 5.113–118, 5.114f, 5.117t, 5.317–318, 6.369, 6.369f
- CMV infection causing, 5.349, 5.349f
- color vision affected in, 5.78, 5.114
- contrast sensitivity affected by, 3.136
- corticosteroids for, 5.116
 - route of administration of, 2.333t
- cryptococcal, 5.356
- hallucinations and, 5.176
- herpes infection and, 5.350
- illusions and, 5.175
- isolated, 5.113–115, 5.114f
- in multiple sclerosis, 5.107t, 5.114, 5.114f, 5.115, 5.116, 5.317–318
- NAION differentiated from, 5.123, 5.123t
- neuroimaging in evaluation of, 5.66f, 5.72t, 5.114f, 5.115
- in neuromyelitis optica, 5.107t, 5.116–118, 5.117t, 5.320–323
- retrobulbar, 5.113, 5.114
 - in cryptococcosis, 5.356
- in syphilis, 9.240
- tests in diagnosis of, 5.115
- toxoplasmic, 5.352
- treatment of, 5.116
- Optic neuropathy, 5.103–146
 - amiodarone, 1.117, 5.137
 - anterior, 5.104
 - ischemic, 5.107t, 5.119–124, 5.120t, 5.121f, 5.123t
 - in antiphospholipid antibody syndrome, 1.161
 - autosomal dominant optic atrophy and, 5.135, 5.136f
 - causes of, 5.104–146. *See also specific disorder*
 - cerebral aneurysms causing, 5.339
 - classification of, 5.104, 5.105t
 - CMV infection causing, 5.349, 5.349f
 - color vision affected in, 5.78
 - compressive or infiltrative, 5.107t, 5.126, 5.126f, 5.126–131, 5.127f, 5.128t, 5.129f, 5.131–133. *See also specific cause*
 - congenital disc and nerve anomalies and, 5.107t, 5.143f, 5.143–145, 5.144f
 - congenital tilted disc syndrome and, 5.144, 5.144f
 - diabetic papillopathy and, 5.125, 5.125f
 - drusen and, 5.107t, 5.108f, 5.140–143, 5.141f. *See also* Drusen
 - excavated optic nerve/nerve head/disc anomalies and, 5.145
 - in giant cell arteritis, 5.120, 5.313
 - in glaucoma, 5.107t, 5.136, 5.137f, 10.3, 10.46–59, 10.47f, 10.49f, 10.50f, 10.51f, 10.55f, 10.56f, 10.57f, 10.58f
 - indications for surgery and, 10.197
 - optic nerve evaluation and, 10.41–46, 10.43f, 10.44f, 10.45f
 - optic nerve/nerve head/disc evaluation/cup changes and
 - imaging and, 10.53–59, 10.55f, 10.56f, 10.57f, 10.58f
 - normal-tension glaucoma and, 10.86
 - perimetry changes correlated with, 10.74–75
 - recording findings and, 10.53
 - patterns of nerve loss and, 10.67–69, 10.68f, 10.69f, 10.70f
 - phacoantigenic glaucoma and, 10.98

- in granulomatosis with polyangiitis (Wegener granulomatosis), 9.138
- hallucinations and, 5.176
- hereditary, 5.107*t*, 5.133–135, 5.134*f*, 5.136*f*
 - autosomal dominant optic atrophy and, 5.135, 5.136*f*
 - Leber (LHON), 2.158, 5.133–135, 5.134*f*
 - mitochondrial DNA mutations and, 2.157, 2.158, 5.133
 - optic neuritis and, 5.115, 5.133
- herpes infection and, 5.350
- hypertensive, 12.123, 12.125
- idiopathic intracranial hypertension and, 5.110–113, 5.111*t*
- of increased intracranial pressure, 5.105–113, 5.107*t*, 5.108*f*, 5.109*f*, 5.110*f*, 5.111*t*. *See also* Papilledema
- indirect traumatic, 2.89
- infiltrative, 5.107*t*, 5.126*f*, 5.126–127, 5.131–133
- inflammatory, 5.113–118, 5.114*f*, 5.117*t*. *See also*
 - Optic neuritis
 - chronic relapsing inflammatory, 5.116
 - pain in, 5.295–296
- intraorbital/intracanalicular lesions and, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
- ischemic, 5.107*t*, 5.119–125, 5.120*t*, 5.121*f*, 5.123*t*
 - anterior (AION), 5.107*t*, 5.119–124, 5.120*t*, 5.121*f*, 5.123*t*
 - arteritic (AAION), 5.107*t*, 5.120, 5.120*t*, 5.120–122, 5.121*f*, 5.313
 - nonarteritic (NAION), 5.107*t*, 5.120, 5.120*t*, 5.121*f*, 5.122–124, 5.123*t*
 - OCT in evaluation of, 5.91*f*
 - perioperative, 5.124–125
 - posterior (PION), 5.107*t*, 5.119, 5.124
- Leber hereditary. *See* Leber hereditary optic neuropathy
- light–near dissociation caused by, 5.266, 5.266*t*
- maculopathy differentiated from, 5.78–79, 5.99–100, 5.100*t*
- mechanisms of, 5.104, 5.107*t*
- neuroimaging in evaluation of, 5.66*f*, 5.72*t*, 5.114*f*, 5.115
- neuromyelitis optica/neuromyelitis optic spectrum disorder (NMO/Devic disease/NMOSD) and, 5.107*t*, 5.116–118, 5.117*t*, 5.320–323
- neuroretinitis and, 5.118*f*, 5.118–119
- nutritional, 5.107*t*, 5.137–139, 5.138*f*
- nystagmus and
 - childhood/infantile nystagmus syndrome, 5.236
 - pendular, 5.246
- OCT in evaluation of, 5.91, 5.91*f*, 5.92
- optic atrophy and, 5.135, 5.136*f*, 5.145–146
- optic nerve hypoplasia and, 5.143*f*, 5.143–144
- with optic nerve/nerve head/disc edema, 5.104
- optic nerve/pathway glioma and, 5.126, 5.128*t*, 5.129*f*, 5.129–131
- optic nerve sheath meningioma and, 5.126, 5.127*f*, 5.127–129, 5.128*t*
- optic neuritis and, 5.107*t*, 5.113–118, 5.114*f*, 5.117*t*
- optic perineuritis and, 5.119
- orbital lesions and, 5.126*f*, 5.126–131, 5.127*f*, 5.129*f*
- orbital varices and, 7.71
- papillitis and, 5.113
- papillophlebitis and, 5.125–126, 5.126*f*
- perimetric findings in, 5.86
- posterior, 5.104
 - ischemic (PION), 5.107*t*, 5.119, 5.124
- radiation (RON), 1.231, 5.358, 5.358*f*
- retrobulbar optic neuritis and, 5.113, 5.114
- in sarcoidosis, 5.115, 5.126*f*, 5.327
- thyroid eye disease and, 5.131, 5.132*f*, 7.52, 7.54, 7.56, 7.59
- toxic, 1.192, 5.107*t*, 5.137–139
- traumatic, 2.89, 5.107*t*, 5.139*f*, 5.139–140, 6.381, 7.113
- visual field patterns in, 5.103, 5.104*f*, 5.105*t*, 5.106*f*
 - versus maculopathy, 5.99, 5.100, 5.100*t*
- Optic pathway glioma, 6.223, 6.396, 6.396*f*. *See also*
 - Optic nerve gliomas
- Optic perineuritis, 5.119
 - radial (radial keratoneuritis), in *Acanthamoeba* keratitis, 4.79
 - in sarcoidosis, 5.327
- Optic pits (optic nerve/disc pits, optic holes, optic pit maculopathy), 5.145, 6.364–365, 6.365*f*, 12.328–329, 12.329*f*
 - acquired, 10.49–50
- Optic radiations (geniculocalcarine pathways), 2.90, 2.90*f*, 2.93, 5.18*f*, 5.19, 5.24*f*, 5.29, 5.30
 - lesions of, 5.153, 5.155
 - in multiple sclerosis, 5.318
- Optic stalk, 2.117*f*, 2.118*f*, 2.124
- Optic strut, 2.6*f*, 2.9*f*, 5.7*f*, 5.16*f*, 5.26, 7.6*f*, 7.10, 7.13*f*
- Optic tract, 2.90, 2.90*f*, 2.93, 5.23*f*, 5.28–29, 5.55*f*
 - lesions of, 5.147*f*, 5.153
 - in multiple sclerosis, 5.318
- Optic tract syndrome, 5.18, 5.153
- Optic vesicle, 2.115, 2.116*t*, 2.117*f*, 2.118*f*
 - lens development and, 2.118, 11.25, 11.26*f*
- Optical aberrations. *See* Aberrations
- Optical (optic) axis, 3.51, 3.124, 3.129, 3.129*f*, 11.9, 11.10*f*
- Optical biometer, for axial length measurement, 3.247, 3.247*f*
- Optical clarity, of ophthalmic viscosurgical device, 11.97
- Optical coherence tomographic angiography (OCTA)
 - artifacts in, 12.29, 12.30*f*
 - choroidal circulation abnormalities, 12.198
 - choroidal neovascularization on, 12.75–76, 12.76–78*f*, 12.192
 - depth resolution using, 12.29
 - diabetic retinopathy on, 12.93, 12.94*f*
 - fluorescein angiography versus, 12.29
 - macular telangiectasia type 2 on, 12.163, 12.164*f*
 - motion artifacts in, 12.29
 - projection artifacts in, 12.29, 12.30*f*
 - pseudoxanthoma elasticum on, 12.199*f*
 - retinal capillary layers on, 12.16
 - retinal disease evaluations using, 12.28–29
 - retinal vasculature on, 12.29, 12.30*f*
 - severity of, 12.93, 12.94*f*
- Optical coherence tomography (OCT), 5.90–94, 5.91*f*, 5.92*f*, 5.93*f*, 5.93–94*f*, 8.21–22, 8.22*f*, 8.35*t*, 13.20*f*
 - in acute idiopathic blind-spot enlargement and multiple evanescent white dot syndrome, 5.92, 5.101
 - acute idiopathic maculopathy on, 12.228

- acute macular neuroretinopathy on, 12.228
 in acute posterior multifocal placoid pigment epitheliopathy, 9.142t, 9.149, 9.150f, 12.221f, 12.222
 in acute retinal pigment epitheliitis, 9.142t, 9.164
 in acute zonal occult outer retinopathy, 5.92, 9.142t, 9.165, 12.227, 12.227f
 anterior segment, 8.21–22, 8.22f
 in glaucoma, 10.77
 in keratoconus, 8.165–166
 in Behçet disease, 9.187f, 9.187–188
 in birdshot uveitis, 9.142t, 9.145, 9.146f
 cancer-associated retinopathy on, 12.287f
 before cataract surgery, 11.82
 central serous chorioretinopathy evaluations, 12.32
 in choroidal hemangioma, 4.281, 4.282f
 in choroidal melanoma/ciliary body melanoma, 4.265, 4.268
 choroidal neovascularization on, 12.192, 12.194
 in choroidal nevus, 4.258
 coherence length and, 3.101–102
 coherence time and, 3.101–102
 in corneal biomechanics evaluation, 8.43
 before corneal transplantation, 8.418
 in cysticercosis, 9.231
 in cystoid macular edema, 12.132f, 12.157, 12.158f
 in uveitis, 9.289
 definition of, 3.282, 3.303, 12.25
 in dengue fever, 9.213
 diabetic macular edema on, 12.111f
 drusen on, 12.65–66
 enhanced depth imaging, 12.25
 epiretinal membranes on, 12.335, 12.383f
 eye movement tracking with, 12.27
 Fourier-domain, 3.304–305
 frequency-domain, 3.304
 in glaucoma, 10.77
 in idiopathic intracranial hypertension, 5.111–112
 in idiopathic macular hole, 4.131–132, 4.132f
 in inflammatory chorioretinopathies, 9.142t
 intraoperative, 8.22
 in IOL power determination, 8.22, 11.82, 11.84–85, 11.87
 in iris melanoma, 4.260, 4.261f
 in keratoconus, 8.165–166
 low-coherence light in, 12.25
 in low vision assessment, 5.90–94, 5.91f, 5.92f, 5.93f, 5.93–94f
 macular hole on, 12.27f
 in metastatic eye disease, 4.307
 in multifocal choroiditis and panuveitis syndrome, 9.142t, 9.156
 in multiple evanescent white dot syndrome, 9.142t, 9.162, 9.163f
 myopic macular schisis on, 12.210f
 nerve fiber layer measurement using, 12.218
 nomenclature terminology for, 12.26–27
 in optic nerve/nerve head/disc drusen, 5.142, 6.373f
 in optic nerve/nerve head/disc/retinal nerve fiber layer evaluation, 10.53–56, 10.55f, 10.56f, 10.57f, 10.58f
 peripapillary intrachoroidal cavitations on, 12.215, 12.215f
 pigment epithelial detachment on, 12.74f
 posterior vitreous detachment on, 12.309, 12.332
 in primary congenital glaucoma evaluations, 6.283
 in punctate inner choroiditis, 9.142t, 9.158
 before refractive lens exchange, 13.149–150
 retinal disease evaluations using, 12.25–27, 12.27f
 in serpiginous choroiditis, 9.142t
 solar retinopathy on, 12.368f
 spectral-domain, 3.304
 adult-onset vitelliform maculopathy on, 12.67–68, 12.68f
 alkyl nitrite findings, 12.300, 12.300f
 chloroquine toxicity monitoring uses of, 12.297
 choroidal neovascularization on, 12.73–75, 12.75f
 diabetic macular edema on, 12.109f, 12.125
 drusen on, 12.64f, 12.65
 epiretinal membranes on, 12.335f
 Gaucher disease on, 12.291
 pathologic myopia on, 12.90f
 reticular pseudodrusen on, 12.65f
 retinal layers on, 12.10–11, 12.11, 12.12f
 retinitis pigmentosa findings, 12.263f
 sensitivity of, 12.26
 swept-source optical coherence tomography versus, 12.25–26
 in subretinal fibrosis and uveitis syndrome, 9.142t
 swept-source
 pathologic myopia findings, 12.209f
 sensitivity of, 12.26
 spectral-domain optical coherence tomography versus, 12.25–26
 in sympathetic ophthalmia, 9.174
 time-domain, 3.303–304, 12.25
 in uveitis, 9.90–91, 9.91f, 9.289
 vitreoretinal traction syndrome on, 12.337, 12.337f
 in Vogt-Koyanagi-Harada syndrome, 9.180, 9.181f
 volume rendering, 12.27, 12.28f
 X-linked retinoschisis on, 12.278, 12.278f
 Optical conjugacy. *See* Conjugacy
 Optical infinity, 3.3
 Optical instruments. *See* *specific instrument*
 Optical (ocular) medium/media
 abnormalities of, 5.99
 diplopia and, 5.185
 fundus examination in evaluation of, 5.81
 perimetry affected by, 5.86
 transient visual loss and, 5.164
 clear, traumatic vision loss with, 7.112–114
 opaque. *See* Cataract; Opacities
 Optical pachymetry/pachymeter, 8.41. *See also* Pachymetry/pachymeter
 Optical pumping, 3.111
 Optical systems. *See also* Optics, of human eye
 aberrations of. *See* Aberrations
 reduced, 3.67–68, 3.68–69f
 Optical zone, corneal, 8.25
 arcuate keratotomy and, 13.54–55, 13.56
 in photoablation, 13.74f
 preoperative laser programming and, 13.81
 pupil size and, 13.40
 radial keratotomy and, 13.50, 13.50f, 13.51
 IOL power calculations affected by, 13.193

- Optically empty vitreous, hereditary
hyaloideoretinopathies with, 12.342–343, 12.343*f*
- Opticin, in vitreous, 2.249, 2.252
angiogenesis suppression and, 2.254
- Opticrom. *See* Cromolyn
- Optics
adaptive, 3.281, 3.305–306, 3.306*f*
challenges for, 3.7
cosmetic, for anophthalmic socket, 7.136
definition of, 3.4
Gaussian, 3.40, 3.60
geometric. *See* Geometric optics
of human eye
accommodation, 3.140–141
axes, 3.128–129, 3.129*f*
binocular states, 3.139–140
contrast sensitivity, 3.134–136, 3.135–136*f*
contrast sensitivity function, 3.134–136
developmental hyperopia, 3.143
developmental myopia, 3.142–143
illusions and, 5.174
mathematical models of, 3.125, 3.126*f*
pupil size effects on visual resolution, 3.129–131
refractive errors, 3.141*f*, 3.141–142
refractive states and, 3.136–139, 3.137–138*f*,
13.7–9. *See also under* Refractive
schematic eye and, 3.125–128, 3.126*f*, 3.127*t*,
3.128*f*. *See also* Schematic eye
visual acuity, 3.131–134, 3.132–133*f*
wavefront analysis and, 13.9–13, 13.10*f*, 13.11*f*,
13.12*f*, 13.13*f*
lenticular, 3.8*f*
nonspherical, 3.257
physical. *See* Physical optics
- OptiPranolol. *See* Metipranolol
- Optisol GS, for donor cornea preservation, 8.414, 8.416*f*
- Optivar. *See* Azelastine
- OPTN* gene, 10.11*t*
- Optociliary shunt vessels (retinochoroidal/retinociliary
venous collaterals), 5.22, 7.22, 7.22*f*
in optic nerve sheath meningioma, 5.127*f*, 5.128
in papilledema, 5.109
- Optokinetic nystagmus (OKN) drum, 5.218–219
congenital motor nystagmus and, 6.148–149
convergence-retraction nystagmus and, 5.250
reflexive saccades and, 5.221
smooth-pursuit system and, 5.224–225, 5.225
- Optokinetic system/nystagmus (OKN), 5.212, 5.212*t*,
5.218–219, 6.40
dysfunction of, 5.218–219
in congenital nystagmus, 5.235
parietal lobe lesions and, 5.156, 5.219
nonorganic disorders and, 5.301–302
- Optotypes, 3.23, 3.124, 3.133*f*
age-appropriate, 6.8
contour interaction bars around, 6.7*f*, 6.8, 6.54
crowding phenomenon for, 6.54
LEA symbols, 6.6, 6.7*f*
in nonorganic disorder evaluation, 5.306
for potential acuity meter testing, 5.88–89
for visual acuity assessment in children, 6.6*t*, 6.6–8, 6.7*f*
- OPV (oral polio vaccine/Sabin vaccine), 1.222
- OR. *See* Odds ratio
- ORA. *See* Ocular Response Analyzer
- Ora bays
definition of, 12.10
illustration of, 12.11*f*
retinal tears near, 12.312
- Ora serrata, 2.37*f*, 2.67, 2.78, 2.79*f*
anatomy of, 12.7, 12.11*f*
binocular indirect ophthalmoscopy of, 12.22
definition of, 12.10
muscle insertion relationships and, 2.15
topography of, 2.37*f*
- Oral contraceptives
central retinal vein occlusion risks, 12.134
hypercoagulability associated with, 1.148
hypertension and, 1.77
ocular effects/retinal toxicity of, 1.308*t*
tetracycline use and, 2.350
thyroxine levels affected by, 1.51
uveitis caused by, 9.121
- Oral facial dyskinesias, 5.285
- Oral glucose tolerance test (OGTT), 1.34
in prediabetes, 1.37
- Oral hypoglycemic agents, 1.43–46, 1.44*f*, 1.45*t*. *See also*
specific type
surgery and, 1.287
- Oral medication, sustained-release preparations of, 2.301
- Oral polio vaccine (OPV/Sabin vaccine), 1.222
- Oral ulcers
in Behçet disease, 1.169, 9.184, 9.184*f*
in SLE, 1.157
- Orbicularis oculi muscle, 2.20*f*, 2.21, 2.23*f*, 4.201, 4.201*f*,
4.202, 5.52, 7.16, 7.141, 7.143*f*, 7.146*f*, 7.147–149,
7.148*f*, 7.154*f*, 8.3, 8.4*f*
blepharospasm and, 5.281
in facial myokymia, 5.284
hemifacial spasm and, 5.283
in involutional entropion, 7.203, 7.204
in lacrimal pump, 7.147, 7.255, 7.256*f*
myectomy for benign essential blepharospasm and,
7.228
spasm of, entropion caused by, 7.205–206
spastic parietic facial contracture and, 5.284
weakness of, in myasthenia gravis, 5.324
- Orbicularis oris muscle, 7.143*f*
- Orbit, 4.223–240. *See also under* Orbital
abscesses of, 7.47, 7.47*f*
adipose tissue in, 6.25
amyloid deposits in, 4.228
anatomy of, 2.5–11, 2.6*f*, 2.8*f*, 2.9*f*, 2.10*f*, 4.223,
5.6–11, 5.7–8*f*, 5.9*f*, 5.10*f*, 7.5–19
assessment of, before refractive surgery, 13.41
sensory and motor components, 5.47–52, 5.48*f*
vascular, 7.13–16, 7.14*f*, 7.15*f*, 7.16*f*
arterial supply, 2.32–35, 2.33*f*, 2.34*f*, 5.12–14,
5.13–14*f*
venous drainage, 2.35, 2.35*f*, 5.21, 5.21*f*
angiography/arteriography in evaluation of, 7.32
anophthalmic socket and, 7.35
apertures in walls of, 7.6*f*, 7.7*f*, 7.8*f*, 7.9–10
basal cell cancer involving, 7.180, 7.181
biopsy of, 7.32–33
fine-needle aspiration, 4.43, 7.33, 7.88
in lymphoproliferative lesions, 4.232

- in nonspecific orbital inflammation, 7.65–66
- in rhabdomyosarcoma, 7.82, 7.83
- bony/bones of, 2.5, 4.223, 5.6–11, 5.7f, 5.9f, 7.5–6, 7.6f, 7.7f, 7.8f
- canals in, 5.11
- cavernous hemangioma of, 4.6, 4.233, 4.234f
- cellulitis affecting. *See* Orbital cellulitis
- compressive lesions. *See* Orbital decompression
- congenital/developmental disorders of, 4.223–224, 4.224f, 7.35–41, 7.37f, 7.38f, 7.39f, 7.41f
- CT in evaluation of, 5.58, 5.58f, 5.60, 5.61t, 5.72t, 5.73f, 7.26f, 7.26–27, 7.27f, 7.30f
- MRI compared with, 7.29t, 7.29–31, 7.30f
- cysts of, 4.223–224, 4.224f
 - dermoid, 4.223, 4.224f, 6.223–224, 6.224f, 7.39f, 7.39–40
 - epidermoid/simple epithelial, 4.223–224, 7.39
 - with microphthalmia (colobomatous cyst), 7.36
- degenerations of, 4.228
- in dermal melanocytosis, 4.64
- development of, 2.124–126, 6.181
- dimensions of, 7.5, 7.5t
- diplopia caused by disorders of, 5.206–209, 5.207f
- disorders of, 4.223–240. *See also specific type*
 - in children
 - congenital/developmental anomalies, 4.223–224, 4.224f, 7.35–41, 7.37f, 7.38f, 7.39f, 7.41f
 - neoplasms, 4.228, 4.229
 - compressive lesions, 5.107t, 5.126, 5.126f, 5.126–131, 5.127f, 5.128t, 5.129f
 - congenital/developmental anomalies, 4.223–224, 4.224f, 7.35–41, 7.37f, 7.38f, 7.39f, 7.41f
 - craniosynostosis. *See* Craniosynostosis
 - dermoid cysts, 6.223–224, 224f
 - ectopic lacrimal gland, 6.226
 - ectopic tissue masses, 6.223–225f, 6.223–226
 - encephalocele, 6.225
 - evaluation of, 7.21–41
 - auscultation in, 7.26
 - biopsy in, 7.32–33. *See also* Orbit, biopsy of
 - history in, 7.21–22, 7.22f, 7.23t
 - imaging studies in, 5.71–73, 5.72t, 5.73f, 7.26f, 7.26–31, 7.27f, 7.28f, 7.29t, 7.30f, 7.32
 - CT, 5.58, 5.58f, 5.60, 5.61t, 5.72t, 5.73f, 7.26f, 7.26–27, 7.27f, 7.30f
 - MRI, 5.44t, 5.58–59f, 5.60–67, 5.61t, 5.62f, 5.63f, 5.63t, 5.64f, 5.65f, 5.66f, 5.67f, 5.72t, 7.28f, 7.28–29, 7.30f
 - primary, 7.26f, 7.26–31, 7.27f, 7.28f, 7.29t, 7.30f
 - secondary, 7.32
 - ultrasonography, 5.70–71, 5.72t, 7.31
 - inspection in, 7.23–25, 7.24f, 7.25f
 - laboratory studies in, 7.33–34
 - palpation in, 7.25–26
 - physical examination in, 7.23–26, 7.24f, 7.25f
 - globe displacement and, 7.11–12, 7.23–24, 7.95, 7.95f
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137–138
 - granulomatous, 7.43t
 - infections, 4.226–228, 4.228f, 7.43t, 7.44–51. *See also* Orbit, infection/inflammation of
 - infiltrative, 5.126f, 5.126–127
 - inflammation, 4.224–226, 4.225f, 4.226f, 6.215–216. *See also* Nonspecific orbital inflammation; Orbit, infection/inflammation of
 - malformations
 - arteriovenous, 6.222
 - lymphatic, 6.221–222
 - vascular, 6.221–222
 - venous, 6.222
 - meningocele, 6.225
 - metastatic tumors, 6.218
 - microphthalmia with cyst, 6.224, 6.225f
 - mucocoele, 6.224
 - mucormycosis, 6.215, 6.215f
 - neoplasms, 4.228–240, 7.67–101. *See also* Orbit, tumors of
 - benign, 6.219–223
 - in children, 4.228, 4.229
 - differential diagnosis of, 6.216–217
 - hemangiomas, 6.219–221
 - hematopoietic, 6.218–219
 - histiocytic, 6.218–219
 - Langerhans cell histiocytosis, 6.218–219
 - leukemia, 6.218
 - lymphoma, 6.218
 - lymphoproliferative, 6.218–219
 - metastatic, 6.218
 - neuroblastoma, 6.218
 - primary malignant, 6.217–218
 - rhabdomyosarcoma, 6.217f, 6.217–218
 - sarcomas, 6.218
 - vascular, 6.219–221, 6.220–221f
 - orbital cellulitis, 6.213–215, 6.214f
 - pain and, 5.295–296, 7.21. *See also* Pain
 - periorbital changes and, 7.22, 7.22f, 7.23t
 - preseptal cellulitis, 6.212–214
 - pulsation and, 7.26
 - rate of progression of, 7.21–22
 - space-occupying lesions, 6.216
 - teratoma, 6.225f, 6.225–226
 - Th1-mediated delayed hypersensitivity and, 9.46t
 - tonic pupil caused by, 5.265
 - transient visual loss and, 5.164
 - tumors
 - bony, 6.222
 - connective tissue origin, 6.222
 - neural origin, 6.223
 - vasculitic, 7.43t, 7.60–63, 7.62f
 - emphysema of, in orbital floor/blowout fracture, 7.109
 - extraocular muscles in, 6.25–28, 6.26–27f
 - fascia of, 6.27
 - fibro-osseous dysplasia (juvenile ossifying fibroma) of, 4.239, 4.240f
 - fibrous dysplasia of, 4.239, 4.240f
 - fissures in. *See* Orbital fissures
 - floor of, 2.6–7, 5.9f, 7.8f, 7.8–9
 - fractures of, 7.108–112, 7.110f
 - foramina in, 2.7–8
 - foreign bodies in, 7.112
 - MRI and, 7.30–31, 7.112
 - fractures of, 7.103–112
 - diplopia after, 5.206

- midfacial (Le Fort) fractures, 7.103, 7.104f
- zygomatic/zygomaticomaxillary complex (quadripod), 7.103–105, 7.105f
- healing/repair of, 4.17
- hemorrhages in, 7.74, 7.112
 - after blepharoplasty, vision loss and, 7.233–234
 - in orbital floor/blowout fracture, 7.108, 7.109
 - from orbital lymphatic malformation, 7.70, 7.70f, 7.71
 - after surgery, 7.121, 7.125
- hypoplasia of, in microphthalmia, 7.36
- infection/inflammation of, 4.225f, 4.225–228, 4.227f, 4.228f, 7.43t, 7.43–66
 - in aspergillosis, 4.227–228, 4.228f, 7.50–51
 - autoimmune, 7.43t
 - granulomatous, 7.43t
 - in histiocytic disorders, 7.90
 - idiopathic. *See* Nonspecific orbital inflammation
 - infectious, 7.43t, 7.44–51
 - nonspecific. *See* Nonspecific orbital inflammation
 - pain in, 5.295
 - vasculitic, 7.43t, 7.60–63, 7.62f
- lacrimal gland neoplasia and, 4.229–231, 4.230f, 4.231f, 7.287
- lacrimal sac neoplasia and, 4.229
- lateral wall of, 2.7, 7.7–8
- leukemic infiltration of, 4.316, 7.98–99
- lipodermoids of, 7.40, 7.41f
- lymphoproliferative lesions of, 4.231–232, 4.233f, 7.85–91
- malformations of, 7.67–101
- margin of, 2.5
- medial wall of, 2.6, 7.5, 7.5t, 7.8
 - fracture of, 7.8, 7.106–108, 7.107f
- melanoma affecting, 4.194
- meningioma affecting, 4.250, 5.127, 7.78–82, 7.79f, 7.80f
 - transient visual loss and, 5.164
- morphologic measurements of, 6.191, 6.192f
- MRI in evaluation of, 5.58–59f, 5.60–67, 5.61t, 5.62f, 5.63f, 5.63t, 5.64f, 5.65t, 5.65f, 5.66f, 5.67f, 5.72t, 7.28f, 7.28–29, 7.30f
 - CT compared with, 7.29t, 7.29–31, 7.30f
- myositis affecting, 4.224, 4.225f, 5.207f, 5.207–208
 - nonspecific orbital inflammation and, 4.225, 4.225f, 7.63–64
- nerves of, 7.16–18, 7.17f
 - parasympathetic, 5.52, 5.54–56, 5.55f
 - sympathetic, 5.52–54, 5.53f
- neuroblastoma involving, 7.98, 7.98f
- optic nerve in, 2.83, 2.85, 2.85t, 2.87–89, 7.5
 - blood supply of, 2.85t, 2.91, 2.91f
 - length of, 7.5t
- paranasal sinuses and, 7.5, 7.7f, 7.18–19, 7.19f
- periosteal structures and, 7.11, 7.18–19, 7.19f. *See also* Periorbital
 - disorders causing changes in, 7.22, 7.22f, 7.23t
- retinoblastoma affecting, 4.294, 4.294f
- roof of, 2.5–6, 5.9f, 7.6
 - fractures of, 7.106
- sebaceous carcinoma involving, 7.184
- septum of, 2.20f, 2.22–23, 7.5, 7.146f, 7.149
- lacerations of, 7.188
- soft tissues of, 4.223, 7.11–18
 - tumors arising in, 4.233
- surgery of, 7.115–125. *See also specific procedure*
 - decompression, 7.121–123, 7.122f, 7.123f. *See also* Orbital decompression
 - incisions for, 7.116f, 7.116–121
 - for orbital floor/blowout fracture, 7.111–112
 - indications for, 7.110–111
 - orbitotomy, 7.116–121. *See also* Orbitotomy
 - postoperative care and, 7.124
 - special techniques in, 7.124
 - surgical spaces and, 7.115f, 7.115–116, 7.116f
- teratoma of, 4.7f, 7.41
- in thyroid eye disease, 4.226, 7.51–60, 7.52f, 7.53f, 7.54f, 7.57t
- tight, 7.113
- topography of, 4.223, 7.5–9, 7.6f, 7.7f, 7.8f
- trauma to, 7.103–114
 - foreign bodies, 7.112
 - fractures, 7.103–112
 - hemorrhages, 7.74, 7.112
 - midfacial (Le Fort) fractures, 7.103, 7.104f
 - orbital fractures, 7.103–112
 - vision loss with clear media and, 7.112–114
- tuberculosis affecting, 7.49, 7.49f
- tumors of, 4.228–240, 7.67–101. *See also specific type*
 - adipose, 4.238
 - bony, 4.239, 4.240f
 - in children, 4.228, 4.229
 - congenital, 7.39f, 7.39–41, 7.41f
 - metastatic, 7.98f, 7.98–99
 - computed tomography in evaluation of, 7.27
 - congenital, 7.39f, 7.39–41, 7.41f
 - diplopia and, 5.208
 - enucleation for, 7.128
 - exenteration for, 7.136
 - with fibrous differentiation, 4.235f, 4.235–236
 - inspection in evaluation of, 7.23, 7.24, 7.25
 - lacrimal sac/gland involvement and, 4.229–231, 4.230f, 4.231f, 7.91–94, 7.92f
 - lymphoproliferative, 4.231–232, 4.233f, 7.85–91
 - mesenchymal, 7.82f, 7.82–85, 7.85f
 - metastatic, 4.228, 4.240, 7.98f, 7.98–101, 7.99f, 7.100f
 - in adults, 7.99f, 7.99–101, 7.100f
 - in children, 7.98f, 7.98–99
 - management of, 7.101
 - MRI of, 5.64f, 5.65f
 - with muscle differentiation, 4.236–237, 4.237f
 - nerve sheath, 4.237–238, 4.238f, 4.239f
 - neural/neurogenic, 7.74–82
 - pain caused by, 5.296
 - palpation in evaluation of, 7.25
 - pathologic examination of, 7.32–33
 - secondary, 4.228, 4.240, 7.94–98
 - eyelid carcinoma and, 7.96f, 7.96–97
 - soft tissue, 4.233
 - vascular (vascular malformations/fistulas), 4.233, 4.234f, 7.67–74
- ultrasonography of, 5.70–71, 5.72t, 7.31
- vascular system of, 7.13–16, 7.14f, 7.15f, 7.16f
 - anatomy of, 2.32–35, 2.33f, 2.34f, 2.35f, 5.12–14, 5.13–14f, 5.21, 5.21f, 7.13–16, 7.14f, 7.15f, 7.16f
- venography in evaluation of, 7.32

- volume of, 2.5, 5.7, 7.5*t*
 - augmentation of, for anophthalmia/microphthalmia, 7.36
 - loss of, in anophthalmic socket, 7.129
- walls of
 - apertures in, 7.6*f*, 7.7*f*, 7.8*f*, 7.9–10
 - lateral, 2.7, 5.9*f*, 7.7–8
 - medial, 2.6, 5.7, 5.9*f*, 7.5, 7.5*t*, 7.8
 - fracture of, 7.8, 7.106–108, 7.107*f*
- Orbital apex, 7.5, 7.6*f*, 7.10*f*, 7.13*f*
 - fracture of, 7.106
- Orbital apex syndrome, 5.203
 - in nonspecific orbital inflammation, 7.64
 - in zygomycosis, 7.50
- Orbital cellulitis, 6.170, 6.170*f*, 6.213–215, 6.214*f*, 7.46*f*, 7.46–48, 7.47*f*
 - in children, 7.47
 - pain in, 5.295, 7.45, 7.46
- Orbital decompression, 7.121–123, 7.122*f*, 7.123*f*
 - complications of, 7.125
 - for orbital hemorrhage, 7.112
 - for thyroid eye disease, 7.52, 7.58, 7.59, 7.121
 - for traumatic vision loss, 7.113
 - for vision loss after blepharoplasty, 7.233
- Orbital Doppler sonography, 5.70–71, 7.31
- Orbital eyelid muscles, 5.52
- Orbital fat, 2.20*f*, 2.23, 7.11, 7.146*f*, 7.149, 8.5*f*
 - dermatochalasis and, 7.229
 - eyelid lacerations and, 7.149, 7.187, 7.188
- Orbital fibroblasts, in thyroid eye disease, 4.226, 7.55
- Orbital fissures, 2.6*f*, 2.8*f*, 2.8–10, 2.9*f*, 5.6*f*, 5.7*f*, 5.11, 7.6*f*, 7.7, 7.7*f*, 7.8*f*, 7.9, 7.10*f*
 - inferior, 2.6*f*, 2.8–10, 5.7*f*, 5.9*f*, 5.11, 7.6*f*, 7.7*f*, 7.8*f*, 7.9
 - superior, 2.6*f*, 2.8, 2.8*f*, 2.9*f*, 2.14*f*, 5.5, 5.6*f*, 5.7*f*, 5.9*f*, 5.11, 7.6*f*, 7.7, 7.7*f*, 7.9, 7.10*f*
 - ophthalmoplegia caused by lesions of, 5.203
- Orbital floor fractures, 6.127–128, 6.128*f*, 6.379–380, 6.380*f*, 7.108–112, 7.110*f*
- Orbital groove, inferior, 5.9*f*
- Orbital implant, 7.131*f*, 7.131–132
 - in children, 7.129
 - after evisceration, 7.130, 7.131–132
 - exposure and extrusion of, 7.130, 7.131, 7.133–134, 7.134*f*
 - contracted socket and, 7.134
 - migration of, 7.130, 7.131
 - for orbital floor/blowout fracture, 7.111
 - for superior sulcus deformity, 7.132
- Orbital inflammatory disease, 4.225*f*, 4.225–228, 4.227*f*, 4.228*f*, 7.43*t*, 7.43–66. *See also* Orbit, infection/inflammation of; *specific type or cause*
 - pain in, 5.295
- Orbital inflammatory syndrome (OIS). *See* Nonspecific orbital inflammation
- Orbital lacrimal gland, 2.28, 2.216
- Orbital layer, of extraocular muscles, 6.24
- Orbital melanocytosis, dermal, 4.64. *See also* Dermal/dermal orbital/oculodermal (nevus of Ota) melanocytosis
- Orbital myositis, 6.216. *See also* Orbit, myositis affecting
- Orbital orbicularis muscle, 7.146*f*, 7.147, 7.148*f*, 7.148–149
 - myectomy for benign essential blepharospasm and, 7.228
- Orbital pseudotumor. *See* Nonspecific orbital inflammation
- Orbital rim, 5.7–8
- Orbital roof fractures, 6.380, 6.380*f*, 7.106
- Orbital varices, 7.71
 - glaucoma associated with, 10.30
- Orbital veins, 6.23
 - eyelids drained by, 7.154
- Orbitectomy, for lacrimal gland tumors, 7.93
- Orbititis, sclerosing. *See* Nonspecific orbital inflammation
- Orbitomalar ligament, 7.141
- Orbitopathy
 - in IgG4 disease, 7.60
 - neuroimaging in, 5.72*t*
 - thyroid/thyroid-associated/Graves. *See* Thyroid eye disease
- Orbitotomy, 7.116–121
 - incisions for, 7.116*f*, 7.116–121
 - inferior approach for, 7.118
 - lateral approach for, 7.120–121
 - medial approach for, 7.116*f*, 7.118–120, 7.120*f*
 - for specimen collection, 7.32
 - in rhabdomyosarcoma, 7.82
 - superior approach for, 7.116–118, 7.117*f*
- ORF. *See* Open reading frame
- Organ culture storage techniques, for donor cornea, 8.416
- Organ transplantation. *See* Transplantation
- Organic mental syndromes. *See* Mental disorders due to general medical condition
- Organophosphates, 2.312
- Ornithine aminotransferase (OAT) gene mutations/defects, in gyrate atrophy, 2.175*t*, 2.265
- Orphenadrine, for benign essential blepharospasm, 7.228
- Orthokeratology, 3.228, 13.70–71
- Orthomyxoviruses, 8.240*t*
- Orthophoria
 - abbreviation for, 6.17
 - definition of, 6.15
- Orthoptics
 - convergence insufficiency treated with, 6.103
 - fusional vergence affected by, 6.72
 - for suppression, 6.50
- Orthostatic hypotension, 1.77
- Orthotropia
 - definition of, 6.15
 - treatment of, 6.58
- OS. *See* Outer segments
- OSAS. *See* Obstructive sleep apnea syndrome
- Oscillatory potentials, 12.43*f*, 12.43–44
- Oscillations. *See* Saccadic intrusions/oscillations
- Oscillopsia, 5.233
 - in superior oblique myokymia, 5.250, 5.251
 - vestibular nystagmus and, 5.241, 5.243
- Oseltamivir, 1.220, 1.281
- Osmitol. *See* Mannitol
- Osmoglyn. *See* Glycerin
- Osmolarity, tear film, 2.214*t*, 8.39
 - dysfunctions and, 2.220
- Osmotic force, transendothelial, 8.9
- Osmotic/hyperosmotic agents, 2.328–329, 2.329*t*, 10.174*t*

- Osmotic hypothesis, of carbohydrate ("sugar") cataract formation, 2.247
- Osseous choristoma, 4.48, 4.49f
- Ossifying fibroma, juvenile, of orbit, 4.239, 4.240f
- OSSN. *See* Ocular surface squamous neoplasia
- Osteo-odonto-keratoprosthesis, 8.452
- Osteocutaneous ligaments, 7.141
- Osteodystrophy, Albright hereditary, 8.191t
- Osteogenesis imperfecta, 1.142, 8.192t, 8.194
blue sclera in, 1.143, 8.194, 8.194f
- Osteogenic sarcoma (osteosarcoma)
of orbit, 7.84
retinoblastoma associated with, 4.302, 4.302t
- Osteoma
choroidal, 4.198–199, 4.270f, 4.271
melanoma differentiated from, 4.270f, 4.271
orbital, 4.239, 7.84
secondary, 7.97, 7.97f
- Osteoporosis, 1.184
corticosteroid use and, 1.171, 9.100
- Osteosarcoma (osteogenic sarcoma)
of orbit, 7.84
retinoblastoma associated with, 4.302, 4.302t
- Osteotomy, for dacryocystorhinostomy, 7.279
- OT (ocular toxocariasis). *See* *Toxocara* (toxocariasis)
- Ota, nevus of. *See* Nevus/nevus, of Ota
- Otoconia, in benign paroxysmal positional vertigo, 5.242–243
- Otoliths/otolithic organs, 5.38, 6.40
vestibular-ocular reflex and, 5.214, 5.215
peripheral vestibular nystagmus and, 5.215, 5.216, 5.241, 5.242
skew deviation and, 5.216–217
- Ototoxicity
of aminoglycosides, 1.278, 5.243
mitochondrial DNA mutations and, 2.157
peripheral vestibular dysfunction and, 5.243
- Outcome/outcome measures, 1.5–6, 1.23
baseline probability of, 1.21–22
in clinical research, 1.5–6
case series and, 1.9
investigator bias and, 1.6
measurement standardization and, 1.6
- Outer eye. *See* External (outer) eye
- Outer ischemic retinal atrophy, 4.151, 4.151f
- Outer nuclear layer (ONL), 2.70f, 2.71f, 2.72f, 2.74f, 2.76f, 2.88f, 4.140f, 4.141f, 12.11, 12.12f
- Outer plexiform layer (OPL), 2.70f, 2.71f, 2.72f, 2.74, 2.74f, 2.88f, 4.140f, 4.141f
histology of, 12.11, 12.12f
oxygen supply to, 12.16
paracentral acute middle maculopathy of, 12.143
typical degenerative retinoschisis findings, 12.326
- Outer-schisis-layer holes, 12.327, 12.327f
- Outer segments (OS), 2.69, 2.70, 2.70f, 2.72f, 2.74f, 4.140f, 4.141f. *See also* Cone outer segments; Rod outer segments
of cones, 12.11, 12.12f
development of, 2.116t
oxidative damage and, 2.285
phagocytosis of, 12.17
of rods, 12.11, 12.12f
- Outflow facility, 10.19
classification of glaucomas and, 10.3–5, 10.4t, 10.6t
intraocular pressure and, 10.5, 10.5f, 10.13, 10.14f, 10.19
laser trabeculoplasty affecting, 10.188
tonography in measurement of, 10.19
- Outpatient visits, geriatric patient and, 1.179
- Ovarian cancer, paraneoplastic-induced saccadic intrusions and, 5.249
- OVDs. *See* Ophthalmic viscosurgical devices
- Over-the-counter contact lenses, 3.235
- Over-the-counter drugs, perioperative discontinuation of, 1.286
- Overcorrection, with photoablation, 13.101–102, 13.108–109
- Overdepression in adduction (ODAd)
causes of, 6.17, 6.116f, 6.116–118
description of, 6.17
pattern strabismus and, 6.107, 6.108f, 6.109
superior oblique muscle overaction as cause of, 6.118, 6.118f, 6.137
- Overelevation in adduction (OEAd)
causes of, 6.17, 6.116f, 6.116–118
description of, 6.17
inferior oblique muscle overaction as cause of, 6.117f, 6.117–118
pattern strabismus and, 6.107, 6.108f, 6.109
- Overlap syndromes (mixed connective tissue disease/MCTD), 1.162
- Overrefraction
cataract surgery evaluation and, 11.76
in children, 3.169
contact lenses, 3.217, 3.227
- Ovum, 2.186
- Ox eye (buphthalmos)
in megalocornea, 8.99, 8.100
in primary congenital glaucoma, 8.100, 8.108, 10.151, 10.152f, 10.158, 10.166
- Oxacillin, 1.275, 2.344
- Oxalate, 12.303
- Oxaprozin, 2.335t
- Oxazolidines, 1.273t
- Oxcarbazepine, 1.202t
- Oxidative lens damage, 11.19–20
- Oxidoreductases, taxon-specific crystallins as, 2.244
- Oxitropium, 1.134
- Oxy radicals, 2.282, 2.282f, 2.283. *See also* Free radicals
- Oxybuprocaine (benoxinate with fluorescein), 2.363t, 2.365
- Oxychloro complex, as ocular medication preservative, 2.294
- Oxygen
in aqueous humor, 2.235–236
corneal supply of, 2.224
hyalocyte consumption of, 12.7
metabolism of, 2.281, 2.282f
retinal supply of, 12.16f, 12.16–17
singlet, 2.281, 2.283
supplementation of, retinopathy of prematurity and, 12.184
vitrectomy affecting movement of, 2.254

Oxygen demand
 in high-output failure, 1.108
 reduction of
 for angina, 1.99
 for non-ST-segment elevation acute coronary syndrome, 1.103
 Oxygen radicals. *See* Free radicals
 Oxygen tension
 in lens, energy production and, 2.246
 in retina, oxidative damage and, 2.285–286
 Oxygen therapy
 for anaphylaxis, 1.302
 in CPR, 1.299
 for heart failure, 1.111
 hyperbaric, oxidative lens damage and, 11.20, 11.65
 for non-ST-segment elevation acute coronary syndrome, 1.103
 for pulmonary diseases/asthma, 1.132, 1.134
 for shock, 1.300, 1.301
 Oxymentazoline, 2.342
 Oxytetracycline, 2.350
 with polymyxin B, 2.347*t*
 Oxytocin, 1.56

P

P2Y₂ receptors, diquafosal mechanism of action and, 2.342
 p21, in cancer, 1.228
 P23H rhodopsin mutation, 2.263
 P50, 12.45, 12.47*f*
 p53 gene
 in adenoid cystic carcinoma, 4.231
 in cancer, 1.228
 in DNA repair, 2.154
 in ocular surface squamous neoplasia, 4.60
 in orbital solitary fibrous tumors, 4.236
 in pingueculae/pterygia, 4.57
 p63 gene, in pingueculae/pterygia, 4.57
 p arm, 2.141, 2.148*f*
 P cells (parvocellular neurons/system), 5.28, 5.32, 10.42
 P gene (*OCA2* gene), in albinism, 2.185
 P-selectin, in neutrophil rolling, 9.17, 9.18*f*
 P value, 1.7
 PA. *See* Polyacrylamide
 PABA. *See* Para-aminobenzoic acid
 PABPN1 gene mutation, in oculopharyngeal dystrophy, 5.329
 PAC. *See* Primary angle closure
 Pacchionian granulations, 5.22
 PACD. *See* Posterior amorphous corneal dystrophy
 Pacemakers
 for heart failure, 1.111
 laser surgery in patient with, 13.37
 PACG. *See* Primary angle-closure glaucoma
 Pachychoroid, 12.19, 12.76
 Pachymetry/pachymeter, 8.41–42, 10.159, 13.21*f*, 13.45–46
 before cataract surgery, 11.84
 in children, 10.159
 forme fruste keratoconus and, 13.176, 13.177*f*
 in Fuchs endothelial dystrophy, 8.158
 intraoperative, 13.79
 for intrastromal corneal ring segment placement, 13.64
 before LASIK, 13.79, 13.125, 13.176, 13.177*f*
 corneal perforation and, 13.111
 before refractive surgery, 13.45–46, 13.78, 13.79, 13.125, 13.176, 13.177*f*
 Paclitaxel, 1.231–235, 1.233*t*, 12.301
 PACS. *See* Primary angle-closure suspect
 PACs (premature atrial complexes/contractions).
 See Premature complexes/contractions, atrial
 PACT. *See* Prism alternate cover test
Paecilomyces, 8.251
 lilacinus, postoperative endophthalmitis caused by, 9.262
 PAFs. *See* Platelet-activating factors
 Pagetoid spread
 of melanoma, 4.220
 in primary acquired melanosis, 4.66–68
 of sebaceous carcinoma, 4.216, 4.217*f*, 7.183, 7.184
 PAHX gene, Refsum disease caused by mutation in, 2.266
 Pain. *See also specific type*
 arterial dissection and, 5.342
 cerebral aneurysms causing, 5.339, 5.340
 congenital insensitivity to, with anhidrosis (CIPA), congenital corneal anesthesia and, 8.108
 corneal abrasion causing, 8.398
 cranial nerve palsies and, 5.192
 third nerve (oculomotor) palsy, 5.196, 5.197
 in endophthalmitis, 9.264, 9.266
 enucleation/evisceration for, 7.128
 facial, 5.289*t*, 5.296–298
 head, 5.287–295, 5.288*t*. *See also* Headache
 headache causing. *See* Headache
 in Horner syndrome, 5.261, 5.262*f*
 in NAION, 5.123*t*
 ocular, 5.295–296
 in ocular ischemic syndrome, 5.170
 in optic neuropathy
 infiltrative, 5.131
 inflammatory, 5.295–296
 versus maculopathy, 5.100*t*
 orbital, 5.295–296, 7.21
 in cellulitis, 5.295, 7.45, 7.46
 enucleation/evisceration for, 7.128
 in myositis, 5.207
 in necrotizing fasciitis, 7.48
 in nonspecific orbital inflammation, 4.224, 5.295, 7.64
 in orbital floor/blowout fracture, 7.108
 after surgery, 7.125
 in thyroid eye disease, 7.56
 periocular, 5.295
 in optic neuritis, 5.78, 5.113–114, 5.123*t*
 postoperative, 1.290
 in recurrent corneal erosion, 5.295, 8.86, 8.87
 in scleritis, 5.295, 8.319, 8.320, 8.322, 9.112
 somatic symptom disorder (SSD) with, 1.190
 in Tolosa-Hunt syndrome, 5.203
 in trochlear headache/trochleitis, 5.296
 in uveitis, 9.78, 9.113
 with vision loss, assessment and, 5.78, 5.164

- Painful oculomotor neuropathy, recurrent, 5.197
 "Painless" (subacute lymphocytic) thyroiditis, 1.55
 Paired box genes, 2.152
 Paired-like homeodomain transcription factor 2 gene.
 See PITX2 gene
 PAL. *See* Progressive addition lenses
 Palatal myoclonus/tremor, pendular nystagmus and,
 5.246–247
 Palatine air cells, 2.10
 Palatine bone, 2.5, 2.6f, 5.8, 5.9f, 7.7f, 7.8, 7.8f
 Palinopsia, 5.176
 Palisades of Vogt, 8.10
 Pallidotomy, for Parkinson disease, 1.199–200
 Palmitic acid, in retinal pigment epithelium, 2.274,
 2.275
 Palpation, orbital, 7.25–26
 Palpebral arteries, 2.26f, 2.33f, 5.13f, 5.14f, 5.15f, 7.16f
 superior and inferior, 5.13f
 Palpebral conjunctiva, 2.25, 2.26f, 2.30, 4.47, 4.48f,
 4.201, 4.201f, 4.202, 8.6. *See also* Conjunctiva
 Palpebral fissures, 2.18f, 2.18–19, 2.25f, 7.153
 in blepharophimosis–ptosis–epicanthus inversus
 syndrome (BPES), 6.198
 in Brown syndrome, 6.137
 in cryptophthalmos, 6.191
 dermolipomas of, 6.257
 downward-slanting
 description of, 6.196
 pattern strabismus and, 6.107, 6.108f
 syndromes with, 6.196
 in euryblepharon, 7.157
 growth and development of, 6.181
 inferior rectus muscle alteration effect on, 6.29, 6.30f
 in Möbius syndrome, 6.135
 slants of, 6.196
 vertical height of, in ptosis, 7.210, 7.210f
 Palpebral lacrimal gland, 2.28, 2.216
 Palpebral muscles, 5.52
 Palpebral orbicularis muscle, 7.147
 myectomy for benign essential blepharospasm and,
 7.228
 Palpebral veins, inferior/superior, 5.21f
 Palpebral vernal keratoconjunctivitis, 6.248, 6.248f,
 8.289, 8.290f
 PALS. *See* Pediatric advanced life support
 PALs. *See* Progressive addition lenses
 Palsy. *See* Paralysis; *specific palsy*
 2-PAM. *See* Pralidoxime
 PAM. *See* Primary acquired melanosis
 PAM (Potential Acuity Meter). *See* Potential acuity
 estimation/potential acuity meter (PAM) testing
 PAMM. *See* Paracentral acute middle maculopathy
 PAMPs (pathogen-associated molecular patterns),
 1.239–240
 PAN. *See* Periodic alternating nystagmus; Polyarteritis
 nodosa
 Pancoast syndrome/tumor, Horner syndrome and,
 5.260, 5.260t, 5.261f
 Pancreas
 β cells in, in diabetes mellitus, 1.34
 destruction of, 1.34, 1.35
 cancer of, 1.213
 transplantation of, for diabetes mellitus, 1.47
 Pancuronium, 2.315t
 Panel D-15 (Farnsworth) test, 12.55f, 12.55–56
 in low vision evaluation, 5.79
 Panencephalitis, subacute sclerosing (SSPE), 8.239,
 9.207–208, 9.208f
 Panic disorder, 1.191
 Panipenem, 1.276
 Pannus/micropannus, 4.83, 4.84f, 8.52, 8.52f
 in band keratopathy, 8.119
 cataract surgery in patient with, 11.79
 in Terrien marginal degeneration, 8.123, 8.123f
 in trachoma/chlamydial conjunctivitis, 8.262, 8.262f
 in vernal keratoconjunctivitis, 8.290
 Panophthalmitis, in nocardiosis, 9.249
 Panretinal dystrophies
 clinical findings of, 12.261, 12.263f
 Coats reaction associated with, 12.260
 nonsyndromic, 12.258–259
 syndromic, 12.259
 Panretinal photocoagulation (PRP), 3.115. *See also*
 Photocoagulation
 adverse effects of, 12.106
 angle-closure glaucoma after, 10.143
 applications of, 12.376–377, 12.377f
 central retinal vein occlusion treated with, 12.135
 idiopathic retinal vasculitis, aneurysms, and
 neuroretinitis treated with, 12.156
 iris neovascularization and, 12.135
 macular edema exacerbation by, 12.379
 for neovascular glaucoma, 10.135
 nonproliferative diabetic retinopathy treated with,
 12.101
 oxygen tension affected by, 12.104
 proliferative diabetic retinopathy treated with, 12.104,
 12.106, 12.106f
 retinal vein occlusion treated with, 12.126
 for retinopathy of prematurity, 6.332, 6.333f
 Pantoscopic tilt, 3.192, 3.199
 Panum's area of single binocular vision, 6.42, 6.42f,
 6.48
 Panuveitis, 6.318f, 6.318–319, 9.72t, 9.74t, 9.77,
 9.166–189. *See also* Uveitis; *specific cause*
 in acute retinal necrosis, 9.194
 in Behçet disease, 9.182–188, 9.183f, 9.183t, 9.184f,
 9.184t, 9.185f, 9.186f, 9.187f
 Ebola virus, 12.247
 incidence/prevalence of, 9.87t
 in leptospirosis, 9.249
 in Lyme disease, 9.245
 multifocal choroiditis and (MCP/MFCPU),
 9.141–143t, 9.154–158, 9.155f, 9.157f, 12.226f.
 See also Multifocal choroiditis
 neovascularization in, 9.291
 in nocardiosis, 9.249
 noninfectious, 9.166–189
 retinal detachment and, 9.291
 sarcoid, 9.166–171, 9.167f, 9.168f, 9.169f
 in subretinal fibrosis and uveitis syndrome, 9.141–
 143t, 9.160f, 9.160–161
 sympathetic ophthalmia and, 4.185, 9.47–48,
 9.171–175, 9.172f, 9.173f, 9.174f
 in syphilitic uveitis, 12.241
 in toxocariasis, 12.245

- in Vogt-Koyanagi-Harada syndrome, 9.175–182, 9.177f, 9.178f, 9.179t, 9.180f, 9.181f, 12.233
- in Whipple disease, 9.258
- Papanicolaou test (“Pap smear”), for cancer screening, 1.209–210, 1.210t, 1.262
- in HIV infection/AIDS, 1.266
- Papillae
 - Bergmeister, 2.80, 4.126, 4.127f
 - conjunctival, 8.46t, 8.47f, 8.47t, 8.47–48, 8.48f
 - in atopic keratoconjunctivitis, 8.292, 8.293f
 - in floppy eyelid syndrome, 8.82, 8.83f
 - in palpebral vernal keratoconjunctivitis, 8.289, 8.290f
- Papillary carcinoma of thyroid gland, 1.55
- Papillary conjunctivitis, 4.50, 4.50f, 4.51f, 8.47t, 8.48f
 - giant (GPC), after penetrating keratoplasty, 8.426
 - in reactive arthritis/Reiter syndrome, 8.305–306
- Papillary endothelial hyperplasia, intravascular, 8.345t
- Papilledema, 5.82, 5.83f, 5.105–113, 5.107t, 5.108f, 5.109f, 5.110f, 5.111t. *See also* Optic nerve head (ONH/optic disc), edema of
 - acute, 5.105–107
 - chronic, 5.109f, 5.109–110, 5.110f
 - in cryptococcal meningitis, 5.356
 - definition of, 6.370
 - drusen differentiated from, 5.107, 5.108f, 5.141f, 5.142–143
 - idiopathic intracranial hypertension and, 5.110–113, 5.111t, 6.370f, 6.370–371
 - pseudopapilledema and, 5.107–109, 5.108f
 - in sarcoidosis, 5.327
 - transient visual loss and, 5.161, 5.164
 - ultrasonography in identification of, 5.95
- Papillitis, 5.113
 - in acute posterior multifocal placoid pigment epitheliopathy, 9.148
 - in Behçet disease, 9.186
 - in Lyme disease, 9.246
- Papillomacular bundle/fibers, 2.68, 2.68f, 2.71, 5.25, 5.103, 5.104f
 - visual field defects and, 5.103, 5.106f
- Papillomas, 6.250, 8.238–239, 8.239f
 - conjunctival, 4.59–60, 4.60f, 8.238–239, 8.239f, 8.332t, 8.332–334, 8.333f
 - eyelid, 4.204, 4.205f, 7.166, 7.166f
 - lacrimal sac, 7.287
- Papillomatosis, definition of, 4.202
- Papillomavirus. *See* Human papillomavirus
- Papillopathy, diabetic, 5.125, 5.125f
- Papillophlebitis, 5.125–126, 5.126f
- Papillorenal syndrome, dysplastic optic nerve and, 5.145
- Papovaviruses/papovavirus infection, 8.238–239, 8.239f
- Papule
 - of eyelid, 8.45t
 - in rosacea, 8.71, 8.71f
- Para-aminobenzoic acid (PABA), sulfonamides derived from, 2.349
- Para-aminoclonidine. *See* Apraclonidine
- Paracentesis
 - anterior chamber/aqueous
 - in acute retinal necrosis, 9.196
 - in coccidioidomycosis, 9.271
 - in cysticercosis, 9.231
 - in endogenous endophthalmitis, 9.264
 - for hyphema, 8.395
 - in uveitis, 9.91–92
 - in phacoemulsification, 11.105
 - in trabeculectomy, 10.201, 10.203f
- Paracentral acute middle maculopathy (PAMM), 12.143
- Paracentral scotomas, 3.315f, 12.367
 - in acute macular neuroretinopathy, 12.228
 - in age-related macular degeneration, 12.71, 12.87
 - in central serous chorioretinopathy, 12.189
 - in glaucoma, 10.68, 10.70f, 10.86
- Paracentral stromal inflammation, 8.52
- Paracentral zone, of cornea, 8.25, 8.25f
- Paracrine actions, of cytokines, 9.26
- Paradoxical diplopia, 6.50, 6.50f
- Paradoxical pupils, 6.335, 6.336t
- Paraflocculus, 5.33, 5.40
- Parafollicular (C) cells, 1.50
 - medullary carcinoma arising in, 1.56
- Parafovea/parafoveal zone
 - characteristics of, 12.10t
 - definition of, 12.9
 - description of, 2.77, 4.140
- Parafoveal macula, 12.9f
- Parakeratosis
 - in actinic keratosis, 4.211, 4.211f
 - definition of, 4.202
- Parallelepiped (corneal light wedge) technique, in gonioscopy, 10.36
- Paralysis (paresis/paretic syndromes). *See also specific type or structure affected*
 - convergence, 6.105–106
 - diplopia caused by, 5.186
 - multiple cranial nerve involvement and, 5.202
 - restrictive syndromes differentiated from, 5.186, 5.186f
 - in multiple sclerosis, 5.317
- Paralysis of accommodation, 3.174
- Paralytic ectropion, 7.198f, 7.224–226, 7.225f
- Paralytic lagophthalmos, 7.226
- Paralytic strabismus
 - extraocular muscle surgery for, 6.161
 - Hering’s law of motor correspondence and, 6.38
- Paramedian pontine reticular formation (PPRF), 2.102, 2.102f, 5.33, 5.35, 5.35f, 5.219
 - horizontal gaze and, 5.36, 5.37, 5.37f
 - in one-and-a-half syndrome, 5.191
 - saccades generated by, 5.219–220, 5.221
- Paramyxoviruses (Paramyxoviridae), 8.239–240, 8.240t
- Paranasal sinuses, 2.10f, 2.10–11, 5.8, 5.10f, 7.5, 7.7f, 7.18–19, 7.19f
 - Aspergillus* causing infection of, 5.353, 7.50–51
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137
 - nasolacrimal duct obstruction caused by disorders of, 7.277
 - neuroimaging in evaluation of disorders of, 5.72t
 - orbital cellulitis caused by infection of, 7.19, 7.44, 7.46, 7.47
 - orbital tumors originating in, 7.95f, 7.95–98, 7.96f, 7.97f
 - osteoma involving, 7.84
 - preseptal cellulitis caused by infection of, 7.44

- silent sinus syndrome caused by infection of, 7.95–96, 7.96f
- tuberculous infection of, orbital involvement and, 7.49
- Paranasal sinusitis, 6.213, 6.214f
- Paraneoplastic disorders
- retinopathies, 5.102–103, 12.286–287
 - saccadic intrusions caused by, 5.249
- Paraprotein, corneal deposition of, 8.198
- Parasellar region, 5.5, 5.6f
- lesions of
 - chiasm affected by, 5.146, 5.150
 - meningiomas, 5.147, 5.150
 - neuroimaging in evaluation of, 5.72t, 5.150, 5.151
 - nystagmus caused by, 5.247
- Parasellar (sphenocavernous) syndrome, 5.202
- Parasites, 8.208t, 8.252–253, 12.244
- ocular infection caused by, 8.208t, 8.252–253. *See also specific organism or type of infection*
 - cornea and scleral involvement and, 8.208t, 8.266–283
 - eyelid margin involvement and, 8.254–255, 8.255f
 - Mooren ulcer and, 8.314, 8.315
 - orbital involvement and, 4.228, 7.51
- Parasitology, 8.208t, 8.252–253. *See also* Parasites
- Parasol plugs, for dry eye, 8.64–65
- Parastriate cortex (Brodmann area 18), 5.20f, 5.30f, 5.30–31. *See also* Visual (calcarine/occipital/striate) cortex
- Parasympathetic fibers, lacrimal functional unit
- innervated by, 8.5f
- Parasympathetic ganglia/nerves/pathway, 5.52, 5.54–56, 5.55f
- cholinergic drug action and, 2.307, 2.307f, 2.308
 - in ciliary ganglion, 2.11–12, 2.12f, 2.95
 - ciliary muscle innervation and, 2.59, 2.100
 - cranial nerve III (oculomotor) and, 2.94, 2.95
 - cranial nerve VII (facial) and, 2.103, 2.104
 - dilator muscle innervation and, 2.55
 - orbit supplied by, 7.14f, 7.15f, 7.16, 7.17f
 - in reflex tear arc, 7.251
 - sphincter muscle innervation and, 2.56, 2.94, 2.95, 2.100
 - in tear secretion, 2.214, 2.216, 2.217–218, 2.218f, 2.219, 2.219f
- Parasympatholytic agents, accommodation affected by, 11.23
- Parasympathomimetic agents, 6.289t
- accommodation affected by, 11.23
 - for glaucoma, 10.173t, 10.181–182
- Parathyroid hormone/disease, corneal changes and, 8.200–201
- Paratopes, 9.37–38
- Paratrigeminal syndrome, Raeder, 5.261
- Paraxial rays, 3.41, 3.70
- Parcaine. *See* Proparacaine
- Parecoxib, 1.172
- Paredrine. *See* Hydroxyamphetamine
- Pareryd. *See* Hydroxyamphetamine, with tropicamide
- Parental age, chromosomal abnormalities/Down syndrome and, 2.190
- Parental diagnosis. *See also* Genetic testing/counseling
- in sickle cell disease, 1.135, 1.139
- Paresis. *See* Paralysis; *specific type*
- Pareto chart, 1.27, 1.29f
- Parietal bone, 5.5
- Parietal cortex, posterior (PPC), 5.30, 5.30f
- Parietal eye field, 5.32f
- Parietal lobe, 5.24f
- lesions of, 5.156
 - illusions/hallucinations and, 5.175, 5.177
 - visual field defects in, 5.84, 5.156, 5.219
- Parieto-occipital artery, 5.19f, 5.20
- Parinaud oculoglandular syndrome (POS), 4.51, 6.240f, 6.240–241, 8.265–266, 9.256, 12.242. *See also* Cat-scratch disease
- Parinaud (dorsal midbrain) syndrome, 5.37, 5.229, 5.230f
- in children, 5.231
 - convergence-retraction nystagmus in, 5.229, 5.250
 - eyelid retraction in, 5.229, 5.250, 5.274, 5.275t, 7.223
 - light–near dissociation in, 5.229, 5.230f, 5.266t, 5.266–267
 - multiple sclerosis and, 5.319
- Parkinson disease/parkinsonism, 1.198–200
- convergence insufficiency in, 5.227, 6.103
 - exposure keratopathy and, 8.79
 - facial weakness/paralysis in, 5.278
 - medications for, 1.199
 - tear production affected by, 8.62t
 - ophthalmic considerations in, 1.200
- Parks-Bielschowsky 3-step test, 6.73, 6.120. *See also* 3-step test
- in fourth nerve (trochlear) palsy, 5.198–199
- Parotid gland, 7.142f, 7.144f
- Parotideomasseteric fascia, 7.142f, 7.143
- Parotidocutaneous ligament, 7.141
- Paroxetine, angle-closure glaucoma caused by, 1.196
- Paroxysmal atrial tachycardia, 1.114
- Paroxysmal hemicrania, 5.289t, 5.294
- Paroxysmal nocturnal hemoglobinuria (PNH), 1.138–139
- hypercoagulability and, 1.148
 - screening test for, 1.135, 1.138
- Parry-Romberg syndrome (progressive facial hemiatrophy), 8.192t
- Pars plana, 2.57, 4.115f, 4.182, 4.183f, 12.10
- in uveitis, 9.73, 9.80t. *See also* Intermediate uveitis; Pars planitis
- Pars plana lensectomy, for uveitis, 9.283
- juvenile idiopathic (chronic/rheumatoid) arthritis and, 9.124
- Pars plana vitrectomy. *See also* Vitrectomy
- angle-closure glaucoma after, 10.143
 - branch retinal vein occlusion treated with, 12.130
 - for capsular rupture during cataract surgery, 11.143
 - cataract/ataract surgery after, 11.55, 11.190
 - central retinal vein occlusion treated with, 12.135
 - complications of, 12.402t, 12.402–403
 - for cystoid macular edema, 12.393, 12.394f
 - in uveitis, 9.289–290
 - diabetic macular edema treated with, 12.115, 12.388
 - diabetic retinopathy complications treated with, 12.107
 - for endophthalmitis
 - acute-onset, 12.388–390, 12.390f
 - Aspergillus*, 9.269

- bleb-associated, 12.390–391, 12.391*f*
- Candida*, 9.267
- chronic (delayed-onset), 12.390, 12.391*f*
- postoperative, 9.262, 9.263, 11.162
- epiretinal membranes treated with, 12.382, 12.383
- for Fuchs heterochromic uveitis/iridocyclitis, 9.127
- for hemolytic/ghost cell glaucoma, 10.106
- idiopathic macular holes treated with, 12.384–385, 12.385*f*
- indications for, 12.381
- infectious scleritis after, 9.259
- intraocular foreign body removed with, 12.361
- for intraocular lymphoma diagnosis, 4.312
- for IOL decentration/dislocation, 11.145
- for malignant/ciliary block glaucoma (aqueous misdirection), 10.141
- needle perforation/penetration of globe treated with, 12.396
- for pars planitis, 9.131
- with phacoemulsification, in uveitis, 9.283
- posteriorly dislocated intraocular lenses treated with, 12.393
- for retained lens fragments after phacoemulsification, 11.141, 12.391–393, 12.392*f*
- for retinal detachment
 - cataract surgery/IOL and, 11.166
 - in CMV retinitis, 9.295
 - in uveitis, 9.291
- rhegmatogenous retinal detachment treated with, 12.400*f*, 12.400–401
- submacular hemorrhage treated with, 12.385, 12.386*f*
- suprachoroidal hemorrhage treated with, 12.394–395, 12.395*f*
- sympathetic ophthalmia and, 9.172
- technique for, 12.381
- tractional retinal detachment treated with, 12.387–388
- for uveal lymphoid proliferation/infiltration diagnosis, 4.314
- for uveitis, 9.283
 - cystoid macular edema and, 9.289–290
 - juvenile idiopathic (chronic/rheumatoid) arthritis-associated, 9.124
 - vitreous biopsy and, 9.92
- for vitreous opacification/vitritis, 9.290
- vitreous opacities treated with, 12.386
- Pars planitis, 6.316, 9.72*t*, 9.128*f*, 9.128–131, 12.231.
 - See also* Intermediate uveitis; Uveitis
 - clinical characteristics of, 9.128*f*, 9.128–129
 - complications of, 9.131
 - cystoid macular edema and, 9.128, 9.131
 - diagnosis/differential diagnosis of, 9.129
 - multiple sclerosis and, 5.318, 9.129
 - neovascularization in, 9.128–129, 9.130, 9.131
 - prognosis for, 9.129–130
 - retinal detachment and, 9.129, 9.131, 9.291
 - in toxocariasis, 9.228
 - treatment of, 9.130–131
- Pars plicata, 2.54*f*, 2.57, 4.115*f*, 4.182, 4.183*f*, 10.15*f*
- Part-time occlusion, for amblyopia, 6.58
- Partial seizures, 1.201
- Partial third nerve (oculomotor) palsy, 5.193, 5.193*f*, 5.195–196, 5.196*f*
- Partial thromboplastin time, activated (aPTT), 1.141
- Partially accommodative esotropia, 6.90–92
- Partially polarized light, 3.99
- Particle theory of light, 3.94
- Partition coefficient, drug lipid solubility and, 2.298
- Parvocellular neurons (P cells/system), 5.28, 5.32, 10.42
- PAS. *See* Peripheral anterior synechia
- PAS (periodic acid–Schiff) stain, 4.31*t*
- Passive immunization, 1.217, 1.225
- Passive transport, in aqueous humor dynamics, 2.230
- Pataday. *See* Olopatadine
- Patanol. *See* Olopatadine
- Patau syndrome, 6.386*t*
- Patching. *See also* Occlusion therapy
 - for conjunctivochalasis, 8.86
 - for corneal defects/abrasions, 8.368, 8.369*f*, 8.369–370, 8.370*f*, 8.398
 - for dellen, 8.79, 8.92, 8.368
 - for hyphema, 10.105
 - for penetrating and perforating ocular trauma, 8.402
 - for recurrent corneal erosion, 8.87, 8.368
 - for topical anesthetic abuse diagnosis/management, 8.90
- Patellar fossa, 12.7
- Pathergy, in Behçet disease, 1.169, 9.184
- Pathogen-associated molecular patterns (PAMPs), 1.239–240
- Pathologic myopia. *See* High (pathologic) myopia
- Pathologic suppression, 6.48
- Pathology, ophthalmic. *See* Ophthalmic pathology
- Patient
 - examination of. *See* Examination
 - perimetry results affected by, 10.59, 10.60
 - selection/preparation of. *See also* Preoperative assessment/preparation for surgery
 - for corneal crosslinking, 13.131–132
 - expectations/motivations and, 13.35–36, 13.36*t*, 13.47
 - for LASIK, 13.78–80
 - for monovision, 13.39, 13.165
 - for multifocal IOLs, 13.155, 13.166–167
 - for phakic IOLs, 13.140–141
 - for photoablation, 13.77–80, 13.78*t*
 - for refractive lens exchange, 13.147–149
 - for surface ablation, 13.77–78
 - for toric IOLs, 13.151
- Patient database, monitoring systems and, 1.25–26
- Patient education
 - before cataract surgery, 11.87–88
 - interpreting research results for patients and, 1.21–23
 - for medication instillation, 10.184–185
 - adherence and, 10.186
 - in children, 10.165
 - ophthalmic considerations in
 - diabetes mellitus and, 1.49
 - psychiatric medications and, 1.198
- Patient Health Questionnaire-2 (PHQ-2), 1.183
- Pattern-appearance stimulation, of visual evoked potentials, 12.53
- Pattern-appearance visual evoked potential, 5.95
 - in nonorganic disorder evaluation, 5.302
- Pattern deviation map/plot, 5.86, 5.87*f*, 10.65, 10.65*f*

- Pattern dystrophies, 4.170, 4.171*f*, 12.67, 12.272, 12.276*f*, 12.276–277
 adult-onset foveomacular vitelliform, 4.170, 4.171*f*
 butterfly-type (BPD), 4.170
 Pattern electroretinography (PERG), 12.45–46, 12.46–49*f*
 Pattern-reversal visual evoked potential, 12.52, 12.53*f*
 Pattern Standard Deviation (PSD), 10.65
 Pattern strabismus
- A-
 clinical features of, 6.109
 clinically significant, 6.109
 definition of, 6.107
 etiology of, 6.107–109, 6.108*f*
 exotropia, 6.108*f*, 6.112
 in exotropia, 6.109
 horizontal rectus muscle transposition for, 6.112
 identification of, 6.109
 intorsion as cause of, 6.107, 6.110
 medial rectus muscle displacement for, 6.110, 6.111*f*
 palpebral fissure slanting associated with, 6.196
 superior oblique muscle overaction associated with, 6.107
 superior oblique tenotomy for, 6.112
 surgical treatment of, 6.112, 6.112*t*
 anomalous innervation as cause of, 6.109
- λ-
 clinical features of, 6.110
 surgical treatment of, 6.113
 management of, 6.110–113, 6.111*f*, 6.112*t*
 ocular torsion as cause of, 6.107
 surgical correction of, 6.110–113, 6.111*f*, 6.112*t*
 types of, 6.107
- V-
 bilateral superior oblique palsy and, 6.122
 in Brown syndrome, 6.137
 clinical features of, 6.109
 clinically significant, 6.109
 craniofacial anomalies and, 6.107
 in craniosynostosis, 6.208
 definition of, 6.107
 etiology of, 6.107–109, 6.108*f*
 exotropia with, 6.108*f*, 6.111
 extorsion as cause of, 6.107, 6.110
 heterotopy as cause of, 6.28
 identification of, 6.109
 infantile esotropia associated with, 6.109, 6.112
 inferior oblique muscle overaction associated with, 6.107
 palpebral fissure slanting associated with, 6.196
 clinical features of, 6.109–110
 definition of, 6.107
 downward-slanting palpebral fissures and, 6.107, 6.108*f*
 etiology of, 6.107–109, 6.108*f*
 horizontal rectus muscles and, 6.109
 identification of, 6.109–110
 superior oblique palsy and, 6.122
 surgical treatment of, 6.111–112, 6.112*t*
- X-
 clinical features of, 6.110
 surgical treatment of, 6.113
- Y-
 clinical features of, 6.109–110
 surgical treatment of, 6.113
- Patti Stripes Square Wave Grating Paddles, 6.8
 Patton lines, 12.201
 Pauciarticular (oligoarticular)-onset juvenile idiopathic (chronic/rheumatoid) arthritis (oligoarthritis), 1.156, 9.122. *See also* Juvenile idiopathic (chronic/rheumatoid) arthritis
 eye examination schedule for children with, 9.124*t*
 uveitis in, 9.122
 Pauciarticular juvenile idiopathic arthritis, 6.313, 6.314*t*
 Paving-stone (cobblestone) degeneration, 4.150, 4.150*f*, 12.313, 12.314*f*
 PAX genes, 2.126, 2.137, 2.152. *See also specific type*
 in aniridia, 2.152, 2.177, 2.193, 4.184, 10.150, 10.155, 11.33
 PAX2 gene, 2.126
 mutation in, 2.152
 optic nerve dysplasia and, 5.145
 PAX3 gene, mutation of, 2.152, 2.177
 PAX6 gene, 2.126, 2.152, 2.193, 6.267, 6.338
 mutation in, 2.152, 2.193
 in aniridia, 2.152, 2.177, 2.193, 4.184, 10.150, 10.155, 11.33
 in Axenfeld-Rieger syndrome, 8.97*t*, 8.102
 in microcornea, 8.95
 in Peters anomaly, 8.97*t*, 8.103, 10.150, 11.32
- Pazopanib, 1.235
 PBK. *See* Pseudophakic (aphakic) bullous keratopathy
 PC. *See* Posterior commissure
 PCA. *See* Posterior cerebral artery
 PCAB (Pharmacy Compounding Accreditation Board), 2.306
 PCD. *See* Programmed cell death
 PCG. *See* Primary congenital glaucoma
 PCI. *See* Percutaneous coronary intervention
 PCIOLs. *See* Posterior chamber intraocular lenses
 PCNSL. *See* Primary central nervous system/ intraocular/vitreoretinal/retinal lymphoma
 PCO. *See* Posterior capsular/capsule opacification
 PCoA. *See* Posterior communicating artery
 PCP. *See* *Pneumocystis jirovecii* (*Pneumocystis carinii*) infections, pneumonia
 PCR. *See* Polymerase chain reaction
 PCV. *See* Pneumococcal vaccines; Polypoidal choroidal vasculopathy
 PD. *See* Proton density; Proton density (PD) MRI
 PD-L1. *See* Programmed death ligand-1
 PDCD. *See* Pre-Descemet corneal dystrophy
 PDE. *See* Phosphodiesterase
 PDGFs. *See* Platelet-derived growth factors
 PDR. *See* Proliferative diabetic retinopathy
 PDT. *See* Photodynamic therapy
 Pearson marrow-pancreas syndrome, 2.158
 mitochondrial DNA defects and, 2.157, 2.158
 Peau d'orange, 12.87, 12.89*f*
 “Peculiar substance,” in Meesmann corneal dystrophy, 8.139
 PED (pigment epithelial detachment). *See* Retinal pigment epithelium (RPE), detachment of
 Pediatric advanced life support (PALS), 1.295, 1.299
 Pediatric cataract. *See* Cataract, pediatric

- Pediatric corneal transplantation, 8.450–451
- Pediatric glaucoma. *See* Childhood glaucoma; Glaucoma, pediatric
- Pediatric granulomatous arthritis, 6.318
- Pediatric low vision. *See* Low vision, in infants
- Pedicle, of cone, 2.70, 2.73*f*
- Pedicle flap, 7.191
for canthal repair, 7.195
- Pediculus* (pediculosis/lice)
humanus capitis, 8.255
humanus corporis, 8.255
ocular infection caused by, 8.255
- Pedigree analysis, 2.172*f*, 2.172–173
- PEDs. *See* Pigment epithelial detachment
- Peduncular hallucinosis, 5.176
- Pedunculated papillomas, conjunctival, 4.59–60, 4.60*f*
- PEE. *See* Punctate epithelial defects/erosions
- PEG-400. *See* Polyethylene glycol (PEG)-400
- Pegaptanib, 2.372, 12.80
- Pegged porous orbital implant, 7.131, 7.131*f*. *See also* Orbital implant
- Peginterferon. *See also* Interferons
for hepatitis C, 1.261
- PEHCR. *See* Peripheral exudative hemorrhagic chorioretinopathy
- PEK. *See* Punctate epithelial keratitis/keratopathy
- Pelizaeus-Merzbacher disease, 12.283*t*
- Pelli-Robson chart/test, 3.316*f*, 5.88, 12.56–57, 12.57*f*
- Pellucid marginal degeneration (PMD), 4.95, 8.16*f*, 8.168*f*, 8.168–169, 8.169*f*, 8.170*f*
corneal topography in evaluation of, 8.31, 8.33*f*, 8.169, 8.170*f*
refractive lens exchange and, 13.149
refractive surgery contraindicated in, 13.24, 13.44, 13.79, 13.176, 13.176*f*
corneal topography and, 13.24, 13.44, 13.45*f*, 13.79, 13.176, 13.176*f*
- “Pellucid suspect” pattern, LASIK contraindicated in, 13.176, 13.176*f*
- Pelopsia, 5.175
- Pelvic examination, for cancer screening, 1.210*t*
- Pemirolast, 2.238, 2.337, 2.338*t*
- Pemphigoid, mucous membrane (MMP/cicatricial), 4.53–55, 4.54*f*, 8.285, 8.299–303, 8.300*f*, 8.301*f*, 8.301*t*, 8.302*t*
cataract surgery in patient with, 11.173
drug-induced (pseudopemphigoid), 8.91, 8.92, 8.299
mucous membrane grafting for, 8.303, 8.366
staging of, 8.299–300, 8.300*f*, 8.302, 8.302*t*
- Penbutolol, 1.68*t*
- Penciclovir, 2.302, 2.359, 8.215*t*
for herpes simplex virus infections, 8.215*t*
- Pendular nystagmus, 5.214, 5.233, 5.234*f*, 5.246–247, 6.147
acquired, 5.246–247
in multiple sclerosis, 5.246, 5.319
- Penetrance/penetrant gene, 2.141, 2.195–196, 2.205
incomplete (skipped generation), 2.177
- Penetrating and perforating ocular trauma, 8.396–409.
See also Lacerations; Trauma
anterior segment, 8.396–409
ancillary tests in, 8.402, 8.402*t*
conjunctival foreign body, 8.397, 8.397*f*, 8.398*f*
conjunctival lacerations, 8.396–397
corneal abrasion, 8.8–9, 8.398*f*
corneal foreign body, 8.399–400, 8.400*f*, 8.401*f*, 8.403
evaluation of, 8.401–402, 8.402*t*
examination in, 8.401–402, 8.402*t*
history in, 8.401
management of
nonsurgical, 8.402–403
postoperative, 8.409
preoperative, 8.403
surgical, 8.403–409, 8.404*f*, 8.405*f*, 8.407*f*, 8.408*f*
ocular signs of, 8.402*t*
uveal prolapse in, repair of, 8.375
canthal soft tissue, 7.189
in children, 6.376–378, 6.377*f*
definitions of, 8.396
eyelid, 7.187–189, 7.188*f*. *See also* Lacerations, eyelid
fibrocellular proliferation and, 4.20–22, 4.21*f*
fibrous ingrowth/angle-closure glaucoma and, 10.142, 10.143*f*
infectious scleritis after, 9.259
lens damage caused by, 11.55, 11.55*f*, 11.56*f*
glaucoma and, 11.67
preseptal cellulitis caused by, 7.44
Seidel test in identification of, 8.36–37, 8.38*f*
sympathetic ophthalmia and, 9.47–48, 9.172, 9.174, 12.233. *See also* Trauma
- Penetrating keratoplasty (PK/PKP). *See* Keratoplasty, penetrating
- Penetrating wound, 8.396. *See also* Penetrating and perforating ocular trauma
- Penicillamine, for Wilson disease, 2.203, 8.189
- Penicillin G, 2.343, 2.344*t*, 6.413
- Penicillin-resistant *N gonorrhoeae* (PRNG), 8.259, 8.264
- Penicillin V (phenoxymethyl penicillin), 2.343
- Penicillinase (β -lactamase), 1.275, 2.343, 2.345, 2.346
- Penicillinase-resistant penicillins, 1.275, 2.344
- Penicillins, 1.275, 2.343–345, 2.344*t*. *See also specific agent*
allergic reaction to, 1.275, 2.343
broad-spectrum, 2.345
for leptospirosis, 9.249
for Lyme disease, 9.247*t*
penicillinase-resistant, 1.275, 2.344
for syphilis, 1.249, 1.250, 9.240, 9.242*t*, 9.242–243
in HIV infection/AIDS, 9.240, 9.298
- Pentacam system, for corneal power measurements, 3.248, 3.248*f*
- Pentagonal resection, for trichiasis, 7.208
- Pentamidine
for *Pneumocystis jirovecii* choroiditis, 9.298
for *Pneumocystis jirovecii* pneumonia, 1.267
- Pentolair. *See* Cyclopentolate
- Pentose phosphate pathway (hexose monophosphate [HMP] shunt), in glucose/carbohydrate metabolism
in cornea, 2.224
in lens, 2.246, 11.17, 11.18*f*, 11.19
in rod outer segments, 2.261
- Penumbra, 1.120
stroke treatment and, 1.122
- Peptide hormones
in aqueous humor, 2.231
in tear secretion, 2.219–220

- Peptidoglycan, in bacterial cell wall, 8.244
- Peptidyl-glycine- α -amidating monooxygenase, in aqueous humor, 2.231
- Perampanel, 1.202*t*
- Percent agreement, 1.24
- Perception disorders. *See also* Hallucinations; Illusions; Metamorphopsia
- cortical lesions and, 5.158, 5.175
 - nonvisual causes of, 5.174*t*
 - parietal lobe lesions and, 5.175, 5.177
 - retinal/macular disorders and, 5.174–175
- Percheron, artery of, 5.20, 5.229–230
- Percutaneous coronary intervention (PCI), 1.91, 1.94, 1.100–102
- for angina, 1.100–102
 - for ST-segment elevation myocardial infarction, 1.104
- Perennial allergic conjunctivitis, 6.246–248, 8.288–289
- Perfluorocarbon
- description of, 12.382
 - intravitreal administration of, 2.300*t*
- Perfluoropropane, 12.382, 12.401
- Perforating and penetrating ocular trauma, 8.396–409.
- See also* Lacerations; Penetrating and perforating ocular trauma; Trauma
 - in children, 6.376–378, 6.377*f*
 - definitions of, 8.396
- Perforating wound, 8.396. *See also* Penetrating and perforating ocular trauma; Trauma
- Perforators
- of basilar artery, 5.20
 - of posterior cerebral arteries, 5.20
 - of superior cerebellar arteries, 5.20
- Perforin, 9.48, 9.49*f*
- Perforin-granzyme pathway, in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
- Perfusion pressure, ocular, glaucoma and, 10.83
- PERG. *See* Pattern electroretinography
- Peribulbar anesthesia, 1.291, 1.305, 6.174
- for cataract surgery, 11.91
 - for phakic IOL insertion, 13.141
- Pericallosal artery, 5.16*f*
- Pericanalicular connective tissue, 2.49–50, 2.50*f*
- Pericarditis, post-MI, 1.94
- Pericentral scotoma, 5.105*t*
- Pericytes, 12.93
- choriocapillaris, 2.61, 2.62*f*
 - in hemangiopericytoma, 7.69
 - retinal blood vessel, 2.73
- Perifovea/perifoveal zone
- characteristics of, 12.10*t*
 - definition of, 12.9
 - description of, 2.77, 4.140
- Perifoveal macula, 12.9*f*
- Perimacular folds, in abusive head trauma, 6.382–383
- Perimetrist, perimetry results affected by, 10.59, 10.60
- Perimetry, 5.84–88, 5.85*f*, 5.87*f*, 10.59–77. *See also*
- Visual field testing
 - automated
 - short-wavelength (SWAP), 10.75
 - standard (SAP/achromatic), 10.59
 - static, 5.84, 5.85*f*, 5.85–88, 5.87*f*, 10.59, 10.60–62
 - artifacts seen on, 10.66*f*, 10.66–67, 10.67*f*
 - in glaucoma, 10.59, 10.60–62
 - high false-positive rate in, 10.67, 10.67*f*
 - incorrect corrective lens used in, 10.66
 - learning effect and, 10.71
 - in nonorganic disorder evaluation, 5.306–307, 5.307*f*, 5.308*f*
 - screening tests, 10.62
 - threshold, 10.61*f*, 10.61–62, 10.63*f*
 - for central visual field assessment, 5.85, 5.85*f*
 - factors affecting, 10.59–60
 - false-negative/positive responses and, 5.86, 10.62, 10.67, 10.67*f*
 - frequency-doubling technology (FDT), 10.75
 - in glaucoma suspect screening, 10.89
 - in glaucoma, 10.59–77
 - preperimetric glaucoma and, 10.3
 - in glaucoma suspect screening, 10.62, 10.89
 - Goldmann, 5.84, 5.85*f*
 - in nonorganic disorder evaluation, 5.308, 5.308*f*
 - interpretation in
 - artifacts and, 10.66*f*, 10.66–67, 10.67*f*
 - normality versus abnormality of field and, 10.62–65, 10.64*f*, 10.65*f*
 - optic nerve/nerve head/disc changes and, 10.74–75
 - patterns of field loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
 - quality/reliability and, 10.62
 - serial fields/detection of visual field progression, 10.71–75, 10.72*f*, 10.73*f*, 10.74*f*
 - single field, 10.62–67, 10.64*f*, 10.65*f*, 10.66*f*, 10.67*f*
 - kinetic, 5.84, 5.85*f*, 10.59
 - in nonorganic disorder evaluation, 5.308, 5.308*f*
 - in optic neuropathy, 5.86
 - preperimetric glaucoma and, 10.3
 - screening, 10.62
 - static. *See* Perimetry, automated, static
 - Swedish interactive thresholding algorithm (SITA), 5.86, 10.60–61, 10.62
 - tangent screen in. *See* Tangent screen
 - tendency-oriented algorithm (TOP), 10.61
 - terminology used in, 5.105*t*
 - threshold, 5.86, 10.61*f*, 10.61–62, 10.63*f*
- Perinatal infections. *See specific type*
- Perindopril, 1.68*t*
- Perineural invasion, pain caused by, 5.298
- Perineuritis, optic, 5.119
- radial (radial keratoneuritis), in *Acanthamoeba* keratitis, 4.79, 8.277
 - in sarcoidosis, 5.327
- Periocular drug administration, 2.299
- for pars planitis, 9.130
 - for sympathetic ophthalmia, 9.175
 - for uveitis, 9.96*f*, 9.96–97, 9.97*f*
 - cystoid macular edema and, 9.289
- Periocular tissues
- malpositions/involucional changes and, 7.197–247.
 - See also specific type*
 - blepharochalasis, 7.230
 - blepharoplasty and, 7.230–234, 7.232*f*

- blepharoptosis (ptosis), 7.209–222, 7.210f, 7.211f, 7.213f, 7.214f, 7.216f, 7.218f, 7.219f, 7.220f, 7.221f
- brow ptosis, 7.234–235, 7.235f
- dermatochalasis, 7.229f, 7.229–230
- ectropion, 7.197–201, 7.198f, 7.200f
- entropion, 7.202–207, 7.203f, 7.204f, 7.205f, 7.206f, 7.207f
- eyelid retraction, 7.222f, 7.222–224
- facial dystonia, 7.226–229, 7.227f
- facial paralysis, 7.224–226, 7.225f
- facial rejuvenation and, 7.235–247
 - nonsurgical, 7.237–240, 7.239f, 7.240f
 - surgical, 7.241–247, 7.242f, 7.243f, 7.244f, 7.245f, 7.246f
- history/examination in evaluation of, 7.197
 - aging face and, 7.236–237
- pathogenesis of aging face and, 7.236
- symblepharon, 7.208
- trichiasis, 7.208–209
- prostaglandin analogues affecting pigmentation of, 10.175
- Periodic acid–Schiff (PAS) stain, 4.31t
- Periodic alternating nystagmus (PAN), 5.243t, 5.245–246, 6.149
- Perioperative ischemic optic neuropathy, 5.124–125
- Perioperative management in ocular surgery, 1.283–293, 1.289t
 - intraoperative considerations and, 1.290–293, 1.293t
 - in older patients, 1.180–181
 - preoperative assessment and, 1.283–290, 1.289t. *See also* Preoperative assessment/preparation for surgery
 - recent developments and, 1.283
- Perioperative medications, 1.285–287
- Periorbita (periorbital structures), 7.11, 7.18–19, 7.19f. *See also specific structure*
 - cellulitis affecting, 7.44–48, 7.46f, 7.46t, 7.47f. *See also* Orbital cellulitis; Preseptal cellulitis
 - ecchymoses of, 6.379, 6.384, 7.22, 7.22f
 - in neuroblastoma, 7.98, 7.98f
 - in orbital floor/blowout fracture, 7.108
 - in orbital roof fracture, 7.106
 - innervation of, 7.16, 7.16f
 - involutional changes in, 7.229f, 7.229–230
 - orbital diseases causing changes in, 7.22, 7.22f, 7.23t
- Periorbital pain, 5.295
 - in optic neuritis, 5.78, 5.113–114, 5.123t
- Periorbital sinuses, 2.10f, 2.10–11
- Periorbitopathy, prostaglandin-association, 10.176
- Peripapillary atrophy (PPA), in glaucoma, 10.48, 10.52
- Peripapillary fibers, 2.86. *See also* Nerve fiber layer
 - assessment of, OCT in assessment of, 5.91
 - gliosis of, 5.109
 - in ONH edema, 5.82, 5.82f, 5.83f, 5.105
- Peripapillary hemorrhages, 6.373
- Peripapillary intrachoroidal cavitations, 12.215, 12.215f
- Peripapillary staphyloma, 6.366
- Peripheral airway disease, 1.130
- Peripheral anterior synechiae (PAS), in glaucoma
 - angle closure and, 10.117, 10.121
 - inflammation and, 10.138, 10.139f
 - anterior segment/iris neovascularization and, 10.39, 10.39f, 10.133, 10.133f, 10.134f
- chamber deepening/goniosynechialysis in
 - management of, 10.220
- flat anterior chamber and, 10.144
- gonioscopy in identification of, 10.34f, 10.39, 10.39f
- iridocorneal endothelial syndrome and, 4.100–101, 4.101f, 10.136, 10.136f
- plateau iris and, 10.128
- uveitis and, 9.286
- Peripheral arterial arcade, eyelids supplied by, 2.25–26, 2.26f, 7.16f, 7.146f, 7.154, 8.4f
- Peripheral arterial/peripheral vascular disease
 - diabetes mellitus and, 1.48–49
 - hypertension and, 1.76
- Peripheral corneal guttae (Hassall-Henle bodies/warts), 2.41, 8.115, 8.128
- Peripheral corneal transparency abnormalities, 6.255–256f, 257
- Peripheral curve, 3.205, 3.215f, 3.216
- Peripheral cystoid degeneration, 4.148, 4.149f
 - description of, 12.314
 - reticular, 12.326
 - reticular (RPCD), 4.148, 4.149f
 - typical (TPCD), 4.148, 4.149f, 12.326
- Peripheral exudative hemorrhagic chorioretinopathy (PEHCR), 4.270f, 4.271
- Peripheral fusion, 6.51–52
- Peripheral granuloma, in toxocariasis, 12.244, 12.245f
- Peripheral hypertrophic subepithelial corneal degeneration, 8.124–125, 8.125f
- Peripheral (surgical) iridectomy. *See also* Iridectomy
 - for angle-closure glaucoma, 10.125, 10.220
- Peripheral iridoplasty
 - for angle-closure glaucoma, 10.193–194
 - for plateau iris, 10.127f, 10.128
- Peripheral iris suture fixation, for IOL decentration, 11.145, 11.146f
- Peripheral keratitis, 8.50t
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168
- scleritis and, 8.323
- ulcerative (PUK), 8.51f, 8.311t, 8.311–313, 8.312f
 - differential diagnosis of, 8.311, 8.311t
 - in microscopic polyangiitis, 1.168
 - in polyarteritis nodosa, 9.136
 - in rosacea, 8.71
 - in systemic immune-mediated diseases, 8.51f, 8.311t, 8.311–313, 8.312f
- Peripheral neovascularization, vitreous hemorrhage associated with, 12.232
- Peripheral neurofibromatosis, 10.156. *See also* Neurofibromatosis 1
- Peripheral resistance, reduction of, in heart failure management, 1.109
- Peripheral retina
 - definition of, 12.10
 - excavations, 12.312–313
- Peripheral retinal neovascularization, 12.154t
- Peripheral stromal inflammation, 8.52
- Peripheral suppression, 6.48

- Peripheral surgical space (extraconal fat/surgical space), 7.11, 7.115, 7.115f
- Peripheral ulcerative keratitis (PUK). *See* Peripheral keratitis, ulcerative
- Peripheral uveitis. *See* Intermediate uveitis; Pars planitis
- Peripheral vacuolar cataracts, 6.298
- Peripheral vestibular nystagmus, 5.216, 5.241t, 5.241–243
- Peripheral visual field
defects of. *See* Visual field defects
description of, 3.318
- Peripheral vitreous, 12.7
- Peripheral zone
corneal, 8.25, 8.25f
of lens epithelium, 2.64
- Peripherin, 2.261
- Peripherin/RDS (*PRPH2*) gene mutation, 2.161, 2.264
in pattern dystrophies, 4.170
in retinitis pigmentosa, 2.161, 2.264
in Stargardt disease, 4.168
- Periphelebitis
in cytomegalovirus retinitis, 12.235
in dengue fever, 9.213
in multiple sclerosis, 5.318, 9.132
in sarcoidosis, 4.187, 9.169
in tuberculosis, 9.253
- Peristaltic pump, for phacoemulsification aspiration, 11.103, 11.103f
- Peritomy
description of, 6.163
incision, or Gundersen flap, 8.358, 8.358f
- Periventricular leukomalacia (PVL), 6.187, 6.361–362
- PERK (Prospective Evaluation of Radial Keratotomy) study, 13.50
- Perkins tonometer, 6.10, 6.281, 10.23
in infants and children, 10.158
infection control and, 10.27
- Perls Prussian blue stain, 4.31t
- Pernicious anemia, 1.138
- Peroxidase, 2.282f, 2.287
in retina and retinal pigment epithelium, 2.273
- Peroxidation, lipid, 2.281, 2.282–283
in lens opacification, 11.19
- Peroxisomal disorders, 12.290
- Peroxy/peroxyl radicals, 2.281, 2.283. *See also* Free radicals
- Persantine. *See* Dipyridamole
- Persistent corneal epithelial defects, 8.46t, 8.80–82, 8.81t, 8.82f
after cataract surgery, 11.132, 11.173
glaucoma medication toxicity and, 10.31
after LASIK, 13.112
management of, 8.368
after penetrating/deep anterior lamellar keratoplasty, 8.80, 8.424
after surface ablation, 13.107–108
topical anesthetic use/abuse and, 8.80–81, 8.81t, 8.89, 8.89f
in toxic keratoconjunctivitis, 8.80–81, 8.81t
- Persistent fetal vasculature (PFV/persistent hyperplastic primary vitreous/PHPV), 4.125–126, 4.126f, 4.294–295, 6.298f, 6.298–299, 6.301, 11.42, 12.341–342
Bergmeister papilla and. *See* Bergmeister papilla
cataract and, 4.126, 11.42
glaucoma and, 10.144
retinoblastoma differentiated from, 4.294–295
- Persistent generalized lymphadenopathy (PGL), in HIV infection/AIDS, 1.264
- Persistent hyaloid artery/system, 4.125–126, 4.126f.
See also Persistent fetal vasculature
- Persistent positive visual phenomena, 5.177, 5.201, 5.290
- Persistent pupillary membrane, 6.264, 6.264f, 6.266f
- Personal emergency kits, 1.302
- Personality/personality disorders, 1.191
- Personalized genetics, 2.141
- Perturbations, 3.119
- Pertussis, immunization against, 1.218t
- Pes anserinus, 2.104
- PET. *See* Positron emission tomography
- Petechiae, 1.142
- Peters anomaly, 2.152, 4.74, 4.75f, 4.98, 6.259, 6.260f, 8.97t, 8.102–104, 8.103f, 10.150, 10.154, 11.31–32.
See also Axenfeld-Rieger syndrome
Axenfeld-Rieger syndrome differentiated from, 10.154t
glaucoma and, 4.74, 10.150, 10.154
pediatric keratoplasty for, 8.450
- Peters plus syndrome, 6.259, 8.104
- “Petit mal” (absence) seizures, 1.201
- Petroclinoïd (Gruber) ligament, 2.102, 5.41
- Petrosal nerve
deep, 2.101f, 2.104
greater superficial, 2.101f, 2.103, 2.104, 5.276–277f, 5.277
inferior, 2.103
- Petrosal sinuses, inferior/superior, 2.105, 2.106f, 5.22, 5.22f, 5.23f
- Petrous bone, 5.5
inflammation of, sixth nerve (abducens) palsy and, 5.201
- PEX1* gene, Refsum disease caused by mutation in, 2.265
- Pfeiffer syndrome, 6.207
- PFV. *See* Persistent fetal vasculature
- PG analogues. *See* Prostaglandin (PG) analogues
- PG/PGH synthetase (prostaglandin synthetase/prostaglandin G/H synthetase). *See* Cyclooxygenase
- PGD. *See* Preimplantation genetic diagnosis
- PGI₂. *See* Prostaglandin I₂
- PGL. *See* Persistent generalized lymphadenopathy
- PGs. *See* Prostaglandins
- pH
of ocular medication, absorption affected by, 2.298
of tear film, 2.214t
- PHACE syndrome, 6.220, 6.363
- Phaco. *See* Phacoemulsification
- Phaco chop technique, 11.114
- Phaco fracture technique, 11.112–114, 11.113f
- Phaco handpiece, 11.98, 11.98f
- Phaco tip, 11.98f, 11.100, 11.101f
- Phacoanaphylactic endophthalmitis. *See* Phacoantigenic (lens-associated) uveitis
- Phacoanaphylaxis. *See* Phacoantigenic glaucoma
- Phacoantigenic glaucoma, 10.98

- Phacoantigenic (lens-associated) uveitis (lens-induced granulomatous/phacoanaphylactic endophthalmitis), 4.118–119, 4.119*f*, 9.118, 9.119, 11.66
- sympathetic ophthalmia and, 9.174
- Phacodonesis
- cataract surgery and, 11.182
- in exfoliation syndrome/pseudoexfoliation, 10.92
- Phacodynamics, terminology used in, 11.102–103
- Phacoemulsification, 11.90–91, 11.98–118. *See also*
- Cataract surgery
- for advanced cataract, 11.180
- anterior capsulotomy for, 11.109–110
- in anterior chamber, 11.112
- anticoagulant use and, 11.171–172, 11.172*t*
- aspiration system for, 11.102, 11.115
- burst-mode, 11.101
- capsular rupture during, 11.142–143
- capsule staining for, 11.178–179, 11.179*f*
- capsulorrhexis in, 11.108–110, 11.109*f*
- clear corneal incision for, 11.106*f*, 11.106–107
- cystoid macular edema after, 11.164, 11.187
- elliptical, 11.101
- eye marking/time-out before, 11.104–105
- flat or shallow anterior chamber and, 11.134–136
- intraoperative complications and, 11.134–135
- posterior fluid misdirection syndrome and, 11.134–135
- postoperative complications and, 11.135–136
- foldable IOLs for, 11.116, 11.120, 11.120*f*. *See also*
- Foldable intraocular lenses
- in glaucoma, 11.186
- combined with trabeculectomy, 10.213
- after filtering surgery, 11.187
- intraocular pressure lowered by, 11.186
- globe exposure for, 11.105, 11.105*f*
- high myopia and, 11.184–185
- historical overview of, 11.90–91
- hydrodelineation in, 11.110
- hydrodissection in, 11.110
- incisions for. *See also* Incisions, for cataract surgery
- clear corneal incisions, 11.106*f*, 11.106–107
- scleral tunnel incisions, 11.107*f*, 11.107–108
- instrumentation for, 11.98*f*, 11.98–99
- for intumescent cataract extraction, 11.179–180
- IOLs for, 11.115–117, 11.118–122. *See also* Foldable intraocular lenses
- procedures after insertion of, 11.117–118
- at iris plane, 11.112
- irrigation in, 11.101–102, 11.115
- posterior fluid misdirection and, 11.134–135
- toxic solutions exposure and, corneal edema caused by, 11.129, 11.133–134
- lens particle glaucoma and, 11.67
- locations of, 11.111–112
- nuclear rotation in, 11.111
- nucleus disassembly/removal in, 11.111, 11.112–114, 11.113*f*
- locations for emulsification and, 11.111–112
- techniques of, 11.112–114, 11.113*f*
- chopping techniques, 11.114
- phaco fracture, 11.112–114, 11.113*f*
- ocular trauma affecting visualization and, 11.191
- paracentesis for, 11.105
- after pars plana vitrectomy, 11.190
- posterior capsule opacification and, 11.152–153
- Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser therapy, capsulotomy
- in posterior chamber, 11.111–112
- for posterior polar cataract, 11.180–181
- hydrodissection/nucleus rotation and, 11.111, 11.181
- power delivery and, 11.99
- advances in, 11.100*f*, 11.100–101
- procedure for, 11.104–118
- pulsed, 11.100
- retained lens fragments after, 11.141
- retinal detachment and, 11.127, 11.166–167
- scleral tunnel incisions for, 11.107*f*, 11.107–108
- supracapsular, 11.110
- suprachoroidal effusion/hemorrhage risk and, 11.171
- torsional, 11.101
- for traumatic cataract, 11.192
- in triple procedure, 11.175
- ultrasonic technology terminology and, 11.99–100
- in uveitis, 9.281, 9.283
- with pars plana vitrectomy, 9.283
- after vitrectomy, 11.190
- vitrectomy for retained lens fragments after, 12.391–393, 12.392*f*
- in zonular dehiscence with lens subluxation or dislocation, 11.181–183, 11.182*f*, 11.183*f*
- Phacolysis, fluid-based, 11.125
- Phacolytic glaucoma (phacolytic uveitis), 4.103, 4.103*f*, 4.122, 9.21, 9.118, 9.118*f*, 9.119, 10.97*f*, 10.97–98, 11.67
- Phacomorphic glaucoma, 10.119, 10.128, 10.129*f*, 11.67, 11.68*f*
- Phagocytes, 9.19
- Phagocytosis, 9.19, 9.33
- of outer segments, 12.17
- pathologic changes that affect, 12.17
- by resting/scavenging macrophages, 9.19–20, 9.20*f*
- by retinal pigment epithelium, 2.276*f*, 2.276–277
- retinal pigment epithelium cell, 12.17
- Phagolysosomes/phagosomes, 9.19
- in retinal pigment epithelium, 2.69, 2.272
- Phakic intraocular lenses (PIOLs), 13.8*t*, 13.137, 13.138–147, 13.139*t*, 13.142*f*, 13.143*f*
- advantages of, 13.138
- for amblyopia/anisometropic amblyopia/strabismus, 13.185–186, 13.187
- ancillary preoperative tests for, 13.141
- angle-supported, 13.137, 13.138, 13.139*t*, 13.144
- complications of, 13.146–147
- anterior chamber, 13.8*t*
- for astigmatism after penetrating keratoplasty, 8.432
- background of, 13.138
- in children, 13.187
- complications of, 13.145–147
- contraindications for, 13.140
- corneal crosslinking with, 13.134, 13.207–208
- disadvantages/limitations of, 13.47*t*, 13.138–140
- indications for, 13.140
- informed consent for, 13.140–141

- iris-fixated/supported, 13.8*t*, 13.137, 13.138, 13.139*t*, 13.141–142, 13.142*f*
 - complications of, 13.145
 - sizing, 13.142, 13.142*f*
- outcomes of, 13.144–145
- patient evaluation for, 13.140
- patient selection for, 13.140–141
- posterior chamber, 13.8*t*, 13.138, 13.142*f*, 13.142–144, 13.143*f*
 - complications of, 13.145–146
 - corneal crosslinking with, 13.207–208
 - sizing, 13.144
- retinal detachment and, 13.138, 13.145, 13.146
- sulcus-supported, 13.137, 13.139*t*
- surgical technique for insertion of, 13.141–144, 13.142*f*, 13.143*f*
- Phakic refractive procedures, 13.8*t*
- Phakinin, 2.245, 11.16
- Phakoma/phakomatosis (neurocutaneous syndromes). *See also* Neurofibromatosis; *specific type*
 - definition of, 12.165
 - description of, 5.330*f*, 5.330–333, 5.331*f*, 5.332*f*, 5.333*f*, 5.334*t*, 6.397, 6.399
 - retinal cavernous hemangioma, 12.168, 12.169*f*
 - von Hippel–Lindau syndrome, 12.165–168, 12.166–167*f*
 - Wyburn–Mason syndrome, 12.168
- Phakomatous choristoma (Zimmerman tumor), 4.202–203, 4.203*f*
- Pharmacodynamics, 2.293, 2.304
 - age-related changes in, 2.295
- Pharmacogenetics/pharmacogenomics, 2.141, 2.201–202
- Pharmacogenomic testing, for age-related macular degeneration, 12.63
- Pharmacokinetics, 2.293, 2.295–304, 2.296*f*, 2.300*t*
 - age-related changes in, 2.295
- Pharmacologic anisocoria, 5.258*t*, 5.263
- Pharmacologic blockade, fixed, dilated pupil caused by, 5.310
- Pharmacology, ocular. *See also* Drugs, ocular; *specific agent*
 - age/aging and, 2.295
 - legal aspects of, 2.205–207
 - principles of, 2.293–304
- Pharmacotherapeutics, 2.293, 2.294, 2.305–372. *See also* Drugs, ocular; *specific agent*
 - legal aspects of, 2.205–207
 - principles of, 2.293–304
- Pharmacy Compounding Accreditation Board (PCAB), 2.306
- Pharyngoconjunctival fever, 6.242, 8.233, 8.234
- Phasic cells, 2.267, 2.268*f*
- Phenethicillin, 2.343
- Pheniramine, 2.337
- Pheniramine/naphazoline, 2.337, 2.338*t*
- Phenobarbital, for seizures, 1.202*t*
- Phenocopy, 2.141, 2.194, 2.205
- Phenol red–impregnated cotton thread test, of tear secretion, 8.39
- Phenothiazines, 12.297–298, 12.298*f*
 - cornea verticillata caused by, 8.130
 - corneal pigmentation caused by, 8.130, 8.132
 - lens changes caused by, 11.52, 11.52*f*
- Phenotype, 2.141, 2.194
 - alleles and, 2.184, 2.185
 - database of, 2.134
- Phenoxybenzamine, 2.308*t*
- Phenoxymethyl penicillin. *See* Penicillin V
- Phentolamine, 2.308*t*
 - for hypertension, 1.74
- Phenylalanine, in alkaptonuria, 8.184
- Phenylephrine, 2.308*t*, 2.314*t*, 2.317–318, 2.342
 - with cyclopentolate, 2.314*t*
 - drug interactions and, 2.317
 - Horner syndrome diagnosis and, 5.258–259
 - for intraoperative floppy iris syndrome, 11.138
 - for uveitis, 9.113
- Phenytoin, 1.113*t*, 1.202*t*
 - ophthalmic considerations and, 1.203
- Pheochromocytoma
 - hypertension in, 1.64, 1.64*t*
 - in multiple endocrine neoplasia, 1.58, 1.59
- Φ_e . *See* Radiant flux
- Φ_v . *See* Luminous flux
- Phialophora, 8.251
- Phimosis, capsular, 11.153–154
 - Nd:YAG laser capsulotomy for, 11.154, 11.154*f*, 11.154–157, 11.156*f*
 - in pseudoexfoliation/exfoliation syndrome, 11.184
- Phleboliths, orbital varices and, 7.71
- Phlyctenules/phlyctenulosis, 8.46*t*, 8.75, 8.75*f*
 - in blepharitis, 8.74, 8.75, 8.75*f*, 8.76
- PHMB. *See* Polyhexamethylene biguanide
- PHN. *See* Postherpetic neuralgia
- “Phone first,” in emergencies, 1.297
- phoria (suffix), 6.16
- Phorias. *See also* Heterophorias/phorias
 - refractive surgery and, 13.41
- Phoropter. *See also* Trial frames
 - converging of, 3.37, 3.37*f*
 - definition of, 3.27, 3.148
 - minus cylinder
 - advantages of, 3.148
 - astigmatism detection using, 3.29
 - cylinder axis refinement using, 3.29–30, 3.30*f*
 - with Jackson cross cylinder, 3.29, 3.30–31*f*
 - near-point chart with, 3.37*f*
 - occluding of, 3.26*f*
 - operating principles of, 3.27
 - pictorial representation of, 3.26–27*f*
 - plus cylinder
 - astigmatism detection using, 3.29
 - cylinder axis refinement using, 3.30
 - cylinder power refinement using, 3.31–32
 - retinoscopy using, 3.159*t*
 - working distances for, 3.154
- Phosphate, in aqueous humor, 2.232
- Phosphatidylcholine, in retinal pigment epithelium, 2.274
- Phosphatidylethanolamine, in retinal pigment epithelium, 2.274
- Phosphenes, optic neuritis causing, 5.176, 5.317
- Phosphocreatine shuttle, in rod outer segments, 2.261
- Phosphodiesterase-5 inhibitors, 12.304
- Phosphodiesterase (PDE), rod (rod PDE), 2.259–261, 2.260*f*
 - mutation in, 2.161, 2.263

- Phosphofructokinase, in lens glucose/carbohydrate metabolism, 11.17, 11.18f
- Phosphoinositide kinase, FYVE finger containing-PIKFYVE (*PIKFYVE*) gene, in Fleck corneal dystrophy, 8.136t
- Phospholine. *See* Echothiophate
- Phospholipase A₂ (PLA₂), 9.24, 9.26
in eicosanoid synthesis, 2.237, 2.238f
NSAID derivation and, 2.334
in tear film, 2.216
- Phospholipase C, in tear secretion, 2.218, 2.218f
- Phospholipases, in innate immune response, 9.16
- Phospholipids. *See also* Lipids
oxidation of, 2.281, 2.285
in retina/retinal pigment epithelium, 2.274
oxidative damage and, 2.285
in tear film, 2.215. *See also* Lipid layer of tear film
- Phosphonoformic acid. *See* Foscarnet
- Phosphorescence, 3.111
- Photic damage/phototoxicity/light toxicity, 12.367–369, 12.368f
cataract surgery and, 11.166
free-radical damage and, 2.283, 2.286
from ophthalmic instrumentation, 12.368–369
ophthalmic instrumentation causing, cataract surgery and, 11.166
retinal, 2.286
- Photisms, in optic neuropathy/neuritis, 5.176, 5.317
- Photo-oxidation, 2.283
in retina, 2.286
- Photoablation, 3.113, 3.113t, 3.113f, 3.115, 13.29–32, 13.30f, 13.73–74, 13.74–75f, 13.101–126. *See also* LASEK; LASIK; Surface ablation; Wavefront-guided (custom) laser ablation; Wavefront-optimized laser ablation
aberrations after, 13.11, 13.12, 13.13, 13.102–103, 13.103f
application of laser treatment for, 13.91f, 13.91–93
bioptics with, 13.157
Bowman layer/stromal bed preparation for, 13.82–90
central islands and, 13.103–104, 13.104f
central toxic keratopathy after, 13.105f, 13.105–106
complications/adverse effects of, 13.101–126. *See also specific type*
contact lens use after, 13.200
corneal curvatures affected by, 13.9, 13.26–28, 13.27f, 13.28f
IOL power calculation and, 13.44, 13.193–197, 13.196f
corneal ectasia after, 13.124–125
corneal crosslinking for, 13.124, 13.130, 13.131
corneal transplantation after, 13.198
corticosteroids after, 13.92
complications associated with, 13.104–105
pressure-induced stromal keratopathy, 13.119
corneal haze reduction and, 13.33, 13.94, 13.108–109
for diffuse lamellar keratitis, 13.117
elevated intraocular pressure/glaucoma and, 13.41, 13.104–105, 13.182, 13.201
fungal keratitis and, 13.106
herpes simplex keratitis and, 13.174
LASIK, 13.93, 13.94
regression in overcorrection and, 13.101, 13.108–109
regression in undercorrection and, 13.102, 13.108
surface ablation, 13.92, 13.94, 13.108–109
custom, 13.31, 13.46, 13.76–77, 13.97. *See also* Custom (wavefront-guided) ablation
decentered ablation and, 13.104, 13.104f
dry eye after, 13.78–79
elevated intraocular pressure after, 13.104–105, 13.180–183, 13.182f, 13.200–201
fundamentals of, 13.29–30, 13.30f
glaucoma/ocular hypertension and, 13.104–105, 13.180–183, 13.182f, 13.200–201
herpes simplex virus keratitis and, 13.173–174
infectious keratitis after, 13.106f, 13.106–107, 13.107f
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118f, 13.118t
keratoconus and, 13.42–43, 13.175f, 13.175–178, 13.176f, 13.177f
laser types for, 13.30–32
outcomes of, 13.95–97
techniques and, 13.73–100
overcorrection and, 13.101–102, 13.108–109
patient selection for, 13.77–80, 13.78t
postoperative care for, 13.93–95
immediate postablation measures, 13.92–93
preoperative care for
patient preparation and, 13.81–82
patient selection/relative contraindications and, 13.77–80, 13.78t
planning/laser programming and, 13.31, 13.40, 13.81
re-treatment/enhancements and, 13.97–100, 13.99f
for overcorrection, 13.101–102
for undercorrection, 13.102
for retinoblastoma, 4.300
surgical technique for, 13.80–95
techniques for, 13.73–100
topography-guided, 13.32, 13.77
outcomes of, 13.97
tracking/centration/ablation and, 13.91f, 13.91–92
undercorrection and, 13.102, 13.108
- Photoactivation, 3.113
- Photochemical (actinic) injury, 12.367
pinguecula as, 4.56, 4.56f
- Photochemical interactions, laser–tissue, 3.113t, 3.113–114
- Photochromic lenses, 3.193, 3.193f
- Photocoagulation
anesthesia for, 12.375
angle-closure glaucoma after, 10.143
Bruch membrane rupture caused by, 12.378
choroidal detachment caused by, 12.379, 12.379f
for choroidal hemangioma, 4.283
for choroidal neovascularization, 9.291
in ocular histoplasmosis syndrome, 9.217, 9.218f
clinically significant diabetic macular edema treated with, 12.110
Coats disease treated with, 12.161
complications of, 12.378–379
for cysticercosis, 9.232
description of, 3.114
diabetic macular edema treated with, 12.376

- for diabetic retinopathy, 4.160, 4.161*f*
- for diffuse unilateral subacute neuroretinitis, 9.233, 9.233*f*
- Early Treatment Diabetic Retinopathy Study findings for, 12.100
- exudative retinal detachment caused by, 12.379
- factors that affect, 12.373
- foveal burns caused by, 12.378
- indications for, 12.375–377
- lasers used in
 - alternative systems, 12.377–378
 - wavelength of, 12.373–375
- lenses for, 12.375, 12.376*f*
- macular applications of, 12.375–376
- for malignant glaucoma, 10.140
- neovascular age-related macular degeneration treated with, 12.79
- for neovascular glaucoma, 10.135
- for ocular histoplasmosis syndrome, 9.217, 9.218*f*
- ophthalmic applications of, 3.115
- parameters for, 12.375–377
- for pars planitis, 9.130–131
- principles of, 12.373–379
- proliferative diabetic retinopathy treated with
 - description of, 12.104
 - in pregnancy, 12.94
- prophylactic, in acute retinal necrosis, 9.197
- for retinal arterial macroaneurysms, 12.147
- for retinal cavernous hemangioma, 12.168
- for retinal hemangioblastoma, 4.285
- retinal holes caused by, 12.378
- retinal lesions caused by, 12.378–379
- retinal vascular lesions treated with, 12.377
- for retinopathy of prematurity, 6.332, 6.333*f*, 12.186*f*
- slit-lamp delivery systems, 12.377
- for toxocariasis, 9.230
- for uveitic neovascularization, 9.291
- vitreous hemorrhage caused by, 12.379
- for von Hippel–Lindau syndrome/disease (retinal angiomatosis), 4.284, 12.167
- Photodisruption, 3.113, 3.113*t*, 3.113*f*, 3.116–117, 3.117*f*, 13.29
- femtosecond laser, 13.29
- Photodynamic therapy (PDT), 3.114. *See also* Verteporfin
 - applications of, 12.380
 - central serous chorioretinopathy treated with, 12.194
 - for choroidal hemangioma, 4.283
 - for choroidal melanoma/ciliary body melanoma, 4.276
 - for choroidal neovascularization, 12.212, 12.213*f*, 12.380
 - in ocular histoplasmosis, 9.217
 - in uveitis, 9.292
 - complications of, 12.380
 - half-fluence, 12.380
 - neovascular age-related macular degeneration treated with, 12.79
 - photosensitivity reactions caused by, 12.380
 - polypoidal choroidal vasculopathy treated with, 12.76
 - ranibizumab added to, 12.85
 - for retinal hemangioblastoma, 4.285
 - steps involved in, 12.380
 - von Hippel–Lindau syndrome treated with, 12.167
- Photography, for recording optic nerve/nerve head/disc evaluation, 10.53
- Photokeratoscopy, evaluation of astigmatism after penetrating keratoplasty and, 8.431
- Photolysis, laser, 11.125
- Photometry, 3.92, 3.108–110, 3.109*t*
- Photomicroscopy, specular. *See* Specular microscopy
- Photomultiplier, 3.94
- Photomydriasis, multifocal IOLs and, 13.156
- Photon, 3.95, 3.110
- Photophobia, 5.296, 12.46, 12.264
 - in cone dystrophies, 5.102
 - after intrastromal corneal ring segment implantation, 13.65, 13.69
 - in optic neuropathy versus maculopathy, 5.100*t*
 - in primary congenital glaucoma, 10.151, 10.152
 - in recurrent corneal erosion, 8.86, 8.87
 - in thyroid eye disease, 7.56, 7.58
 - in uveitis, 9.78, 9.94, 9.112
- Photopic electroretinogram. *See also* Electrophoretography/electroretinogram
 - in cone dystrophies, 5.102
 - LA 3.0 (photopic single-flash), in cone dystrophies, 5.102
- Photopsias, 5.175. *See also* Floaters
 - electroretinography findings in, 12.46
 - in multiple evanescent white dot syndrome, 5.101, 9.163
 - in optic neuropathy versus maculopathy, 5.100*t*
 - in posterior vitreous detachment, 12.308
 - retinal disease causing, 5.175
 - in rhegmatogenous retinal detachment, 12.320
 - in uveitis, 9.78
 - vertebrobasilar disease causing, 5.336
- Photoreceptor dystrophies
 - cone, 12.264–265
 - cone–rod, 12.264–265
 - diffuse, 4.170, 4.172*f*. *See also* Cone dystrophies/ degenerations; Cone–rod dystrophies/ degenerations; Retinitis pigmentosa
 - rod–cone, 12.261–264, 12.262–264*f*
- Photoreceptor inner segments (IS), 2.69, 2.70, 2.70*f*, 2.72*f*, 2.74*f*. *See also* Cone inner segments; Photoreceptors
- Photoreceptor outer segments (OS), 2.69, 2.70, 2.70*f*, 2.72*f*, 2.74*f*. *See also* Cone outer segments; Photoreceptors; Rod outer segments
 - development of, 2.116*t*
 - shed, retinal pigment epithelium phagocytosis of, 2.276*f*, 2.276–277
- Photoreceptors, 2.69–70, 2.70*f*, 2.71*f*, 2.72*f*, 2.77, 2.257–266, 2.258*f*, 4.140*f*, 5.24, 6.44. *See also* Cones; Rods
 - age-related changes in, 12.61
 - atrophy of, in macular degeneration, 4.163–164
 - biochemistry and metabolism of, 2.257
 - blue-light damage to, 2.286
 - cone. *See* Cones
 - density of, 12.11
 - development of, 2.116*t*, 2.122
 - disorders of. *See* Achromatopsia
 - distribution of, 12.11
 - drusen effects on, 12.64

- iron damage to, 12.362
- in macular degeneration/choroidal neovascularization, 4.163–164
- oxidative damage to, 2.285–286
- ratio of, to ganglion cells, 5.24
- rods. *See* Rods
- as waveguides, 12.33
- Photorefractive keratectomy (PRK), 8.412*t*, 13.8*t*, 13.73, 13.74, 13.76. *See also* Keratorefractive surgery; Surface ablation
 - for accommodative esotropia, 13.188
 - arcuate keratotomy and, 13.54, 13.58
 - for astigmatism and refractive errors after penetrating keratoplasty, 8.432
 - Bowman layer and, 2.225
 - cataract surgery after, 11.177
 - IOL power calculation and, 11.86
 - central toxic keratopathy after, 13.105*f*, 13.105–106
 - in children, 13.187
 - contraindications/relative contraindications to, 13.171
 - corneal biomechanics affected by, 13.14
 - corneal crosslinking with, 13.134, 13.206–207
 - corneal haze after, 13.94, 13.109, 13.109*f*
 - corneal wound healing/repair and, 13.32–33, 13.94
 - corticosteroids after, 13.94
 - drugs affecting success of, 13.37
 - dry eye after, 13.79
 - ectatic disorders after, 8.166
 - glaucoma/ocular hypertension and, 13.181
 - herpes simplex virus keratitis and, 13.174
 - hyperopic, 13.94, 13.96
 - infectious keratitis after, 13.106–107
 - intraocular pressure measurement after, 10.25, 13.181
 - IOL power calculations after, OCT in, 8.22
 - limbal relaxing incisions and, 13.54, 13.58
 - myopia correction using, 3.271, 3.271*f*
 - myopic, 13.95
 - conductive keratoplasty for overcorrection and, 13.129
 - outcomes of, 13.95
 - ocular and systemic disease and, 13.171
 - after penetrating keratoplasty, 13.179, 13.180
 - postoperative care for, 13.94
 - after radial keratotomy, 13.52
 - for recurrent corneal erosions, 8.79, 8.87–88
 - after retinal detachment surgery, 13.185
 - topography-guided (T-PRK), corneal crosslinking with, 13.206–207
- Photorefractor, initial estimate of refractive error obtained using, 3.28
- Photosensitive retinal ganglion cells, 5.24, 5.28
- Phototoxicity. *See also* Photic damage/phototoxicity/light toxicity
 - in SLE, 1.157
- Photosensitizing dye, 3.114
- Photostress recovery time, testing, 5.88
 - in optic neuropathy versus maculopathy, 5.100*t*
 - transient visual loss and, 5.163, 5.164
- Phototherapeutic keratectomy (PTK), 8.367, 8.412*t*
 - for band keratopathy, 6.322
 - for calcific band keratopathy, 8.120
 - corneal crosslinking with, 13.206–207
 - for corneal/epithelial erosions, 11.129
 - after LASIK, 13.112
 - recurrent, 8.87
 - for corneal haze after surface ablation, 13.109
 - glaucoma/ocular hypertension and, 13.182
 - herpes simplex virus keratitis and, 13.174
 - layer-based approach to use of, 8.417*t*
 - for striae in LASIK flaps, 13.115
- Photothermal laser therapy, 13.29
- Phototoxicity. *See* Photic damage/phototoxicity/light toxicity
- Phototransduction
 - cone, 2.261–263
 - rod, 2.257–261, 2.259*f*, 2.260*f*
- PHOX2A* gene disorders, congenital extraocular muscle disorders and, 2.124
- PHP. *See* Preferential hyperacuity perimetry
- PHPV (persistent hyperplastic primary vitreous). *See* Persistent fetal vasculature
- PHQ-2. *See* Patient Health Questionnaire-2
- Phthiriasis/phthiriasis palpebrum (*Phthirus pubis* infection), 8.253, 8.255
- Phthirus pubis* (crab/pubic louse), 8.253, 8.254*f*
 - ocular infection caused by, 8.208*t*, 8.253, 8.255
- Phthisis bulbi (phthisical eye), 4.22, 4.23, 4.23*f*
 - retinoblastoma regression and, 4.301
 - sympathetic ophthalmia and, 9.175
- Phycomycetes infection (phycomycosis/mucormycosis/zygomycosis), 5.355*f*, 5.355–356, 8.251
 - cornea involved in (keratitis), 4.78
 - optic nerve involved in, 4.243
 - orbit involved in, 4.226–227, 4.228*f*, 5.355, 7.50
 - exenteration in management of, 7.50, 7.136
- Physical activity. *See* Exercise/activity
- Physical examination. *See also* Examination
 - preoperative assessment and, 1.283
- Physical optics
 - description of, 3.92–93
 - geometric optics and, 3.119
 - light scattering, 3.97–98
 - reflection, 3.96
 - refraction, 3.96
 - Tyndall effect, 3.97
- Physician Quality Reporting Initiative, 1.31
- Physiologic (simple/essential) anisocoria, 5.256*f*, 5.257, 6.275
- Physiologic cup/physiologic cupping, 2.86, 10.48.
 - See also* Cupping of optic nerve/nerve head/disc; Optic cup
- Physiologic suppression, 6.48
- Physostigmine, 2.309*f*, 2.311*t*, 2.312, 2.313
 - for muscarinic antagonist adverse effects, 2.314
- Phytanic acid α -hydrolase, defective/deficiency of. *See* Refsum disease/syndrome
- Phytanic acid oxidase, defective/deficiency of, 2.175*t*.
 - See also* Refsum disease/syndrome
- Phytanic acid storage disease. *See* Refsum disease/syndrome
- Pia mater, optic nerve, 2.87, 2.88*f*, 2.89*f*, 4.241, 4.242*f*, 5.17*f*
- Pial arteries, optic nerve supplied by, 10.46
- PIC. *See* Punctate inner choroiditis/chorioidopathy
- PICA. *See* Posterior inferior cerebellar artery

- Pica, in iron deficiency anemia, 1.136
- Picornaviruses, ocular infection caused by, 8.208*t*, 8.240*t*
- Picture charts, 3.134
- Pie-in-the-sky defect, 2.93, 5.155, 5.155*f*
- PIER study, 12.80
- Pierre Robin malformation/sequence, 6.183, 6.211, 8.192*t*
- Piezoelectric crystal, in phacoemulsification handpiece, 11.99, 11.100
- Piggyback intraocular lenses
definition of, 3.240
description of, 3.226
intralenticular fibrosis after placement of, 3.241
power calculations for, 3.251
refractive lens exchange and, 13.150
- Pigment/pigmentary dispersion syndrome, 4.105, 4.105*f*, 9.79, 9.280, 10.93–96, 10.94*f*, 10.95*f*, 10.96*f*
anterior chamber and trabecular meshwork affected in, 4.104–105, 4.105*f*
cornea affected in, 8.128
gene for, 10.11*t*
glaucoma and, 4.105, 4.105*f*, 10.93–96, 10.94*f*, 10.95*f*, 10.96*f*
posterior chamber phakic IOLs and, 13.145–146
- Pigment epithelial detachment (PED). *See* Retinal pigment epithelium (RPE), detachment of
- Pigment epithelium. *See* Ciliary epithelium, pigmented; Iris pigment epithelium; Retinal pigment epithelium
- Pigment epithelium cysts, of iris, 6.272, 6.272*f*
- Pigment epithelium–derived factor
in aqueous humor, 2.231
in vitreous, 2.253
- Pigment granules, 12.348
in retinal pigment epithelium, 2.277–278
- Pigment ruff, iris, 2.54*f*, 2.55
- Pigment spot of sclera, 8.338
- Pigmentary glaucoma, 4.105, 4.105*f*, 10.95–96, 10.96*f*
- Pigmentary retinopathy. *See also* Retinitis pigmentosa
in congenital rubella syndrome, 9.203, 9.204*f*
hearing loss and. *See* Usher syndrome
in measles, 9.206–207
- Pigmentations/pigment deposits. *See also* Pigmented (melanocytic) lesions
conjunctival, 8.131*f*, 8.131–132, 8.338
corneal, 4.86, 8.118*t*
drug-induced, 8.129*t*, 8.129–132, 8.130*f*, 8.131*f*
iris, 2.53, 2.54, 2.55, 2.56*f*, 2.236
prostaglandin analogues/latanoprost and, 2.327, 10.175
after laser skin resurfacing, 7.238
- lens
aging and, 11.43, 11.44*f*
blunt injury causing (Vossius ring), 4.18, 11.53
drugs causing, 11.52, 11.52*f*
in pigment dispersion syndrome, 10.93–96, 10.94*f*, 10.95*f*
in pseudoexfoliation/exfoliation syndrome, 10.39, 10.91*f*, 10.91–93, 10.92*f*
retinal/retinal pigment epithelium, 2.277–278.
See also Pigmentary retinopathy
trabecular meshwork, 4.104–105, 4.105*f*, 10.18, 10.39
in pigmentary glaucoma, 10.94, 10.95*f*
in pseudoexfoliation/exfoliation syndrome, 10.39, 10.93
- Pigmented (melanocytic) lesions, conjunctival/ocular surface, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*, 8.338*t*, 8.338–345. *See also* Melanocytic tumors; *specific type*
benign, 8.338*t*, 8.338–341, 8.339*f*, 8.339*t*, 8.340*f*, 8.341*f*
malignant, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
preinvasive, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
- Pigmented paravenous retinopathy, 12.263
- Pigments
in retinal pigment epithelium, 12.12*f*, 12.17
visual, retinal pigment epithelium in regeneration of, 2.274–276, 2.275*f*
- PIKFYVE (phosphoinositide kinase, FYVE finger containing–PIKFYVE) gene, in Fleck corneal dystrophy, 8.136*t*
- Pilagan. *See* Pilocarpine
- Pilar (trichilemmal) cyst, 7.168
- Pili, bacterial, 8.244
- Pilocar. *See* Pilocarpine
- Pilocarpine, 2.309*f*, 2.310, 2.311, 2.311*t*, 3.272, 10.173*t*, 10.181–182
accommodation affected by, 11.23
for acute angle closure, 10.124
in Adie tonic pupil diagnosis, 5.256*f*, 5.264–265, 5.265*f*
anisocoria evaluation and, 5.256*f*
cataracts caused by, 11.52
for dry eye, 8.61*t*, 8.64
in fixed, dilated pupil evaluation, 5.310
in mydriasis evaluation, 5.263
sustained-release gel for administration of, 2.302
- Pilocytic astrocytoma, 6.396
optic. *See* Optic nerve (optic pathway/chiasm) gliomas
- Pilomatricoma (pilomatixoma), 6.200, 6.200*f*, 7.172, 7.173*f*
- Pilopine/Pilopine gel. *See* Pilocarpine
- Piloptoc. *See* Pilocarpine
- Pilostat. *See* Pilocarpine
- Pindolol, 1.68*t*
- Pineal gland, 5.24*f*
- Pinealoblastoma, primary intracranial, retinoblastoma and, 4.298, 4.302
- Pinguecula, 4.56, 4.56*f*, 4.57–58, 8.112, 8.112*f*
conjunctival graft for, 8.356
- Pinhole, in camera obscura, 3.5, 3.5*f*
- Pinhole apertures
double, 3.285, 3.286*f*
monocular diplopia and, 3.130
- Pinhole occluder, visual acuity testing use of, 3.23–24, 3.24*f*, 3.130
- Pinhole visual acuity, 3.124, 3.130
- Pink-eyed dilution gene defects, in albinism, 2.278
- Pioglitazone, 12.301
for diabetes mellitus, 1.45*t*, 1.46
- PIOL. *See* Primary intraocular/central nervous system lymphoma
- PIOLs. *See* Phakic intraocular lenses
- PION. *See* Posterior optic neuropathy, ischemic
- PIP5K3 (phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase type III) gene. *See* PIKFYVE (phosphoinositide kinase, FYVE finger containing–PIKFYVE) gene

- Piperacillin, 1.275, 2.345
with tazobactam, 1.276
- Piroxicam, 2.335*t*
- PIs. *See* Protease inhibitors
- PISK. *See* Pressure-induced stromal keratopathy
- Piston (wavefront aberration), 13.11
- Pitavastatin, for hypercholesterolemia/heart disease prevention, 1.86*t*
- PITS. *See* Pulled-in-two syndrome
- Pits
lens, 11.25, 11.26*f*
optic (optic nerve/disc pits, optic holes, optic pit maculopathy), 5.145. *See also* Optic pits
acquired, 10.49–50
- Pituitary adenoma, 1.57–58
chiasmal syndromes caused by, 5.147, 5.148*f*
neuroimaging in evaluation of, 1.58, 5.72*t*, 5.92*f*, 5.93–94*f*
in pregnancy, 5.147, 5.333
- Pituitary apoplexy (Sheehan syndrome), 1.58, 5.149, 5.150*f*
- Pituitary fossa, 5.6*f*
- Pituitary gland, 5.27*f*
- Pituitary gland disorders, in lymphocytic hypophysitis, 5.335
- Pituitary hormones, hypothalamic hormones and, 1.56, 1.56*t*
- PITX2 gene, 2.126, 6.265, 10.11*t*
in Axenfeld-Rieger syndrome, 8.97*t*, 8.102, 10.150
in glaucoma, 10.11*t*
in Peters anomaly, 8.97*t*, 8.103, 10.150, 11.32
- PJCs (premature junctional complexes/contractions).
See Premature complexes/contractions,
junctional
- PK/PKP (penetrating keratoplasty). *See* Keratoplasty,
penetrating
- PKC. *See* Protein kinase C
- PL. *See* Preferential looking
- PLA₂. *See* Phospholipase A₂
- Placental-like growth factor (PLGF), in aqueous humor, 2.235
- Placode-based topography/Placido disk, 3.248, 8.27–28, 8.28, 8.35*t*, 13.7–9, 13.14–16, 13.15*f*, 13.17, 13.20, 13.21*f*, 13.25*f*
computerized, 3.288*f*
in corneal biomechanics evaluation, 8.43
errors in, 3.252
IOL power calculation after refractive surgery and, 13.193
- Placode, lens, 2.115, 2.116*t*, 2.117*f*, 11.25, 11.26*f*
- Placoid chorioretinitis
relentless (ampiginous choroiditis), 9.150–151, 9.151*f*
syphilitic posterior, 9.239, 9.239*f*, 9.297–298
- Plagioccephaly, 6.204–205
- Planck constant, 3.110
- Plane mirror setting, on retinoscope, 3.150, 3.151*f*
- Plane mirrors, 3.81
- Plano/plano power intraocular lenses, 13.150
hard contact lens method for IOL power calculation and, 13.195
- Pianoconcave lenses, 12.375
- Plant alkaloids, in cancer chemotherapy, 1.233*t*
- Plants/vegetation, ocular injuries caused by, 8.387
corneal abrasions, 8.399
corneal foreign body, 8.387, 8.399
fungal keratitis and, 4.78, 8.273, 8.387, 8.399
- Planum sphenoidale, 5.6*f*
- Plaque hemangioma, 6.220, 6.220*f*
- Plaque radiotherapy. *See* Radioactive plaque therapy
- Plaques
anterior subcapsular fibrous, 4.120, 4.120*f*
atherosclerotic, 1.82, 1.92
rupture of, in acute coronary syndrome, 1.93
demyelinating, in multiple sclerosis, 5.316, 5.316*f*
Hollenhorst (cholesterol emboli)
in branch retinal artery occlusion, 4.156
transient visual loss and, 5.165, 5.165*f*, 5.166*t*
optic nerve, 4.244
posterior subcapsular fibrous, 4.120*f*, 4.120–121
senile calcific, scleral, 4.111, 4.111*f*
senile scleral (Cogan), 8.128, 8.129*f*
- Plasma, 1.135
- Plasma cell-rich pseudotumors, 7.89
- Plasma cell tumors, of orbit, 7.89–90
- Plasma cells, 4.9, 9.38
monoproliferation of, crystalline corneal deposits and, 8.198
- Plasma-derived enzyme systems, 9.22*t*, 9.22–24, 9.23*f*.
See also specific component
- Plasma formation, 3.116, 3.116*f*
- Plasma-induced ablation, 3.113, 3.113*t*, 3.113*f*, 3.115–116, 3.116–117*f*
- Plasma proteins. *See also* Proteins
in aqueous humor, 2.231, 2.233
drug-binding by, systemic administration and, 2.300–301
in retinal pigment epithelium, 2.273, 2.277
- Plasmacytoma, of orbit, 7.89
- Plasmid-liposome complexes, in gene therapy, 2.169
- Plasmid resistance, 1.274
- Plasmids, 8.243
- Plasmin, 9.23
in aqueous humor, 2.234
for enzymatic vitreolysis, 2.255
- Plasminogen, 9.23
antifibrinolytic agents affecting, 2.369
in aqueous humor, 2.234
in ligneous conjunctivitis, 8.294, 8.295
- Plasminogen activators
in aqueous humor, 2.234
tissue. *See* Tissue plasminogen activator
- Plastic prisms, in minimum deviation position, 3.45, 3.46*f*
- Plateau iris/plateau iris syndrome, 10.4*t*, 10.9, 10.32, 10.120, 10.127*f*, 10.127–128
laser iridotomy for, 10.128
- Platelet-activating factors (PAFs), 9.24, 9.25*f*, 9.25–26
- Platelet count, 1.141
- Platelet-derived growth factors (PDGFs), 2.371, 9.28*t*
- Platelet dysfunction, 1.144
NSAID use and, 1.172
- Platelet-fibrin embolus, transient visual loss and, 5.165, 5.165*f*, 5.166*t*
- Platelet function analyzer, 1.141

- Platelet glycoprotein IIb/IIIa inhibitors. *See* Glycoprotein IIb/IIIa inhibitors
- Platelets, 1.135
 aspirin affecting, 2.335, 2.336
 disorders of, 1.143–144
 drugs causing, 1.143–144
 in hemostasis/hemostasis disorders, 1.143–144
- Platinum eyelid weights
 for corneal exposure in facial palsy, 5.281
 for exposure keratopathy, 8.80
- Platysma muscle, 7.141, 7.142f
- Platysmaplasty, 7.246f, 7.246–247
- Plavix. *See* Clopidogrel
- Pleiotropism, 2.141, 2.196
- Pleistophora*, 8.252
- Pleomorphic adenoma (benign mixed tumor)
 of eyelid, 7.170
 of lacrimal gland, 4.229–230, 4.230f, 7.91, 7.92f, 7.92–93
- Pleomorphic rhabdomyosarcoma, 4.236, 7.83
- Pleomorphism
 in Fuchs endothelial corneal dystrophy, 8.156
 specular microscopy in evaluation of, 8.23
 before cataract surgery, 11.84
- Plexiform layer
 inner (IPL), 2.70f, 2.71f, 2.74, 2.74f, 2.88f, 4.140f, 4.141f
 outer (OPL), 2.70f, 2.71f, 2.72f, 2.74, 2.74f, 2.88f, 4.140f, 4.141f
- Plexiform neurofibromas, 5.334t, 6.223, 6.395f, 6.395–396, 7.77, 7.77f, 7.78, 7.78f
 eyelid involvement/ptosis and, 5.269t, 7.77f, 7.78, 7.78f
 glaucoma and, 10.30, 10.156
 of orbit, 4.238, 4.238f, 7.77, 7.77f, 7.78, 7.78f
- PLG gene, in ligneous conjunctivitis, 8.294
- PLGF. *See* Placental-like growth factor
- Plica semilunaris, 2.18f, 2.27, 8.6
 advancement of, 6.171
 hypertrophy of, 6.172f
- Plication (conjunctiva)
 for conjunctivochalasis, 8.86, 8.361
 description of, 6.164t
- Plurihormonal adenomas, 1.58
- Pluripotent stem cells, 1.135
- Plus cylinder lens, 3.17f
 astigmatic dial refraction with, 3.162
 description of, 3.148–149
 minus cylinder conversion to, 3.149
 for with movement, 3.155
- Plus cylinder phoropter
 astigmatism detection using, 3.29
 cylinder axis refinement using, 3.30
 cylinder power refinement using, 3.31–32
 retinoscopy using, 3.159t
- Plus disease, 6.326, 6.327t, 6.330f, 12.176t, 12.176–177, 12.178t, 12.178f, 12.179f, 12.184t, 12.186, 12.186f
- Plus lenses/plus-power lenses. *See also* Convex (plus/positive) lenses
 amblyopia treated with, 6.59
 anophthalmic socket camouflage and, 7.136
 convergence paralysis treated with, 6.106
- PMD. *See* Pellucid marginal degeneration
- PML. *See* Progressive multifocal leukoencephalopathy
- PMMA. *See* Polymethyl methacrylate
- PMNs. *See* Polymorphonuclear leukocytes
- PND. *See* Prenatal diagnosis
- PNET. *See* Primitive neuroectodermal tumor
- Pneumatic displacement, 12.85
- Pneumatic retinopexy, for rhegmatogenous retinal detachment, 12.324, 12.397–398, 12.398f
- Pneumatic tonometer (pneumatonometer/pneumotonometer), 10.25–26
 in infants and children, 10.158
 for intraocular pressure measurement after refractive surgery, 13.119, 13.200
- Pneumocandins, 1.281
- Pneumococcal vaccines (PCV/PPSV23), 1.218t, 1.222–223, 1.243
- Pneumococcus. *See* *Streptococcus pneumoniae*
- Pneumocystis jirovecii* (*Pneumocystis carinii*) infections
 choroiditis, 9.298, 9.298f
 pneumonia (PCP), 1.262, 1.267–268, 9.298
 prophylaxis of, 9.102, 9.106
- Pneumolysin, 8.245
- Pneumonia
 in HIV infection/AIDS, 1.262, 1.267–268, 9.298
 pneumococcal, 1.242
 immunization against, 1.218t, 1.222–223, 1.243
- Pneumonitis, in coccidioidomycosis, 9.271
- Pneumotonometer/pneumatonometer, 10.25–26
 in infants and children, 10.158
 for intraocular pressure measurement after refractive surgery, 13.119, 13.200
- PNH. *See* Paroxysmal nocturnal hemoglobinuria
- PO (pupil–optic nerve) section, 4.29f, 4.29–30
- POAG (primary open-angle glaucoma). *See* Open-angle glaucoma, primary
- Podophyllin derivatives/podophyllotoxins, in cancer chemotherapy, 1.231, 1.233t
- POHS (presumed ocular histoplasmosis syndrome). *See* Ocular histoplasmosis syndrome/presumed
- Point mutations, 2.193. *See also* Mutation screening for, 2.161, 2.163f, 2.164f, 2.165f, 2.166f
- Point spread function (PSF), 3.41, 3.69–70, 3.105, 3.275, 3.275f, 3.305. *See also* Blur circles
- Poker spine, in ankylosing spondylitis, 1.153
- Poland syndrome, 6.135
- Polar cataracts, 11.35–36, 11.37f
 anterior, 6.55, 6.295, 6.295f
 posterior, 11.36
 surgery for, 11.180–181
 hydrodissection/nucleus rotation and, 11.111, 11.181
- Polarimetry/polarimeter, scanning laser (GDx/SLP), in optic nerve/nerve head/disc evaluation, 10.56
- Polarization, of light, 3.92, 3.98–99
- Polarized lens test, in nonorganic disorder evaluation
 monocular no light perception and, 5.303–305
 monocular reduced vision and, 5.305
- Polarized Worth 4-dot test, 6.80
- Polio (poliomyelitis), immunization against, 1.222
- Poliosis
 in staphylococcal blepharitis, 8.74
 in Vogt-Koyanagi-Harada syndrome, 9.178, 9.178f

- Poly-Dex. *See* Dexamethasone, in combination preparations
- Poly-Pred. *See* Neomycin, in combination preparations
- Polyacrylamide (PA), as viscoelastic, 2.368
- Polyallelism, 2.184
- Polyangiitis
- eosinophilic granulomatosis with (EGPA/Churg-Strauss syndrome), 1.165*t*, 1.168
 - with granulomatosis (GPA/Wegener granulomatosis), 1.165*t*, 1.167–168, 7.61–62, 7.62*f*, 9.137–139, 9.138*f*
 - eyelid manifestations of, 4.207*t*
 - optic neuritis and, 5.115
 - scleritis/retinal vasculitis and, 7.61, 9.138
 - screening/diagnostic tests for, 7.33–34
 - microscopic (MPA), 1.165*t*, 1.168, 9.137
- Polyarteritis nodosa (PAN), 1.165*t*, 1.166–167, 7.62–63, 9.135–137, 9.136*f*
- choroidal perfusion abnormalities and, 1.167
 - Cogan syndrome and, 8.309
 - eyelid manifestations of, 4.207*t*
 - refractive surgery contraindicated in, 13.191
- Polyarthritits. *See also* Arthritis
- juvenile. *See* Polyarticular-onset juvenile idiopathic (chronic/rheumatoid) arthritis/polyarthritits in SLE, 1.157
- Polyarticular-onset juvenile idiopathic (chronic/rheumatoid) arthritis/polyarthritits, 1.156, 6.313, 6.314*t*, 9.122. *See also* Juvenile idiopathic (chronic/rheumatoid) arthritis
- eye examination schedule for children with, 9.124*t*
 - rheumatoid factor (RF)-negative, uveitis in, 9.122–126, 9.123*f*, 9.124*t*
- Polycarbonate, 3.195–196, 3.314
- Polychondritis, relapsing, 1.164
- eyelid manifestations of, 4.207*t*
- Polycin-B. *See* Polymyxin B, in combination preparations
- Polyclonal response, 9.42
- Polycystic kidney disease, hypertension in, 1.64
- Polycythemia vera, transient visual loss and, 5.171
- Polydactyly, 6.391, 6.391*f*
- Polydioxanone intracanalicular plugs, for dry eye, 8.64
- Polydystrophy, pseudo-Hurler (ML III), 8.178
- Polyenes, 2.354, 2.355*t*
- Polyethylene glycol (PEG)-400, in artificial tears, 2.341
- Polyethylene orbital implant, 7.131, 7.131*f*. *See also* Orbital implant
- exposure of, 7.134*f*
- Polygenic/multifactorial inheritance, 2.140, 2.141, 2.200–201
- Polyhedral cells, in choroidal/ciliary body nevus, 4.191
- Polyhexamethylene biguanide (PHMB), for *Acanthamoeba* infection, 2.361, 8.278, 8.279
- Polyinosinic acid–polycytidylic acid, 2.370
- Polymergethism, 8.10
- in Fuchs endothelial corneal dystrophy, 8.156
 - specular microscopy in evaluation of, 8.23
 - before cataract surgery, 11.84
- Polymerase chain reaction (PCR), 2.141–142, 4.36–40, 4.38*t*, 4.39*t*, 4.40*f*, 7.124
- in acute retinal necrosis, 9.196
 - clinical use of, 4.40, 4.41–42
 - in CMV infection, 1.259
 - in endogenous endophthalmitis, 9.264
 - in HTLV-1 infection, 9.212
 - in human papillomavirus infection, 1.209, 1.262
 - in infection diagnosis, 1.239
 - in Lyme disease, 1.252, 9.246
 - in orbital lymphoma, 7.88
 - in postoperative endophthalmitis, 9.262–263
 - in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.136, 9.275
 - real-time quantitative (RT-PCR/qPCR), 2.141–142, 4.39*t*
 - reverse (RT-PCR), 4.38*t*
 - in syphilis, 9.241–242
 - in toxoplasmosis, 1.257, 9.224
 - in uveitis, 9.89*t*, 9.91, 9.92
- Polymethyl methacrylate (PMMA)
- contact lenses constructed of, 3.213
 - intraocular lenses constructed of, 3.240, 6.302
 - intrastromal corneal ring segments made from, 13.59, 13.62
 - IOLs made from, 11.116, 11.118, 11.119
 - capsular opacification and, 11.153
 - insertion of, 11.116
 - for manual small-incision cataract surgery, 11.198
 - phakic IOLs, 13.138, 13.139*t*
- Polymorphic amyloid degeneration, 8.122, 8.123*f*, 8.186*t*
- Polymorphisms, 2.142, 2.155, 2.156, 2.194, 8.10
- restriction fragment length (RFLP), 2.162
 - single-nucleotide (SNP), 2.144, 2.194
 - in genome-wide association studies (GWAS), 2.163–168, 2.168*f*, 2.194
 - single-stranded conformational (SSCP), 2.162
- Polymorphonuclear leukocytes (PMNs), 4.7, 4.8*f*, 9.9–10. *See also* Basophils; Eosinophils; Neutrophils
- Polymorphous dystrophy, posterior (PPCD/PPMD/CHED1), 4.93–94, 4.94*f*, 8.135*t*, 8.136*t*, 8.158–160, 8.159*f*, 8.160*f*
- glaucoma and, 8.159, 10.31
- Polymyositis, 1.163–164
- Polymyxin B, 2.344*t*, 2.353
- for *Acanthamoeba* keratitis, 2.361
 - in combination preparations, 2.347*t*, 2.348*t*, 2.353
- Polymyxin B-trimethoprim, for acute purulent conjunctivitis, 8.258
- Polymyxins, 1.272
- Polyneuropathy
- in diabetes mellitus, 1.48–49
 - familial amyloid (FAP), 4.134, 4.134*f*, 4.206. *See also* Familial amyloidosis
 - vitreous involvement/opacification in, 4.134, 4.134*f*
- Polyol (sorbitol) pathway
- in cataract formation, 2.247–248, 11.19
 - in lens glucose/carbohydrate metabolism, 2.247*f*, 2.247–248, 11.18*f*, 11.19
- Polyopia, 5.185
- in cataracts, 11.70–71
- Polypoidal choroidal vasculopathy (PCV/posterior uveal bleeding syndrome), 4.166*f*, 4.166–168, 4.167*f*
- central serous chorioretinopathy versus, 12.193
 - clinical presentation of, 12.75
 - definition of, 12.75
 - indocyanine green angiography for, 12.38, 12.38*f*
 - subretinal hemorrhage associated with, 12.76
 - verteporfin for, 12.76

- Polyposis, familial adenomatous (FAP/Gardner syndrome), 12.285–286
 retinal manifestations of, 4.144–145, 4.269
 Polypropylene glycol, in artificial tears, 2.341
 Polyps, colorectal cancer and, 1.213
 Polyquaternium-1, as ocular medication preservative, 2.294
 Polysaccharide encapsulation, as microbial virulence factor, 1.240
 Polysorbate, in artificial tears, 2.341
 Polysporin. *See* Polymyxin B
 Polythiazide, 1.68*t*
 Polytrim. *See* Trimethoprim, with polymyxin B
 Polyvinyl alcohol (PVA), 2.297
 in artificial tears, 2.341
 Pons, 5.27*f*. *See also under* Pontine
 horizontal eye movements and, 5.36, 5.37*f*, 5.37–38
 Pontine cistern, lateral, 2.103
 Pontine lesions
 facial myokymia caused by, 5.284
 facial weakness/paralysis caused by, 5.278, 5.278*t*
 gaze palsy caused by, 5.191, 5.228, 5.229*f*
 Horner syndrome and, 5.260*t*
 Millard-Gubler syndrome caused by, 5.192
 motility disorders caused by, 5.187*f*, 5.191, 5.192
 one-and-a-half syndrome caused by, 5.191
 spastic paretic facial contraction caused by, 5.284
 Pontine nuclei, 5.33
 dorsolateral (DLPN), 5.33, 5.34*f*, 5.35, 5.224
 Pontine paramedian reticular formation (PPRF), 2.102, 2.102*f*, 5.33, 5.35, 5.35*f*, 5.219
 horizontal gaze and, 5.36, 5.37, 5.37*f*
 in one-and-a-half syndrome, 5.191
 saccades generated by, 5.219–220, 5.221
 Pontine pathways, in pursuit system, 5.33, 5.34*f*, 5.224
 Pontocaine. *See* Tetracaine
 Pontomedullary junction, 2.102, 2.103
 Pooling, fluorescein, 12.35, 12.36*f*. *See also* Hyperfluorescence
 Population-wide immunity, 9.65
 Pork tapeworm (*Taenia solium*), 9.230–231
 orbital infection caused by, 4.228, 7.51
 PORN. *See* Progressive outer retinal necrosis
 Porous polyethylene orbital implant, 7.131, 7.131*f*.
 See also Orbital implant
 Porphyria/porphyria cutanea tarda, 8.190
 PORT. *See* Punctate outer retinal toxoplasmosis
 Port-wine stain (PWS/port-wine nevus/nevus flammeus), 8.345*t*, 8.346. *See also* Vascular malformations
 in children, 6.199, 6.401, 6.401*t*, 6.402*f*
 increased episcleral venous pressure and, 10.30
 in Sturge-Weber syndrome, 5.332*f*, 5.334*t*, 8.346, 10.30, 10.155
 Portable defibrillators, 1.295, 1.298
 Portable electronic applanation devices, 10.25
 POS. *See* Parinaud oculoglandular syndrome
 Posaconazole, for fungal keratitis, 8.275
 Position, in schematic eye, 3.127*t*
 Positional candidate gene screening, 2.161
 Positions of gaze. *See* Gaze, positions of
 Positive angle kappa, 6.67, 6.68*f*
 Positive defocus, 3.276, 13.11, 13.11*f*
 Positive dysphotopsias, 3.255
 IOLs and, 5.174, 11.150
 Positive lenses. *See* Convex (plus/positive) lenses
 Positive numbers, in vergence equation, 3.10
 Positive predictive value (PPV), of screening/diagnostic test, 1.15, 1.16
 pretest probability of disease and, 1.19*t*
 Positive spherical aberrations, 3.74, 3.74*f*
 Positive staining (fluorescein), 8.36
 “Positive vitreous pressure,” flat or shallow anterior chamber and, 11.134
 Positron emission tomography (PET), 5.70
 in ischemic heart disease, 1.98
 in sarcoidosis, 5.328
 in uveal lymphoma, 12.234
 Posner goniolens, 10.35
 Posner-Schlossman syndrome (glaucomatocyclitic crisis), 9.118, 10.100–101
 Post-MI pericarditis, 1.94
 Post-refractive intraocular lens power calculator, online, (ASCRS), 13.52, 13.195–197, 13.196*f*
 Post-traumatic stress disorder (PTSD), 1.191
 Postcentral gyrus, 5.47*f*
 Posterior alveolar nerve, 5.49
 Posterior amorphous corneal dystrophy (PACD), 8.135*t*, 8.136*t*, 8.154*f*, 8.154–155
 Posterior aqueous diversion syndrome. *See* Malignant glaucoma
 Posterior capsular/capsule opacification (PCO), 3.240, 6.302, 12.260
 cataract surgery and, 11.152–153
 IOLs and, multifocal IOLs, 13.156, 13.167
 Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser therapy, capsulotomy
 multifocal IOLs and, 13.156, 13.167
 in uveitis, 9.284
 Posterior capsular cataract, 6.387*f*
 Posterior capsular rupture, cataract surgery and, 11.142–143
 Posterior capsulectomy, 6.303
 Posterior cerebral artery (PCA), 2.93, 2.107*f*, 5.12, 5.18, 5.18*f*, 5.19*f*, 5.20
 aneurysm of, 5.339*f*
 cranial nerve relationship and, 2.84*f*, 5.42*f*
 Posterior chamber, 2.37, 2.37*f*, 2.47*f*. *See also* Posterior segment
 phacoemulsification in, 11.111–112
 topography of, 2.37, 2.37*f*
 in uveitis, 9.80*t*. *See also* Posterior uveitis
 Posterior chamber intraocular lenses (PCIOs), 12.393. *See also* Intraocular lenses (IOLs), posterior chamber
 anterior chamber depth prediction formula for, 3.249
 dislocated, 12.393
 image magnification with, 3.255
 near-addition power for, 3.259
 pachymetry studies of, 3.249
 pictorial representation of, 3.241*f*
 Posterior/posterior lateral choroidal artery, 5.18*f*, 5.19*f*
 Posterior ciliary arteries, 2.17*f*, 2.32, 2.33*f*, 2.34*f*, 2.90, 2.91, 2.91*f*, 2.92*f*, 5.15–17, 5.17*f*, 7.14*f*, 7.15*f*
 anatomy of, 12.195*f*

- choroid blood supply from, 12.19, 12.20*f*, 12.195*f*
 optic nerve supplied by, 10.44
- Posterior ciliary nerves, 2.32, 2.223–224, 5.55
- Posterior circulation. *See* Vertebrobasilar system
- Posterior clinoid process, 2.84*f*, 2.95, 2.102
- Posterior collagenous layer (retrocorneal fibrous membrane/RCFM), 2.227, 4.84, 4.85*f*
- Posterior commissure (PC), 5.35, 5.35*f*, 5.55*f*
 vertical gaze and, 5.36, 5.36*f*
- Posterior communicating artery (PCoA), 2.107*f*, 5.16*f*, 5.18, 5.18*f*, 5.19*f*, 5.20
 aneurysm of, 5.339*f*
 third nerve (oculomotor) palsy and, 5.20, 5.194, 5.194*f*, 5.339
 cranial nerve relationship and, 2.84*f*, 2.85*f*, 5.42*f*
- Posterior conjunctival arteries, 2.30
- Posterior corneal defects/depression, 6.259. *See also* Peters anomaly; Posterior keratoconus
- Posterior cranial fossa, 5.6*f*
 neuroimaging in evaluation of, 5.72*t*
- Posterior cyclitis, 9.72*t*
- Posterior embryotoxon, 4.99, 4.99*f*, 4.100*f*, 6.255, 6.255*f*, 8.97*t*, 8.101–102, 8.102*f*. *See also* Anterior segment, dysgenesis of
 in Axenfeld-Rieger syndrome, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.102, 10.31, 10.153
 isolated, Axenfeld-Rieger syndrome differentiated from, 10.154*t*
- Posterior ethmoidal artery, 5.12, 5.13*f*, 5.14*f*, 5.16*f*
- Posterior ethmoidal foramen, 2.6*f*, 2.7–8, 5.11
- Posterior fixation
 definition of, 6.164*t*, 6.167
 suture for, 6.164*t*
- Posterior fluid misdirection syndrome, 11.134–135
- Posterior fossa malformations, hemangiomas, arterial lesions, and eye anomalies. *See* PHACE syndrome
- Posterior inferior cerebellar artery (PICA), 5.19, 5.19*f*, 5.20
- Posterior keratoconus, 4.98, 8.97*t*, 8.104, 8.105*f*
- Posterior lacrimal crest, 2.5, 2.6*f*
- Posterior lamellar deficiency, surgery for eyelid retraction and, 7.224
- Posterior lenticonus/lentiglobus, 4.118, 4.118*f*, 6.296–297, 6.297*f*, 11.30, 11.30*f*
- Posterior microphthalmos, 6.263
- Posterior nonbanded zone, of Descemet membrane, 2.41, 2.42*f*
- Posterior optic neuropathy, 5.104. *See also* Optic neuropathy
 ischemic (PION), 5.107*t*, 5.119, 5.124
 perioperative, 5.124–125
- Posterior parietal cortex (PPC), 5.30, 5.30*f*
- Posterior persistent fetal vasculature, 12.342
- Posterior pigmented layer, of iris, 2.53*f*, 2.55, 2.56*f*
- Posterior pituitary hormones, 1.56
- Posterior placoid chorioretinitis, syphilitic/acute syphilitic (ASPPC), 9.239, 9.239*f*, 9.297–298, 12.241
- Posterior polar cataract, 11.36
 surgery for, 11.180–181
 hydrodissection/nucleus rotation and, 11.111, 11.181
- Posterior pole, 2.65*f*, 2.75, 2.242*f*, 11.9, 11.10*f*, 11.12*f*.
See also Macula/macula lutea
 distortion of, 6.317*f*
 familial exudative vitreoretinopathy findings, 6.347, 6.348*f*
 granuloma, 12.245
 metastatic tumors of, 4.305–306, 4.306*f*, 4.307*f*, 4.308*f*
 traction of, 6.334*f*
- Posterior polymorphous corneal dystrophy (PPCD/PPMD/CHED1), 4.93–94, 4.94*f*, 8.135*t*, 8.136*t*, 8.158–160, 8.159*f*, 8.160*f*
 glaucoma and, 8.159, 10.31
- Posterior pupillary membrane, 11.29*f*
 remnant of (Mittendorf dot), 11.29, 11.31, 11.32*f*
- Posterior reversible encephalopathy syndrome (PRES), 5.333–335, 5.335*f*
- Posterior segment
 anterior segment surgery complications of, vitrectomy for, 12.388–396
 assessment of, before refractive surgery, 13.44
 in *Bartonella*-associated neuroretinitis, 9.256
 in Behçet disease, 9.186, 12.230
 blunt trauma to, 12.353
 in coccidioidomycosis, 9.271
 in cysticercosis, 9.231
 development of, 2.122–124, 2.123*f*
 in Epstein-Barr virus infection, 9.202, 9.203*f*
 hereditary dystrophies of. *See* Hereditary dystrophies
 inflammation of. *See* Posterior uveitis
 laser effects on, 12.374
 laser therapy for diseases of. *See* Photocoagulation
 metastatic tumors of, 4.305–306, 4.306*f*, 4.307*f*, 4.308*f*
 in Rift Valley fever, 9.211
 in sarcoidosis, 9.169
 in sympathetic ophthalmia, 9.172–173, 9.173*f*
 in syphilis, 9.238*f*, 9.238–240, 9.239*f*, 9.240*f*
 in toxocariasis, 9.228
 trauma to. *See* Trauma
 in uveitis, 9.72*t*, 9.84. *See also* Posterior uveitis
- Posterior subcapsular cataract (PSC), 4.120*f*, 4.120–121, 4.121*f*, 6.297, 11.46–48, 11.51*f*
 characteristics and effects of, 11.47, 11.70*t*
 corticosteroids causing, 11.51–52
 ischemia causing, 11.68
 in myotonic dystrophy, 11.62
 race and, 11.6
 silicone oil use and, 11.190
 uveitis and, 11.64
 vitrectomy and, 11.55, 11.190
- Posterior subcapsular lens, opacity of, 3.67
- Posterior superior alveolar nerve, 7.17*f*
- Posterior synechiae
 in glaucoma
 inflammation and, 10.138, 10.138*f*
 pupillary block/angle closure and, 10.119
 uveitis and, 9.285
 mydriasis in prevention of, 2.313
 in pars planitis, 9.129
 pupillary block/angle closure and, 10.119
 in sarcoidosis, 9.81*f*, 9.169
 in sympathetic ophthalmia, 9.172
 in uveitis, 9.79, 9.80*f*, 9.81*f*, 9.82
 glaucoma and, 9.285
 lens changes/cataract and, 11.64

- Posterior temporal artery, 5.16*f*, 5.19*f*
- Posterior uveal bleeding syndrome (polypoidal choroidal vasculopathy/PCV), 4.166*f*, 4.166–168, 4.167*f*, 12.75
- Posterior uveal melanoma, 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279, 9.277.
See also Choroidal melanoma/ciliary body melanoma
- classification of, 4.194, 4.271–272, 4.272*t*
- clinical characteristics of, 4.262–263, 4.264*f*
- diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
- differential, 4.267–271, 4.269*f*, 4.270*f*
- glaucoma caused by, 4.105*f*, 4.106, 4.194
- metastatic, 4.196, 4.272–274, 4.273*t*, 4.306
- prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
- in toxoplasmosis, 9.222
- treatment of, 4.253, 4.274–277, 4.275*f*
- Posterior uveitis, 9.72*t*, 9.75–76*t*, 9.77, 9.78–79, 9.84, 9.132–166. *See also* Choroiditis; Retinitis; Uveitis; *specific cause*
- in collagen vascular diseases, 9.132–139
- corticosteroid route of administration in, 2.333*t*
- definition of, 6.317
- differential diagnosis of, 6.312*t*
- diffuse unilateral subacute neuroretinitis and, 9.232
- electroretinography findings in, 12.44
- flowchart for evaluation of, 9.75–76*t*
- glaucoma and, 10.139
- incidence/prevalence of, 9.87*t*
- inflammation in, 6.320
- inflammatory chorioretinopathies (white dot syndromes) and, 9.140–166, 9.141–143*t*
- intermediate uveitis, 12.231
- laboratory tests for, 6.321*t*
- in Lyme disease, 9.245
- noninfectious, 9.132–166
- nonnecrotizing (nonnecrotizing herpetic retinitis), 9.198
- retinal detachment and, 9.291
- signs of, 9.84
- symptoms of, 9.78–79
- toxocariasis as cause of, 6.317*f*, 6.317–318
- toxoplasmosis as cause of, 6.317
- Posterior vitrectomy, 6.303
- Posterior vitreoschisis, 12.332–333
- Posterior vitreous detachment (PVD), 2.80, 2.80*f*, 2.81*f*, 2.252–253, 4.128–129, 4.129*f*
- age-related, 12.307–308
- anatomy of, 12.331
- atrophic holes presenting with, 12.318
- in children, 6.347
- cholesterolosis and, 12.348
- conditions associated with, 12.307
- definition of, 12.331
- diagnosis of, 12.331
- epiretinal membranes. *See* Epiretinal membranes (ERMs)
- examination of, 12.309
- fibroglial tissue in, 12.331
- floaters associated with, 12.308–309
- idiopathic macular holes, 12.337–339, 12.338*f*
- imaging of, 12.308*f*
- indirect ophthalmoscopy of, 12.309, 12.331
- management of, 12.309
- myopia macular retinoschisis in, 12.209
- nonproliferative diabetic retinopathy progression affected by, 12.102
- optical coherence tomography of, 12.309, 12.332
- in pars plana vitrectomy for diabetic macular edema, 12.115
- pathologic conditions caused by, 12.332
- photopsias associated with, 12.308
- prevalence of, 12.331
- retinal breaks associated with, 12.309
- retinal detachment after cataract surgery and, 11.166
- retinal tears and, 2.81*f*, 2.253, 12.307, 12.308*f*, 12.309
- risk factors for, 12.309
- signs and symptoms of, 12.308
- slit-lamp biomicroscopy of, 12.331
- vitrectomy for, 12.333*f*, 12.359
- vitreomacular adhesions, 12.336, 12.336*t*
- vitreomacular traction syndrome, 12.332, 12.332*f*, 12.336*t*, 12.336–337, 12.337*f*
- vitreous hemorrhage and, 4.133, 12.309
- Postexposure immunity/prophylaxis, 1.216
- hepatitis B, 1.219
- measles, 1.221
- Postganglionic Horner syndrome, 5.258, 5.259, 5.260, 5.260*t*, 5.261, 5.262*f*
- Postganglionic nerves/neurons
- cholinergic drug action and, 2.308
- dilator muscle innervation and, 2.56
- sphincter muscle innervation and, 2.56
- Postherpetic neuralgia (PHN), 1.258, 5.280, 5.298, 8.226*t*, 8.227, 8.229, 8.230
- Postherpetic neurotrophic keratopathy, 4.77*f*, 4.78
- Postictal paresis (Todd paralysis), 1.201, 5.285
- Postictal period, 1.201
- Postmeasles blindness, 9.206
- Postoperative care of ophthalmic surgery patient
- cataract surgery and
- antimicrobial prophylaxis, 11.95
- after ECCE, 11.198
- after ICCE, 11.201
- corneal imaging in, 13.23*f*, 13.23–24, 13.24*f*
- DSEK and, 8.441, 8.441*f*, 8.442*f*
- LASIK and, 13.94–95
- orbital surgery and, 7.124
- penetrating and perforating trauma repair and, 8.409
- penetrating keratoplasty and, 8.423–430
- refractive/keratorefractive surgery and, 13.93–95, 13.193–201
- surface ablation and, 13.93–94
- immediate postablation measures and, 13.92–93
- trabeculectomy and, 10.208–209
- Postoperative chest physiotherapy, 1.132
- Postoperative endophthalmitis, 9.119, 12.388–391, 12.390–391*f*. *See also* Uveitis, postoperative
- acute-onset, 9.261
- bleb-associated, 10.163, 10.209, 10.209*t*, 10.210*f*
- after cataract surgery, 4.119, 4.119*f*, 9.261–263, 9.262*f*, 11.127, 11.160–163, 11.161*f*
- prevention of, 11.93–95, 11.94*f*, 11.161–162

- Propionibacterium acnes* causing, 4.119, 4.119f, 9.119, 9.261–262, 9.262f, 11.140, 11.162
- chronic (delayed-onset), 9.261–263, 9.262f
- bacterial, 9.261–262, 9.262f
- fungal, 9.262
- after penetrating keratoplasty, 8.424
- prophylaxis of, cataract surgery and, 11.93–95, 11.94f, 11.161–162
- Propionibacterium acnes* causing, 4.119, 4.119f, 8.246, 9.119, 9.261–262, 9.262f, 11.140, 11.162
- Postoperative nausea and vomiting, 6.174
- Postoperative state, hypercoagulability and, 1.148
- Postpartum period
- neuro-ophthalmic disorders and, 5.333–335
- reversible cerebral vasoconstriction syndrome and, 5.346
- Postpartum thyroiditis, 1.55
- Postpubescent children. *See* Children
- Postseptal venous drainage system, 7.154
- Postsurgical consecutive esotropia, 6.95
- Postsurgical esotropia, 6.102
- Postsurgical exotropia, 6.104
- Posttest probability of disease, 1.19
- test combinations and, 1.20
- Posttransfusion hepatitis, transfusion-transmitted virus (TTV) causing, 1.261–262
- Posttranslational modification, 2.142
- of lens proteins, 2.245
- Posttraumatic angle recession, 4.18, 4.19f, 4.103–104
- glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40f, 10.41f, 10.106–108, 10.107f
- Posttraumatic cellulitis
- orbital, 7.47
- preseptal, 7.44, 7.45
- Posttraumatic endophthalmitis, 12.362–363
- Postural change, transient visual loss and, 5.161, 5.164, 5.170
- Postural hypotension, 1.77
- Postviral neurorretinitis, 5.118
- Postviral optic neuritis, 5.113
- Postvitrectomy cataract, 11.55, 11.190
- Potassium (K)
- in aqueous humor, 2.232
- in lens, 2.245–246, 11.21
- in tear film, 2.214t, 2.216
- in vitreous, 2.252
- Potassium balance, in lens, pump–leak theory of
- maintenance of, 11.21, 11.22f
- Potassium channels, in lens, 2.246
- Potassium hydroxide (KOH), ocular injury caused by, 8.376t
- Potassium-sparing diuretics
- for heart failure, 1.109
- for hypertension, 1.68t, 1.71
- Potential acuity estimation/potential acuity meter (PAM) testing, 5.88–89
- in cataract surgery evaluation, 11.81–82
- in nonorganic disorder evaluation, 5.306
- Potential energy, 3.106
- Potentials, visual evoked/visual evoked cortical/visual evoked response (VEP/VECP/VER), 5.95. *See also* Visual evoked potential
- in low vision evaluation, 5.95
- in nonorganic disorder evaluation, 5.302
- Povidone, in artificial tears, 2.341
- Povidone-iodine, 2.353–354
- Power (optical). *See also* Transverse magnification
- contact lenses, 3.220–221f, 3.220–222
- corneal
- central, 3.243, 3.248
- in schematic eye, 3.127t
- definition of, 3.4, 3.8, 3.106, 3.112
- equation for, 3.8
- IOL, determination of, 11.84–87
- biometry in, 11.82–83, 11.83f, 11.84–85, 11.87
- hypotony affecting, 11.185
- contact lens method for, 13.195
- formulas for, 11.84, 11.85–87
- regression formulas, 11.85–87
- historical methods for, 11.86–87, 13.194
- improving outcomes of surgery and, 11.87
- incorrect, 11.85
- online post-refractive calculator for (ASCRS), 13.52, 13.195–197, 13.196f
- preventing errors in, 11.87
- after radial keratotomy, 13.51, 13.52–53, 13.193
- refraction and, 11.76
- refractive lens exchange and, 13.150
- refractive surgery and, 11.85–87, 11.176, 11.177f, 13.44, 13.193–197, 13.196f
- topographical method for, after refractive surgery, 13.193, 13.194
- triple procedure and, 11.175
- unexpected refractive results after surgery and, 11.86, 11.150
- lensmaker's equation for comparing, 3.52
- in phacoemulsification, 11.100
- delivery of, 11.99
- advances in, 11.100f, 11.100–101
- refractive. *See* Refractive power
- Power (research study), sample size and, 1.5
- Power calculations
- axial length, 3.243–248
- central corneal power, 3.243, 3.248
- in children, 3.254–255
- in corneal transplant eyes, 3.253–254
- double-K method, 3.252
- formulas
- biometric, 3.244–250
- errors in, 3.252
- for post-keratorefractive procedure eye, 3.252–253
- prediction, 3.243–244
- theoretical, 3.243
- geometric optics and, 3.243
- multifocal lenses, 3.258
- piggyback lenses, 3.251
- after refractive surgery, 3.251–253
- for sample size in monitoring system, 1.25–26
- in silicone oil-filled eyes, 3.254
- sulcus placement adjustments, 3.250t
- Power cross, 3.4, 3.16, 3.17f, 3.41, 3.77, 3.77–78f. *See also* Cylinder power
- Power maps, 8.28–33, 8.29f, 8.30f, 8.31f, 8.32f, 8.33f, 13.14–19, 13.15f, 13.17f, 13.19f, 13.44–45, 13.45f. *See also* Cornea, topography of
- interpretation of, 8.28–31
- in keratoconus, 8.165, 8.165f, 8.167f

- in pellucid marginal degeneration, 8.31, 8.33*f*, 8.169, 8.170*f*
- postoperative, 13.23, 13.24*f*
- Power per unit area, 3.107
- Power prediction formulas, for IOLs, 11.84, 11.85–87
- regression formulas, 11.85–87
- Power-versus-meridian graph (PVMG), 3.41, 3.79*f*, 3.79–80
- Poxviruses (Poxviridae)/poxvirus infection, 8.236–238
- pp65 antigen, CMV infection and, 1.259
- PPA. *See* Peripapillary atrophy
- PPC. *See* Posterior parietal cortex
- PPCD. *See* Posterior polymorphous corneal dystrophy
- PPD test. *See* Purified protein derivative (PPD) test
- PPMD. *See* Posterior polymorphous corneal dystrophy
- PPRF. *See* Paramedian pontine reticular formation
- PPSV23. *See* Pneumococcal vaccines
- PPV. *See* Positive predictive value
- Practice Improvement Modules, 1.25
- Prader-Willi syndrome, imprinting abnormalities
 - causing, 2.138, 2.153–154
- Prager shell, 3.246*f*
- Pralidoxime (2-PAM), 2.309*f*, 2.312
- Pramipexole, for Parkinson disease, 1.199
- Prasugrel, for ischemic heart disease, 1.99, 1.100, 1.100*t*
- Pravachol. *See* Pravastatin
- Pravastatin, for hypercholesterolemia/heart disease
 - prevention, 1.86*t*
- Praziquantel, for cysticercosis, 9.232
- Prazosin, 2.308*t*
 - for heart failure, 1.110
 - for hypertension, 1.68*t*
 - intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137*t*
- PRDM5 gene, 6.254
- Pre-Descemet corneal dystrophy (PDCD), 8.135*t*, 8.136*t*, 8.155*f*, 8.155–156
- Pre-Descemet (Dua's) layer, 4.73, 4.74*f*, 8.9
- Preadolescents. *See* Children
- Prealbumin. *See* Transthyretin
- Preauricular skin tags, in Goldenhar-Gorlin syndrome, 8.195
- Precancerous eyelid lesions
 - epidermal (actinic keratosis), 7.175–176, 7.176*f*
 - melanocytic, 7.177
- Precancerous melanosis (lentigo maligna/Hutchinson melanotic freckle), 7.177
- Precentral gyrus, 5.49
 - facial weakness/paralysis caused by lesion of, 5.277
- Precorneal tear film, 2.38, 2.213*f*, 2.213–214, 7.252.
 - See also* Tear film (tears)
 - dysfunction of, 2.220–222
- Precortical vitreous pocket, 12.7, 12.8*f*
- Precursor cytotoxic T lymphocytes, 9.48, 9.49*f*
- Precursor messenger RNA (mRNA precursor), 2.15, 2.148, 2.151*f*
- Pred Forte/Pred Mild. *See* Prednisolone
- Pred-G. *See* Prednisolone, in combination preparations
- Prediabetic states, 1.37
- Prednisol. *See* Prednisolone
- Prednisolone, 1.171*t*, 2.330*t*
 - anti-inflammatory potency of, 1.171*t*, 2.333*t*
 - for bacterial keratitis, 8.272
 - in combination preparations, 2.348*t*
 - for corneal graft rejection prophylaxis, 8.430, 8.447, 8.448
 - for cystoid macular edema, after cataract surgery, 11.165
 - off-label use of, 2.306
 - pressure-elevating potency of, 2.332, 2.333*t*
 - for stromal keratitis, 8.222, 8.223*t*
 - for uveitis, 9.95–96
- Prednisone, 1.171*t*
 - for acute retinal necrosis/herpetic retinitis, 9.196
 - for Behçet disease, 9.188
 - for giant cell arteritis/AAION, 5.121, 5.314
 - for herpetic retinitis, 12.238*t*
 - for hyphema, 8.395
 - for nonspecific orbital inflammation, 7.65
 - for optic neuritis, 5.116
 - after penetrating and perforating trauma repair, 8.409
 - for sarcoidosis, 9.171
 - for scleritis, 8.324
 - for thyroid eye disease, 7.58
 - for toxoplasmosis, 9.225, 9.226
 - for uveitis, 9.99
 - for Vogt-Koyanagi-Harada syndrome, 9.181
- Preeclampsia, 1.77, 1.78, 12.197*f*. *See also* Eclampsia
- neuro-ophthalmic signs of, 5.333
- Preferential hyperacuity perimetry (PHP), 12.69
- Preferential looking (PL), for visual acuity assessment, 6.5, 6.8–9, 6.9*f*, 6.182, 6.300
- Preferred Practice Pattern guidelines, 1.25, 1.190
- on vision rehabilitation, 1.177
- Preferred retinal loci (PRL), 3.310, 3.313, 3.314*f*, 3.317, 3.325
- Pregabalin, for postherpetic neuralgia, 8.230
- Preganglionic autonomic nerves, cholinergic drug
 - action and, 2.307, 2.307*f*
- Preganglionic Horner syndrome, 5.257, 5.259, 5.260, 5.260*t*, 5.261*f*
- Preganglionic neurons, dilator muscle innervation and, 2.56
- Pregeniculate visual impairment, 6.186–187
 - in infantile nystagmus syndrome, 5.235–236
- Pregnancy. *See also specific Congenital entries*
 - alcohol use during (fetal alcohol syndrome), 1.192
 - antifibrinolytic use contraindicated in, 2.370
 - antiphospholipid antibody syndrome and, 1.148, 1.159, 1.160, 1.161
 - aspiration during surgery and, 1.288
 - carbonic anhydrase use during, 2.326
 - cavernous hemangioma growth during, 7.68
 - cerebral ischemia and, 1.120
 - cerebral venous thrombosis and, 5.346
 - CMV infection during, 1.259, 9.199
 - diabetes during (gestational diabetes mellitus), 1.36–37
 - diabetic retinopathy in
 - progression of, 12.93–94
 - proliferative, 12.94
 - drug safety and, 1.174, 1.174*t*
 - fluorescein angiography in, 12.36
 - glaucoma medication use during, 2.326, 10.185–186
 - gonococcal infection during, ophthalmia neonatorum and, 8.257*t*, 8.264

- herpes simplex virus infection during, 1.258, 8.213
- HIV screening in, 1.265
- hypercoagulability associated with, 1.135, 1.148
- hypertension/hypertension management and, 1.78
 - labetalol in, 1.74
 - methyl dopa in, 1.73
- immunization during, 1.216, 1.217, 1.220, 1.222
- leptospirosis during, 9.248
- lymphocytic choriomeningitis virus infection during, 9.205
- maternally transmitted eye infection and. *See also specific type*
 - keratitis, 8.107, 8.308–309, 8.309f
 - ophthalmia neonatorum and, 8.257t, 8.263–265
- measles during, 9.206
- neuro-ophthalmic disorders and, 5.333–335
- phenytoin use during, 1.203
- pituitary tumors affected during, 5.147, 5.333
- radiation exposure during, 1.230
- refractive surgery contraindicated during, 13.37
- reversible cerebral vasoconstriction syndrome and, 5.346
- rubella during, 1.221, 8.240, 8.240t, 9.203
- statins contraindicated in, 1.87
- syphilis during, 1.248, 9.236
- thyroiditis after, 1.55
- thyroxine levels affected by, 1.51
- toxemia. *See* Eclampsia; Preeclampsia
- Toxoplasma gondii* exposure, 12.243
- toxoplasmosis during, 1.256, 9.221, 9.226
- Zika virus exposure during, 12.247
- Pregnancy tests, preoperative, 1.284
- Prehypertension, 1.62, 1.62t
 - in children and adolescents, 1.78
- Preimplantation genetic diagnosis (PGD), genetic counseling and, 2.206, 2.207
- Prelaminar nerve/prelaminar area of optic nerve, 2.85t, 2.86, 10.42, 10.43, 10.45f, 10.45–46. *See also* Optic nerve head
 - blood supply of, 2.85t, 2.91, 2.91f, 2.92f
- Preliterate children, optotypes for visual acuity assessment in, 6.6t, 6.6–7, 6.7f
- Preload, 1.108
 - reduction of, for heart failure, 1.109, 1.110
- Premacular bursa, 12.7, 12.8f
- Pre malignant eyelid lesions
 - epidermal (actinic keratosis), 4.210–212, 4.211f, 4.212f, 7.175–176, 7.176f
 - melanocytic, 7.177
- Premature complexes/contractions, 1.112–113
 - atrial (PACs), 1.112, 1.113
 - junctional (PJC), 1.112, 1.113
 - ventricular (PVCs), 1.112, 1.113
- Prematurity
 - ocular deviations and, 5.231
 - retinopathy of. *See* Retinopathy, of prematurity
- Premelanosomes, in retinal pigment epithelium, 2.69
- “Premium” IOLs, 11.120–121
 - contraindication for, capsular decentration and, 11.183
 - dry eye therapy before use of, 11.173
- Premotor neurons, 5.33
- Prenatal diagnosis (PND), 2.188, 2.206–207
- Prentice position
 - definition of, 3.41, 3.45
 - pictorial representation of, 3.46f
 - power of prism in, 3.49f
- Prentice rule
 - bifocal lens design and, 3.184–190, 3.185–189f
 - contact lenses and, 3.206
 - definition of, 3.148, 3.184
- Prenuclear (supranuclear/cortical) pathways, 5.32f, 5.32–33, 5.33–34, 5.34f, 5.211. *See also specific system*
 - disorders of, 5.188, 5.188t, 5.211–231
 - diplopia and, 5.188, 5.188t
 - facial weakness/paralysis caused by, 5.276f, 5.277–278
 - gaze preference/palsy and, 5.228–230, 5.229f, 5.230f
 - ocular fixation system and, 5.212, 5.212t, 5.213–214
 - optokinetic system/nystagmus and, 5.212, 5.212t, 5.218–219
 - saccades/saccadic system and, 5.32–33, 5.38, 5.212, 5.212t, 5.219–223, 5.220f
 - smooth-pursuit system and, 5.32, 5.33, 5.34f, 5.212, 5.212t, 5.224–226, 5.225f
 - tonic deviations and, 5.230–231
 - vergence system and, 5.212, 5.212t, 5.226–228
 - vestibular-ocular system and, 5.38–39, 5.39f, 5.212, 5.212t, 5.214–218, 5.216t
- Preoperative assessment/preparation for surgery, 1.283–290, 1.289t
 - blepharoplasty, 7.231
 - cataract surgery, 11.74–76, 11.87–88
 - antimicrobial prophylaxis and, 11.93–94
 - in diabetes mellitus, 11.80–81
 - ECCE, 11.196
 - ICCE, 11.199
 - medical evaluation and, 11.170–171
 - ocular trauma and, 11.190–191
 - in children and adolescents, 1.284–285
 - corneal transplantation, 8.418–419
 - facial rejuvenation surgery, 7.236, 7.241, 7.245
 - fasting and, 1.288
 - latex allergy and, 1.288–289
 - lower face and neck rejuvenation, 7.245
 - medication management and, 1.285–287
 - in older patients, 1.180–181
 - penetrating and perforating trauma repair, 8.403
 - recent developments and, 1.283
 - refractive/keratorefractive surgery, 13.35–48, 13.36t. *See also specific procedure*
 - corneal imaging/ancillary tests and, 13.14–26, 13.44–46, 13.45f, 13.79–80. *See also* Cornea, topography of; *specific type*
 - discussion of findings/informed consent and, 13.36t, 13.46–48, 13.47t
 - history and, 13.35–39, 13.36t
 - ocular examination and, 13.36t, 13.39–44, 13.42f, 13.43f
 - patient expectations/motivations and, 13.35–36, 13.36t, 13.47
 - patient preparation and, 13.81–82
 - patient selection and, 13.77–80, 13.78t
 - planning and laser programming and, 13.81

- respiratory diseases and, 1.134, 1.284–285
- testing recommendations and, 1.283
- trabeculectomy, 10.198–199
- Universal Protocol and, 1.289–290
- Preorbital orbicularis muscle, 7.146f, 7.147, 7.148f, 7.148–149
- Prepapillary vascular loops, 4.126, 12.341, 12.341f
- Preperimetric glaucoma, 10.3
- Preperiosteal approach, for midface lift, 7.242–243, 7.243f
- Pre-plus disease, 6.326, 6.327t, 6.330f
- Prepubescent children. *See* Children
- Preretinal macular fibrosis, 12.335
- Preretinal tract, 12.7
- PRES. *See* Posterior reversible encephalopathy syndrome
- Presbyopia, 1.178, 2.58, 2.63, 11.23, 13.159–170
 - age/aging and, 2.63, 11.23, 13.159
 - age of onset, 3.175
 - bifocal contact lenses for, 3.224–225
 - contact lenses for, 3.223–225. *See also* Contact lenses, bifocal
 - definition of, 3.124, 3.140, 3.148, 3.175
 - Goldberg theory of reciprocal zonular action and, 13.162
 - Helmholtz hypothesis (capsular theory) of accommodation and, 11.22, 13.159–160, 13.160f
 - monovision for, 3.224
 - with myopia, refractive lens exchange for, 13.148
 - perimetry results affected by, 10.60
 - premature, 3.176
 - progressive addition lenses for, 3.183
- Schachar theory of accommodation and, 13.160–162, 13.161f
- surgical correction of, 13.38–39, 13.159–170
 - accommodative, 13.162–164, 13.163f, 13.164f
 - conductive keratoplasty for, 13.128, 13.128f, 13.165
 - corneal inlays for, 13.59–71, 13.169
 - corneal intrastromal femtosecond laser treatment for, 13.168
 - custom/multifocal ablations for, 13.167, 13.168f
 - IOLs for
 - accommodating lenses, 13.8t, 13.154, 13.163–164, 13.164f
 - experimental lenses, 13.170, 13.170f
 - multifocal lenses, 13.165–167, 13.166f
 - keratophakia for, 13.59–62, 13.62f
 - monovision and, 13.39, 13.164–165
 - nonaccommodative, 13.164–169, 13.166f, 13.168f
 - refractive lens exchange for, 13.149
 - scleral surgery for, 13.162–163, 13.163f
- theories of accommodation and, 13.159–162, 13.160f, 13.161f
- Preschool-aged children. *See* Children
- Preseptal cellulitis, 4.204, 4.204f, 6.170, 6.212–214, 7.44–46
 - in children, 7.44, 7.45
 - Haemophilus* causing, 7.44, 8.256
- Preseptal orbicularis muscle, 7.146f, 7.147, 7.148, 7.148f
 - in involutional entropion, 7.203, 7.204
- Preseptal palpebral muscles, 5.52
- Preseptal tissues, 7.147
- Preseptal venous drainage system, 7.154
- Preservatives, in ocular medications
 - allergic/adverse reactions to, 2.294, 10.184
 - preservative-free formulations and, 8.62, 8.63, 8.80, 8.90, 8.90t, 8.91, 10.170–175, 10.175t
 - artificial tears/demulcents, 8.62, 8.63
 - contact dermatoblepharitis and, 8.286
 - demulcents, 2.341, 2.342
 - irrigating solutions, 2.367
 - persistent corneal defects/toxic keratoconjunctivitis/keratopathy caused by, 8.80, 8.90, 8.90t, 8.91
- Press-on prisms
 - for diplopia, 6.96
 - induced anisophoria correction using, 3.188
- Pressure-induced stromal keratopathy (PISK), after LASIK, 13.119, 13.120f
- Pressure-insensitive (uveoscleral) outflow, 10.5f, 10.13, 10.19
- Presumed ocular histoplasmosis syndrome (POHS), 12.87. *See also* Ocular histoplasmosis syndrome
- Pretarsal orbicularis muscle, 7.14f, 7.146f, 7.147–148, 7.148f
 - gray line and, 7.149, 7.153, 7.154f
- Pretarsal palpebral muscles, 5.52
- Pretarsal tissues, 7.147
- Pretectal nuclei. *See* Pretectum/pretectal nuclei
- Pretectal (Parinaud/dorsal midbrain) syndrome, 5.37, 5.229, 5.230f
 - in children, 5.231
 - convergence-retraction nystagmus in, 5.229, 5.250
 - eyelid retraction in, 5.229, 5.250, 5.274, 5.275t, 7.223
 - light–near dissociation in, 5.229, 5.230f, 5.266t, 5.266–267
 - multiple sclerosis and, 5.319
- Pretectum/pretectal nuclei, 2.96, 5.54, 5.55f
 - convergence insufficiency caused by damage to, 5.227
 - vertical gaze palsy caused by damage to, 5.229
- Pretest probability of disease, 1.18–19, 1.19t
- Prethreshold disease (retinopathy of prematurity), 6.326, 12.178t, 12.179, 12.185
- Pretibial myxedema (infiltrative dermopathy), hyperthyroidism/thyroid eye disease and, 1.53, 7.56
- Pretrichial incision, for brow- and forehead-lift, 7.241, 7.243f
- Preussner formula, for IOL power determination/selection, 11.85
- Preventive medicine, 1.207–225
 - immunization in, 1.216–225
 - recent developments in, 1.207
 - screening procedures in, 1.207–216. *See also* Screening/diagnostic tests
- Preventive Services Task Force
 - on lipid disorder screening, 1.82
 - on mammography, 1.211
 - on prostate cancer screening, 1.212
- Preverbal children
 - fixation assessments in, 6.300
 - visual acuity assessment methods in, 6.8–9, 6.154
- Primaquine, for *Pneumocystis jirovecii* pneumonia, 1.267–268
- Primary aberrant regeneration, 5.198
- Primary acquired melanosis (PAM), 4.63t, 4.65, 4.66–68, 4.67f, 8.327, 8.338t, 8.339t, 8.342f, 8.342–343
 - melanoma and, 4.66–68, 4.67f, 4.68, 4.68f, 8.327, 8.342, 8.343

- Primary angle closure (PAC), 10.4*t*, 10.117, 10.117*t*, 10.118, 10.120–122. *See also* Angle closure; Angle-closure glaucoma
- acute, 10.123–125, 10.124*f*
management of, 10.184
- chronic, 10.4*t*, 10.126–127
- pupillary block causing, 10.118–119
- Primary angle-closure glaucoma (PACG), 10.4*t*, 10.117, 10.117*t*, 10.118, 10.120–122. *See also* Angle-closure glaucoma
- acute, 10.123–125, 10.124*f*
management of, 10.184
- epidemiology of, 10.9–10
- prevalence of, 10.9, 10.117
- with pupillary block, 10.119
- iridotomy/iridectomy for, 10.124, 10.125, 10.191–193, 10.192*f*
- without pupillary block (plateau iris), 10.4*t*, 10.9, 10.120, 10.127*f*, 10.127–128
- risk factors for, 10.9, 10.120–122
- subacute/intermittent, 10.125–126
- Primary angle-closure suspect (PACS), 10.4*t*, 10.117, 10.117*t*, 10.122–123
- Primary anophthalmia, 7.35
- Primary antiphospholipid antibody syndrome, 1.160
- Primary aphakia, 4.117, 11.30. *See also* Aphakia
- Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma (PCNSL/PIOL), 1.237, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 9.273–276, 9.274*f*, 9.275*f*
- in HIV infection/AIDS, 5.349, 9.301
- uveitis differentiated from, 9.129, 9.274
- Primary coloboma, 11.30–31. *See also* Colobomas
- Primary congenital glaucoma (PCG), 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*. *See also* Glaucoma, pediatric
- anterior segment findings in, 6.282, 6.282*f*
- axial length in, 6.283
- central corneal thickness in, 6.281
- clinical manifestations of, 6.279–280, 6.280*f*
- cornea affected in, 8.108–109
- corneal edema and, 6.279–280, 8.108–109
- corneal findings in, 6.280*f*, 6.280–281
- corneal opacities and, 8.108–109
- definition of, 6.278
- diagnostic examination for, 6.280–283, 6.282–283*f*
- differential diagnosis of, 6.281*t*, 10.151–152, 10.152*t*
- genetics of, 6.277–278, 10.11*t*, 10.150
- gonioscopy for, 6.282, 6.282*f*
- goniotomy for, 6.285, 6.286*f*
- incidence of, 6.278
- megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
- natural history of, 6.283–284
- optic nerve findings in, 6.282–283, 6.283*f*, 10.160
- optical coherence tomography of, 6.283
- pathophysiology of, 6.278
- surgical treatment of, 6.285–287, 6.286*f*
- tonometry in, 6.281–282
- trabeculotomy, 6.286*f*, 6.286–287
- treatment of, 10.153
- medical, 10.153
- surgical, 10.153, 10.160–164, 10.161*f*, 10.162*f*, 10.187
- Primary conjunctival melanosis (complexion-associated/hypermelanosis), 4.63*t*, 4.65, 4.66, 4.66*f*
- Primary deviation
- definition of, 6.38
- secondary deviation versus, 6.115
- Primary divergence insufficiency, 6.94
- Primary dye test (Jones I test), 7.269
- Primary endothelial failure
- after endothelial keratoplasty (DMEK/DSEK), 8.447
- after penetrating keratoplasty, 8.423, 8.423*f*
- Primary glaucoma. *See* Angle-closure glaucoma, primary; Glaucoma; Open-angle glaucoma, primary; Primary congenital glaucoma
- Primary HIV infection, 1.264
- Primary (essential) hypertension, 1.63, 1.63*f*
- in children and adolescents, 1.78
- Primary hypothyroidism, 1.54
- Primary intracranial pinealoblastoma, retinoblastoma and, 4.298, 4.302
- Primary intraocular/central nervous system lymphoma (PIOL/PCNSL), 1.237, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 9.273–276, 9.274*f*, 9.275*f*. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
- Primary lens fibers, development of, 2.118, 11.26–27, 11.27*f*
- Primary lipid keratopathy, 8.126
- Primary megalocornea, 6.253–254
- Primary open-angle glaucoma (POAG). *See* Open-angle glaucoma, primary
- Primary position hypotropia, with Brown syndrome, 6.137
- Primary position of gaze, 6.31, 6.64
- Primary posterior capsulectomy, 6.303
- Primary telecanthus, 6.203
- Primary visual (striate/occipital) cortex, 2.90, 2.93, 5.24*f*, 5.29*f*, 5.29–30, 5.30*f*, 5.32*f*. *See also* Visual (calcarine/occipital/striate) cortex
- abnormal visual experience effects on, 6.53
- disorders of, 5.158, 5.178*t*, 5.178–181
- illusions and, 5.175
- Primary vitreoretinal lymphoma, 12.233–234. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
- Primary vitreous, 2.122, 2.123*f*, 4.125
- persistent hyperplasia of (PHPV). *See* Persistent fetal vasculature
- Primed macrophages, 9.19, 9.20*f*, 9.20–21
- Primers, in polymerase chain reaction, 2.141, 4.37, 4.40*f*
- Priming, of effector lymphocytes, 9.36*f*, 9.36–38, 9.38
- Primitive neuroectodermal tumor (PNET), 6.357–358
- retinoblastoma associated with, 4.298, 4.302, 4.302*t*
- Primitive streak, 2.112*f*
- Prince rule, 3.179, 3.179*f*
- Principal axes, of astigmatism, 3.138–139
- Principal line of vision, 3.128
- Principal meridians
- definition of, 3.4, 3.16
- in irregular astigmatism, 3.139
- refractive powers of, 3.16
- Principal planes
- definition of, 3.41
- description of, 3.56–57, 3.57*f*
- distant objects and, 3.59

- Principal points, 3.41, 3.56–57
- Prinzmetal (variant) angina, 1.93
- Prions/prion diseases, 5.357, 8.254
- Prism Adaptation Study, 6.93
- Prism adaptation test, 6.82
- Prism alternate cover test (PACT), 6.65–66, 6.66*f*
 in fourth nerve (trochlear) palsy, 5.198
 in ocular misalignment, 5.184
- Prism and cover test
 exodeviation evaluations, 6.100
 simultaneous, 6.66–67
- Prism diopter
 definition of, 3.41, 3.46, 3.47*f*
 pictorial representation of, 3.47*f*
- Prism dissociation
 for binocular balance, 3.168, 3.168*f*
 for nonorganic disorder evaluation, 5.303, 5.303*f*
- Prism power. *See also* Transverse magnification
 definition of, 3.45
 nonadditive nature of, 3.46, 3.47*f*
 in Prentice position, 3.49*f*
 Snell's law used to calculate, 3.48
- Prisms
 angle of deviation in, 3.45, 3.46*f*
 anophthalmic socket camouflage and, 7.136
 apex of, 3.46
 base-down, 3.188
 base-in, 3.211
 base of, 3.46
 base-out, 3.211
 convergence insufficiency and, 6.103
 convergence paralysis and, 6.106
 dissociated vertical deviation and, 6.129
 nystagmus treated with, 6.155
 base-up, 3.188
 convergence insufficiency treated with, 6.103
 convergence paralysis treated with, 6.106
 diplopia treated with, 6.72
 in fourth nerve (trochlear) palsy evaluation, 5.198
 Fresnel. *See* Fresnel prisms
 in fusional convergence evaluation, 5.226
 horizontal heterophoria correction using, 3.196–197
 image position affected by, 3.48*f*
 intermittent exotropia treated with, 6.102
 for myasthenia gravis, 5.326
 in nonorganic disorder evaluation, 5.302–303, 5.303*f*
 for nystagmus, 5.236
 nystagmus treated with, 6.155
 in ocular misalignment evaluation, 5.184
 orientation of, 3.46
 positioning of, 3.45, 3.46*f*
 press-on, 3.188
 in relative cyclotropia evaluation, 5.185
 slab-off
 definition of, 3.148
 induced anisophoria correction using, 3.188, 3.188*f*
 spectacle lens, incorporation of, 3.197, 3.285
 therapeutic use of, 3.196–197
 uses of, 3.45
 vertical heterophoria correction using, 3.197
 visual acuity assessment in children using, 6.6
- Prisms (wavefront aberrations), 13.11
- PRK. *See* Photorefractive keratectomy
- PRL. *See* Preferred retinal loci
- PRNG. *See* Penicillin-resistant *N gonorrhoeae*
- Probability of the outcome, baseline, 1.21–22
- Proband, 2.142, 2.172
- Probe amplification, multiplex ligation-dependent (MLPA), 4.39*t*
- Probes, DNA. *See* DNA probes
- Probing
 for congenital nasolacrimal duct obstruction, 6.232–234, 6.233*f*
 of lacrimal system
 for acquired nasolacrimal duct/canalicul
 obstruction, 7.271–272, 7.273
 for canalicul trauma, 7.283
 for congenital dacryocystocele/dacryoce
 le, 7.265
 for congenital nasolacrimal duct obstru
 ction, 7.260, 7.261*f*, 7.261–262, 7.262*f*, 7.263*f*
 for meibomian gland dysfunction, 8.68
- Procainamide, 1.113*t*, 12.300
 for cardioversion, 1.114, 1.115
 for medical emergencies, 1.296*t*
- Procaine, 2.362*t*
 cholinesterase inhibitor use and, 2.312
- Procerus muscle, 7.16, 7.141, 7.143*f*, 7.148*f*
- Process, care system, 1.23
- Processing phase of immune response arc, 9.33*f*, 9.36*f*, 9.36–38
 in primary versus secondary immune response, 9.40
 response to tuberculosis and, 9.31
- Prodrugs, 2.302
 for β -blockers, 2.323
- Profenal. *See* Suprofen
- Programmed cell death (PCD/apoptosis), 2.132, 2.154, 2.155
 by cytotoxic T lymphocytes, 9.48–49, 9.49*f*
 in DNA repair, 2.154, 2.155
 Fas ligand (CD95 ligand/FasL) in, 9.48–49, 9.49*f*, 9.58
- Programmed death ligand-1 (PD-L1), in external eye defense, 8.12–13*f*
- Progressive addition lenses (PALs)
 candidates for, 3.183
 description of, 3.182–184, 3.183*f*
 fitting of, 3.183
 hard-design, 3.182, 3.183*f*
 prescription for, 3.198
 soft-design, 3.182, 3.183*f*
- Progressive (chronic progressive) external ophthalmoplegia (CPEO), 2.158, 5.328–329, 5.329*f*
 mitochondrial DNA defects and, 2.157, 2.158
 ptosis in, 5.273, 5.273*t*, 5.328, 5.329*f*
 syndromes associated with, 2.158
- Progressive facial hemiatrophy (Parry-Romberg syndrome), 8.192*t*
- Progressive flattening effect, after radial keratotomy, 13.51
- Progressive multifocal leukoencephalopathy (PML), 5.351*f*, 5.351–352
 natalizumab causing, 5.318, 5.351
- Progressive multiple sclerosis, 5.315
- Progressive outer retinal necrosis (PORN) syndrome, 9.197*f*, 9.197–198, 9.295–296, 9.296*f*, 12.236–237, 12.237*f*

- Progressive supranuclear palsy (PSP)
 convergence insufficiency in, 5.227
 facial weakness/paralysis in, 5.278
 pursuit dysfunction in, 5.226
 saccadic dysfunction in, 5.214, 5.221
- Progressive systemic sclerosis. *See* Systemic sclerosis
- Projection artifact, 12.29, 12.30f
- Prokaryotes. *See* Bacteria
- Prolactinomas (lactotroph adenomas), 1.57
- Prolate, 3.267–268
- Prolate cornea, 8.25, 13.9, 13.14, 13.26
 Q value and, 13.14
- Prolensa. *See* Bromfenac
- Proliferative diabetic retinopathy (PDR). *See also*
 Diabetic retinopathy
 anti-VEGF therapy for, 12.103–104, 12.386
 complications of, 12.103–108
 definition of, 12.91–92
 description of, 12.91–92
 extraretinal fibrovascular proliferation associated
 with, 12.102
 high-risk characteristics of, 12.103
 laser surgery for, 12.104–107
 management of, 12.103–108
 neovascular proliferation associated with, 12.102
 neovascularization in, 12.151
 nonproliferative diabetic retinopathy progression to,
 12.101
 nonsurgical management of, 12.103–104
 optical coherence tomography angiography of, 12.94f
 panretinal photocoagulation for, 12.104, 12.106,
 12.106f
 photocoagulation for, 12.94
 in pregnancy, 12.94
 proangiogenic factors in, 12.102
 proliferative sickle cell retinopathy versus, 12.151
 ranibizumab for, 12.104
 scatter photocoagulation for, 12.116
 severe carotid artery occlusive disease associated
 with, 12.98
 severity of, 12.95t
 stages of, 12.102
 steroids for, 12.103–104
 surgical management of, 12.104–107
 tractional retinal detachment caused by, 12.103,
 12.108, 12.387–388
 vitreous hemorrhage caused by, 12.103, 12.103f,
 12.107–108, 12.386–387
- Proliferative sickle cell retinopathy (PSR). *See* Sickle cell
 retinopathy
- Proliferative vitreoretinopathy (PVR), 4.20, 4.21f, 4.131,
 4.131f, 12.320, 12.323t, 12.323f, 12.323–324
 rhegmatogenous retinal detachment and, 9.291
- Promoter, 2.142, 2.151
 in alternative splicing, 2.152–153
- Prone-position test, for primary angle-closure suspect,
 10.122
- Propafenone, 1.113t
- Propamidine, for *Acanthamoeba* keratitis, 2.361
- Proparacaine, 2.363t, 2.365
 for cataract surgery, 11.92
 with fluorescein, 2.363t
- Prophase, 2.148, 2.149f
- Propine. *See* Dipivefrin
- Propionibacterium/Propionibacterium acnes*, 8.244t,
 8.246, 8.246f, 12.390
 endophthalmitis/postoperative endophthalmitis
 caused by, 4.119, 4.119f, 8.246, 9.119, 9.261–262,
 9.262f, 11.140, 11.162
 as normal flora, 8.206t, 8.246
 ocular infection caused by, 8.246
- Propofol, perioperative, 1.291
- Proposita/propositus, 2.142
- Propranolol, 2.308t, 2.317f
 for arrhythmias, 1.113t
 for hemangioma, 6.220, 6.221f
 for hypertension, 1.68t, 1.69t
 for infantile (capillary) hemangioma, 7.67f, 7.68, 7.161
- Proptosis (exophthalmos/exorbitism), 4.223, 5.271, 7.23,
 7.24, 7.25f
 in aspergillosis, 5.353, 5.354f
 in carotid-cavernous fistula, 7.73
 in cavernous hemangioma, 7.68, 7.69f
 in craniosynostosis, 6.207, 7.37
 dermoid cyst causing, 7.40
 exposure keratopathy/lagophthalmos and, 8.80
 in lymphatic malformation–associated hemorrhage,
 7.70, 7.70f, 7.71
 in meningioma, 7.79, 7.79f, 7.81
 in neurofibromatosis, 7.78
 in nonspecific orbital inflammation, 7.64
 nonspecific orbital inflammation as cause of, 6.215
 in optic nerve glioma, 7.74, 7.75f
 in orbital leukemia, 4.316
 in orbital lymphatic malformations, 4.233
 in orbital lymphoproliferative lesions, 4.232
 orbital mass causing, 7.24, 7.95
 orbital varices and, 7.71
 in orbital zygomycosis, 7.50
 in pleomorphic adenoma, 4.230f
 in retinoblastoma, 4.294, 4.294f
 in rhabdomyosarcoma, 4.236, 4.237f, 7.82
 in teratoma, 7.41
 in thyroid eye disease, 4.226, 4.227f, 5.131, 7.24, 7.52,
 7.52f, 7.54, 7.56. *See also* Thyroid eye disease
 in uveal lymphoid proliferation/infiltration, 4.314
- Propylene glycol, in artificial tears, 2.341
- Propylthiouracil, for hyperthyroidism, 1.53
- PROSE treatment
 for graft-vs-host disease, 8.304
 for Stevens-Johnson syndrome (Stevens-Johnson
 syndrome/toxic epidermal necrolysis overlap and
 toxic epidermal necrolysis), 8.298
- Prosopagnosia, 5.179
- Prospective Evaluation of Radial Keratotomy (PERK)
 study, 13.50
- Prostacyclin (PGI₂), 2.237, 2.334
- Prostaglandin (PG) analogues, 2.302, 2.327t, 2.327–328,
 6.289t, 6.290, 10.170–176, 10.171t, 10.175f
 adnexal changes associated with, 10.30, 10.165–166
 in children, 10.165–166
 for glaucoma, 2.237–238, 2.318t, 2.327t, 2.327–328
 cystoid macular edema after cataract surgery and,
 11.164, 11.187
 inflammatory glaucoma and, 10.100
 uveitic glaucoma and, 9.287

- during pregnancy/lactation, 10.185
- uveitis caused by, 9.121
- Prostaglandin-associated periorbitopathy, 10.176
- Prostaglandin E₂, thyroid eye disease and, 7.55
- Prostaglandin G/H synthase. *See* Cyclooxygenase
- Prostaglandin I₂ (PGI₂/prostacyclin), 2.237, 2.334
- Prostaglandins (PGs), 2.237, 2.327–328, 2.334, 9.24–25, 9.25*f*
 - anti-inflammatory drugs and, 1.172, 2.239, 2.331
 - cystoid macular edema after cataract surgery and, 11.164, 11.187
 - receptors for, 2.239–240, 2.316*t*
 - in signal transduction, 2.316*t*
 - synthesis of, 9.24, 9.25*f*
 - by mast cells, 9.10
- Prostamides. *See* Bimatoprost; Prostaglandin analogues
- Prostate cancer, 1.212
 - choroidal metastases and, 4.304*t*
 - eye/orbital metastases and, 4.304*t*, 7.101
 - screening for, 1.210*t*, 1.212
- Prostate-specific antigen (PSA), in cancer screening, 1.210*t*, 1.212
- Prostheses, ocular, 7.36, 7.132
 - anophthalmic ectropion and, 7.135, 7.137
 - for graft-vs-host disease, 8.304
 - for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
- Prostigmin. *See* Neostigmine
- Protan red-green color deficiency, 12.54
- Protanomalous dichromatism, 12.250*t*
- Protanomalous trichromatism, 12.250*t*
- Protanopia (protan defects), ocular findings in carriers of, 2.199*t*
- Protease inhibitors (PIs), 1.266
- Proteases, microbial, in ocular infections, 8.207
- Protein C/activated protein C, 1.141
 - deficiency of, 1.141, 1.147, 12.134
 - resistance to, 1.147
- Protein kinase C (PKC)/Ca²⁺-dependent pathway, in tear secretion, 2.218, 2.218*f*
- Protein S, 1.141
 - deficiency of, 1.141, 1.147, 12.134
- Proteinase-3, in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168, 9.138
- Proteinase inhibitors
 - in aqueous humor, 2.234
 - in cornea, 2.226
- Proteinases, in aqueous humor, 2.231, 2.233–234
- Proteins
 - in aqueous humor, 2.229, 2.233–234
 - breakdown of blood–aqueous barrier and, 2.236
 - corneal, 2.224
 - disorders of metabolism of
 - corneal changes in, 8.181*f*, 8.181–190, 8.182*t*, 8.183*t*, 8.184*f*, 8.185*f*, 8.186*t*, 8.187*f*, 8.188*f*, 8.189*f*
 - corneal crystal deposition and, 8.182*t*
 - drug-binding by, systemic administration and, 2.300–301
 - lens. *See* Lens proteins
 - in retinal pigment epithelium, 2.273, 2.277
 - in rod outer segments (“rim” proteins), 2.261
 - in tear film, 2.216
 - vitreous, 2.251–252
- Proteoglycans, corneal, 2.41, 2.226, 8.9
- Proteomics, 2.136
- Proteus*, 8.247
 - conjunctivitis caused by, 8.257*t*
- Prothrombin, mutation in gene for, 1.147
- Prothrombin time (PT), 1.141
 - international normalized ratio and, 1.142
- Proto-oncogene, 2.156
- Proto-oncogene Neu, in immunohistochemistry, 4.35
- Proton density (PD), 7.28
- Proton density (PD) MRI, 5.62, 5.63*f*, 5.63*t*, 5.64*f*, 5.75, 7.28
- Proton pump inhibitors, corticosteroid treatment in uveitis and, 9.100
- Protoplasmic astrocytes, 2.73
- Protozoa/protozoal infection. *See also specific causative organism*
 - intestinal, in HIV infection/AIDS, 1.268–269
 - ocular, 4.147–148, 4.148*f*, 8.252, 9.219–227
 - Acanthamoeba* keratitis, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*
 - corneal opacity and, 8.16*f*
 - retinitis, 4.147–148, 4.148*f*
 - uveitis, 9.219–227
- Protractors, eyelid, 7.147–149, 7.148*f*
 - spasm of (benign essential blepharospasm/BEB), 7.226–227, 7.227*f*. *See also* Blepharospasm
- Provera. *See* Medroxyprogesterone
- Proximal (instrument) convergence, 6.39
- Proximal illumination, for slit-lamp biomicroscopy, 8.18–19
- PRP. *See* Panretinal photocoagulation
- PRP gene, 5.357
- PrP^C, 5.357
- PrP^{CJD}, 5.357
- PRPH2 (RDS/peripherin) gene mutation, 2.161, 2.264, 12.272, 12.273*f*
 - in pattern dystrophies, 4.170
 - in retinitis pigmentosa, 2.161, 2.264
 - in Stargardt disease, 4.168
- PrP^{SC}, 5.357
- PRSS56 gene, 6.263
- Prulifloxacin, 1.277
- Prussian blue stain, Perls, 4.31*t*
- PSA. *See* Prostate-specific antigen
- Psammoma bodies, in optic nerve meningioma, 4.250
- PSC. *See* Posterior subcapsular cataract
- PSD. *See* Pattern Standard Deviation
- Pseudo–anterior chamber, after lamellar keratoplasty, 8.435
- Pseudo–eyelid retraction, 5.274, 5.275*t*
- Pseudo–Foster Kennedy syndrome, 5.122
- Pseudo–Hurler polydystrophy (ML III), 6.388*t*, 8.178
- Pseudo–internuclear ophthalmoplegia, myasthenic, 5.190, 5.324
- Pseudo–presumed ocular histoplasmosis syndrome (pseudo-POHS), 12.225. *See also* Multifocal choroiditis
- Pseudo–Roth spots, in leukemia, 4.315
- Pseudo–spasmus nutans, 5.130

- Pseudoaccommodating intraocular lenses, 11.122
 complications of, 11.151
- Pseudoadenomatous hyperplasia (Fuchs adenoma), 4.179, 4.279
- Pseudocholinesterase, 2.312. *See also* Cholinesterase/ acetylcholinesterase
 defective, succinylcholine effects and, 2.201–202
- Pseudocolobomas, 6.211
- Pseudocrystalline/crystalline keratopathy, infectious, 4.79–80, 4.80f
 after penetrating keratoplasty, 4.79
- Pseudodendrites
 in *Acanthamoeba* keratitis, 8.277
 herpes zoster, 8.227–228
 in tyrosinemia, 8.183, 8.184f
- Pseudodominance, 2.142, 2.177
- Pseudodrusen
 characteristics of, 12.200, 12.200f
 imaging of, 12.200
 in pseudoxanthoma elasticum, 12.198
 reticular (RPD/subretinal drusenoid deposits), 4.162, 4.163, 4.163f, 4.171f, 12.65f, 12.65–66
 scanning laser ophthalmoscopy of, 12.24
- Pseudoepiphora, 7.267–268
- Pseudoepitheliomatous hyperplasia, 7.167, 8.332t
- Pseudoesotropia, 6.85–87, 6.86f, 6.99
- Pseudoexfoliation/exfoliation syndrome, 4.101–103, 4.102f, 4.124, 10.11t, 10.31, 10.91f, 10.91–93, 10.92f, 10.130, 10.131f, 11.65f, 11.65–66
 cataract surgery in patient with, 11.79, 11.184
 glaucoma and (pseudoexfoliation glaucoma), 10.11t, 10.31, 10.91, 10.93, 10.130, 10.131f
 IOL decentration/dislocation and, 11.144
 postoperative hyphema and, 11.158
 zonular incompetence and, 10.92, 10.93, 10.130, 10.131f, 11.65–66, 11.181, 11.182f, 11.184
- Pseudoexotropia
 description of, 6.99
 in retinopathy of prematurity, 6.334, 6.335f
- Pseudogene, 2.142
- Pseudogliomas, 4.172
- Pseudoguttiae, inflammatory, 8.52
- Pseudohermaphrodites, 2.192
- Pseudohorn cysts, 4.209, 4.209f
- Pseudohyphae, 8.249
- Pseudohypopyon, 6.342
 in leukemia, 4.315
 in retinoblastoma, 4.292, 4.293f, 9.277
- Pseudoisochromatic plates
 for color vision testing, 12.54, 12.55f
 in low vision evaluation, 5.78
- Pseudolymphoma. *See* Lymphoid hyperplasia
- Pseudomembrane, conjunctival, 8.46t, 8.47t
 in epidemic keratoconjunctivitis, 8.234
 in ligneous conjunctivitis, 8.294
- Pseudomembranous conjunctivitis, 6.251
- Pseudomembranous enterocolitis, *Clostridium difficile* causing, 1.244
- Pseudomonas corneal ulcer, 3.231f
- Pseudomonas/Pseudomonas aeruginosa*, 1.247, 8.208t, 8.244t, 8.247, 8.247f, 8.257t
 ocular infection/conjunctivitis/keratitis caused by, 8.208t, 8.247, 8.257t, 8.267, 8.268f
- Pseudoneutralization, 3.159–160
- Pseudopapilledema, 5.107–109, 5.108f, 6.372–373f, 374
 drusen and, 4.247, 5.107, 5.108f, 5.141f, 5.142–143
- Pseudopemphigoid (drug-induced pemphigoid), 8.91, 8.92, 8.299
- Pseudophakia
 retinal detachment risks associated with, 12.319
 surgically induced
 accommodating IOLs for, 13.163–164, 13.164f
 cataract surgery and, 11.166–167
- Pseudophakic (aphakic) bullous keratopathy (PBK)
 after cataract surgery, 4.83–84, 4.84f, 11.129, 11.129f
 IOL design and, 11.149
 DMET for, 8.449
- Pseudophakic cystoid macular edema
 definition of, 12.157
 imaging of, 12.394f
 optical coherence tomography of, 12.158f
 pars plana vitrectomy for, 12.394f
- Pseudophakic glaucoma, 10.130–132
- Pseudophakic refractive procedures, 13.8t
- Pseudophakodonesis
 anterior capsule contraction and, 11.154
 IOL dislocation and, 11.145
- Pseudoplasticity, of ophthalmic viscosurgical device, 11.96
- Pseudopolyopia, 6.268, 6.268f
- Pseudoproptosis, 6.217, 6.283, 7.24–25
- Pseudopterygium, 8.113, 8.124–125, 8.125f
- Pseudoptosis
 description of, 5.270f, 5.274, 7.218, 7.218f
 in hypotropia, 6.30
- Pseudorosettes, in retinoblastoma, 4.173, 4.173f
- Pseudostrabismus, in epicanthus, 7.158
- Pseudosuction, in flap creation, 13.86
- Pseudotumor
 benign lymphoid (pseudolymphoma). *See* Lymphoid hyperplasia
 orbital. *See* Nonspecific orbital inflammation
 plasma cell-rich, 7.89
- Pseudotumor cerebri (PTC/idiopathic intracranial hypertension/IIH), 5.110–113, 5.111t
 in children, 5.113
 headache and, 5.110, 5.112, 5.113, 5.288
- Pseudoxanthoma elasticum (PXE/Grönblad-Strandberg syndrome), 1.142, 12.87
 angioid streaks in, 1.143, 12.87, 12.89f
 Bruch membrane calcification in, 2.61, 12.19
 optical coherence tomographic angiography of, 12.199f
 pseudodrusen in, 12.198
- PSF. *See* Point spread function
- Psoriasis/psoriatic arthritis, 1.155, 9.116f, 9.116–117
 anterior uveitis in, 9.116–117
- PSP. *See* Progressive supranuclear palsy
- Psychiatric disorders. *See* Behavioral/psychiatric disorders; Nonorganic (functional/nonphysiologic) ophthalmic disorders
- Psychological counseling, 3.327
- Psychophysical testing. *See also specific test*
 color vision, 12.54–56, 12.55f
 contrast sensitivity, 12.56–57, 12.57f
 dark adaptometry, 12.57–58
 tests used in, 12.53–54

- Psychotic disorder. *See also* Schizophrenia
 brief, 1.189
- Psychotropic drugs, tear production affected by, 8.62*t*
- PT. *See* Prothrombin time
- PTC. *See* Pseudotumor cerebri
- Pterygium, 4.57, 4.57*f*, 4.57–58, 8.111, 8.112–113, 8.113*f*, 8.351, 8.352, 8.352*f*
 conjunctival transplantation for, 8.351
 excision of, 8.351, 8.352–356, 8.353*t*, 8.354*f*
 bacterial scleritis after, 8.282, 8.283*f*
 infectious scleritis after, 9.259
 recurrent, 8.351, 8.352, 8.353, 8.353*t*, 8.355
- Pterygoid canal, nerve of, 2.101*f*, 2.104
- Pterygoid process, of sphenoid bone, 5.5
- Pterygoid venous plexus, 2.35*f*, 5.21*f*, 5.22
 eyelids drained by, 7.154
- Pterygomaxillary area, 5.11, 5.56
- Pterygopalatine area, 5.11
- Pterygopalatine fossa, 5.12, 7.7*f*
- Pterygopalatine ganglion/nerves, 2.101*f*, 2.104, 5.11, 5.49
- PTK. *See* Phototherapeutic keratectomy
- Ptosis, brow, 7.234–235, 7.235*f*
 dermatochalasis and, 7.229, 7.234, 7.235
- Ptosis (blepharoptosis), 5.269, 5.269*f*, 5.270*f*, 5.272*f*, 5.272–274, 5.273*t*, 7.209–222
 acquired, 5.273*t*, 5.273–274, 7.209, 7.214*t*
 aponeurotic, 7.214, 7.214*f*, 7.214*t*
 eyelid position in downgaze and, 7.211, 7.214*t*
 mechanical, 7.218
 myogenic, 7.213
 neurogenic, 7.215–216
- ancillary tests in evaluation of, 7.212
- anophthalmic, 7.135
- aponeurotic, 5.273, 5.273*t*, 7.214, 7.214*f*, 7.214*t*
- apparent (pseudoptosis), 5.270*f*, 5.274, 7.218, 7.218*f*
- apraxia of eyelid opening and, 5.273*t*, 5.274
- in blepharochalasis, 7.230
- in blepharophimosis–ptosis–epicanthus inversus syndrome, 7.155, 7.212
- botulinum toxin causing, 7.216
- cerebral, 5.273
- in chronic progressive external ophthalmoplegia, 5.273, 5.273*t*, 5.328, 5.329*f*
- classification of, 6.197*t*, 7.213–218
- congenital, 5.269*f*, 5.272*f*, 5.272–273, 6.196–198, 6.197*t*, 6.198*f*, 7.209, 7.214*t*
 amblyopia in, 7.211–212
 eyelid position in downgaze and, 7.211, 7.214*t*
 mechanical, 7.217–218
 myogenic, 7.213, 7.213*f*, 7.214*t*
 neurogenic, 7.215, 7.216*f*
- as cosmetic versus functional issue, 7.212, 7.218–219
- in dermatochalasis, 7.229, 7.229*f*
- downgaze exacerbating, 7.209
- enucleation/evisceration and, 7.130
- evaluation of, 5.269*f*, 5.269–271, 5.270*f*, 6.197, 7.209
- eyelid position in downgaze and, 7.211, 7.214*t*
- in Horner syndrome, 5.257, 5.259*f*, 5.272, 5.273*t*, 7.212
 pharmacologic testing for, 7.212
- Marcus Gunn jaw-winking, 5.272, 5.272*f*, 7.211, 7.215, 7.216*f*
- synkinesis in, 7.211, 7.215, 7.216*f*
- mechanical, 5.273*t*, 5.274, 7.217–218
- in monocular elevation deficiency (double-elevator palsy), 7.213
- in myasthenia gravis, 5.206, 5.270*f*, 5.271, 5.273, 5.273*t*, 5.324, 7.209, 7.216–217
 edrophonium chloride test and, 7.217
- myogenic, 5.273*t*, 7.213*f*, 7.213–214, 7.214*t*
- in myotonic dystrophy, 5.273, 5.273*t*, 5.329, 5.330
- neurogenic, 5.273, 5.273*t*, 7.215–217, 7.216*f*
 congenital, 5.272–273
- neuromuscular junction causes of, 5.206, 5.273*t*
- nonorganic, 5.310–311
- in oculopharyngeal dystrophy, 5.273, 5.273*t*, 5.329
- in orbital floor/blowout fracture, 7.109
- pharmacologic testing in, 7.212
- physical examination of patient with, 7.209–212, 7.210*f*, 7.211*f*
- reverse, lower eyelid, 7.212, 7.215
- in rhabdomyosarcoma, 7.82
- “senile,” 5.273
- steroid-induced, 5.273, 5.273*t*
- synkinesis in, 7.211
- third nerve (oculomotor) palsy causing, 5.272, 5.273*t*
- traumatic, 5.273*t*, 5.274, 7.190, 7.218
 amblyopia and, 7.190
- treatment of, 7.218–222, 7.219*f*, 7.220*f*, 7.221*f*
 anophthalmic socket and, 7.135
 complications of, 7.222
- visual field testing in, 7.212
- Ptosis repair, 7.218–222, 7.219*f*, 7.220*f*, 7.221*f*. *See also* *specific procedure*
 in blepharophimosis–ptosis–epicanthus inversus syndrome, 7.155
 complications of, 7.222
 cosmetic versus functional, 7.212, 7.218–219
- PTSD. *See* Post-traumatic stress disorder
- Pubic louse (*Phthirus pubis*), 8.253, 8.254*f*
 ocular infection caused by, 8.208*t*, 8.253, 8.255
- PubMed, 1.3
- PUK. *See* Peripheral keratitis, ulcerative
- Pulfrich phenomenon, 5.175
- Pulled-in-two syndrome (PITS), 6.169–170
- Pulley system, 2.31, 2.31*f*
 abnormalities of, 6.107
 of extraocular muscles, 6.28, 6.32
- Pulmonary arterial hypertension, 1.132
 recent developments in treatment of, 1.129
- Pulmonary diseases, 1.129–134
 in Behçet disease, 9.185
 in coccidioidomycosis, 9.271
 evaluation of, 1.131
 in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137
 irreversible, 1.129, 1.130
 obstructive, 1.129–130
 ocular surgery in patient with, 1.288
 ophthalmic considerations in, 1.132
 pre- and postoperative considerations and, 1.134, 1.288
 recent developments in, 1.129
 restrictive, 1.130–131

- reversible, 1.129, 1.130
- in sarcoidosis, 9.167–168, 9.170
- in SLE, 1.157
- in systemic sclerosis, 1.162
- treatment of, 1.131–134
 - nonpharmacologic, 1.132
 - pharmacologic, 1.132–134, 1.133*t*
- tuberculosis (TB), 1.215–216, 1.254–255, 9.250–255, 9.251*f*, 9.252*f*, 9.253*f*. *See also* Tuberculosis
- Pulmonary edema, in heart failure, 1.105, 1.109
- Pulmonary function tests, 1.131
- Pulmonary metastases, ocular metastases associated with, 4.197, 4.198*f*, 4.304, 4.304*t*, 4.308–309, 4.309*f*
- Pulsation, orbital, 7.26
- Pulse
 - gaze-evoked nystagmus and, 5.240
 - saccadic eye movement and, 5.219, 5.220*f*, 5.221, 5.222
- Pulse (term), in phacoemulsification, 11.100
- Pulsed-light therapy, intense (IPL)
 - for meibomian gland dysfunction, 8.69
 - for rosacea, 8.71
- Pulsed phacoemulsification, 11.100
- Pulseless disease (Takayasu arteritis), 1.165*t*, 1.166
 - cataract caused by, 11.68
- Pulvinar, 5.18*f*, 5.30, 5.34
- Pump–leak theory, 11.21, 11.22*f*
- Punch (incisional) biopsy, 7.179*f*, 7.180
- Puncta. *See* Punctum (puncta)
- Punctal occlusion/plugs
 - drug-delivery systems using, 2.303
 - for dry eye, 2.220, 7.281–282, 8.61*t*, 8.64–65, 8.65*f*
 - canalicular obstruction and, 7.274, 7.282
 - extrusion/migration of, 7.282
 - nasolacrimal duct obstruction and, 7.278, 7.282
 - for graft-vs-host disease, 8.304
 - for mucous membrane pemphigoid, 8.303
 - for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81, 8.224, 8.230
- Punctate epithelial defects/erosions (PEEs)
 - conjunctival, 8.46*t*
 - corneal, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
 - in exposure keratopathy, 8.80
 - in herpetic eye disease/neurotrophic keratopathy, 8.224
 - refractive surgery and, 13.42, 13.42*f*
 - in vernal keratoconjunctivitis, 8.290
- Punctate epithelial keratitis/keratopathy (PEK), 6.269, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
 - adenoviruses causing, 8.234
 - blepharitis/blepharoconjunctivitis and, 8.72, 8.73*t*, 8.74
 - exposure causing, 8.80
 - herpes simplex causing, 8.216, 8.216*f*
 - in herpes zoster, 8.227
 - microsporidial, 8.280, 8.280*f*
 - superficial Thygeson (SPK), 8.306–307, 8.307*f*
 - topical anesthetic abuse causing, 8.89
- Punctate inner choroiditis/chorioidopathy (PIC), 9.141–143*t*, 9.158*f*, 9.158–160, 9.159*f*, 12.225. *See also* Multifocal choroiditis
- Punctate keratitis, 3.232–233, 6.197
- Punctate outer retinal toxoplasmosis (PORT), 9.223, 9.224*f*
- Punctate staining patterns (fluorescein), 8.36, 8.37*f*
- Punctoplasty, 7.272, 7.273
- Punctum (puncta), 2.18*f*, 2.22*f*, 2.29, 7.252–253, 7.253*f*, 7.254*f*
 - agenesis/dysgenesis of, 7.259–260
 - aplasia/hypoplasia of, 7.258
 - disorders of, 7.272–273
 - duplication of, 7.257
 - in external eye defense, 8.11
 - large, 7.273
 - malposition of, 7.273
 - stenosis and occlusion of, 7.258, 7.272, 7.273
 - surgical closure of, 7.282
- Pupil. *See* Pupils
- Pupil expansion devices, 11.177, 11.178*f*
 - for intraoperative floppy iris syndrome, 11.178
 - for traumatic inflammation, 11.191
- Pupil-involving third nerve (oculomotor) palsy, 5.193, 5.194*f*, 5.194–195, 5.265
 - in young patients, 5.197
- Pupil–optic nerve (PO) section, 4.29*f*, 4.29–30
- Pupil size. *See* Pupils, size of
- Pupil-sparing third nerve (oculomotor) palsy, 2.95, 5.195–196, 5.196*f*
 - complete, 5.195
 - partial, 5.195–196, 5.196*f*
- Pupil testing
 - in children, 6.10
 - in nystagmus evaluations, 6.154
- Pupillary axis, 3.124, 3.129, 3.129*f*, 3.272
- Pupillary block, 10.118–119
 - absolute, 10.119
 - angle closure/angle-closure glaucoma with, 10.4*t*, 10.6*t*, 10.118–119
 - iridotomy/iridectomy for, 10.124, 10.125, 10.191
 - uveitis and, 9.83
 - angle closure/angle-closure glaucoma without, 10.4*t*, 10.6*t*, 10.119*t*, 10.119–120
 - angle closure caused by, 10.118–119
 - anterior chamber intraocular lenses and, 10.131–132
 - in aphakic/pseudophakic eye, 10.130
 - after cataract surgery, flat or shallow anterior chamber and, 11.135–136
 - ectopia lentis and, 10.129
 - after endothelial keratoplasty (DMEK/DSEK), 8.444*f*, 8.444–445
 - mechanism of angle closure and, 10.118–119
 - microspherophakia causing, 10.130, 10.131*f*, 11.33
 - after penetrating keratoplasty, 8.424
 - phacomorphic glaucoma and, 10.119, 11.67, 11.68*f*
 - reverse, in pigmentary glaucoma, 10.93
- Pupillary-block glaucoma, in retinopathy of prematurity, 12.181
- Pupillary capture, after cataract surgery, 11.148, 11.148*f*
 - IOL decentration and, 11.145
- Pupillary defects, 5.253–267. *See also specific type and under Pupils*
 - afferent
 - in meningioma, 7.81
 - in optic nerve glioma, 7.74
 - relative (RAPD). *See* Relative afferent pupillary defect
 - in traumatic optic neuropathy, 7.113

- benign episodic unilateral mydriasis, 5.267
 examination of patient with, 5.79f, 5.79–81, 5.253–254
 history in, 5.253
 irregularity, 5.255
 in myasthenia gravis, 5.324
 nonorganic, 5.302, 5.310
 in ptosis, 7.212
 reactivity disorders (light–near dissociation), 5.254, 5.266t, 5.266–267
 in sarcoidosis, 5.327
 size/shape/location abnormalities, 5.255–266. *See also* Anisocoria
 evaluation of, 5.253–254, 5.256f
 nonorganic, 5.310
 in third nerve (oculomotor) palsy, 5.193, 5.194–196, 5.195f, 5.196f, 5.265
 in young patients, 5.197
 Pupillary light reflex (pupillary response to light), 5.55f, 5.255–257. *See also* Pupils, examination of
 in cataract surgery evaluation, 11.78
 in children, 6.10
 consensual response in, 5.254
 development of, 6.181
 direct response in, 5.254
 disorders of/light–near dissociation and, 5.254, 5.266t, 5.266–267
 in Horner syndrome, 5.258
 indirect-acting adrenergic agonists in evaluation of, 2.320
 in myotonic dystrophy, 5.330
 near response and, 5.254, 5.266
 nonorganic disorders and, 5.301, 5.310
 pathways for, 2.96, 5.28, 5.44, 5.44f, 5.54, 5.55, 5.55f
 testing, 5.79f, 5.79–81, 5.254, 5.255–257
 Pupillary membrane
 anterior, 11.29, 11.29f
 in cataract surgery, 11.188
 development and, 2.116t, 2.121f, 2.123f, 11.29, 11.29f
 posterior, 11.29f
 remnant of (Mittendorf dot), 11.29, 11.31, 11.32f
 Pupillary muscles, innervation of, 5.44, 5.44f, 5.52, 5.54, 5.55
 Pupillary near reflex. *See also* Near reflex
 spasm of, 5.227, 5.309–310
 Pupillometer, 13.40
 Pupilloplasty
 for cataracts, 11.71–72
 for IOL decentration/dislocation, 11.145
 Pupils
 abnormalities of, 5.253–267, 6.267–268, 6.268f.
 See also Pupillary defects; *specific type*
 Adie tonic, 5.256f, 5.263f, 5.263–265, 5.264f, 5.265f
 light–near dissociation and, 5.263, 5.264f, 5.266t
 pharmacologic testing for, 2.310, 5.256f, 5.264–265, 5.265f
 aging and, 1.178
 anisocoria of, 6.275
 Argyll Robertson, 5.267
 in syphilis, 9.240
 Argyll Robertson–like, 5.267
 congenital miosis of, 6.267–268
 constriction of, in near and light reflexes, 2.96, 5.254, 5.266t, 5.266–267. *See also* Pupillary light reflex
 corectopia of, 6.268
 diameter of, 3.105
 dilation of. *See also* Mydriasis/mydriatics
 for retinopathy of prematurity examination, 6.331
 displacement of (corectopia), 5.255
 cataract surgery in patient with, 11.180
 in iridocorneal endothelial syndrome, 10.136, 10.137f
 dyscoria of, 6.267
 in ectopia lentis et pupillae, 11.42
 entrance, 3.124, 3.130–131
 examination of, 5.253–254
 before cataract surgery, 11.78
 in glaucoma, 10.30, 10.33t
 in low vision, 5.79f, 5.79–81
 after penetrating and perforating ocular trauma, 8.401
 in ptosis, 7.212
 before refractive surgery, 13.40–41
 fixed, dilated, nonorganic causes of, 5.310
 growth and development of, 6.181
 irregular, 5.255
 Marcus Gunn. *See* Marcus Gunn pupil
 mydriasis of, 6.268
 ovalization of, after angle-supported phakic IOL
 implantation, 13.146–147
 paradoxical, 6.335, 6.336t
 pharmacologic testing of, 5.256f, 5.258–259, 5.259f, 5.261f, 5.264–265, 5.265f
 pseudopolyopia of, 6.268, 6.268f
 reactivity/response of, to light. *See* Pupillary light reflex
 secluded, 10.119, 10.138, 10.139f
 seizures affecting, 1.203
 size of
 abnormalities in, 5.255–266. *See also* Anisocoria
 Airy disc and, 3.106
 baseline, 5.254–255
 cataract surgery and, 11.78, 11.177–178, 11.178f
 IOL selection and, 11.78
 trauma and, 11.191
 uveitis and, 11.188
 diffraction effects affected by, 3.105
 evaluation of, 5.253–254, 5.256f
 before refractive surgery, 13.40
 glaucoma/glaucoma therapy and, 5.254, 10.30
 higher-order aberrations and, 3.106
 keratorefractive surgery and, 3.272–273
 multifocal IOLs and, 13.156
 near point of accommodation and, 3.130
 nonorganic causes of changes in, 5.310
 perimetry results affected by, 10.60
 refractive surgery and, 13.40
 visual resolution affected by, 3.129–131
 wavefront aberrations and, 13.11
 springing, 5.267
 substance use/abuse and, 1.192
 tadpole, 5.255

- tonic (Adie pupil/syndrome), 5.256*f*, 5.263*f*, 5.263–265, 5.264*f*, 5.265*f*, 6.275
 light–near dissociation and, 5.263, 5.264*f*, 5.266*t*
 pharmacologic testing for, 2.310, 5.256*f*, 5.264–265, 5.265*f*
 trauma affecting, 5.255
 in uveitic eye, cataract surgery and, 11.188
 wavefront aberrations and, 3.275, 13.11
 white. *See* Leukocoria
- Purified neurotoxin complex, 2.366
- Purified protein derivative (PPD) test, 1.254, 9.32, 9.253.
See also Tuberculin skin test
 in HIV infection/AIDS, 9.253
 immune response and, 9.32
 uveitis associated with, 9.121
- Purine antagonists, in cancer chemotherapy, 1.232*t*
- Purine nucleotides/purines, 2.140
 hyperuricemia caused by disorders of metabolism of, 8.188
- Purite. *See* Oxychloro complex
- Purkinje cells, 5.40
- Purpura, 1.142
 in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137
 Henoch-Schönlein, 1.165*t*
 idiopathic thrombocytopenic (ITP), 1.143
 thrombotic thrombocytopenic (TTP), 1.144
- Pursuit eye movements/pursuit pathways/system, 5.32, 5.33, 5.34*f*, 5.212, 5.212*t*, 5.224–226, 5.225*f*
 dysfunction/injury of, 5.156, 5.224, 5.225–226
 optokinetic nystagmus/system and, 5.156, 5.218, 5.219
- Pursuit latency, 6.40
- Purtscher flecken, 12.171
- Purtscher retinopathy, 12.171–173, 12.173*t*
- Purtscherlike retinopathy, 12.171–173, 12.172*f*, 12.173*t*
- “Pushing plus,” before refractive surgery, 13.39
- Pustule, of eyelid, 8.45*t*
- PVA. *See* Polyvinyl alcohol
- PVCs (premature ventricular complexes/contractions).
See Premature complexes/contractions, ventricular
- PVD. *See* Posterior vitreous detachment
- PVL. *See* Periventricular leukomalacia
- PVMG. *See* Power-versus-meridian graph
- PVR. *See* Proliferative vitreoretinopathy
- PWS. *See* Port-wine stain
- PXE. *See* Pseudoexfoliation/exfoliation syndrome; Pseudoxanthoma elasticum
- Pyoceles
 in dacryocystitis, 7.286
 orbital invasion by, 7.95
- Pyogenic granuloma, 4.55, 4.55*f*, 6.170, 6.171*f*, 6.199, 6.199*f*, 8.345*t*, 8.346, 8.346*f*
 after pterygium excision, 8.356
- Pyridostigmine, in myasthenia gravis treatment, 5.326
- Pyridoxine (vitamin B₆), for homocystinuria, 2.203, 11.41
- Pyrimethamine, 2.349
 for toxoplasmosis, 6.409, 9.225, 9.297
- Pyrimidine antagonists, in cancer chemotherapy, 1.232*t*
- Pyrimidine nucleotides/pyrimidines, 2.140
 fluorinated, 2.355*t*
- Pyruvate carboxylase, defective/deficiency of, 2.175*t*
- Pyruvate dicarboxylase, defective/deficiency of, 2.175*t*
- Pythium insidiosum*, 8.251
 keratitis caused by, 8.251, 8.275
- ## Q
- Q_e. *See* Radiant energy
- Q_λ. *See* Radiant energy
- q arm, 2.142, 2.148*f*
- Q/D. *See* Quinupristin/dalfopristin
- Q factor, 3.267, 3.269, 3.279
- Q formula, Hoffer, for IOL power determination/selection, 11.85
- Q-switching, 3.112
- Q value, 13.14
- Q waves/Q-wave infarction, 1.93, 1.94, 1.96
 management of, 1.104
- QED. *See* Quantum electrodynamics
- qPCR. *See* Quantitative (real-time) polymerase chain reaction
- QRISK, 1.83
- Quadrantanopia, 5.105*t*
 hallucinations with, 5.177
 occipital lobe lesions causing, 5.156
 temporal lobe lesions causing, 5.155*f*
- Quadripod (zygomaticomaxillary complex) fractures, 7.103–105, 7.105*f*
- Quadruple sectoranopia, lateral geniculate body lesions causing, 5.154, 5.154*f*
- Quadruple therapy, for toxoplasmic retinochoroiditis, 12.243
- Quality of care
 continuous improvement in
 data presentation in, 1.27–30, 1.28*f*, 1.29*f*
 other tools in, 1.30, 1.30*f*
 patient factors in, 1.27
- Quality/reliability of field, perimetry interpretation and, 10.62
- Quantitative (real-time) polymerase chain reaction (qPCR/RT-PCR), 2.141–142, 4.39*t*
- Quantum electrodynamics (QED)
 definition of, 3.92
 origins of, 3.95–96
 principles of, 3.96
 reflection, 3.96
 refraction, 3.96
- Quantum theory, 3.95*f*, 3.110
- Quetiapine, 1.194
- Quickert sutures, for involutional/spastic entropion, 7.203, 7.203*f*, 7.206
- Quinapril, 1.68*t*, 1.69*t*
- Quinidine, 1.113*t*
 for cardioversion, 1.114
- Quinine, 12.301
- Quinolones, 1.272, 1.277
- Quinupristin/dalfopristin, 1.273*t*
- Quixin. *See* Levofloxacin

R

R9AP gene, 12.49

RA. *See* Retinoic acid; Rheumatoid arthritis

Rab escort protein 1 (*REP-1/CHM*) gene mutation, 2.265

in choroideremia, 2.265

Rabies vaccination, 1.224

Rabies virus

corneal transplantation in transmission of, 8.240, 8.240*t*, 8.416*t*

ocular infection caused by, 8.240, 8.240*t*

Raccoon roundworm (*Baylisascaris procyonis*), 9.232, 12.246

Race. *See also* Ethnic background

age-related macular degeneration and, 12.62

angle-closure glaucoma and, 10.9, 10.117, 10.120

Behçet disease and, 9.182–183

cataract development and, 11.6

choroidal/ciliary body melanoma risk and, 4.262

complexion-associated melanosis and, 8.341

corneal thickness and, 10.81, 10.82, 10.90

dermal melanocytosis (nevus of Ota) and, 7.175

eyelid crease/fold and, 7.147, 7.147*f*

genetic disorders and, 2.196–197

glaucoma risk and, 10.7–8, 10.9, 10.81, 10.82, 10.120

hypertension and, 1.62, 1.78–79

multiple sclerosis and, 5.315

ocular melanocytosis and, 8.338

open-angle glaucoma and, 10.7–8, 10.81, 10.82

optic nerve/nerve head/disc size and, 10.48

pharmacogenetics and, 2.201

polypoidal choroidal vasculopathy and, 4.168, 12.75

pseudoexfoliation/exfoliation syndrome and, 10.93

sarcoidosis and, 5.327, 7.63, 9.167

sickle cell disease/hemoglobinopathies and, 1.139, 12.149, 12.154

SLE and, 9.133

spasmus nutans and, 5.239

systemic lupus erythematosus and, 12.230

Vogt-Koyanagi-Harada syndrome and, 4.186, 9.175–176, 9.177–178, 12.232

Racemose angioma/hemangioma (Wyburn-Mason syndrome/Bonnet-Dechaume-Blanc syndrome), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*

Racial melanosis (complexion-associated melanosis/CAM), 8.338*t*, 8.339*t*, 8.341, 8.341*f*

Radial axis index, skewed, in keratoconus/corneal ectasia, 8.32*t*, 8.165

Radial incisions

for intrastromal corneal ring segment placement, 13.64

for keratorefractive surgery, 13.27

for radial keratotomy, 13.50, 13.50*f*
traumatic rupture of, 13.52

Radial keratoneuritis/perineuritis, in *Acanthamoeba* keratitis, 4.79, 8.277

Radial keratotomy (RK), 13.8*t*, 13.49–53, 13.50*f*, 13.51*f*.

See also Keratorefractive surgery

aberrations after, 13.11, 13.12

additional refractive surgery and, 13.37

cataract surgery after, 11.79, 11.177, 13.52–53

IOL power calculation and, 11.86

complications of, 13.51*f*, 13.51–52

contact lens use after, 13.52, 13.199, 13.199*f*, 13.199–200

corneal topography after, 13.50–51

corneal transplantation/penetrating keratoplasty after, 13.52, 13.198

herpes simplex virus keratitis and, 13.174

hyperopic shift and, 11.177, 13.51

IOL power calculations after, 3.251, 13.51, 13.52–53, 13.193

iron lines associated with, 8.117

ocular surgery after, 13.52–53

refraction after, 13.50–51

stability of, 13.51

surgical technique for, 13.50, 13.50*f*

visual acuity after, 13.50–51, 13.51–52

Radial perineuritis/keratoneuritis, in *Acanthamoeba* keratitis, 4.79, 8.277

Radial peripapillary capillary network, 12.16

Radial perivascular lattice degeneration, 4.150

Radial thermokeratoplasty, 13.127

Radiance, 3.107, 3.107*t*, 3.109

Radiant energy, 3.107*t*

Radiant exitance, 3.108

Radiant flux, 3.107*t*

Radiant intensity, 3.107, 3.107*t*

Radiation exposure. *See also* Radiation therapy;

Ultraviolet (UV) light

anterior segment injury caused by, 8.385–386

cancer caused by, 1.228

cataracts caused by, 11.57–58

DNA repair after, 2.154

eye and adnexa affected by, 1.230–231

fetal exposure and, 1.230

in free-radical generation, 2.282, 2.283

ionizing, retinopathy caused by, 12.170*f*, 12.170–171

neuroimaging in evaluation of disorders caused by, 5.72*t*

primary vitreoretinal lymphoma treated with, 12.234

Radiation necrosis, 5.358

Radiation optic neuropathy (RON), 1.231, 5.358, 5.358*f*

Radiation retinopathy, 1.230–231, 12.170*f*, 12.170–171

Radiation surgery, 5.357

Radiation therapy (RT), 1.229–231, 5.357

for basal cell carcinoma of eyelid, 7.181

carcinogenic effects of, 1.228

for choroidal hemangioma, 4.283

for choroidal melanoma/ciliary body melanoma, 4.253, 4.275*f*, 4.275–276

complications of, 5.358, 5.358*f*

contracted socket and, 7.134

for infantile (capillary) hemangioma, 7.68

for iris melanoma, 4.261

for lacrimal gland tumors, 7.93

for lacrimal sac tumors, 7.287

for lymphoma, 4.312, 9.275

for metastatic eye disease, 4.310

neuro-ophthalmic complications of, 5.358, 5.358*f*

neuromyotonia after, 5.202, 5.358

ophthalmic considerations and, 1.230–231

for optic nerve glioma, 5.130, 7.77

- for optic nerve sheath meningioma, 5.128, 5.129, 7.81
- for orbital lymphoma, 7.89
- for retinal hemangioblastoma, 4.285
- for retinoblastoma, 4.301
 - secondary tumors and, 4.302, 4.302*t*
- retinopathy after, 1.230–231
- for rhabdomyosarcoma, 7.83, 7.84
- for thyroid eye disease, 7.59
- for uveal lymphoid proliferation/infiltration, 4.314
- Radiculitis, herpes infection and, 5.350
- Radioactive iodine (RAI)
 - for block-and-replace therapy in thyroid eye disease, 7.58
 - for hyperthyroidism, 1.53–54
 - nasolacrimal duct obstruction and, 7.278
 - for retinoblastoma, 4.301
 - for thyroid scanning, 1.52
 - thyroid uptake of, 1.52
 - for uveal melanoma, 4.275
- Radioactive iodine uptake (RAIU) test, 1.52
- Radioactive plaque therapy (brachytherapy), 1.229, 1.230
 - for choroidal hemangioma, 4.283
 - for choroidal melanoma/ciliary body melanoma, 4.253, 4.275*f*, 4.275–276
 - for iris melanoma, 4.261
 - for medulloepithelioma, 4.296
 - for metastatic eye disease, 4.310
 - for retinal hemangioblastoma, 4.285
 - for retinoblastoma, 4.301
- Radiofrequency
 - for conductive keratoplasty, 13.128, 13.128*f*
 - for punctal occlusion, 8.65
- Radiofrequency ablation
 - for atrial fibrillation/flutter, 1.114
 - of renal sympathetic nerves, for resistant hypertension, 1.75
 - for trichiasis, 7.208
- Radiography
 - chest. *See* Chest radiograph
 - in uveitis, 9.89*t*
- Radiometry, 3.92, 3.107*t*, 3.107–108, 3.110
- Radionuclide scintigraphy/scans
 - in ischemic heart disease, 1.97–98
 - for lacrimal drainage evaluation, 7.272
- Radiosurgery, 5.357
- Radius of curvature, corneal, 8.8, 8.27
 - in cornea plana, 8.100
 - instantaneous (meridional/tangential power), 13.16–17, 13.17*f*
 - keratometry in measurement of, 8.27. *See also* Keratometry/keratometer
 - in schematic eye, 3.127*t*
- Raeder paratrigeminal syndrome, 5.261
- Ragged red fibers, in chronic progressive external ophthalmoplegia, 5.328, 5.329*f*
- RAI. *See* Radioactive iodine
- Rainbow glare, after LASIK with femtosecond laser flap creation, 13.123–124
- Raindrop Near Vision Inlay, 13.28, 13.169
- RAIU. *See* Radioactive iodine uptake (RAIU) test
- Rake defects, 5.82, 5.82*f*
- Raltegravir, 1.266
- RAM. *See* Retinal Acuity Meter
- Ramipril
 - for heart failure, 1.110
 - for hypertension, 1.68*t*
- Ramsay Hunt syndrome, 5.280
- Random-Dot E test, 6.81
- Random-dot stereopsis tests, 6.81
- Randomization
 - in clinical trials, 1.4
 - selection bias and, 1.4
- Randot test, 6.81
- Range of accommodation, 3.140
- Ranibizumab, 2.372
 - bevacizumab and, comparison between, 12.83, 12.84*t*
 - branch retinal vein occlusion treated with, 12.135
 - central retinal vein occlusion treated with, 12.135
 - clinical trials of, 12.82*t*
 - diabetic macular edema treated with, 12.111–112, 12.112*f*
 - diabetic retinopathy treated with, 12.102
 - intravitreal administration of, 2.300*t*
 - for macular edema, 4.152
 - neovascular age-related macular degeneration treated with, 12.80–82, 12.82*t*
 - photodynamic therapy and, 12.85
 - proliferative diabetic retinopathy treated with, 12.104
 - retinal vein occlusion treated with, 12.135
 - for retinopathy of prematurity, 6.333
- Ranitidine, preoperative, 1.288
- RAP. *See* Retinal angiomatous proliferations
- RAPD. *See* Relative afferent pupillary defect
- Rapid-acting insulin, 1.41, 1.41*t*
 - in insulin pumps, 1.42
- Rapid plasma reagin (RPR) test, 1.248, 9.241, 12.241
- RAPs. *See* Retinal angiomatous proliferations
- ras oncogene, 2.156
- Rathke pouch, 2.113*f*
- Ray-deflection autorefractors, 3.289
- Ray-deflection principle, 3.282, 3.286
- Ray tracing
 - for concave mirrors, 3.82*f*, 3.83
 - for convex mirrors, 3.82*f*
 - definition of, 3.41
 - description of, 3.64–66, 3.65–66*f*
 - for Galilean telescope, 3.84*f*
 - for general optical system, 3.69*f*
 - for Keplerian telescope, 3.84*f*
 - mirrors and, 3.81, 3.82*f*
 - nodal points in, 3.67
 - for wavefront aberrations, 3.277
- Rayleigh scattering, 3.92, 3.97
- Raynaud phenomenon, 1.157*f*
 - cold-induced anterior segment trauma and, 8.385
 - in SLE, 1.157, 1.157*f*, 9.133
 - in systemic sclerosis, 1.162
- Rays, divergent. *See* Vergences/vergence system
- RB. *See* Reticulate body; Retinoblastoma
- RB1 (retinoblastoma) gene, 2.159, 2.192, 4.172–173, 4.253, 4.289–290, 6.354, 6.358
 - in pinealoblastoma, 4.298
 - in retinocytoma, 4.298
 - secondary malignancies and, 4.302
- Rb locus, 2.192. *See also* RB1 (retinoblastoma) gene

- RBCD. *See* Reis-Bücklers corneal dystrophy
- RBCs. *See* Red blood cells
- RCFM. *See* Retrocorneal fibrous membrane
- RCVS. *See* Reversible cerebral vasoconstriction syndrome
- RDH5* gene, 12.252
- RDS/peripherin (*PRPH2*) gene mutation, 2.161, 2.264
in pattern dystrophies, 4.170
in retinitis pigmentosa, 2.161, 2.264
in Stargardt disease, 4.168
- Reactive arthritis syndrome/Reiter syndrome, 1.154–155, 6.315*t*, 8.305–306, 9.115, 9.116*f*
conjunctivitis/episcleritis associated with, 8.305–306
HLA association in, 1.154, 9.65, 9.67*t*, 9.115
- Reactive lymphoid hyperplasia (RLH). *See also* Lymphoid hyperplasia
of conjunctiva, 4.69, 4.70*f*
of orbit, 4.231, 4.232, 7.86–88, 7.88
uveal. *See* Uveal lymphoid proliferation/infiltration/lymphoma
- Reactive nitrogen products, 9.22*t*, 9.29–30
- Reactive oxygen intermediates (ROIs), 2.281, 9.22*t*, 9.29.
See also Free radicals
- Reading-add power, 3.285
- Reading glasses, 3.320
- Reading tests, 3.318
- REAL (Revised European American Lymphoma) classification, 7.85, 7.86
- Real images, 3.41, 3.60–61
- Real objects
definition of, 3.41
virtual objects versus, 3.61
- Real-time quantitative polymerase chain reaction (RT-PCR/qPCR), 2.141–142, 4.39*t*
- Reattachment surgery. *See* Retinal detachment, surgery for
- Rebamipide, 2.342
- Rebif. *See* Beta (β)-interferon
- Rebleeding, after traumatic hyphema, 8.394, 8.394*f*, 10.104, 10.105
- Rebound headache, analgesic, 5.293
- Rebound hyperglycemia, 1.42
- Rebound hypertension, 1.79, 1.285
- Rebound nystagmus, 5.240–241
- Rebound tonometry, 10.26
in infants and children, 10.158
- Rebubbling, after endothelial keratoplasty, 8.438
- Recall bias, 1.11
- Receiver operating characteristic (ROC) curve
comparison of different screening devices and, 1.17–18, 1.18*f*
comparison of screening thresholds with continuous predictive variable and, 1.16–17, 1.17*f*
- Receptor agonist, 2.304
- Receptor antagonist, 2.304
- Receptor tyrosine-protein kinase *erbB-2*, in immunohistochemistry, 4.35
- Receptors, 2.240
adaptive immune, 9.33*f*, 9.34, 9.34*f*, 9.35, 9.35*f*, 9.37, 9.38
innate immune, 9.12
ocular drug interactions and, 2.304
in signal transduction, 2.316*t*
- Recession-resection procedures
definition of, 6.164*t*
of horizontal rectus muscles
description of, 6.139
for esodeviations, 6.160
monocular, 6.161
for nystagmus correction, 6.157
of inferior rectus muscle
description of, 6.29
eyelid position affected by, 6.173
of lateral rectus muscle
for Duane retraction syndrome, 6.134
for exodeviations, 6.160
for high myopia, 6.143
for intermittent exotropia, 6.102
for third nerve palsy, 6.139
for X-pattern strabismus, 6.113
of medial rectus muscle
for convergence insufficiency, 6.103
for Duane retraction syndrome, 6.133
for esotropia from nystagmus blockage syndrome, 6.155
for infantile esotropia, 6.89
for internuclear ophthalmoplegia, 6.144
for Möbius syndrome, 6.136
for nystagmus, 5.236, 5.237*f*
- Recessive inheritance (recessive gene/trait), 2.142, 2.173–174
autosomal, 2.174–177, 2.175*t*, 2.177*t*
disorders associated with, 2.142, 2.174–177, 2.175*t*
gene therapy for, 2.169
X-linked, 2.179, 2.180*t*
- Recessive optic atrophy, 6.368
- Recessive tumor-suppressor gene, *Rb* locus as, 2.192
- Recognition disorders, 5.178*t*, 5.179, 5.180*f*
- Recombinant, definition of, 2.142
- Recombinant DNA, 2.143
- Recombinant tissue plasminogen activator (rtPA). *See* Tissue plasminogen activator
- Recombination, 2.134, 2.143
- Recombination frequency, 2.160
- Recombivax HB (hepatitis B vaccine), 1.219
- Reconstructive surgery
for canalicular obstruction, 7.275
eyelid, 7.191–196, 7.193*f*, 7.194*f*. *See also* Eyelids, surgery/reconstruction of
after basal cell carcinoma surgery, 7.180, 7.181
for blepharophimosis-ptosis-epicanthus inversus syndrome, 7.155
for coloboma, 7.161
for epicanthus, 7.159
for euryblepharon, 7.157–158
for eyelid defects involving eyelid margin, 7.188*f*, 7.188–189, 7.192–195, 7.193*f*, 7.194*f*
for eyelid defects not involving eyelid margin, 7.187–188, 7.191–192
lateral canthal defects and, 7.195
for lower eyelid defects, 7.192–195, 7.194*f*
medial canthal defects and, 7.195–196
after Mohs micrographic surgery, 7.181
principles of, 7.191
priorities in, 7.191

- secondary repair after trauma and, 7.189–190
- for upper eyelid defects, 7.192, 7.193*f*
- socket, 7.134, 7.136. *See also* Anophthalmic socket
- Recoverin (CAR antigen), 2.260*f*, 2.261, 5.102
- Recruitment, 6.33
- Rectal examination, in cancer screening, 1.210*t*
- Rectus muscles, 2.9*f*, 2.13, 2.13*f*, 2.14*f*, 2.15*t*, 2.16*f*, 2.20*f*, 5.8*f*, 5.45, 5.46*f*, 7.11, 7.12*f*, 7.13*f*, 7.14*f*, 7.15*f*, 7.146*f*.
See also specific muscle
- anatomy of, 2.9*f*, 2.13*f*, 2.14*f*, 2.16*f*, 2.20*f*, 5.8*f*
- blood supply of, 2.15*t*, 2.17, 2.33*f*, 2.34*f*
- capsule of, 6.26
- entrapment of, in orbital floor/blowout fracture, 7.108, 7.109–110
- horizontal. *See also* Lateral rectus (LR) muscle; Medial rectus (MR) muscle
- anatomy of, 6.20, 6.35*f*
- inferior zone of, 6.24
- innervation of, 6.34
- in pattern strabismus, 6.109–110
- primary position of, 6.35, 6.35*f*
- recession/resection of
- description of, 6.139
- for esodeviations, 6.160
- monocular, 6.161
- for nystagmus correction, 6.157
- superior zone of, 6.24
- transposition of, 6.110, 6.112
- horizontal gaze and, 5.37*f*, 5.38
- innervation of, 2.17, 2.94, 2.94*f*, 2.95, 5.38, 5.44, 5.44*f*, 6.24, 7.12, 7.14*f*, 7.15*f*
- insertion of, 2.13–15, 2.14*f*, 2.15*t*, 6.22, 6.23*f*
- optic nerve and, 2.87
- origins of, 2.15*t*, 2.16–17
- posterior fixation of, 6.164*t*, 6.167
- pulley system for, 6.28
- “restrained shortest-path model” of, 6.28
- surgery of
- eyelid position changes after, 7.222, 7.223
- for orbital floor/blowout fracture, 7.110, 7.111
- in thyroid eye disease, 4.226, 5.206, 7.25, 7.54
- tightening procedures for, 6.163–164, 6.164*t*
- vertical. *See also* Inferior rectus (IR) muscle; Superior rectus (SR) muscle
- anatomy of, 6.20, 6.22*f*
- eyelid attachments to, 6.30*f*
- insertion of, 6.22
- surgery of
- for nystagmus, 6.156
- for pattern strabismus correction, 6.111
- vertical strength of, 6.35
- weakening procedures for, 6.163, 6.164*t*
- Recurrent corneal erosion, 8.79, 8.86–88
- dystrophic, 8.86, 8.87, 8.133, 8.135*t*
- in epithelial basement membrane dystrophy, 8.86, 8.87, 8.133, 8.138
- in lattice corneal dystrophy type 1, 8.147
- in Reis-Bücklers corneal dystrophy, 8.143
- management of, 8.368
- pain caused by, 5.295, 8.86, 8.87
- posttraumatic, 8.86, 8.87
- Recurrent erosion corneal dystrophies (EREDs), 8.86, 8.87, 8.133, 8.135*t*. *See also* Recurrent corneal erosion
- Recurrent meningeal artery, 5.14, 5.14*f*, 5.15*f*
- Recurrent multifocal choroiditis (RMC). *See* Multifocal choroiditis
- Recurrent painful oculomotor neuropathy, 5.197
- Recurrent pterygia, 4.57, 8.351, 8.352, 8.353, 8.353*t*, 8.355
- Recurrent uveitis, 9.73*t*, 9.78, 9.113
- equine, 9.63
- Red blood cells (RBCs/erythrocytes), 1.135
- in anemia, 1.136
- hemolytic anemia, 1.138
- development of, 1.135–136
- Red cell distribution width, in anemia, 1.136
- Red comparison test, in confrontation testing, 5.84
- Red cones. *See* L cones
- Red eye. *See* Conjunctival hyperemia/congestion; Conjunctivitis
- Red-glass test, 6.51, 6.75–76, 6.76*f*
- Red-green color vision, 2.262
- defects in
- gene defects causing, 2.262–263
- ocular findings in carriers of, 2.199*t*
- screening/testing for, 5.78. *See also* Red-green test deficiency
- anomaloscope of, 12.54
- types of, 12.54
- Red-green dyschromatopsia, 6.368
- Red-green test, duochrome/bichrome/Worth 4-dot
- in nonorganic disorder evaluation
- monocular no light perception and, 5.303, 5.304*f*
- monocular reduced vision and, 5.305
- before refractive surgery, 13.39
- Red laser, 12.374
- Red Maddox rod, 5.184, 5.184*f*. *See also* Maddox rod/ Maddox rod test
- “Red-man syndrome,” 2.352
- Red nucleus, 5.18*f*, 5.34*f*, 5.35*f*, 5.41*f*, 5.55*f*
- in Benedikt syndrome, 5.191
- Red perception testing, for relative afferent pupillary defect, 5.81
- Red reflex. *See also* Retinal reflex
- in complete cataract, 11.38
- after ECCE, 11.198
- in keratoconus, 8.163
- in lenticonus/lentiglobus, 4.118, 11.30
- media opacity effects on, 6.68
- poor, cataract surgery and, 11.178–179, 11.179*f*
- refractive error effects on, 6.68
- testing of
- in children, 6.9
- ocular alignment assessments using, 6.67–68
- Red target test, kinetic, in confrontation testing, 5.83
- Reduced schematic eye, 3.124, 3.126
- Reduced vergence
- definition of, 3.41, 3.51
- intraocular power and, 3.247
- Reduction division, in meiosis, 2.139
- Reese-Ellsworth Classification for Intraocular Tumors, 6.354
- retinoblastoma and, 4.297
- Reference genomes, 2.143
- Reference sphere
- definition of, 3.41, 3.70, 3.70*f*
- in wavefront analysis, 3.274, 3.274*f*

- Refixation movements, microsaccadic, 5.213
- Reflection
- description of, 3.96
 - law of
 - definition of, 3.40
 - description of, 3.80–81
 - vergence equation for mirrors derived from, 3.88–89, 3.89f
 - light, specular, for slit-lamp biomicroscopy, 8.17f, 8.17–18, 8.19f
 - total internal, 3.42, 3.50, 3.50f
- Reflex. *See specific type*
- vestibular-ocular. *See Vestibular-ocular system/ vestibular-ocular reflex*
- Reflex arc, neural, immune response arc compared with, 9.32, 9.33f
- Reflex blepharospasm, 5.281, 7.227
- Reflex secretors, 2.217
- Reflex tear arc, 2.101f, 7.251, 7.252f
- Reflex tearing, 2.104, 2.217
- absorption of ocular medication affected by, 2.295, 2.298
 - initiation of, 2.126, 2.217
 - parasympathetic nerves and, 2.104, 5.56
 - tests of, 8.39
- Reflexive saccades, 5.219, 5.220
- in progressive supranuclear palsy, 5.221
- Refractec system. *See Conductive keratoplasty*
- Refractile bodies/spots, in papilledema, 5.110, 5.110f
- Refracting power, 8.27. *See also Refractive power*
- in IOL power determination, 11.84
- Refracting systems
- axial (longitudinal) magnification, 3.63–64
 - composition of, 3.58
 - conjugate points, 3.64
 - Gaussian optics, 3.60
 - general, 3.58–67
 - nodal points, 3.66–67, 3.67f
 - ray tracing, 3.64–66, 3.65–66f
 - transverse magnification, 3.62
- Refraction. *See also Refractive errors*
- bifocal lenses. *See Bifocal lenses*
 - in children, glaucoma and, 10.158
 - clinical
 - in cataract
 - nonsurgical management and, 11.71
 - before surgery/IOL power determination, 11.76
 - cycloplegic, before refractive surgery, 13.40
 - laser programming and, 13.40, 13.81
 - in glaucoma evaluation, 10.29
 - in children and adolescents, 10.158
 - in low vision/vision rehabilitation, 5.78
 - manifest (noncycloplegic). *See Refraction, clinical, noncycloplegic (manifest)*
 - noncycloplegic (manifest)
 - after penetrating keratoplasty, 8.431–432, 8.432f
 - refractive surgery and, 13.39, 13.40
 - IOL power calculation and, 13.194, 13.195
 - laser programming and, 13.40, 13.81
 - objective (retinoscopy). *See Retinoscope/ retinoscopy*
 - in ptosis, 7.211–212
 - after radial keratotomy, 13.50–51
 - stability of, 13.51
 - after refractive surgery, IOL power calculation and, 13.194
 - before refractive surgery, 13.38, 13.39–40
 - for accommodative esotropia, 13.188
 - IOL power calculation and, 13.194
 - laser programming and, 13.31, 13.40, 13.81
- cycloplegic, 3.168–169
- definition of, 3.21, 3.96
- description of, 3.96
- exam room length for, 3.149–150
- goal of, 3.34
- instruments for, 3.283–292
- law of (Snell's law), 8.26
- low vision, 3.314
- manifest. *See Manifest refraction*
- minus cylinder, 3.148–149
- at near, 3.36–38
- noncycloplegic, 3.168–169
- overrefraction, 3.169
- plus cylinder, 3.148–149
- pseudoneutralization, 3.159–160
- purpose of, 3.148
- recommendations for, 3.38
- retinoscopy. *See Retinoscope/retinoscopy*
- single curved surface, 3.51–54
- subjective. *See Subjective refraction*
- terminology associated with, 3.148–149
- “Refraction operator,” 3.60
- Refractive accommodative esotropia, 6.90–92
- Refractive amblyopia, 3.175, 6.54–55
- Refractive ametropia, 3.137, 3.257
- Refractive errors. *See also Ametropia; specific type*
- accommodation in progression of, 3.144
 - age-based prevalence of, 3.142f
 - astigmatic. *See Astigmatism*
 - axial, correction of, 3.12–13
 - in cornea plana, 8.96f, 8.100, 8.101
 - correction/treatment of. *See also Contact lenses; Intraocular lenses (IOLs), for refractive errors; Refractive surgery; Spectacle lenses*
 - in amblyopia, 6.57–58
 - in intermittent exotropia, 6.101
 - from lens dislocation, 6.310
 - options for, 3.144
- epidemiology of, 3.141f, 3.141–142
- extraocular muscle surgery effects on, 6.173–174
- in glaucoma, 10.9, 10.29, 10.122, 10.166
- headaches and, 3.25
- initial estimate of, 3.27f, 3.27–29
- myopia. *See Myopia*
- optical principles/wavefront analysis and, 13.9–13, 13.10f, 13.11f, 13.12f, 13.13f
- after penetrating keratoplasty, 8.431–432, 8.432f
- perimetry results affected by, 10.60
- postoperative
- overcorrection and, 13.101–102, 13.108–109
 - re-treatment/enhancements and, 13.97–100, 13.99f
 - undercorrection and, 13.102, 13.108
- postsurgical, 3.255
- prevention of, 3.144

- in ptosis, 7.211–212
- red reflex affected by, 6.68
- unexpected, after cataract surgery, 11.86, 11.149–150
- Refractive index
 - of air, 8.26
 - of aqueous, 8.26
 - of cornea, 8.8, 8.26
 - definition of, 3.4, 3.41
 - description of, 3.43–44
 - dispersion effects on, 3.45
 - equation for, 3.43
 - errors in, 3.252
 - of lens, 11.11
 - in schematic eye, 3.127*t*
 - of spectacle lens materials, 3.194
 - of tear (fluid) lens, 3.220, 8.26
- Refractive keratotomy. *See* Keratotomy
- Refractive lens exchange (RLE), 13.8*t*, 13.137, 13.147–151
 - advantages of, 13.147
 - for astigmatism, 13.148–149
 - complications of, 13.151
 - disadvantages/limitations of, 13.47*t*, 13.147
 - for hyperopia, 13.148, 13.150
 - indications for, 13.147
 - informed consent for, 13.147–148
 - IOL power calculations in, 13.150
 - for myopia, 13.148, 13.150
 - patient selection for, 13.147–149
 - for presbyopia, 13.149
 - retinal detachment and, 13.148
 - surgical planning/techniques for, 13.149–150
- Refractive lenticule extraction (ReLEx), 13.8*t*, 13.27, 13.203–206
 - complications of, 13.205
 - indications and preoperative evaluation for, 13.204
 - LASIK compared with, 13.206
 - outcomes of, 13.205
 - re-treatment and, 13.206
 - surgical technique for, 13.204–205
- Refractive multifocal intraocular lenses, zonal, 13.166, 13.166*f*. *See also* Multifocal lenses, intraocular
- Refractive power. *See also* Transverse magnification
 - of cornea, 8.25–26, 13.7–9
 - measurement of, 8.26–27, 8.27*f*, 13.7–9. *See also* Keratometry/keratometer
 - in schematic eye, 3.127*t*
 - of schematic eye, 3.127*t*
- Refractive procedure–induced diplopia, 5.209
- Refractive states, 6.180*f*, 6.180–181. *See also* Refractive errors
 - ametropia, 3.136–137, 3.137*f*
 - astigmatism. *See* Astigmatism
 - emmetropia, 3.136, 3.137*f*
 - far point concept of, 3.136
 - focal point concept of, 3.136
 - spherical equivalent of, 3.139
- Refractive surgery, 13.7, 13.8*t*. *See also* Keratorefractive surgery; Ocular (intraocular) surgery, refractive; *specific procedure*
 - abbreviations and acronyms used in, 13.3–5
 - amblyopia/anisometropic amblyopia and, 13.185–187
 - astigmatism and
 - corneal topography in detection/management of, 8.32, 13.18–19, 13.22–23, 13.44, 13.45, 13.45*f*
 - penetrating keratoplasty and, 13.178–180
 - in autoimmune disease, 13.191
 - cataract/cataract surgery and, 11.123–124, 11.176–177, 11.177*f*, 13.43–44
 - IOL power calculation and, 11.85–87, 11.176, 11.177*f*, 13.44, 13.194
 - preoperative evaluation/planning and, 11.76, 11.79
 - in children, 13.187–188
 - in collagen vascular/connective tissue diseases, 13.37, 13.171, 13.191
 - contact lens use after, 13.198–200, 13.199*f*
 - contraindications to
 - corneal topography in identification of, 13.23, 13.24–26, 13.25*f*
 - in ocular and systemic disease, 13.171
 - corneal, 13.7, 13.8*t*. *See also* Keratorefractive surgery; Photoablation
 - collagen shrinkage, 13.8*t*, 13.28, 13.28*f*, 13.127–129, 13.128*f*, 13.129*f*
 - corneal crosslinking, 13.8*t*, 13.130–135, 13.131*f*, 13.133*f*, 13.133*t*
 - incisional, 13.8*t*, 13.26–27, 13.27*f*, 13.49–58
 - inlays/onlays, 13.59–71, 13.169
 - photoablation, 13.29–32, 13.30*f*, 13.73–74, 13.74–75*f*, 13.101–126
 - corneal biomechanics affected by, 13.13–14
 - corneal imaging/evaluation and, 13.14–26, 13.44–45, 13.45*f*. *See also* Cornea, topography of; *specific type*
 - indications for, 13.22–24, 13.23*f*, 13.24*f*
 - postoperative, 13.23*f*, 13.23–24, 13.24*f*
 - preoperative, 13.14–26, 13.44–45, 13.45*f*, 13.79–80
 - corneal optics and, 13.7–9
 - corneal shape and, 13.9
 - corneal topography and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79. *See also* Cornea, topography of
 - astigmatism and, 8.32, 13.18–19, 13.22–23, 13.44, 13.45, 13.45*f*
 - dry eye and, 13.173
 - indications for, 13.22–23, 13.23*f*, 13.24*f*
 - postoperative evaluation and, 13.23*f*, 13.23–24, 13.24*f*
 - preoperative evaluation and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79–80
 - refractive lens exchange and, 13.149
 - toric IOLs and, 13.151–152
 - after corneal transplant, 13.37, 13.178–180
 - corneal transplant after, 13.197–198
 - in diabetes mellitus, 13.37, 13.190–191
 - diplopia caused by, 5.209
 - donor cornea suitability and, 8.414
 - emerging technologies in, 13.203–208
 - excimer laser, 13.8*t*, 13.29, 13.73–77, 13.74–75*f*
 - glaucoma/ocular hypertension and, 13.180–183, 13.182*f*, 13.200–201
 - herpes simplex virus infection and, 13.173–174
 - in HIV infection/AIDS, 13.188–190

- incisional, 13.8*t*, 13.26–27, 13.27*f*, 13.49–58
 for astigmatism, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*, 13.57*f*
 corneal effects of, 13.9, 13.26–28, 13.27*f*, 13.28*f*
 for myopia, 13.49–53, 13.50*f*, 13.51*f*
 induced anisophoria corrected using, 3.190
 informed consent for, 13.36*t*, 13.46–48, 13.47*t*
 instrument error after, 3.251–252
 intraocular procedures in, 13.7, 13.8*t*, 13.137–157.
 See also Ocular (intraocular) surgery,
 refractive
 with keratorefractive (corneal) surgery (bioptics),
 13.137, 13.157
 IOL power calculations after, 3.251–253, 13.44,
 13.193–197, 13.196*f*
 iron lines associated with, 8.117
 irregular astigmatism and, 13.18–19, 13.22–23, 13.44,
 13.45
 keratoconus and, 13.23, 13.24, 13.25*f*, 13.38, 13.42–
 43, 13.44, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*.
 See also Keratoconus
 keratometric power measurements affected by,
 13.193
 laser biophysics and, 13.29–32, 13.30*f*
 lenticular. *See specific procedure*
 limitations of procedures used in, 13.47*t*
 medical history and, 13.36*t*, 13.37
 monovision and, 13.39, 13.164–165
 in ocular and systemic disease, 13.171–191. *See also*
 specific disorder
 ocular history and, 13.36*t*, 13.37–38
 optical considerations/principles in, 13.9–13, 13.10*f*,
 13.11*f*, 13.12*f*, 13.13*f*
 overview of procedures used in, 13.7, 13.8*t*
 patient age and, 13.38–39
 patient evaluation for, 13.35–48, 13.36*t*. *See also*
 Refractive surgery, preoperative evaluation for
 after penetrating keratoplasty, 8.432, 13.37,
 13.178–180
 penetrating keratoplasty after, 13.197–198
 postoperative considerations and, 13.193–201
 contact lens use after, 13.198–200, 13.199*f*
 corneal imaging and, 13.23*f*, 13.23–24, 13.24*f*
 corneal transplantation after, 13.197–198
 glaucoma and, 13.200–201
 IOL power calculations and, 13.193–197,
 13.196*f*
 retinal detachment repair after, 13.197
 preoperative evaluation for, 13.35–48, 13.36*t*
 corneal imaging/ancillary tests and, 13.14–26,
 13.44–46, 13.45*f*, 13.79–80. *See also* Cornea,
 topography of; *specific type*
 discussion of findings/informed consent and,
 13.36*t*, 13.46–48, 13.47*t*
 history and, 13.35–39, 13.36*t*
 ocular examination and, 13.36*t*, 13.39–44, 13.42*f*,
 13.43*f*
 patient expectations/motivations and, 13.35–36,
 13.36*t*, 13.47
 in presbyopia, 13.38–39, 13.159–170
 after radial keratotomy, 13.52
 retinal disease/detachment and, 13.44, 13.183–185,
 13.197
 science of, 13.7–33
 social/occupational history and, 13.36*t*, 13.36–37
 strabismus and, 13.41, 13.185–187
 wavefront aberrations/analysis and, 13.9–13, 13.10*f*,
 13.11*f*, 13.12*f*, 13.13*f*, 13.31, 13.46
 postoperative, 13.102–103, 13.103*f*
 Refractor. *See* Phoropter
 Refsum disease/syndrome (phytanic acid storage
 disease), 2.175*t*, 6.389*t*, 12.283*t*, 12.286, 12.290
 gene defects causing, 2.265, 2.266
 infantile, 2.175*t*
 gene defects causing, 2.265, 2.266
 Regeneration, 4.13. *See also* Wound healing/repair
 aberrant nerve. *See* Aberrant nerve regeneration
 Regional anesthesia, 2.362*t*, 2.362–366. *See also*
 Anesthesia (anesthetics), local
 for anterior segment surgery, 2.365–366
 cholinesterase inhibitor use and, 2.312, 2.363
 Regional enteritis (Crohn disease), 1.155, 9.116
 Regional immunity, 9.53, 9.54*t*. *See also* Immunologic
 microenvironments
 Registration, for laser centration, 13.91, 13.91*f*
 Regression formulas, for IOL power determination/
 selection, 11.85–87
 Regular astigmatism, 3.124, 3.139, 3.276
 corneal topography in detection/management of,
 13.17, 13.18*f*
 wavefront aberrations produced by, 13.11, 13.11*f*
 Regular/short-acting insulin, 1.41*t*
 Regulatory (Treg/suppressor) T cells, 9.34, 9.36*f*, 9.37,
 9.38. *See also* T cells
 in corneal transplant tolerance, 8.316
 in external eye defense, 8.12–13*f*, 8.13, 8.14
 in immune processing, 9.36*f*, 9.37, 9.38
 MHC molecules as antigen-presenting platform for,
 9.34*f*, 9.34–36, 9.35*f*
 in sympathetic ophthalmia, 9.48
 Rehabilitation. *See* Vision rehabilitation
 Reichert Phoropter, 3.173
 Reis-Bücklers corneal dystrophy (RBCD/CDB1/atypical
 granular corneal dystrophy), 4.88, 4.88*f*, 4.91*t*,
 8.135*t*, 8.136*t*, 8.142*f*, 8.142–143
 Reiter syndrome/reactive arthritis, 1.154–155,
 8.305–306, 9.115, 9.116*f*
 conjunctivitis/episcleritis associated with,
 8.305–306
 HLA association in, 1.154, 9.65, 9.67*t*, 9.115
 Rejection (corneal transplant), 4.84, 4.85*f*, 8.316–318,
 8.428–431, 9.59, 9.60, 9.60*f*
 after endothelial keratoplasty (DMEK/DSEK), 8.437*t*,
 8.447*f*, 8.447–448
 after lamellar keratoplasty, 8.411, 8.435, 8.435*f*
 after penetrating keratoplasty, 8.316–318, 8.428–431,
 8.437*t*, 9.59, 9.60, 9.60*f*
 prevention of, 8.430–431
 treatment of, 8.429–430
 transplantation antigens and, 9.60
 Rejuvenation surgery, facial, 7.241–247, 7.242*f*, 7.243*f*,
 7.244*f*, 7.245*f*, 7.246*f*. *See also* Facial surgery; *specific*
 procedure
 Relapsing polychondritis, 1.164
 eyelid manifestations of, 4.207*t*
 Relapsing-remitting multiple sclerosis, 5.315

- Relative afferent pupillary defect (RAPD/Marcus Gunn pupil), 5.253
 in acute idiopathic blind-spot enlargement/
 acute zonal occult outer retinopathy/multiple
 evanescent white dot syndrome, 5.101
 cataract surgery in patient with, 11.78
 in NAION, 5.122
 in ocular trauma, 8.401
 in optic neuropathy versus maculopathy, 5.81, 5.99,
 5.100*t*
 in optic tract syndrome, 5.153
 testing for, 5.79*f*, 5.79–81
 in glaucoma evaluation, 10.30
 nonorganic disorders and, 5.302
- Relative risk, 1.21, 1.208, 9.66
 baseline probability of the outcome and, 1.21–22
- Relatives, first-degree/second-degree, 2.143
- Relaxation, in MRI, 5.75
- Relaxation times, in MRI, 5.62, 5.63*t*, 5.76, 7.28
- Relaxing incisions
 for anterior capsule contraction, 11.154*f*, 11.156
 for corneal astigmatism after penetrating keratoplasty,
 8.432
- limbal (LRIs), 13.8*t*, 13.27*f*, 13.53–54, 13.54*f*,
 13.54–58, 13.55*f*, 13.56*f*, 13.56*t*, 13.57*f*
 cataract surgery and, 11.123–124
 complications of, 13.58
 instrumentation for, 13.55, 13.56*f*
 ocular surgery after, 13.58
 outcomes of, 13.57
 refractive lens exchange and, 13.149
 technique for, 13.55–57, 13.56*t*, 13.57*f*
- Relentless placoid chorioretinitis (ampiginous
 chorioiditis), 9.150–151, 9.151*f*
- ReLEX. *See* Refractive lenticule extraction
- Reliability
 measurement system, 1.24
 outcome, 1.5–6
- Relocation of images, 3.62
- Remodeling pathway, platelet-activating factors in, 9.26
- Renal cell carcinoma, metastatic eye disease and, 4.304*t*
- Renal coloboma syndrome, dysplastic optic nerve and,
 5.145
- Renal disease
 contrast agents contraindicated in, 5.60
 diabetes mellitus/diabetic retinopathy and, 1.38, 1.48.
 See also Diabetic retinopathy
 in granulomatosis with polyangiitis (Wegener
 granulomatosis), 9.137
 hypertension management and, 1.66, 1.69*t*, 1.76
 in microscopic polyangiitis, 1.168
 in polyarteritis nodosa, 9.136
 retinal degeneration associated with, 12.285
 in SLE, 1.157, 9.133
 in systemic sclerosis, 1.163
 vancomycin dose adjustments in, 2.352
- Renal failure
 anemia caused by, 1.137
 in diabetes mellitus, 1.48
- Renal metabolic acidosis, carbonic anhydrase inhibitors
 causing, 2.325–326
 aspirin interactions and, 2.336
- Renal transplantation, for cystinosis, 2.203
- Rendu-Osler-Weber disease (hereditary hemorrhagic
 telangiectasia), 1.142, 1.143
- Renin-angiotensin-aldosterone system, in hypertension,
 1.63, 1.63*f*
- Renin inhibitors, for hypertension, 1.68*t*, 1.74
- Renovascular hypertension, 1.64, 1.64*t*
- Renu with MoistureLoc contact lens solution, *Fusarium*
 keratitis and, 8.274
- REP-1 (Rab escort protein 1/*CHM*) gene mutation,
 2.265
 in choroideremia, 2.265
- Repaglinide, for diabetes mellitus, 1.45*t*, 1.46
- Repair, 4.13. *See also* Wound healing/repair
- Reparative (stimulated/inflammatory) macrophages,
 9.19, 9.20*f*, 9.21
- Repeat element/sequence, Alu, 2.150
- Reperfusion
 for angina, 1.99–100
 for cerebral ischemia/stroke, 1.122–123
 for ST-segment elevation acute coronary syndrome,
 1.94, 1.104–105
- Repetitive nerve stimulation, electromyographic, in
 myasthenia gravis, 5.326
- Replication, DNA, 2.143
- Replication slippage, 2.143
- Replicative segregation, 2.143, 2.157
- Reproducibility
 in clinical study, 1.5
 test-retest reliability and, 1.24
- Reproductive issues, genetic counseling and, 2.206–207
- Rescue breathing, 1.297*f*, 1.298
 face shield/mask for, 1.298, 1.299
- Rescue percutaneous coronary intervention, 1.104
- Rescula. *See* Unoprostone
- Research studies. *See* Clinical research/studies;
 Experimental (interventional) studies
- Resection. *See* Recessio-resection procedures
- Reserpine, 1.68*t*, 1.69*t*, 1.73
- Residence time (of medication), 2.295
- Residual stromal bed (RSB), thickness of, LASIK and,
 13.30, 13.45–46, 13.79–80
 calculation of, 13.46, 13.79
 corneal perforation and, 13.111
 ectasia and, 13.79, 13.124
- Resistance (drug). *See also specific agent and specific
 organism*
 antibiotic, 1.272–274, 2.343, 2.346, 2.351, 2.352, 2.353
 new drugs/drug classes and, 1.239, 1.280
 antiretroviral, 1.264
 antiviral, 2.358, 2.360
 in tuberculosis, 1.255, 1.269, 9.254
- Resistance (vascular), reduction of, in heart failure
 management, 1.109
- Resistance factor, corneal (CRF), 8.43
- Resistant hypertension, 1.64*t*, 1.64–65, 1.75
- Resolution
 minimum angle of (MAR), logarithm of (logMAR),
 cystoid macular edema after cataract surgery and,
 11.164
 pupil size effects on, 3.129–131
- Resolving power. *See* Transverse magnification
- Resonator cavity, 3.111
- Respiratory disorders. *See* Pulmonary diseases

- Respiratory failure. *See* Ventilatory failure
- Response accommodative convergence/accommodation (AC/A) ratio, 6.71. *See also* Accommodative convergence/accommodation (AC/A) ratio
- Restasis. *See* Cyclosporine/cyclosporine A, topical
- Restimulation, of effector lymphocytes, 9.38
- Resting macrophages, 9.19–20, 9.20f
- Resting neutrophils, 9.16
- “Restrained shortest-path model,” 6.28
- Restriction endonucleases, 2.135
- Restriction fragment length polymorphisms (RFLPs), 2.162
- Restrictive pulmonary diseases, 1.130–131
- Restrictive strabismus, Hering’s law of motor correspondence and, 6.38
- Restrictive syndromes, diplopia caused by, 5.186, 5.206–209, 5.207f
- paretic syndromes differentiated from, 5.186, 5.186f
- postsurgical, 5.207
- posttraumatic, 5.186, 5.206
- Resuscitation. *See* Cardiopulmonary resuscitation
- RET* gene, in multiple endocrine neoplasia, 8.200
- Retained lens material, cataract surgery and, 11.140–141, 12.391–393, 12.392f
- Reteplase, for ST-segment elevation acute coronary syndrome, 1.105
- Reticular degenerative (bullous) retinoschisis, 4.148, 12.326, 12.327
- Reticular formation
- mesencephalic (MRF), 5.35f
- paramedian pontine (PPRF), 2.102, 2.102f, 5.33, 5.35, 5.35f, 5.219
- horizontal gaze and, 5.36, 5.37, 5.37f
- in one-and-a-half syndrome, 5.191
- saccades generated by, 5.219–220, 5.221
- Reticular peripheral cystoid degeneration (RPCD), 4.148, 4.149f, 12.326
- Reticular pseudodrusen (RPD/subretinal drusenoid deposits), 4.162, 4.163, 4.163f, 4.171f, 12.65f, 12.65–66
- Reticular-type pattern dystrophy, 12.276, 12.276f
- Reticulate body (RB), 8.249
- Reticulum cell sarcoma. *See* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma; Primary vitreoretinal lymphoma
- Retina, 2.37f, 2.38, 2.67–75, 2.257–269, 4.139–180, neovascularization of; Retinal disease, vascular, vascular abnormalities/vascularization of. *See* Retina. *See also under* Retinal
- anatomy of, 2.37f, 2.38, 2.67–75, 2.68f, 2.70f, 2.71f, 2.72f, 2.74f, 2.76f, 2.257, 2.258f, 4.139–140, 4.140f, 4.141f, 5.17f, 5.23–25, 5.24f, 5.25f
- angiography in examination of. *See* Fluorescein angiography; Indocyanine green (ICG) angiography
- angiomas of, 12.168
- antioxidants in, 2.286–288, 2.289f
- arteriovenous anastomoses/malformations in, in Takayasu arteritis, 1.166
- astrocytic hamartoma of, 4.295, 4.296f
- optic nerve/nerve head/disc drusen differentiated from, 5.108f, 5.143
- retinoblastoma differentiated from, 4.295, 4.296f
- atrophy of
- gyrate, 2.175t
- ischemia causing. *See also* Retinal ischemia in diabetic retinopathy, 4.159
- in retinal arterial and venous occlusions, 4.156, 4.159
- biochemistry and metabolism of, 2.257–269
- in birdshot uveitis, 9.141–143t, 9.144–147, 9.145f, 9.146f
- blood supply of, 12.140. *See also* Retinal blood vessels
- capillary hemangioblastoma of, 4.283–285, 4.284f. *See also* Retinal angiomas
- cavernous hemangioma of, 4.285f, 4.285–286
- circulation of, 12.16f, 12.16–17
- combined hamartoma of the retina and retinal pigment epithelium, 6.350
- congenital disorders of, 4.142f, 4.142–145, 4.143f, 4.144f, 4.145f
- degenerations of. *See* Retinal degenerations
- detachment of. *See* Retinal detachment
- development of, 2.115, 2.116t, 2.117f, 2.119f, 2.122–124, 2.123f, 2.257
- melanin in, 2.278
- diabetes mellitus affecting. *See* Diabetic retinopathy
- disorders of. *See* Retinal disease; Retinopathy; *specific type*
- drug-induced toxicity of
- alkyl nitrites, 12.300, 12.300f
- chloroquine derivatives, 12.295–297, 12.296f
- clofazimine, 12.298
- deferoxamine, 12.298–299
- dideoxyinosine, 12.299
- hydroxychloroquine, 12.295–297, 12.296f
- MEK inhibitors, 12.299, 12.299f
- nucleoside reverse transcriptase inhibitors, 12.299
- phenothiazines, 12.297–298, 12.298f
- dystrophies of. *See* Retinal dystrophies
- edema of. *See* Retinal edema
- electro-oculography of, 12.50–51, 12.51–52f
- electrophysiology of, 2.268–269, 2.269f, 12.41–42. *See also specific test*
- electroretinography of. *See* Electroretinography/electroretinogram (ERG)
- emboli in, 5.166t. *See also* Emboli
- transient visual loss caused by, 5.161, 5.162, 5.165, 5.165f, 5.165–169, 5.166t
- equatorial, 12.9–10
- examination of
- before cataract surgery, 11.80–81
- imaging in. *See* Retina, imaging techniques in evaluation of
- before refractive surgery, 13.44, 13.183
- free radicals affecting, 2.285–286
- gliosis of, 4.157, 4.158, 4.158f
- of peripapillary nerve fiber layer, 5.5, 5.109
- in granulomatosis with polyangiitis (Wegener granulomatosis), 9.138, 9.138f
- growth and development of, 6.182, 6.325
- gyrate atrophy of, 2.175t
- hamartomas of, 4.179, 4.180f, 4.280, 4.280f
- optic nerve/nerve head/disc drusen differentiated from, 5.108f, 5.143
- healing/repair of, 4.17

- hemangioblastomas of, 4.283–285, 4.284f
 in von Hippel–Lindau syndrome, 5.330, 5.331f, 5.334t, 12.165–166, 12.166f, 12.168
- histologic sequelae of trauma to, 4.18–20, 4.20f
- in HIV infection/AIDS. *See also* Retinitis
 progressive outer retinal necrosis and, 9.197–198, 9.296, 9.296f
- imaging techniques in evaluation of
 angiography. *See* Fluorescein angiography;
 Indocyanine green (ICG) angiography
 OCT, 5.90–94, 5.92f, 5.93f, 5.94f
- immune response/features/microenvironment of, 9.54t, 9.61–62
- infection/inflammation of, 4.145–148, 4.146f, 4.147f, 4.148f. *See also* Retinitis
 acute retinal necrosis, 12.236, 12.236f
 cat-scratch disease, 12.242–243, 12.243f
 cytomegalovirus retinitis, 12.235–236
 diffuse unilateral subacute neuroretinitis, 12.246
 endogenous bacterial endophthalmitis, 12.237–239, 12.238f
 fungal endophthalmitis, 12.239, 12.239f
 infectious causes, 12.235–247
 Lyme disease, 12.245–246
 necrotizing herpetic retinitis, 12.236–237f, 12.236–237, 12.238t
 noninfectious causes, 12.219–234
 progressive outer retinal necrosis syndrome, 12.236–237, 12.237f
 syphilitic chorioretinitis, 12.241–242, 12.242f
 toxocariasis, 12.244–245, 12.245f
 toxoplasmic retinochoroiditis, 12.243–244, 12.244f
 tuberculosis, 12.240–241, 12.241f
 West Nile virus chorioretinitis, 12.246, 12.247f
 white dot syndromes as cause of. *See* White dot syndromes
 yeast endophthalmitis, 12.239–240, 12.240f
- ischemic lesions of. *See* Retinal ischemia
- layers of, 4.139–140, 4.140f, 4.141f
 blood supply to, 12.140
 external limiting membrane, 12.11, 12.12f
 ganglion cell layer, 12.11, 12.12f
 Henle fiber layer, 12.11, 12.12f
 imaging of, 12.10–11, 12.11, 12.12f
 inner nuclear layer, 12.11, 12.12f
 inner plexiform layer, 12.11, 12.12f
 internal limiting membrane, 12.11, 12.12f
 middle limiting membrane, 12.11, 12.12f
 nerve fiber layer, 12.11, 12.12f
 optical coherence tomography angiography of, 12.29
 outer nuclear layer, 12.11, 12.12f
 outer plexiform layer, 12.11, 12.12f, 12.16
 oxygen supply to, 12.16
- lesions of, 12.378–379
 in leukemia, 4.315, 4.315f
 light-related injury to, 12.367
- lymphoma of, 1.237, 4.135f, 4.135–137, 4.136f, 4.311f, 4.311–313, 4.313f, 5.349, 9.273–276, 9.274f, 9.275f. *See also* Primary central nervous system/ intraocular/vitreoretinal/retinal lymphoma
- melanoma invading, 4.194, 4.195f
- mesenchymal tissue, 6.325
- metabolic needs of, 12.20
- nasal, 5.24f, 5.25, 5.27
- necrosis of
 acute, 4.145, 4.146f, 9.193–198, 9.194f, 9.194t, 9.195f
 progressive outer, 9.197f, 9.197–198, 9.295–296, 9.296f
- neovascularization of. *See also* Neovascularization
 in age-related macular degeneration, 4.161f, 4.164–166, 4.165f
 ischemia causing, 4.154, 4.156f
 in uveitis, 9.291
- neuro-ophthalmic elements of, 5.23–25, 5.24f, 5.25f
- neurosensory, 2.69–75, 2.257–266, 2.258f, 4.139–140, 4.140f, 4.141f, 12.9–17
 anatomy of, 2.69–75, 2.70–71f, 2.72f, 2.73f, 2.74f, 2.258f, 4.139–140, 4.140f, 4.141f
 biochemistry and metabolism of, 2.257–266
 development of, 2.115, 2.116t, 2.117f, 2.119f, 2.122
 glial elements of, 2.73
 neuronal elements of, 2.69–73, 2.72f, 2.73f
 ischemia affecting, 4.151f, 4.151–152, 4.152f
 stratification of, 2.70–71f, 2.74f, 2.74–75
 vascular elements of, 2.70f, 2.73–74. *See also* Retinal blood vessels
 development of, 2.116t
- noninfectious inflammation of
 acute idiopathic maculopathy, 12.228–229
 acute macular neuroretinopathy, 12.228, 12.229f
 acute zonal occult outer retinopathy, 12.226–228, 12.227f
 white dot syndromes. *See* White dot syndromes
- oxidative lens damage during surgery on, 11.20
- oxygen supply to, 12.16f, 12.16–17
- in pathologic myopia, 12.207–216, 12.209–215f
 peripheral, 12.10. *See also* Peripheral retina
- phakomas of, 6.397, 6.399. *See also* Phakoma/phakomatosis
- photic injury of, during cataract surgery, 11.166
- pigment epithelium of. *See* Retinal pigment epithelium
- psychophysical testing of. *See* Psychophysical testing
- regional differences in, 2.68, 2.68f
- retinal pigment epithelium separation of, 12.17
- in SLE, 1.159, 9.133f, 9.133–134, 9.134f
- splitting of. *See* Juvenile retinoschisis
- surface of, in exudative retinal detachment, 12.326
- temporal, 5.24f, 5.25
- thickness of, in pathologic myopia, 12.208
- topography of, 2.37f, 2.38, 4.139–140, 4.140f, 4.141f, 12.9f, 12.9–10
- transplantation of, 9.62
- tumors of, 4.172–180. *See also* Retinoblastoma
 glaucoma caused by, 10.98–100, 10.99f, 10.138
 metastatic, 4.303, 4.308, 4.309f, 9.278
 pigmented, 4.279–280, 4.280f
- in uveitis, 9.72t, 9.77, 9.80t, 9.84. *See also* Posterior uveitis
- vascular occlusion of, 12.231
- vascularization of, 6.182, 6.325, 12.180

- vasculature of
 - description of, 12.16*f*, 12.16–17
 - optical coherence tomography angiography of, 12.29, 12.30*f*
- venous pressure in, 12.125
- visual evoked cortical potentials of, 12.52–53
- in von Hippel–Lindau disease. *See* Retinal angiomatosis
- zones of, 6.328*f*
- Retinal Acuity Meter (RAM), in cataract surgery
 - evaluation, 11.81
- Retinal adhesion, retinal pigment epithelium in
 - maintenance of, 2.278
- Retinal angiography. *See* Fluorescein angiography; Indocyanine green (ICG) angiography
- Retinal angiomatosis (angiomatosis retinae, von Hippel/von Hippel–Lindau syndrome/disease), 4.144, 4.144*f*, 4.283–285, 4.284*f*, 5.330, 5.331*f*, 5.334*t*, 6.400*f*, 12.168. *See also* von Hippel–Lindau (VHL) disease/syndrome
- Retinal angiomatous proliferations (RAPs), 12.72, 12.78*f*
- Retinal arterial arcades, inferior/superior, 5.14
- Retinal arterial macroaneurysms, 12.147–148, 12.148*f*
- Retinal arterioles
 - capillary obstruction. *See* Cotton-wool spots
 - optic nerve supplied by, 5.17*f*, 10.45
- Retinal artery, 5.17*f*
 - central (CRA), 2.73, 2.88*f*, 2.90, 2.91, 2.91*f*, 2.92*f*, 5.12, 5.13*f*, 5.14, 5.14*f*, 5.16*f*, 5.17*f*, 10.44–45, 10.45*f*
 - optic nerve supplied by, 5.17*f*, 5.26, 10.44–45, 10.45*f*
 - microaneurysms of, 4.154, 4.155*f*
 - in diabetes mellitus, 4.155*f*, 4.159
 - in diabetic retinopathy, 4.159
 - in retinal vein occlusion, 4.158, 4.159
 - occlusion of. *See* Retinal artery occlusion
- Retinal artery occlusion
 - in Behçet disease, 9.186
 - branch. *See* Branch retinal artery occlusion (BRAO)
 - capillary retinal arteriole obstruction, 12.140*f*, 12.140–141
 - central. *See* Central retinal artery occlusion (CRAO)
 - cilioretinal artery occlusion, 12.143
 - ophthalmic artery occlusion, 12.146, 12.147*f*
 - paracentral acute middle maculopathy, 12.143
 - in SLE, 9.134
 - transient visual loss and, 5.161
- Retinal blood vessels, 2.70*f*, 2.73–74, 4.139. *See also specific vessel*
 - anomalies of, 4.143*f*, 4.143–144, 4.144*f*
 - development of, 2.116*t*, 2.119*f*
 - disease of. *See* Retinal disease, vascular
 - ischemia and, 4.140, 4.151, 4.151*f*, 4.152–156, 4.153*f*, 4.154*f*, 4.155*f*, 4.156*f*. *See also* Retinal ischemia
 - in retinoblastoma, 4.292, 4.292*f*, 4.293*f*
- Retinal blur, vergence system and, 5.226
- Retinal breaks. *See also* Retinal tears
 - in acute retinal necrosis/herpetic retinitis, 9.194, 9.197
 - aphakia and, 12.319
 - asymptomatic, 12.318
 - classification of, 12.315
 - cryotherapy of, as prophylactic treatment, 12.317
 - definition of, 12.314
 - description of, 12.396
 - lattice degeneration and, 12.310
 - Lincoff rules for finding, 12.320, 12.322*f*
 - posterior vitreous detachment and, 12.309
 - prophylactic treatment of, 12.317*t*, 12.317–320
 - pseudophakia and, 12.319
 - retinal detachment caused by
 - illustration of, 12.318*f*
 - prophylactic treatment to prevent, 12.317*t*, 12.317–320
 - rhegmatogenous, 12.314–315, 12.320, 12.322*f*, 12.324
 - significance of, 12.314
 - symptomatic, 12.318
 - traumatic, 12.315–316, 12.316*f*
 - vitreoretinal traction as cause of, 12.315
- Retinal capillaries
 - nonperfusion of, in diabetic retinopathy, 12.101
 - perifoveal, 12.157
- Retinal capillary hemangioblastomas, 6.400
- Retinal capillary hemangioma, 4.283–285, 4.284*f*
- Retinal correspondence
 - anomalous
 - afterimage test for, 6.79*f*
 - definition of, 6.50
 - diplopia and visual confusion eliminated with, 6.49*f*
 - eccentric fixation versus, 6.51
 - Maddox rod testing in, 6.68
 - major amblyoscope for, 6.70
 - red-glass test findings in, 6.76*f*
 - after strabismus surgery, 6.50
 - testing for, 6.50–51
 - description of, 6.41–42
 - normal
 - afterimage test for, 6.79*f*
 - strabismus and, 6.48, 6.49*f*
 - testing for, 6.51
- “Retinal crystals.” *See* Refractile bodies/spots
- Retinal degenerations, 4.148–170, 4.171*f*, 4.172*f*, 6.385. *See also* Pigmentary retinopathy; Retinal disease; Retinal dystrophies; Retinopathy; *specific type*
 - amino acid disorders that cause, 12.293
 - autoimmune causes of, 12.286–287
 - cancer-associated retinopathy as cause of, 12.286, 12.287*f*
 - dental diseases associated with, 12.286
 - dermatologic diseases associated with, 12.286
 - gastrointestinal diseases associated with, 12.285–286
 - gene defects causing, 2.265–266
 - hearing loss and. *See* Usher syndrome
 - ischemic, 4.140, 4.150–160. *See also* Retinal ischemia
 - lattice, 4.148–150, 4.149*f*
 - radial perivascular, 4.150
 - liver diseases associated with, 12.285
 - melanoma-associated retinopathy as cause of, 12.286
 - metabolic diseases that cause
 - abetalipoproteinemia, 12.289–290
 - albinism, 12.288
 - central nervous system, 12.288–292
 - lysosomal, 12.291–292, 12.292*f*
 - mucopolysaccharidoses, 12.290–291
 - neuronoid ceroid lipofuscinoses, 12.289, 12.290*f*
 - Niemann–Pick disease, 12.291

- peroxisomal disorders, 12.290
- Refsum disease, 12.290
- Tay-Sachs disease, 12.291, 12.292*f*
- vitamin A deficiency, 12.289–290
- Zellweger syndrome, 12.290
- mitochondrial disorders that cause, 12.293–294
- neuromuscular disorders associated with, 12.285
- paraneoplastic retinopathies that cause, 12.286–287
- paving-stone (cobblestone), 4.150, 4.150*f*
- peripheral cystoid, 4.148, 4.149*f*
 - reticular (RPCD), 4.148, 4.149*f*
 - typical (TPCD), 4.148, 4.149*f*
- renal diseases associated with, 12.285
- retinal pigment epithelium and, 2.278–279
- systemic disorders associated with
 - Bardet-Biedl syndrome, 12.281, 12.282*t*, 12.284, 12.284*f*
 - Leber congenital amaurosis, 12.281
 - list of, 12.282–283*t*
 - overview of, 12.281
 - Usher syndrome, 12.284
- Retinal detachment, 2.68, 4.130*f*, 4.130–131, 4.131*f*
 - in acute retinal necrosis/herpetic retinitis, 9.194, 9.195*f*, 9.197, 9.291
 - angle-closure glaucoma and, 10.141
 - anterior segment trauma and, 8.409
 - after cataract surgery, 6.304, 11.127, 11.166–167, 12.319
 - family history as risk factor and, 11.75
 - Nd:YAG laser capsulotomy and, 11.157, 11.166
 - central serous chorioretinopathy as cause of, 12.189, 12.191
 - choroidal hemangioma and, 4.281, 4.283
 - choroidal melanoma/ciliary body melanoma and, 4.193*f*, 4.194, 4.194*f*, 4.263, 4.264*f*
 - choroidal nevi and, 4.156–157, 4.257*f*
 - chronic, 12.324*f*
 - classification of, 12.320
 - in CMV retinitis, 9.201, 9.291, 9.295
 - in Coats disease, 4.143, 4.143*f*, 4.295, 4.295*f*
 - cobblestone degeneration and, 12.313, 12.314*f*
 - diagnostic features of, 12.320, 12.321*t*
 - differential diagnosis of
 - description of, 12.320
 - retinoschisis, 12.326–328
 - extrafoveal, in retinopathy of prematurity, 6.329*f*
 - exudative (secondary/nonrhegmatogenous)
 - causes of, 12.320
 - diagnostic features of, 12.321*t*
 - in familial exudative vitreoretinopathy, 12.343
 - glaucoma and, 9.279, 10.141
 - imaging of, 12.325*f*
 - management of, 12.325–326
 - photocoagulation as cause of, 12.379
 - retinal surface in, 12.326
 - subretinal fluid findings in, 12.326
 - in fellow eye, 12.319
 - glaucoma and, 9.279, 10.141
 - hallucinations caused by, 5.175
 - intravitreal corticosteroids and, 9.98
 - lattice degeneration and, 4.148, 4.150, 12.309–311, 12.310–311*f*, 12.316*f*, 12.319
 - lesions not predisposing to, 12.313–314
 - lesions predisposing to, 12.309–312, 12.310–313*f*
 - in leukemia, 4.315
 - macular hole as cause of, 12.330, 12.330*f*
 - macular lesions associated with, 12.328–329
 - management of, 12.324, 12.324*f*
 - in Marfan syndrome, 1.143
 - meridional folds and, 12.312, 12.313*f*
 - metastatic eye disease and, 4.305–306, 4.306*f*
 - myopia/high myopia and, 13.44, 13.183–184, 13.184, 13.197
 - after Nd:YAG laser capsulotomy, 11.157, 11.166
 - nonrhegmatogenous. *See* Retinal detachment, exudative
 - in ocular histoplasmosis syndrome, 9.215, 9.216
 - optic pit maculopathy and, 12.328–329, 12.329*f*
 - in pars planitis, 9.129, 9.131, 9.291
 - paving-stone degeneration and, 12.313, 12.314*f*
 - peripheral cystoid degeneration and, 12.314
 - phakic IOLs and, 13.138, 13.145, 13.146
 - iris-fixated lenses, 13.145
 - posterior chamber lenses, 13.146
 - posterior vitreous detachment and, 2.80, 2.80*f*, 2.81*f*, 2.253
 - cataract surgery and, 11.166
 - in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 9.273
 - in progressive outer retinal necrosis, 9.296
 - proliferative vitreoretinopathy and, 4.131, 4.131*f*
 - uveitis and, 9.291
 - in punctate inner choroiditis, 9.158
 - after refractive lens exchange, 13.148
 - refractive surgery and, 13.44, 13.183–184, 13.184, 13.197
 - in retinal angiomatosis/hemangioblastoma/von Hippel-Lindau disease/syndrome, 4.284
 - retinal pigment epithelial hyperplasia and, 12.313–314
 - retinal pigment epithelial hypertrophy and, 12.314
 - retinal pigment epithelial maintenance of adhesion and, 2.278
 - retinal tear progression to, 12.347
 - in retinoblastoma, 4.292, 4.293*f*
 - retinopathy of prematurity as risk factor for, 6.334
 - in retinoschisis, 12.328
 - rhegmatogenous (RRD), 4.130*f*, 4.130–131, 4.131*f*, 9.279, 9.291
 - after cataract surgery, 11.166–167
 - family history as risk factor and, 11.75
 - Nd:YAG laser capsulotomy and, 11.157, 11.166
 - child abuse and, 6.384
 - chronic, 12.324*f*
 - chronic peripheral, 9.279
 - complex, 12.401
 - definition of, 12.396
 - diagnostic features of, 12.320, 12.321*t*
 - floaters associated with, 12.320
 - glaucoma and, 9.279, 10.141
 - incidence of, 12.320
 - intraocular pressure in, 12.320
 - lattice degeneration associated with, 12.310
 - “macula-off,” 12.401
 - macular hole as cause of, 12.330, 12.330*f*
 - management of, 12.324, 12.324*f*, 12.397

- pigmented demarcation lines with, 12.324
 pneumatic retinopexy for, 12.324, 12.397–398, 12.398*f*
 posterior vitreous detachment and, 2.80, 2.80*f*, 2.81*f*, 2.253
 after cataract surgery, 11.166
 proliferative vitreoretinopathy associated with, 12.320, 12.323*t*, 12.323*f*, 12.323–324
 reattachment surgery for, 12.401–402
 retinal breaks as cause of, 12.314–315, 12.396
 retinoschisis versus, 12.320, 12.322*f*, 12.327*t*, 12.327–328
 risk factors for, 12.396
 scatter photocoagulation as cause of, 12.155
 Schwartz (Schwartz-Matsuo) syndrome and, 9.279, 10.109
 scleral buckling for, 12.324, 12.398–400, 12.399*f*
 Shafer sign, 12.320
 surgical repair of, 12.397–401, 12.398–400*f*
 tractional retinal detachment versus, 12.325
 vision loss caused by, 12.128
 vitrectomy for, 12.324, 12.400*f*, 12.400–401
 word origin of, 12.320
 Schwartz (Schwartz-Matsuo) syndrome and, 9.279, 10.109
 scleral buckling for
 after cataract surgery, 11.166–167
 refractive surgery after, 13.185
 in uveitis, 9.291
 scleral perforation as cause of, 6.170
 secondary (nonrhegmatogenous). *See* Retinal detachment, exudative
 serous, 6.362
 in intraocular lymphoma, 12.234
 MEK inhibitors as cause of, 12.299
 in sickle cell retinopathy, 12.155
 in Stickler syndrome, 6.346
 subclinical, 12.319–320
 surgery for
 angle-closure glaucoma after, 10.143
 in children, 6.146
 in CMV retinitis, 9.295
 LASIK and, 13.185, 13.197
 refractive surgery and, 13.185, 13.197
 in uveitis, 9.291
 vitrectomy. *See* Retinal detachment, vitrectomy for
 in sympathetic ophthalmia, 9.172, 9.173*f*
 in syphilis, 9.238–239, 9.299
 tractional, 6.348*f*, 6.360
 causes of, 12.320
 description of, 12.286
 diagnostic features of, 12.321*t*, 12.325
 in familial exudative vitreoretinopathy, 12.343
 imaging of, 12.387*f*
 management of, 12.325
 pathophysiology of, 12.387
 in proliferative diabetic retinopathy, 12.103, 12.108, 12.387–388
 rhegmatogenous retinal detachment versus, 12.325
 vitrectomy for, 12.325, 12.387–388
 trauma and, 12.317
 anterior segment, 8.409
 in uveal lymphoid proliferation/infiltration, 4.314
 uveitis and, 9.291
 vitrectomy for, refractive surgery after, 13.185
 vitreoretinal tufts and, 12.311–312, 12.312*f*
 vitreous contraction as cause of, 12.349
 in Vogt-Koyanagi-Harada syndrome, 9.177, 9.177*f*
 Retinal dialyses, 4.19–20, 4.20*f*, 12.315
 Retinal disease, 4.139–180. *See also* Macula/macula lutea, diseases of; Retinitis; Retinopathy; *specific type*
 acquired, 6.358–360, 6.359*f*
 angiography in. *See* Fluorescein angiography; Indocyanine green (ICG) angiography
 arterial macroaneurysms, 12.147–148, 12.148*f*
 arterial occlusive
 branch retinal artery occlusion. *See* Branch retinal artery occlusion (BRAO)
 capillary retinal arteriole obstruction, 12.140*f*, 12.140–141
 central retinal artery occlusion. *See* Central retinal artery occlusion (CRAO)
 cilioretinal artery occlusion, 12.143
 ophthalmic artery occlusion, 12.146, 12.147*f*
 paracentral acute middle maculopathy, 12.143
 after cataract surgery, 11.163–167, 11.164*f*
 cataract surgery in patient with, 11.189
 chloroquine/hydroxychloroquine toxicity and, 1.173
 Coats disease, 6.358–360, 6.359*f*
 combined hamartoma of the retina and retinal pigment epithelium, 6.350
 congenital/developmental, 4.142*f*, 4.142–145, 4.143*f*, 4.144*f*, 4.145*f*
 degenerative, 4.148–170, 4.171*f*, 4.172*f*. *See also* Retinal degenerations
 in diabetes mellitus. *See* Diabetic retinopathy
 electrophysiologic testing in, 5.95–97, 5.96*f*. *See also specific test*
 ERG in, 5.96*f*, 5.96–97
 hallucinations caused by, 5.175
 hereditary
 achromatopsia, 6.337–338
 Aicardi syndrome, 6.338–339, 6.339*f*
 congenital stationary night blindness, 6.338
 evaluative tests for, 6.335
 foveal hypoplasia, 6.338
 Leber congenital amaurosis, 6.335–336, 6.337*f*
 nyctagmus associated with, 6.335
 paradoxical pupils associated with, 6.335, 6.336*t*
 human immunodeficiency virus complications, 6.348
 illusions caused by, 5.174–175
 imaging modalities for
 adaptive optics imaging, 12.33
 fluorescein angiography, 12.33–38, 12.34*f*, 12.36–37*f*
 fundus autofluorescence, 12.29, 12.31–33
 fundus camera imaging, 12.22–23, 12.23*f*
 indirect ophthalmoscopy, 12.21–22
 indocyanine green angiography, 12.38–39
 ophthalmoscopy, 12.21–22
 optical coherence tomography, 12.25–27, 12.27*f*. *See also* Optical coherence tomography
 optical coherence tomography angiography, 12.28–29

- scanning laser ophthalmoscopy, 12.24
ultrasonography, 12.39–40
- infectious, 6.348
- inflammatory, 4.145–148, 4.146f, 4.147f, 4.148f.
See also Retinitis; *specific disease*
infectious, 4.145–148, 4.146f, 4.147f, 4.148f
- macular dystrophies
Best disease, 6.340–342, 6.342f
Stargardt disease, 6.339–340, 6.340–341f
- neoplastic, 4.172–180. *See also* Retinoblastoma
glaucoma caused by, 10.98–100, 10.99f
metastatic, 4.303, 4.308, 4.309f
pigmented, 4.279–280, 4.280f
- nystagmus associated with, 5.236
- psychophysical testing in. *See specific test*
- refractive surgery and, 13.44, 13.183–185
- retinoblastoma. *See* Retinoblastoma
- retinopathy of prematurity. *See* Retinopathy, of prematurity
- Th1-mediated delayed hypersensitivity and, 9.46t
- tuberculous, 9.253, 9.253f
- tumors, 6.349–358
- vascular. *See also* Retinal vasculitis; *specific type*
angle-closure glaucoma and, 10.84, 10.134–135, 10.141, 10.143–144
antiphospholipid antibody syndrome and, 1.161, 9.134
arterial occlusion. *See* Retinal artery occlusion
Behçet disease and, 9.186, 9.186f, 9.187f
branch retinal vein occlusion. *See* Branch retinal vein occlusion (BRVO)
cavernous hemangioma, 4.285f, 4.285–286, 12.168, 12.169f
central retinal vein occlusion. *See* Central retinal vein occlusion (CRVO)
Coats disease, 12.159–161, 12.160f, 12.326
congenital, 4.143f, 4.143–144, 4.144f
cystoid macular edema. *See* Cystoid macular edema (CME)
in diabetes mellitus, 4.159. *See also* Diabetic retinopathy
hypercoagulability and, 1.147
hypertension and, 1.79, 12.121–125, 12.122–124f
lupus vasculitis, 9.134, 9.134f
macular telangiectasia. *See* Macular telangiectasia
microaneurysms, 4.154, 4.155f
in diabetes mellitus, 4.155f, 4.159
in diabetic retinopathy, 4.159
in retinal vein occlusion, 4.158, 4.159
ocular ischemic syndrome, 12.138–140, 12.139f
Purtscher retinopathy, 12.171–173, 12.173t
Purtscherlike retinopathy, 12.171–173, 12.172f, 12.173t
radiation retinopathy, 12.170f, 12.170–171
retinal vein occlusion. *See* Retinal vein occlusion (RVO)
sickle cell retinopathy. *See* Sickle cell retinopathy
systemic arterial hypertension, 12.121–125, 12.122–124f
Terson syndrome, 12.173
Valsalva retinopathy, 12.171
vasculitis and, 12.155f, 12.155–156. *See also* Retinal vasculitis
- venous occlusion. *See* Retinal vein occlusion
- von Hippel–Lindau disease/syndrome and, 4.144, 4.144f, 4.284–285, 5.330, 5.331f, 5.334t, 12.165–168, 12.166–167f
Wyburn–Mason syndrome and, 4.286f, 4.286–287, 5.331, 5.333f, 5.334t, 12.168
- vitreoretinopathies
familial exudative, 6.347–348, 6.348f
juvenile retinoschisis. *See* Juvenile retinoschisis
Knobloch syndrome, 6.346f, 6.346–347
Norrie disease, 6.347
Stickler syndrome, 6.345–346
- Retinal disparity, vergence system and, 5.226
- Retinal dystrophies. *See also* Retinal degenerations; *specific type*
classification of, 12.255
congenital sensory nystagmus from, 6.154
hereditary. *See also* Hereditary dystrophies; *specific type*
bilateral symmetric involvement of, 12.258
blindness concerns of patients with, 12.260
cystoid macular edema in, 12.260, 12.260f
diagnostic considerations for, 12.258–259
enhanced S-cone disease, 12.266, 12.267f
gene therapy for, 12.260, 12.266
genes and loci associated with, 12.256–257t
genetic considerations for, 12.259
inheritance patterns for, 12.259
Leber congenital amaurosis, 12.265–266
management of, 12.259–260, 12.260f
molecular genetic testing for, 12.259
photoreceptor (diffuse), 4.170, 4.172f
rod–cone dystrophies, 12.261–264, 12.262–264f
stem cell therapy for, 12.260
- infantile nystagmus syndrome and, 5.236
- inner, 12.278–279
- juvenile, 6.390f
- nystagmus associated with, 6.391f
- sporadic, 12.263
- X-linked retinoschisis, 12.278f, 12.278–279
- Retinal edema, 4.152, 4.153f, 4.154f. *See also* Macular edema
illusions and, 5.174–175
myopia choroidal neovascularization as cause of, 12.212
- Retinal examination, before refractive surgery, 13.44, 13.183
- Retinal folds
in familial exudative vitreoretinopathy, 12.343, 12.345f
fixed, 12.326
- Retinal ganglion cells (RGCs), 12.45. *See also* Ganglion cells/ganglion cell layer (GCL), retinal
apoptosis of, 6.44
development of, 6.44
- Retinal gene therapy, 9.62
- Retinal grafts, 12.340
- Retinal hemorrhages
in abusive head trauma, 6.382–383, 383f, 12.366, 12.366f
in *Aspergillus* endophthalmitis, 9.269
in branch retinal vein occlusion, 4.159
in carotid occlusive disease, 12.138

- in central retinal vein occlusion, 4.156, 4.158f
- in dengue fever, 9.213
- dot-and-blot, 4.153–154, 4.155f, 5.170, 5.171f
 - ischemia causing, 4.153–154, 4.155f, 5.170, 5.171f
- flame, ischemia causing, 4.153, 4.155f
- ischemia causing, 4.153–154, 4.155f, 5.170, 5.171f
- in leukemia, 4.315, 6.414
- in ocular histoplasmosis syndrome, 9.216
- in Rift Valley fever, 9.211
- SLE and, 9.133
- Retinal holes
 - atrophic
 - definition of, 12.315
 - lattice degeneration and, 4.150
 - lattice degeneration with, 12.310, 12.311f, 12.316f
 - retinal detachment secondary to, 12.310
 - description of, 12.378
 - lattice degeneration and, 4.150
 - operculated, 12.315–316
- Retinal image size, 3.126
- Retinal ischemia, 4.140, 4.150–160, 12.140
 - in Behçet disease, 9.186
 - cataract surgery and, 11.80–81
 - cellular responses to, 4.151f, 4.151–152, 4.152f
 - central and branch retinal artery and vein occlusions
 - causing, 4.151f, 4.156–159, 4.157f, 4.158f
 - diabetic retinopathy and, 4.155f, 4.159–160, 4.160f, 4.161f
 - illusions and, 5.175
 - inner ischemic retinal atrophy and, 4.151, 4.151f
 - in diabetic retinopathy, 4.159
 - in retinal arterial and venous occlusions, 4.156, 4.159
 - outer ischemic retinal atrophy and, 4.151, 4.151f
 - stroke and, 5.167, 5.168–169
 - transient visual loss and, 5.161, 5.164, 5.167, 5.168–169
 - vascular responses to, 4.152–156, 4.153f, 4.154f, 4.155f, 4.156f
- Retinal light toxicity. *See* Photic damage/phototoxicity/light toxicity
- Retinal (intraocular/primary central nervous system) lymphoma, 1.237, 4.135f, 4.135–137, 4.136f, 4.311f, 4.311–313, 4.313f, 5.349, 9.273–276, 9.274f, 9.275f. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
- Retinal neovascularization. *See also* Neovascularization; Retinal disease, vascular
 - in age-related macular degeneration, 4.161f, 4.164–166, 4.165f
 - ischemia causing, 4.154, 4.156f
- Retinal nerve fiber layer (RNFL), 3.99, 3.303. *See also* Nerve fiber layer
- Retinal nerve fibers, 4.140. *See also* Nerve fiber layer
 - distribution of, 10.42–43, 10.43f
 - imaging in evaluation of, 10.53–59, 10.55f, 10.56f, 10.57f, 10.58f
 - loss of, in glaucoma, 10.50–52, 10.51f
 - myelinated, 4.143
- Retinal photocoagulation, 3.118
- Retinal pigment epithelium (RPE), 2.60, 2.61f, 2.67–69, 2.68f, 2.70f, 2.71f, 2.74f, 2.88f, 2.271f, 2.271–279, 4.139, 4.140f, 4.141, 4.141f, 5.24
 - abnormalities of
 - in age-related macular degeneration, 12.66–67
 - central serous chorioretinopathy as cause of, 12.67
 - focal atrophy, 12.66
 - geographic atrophy, 12.64, 12.66, 12.67f, 12.68
 - hyperpigmentation, 12.68
 - pattern dystrophies, 12.67
 - adenomas/adenocarcinomas of, 4.180, 4.279
 - age-related changes in, 12.62
 - anatomy of, 2.60, 2.61f, 2.67–69, 2.68f, 2.71f, 2.271f, 2.271–273, 2.272f, 4.139, 4.140f, 4.141, 4.141f, 5.24, 12.17–19, 12.18f
 - antioxidants in, 2.286–288, 2.289f
 - atrophy of, 4.164, 4.164f, 12.106f, 12.294f
 - in cone dystrophies, 5.102
 - barrier functions of, 12.18
 - biochemistry and metabolism of, 2.271–279
 - burns of, during cataract surgery, 11.166
 - cells of
 - bis-retinoid accumulation in, 12.31
 - description of, 12.17, 12.20
 - in epiretinal membranes, 12.334
 - fluorescein angiography of, 12.34
 - pigment-laden, 12.66
 - choroidal nevi and, 4.256, 4.257f
 - combined hamartoma of the retina and, 6.350
 - composition of, 2.273–274
 - congenital abnormalities of, 4.142f, 4.142–145, 4.143f, 4.144f, 4.145f
 - hypertrophy (CHRPE), 4.144–145, 4.145f, 4.268–269, 4.269f, 6.349, 6.349f
 - melanoma differentiated from, 4.144, 4.268–269, 4.269f
 - degeneration of, 12.258
 - depigmentation of, 12.227, 12.293
 - detachment of (PED/RPED), 2.68, 6.342. *See also* Retinal detachment
 - definition of, 12.64
 - drusenoid, 12.64, 12.272, 12.274f
 - fibrovascular
 - anti-VEGF therapy for, 12.201f
 - description of, 12.72–73
 - retinal pigment epithelial tear risks, 12.82
 - in hypertensive choroidopathy, 12.123
 - multiple recurrent serosanguineous (polypoidal choroidal vasculopathy), 4.166f, 4.166–168, 4.167f
 - optical coherence tomography of, 12.74f
 - in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.135, 4.135f, 4.136f, 9.273
 - serous, 12.72–73, 12.74f
 - subfoveal, 12.74–75f
 - development of, 2.115, 2.116t, 2.117f, 2.119f, 2.122–124, 2.271
 - in disease, 2.278–279
 - disorders of, 4.139–180. *See also specific type*
 - drugs that affect
 - alkyl nitrites, 12.300, 12.300f
 - chloroquine derivatives, 12.295–297, 12.296f
 - chlorpromazine, 12.297

- clofazimine, 12.298
- deferoxamine, 12.298–299
- dideoxyinosine, 12.299
- MEK inhibitors, 12.299, 12.299f
- nucleoside reverse transcriptase inhibitors, 12.299
- phenothiazines, 12.297–298
- thioridazine, 12.297
- electro-oculography of, 12.50
- functions of, 12.17–18
- gene defects affecting, 2.264–265
- geographic atrophy of, 4.164, 4.164f
- hamartoma of
 - combined, 4.179, 4.180f, 4.280, 4.280f
 - in Gardner syndrome, 4.145
 - simple, 4.279, 4.280f
- healing/repair of, 4.17
- hyperpigmentation of, 12.106f
- hyperplasia of
 - around retinal tuft, 12.312
 - retinal detachment and, 12.313–314
- hypertrophy of, 12.314
- congenital (CHRPE), 4.144–145, 4.145f, 4.268–269, 4.269f
- melanoma differentiated from, 4.144, 4.268–269, 4.269f
- immune response/features/microenvironment of, 9.54t, 9.61
- inflammation of (acute retinal pigment epitheliitis/ARPE/Krill disease), 9.141–143t, 9.164, 9.164f
- in Knobloch syndrome, 6.346
- leaks from, 12.190, 12.190f
- in Leber congenital amaurosis, 6.336
- lesions of, 6.349, 6.349f
- lipids in, 2.274
- lipofuscin in, 12.32
- lipofuscin-like material, 12.270, 12.270f
- nucleic acids in, 2.274
- nummular loss of, 12.204
- in onchocerciasis, 9.235
- phagocytosis by, 2.276f, 2.276–277
- physiologic roles of, 2.274–278, 2.275f, 2.276f
- pigmentation of, 12.214, 12.277
- pigments in
 - description of, 12.12f, 12.17
 - granules, 2.277–278
 - mottling of, 12.79, 12.87, 12.90f
- in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.135, 4.135f, 4.136f, 4.136–137, 4.311, 9.273, 9.274f
- progressive atrophy of, 12.66
- proteins in, 2.273, 2.277
- regional differences in, 2.68, 2.68f
- retinal adhesion and, 2.278
- retinal separation from, 12.17
- in retinitis pigmentosa, 4.170, 4.172f
- rubella and, 9.204, 9.205
- siderosis bulbi effects on, 12.362
- standing potential, 12.50, 12.51f
- Stargardt disease findings, 2.279, 4.168–169f, 4.169–170, 6.339, 6.341f, 12.270, 12.270f
- in subacute sclerosing panencephalitis, 9.207
- subretinal space maintenance and, 2.277
- in syphilis, 9.237, 9.239
- tears of
 - autofluorescence of, 12.31, 12.32f
 - in choroidal neovascularization, 12.31
 - fibrovascular pigment epithelial detachment as risk for, 12.82
- thermal injury to, 12.367
- topography of, 4.140f, 4.141, 4.141f
- transplantation of, 9.62
- transport functions of, 2.273, 2.277
- tumors of, 4.180
- visual pigment regeneration and, 2.274–276, 2.275f
- water transport in, 12.18
- Retinal pigment epithelium–photoreceptor complex, in multiple evanescent white dot syndrome, 9.162, 9.163f
- Retinal precipitates, 12.241
- Retinal reflex
 - aberrations of, 3.159
 - break in, 3.156, 3.157f
 - description of, 3.152–153f, 3.152–153
 - against movement, 3.152, 3.153f, 3.155
 - with movement, 3.152, 3.153f, 3.155
 - skew of, 3.156, 3.157f
 - width of, 3.156, 3.157f
- Retinal rivalry, 6.47, 6.47f
- Retinal scars, 4.17
- Retinal sclopetaria, 4.22, 12.356–358, 12.357f
- Retinal sheathing
 - in Behçet disease, 9.186
 - in sarcoidosis, 9.169, 9.169f
 - in toxoplasmosis, 9.222
- Retinal tears, 4.20, 4.20f, 4.129–130, 4.130f. *See also*
 - Retinal breaks
 - chorioretinal adhesions around, using laser retinopexy, 12.377
 - classification of, 12.315
 - flap, 12.315, 12.318–319
 - giant, 12.315
 - horseshoe-shaped, 12.316, 12.323f
 - lattice degeneration and, 4.150
 - mechanisms of, 12.308f
 - ora bays and, 12.312
 - peripheral retinal excavations and, 12.312–313
 - in posterior vitreous detachment, 2.81f, 2.253, 12.307, 12.308f, 12.309
 - retinal detachment, progression of, 12.347
 - ultrasonography of, 12.39
 - vitreoretinal/vitreous traction and, 4.129–130
 - in vitreous hemorrhage, 12.347
- Retinal telangiectasia. *See* Coats disease
- Retinal transient ischemic attack (RTIA)
 - carotid disease and, 1.125
 - stroke and, 5.167, 5.168–169
 - transient monocular visual loss and, 5.164, 5.167, 5.168–169, 5.171
- Retinal tufts, 12.311–312, 12.312f
- Retinal vascular sheathing, 12.231f
- Retinal vasculitis, 12.155f, 12.155–156
 - in Behçet disease, 1.169–170, 9.186, 9.186f, 9.187f
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168, 9.138
 - HLA association in, 9.67t
 - in HTLV-1 infection, 9.212
 - in leptospirosis, 9.249

- in Lyme disease, 9.245
- neovascularization in, 9.291
- in polyarteritis nodosa, 1.167, 9.136, 9.136*f*
- in Rift Valley fever, 9.211
- in SLE, 9.134, 9.134*f*
- in syphilis, 9.237, 9.238–239, 9.240
- in toxoplasmosis, 9.222
- in tuberculosis, 9.253
- in uveitis, 9.76*t*, 9.77*t*, 9.77–78. *See also* Posterior uveitis
- in Whipple disease, 9.258
- Retinal vasospasm, transient visual loss and, 5.161, 5.162, 5.171
- Retinal vein, 5.17*f*
 - arcade, 5.21
 - central, 2.35*f*, 2.88*f*, 2.91*f*, 2.92*f*, 5.17*f*, 5.21, 5.21*f*, 10.44, 10.45*f*, 10.46
 - optic nerve drained by, 5.17*f*, 10.45*f*, 10.46
 - occlusion of. *See* Retinal vein occlusion
- Retinal vein occlusion (RVO)
 - aflibercept for, 12.135
 - anti-VEGF drugs for, 12.126, 12.136–137
 - in Behçet disease, 9.186
 - bevacizumab for, 12.135
 - branch (BRVO), 4.158–159
 - aflibercept for, 12.135
 - at arteriovenous crossing, 12.126
 - bevacizumab for, 12.135
 - clinical findings of, 12.125–127, 12.126*f*
 - corticosteroids for, 12.137–138
 - diabetes mellitus and, 12.128
 - fluorescein angiography of, 12.129*f*
 - glaucoma as risk factor for, 12.125
 - hypertensive retinopathy and, 12.122
 - intra retinal hemorrhages associated with, 12.125, 12.126*f*
 - macular laser surgery for, 12.128
 - neovascularization in, 4.159, 12.125, 12.128, 12.129*f*
 - pars plana vitrectomy for, 12.130
 - pharmacologic management of, 12.135–138
 - prognosis for, 12.128
 - ranibizumab for, 12.135
 - risk factors for, 12.127–128
 - scatter photocoagulation for, 12.128–130
 - spontaneous resolution of, 12.125
 - surgical management of, 12.128–130
 - treatment of, 12.128–130
 - triamcinolone for, 12.137
 - vision loss caused by, 12.128
 - central (CRVO), 4.156–158, 4.158*f*
 - aflibercept for, 12.135
 - age and, 12.133
 - angle-closure glaucoma and, 10.143–144
 - neovascularization and, 10.134–135
 - bevacizumab for, 12.135
 - causes of, 12.133–134
 - chronic changes caused by, 12.127*f*
 - cilioretinal artery occlusion caused by, 12.143
 - clinical findings of, 12.127*f*, 12.130
 - complications of, 12.135
 - corticosteroids for, 12.137–138
 - cystoid macular edema caused by, 12.136*f*
 - differential diagnosis of, 12.134
 - diuretic and, 12.134
 - electroretinography findings in, 12.50
 - evaluation of, 12.134–135
 - follow-up for, 12.134
 - hypercoagulable conditions presenting with, 12.134
 - hypertensive retinopathy and, 12.122
 - hyperviscosity retinopathy versus, 12.134
 - intraocular pressure in, 12.133
 - iris neovascularization in, 12.133, 12.135
 - ischemic/complete/nonperfused, 4.156, 4.157–158, 4.158*f*, 12.132*f*
 - macular laser surgery for, 12.135
 - management of, 12.134–135
 - neovascularization in, 12.125
 - nonischemic, 12.130, 12.131*f*
 - ocular ischemic syndrome versus, 12.134
 - open-angle glaucoma and, 10.84, 12.133
 - oral contraceptives and, 12.134
 - panretinal photocoagulation for, 12.135
 - pars plana vitrectomy for, 12.135
 - pharmacologic management of, 12.135–138
 - progression of, follow-up for, 12.134
 - ranibizumab for, 12.135
 - retinal microvascular changes in, 12.125, 12.127*f*
 - risk factors for, 12.133–134
 - spontaneous resolution of, 12.125
 - treatment of, 12.135
 - vision loss caused by, 12.130
 - vitreous hemorrhage secondary to, 12.135
 - cystoid macular edema caused by, 12.135, 12.136*f*
 - dexamethasone implant for, 12.137
 - glaucoma as risk factor for, 12.125
 - hypercoagulability and, 1.147
 - improvements in, 12.125
 - intravitreal corticosteroids for, 12.137–138
 - ocular examination for, 12.125
 - panretinal photocoagulation for, 12.126
 - pharmacologic management of, 12.135–138
 - ranibizumab for, 12.135
 - in sarcoidosis, 9.169–170
 - in SLE, 9.134
 - spontaneous resolution of, 12.125
 - transient visual loss and, 5.170
 - triamcinolone for, 12.137
 - Retinaldehyde, in retinal pigment epithelium, 2.274–275
 - Retinitis, 9.72*t*, 9.77
 - in acute retinal necrosis, 4.145, 4.146*f*, 5.350, 9.193–198, 9.194, 9.194*f*, 9.194*t*, 9.195*f*
 - in Behçet disease, 9.186, 9.187*f*
 - Candida* causing, 9.266, 9.266*f*, 9.267*f*
 - Chikungunya virus, 9.213–214, 12.247
 - CMV, 1.259, 1.260, 4.145, 4.146*f*, 5.349, 6.411, 9.198–201, 9.199*f*, 9.200*f*, 12.235–236, 12.238*t*
 - acute retinal necrosis, 9.196
 - cidofovir for, 1.260, 1.281, 2.357*t*, 2.360–361
 - congenital (cytomegalic inclusion disease), 9.198, 9.199, 9.200
 - foscarnet for, 1.239, 1.260, 1.268, 1.281, 2.357*t*, 2.360, 9.201
 - ganciclovir for, 1.239, 1.260, 1.268, 1.281, 2.357*t*, 2.358*t*, 2.359–360, 9.201
 - in HIV infection/AIDS, 1.259, 1.268, 5.349, 9.198, 9.200–201, 9.294–295

- immune recovery uveitis and, 1.271, 9.201, 9.294–295
- recent developments in treatment of, 1.239
- retinal detachment and, 9.201, 9.291, 9.295
- valganciclovir for, 1.239, 1.260, 1.268, 1.281, 9.201
- foveomacular. *See* Solar retinopathy
- in granulomatosis with polyangiitis (Wegener granulomatosis), 9.138, 9.138*f*
- herpetic, 4.145, 5.350, 9.193–198, 9.194*t*, 9.194*f*, 9.195*f*, 9.197*f*, 9.295–296, 9.296*f*
- necrotizing, 4.145, 9.193–198, 9.194*f*, 9.194*t*, 9.195*f*, 9.295–296, 9.296*f*, 12.236–237*f*, 12.236–237, 12.238*t*
- nonnecrotizing (nonnecrotizing posterior uveitis), 9.198
- in neuroretinitis, 12.242
- pigmentosa. *See* Retinitis pigmentosa
- in progressive outer retinal necrosis, 9.197, 9.197*f*
- punctata albescens, CRALBP defects causing, 2.265
- in Rift Valley fever, 9.211, 9.211*f*
- rubella, 9.205
- solar. *See* Solar retinopathy
- in subacute sclerosing panencephalitis, 9.207–208, 9.208*f*
- in syphilis, 9.239–240, 9.240*f*
- in toxoplasmosis, 4.147–148, 4.148*f*
- Retinitis pigmentosa (RP), 4.170, 4.172*f*, 9.278. *See also*
 - Rod–cone dystrophies
 - autofluorescence imaging of, 12.261
 - autosomal dominant (ADRP), 2.177
 - peripherin/RDS gene mutation causing, 2.161, 2.264
 - rhodopsin mutation causing, 2.161, 2.263
 - autosomal recessive (ARRP)
 - retinal pigment epithelium defects in, 2.278
 - rhodopsin mutation causing, 2.263
 - rod cGMP-gated channel mutation causing, 2.161, 2.263
 - rod cGMP phosphodiesterase mutation causing, 2.161, 2.263
- cataract/cataract surgery in patient with, 11.68
- clinical presentation of, 12.261
- congenital stationary night blindness versus, 12.251
- cystoid macular edema associated with, 12.260
- electroretinography findings in, 12.44, 12.261
- ERG in, 5.96
- fundal findings in, 12.261, 12.262*f*
- genes and loci associated with, 12.257*t*
- genetics of, 4.170. *See also specific mutation type*
- hearing loss and, 12.284. *See also* Usher syndrome
- MAK-associated, racial and ethnic concentration of, 2.197
- management of, 12.264
- with neuropathy (neurogenic muscle weakness) and ataxia (NARP), 2.158–159
 - mitochondrial DNA mutations and, 2.157, 2.158–159
- nutritional supplements for, 12.264
- retinal pigment epithelium in, 2.278, 4.170, 4.172*f*
- ROM1 gene mutation in, 2.264
- sectorial, 12.263, 12.264*f*
- sine pigmento, 12.261
- spectral-domain optical coherence tomography
 - findings, 12.263*f*
- unilateral, 12.263
- uveitis differentiated from, 9.278
- visual fields in, 12.263*f*
- X-linked (XLRP), 12.50
 - ocular findings in carriers of, 2.198*f*, 2.199*t*
 - retinal pigment epithelium in, 2.278
- Retinitis punctata albescens, 12.258, 12.258*f*
- Retinoblastoma (RB), 2.192, 2.193, 4.172–177, 4.253, 4.289–302, 9.277
 - bilateral, 6.357*f*
 - brachytherapy for, 4.301
 - chemotherapy for, 4.253, 4.299–300, 4.300*f*, 6.356–357
 - classification of, 4.297, 4.297*t*, 6.354, 6.356*t*
 - clinical evaluation/diagnosis of, 4.291*f*, 4.291*t*, 4.291–294, 4.292*f*, 4.293*f*, 4.294*f*
 - differential diagnosis and, 4.294*t*, 4.294–297, 4.295*f*, 4.296*f*
 - clinical trials in, 4.301
 - Coats disease differentiated from, 4.295, 4.295*f*, 6.352–353, 6.360
 - conditions associated with, 4.298
 - cryotherapy for, 4.300
 - description of, 6.299, 6.351
 - diagnosis of, 6.352–353*f*, 354
 - diffuse infiltrating, 4.292
 - diffuse infiltrative, 6.353
 - endophytic, 6.352, 6.352*f*
 - enucleation for, 4.299, 7.128
 - evaluation of, 6.353
 - exenteration for, 7.136
 - exophytic, 6.352–353, 6.353*f*
 - external-beam radiation for, 4.301
 - extraocular, 6.357
 - fleurettes in, 4.175, 4.175*f*
 - Flexner-Wintersteiner rosettes associated with, 6.353
 - genetics of, 2.192, 4.172–173, 4.253, 4.289–291, 4.290*f*, 6.354, 6.355*f*
 - counseling and, 4.289–291, 4.290*f*
 - histologic features of, 4.173*f*, 4.173–175, 4.174*f*, 4.175*f*, 6.353–354
 - intracranial, 4.298
 - iris affected in, 4.174, 4.174*f*
 - laser therapy for, 4.300
 - leukocoria associated with, 6.351, 6.351*f*, 6.351*t*
 - leukocoria in, 4.291, 4.291*f*, 4.291*t*
 - long arm 13 deletion syndrome and, 2.192
 - malignant mesenchymal tumors in children with, 7.84
 - metastatic, 4.177, 4.177*f*, 4.293–294
 - monitoring of, 6.358
 - ocular inflammation in, 4.291, 4.291*t*
 - optic nerve affected in, 4.176*f*, 4.176–177, 4.177*f*, 4.293
 - orbit affected in, 4.294, 4.294*f*
 - pathogenesis of, 4.172–173
 - persistent fetal vasculature differentiated from, 4.294–295
 - plaque radiotherapy for, 4.301
 - presenting signs and symptoms of, 4.291*f*, 4.291*t*, 4.291–294, 4.292*f*, 4.293*f*, 4.294*f*
 - prognosis for, 4.302, 4.302*t*

- progression of, 4.176*f*, 4.176–177, 4.177*f*
 radiation therapy for, 4.301
 secondary tumors and, 4.302, 4.302*t*
 recurrence of, 6.358
 retinocytoma and, 4.178, 4.178*f*, 4.298
 rosettes in, 4.174–175, 4.175*f*
 secondary malignancies in, 4.302, 4.302*t*, 6.358
 spontaneous regression of, 4.301, 6.353
 staging of, 4.297
 strabismus in, 4.291, 4.291*f*, 4.291*t*
 toxocariasis differentiated from, 9.229–230
 transpupillary thermotherapy for, 4.300
 treatment of, 4.299–301, 4.300*f*, 6.356–358
 unilateral, 4.298, 6.357
 vitreous seeds and, 4.292, 4.293*f*
- Retinoblastoma (*RB1*) gene, 2.159, 2.192, 4.172–173, 4.253, 4.289–290
 in pinealoblastoma, 4.298
 in retinocytoma, 4.298
 secondary malignancies and, 4.302
- Retinochoroidal/retinociliary venous collaterals
 (optociliary shunt vessels), 5.22, 7.22, 7.22*f*
 in optic nerve sheath meningioma, 5.127*f*, 5.128
 in papilledema, 5.109
- Retinochoroidal scarring, toxoplasmic chorioretinitis
 and, 4.147, 4.148*f*, 9.222, 9.222*f*, 9.223, 9.223*f*, 9.296
- Retinochoroiditis, 9.72*t*
 in cat-scratch disease, 9.256
 cytomegalovirus, 6.411, 6.411*f*
 necrotizing, 12.243
 in syphilitic uveitis, 12.241
Toxoplasma causing, 9.219–227, 9.222*f*, 9.223*f*, 9.296–297, 9.297*f*
 congenital, 9.221, 9.222*f*, 9.226
 in HIV infection/AIDS, 9.223, 9.225, 9.226, 9.296–297, 9.297*f*
 toxoplasmic, 12.243–244, 12.244*f*
- Retinochoroidopathies. *See also specific disorder*
 birdshot (birdshot uveitis/birdshot chorioretinopathy/vitiliginous chorioretinitis), 9.141–143*t*, 9.144–147, 9.145*f*, 9.146*f*
 ERG in, 9.143*t*, 9.147
 HLA association in, 9.67, 9.67*t*, 9.141*t*, 9.144
- Retinociliary venous/retinochoroidal collaterals
 (optociliary shunt vessels), 5.22, 7.22, 7.22*f*
 in optic nerve sheath meningioma, 5.127*f*, 5.128
 in papilledema, 5.109
- Retinocytoma, 4.178, 4.178*f*, 4.298
- Retinogeniculocortical pathway
 abnormal visual experience affecting, 6.44–47, 6.45–46*f*
 development of, 6.44–47
- Retinoic acid (RA), gene expression/ocular development
 and, 2.127
- Retinoid-binding proteins, 2.275–276
 interphotoreceptor (IRBP), 2.275, 2.275*f*, 4.172
 in AIRE (autoimmune regulator)–deficient mice, 9.64
 in experimental autoimmune uveoretinitis, 9.63
 transgenic mice/specific T-cell receptor and, 9.64
- Retinol, 2.275, 2.275*f*, 2.276
- Retinopathy, 5.99–103, 5.100*t*. *See also* Retinitis; *specific type*
 acute zonal occult outer (AZOOR), 9.141–143*t*, 9.164–166, 9.165*f*, 12.226–228, 12.227*f*
 aging and, 1.178
 in antiphospholipid antibody syndrome, 9.134
 arteriosclerotic, 12.122
 autoimmune, 5.103, 12.286
 cancer-associated (CAR), 5.102, 12.286, 12.287*f*
 ERG in, 5.96, 5.102
 central serous (CSR). *See* Central serous chorioretinopathy
 chloroquine/hydroxychloroquine, 1.173
 in congenital rubella syndrome, 9.203, 9.204*f*
CRB1-related, 12.258
 crystalline
 cause of, 12.302–304, 12.303*t*
 drugs that cause, 12.302–304
 tamoxifen as cause of, 12.303, 12.304*f*
 West African, 12.303–304, 12.305*f*
 diabetic. *See* Diabetic retinopathy
 herpetic necrotizing, 9.193–198, 9.194*f*, 9.194*t*, 9.195*f*, 9.295–296, 9.296*f*
 HIV, 9.293, 9.294*f*. *See also* HIV infection/AIDS, retinitis in
 hydroxychloroquine/chloroquine, 1.173
 hypertensive, 1.79, 1.80*t*, 12.121–123, 12.122*f*, 12.124*f*
 hyperviscosity, 12.134
 in leukemia, 4.315, 4.315*f*
 lupus, 9.133*f*, 9.133–134, 9.134*f*
 in measles, 9.206–207
 melanoma-associated (MAR), 5.102–103, 12.286
 ERG in identification of, 5.96, 5.102–103
 neurotrophic keratopathy/persistent corneal epithelial defect and, 8.81, 8.81*t*
 occlusive, 12.300–301
 in ocular ischemic syndrome, 5.170, 5.171*f*, 12.138
 optic neuropathy differentiated from, 5.99–100, 5.100*t*
 paraneoplastic, 5.102–103
 pigmentary, 12.282–283*t*. *See also* Retinitis pigmentosa
 in congenital rubella syndrome, 9.203, 9.204*f*
 hearing loss and. *See* Usher syndrome
 in measles, 9.206–207
 pigmented paravenous, 12.263
 in polyarteritis nodosa, 1.167, 9.136
 of prematurity (ROP)
 aggressive posterior, 6.326, 6.327*t*, 6.330*f*, 6.333, 12.177
 angle-closure glaucoma in, 12.181
 anti-VEGF agents for, 6.333
 bevacizumab for, 6.333
 birth weight and, 12.182
 blindness caused by, 6.335, 12.182
 cicatrical, 6.67, 12.181
 classification of, 6.325–326, 6.327*t*, 6.328–330*f*, 6.331*t*, 12.175–179, 12.176*t*, 12.178*t*
 clinically significant, 12.184*t*
 complications of, 6.334–335
 conditions associated with, 12.181–182
 cryotherapy for, 6.331
 definition of, 12.175
 demarcation line in, 6.328*f*
 diagnosis of, 6.329, 6.331

- diet and, 12.184–185
- digital retinal photography for, 6.331
- discovery of, 6.325
- Early Treatment for Retinopathy of Prematurity
 - classification of, 6.326, 6.331*t*
- end stage of, 12.175
- epidemiology of, 12.175
- extrafoveal retinal detachment in, 6.329*f*
- extraretinal fibrovascular proliferation in, 6.329*f*
- familial exudative vitreoretinopathy versus, 12.344
- follow-up examinations for, 6.332*t*
- glaucoma and, 10.144
- incidence of, in premature infants, 12.182
- in infants, 12.175
- insulin growth factor-1 in, 6.325, 6.326*t*, 12.182
- International Classification of Retinopathy of Prematurity, 6.325, 6.327*t*
- late sequelae of, 12.181–182
- location of, 6.327*t*
- macular dragging associated with, 6.334, 6.334*f*
- myopia associated with, 6.334
- natural course of, 12.181
- neovascularization in, 12.180–181
- ocular examination for, 6.329, 6.331, 6.332*t*
- oxygen supplementation and, 12.184
- panretinal photocoagulation for, 6.332, 6.333*f*
- pathophysiology of, 6.325, 6.326*t*, 12.180–182
- plus disease, 6.326, 6.327*t*, 6.330*f*
- posterior persistent fetal vasculature versus, 12.342
- pre-plus disease, 6.326, 6.327*t*, 6.330*f*
- prethreshold disease, 6.326, 12.178*t*, 12.179, 12.185
- prevention of, 12.184–185
- pseudoexotropia associated with, 6.334, 6.335*f*
- pupillary-block glaucoma in, 12.181
- ranibizumab for, 6.333
- risk factors for, 6.326–327, 12.184–185
- scleral buckling for, 6.335
- screening of, 6.329, 6.331, 6.332*t*
 - birth weight–based criteria for, 12.182
 - criteria for, 12.182–183
 - discontinuation of, criteria for, 12.183
 - fundus photographic, 12.184
 - intervals for, 12.183
- sequelae of, 6.334–335, 12.181–182
- severity of, 12.176*t*
- spontaneous regression of, 12.181
- stage 1, 6.327*t*, 6.328*f*, 12.176, 12.176*f*, 12.180
- stage 2, 6.327*t*, 6.328*f*, 12.176, 12.176*f*, 12.180
- stage 3, 6.327*t*, 6.329*f*, 12.176, 12.177*f*, 12.180
- stage 4, 6.327*t*, 6.329*f*, 12.176, 12.177*f*, 12.180, 12.187–188
- stage 5, 6.327*t*, 6.335, 12.188
- supplemental oxygen as risk factor for, 6.326–327
- telemedicine for, 6.331
- terminology for, 12.175–176, 12.176*f*
- threshold disease, 12.177, 12.178*t*, 12.179, 12.180*f*, 12.181, 12.185
- threshold level of, 6.331
- treatment of, 6.331–334
 - anti-VEGF drugs, 12.186–187
 - bevacizumab, 12.186–187
 - cryoblation, 12.185–186
 - intravitreal injections, 12.187
 - laser surgery, 12.185–186
 - overview of, 12.185
 - photocoagulation, 12.186*f*
 - scleral buckling surgery, 12.187–188
 - vitreotomy, 12.187–188
- type 1, 6.326, 6.331*t*, 6.332
- type 2, 6.326, 6.331*t*, 6.332
- vascular endothelial growth factor in, 6.325, 6.326*t*
- vitreotomy for, 6.335
- weight, IGF-1, neonatal ROP algorithm for, 12.182
- zones of, 6.325, 6.328*f*
- Purtscher, 12.171–173, 12.173*t*
- Purtscherlike, 12.171–173, 12.172*f*, 12.173*t*
- radiation, 1.230–231, 12.170*f*, 12.170–171
- refractive surgery in patient with, 13.190
- in rubella (congenital), 9.203, 9.204*f*
- sickle cell. *See* Sickle cell retinopathy
- solar, 12.277, 12.367, 12.368*f*
- syndromic/systemic diseases associated with, 12.257*t*
- in systemic sclerosis, 1.163
- thioridazine as cause of, 12.297
- Valsalva, 12.171
- venous stasis (VSR), 5.170
- Retinopexy
 - laser, 12.376–377
 - pneumatic, for rhegmatogenous retinal detachment, 12.397–398, 12.398*f*
- Retinoschisis, 12.279
- Retinoschisis
 - bullous, 12.326
 - demarcation lines in, 12.328
 - imaging of, 12.327*f*
 - juvenile
 - abusive head trauma as cause of, 6.383
 - description of, 6.342–343
 - diagnosis of, 6.344–345*f*
 - treatment of, 6.344
 - outer-schisis-layer holes associated with, 12.327, 12.327*f*
 - reticular degenerative (bullous), 4.148, 12.326, 12.327
 - retinal detachments and, 12.326–328, 12.328
 - rhegmatogenous retinal detachment versus, 12.327*t*, 12.327–328
 - typical degenerative, 4.148, 12.326
- Retinoscope/retinoscopy
 - alignment of, 3.151
 - applications of, 3.150
 - cataract evaluations, 6.299
 - before cataract surgery, 11.80
 - concave mirror setting with, 3.150, 3.151*f*
 - correcting lens in, 3.153–155, 3.154*f*
 - definition of, 3.148
 - dynamic
 - accommodation measurements using, 6.9
 - in children, 6.9
 - examiner positioning during, 3.151
 - fixation for, 3.152
 - fogging for, 3.152
 - initial estimate of refractive error obtained using, 3.28
 - irregular astigmatism and, 8.163
 - against movement in, 3.152, 3.153*f*, 3.155
 - with movement in, 3.152, 3.153*f*, 3.155
 - neutrality, 3.152, 3.153–154*f*, 3.155

- pictorial representation of, 3.150f
- plane mirror setting with, 3.150
- plus cylinder phoropter for, 3.159t
- regular astigmatism application of
 - cylinder axis, 3.156–158, 3.157–158f
 - cylinder power, 3.158
 - overview of, 3.155–156
- retinal reflex, 3.152–153f, 3.152–153
- streak projection system used in, 3.150, 3.273
- summary of, 3.159t
- working distance in, 3.154
- Retinoscopic reflex. *See* Retinal reflex
- Retinyl ester, 2.275, 2.275f, 2.276
- Retisert. *See* Fluocinolone implant
- Retraction, eyelid, 5.274, 5.275f, 5.275t, 7.222f, 7.222–224
 - after blepharoplasty, 7.223, 7.234
 - in dorsal midbrain (Parinaud) syndrome, 5.229, 5.250, 5.274, 5.275t, 7.223
 - pseudoptosis/ptosis and, 5.274, 5.275t
 - seizures causing, 1.203
 - in thyroid eye disease, 4.226, 4.227f, 5.131, 5.274, 5.275f, 5.275t, 7.52, 7.52f, 7.54, 7.56, 7.59, 7.222–223, 7.223, 7.224
 - treatment of, 7.223–224
- Retractors, eyelid, 7.149–151, 7.150f
 - lower eyelid, 7.146f, 7.151
 - in involutional ectropion, repair of, 7.200–201
 - in involutional entropion, 7.202–203
 - repair of, 7.204, 7.205f
 - upper eyelid, 7.149–151, 7.150f
- Retro-orbicularis oculi fat (ROOF), 7.146f, 7.152, 7.153
- Retro-orbital plexus, 2.101f
- Retrobulbar anesthesia, 6.174. *See also* Anesthesia
 - adverse reactions to, 1.291, 1.305
 - agents for, 2.363
 - for cataract surgery, 11.91, 11.91f
 - hemorrhage and, 11.158, 11.171
 - for phakic IOL insertion, 13.141
- Retrobulbar drug administration, 2.299
- Retrobulbar hemorrhage
 - after blepharoplasty, vision loss and, 7.233
 - cataract surgery and, 11.158, 11.171
- Retrobulbar optic neuritis, 5.113, 5.114
 - in cryptococcosis, 5.356
- Retrochiasmal lesions, 5.146, 5.152–159
 - lateral geniculate body lesions, 5.154, 5.154f
 - in multiple sclerosis, 5.318
 - occipital lobe lesions, 5.147f, 5.156–158, 5.157f, 5.158f, 5.159f
 - optic tract lesions, 5.147f, 5.153
 - parietal lobe lesions, 5.156
 - temporal lobe lesions, 5.147f, 5.155, 5.155f
- Retrocorneal fibrous membrane (RCFM/posterior collagenous layer), 2.227, 4.84, 4.85f
- Retrogeniculate (cerebral/cortical) visual impairment, 6.186. *See also* Cerebral/cortical blindness
- Retroillumination, 3.292, 3.293f
 - for slit-lamp biomicroscopy, 8.17f, 8.19, 8.20f
- Retrolaminar nerve/retrolaminar area of optic nerve, 2.86, 2.87, 10.42, 10.43, 10.45f, 10.46
 - blood supply of, 2.90–91, 2.92f
- Retrolental fibroplasia. *See* Retinopathy, of prematurity
- Retroviruses (Retroviridae), 8.240t, 8.240–241
 - cancer association of, 1.228
 - HIV as, 1.263
- Rev-Eyes. *See* Dapiprazole
- Revascularization procedures. *See also* Coronary artery bypass graft; Percutaneous coronary intervention
 - for angina, 1.99–100
 - for carotid occlusive disease, 1.124
 - for heart failure, 1.111
- Reverse amblyopia, 6.55–56, 6.59–60
- Reverse-geometry lens, after radial keratotomy, 13.199
- Reverse Marcus Gunn response, in ocular trauma, 8.401
- Reverse slab-off, induced anisophoria correction using, 3.188–189
- Reverse transcriptase, 1.263, 8.240
- Reverse transcriptase inhibitors
 - nonnucleoside (NNRTIs), 1.266
 - nucleoside (NRTIs), 1.266
- Reverse transcriptase–polymerase chain reaction (RT-PCR), 4.38t
- Reverse transcription, 2.143
- Reversible cerebral vasoconstriction syndrome (RCVS), 5.346–348, 5.347f
- Reversible cholinesterase inhibitors, 2.312
- Reversible encephalopathy syndrome, posterior (PRES), 5.333–335, 5.335f
- Revised European American Lymphoma (REAL) classification, 7.85, 7.86
- Reye syndrome, aspirin use and, 2.335–336
- ReZoom zonal refractive intraocular lens, 13.166
- RF. *See* Rheumatoid factor
- RF-negative polyarthritis, uveitis in, 9.122–126, 9.123f, 9.124t
- RFLPs (restriction fragment length polymorphisms), 2.162
- RGCs (retinal ganglion cells). *See* Ganglion cells/ ganglion cell layer (GCL), retinal
- RGP contact lenses. *See* Rigid gas-permeable (RGP) contact lenses
- RGS9 gene, 12.49
- Rhabdomyosarcoma
 - eyelid, 6.200
 - of orbit, 4.236, 4.237f, 7.82f, 7.82–84
 - orbital, 6.217f, 6.217–218
 - retinoblastoma associated with, 4.302t
- Rhabdoviridae, 8.240, 8.240t
- Rhegmatogenous retinal detachment (RRD)
 - child abuse and, 6.384
 - chronic, 12.324f
 - complex, 12.401
 - definition of, 12.396
 - diagnostic features of, 12.320, 12.321t
 - floaters associated with, 12.320
 - incidence of, 12.320
 - intraocular pressure in, 12.320
 - lattice degeneration associated with, 12.310
 - “macula-off,” 12.401
 - macular hole as cause of, 12.330, 12.330f
 - management of, 12.324, 12.324f, 12.397
 - pigmented demarcation lines with, 12.324
 - pneumatic retinopexy for, 12.324, 12.397–398, 12.398f

- proliferative vitreoretinopathy associated with, 12.320, 12.323*f*, 12.323*t*, 12.323–324
 reattachment surgery for, 12.401–402
 retinal breaks as cause of, 12.314–315, 12.320, 12.322*f*, 12.396
 retinoschisis versus, 12.327*t*, 12.327–328
 risk factors for, 12.396
 scatter photocoagulation as cause of, 12.155
 scleral buckling for, 12.324, 12.398–400, 12.399*f*
 Shafer sign, 12.320
 surgical repair of, 12.397–401, 12.398–400*f*
 tractional retinal detachment versus, 12.325
 vision loss caused by, 12.128
 vitrectomy for, 12.324, 12.400*f*, 12.400–401
 word origin of, 12.320
- Rheopheresis, 12.71
- Rheumatic disorders, 1.151–176. *See also specific type*
 medical therapy for, 1.170–176, 1.171*t*, 1.174*t*
 recent developments in, 1.151
- Rheumatoid arthritis (RA), 1.151–152
 cataract surgery in patient with, corneal melting/keratolysis and, 11.132
 juvenile. *See Juvenile idiopathic (chronic/rheumatoid) arthritis*
 peripheral ulcerative keratitis and, 8.311, 8.312, 8.312*f*
 refractive surgery contraindicated in, 13.191
 scleritis/scleromalacia perforans and, 8.321–322, 8.322*f*
- Rheumatoid factor (RF), 1.152
 in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.122
 uveitis and, 9.122
- Rheumatoid melt, 8.368
- Rheumatoid nodules, 1.152
- Rhinocerebral zygomycosis, 5.355, 5.355*f*
- Rhinophyma, in rosacea, 8.71, 8.71*f*
- Rhinosporidium/Rhinosporidium seeberi* (rhinosporidiosis), 8.249*t*, 8.251
- Rhinoviruses, 8.240*t*
- Rhizopus*, 8.249*t*, 8.251
 ocular infection caused by, 5.355*f*, 5.355–356
 orbital, 7.50
- Rhodopsin, 2.258–259, 2.259*f*, 2.260*f*, 2.261, 12.252, 12.264
 light affecting, 2.258, 2.259, 2.259*f*, 2.261
 phosphorylation of, 2.258, 2.259*f*, 2.261
 regeneration of, retinal pigment epithelium in, 2.274–276, 2.275*f*
- Rhodopsin (*RHO*) gene mutation, in retinitis pigmentosa, 2.161, 2.263, 4.170
- Rhodopsin kinase, 2.260*f*, 2.261
 mutation in, 2.263
- RHoT. *See Right hypotropia*
- Rhytidectomy, 7.245*f*, 7.245–246
- Ribavirin, for hepatitis C, 1.261
- Riboflavin (vitamin B₂), 3.114
 in corneal crosslinking, 13.130–131, 13.132–134, 13.133*f*
- Ribonucleic acid. *See RNA*
- Ribosomal RNA (rRNA), mitochondrial DNA-encoded, mutations of, 2.157
- Ribosomes, 2.147, 2.148*f*, 2.151*f*, 2.152
- Richner-Hanhart syndrome, 6.270, 8.183. *See also Tyrosinemia*
- Riddoch phenomenon, 5.158, 5.181
- Riders, 11.35
- Ridley intraocular lens, 11.118*f*, 11.118–119
- RIEG1/RIEG2* genes, 10.11*t*. *See also PITX2* gene
- Rieger anomaly/syndrome, 8.102, 10.153. *See also Axenfeld-Rieger syndrome*
 gene for, 10.11*t*
- Rifabutin, 1.255, 12.305
 endothelial pigmentation caused by, 8.132
 uveitis caused by, 9.121
- Rifampicins, 1.272
- Rifampin, 1.255, 1.279
 for cat-scratch disease/bartonellosis, 9.258, 12.243
 ocular effects of, 1.307*t*
- Rift Valley fever (RVF), 9.210–212, 9.211*f*
- Right hypotropia (RHoT), 6.17
- Right to Sight, 11.6
- Rigid contact lenses (hard contact lenses). *See Rigid gas-permeable (RGP) contact lenses*
- Rigid gas-permeable (RGP) contact lenses. *See also Contact lenses*
 advantages of, 3.214*t*, 3.215
 apical alignment fit of, 3.218–219, 3.219*f*
 apical bearing of, 3.218
 apical clearance of, 3.218
 for astigmatism, 13.17
 after refractive surgery, 13.199
 base curve of, 3.218, 3.219*f*
 central fit of, 3.219
 characteristics of, 3.213–214
 corneal abnormalities corrected using, 3.226
 corneal reshaping, uses of, 3.228
 disadvantages of, 3.215
 discontinuing use of before refractive surgery, 13.38
 fitting of, 3.218–221*f*, 3.218–222, 3.220*t*
 fluorescein patterns for fitting evaluations, 3.219*f*, 3.219–220
 indications for, 3.207*t*, 3.227
 interpalpebral fit of, 3.219
 keratoconus correction using, 3.226
 after LASIK, 13.199, 13.200
 for myopia reduction (orthokeratology), 13.70–71
 orthokeratology, 3.228
 pannus associated with, 3.232
 parameters of, 3.220*t*
 ptosis secondary to, 3.233
 after radial keratotomy, 13.199
 after refractive surgery, 13.199
 scleral, 3.226–227
 soft lenses versus, 3.218
 tear layer created by, 3.221
 tear lens, 3.218, 3.218*f*
- Rigidity, in Parkinson disease, 1.199
- Riley-Day syndrome (familial dysautonomia/FD), 2.175*t*, 6.271
 congenital corneal anesthesia and, 8.108
 racial and ethnic concentration of, 2.197
- Rilpivirine, 1.266
- “Rim”/RIM proteins, 2.261. *See also specific type*
 mutations in, 4.168–169
- RimabotulinumtoxinB, 5.281. *See also Botulinum toxin*

- Rimantadine, 1.281
- Rimexolone, 2.330*t*, 2.334
for uveitis, ocular hypertension/glaucoma and, 9.286
- riMLF. *See* Rostral interstitial nucleus of medial longitudinal fasciculus
- Ring infiltrate, in *Acanthamoeba* keratitis, 4.79, 4.79*f*, 8.277, 8.277*f*
- Ring melanoma, 4.193, 4.194*f*, 4.262, 4.263*f*
- Ring of Elschnig, 10.43
- Ring opacity, topical anesthetic abuse and, 8.89, 8.89*f*
- "Ring sideroblast," 1.137
- Ring sign
in nonspecific orbital inflammation, 7.64
in optic nerve sheath meningioma, 5.127*f*
- Riolan muscle, 2.21, 4.201, 7.149, 7.153, 7.154*f*
- Rise time, in phacoemulsification, 11.102, 11.103
- Risk, 1.21
relative, 1.21, 1.208
baseline probability of the outcome and, 1.21–22
- Risk calculators, 1.22–23
for acute coronary syndrome, 1.103, 1.104
for atrial fibrillation, 1.114
- Risk difference, 1.21
- Risk factor, 1.22. *See also specific disorder*
in cohort studies, 1.10*f*, 1.11–12
in cross-sectional studies, 1.10*f*, 1.11
pretest probability of disease and, 1.18–19, 1.19*t*
- Risk ratio, 1.21–22
- Risorius muscle, 7.141, 7.143*f*
- Ritipenem, 1.276
- Rituximab, 1.175, 6.322, 9.42, 9.108
for antiphospholipid antibody syndrome, 1.161
for cancer chemotherapy, 1.236
for granulomatosis with polyangiitis (Wegener granulomatosis), 1.168
for primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.312, 9.275
for primary vitreoretinal lymphoma, 12.234
for scleritis, 8.324
for thyroid eye disease, 7.58
for uveitis, 9.108
- Rivaroxaban, 1.148
for heart failure, 1.111
in perioperative setting, 1.286
- River blindness (onchocerciasis), 8.252–253, 9.234–235, 9.235*f*
- Rizzutti sign, 8.163
- RK. *See* Radial keratotomy
- RLBP1* gene, 12.252
- RLE. *See* Refractive lens exchange
- RLF (retrolental fibroplasia). *See* Retinopathy, of prematurity
- RLH. *See* Reactive lymphoid hyperplasia
- RMC (recurrent multifocal choroiditis). *See* Multifocal choroiditis
- RMS (root mean square) error, magnitude of wavefront deviation and, 13.9
- RNA
amplification of, in polymerase chain reaction, 2.141–142
messenger (mRNA), 2.147, 2.151, 2.151*f*, 2.152
precursor, 2.148, 2.151*f*, 2.152
micro (miRNA), 2.1139
in retinal pigment epithelium, 2.274
ribosomal (rRNA), mitochondrial DNA-encoded, mutations of, 2.157
short interfering (small interference) (siRNA), 2.143
in gene therapy, 2.170
splicing of, 2.144, 2.152
alternative, 2.148, 2.152–153
transfer (tRNA), mitochondrial DNA-encoded, mutations of, 2.157
virus, 8.211. *See also* RNA viruses
- RNA viruses, 8.211, 8.239–241, 8.240*t*. *See also specific virus*
cancer association of, 1.228
- RNFL (retinal nerve fiber layer). *See* Nerve fiber layer
- ROC (receiver operating characteristic) curve
comparison of different screening devices and, 1.17–18, 1.18*f*
comparison of screening thresholds with continuous predictive variable and, 1.16*f*, 1.16–17, 1.17*f*
- Rochalimaea henselae*. *See* *Bartonella (bartonellosis), henselae*
- Rod cGMP-gated channel, 2.259, 2.260*f*, 2.261
mutations in, 2.161, 2.263
- Rod cGMP phosphodiesterase (rod PDE), 2.259–261, 2.260*f*
mutation in, 2.161, 2.263
- Rod inner segments, 2.69, 2.72*f*, 4.140*f*. *See also* Photoreceptor inner segments; Rods
free-radical leakage from, 2.285
- Rod monochromatism, 2.264, 6.337, 12.250, 12.250*t*.
See also Achromatopsia
- Rod outer segment protein 1 (ROM1), 2.261
mutation in, 2.264
- Rod outer segments, 2.69, 2.70, 2.72*f*, 2.257–258, 2.258*f*, 4.140*f*. *See also* Photoreceptor outer segments; Rods
antioxidants in, 2.288, 2.289*f*
energy metabolism in, 2.261
oxidative damage to, 2.285
phototransduction in, 2.257–261, 2.259*f*, 2.260*f*
shed, retinal pigment epithelium phagocytosis of, 2.276*f*, 2.276–277
- Rod phosphodiesterase (rod PDE), 2.259–261, 2.260*f*
mutation in, 2.161, 2.263
- Rod response, 2.262, 2.269, 2.269*f*. *See also* Dark adaptation
- Rod transducin, 2.259, 2.260*f*, 2.261
mutation in, 2.263
- Rod-cone dystrophies. *See also* Retinitis pigmentosa
in Bardet-Biedl syndrome, 12.284
characteristics of, 12.261–264, 12.262–264*f*
conventional testing of, 12.261
electroretinography evaluations, 12.46, 12.47*f*, 12.261
imaging of, 12.262–264*f*
macula-spared, 12.46, 12.47*f*
- Rods, 2.69, 2.71*f*, 2.72*f*, 2.88*f*, 2.257, 2.258*f*, 5.24. *See also* Rod outer segments
abnormalities of. *See* Night blindness; Night-vision abnormalities
amacrine cells for, 2.267
bipolar cells for, 2.257, 2.258*f*
density of, 12.11–12
development of, 2.116*t*, 2.122

- electrophysiologic responses of, 2.269, 2.269*f*
 in foveal center, 12.11
 gene defects in, 2.263–264, 2.264
 inner segments of, 12.11–12, 12.12*f*
 light-sensitive molecules in, 12.12
 outer segments of, 12.11, 12.12*f*
 phototransduction in, 2.257–261, 2.259*f*, 2.260*f*
 schematic diagram of, 12.14*f*
- Rods (bacteria), 8.244*t*
 gram-negative, 8.244*t*, 8.247*f*, 8.247–248
 therapy for infection caused by, 8.270*t*
 gram-positive, 8.244*t*, 8.245–247, 8.246*f*
- Rofecoxib
 cardiovascular toxicity and, 2.239
 withdrawal of, from market, 1.172, 9.94
- ROIs. *See* Reactive oxygen intermediates
- ROM1 (rod outer segment) gene/protein, 2.261
 mutation in, 2.264
- Romiplostim, for idiopathic thrombocytopenic purpura, 1.143
- Romycin. *See* Erythromycin
- RON. *See* Radiation optic neuropathy
- ROOF (retro-orbicularis oculi fat), 7.146*f*, 7.152, 7.153
- ROOH. *See* Hydroperoxides
- Root mean square (RMS) error, magnitude of wavefront deviation and, 13.9
- ROP. *See* Retinopathy, of prematurity
- Ropinirele, for Parkinson disease, 1.199
- Rosacea, 6.244, 8.69–71, 8.70*f*, 8.71*f*
 blepharitis and, 8.70, 8.73*t*
 cataract surgery in patient with, 11.172–173
 meibomian gland dysfunction and, 8.60, 8.70
- Rose bengal stain, 2.367, 8.37
 in superior limbic keratoconjunctivitis, 8.84, 8.84*f*
 in tear film/dry eye evaluation, 8.37, 8.56
- Rosenmüller, valve of, 7.253, 7.254*f*
- Rosenthal, basilar vein of, 5.22
- Rosenthal fibers, in optic nerve gliomas, 4.249, 4.249*f*, 7.76
- Roseolovirus, 1.257
- Rosette cataract, 11.54, 11.54*f*
- Rosettes
 in medulloepithelioma, 4.178*f*, 4.179
 in primary intracranial pinealoblastoma, 4.298
 in retinoblastoma, 4.174–175, 4.175*f*
- Rosiglitazone, 12.301
 for diabetes mellitus, 1.45*t*, 1.46
 with metformin, 1.46
- Rostral interstitial nucleus of medial longitudinal fasciculus (riMLF), 5.33, 5.35, 5.35*f*, 5.220
 saccadic eye movements and, 5.220
 vertical gaze and, 5.36, 5.36*f*, 5.220
- Rosuvastatin, for hypercholesterolemia/heart disease prevention, 1.86*t*
- Roswell Park Memorial Institute (RPMI) tissue culture medium, as tissue fixative, 4.26*t*
- Rotation/rotational flap
 for eyelid repair, 7.191, 7.192
 for wound closure after pterygium excision, 8.354*f*
- Rotational corneal autograft, 8.451
- Rotations, ocular
 definition of, 6.31
 horizontal, 6.31
 torsional, 6.31
 vertical, 6.31
- Roth spots, 4.154, 9.264
- Rothmund-Thomson syndrome, 8.192*t*
- Rotigotine, for Parkinson disease, 1.199
- Rotterdam Study, 10.82, 10.83
- Rowland-Payne syndrome, Horner syndrome and, 5.260*t*
- RP. *See* Retinitis pigmentosa
- RPCD. *See* Reticular peripheral cystoid degeneration
- RPD. *See* Reticular pseudodrusen
- RPE. *See* Retinal pigment epithelium
- RPE65 gene, 6.337, 12.266
 RPE65 gene/RPE65 protein, 2.273, 2.275, 2.275*f*
 mutation in, 2.264
 gene therapy and, 2.169, 9.62
 in Leber congenital amaurosis, 2.264
- RPED. *See* Retinal pigment epithelium (RPE), detachment of
- RPMI. *See* Roswell Park Memorial Institute (RPMI) tissue culture medium
- RPR. *See* Rapid plasma reagin (RPR) test
- RPR (rapid plasma reagin) test, 1.248, 9.241
- RRD (rhegmatogenous retinal detachment). *See* Retinal detachment
- rRNA. *See* Ribosomal RNA
- RS1 gene, 6.342, 12.279
- RSB. *See* Residual stromal bed
- RT. *See* Radiation therapy
- RT-PCR. *See* Real-time quantitative polymerase chain reaction; Reverse transcriptase–polymerase chain reaction
- RTIA. *See* Retinal transient ischemic attack
- rtPA (recombinant tissue plasminogen activator). *See* Tissue plasminogen activator
- Rubella, 1.221–222, 6.410, 6.410*f*, 6.410–411, 9.203–205, 9.204*f*
 acquired, 9.204–205
 congenital (CRS), 1.221, 8.240, 8.240*t*, 9.203–204, 9.204*f*, 9.205
 aphakia and, 4.117
 cataracts and, 9.203, 9.204*f*, 11.38–39
 glaucoma and, 10.150*t*
 Fuchs heterochromic uveitis/iridocyclitis and, 9.44, 9.127, 9.205
 immunization against, 1.218*t*, 1.221–222
- Rubeola (measles) virus, 8.239, 8.240*t*, 9.206
 immunization against, 1.218*t*, 1.221
 travel and, 1.224
 ocular infection caused by, 8.239, 8.240*t*, 9.206–208, 9.208*f*
- Rubeosis iridis (iris neovascularization), 4.188, 4.189*f*
 in diabetes mellitus, 4.159, 4.160*f*
 glaucoma and, 4.188, 10.32, 10.39, 10.132*t*, 10.133, 10.133*f*, 10.135*f*. *See also* Neovascular glaucoma
 in children and adolescents, 10.149*t*
 incisional surgery contraindicated in, 10.198
 laser iridotomy contraindicated in, 10.191
 in retinoblastoma, 4.174, 4.174*f*, 4.292
- Rubinstein-Taybi syndrome, congenital corneal keloids in, 8.107
- Ruby laser. *See* Lasers
- Rufinamide, 1.202*t*

Ruiz procedure, 13.8t
 “Rule-1” test, for accommodative control, 3.35
 Run chart, 1.27–29, 1.29f
 Rush disease, 12.177, 12.178t. *See also* Aggressive posterior retinopathy of prematurity (AP-ROP)
 Russell bodies, 4.9
 “Rust ring,” iron foreign body causing, 8.399, 8.400f
 Ruthenium 106
 for retinoblastoma, 4.301
 for uveal melanoma, 4.275
 RVF. *See* Rift Valley fever
 RVO. *See* Retinal vein occlusion
 RX gene, 2.126
 Ryanodine receptor 1 (*RYR1*) gene, in malignant hyperthermia, 1.292

S

S-100 protein, in immunohistochemistry, 4.33
 in adenoid cystic carcinoma, 4.231
 S-antigen, in experimental autoimmune uveitis/
 sympathetic ophthalmia, 9.63
 S-cone (blue-cone) monochromatism, 2.264, 12.250
 ocular findings in carriers of, 2.199t
 S cones, 2.262, 12.54
 horizontal cells for, 2.266
 retinal ganglion cells for, 2.267, 2.267f
 S phase, cell cycle, 2.148, 2.149, 2.149f
 SA. *See* Sideroblastic anemia
 SA node. *See* Sinoatrial (SA) node
 Sabin vaccine (oral polio vaccine/OPV), 1.222
 Sabin's tetrad, 9.221
 Saccades/saccadic system, 5.32–33, 5.38, 5.212, 5.212t,
 5.219–223, 5.220f
 antiepileptic drugs affecting, 1.203
 in diplopia, 5.186
 dysfunction of, 5.221–223. *See also* Saccadic
 intrusions/oscillations
 in Alzheimer disease, 1.206
 in internuclear ophthalmoplegia, 5.189
 ocular motor apraxia and, 5.221, 5.222–223
 in progressive supranuclear palsy, 5.214, 5.221
 dysmetric saccades and, 5.222
 hallucinations and, 5.175
 hypermetric saccades and, 5.221, 5.222, 5.248,
 5.248f
 hypometric saccades and, 5.221, 5.222
 inability to initiate/ocular motor apraxia, 5.221,
 5.222–223
 velocity of, 5.219–220, 5.221
 Saccadic initiation failure (ocular motor apraxia), 5.221,
 5.222–223
 Saccadic interval, intrusions and
 normal, 5.247–248, 5.248f
 not normal, 5.248f, 5.248–249
 Saccadic intrusions/oscillations, 5.214, 5.221, 5.233,
 5.247–250, 5.248f
 intersaccadic intervals and
 normal, 5.247–248, 5.248f
 not normal, 5.248f, 5.248–249
 macrosaccadic, 5.248, 5.248f
 in multiple sclerosis, 5.319
 ocular flutter and, 5.243t, 5.248, 5.248f, 5.249
 voluntary flutter/“nystagmus” and, 5.249–250
 Saccadic (cogwheel) pursuit, 5.219, 5.224, 5.225, 5.226
 Saccadic system, 6.40
 Saccadic velocity, 6.73
 Saccadomania (opsoclonus), 5.248–249
 in neuromyelitis optica, 5.322
 Saccomanno fixative, for tissue preservation, 4.26t
 Saccular (berry) aneurysm, 1.126, 5.338
 Saccule, 5.38, 5.39f, 5.214, 5.215, 6.40
 Sacroiliitis, in spondyloarthropathies/spondyloarthritis,
 1.153
 Saddle-nose deformity, in relapsing polychondritis,
 1.164
 Saethre-Chotzen syndrome, 6.207, 6.208f
 SAG gene, 12.253
 Sagging eye syndrome, 5.209, 5.228
 Sagittal curvature. *See* Axial curvature
 Sagittal depth or vault, of contact lenses, 3.205, 3.215f,
 3.216
 Sagittal sinus
 inferior, 5.22f
 superior (SSS), 2.105, 2.106f, 5.22, 5.22f
 thrombosis in, 5.346
 Sagittal suture, 5.5
 SAILOR study, 12.81
 Sakacin, 1.280
 Salbutamol, 1.133
 Saline solution, for contact lens, 3.229
 Salisbury Eye Evaluation project, 11.6
 Salivary glands, in Sjögren syndrome, 8.57, 8.58t
 Salivatory (salivary) nucleus, 2.101f, 2.103, 2.104, 5.51f,
 5.55, 5.276–277f
 superior, 8.5f
 Salk vaccine (inactivated poliovirus vaccine/IPV), 1.222
 Salmeterol, 1.133–134
 Salmon patches/salmon patch hemorrhages, 12.150,
 12.150f
 description of, 6.269
 in orbital lymphoma, 7.86, 7.87f
 in syphilitic keratitis, 8.107, 8.308, 8.309f
Salmonella, 8.247
 Salt-and-pepper fundus/retinopathy
 rubella and, 9.203, 9.204f
 syphilis and, 9.237
 Salzmann nodular degeneration, 4.81, 4.82f, 8.124f,
 8.124–125, 8.125f
 Sampaulesi line
 in pigment dispersion syndrome/pigmentary
 glaucoma, 10.94
 in pseudoexfoliation/exfoliation syndrome, 10.39,
 10.93
 Sample size, 1.5
 clinical and statistical significance and, 1.26
 monitoring system implementation and, 1.25–26
 Sandhoff disease (GM₂ gangliosidosis type II), 2.175t,
 6.389t
 Sanfilippo syndrome (MPS III A–D), 2.175t, 6.388t,
 8.175t, 12.282t, 12.291
 Sanger sequencing, 2.143, 2.161, 2.162, 2.162f
 SAP. *See* Standard automated perimetry
 Sarcoid granuloma/nodule, 5.126f, 5.327, 8.347, 9.166,
 9.168, 9.169

- Sarcoidosis, 4.186–187, 4.187*f*, 5.327–328, 6.318*f*, 6.318–319, 7.63, 9.80*f*, 9.81*f*, 9.86, 9.166–171, 9.167*f*, 9.168*f*, 9.169*f*, 12.134, 12.231, 12.231*f*
 anterior uveitis and, 9.90*f*, 9.167, 9.168
 conjunctivitis and, 4.52, 4.52*f*
 cranial nerve VII (facial) involvement and, 5.280, 5.327
 diagnosis and treatment of, 5.327–328
 eyelid manifestations of, 4.207*t*
 glaucoma and, 9.169
 HLA association in, 9.67*t*
 intraocular manifestations of, 5.327
 keratic precipitates in, 9.80*f*, 9.168, 9.168*f*
 neovascularization in, 9.291
 neuro-ophthalmologic manifestations in, 5.327
 optic nerve involvement and, 4.187, 4.245, 4.245*f*, 5.115, 5.126*f*, 5.327
 orbit affected in, 7.63
 panuveitis and, 9.166–171, 9.167*f*, 9.168*f*, 9.169*f*
 pars planitis and, 9.129
 posterior synechiae/iris nodules in, 9.81*f*, 9.168, 9.168*f*, 9.169
 screening/diagnostic tests for, 7.34, 7.63
 uveal tract affected in, 4.186–187, 9.80*f*, 9.81*f*
- Sarcoma, 4.10, 4.10*t*, 4.11*f*
 Ewing, retinoblastoma associated with, 4.302*t*
 granulocytic (chloroma), 4.316, 7.98–99
 Kaposi. *See* Kaposi sarcoma
 orbital, 7.84
 exenteration for, 7.136
 secondary, 7.97
 reticulum cell. *See* Primary central nervous system/
 intraocular/vitreoretinal/retinal lymphoma
 retinoblastoma associated with, 4.302, 4.302*t*
- Satellite DNA, 2.150
 Satellite lesion, 6.409
 Sattler layer, 12.19
 Sattler veil, 3.232
 Saxagliptin, for diabetes mellitus, 1.45*t*, 1.46–47
 SBE (subacute bacterial endocarditis). *See* Endocarditis/
 endocarditis prophylaxis
- SC. *See* Sickle cell hemoglobin C; Superior colliculus
 SCA. *See* Superior cerebellar artery
- Scanning, in ophthalmic examination, 8.20–24, 8.21*f*, 8.22*f*, 8.23*f*, 8.24*f*. *See also specific type*
- Scanning laser ophthalmoscopy/ophthalmoscope (SLO), 3.282, 3.301–303
 angiography versus, 12.24
 blue excitation light used by, 12.31
 choroidal nevi on, 12.24
 digital resolution of, 12.24
 ellipsoidal mirror in, 12.24
 epiretinal membrane on, 12.334*f*
 in optic nerve/nerve head/disc evaluation, 10.56
 pseudodrusen on, 12.24
 resolution of, 12.24
 retinal disease evaluations, 12.24
 wavelengths in, 12.24
- Scanning laser polarimetry/polarimeter (GDx/SLP), 3.99, 3.303
 in optic nerve/nerve head/disc evaluation, 10.56
- Scanning-slit confocal microscope, 8.24. *See also*
 Confocal microscopy
- Scanning-slit lasers, for photoablation, 13.30–31, 13.31
- Scanning-slit technology, 8.35*t*
 for corneal tomography, 13.19
 for pachymetry, 13.45. *See also* Pachymetry/
 pachymeter
 with Placido disk–based topography, 8.34
- Scanning training, 3.310, 3.325
- Scaphocephaly, 6.205
- Scars
 keloid
 corneal, 8.125
 congenital, 8.107–108, 8.125
 refractive surgery in patient with history of, 13.77
 retinal, 4.17
 wound repair and, 4.13, 4.14*f*
- Scatter diagram, 1.27, 1.28*f*
 for flow cytometry results, 4.37*f*
- Scatter photocoagulation. *See also* Panretinal
 photocoagulation; Photocoagulation
 branch retinal vein occlusion treated with, 12.128–130
 sickle cell retinopathy treated with, 12.155
 vitreoretinal surgery for, 12.155
- Scattering, of light
 age-related increase in, 3.98
 definition of, 3.96–97
 geometric, 3.91, 3.97–98
 Mie, 3.92, 3.97–98
 Rayleigh, 3.92, 3.97
 for slit-lamp biomicroscopy, 8.17*f*, 8.19
 Tyndall effect and, 3.97
- Scavenging/scavenging macrophages, 9.19–20, 9.20*f*
 phacolytic glaucoma and, 9.21
- Scavenging receptors, 9.20
- SCC. *See* Squamous cell carcinoma
- SCD. *See* Schnyder corneal dystrophy; Sudden cardiac
 death
- Scedosporium*, 8.251
- Schachar theory of accommodation, 13.160–162, 13.161*f*
- Schaumann bodies, in sarcoidosis, 4.187
- Scheie stripe, 10.94, 10.95*f*
- Scheie syndrome (MPS IS/MPS1-S), 2.175*t*, 2.184, 6.270, 6.388*t*, 8.174, 8.175*t*, 12.282*t*, 12.290–291
- Scheimpflug camera systems, 3.248, 3.289
 in corneal biomechanics evaluation, 8.43
 for corneal tomography, 8.34, 8.34*f*, 8.35*f*, 8.35*t*, 13.19, 13.21*f*
 in keratoconus, 8.165*f*, 8.165–166
- Scheimpflug principle, 3.282, 3.289
- Scheiner, Christopher, 3.285
- Scheiner disk, 3.285, 3.289
- Scheiner principle, 3.282, 3.285, 3.286*f*
- Schematic eye, 3.125–128, 3.126*f*, 3.127*t*, 3.128*f*
 description of, 3.244*f*
 reduced, 3.124, 3.126
- Schiötz (indentation) tonometry, 10.19, 10.26
- Schirmer tests, 8.38–39, 8.57*t*
 in pseudoepiphora, 7.268
 type I, 7.268, 8.38–39
 type II, 7.268, 8.39
- Schisis, macular, 12.328
- Schizoaffective disorder, 1.189
 treatment of, 1.197–198

- Schizophrenia, 1.188–189
 drugs for (antipsychotic drugs), 1.193*t*, 1.193–194, 1.198
 oculoerythric crisis caused by, 5.231
- Schizophreniform disorder, 1.189
- Schlaegel lines, 12.225
- Schlemm canal, 2.45*f*, 2.46*f*, 2.50*f*, 2.50–51, 2.51*f*, 2.52*f*, 2.59*f*, 4.98, 6.286, 6.286*f*, 10.5*f*, 10.13, 10.18, 10.18*f*
 development of, 2.116*t*
 gonioscopic visualization of, 10.38, 10.38*f*
- Schlichting dystrophy. *See* Posterior polymorphous corneal dystrophy
- Schnabel, cavernous optic atrophy of, 4.246, 4.247*f*
- Schnyder corneal dystrophy (SCD), 6.270, 6.387*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.151–152, 8.152*f*
 crystalline form of, 8.151, 8.152*f*
 hyperlipoproteinemia and, 8.151, 8.179
- Schocket procedure, 10.214
- School-aged children. *See also* Children
 eye examination in, glaucoma and, 10.157, 10.157*t*
- Schwalbe line, 2.38, 2.44, 2.45*f*, 2.46*f*, 2.54*f*, 4.97, 4.97*f*, 4.98*f*, 6.255, 8.9, 8.101, 10.33*t*, 10.34*f*, 10.36
 gonioscopic appearance of, 10.33*t*, 10.34*f*, 10.36
 prominent (posterior embryotoxon), 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.101–102, 8.102*f*
 in Axenfeld-Rieger syndrome, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.102, 10.31, 10.153
 isolated, Axenfeld-Rieger syndrome differentiated from, 10.154*t*
- Schwann cells
 in neurofibroma, 7.77
 retinal, 2.38
- Schwannoma (neurilemoma/neurinoma)
 conjunctival/ocular surface, 7.82, 8.345
 of orbit, 4.238, 4.239*f*, 6.223, 7.82
 of uveal tract, 4.199
 vestibular, Bruns nystagmus and, 5.243
- Schwartz (Schwartz-Matsuo) syndrome, 9.279, 10.109
- Schwinger, Julian, 3.96
- Scientific studies. *See* Clinical research/studies
- Scintigraphy. *See* Radionuclide scintigraphy/scans;
specific type
- Scintillating scotomata/scintillating scotoma with fortification spectrum. *See also* Scotomata
 in arteriovenous malformation, 5.343
 in migraine headache, 5.161, 5.177, 5.290*f*, 5.290–291, 5.291
- Scissors reflex, 3.159
- sCJD. *See* Sporadic Creutzfeldt-Jakob disease
- Sclera, 2.17*f*, 2.37*f*, 2.38, 2.43–44, 2.46*f*, 4.107*f*, 4.107–112, 4.108*f*, 4.113*f*, 5.17*f*. *See also* Episclera
 aging of, 4.111, 4.111*f*
 anatomy of, 2.17*f*, 2.37*f*, 2.38, 2.43–44, 2.46*f*, 4.107*f*, 4.107–108, 4.108*f*, 5.17*f*, 12.20
 bare, wound closure after pterygium excision and, 8.351, 8.353*t*, 8.353–355, 8.354*f*
 recurrence rate and, 8.353*t*
 blue, 8.195*t*
 in Ehlers-Danlos syndrome, 8.191*t*, 8.193
 in keratoglobus, 8.171
 in Marfan syndrome, 8.194
 in osteogenesis imperfecta, 1.143, 8.194, 8.194*f*
 congenital anomalies of, 4.108–109, 8.95–109, 8.96–98*t*
 degenerations of, 4.111*f*, 4.111–112, 4.112*f*, 8.128, 8.129*f*
 development of, 2.116*t*, 2.124
 disorders of, 4.107–112, 4.113*f*, 8.46*t*. *See also*
 Episcleritis; Scleritis; *specific type*
 common clinical findings in, 8.46*t*
 immune-mediated, 8.318–326
 ionizing radiation causing, 8.386
 neoplastic, 4.112, 4.113*f*
 in polyarteritis nodosa, 9.136
 Th1-mediated delayed hypersensitivity and, 9.46*t*
 in glaucoma, 10.31
 healing/repair of, 4.16
 immune response/features/microenvironment of, 9.54*t*
 indentation of, 12.310*f*
 infection/inflammation of, 4.109–110, 4.110*f*, 4.111*f*, 8.282–283, 8.283*f*. *See also* Episcleritis; Scleritis
 laceration/penetrating wound of, 12.359. *See also*
 Corneoscleral lacerations
 melanoma involving, 4.194, 4.195*f*
 nonspecific orbital inflammation involving, 7.64
 in pathologic myopia, 12.216–217, 12.217*f*
 perforation of
 repair of. *See* Corneoscleral lacerations, repair of
 traumatic, 2.43–44
 permeability of, 12.20
 pigment spot of, 8.338
 rupture of, 2.43–44, 12.352, 12.358
 stroma of, 2.44, 4.107*f*, 4.107–108, 4.108*f*
 surgical perforation of, 6.30, 6.170
 thickness of, 12.20, 12.216
 thinning of
 from primary congenital glaucoma, 6.283
 in scleritis, 8.321–322, 8.323
 topography of, 2.37*f*, 2.38, 4.107*f*, 4.107–108, 4.108*f*
 traumatic injuries to, 12.352, 12.358
 in uveitis, 9.73
- Scleral buckling/buckle, 12.201
 complications of, 12.400
 intraocular pressure affected by, 12.399
 for retinal detachment
 angle-closure glaucoma after, 10.143
 after cataract surgery, 11.166–167
 refractive surgery after, 13.185
 in uveitis, 9.291
 for retinal hemangioblastoma, 4.285
 for retinopathy of prematurity, 6.335
 retinopathy of prematurity treated with, 12.187–188
 rhegmatogenous retinal detachment treated with, 12.324, 12.398–400, 12.399*f*
- Scleral contact lenses. *See also* Contact lenses, scleral
 for dry eye, 8.61*t*, 8.63
 for graft-vs-host disease, 8.304, 8.305*f*
 for limbal stem cell deficiency, 8.94
- Scleral expansion bands, for presbyopia, 13.162, 13.163*f*
- Scleral-fixated posterior chamber intraocular lenses
 after ICCE, 11.200
 insertion of, 11.116–117
 after keratoplasty, 11.176
 ocular trauma and, 11.193
 uveitis and, 11.188

- Scleral fixation, 12.393
- Scleral flap, for trabeculectomy, 10.200–201, 10.203f
closure of, 10.202–204, 10.205f
management of, 10.207–208
- Scleral graft
for cicatricial entropion, 7.207
for exposure and extrusion of orbital implant, 7.133
- Scleral plaques
senile (Cogan), 8.128, 8.129f
senile/senile calcific, 4.111, 4.111f
- Scleral shells, for cosmesis/pain, 7.128
- Scleral spur, 2.45f, 2.46f, 2.47f, 2.48, 4.97–98, 4.98f, 6.181, 10.33t, 10.34f, 10.36
- Scleral spur cells, 2.48
- Scleral sulcus, internal, 2.48, 4.98
- Scleral support ring, for ICCE, 11.199
- Scleral surgery. *See also specific procedure*
infectious scleritis after, 9.259
for presbyopia, 13.162–163, 13.163f
for scleritis, 9.112
- Scleral tunnel incisions, for cataract surgery, 11.107f, 11.107–108
after radial keratotomy, 11.177, 13.53
- Sclerectomy, for glaucoma
deep (nonpenetrating), 10.217–219
in uveitis, 9.287
- Scleritis, 4.109–110, 4.110f, 4.111f, 8.282–283, 8.283f, 8.319–326, 8.320t, 8.320f, 8.321f, 8.322f, 8.323f, 8.324t, 8.325f
anterior, 8.320, 8.320f, 8.320t, 8.321f
brawny, 4.110, 4.110f
cataract surgery in patient with, 11.170–171
clinical presentation of, 8.319–323, 8.320f, 8.320t, 8.321f, 8.322f
complications of, 8.323
corticosteroids for, 8.324, 9.111, 9.260
route of administration of, 2.333t, 9.111
diffuse anterior, 8.320, 8.320f, 8.320t, 8.321f, 8.325f
in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168, 7.61, 9.138
in herpes zoster, 8.227, 8.282, 9.259
immune-mediated, 8.319–326, 8.320f, 8.320t, 8.321f, 8.322f, 8.323f, 8.324t, 8.325f
infectious/microbial, 8.282–283, 8.283f, 9.259–260
laboratory evaluation of, 8.323–324, 8.324t, 9.259–260
management of, 8.324–326, 8.325f, 9.260
necrotizing, 4.110, 4.110f, 8.46t, 8.320t, 8.320–322, 8.321f, 8.322f, 8.325f, 9.111, 9.259, 9.260, 9.260f
with inflammation, 8.320t, 8.320–321, 8.321f
without inflammation (scleromalacia perforans), 4.110, 8.320t, 8.321–322, 8.322f
surgically induced (SINS), 8.282
nodular anterior, 8.320, 8.320t, 8.321f, 8.325f
noninfectious, 9.111–112
nonnecrotizing, 4.110, 8.46t, 9.111
nonspecific orbital inflammation and, 7.64
pain and, 5.295, 8.319, 8.320, 8.322, 9.112
pathogenesis of, 8.319
in polyarteritis nodosa, 9.136
posterior, 8.319, 8.320t, 8.322f, 8.322–323
staphylococcal and, 4.110, 4.111f, 4.112, 8.322
subtypes and prevalence of, 8.319, 8.320t
ultrasonography in identification of, 5.95
- Sclerocornea, 6.257t, 6.260, 6.261f, 8.98t, 8.105, 8.106f
cornea plana and, 8.96t, 8.98t, 8.100, 8.105
in Peters anomaly, 4.74, 4.75f
- Scleroderma. *See* Systemic sclerosis
- Scleroderma renal crisis, 1.163
- Sclerokeratitis, 8.323
- Scleromalacia perforans, 4.110, 8.320t, 8.321–322, 8.322f
- Sclerosing agents, for lymphatic malformation, 7.71
- Sclerosing (morpheaform) basal cell carcinoma, 4.212–213, 4.213f, 7.178f, 7.178–179, 7.180. *See also* Basal cell carcinoma
- Sclerosing nonspecific orbital inflammation, 7.65, 7.66.
See also Nonspecific orbital inflammation
- Sclerosis
multiple. *See* Multiple sclerosis
nuclear, 11.43, 11.45f, 11.48f, 11.50f
smoking and, 11.6–7
systemic. *See* Systemic sclerosis
tuberosus (TS/Bourneville disease/syndrome), 5.330, 5.331f, 5.334t
glaucoma associated with, 10.30
- Sclerosis sine scleroderma, 1.162
- Sclerostomy, for uveitic glaucoma, 9.287
- Sclerotic (gliotic) lesions, in multiple sclerosis, 5.316, 5.316f
- Sclerotic scatter, 3.292–293, 3.293f
for slit-lamp biomicroscopy, 8.17f, 8.19
- Sclerotomy
anterior ciliary (ACS), for presbyopia, 13.162
for suprachoroidal hemorrhage, 11.160
- Sclerouveitis, 9.73
in inflammatory bowel disease, 9.116
- SCLO. *See* Confocal scanning laser ophthalmoscopy/ophthalmoscopy
- Sclopetaria, 4.22
chorioretinitis, 4.22
- Scopolamine, 2.313, 2.314t, 2.315t
- Scotomas
absolute, 12.327
central, 12.86, 12.265
central suppression, 4Δ base-out prism test for, 6.79
foveal-sparing, 3.314, 3.315f
paracentral, 12.228, 12.367
pictorial representation of, 3.318f
retinoschisis as cause of, 12.327
suppression
description of, 6.49
4Δ base-out prism test for, 6.79
Worth 4-dot test for, 6.80f, 6.80–81
variations in, 3.317
vision rehabilitation and, 3.317
- Scotomata, 5.105t
arcuate (Bjerrum), 5.103, 5.105t, 5.106f, 10.68, 10.68f
in arteriovenous malformation, 5.343
arteriovenous malformations causing, 5.291, 5.343
cecocentral, 5.103, 5.105t, 5.106f
central, 5.103, 5.105t, 5.106f
in glaucoma, 10.68, 10.68f, 10.70f, 10.86

- “junctional,” 5.146–147, 5.148f, 5.151f
 in migraine aura without headache, 5.291
 in migraine headache, 5.161, 5.171–172, 5.177, 5.290f, 5.290–291, 5.291
 in multiple evanescent white dot syndrome, 9.161
 as nonorganic disorders, 5.306–308, 5.307f, 5.308f, 5.309f
 papillomacular fiber lesions causing, 5.103, 5.106f
 paracentral, 5.103, 5.105t, 5.106f, 10.68, 10.70f, 10.86
 pericentral, 5.105t
 physiologic (blind spot), 5.24
 cortical area corresponding to, 5.29f
 enlargement of, 5.103, 5.106f
 acute idiopathic (AIBSE), 5.100–101, 5.101f
 in multiple choroiditis and panuveitis, 9.156
 in multiple evanescent white dot syndrome, 9.161, 9.163
 in serpiginous choroiditis, 9.151
 systemic hypoperfusion causing, 5.157–158, 5.159f
 in uveitis, 9.78
- Scotopic spectral luminous efficiency function, 3.109
- Scrapie, 5.357
- Scraping, for specimen collection, 8.210
- Screen reading, 3.323, 3.324f
- Screening/diagnostic tests, 1.207–216. *See also specific test or disorder*
 interpretation of, 1.14–21, 1.15t
 clinical acceptance/ethics and, 1.20
 combination strategies and, 1.19–20
 complicating features in, 1.16f, 1.16–19, 1.17f, 1.18f, 1.19t
 continuous value measurement and, 1.17f, 1.17–18, 1.18f
 criteria for diagnosis and, 1.22
 generalizability and, 1.20
 pretest probability and, 1.18–19, 1.19t
 ROC curves in, 1.17–18, 1.18f
 of lacrimal drainage function, 7.269f, 7.269–272, 7.270f, 7.271f
 in orbital disorders, 7.33–34
 for thyroid eye disease, 7.33, 7.57t
- Screening threshold, comparison of, to continuous predictive value, 1.16–17, 1.17f
- Sculpting, in phacoemulsification, settings for, 11.111
- Scurf, in seborrheic blepharitis, 8.72, 8.72f
- Scurvy (ascorbic acid deficiency), 1.142–143
- SD-OCT. *See* Spectral-domain optical coherence tomography
- SDH. *See* Shape-discrimination hyperacuity
- SE (spin echo) technique, 5.62, 5.75
- Sea-blue histiocyte syndrome (chronic Niemann-Pick disease), 12.291. *See also* Niemann-Pick disease
- Sea fan neovascularization, 12.151, 12.153f
- Seasonal conjunctivitis
 allergic, 6.246f, 6.246–248, 8.288–289
 vernal, 8.289–292, 8.290f, 8.291f
- Sebaceous adenoma, 4.210t, 4.215, 4.216f, 7.170
 in tuberous sclerosis, 5.331f, 10.30
- Sebaceous carcinoma/adenocarcinoma, 4.210t, 4.215–218, 4.216f, 4.217f, 7.183f, 7.183–184, 8.327, 8.337f, 8.337–338
- Sebaceous cysts (epidermal inclusion cysts), of eyelid, 4.208, 4.208f, 7.168, 7.168f
- Sebaceous glands of eyelid, 2.19, 2.24, 4.201, 4.202, 7.170, 8.4
 glands of Zeis, 2.19, 2.22f, 2.23t, 2.215
 meibomian glands, 2.20f, 2.22f, 2.23t, 2.24, 2.25f
 tumors/lesions of, 4.210t, 4.215–218, 4.216f, 4.217f, 8.327, 8.337f, 8.337–338
 benign, 4.215, 7.170
 malignant, 4.210t, 4.215–218, 4.216f, 4.217f, 7.183f, 7.183–184
- Sebaceous hyperplasia, 4.215, 4.216f, 7.170
- Seborrheic blepharitis, 8.72, 8.72f, 8.73t
- Seborrheic keratosis, 4.209, 4.209f, 4.210f, 7.167, 7.167f
- Sebum, in chalazion formation, 7.162
- Secluded pupil, 10.119, 10.138, 10.139f
- “Second corneal apex,” 3.272
- Second cranial nerve. *See* Optic nerve
- Second-degree relatives, 2.143
- Second nodal point, 3.66
- Second-order aberrations, 3.276f, 13.11, 13.11f
- Second-order neuron, 5.52, 5.53f, 5.53–54
 dilator muscle innervation and, 2.56
 Horner syndrome caused by lesions of, 5.257, 5.259, 5.260, 5.260t, 5.261f
- Second-order Zernike polynomials, 3.73
- Second principal plane, 3.56
- “Second sight,” 11.43, 11.70
- Secondary acquired melanosis, 4.65–66
- Secondary anophthalmia, 7.35
- Secondary aphakia, 4.117, 11.30. *See also* Aphakia
- Secondary childhood glaucoma
 acquired condition, 6.284
 after cataract surgery, 6.285
 classification of, 6.278t
 nonacquired conditions associated with, 6.284t
- Secondary coloboma, 11.31. *See also* Colobomas
- Secondary deviation
 definition of, 6.39
 primary deviation versus, 6.115
- Secondary diagnostic position of gaze, 6.31
- Secondary glaucoma. *See* Angle-closure glaucoma, secondary; Glaucoma; Open-angle glaucoma, secondary
- Secondary hypertension, 1.64, 1.64t
 in children and adolescents, 1.78
- Secondary hypothyroidism, 1.54
- Secondary lens fibers, development of, 11.27f, 11.27–28
 microspherophakia and, 11.33
- Secondary lipid keratopathy, 8.125, 8.126f
- Secondary megalocornea, 6.254
- Secondary vasculitis, 1.165
- Secondary vitreous, 2.122, 2.123f, 4.125
- Secretogranin II, in aqueous humor, 2.231
- Secretory immunoglobulin A (IgA), in tear film, 2.216
- Secretory lacrimal apparatus, 2.22f, 2.28f, 2.28–29, 2.217–220, 2.218f, 2.219f, 7.251–252, 7.252f. *See also* Lacrimal gland
 anatomy of, 7.251–252, 7.252f
 development of, 7.255
 abnormalities of, 7.257
 disorders of, 7.257–287
- Sectoral cataracts, 6.297–298

- Sectoral iris palsy, 5.254
 anisocoria/Adie tonic pupil and, 5.256f, 5.263, 5.263f
- Sectoranopia, lateral geniculate body lesions causing, 5.154, 5.154f
- Sectorial retinitis pigmentosa, 12.263, 12.264f
- Sedative-hypnotics/sedation, 1.194–198, 1.195t, 1.196t
 for benign essential blepharospasm, 7.228
 perioperative, 1.289t, 1.290–291
- See-saw (vision loss) nystagmus, 5.243t, 5.247, 6.152
- SEFs. *See* Supplementary eye fields
- Segment removal, in phacoemulsification, settings for, 11.111
- Segmental phlebitis, 12.232
- Segmented contact lenses, 3.224–225
- Segregation (genetic), 2.143, 2.184, 2.186–187
 replicative, 2.143, 2.157
- Seidel aberrations, 3.41, 3.72, 3.72f
- Seidel test, 8.36–37, 8.38f
 after penetrating keratoplasty, 8.423
- Seizures, 1.200–204, 1.303–304. *See also* Epilepsy
 arteriovenous malformations causing, 5.343
 diagnosis of, 1.201–202
 etiology of, 1.201
 facial movements/palsy/Todd paralysis and, 1.201, 5.285
 hallucinations and, 5.177
 intracranial hemorrhage and, 1.126
 local anesthetics causing, 1.292
 ocular deviations caused by, 5.230
 ophthalmic considerations and, 1.203–204
 transient visual loss caused by, 5.161, 5.162, 5.172
 treatment of/antiepileptic drugs, 1.202t, 1.202–204, 1.303–304
 in emergencies, 1.296t, 1.303–304
 ocular effects of, 1.203, 1.307t
- Selectins, in neutrophil rolling, 9.17, 9.18f
- Selection bias, 1.4
 in case-control studies, 1.11
 in case series, 1.9
- Selective laser trabeculoplasty (SLT), 10.188, 10.189, 10.190, 10.190f
- Selective serotonin reuptake inhibitors (SSRIs), 1.196t, 1.196–197
- Selegiline, for Parkinson disease, 1.199
- Selenium, in retina and retinal pigment epithelium, 2.287, 2.289f
- Selenium-dependent glutathione peroxidase (GSH-Px), 2.287
- Selenoprotein P, in aqueous humor, 2.231, 2.233
- Self-examination, breast, for cancer screening, 1.210t
- Self-monitoring of blood glucose, 1.40–41
- Self-sealing incision, for cataract surgery, 11.118
 beveled/biplanar, clear corneal incision and, 11.106f, 11.106–107
- Self-tolerance
 AIRE (autoimmune regulator) and, 9.64
 T regulatory cells in, 9.37, 9.38
- Sella turcica, 5.5, 5.6f, 5.10f
- Semi-scleral contact lenses, 3.227
- Semicircular canals, 6.40
 hair cells of, 5.38, 5.39f
 vestibular-ocular reflex and, 5.214–215
 peripheral vestibular nystagmus and, 5.215, 5.216, 5.241, 5.242
- Semicircular flap
 for canthal repair, 7.195
 for eyelid repair, 7.161, 7.192, 7.193f, 7.194f, 7.195
- Semilunar ganglion (gasserian/trigeminal ganglion), 2.9f, 2.98f, 2.99, 2.99f, 2.101f, 5.42f, 5.48, 5.48f, 7.16, 7.17f
 herpes simplex/varicella zoster virus latency and, 8.205, 8.207, 8.212, 8.213, 8.226
- Senile furrow degeneration, 8.122
- Senile lentigo, 7.174
- Senile macular degeneration. *See* Age-related macular degeneration/maculopathy
- “Senile” ptosis, 5.273
- Senile scleral (Cogan) plaque, 8.128, 8.129f
- Senile/senile calcific/Cogan plaques, scleral, 4.111, 4.111f, 8.128, 8.129f
- Senior-Løken syndrome, 6.391
- Sensation, in cornea, 8.8
 esthesiometry in evaluation of, 8.42–43
 reduction/absence of
 congenital, 8.108
 in herpes simplex epithelial keratitis, 8.217–218, 8.226t
 in herpes zoster, 8.226t, 8.228
 keratoplasty and, 8.418, 8.424
 in neurotrophic keratopathy/persistent corneal epithelial defects, 8.80, 8.224
- Sensitivity, of screening/diagnostic test, 1.15, 1.208
 continuous value measurement and, 1.17f, 1.17–18, 1.18f
 likelihood ratio calculation and, 1.19
- Sensitivity threshold, in perimetry, 5.86, 5.87f, 5.91.
See also Threshold stimulus/testing
- Sensitization (activation/priming), lymphocyte, 9.36f, 9.36–38, 9.38
- Sensorcaine. *See* Bupivacaine
- Sensory adaptation testing
 afterimage test, 6.79, 6.79f
 amblyoscope testing, 6.79–80
 Bagolini lenses, 6.77f, 6.77–78
 description of, 6.75
 4Δ base-out prism test, 6.78f, 6.78–79
 red-glass test, 6.75–76, 6.76f
 Worth 4-dot test, 6.80f, 6.80–81
- Sensory binocularity, 6.75
- Sensory esotropia, 6.93–94
- Sensory exotropia, 6.104
- Sensory fusion, 6.43
- Sensory nucleus
 of cranial nerve V (trigeminal), 2.97, 2.98f, 2.99, 2.99f, 2.101f, 5.47, 5.47f
 of cranial nerve VII (facial), 2.103
- Sensory nystagmus, 6.187
- Sensory pathways, 5.47f, 5.47–49, 5.48f. *See also* Cranial nerve V
- Sensory root
 of cranial nerve V₁ (ophthalmic), 2.11, 2.12f
 of cranial nerve V (trigeminal), 2.97
 of cranial nerve VII (facial), 2.102–103
- Sentinel bleed, before aneurysm rupture, 5.340
- Sentinel lymph node (SLN) biopsy
 in conjunctival/ocular surface melanoma, 8.344
 in eyelid melanoma, 7.185
 in sebaceous adenocarcinoma, 7.184

- Sentinel vessels, 4.68, 4.69*f*, 4.262, 4.263*f*, 10.31
Septata, keratoconjunctivitis caused by, 8.280
 Septate filamentous fungi, 8.249, 8.249*t*, 8.250*f*, 8.251.
 See also Filamentous fungi; Fungi
 Septic emboli, 12.141
 Septic shock (sepsis), 1.301
 Septic thrombosis
 cavernous sinus, 5.345
 orbital infection/cellulitis and, 5.345, 7.48
 lateral (transverse) sinus, 5.345
 Septo-optic dysplasia (de Morsier syndrome), 5.143–144, 6.361, 6.363*f*
 Sequence, 6.183
 Sequencing, DNA, 2.161–162, 2.162*f*, 2.163*f*, 2.164*f*, 2.165*f*, 2.166*f*
 next-generation (NGS/massively parallel), 2.140, 2.142, 2.161, 2.163*f*, 2.164*f*, 2.165*f*, 2.166*f*, 4.39*t*
 Seroconversion conjunctivitis, in HIV infection/AIDS, 8.240*t*, 8.241
 Seroconversion syndrome, acute, 1.264
 Serologic tests. *See also specific type*
 in Lyme disease, 1.251–252, 9.246
 in syphilis, 1.248–249, 9.241
 on CSF, 9.241
 in uveitis, 9.88–89*t*
 Seronegative spondyloarthropathies, 1.153–156. *See also* Spondyloarthropathies/spondyloarthritis; *specific type*
 uveitis in, 9.114–117, 9.116*f*
 Serotonin, antipsychotic mechanism of action and, 1.193
 Serotonin modulators, 1.196*t*
 Serotonin–norepinephrine reuptake inhibitors, 1.196*t*
 Serotonin reuptake inhibitors, selective (SSRIs), 1.196*t*, 1.196–197
 Serous choroidal detachment, melanoma differentiated from, 4.270–271
 Serous pigment epithelial detachment, 12.72–73, 12.74*f*
 Serous retinal detachment
 in children, 6.362
 in intraocular lymphoma, 12.234
 MEK inhibitors as cause of, 12.299
 Serpiginoid/serpiginous-like choroiditis (tuberculosis-related), 9.154, 9.252, 9.252*f*
 Serpiginous choroiditis/choroidopathy (geographic/helicoid peripapillary), 9.141–143*t*, 9.151–154, 9.152*f*, 9.153*f*, 12.220*t*, 12.222–223, 12.223*f*
 tuberculosis and (serpiginoid/serpiginous-like), 9.154, 9.252, 9.252*f*
Serratia, 8.247
 Serum drops
 for dry eye, 2.342, 8.61*t*, 8.63
 for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81, 8.824
 for superior limbic keratoconjunctivitis, 8.84
 Sessile papillomas, conjunctival, 4.60
 Setting sun sign, 5.231
 Seventh cranial nerve. *See* Cranial nerve VII
 Seventh nerve (facial) palsy. *See* Facial paralysis/weakness
 Sex chromosomes, 2.147, 2.184, 2.189*f*
 aneuploidy of, 2.189
 mosaicism and, 2.191–192
 Sex-determining region Y (SRY/testis-determining factor/TDF), 2.179
 Sex-linked inheritance (sex-linked genes), 2.143, 2.178.
 See also X-linked inheritance; Y-linked inheritance
 Sex (gender), in glaucoma, 10.9, 10.121
 SF. *See* Surgeon factor
 SF₆. *See* Sulfur hexafluoride
 SF3B1 gene, in choroidal/ciliary body melanoma, 4.197, 4.278
 SFU. *See* Subretinal fibrosis and uveitis syndrome
 SGLT2 inhibitors. *See* Sodium-glucose transporter-2 (SGLT2) inhibitors
 Shafer sign, 12.320, 12.348
 Shaffer gonioscopic grading system, 10.37
 Shagreen, crocodile, 8.121
 Shagreen patch, in tuberous sclerosis, 5.334*t*
 Shaken baby syndrome, 12.365–366, 12.366*f*. *See also* Abusive head trauma
 Shallow anterior chamber. *See* Anterior chamber, flat or shallow
 Shape-discrimination hyperacuity (SDH), 12.69
 Shave biopsy, 7.179*f*
 Sheathing, retinal vascular
 in Behçet disease, 9.186
 in sarcoidosis, 9.169, 9.169*f*
 in toxoplasmosis, 9.222
 Sheehan syndrome (pituitary apoplexy), 1.58, 5.149, 5.150*f*
 Sherrington's law of reciprocal innervation, 6.33
 Shh factor, gene expression/ocular development and, 2.127
 Shield ulcer, 6.248, 6.249*f*, 8.290, 8.291*f*
Shigella, 8.207, 8.247
 invasive capability of, 8.207
 Shimmering, electroretinography findings in, 12.46
 Shingles. *See* Herpes zoster
 Shock, 1.300–305. *See also specific type*
 anaphylactic, 1.301–303
 assessment of, 1.301
 classification of, 1.300–303
 treatment of, 1.296*t*, 1.301
 Short arm 11 deletion syndrome (11p13 syndrome/PAX6 gene mutation), 2.193
 in aniridia, 2.152, 2.177, 2.193, 4.184, 10.150, 11.33
 Short (p) arm, 2.141, 2.148*f*
 Short ciliary arteries, 5.13*f*, 5.14*f*, 5.15–17, 5.17*f*
 optic nerve supplied by, 10.44, 10.45*f*, 10.45–46
 Short ciliary nerves, 2.12, 2.12*f*, 2.100, 5.55*f*, 7.12*f*, 7.14*f*, 7.15*f*, 7.16, 7.17*f*
 Adie tonic pupil and, 5.263, 5.264, 5.264*f*, 5.265
 ciliary muscle supplied by, 2.95
 posterior, 2.32
 sphincter muscle supplied by, 2.56
 Short interfering (small interference) RNA (siRNA), 2.143
 in gene therapy, 2.170
 Short interspersed elements (SINEs), 2.150
 Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), 5.289*t*, 5.294
 Short tau inversion recovery (STIR) technique, 5.62–65, 5.63*t*, 5.75
 Short-wavelength automated perimetry (SWAP), 10.75

- Short-wavelength sensitive cones. *See* S cones
- Shotgun sequencing, whole-genome, 2.163*f*
- Shunting surgery
for glaucoma, 10.213–217, 10.214*t*, 10.218*t*, 10.219–220. *See also* Microshunts; Tube shunts
for idiopathic intracranial hypertension, 5.112, 5.113, 6.371
- Sialic acid, in microbial adherence, 8.207
- Sialidases, dysmorphic (ML I), 8.178
- Sialidosis, 6.388*t*
- Sickle cell disease/sickle cell anemia (hemoglobin SS), 1.139
genetic testing/counseling for, 1.135, 1.139
hyphema/elevated intraocular pressure and, 8.395, 8.395*t*, 8.396, 10.104, 10.105
mutations causing, 2.184
ophthalmic manifestations of. *See also* Sickle cell retinopathy
traumatic hyphema and, 8.395*t*, 8.396
elevated intraocular pressure and, 8.395, 8.395*t*, 8.396
surgery for, 8.395, 8.395*t*, 8.396
preoperative screening for, 1.284
proliferative sickle cell retinopathy complications in, 12.150
racial and ethnic concentration and, 2.197
- Sickle cell hemoglobin C disease (SC), 1.139, 2.184
ocular findings in, 12.153*f*
proliferative sickle cell retinopathy complications in, 12.150
- Sickle cell hemoglobinopathies
description of, 12.149
incidence of, 12.149*t*
ocular abnormalities in, 12.154
racial predilection for, 12.149, 12.154
- Sickle cell retinopathy
hyphema/elevated intraocular pressure and, 10.104, 10.105
management of, 12.154–155
nonproliferative
branch retinal artery occlusions in, 12.152*f*
characteristics of, 12.149–150
imaging of, 12.150–152*f*
retinal arteriolar occlusions in, 12.151*f*
salmon-patch hemorrhage in, 12.150*f*
proliferative
complications of, 12.150
proliferative diabetic retinopathy versus, 12.151
scatter photocoagulation for, 12.155
sea fan neovascularization associated with, 12.151, 12.153*f*
stages of, 12.150–151
retinal detachment secondary to, 12.155
scatter photocoagulation for, 12.155
thalassemia as cause of, 12.149
- Sickle cell trait/disease, 6.378
- SICRET (Susac) syndrome, 9.139*f*, 9.139–140
- Sideroblastic anemia (SA), 1.137
- Siderosis/siderosis (hemosiderosis) bulbi, 4.103, 4.120, 11.58*f*, 11.58–59, 12.362, 12.363*t*
corneal deposits/pigmentation in, 8.118*t*
glaucoma and, 4.103, 10.103
- Siegrist streaks, 12.123, 12.198
- Siepsler slipknot technique, for IOL decentration, 11.145, 11.146*f*
- sIgA. *See* Secretory immunoglobulin A
- Sight substitution devices, 3.325
- Sigmoid sinus, 2.105, 2.106*f*, 5.22, 5.22*f*
- Sigmoidoscopy, in cancer screening, 1.210*t*, 1.214
- Signal error information, 5.40
- Signal transduction
mechanisms of, 2.316*t*
in tear secretion, 2.217–219, 2.218*f*, 2.219*f*
- Significance
clinical, 1.7, 1.26
statistical, 1.7, 1.14, 1.26. *See also* P value
- Sildenafil, 12.299, 12.304
color vision affected by, 5.175
ocular effects/retinal toxicity of, 1.306, 1.308*t*, 5.175
for pulmonary arterial hypertension, 1.129
- Silent sinus syndrome, 7.95–96, 7.96*f*
- Silent visual fields, nonorganic disorder evaluation and, 5.308
- Silicone foldable intraocular lenses, 11.120. *See also* Foldable intraocular lenses
IOL opacification and, 11.151
after ocular trauma, 11.193
in uveitis, 11.188, 11.188*f*
- Silicone oil, 12.401
cataract/cataract surgery and, 11.83, 11.120, 11.190
intraocular lenses in eyes filled with, 3.254
intravitreal administration of, 2.300*t*
- Silicone oil tamponade, with vitrectomy, for retinal detachment
in CMV retinitis, 9.295
in uveitis, 9.291
- Silicone plugs, for dry eye, 7.281–282, 8.64–65, 8.65*f*.
See also Lacrimal plugs
- Silicone rods, for frontalis suspension, 7.221
- Silicone stent, for intubation, 7.262, 7.263. *See also* Lacrimal intubation
- Silicone suspension sling, for paralytic ectropion, 7.226
- Silodosin, intraoperative floppy iris syndrome and, 11.74, 11.136, 11.137*t*
- Silver, 12.306
- Silver compounds, corneal deposits of/pigmentation caused by, 8.118*t*, 8.132
- Silver nitrate, for gonorrheal ophthalmia neonatorum, 6.239
- SIM K. *See* Corneal power simulation measurements
- Simcoe cannula, 11.198, 11.199*f*
- Simple (physiologic/essential) anisocoria, 5.256*f*, 5.257
- Simple diffusion, glucose transport into lens and, 11.17*f*
- Simple (diffuse injection) episcleritis, 4.109, 8.318
- Simple epithelial (epidermoid) cysts, of orbit, 4.223–224, 7.39. *See also* Epithelial cysts
- Simple hyperopic astigmatism, 3.138, 3.138*f*
- Simple lentigines (lentigo simplex), 7.174
- Simple limbal epithelial transplantation (SLET), 8.365
for chemical injury, 8.384
in pterygium surgery, 8.355
- Simple myopic astigmatism, 3.138, 3.138*f*
- Simple partial seizures, 1.201
- Simplex case/genetic disease, 2.143, 2.182

- Simultanagnosia, 5.180, 5.181*f*, 5.223
in Alzheimer disease, 1.206
- Simultaneous prism and cover test, 6.66–67
- Simultaneous vision bifocal contact lenses, 3.225, 3.225*f*
- Simvastatin
cataract risk and, 11.53
diabetic retinopathy progression affected by, 1.89
for hypercholesterolemia/heart disease prevention, 1.86*t*, 1.87
- SINES. *See* Short interspersed elements
- Single binocular vision, 6.81–82, 6.82*f*
- Single curved surface, refraction by, 3.51–54
- Single-fiber electromyography, in myasthenia gravis, 7.217
- Single-flash (LA 3.0/photopic) electroretinogram, in cone dystrophies, 5.102
- Single-gene disorder (mendelian disorder), 2.139, 2.194
- Single-nucleotide polymorphism (SNP), 2.144, 2.194
in genome-wide association studies (GWASs), 2.163–168, 2.168*f*, 2.194
- Single-nucleotide polymorphism (SNP) oligonucleotide microarray analysis (SOMA), 4.39*t*
- Single pedicle flap, 8.359*f*, 8.359–360
- Single-photon emission computed tomography (SPECT), 5.70
in ischemic heart disease, 1.98
- Single-stranded conformational polymorphism (SSCP), 2.162
- Single-vision reading glasses with lowered optical centers, induced anisophoria corrected using, 3.189–190
- Singlet oxygen, 2.281, 2.283
- Sinoatrial (SA) node, 1.112
- SINS. *See* Surgically induced necrotizing scleritis
- Sinus surgery, in orbital cellulitis, 7.48
- Sinus thrombosis, 2.105
cavernous (CST), 5.345
orbital infection/cellulitis and, 5.345, 7.48
lateral (transverse), 5.69*f*, 5.345–346
superior sagittal, 5.346
- Sinuses, 7.5, 7.7*f*, 7.18–19, 7.19*f*. *See also* Paranasal sinuses; *specific type*
ethmoid, 7.8, 7.8*f*, 7.18, 7.19, 7.19*f*
frontal, 7.7*f*, 7.18–19, 7.19*f*
maxillary, 7.7*f*, 7.9, 7.18, 7.19, 7.19*f*
osteoma involving, 7.84
sphenoid, 7.7*f*, 7.8, 7.8*f*, 7.18, 7.19, 7.19*f*
- Sinusitis
allergic aspergillosis, 5.353, 7.51
in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137
orbital cellulitis caused by, 7.19, 7.44, 7.46, 7.47
orbital tumors/inflammation and, 7.95, 7.95*f*
paranasal, 6.213, 6.214*f*
preseptal cellulitis caused by, 7.44
silent sinus syndrome and, 7.95–96, 7.96*f*
tuberculous, orbital infection and, 7.49
- siRNA. *See* Short interfering (small interference) RNA
- Sirolimus, 9.104
- Sister chromatids, 2.133
- SITA. *See* Swedish interactive thresholding algorithm
- SITA Fast, 10.61
- SITA Standard, 10.61, 10.62
- Sitagliptin, for diabetes mellitus, 1.45*t*, 1.46–47
- Sixth nerve (abducens) palsy, 5.189, 5.200*f*, 5.200–201, 6.95–97, 6.96*f*, 6.176
carotid-cavernous fistula and, 5.201, 5.205–206
cavernous sinus thrombosis and, 5.345
in cryptococcosis, 5.356
description of, 6.95–97, 6.96*f*, 6.140
diplopia and, 5.189, 5.200*f*, 5.200–201
divergence insufficiency/paralysis and, 5.200
isolated, 5.200, 5.201
lateral (transverse) sinus thrombosis and, 5.345–346
in Möbius syndrome, 6.135
multiple sclerosis and, 5.318
- Sjögren syndrome (SS), 1.163, 8.56–58, 8.58*t*
aqueous tear deficiency/dry eye and, 8.39, 8.55*f*, 8.56–58, 8.58*t*
cataract surgery in patient with, corneal melting/keratolysis and, 11.132
lacrimal lymphoepithelial lesions in, 7.94
peripheral ulcerative keratitis and, 8.312
- Sjögren Syndrome Foundation, 8.53
- SJS/SJS–TEN. *See* Stevens–Johnson syndrome (Stevens–Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis/SJS–TEN)
- SK. *See* Superficial keratectomy
- Skeletal disorders. *See also* Connective tissue disorders
corneal changes in, 8.190–196, 8.191–192*t*, 8.193*f*, 8.194*f*, 8.195*f*, 8.195*t*
- Skew, of retinal reflex, 3.156, 3.157*f*
- Skew deviation, 5.216–217, 6.125
alternating, 5.216
fourth nerve (trochlear) palsy differentiated from, 5.198–199, 5.216
in internuclear ophthalmoplegia, 5.189
in multiple sclerosis, 5.318
vestibular-ocular dysfunction and, 5.216–217
- “Skew” rays, 3.51
- Skewed radial axis index, in keratoconus/corneal ectasia, 8.32*t*, 8.165
- Skin
disorders of. *See also* Dermatitis
in Behçet disease, 1.169, 9.184
cataracts associated with, 11.66
corneal changes in, 8.201–203
in dermatomyositis, 1.163, 1.164*f*
in granulomatosis with polyangiitis (Wegener granulomatosis), 9.137
in Lyme disease, 1.250
retinal degeneration associated with, 12.286
in rubella, 9.204
in sarcoidosis, 9.168, 9.168*f*
in SLE, 1.157, 9.133
in systemic sclerosis, 1.162
in uveitis, 9.80*t*
in Vogt–Koyanagi–Harada syndrome, 9.178, 9.178*f*
in xanthogranuloma, 4.187, 7.91
- eyelid, 2.19, 2.20*f*, 2.21*f*, 4.210, 7.146*f*, 7.146–147, 8.3–4
amyloid deposits in, 4.206–207, 4.207*f*, 4.207*t*, 8.186*t*, 8.187
excessive removal of, in blepharoplasty, 7.234
healing/repair of, 4.17
melanoma arising in, 4.220, 4.221*f*

- redundancy of. *See* Dermatochalasis
 tumors of, 7.165. *See also* Eyelids, tumors of
 medial canthal/lacrimal drainage involvement
 and, 7.180
 melanoma, 4.220, 4.221f, 7.184–186, 7.185f
 facial, aging affecting, 7.236–237
 fluorescein angiography effects on, 12.36
 laser resurfacing of, 7.237–238
Skin cancer
 eyelid involvement and, 7.165
 melanoma, 7.184–186, 7.185f
 melanoma, 1.214–215, 7.184–186, 7.185f
 metastatic eye disease and, 4.304t
Skin grafts. *See* Flaps; Grafts
Skin–muscle flap, for eyelid repair, 7.192
Skin tags (acrochordon), 7.166, 7.166f
 in Goldenhar-Gorlin syndrome, 8.195
Skin tests. *See also specific type*
 histoplasmin, 9.213
 tuberculin, 1.215, 1.254, 9.32
 false-negative/positive results and, 9.254
 in HIV infection/AIDS, 9.253
 immune response and, 9.32
 uveitis associated with, 9.121
 “Skip lesions,” 4.245, 5.314
Skipped generation (incomplete penetrance), 2.177
Skull
 abnormal shapes of. *See* Craniosynostosis
 bony growth of, 6.203
 sutures of, 6.203–204, 6.204–205f
Skull base, bony anatomy of, 5.5–6, 5.6f, 5.7–8f
Slab-off prism
 definition of, 3.148
 induced anisophoria correction using, 3.188, 3.188f
SLC4A11 (sodium borate transporter, member 11)
 gene
 in congenital hereditary endothelial dystrophy, 8.136t
 description of, 6.258
SLE. *See* Systemic lupus erythematosus
Sleep apnea/sleep deprivation
 floppy eyelids and, 8.79, 8.82
 hypertension/hypertension management and, 1.67t,
 1.76
 nasal continuous positive airway pressure for, 1.129,
 1.132
 ocular conditions associated with, 1.129, 1.132
Sleep-associated visual hallucinations, 5.177
Sleep test, for myasthenia gravis, 5.324, 5.325
SLET. *See* Simple limbal epithelial transplantation
Slide preparation, for pathologic examination, 4.30
Sliding flap, for wound closure after pterygium excision,
 8.353, 8.354f, 8.355
Slit-beam illumination, for slit-lamp biomicroscopy,
 8.17, 8.18f
Slit-lamp biomicroscopy/examination, 3.292–293,
 3.293f, 8.15–20, 8.16f, 8.17f, 8.18f, 8.19f, 8.20f
 in aqueous tear deficiency, 8.56
 auxiliary lenses for, 3.295–296, 3.296t
 in cataract evaluation, 6.300
 before cataract surgery, 11.78–80
 limitations of, 11.80
 in children, 6.4–5, 10.160
 in choroidal/ciliary body melanoma, 4.263f, 4.265
 clinical procedure for, 8.19–20
 definition of, 3.282
 description of, 3.292–293, 3.293f, 3.306
 in Duane retraction syndrome, 6.133
 in fundus examination, 5.81
 in glaucoma, 10.30–32
 illumination methods for
 direct, 8.16–18, 8.17f, 8.18f, 8.19f
 indirect, 8.17f, 8.18–19, 8.20f
 in iris nevus, 4.255
 in meibomian gland dysfunction, 8.40
 operculated holes on, 12.318
 in optic nerve/nerve head/disc evaluation, 10.32,
 10.48, 10.53
 posterior vitreous detachment diagnosis using,
 12.331
 in pupillary examination, 5.254, 5.256f
 in recurrent corneal erosions, 8.87
 before refractive surgery, 13.41–44, 13.42f, 13.43f
 in striae in LASIK flaps, 13.113, 13.114t
 in uveitis associated with juvenile idiopathic arthritis,
 6.314f
Slit-lamp photography. *See* Slit-lamp biomicroscopy/
 examination
SLK. *See* Superior limbic keratoconjunctivitis
SLN biopsy. *See* Sentinel lymph node (SLN) biopsy
SLO. *See* Scanning laser ophthalmoscopy/
 ophthalmoscope
Sloan letters
 definition of, 3.134
 on ETDRS-type eye chart, 3.23f
Slow channel calcium blockers, for angina, 1.99
Slow inactivators, isoniazid use in, 2.201
Slow-reacting substance of anaphylaxis, 2.335. *See also*
 Leukotrienes
Slow twitch (tonic) fibers, 2.18
SLP. *See* Scanning laser polarimetry/polarimeter
SLT. *See* Selective laser trabeculoplasty
Sly syndrome (MPS VII), 6.388t, 8.175t
Small-aperture corneal inlay, 13.61, 13.61f
Small-incision cataract surgery, 11.198, 11.199f
 in eye with functioning filter, 11.187
 in glaucoma, 11.186, 11.187
Small-incision lenticule extraction (SMILE), 13.8t,
 13.28, 13.203–206
 complications of, 13.205
 disadvantages of, 13.205
 indications and preoperative evaluation for, 13.204
 LASIK compared with, 13.205, 13.206
 outcomes of, 13.205
 re-treatment and, 13.206
 surgical technique for, 13.204–205
Small-incision phacoemulsification. *See*
 Phacoemulsification
Small interference (short interfering) RNA (siRNA),
 2.143
 in gene therapy, 2.170
Small nuclear ribonucleoprotein polypeptide N
 (SNRPN) gene, imprinting of, 2.153, 2.154
Smallpox vaccination, ocular complications of, 8.238
SMART. *See* Stroke-like migraine attacks after radiation
 therapy
Smart System PC-Plus, 6.81

- SMAS. *See* Superficial musculoaponeurotic system
- SMCD. *See* Subepithelial mucinous corneal dystrophy
- SMILE. *See* Small-incision lenticule extraction
- Smoking/smoking cessation
- age-related macular degeneration risks and, 12.62
 - basal cell carcinoma and, 7.177
 - cancer and, 1.212, 1.213
 - cataract development and, 11.6–7, 11.63–64
 - dry eye and, 8.61
 - heart disease and, 1.65*t*, 1.66, 1.83*t*, 1.91, 1.101*t*
 - hypertension and, 1.66
 - optic neuropathy and, 5.137, 5.138
 - perioperative considerations and, 1.288
 - pulmonary disease and, 1.130, 1.132
 - thyroid disease and, 1.53, 7.52, 7.56, 7.58
 - thyroid eye disease and, 6.140
- Smooth-muscle tumors, conjunctival/ocular surface, 8.345
- Smooth-pursuit eye movements/system, 5.32, 5.33, 5.34*f*, 5.212, 5.212*t*, 5.224–226, 5.225*f*. *See also* Pursuit eye movements/pursuit pathways/system
- description of, 6.40
 - dysfunction/injury of, 5.156, 5.224, 5.225–226
 - in infantile esotropia, 6.88
 - optokinetic nystagmus/system and, 5.156, 5.218, 5.219
- Snapback test, 7.199, 7.203
- Snellen charts
- for bottom-up acuity testing, 5.306
 - disadvantages of, 3.132–133
 - letters on
 - description of, 3.131–134, 3.132*f*
 - monofixation syndrome and, 6.51
 - optotypes, 3.133*f*, 3.134
- Snellen visual acuity, 3.124, 3.131, 3.132*f*, 3.134. *See also* Visual acuity
- in low vision, 5.78, 5.88
 - after radial keratotomy, 13.51–52
- Snell's law (law of refraction), 8.26
- definition of, 3.42
 - description of, 3.44*f*, 3.44–45
 - lensmaker's equation derivation from, 3.85–86
 - linearization of, 3.60
 - prism power calculation using, 3.48
 - vergence equation derivation from, 3.85–86
- SNOOP mnemonic, in headache evaluation, 5.287
- "Snow bank," 6.316*f*
- Snow blindness, 8.385
- Snowballs
- in *Candida* endophthalmitis, 9.267
 - in chronic postoperative fungal endophthalmitis, 9.262
 - in intermediate uveitis/pars planitis, 9.78, 9.83, 9.127, 9.128*f*, 12.231
 - in sarcoidosis, 9.168, 9.169
- Snowbanks
- in intermediate uveitis, 12.231–232, 12.245
 - in intermediate uveitis/pars planitis, 9.83, 9.128
 - cryoablation of, 9.130
- "Snowflakes," 2.247, 11.60, 11.60*f*, 12.326
- SNP. *See* Single-nucleotide polymorphism
- SNP oligonucleotide microarray analysis (SOMA), 4.39*t*
- SNRPN (small nuclear ribonucleoprotein polypeptide N) gene, imprinting of, 2.153, 2.154
- SO. *See* Superior oblique (SO) muscle; Sympathetic ophthalmia
- Social history
- cataract surgery evaluation and, 11.72, 11.76
 - refractive surgery evaluation and, 13.36*t*, 13.36–37
 - uveitis and, 9.84*t*, 9.303
- Socket contraction, 7.134–135, 7.135*f*. *See also* Anophthalmic socket
- Socket expansion, for anophthalmia/microphthalmia, 7.36
- SOD. *See* Superoxide dismutase
- Sodium
- in aqueous humor, 2.231*t*, 2.232
 - dietary
 - congestive heart failure and, 1.111
 - hypertension/hypertension management and, 1.64*t*, 1.65, 1.66, 1.67*t*
 - in lens, 2.245–246, 11.21
 - in tear film, 2.214*t*, 2.216
 - transport of
 - aqueous humor composition/secretion and, 2.230–231, 2.323, 2.324*f*
 - carbonic anhydrase inhibitors affecting, 2.323–324
 - in vitreous, 2.231*t*, 2.252
- Sodium balance, in lens, pump–leak theory of maintenance of, 11.21, 11.22*f*
- Sodium bicarbonate. *See* Bicarbonate
- Sodium borate transporter member 11 (*SLC4A11*) gene, in congenital hereditary endothelial dystrophy, 8.136*t*
- Sodium chloride, for ocular edema, 2.366
- Sodium citrate, for chemical injuries, 8.383
- Sodium fluorescein. *See* Fluorescein
- Sodium-glucose transporter-2 (SGLT2) inhibitors, for diabetes mellitus, 1.45*t*, 1.47
- Sodium hyaluronate, as viscoelastic, 2.368, 11.95
- elevated intraocular pressure and, 10.108
- Sodium hydroxide (NaOH), ocular injury caused by, 8.376*t*
- Sodium morrhuate, for lymphatic malformation, 7.71
- Sodium perborate, as ocular medication preservative, 2.294
- Sodium-potassium-calcium exchanger (Na^+ , K^+ -Ca exchanger), in rods, 2.259
- Sodium-potassium pump (Na^+ , K^+ -ATPase)
- in aqueous humor secretion/suppression, 2.230, 2.323, 10.16–17
 - cold affecting, 8.385
 - corneal hydration and, 8.9
 - in Fuchs endothelial corneal dystrophy, 8.156
 - in lens active transport, 11.21
 - pump–leak theory and, 11.21, 11.22*f*
 - in lens ionic balance, 2.246
 - in retinal pigment epithelium, 2.273, 2.277
 - in rods, 2.259
- Soemmering ring lens remnant/Soemmering ring cataract, 4.121, 4.122*f*, 11.152
- Soft (flexible) contact lenses. *See also* Contact lenses
- adjustment of, 3.217*t*
 - advantages of, 3.214, 3.214*t*
 - daily-wear, 3.214–215

- discontinuing use of before refractive surgery, 13.38
duration of use, 3.214
evaluation of, 3.217*t*
extended-wear, 3.215
fitting of, 3.216–217, 3.217*f*, 3.217–218*t*
hydrogel, 3.213
after LASIK, 13.200
materials used in, 3.213
overrefraction testing, 3.217
parameters for, 3.217, 3.218*t*
after radial keratotomy, 13.199
after refractive surgery, 13.199
rigid gas-permeable lenses versus, 3.218
selection of, 3.217*t*
spherical, 3.207*t*
after surface ablation, 13.200
tonometry accuracy and, 10.24
toric, 3.207*t*, 3.222–223
 discontinuing use of before refractive surgery, 13.38
 after radial keratotomy, 13.200
Soft-design progressive addition lenses, 3.182, 3.183*f*
Soft drusen, 4.162, 4.162*f*, 12.65, 12.68, 12.75, 12.200*f*, 12.272
Soft exudates, 12.122. *See also* Cotton-wool spots
Soft-tissue dermal fillers, in facial rejuvenation, 7.239*f*, 7.239–240, 7.240*f*
Soft-tissue histiocytosis, diffuse, 7.90
Soft-tissue tumors, 4.10*t*, 4.11*f*
 of orbit, 4.233
 retinoblastoma associated with, 4.302, 4.302*t*
Soil contamination, *Bacillus* endophthalmitis and, 8.247, 8.403
Solar elastosis, of eyelid, 4.211–212, 4.212*f*
Solar lentigo, 7.174
Solar retinitis. *See* Solar retinopathy
Solar retinopathy, 12.277, 12.367, 12.368*f*
Solexa technology, in next-generation sequencing, 2.165*f*. *See also* Next-generation sequencing
Solid-state laser. *See also* Lasers
 for photoablation, 13.29. *See also* Photoablation
Solitary fibrous tumor, of orbit, 4.235*f*, 4.235–236, 7.84
Solute carrier family 4, in congenital hereditary endothelial dystrophy, 8.136*t*
Solutions, contact lens, 3.229*t*, 3.229–230
SOM. *See* Superior oblique myokymia
SOMA (SNP oligonucleotide microarray analysis), 4.39*t*
Somatic afferent fibers, 2.103
Somatic motor nerves, cholinergic drug action and, 2.307, 2.307*f*
Somatic symptom disorder (SSD), 1.190
 with pain features, 1.190
Somatization disorder. *See* Somatic symptom disorder
Somatoform disorders, 1.190–191
Somatoform pain disorder. *See* Somatic symptom disorder (SSD), with pain features
Somatostatin, 1.56*t*
Somatotroph adenomas, 1.57
Somesthetic cortex (postcentral gyrus), 5.47*f*
Somogyi phenomenon, 1.42
Sondermann channels, 2.52*f*
Sonography. *See* Ultrasonography/ultrasound (echography)
SOOF (suborbicularis oculi fat), 7.146*f*, 7.152–153, 7.242, 7.243*f*
Sorbitol/sorbitol pathway
 in cataract formation, 2.247–248, 11.19, 11.60
 in lens glucose/carbohydrate metabolism, 2.247*f*, 2.247–248, 11.18*f*, 11.19
Sorsby macular dystrophy, 12.275*f*, 12.275–276
 retinal pigment epithelium in, 2.278
 TIMP3 defects causing, 2.161, 2.265
Sotalol, 1.113*t*
 for ventricular fibrillation, 1.115
Sound-induced photisms, 5.176
SP. *See* Swelling pressure
Space maintenance, by ophthalmic viscosurgical device, 11.97
Spaeth gonioscopic grading system, 10.37, 10.37*f*
Spasm
 of accommodation (ciliary muscle spasm), 5.310
 benign essential blepharospasm (BEB), 5.281–283, 5.282*f*, 5.282*t*, 7.226–228, 7.227*f*
 of convergence, 5.227
 of fixation. *See* Ocular motor apraxia habit, 5.285
 hemifacial (HFS), 5.282*t*, 5.283*f*, 5.283–284, 7.228–229
 of near reflex, 3.177, 5.227, 5.309–310
Spasmus nutans/spasmus nutans syndrome, 5.239, 6.151–152
 pseudo-spasmus nutans and, 5.130
Spastic/acute spastic entropion, 7.203, 7.204*f*
Spastic parietic facial contracture, 5.284
Spatial coherence, 3.101
Spatial frequency, 3.125, 3.135, 12.56, 12.57*f*
“Special cause” variance, 1.29
Specific gravity, of spectacle lens materials, 3.194
Specific (adaptive) immunity, 1.240. *See also* Adaptive immune response/adaptive immunity
Specificity, of screening/diagnostic test, 1.15, 1.208
 continuous value measurement and, 1.17*f*, 1.17–18, 1.18*f*
 likelihood ratio calculation and, 1.19
Specimen collection/handling, 4.25–30, 4.31*t*, 8.208–211, 8.209*t*, 8.211*f*
 communication with health care team and, 4.25–26
 fixatives for tissue preservation and, 4.26, 4.26*t*
 gross dissection/transillumination and, 4.28*f*, 4.28–30, 4.29*f*
 orientation of globe and, 4.27, 4.27*f*
 processing/staining tissues and, 4.30, 4.31*t*
 special procedures and, 4.33–45
 transillumination and, 4.28*f*, 4.28–29
SPECT. *See* Single-photon emission computed tomography
Spectacle blur, 3.233
Spectacle lenses (spectacles). *See also* Lenses
 absorptive. *See* Sunglasses
 accommodation affected by, 3.178
 accommodative demand through, 3.210*t*
 anisometropia correction with, 3.139
 anophthalmic socket camouflage and, 7.136
 antireflection coatings on, 3.103, 3.104*f*
 aphakic. *See* Aphakic spectacles
 contact lenses versus, 3.206, 3.216*t*

- convergence affected by, 3.178, 3.212*f*
- dissatisfied wearers of, troubleshooting of, 3.198–199
- frames for, anophthalmic socket camouflage and, 7.136
- glass, 3.195
- history of use of, refractive surgery evaluation and, 13.38
- for hyperopia, 3.211, 3.212*f*
- materials for, 3.194–196
- for myopia, 3.211, 3.212*f*
- optical centers of, 3.211
- prescription for, 3.198
- prisms incorporated into, 3.197, 3.285. *See also* Prisms
- standard plastic, 3.195
- Spectacle telescope, 3.322*f*
- Spectinomycin, for gonococcal conjunctivitis, 8.259
- Spectral bandwidth, coherence length and, 3.102, 3.103*f*
- Spectral-domain optical coherence tomography (SD-OCT), 3.304, 8.22
 - adult-onset vitelliform maculopathy on, 12.67–68, 12.68*f*
 - alkyl nitrite findings, 12.300, 12.300*f*
 - Best disease on, 6.342, 6.343*f*
 - central retinal artery occlusion on, 12.144*f*
 - chloroquine toxicity monitoring, uses of, 12.297
 - choroidal neovascularization on, 12.73–75, 12.75*f*
 - commotio retinae on, 12.353
 - diabetic macular edema on, 12.109*f*, 12.125
 - drusen on, 12.64*f*, 12.65
 - epiretinal membranes on, 12.335*f*
 - Gaucher disease on, 12.291
 - juvenile retinoschisis on, 6.344, 6.344*f*
 - in multiple evanescent white dot syndrome, 9.162, 9.163*f*
 - in optic nerve/nerve head/disc/retinal nerve fiber layer evaluation, 10.54–56, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
 - pathologic myopia on, 12.90*f*
 - reticular pseudodrusen on, 12.65*f*
 - retinal layers on, 12.10–11, 12.11, 12.12*f*
 - retinitis pigmentosa findings on, 12.263*f*
 - sensitivity of, 12.26
 - swept-source optical coherence tomography versus, 12.25–26
 - in uveitis, 9.90–91
 - cystoid macular edema and, 9.289
 - vitreomacular traction on, 12.332*f*
 - in Vogt-Koyanagi-Harada syndrome, 9.180
- Spectral luminous efficiency function, 3.108–109
- Spectroscopy, magnetic resonance (MRS), 5.70
- Specular microscopy, 3.282, 3.295, 8.23, 8.23*f*
 - before cataract surgery, 11.84
 - in Fuchs endothelial corneal dystrophy, 8.23*f*, 8.158
 - in iridocorneal endothelial syndrome diagnosis, 10.137
 - before phakic IOL insertion, 13.141
- Specular reflection, 3.80, 3.293, 3.293*f*
 - for slit-lamp biomicroscopy, 8.17*f*, 8.17–18, 8.19*f*
- Specular transmission. *See* Law of refraction
- Speed
 - of light, 3.43
 - of retinal reflex, 3.153
- Sperm, 2.186
- Sphenocavernous (parasellar) syndrome, 5.202
- Sphenothmoidal recess, 7.18
- Sphenoid bone, 2.5, 2.6, 2.6*f*, 2.7, 5.5, 5.7*f*, 5.8, 5.9*f*, 7.6, 7.6*f*, 7.7, 7.7*f*, 7.8, 7.8*f*
 - in metastatic disease, 7.99, 7.99*f*
 - pterygoid process of, 5.5
- Sphenoid dysplasia, 6.397
- Sphenoid sinuses, 2.10*f*, 2.10–11, 2.17*f*, 5.8, 5.9, 5.10*f*, 7.7*f*, 7.8, 7.8*f*, 7.18, 7.19, 7.19*f*
- Sphenoid wings, 2.5, 2.6, 2.6*f*, 2.7, 5.5, 5.7*f*, 5.9*f*, 7.6, 7.6*f*, 7.7, 7.7*f*, 7.8, 7.8*f*
 - meningiomas of, 7.79, 7.79*f*, 7.81
- Sphenopalatine ganglion, 5.51*f*, 5.56, 5.276–277*f*, 7.14*f*, 7.15*f*, 8.5*f*
- Sphenoparietal sinus, 2.106*f*
- Sphere (refining the), for refraction, 3.165–167, 3.167*f*
- Sphere power, refinement of, 3.33
- Spherical aberration, 3.42, 3.72, 3.72*f*, 3.74*f*, 3.159, 3.268–269, 3.272, 3.275–276*f*, 3.276, 13.9, 13.12, 13.12*f*, 13.102
 - after LASIK, 13.12, 13.102
 - after radial keratotomy, 13.50
 - after surface ablation, 13.12, 13.102
- Spherical aniseikonia, 3.255
- Spherical concave lenses
 - combining of, 3.16
 - convex lens combined with, 3.17
 - description of, 3.11
- Spherical correcting lenses, ametropia correction using, 3.170, 3.170*f*
- Spherical equivalent
 - definition of, 3.42
 - description of, 3.76
 - of refractive state, 3.139
- Spherical refractive error, direct initial measurement of, 3.28
- Spherocytosis, hereditary, 1.138
- Spheroidal degeneration (actinic/climatic droplet/Labrador keratopathy), 4.83, 4.83*f*, 8.115–117, 8.116*f*
- Spherophakia, 6.305
- Spherule, of rod, 2.69, 2.73*f*
- Sphincter muscle (iris), 2.53*f*, 2.54*f*, 2.56, 4.182, 4.182*f*
 - damage to, 4.18
 - Adie tonic pupil and, 5.256*f*, 5.263, 5.263*f*
 - anisocoria and, 5.256*f*, 5.262–263
 - cataract surgery in patient with, 11.191
 - in Horner syndrome, 5.258
 - pupil irregularity and, 5.255
 - traumatic mydriasis and, 8.388, 8.389*f*
 - development of, 2.56, 2.116*t*, 2.122
 - innervation of, 2.56, 2.94, 2.95, 5.52, 5.55
 - miotic/muscarinic drugs affecting, 2.308
 - mydriatics affecting, 2.313, 5.263
- Sphingolipidoses, 8.176–178
 - corneal changes in, 8.176–178, 8.177*f*
- Sphingomyelinase, defective/deficiency of, in Niemann-Pick disease, 2.175*t*
- SPIKES Healthcare Model of Communication, 3.326*f*
- Spin echo (SE) technique, 5.62, 5.75
- Spin-lattice (longitudinal) relaxation time (T1), 5.62, 5.63*t*, 5.76, 7.28

- Spin-spin (transverse) relaxation time (T2), 5.62, 5.63*t*, 5.76, 7.28
- Spinal cord lesions, Horner syndrome and, 5.260*t*
- Spinal nucleus and tract, of cranial nerve V (trigeminal), 2.97–99, 2.99*f*, 2.101*f*, 5.47, 5.47*f*
- Spindle cell carcinoma, 4.61, 8.336
- Spindle cell melanoma, 4.192*f*, 4.192–193, 4.194, 4.195
- Spindle cells
- in choroidal/ciliary body melanoma, 4.192*f*, 4.192–193, 4.194, 4.195
 - in choroidal/ciliary body nevus, 4.191, 4.192*f*
 - in iris melanoma, 4.190
 - in iris nevus, 4.189
 - in neurilemoma, 4.238, 4.239*f*
 - in nodular fasciitis, 4.112, 4.113*f*
 - in orbital neurofibroma, 4.237
 - in orbital rhabdomyosarcoma, 4.236
- Spindle pattern, in pigment dispersion syndrome, 10.94
- Spindle procedure, medial, for involutional ectropion, 7.199, 7.200*f*
- Spinocerebellar degeneration, 12.282*t*
- Spiral (helical) computed tomography
- chest, in cancer screening, 1.210*t*, 1.212
 - in orbital evaluation, 7.27
- Spiral of Tillaux, 2.13, 2.14*f*, 5.45, 6.22, 6.23*f*, 6.169
- Spiramycin, for toxoplasmosis, 9.226
- Spironolactone
- for heart failure, 1.109
 - for hypertension, 1.68*t*, 1.69*t*
- SPK. *See* Thygeson superficial punctate keratitis
- Splenectomy, for idiopathic thrombocytopenic purpura, 1.143
- Splice junction site, 2.144
- Spliceosome, 2.144, 2.152
- Splicing, 2.144, 2.152
- alternative, 2.148, 2.152–153
- Split bifocal intraocular lens, 3.258, 3.259*f*
- Spondylitis, ankylosing (AS), 1.153–154, 9.113*f*, 9.114–115
- cataract surgery in patient with, 11.171, 11.171*f*
 - HLA in, 1.153, 9.114
 - juvenile, 1.155
- Spondyloarthropathies/spondyloarthritis, 1.153–156.
- See also specific type*
 - juvenile, 1.155
 - undifferentiated, 1.153
 - uveitis in, 1.153, 9.114–117, 9.116*f*
- Spongiform encephalopathies, transmissible, 5.357
- Spontaneous consecutive esotropia, 6.95
- Spontaneous emission, 3.110
- Spontaneous eye movements, 5.233–251. *See also* Nystagmus
- Spontaneous hyphema, 8.393. *See also* Hyphema
- Spontaneous nystagmus. *See* Nystagmus
- Sporadic, definition of, 2.144
- Sporadic Alzheimer disease, 1.205
- Sporadic Creutzfeldt-Jakob disease (sCJD), 5.357
- Spore-forming intestinal protozoa, intestinal infection
- in HIV/AIDS and, 1.268–269
- Spread of comitance, 5.186
- Spreading depression, cortical, 5.177
- Springing pupils, 5.267
- Sputum cytology, in cancer screening, 1.212
- Squamous cell carcinoma (SCC)
- of conjunctiva, 4.61, 4.63*f*
 - in situ, 4.61, 4.63*f*
 - invasive, 4.61, 4.62*f*, 4.63*f*
 - of eyelid, 4.213, 4.214*f*, 7.182, 7.182*f*
 - actinic keratosis and, 4.211, 7.176, 7.182
 - in situ (Bowen disease), 7.176
 - well-differentiated (keratoacanthoma), 4.209–210, 4.210*t*, 4.211*f*, 7.176–177, 7.177*f*
 - of lacrimal sac, 7.287
 - ocular surface, 8.332*t*, 8.336, 8.336*f*
 - in situ, 8.334. *See also* Conjunctival or corneal intraepithelial neoplasia
 - management of, 8.330*f*, 8.336–337
 - of orbit, secondary, 7.96*f*, 7.96–97
 - retinoblastoma associated with, 4.302*t*
- Squamous cell papilloma
- of conjunctiva, 4.59–60, 4.60*f*
 - of eyelid (acrochordon/skin tag), 7.166, 7.166*f*
 - of lacrimal sac, 7.287
- Squamous dysplasia, ocular surface, 8.334. *See also* Conjunctival or corneal intraepithelial neoplasia
- Squamous neoplasia, ocular surface (OSSN), 4.60–61, 4.62*f*, 4.63*f*, 8.334–337, 8.335*f*, 8.336*f*
- invasive, 8.332*t*, 8.336, 8.336*f*. *See also* Squamous cell carcinoma
 - management of, 8.330*f*, 8.336–337
 - noninvasive, 8.334–335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
- Square waves/square-wave jerks (SWJs), 5.213, 5.214, 5.247–248, 5.248*f*
- SR. *See* Superior rectus (SR) muscle
- SRK (SRK/T) formula, 3.249, 3.249*f*
- for IOL power determination/selection, 11.85
- SRY. *See* Sex-determining region Y
- SS. *See* Sickle cell disease/sickle cell anemia (hemoglobin SS); Sjögren syndrome
- SS-A antigen, antibodies to (anti-Ro antibodies)
- in Sjögren syndrome, 1.163, 8.56, 8.58*t*
 - in SLE, 1.159, 9.133
- SS-B antigen, antibodies to (anti-La antibodies)
- in Sjögren syndrome, 1.163, 8.56, 8.58*t*
 - in SLE, 1.159, 9.133
- SS-OCT. *See* Swept-source optical coherence tomography
- SSCP. *See* Single-stranded conformational polymorphism
- SSD. *See* Somatic symptom disorder
- SSPE. *See* Subacute sclerosing panencephalitis
- SSRIs. *See* Selective serotonin reuptake inhibitors
- SSS. *See* Superior sagittal sinus
- SST (Submacular Surgery Trials), 9.217
- St John's wort, perioperative use of, 1.286
- ST-segment changes, in ischemic heart disease, 1.93, 1.95–96
- ST-segment elevation myocardial infarction (STEMI), 1.93, 1.94. *See also* Acute coronary syndrome
- management of, 1.103, 1.104–105
- Stab incisions (adits), for neck liposuction, 7.246
- Stabbing headache, idiopathic, 5.294
- Stable angina pectoris, 1.93
- hypertension management and, 1.75
 - management of, 1.99–102, 1.100–101*t*

- Stains/staining techniques, 4.30, 4.31*t*, 8.36–37, 8.37*f*, 8.38*f*, 8.56
 fluorescein. *See* Hyperfluorescence
 hyperfluorescence and, 12.35
 immunohistochemical, 4.33
 for infectious keratitis, 8.209*t*, 8.269, 8.273, 8.275
- Stallard-Wright incision, for orbitotomy, 7.116*f*, 7.120–121
- Stand magnifiers, 3.320–321, 3.321*f*
- Standard automated perimetry (SAP), 10.59. *See also* Perimetry
- Standard plastic lenses, 3.195
- Standardization of Uveitis Nomenclature (SUN)
 Working Group, uveitis classification/grading systems and, 9.71–72, 9.72*t*, 9.73*t*, 9.82, 9.82*t*, 9.83, 9.127, 9.132
- Standing potential, 12.50, 12.51*f*
- Stapedial/stapedius nerve/muscle, 2.101*f*, 2.103, 5.52, 5.276–277*f*
- Staphylococcus*, 1.241–242, 8.244, 8.244*t*
aureus, 1.241, 6.213, 6.240
 blepharitis/blepharoconjunctivitis caused by, 8.72, 8.74, 8.75, 8.208*t*, 8.256, 8.257*t*
 chalazion caused by, 7.162
 endogenous endophthalmitis caused by, 9.119
 keratitis caused by, 8.208*t*
 after photoablation, 13.106
 methicillin-resistant (MRSA), 1.241, 8.244, 8.271
 dacryoadenitis caused by, 7.284
 keratitis after photoablation caused by, 13.106
 preseptal cellulitis caused by, 7.45
 as normal flora, 8.205, 8.206*t*, 8.244
 postoperative endophthalmitis caused by, 11.140, 11.161
 preseptal cellulitis caused by, 7.45
 blepharitis/blepharoconjunctivitis caused by, 8.72, 8.72*f*, 8.72–76, 8.73*f*, 8.73*t*, 8.74*f*, 8.75*f*, 8.208*t*, 8.254, 8.256, 8.257*t*
 keratitis and, 8.73*t*, 8.74
 marginal infiltrates in, 8.74, 8.74*f*
 cellulitis caused by, preseptal, 7.45
 chalazion caused by, 7.162
 dacryoadenitis caused by, 7.284
 endocarditis prophylaxis and, 1.243, 1.243*t*
 endophthalmitis caused by, 12.238
 endogenous bacterial, 9.119, 9.264
 postoperative, 9.119, 11.161
epidermidis, 1.242
 as normal flora, 8.205, 8.206*t*
 ocular infection caused by, 8.208*t*
 postoperative endophthalmitis caused by, 9.119, 11.140, 11.161
 uveitis/endophthalmitis after cataract surgery caused by, 11.140, 11.162
 keratitis caused by, 8.208*t*, 13.106
 as normal flora, 8.205, 8.206*t*, 8.244
 ocular infection caused by, 8.208*t*. *See also specific type*
 orbital cellulitis caused by, 6.213
 phlyctenulosis caused by, 8.75, 8.75*f*
 postoperative endophthalmitis caused by, 12.389
 preseptal cellulitis caused by, 6.213
 resistant strains of, 1.241, 8.244
 uveitis caused by, after cataract surgery, 11.140
- Staphylomas, 3.245, 3.246*f*, 12.209, 12.216, 12.217*f*, 12.330
 axial length measurement for IOL power determination and, 13.150
 in children, 4.112
 congenital, 8.98*t*, 8.106*f*, 8.106–107
 peripapillary, 6.366
 scleral, 4.111–112, 4.112*f*
 in scleritis, 4.110, 4.111*f*, 4.112, 8.322
 Starburst effects, after radial keratotomy, 13.51
 “Stare test,” 8.55–56
- Stargardt disease (juvenile macular degeneration/fundus flavimaculatus), 4.168–169*f*, 4.168–170, 6.339–340, 6.340–341*f*
ABCA4 gene mutations as cause of, 12.271
 ATP-binding cassette (ABC) transporter protein mutation causing, 2.263, 4.168–169
 clinical findings of, 12.269–270, 12.270*f*
 description of, 12.31, 12.44
 electroretinography findings in, 12.48*f*
 fluorescein angiography findings, 12.269–270, 12.270*f*
 fundus autofluorescence findings, 12.270
 phenotype of, 12.269
 retinal pigment epithelium in, 2.279, 4.168–169*f*, 4.169–170, 12.270, 12.270*f*
 visual acuity in, 12.269
 “Starry night” sign, in Vogt-Koyanagi-Harada disease, 12.232
- STAT6 expression, in orbital solitary fibrous tumors, 4.235
- Static dyschromatopsia, 12.249
- Static perimetry, automated, 5.84, 5.85*f*, 5.85–88, 5.87*f*
 in nonorganic disorder evaluation, 5.306–307, 5.307*f*, 5.308*f*
- Staticokinetic dissociation (Riddoch phenomenon), 5.158, 5.181
- Statins, 1.81, 1.85*t*, 1.86*t*, 1.86–88
 age-related macular degeneration and, 1.89
 cataracts and, 1.89, 11.53
 chronic obstructive pulmonary disease and, 1.132
 diabetic retinopathy progression affected by, 1.89
 heart disease prevention and, 1.81, 1.85*t*, 1.91, 1.99
 for hypercholesterolemia, 1.81, 1.85*t*
 stroke prevention and, 1.119, 1.123
- Stationary night blindness, congenital (CSNB), with myopia, ocular findings in carriers of, 2.199*t*
- Stationary nyctalopia, rod-specific mutations causing, 2.263, 2.264
- Stationary retinal disease. *See specific disorder*
- Statistical analysis
 clinical relevance of research/study and, 1.6–7
 measurement/improvement of clinical practice and, 1.26–27
- Statistical significance, 1.7, 1.14, 1.26
- Statistics in clinical practice, 1.2–31
 diagnostic/screening test interpretation and, 1.14–21, 1.15*t*
 clinical acceptance/ethics and, 1.20
 complicating features in, 1.16*f*, 1.16–19, 1.17*f*, 1.18*f*, 1.19*t*
 generalizability and, 1.20
 test combinations in, 1.19–20

- interpreting results of studies for patients and, 1.21–23
- measurement/improvement of clinical practice and data presentation and, 1.27–30, 1.28*f*, 1.29*f*
- measurement system design and, 1.23–25
- monitoring system implementation and, 1.25–26
- quality improvement and, 1.27–30, 1.28*f*, 1.29*f*, 1.30*f*
- results analysis and, 1.26–27
- research questions and, 1.3–7
- study design and, 1.7–14, 1.8*f*. *See also specific type of study*
 - case-control studies, 1.8*f*, 1.9–11, 1.10*f*
 - case reports, 1.8, 1.8*f*
 - case series, 1.8*f*, 1.9
 - clinical trials, 1.7, 1.8, 1.8*f*, 1.13*f*, 1.13–14
 - cohort study differences and, 1.13, 1.13*f*
 - systematic reviews/meta-analyses of, 1.8, 1.8*f*, 1.14
 - cohort studies, 1.8*f*, 1.10*f*, 1.11–12
 - clinical trial differences and, 1.13, 1.13*f*
 - cross-sectional studies, 1.11
- study evaluation and, 1.4–7
 - analysis and, 1.7
 - clinical relevance and, 1.6–7
 - clinical significance and, 1.7
 - follow-up and, 1.6
 - generalizability and, 1.4–5, 1.20, 1.22
 - outcome definition/reliability and, 1.5–6
 - reproducibility and, 1.5
 - sample size and, 1.5
- Status epilepticus, 1.303–304
 - drugs for management of, 1.296*t*
- Status epilepticus amauroticus, 5.172
- Steady fixation, 6.6
- Stearic acid, in retinal pigment epithelium, 2.274, 2.276
- Steepening, in hyperopia surgery, 13.26, 13.79, 13.96
- Steinert disease, 12.282*t*
- Stellate (sutural) cataracts, 11.37, 11.37*f*
- Stellate ganglion, dilator muscle innervation and, 2.56
- Stem cell transplantation, 2.203. *See also* Limbal transplantation
 - for thalassemia, 1.135, 1.137
- Stem cells, 2.127, 8.8, 8.10–11. *See also* Limbal stem cells
 - blood cell formation and, 1.135–136
 - conjunctival, 8.92, 8.362
 - corneal, 2.40, 8.8, 8.92
 - culture of, 8.365
- STEMI. *See* ST-segment elevation myocardial infarction
- Stenopeic slit effect, 3.130
- Stenopeic slit technique, 3.162, 3.162*f*
- Stents. *See also* Lacrimal intubation
 - for canalicular obstruction, 7.274, 7.275
 - for canalicular trauma, 7.283
 - carotid artery, 1.125
 - for carotid occlusive disease, 1.125
 - for cerebral aneurysm, 5.342
 - coronary, 1.91, 1.94
 - for angina, 1.100, 1.102
 - in myocardial infarction management, 1.91, 1.94
 - for nasolacrimal duct obstruction, 6.234–235, 7.262–263, 7.264*f*, 7.278
 - for punctal occlusion/stenosis, 7.272
 - vertebrobasilar artery, 5.338
- Step
 - gaze-evoked nystagmus and, 5.222, 5.240
 - saccadic eye movement and, 5.219, 5.220*f*, 5.222
- Step innervation, 5.220
- Stereo Fly test, 3.99
- Stereoacuity. *See also* Stereopsis
 - development of, 6.182
 - tests/testing of
 - in monocular no light perception, 5.305
 - in monocular reduced vision, 5.305, 5.305*t*
 - in monofixation syndrome, 6.51
 - in nonorganic disorder evaluation
 - monocular no light perception and, 5.305
 - monocular reduced vision and, 5.305, 5.305*t*
 - sensory adaptation assessments using, 6.81
 - visual acuity relationship and, 5.305, 5.305*t*
- Stereophotography, for recording optic nerve/nerve head/disc evaluation, 10.53
- Stereopsis
 - binocular indirect ophthalmoscopes for, 12.22
 - contour, 6.81
 - definition of, 6.43, 6.81
 - depth perception versus, 6.43
 - development of, 6.43
 - random-dot tests, 6.81
 - sensory tests for, 6.100
 - testing
 - linear polarizers used in, 3.99
 - in nonorganic disorder evaluation
 - monocular no light perception and, 5.305
 - monocular reduced vision and, 5.305, 5.305*t*
 - visual acuity relationship and, 5.305, 5.305*t*
- Sterile corneal infiltrates, 3.231*f*, 3.234
- Sterile endophthalmitis, 9.261
 - intravitreal corticosteroids and, 9.98
- Sterile infiltrates, after surface ablation, 13.108, 13.108*f*
- Sterile interface inflammation (diffuse lamellar keratitis/DLK), after LASIK, 13.116*f*, 13.116–117, 13.117*t*
- infectious keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
- pressure-induced stromal keratopathy differentiated from, 13.119
- Steroids. *See* Corticosteroids
- Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis/SJS-TEN), 6.251–252, 6.252*f*, 8.285, 8.295–298, 8.296*f*, 8.297*f*
- STGD4 gene, in Stargardt disease, 4.168
- SThal. *See* Sickle cell thalassemia
- Stickler syndrome (arthro-ophthalmopathy), 6.183, 6.345–346, 12.282*t*, 12.309, 12.342–343, 12.343*f*
- vitreous collapse in, 2.255
- Stigmatic imaging, 3.42, 3.69, 3.274
- Still disease (systemic-onset juvenile idiopathic [chronic/rheumatoid] arthritis), 1.156, 9.122
 - eye examination schedule for children with, 9.124*t*
- Stimulated absorption, 3.110
- Stimulated emission, 3.111, 3.111*f*
- Stimulated (reparative/inflammatory) macrophages, 9.19, 9.20*f*, 9.21
- Stimulatory hypersensitivity (type V) reaction, 9.41, 9.41*t*
- Stimulus, perimetry results affected by, 10.60

- Stimulus accommodative convergence/accommodation (AC/A) ratio, 6.71. *See also* Accommodative convergence/accommodation (AC/A) ratio
- Stimulus deprivation amblyopia, 6.55
- STIR (short tau inversion recovery) technique, 5.62–65, 5.63*t*, 5.75
- Stocker-Holt variant Meesmann corneal dystrophy, 8.136*t*, 8.139
- Stocker lines, 8.113, 8.118*t*. *See also* Iron lines
- Stomach cancer, 1.213
- Stomodeum, 2.113*f*
- Stool for ova and parasites, in uveitis, 9.89*t*
- Stool guaiac slide test, in cancer screening, 1.207
- Stop and chop technique, in phacoemulsification, 11.114
- Stop codon (termination codon), 2.144
- frameshift mutation and, 2.135, 2.155
- Storage diseases, enzyme defects/ocular signs in, 2.175*t*. *See also* Enzyme defects, disorders associated with
- Storiform pattern, in solitary fibrous tumor, 4.235, 4.235*f*
- Strabismic amblyopia
- anisometropic amblyopia versus, 6.54–55
 - clinical features of, 6.54
 - critical period for, 6.45
 - development of, 6.46–47
 - eccentric fixation in, 6.54
 - grating acuity associated with, 6.54, 6.56
 - occlusion therapy for, 6.58
 - pathophysiology of, 6.54
 - visual acuity in, 6.54
- Strabismus. *See also* Deviations; Diplopia
- A-pattern. *See* A-pattern strabismus
 - abbreviations for, 6.17
 - abnormal visual experience caused by, 6.44
 - accommodative convergence/accommodation ratio abnormalities as cause of, 6.39
 - acquired, 6.16
 - acute paralytic, 6.175
 - age at onset, 6.16
 - amblyopia and, 6.59–60. *See also* Amblyopia
 - animal models of, 6.46
 - in Apert syndrome, 6.208, 6.209*f*
 - botulinum toxin for, 2.366
 - in Brown syndrome. *See* Brown syndrome
 - after cataract surgery, 6.304
 - classification terms for, 6.16–17
 - comitant/incomitant deviations in, 5.184, 5.186, 5.187
 - congenital, 6.16
 - congenital nystagmus and, 5.235
 - consecutive, 6.16
 - convergent, 6.15
 - in craniosynostosis, 6.208
 - cyclic, 6.93
 - cyclovertical, 6.162
 - definition of, 6.15
 - diagnosis of. *See also* Ocular motility, assessment of; *specific test*
 - screening tests in, 1.14–16, 1.15*t*
 - dissociated strabismus complex, 6.17, 6.105*f*
 - divergent, 6.15
 - early-onset, 6.154
 - extraocular muscle surgery and. *See* Strabismus surgery
 - fixus, 5.208
 - in Graves eye disease. *See* Strabismus, in thyroid eye disease
 - history-taking for, 6.63
 - incomitant
 - abnormal head position caused by, 6.83
 - prism alternate cover test for, 6.66
 - infantile
 - description of, 6.16
 - dissociated vertical deviation associated with, 6.129
 - fusion maldevelopment nystagmus syndrome associated with, 6.151, 6.154
 - primary inferior oblique muscle overaction associated with, 6.117
 - in infantile (capillary) hemangioma, 7.68, 7.161
 - intermittent, 6.182
 - latent
 - alternate cover test for, 6.65, 6.66*f*
 - description of, 6.15
 - exodeviation as, 6.99
 - manifest
 - alternate cover test for, 6.65, 6.66*f*
 - description of, 6.15
 - exodeviation as, 6.99
 - monocular cover-uncover test for, 6.64, 6.65*f*
 - normal retinal correspondence and, 6.48–49, 6.49*f*
 - nystagmus associated with, 6.154, 6.156–157
 - ocular surgery–related, 6.145–146
 - in orbital floor/blowout fracture, 7.109, 7.111
 - paralytic
 - extraocular muscle surgery for, 6.161
 - Hering's law of motor correspondence and, 6.38
 - pattern. *See* Pattern strabismus
 - pediatric glaucoma and, 10.166–167
 - prefixes associated with, 6.15–16
 - refractive surgery and, 13.41, 13.185–187
 - restrictive, 6.146
 - in retinoblastoma, 4.291, 4.291*f*, 4.291*t*
 - in rhabdomyosarcoma, 7.82
 - screening for, 6.56
 - sensory adaptations in
 - anomalous retinal correspondence, 6.50–51
 - monofixation syndrome, 6.51–52
 - suppression, 6.48–50, 6.49*f*
 - sensory response to, 6.75
 - small-angle, 6.89
 - squinting associated with, 6.202
 - suffixes associated with, 6.15–16
 - suppression in, 5.186
 - supranuclear causes of, 5.188*t*
 - terminology related to, 6.15–17
 - third nerve palsy. *See* Third nerve (oculomotor) palsy
 - in thyroid eye disease, 5.206, 7.54
 - torticollis and, 6.63
 - treatment of
 - chemodenervation (botulinum toxin), 2.366
 - surgical. *See* Strabismus surgery
 - types of, 6.17
 - V-pattern. *See* V-pattern strabismus

- vertical. *See also* Vertical deviations
 description of, 6.15–16
 diagnostic positions of gaze for, 6.64
 word origin of, 6.15
- Strabismus fixus, 6.135
- Strabismus surgery. *See also* Extraocular muscle surgery;
specific type or disorder
 anomalous retinal correspondence after, 6.50
 diplopia after, 5.209
 esotropia treated with, 6.91
 infantile, monofixation syndrome after, 6.51
 pediatric glaucoma and, 10.166–167
 thyroid eye disease and, 7.52, 7.58
 tightening procedures in, 6.164*t*
 weakening procedures in, 6.164*t*. *See also* Weakening
 procedures
- Straddling, 3.158, 3.158*f*
- Straight sinus, 2.105, 2.106*f*, 5.22, 5.22*f*
- Stratum album profundum, 5.33
- Stratum griseum profundum, 5.33
- Strawberry hemangioma. *See* Hemangiomas
- Strawberry tongue, in Kawasaki disease, 1.167
- Streak reflex. *See* Retinal reflex
- Streak retinoscopy, 3.273
- Streptococcus*, 1.242–244, 8.244*t*, 8.244–245, 8.245*f*
 α-hemolytic
 endocarditis prophylaxis and, 1.243, 1.243*t*
 infectious pseudocrystalline/crystalline
 keratopathy caused by, 4.79, 8.268, 8.268*f*
 bacterial conjunctivitis caused by, 6.240
 β-hemolytic. *See Streptococcus, pyogenes*
 conjunctivitis caused by, 8.208*t*, 8.256, 8.257*t*
 in children, 4.52
 endophthalmitis caused by
 bleb-associated, 12.391
 endogenous, 9.264, 12.238
 postoperative, 11.161, 12.389
 group A β-hemolytic. *See Streptococcus, pyogenes*
 keratitis caused by, 8.208*t*
 after penetrating keratoplasty, 8.427
 after photoablation, 13.106
 necrotizing fasciitis caused by, 7.48
 as normal flora, 8.205, 8.206*t*, 8.244
 ocular infection caused by, 8.208*t*. *See also specific*
type
pneumoniae (pneumococcus), 1.242–243, 6.213,
 6.240, 8.245, 8.245*f*
 conjunctivitis caused by, 8.256, 8.257*t*
 in children, 4.52
 immunization against, 1.218*t*, 1.222–223, 1.243
 keratitis caused by, 8.208*t*
 after photoablation, 13.106
 as normal flora, 8.205
 ocular infection caused by, 8.208*t*
 preseptal cellulitis caused by, 6.213
pyogenes (group A β-hemolytic), 1.242, 6.213
 orbital necrotizing fasciitis caused by, 7.48
 resistant strains of, 1.243
viridans, 12.404
 conjunctivitis caused by, 8.256, 8.257*t*
 infectious pseudocrystalline keratopathy caused
 by, 4.79
 keratitis caused by, after photoablation, 13.106
- Streptogramins, 1.273*t*
- Streptokinase, 1.149, 2.369
- Streptomycin, 1.255, 1.278, 2.351
- Stress-induced (Takotsubo) cardiomyopathy, 1.92
- Stress (exercise) tests, in ischemic heart disease, 1.97
- Striae
 after conductive keratoplasty, 13.128, 13.129*f*
 in LASIK flaps, 13.112–115, 13.114*t*, 13.115*f*
- Striate cortex (Brodmann area 17), 5.24*f*, 5.29*f*, 5.29–30,
 5.30*f*, 5.32*f*, 5.34*f*. *See also* Visual (calcarine/
 occipital/striate) cortex
 description of, 6.44
 disorders of, 5.158, 5.178*t*, 5.178–181
 illusions and, 5.175
 monocular visual deprivation in, 6.44, 6.45
- Striate melanokeratosis, 4.65, 8.341
- String of pearls
 in candidal endophthalmitis, 9.266
 in chronic postoperative fungal endophthalmitis,
 9.262
 in sarcoidosis, 9.169
- “String sign,” in internal carotid artery dissection,
 5.262*f*
- Stroke, 1.119–123
 acquired ocular motor apraxia and, 5.223
 arterial dissection causing, 5.342
 carotid artery disease and, 1.120, 5.167, 5.168, 5.169.
 See also Carotid occlusive disease
 transient visual loss and, 5.167, 5.168, 5.169
 completed, 1.120
 diabetes mellitus and, 1.49, 1.125
 diagnosis of, 1.121–122
 gaze preference and, 5.228
 hemispheric transient ischemic attack and, 5.167,
 5.168–169
 hemorrhagic, 1.120
 homonymous hemianopia caused by, 5.153, 5.156,
 5.157, 5.157*f*, 5.158*f*
 hypercholesterolemia and, 1.82
 hypertension/hypertension management and, 1.69*t*,
 1.76, 1.123
 incidence of, 1.119
 internuclear ophthalmoplegia caused by, 5.190
 ischemic, 1.120–123, 1.295
 MRI in evaluation of, 5.65*t*, 5.66, 5.67*f*, 5.75
 occipital lobe lesions caused by, 5.156
 in ocular ischemic syndrome patients, 12.139
 retinal transient ischemic attack and, 5.167,
 5.168–169
 risk factors for, 1.121, 5.168–169
 transient monocular visual loss and, 5.164, 5.167,
 5.168–169
 clinical/laboratory evaluation and, 5.166–167
 prognosis/treatment and, 5.168–169
 treatment of, 1.122–123
 emergency transport and, 1.295, 1.299
 recent developments in, 1.119
 vestibular-ocular dysfunction and, 5.217
- Stroke-like migraine attacks after radiation therapy
 (SMART), 5.358
- Stroke scale, 1.121
- Stroke/stroke length (phacoemulsification), 11.99,
 11.100

Stroma

- choroidal, 4.182
- ciliary body, 2.57–58, 2.58f
- conjunctival (substantia propria), 4.47, 4.48f, 8.7, 9.53
 - age-related changes in, 8.112
 - in external eye defense, 8.13
 - immune and inflammatory cells in, 8.13, 9.53
- corneal, 2.40–41, 2.42f, 2.223f, 2.225–226, 4.73, 4.74f, 8.7f, 8.8–9, 8.9f
 - anatomy of, 2.40–41, 2.42f, 2.223f, 8.7f, 8.8–9, 8.9f
 - biochemistry and metabolism of, 2.225–226
 - biomechanics and, 13.13–14
 - degenerations of, 8.120–126
 - development of, 2.118, 2.120, 2.121f
 - dystrophies of. *See* Stromal corneal dystrophies
 - healing/repair of, 4.14, 4.15f
 - inflammation of, 8.50t, 8.50–52, 8.51f
 - in systemic infections, 8.279
 - neovascularization of, 8.52
 - pigmentation of/deposits in, 8.118t
 - drug-induced, 8.129t, 8.132
 - refractive index of, 8.26
- iris, 2.54–55, 2.56f, 4.181
 - development of, 2.122
 - healing/repair of, 4.16
- scleral, 2.44, 4.107f, 4.107–108, 4.108f

Stromal bed

- preparation of, for LASIK, 13.84–90. *See also* LASIK (laser in situ keratomileusis), flap creation for with femtosecond laser, 13.87–90, 13.88f, 13.89f, 13.90t
- with microkeratome, 13.84–87, 13.85f, 13.86f, 13.87f
- residual (RSB), thickness of, LASIK and, 13.30, 13.45–46, 13.79–80
 - calculation of, 13.46, 13.79
- corneal perforation and, 13.111
- ectasia and, 13.79, 13.124

Stromal corneal dystrophies, 4.91, 4.92f, 8.135t,

- 8.149–156. *See also* Epithelial–stromal *TGFBI* dystrophies; *specific type*
- congenital/congenital hereditary (CHSD/CSCD), 8.135t, 8.136t, 8.152, 8.153f
- Fleck (FCD), 8.135t, 8.136t, 8.153, 8.154f
- macular (MCD), 4.91, 4.91t, 4.92f, 8.135t, 8.136t, 8.145t, 8.149–151, 8.150f
- posterior amorphous (PACD), 8.135t, 8.136t, 8.154f, 8.154–155
- pre-Descemet (PDCD), 8.135t, 8.136t, 8.155–156, 8.156f
- recurrence of after corneal transplantation, 8.425
- Schnyder (SCD), 8.135t, 8.136t, 8.145t, 8.151–152, 8.152f
 - crystalline form of, 8.151, 8.152f
 - hyperlipoproteinemia and, 8.151, 8.179

Stromal corneal infiltrates

- in epidemic keratoconjunctivitis, 8.234f, 8.234–235, 8.235f
- after surface ablation, 13.108, 13.108f

Stromal edema, 8.42

- after cataract surgery, 11.128t, 11.128–130
- cold-induced, 8.385

Stromal graft rejection, 8.429. *See also* Rejection

- Stromal keratitis, 8.46t, 8.50t, 8.50–52, 8.51f
 - CMV causing, 8.232
 - in Cogan syndrome, 8.309–310
 - Epstein-Barr virus causing, 8.230–231, 8.231f
 - herpes simplex virus causing, 4.77f, 4.78, 8.219–222, 8.220f, 8.221f, 8.223t
 - penetrating keratoplasty for, 8.225
 - recurrence of in graft, 8.225
 - in herpes zoster ophthalmicus, 8.228, 8.228f
 - microsporidial, 8.280–281
 - necrotizing, 8.52, 8.219, 8.220–221, 8.221f, 8.222, 8.223t
 - nonnecrotizing, 8.51f, 8.219, 8.220f, 8.221f, 8.223t
 - nonsuppurative, 8.46t, 8.50, 8.50t, 8.51f, 8.52
 - in rosacea, 8.70, 8.70f
 - suppurative, 8.46t, 8.50, 8.50t, 8.51f, 8.52
 - syphilitic, 8.308–309, 8.309f

Stromal keratopathy, pressure-induced (PISK), after LASIK, 13.119, 13.120f

Stromal nevi, 4.64, 8.338t, 8.340

Stromal puncture, for recurrent corneal erosions, 8.79, 8.87

Stromal thinning. *See also* Cornea, thinning of

- in ectatic disorders, 8.133
- microsporidial, penetrating keratoplasty for, 8.281

Strong Heart Study, 1.74

Structure, care system, 1.23

Student *t* test, 1.7Study design. *See* Clinical research/studies, design of

STUMPED mnemonic, for corneal opacities, 6.257t, 6.257–258

Sturge-Weber syndrome (SWS/cerebrofacial/

- encephalotrigeminal/encephalofacial angiomatosis/hemangiomatosis), 5.331, 5.332f, 5.334t, 6.199, 6.251, 6.285, 6.349, 6.394t, 6.401t, 6.401–403, 6.402f, 10.30, 10.155, 12.202

choroidal hemangioma in, 4.197, 4.281, 5.332f, 5.334t

glaucoma associated with, 5.332f, 5.334t, 10.30, 10.155

in children, 5.332f, 10.155

port-wine stain (port-wine nevus/nevus flammeus) in, 5.332f, 5.334t, 8.346, 10.30, 10.155

Stye (external hordeolum), 4.203–204, 7.163–164, 8.76, 8.76f

Sub-Tenon drug administration, 2.299

corticosteroid, 9.96f, 9.96–97

in cystoid macular edema

after cataract surgery, 11.165

in uveitis, 9.289

in pars planitis, 9.130

lidocaine, for cataract surgery, 11.92, 11.92f

local anesthetic, 2.365

Sub-Tenon (episcleral) surgical space, 7.115, 7.115f, 12.20

Subacute bacterial endocarditis (SBE). *See* Endocarditis/endocarditis prophylaxis

Subacute sclerosing panencephalitis (SSPE), 8.239, 9.207–208, 9.208f

Subacute thyroiditis, 1.54

granulomatous, 1.55

lymphocytic (“painless”), 1.55

- Subarachnoid hemorrhage, 1.126, 1.127, 6.382, 12.173.
See also Intracranial hemorrhage
arteriovenous malformations causing, 5.343
ocular hemorrhage with, 5.340, 5.340f
ruptured aneurysm causing, 5.340
- Subarachnoid ocular motor nerve course, 5.42f
cranial nerve palsies and, 5.192
- Subarachnoid space, optic nerve in, 2.87–89, 4.241, 5.17f
- Subarachnoid surgical space, 7.115f, 7.116
- Subcapsular cataract
anterior (subcapsular fibrous plaques), 4.120, 4.120f
after posterior chamber phakic IOL insertion,
13.146
posterior (PSC), 4.120f, 4.120–121, 4.121f, 11.46–48,
11.51f
characteristics and effects of, 11.47, 11.70t
corticosteroids causing, 11.51–52
ischemia causing, 11.68
in myotonic dystrophy, 11.62
race and, 11.6
silicone oil use and, 11.190
uveitis and, 11.64
vitrectomy and, 11.55, 11.190
- Subciliary incision, for orbitotomy, 7.116f
- Subclavian artery, 5.13f, 5.19
- Subclavian steal, 5.337–338
- Subclinical hypothyroidism, 1.54
- Subclinical retinal detachment, 12.319–320
- Subconjunctival disorders, 6.250–252
- Subconjunctival drug administration, 2.299
for anesthetics, 2.365
- Subconjunctival fibrosis, medications causing, 8.91
- Subconjunctival hemorrhage, 8.115t, 8.387–388, 8.388f
in dengue fever, 9.213
- Subcortical structures. *See also specific structure*
in ocular motility, 5.33–34
- Subcutaneous fat/tissue, eyelid, 7.146f, 7.146–147
- Subcutaneous nodules
in rheumatoid arthritis, 1.152
in sarcoidosis, 4.187, 4.187f
- Subcutaneous (vintage) rhytidectomy, 7.245
- Subdural hematoma, 6.382
- Subendocardial (NSTEMI/nontransmural) infarction,
1.93, 1.94
- Subepithelial amyloidosis (gelatinous droplike
dystrophy/primary familial amyloidosis), 8.135t,
8.136t, 8.140–141, 8.141f, 8.185–187, 8.186t
- Subepithelial corneal degenerations, 8.115–120, 8.116f,
8.117f, 8.118t, 8.119f
- Subepithelial corneal dystrophies. *See* Epithelial
dystrophies, epithelial and subepithelial
- Subepithelial corneal infiltrates, 8.46t
in epidemic keratoconjunctivitis, 8.234f, 8.234–235,
8.235f
- Subepithelial fibrosis, in mucous membrane
pemphigoid, 8.299, 8.300f, 8.302t
- Subepithelial graft rejection, 8.428–429, 8.429f. *See also*
Rejection
- Subepithelial mucinous corneal dystrophy (SMCD),
8.135t
- Subepithelial nevi, 4.64, 8.338t, 8.340
- Subfoveal pigment epithelial detachment, 12.74–75f
- Subgroup evaluation, 1.14
- Subhyaloid hemorrhage, 12.173
- Subjective refraction, 3.155
astigmatic dial technique in, 3.160–162, 3.161f, 3.166
binocular balance, 3.167–168, 3.168f
cross cylinder technique, 3.163–165, 3.164f, 3.165t
cylinder power refinement for, 3.164–165
description of, 3.160
Jackson cross cylinder for, 3.163–165, 3.164f
refining the sphere for, 3.165–167, 3.167f
stenopeic slit technique in, 3.162, 3.162f
- Subluxation, IOL, 11.144f, 11.144–147, 11.146f, 11.147f.
See also Decentration/dislocation
- Subluxed/subluxated lens, 10.129–130, 10.130f, 10.130t,
11.39–40, 11.40f. *See also* Ectopia lentis
angle closure/pupillary block and, 10.119, 10.129–
130, 10.130f, 10.130t
- cataract surgery in patient with, 11.181–183, 11.182f,
11.183f
- in megalocornea, 8.100
- traumatic, 11.40, 11.54f, 11.54–55
- Submacular hemorrhage
in neovascular age-related macular degeneration,
12.85, 12.385
posttraumatic, 12.354f
vitrectomy for, 12.385, 12.386f
- Submacular surgery, for ocular histoplasmosis
syndrome, 9.217
- Submacular Surgery Trials (SST), 9.217
- Submandibular ganglion, 2.101f, 2.103, 2.104,
5.276–277f
- Suborbicularis fat pads (suborbicularis oculi fat/SOOF),
7.146f, 7.152–153
midface rejuvenation surgery (SOOF lift) and, 7.242,
7.243f
- Subperiosteal (subperiosteal) surgical space, 7.115,
7.115f
- Subperiosteal abscess, 6.213, 6.214f, 7.47, 7.47f
- Subperiosteal approach, for midface lift, 7.243, 7.244f
- Subretinal drusenoid deposits (reticular pseudodrusen/
RPD), 4.162, 4.163, 4.163f, 4.171f, 12.65, 12.65f,
12.200
- Subretinal fibrosis
in Coats disease, 6.360
in multifocal choroiditis, 12.226, 12.226f
- Subretinal fibrosis and uveitis syndrome (SFU),
9.141–143t, 9.160f, 9.160–161
- Subretinal fluid
in central serous chorioretinopathy, 12.76
in choroidal neovascularization, 12.71
in exudative retinal detachment, 12.326
optic pit and, 12.329f
- Subretinal hemorrhage, 6.373
choroidal neovascularization versus, 12.211
in polypoidal choroidal vasculopathy, 12.76
- Subretinal hyperreflective material (SHRM), 12.75
- Subretinal infiltrates/sub-retinal pigment epithelium
infiltrates, in primary central nervous system/
intraocular/vitreoretinal/retinal lymphoma, 4.135,
4.135f, 4.136–137, 4.311, 4.311f
- Subretinal neovascularization, 12.162, 12.164
- Subretinal space, 2.70f, 2.257
biopsy of, in intraocular lymphoma, 4.135–136, 4.312
fluorophore accumulation in, 12.32

- immune response/features/microenvironment of, 9.54*t*, 9.61, 9.62
- retinal pigment epithelium in maintenance of, 2.277
- retinal pigment epithelium-mediated dehydration of, 12.18
- worms in
- in cysticercosis, 9.230, 9.231, 9.231*f*
 - in diffuse unilateral subacute neuroretinitis, 9.232, 9.233*f*
- Substance abuse disorders, 1.192–193. *See also specific substance*
- HIV transmission and, 1.265
 - ophthalmic considerations and, 1.192–193
- Substance P, 9.28*t*
- in tear secretion, 2.216
- Substantia nigra, 5.41*f*
- in Benedikt syndrome, 5.191
 - in Parkinson disease, 1.198–199
- Substantia propria
- conjunctival (conjunctival stroma), 4.47, 4.48*f*, 8.7, 9.53
 - age-related changes in, 8.112
 - in external eye defense, 8.13
 - immune and inflammatory cells in, 8.13, 9.53
 - corneal. *See* Stroma, corneal
- Subtractive interference, 3.100
- Succinylcholine, 2.315, 2.315*t*
- cholinesterase inhibitor use and, 2.312
 - pharmacogenetics and, 2.201–202
- Suction ring
- for femtosecond laser flap creation, 13.88*f*, 13.89, 13.89*f*
 - after glaucoma surgery, 13.182
 - for microkeratome flap creation, 13.84–85, 13.85*f*, 13.86, 13.86*f*
- Sudden cardiac death (SCD), 1.95
- premature ventricular complexes and, 1.113
 - ventricular fibrillation and, 1.115
- Sufentanil, 1.290
- “Sugar” cataracts, 2.246–248
- aldose reductase in development of, 2.247*f*, 2.247–248, 11.19
- Sugiura sign, 9.178, 9.178*f*, 12.233
- Suicide, 1.189
- in older patients, 1.182
 - SSRI use and, 1.197
- Suicide induction (cell), by cytotoxic T lymphocytes, 9.48–49, 9.49*f*
- Sulamyd. *See* Sulfacetamide
- Sulbactam, 1.276. *See also specific antibiotic combination*
- Sulcus
- intermarginal (gray line), 2.19, 2.22*f*, 2.215, 7.149, 7.153, 7.154*f*
 - internal scleral, 2.48, 4.98
- Sulcus-supported intraocular lenses, 13.137, 13.139*t*
- Sulfacetamide, 2.347*t*, 2.349
- in combination preparations, 2.348*t*
- Sulfadiazine, 2.349
- for toxoplasmic retinochoroiditis, 12.243
 - for toxoplasmosis, 6.410, 9.225, 9.297
- Sulfasalazine, 1.174
- for ankylosing spondylitis, 9.115
 - for rheumatoid arthritis, 1.152, 1.174
- Sulfatase deficiency, multiple, 8.177
- Sulfite oxidase deficiency, 2.175*t*, 6.310
- Sulfohyduronate sulfatase, defective/deficiency of, 2.175*t*
- Sulfonamides, 1.272, 2.349. *See also specific agent*
- for toxoplasmosis, 9.226
 - uveitis caused by, 9.121
- Sulfonylureas, for diabetes mellitus, 1.43–45, 1.44*f*, 1.45*t*
- Sulfur hexafluoride (SF₆), 12.382
- Sulfuric acid (H₂SO₄), ocular injury caused by, 8.376*t*
- Sulfurous acid (H₂SO₃), ocular injuries caused by, 8.376*t*
- Sulindac, 2.335*t*
- Sumatriptan, refractive surgery in patient taking, 13.37
- SUN (Standardization of Uveitis Nomenclature) Working Group, uveitis classification/grading systems and, 9.71–72, 9.72*t*, 9.73*t*, 9.82, 9.82*t*, 9.83, 9.127, 9.132
- SUNCT (short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing), 5.289*t*, 5.294
- Sunflower cataract, in chalcosis/Wilson disease, 8.189, 11.59, 11.62
- Sunglasses
- contrast sensitivity improvements using, 3.192
 - graded-density, 3.192–193
 - polarized, 3.99
 - ultraviolet-absorbing lenses and, cataract prevention and, 11.58
 - ultraviolet light absorption by, 3.194
- Sunlight. *See* Ultraviolet (UV) light
- “Sunset glow” fundus/sign, in Vogt-Koyanagi-Harada syndrome, 9.176, 9.177, 9.177*f*, 9.178, 9.178*f*, 12.232*f*, 12.232–233
- Sunsetting, 6.185
- Superficial basal cell carcinoma, 7.179. *See also* Basal cell carcinoma
- Superficial cervical fascia, 7.143
- Superficial facial fascia, 7.141
- Superficial keratectomy (SK), 8.366–367, 8.412*t*
- layer-based approach to use of, 8.417*t*
- Superficial mimetic muscles, 7.141
- Superficial musculoaponeurotic system (SMAS), 2.104, 7.141, 7.142*f*
- cosmetic surgery and, 7.141, 7.142*f*, 7.245
 - elevation/refixation of, in rhytidectomy, 7.245, 7.245*f*
- Superficial petrosal nerve, greater, 2.101*f*, 2.103, 2.104, 5.276–277*f*, 5.277
- Superficial punctate keratitis of Thygeson (SPK), 6.269, 8.306–307, 8.307*f*
- Superficial spreading melanoma, 4.220, 4.221*f*, 7.185
- Superficial temporal artery, 5.12, 5.15*f*
- eyelids supplied by, 2.26, 2.26*f*
- Superficial temporal fascia (temporoparietal fascia), 7.141, 7.142*f*, 7.144
- Superficial vascular plexus, 12.16
- Superior cerebellar artery (SCA), 5.18*f*, 5.19*f*, 5.20
- cranial nerve relationship and, 2.94, 2.95*f*, 2.97, 5.42*f*
- Superior cervical ganglion, 2.11, 5.53*f*, 5.54
- dilator muscle innervation and, 2.56
 - Horner syndrome caused by lesions of, 5.260*t*
- Superior colliculus (SC), 5.18*f*, 5.33–34
- saccadic control and, 5.219
- Superior displacement of globe, in orbital disorders, 7.24

- Superior limbic keratoconjunctivitis (SLK), 8.83–85, 8.84f
- Superior marginal arcade, 5.13f
- Superior meatus, 7.19
- Superior muscular artery, 5.14–15
- Superior oblique (SO) muscle, 2.9f, 2.13, 2.13f, 2.14f, 2.15t, 2.16f, 2.20f, 5.8f, 5.36f, 5.46, 5.46f, 7.11, 7.12f, 7.13f, 7.14f, 7.15f, 7.146f
- action of, 6.34t, 6.37f
- anatomy of, 2.9f, 2.13f, 2.14f, 2.16f, 2.20f, 5.8f, 5.36f, 5.46, 5.46f
- blood supply of, 2.15t, 2.34f
- characteristics of, 6.21t
- congenital palsy of, 6.69
- depressor function of, 6.73
- field of action for, 6.33
- innervation of, 2.17, 5.40, 5.44, 6.19, 7.12
- insertions of, 2.14f, 2.15, 2.15t
- myokymia affecting, 5.250–251
- origins of, 2.15t, 2.17, 6.20, 6.21t
- overaction of
- A-pattern strabismus associated with, 6.107, 6.111
 - bilateral, 6.118f
 - description of, 6.17
 - horizontal deviation associated with, 6.118
 - overdepression in adduction caused by, 6.118, 6.118f, 6.137
- palsy of
- bilateral, 6.122–124
 - causes of, 6.119
 - clinical features of, 6.119–122
 - congenital versus acquired, 6.119
 - description of, 6.69
 - hypertropia associated with, 6.123
 - inhibitional palsy of contralateral antagonist, 6.120–121, 6.121f
 - management of, 6.122–124, 6.123t
 - masked bilateral, 6.122
 - neuroimaging evaluations, 6.119
 - right, 6.120–121f
 - surgical management of, 6.122–124, 6.123t
 - 3-step test for, 6.120
 - unilateral, 6.119–121, 6.120–121f, 6.122–123, 6.123t
 - V-pattern strabismus associated with, 6.109
- paralysis of, inferior oblique muscle overaction secondary to, 6.166
- right, palsy of, 6.120–121f
- surgery of, for superior oblique myokymia, 5.251
- tenotomy, 6.112, 6.138
- tightening of, 6.123, 6.123t, 6.167
- underaction of, 6.17
- weakening of
- bilateral, 6.166
 - for Brown syndrome, 6.138, 6.166
 - for lambda-pattern strabismus, 6.113
 - for nystagmus, 6.156
 - surgical procedures for, 6.164t, 6.166
 - tenotomy for, 6.166
 - unilateral, 6.166
- weakness of, 6.119
- Superior oblique myokymia (SOM), 5.250–251, 6.145
- Superior oblique tendon, 2.13f, 2.14f, 7.14f, 7.15f
- anatomy of, 6.19f
- fossa for trochlea of, 7.6
- tightening of, 6.167
- Superior oblique tenotomy, for superior oblique myokymia, 5.251
- Superior ophthalmic vein, 5.8f, 5.21, 5.21f, 5.22f, 5.23, 5.23f, 7.10f, 7.12f, 7.13–14, 7.14f, 7.15f
- Superior orbital fissure, 2.6f, 2.8, 2.8f, 2.9f, 2.14f, 5.5, 5.6f, 5.7f, 5.9f, 5.11, 7.6f, 7.7, 7.7f, 7.9, 7.10f
- ophthalmoplegia caused by lesions of, 5.203
- Superior orbital vein, 6.23
- Superior palpebral artery, 5.13f
- Superior palpebral vein, 5.21f
- Superior petrosal sinus, 2.106f, 5.22, 5.23f
- Superior punctum, 2.29. *See also* Punctum (puncta)
- Superior rectus (SR) muscle, 2.9f, 2.13, 2.14f, 2.15t, 2.20f, 5.8f, 5.36f, 5.45, 5.46f, 7.11, 7.13f, 7.14f, 7.15f, 7.146f
- action of, 6.34t, 6.35, 6.36f
- anatomy of, 2.9f, 2.13f, 2.14f, 2.20f, 5.8f, 5.36f, 5.45, 5.46f
- blood supply of, 2.15t, 2.17, 2.34f
- characteristics of, 6.21t
- elevator function of, 6.73
- innervation of, 2.17, 2.94, 2.94f, 2.95, 5.44, 5.44f, 6.19, 7.12
- insertions of, 2.13–15, 2.14f
- intorsion of, 6.34
- Knapp procedure, 6.127
- optic nerve and, 2.87
- origins of, 2.15t, 2.16–17, 6.20, 6.21t, 6.22f
- recession of, 6.30, 6.128, 6.130
- resection of, 6.30
- surgery considerations for, 6.29–30
- transposition of, 6.167
- Superior rectus subnucleus, 5.44
- Superior rectus tendon, 2.13f, 2.14f, 6.19f
- Superior retinal arcade, 5.14
- Superior sagittal sinus (SSS), 2.105, 2.106f, 5.22, 5.22f
- thrombosis in, 5.346
- Superior salivatory (salivary) nucleus, 2.101f, 2.103, 2.104, 5.51f, 5.55, 5.276–277f, 8.5f
- Superior segmental hypoplasia, 5.144
- Superior sulcus deformity, anophthalmic socket and, 7.132–133, 7.133f
- Superior tarsal muscle of Müller, 2.20f, 2.24, 4.202, 7.146f, 7.149, 7.151, 8.3, 8.4f
- in Horner syndrome, 7.215
- innervation of, 5.53, 5.53f, 5.54
- internal (transconjunctival) resection of, for ptosis correction, 7.220, 7.220f
- anophthalmic socket and, 7.135
- Superior transverse (Whitnall) ligament, 2.20f, 2.24, 7.7, 7.14f, 7.15f, 7.146f, 7.150, 7.150f, 7.251
- Superior turbinate/concha, 7.18
- Superior vena cava syndrome, glaucoma associated with, 10.30
- Superoxide, 2.281, 2.282, 2.287, 9.29. *See also* Free radicals
- Superoxide dismutase (SOD), 2.282f, 2.287, 9.29
- in lens, 2.284, 11.20
- in retina and retinal pigment epithelium, 2.273, 2.287

- Supertraction crescent, 12.210
- Supplemental intraocular lenses (piggybacking), refractive lens exchange and, 13.150
- Supplemental oxygen, retinopathy of prematurity risks secondary to, 6.326–327
- Supplementary eye fields (SEFs), 5.32f, 5.33
- Support groups, genetic disorders and, 2.207
- Suppression, 5.186
 - alternating, 6.49
 - central, 6.48
 - constant, 6.49
 - definition of, 6.48
 - facultative, 6.49
 - management of, 6.50
 - nonalternating, 6.49
 - orthoptic exercises for, 6.50
 - pathologic, 6.48
 - peripheral, 6.48
 - physiologic, 6.48
 - red-glass test findings in, 6.76f
 - as strabismus adaptation, 6.48–50, 6.49f
- Suppression scotoma
 - description of, 6.49
 - 4Δ base-out prism test for, 6.79
 - Worth 4-dot test for, 6.80f, 6.80–81
- Suppressor (regulatory/Treg) T cells. *See also* T cells
 - in corneal transplant tolerance, 8.316
 - in external eye defense, 8.12–13f, 8.13, 8.14
- Supracapsular phacoemulsification, 11.110
- Suprachoroidal effusion. *See also* Suprachoroidal hemorrhage/choroidal hemorrhage
 - angle-closure glaucoma and, 10.141, 10.142f, 10.144, 10.145, 10.145f
 - cataract surgery and, 11.159
 - flat or shallow anterior chamber and, 11.134
 - after filtering surgery, 10.210–211
- Suprachoroidal hemorrhage/choroidal hemorrhage, 4.18, 4.19f, 12.394–395, 12.395f
 - angle-closure glaucoma and, 10.141
 - cataract surgery and, 11.159, 11.171
 - delayed, 11.160
 - expulsive, 11.159–160
 - flat or shallow anterior chamber and, 11.134
 - expulsive, 4.18, 4.19f
 - cataract surgery and, 11.159–160
 - after filtering surgery, 10.210–211
- Suprachoroidal shunts, 10.220
- Supraduction. *See* Elevation of eye
- Supramarginal gyrus, 5.32f
- Supranuclear control systems, for eye movements, 6.40
- Supranuclear palsy, progressive (PSP)
 - convergence insufficiency in, 5.227
 - facial weakness/paralysis in, 5.278
 - pursuit dysfunction in, 5.226
 - saccadic dysfunction in, 5.214, 5.221
- Supranuclear (cortical) pathways, 5.32f, 5.32–33, 5.33–34, 5.34f, 5.211. *See also specific system disorders of*, 5.188, 5.188t, 5.211–231
 - diplopia and, 5.188, 5.188t
 - facial weakness/paralysis caused by, 5.276f, 5.277–278
 - gaze preference/palsy and, 5.228–230, 5.229f, 5.230f
 - ocular fixation system and, 5.212, 5.212t, 5.213–214
 - optokinetic system/nystagmus and, 5.212, 5.212t, 5.218–219
 - saccades/saccadic system and, 5.32–33, 5.38, 5.212, 5.212t, 5.219–223, 5.220f
 - smooth-pursuit system and, 5.32, 5.33, 5.34f, 5.212, 5.212t, 5.224–226, 5.225f
 - tonic deviations and, 5.230–231
 - vergence system and, 5.212, 5.212t, 5.226–228
 - vestibular-ocular system and, 5.38–39, 5.39f, 5.212, 5.212t, 5.214–218, 5.216t
- Supraorbital artery, 2.16f, 2.26f, 2.33f, 5.12, 5.13f, 5.14f, 5.15f, 7.14f, 7.15f, 7.16f
 - eyelids supplied by, 7.154
- Supraorbital ethmoids, 7.19
- Supraorbital foramen/notch, 2.5, 2.7, 5.9f, 7.6, 7.6f
- Supraorbital nerve, 2.7, 2.16f, 2.100, 5.48, 5.48f, 7.14f, 7.15f, 7.142f, 7.145f
- Supraorbital vein, 2.35f, 5.21f
- Supratarsal corticosteroid injections, for vernal keratoconjunctivitis, 8.291
- Supratrochlear artery, 2.26f, 2.33f, 5.12, 5.13f, 5.14f, 5.15f, 7.16f
- Supratrochlear nerve, 2.100, 5.48, 7.14f, 7.15f, 7.142f, 7.145f
- Supratrochlear vein, 5.21f
- Supraventricular tachycardias, 1.113, 1.114
 - paroxysmal atrial, 1.114
- Suprofen, 2.239
- Surface ablation, 13.8t, 13.30, 13.73, 13.74–76. *See also* Photoablation; *specific procedure*
 - aberrations and, 13.11, 13.12, 13.13, 13.102
 - advanced (ASA). *See* Photorefractive keratectomy
 - application of laser treatment and, 13.30, 13.91f, 13.91–93
 - bandage contact lenses after, 13.92, 13.107, 13.200
 - sterile infiltrates and, 13.108, 13.108f
 - bioptics with, 13.157
 - calibration of excimer laser for, 13.80
 - complications/adverse effects of, 13.107–110, 13.108f, 13.109f
 - contact lens use after, 13.200
 - contraindications for, 13.77–78
 - corneal ectasia after, 13.124
 - corneal crosslinking for, 13.124, 13.130, 13.131
 - corneal haze and, 13.33, 13.52, 13.92, 13.108–110, 13.109f
 - corticosteroids in reduction of, 13.33, 13.94, 13.108–109
 - mitomycin C in reduction of, 13.33, 13.92, 13.109
 - undercorrection and, 13.102, 13.108
 - corneal healing/repair and, 13.33
 - corneal preparation for, 13.82–84, 13.83f
 - corneal transplantation after, 13.198
 - corticosteroids after, 13.92, 13.94
 - complications associated with, 13.41, 13.104–105
 - dry eye after, 13.76
 - epithelial defect and, 13.107–108
 - epithelial debridement for, 13.82–84, 13.83f
 - epithelial/persistent epithelial defects after, 13.107–108
 - debridement for, 13.108
 - epithelial preservation techniques for, 13.84

- glaucoma/ocular hypertension and, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
- infectious keratitis and, 13.106–107
- intraocular pressure measurement after, 13.104–105, 13.181, 13.200–201
- keratoconus and, 13.175
- for LASIK enhancement, 13.98–99
- limitations of, 13.47*t*
- outcomes of, 13.95
- postoperative care for, 13.93–94
- immediate postablation measures and, 13.92–93
- preoperative care for
- patient preparation and, 13.81–82
- patient selection/relative contraindications and, 13.77–78, 13.78
- planning/laser programming and, 13.81
- after radial keratotomy, 13.52
- re-treatment/enhancements and, 13.98–99
- refractive lens exchange and, 13.149
- sterile infiltrates and, 13.108, 13.108*f*
- surgical technique for, 13.80–95
- tracking/centration/ablation and, 13.91*f*, 13.91–92
- undercorrection and, 13.102, 13.108
- wavefront-guided. *See* Wavefront-guided (custom) laser ablation
- Surface dyslexia, in Alzheimer disease, 1.206
- Surface ectoderm, lens development and, 11.25, 11.26*f*
- Surface markers, 9.12
- Surface normal, 3.42, 3.44, 3.44*f*
- Surface tension, of ophthalmic viscosurgical device, 11.96
- Surfactants, in eyedrops
- absorption and, 2.298
- toxicity and, 2.294
- Surge, in phacoemulsification, 11.102
- Surgeon factor (SF), 3.249
- Surgery. *See also* Cataract surgery; Ocular (intraocular) surgery; *specific procedure*
- cataract. *See* Cataract surgery
- childhood glaucoma treated with, 6.285–288, 6.286*f*, 6.288*f*
- diabetes mellitus and, 1.287
- diabetic macular edema treated with, 12.114–115
- endophthalmitis after, 9.119, 12.388–391, 12.390–391*f*. *See also* Postoperative endophthalmitis
- acute-onset, 9.261
- chronic (delayed-onset), 9.261–263, 9.262*f*
- extraocular muscle. *See* Extraocular muscle surgery
- high AC/A ratio accommodative esotropia treated with, 6.92
- intermittent exotropia treated with, 6.102–103
- intraocular foreign bodies removed with, 12.360–362
- lens subluxation treated with, 6.310
- macular holes managed with, 12.339–340
- neovascular age-related macular degeneration treated with, 12.85–86
- in older patients, 1.180–181
- open-globe injuries managed with, 12.359–360
- primary congenital glaucoma treated with, 6.285–288, 6.286*f*, 6.288*f*
- pulmonary disease and, 1.288
- rhegmatogenous retinal detachment treated with, 12.397–401, 12.398–400*f*
- sympathetic ophthalmia caused by, 9.171, 9.172, 9.174, 12.233
- for uveitis, 9.109
- vitreous loss during, 12.349
- Surgical instruments
- for arcuate keratotomy, 13.55
- for intrastromal corneal ring segment placement, 13.63
- for limbal relaxing incisions, 13.55, 13.56*f*
- for phacoemulsification, 11.98*f*, 11.98–99
- Surgical/operating microscope, 3.294, 3.295*f*
- for intraorbital surgery, 7.121
- for manual small-incision cataract surgery, 11.198
- phototoxicity and, 11.166
- Surgical spaces, orbital, 7.115*f*, 7.115–116, 7.116*f*
- Surgically induced necrotizing scleritis (SINS), 8.282
- Sursumduction/sursumversion. *See* Elevation of eye
- Sursumversion, 6.37
- Susac (SICRET) syndrome, 9.139*f*, 9.139–140, 12.156
- Susceptibility testing, antimicrobial, 1.274
- Suspensory ligament of Lockwood (Lockwood ligament), 2.32, 2.32*f*, 7.7, 7.150, 7.151
- Suspensory ligaments of lens. *See* Zonular fibers, lens
- Sussman goniolens, 10.35
- SUSTAIN study, 12.81
- Sustained-release preparations
- oral, 2.301
- for topical administration, 2.302
- Sutural cataracts, 11.37, 11.37*f*
- Sutural cysts, 6.224
- Suture abscess, after penetrating keratoplasty, 8.426
- Sutures (lens), 2.64, 2.65*f*, 11.13
- development of, 11.27*f*, 11.28*f*, 11.28–29
- opacification of (sutural/stellate cataract), 11.37, 11.37*f*
- Sutures (surgical)
- for cataract surgery
- astigmatism and, 11.131–132
- posterior chamber IOL fixation and, 11.116–117, 11.119, 11.119*f*
- McCannel, for IOL decentration, 11.145
- for penetrating keratoplasty, 8.419*f*
- corneoscleral laceration repair and, 8.406, 8.407*f*, 8.408*f*
- postoperative problems and, 8.426*f*, 8.426–427, 8.431–432, 8.432*f*
- Quickert, for involutional/spastic entropion, 7.203, 7.203*f*, 7.206
- removal/adjustment of
- after corneal transplant
- for astigmatism, 8.419*f*, 8.431–432, 8.432*f*
- in children, 8.451
- after penetrating and perforating trauma repair, 8.409
- for trabeculectomy, laser lysis of, scleral flap closure and, 10.202–203, 10.207–208
- Swabbing, for specimen collection, 8.210–211, 8.211
- Swan-neck deformity, 1.152
- SWAP. *See* Short-wavelength automated perimetry
- Sweat glands, of eyelid, 2.19, 2.22*f*, 2.23*t*, 4.201, 4.202, 7.170, 8.4
- cyst arising in, 4.208, 4.208*f*
- syngoma associated with malformation of, 4.214, 4.215*f*
- tumors originating in, 7.170, 7.171, 7.171*f*

- Swedish interactive thresholding algorithm (SITA)
 (perimetry), 5.86, 10.60–61, 10.62
 short-wavelength automated perimetry (SWAP)
 using, 10.75
- Swelling pressure (SP), 8.9
- Swept-source optical coherence tomography (SS-OCT),
 8.22
 pathologic myopia findings, 12.209f
 sensitivity of, 12.26
 spectral-domain optical coherence tomography
 versus, 12.25–26
- Swinging flashlight test, for relative afferent pupillary
 defect, 5.79, 5.79f, 5.80
 before cataract surgery, 11.78
- Switch flap, for eyelid repair, 7.193f
- SWJs. *See* Square waves/square-wave jerks
- SWS. *See* Sturge-Weber syndrome
- Sylvius, cerebral aqueduct of, 5.36f, 5.41f, 5.192
- Symblepharon, 6.146, 7.208
 acid burn causing, 8.381, 8.381f
 cataract surgery in patient with, 11.173
 in mucous membrane pemphigoid, 8.299, 8.300,
 8.300f, 8.302t
 in Stevens-Johnson syndrome (Stevens-Johnson
 syndrome/toxic epidermal necrolysis overlap and
 toxic epidermal necrolysis), 8.297, 8.297f
- Symbol charts, 6.7
- Symmetric convergence, 6.41
- Sympathetic fibers, lacrimal functional unit innervated
 by, 8.5f
- Sympathetic ganglia/nerves/pathway, 5.52–54,
 5.53f
 in ciliary ganglion, 2.11, 2.12f, 2.12–13
 ciliary muscle innervation and, 2.59
 dilator muscle innervation and, 2.55
 orbit supplied by, 7.16–18, 7.17f
 sphincter muscle innervation and, 2.56
 in tear secretion, 2.214, 2.216, 2.218, 2.218f, 2.219,
 2.219f
- Sympathetic ophthalmia (SO), 4.185, 4.186f, 9.47–48,
 9.171–175, 9.172f, 9.173f, 9.174f
 characteristics of, 12.233
 corticosteroids for, 9.175
 route of administration of, 2.333t
 enucleation in prevention of, 7.128, 8.404, 9.175
 evisceration and, 7.130, 9.175
 glaucoma/glaucoma surgery and, 9.285, 10.195,
 10.196, 10.198
 histologic/histopathologic features of, 4.185, 4.186f,
 9.174
 HLA association in, 9.67t, 9.174
 incidence of, 7.128
 surgical procedures/injuries leading to, 4.185, 9.171,
 9.172, 9.174
 trauma as cause of, 12.364–365
 Vogt-Koyanagi-Harada disease versus, 12.232
- Sympathetic root, in ciliary ganglion, 2.11, 2.12f
- Sympathizing eye, 4.185, 9.171, 9.172, 9.172f, 9.173,
 9.174, 9.175. *See also* Sympathetic ophthalmia
- Sympatholytics, for hypertension, 1.73
- Sympathomimetic activity, intrinsic (ISA), β -blockers
 with, 1.68t, 1.72
- Symptomatic retinal breaks, 12.318
- Synaptic body
 of cone (pedicle), 2.70, 2.73f
 of rod (spherule), 2.69, 2.73f
- Synaptophysin, in immunohistochemistry, 4.34
- Synchysis scintillans, 4.133, 12.348
- Syncope, 1.300
- Syndactyly, in Apert syndrome, 6.206, 6.207f, 7.38f
- Syndrome, 6.183. *See also specific syndrome*
- Syndrome X. *See* Metabolic syndrome
- Syndromic congenital craniofacial anomalies, 7.35–38,
 7.37f, 7.38f. *See also* Craniofacial malformations;
specific type
- Syndromic craniosynostosis, 7.37–38, 7.38f. *See also*
 Craniosynostosis
- Syndromic panretinal dystrophies, 12.259
- Synechia
 anterior
 angle closure and, 10.117, 10.121
 in glaucoma
 angle closure and, 10.117, 10.121
 inflammation and, 10.138, 10.139f
 anterior segment/iris neovascularization and,
 10.39, 10.39f, 10.133, 10.133f, 10.134f
 chamber deepening/goniosynechialysis in
 management of, 10.220
 flat anterior chamber and, 10.144
 gonioscopy in identification of, 10.34f, 10.39,
 10.39f
 iridocorneal endothelial syndrome and,
 4.100–101, 4.101f, 10.136, 10.136f
 plateau iris and, 10.128
 uveitis and, 9.285, 9.286
 in sarcoidosis, 9.169
 traumatic hyphema and, 8.394, 8.395t
 in uveitis, 9.79, 9.82
 glaucoma and, 9.286
 posterior
 in glaucoma
 inflammation and, 10.138, 10.138f
 pupillary block/angle closure and, 10.119
 uveitis and, 9.285
 mydriasis in prevention of, 2.313
 in pars planitis, 9.129
 pupillary block/angle closure and, 10.119
 in sarcoidosis, 9.81f, 9.169
 in sympathetic ophthalmia, 9.172
 in uveitis, 9.79, 9.80f, 9.81f, 9.82
 glaucoma and, 9.285
 lens changes/cataract and, 11.64
 pupil irregularity and, 5.255
 in sarcoidosis, 9.81f, 9.169
 in uveitis, 9.79, 9.80f, 9.81f, 9.82
- Synercid. *See* Quinupristin/dalfopristin
- Syneresis, 4.128, 4.129f
 posterior vitreous detachment and, 4.128–
 129, 4.129f
 vitreous, 12.307, 12.316
 vitreous hemorrhage and, 4.133
- Synergist, 6.33
- Synergistic divergence, 6.133
- Synergistins (streptogramins), 1.273t
- Synkinesis
 aberrant nerve regeneration and, 7.211, 7.229

- facial, 5.271, 5.271f, 5.277
 in Marcus Gunn jaw-winking syndrome/ptosis, 7.211, 7.215, 7.216f
 near reflex and. *See* Near reflex
 Syntonic traits, 2.187
 Syphilis, 1.216, 1.248–250, 8.107, 8.308–309, 8.309f, 9.236–243, 9.237f, 9.238f, 9.239f, 9.240f, 9.242t
 acquired, 9.237–243, 9.238f, 9.239f, 9.240f, 9.242t
 acute syphilitic posterior placoid chorioretinitis caused by, 12.241
 Argyll Robertson pupil in, 5.267
 chorioretinitis in, 9.237, 9.238f, 9.238–239, 9.239f, 9.297–298, 12.241–242, 12.242f
 posterior placoid, 9.239, 9.239f, 9.297–298
 congenital/intrauterine, 1.216, 1.248, 6.269, 6.412–413, 8.107, 8.308–309, 8.309f, 9.236–237, 9.237f
 corneal manifestations of, 4.80, 4.81f, 8.107, 8.308–309, 8.309f, 9.237, 9.237f
 serodiagnosis of, 9.241
 treatment of, 9.242
 conjunctivitis in, 8.260t
 diagnosis/screening/testing for, 1.216, 1.248–249, 9.241–242
 optic neuritis and, 5.115
 false-positive/negative tests for, 9.241
 in HIV infection/AIDS, 1.249–250, 9.240, 9.297–298
 keratitis in, 4.80, 4.81f, 8.107, 8.308–309, 8.309f, 9.237, 9.237f
 latent, 1.216, 1.248, 9.238, 9.242t
 neuro-ophthalmic signs of, 5.351
 pars planitis and, 9.129
 primary, 1.248, 9.236, 9.237, 9.241, 9.242t
 secondary, 1.248, 9.236, 9.238, 9.239, 9.239f, 9.242t
 tertiary, 1.248, 9.238, 9.242t
 treatment of, 1.249–250, 9.242t, 9.242–243, 9.298
 uveitis caused by, 12.241
 Syphilitic posterior placoid chorioretinitis, 9.239, 9.239f, 9.297–298
 Syringoma, 4.214, 4.215f, 7.170, 7.171f
 Systematic reviews, of clinical trials, 1.8, 1.8f, 1.14
 Systemic diseases
 ataxia-telangiectasia, 6.393t, 6.403t, 6.403f, 6.403–404
 chromosomal abnormalities, 6.385, 6.386t
 diabetes mellitus, 6.408–409
 familial oculorenal syndromes, 6.391–392, 392f
 inborn errors of metabolism. *See* Inborn errors of metabolism
 intrauterine infections, 6.409–413
 intrauterine/perinatal infections, 6.409–413
 Leber congenital amaurosis–like phenotypes in, 6.336
 leukemia, 6.413–414
 malignant, 6.413–415
 neuro-oculocutaneous syndromes. *See* Neuro-oculocutaneous syndromes
 neuroblastoma, 6.414–415, 6.415f
 ocular manifestations of, 6.385–415
 von Hippel–Lindau syndrome, 6.393t, 6.399–401, 6.400t, 6.400f
 Systemic drug therapy, 2.300–301
 corticosteroid, for uveitis, 9.99–100
 Systemic fibrosis, nephrogenic (NSF), gadolinium causing, 5.60
 Systemic lupus erythematosus (SLE), 1.156–159, 1.157f, 1.158t, 9.132–135, 9.133, 9.134f
 description of, 12.134
 eyelid manifestations of, 1.169, 4.207t
 HLA association in, 1.156
 optic neuritis and, 5.115
 procainamide as cause of, 12.300
 refractive surgery contraindicated in, 13.191
 retinal manifestations of, 1.159, 9.133f, 9.133–134, 9.134f
 vasculitis associated with, 12.230–231, 12.231f
 Systemic (visceral/nodal) lymphoma. *See also* Lymphomas
 secondary eye involvement and, 4.135f, 4.135–137, 4.136f, 4.314
 prognosis for, 4.314
 Systemic nocturnal hypotension, glaucoma and, 1.77
 Systemic-onset juvenile idiopathic (chronic/rheumatoid) arthritis (Still disease), 1.156, 9.122
 eye examination schedule for children with, 9.124t
 Systemic sclerosis (SSc/scleroderma), 1.161–163
 eyelid manifestations of, 1.163, 4.207t
 Systemic sclerosis sine scleroderma, 1.162
 Systole (systolic phase), 1.108
 Systolic dysfunction, 1.108
 causes of, 1.108–109
 management of, 1.109–110
- ## T
- T. *See* Transducin
 T1 (spin-lattice/longitudinal relaxation time), 5.62, 5.63t, 5.76, 7.28
 T1-weighted images, 5.58f, 5.62, 5.62f, 5.63f, 5.64f, 5.65f, 5.66f, 5.67f, 7.28f, 7.28–29
 T2 “shine through” artifact, 5.64f, 5.66
 T2 (spin-spin/transverse relaxation time), 5.62, 5.63t, 5.76, 7.28
 T2-weighted images, 5.58f, 5.62, 5.62f, 5.63f, 5.64f, 5.66f, 5.67f, 5.76, 7.28–29
 T₃. *See* Triiodothyronine
 T₄. *See* Thyroxine (T₄)
 T4/T8 ratio, in HIV infection/AIDS, 1.263. *See also* CD4⁺ T cells; CD8⁺ T cells
 T-cell lymphomas
 central nervous system/intraocular, 9.273. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
 neoplastic masquerade syndromes secondary to, 9.276
 orbital, 4.232, 7.86. *See also* Lymphomas
 T-cell receptor CD28, for rheumatic disorders, 1.151
 T-cell signaling inhibitors
 for pars planitis, 9.130
 for uveitis, 9.104–105
 T cells, 4.9, 9.12. *See also specific type*
 activation/sensitization/priming of, 9.36, 9.36f, 9.37, 9.38
 in allergic conjunctivitis, 9.51
 CD4⁺, 12.235

- in cell-mediated/cellular immunity, 1.241, 9.38, 9.39*f*, 9.45, 9.45*f*, 9.46*t*. *See also* Lymphocyte-mediated immune effector responses
- class I MHC molecules as antigen-presenting platform for, 9.34*f*, 9.34–35
- class II MHC molecules as antigen-presenting platform for, 9.35*f*, 9.35–36
- in corneal transplant rejection, 8.316, 8.317
- cytotoxic, 9.38–39, 9.39*f*, 9.48–49, 9.49*f*
 - in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
 - in viral conjunctivitis, 9.56
- delayed hypersensitivity (DH), 9.38, 9.39*f*, 9.45, 9.45*f*, 9.46*t*
- differentiation of, 9.37
- effector (Teff), 9.38–39, 9.39*f*
 - in external eye defense, 8.12–13*f*
- helper. *See* T helper cells
- in HIV infection/AIDS, 1.263, 8.241, 9.293, 9.294
- in immune processing, 9.36, 9.36*f*, 9.37, 9.38
- killer. *See* Killer cells
- primary versus secondary immune response and, 9.40
- receptors on. *See* T-lymphocyte antigen receptors
- regulatory (Treg/suppressor). *See* T regulatory (Treg) cells
- in Sjögren syndrome, 8.57
- in sympathetic ophthalmia, 9.48
- in tuberculosis, 9.31, 9.32
- in viral conjunctivitis, 9.55, 9.56
- in Vogt-Koyanagi-Harada syndrome, 9.176
- T helper cells. *See also specific type*
 - in B-lymphocyte activation, 9.37–38
 - class II MHC molecules as antigen-presenting platform for, 9.35*f*, 9.35–36
 - cytotoxic T lymphocytes and, 9.48, 9.49*f*
 - in delayed hypersensitivity (type IV) reactions, 9.38, 9.39*f*, 9.45, 9.45*f*, 9.46, 9.46*t*
 - sympathetic ophthalmia and, 9.48
 - Toxocara* granuloma and, 9.47
- differentiation of, 9.37
- in HIV infection/AIDS, 1.263, 9.293, 9.294
- in immune processing, 9.36*f*, 9.37
- T helper-0 (Th0) cells, 9.37
- T helper-1 (Th1) cells, 9.36*f*, 9.37
 - in delayed hypersensitivity (type IV) reactions, 9.38, 9.46, 9.46*t*
 - sympathetic ophthalmia and, 9.48
- T helper-2 (Th2) cells, 9.36*f*, 9.37
 - in delayed hypersensitivity (type IV) reactions, 9.38, 9.46
 - Toxocara* granuloma and, 9.47
- T helper-17 (Th17) cells, 9.37
- T-lymphocyte antigen receptors, 9.34, 9.34*f*, 9.35, 9.35*f*, 9.37
 - HLA disease associations and, 9.67
 - IRBP-specific, in transgenic mice, 9.64
- T-lymphocyte lymphoma. *See* T-cell lymphomas
- T lymphocytes. *See* T cells
- “T” molecules, antiangiogenic, for corneal transplantation rejection, 8.317
- T pallidum* hemagglutination assay (TPHA), 1.249
- T-PRK. *See* Topography-guided photorefractive keratectomy
- T regulatory (Treg) cells, 9.34, 9.36*f*, 9.37, 9.38. *See also* T cells
 - in corneal transplant tolerance and, 8.316
 - in external eye defense, 8.12–13*f*, 8.13, 8.14
 - in immune processing, 9.36*f*, 9.37, 9.38
 - MHC molecules as antigen-presenting platform for, 9.34*f*, 9.34–36, 9.35*f*
 - in sympathetic ophthalmia, 9.48
- t* test (Student *t* test), 1.7
- T waves, in ischemic heart disease, 1.95, 1.96
- TAB. *See* Temporal artery biopsy
- Taches de bougie, in sarcoidosis, 9.169
- Tachyarrhythmias, 1.113–118
 - heart failure and, 1.111
 - supraventricular, 1.113, 1.114
 - ventricular, 1.113, 1.114–116
- Tachycardia
 - atrioventricular junctional, 1.114
 - narrow-complex, 1.113
 - supraventricular, 1.113, 1.114
 - ventricular, 1.113, 1.114–115
 - wide-complex, 1.113
- Tachyphylaxis
 - with α -agonists, 10.178
 - with β -blockers, 10.177
- Tacrolimus, 1.175–176, 9.104
 - for atopic dermatitis, 8.287
 - for atopic keratoconjunctivitis, 8.294
 - for Behçet disease, 9.188
 - for contact dermatoblepharitis, 8.287
 - for corneal graft rejection prophylaxis, 8.430
 - for graft-vs-host disease, 8.304
 - for scleritis, 8.324
 - for Thygeson superficial punctate keratitis, 8.307
 - for uveitis, 9.104, 9.105
 - for vernal keratoconjunctivitis, 8.290*f*, 8.291
- TACs. *See* Trigeminal autonomic cephalgias
- TACSTD2 gene, in gelatinous droplike corneal dystrophy, 8.136*t*
- Tactile tension, for intraocular pressure estimation, 10.26
- Tadalafil, 12.304
 - ocular effects of, 1.308*t*
 - for pulmonary arterial hypertension, 1.129
- Tadpole pupil, 5.255
- Taenia solium* (pork tapeworm), 9.230–231
 - orbital infection caused by, 4.228, 7.51
- Tafluprost, 2.237, 2.302, 2.327, 2.327*t*, 10.170–176, 10.171*t*, 10.175*t*
- Takayasu arteritis (aortic arch arteritis/aortitis syndrome/pulseless disease), 1.165*t*, 1.166
 - cataract caused by, 11.68
- Takotsubo (stress-induced) cardiomyopathy, 1.92
- Talc emboli, 12.141, 12.303
- Tamoxifen, 1.234*t*, 12.302–303, 12.304*f*
 - cataract risk and, 11.53
 - cornea verticillata caused by, 8.130
 - maculopathy caused by, 11.53
 - ocular effects of, 1.308*t*
- Tamsulosin, intraoperative floppy iris syndrome and, 11.74, 11.136, 11.137, 11.137*t*

- Tandem repeats, variable/variable number of (VNTRs/VTRs/microsatellites), 2.139, 2.150
- Tandem scanning confocal microscopy, 8.24. *See also* Confocal microscopy
- Tangent screen, in nonorganic disorder evaluation, 5.308, 5.309f
- Tangential curvature, 8.29f
- Tangential incisions, for keratorefractive surgery, 13.27, 13.27f
- coupling and, 13.27, 13.27f, 13.54
- Tangential (transverse) keratotomy, for astigmatism, 13.53, 13.54, 13.54f
- Tangential map, 8.28, 8.29f. *See also* Cornea, topography of
- Tangential power (instantaneous radius of curvature), 13.16–17, 13.17f
- Tangier disease, 8.180–181
- Tap/biopsy of vitreous. *See* Vitreous, biopsy of
- Tapeworms
- dog (*Echinococcus granulosus*), orbital infection caused by, 4.228, 7.51
- eye invaded by, 7.51, 9.230–232, 9.231f
- pork (*Taenia solium*), 9.230–231
- orbital infection caused by, 4.228, 7.51
- Tarantula hairs, ocular inflammation caused by, 8.387
- Tardive dyskinesia
- blepharospasm and, 5.281
- facial movements and, 5.285
- Target, in microarray, 4.41
- Target recognition/selection, smooth pursuit movements and, 5.33, 5.224, 5.225, 5.225f
- Tarsal conjunctiva, 8.6. *See also* Conjunctiva
- in superior limbic keratoconjunctivitis, 8.83, 8.84
- Tarsal ectropion, 7.200
- Tarsal fracture operation, for cicatricial entropion, 7.207, 7.207f
- Tarsal glands. *See* Meibomian glands
- Tarsal kink, 6.194–195, 7.159
- Tarsal muscles
- in Horner syndrome, 5.257, 7.215
- inferior, 7.151
- superior (Müller), 2.20f, 2.24, 4.202, 7.146f, 7.149, 7.151, 8.3, 8.4f
- in Horner syndrome, 7.215
- innervation of, 5.53, 5.53f, 5.54
- internal (transconjunctival) resection of, for ptosis correction, 7.220, 7.220f
- anophthalmic socket and, 7.135
- Tarsal plates/tarsus, 2.20f, 2.24, 2.25f, 4.201, 4.201f, 4.202, 7.146f, 7.151–152, 7.152f, 8.3, 8.4f
- sebaceous adenocarcinoma arising in, 4.215, 7.183, 7.184
- Tarsal-sharing procedures, for eyelid repair, 7.192
- Tarsal strip procedure
- for cicatricial ectropion, 7.201
- for involutional ectropion, 7.199, 7.200f
- for involutional entropion, 7.204
- Tarsoconjunctival flap, for eyelid repair, 7.193, 7.193f, 7.194, 7.194f
- Tarsoconjunctival grafts
- for chemical injuries, 8.384
- for cicatricial entropion, 7.207
- for eyelid repair, 7.190, 7.192–193, 7.193f, 7.194f, 7.195
- Tarsorrhaphy, 6.207–208, 8.351, 8.372f, 8.372–373
- for chemical injuries, 8.383–384
- for dry eye, 8.61t, 8.65, 8.368
- for exposure keratopathy, 8.80
- for eyelid burns, 7.190
- for eyelid retraction, 7.223
- for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82, 8.224, 8.230
- for paralytic ectropion, 7.225f, 7.225–226
- for thermal injuries, 8.385
- Tarsotomy, for trichiasis/distichiasis, 8.88
- Tarsus, 8.3, 8.4f. *See also* Tarsal plates/tarsus
- TASS. *See* Toxic anterior segment syndrome
- TATA box, 2.142
- Tattoo, corneal, 8.118t, 8.371f, 8.371–372
- Tauber staging system, 8.302, 8.302t
- Taxanes, 12.301
- Taxon-specific crystallins, 2.244
- Tay-Sachs disease (GM₂ gangliosidosis), 2.175t, 6.389t, 8.176–178, 12.291, 12.292f
- racial and ethnic concentration of, 2.197
- Tazobactam, 1.276. *See also* specific antibiotic combination
- Tazolol, 2.308t
- TB. *See* Tuberculosis
- TBCD. *See* Thiel-Behnke corneal dystrophy
- TBG. *See* Thyroxine-binding globulin
- TBI. *See* Traumatic brain injury
- TBUT. *See* Tear breakup time
- Tc-99. *See* specific Technetium-99 entries
- TCA cycle. *See* Tricarboxylic acid (TCA) cycle
- TCF4 gene, in Fuchs endothelial corneal dystrophy, 8.136t, 8.156
- TCOF1 gene, 6.211
- TD-OCT. *See* Time-domain optical coherence tomography
- Td vaccine, 1.218t, 1.222
- Tdap vaccine, 1.207, 1.218t, 1.222
- TDF. *See* Testis-determining factor
- TE (time to echo), 5.62, 5.75, 5.76
- Tear breakup, 8.60
- Tear breakup time (TBUT), 8.36, 8.57t, 8.60
- fluorescein in evaluation of, 7.267, 8.36, 8.57t, 8.60
- in pseudoepiphora evaluation, 7.267–268
- refractive surgery and, 13.42, 13.42f
- Tear-deficiency states, 2.220–222, 2.221f. *See also* Dry eye; specific type
- aqueous, 2.220, 2.221f, 2.221–222, 8.45, 8.53, 8.54f, 8.55f, 8.55–58, 8.61t, 8.61–65, 8.62t, 8.65f
- evaporative dry eye, 8.45, 8.53–54, 8.54f, 8.55f, 8.58–60, 8.59f, 8.60f, 8.66t, 8.66–67t, 69
- mucin, 2.217, 2.220
- refractive surgery and, 13.42, 13.78–79, 13.172–173
- stains in evaluation of, 8.37
- tests of, 8.38–39
- qualitative tests, 8.40f, 8.40–41
- quantitative tests, 8.39
- Tear film (tears), 2.213f, 2.213–222, 2.214t, 2.215f, 7.255, 7.256f, 8.5–6, 8.6f
- aqueous layer of, 2.38, 2.213f, 2.215–217, 7.252
- secretion of, 2.216–217
- biochemistry and metabolism of, 2.213–222

- composition of, 7.252, 8.5–6, 8.6f
 corneal topography affected by, 13.14, 13.19
 drug absorption and, 2.295–296, 2.296f, 2.298
 dysfunction/alterations of, 2.220–222, 2.221f.
See also Dry eye; Tear-deficiency states
 decreased vision/transient visual loss and, 5.164, 13.7
 illusions caused by, 5.174
 refractive surgery and, 13.172–173
 multifocal IOLs, 13.155
 seventh nerve lesions causing, 5.276–277f
 tests of, 7.269f, 7.269–272, 7.270f, 7.271f
 before refractive surgery, 13.173
 evaluation of, 8.38–41, 8.40f
 in ptosis, 7.211
 stains used in, 8.36–37, 8.37f, 8.38f, 8.56
 in external eye defense, 8.11
 functions of, 2.213, 8.6
 hypersecretion of (lacrimation), 7.267. *See also*
 Tearing/epiphora
 instability of, 2.220, 8.54, 8.54f
 lacrimal functional unit in maintenance of, 8.5, 8.6
 lipid layer of, 2.38, 2.213f, 2.214–215, 2.215f
 mucin layer of, 2.38, 2.213f, 2.217, 7.252
 osmolality of, 8.39
 pH of, 2.214t
 precorneal, 2.38, 2.213f, 2.213–214, 7.252
 preocular, 2.220
 production of
 evaluation of, 8.38–41, 8.40f
 medications affecting, 8.61–62, 8.62t
 pharmacologic stimulation of, 8.64
 refractive index of, 8.26
 secretion of, 2.214t, 2.217–220, 2.218f, 2.219f, 7.268
 solutes in, 2.216
 thickness of, 2.213, 2.213f, 2.214t
 Tear film hyperosmolarity, dry eye and, 8.39, 8.53
 Tear function tests, 7.269f, 7.269–272, 7.270f, 7.271f.
See also specific test
 Tear lens
 definition of, 3.206, 3.211
 power of, 3.220
 refractive index of, 3.220
 rigid gas-permeable contact lens creation of, 3.218, 3.218f
 Tear meniscus (marginal tear strip), 2.213
 inspection of, 8.56
 in pseudoepiphora evaluation, 7.267
 Tear pump. *See* Lacrimal pump
 Tear sac. *See* Lacrimal sac
 Tear secretion. *See* Tear film (tears), secretion of
 “Tear star,” 8.117
 Tearing/epiphora, 7.267, 8.46t. *See also* Lacrimal
 drainage system, obstruction of; *specific cause*
 acquired, 7.267–281
 evaluation of, 7.267–272, 7.269f, 7.270f, 7.271f
 chewing causing (crocodile tears), 5.277
 congenital, 7.259–267
 evaluation of, 7.259
 diagnostic tests for evaluation of, 7.269f, 7.269–272, 7.270f, 7.271f
 examination in patient with, 7.267–268
 history in patient with, 7.259, 7.267
 lacrimal outflow evaluation in patient with, 7.268–269
 in nasolacrimal duct obstruction
 acquired, 7.276–281, 7.277f, 7.280f, 7.281f
 congenital, 7.260–265, 7.261f, 7.262f, 7.263f, 7.264f
 in primary congenital glaucoma, differential
 diagnosis and, 10.151, 10.152t
 pseudoepiphora evaluation and, 7.267–268
 punctal disorders and, 7.272–273
 reflex, 2.104
 absorption of ocular medication affected by, 2.295, 2.298
 initiation of, 2.126
 parasympathetic nerves and, 2.104, 5.56
 weakened blink and, 7.255
 Tears (artificial), 2.220, 2.221, 2.341, 2.342. *See also*
 Lubricants
 for corneal exposure in facial palsy, 5.280
 for dry eye, 2.220, 2.221, 2.341, 2.342, 8.61t, 8.62–63
 for exposure keratopathy, 8.80
 for hay fever conjunctivitis, 8.288
 for paralytic ectropion, 7.224–225
 refractive surgery and, 13.173
 for Stevens-Johnson syndrome (Stevens-Johnson
 syndrome/toxic epidermal necrolysis overlap and
 toxic epidermal necrolysis), 8.297, 8.298
 for Thygeson superficial punctate keratitis, 8.307
 Tears (retinal). *See* Retinal tears
 Tecfidera. *See* Dimethyl fumarate
 Technetium-99 pyrophosphate scintigraphy, in ischemic
 heart disease, 1.97
 Technetium-99m sestamibi scintigraphy, in ischemic
 heart disease, 1.97
 Technetium-99m tetrofosmin scintigraphy, in ischemic
 heart disease, 1.97
 Technetium-99m thyroid scanning, 1.52
 TECNIS Symphony intraocular lens, 3.263, 13.166
 Tectonic penetrating keratoplasty
 for herpetic eye disease, 8.225
 for keratoglobus, 8.171
 for peripheral ulcerative keratitis, 8.313
 TED. *See* Thyroid eye disease
 Teenagers. *See* Adolescents
 Teff cells. *See* Effector T (Teff) cells
 Teichoic acid, in bacterial cell wall, 8.244
 Teichopsia, 5.177
 Teicoplanin, 1.277
 Telangiectasias. *See also* Macular telangiectasia
 aneurysmal, 12.161
 in ataxia-telangiectasia (Louis-Bar syndrome), 5.332f,
 5.334t, 8.115t, 8.346
 capillary, intracranial bleeding risk and, 1.126
 conjunctival, 5.332f, 5.334t, 8.115t, 8.346
 hereditary hemorrhagic (Rendu-Osler-Weber
 disease), 1.142, 1.143
 juxtafoveal, 12.161
 retinal. *See* Coats disease
 in rosacea, 8.70, 8.71
 in systemic sclerosis, 1.162
 Telecanthus, 6.203, 7.23
 in blepharophimosis-ptosis-epicanthus inversus
 syndrome, 7.155
 Telemedicine, 6.331

- Telemicroscopes, 3.322
 Teleopsia, 5.175
 Telescopes
 astronomical. *See* Telescopes, Keplerian
 Galilean, 3.40, 3.83–84, 3.84f, 3.140, 3.166, 3.255, 3.292, 3.298, 3.322
 Keplerian, 3.40, 3.83–84, 3.84f, 3.322
 low vision managed with, 3.322t, 3.322f, 3.322–323
 spectacle, 3.322f
 Telithromycin, 1.273t, 1.278
 Teller Acuity Cards II, 6.8, 6.9f, 6.56, 6.154, 6.187
 Telmisartan, 1.68t, 1.69t
 Telomeres/telomeric DNA, 2.144, 2.150
 Telophase, 2.149, 2.149f
 Telorbitism (hypertelorism), 7.23
 in craniosynostosis, 7.37
 with midline clefts, 7.37
 Temafloracin, 1.277, 2.346
 Temperature, anterior segment injury and, 8.384–385, 8.385f
 Tempering, 3.195
 Temporal (giant cell) arteritis. *See* Giant cell arteritis
 Temporal artery, 7.16f
 deep, 5.15f
 eyelids supplied by, 7.154
 posterior, 5.16f, 5.19f
 superficial, 5.12, 5.15f
 Temporal artery biopsy (TAB), in giant cell arteritis/
 AAION, 4.244f, 4.244–245, 5.121, 5.314, 7.61
 Temporal bone, 5.5
 Temporal coherence, 3.100f, 3.101
 Temporal crescent, 5.29f, 5.30, 5.156
 Temporal fascia
 deep, 7.141, 7.142f, 7.144
 superficial (temporoparietal fascia), 7.141, 7.142f, 7.144
 Temporal fat pad, 7.142f
 Temporal flare, in thyroid-related eyelid retraction, 7.223
 Temporal fossa, 5.8, 5.10f
 Temporal lobe, 5.24f
 lesions of, 5.147f, 5.155, 5.155f
 hallucinations and, 5.155, 5.176–177
 resection of, for seizures, visual field defects and, 5.155
 Temporal nerve, 2.104, 5.51f, 5.52, 5.276–277f, 7.142f, 7.143, 7.144, 7.144f
 Temporal occipital parietal pontine pathway, 5.34f
 Temporal orbital fat pad, 7.149
 Temporal retina, 5.24f, 5.25
 Temporal veins, eyelids drained by, 7.154
 Temporal wedge, 5.103
 in glaucoma, 10.69
 Temporalis muscle, 7.142f, 7.143, 7.143f
 Temporin A/temporin L, 1.280
 Temporofacial division, of cranial nerve VII (facial), 2.104, 5.52
 Temporomandibular joint (TMJ) disease, pain and, 5.297
 Temporoparietal fascia (superficial temporal fascia), 7.141, 7.142f, 7.144
 TEN. *See* Toxic epidermal necrolysis
 Tenacious proximal fusion
 definition of, 6.100
 in intermittent exotropia, 6.71, 6.100
 Tendency-oriented perimeter (TOP) algorithm, 10.61
 Tendon–trochlea complex, 6.20
 Tenecteplase, for ST-segment elevation acute coronary syndrome, 1.105
 Tenectomy, 6.164t
 Teniposide, 1.231, 1.233t
 Tenofovir, 1.266, 1.267
 Tenon capsule, 2.31f, 2.31–32, 2.32f, 2.43, 8.6
 anatomy of, 6.25–27, 6.27f
 posterior portion of, 6.27
 scarring of, 6.171
 surgical penetration of, 6.30
 Tenotomy
 definition of, 6.164t
 superior oblique, for superior oblique myokymia, 5.251
 superior oblique muscle, 6.112, 6.138
 Tension rings, capsular (CTRs), for zonular incompetence, 11.180, 11.181f, 11.183
 Tension-type headache, 5.292
 treatment of, 5.292–293
 Tensor fascia lata, autologous/autogenous/banked, for frontalis suspension, 7.221
 Tensor tympani, 5.48
 Tensor veli palatini, 5.48
 Tentorium cerebelli, 5.41f
 Tenzel semicircular rotation flap/modified Tenzel flap, for eyelid repair, 7.192, 7.195
 Terak. *See* Oxytetracycline, with polymyxin B
 Teratogens
 carbonic anhydrase inhibitors as, 2.326
 tetracyclines as, 2.350
 Teratoid medulloepitheliomas, 4.179
 Teratomas, 4.6, 4.7f
 orbital, 6.225f, 6.225–226, 7.41
 Terazosin, 1.68t
 intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137t
 Terbinafine, 1.281
 Teriflunomide, for multiple sclerosis, 5.321t
 Terminal web, 2.42f, 2.42–43
 Termination codon (stop codon), 2.144
 frameshift mutation and, 2.135, 2.155
 Terrien marginal degeneration, 8.122–124, 8.123f
 Terson syndrome, 5.340, 5.340f, 12.366
 Tertiary diagnostic position of gaze, 6.31
 Tertiary vitreous, 2.123f, 4.125
 Tesla, 5.60, 5.76
 Tessellation, 12.214
 Test–retest reliability, 1.24
 Testis-determining factor (TDF/sex-determining region Y/SRY), 2.179
 Tetanic cataract, 11.61–62
 Tetanus
 immunization against, 1.218t, 1.222
 wound management of, 1.222
 Tetanus and diphtheria toxoid vaccine (Td vaccine), 1.218t, 1.222
 Tetanus immunoglobulin, 1.222
 Tetanus toxoid, diphtheria, and acellular pertussis (Tdap) vaccine, 1.207, 1.218t, 1.222

- Tetracaine, 2.363*t*, 2.365, 8.205
 for cataract surgery, 11.92
 maximum safe dose of, 1.304*t*
- Tetracyclic antidepressants, 1.196*t*
- Tetracyclines, 1.272, 1.279, 2.350. *See also specific agent*
 adrenochrome deposition caused by, 8.118*t*, 8.131
 for chemical injuries, 8.383
 for chlamydial conjunctivitis, 8.263
 intravenous administration of, 2.301
 for meibomian gland dysfunction, 8.68
 for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81–82
 after surface ablation, 13.108
 ocular effects of, 1.307*t*
 for rosacea, 8.71
 for syphilis, 9.242*t*, 9.243
 for trachoma, 8.262, 8.263
- Tetrafoil, 3.276*f*
- Tetrahydrotriamcinolone, anti-inflammatory/pressure-elevating potency of, 2.333*t*
- Tetrahydrozoline, 2.342
- Textural interface opacity, after DSEK, 8.446, 8.446*f*
- TFIIH, in DNA repair, 2.154
- TGF- β s. *See* Transforming growth factor β s
- TGF β I dystrophies, epithelial–stromal, 4.86, 4.88*f*, 4.88–91, 4.89*f*, 4.90*f*, 4.91*t*, 4.91*f*, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149
 granular, 8.135*t*
 type 1 (GCD1/classic), 4.90, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.147–148, 8.148*f*
 type 2 (GCD2/Avellino), 4.90, 4.91*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.148–149, 8.149*f*
 amyloid deposits in, 8.148, 8.186*t*
 refractive surgery and, 13.43
 lattice (LCD), 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–147, 8.146*f*, 8.147*f*. *See also specific type*
 recurrence of after corneal transplantation, 8.425
 Reis-Bücklers (RBCD/CDB1/atypical granular), 4.88, 4.88*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.142*f*, 8.142–143
 Thiel-Behnke (TBCD/CDB2), 4.88, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.143–144, 8.144*f*
- Th0 cells. *See* T helper-0 (Th0) cells
- Th1 cells. *See* T helper-1 (Th1) cells
- Th2 cells. *See* T helper-2 (Th2) cells
- Th17 cells. *See* T helper-17 (Th17) cells
- Thalamostriate arteries, 5.20
- Thalamotomy, for Parkinson disease, 1.199–200
- Thalamus, 5.24*f*, 5.33, 5.34
- Thalassemia, 1.137, 12.149, 12.149*t*
 α , 1.137
 β , 1.137
 stem cell transplantation for, 1.135, 1.137
- Thallium-201 myocardial scintigraphy, 1.97–98
- Theques, 4.63–64
- Therapeutic contact lenses, 8.368. *See also* Bandage contact lenses
- Therapeutic lifestyle changes (TLCs). *See* Lifestyle modification/therapeutic lifestyle changes
- Thermal cautery
 for conjunctivochalasis, 8.86, 8.361
 for punctal occlusion, 7.282, 8.65
 for superior limbic keratoconjunctivitis, 8.84
- Thermal energy, 3.106
- Thermal injury (burns), 6.376
 anterior segment, 8.384–385, 8.385*f*
 cataract surgery incision, 11.131
 eyelid, 7.190
- Thermal interactions, laser–tissue, 3.113–114*t*, 3.113–114*f*, 3.113–115
- Thermal laser
 for neovascular age-related macular degeneration, 12.79
 photocoagulation. *See* Photocoagulation
- Thermokeratoplasty, 13.8*t*, 13.28, 13.28*f*, 13.127–128
 laser (LTK), 13.8*t*, 13.127–128
 corneal transplantation after, 13.198
 radial, 13.127
- Thermoplastic acrylic gel, for IOLs, 13.170
- Thermotherapy, transpupillary (TTT)
 for choroidal/ciliary body melanoma, 4.276
 for metastatic eye disease, 4.310
 for retinoblastoma, 4.300
- θ_c . *See* Critical angle
- θ_i . *See* Angle of incidence
- θ_r . *See* Angle of reflection; Angle of refraction/transmission
- θ_t . *See* Angle of refraction/transmission
- Thiabendazole
 for diffuse unilateral subacute neuroretinitis, 9.233–234
 for toxocariasis, 9.230
- Thiamine deficiency, optic neuropathy caused by, 5.138
- Thiazide diuretics
 for heart failure, 1.109, 1.110
 for hypertension, 1.68, 1.68*t*, 1.70, 1.71
 ocular effects of, 1.308*t*
- Thiazolidinediones, for diabetes mellitus, 1.45*t*, 1.46
- Thick lenses
 formula for, 3.54–55
 power of, 3.55*f*
- Thiel-Behnke corneal dystrophy (TBCD/CDB2), 4.88, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.143–144, 8.144*f*
- Thimerosal
 allergic/sensitivity/toxic reactions and, 2.294, 2.341, 8.90*t*, 8.91
 in MMR vaccine, 1.221
- Thin-lens approximation, 3.42, 3.54, 3.56
- Thioflavin T (ThT) stain, 4.31*t*
- Thiopental, perioperative, 1.291
- Thiopurine methyltransferase/thiopurine S-methyltransferase (TPMT), azathioprine response and, 1.175, 9.103
- Thioridazine, 12.297
 lens changes caused by, 11.52
 ocular effects/retinal toxicity of, 1.194
- Thioureas, for hyperthyroidism, 1.53
- Third cranial nerve. *See* Cranial nerve III
- Third law of motion, 3.293
- Third nerve (oculomotor) palsy, 2.95, 5.188, 5.191, 5.193*f*, 5.193–198, 5.194*f*, 5.196*f*, 5.198*f*
 aberrant nerve regeneration and, 5.197–198, 5.198*f*
 anisocoria and, 5.265–266
 light–near dissociation and, 5.266*t*, 5.267
 acquired, 6.138
 amblyopia with, 6.138

- aneurysm and, 5.20, 5.194*f*, 5.194–195, 5.196, 5.196*f*, 5.339
- anisocoria and, 5.256*f*, 5.265–266
- clinical features of, 6.138
- complete, 6.139
- congenital, 6.138
- diplopia and, 5.188, 5.191, 5.193*f*, 5.193–198, 5.194*f*, 5.196*f*, 5.198*f*, 6.139
- divisional, 5.197
- incomplete, 6.139
- isolated, 5.192, 5.194, 5.197
- in multiple sclerosis, 5.318
- management of, 6.138–140
- neuroimaging in evaluation of, 5.70
- partial, 5.193, 5.193*f*, 5.195–196, 5.196*f*
- ptosis in, 5.272, 5.273*t*, 7.215–216
- pupil-involving, 5.193, 5.194*f*, 5.194–195, 5.265
- in younger patients, 5.197
- pupil-sparing, 2.95, 5.195–196, 5.196*f*
- complete, 5.195
- partial, 5.195–196, 5.196*f*
- spontaneous recovery of, 6.138
- surgical management of, 6.139–140
- upper eyelid ptosis associated with, 6.138, 6.139*f*
- in younger patients, 5.197
- Third-order aberrations, 3.276*f*, 13.12, 13.12*f*
- Third-order neurons, 5.52, 5.53*f*, 5.54
- dilator muscle innervation and, 2.56
- Horner syndrome caused by lesions of, 5.258, 5.259, 5.260, 5.260*t*, 5.261, 5.262*f*
- Third-order Zernike polynomials, 3.73
- 13q14 (long arm 13 deletion) syndrome, 2.192
- 30° test, 5.95
- Three cone opsins, 2.262. *See also* Color vision
- Three-dimensional computed tomography, in orbital evaluation, 7.27, 7.27*f*
- 3-mirror lens, 12.22
- 3-o'clock staining, 3.233, 3.233*f*
- 3-piece foldable intraocular lens, insertion of, 11.116
- 3' untranslated region, 2.145, 2.147
- 3-step test
- description of, 6.73–75, 6.74*f*
- in fourth nerve (trochlear) palsy, 5.198–199
- unilateral superior oblique muscle palsy diagnosis using, 6.120
- Three-zone multifocal intraocular lens, 3.259, 3.259*f*
- Threshold
- genetic, 2.144
- screening, comparison of, to continuous predictive value, 1.16–17, 1.17*f*
- sensitivity, 5.86, 5.87*f*, 5.91
- Threshold disease (retinopathy of prematurity), 12.177, 12.178*t*, 12.179, 12.180*f*, 12.181, 12.185
- Threshold stimulus/testing (perimetry), 5.86, 10.61*f*, 10.61–62, 10.63*f*
- Thrombectomy, for stroke, 1.123
- Thrombi/thrombus. *See* Thrombosis/thrombotic disorders
- Thrombin, 1.141, 2.369, 9.23
- Thrombin inhibitors, 1.148
- for cerebrovascular disease/atrial fibrillation, 1.119
- for non-ST-segment elevation acute coronary syndrome, 1.103
- Thromboangiitis obliterans (Buerger disease), cataract caused by, 11.68
- Thrombocytopenia, 1.143–144
- hemangiomas and (Kasabach-Merritt syndrome), 7.67–68
- liver disease and, 1.146
- Thrombocytopenic purpura
- idiopathic (ITP), 1.143
- thrombotic (TTP), 1.144
- Thrombolysis/thrombolytic therapy (fibrinolytic agents), 1.149, 2.369
- for cerebral ischemia/stroke, 1.122–123
- emergency transport and, 1.295, 1.299
- for myocardial infarction/STEMI, 1.94, 1.104–105
- Thrombophilia, 1.146. *See also* Hypercoagulable states; Thrombosis/thrombotic disorders
- fetal loss/preeclampsia and, 1.135
- Thromboplastin time, activated partial (aPTT), 1.141
- Thrombopoietin, 1.136
- Thrombosis/thrombotic disorders, 1.146. *See also* Hypercoagulable states
- antiphospholipid antibody syndrome and, 1.148, 1.159, 1.160
- antithrombotic component deficiencies and, 1.141
- atrial fibrillation and, 1.114
- cerebral venous (CVT), 5.345–346
- in diabetes mellitus, 1.49
- in idiopathic intracranial hypertension, 5.111
- neuroimaging in, 5.69, 5.69*f*, 5.72*t*, 5.346
- comma-shaped, 12.154
- fetal loss/preeclampsia and, 1.135, 1.148
- myocardial infarction and, 1.93
- in NAION, 5.123
- after percutaneous coronary intervention, 1.100
- retinal vasculitis versus, 12.156
- stroke and, 1.120
- in diabetes mellitus, 1.49
- in thrombotic thrombocytopenic purpura, 1.144
- Thrombospondin I, in vitreous, 2.253
- Thrombotic thrombocytopenic purpura (TTP), 1.144, 12.195
- Thromboxanes (TXAs), 2.237, 2.334
- aspirin affecting, 2.335
- ThT (thioflavin T) stain, 4.31*t*
- “Thunderclap headaches,” 5.346
- Thygeson superficial punctate keratitis (SPK), 6.269, 8.306–307, 8.307*f*
- Thymectomy, for myasthenia gravis, 5.326
- Thymoma, in myasthenia gravis, 5.326, 7.216–217
- Thymoxamine, 2.308*t*, 2.321
- Thyroglobulin, 1.50
- antibodies to, 1.52
- Thyroid adenoma, 1.54, 1.55
- Thyroid antibody tests, 1.52
- Thyroid-associated ophthalmopathy/orbitopathy. *See* Thyroid eye disease
- Thyroid-binding inhibitory immunoglobulins, in thyroid eye disease, 7.53
- Thyroid biopsy, 1.52
- Thyroid carcinoma, 1.55–56
- retinoblastoma associated with, 4.302*t*
- thyroid scanning in evaluation of, 1.52, 1.55

- Thyroid disease, 1.50–56. *See also* Thyroid eye disease
 hyperthyroidism, 1.52–54
 hypothyroidism, 1.54
 screening/testing for, 1.51–52, 7.33, 7.57*t*
 smoking and, 1.53, 7.52, 7.56, 7.58
 superior limbic keratoconjunctivitis and, 8.83, 8.84
 thyroid gland physiology and, 1.50
 thyroiditis, 1.54–55, 7.52, 7.53, 7.56
 tumors, 1.55–56
- Thyroid eye disease (TED), 1.53, 4.226, 4.227*f*, 5.131, 5.132*f*, 5.326–327, 6.140–141, 6.141*f*, 6.143*t*, 6.175, 6.215, 7.51–60, 7.52*f*, 7.53*f*, 7.54*f*, 7.57*t*
 antithyroid antibodies and, 7.53
 clinical presentation and diagnosis of, 7.52, 7.52*f*, 7.53*f*, 7.53–54, 7.54*f*, 7.56, 7.57*t*
 diplopia caused by, 5.186, 5.206
 epidemiology of, 7.55–56
 eye movements/extraocular myopathy and, 4.226, 4.227*f*, 5.206, 7.25, 7.52, 7.54, 7.54*f*, 7.56
 eyelid abnormalities and, 7.25, 7.52, 7.52*f*, 7.54, 7.56
 management and, 7.59
 retraction, 4.226, 4.227*f*, 5.131, 5.274, 5.275*f*, 5.275*t*, 7.52, 7.52*f*, 7.54, 7.56, 7.59, 7.222–223, 7.223, 7.224
 glaucoma and, 10.30
 myasthenia gravis and, 5.324, 7.56
 neuro-ophthalmic signs of, 5.326–327
 neuroimaging in evaluation of, 5.72*t*, 5.206
 optic neuropathy in, 5.131, 5.132*f*, 7.52, 7.54, 7.56, 7.59
 pathogenesis of, 7.55
 prognosis of, 7.56–60
 proptosis and, 4.226, 4.227*f*, 5.131, 7.24, 7.52, 7.52*f*, 7.54
 radioactive iodine treatment affecting, 7.58
 smoking and, 1.53, 7.52, 7.56, 7.58
 strabismus and, 5.206
 thyroid function tests in, 7.33, 7.57*t*
 treatment of, 7.56–60, 7.57*t*
 von Graefe sign in, 7.25, 7.52
- Thyroid follicles, 1.50
- Thyroid function tests, 7.33, 7.57*t*
- Thyroid hormone-binding protein tests, 1.51
- Thyroid hormones, 1.50
 measurement of, 1.51
- Thyroid medications, in perioperative setting, 1.285
- Thyroid microsomal (antimicrosomal) antibody (TMAb)
 testing for, 1.52
 in thyroid eye disease, 7.53
- Thyroid nodules
 biopsy/fine-needle aspiration biopsy in evaluation of, 1.52
 thyroid scanning in evaluation of, 1.52
- Thyroid ophthalmopathy/orbitopathy/thyroid-related immune orbitopathy. *See* Thyroid eye disease
- Thyroid scanning, 1.52
 for thyroid tumor evaluation, 1.52, 1.55
- Thyroid-stimulating hormone (TSH). *See* Thyrotropin (thyroid-stimulating hormone/TSH)
- Thyroid-stimulating immunoglobulins (TSIs), 6.140
 in thyroid eye disease, 7.33, 7.53
- Thyroid storm, 1.53
- Thyroid tumors, 1.55–56
 thyroid scanning in evaluation of, 1.52, 1.55
- Thyroid ultrasound, 1.52
- Thyroiditis, 1.53, 1.54–55. *See also specific type*
 thyroid antibodies in, 1.52
 thyroid eye disease and, 7.52, 7.53, 7.56
- Thyrotoxic exophthalmos. *See* Thyroid eye disease
- Thyrotoxicosis. *See* Hyperthyroidism
- Thyrotroph adenomas, 1.57
- Thyrotropin (thyroid-stimulating hormone/TSH), 1.50
 receptor for (TSH-R)
 antibodies to
 in Graves hyperthyroidism, 1.53
 in thyroid eye disease, 7.33, 7.53
 in thyroid eye disease, 7.33, 7.53
 radioactive iodine treatment and, 7.58
 serum levels of, 1.51, 7.33
- Thyrotropin (thyroid-stimulating hormone/TSH)
 receptor antibodies
 in Graves hyperthyroidism, 1.53
 in thyroid eye disease, 7.33, 7.53
- Thyrotropin-releasing hormone (TRH), 1.50, 1.56*t*
- Thyroxine (T₄), 1.50
 for block-and-replace therapy in thyroid eye disease, 7.58
 serum levels of, 1.51, 7.33
- Thyroxine-binding globulin (TBG), 1.50
 serum levels of, 1.51
 total thyroxine (T₄) levels affected by, 1.51
- TI (interpulse time), 5.75
- TIA. *See* Transient ischemic attack
- Tiagabine, 1.202*t*
- Tibia bone tissue keratoprosthesis (TKPro), 8.452
- Tic douloureux (trigeminal neuralgia), 5.289*t*, 5.297
- Ticagrelor, for ischemic heart disease, 1.99, 1.100, 1.100*t*
- Ticarcillin, 1.275, 2.344*t*, 2.345
 with clavulanic acid, 1.276
- Tick-borne diseases, 12.245–246
- Ticks, Lyme disease transmitted by, 1.250, 8.249, 9.243
- Tics
 facial (habit spasm), 5.285
 ocular, 6.201–202
- Tigecycline, 1.280
- Tight junctions (zonulae occludentes)
 in ciliary body epithelium, 2.57
 in corneal endothelium, 2.227
 in corneal epithelium, 8.8
 in retinal pigment epithelium, 2.68, 2.272
- Tight orbit, 7.113
- Tightening procedures
 for inferior oblique muscle, 6.166
 for oblique muscles, 6.164*t*, 6.166–167
 for rectus muscles, 6.163–164, 6.164*t*
 for superior oblique muscle, 6.167
- TIGR/myocilin (TIGR/MYOC) gene, 2.200, 10.10, 10.11*t*, 10.150
 in pediatric glaucoma, 8.108
- TIGR protein, 10.10
- Tillaux, spiral of, 2.13, 2.14*f*, 5.45
- Tilt
 definition of, 3.42
 intraocular lenses, 3.250

- Tilted disc syndrome, 6.365–366, 6.366*f*, 12.217
 congenital, 5.144, 5.144*f*
- Time-domain optical coherence tomography (TD-OCT), 3.303–304, 3.304*f*, 8.22, 10.54
- Time-out
 before ECCE, 11.196
 before phacoemulsification, 11.104–105
 preoperative, 13.82
- Time to echo (TE), 5.62, 5.75, 5.76
- Time to repetition (TR), 5.62, 5.76
- Timentin (intravenous ticarcillin and clavulanic acid), 1.276
- TIMI risk calculator, 1.103, 1.104
- Timolol, 2.308*t*, 2.321, 2.322*t*, 2.323, 10.171*t*, 10.175*t*, 10.176–177
 in children, 7.68, 7.161, 10.165
 cholesterol levels affected by, 1.89
 in combination preparations, 2.318*t*, 2.322*t*, 2.325, 2.325*t*, 2.327*t*, 10.174*t*, 10.182
 for glaucoma, 2.321, 2.322*t*, 2.325, 2.325*t*, 2.327*t*, 10.171*t*, 10.176–177
 in children, 10.165
 in combination preparations, 10.174*t*
 for hypertension, 1.68*t*, 1.69*t*
 for infantile (capillary) hemangioma, 7.68, 7.161
- TIMP 1. *See* Tissue inhibitor of matrix metalloproteinase 1
- TIMP3 gene/TIMP3 protein mutation, 2.161, 2.265, 12.275–276
- Tinnitus
 vestibular nystagmus and, 5.241, 5.241*t*, 5.242
 Vogt-Koyanagi-Harada syndrome and, 9.176
- TINU. *See* Tubulointerstitial nephritis and uveitis (TINU) syndrome
- TINU syndrome. *See* Tubulointerstitial nephritis and uveitis (TINU) syndrome
- Tiotropium, 1.134
- TIR. *See* Total internal reflection
- Tirofiban
 for ischemic heart disease, 1.101*t*
 non-ST-segment elevation acute coronary syndrome, 1.103–104
- Tissue
 laser interactions with. *See* Laser-tissue interactions
 ultraviolet light effects on, 3.194
- Tissue addition/subtraction techniques, 13.27–28.
See also specific procedure
- Tissue adhesives
 cyanoacrylate, 8.370–371. *See also* Cyanoacrylate glue/adhesive
 fibrin (fibrin glue/sealant), 2.369, 8.355. *See also* Fibrin glue/sealant/tissue adhesive
- Tissue expanders, intraorbital, in congenital anophthalmia/microphthalmia management, 7.36
- Tissue factor pathway inhibitor, 1.141
- Tissue inhibitor of matrix metalloproteinase 1 (TIMP 1), 8.6*f*
- Tissue microarrays (TMAs), 4.40, 4.41*f*
- Tissue plasminogen activator (tPA/rtPA), 1.149, 2.369, 9.23
 in aqueous, 2.369
 for cerebral ischemia/stroke, 1.119, 1.122–123
 intracameral administration of, 2.300*t*
 off-label use of, 2.306, 2.369
 for ST-segment elevation acute coronary syndrome, 1.104–105
 in vitreous, 2.252
- Tissue preparation/preservation
 donor corneas, 8.414–416, 8.416*f*
 for pathologic examination, 4.25–30, 4.31*t*
 from conjunctival biopsy, 8.361
 from corneal biopsy, 8.367
 fixatives for, 4.26, 4.26*t*
 processing and, 4.30
 slide preparation and, 4.30
 special procedures and, 4.33–45
 staining and, 4.30, 4.31*t*
- Tissue-resident macrophages, 9.11
- Titmus test, 6.81
- TK. *See* Transverse keratotomy
- TKIs. *See* Tyrosine kinase inhibitors
- TKPro. *See* Tibia bone tissue keratoprosthesis
- TLCs (therapeutic lifestyle changes). *See* Lifestyle modification/therapeutic lifestyle changes
- TLR2 (toll-like receptor), 9.13
 in lipopolysaccharide-induced uveitis, 9.15
- TLR4 (toll-like receptor), 9.13
- TMAb. *See* Thyroid microsomal (antimicrosomal) antibody
- TMAs. *See* Tissue microarrays
- TMEM98 gene, 6.263
- TMJ disease. *See* Temporomandibular joint (TMJ) disease
- TMP-SMX. *See* Trimethoprim-sulfamethoxazole
- TMVL (transient monocular visual loss).
See Monocular transient visual loss
- TNF. *See* Tumor necrosis factor
- TNO test, 6.81
- Tobacco use. *See also* Smoking/smoking cessation
 cataract development and, 11.6–7, 11.63–64
 esophageal cancer and, 1.213
 optic neuropathy and, 5.137
- Tobradex. *See* Tobramycin, in combination preparations
- Tobramycin, 1.278, 2.344*t*, 2.347*t*, 2.351
 for bacterial keratitis, 8.270*t*
 in combination preparations, 2.334, 2.348*t*
- Tobrasol. *See* Tobramycin
- Tobrex. *See* Tobramycin
- Tocilizumab, 1.175, 9.108
 for uveitis, 9.108
- α -Tocopherol. *See* Vitamin E
- Todd paralysis, 1.201, 5.285
- Togaviruses, 8.240, 8.240*t*
- Tolbutamide, for diabetes mellitus, 1.45*t*
- Tolerance (immunologic)
 AIRE (autoimmune regulator) and, 9.64
 corneal transplantation and, 8.316
 ocular surface immunoregulation and, 8.11
 T regulatory cells in, 9.37, 9.38
- Toll-like receptors, 9.13
 in lipopolysaccharide-induced uveitis, 9.15
- Tolmetin, 2.335*t*
- Tolosa-Hunt syndrome, 5.203
- Tomato ketchup fundus, 4.281, 4.283*f*
- Tomography
 computed (CT). *See* Computed tomography

- corneal, 8.33–36, 8.34f, 8.35f, 8.35t, 13.19–22, 13.20–21f, 13.194
 in keratoconus, 8.35, 8.35f, 8.165f, 8.165–166
 after refractive/keratorefractive surgery, 13.23
 IOL power determination/selection and, 13.194
 optical coherence (OCT). *See* Optical coherence tomography
- Tomonaga, Sin-Iitiro, 3.96
- Tomopenem, 1.276
- TON. *See* Traumatic optic neuropathy
- Tongue claudication, in giant cell arteritis, 5.313
- Tonic cells, 2.267, 2.267f
- Tonic-clonic (“grand mal”) seizures, 1.201
- Tonic convergence, 6.40
- Tonic deviations, 5.230–231
 in gaze preference, 5.228
- Tonic (slow twitch) fibers, 2.18
- Tonic pupil (Adie tonic pupil), 5.256f, 5.263f, 5.263–265, 5.264f, 5.265f, 6.275
 light–near dissociation and, 5.263, 5.264f, 5.266t
 pharmacologic testing for, 2.310, 5.256f, 5.264–265, 5.265f
- Tonic vergence, 5.226
- Tono-Pen, 6.10, 6.281
 for intraocular pressure measurement, 10.25
 in infants and children, 10.158
 after refractive surgery, 13.181
- Tonography, in aqueous outflow measurement, 10.19
- Tonometry (tonometer), 10.22–27, 10.23f, 10.24f
 applanation. *See* Applanation tonometry/tonometer
 corneal thickness affecting, 10.25, 10.81, 10.82, 10.86, 13.105, 13.181
 description of, 3.282
 dynamic contour, 10.26
 Goldmann (GAT), 10.22–23, 10.23f, 10.24f. *See also* Goldmann applanation tonometry
 in infants and children, 6.10, 10.158–159
 infection control and, 10.27
 noncontact (air-puff), 10.26
 Perkins, 10.23
 in infants and children, 10.158
 pneumatic (pneumatonometer/pneumotonometer), 10.25–26
 in infants and children, 10.158
 for intraocular pressure measurement after refractive surgery, 13.119, 13.200
 in primary congenital glaucoma evaluations, 6.281–282
 after refractive surgery, 13.105, 13.119, 13.181, 13.200–201
 LASIK, 13.105
 surface ablation, 13.105
 Schiötz (indentation), 10.19, 10.26
 sources of error in, 10.23–24, 10.24t
- TOP algorithm. *See* Tendency-oriented perimeter (TOP) algorithm
- Topical anesthesia, 2.362–366, 2.363t. *See also* Anesthesia (anesthetics), local
 for anterior segment surgery, 2.365–366
 for cataract surgery, 11.92
 cholinesterase inhibitor use and, 2.312, 2.363
 for penetrating and perforating trauma repair, 8.403–404
 for phakic IOL insertion, 13.141
 for photoablation, 13.82
- Topical medications, 2.295–299, 2.296f. *See also* Eyedrops
 sustained-release devices for, 2.302
- Topiramate, 1.202t
 choroidal swelling caused by, 12.201
 glaucoma caused by, 6.284
 for idiopathic intracranial hypertension, 5.112, 6.371
 for migraine prophylaxis, 5.293
 myopia caused by, 12.305
 ophthalmic/retinal side effects of, 1.187, 1.203, 1.307t
 glaucoma and, 1.187, 1.203, 10.145f, 10.145–146
- Topographic maps, 8.28–33, 8.29f, 8.30f, 8.31f, 8.32f, 8.33f, 13.14–19, 13.15f, 13.17f, 13.19f, 13.44–45, 13.45f. *See also* Cornea, topography of
 interpretation of, 8.28–31
 in keratoconus, 8.165, 8.165f, 8.167f
 in pellucid marginal degeneration, 8.31, 8.33f, 8.169, 8.170f
 postoperative, 13.23, 13.24f
- Topography, 2.37f, 2.37–38, 4.6, 4.12t
 anterior chamber, 2.37, 2.37f, 4.97f, 4.97–98, 4.98f
 choroidal, 4.181f, 4.182–183, 4.183f
 ciliary body, 2.37f, 4.181f, 4.182, 4.183f
 conjunctival, 4.47, 4.48f
 corneal, 2.37, 2.37f, 2.38, 4.73, 8.15, 8.28–36, 8.29f, 8.30f, 8.31f, 8.32f, 8.32t, 8.33f, 8.35t, 13.14–19, 13.15f, 13.16f, 13.17f, 13.18f, 13.19f, 13.44–45, 13.45f, 13.79. *See also* Cornea, topography of
 before cataract surgery, 11.84, 11.86, 11.174
 immunologic environments and, 9.59, 9.59f
 Placido-based, 13.7–9, 13.14–16, 13.15f, 13.17, 13.20–21f, 13.25f
 eyelid, 4.201f, 4.201–202
 iris, 2.37f, 4.181f, 4.181–182, 4.182f
 lens, 2.37f, 4.115f, 4.115–117, 4.116f
 optic nerve/nerve head/disc, 4.241, 4.242f, 10.53
 orbital, 4.223, 7.5–9, 7.6f, 7.7f, 7.8f
 Placido-based. *See* Placido-based topography/Placido disk
 retinal, 2.37f, 2.38, 4.139–140, 4.140f, 4.141f, 12.9f, 12.9–10
 retinal pigment epithelium, 4.140f, 4.141, 4.141f
 scleral, 2.37f, 2.38, 4.107f, 4.107–108, 4.108f
 trabecular meshwork, 4.97f, 4.97–98, 4.98f
 uveal tract, 2.38, 4.181f, 4.181–183, 4.182f, 4.183f
 vitreous, 2.37, 2.37f, 4.125
- Topography-guided photoablation, 13.32, 13.77
 outcomes of, 13.97
- Topography-guided photorefractive keratectomy (T-PRK), corneal crosslinking and, 13.206–207
- TORCH (toxoplasmosis, other agents, rubella, cytomegalovirus, and herpesviruses). *See also specific disorder*
 lymphocytic choriomeningitis virus causing, 9.205
- Torcular Herophili, 5.22, 5.22f
- Toric contact lenses
 definition of, 3.4, 3.15
 intraocular
 astigmatism correction using, 3.257
 plate-haptic, 3.257

- meridians, 3.78f
- overrefraction with, 3.169
- paraxial power of, 3.79
- power-cross representation of, 3.77
- power-versus-meridian graph of, 3.79f
- properties of, 3.74
- soft, 3.222–223
 - discontinuing use of before refractive surgery, 13.38
 - after radial keratotomy, 13.200
 - spherical equivalent of, 3.76
- Toric intraocular lenses, 11.124, 13.8t, 13.137, 13.148–149, 13.151–153
 - complications of, 11.151, 13.153
 - contraindication for, capsular decentration and, 11.183
 - corneal crosslinking with, 13.134, 13.207–208
 - dry eye therapy before use of, 11.173
 - outcomes of, 13.152–153
 - patient selection for, 13.151
 - after penetrating keratoplasty, 8.432, 13.179
 - planning/surgical technique for, 13.151–152
- Toric surface
 - curvature variation of, along meridian, 3.16f
 - definition of, 3.42, 3.71
 - formation of, 3.15f
 - methods of describing, 3.18
 - non-ocular objects with, 3.15
 - normal plane and, intersection between, 3.15f
- Torsades de pointes, 1.114
- Torsemid
 - for heart failure, 1.109
 - for hypertension, 1.68t
- Torsional deviations, dissociated, 6.17, 6.129
- Torsional fusional vergence, 6.72
- Torsional nystagmus, 5.245
- Torsional phacoemulsification, 11.101
- Torticollis
 - abnormal head position associated with, 6.82
 - definition of, 6.82
 - differential diagnosis of, 6.82–84, 6.83t
 - evaluation of, 6.84
 - facial asymmetry and, 6.82
 - history-taking for, 6.63
 - ocular, 6.82–84, 6.83t
 - spasmus nutans and, 5.239
 - strabismus and, 6.63
- Tortuosity, conjunctival vascular, 8.114, 8.115t
- Torulopsis candida*, postoperative endophthalmitis caused by, 9.262
- Tositumomab, in cancer therapy, 1.236
- Total, 1.51, T₄
- Total cataract, 11.38
- Total cholesterol, target level for, 1.81, 1.85
- Total internal reflection, 3.42, 3.50, 3.50f
- Tourette syndrome, 6.202
 - facial twitching and, 5.285
- Touton giant cells, 4.7, 4.9f, 6.271
 - in juvenile xanthogranuloma, 4.187, 4.188f, 9.277
- Toxemia of pregnancy. *See* Eclampsia; Preeclampsia
- Toxic anterior segment syndrome (TASS), 11.129, 11.133–134
- Toxic conjunctivitis, 3.232
- Toxic epidermal necrolysis (Stevens-Johnson syndrome and Stevens-Johnson syndrome/toxic epidermal necrolysis overlap/SJS–TEN), 6.251–252, 8.285, 8.295–298, 8.296f, 8.297f
- Toxic goiter. *See also* Thyroid eye disease
 - diffuse, 1.53. *See also* Graves hyperthyroidism/ophthalmopathy/eye disease
 - nodular, 1.53, 1.54
- Toxic keratitis, 8.91. *See also* Toxic keratoconjunctivitis
- Toxic keratoconjunctivitis, medications causing, 8.80–81, 8.81t, 8.90t, 8.90–91
- Toxic keratopathy
 - central, after photoablation, 13.105f, 13.105–106
 - ulcerative, 8.80–81, 8.81t. *See also* Toxic keratoconjunctivitis
- Toxic optic neuropathy, 1.192, 5.107t, 5.137–139
- Toxic solutions, exposure to during cataract surgery, corneal edema caused by, 11.129, 11.133–134
- Toxicity
 - anterior segment injuries and, 8.375–409
 - drug, 2.294
 - age/aging and, 2.294, 2.295
 - tissue binding and, 2.298
 - light. *See* Light toxicity/photoc damage/phototoxicity
- Toxocara* (toxocariasis), 4.295, 6.317f, 6.317–318, 8.253, 9.30, 9.228, 9.229f, 9.229t, 9.230f, 12.244–245, 12.245f
- canis*, 6.317, 8.253, 9.47, 9.228, 9.232, 12.244, 12.246
- cati*, 6.317, 8.253, 9.228, 12.244, 12.246
- diffuse unilateral subacute neuroretinitis caused by, 9.232
- granuloma caused by, 9.47, 9.228, 9.229f, 9.229t
- retinoblastoma differentiated from, 4.295
- Toxoplasma* (toxoplasmosis), 1.256–257, 5.352, 9.219–227, 9.220f, 9.222f, 9.223f, 9.224f, 9.227f
- acquired, 9.221–222
- anterior uveitis caused by, 6.317
- chorioretinitis caused by, 1.257, 4.147–148, 4.148f, 6.409, 6.410f
- congenital, 1.256, 9.221, 9.222f, 9.226
- gondii*, 1.256, 6.409, 9.219
- definition of, 12.243
- retinochoroiditis caused by, 12.243–244, 12.244f
- in HIV infection/AIDS, 1.270, 5.352, 9.223, 9.225, 9.226, 9.227f, 9.296–297, 9.297f
- ocular infection/inflammation caused by, 1.256–257, 4.147–148, 4.148f, 9.219–227, 9.220f, 9.222f, 9.223f, 9.224f, 9.227f
- ocular manifestations of, 6.409–410, 6.410f
- during pregnancy, 1.256, 9.221, 9.226
- punctate outer retinal (PORT), 9.223, 9.224f
- retinal, 4.147–148, 4.148f
- transmission of, 1.256, 9.220
- treatment of, 1.257
- uveitis in, 1.256–257, 4.147, 9.219–227, 9.220f, 9.222f, 9.223f, 9.224f, 9.227f
- TP-PA. *See* *Treponema pallidum* particle agglutination assay
- tPA. *See* Tissue plasminogen activator
- TPCD. *See* Typical peripheral cystoid degeneration
- TPHA (*T. pallidum* hemagglutination assay), 1.249
- TPMT. *See* Thiopurine methyltransferase/thiopurine S-methyltransferase

- TR (time to repetition), 5.62, 5.76
- Trabecular meshwork, 2.45*f*, 2.46*f*, 2.48–52, 2.49*f*, 2.50*f*, 4.97*f*, 4.97–106, 4.98*f*, 10.5*f*, 10.13, 10.17–18, 10.19*f*
- chemical injury of, glaucoma and, 10.104
- congenital anomalies of, 4.98–99, 4.99*f*, 4.100*f*
- corneoscleral, 2.48, 2.49, 2.50*f*
- degenerations of, 4.100–105, 4.101*f*, 4.102*f*, 4.103*f*, 4.104*f*, 4.105*f*
- disorders of, 4.97–106. *See also specific type*
- endothelial, 2.49–50
- in glaucoma, 4.105*f*, 4.106, 4.194, 10.94, 10.95*f*
- gonioscopic appearance of, 4.97–98, 4.98*f*, 10.33*t*, 10.34*f*
- melanoma of, 4.106, 4.106*f*, 4.195*f*
- neovascularization and, 10.133
- pigment in, 4.104–105, 4.105*f*, 10.18, 10.39
- in pigment dispersion syndrome/pigmentary glaucoma, 4.104–105, 4.105*f*, 10.94, 10.95*f*
- in pseudoexfoliation/exfoliation syndrome, 4.102–103, 10.39, 10.93
- topography of, 4.97*f*, 4.97–98, 4.98*f*
- uveal, 2.48, 2.49
- in uveitis, 9.83
- Trabecular meshwork inducible glucocorticoid response/myocilin (*TIGR/MYOC*) gene, 10.10, 10.11*t*, 10.150
- in pediatric glaucoma, 8.108
- Trabecular microbypass, cataract surgery and, 11.186
- Trabecular outflow, 10.5*f*, 10.13, 10.17–18, 10.18*f*
- drugs affecting, 2.318*t*
- Trabeculectomy, 6.323, 10.113–115, 10.187, 10.196, 10.197–211. *See also* Filtering procedures
- ab interno, 10.219
- antifibrotic agents used with, 2.340, 10.205–207, 10.207*f*, 10.208*f*
- bleb-related endophthalmitis and, 10.163, 10.209
- cataract risk and, 11.56
- with cataract surgery, 10.211–213
- in children, 10.161, 10.163
- complications of, 10.209*t*, 10.209–211, 10.210*f*
- contraindications for, 10.198
- in elderly patients, 10.221
- failed, tube shunt implantation after, 10.215
- flap management in, 10.207–208
- indications for, 10.197
- for open-angle glaucoma, 10.113–115
- postoperative considerations in, 10.208–209
- preoperative evaluation for, 10.198–199
- technique for, 10.199–205
- for conjunctival incision/flap, 10.200, 10.201*f*, 10.202*f*
- closure and, 10.204, 10.206*f*
- management and, 10.207–208
- for exposure, 10.199, 10.200*f*
- for iridectomy, 10.202, 10.204*f*
- for keratectomy, 10.201–202, 10.204*f*
- for paracentesis, 10.201, 10.203*f*
- for scleral flap, 10.200–201, 10.203*f*
- closure and, 10.202–204, 10.205*f*
- management and, 10.207–208
- uveitic glaucoma and, 9.287
- Trabeculitis, 9.83, 9.113, 9.286
- in glaucomatocyclitic crisis (Posner-Schlossman syndrome), 10.101
- herpetic infection causing, 9.192–193
- Trabeculocytes, 2.48
- Trabeculodialysis, for uveitic glaucoma, 9.287
- Trabeculoplasty, 10.113–115, 10.188–191, 10.190*f*
- for exfoliation glaucoma, 10.93
- for normal-tension glaucoma, 10.88
- for open-angle glaucoma, 10.113–115, 10.188–191
- for pigmentary glaucoma, 10.96
- selective (SLT), 10.188, 10.189, 10.190, 10.190*f*
- uveitic glaucoma and, 9.287
- Trabeculotome, 10.161, 10.162*f*
- Trabeculotomy
- description of, 10.160, 10.161–162, 10.162*f*, 10.163
- for primary congenital glaucoma, 6.286*f*, 6.286–287
- Tracheotomy, for anaphylaxis, 1.302
- Trachipleistophora*, 8.252
- Trachoma, 6.241, 8.260–263, 8.261*f*, 8.262*f*
- cicatricial conjunctivitis differentiated from, 8.301*t*
- Tracking systems (excimer laser), 13.91
- Traction test. *See* Forced duction test
- Tractional retinal detachment, 6.348*f*, 6.360. *See also*
- Retinal detachment
- description of, 12.286
- diagnostic features of, 12.321*t*, 12.325
- in familial exudative vitreoretinopathy, 12.343
- imaging of, 12.387*f*
- management of, 12.325
- pathophysiology of, 12.387
- in proliferative diabetic retinopathy, 12.103, 12.108, 12.387–388
- rhegmatogenous retinal detachment versus, 12.325
- vitreotomy for, 12.325, 12.387–388
- Tractus solitarius, nucleus of, 5.55
- Trade magnification, 3.321–322
- Trait, 2.173
- Tram-tracking/tram-track sign, in optic nerve sheath meningioma, 5.127*f*, 5.128*t*, 7.80*f*, 7.81
- Trandolapril, 1.68*t*, 1.69*t*
- Tranexamic acid, 2.369, 2.370
- for hyphema, 8.395
- 11-*trans*-retinal, 12.31
- 11-*trans*-retinaldehyde, 12.17
- Trans-RPE potential, electro-oculogram and, 2.277
- Transbronchial biopsy, 1.131
- Transcaruncular incision
- for orbital decompression, 7.122
- for orbitotomy, 7.116*f*, 7.120
- Transconjunctival cryopexy, 12.398
- Transconjunctival incision
- for lower blepharoplasty, 7.232
- for orbital decompression, 7.122, 7.122*f*
- for orbitotomy
- inferior approach, 7.116*f*, 7.118, 7.119*f*
- medial approach, 7.116*f*, 7.119–120, 7.120*f*
- superior approach, 7.117
- for ptosis repair, 7.220, 7.220*f*
- Transcranial Doppler ultrasonography, in cerebral ischemia/stroke, 1.122
- Transcranial magnetic stimulation, for depression, 1.197

- Transcranial orbitotomy, coronal incision for, 7.117
- Transcribed strand of DNA (antisense/noncoding DNA), 2.132, 2.148f, 2.150, 2.151
in gene therapy, 2.170
- Transcription (gene), 2.144, 2.147, 2.151, 2.151f, 2.152
embryogenesis and, 2.111
reverse, 2.143
- Transcription factor 4 (*TCF4*) gene, in Fuchs endothelial corneal dystrophy, 8.136t, 8.156
- Transcription factors, 2.152
- Transcriptomics, 2.136
- Transcutaneous incision
for levator advancement, in ptosis correction, 7.219, 7.219f
for orbital decompression, 7.121
for orbitotomy
inferior approach, 7.118
medial approach, 7.116f, 7.119
superior approach, 7.116–117, 7.117f
- Transducin, rod, 2.259, 2.260f, 2.261
mutation in, 2.263
- Transendothelial osmotic force, 8.9
- Transepithelial ablation, debridement for, 13.83
- Transepithelial corneal crosslinking, 13.132–134, 13.133f. *See also* Corneal (collagen) crosslinking
- Transesophageal echocardiography, in cerebral ischemia/stroke, 1.125
- Transfer of energy, 3.106
- Transfer RNA (tRNA), mitochondrial DNA-encoded, mutations of, 2.157
- Transferrin
in aqueous humor, 2.233, 2.234
in vitreous, 2.252
- Transforming growth factor β -induced gene, dystrophies associated with, 8.133, 8.134, 8.135t, 8.136t, 8.142–149. *See also* *TGFBI* dystrophies
- Transforming growth factor β -induced (*TGFBI*) keratoepithelin, in corneal dystrophies, 8.133, 8.134, 8.136t. *See also* *TGFBI* dystrophies
- Reis-Bücklers, 8.142
- Transforming growth factor β s (*TGF- β s*), 2.371, 9.28t
in aqueous humor, 2.234
in external eye defense, 8.12–13f
in pseudoexfoliation/exfoliation syndrome, 11.65
retinal pigment epithelial cell transformation and, 2.279
in tear film, 2.217, 8.6f
- Transfusion-associated CMV infection, 1.259
- Transfusion-transmitted virus (TTV), 1.261–262
- Transgenic mice, IRBP-specific T-cell receptor, 9.64
- Transient amplifying cells, in corneal epithelium, 2.40
- Transient ischemic attack (TIA), 1.120
diagnosis/management of, 1.121–123
hemispheric, stroke and, 5.168–169
occipital, binocular transient visual loss and, 5.172
retinal (RTIA)
carotid disease and, 1.125
stroke and, 5.167, 5.168–169
transient monocular visual loss and, 5.164, 5.167, 5.168–169, 5.171
vertebrobasilar, 5.336–337
- Transient obscurations of vision, 5.161, 5.164. *See also* Transient visual loss
- Transient visual loss (TVL), 5.161–172. *See also*
Amaurosis, fugax
age of patient and, 5.161
binocular, 5.161, 5.171–172
carotid artery disease causing, 1.125, 5.162, 5.165–166, 5.167f, 5.168
cerebrovascular disease causing, 5.161, 5.162, 5.164–165, 5.326, 5.336
duration of, 5.161
examination of patient with, 5.163
migraine headache and, 5.161, 5.162, 5.171–172, 5.177, 5.291
monocular (TMVL), 5.161, 5.163t, 5.163–171.
See also Monocular transient visual loss
pattern of, 5.162
recovery pattern and, 5.162
- Transillumination, 4.28f, 4.28–29
in choroidal melanoma/ciliary body melanoma
diagnosis, 4.267, 4.267f
iris, 6.265
in albinism, 4.142, 4.142f
in pathologic examination, 4.28f, 4.28–29
- Transit amplification, in stem cell differentiation, 8.92
- Transitional zone (peripheral zone), corneal, 8.25, 8.25f
- Transketolase, in cornea, 2.224
- Translation, 2.144, 2.147, 2.151, 2.151f, 2.152
gene product changes/modification after (posttranslational modification), 2.142
of lens proteins, 2.245
“Translation operator,” 3.60
- Translocation, chromosome, 2.144
Down syndrome caused by, 2.190
- Transmigration, in neutrophil recruitment and activation, 9.16, 9.17–18, 9.18f
- Transmissible spongiform encephalopathies, 5.357
- Transmission defect, hyperfluorescence in, 12.36
- Transmission (window) defect, of fluorescence. *See* Hyperfluorescence
- Transmural (subendocardial/NSTEMI) infarction, 1.93, 1.94
- Transnasal endoscopy
for lacrimal drainage evaluation/obstruction, 7.272
for orbital decompression, 7.122
- Transplant rejection. *See* Rejection
- Transplantation. *See also specific type*
amniotic membrane. *See* Amniotic membrane
transplantation/graft
cardiac, for heart failure, 1.111
conjunctival, 8.351t, 8.353t, 8.353–355, 8.354f, 8.356
autografts/autologous, 8.351t, 8.353t, 8.353–355, 8.354f, 8.356
for chemical injuries, 8.383
indications for, 8.351t, 8.353, 8.356
for limbal stem cell deficiency, 8.94
in pterygium surgery, 8.351, 8.353t, 8.353–355, 8.354f, 8.356
recurrence rate and, 8.353t
after tumor removal surgery, 8.329
corneal, 8.316, 8.411–452, 8.412t, 8.412–413t. *See also* Donor cornea; Keratoplasty; *specific procedure*
allografts/allogeneic, 8.316, 8.411–451, 8.412t, 8.412–413t

- autografts/autologous, 8.411, 8.451–452
- cataract/cataract surgery and, 11.56, 11.175, 11.176
- for chemical injuries, 8.384
- definition of/terminology and, 8.412–413
- disease transmission and, 8.414, 8.415*t*, 8.416*t*
 - Creutzfeldt-Jakob disease, 8.254, 8.416*t*
 - rabies virus, 8.240, 8.240*t*, 8.416*t*
- donor selection and, 8.414, 8.415*t*, 8.416*t*
- eye banking and, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
- immune privilege and, 8.316, 9.60
- indications for, 8.412–413*t*
- patient selection and, 8.418
- pediatric, 8.450–451
- preoperative evaluation/preparation and, 8.418–419
- after refractive surgery, 13.197–198
- refractive surgery after, 13.37, 13.178–180
- rejection and, 4.84, 4.85*f*, 8.316–318, 8.428–431, 9.59, 9.60, 9.60*f*. *See also* Rejection
- in triple procedure, 11.175–176
- limbal, 8.94, 8.351*t*
 - for chemical injuries, 8.380, 8.384
 - indications for, 8.351*t*
- mucous membrane, 8.351*t*, 8.365–366
 - indications for, 8.351*t*, 8.366
 - for mucous membrane pemphigoid, 8.303, 8.366
- organ, for enzyme deficiency disease, 2.203
- pancreatic, for diabetes mellitus, 1.47
- rejection and. *See* Rejection
- retinal/retinal pigment epithelium, 9.62
- Transport mechanisms
 - in aqueous humor dynamics, 10.16
 - lens, 11.21, 11.22*f*
 - retinal pigment epithelium, 2.273, 2.277
- Transposition
 - definition of, 3.18, 3.77
 - practice with, 3.78
- Transposition flaps
 - for canthal repair, 7.195
 - for eyelid repair, 7.191
- Transpupillary thermotherapy (TTT), 3.115, 12.380
 - for choroidal/ciliary body melanoma, 4.276
 - for metastatic eye disease, 4.310
 - for retinoblastoma, 4.300
- Transscleral cryopexy, 12.398
- Transscleral cyclophotocoagulation (cyclodestruction), 10.194, 10.195–196, 10.196
 - for pediatric glaucoma, 10.163–164
- Transseptal injection, for periocular corticosteroids, 9.97, 9.97*f*
- Transthoracic echocardiography, in cerebral ischemia/stroke, 1.125
- Transthyretin (TTR/prealbumin), 1.50
 - amyloidosis/amyloid deposits and, 4.134, 4.135, 4.206, 8.187
 - serum levels of, 1.51
- Transverse facial artery, 5.13*f*, 5.15*f*
- Transverse keratotomy, 13.53, 13.54, 13.54*f*
- Transverse ligament, superior (Whitnall), 2.20*f*, 2.24, 7.7, 7.14*f*, 7.15*f*, 7.146*f*, 7.150*f*, 7.251
- Transverse magnification, 3.42, 3.62, 3.300
- Transverse (spin-spin) relaxation time (T2), 5.62, 5.63*t*, 5.76, 7.28
- Transverse sinus, 2.105, 2.106*f*, 5.22, 5.22*f*
 - endovascular stenting of, for idiopathic intracranial hypertension, 5.113
 - thrombosis in, 5.69*f*, 5.345–346
- Trapdoor fracture, 7.109–110, 7.110*f*
- Traquair, junctional scotoma of, 5.146–147
- Trastuzumab, for cancer therapy, 1.236
- Trauma. *See also* Lacerations; Penetrating and perforating ocular trauma; Wound healing/repair
 - abusive head, 6.381–384, 6.382–383*f*, 12.365–366, 12.366*f*
 - accidental, 6.375–381, 6.377–378*f*, 6.380*f*
 - amblyopia secondary to, 6.375
 - angle recession/angle-recession glaucoma and, 4.18, 4.19*f*, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
 - animal and plant substances causing, 8.386–387
 - anterior segment, 8.375–409, 10.39–40, 10.40*f*, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*. *See also* Anterior segment, trauma to
 - anterior uveitis caused by, 6.316
 - assessment of, 11.190–191
 - bleeding due to, coagulation disorders and, 1.142
 - blunt, 6.378–379, 8.387–396, 8.388*f*, 8.389*f*, 8.390*f*, 8.391*f*, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*, 12.315, 12.353–358, 12.354–357*f*. *See also* Blunt (concussive) trauma
 - canalicular, 7.282–283
 - obstruction caused by, 7.274
 - canthal soft tissue, 7.189
 - cataract surgery after, 11.190–193, 11.192*f*
 - cellulitis caused by
 - orbital, 7.47
 - preseptal, 7.44, 7.45
 - chemical injuries, 6.376, 8.375–384, 8.376*t*
 - chiasmal injury caused by, 5.152
 - in children, 12.316–317
 - choroidal rupture, 12.354–356*f*, 12.354–355
 - classification of, 12.351
 - closed-globe, 12.351–352
 - commotio retinae, 12.353, 12.354*f*
 - concussive (blunt), 8.387–396, 8.388*f*, 8.389*f*, 8.390*f*, 8.391*f*, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*. *See also* Blunt (concussive) trauma
 - convergence insufficiency caused by, 5.227
 - corneal abrasion, 6.376
 - corneal blood staining and, 8.394, 8.394*f*, 8.395, 8.395*t*, 10.104, 10.104*f*, 10.105
 - Descemet membrane rupture and, 4.17, 4.18*f*
 - diplopia after, 5.186, 5.206
 - ectopia lentis caused by, 11.40
 - endophthalmitis after, 12.362–363
 - evaluation of patient after, 12.351–353, 12.352*t*
 - eyelid, 7.187–190, 7.188*f*. *See also* Eyelids, surgery/reconstruction of; Eyelids, trauma to
 - fibrocellular proliferation and, 4.20–22, 4.21*f*, 12.315
 - fourth nerve (trochlear) palsy caused by, 5.199, 5.200
 - fungal keratitis associated with, 4.78

- glaucoma associated with, 4.103–104, 4.104*f*, 10.39–40, 10.40*f*, 10.41*f*, 10.98, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*
- angle closure/angle-closure glaucoma and, 10.142
- fibrous ingrowth and, 10.142, 10.143*f*
- angle recession and, 4.18, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
- in children and adolescents, 10.149*t*
- lens particle glaucoma and, 10.98, 11.67
- open-angle glaucoma and, 10.40*f*, 10.40–41, 10.41*f*, 10.106–108, 10.107*f*
- phacoantigenic glaucoma and, 10.98
- handheld laser-pointer injury, 12.369
- histologic sequelae of, 4.17–23, 4.18*f*, 4.19*f*, 4.20*f*, 4.21*f*, 4.22*f*, 4.23*f*
- hypercoagulability associated with, 1.148
- hyphema and. *See* Traumatic hyphema
- incidence of, 6.375
- in infants, 12.316–317
- infectious scleritis after, 9.259
- innate immune response and, 9.16
- intraocular pressure evaluations, 12.352
- lacrimal system, 7.282–284
- laser-pointer injury, 12.369
- LASIK flap dislocation and, 13.115–116
- lens damage/cataracts caused by, 4.18, 11.53–59, 11.54*f*, 11.55*f*, 11.56*f*, 11.58*f*, 11.59*f*, 11.190–193, 11.192*f*
- glaucoma and, 10.98, 11.67
- phacoantigenic uveitis and, 4.118–119, 4.119*f*, 11.66, 11.191
- surgery for, 11.192
- macular hole caused by, 12.355–357, 12.356*f*
- management of, 6.375
- microsurgery for, 12.351
- Mooren ulcer and, 8.314
- nasolacrimal duct obstruction caused by, 7.278
- neuroimaging in evaluation of, 5.72*t*, 5.73*f*, 5.139*f*, 5.140
- nonaccidental
- abusive head trauma, 6.381–384, 6.382–383*f*, 12.365–366, 12.366*f*
 - ocular injury secondary to, 6.384
- occupational light toxicity, 12.369
- ocular infection and, 8.247, 8.403
- ocular surface, 8.375–409
- Ocular Trauma Score, 12.364, 12.364*t*
- open-globe
- description of, 12.351–352
 - intraocular foreign bodies, 12.351–352, 12.360–362, 12.361*f*
 - lacerating injuries, 12.358
 - needle perforation/penetration, 12.358, 12.395*f*, 12.395–396
 - penetrating injuries, 12.358
 - prognosis for, 12.363–364
 - scleral rupture, 12.358
- optic canal fracture caused by, 7.10
- optic nerve head avulsion caused by, 12.365, 12.365*f*
- optic neuropathy caused by, 2.89, 5.107*t*, 5.139*f*, 5.139–140, 6.381, 7.113
- orbital, 7.103–114. *See also* Orbit, trauma to
- orbital floor fractures, 6.127–128, 6.128*f*, 6.379–380, 6.380*f*
- orbital roof fractures, 6.380, 6.380*f*
- penetrating and perforating, 6.376–378, 6.377*f*, 8.396–409. *See also* Penetrating and perforating ocular trauma; Trauma
- photic damage, 12.367–369, 12.368*f*
- phototoxicity from ophthalmic instrumentation, 12.368–369
- posterior segment. *See* Trauma
- prognosis after, 12.363–364
- ptosis caused by, 5.273*t*, 5.274, 7.190, 7.218
- amblyopia and, 7.190
- pupil irregularity caused by, 5.255
- restrictive conditions caused by, 5.186, 5.206
- retinal breaks caused by, 12.315–316, 12.316*f*
- retinal detachments caused by, 12.317
- retinal sclopetaria, 12.356–358, 12.357*f*
- scleral rupture, 12.352
- seventh nerve (facial) palsy caused by, 5.278*t*, 5.280
- sixth nerve (abducens) palsy caused by, 5.201
- spheroidal degeneration and, 8.116–117
- subconjunctival hemorrhage caused by, 8.387–388, 8.388*f*
- submacular hemorrhage secondary to, 12.354*f*
- surgical, open-angle glaucoma and., 10.108–109
- sympathetic ophthalmia and, 4.185, 9.47–48, 9.172, 12.364–365
- enucleation in prevention of, 7.128, 9.175
- temperature and radiation causing, 8.384–386, 8.385*f*
- thermal injury, 6.376
- uveal tract, 4.18, 4.19*f*
- vitreous hemorrhage secondary to, 12.357
- whiplash, 12.356–357
- in young patients, 12.316–317
- Traumatic anterior uveitis, 8.389–390
- Traumatic brain injury (TBI), falls in older patients and, 1.184
- Traumatic breaks in Descemet membrane, 6.262, 6.262*f*
- Traumatic corneal endothelial rings, 8.388
- Traumatic hyphema, 6.378*f*, 6.378–379, 8.391–396, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*
- glaucoma/elevated intraocular pressure and, 8.394, 10.104*f*, 10.104–105
- medical management of, 8.394–395
- rebleeding after, 8.394, 8.394*f*, 10.104, 10.105
- sickle cell disease/retinopathy/elevated intraocular pressure and, 8.395, 8.395*t*, 8.396, 10.104, 10.105
- surgery for, 8.395*t*, 8.395–396, 8.396, 10.105
- Traumatic miosis, 5.262, 8.389
- Traumatic mydriasis, 5.262, 8.388, 8.389*f*
- Traumatic optic neuropathy (TON), 2.89, 5.107*t*, 5.139*f*, 5.139–140, 7.113
- Traumatic posterior annular keratopathy, 8.388
- Traumatic recession of anterior chamber angle, 4.18, 4.19*f*, 4.103–104
- glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
- Traumatic vision loss with clear media, 7.112–114
- Travatan/Travatan Z. *See* Travoprost
- Travel immunizations, 1.224–225
- Travoprost, 2.237, 2.302, 2.327, 2.327*t*, 10.170–176, 10.171*t*, 10.175*t*
- in combination preparations, 2.327*t*, 10.174*t*

- Treacher Collins/Treacher Collins–Franceschetti syndrome (mandibulofacial dysostosis), 6.196, 6.211, 6.211*f*, 7.37, 7.37*f*, 8.192*t*
 eyelid manifestations of, 4.207*t*
 Tree sap, ocular injuries caused by, 8.387
 Trefoil, 3.275–276*f*, 13.9, 13.12, 13.13*f*, 13.103*f*
 after LASIK, 13.103*f*
 Treg cells. *See* T regulatory (Treg) cells
 Tremor, in Parkinson disease, 1.199
 Trend-based analysis, of visual field progression, 10.71
 Trephination/trephines, for mechanical keratectomy, 8.367
Treponema pallidum, 1.248–250, 6.240, 6.412, 8.107, 8.309, 9.236. *See also* Syphilis
 conjunctivitis caused, 8.260*t*
 interstitial keratitis caused by, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*, 9.237, 9.237*f*
Treponema pallidum particle agglutination assay (TP-PA), 12.241
 Treponemal tests, for syphilis, 1.216, 9.241
 TRH. *See* Thyrotropin-releasing hormone
 Trial contact lens fitting. *See also* Fitting (contact lens) disinfection and, 1.271
 Trial frames. *See also* Phoropter
 for nonorganic disorder evaluation, 5.306
 Trial lens, 3.164*f*
 Triamcinolone, 1.171*t*
 branch retinal vein occlusion treated with, 12.137
 for chalazion, 8.77
 for corneal graft rejection, 8.430
 for cystoid macular edema, in uveitis, 9.289
 diabetic macular edema treated with, 12.113
 intravitreal (IVTA), 2.300*t*, 2.334
 for macular edema/diabetic macular edema, 4.152
 for macular hole repair, 2.367
 for pars planitis, 9.130
 uveal effusion syndrome treated with, 12.203
 for uveitis, 9.98, 9.289
 for vernal keratoconjunctivitis, 8.291
 Triamterene
 for heart failure, 1.109
 for hypertension, 1.68*t*, 1.69*t*
 Triazoles, 2.355*t*, 2.356
 for *Acanthamoeba* keratitis, 2.361, 8.278
 Tricarboxylic acid (TCA) cycle, in corneal glucose metabolism, 2.224
 Trichiasis, 2.24, 7.208–209, 8.88
 in cicatricial entropion, 7.208
 in involutional entropion, 7.203
 in staphylococcal blepharitis, 8.74
 Trichilemmal (pilar) cyst, 7.168
 Trichilemmomas, 4.210*t*, 7.172
Trichinella spiralis (trichinosis), orbital infection caused by, 7.51
 Trichoepithelioma, 7.172, 7.172*f*
 Trichofolliculoma, 7.172
 Trichotillomania, 6.201, 6.201*f*, 7.165
 Trichromatism, 12.249
 Tricyclic antidepressants, 1.196*t*, 1.197
 apraclonidine/brimonidine interactions and, 2.319, 10.179
 Trifluridine, 2.356, 2.357*t*, 8.215*t*
 for herpes simplex virus infections, 8.215*t*, 8.219, 8.222, 8.223*t*
 epithelial keratitis, 8.219
 stromal keratitis, 8.222, 8.223*t*
 for vaccinia infection, 8.238
 Trifocal lenses, 3.180–182
 Trifocal optics, for multifocal IOL, 13.166
 Trigeminal autonomic cephalgias (TACs), 5.293–294
 Horner syndrome and, 5.260*t*, 5.261
 Trigeminal ganglion (gasserian/semilunar ganglion), 2.9*f*, 2.98*f*, 2.99, 2.99*f*, 2.101*f*, 5.42*f*, 5.48, 5.48*f*, 7.16, 7.17*f*
 herpes simplex/varicella-zoster virus latency and, 8.205, 8.207, 8.212, 8.213, 8.226
 Trigeminal lemniscus, 5.47*f*
 Trigeminal nerve. *See* Cranial nerve V
 Trigeminal neuralgia (tic douloureux), 5.289*t*, 5.297
 Trigeminal nucleus, 5.47. *See also* Cranial nerve V
 Triglycerides, 1.82
 drugs affecting metabolism of, 1.85*t*
 lowering levels of, 1.85, 1.85*t*. *See also* Lipid-lowering therapy
 target levels for, 1.82
 Trihexyphenidyl, for Parkinson disease, 1.199
 Triiodothyronine (T₃), 1.50
 resin uptake test, 1.51
 serum levels of, 1.51
 Trilateral retinoblastoma, 4.298
 Trimethaphan, 2.315*t*
 Trimethoprim, 1.272
 with polymyxin B, 2.347*t*, 2.353
 with sulfonamides, 2.349. *See also*
 Trimethoprim-sulfamethoxazole
 Trimethoprim-sulfamethoxazole (TMP-SMX), 1.272, 1.279
 for granulomatosis with polyangiitis (Wegener granulomatosis), 1.168
 for *Pneumocystis jirovecii* choroiditis, 9.298
 for *Pneumocystis jirovecii* pneumonia, 1.267, 1.279
 for *Pneumocystis jirovecii* prophylaxis, alkylating agent treatment and, 9.102, 9.106
 for toxoplasmic retinochoroiditis, 12.243–244
 for toxoplasmosis, 9.226
 for Whipple disease, 9.259
 Trinucleotide repeats, 2.139
 expansion/contraction of, 2.144–145
 anticipation and, 2.132, 2.144, 2.195
 Trinucleotides, 2.147, 2.151
 TRIO (thyroid-related immune orbitopathy).
See Thyroid eye disease
 Triple procedure, 11.175–176
 Triplets, 2.133
 Trisomy, 2.189
 Trisomy 8, in choroidal/ciliary body melanoma, 4.197
 Trisomy 13, 6.386*t*
 Trisomy 18, 6.386*t*
 Trisomy 21 (Down syndrome), 2.189–190, 2.191*t*.
See also Down syndrome
 congenital ectropion and, 7.156
 mosaicism in, 2.191
 pharmacogenetics and, 2.201
 Tritanomalous dichromatism, 12.250*t*
 Tritanomalous trichromatism, 12.250*t*

- Tritanopia (tritan defects/blue-yellow color confusion)
 in optic atrophy, 5.135
 tests for, 5.78–79
- Trivariant color vision, 2.262–263. *See also* Color vision
- Trivex, 3.196
- tRNA. *See* Transfer RNA
- Trochlea, 2.6, 2.13*f*, 2.14*f*, 5.46, 7.14*f*, 7.15*f*
 anatomy of, 6.19*f*
 function of, 6.20
- Trochlear fossa, 2.6
- Trochlear headache/trochleitis, 5.296
- Trochlear nerve. *See* Cranial nerve IV
- Trochlear nerve palsy. *See* Fourth nerve (trochlear) palsy
- Troglitazone, withdrawal of, from market, 1.46
- Tropheryma whippelii*, 5.251, 9.258
- tropia (suffix), 6.16
- Tropias. *See also* Heterotropias/tropias
 refractive surgery and, 13.41
- Tropicacyl. *See* Tropicamide
- Tropicamide, 2.314*t*, 6.11, 6.11*t*
 with hydroxyamphetamine, 2.314*t*
 for uveitis, 9.113
- Troponins, cardiac-specific (troponins T and I), in acute coronary syndrome, 1.93, 1.96
- Trusopt. *See* Dorzolamide
- Trypan blue dye, 2.367, 2.368
 for capsule staining, 11.178–179, 11.179*f*
- TS. *See* Tuberous sclerosis
- TSC1/TSC2* genes, in tuberous sclerosis, 5.334*t*
- TSC2* gene, 6.399
- TSH (thyroid-stimulating hormone). *See* Thyrotropin (thyroid-stimulating hormone/TSH)
- TSH-R. *See* Thyrotropin (thyroid-stimulating hormone/TSH), receptor for
- TSIs. *See* Thyroid-stimulating immunoglobulins
- TTP. *See* Thrombotic thrombocytopenic purpura
- TTR. *See* Transthyretin
- TTR* gene, in amyloidosis, 8.187
- TTT. *See* Transpupillary thermotherapy
- TTV. *See* Transfusion-transmitted virus
- TUBB3* gene, 6.135
- Tube–cornea touch, after tube shunt surgery, 10.217, 10.218*t*
- Tube shunts (glaucoma drainage devices), 6.146, 6.287, 6.323, 10.196–197, 10.213–217, 10.214*t*, 10.218*t*
 cataract extraction combined with, 10.213
 complications associated with, 10.217, 10.218*t*
 corneal graft failure and, 8.428
 in iridocorneal endothelial syndrome, 8.127
 LASIK and, 13.182
 neovascular glaucoma and, 10.135
 pediatric glaucoma and, 10.161, 10.163
 strabismus and, 10.166–167
 uveitis/uveitic glaucoma and, 9.287, 10.214
- Tube Versus Trabeculectomy study, 10.215
- Tubercles
 choroidal, in tuberculosis, 9.251–252, 9.252*f*
 “hard,” 4.7, 4.8*f*
 in sarcoidosis, 4.52, 4.52*f*
- Tubercular serpiginous-like choroiditis, 9.154, 9.252, 9.252*f*, 12.222
- Tuberculin hypersensitivity, 9.32
- Tuberculin skin test, 1.215, 1.254, 9.32
 false-negative/positive results and, 9.254
 in HIV infection/AIDS, 9.253
 immune response and, 9.32
 uveitis associated with, 9.121
- Tuberculoma, choroidal, 9.252
- Tuberculosis (TB), 1.215–216, 1.254–255, 9.250–255, 9.251*f*, 9.252*f*, 9.253*f*
 diagnosis of/screening/testing for, 1.215–216, 1.254, 9.253–254
 in HIV infection/AIDS, 1.255, 1.269, 9.250, 9.253
 immune response to, 9.31–32
 miliary, 9.250
 multidrug-resistant, 1.255, 1.269, 9.254
 neuro-ophthalmic signs of, 5.350
 ocular involvement in, 9.251*f*, 9.251–253, 9.252*f*, 9.253*f*, 12.240–241, 12.241*f*
 choroiditis, 9.154, 9.251–252, 9.252*f*
 dacryoadenitis, 7.284
 orbital, 7.49, 7.49*f*
 primary, 9.251
 secondary, 9.251
 uveitis, 9.250, 9.251*f*, 9.251–252, 9.252*f*, 9.253*f*, 9.255
 treatment of, 1.255, 9.254–255
 in HIV infection/AIDS, 1.269
 prophylactic, 1.254–255
 vaccine for, 1.216
- Tuberculous choroiditis, 9.154, 9.251–252, 9.252*f*
- Tuberculous meningitis, 5.350
 neuro-ophthalmic signs of, 5.350
- Tuberculous scleritis, 8.282
- Tuberculous uveitis, 9.250, 9.251*f*, 9.251–252, 9.252*f*, 9.253*f*, 9.255
- Tuberculum sella, 5.6*f*, 5.27*f*
- Tuberin, 5.334*t*
- Tuberous sclerosis (TS/Bourneville disease/syndrome), 5.330, 5.331*f*, 5.334*t*, 6.393*t*, 6.397–399, 6.398*t*, 6.398*f*
 glaucoma associated with, 10.30
- Tubocurarine, 2.308*t*, 2.315*t*
- Tubulin, 2.245
- Tubulointerstitial nephritis and uveitis (TINU) syndrome, 6.316, 9.67*t*, 9.117
- Tuck, 6.164*t*
- Tumbling E chart, 6.7
- Tumbling E optotypes, 3.133*f*, 3.134
- Tumor-associated calcium signal transducer 2 (*TACSTD2*) gene, in gelatinous droplike corneal dystrophy, 8.136*t*
- Tumor necrosis factor (TNF)
 α , 1.174, 9.27*t*, 9.107
 in dry eye, 8.53
 in mucous membrane pemphigoid, 8.299
 in tear film, 2.217
 β , 9.27*t*
 in delayed hypersensitivity, 9.38, 9.46
 in external eye defense, 8.11–13
- Tumor necrosis factor inhibitors, 1.174, 6.322
 adverse effects of, 9.102, 9.107, 9.121, 9.130, 9.132, 9.171
 for ankylosing spondylitis, 9.115
 for anterior uveitis, 9.113

- anti-idiotypic antibodies and, 9.42
 - for Behçet disease, 9.188
 - multiple sclerosis and, 9.132
 - optic neuropathy caused by, 5.137
 - for pars planitis, 9.130
 - for rheumatic disorders, 1.151, 1.174
 - for sarcoidosis, 9.171
 - for scleritis, 8.324, 8.325*t*
 - for uveitis, 9.107, 9.113
 - uveitis caused by, 9.121
 - Tumor suppressor genes, 1.227–228, 2.145, 2.154, 2.156–157. *See also specific type*
 - in DNA repair, 2.154
 - in ocular surface squamous neoplasia, 4.60
 - in pinguecula/pterygium, 4.57
 - recessive, Rb locus as, 2.192
 - Wilms tumor, imprinting of, 2.138, 2.153
 - Tumors, 4.10, 4.10*t*, 4.11*f*, 4.12*t*. *See also Cancer*; *Intraocular tumors*; *Neoplasia*; *Neoplasms*; *specific tumor and structure or organ affected*
 - anterior chamber and trabecular meshwork, 4.106, 4.106*f*
 - anterior segment, 6.271–274
 - bony, 6.222
 - canalicular obstruction and, 7.274
 - in children
 - orbital, 4.228, 4.229
 - retinoblastoma, 4.289–302
 - choristomatous, 6.225–226
 - choroid and ciliary body, 4.191–197
 - ciliary body, 6.273*f*, 6.273–274
 - conjunctival, 4.59–72
 - connective tissue, 6.222
 - corneal, 4.96, 6.271
 - eyelid, 4.209–221, 4.210*t*
 - iris, 4.189–190, 4.190*f*, 4.191*f*, 6.271–273, 6.272*f*
 - nasolacrimal duct obstruction and, 7.278
 - neural, 6.223
 - neuroimaging in evaluation of, 5.64*f*, 5.65*f*, 5.72*t*
 - ocular surface, 8.327–350. *See also Ocular surface, tumors of*
 - optic nerve/nerve head/disc, 4.248*f*, 4.248–250, 4.249*f*, 4.250*f*
 - orbital, 4.228–240
 - scleral, 4.112, 4.113*f*
 - secondary, 4.303–310. *See also Metastatic eye disease*
 - orbital, 4.228, 4.240
 - retinoblastoma and, 4.302, 4.302*t*
 - uveal tract, 4.189–199, 4.200*f*
 - vitreous, 4.135*f*, 4.135–137, 4.136*f*
 - Tunica vasculosa lentis, 11.29, 11.29*f*, 12.186, 12.340–341
 - remnant of
 - epicapsular star, 11.31, 11.32*f*
 - Mittendorf dot, 2.80, 2.81*f*, 4.126, 11.29, 11.31, 11.32*f*
 - Turban tumors, 7.171
 - Turbinates (conchae), nasal, 7.18, 7.253*f*, 7.254*f*
 - infraction of, for congenital nasolacrimal duct obstruction, 7.265
 - Turkey gobbler defect, 7.236
 - Turner syndrome, 6.386*t*
 - TVL. *See* Transient visual loss
 - Twin studies, 2.182, 2.182*f*
 - in age-related cataract, 11.41–42
 - in glaucoma, 10.10
 - TWIST* gene, 6.206
 - Twitch-type fibers, 2.18
 - fast twitch, 2.18
 - slow twitch, 2.18
 - 2-hit hypothesis, 2.157
 - Two-sided lenses
 - depth of field, 3.57, 3.58*f*
 - depth of focus, 3.57, 3.58*f*
 - description of, 3.54–57
 - principal planes, 3.56–57, 3.57*f*
 - “thick-lens formula” for, 3.54–55
 - TXA. *See* Thromboxanes
 - Tympanic segment of cranial nerve VII (facial), 2.103, 5.52
 - Tyndall effect
 - definition of, 3.97
 - scattering of light and, 3.97
 - Typhoid immunization, 1.224
 - Typical degenerative retinoschisis, 4.148, 12.326
 - Typical peripheral cystoid degeneration (TPCD), 4.148, 4.149*f*, 12.326
 - TYR* (tyrosinase) gene mutation, in albinism, 2.185, 2.278
 - Tyrosinase activity, in albinism, 2.175*t*, 2.185
 - Tyrosinase (*TYR*) gene mutation, in albinism, 2.185, 2.278
 - Tyrosinase promoter, in melanogenesis, 2.277–278
 - Tyrosine aminotransferase, defective/deficiency of, 2.175*t*, 8.183
 - Tyrosine kinase inhibitors (TKIs), for cancer chemotherapy, 1.235
 - Tyrosinemia, 2.175*t*, 8.183*t*, 8.183–184, 8.184*f*
 - alkaptonuria and, 8.184
 - corneal changes in, 8.183–184, 8.184*f*
 - type II, 6.270
 - Tyrosinosis, 2.175*t*
 - Tyrosinuria, 8.183
 - Tysabri. *See* Natalizumab
- ## U
- UbiA prenyltransferase domain-containing protein 1 (*UBIAD1*) gene, in Schnyder corneal dystrophy, 6.270, 8.136*t*
 - UBM. *See* Ultrasound biomicroscopy
 - UC. *See* Uncentral (UC) fixation
 - UC fixation. *See* Uncentral (UC) fixation
 - UCVA/UDVA. *See* Uncorrected/uncorrected distance visual acuity
 - UDAd. *See* Underdepression in adduction
 - UDP (uridine diphosphate) galactose 4-epimerase deficiency, galactosemia/cataract formation and, 11.61
 - UEAd. *See* Undererelevation in adduction
 - UFH (unfractionated heparin). *See* Heparin therapy
 - UGH syndrome. *See* Uveitis-glaucoma-hyphema (UGH) syndrome
 - Uhthoff phenomenon, 5.162, 5.317

- UKPDS (United Kingdom Prospective Diabetes Study), 1.38, 12.96–97
- Ulcerative basal cell carcinoma, 7.178*f*. *See also* Basal cell carcinoma
- Ulcerative colitis, 1.155, 9.116
- Ulcerative keratitis/peripheral ulcerative keratitis (PUK), 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*. *See also* Keratitis
- differential diagnosis of, 8.311, 8.311*t*
- in microscopic polyangiitis, 1.168
- in polyarteritis nodosa, 9.136
- in rosacea, 8.71
- in systemic immune-mediated diseases, 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*
- Ulcerative keratopathy, toxic, 8.80–81, 8.81*t*. *See also* Toxic keratoconjunctivitis
- Ulcers
- conjunctival, 8.47*t*
- corneal. *See* Corneal ulcers; Keratitis
- eyelid, 8.45*t*
- genital and oral, in Behçet disease, 1.169, 9.184, 9.184*f*
- Mooren, 8.313–316, 8.315*f*
- neurotrophic. *See* Neurotrophic keratopathy/ulcers
- ULE. *See* Upper eyelid excursion
- Ultrafiltration, in aqueous humor dynamics/formation, 2.230, 10.16
- Ultralong-acting insulin, 1.41*t*
- Ultrashort laser pulses, 3.117–118
- Ultrasonic (term), 11.99
- Ultrasonic phacoemulsification, 6.302
- Ultrasonography/ultrasound (echography), 5.70–71, 5.72*t*
- A-scan, 3.244–245, 3.245–246*f*. *See also* A-scan ultrasonography/echography
- for axial length measurement
- in IOL power determination/selection, 11.82–83, 11.83*f*, 11.85, 11.87
- in primary congenital glaucoma, 10.160
- anterior segment (ultrasound biomicroscopy/UBM), 2.47, 2.47*f*, 4.265, 8.20–21, 8.21*f*
- in choroidal/ciliary body melanoma, 4.265
- before corneal transplantation, 8.418
- in glaucoma, 10.77, 10.124*f*
- pediatric glaucoma and, 10.160
- uveitic glaucoma and, 9.285
- in pars planitis, 9.129
- applanation, 3.245, 3.245*f*
- applications of, 12.40
- for axial length measurement, 3.244–246, 3.245–246*f*
- in IOL power determination/selection, 11.82–83, 11.83*f*, 11.85, 11.87
- hypotony affecting, 11.185
- in primary congenital glaucoma, 10.160
- B-scan. *See also* B-scan ultrasonography/echography
- in glaucoma, 10.77
- pediatric glaucoma and, 10.160
- cardiac emboli identification and, 5.168
- in carotid artery evaluation, 5.70, 5.167
- in carotid occlusive disease, 1.125
- before cataract surgery, 11.81, 11.82–83, 11.83*f*, 11.87
- hypotony and, 11.185
- in cerebral ischemia/stroke, 1.122
- in choroidal hemangioma, 4.281, 4.282*f*
- in choroidal melanoma/ciliary body melanoma, 4.265–267, 4.266*f*, 9.277
- contact B-scan, 12.39, 12.39*f*
- in corneal topography/tomography, 8.35*t*
- before corneal transplantation, 8.418
- in cysticercosis, 9.231
- immersion, 3.245, 3.246*f*
- intraocular foreign body evaluations, 12.352
- in IOL power determination/selection, 11.82–83, 11.83*f*, 11.87
- in iris melanoma, 4.260, 4.261*f*
- in ischemic heart disease, 1.97
- intravascular, 1.98
- in low vision evaluation, 5.95
- in lymphoma, 4.311–312, 9.274
- in metastatic eye disease, 4.307, 4.307*f*
- in ocular ischemic syndrome, 9.279
- in optic nerve/nerve head/disc drusen, 5.95, 5.141*f*, 5.142
- versus papilledema, 5.141*f*, 5.142–143
- in orbital evaluation, 5.70–71, 5.72*t*, 7.31
- for pachymetry, 8.41. *See also* Pachymetry/pachymeter
- for intrastromal corneal ring segment placement, 13.64
- before refractive surgery, 13.45
- for phacoemulsification, 11.98
- terminology related to, 11.99–100
- in posterior scleritis, 8.322, 8.322*f*
- retinal disease evaluations using, 12.39–40
- in retinoblastoma, 4.292
- in sympathetic ophthalmia, 9.174
- thyroid, 1.52
- in toxocariasis, 9.229
- in uveal lymphoid proliferation/infiltration, 4.314
- in uveitis, 9.90
- for vitreous hemorrhage, 12.347
- in Vogt-Koyanagi-Harada syndrome, 9.180
- Ultrasound biomicroscopy (UBM), 2.47, 2.47*f*, 4.265, 8.20–21, 8.21*f*
- anterior chamber evaluations, 12.40
- in choroidal/ciliary body melanoma, 4.265
- ciliary body evaluations, 12.40
- before corneal transplantation, 8.418
- in glaucoma, 10.77, 10.124*f*
- pediatric glaucoma and, 10.160
- uveitic glaucoma and, 9.285
- in pars planitis, 9.129
- Ultrathin Descemet stripping endothelial keratoplasty (ultrathin DSEK), 8.439–440
- Ultraviolet-A (UVA) light, 3.114, 3.118, 3.193
- Ultraviolet-absorbing chromophores/filters, IOLs with, 11.120
- Ultraviolet-absorbing lenses, 3.193–194. *See also* Sunglasses
- cataract prevention and, 11.58
- Ultraviolet-B (UVB) light, 3.118, 3.193–194
- Ultraviolet-C (UVC) light, 3.193–194
- Ultraviolet (UV) light (ultraviolet [UV] radiation)
- in corneal crosslinking, 13.130–131, 13.132, 13.134

- eye disorders/injury associated with, 2.283, 2.286. *See also* Light toxicity/photoc damage/phototoxicity
- actinic keratopathy, 4.83, 4.83f, 8.116
- actinic keratosis, 4.210, 7.176
- anterior segment injury, 9.385–386
- basal cell carcinoma, 4.212f, 4.212–213, 4.213f, 7.177
- cataracts, 11.57–58
- corneal haze after surface ablation and, 13.109
- eyelid tumors, 4.210, 4.212f, 4.212–213, 4.213, 4.213f, 7.177, 7.182
- lentigines, 7.174
- melanoma, 1.215, 7.184
- ocular surface squamous neoplasia, 4.60
- pinguecula, 4.56, 4.56f, 8.112
- pseudoexfoliation, 11.65f, 11.65–66
- pterygium, 4.57, 4.57f, 8.112
- spheroidal degeneration (actinic/climatic droplet/Labrador keratopathy), 4.83, 4.83f, 8.116
- squamous cell carcinoma and, 4.213, 4.214f
- lenses absorbing. *See also* Sunglasses
- cataract prevention and, 11.58
- for light-adjustable IOLs, 13.153–154, 13.154f
- Umbo (clivus), 2.102, 5.5
- anatomy of, 12.9, 12.9f
- characteristics of, 12.10t
- Unasyn (intravenous ampicillin and sulbactam), 1.276
- Uncentral, unsteady, and unmaintained fixation, 6.6
- Uncentral (UC) fixation, 6.6
- Uncorrected/uncorrected distance visual acuity (UCVA/UDVA), 13.39–40. *See also* Visual acuity
- assessment of, before refractive surgery, 13.39–40
- corneal inlays and, 13.61
- hyperopia correction and, 13.96
- intrastroral corneal ring segment placement and, 13.64
- for keratoconus, 13.66
- LASIK and, 13.95, 13.96, 13.97
- in amblyopia/anisometropic amblyopia, 13.186
- in diabetes mellitus, 13.190
- for mixed astigmatism, 13.97
- after penetrating keratoplasty, 13.180
- after retinal detachment surgery, 13.185
- small-incision lenticule extraction compared with, 13.205
- myopia correction and, 13.95
- patient expectations/motivations and, 13.35–36
- photorefractive keratectomy and, 13.95
- radial keratotomy and, 13.50
- refractive lens exchange and, 13.150
- small-incision lenticule extraction and, 13.205
- toric IOL implantation and, 13.152–153
- wavefront-guided/wavefront-optimized/topography-guided ablation and, 13.32, 13.97
- Uncrossed diplopia, 6.75
- Uncus, 4.45
- Undercorrection, with photoablation, 13.102, 13.108
- Underdepression in adduction (UDAd), 6.17
- Underelevation in adduction (UEAd), 6.17
- Undifferentiated spondyloarthropathy, 1.153
- Unequal crossing over, 2.145
- color vision defects and, 2.262–263
- Unformed hallucinations, 5.158, 5.175, 5.176. *See also* Hallucinations
- Unfractionated heparin (UFH). *See* Heparin therapy
- Unharmonious anomalous retinal correspondence, 6.76
- Unifocal eosinophilic granuloma, 6.219, 6.219f, 7.90
- Unilateral aphakia, 3.140, 3.207
- Unilateral vision loss, 5.161, 5.163t, 5.163–171. *See also* Monocular transient visual loss
- in low vision evaluation, 5.77
- in nonorganic disorders, 5.305, 5.305t
- in optic neuritis, 5.113
- Uniparental disomy, 2.145, 2.154
- United Kingdom Prospective Diabetes Study (UKPDS), 1.38, 12.96–97
- Universal precautions, HIV infection/AIDS and, 9.301
- Universal Protocol of the Joint Commission on Accreditation of Healthcare Organizations, 1.289–290
- University of Washington, on CPR guidelines, 1.296
- Unoprostone, 2.302, 2.327, 2.327t
- Unpolarized light, 3.98
- Unstable angina, 1.93
- hypertension management and, 1.75
- Untranslated region (UTR), 2.145, 2.147
- Upbeat nystagmus, 5.243t, 5.245
- Up gaze (elevation of eye/sursumduction/sursumversion/supraduction), 6.37
- disorders/limitation of, 5.228–229
- in Brown syndrome, 5.208
- in dorsal midbrain (Parinaud) syndrome, 5.229, 5.230f
- in monocular elevation deficiency (double-elevator palsy), 7.213
- in newborns, 5.230
- in orbital floor/blowout fracture, 7.108
- surgery and, 7.110
- saccadic dysfunction and, 5.222
- extraocular muscles controlling, 5.36f, 5.46f
- inferior oblique muscle, 5.36f, 5.46f
- superior rectus muscle, 5.36f, 5.46f
- Upper eyelid excursion (ULE), in ptosis, 7.210, 7.211f
- Upper eyelids. *See* Eyelids, upper
- Upper respiratory tract infection, elective surgery in children with, 1.284–285
- Urate crystal deposition, in gout, 8.119, 8.188
- Urate keratopathy/band keratopathy, 8.119, 8.188
- Urea
- in aqueous humor, 2.233
- as hyperosmotic agent, 2.233, 2.328–329, 2.329t
- in tear film, 2.216
- Urea-insoluble (membrane structural) lens proteins, 2.245, 11.15f, 11.16–17
- Urea-soluble (cytoskeletal) lens proteins, 2.245, 11.15f, 11.16–17
- Ureaphil. *See* Urea
- Uremia, platelet dysfunction associated with, 1.144
- Urethritis, in reactive arthritis syndrome/Reiter syndrome, 1.154–155
- Uric acid levels, in gout, 8.188
- Uridine diphosphate (UDP) galactose 4-epimerase deficiency, galactosemia/cataract formation and, 11.61
- Urinalysis, in uveitis, 9.89t

- Urinary sphincter disturbances, in multiple sclerosis, 5.317
- Urinary tract infections, *Escherichia coli* as cause of, 12.238
- Urinary tract stones, acetazolamide use and, 2.326
- Urokinase, 1.149, 2.369
- uveitis caused by, 9.121
- Urologic cancer, screening for, 1.212
- Uroporphyrinogen decarboxylase deficiency, in porphyria, 8.190
- Urrets-Zavalía syndrome, 5.263
- Urticaria, from fluorescein angiography, 1.302
- Urticating hairs, ocular inflammation caused by, 8.387
- US National Cholesterol Education Program (NCEP), 1.81
- US National Institutes of Health Stroke Scale, 1.121
- US Preventive Services Task Force
- on lipid disorder screening, 1.82
 - on mammography, 1.211
 - on prostate cancer screening, 1.212
- Usher syndrome, 2.202, 2.204, 2.278
- clinical features of, 12.283*t*, 12.284
 - description of, 12.259
 - genes and loci associated with, 2.264, 12.257*t*
 - retinal pigment epithelium in, 2.278
 - types of, 12.284
- UTR. *See* Untranslated region
- Utricle, 5.38, 5.39*f*, 5.214, 5.215, 6.40
- UV light/radiation. *See* Ultraviolet (UV) light
- UVA. *See* Ultraviolet-A (UVA) light
- UVB. *See* Ultraviolet-B (UVB) light
- UVC. *See* Ultraviolet-C (UVC) light
- Uvea (uveal tract), 2.38, 2.53–62, 2.236, 4.181–199, 4.200*f*, 9.71. *See also specific structure*
- bilateral diffuse melanocytic proliferation and, 9.278
 - in coccidioidomycosis, 9.271
 - congenital anomalies of, 4.184, 4.184*f*
 - degenerations of, 4.188, 4.189*f*
 - development of, 2.122
 - disorders of, 4.181–199, 4.200*f*. *See also specific type*
 - neoplastic, 4.189–199, 4.200*f*. *See also* Uvea (uveal tract), tumors of
 - Th1-mediated delayed hypersensitivity and, 9.46*t*
 - healing/repair of, 4.16
 - immune response/features/microenvironment of, 9.54*t*, 9.56–58
 - infection/inflammation of, 4.185–187, 4.186*f*, 4.187*f*, 4.188*f*, 9.71–109. *See also* Endophthalmitis;
 - Uveitis
 - in leukemia, 4.315
 - lymphoid proliferation/infiltration/lymphoma of (primary choroidal lymphoma), 4.199, 4.199*f*, 4.313–314
 - masquerade syndromes secondary to, 9.276–277
 - melanocytoma of, 4.192, 4.257*f*, 4.258, 4.268
 - melanoma differentiated from, 4.268
 - melanoma of, 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279, 9.277. *See also* Choroidal melanoma/ciliary body melanoma; Iris, melanoma of
 - classification of, 4.194, 4.271–272, 4.272*t*
 - clinical characteristics of, 4.262–263, 4.264*f*
 - diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
 - differential, 4.267–271, 4.269*f*, 4.270*f*
 - fine-needle aspiration biopsy in identification/evaluation of, 4.42, 4.43*f*, 4.253
 - glaucoma caused by, 4.105*f*, 4.106, 4.194
 - metastatic, 4.196, 4.272–274, 4.273*t*, 4.306
 - ocular surface/conjunctival involvement and, 4.68, 4.69*f*, 8.343
 - prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
 - treatment of, 4.253, 4.274–277, 4.275*f*
 - nevus involving, 4.191, 4.192*f*
 - sarcoidosis involving, 4.186–187
 - topography of, 2.38, 4.181*f*, 4.181–183, 4.182*f*, 4.183*f*
 - traumatic injury of, 4.18, 4.19*f*
 - tumors of, 4.189–199, 4.200*f*. *See also specific tumor*
 - metastatic, 4.197, 4.198*f*, 4.303, 4.304–306, 4.305*f*, 4.306*f*, 4.307*f*, 4.308*f*, 4.309*t*, 9.278
 - prognosis of, 4.309–310
 - miscellaneous, 4.197–199, 4.198*f*, 4.200*f*
 - pigmented, 4.279–280, 4.280*f*
- Uveal (posterior) bleeding syndrome (polypoidal choroidal vasculopathy/PCV), 4.166*f*, 4.166–168, 4.167*f*
- Uveal effusions/uveal effusion syndrome, 12.203, 12.204*f*
- angle-closure glaucoma and, 10.138–139
- Uveal lymphoid proliferation/infiltration/lymphoma (primary choroidal lymphoma), 4.199, 4.199*f*, 4.313–314
- masquerade syndromes secondary to, 9.276–277
- Uveal lymphoma, 12.234, 12.235*f*
- Uveal thickening, 12.234, 12.235*f*
- Uveal trabecular meshwork, 2.48, 2.49, 10.17, 10.18*f*
- Uveitic glaucoma, 9.285, 9.286–287
- angle-closure, 9.83, 9.285–286, 10.134, 10.139, 10.139*f*
 - corticosteroid-induced ocular hypertension/glaucoma and, 9.285, 9.286–288
 - in infants and children, 10.149*t*
 - after laser trabeculoplasty, 10.190
 - management of, 9.287–288
 - open-angle, 10.100–102, 10.102*f*
 - tube shunt/drainage device implantation for, 9.287, 10.214
- Uveitic ocular hypertension, 9.284–285, 9.285
- corticosteroid-induced, 9.285, 9.286–288
- Uveitis, 4.185–187. *See also* Endophthalmitis; *specific type*
- acute, 9.73*t*, 9.78, 9.112–114, 9.113*f*
 - in AIRE (autoimmune regulator)-deficient mice, 9.64
 - animal models of, 9.63–64
 - in ankylosing spondylitis, 9.114–115
 - anterior. *See* Anterior uveitis; Iridocyclitis; Iritis
 - autoimmune. *See* Uveitis, noninfectious/autoimmune
 - band keratopathy caused by, 6.322
 - in bartonellosis/cat-scratch disease, 9.256–258, 9.257*f*
 - in Behçet disease, 1.169, 9.182, 9.186, 12.230
 - biologic drugs for, 6.322
 - birdshot (birdshot retinochoroidopathy/birdshot chorioretinopathy/vitiliginous chorioretinitis), 9.141–143*t*, 9.144–147, 9.145*f*, 9.146*f*

- characteristics of, 12.220*t*, 12.224–225, 12.225*f*
- ERG in, 9.143*t*, 9.147
- HLA association in, 9.67, 9.67*t*, 9.141*t*, 9.144
- uveal lymphoma and, 12.234
- calcaric band-shaped keratopathy and, 9.79, 9.281
- cataract surgery in, 6.323
- cataracts and, 9.73, 9.281–284, 11.64*f*, 11.64–65, 11.188
 - after cataract surgery, 11.139–140
 - surgery in patients with, 9.119–121, 9.120*f*, 9.281, 11.64–65, 11.75, 11.140, 11.170–171, 11.188, 11.188*f*
- in Chikungunya fever, 9.213–214
- in children, in enthesitis-related arthritis (juvenile ankylosing spondylitis), 1.155
- chronic, 9.73*t*, 9.78, 9.113, 9.121–127
- classification of, 6.311, 9.71–78, 9.72*t*, 9.73*t*, 9.74–76*t*, 9.77*t*
- clinical approach to, 9.71–109
- CMV, 8.231–232, 8.232, 9.198
- coccidioidal, 9.271–272
- in collagen vascular diseases, 9.132–139
- complications of
 - description of, 9.281–292. *See also specific type*
 - surgical treatment of, 6.322–323
- corticosteroids for, 6.320–321, 9.95–100, 9.96*f*, 9.113
- route of administration of, 2.333*t*
- cystoid macular edema and, 9.284
- definition of, 6.311
- in dengue fever, 9.213
- diagnosis of, 6.319, 9.74–76*t*, 9.85, 9.303–306
 - historical factors in, 9.84*t*, 9.84–85, 9.303–306
 - laboratory/medical evaluation in, 9.74–76*t*, 9.88–89*t*, 9.88–93, 9.91*f*
- differential diagnosis of, 6.312*t*, 9.85
- diffuse. *See* Panuveitis
- diffuse unilateral subacute neuroretinitis and, 9.232–234, 9.233*f*
- drug-induced, 9.121
- endotoxin-induced, 9.14–15, 9.63
- epidemiology of, 6.311, 9.85–86, 9.87*t*
- evaluation of, 6.319
- experimental, 9.63–64
 - autoimmune (EAU), 9.63
 - endotoxin-induced (EIU/experimental immune), 9.14–15, 9.63
- fibrin in, 9.24, 9.79, 9.113
- flowchart for evaluation of, 9.74–76*t*
- Fuchs heterochromic (FHU/Fuchs heterochromic iridocyclitis/uveitis syndrome), 9.126*f*, 9.126–127
- cataracts/cataract surgery and, 9.127, 9.282, 11.64*f*, 11.64–65
 - glaucoma and, 9.127, 10.101–102, 10.102*f*
 - rubella reactivation and, 9.44, 9.127, 9.205
- glaucoma and, 9.284–288, 10.100–102, 10.102*f*, 10.134, 10.139, 10.139*f*, 10.149*t*. *See also* Uveitic glaucoma; Uveitis-glaucoma-hyphema (UGH) syndrome
 - in children and adolescents, 10.149*t*
 - after laser trabeculoplasty, 10.190
 - tube shunt/drainage device implantation for, 9.287, 10.214
- glaucoma surgery in, 6.323
- in glaucomatocyclitic crisis/Posner-Schlossman syndrome, 9.118
- granulomatosis with polyangiitis (Wegener granulomatosis) and, 9.138
- granulomatous, 9.78
 - lens-associated, 9.119
 - tuberculous, 9.251*f*, 9.251–252, 9.252*f*
- herpetic, 9.191–202
- history and, 9.84*t*, 9.84–85, 9.303–306
- in HIV infection/AIDS, 9.293
- HLA association in, 9.65–66, 9.67*t*, 9.113, 9.114–117
- HTLV-1 (HU), 9.212–213
- hypotony and, 9.288
- idiopathic, 9.127
- imaging for, 6.321*t*
- immune recovery (IRU), 1.271, 9.201, 9.294–295, 12.235
- immunosuppressive therapy for, 6.321–322
- indocyanine green angiography of, 12.38–39
- infectious. *See also specific causative agent*
 - bacterial, 9.236–259
 - fungal, 9.214–219
 - helminthic, 9.228–235
 - masquerade syndromes and, 9.280
 - protozoal, 9.219–227
 - retinal detachment and, 9.291
 - viral, 9.191–214
- inflammation in, 6.320–322
- in inflammatory bowel disease, 9.116
- inflammatory chorioretinopathies (white dot syndromes) and, 9.140–166, 9.141–143*t*
- intraocular lymphoma and, 1.237, 4.311, 12.233–234
- IOLs and, 9.120–121
 - postoperative inflammation and, 9.119–120, 9.120*f*
- ischemic, 5.170
- in juvenile idiopathic (chronic/rheumatoid) arthritis, 9.122–126, 9.123*f*, 9.124*t*
- cataracts and, 9.123*f*, 9.124–125
- laboratory/medical evaluation of, 9.74–76*t*, 9.88–89*t*, 9.88–93, 9.91*f*
- laboratory tests for, 6.321*t*
- lens-associated/phacoantigenic/phacolytic, 4.103, 4.103*f*, 4.118–119, 4.119*f*, 4.122, 9.21, 9.118*f*, 9.118–119, 11.66
 - sympathetic ophthalmia and, 9.174
- in leptospirosis, 9.248–249
- lipopolysaccharide-induced, 9.14–15
- in Lyme disease, 9.243–248, 9.244*f*, 9.245*f*, 9.247*t*, 12.245
- lymphocytic choriomeningitis virus infection and, 9.205–206
- masquerade syndromes and, 6.319, 6.320*t*, 9.273–280, 9.274*f*, 9.275*f*
- in measles (rubeola), 9.206–208, 9.208*f*
- methotrexate for, 6.322
- in multiple sclerosis, 5.318, 9.129, 9.132
- Mycobacterium tuberculosis*, 12.240
- nongranulomatous, 9.78, 9.112–114, 9.113*f*, 9.115
- noninfectious/autoimmune, 4.127, 4.128*f*. *See also specific cause*
 - anterior uveitis, 9.112–127

- intermediate uveitis, 9.127–132
 - panuveitis, 9.166–189
 - posterior uveitis, 9.132–166
 - vitreous infiltrate in, 4.127, 4.128*f*
 - in onchocerciasis, 9.234–235, 9.235*f*
 - onset/duration/course of, 9.78
 - panuveitis, 6.318*f*, 6.318–319
 - peripheral. *See* Pars planitis
 - posterior. *See* Posterior uveitis
 - postoperative
 - after cataract surgery, 11.139–140
 - infectious endophthalmitis, 9.119. *See also*
 - Postoperative endophthalmitis
 - IOL-associated inflammation and, 9.119–120, 9.120*f*
 - Propionibacterium acnes* causing, 9.119, 11.162
 - prostaglandin analogues causing, 10.166
 - in psoriasis/psoriatic arthritis, 1.155, 9.116*f*, 9.116–117
 - in reactive arthritis syndrome/Reiter syndrome, 1.154, 8.305–306, 9.115, 9.116*f*
 - recurrent, 9.73*t*, 9.78, 9.113
 - equine, 9.63
 - retinal detachment and, 9.291
 - in Rift Valley fever, 9.210–212, 9.211*f*
 - in rubella, 9.203–205, 9.204*f*
 - sarcoidosis and, 4.186–187, 9.80*f*, 9.81*f*, 9.86, 9.166–171, 9.167*f*, 9.168*f*, 9.169*f*
 - scleritis and, 8.323
 - signs of, 9.79–84, 9.80*f*, 9.80*t*, 9.81*f*, 9.82*t*
 - in SLE, 1.159
 - in spondyloarthropathies/spondyloarthritis, 1.153, 9.114–117, 9.116*f*
 - subretinal fibrosis and (SFU), 9.141–143*t*, 9.160*f*, 9.160–161
 - sympathetic ophthalmia and, 4.185, 9.47–48
 - symptoms of, 9.78–79, 9.79*t*
 - syphilitic, 9.236–243, 9.237*f*, 9.238*f*, 9.239*f*, 9.240*f*, 9.242*t*, 12.241
 - systemic disease associations and, 9.84*t*, 9.85
 - terminology associated with, 9.73*t*
 - Th1-mediated delayed hypersensitivity and, 9.46*t*
 - in toxocariasis, 12.245
 - in toxoplasmosis, 1.256–257, 4.147, 9.219–227, 9.220*f*, 9.222*f*, 9.223*f*, 9.224*f*, 9.227*f*
 - traumatic, 8.389–390
 - treatment of, 6.320–322, 9.93–109
 - medical, 9.93–109
 - surgical, 9.109
 - tuberculous, 9.250, 9.251*f*, 9.251–252, 9.252*f*, 9.253*f*, 9.255
 - tubulointerstitial nephritis and, 9.67*t*, 9.117
 - varicella-zoster infection and, 9.191–193, 9.192*f*
 - vitreous opacification/vitritis and, 9.290
 - Vogt-Koyanagi-Harada syndrome and, 4.186, 9.175–182, 9.177*f*, 9.178*f*, 9.179*t*, 9.180*f*, 9.181*f*
 - West Nile virus infection and, 9.208–210, 9.209*f*
 - in Whipple disease, 9.258–259
 - Uveitis-glaucoma-hyphema (UGH) syndrome, 9.17, 10.108–109
 - IOL implantation and, 9.17, 9.120, 11.149
 - decentration and, 11.145
 - transient visual loss and, 5.164
 - Uveoparotid fever (Heerfordt syndrome), 9.167
 - Uveoretinitis, experimental autoimmune (EAU), 9.63
 - Uveoscleral drainage/outflow, 2.46, 10.5*f*, 10.13, 10.19
 - drugs affecting, 2.318*t*, 10.165–166, 10.170, 10.178
 - Uvula, ventral, 5.39
- ## V
- V1 to V6 areas of brain. *See* Visual (calcarine/occipital/striate) cortex
 - V-neck sign, in dermatomyositis, 1.163
 - V-pattern strabismus
 - bilateral superior oblique palsy and, 6.122
 - in Brown syndrome, 6.137
 - clinical features of, 6.109
 - clinically significant, 6.109
 - craniofacial anomalies and, 6.107
 - in craniosynostosis, 6.208
 - definition of, 6.107
 - etiology of, 6.107–109, 6.108*f*
 - exotropia with, 6.108*f*, 6.111
 - extorsion as cause of, 6.107, 6.110
 - heterotopy as cause of, 6.28
 - identification of, 6.109
 - infantile esotropia associated with, 6.109, 6.112
 - inferior oblique muscle overaction associated with, 6.107
 - palpebral fissure slanting associated with, 6.196
 - superior oblique palsy and, 6.122
 - surgical treatment of, 6.111–112, 6.112*t*
 - VA. *See* Vertebral artery
 - Vaccine-associated paralytic poliomyelitis, 1.222
 - Vaccines/vaccine development, 1.216–225. *See also*
 - Immunization; *specific type*
 - for cancer, 1.236
 - for HIV, 1.267
 - Vaccinia/vaccinia infection, 8.238
 - Vaccinia-immune globulin (VIG), 8.238
 - Vacuum, speed of light in, 3.43
 - Vacuum (phacoemulsification), 11.98, 11.103
 - Vacuum rise time (phacoemulsification), 11.102, 11.103
 - Vagus nerve stimulation (VNS)
 - for depression, 1.197
 - for seizures, 1.203
 - Valacyclovir, 1.281, 2.302, 2.357*t*, 2.359, 8.215*t*
 - for acute retinal necrosis/herpetic retinitis, 9.196
 - for herpes simplex virus infections, 1.258, 1.281, 8.215*t*, 8.219, 8.222, 9.193
 - anterior uveitis, 9.193
 - epithelial keratitis, 8.219
 - refractive surgery and, 13.174
 - stromal keratitis, 8.222
 - for herpes zoster virus infections, 1.258, 1.281, 2.357*t*, 2.359, 8.229
 - for herpetic retinitis, 12.238*t*
 - Valcyte. *See* Valganciclovir
 - Valdecocix
 - cardiovascular toxicity and, 2.239
 - withdrawal of, from market, 1.172, 9.94

- Valganciclovir, 1.281, 2.357*t*, 2.360, 8.215*t*
 for CMV infection
 anterior segment, 8.232
 retinitis, 1.239, 1.260, 1.268, 1.281, 9.201
 for herpes simplex virus infections, 8.215*t*
- Validity, 1.23–24
- Valproate/valproic acid
 as mood stabilizer, 1.197
 for seizures, 1.202*t*
- Valsalva maneuver, 6.207
- Valsalva retinopathy, 12.171
- Valsartan
 for heart failure, 1.110
 for hypertension, 1.68*t*, 1.69*t*
- Valtrex. *See* Valacyclovir
- Valve of Hasner, 6.230, 6.231*f*, 7.253*f*, 7.254*f*
 nasolacrimal duct obstruction and, 7.255, 7.260
- Valve of Rosenmüller, 6.228, 7.253, 7.254*f*
- Valved tube shunts, 10.214, 10.214*t*
- Valvular heart disease, heart failure and, 1.108, 1.111
- Van Herick method, 10.31–32
- van Lint nerve block, for cataract surgery, 11.92, 11.93*f*
- Vancomycin, 1.276–277, 2.344*t*, 2.352, 12.300
 for bacterial keratitis, 8.270*t*
 for *Clostridium difficile* colitis, 1.244, 1.276
 after corneoscleral laceration repair, 8.409
 for endophthalmitis, 9.263
 after cataract surgery, 11.162
 resistance and, 1.239, 1.241, 1.277, 2.352, 8.244, 8.245
 for staphylococcal infections, 8.244
- Vancomycin-intermediate *Staphylococcus aureus* (VISA), 1.241, 1.242
- Vancomycin-resistant enterococci (VRE), 1.239, 1.241, 1.276, 8.245
- Vancomycin-resistant *Staphylococcus aureus* (VRSA), 1.239, 1.241
- Vaqta (hepatitis A vaccine), 1.219
- Variability, in genetic disease, 2.194–195
- Variable expressivity, 12.255
- Variable/variable number of tandem repeats (VNTRs/VTRs/microsatellites), 2.139, 2.150
- Variance (statistical), “special cause,” 1.29
- Variant (Prinzmetal) angina, 1.93
- Variant Creutzfeldt-Jakob disease (vCJD), 5.357
- Variant lattice dystrophies, 8.135*t*, 8.146–147, 8.147*f*
- Varicella (chickenpox), 1.258, 8.225, 8.226, 9.191, 9.192*f*.
See also Varicella-zoster virus
 anterior uveitis in, 9.191, 9.192*f*
 conjunctivitis in, 8.225, 8.226
- Varicella keratouveitis, 8.226, 8.229
- Varicella vaccines (Varivax; Zostavax), 1.220–221, 1.259
- Varicella-zoster sine herpete, 5.298, 9.191
- Varicella-zoster vaccine, 5.298, 8.229
- Varicella-zoster virus (VZV), 1.258–259, 6.242–243, 9.191–202. *See also* Herpes zoster
 acute retinal necrosis/progressive outer retinal necrosis/nonnecrotizing herpetic retinitis caused by. *See* Varicella-zoster virus (VZV), retinitis caused by
 anterior uveitis caused by, 9.191–193, 9.192*f*
 conjunctivitis caused by, 8.225–230, 8.226*t*
 dermatoblepharitis caused by, 8.208*t*, 8.225–230, 8.226*t*
 immunization against, 1.218*t*, 1.220–221, 8.229
 latency/recurrence and, 8.205, 8.207, 8.225–226
 necrotizing retinitis caused by, 12.236–237*f*, 12.236–237, 12.238*t*
 ocular infection caused by, 8.208*t*, 8.225–230, 8.226*t*, 8.227*f*, 8.228*f*. *See also* Herpes zoster ophthalmicus
 herpes simplex virus infection differentiated from, 8.225, 8.226*t*
 retinitis caused by, 4.145, 9.193–198, 9.194*f*, 9.194*t*, 9.195*f*, 9.197*f*, 9.295–296, 9.296*f*
- Varices
 orbital, 7.71
 glaucoma associated with, 10.30
 vortex vein, 4.270*f*, 4.271
- Varivax, 1.220–221, 1.259
- Vascular dementia, 1.204
- Vascular endothelial growth factor (VEGF), 2.371–372
 agents inhibiting. *See* Anti-VEGF agents
 alternative splicing and, 2.153
 antibodies against, in cancer therapy, 1.235
 in aqueous humor, 2.234, 2.235
 choroidal neovascularization concentrations of, 12.80
 in corneal angiogenesis/lymphangiogenesis, transplant rejection and, 8.317
 in external eye defense, 8.12*f*
 isoforms of, 12.80
 in retinal ischemia, 4.152
 in retinopathy of prematurity pathophysiology, 6.325, 6.326*t*
 therapy inhibiting. *See* Anti-VEGF agents
 in uveitic cystoid macular edema, 9.289
 in vitreous, 2.254
- Vascular endothelial growth factor (VEGF) inhibitors.
See also Anti-VEGF agents
 for corneal transplantation rejection, 8.317
- Vascular eyelid disorders, 6.199
- Vascular filling defects, in fluorescein angiography, 12.35
- Vascular loops, 2.80
 prepapillary, 4.126
- Vascular malformations. *See also* Cavernous hemangioma
 intracranial hemorrhage caused by, 1.126
 orbital, 7.67–74
- Vascular resistance, reduction of, in heart failure management, 1.109
- Vascular stroke. *See* Stroke
- Vascular system
 anatomy of, 5.11–23
 arterial, 5.11–20, 5.13–14*f*, 5.15*f*, 5.16*f*, 5.17*f*, 5.18*f*, 5.20*f*
 venous, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*
 of anterior optic nerve, 10.44–46, 10.45*f*
 of choroid, 2.59–60, 2.60*f*, 2.61*f*, 2.61–62, 2.62*f*, 4.139–140
 development of, 2.116*t*
 retinal ischemia and, 4.140, 4.151, 4.151*f*
 of ciliary body, 2.57, 2.58*f*
 disorders of, 1.142–143. *See also* Vasculitis
 in diabetes mellitus, 1.48–49
 ophthalmic considerations and, 1.143
 transient visual loss and, 5.163*t*, 5.164–171

- of extraocular muscles, 2.15*t*, 2.17
- of eyelids, 2.25–26, 2.26*f*, 7.154
- imaging of, 5.60*f*, 5.67–71, 5.68*f*, 5.72*t*
- of iris, 2.35, 2.54*f*, 2.55
- of orbit, 7.13–16, 7.14*f*, 7.15*f*, 7.16*f*
 - anatomy of, 2.32–35, 2.33*f*, 2.34*f*, 2.35*f*, 5.12–14, 5.13–14*f*, 5.21, 5.21*f*, 7.13–16, 7.14*f*, 7.15*f*, 7.16*f*
- of retina, 4.139. *See also* Retinal blood vessels
 - anomalies of, 4.143*f*, 4.143–144, 4.144*f*
 - ischemia and, 4.140, 4.151, 4.151*f*, 4.153*f*, 4.154, 4.155*f*
- tumors arising in. *See* Vascular tumors
- Vascular tufts, conjunctival papillae and, 8.47*f*, 8.47–48
- Vascular tumors
 - of eyelid and conjunctiva, 8.345*t*, 8.345–348, 8.346*f*, 8.347*f*
 - benign, 8.345*t*, 8.345–347, 8.346*f*
 - inflammatory, 8.346*f*, 8.346–347
 - malignant, 8.347*f*, 8.347–348
 - of orbit, 4.233, 4.234*f*, 7.67–74
- Vascularized pannus, 8.52, 8.52*f*. *See also* Pannus/micropannus
- Vasculature, retinal, 12.16*f*, 12.16–17
- Vasculitis, 1.165*t*, 1.165–170. *See also* Arteritis; *specific type*
 - in Behçet disease, 1.169–170, 4.187, 9.182, 9.183*f*, 9.184–185
 - classification of, 1.165, 1.165*t*
 - giant cell (temporal) arteritis. *See* Giant cell arteritis
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168, 9.137, 9.138
 - inflammatory, 12.230*t*, 12.230–231, 12.231*f*
 - large-vessel, 1.165*t*, 1.166
 - lupus, 9.134, 9.134*f*, 12.230–231, 12.231*f*
 - medium-sized-vessel, 1.165*t*, 1.166–167
 - optic neuritis and, 5.115
 - orbital manifestations of, 7.43*t*, 7.60–63, 7.62*f*
 - in polyarteritis nodosa, 1.165*t*, 1.166–167, 9.135, 9.136, 9.136*f*
 - retinal, 12.155*f*, 12.155–156
 - in Behçet disease, 1.169–170, 9.186, 9.186*f*, 9.187*f*
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 1.168, 9.138
 - HLA association in, 9.67*t*
 - in HTLV-1 infection, 9.212
 - in leptospirosis, 9.249
 - in Lyme disease, 9.245
 - neovascularization and, 9.291
 - in polyarteritis nodosa, 1.167, 9.136, 9.136*f*
 - in Rift Valley fever, 9.211
 - in SLE, 9.134, 9.134*f*
 - in syphilis, 9.237, 9.238–239, 9.240
 - in toxoplasmosis, 9.222
 - in tuberculosis, 9.253
 - in uveitis, 9.76*t*, 9.77*t*, 9.77–78. *See also* Posterior uveitis
 - herpetic infection and, 9.193
 - in Whipple disease, 9.258
 - rheumatoid, 1.152
 - small-vessel, 1.165*t*, 1.167–168
 - transient visual loss caused by, 5.163*t*, 5.169–170
 - variable-vessel, 1.165*t*, 1.169–170
- Vasculopathy, 9.77
 - polypoidal choroidal (PCV/posterior uveal bleeding syndrome), 4.166*f*, 4.166–168, 4.167*f*
- Vasculotropin. *See* Vascular endothelial growth factor
- Vasoactive intestinal polypeptide (VIP), 9.28*t*
 - in external eye defense, 8.12*f*
 - outflow facility affected by, 2.48
 - in tear secretion, 2.214, 2.216, 2.219, 2.219*f*
- Vasocidin. *See* Prednisolone, in combination preparations
- Vasocon-A. *See* Naphazoline/antazoline
- Vasoconstrictors
 - for hay fever conjunctivitis, 8.288
 - for ocular allergies, 6.247*t*
- Vasodilators, for hypertension, 1.68*t*, 1.73
- Vasopressin (antidiuretic hormone), 1.56
 - for medical emergencies, 1.296*t*
- Vasopressor drugs, for shock, 1.301
- Vasospasm, retinal, transient visual loss and, 5.161, 5.162, 5.171
- Vasovagal episodes (syncope), 1.300
- Vaughan Williams classification, of antiarrhythmic drugs, 1.113, 1.113*t*
- vCJD. *See* Variant Creutzfeldt-Jakob disease
- VDA (Visual Disability Assessment), 11.71
- VDRL test, 1.248–249, 9.241
- VECAT (Vitamin E, Cataract and Age-Related Maculopathy Trial), 2.285
- VECP (visual evoked cortical potential). *See* Visual evoked potential/cortical potential/response
- Vector, 2.145
 - cosmid, 2.145
 - in gene therapy, 2.169
- Vecuronium, 1.290
- Vegetation/plants, ocular injuries caused by, 8.387
 - corneal abrasions, 8.399
 - corneal foreign body, 8.387, 8.399
 - fungal keratitis and, 4.78, 8.273, 8.387, 8.399
- VEGF. *See* Vascular endothelial growth factor
- VEGF gene, 2.372
- VEGF Trap (aflibercept), 2.372, 12.82
 - for age-related macular degeneration/choroidal neovascularization, 2.372
 - for cancer chemotherapy, 1.234*t*, 1.235
 - for macular edema, 4.152
- VEGFR1 gene, 12.82
- VEGFR2 gene, 12.82
- Vein of Galen, 5.22
- Vein of Labbé, 5.22
- Veins, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*. *See also specific vein*
- Velocardiofacial syndrome, 6.255
- Velocity, saccadic, 5.219–220, 5.221
- Velocity storage, unstable, periodic alternating nystagmus (PAN) and, 5.246
- Venereal Disease Research Laboratory (VDRL) test, 1.248–249, 9.241
- Venodilation, for heart failure, 1.110
- Venography
 - in cerebral venous thrombosis, 5.69, 5.69*f*, 5.346
 - computed tomography (CTV), 5.58, 5.70, 5.72*t*, 5.75
 - advantages/disadvantages of/contraindications for, 5.61*t*
 - in cerebral venous thrombosis, 5.346

- magnetic resonance (MRV), 5.58, 5.69, 5.69*f*, 5.72*t*, 5.75
 advantages/disadvantages of/contraindications for, 5.61*t*
 in cerebral venous thrombosis, 5.69, 5.69*f*, 5.346
 in idiopathic intracranial hypertension, 5.111
 in orbital evaluation, 7.32
- Venomous insect stings, ocular injury/infection caused by, 8.386–387
- Venous angiomas, 1.126
- Venous beading, in nonproliferative diabetic retinopathy, 12.100*f*
- Venous capacitance, increasing, for heart failure, 1.110
- Venous malformations (varices), orbital, 6.222, 7.71
 glaucoma associated with, 10.30
- Venous occlusive disease
 antiphospholipid antibody syndrome and, 1.161
 retinal. *See also* Retinal vein occlusion
 branch retinal vein occlusion, 4.158–159
 central retinal vein occlusion, 4.156–158, 4.158*f*
 angle-closure glaucoma and, 10.143–144
 neovascularization and, 10.134–135
 open-angle glaucoma and, 10.84
 hypercoagulability states and, 1.147
- Venous retrobulbar hemorrhage, 11.158. *See also* Retrobulbar hemorrhage
- Venous sinuses, 2.105, 2.106*f*
 imaging in thrombosis of, 5.69, 5.69*f*
- Venous stasis retinopathy (VSR), 5.170
- Venous system, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*. *See also specific vein*
- Venous thrombosis. *See also* Thrombosis/thrombotic disorders
 anticoagulation therapy in prevention of, 1.142
 cerebral (CVT), 5.345–346
 diabetes mellitus and, 1.49
 in idiopathic intracranial hypertension, 5.111
 neuroimaging in, 5.69, 5.69*f*, 5.72*t*, 5.346
- Ventilation (mechanical), for pulmonary diseases, 1.132
- Ventilatory failure
 CPR for, 1.295–299, 1.296*t*, 1.297*f*
 local anesthetic administration causing, 1.291, 1.292, 1.305
 in shock, 1.300
- Ventilatory support, noninvasive, 1.132
- Ventral uvula, 5.39
- Ventricular complexes, premature (PVCs), 1.112, 1.113
- Ventricular fibrillation (VF), 1.114, 1.115
 emergency management of, 1.115
 myocardial infarction and, 1.96, 1.115
- Ventricular flutter, 1.114
- Ventricular hypertrophy, hypertension and, 1.76
- Ventricular tachyarrhythmias, 1.113, 1.114–116
- Ventricular tachycardia (VT), 1.113, 1.114–115
 myocardial infarction and, 1.96
- Ventriculography, coronary, 1.98
- Ventriculoperitoneal shunting, for idiopathic intracranial hypertension, 5.112, 5.113
- Venturi pump, for phacoemulsification aspiration, 11.103, 11.104*f*
- VEP/VEPs/VER. *See* Visual evoked potential/cortical potential/response
- Verapamil
 for arrhythmias, 1.113*t*
 for hypertension, 1.68*t*, 1.69*t*
 for non-ST-segment elevation acute coronary syndrome, 1.103
 for rate control in atrial fibrillation, 1.114
- Vergence equation
 definition of, 3.4, 3.42
 for dense media, 3.12
 derivation of
 for mirrors, 3.88–89
 from Snell's law, 3.85–86
 description of, 3.9–10, 3.51
 for mirrors, 3.81, 3.88–89, 3.89*f*
 negative numbers in, 3.10
 positive numbers in, 3.10
 problems involving, 3.53
 relocation of images and, 3.62
 schematic diagram of, 3.10*f*
- Vergences/vergence system (eye movements), 5.212, 5.212*t*, 5.226–228. *See also specific type*
 convergence, 6.39–40
 definition of, 3.4, 3.10, 3.42, 6.37, 6.39, 6.72
 description of, 3.9–10
 divergence, 6.40
 dysfunction of, 5.227–228
 of eye movements, 6.40
 fusional, 6.72, 6.72*t*
 image, 3.51
 object, 3.51
 reduced, 3.41, 3.51
- Verhoeff–van Gieson stain, 4.31*t*
- Vermis, 5.33, 5.34*f*, 5.40
- Vernal keratoconjunctivitis (VKC), 6.248–249, 6.248–249*f*, 8.289–292, 8.290*f*, 8.291*f*
 atopic keratoconjunctivitis differentiated from, 8.292–293, 8.293*f*
- Vernier acuity, 3.131
- Verocay bodies, 4.238, 4.239*f*
- Verruca/verruca vulgaris (wart)
 of eyelid, 4.204, 4.205*f*, 7.167, 7.167*f*
 papillomavirus causing, 1.262, 4.204, 4.205*f*, 7.167, 8.238
- Versican, in vitreous, 2.249
- Versions, 5.34–35, 5.35*f*. *See also specific type*
 definition of, 6.37
 deorsumversion, 6.37
 dextrocycloversion, 6.38
 dextroversion, 6.37
 in diplopia, 5.184
 in infantile esotropia, 6.37
 levocycloversion, 6.38
 levoversion, 6.37
 smooth-pursuit system and, 5.224
 sursumversion, 6.37
- Vertebral artery (VA), 1.120, 2.105, 5.12, 5.13*f*, 5.19, 5.19*f*
 aneurysms of, 5.339*f*
 dissection of, 5.342

- Vertebrobasilar system, 5.19f, 5.19–20. *See also* Basilar artery; Vertebral artery
arterial dissections in, 5.342
disorders of, 5.336–338, 5.337f
transient visual loss caused by, 5.162, 5.336–337
- Verteporfin. *See also* Photodynamic therapy
central serous chorioretinopathy treated with, 12.194
complications of, 12.380
neovascular age-related macular degeneration treated with, 12.79
photodynamic therapy with
in choroidal neovascularization, 9.292
in ocular histoplasmosis syndrome, 9.217
polypoidal choroidal vasculopathy treated with, 12.76
von Hippel–Lindau syndrome treated with, 12.167
- Vertex, corneal, 8.25, 8.26f
- Vertex distance, 3.148, 3.170–173, 3.171–172f
measurement of, before refractive surgery, 13.40
- Vertex normal, 13.15
- Vertexometer, 3.171, 3.171f
- Vertical chopping techniques, in phacoemulsification, 11.114
- Vertical deviations. *See also specific type and cause*
characteristics of, 6.116
clinical approach to, 6.115–116
comitant, orbital floor/blowout fracture and, 7.108–109
surgery and, 7.110
dissociated
age at onset, 6.129
clinical features of, 6.129, 6.129f
definition of, 6.129
description of, 6.17, 6.105, 6.111, 6.115–116
hypertropia and, 6.115
inferior oblique anterior transposition for, 6.166
inferior oblique muscle overaction versus, 6.129–130
management of, 6.130
with horizontal comitance, 6.125–128
with horizontal incomitance, 6.116–125
inferior oblique muscle palsy
Brown syndrome versus, 6.124, 6.125t
clinical features of, 6.124, 6.124f, 6.125t
management of, 6.124–125
monocular elevation deficiency, 6.125–127, 6.126f
orbital floor fractures, 6.127–128, 6.128f, 7.110
overdepression in adduction
causes of, 6.17, 6.116f, 6.116–118
description of, 6.17
pattern strabismus and, 6.107, 6.108f, 6.109
superior oblique muscle overaction as cause of, 6.118, 6.118f
overelevation in adduction
causes of, 6.17, 6.116f, 6.116–118
description of, 6.17
inferior oblique muscle overaction as cause of, 6.117f, 6.117–118
pattern strabismus and, 6.107, 6.108f, 6.109
skew deviation, 6.125
superior oblique muscle palsy
bilateral, 6.122–124
causes of, 6.119
clinical features of, 6.119–122
congenital versus acquired, 6.119
description of, 6.69
hypertropia associated with, 6.123
inhibitional palsy of contralateral antagonist, 6.120–121, 6.121f
management of, 6.122–124, 6.123t
masked bilateral, 6.122
neuroimaging evaluations, 6.119
right, 6.120–121f
surgical management of, 6.122–124, 6.123t
3-step test for, 6.120
unilateral, 6.119–121, 6.120–121f, 6.122–123, 6.123t
V-pattern strabismus associated with, 6.109
thyroid eye disease as cause of, 6.140
- Vertical diplopia, in orbital floor/blowout fracture, 7.108
- Vertical eyelid splitting, for orbitotomy, 7.116f, 7.117–118
- Vertical fusional vergence, 6.72
- Vertical gaze, 5.36, 5.36f, 5.36–37
- Vertical gaze palsy, 5.228–229
- Vertical heterophoria, 3.197
- Vertical interpalpebral/palpebral fissure height, in ptosis, 7.210, 7.210f
- Vertical nystagmus, 6.152
- Vertical phoria, 3.184
- Vertical prism dissociation test, in nonorganic disorder evaluation, 5.303, 5.303f
- Vertical rectus muscles. *See also* Inferior rectus (IR) muscle; Superior rectus (SR) muscle
anatomy of, 6.20, 6.22f
eyelid attachments to, 6.30f
insertion of, 6.22
surgery of
eyelid position changes after, 7.222, 7.223
for nystagmus, 6.156
for pattern strabismus correction, 6.111
vertical strength of, 6.35
- Vertical retraction syndrome, 6.135
- Vertical rotations, 6.31
- Vertical strabismus, 6.15–16. *See also* Vertical deviations
- Verticillium*, postoperative endophthalmitis caused by, 9.262
- Vertigo
benign paroxysmal positional, nystagmus and, 5.242–243
vertebrobasilar insufficiency causing, 5.336, 5.337f
vestibular nystagmus and, 5.241, 5.241t
- Vertometer. *See* Lensmeters
- Very-low-density lipoproteins (VLDLs), 1.82
- Vesicle
of eyelid, 8.45t
lens, 2.117f, 2.118, 2.120f
formation of, 11.25, 11.26f
optic, 2.115, 2.116t, 2.117f, 2.118f
lens development and, 2.118, 11.25, 11.26f
- Vestibular nerve/nuclei (VN), 5.34f, 5.35, 5.36f, 5.38–39
disruption to, 5.216f, 5.216–218
nystagmus and, 5.215, 5.241, 5.243
horizontal gaze and, 5.37, 5.38
output of, 5.38–39, 5.39f
vertical gaze and, 5.36, 5.36f

- Vestibular neuronitis, peripheral vestibular dysfunction and, 5.242
- Vestibular nystagmus, 5.215, 5.234*f*, 5.241*t*, 5.241–246, 5.243*t*, 5.245*f*
- central, 5.216, 5.243*t*, 5.243–246, 5.245*f*
- instability (periodic alternating/PAN), 5.243*t*, 5.245–246
- peripheral, 5.216, 5.241*t*, 5.241–243
- Vestibular-ocular reflex (VOR) gain, 5.215–216
- in toxic vestibular dysfunction, 5.243
- Vestibular-ocular system/vestibular-ocular reflex (VOR), 5.38–39, 5.39*f*, 5.212, 5.212*t*, 5.214–218, 5.216*t*, 6.40. *See also* Vestibular nerve/nuclei dysfunction of, 5.215, 5.216*f*, 5.216–218
- nystagmus and. *See* Vestibular nystagmus
- optokinetic system/nystagmus and, 5.218
- smooth-pursuit system and, 5.225, 5.225*f*, 5.226
- suppression of, 5.225, 5.225*f*
- Vestibular schwannoma, Bruns nystagmus and, 5.243
- Vestibulocerebellum, 5.39–40
- downbeat nystagmus caused by lesions of, 5.244
- Vexol. *See* Rimexolone
- VF. *See* Ventricular fibrillation
- VF-14 (Visual Function Index), 11.71
- VFI. *See* Visual Field Index
- VHL. *See* von Hippel–Lindau (VHL) disease/syndrome
- VHL disease. *See* von Hippel–Lindau (VHL) disease/syndrome
- VHL gene, 4.144, 6.399
- Vidarabine, 2.356, 2.357*t*, 2.358, 8.215*t*
- for herpes simplex virus infections, 1.258, 8.215*t*, 8.219
- Video magnifiers, 3.310, 3.323, 3.324*f*
- Videokeratography, IOL power determination/selection after refractive surgery and, 11.86
- Videokeratoscopy, 8.28*f*, 8.35*t*. *See also* Keratoscopy
- in keratoconus, 8.28, 8.167*f*
- Vidian canal, 5.11
- Vidian nerve, 5.54, 5.56, 5.276–277*f*, 7.14*f*, 7.15*f*
- Vieth–Müller circle, 6.41
- VIEW 1 study, 12.83
- VIEW 2 study, 12.83
- VIG. *See* Vaccinia-immune globulin
- Vigabatrin, 1.202*t*, 6.399, 12.305
- ophthalmic considerations and, 1.187, 1.203–204
- Vigamox. *See* Moxifloxacin
- Vildagliptin, for diabetes mellitus, 1.45*t*, 1.47
- Vimentin, 2.245, 11.16
- Vinblastine, 1.231, 1.233*t*
- Vinca alkaloids, in cancer chemotherapy, 1.231, 1.233*t*
- Vincristine, 1.231, 1.233*t*
- for retinoblastoma, 4.299
- Vinculin, in retinal pigment epithelium, 2.273
- VIP. *See* Vasoactive intestinal polypeptide
- Vira-A. *See* Vidarabine
- Viral capsid, 8.211, 8.212
- Viral conjunctivitis, 6.241–243, 6.243–244*f*
- Viral load, in HIV infection/AIDS, 1.264, 1.266
- Virchow's law, 6.203, 6.205*f*
- Viridans streptococci. *See* *Streptococcus, viridans*
- Virology, 8.208*t*, 8.211–212. *See also* Viruses
- Viroptic. *See* Trifluridine
- Virtual images
- definition of, 3.42
- formation of, 3.11, 3.11*f*
- Maddox rod and, 3.75, 3.75*f*
- real images versus, 3.61
- Virtual objects
- definition of, 3.42
- real objects versus, 3.61
- Virulence (microbial), 8.206–207
- mechanisms of, 1.240
- Viruses, 8.208*t*, 8.211–212. *See also specific organism or type of infection*
- cancer etiology and, 1.228
- conjunctivitis caused by, 4.52
- immune response to, 9.55–56
- eyelid infection caused by, 4.204
- neuritis/neuroretinitis caused by, 5.113, 5.118
- ocular infection/inflammation caused by, 8.208*t*, 8.211–241
- adherence and, 8.207
- corneal opacity and, 8.16*f*
- isolation techniques for diagnosis of, 8.211
- specimen collection for diagnosis of, 8.209*t*
- optic nerve infection caused by, 4.244
- retinal infection caused by, 4.145, 4.146*f*
- treatment of infection caused by. *See* Antiviral agents
- uveitis caused by, 9.191–214
- VISA. *See* Vancomycin-intermediate *Staphylococcus aureus*
- VISA classification, for thyroid eye disease, 7.57
- Visceral afferent fibers, 2.103
- Visceral efferent fibers, 2.103
- Visceral larval/larvae migrans (VLM), 6.317, 8.253, 9.228, 12.244. *See also* *Toxocara* (toxocariasis)
- Viscoat, 2.368
- Viscocalanostomy, 10.217–219
- for uveitic glaucoma, 9.287
- Viscodissection, 11.115. *See also* Viscoelastic agents
- for advanced cataract, 11.180
- in zonular dehiscence with lens subluxation or dislocation, 11.182
- Viscoelastic agents (ophthalmic viscosurgical/OVDs), 2.368, 8.405*f*, 8.406, 11.95–97
- for cataract surgery, 11.95–97
- advanced cataract and, 11.180
- aniridia and, 11.184
- capsular block syndrome and, 11.148
- capsular rupture during surgery and, 11.142–143
- ECCE, 11.197
- high hyperopia and, 11.185
- ICCE, 11.200
- inflamed eye and, 11.191
- intumescent cataract and, 11.179–180
- IOL implantation and, 11.116, 11.117–118
- in keratoconjunctivitis sicca, dry eye therapy before use of, 11.173
- phacoemulsification, 11.105, 11.109, 11.110, 11.112, 11.115, 11.116, 11.117–118
- posterior polar cataract and, 11.181
- pupil expansion and, 11.178
- selection of, 11.97
- traumatic cataract and, 11.191, 11.192

- uveitis and, 11.191
- zonular dehiscence with lens subluxation or dislocation and, 11.182
- elevated intraocular pressure and, 10.108, 11.136
- for goniotomy and trabeculotomy, in children, 10.162–163
- intracameral administration of, 2.300*t*
- phakic IOL implantation and, 13.141
- posterior chamber lenses, 13.143
- physical properties of, 11.96
- toric IOL implantation and, 13.152
- Viscoelasticity, of ophthalmic viscosurgical device, 11.96
- Viscomydrasis, 11.97
- Viscosity
 - ocular medication absorption affected by, 2.297
 - of ophthalmic viscosurgical device, 11.96
- Viscosurgical devices, ophthalmic (OVDs). *See* Viscoelastic agents
- Visine. *See* Naphazoline/pheniramine
- Vision
 - awareness of, disorders of, 5.178*t*, 5.180–181
 - binocular. *See* Binocular vision
 - color. *See* Color vision
 - decreased. *See also* Low vision; Vision loss/impairment
 - evaluation of, 6.187–188
 - development of
 - abnormal visual experience effects on, 6.44–47, 6.45–46*f*
 - amblyopia and, 6.53
 - description of, 6.44
 - in young infants, 6.185
 - difficulties in, 3.312
 - diurnal fluctuation in, after radial keratotomy, 13.51
 - double. *See* Diplopia
 - intraocular lens–related vision disturbances in, 3.255–256, 3.256*f*
 - island of, in perimetry, 5.84
 - loss of/low. *See* Blindness; Low vision; Vision loss/impairment
 - low. *See* Low vision
 - neurophysiology of, 6.43–52
- VISION 2020, 11.6
- Vision charts
 - Bailey-Lovie, 3.133, 6.8
 - for children, 3.38. *See also* Visual acuity, in children
 - distance from patient to, 3.149
 - Early Treatment Diabetic Retinopathy Study, 3.133, 3.133*f*, 6.8
 - ETDRS-type, with Sloan letters, 3.23*f*
 - pictorial representation of, 3.23*f*
 - Snellen
 - disadvantages of, 3.132–133
 - letters on, 3.131–134, 3.132*f*
 - optotypes, 3.133*f*, 3.134
- Vision loss/impairment. *See also* Blindness; Low vision; Visual acuity; Visual field defects; *specific type*
 - in acute idiopathic blind-spot enlargement, 5.100–101, 5.101*f*
 - in acute posterior multifocal placoid pigment epitheliopathy, 9.141*t*, 9.148, 9.149–150
 - in acute retinal necrosis, 9.194, 9.197
 - in acute retinal pigment epitheliitis, 9.141*t*
 - in acute zonal occult outer retinopathy, 5.101, 9.141*t*, 9.164, 9.166
 - in Alzheimer disease, 1.206
 - amblyopia as cause of, 6.53, 6.56
 - arterial dissection and, 5.162, 5.342
 - arteritic causes of, 12.195
 - in *Aspergillus* endophthalmitis, 9.268
 - assessment of, 5.77–97. *See also* Low vision, assessment of
 - nonorganic disorders and, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
 - awareness of, disorders of, 5.178*t*, 5.180–181
 - in *Bartonella*-associated neuroretinitis, 9.256
 - in Behçet disease, 9.185, 9.186, 9.189
 - bilateral/binocular, 5.77, 5.171–172
 - nonorganic disorders and, 5.306–308, 5.307*f*, 5.308*f*, 5.309*f*
 - in birdshot uveitis, 9.141*t*, 9.144, 9.146–147
 - after blepharoplasty, 7.233–234
 - branch retinal vein occlusion as cause of, 12.128
 - in cancer-associated retinopathy, 5.102
 - in *Candida* chorioretinitis/endophthalmitis, 9.266
 - carotid dissection and, 5.162, 5.342
 - cataract and, 11.5, 11.69–71, 11.70*t*
 - indications for surgery and, 11.72–73
 - causes of, 12.346
 - in central retinal artery occlusion, 5.161, 12.143–144
 - in central retinal vein occlusion, 5.170
 - cerebral, 6.186–187
 - chiasmal lesions causing, 5.146–152
 - childhood glaucoma as cause of, 6.290
 - in children, 3.327
 - classification of, 5.99–159. *See also specific causative factor*
 - in coccidioidomycosis, 9.272
 - in cone dystrophies, 5.102
 - cortical, 6.186
 - in Creutzfeldt-Jakob disease, 5.357
 - in cysticercosis, 9.232
 - delayed visual maturation, 6.186–187
 - in dengue fever, 9.213
 - in diffuse unilateral subacute neuroretinitis, 9.232, 12.246
 - in endophthalmitis, 9.264
 - after endothelial keratoplasty (DMEK/DSEK), 8.438–440
 - functional. *See* Vision loss/impairment, nonorganic
 - fungal endophthalmitis as cause of, 12.239
 - in glaucoma, 10.7, 10.82, 10.84, 10.117. *See also* Visual field defects, in glaucoma
 - in children, 10.158, 10.166–167
 - race and, 10.82
 - after trabeculectomy, 10.199
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 9.138
 - hallucinations and (Charles Bonnet syndrome), 5.177–178
 - in HIV infection/AIDS, 9.293
 - in idiopathic intracranial hypertension, 5.110–113, 5.111*t*
 - in infants, 6.186–187. *See also* Low vision, in infants
 - in inflammatory chorioretinopathies, 9.143*t*

- in leukemia, 4.315, 4.316
- management of, 5.99–159. *See also specific causative factor*
- in measles, 9.206, 9.207–208
- media abnormality causing, 5.99, 5.164
- in meningioma, 7.81
- monocular/unilateral, 5.77, 5.161, 5.163*t*, 5.163–171. *See also* Monocular transient visual loss
- nonorganic disorders and, 5.302–305, 5.303*f*, 5.304*f*, 5.305*t*
- in optic neuritis, 5.113
- in multifocal choroiditis with panuveitis, 9.141*t*, 9.155, 9.156
- in multiple evanescent white dot syndrome, 5.101, 9.141*t*, 9.161
- in neuroretinitis, 5.118*f*, 5.118–119, 9.232, 9.256
- nonorganic, 1.190, 1.198, 5.299*t*, 5.299–312
- afferent visual pathways and, 5.301–305, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*
- clinical profile of patient with, 5.300
- examination techniques in, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
- eyelid position/function and, 5.310–311
- malinger and, 5.299
- management of, 5.311
- ocular motility/alignment and, 5.309–310
- organic disorders misdiagnosed as, 5.299, 5.299*t*
- pupils/accommodation and, 5.301, 5.310
- in nystagmus, 5.235–236, 5.243*t*, 5.247
- in ocular histoplasmosis syndrome, 9.216
- in older patients, 1.177, 1.178
- depression and, 1.182, 1.183, 1.190
- falls and, 1.185
- in onchocerciasis (river blindness), 9.234
- ophthalmologist's role in, 3.311
- in optic nerve glioma, 7.74
- in optic neuritis, 5.107*t*, 5.113–118, 5.114*f*, 5.117*t*, 5.317
- in optic neuropathy, 5.103–146. *See also* Optic neuropathy
- AION, 5.119
- arteritic (AAION), 5.120, 5.121*f*
- nonarteritic (NAION), 5.91*f*, 5.120*t*, 5.121*f*, 5.122, 5.123
- infiltrative, 5.131
- versus maculopathy, 5.99–103, 5.100*t*
- traumatic, 5.139–140
- in optic perineuritis, 5.119
- in orbital floor/blowout fracture, 7.109
- after orbital surgery, 7.125
- in papilledema, 5.105–113, 5.107*t*, 5.108*f*, 5.109*f*, 5.110*f*, 5.111*t*
- after parasellar tumor therapy, 5.150, 5.151
- pregeniculate, 6.186–187
- prevalence of, 3.311
- in ptosis, 7.209, 7.210, 7.211–212, 7.212, 7.214, 7.218–219
- in punctate inner choroiditis, 9.141*t*, 9.158, 9.160
- pupillary abnormalities and, 5.253–267
- quality of life affected by, 3.311
- retinopathies causing. *See specific type*
- retrochiasmal lesions causing, 5.152–158
- retrogeniculate, 6.186
- in reversible cerebral vasoconstriction syndrome, 5.346
- rhegmatogenous retinal detachment as cause of, 12.128
- in Rift Valley fever, 9.211
- in sarcoidosis, 5.327
- in serpiginous choroiditis/choroidopathy, 9.141*t*, 9.151, 9.152
- in SLE, 1.159
- spousal effects of, 3.327
- in subacute sclerosing panencephalitis, 9.207–208
- in subretinal fibrosis and uveitis syndrome, 9.141*t*
- in sympathetic ophthalmia, 9.173
- symptoms associated with, 5.78
- in thyroid eye disease, 5.131, 5.132*f*, 7.56, 7.59–60
- time course of, 5.77–78
- in toxocariasis, 9.228–229, 12.245
- in toxoplasmosis, 9.222
- after trabeculectomy, 10.199
- transient, 5.161–172. *See also* Transient visual loss
- traumatic, 5.139–140
- with clear media, 7.112–114
- unilateral/monocular, 5.77, 5.161, 5.163*t*, 5.163–171. *See also* Monocular transient visual loss
- nonorganic disorders and, 5.302–305, 5.303*f*, 5.304*f*, 5.305*t*
- in optic neuritis, 5.113
- in uveal lymphoid proliferation/infiltration, 4.313, 9.276
- in uveitis, 9.79, 9.79*t*
- cataract and, 9.281–282
- cystoid macular edema and, 9.289
- rehabilitation and, 9.292
- vigabatrin causing, 1.187, 1.203–204
- vitreous hemorrhage as cause of, 12.346
- in Vogt-Koyanagi-Harada syndrome, 9.176–177, 9.182
- in West Nile virus chorioretinitis, 9.210
- in xanthogranuloma, 7.91
- Vision loss (see-saw) nystagmus, 5.243*t*, 5.247, 6.152
- Vision rehabilitation, 1.177, 5.159, 6.188–189, 6.189*t*
- in age-related macular degeneration, 3.315
- for blindness, 3.325
- in cataracts, 11.71
- ocular trauma and, 11.193
- definition of, 3.310
- for field loss, 3.325–326
- low vision evaluations. *See* Low vision
- model of, 3.328*f*
- ongoing eye care during, 3.328
- patient's goals for, 3.312
- psychological counseling included with, 3.327
- resources for, 3.329
- services added to, 3.327–329
- in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
- training in, 3.325
- in uveitis, 9.292
- visual function assessment and. *See* Low vision, assessment of
- Vision Rehabilitation, Preferred Practice Pattern*, 1.177, 3.311

- Vismodegib, for orbital infiltrative basal cell carcinoma, 7.181
- Vistech chart, 3.316f
- Vistide. *See* Cidofovir
- Visual acuity. *See also* Best-corrected visual/Snellen visual acuity; Distance visual acuity; Near visual acuity; Uncorrected/uncorrected distance visual acuity; Vision loss/impairment
- in AION, 5.119
 - arteritic (AAION), 5.120, 5.120t
 - nonarteritic (NAION), 5.120t, 5.122, 5.123
 - in amblyopia, 6.5
 - refractive surgery and, 13.185–186
 - assessments of
 - for amblyopia diagnosis, 6.56
 - in children. *See* Visual acuity, in children
 - in nystagmus, 6.153–154
 - in cataract, 11.69–70, 11.70t
 - indications for surgery and, 11.72–73
 - preoperative evaluation and, 11.75–76, 11.76
 - after cataract surgery, 11.126
 - cystoid macular edema and, 11.163, 11.164
 - with ECCE, 11.198
 - endophthalmitis and, 11.161, 11.162
 - with ICCE, 11.201
 - incorrect lens power and, 11.85
 - with manual small-incision surgery, 11.198–199
 - multifocal IOLs and, 11.121–122
 - in central serous chorioretinopathy, 12.190
 - in children, assessment of
 - age-specific approaches, 6.5
 - alternative methods, 6.8–9
 - Central, Steady, and Maintained method of, 6.6
 - eye charts for, 6.6t, 6.6–8, 6.7f
 - fixation and following behavior for, 6.5
 - fixation behavior, 6.5–6
 - HOTV test, 6.6, 6.6t, 6.7f
 - induced tropia test, 6.6
 - in nystagmus, 6.8
 - occluders used in, 6.8
 - optotypes for, 6.6t, 6.6–8, 6.7f
 - preferential looking, 6.5, 6.8–9, 6.9f, 6.182, 6.300
 - preverbal children, 6.8–9, 6.154
 - sequence of, 6.8
 - symbol charts for, 6.7
 - visual evoked potential for, 6.9, 6.182, 6.300
 - clinical measurement of. *See* Refraction, clinical; Visual acuity, testing
 - in congenital glaucoma, 10.158
 - corneal crosslinking and, 13.131
 - corneal inlays and, 13.61
 - description of, 3.131–134
 - development of, 6.182
 - dynamic, vestibular-ocular reflex evaluation and, 5.216
 - after endothelial keratoplasty (DMEK/DSEK), 8.438–440
 - femtosecond laser corneal intrastromal treatment and, 13.168
 - flap folds/striae and, 13.112, 13.113, 13.114t, 13.115
 - in giant cell arteritis/AAION, 5.120, 5.120t
 - hard contact lens method for IOL power calculation and, 13.195
 - hyperopia correction and, 13.94
 - intrastromal corneal ring segment placement and, 13.64, 13.67
 - for keratoconus, 13.66
 - irregular astigmatism affecting, 13.17
 - after keratoprosthesis implantation, 8.452
 - LASIK and
 - for amblyopia/anisometropic amblyopia, 13.186
 - in diabetes mellitus, 13.190
 - flap folds/striae and, 13.112, 13.113, 13.114t, 13.115
 - for hyperopia/hyperopic astigmatism, 13.97
 - for mixed astigmatism, 13.97
 - for myopia, 13.95, 13.97
 - after penetrating keratoplasty, 13.180
 - after retinal detachment surgery, 13.185
 - in Leber hereditary optic neuropathy, 5.133
 - in low vision, 5.78
 - photostress testing and, 5.88
 - with monovision, 13.39, 13.164–165
 - in morning glory disc anomaly, 6.363
 - with multifocal IOLs, 13.155–156
 - myopia correction and, 13.95
 - in neuromyelitis optica, 5.320
 - in neuroretinitis, 5.118
 - in newborn, 6.44
 - in nystagmus, 5.235
 - in optic atrophy, 5.135
 - in optic nerve hypoplasia, 5.143
 - in optic neuritis, 5.115
 - in optic neuropathy versus maculopathy, 5.99, 5.100t
 - patient expectations/motivations for refractive surgery and, 13.35–36, 13.36, 13.47
 - after penetrating and perforating ocular trauma, 8.401
 - with phakic IOLs, 13.144
 - photorefractive keratectomy and, 13.95
 - pinhole, 3.124, 3.130
 - positive visual phenomena and, 5.173
 - postoperative, 7.124
 - in ptosis, 7.209, 7.211–212
 - radial keratotomy and, 13.50–51, 13.51–52
 - ranibizumab effects on, 12.80
 - refractive lens exchange and, 13.150
 - after small-incision lenticule extraction, 13.205
 - Snellen, 3.124, 3.131, 3.132f, 3.134
 - stereoacuity/stereopsis relationship and, 5.305, 5.305t
 - subnormal, 3.25
 - testing of. *See also* Refraction, clinical
 - cataract surgery and, 11.75–76, 11.76
 - in children, 3.38, 10.158
 - conversion chart for, 3.132t
 - eye charts for, 3.22, 3.23f. *See also* Eyecharts
 - fixation during, 3.313
 - in low vision/vision rehabilitation, 3.313, 5.78
 - in manifest refraction process, 3.22–25
 - at near, 3.24
 - nonorganic disorders and, 5.306
 - photostress testing and, 5.88
 - pinhole occluder used in, 3.23–24, 3.24f
 - refractive surgery and, 13.39–40
 - amblyopia and, 13.185
 - Snellen chart for, 3.131, 3.132f
 - terminology used in, 3.131

- toric IOL implantation and, 13.152–153
- undercorrection after photoablation and, 13.102
- wavefront-guided/wavefront-optimized ablation and, 13.32
- Visual aids. *See* Low vision aids
- Visual allesthesia, 5.180
- Visual aura. *See* Aura
- Visual axis, 3.125, 6.41
 - Nd:YAG laser capsulotomy location and, 11.155
- Visual confusion, 6.47, 6.47f
- Visual (calcarine/occipital/striate) cortex, 2.90, 2.93, 5.24f, 5.29f, 5.29–31, 5.30f, 5.32f, 5.34f, 6.46f
 - disorders of, 5.158, 5.178t, 5.178–181
 - hallucinations and, 5.158, 5.176–178
 - illusions and, 5.175
 - recognition disorders and, 5.178t, 5.179, 5.180f
 - vision/visual deficit awareness disorders and, 5.178t, 5.180–181
 - visual–spatial relationship disorders and, 5.178t, 5.180
 - ocular motor control and, 5.32f, 5.32–33, 5.34f
 - vascular supply of
 - arterial supply, 5.20, 5.20f
 - venous drainage, 5.22f, 5.22–23, 5.23f
- Visual cycle, retinal pigment epithelium in, 2.274–276, 2.275f
- Visual deficits. *See also* Low vision; Vision loss/impairment
 - disorders of awareness of, 5.178t, 5.180–181
- Visual deprivation
 - abnormal visual experience caused by, 6.44
 - monocular, 6.44, 6.45f
- Visual deprivation amblyopia, 6.55
 - causes of, 6.55
 - congenital cataracts as cause of, 6.55
 - congenital nevocellular nevi as cause of, 6.200
 - corneal blood staining as cause of, 6.379
 - critical period for, 6.53
 - reverse amblyopia, 6.55–56
- Visual Disability Assessment (VDA), 11.71
- Visual evoked potential/cortical potential/response (VEP/VECP/VER), 5.95
 - albinism evaluations, 12.288
 - in children, 12.53
 - delayed, 12.52–53
 - demyelinating optic neuritis findings, 12.52
 - description of, 12.52
 - flash, 12.52
 - flash stimulation for, 12.53
 - in low vision evaluation, 5.95
 - in nonorganic disorder evaluation, 5.302
 - in nystagmus, 12.53
 - optic nerve conduction delay diagnosis with, 12.52
 - pattern-appearance stimulation, 12.53
 - pattern electroretinography and, 12.45–46
 - pattern-reversal, 12.52, 12.53f
 - for visual acuity assessment in preverbal children, 6.9, 6.182, 6.300
- Visual evoked response. *See* Visual evoked potential/cortical potential/response
- Visual field. *See also* Visual field defects
 - central, 3.315, 3.317
 - clinical evaluation of. *See* Visual field testing
 - cloverleaf, 10.66, 10.66f
 - cortical areas corresponding to, 5.28, 5.29f
 - normality/abnormality of, perimetry interpretation and, 10.62–65, 10.64f, 10.65f
 - peripheral, 3.318
 - quality/reliability of, perimetry interpretation and, 10.62
 - silent, nonorganic disorder evaluation and, 5.308
- Visual field defects, 2.90, 2.90f
 - in acute zonal occult outer retinopathy, 9.143t, 9.165–166, 12.227
 - age/aging affecting, 10.81
 - in AION, 5.119
 - nonarteritic (NAION), 5.91f, 5.122, 5.123t
 - arteriovenous malformations causing, 5.291, 5.343, 5.344f
 - central, 5.85, 5.85f
 - chiasmal lesions causing, 5.146–147, 5.147f, 5.148f
 - in congenital tilted disc syndrome, 5.144, 5.144f
 - congruous, 5.29
 - retrochiasmal lesions producing, 5.153
 - occipital lobe lesions, 5.156, 5.157f
 - cortical areas/lesions and, 5.28, 5.29f
 - evaluation of, 5.83–88, 5.85f, 5.87f. *See also* Perimetry; Visual field testing
 - in glaucoma, 10.59
 - cataract/media opacities and, 11.186, 11.186f
 - evaluation of, 10.59–77
 - patterns of loss and, 10.67–69, 10.68f, 10.69f, 10.70f
 - serial fields/progression and, 10.71–75, 10.72f, 10.73f, 10.74f
 - single field and, 10.62–67, 10.64f, 10.65f, 10.66f, 10.67f
 - indications for surgery and, 10.197
 - normal-tension glaucoma and, 10.86
 - optic nerve/nerve head/disc changes correlated with, 10.74–75
 - primary open-angle glaucoma (POAG) and, 10.79–80
 - screening tests for, 10.62
 - incongruous, 5.29
 - retrochiasmal lesions producing, 5.153
 - lateral geniculate body lesions causing, 5.154, 5.154f
 - in Leber hereditary optic neuropathy, 5.133, 5.134f
 - in migraine aura without headache, 5.291
 - in migraine headache, 5.171–172, 5.290–291
 - in multiple evanescent white dot syndrome, 9.143t, 9.162
 - in multiple sclerosis, 5.318
 - in neuromyelitis optica, 5.320
 - as nonorganic disorders, 5.306–308, 5.307f, 5.308f, 5.309f
 - occipital lobe lesions causing, 5.156–158, 5.157f, 5.158f, 5.159f
 - in optic atrophy, 5.135, 5.136f
 - in optic nerve hypoplasia, 5.143
 - optic nerve/nerve head/disc drusen causing, 5.141f, 5.141–142
 - in optic neuritis, 5.114, 5.114f, 5.123t

- in optic neuropathy, 5.103, 5.104*f*, 5.105*t*, 5.106*f*
versus maculopathy, 5.99, 5.100, 5.100*t*
- optic tract lesions causing, 5.147*f*, 5.153
- in papilledema, 5.107, 5.110, 5.110*f*
- parietal lobe lesions causing, 5.84, 5.156
- perimetric terms and, 5.105*t*
- in ptosis, 7.209, 7.212, 7.214
- in retrochiasmal lesions, 5.146, 5.153
- in reversible cerebral vasoconstriction syndrome, 5.346
- in sarcoidosis, 5.327
- in stroke, 5.153, 5.156, 5.157, 5.157*f*, 5.158*f*
- temporal lobe lesions causing, 5.155, 5.155*f*
- in thyroid eye disease, 5.131, 5.132*f*
- in tilted disc syndrome, 5.144, 5.144*f*
- in toxic/nutritional optic atrophy, 5.137, 5.138*f*
- in vertebrobasilar insufficiency, 5.336
- vigabatrin causing, 1.187, 1.203–204
- Visual Field Index (VFI)/VFI field progression plot, in
visual field progression identification, 10.72–74, 10.74*f*
- Visual field testing, 5.83–88, 5.85*f*, 5.87*f*, 6.10
 - in acute retinal pigment epitheliitis, 9.164
 - in acute zonal occult outer retinopathy, 9.143*t*, 9.165–166
 - Amsler grid, 5.84
 - in aura evaluation, 5.291
 - in birdshot uveitis, 9.147
 - before cataract surgery, 11.82
 - confrontation testing, 5.83–84
 - in hemispatial neglect, 5.181
 - in glaucoma, 10.59–77. *See also* Perimetry
 - artifacts and, 10.66*f*, 10.66–67, 10.67*f*
 - interpretation in
 - patterns of field loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
 - of serial fields/progression, 10.71–75, 10.72*f*, 10.73*f*, 10.74*f*
 - of single field, 10.62–67, 10.64*f*, 10.65*f*, 10.66*f*, 10.67*f*
 - optic nerve/nerve head/disc changes correlated with, 10.74–75
 - screening tests in, 10.62
 - ultrasound biomicroscopy in, 10.77
- in inflammatory chorioretinopathies, 9.143*t*
- in low vision patients/vision rehabilitation, 5.83–88, 5.85*f*, 5.87*f*
- in measles, 9.206
- in multiple evanescent white dot syndrome, 9.143*t*, 9.162
- in nonorganic disorder evaluation, 5.306–308, 5.307*f*, 5.308*f*, 5.309*f*
- perimetry, 5.84–88, 5.85*f*, 5.87*f*. *See also* Perimetry
- in ptosis, 7.212
- in punctate inner choroiditis, 9.143*t*
- Visual function
 - assessments of
 - central visual field, 3.315, 3.317
 - contrast sensitivity, 3.314–315
 - fixation, 3.313*f*, 3.313–314
 - peripheral visual field, 3.318
 - refraction, 3.314, 3.315*f*
 - visual acuity measurements, 3.313, 3.313*f*
 - improving. *See* Vision rehabilitation
 - measuring. *See also* Low vision, assessment of
 - in cataract evaluation, 11.71
 - indications for surgery and, 11.72
 - after surgery, 11.126
 - before surgery, 11.71, 11.72, 11.76–77
 - central visual field assessment and, 5.85, 5.85*f*
 - reduced. *See* Low vision; Vision loss/impairment
- Visual Function Index (VF-14), 11.71
- Visual history, in manifest refraction process, 3.25
- Visual loss/impairment. *See* Vision loss/impairment
- Visual neglect, in parietal lobe lesions, 5.84
- Visual pathways, 2.90, 2.90*f*, 5.5–56. *See also*
 - Retinogeniculocortical pathway
 - afferent, 5.23–31, 5.24*f*. *See also* Afferent visual pathways
 - autonomic pathways and, 5.52–56
 - parasympathetic, 5.52, 5.54–56, 5.55*f*
 - sympathetic, 5.52–54, 5.53*f*
 - bony anatomy of head and, 5.5–11, 5.6*f*, 5.7–8*f*, 5.9*f*, 5.10*f*
 - central, 6.44
 - development of, 6.44
 - efferent (ocular motor), 5.31–46, 5.211. *See also*
 - Ocular motility, control of; Ocular motor pathways
 - electrophysiologic and psychophysical testing in
 - evaluation of. *See specific test*
 - locations of lesions of, 5.147*f*
 - sensory and facial motor pathways, 5.47–52
 - vascular anatomy and, 5.11–23
 - arterial, 5.11–20, 5.13–14*f*, 5.15*f*, 5.16*f*, 5.17*f*, 5.18*f*, 5.20*f*
 - venous, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*
 - visual evoked potential testing in evaluation of, 5.95
 - white matter of, 6.44
- Visual phenomena, persistent positive, 5.177, 5.201, 5.290
- Visual pigments, retinal pigment epithelium in
 - regeneration of, 2.274–276, 2.275*f*
- Visual processing stream, dorsal, 5.224
- Visual prosthesis, 3.310
- Visual (optic) radiations (geniculocalcarine pathways), 2.90, 2.90*f*, 2.93, 5.18*f*, 5.19, 5.24*f*, 5.29, 5.30
 - lesions of, 5.153, 5.155
 - in multiple sclerosis, 5.318
- Visual rehabilitation. *See* Vision rehabilitation
- Visual resolution. *See* Resolution
- Visual–spatial relationships, disorders of, 5.178*t*, 5.180
- Visual stimulus deprivation amblyopia. *See* Visual deprivation amblyopia
- Visual task performance, 3.318–319
- VIT1, in vitreous, 2.249, 2.252
- Vital capacity, forced (FVC), 1.131
- Vitamin A
 - for abetalipoproteinemia, 2.203
 - deficiency of, 8.196–197, 8.197*f*, 12.261, 12.289–290
 - corneal changes in, 8.196–197, 8.197*f*
 - Corynebacterium xerosis* and, 8.196–197, 8.246
 - illusions caused by, 5.175
 - in retinal pigment epithelium, 2.274, 2.275, 2.276
 - in visual cycle, 2.274–276

- Vitamin B₂ (riboflavin), in corneal crosslinking, 13.130–131, 13.132–134, 13.133f
- Vitamin B₆ (pyridoxine), for homocystinuria, 2.203, 11.41
- Vitamin B₁₂ deficiency, 1.137–138
optic neuropathy caused by, 5.138
- Vitamin C (ascorbic acid)
antioxidant effect of, 2.285, 2.288
in lens, 2.283, 2.285
in retina and retinal pigment epithelium, 2.288
in aqueous humor, 2.231t, 2.232
for chemical injuries, 8.383
corneal wound healing and, 13.33
deficiency of (scurvy), 1.142–143
oral supplements and, 2.285
in phototherapeutic keratectomy, 8.367
in tear film, 2.214
in vitreous, 2.231t
- Vitamin E
abetalipoproteinemia and, 2.203
antioxidant effect of, 2.283, 2.284f, 2.285, 2.286, 2.287, 2.288
in lens, 2.285
oral supplements and, 2.285
in retina and retinal pigment epithelium, 2.286, 2.287, 2.288, 2.289f
perioperative use of, 1.286
- Vitamin E, Cataract and Age-Related Maculopathy Trial (VECAT), 2.285
- Vitamin K deficiency, coagulation disorders and, 1.145
- Vitamin supplements, 2.370
in genetic disorders, 2.203
- Vitamins
for age-related macular degeneration, 12.69, 12.70t
deficiencies of
cataracts caused by, 11.63
optic neuropathy caused by, 5.138
supplementary, 2.370
cataract prevention and, 11.7, 11.20
in genetic disorders, 2.203
- Vitelliform degenerations. *See* Vitelliform macular dystrophy
- Vitelliform exudative macular detachment, 12.272, 12.274f
- Vitelliform macular dystrophy (VMD)
adult-onset, 4.170, 4.171f
description of, 12.32
electro-oculography findings in, 12.51
juvenile-onset (Best disease). *See also* Best disease
bestrophin defect causing, 2.265
identification of carriers for, 2.178, 2.196
retinal pigment epithelium in, 2.278
- Vitelliform macular dystrophy (VMD2/BEST1) gene, 10.11t
- Vitiliginous chorioretinitis (birdshot uveitis/retinochoroidopathy/chorioretinopathy), 9.141–143t, 9.144–147, 9.145f, 9.146f
ERG in, 9.143t, 9.147
HLA association in, 9.67, 9.67t, 9.141t, 9.144
- Vitiligo, in Vogt-Koyanagi-Harada syndrome, 9.178, 9.178f
- Vitrasert. *See* Ganciclovir
- Vitreous syneresis, 6.344
- Vitrectomy. *See also* Pars plana vitrectomy
angle-closure glaucoma after, 10.143
for capsular rupture during cataract surgery, 11.142, 11.143
cataract/cataract surgery after, 11.20, 11.55, 11.75, 11.190
complications of, 12.402t, 12.402–403
for cystoid macular edema, 12.159, 12.393, 12.394f
postoperative, after cataract surgery, 11.165
in uveitis, 9.289–290
delayed, 12.360
diabetic macular edema treated with, 12.388
diabetic retinopathy complications treated with, 12.107
for endophthalmitis
Aspergillus, 9.269
bacterial, 9.264–265
Candida, 9.267
postoperative, 9.262, 9.263, 11.162
in endophthalmitis diagnosis, 9.264
epiretinal membranes treated with, 12.382, 12.383
for Fuchs heterochromic uveitis/iridocyclitis, 9.127
for hemolytic/ghost cell glaucoma, 10.106
idiopathic macular holes treated with, 12.384–385, 12.385f
immediate, 12.359
indications for, 12.359, 12.381
infectious scleritis after, 9.259
instrumentation used in, 12.381–382
in intraocular lymphoma, 4.312
for IOL decentration/dislocation, 11.145
for malignant/ciliary block glaucoma (aqueous misdirection), 10.141
needle perforation/penetration of globe treated with, 12.396
open-angle glaucoma risks secondary to, 12.402
open-globe injuries treated with, 12.359–360
oxidative lens damage and, 11.20
pars plana. *See* Pars plana vitrectomy
for pars planitis, 9.131
with phacoemulsification, in uveitis, 9.283
physiologic changes after, 2.254
posterior vitreous detachment treated with, 12.333f, 12.359
posteriorly dislocated intraocular lenses treated with, 12.393
postoperative endophthalmitis treated with
acute-onset, 12.388–390, 12.390f
bleb-associated, 12.390–391, 12.391f
chronic (delayed-onset), 12.390, 12.391f
in primary central nervous system lymphoma, 4.312
for retained lens fragments after phacoemulsification, 11.141, 12.391–393, 12.392f
for retinal detachment
in acute retinal necrosis, 9.197
cataract surgery/IOL insertion and, 11.166
in CMV retinitis, 9.295
refractive surgery after, 13.185
in uveitis, 9.291
for retinopathy of prematurity, 6.335, 12.187
rhegmatogenous retinal detachment treated with, 12.324, 12.400f, 12.400–401

- smaller-gauge instrumentation used in, 12.382
 submacular hemorrhage treated with, 12.385, 12.386f
 suprachoroidal hemorrhage treated with, 12.394–395, 12.395f
 sympathetic ophthalmia and, 9.172
 technique for, 12.381
 tractional retinal detachment treated with, 12.325, 12.387–388
 in uveal lymphoid proliferation/infiltration, 4.314
 for uveitis, 9.283
 cystoid macular edema and, 9.289–290
 juvenile idiopathic (chronic/rheumatoid) arthritis–associated, 9.124
 vitreous biopsy and, 9.92
 visualization aids used in, 12.381–382
 for vitreocorneal adherence/persistent corneal edema, 11.130
 vitreous hemorrhage treated with, 12.366, 12.386–387
 for vitreous opacification/vitritis, 9.290
 vitreous opacities treated with, 12.348, 12.386
 for vitreous prolapse, 11.142, 11.143–144
 Vitrectorhexis, 6.302
 Vitreocorneal adherence, after cataract surgery, 11.130
 Vitreolysis
 enzymatic, 2.255
 Nd:YAG laser
 for cystoid macular edema, after cataract surgery, 11.165
 for vitreous prolapse in anterior chamber, 11.143
 Vitreomacular adhesions (VMAs), 12.336, 12.336t
 Vitreomacular traction (VMT) syndrome
 description of, 12.332, 12.332f, 12.336t, 12.336–337, 12.337f
 epiretinal membranes versus, 12.382–383
 vitrectomy for, 12.382–384, 12.384f
 Vitreopapillary traction, optic nerve/nerve head/disc edema differentiated from, 5.107
 Vitreoretinal adhesions, 12.337
 Vitreoretinal interface disorders. *See specific type*
 Vitreoretinal/retinal (primary central nervous system/intraocular) lymphoma, 1.237, 4.135f, 4.135–137, 4.136f, 4.311f, 4.311–313, 4.313f, 5.349, 9.273–276, 9.274f, 9.275f, 12.233–234. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
 Vitreoretinal surgery. *See also* Vitrectomy
 angle-closure glaucoma after, 10.143
 for cysticercosis, 9.232
 for ocular histoplasmosis syndrome, 9.217
 after refractive surgery, 13.197
 sympathetic ophthalmia and, 9.172
 for toxocariasis, 9.230
 Vitreoretinal tufts, 12.311–312, 12.312f
 Vitreoretinopathies. *See also specific type*
 cataract surgery in patient with, 11.189
 familial exudative, 6.347–348, 6.348f
 juvenile retinoschisis. *See* Juvenile retinoschisis
 Knobloch syndrome, 6.346f, 6.346–347
 Norrie disease, 6.347
 proliferative (PVR), 4.20, 4.21f, 4.131, 4.131f
 rhegmatogenous retinal detachment and, 9.291
 Stickler syndrome, 6.345–346
 Vitreoschisis. *See* Vitreous detachment
 Vitreous, 2.37f, 2.37–38, 2.78–81, 2.79f, 2.80f, 2.81f, 2.249–255, 4.125–137
 aging affecting, 2.80, 2.252–255
 amyloidosis involving, 4.134f, 4.134–135
 anatomy of, 2.37f, 2.37–38, 2.78–81, 2.79f, 2.80f, 2.81f, 4.125, 12.7–9, 12.8f, 12.331
 as angiogenesis inhibitor, 2.253–254
 ascorbate levels in, 12.9
 attachments of, 12.7
 biochemistry and metabolism of, 2.249–255
 biopsy of
 for endophthalmitis after cataract surgery, 11.162
 for primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.135–136, 4.136f, 4.312, 9.274, 9.275, 9.275f
 for uveal lymphoid proliferation/infiltration, 4.314
 for uveitis, 9.92
 canals in, 12.7
 cataract surgery complications and
 endophthalmitis, 11.161
 with ICCE, 11.200
 posterior vitreous detachment, 11.166
 prolapse, 11.142, 11.143–144
 vitreocorneal adherence, 11.130
 cisterns in, 12.7
 collagen in, 2.78–79, 2.79f, 2.249–250, 2.250f, 2.251f, 12.7, 12.344
 liquefaction and, 2.253
 composition of, 2.249–252, 2.250f, 2.251f, 12.7, 12.331
 congenital anomalies of, 4.125–127, 4.126f, 4.127f
 in cysticercosis, 9.231
 cysts of, 4.126–127
 cytomegalovirus retinitis findings, 12.235
 definition of, 12.331
 degenerations of, 4.128–135, 4.129f, 4.130f, 4.131f, 4.132f, 4.133f, 4.134f, 12.344
 detachment of. *See* Vitreous detachment
 development of
 abnormalities of, 4.125–127, 4.126f, 4.127f
 persistent fetal vasculature, 12.341–342
 prepapillary vascular loops, 12.341, 12.341f
 tunica vasculosa lentis, 12.340–341
 description of, 2.122, 2.123f, 4.125
 disorders of, 4.125–137. *See also specific type*
 neoplastic, 4.135f, 4.135–137, 4.136f
 enhanced depth imaging optical coherence tomography of, 12.25
 familial exudative vitreoretinopathy of, 12.343–344, 12.345f
 genetic disease involving, 2.255
 healing/repair of, 4.17
 hereditary hyaloideoretinopathies with optically empty vitreous, 12.342–343, 12.343f
 hyalocytes in, 12.7
 hyaluronan/hyaluronic acid in, 2.79, 2.79f, 2.250–251
 immune response/features/microenvironment of, 9.54t, 9.56–58
 infection/inflammation of, 2.254, 4.127, 4.128f.
 See also Endophthalmitis; Intermediate uveitis; Vitritis
 injury to, 2.254
 in leukemia, 4.315

- liquefaction of, 2.252–253, 12.316–317, 12.344
 - injury/hemorrhage/inflammation and, 2.254
 - low-molecular-weight solutes in, 2.252
 - macular hole formation and, 2.254–255
 - myopia caused by changes in, 2.252, 2.253
 - opacification of. *See* Vitreous, opacities of
 - opacities of
 - amyloidosis, 12.348, 12.349f
 - asteroid hyalosis, 12.346f, 12.346–347
 - bilateral, 12.348
 - cholesterolosis, 12.348
 - pigment granules, 12.348
 - vitrectomy for, 12.386
 - vitreous degeneration and detachment associated, 12.344
 - vitreous hemorrhage, 12.347
 - primary, 2.122, 2.123f, 4.125
 - primary persistent hyperplasia of (PHPV). *See* Persistent fetal vasculature
 - proteins in, 2.251–252
 - retinal cavernous hemangioma bleeding into, 12.168
 - in sarcoidosis, 9.169, 9.169f
 - secondary, 2.122, 2.123f, 4.125
 - specimen collection from/tap/biopsy of. *See* Vitreous, biopsy of
 - surgery-related abnormalities of, 12.349–350
 - syneresis of, 12.307, 12.316
 - tertiary, 2.123f, 4.125
 - topography of, 2.37f, 2.37–38, 4.125
 - Toxocara* larvae in, 9.229, 9.230f
 - traction, 12.208
 - tumors of, 4.135f, 4.135–137, 4.136f
 - in uveitis, 9.72t, 9.73, 9.80t, 9.83, 9.127. *See also* Intermediate uveitis
 - void of, 12.7
 - zonular fibers in, 2.252, 4.125
- Vitreous base, 2.79**
- avulsion of, 12.315, 12.316f, 12.331
 - posterior border of, 12.10
 - posterior vitreous detachment and, 4.130, 4.130f
 - retinal dialyses at, 12.315
 - vitreous gel attachment to, 12.307
- Vitreous biopsy**
- for endophthalmitis after cataract surgery, 11.162
 - for primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.135–136, 4.136f, 4.312, 9.274, 9.275, 9.275f
 - for uveal lymphoid proliferation/infiltration, 4.314
 - for uveitis, 9.92
- Vitreous block. *See also* Ciliary block glaucoma**
- after cataract surgery, 11.139
- Vitreous body**
- anatomy of, 12.8f
 - anterior surface of, 12.7, 12.8f
 - topographic areas of, 12.7
- Vitreous cellular reaction, in uveitis, 9.79**
- Vitreous detachment**
- hallucinations and, 5.175
 - perifoveal, 12.337
 - posterior (PVD), 2.80, 2.80f, 2.81f, 2.252–253, 4.128–129, 4.129f
 - age-related, 12.307–308
 - anatomy of, 12.331
 - atrophic holes presenting with, 12.318
 - cholesterolosis and, 12.348
 - conditions associated with, 12.307
 - definition of, 12.331
 - diagnosis of, 12.331
 - epiretinal membranes. *See* Epiretinal membranes (ERMs)
 - examination of, 12.309
 - fibroglial tissue in, 12.331
 - floaters associated with, 12.308–309
 - idiopathic macular holes, 12.337–339, 12.338f
 - imaging of, 12.308f
 - indirect ophthalmoscopy of, 12.309, 12.331
 - management of, 12.309
 - myopia macular retinoschisis in, 12.209
 - nonproliferative diabetic retinopathy progression affected by, 12.102
 - optical coherence tomography of, 12.309, 12.332
 - in pars plana vitrectomy for diabetic macular edema, 12.115
 - pathologic conditions caused by, 12.332
 - photopsias associated with, 12.308
 - prevalence of, 12.331
 - retinal breaks associated with, 12.309
 - retinal detachment after cataract surgery and, 11.166
 - retinal tears caused by, 12.307, 12.308f, 12.309
 - risk factors for, 12.309
 - signs and symptoms of, 12.308
 - slit-lamp biomicroscopy of, 12.331
 - vitrectomy for, 12.333f, 12.359
 - vitreomacular adhesions, 12.336, 12.336t
 - vitreomacular traction syndrome, 12.332, 12.332f, 12.336f, 12.336–337, 12.337f
 - vitreous hemorrhage associated with, 4.133, 12.309
- Vitreous gel**
- age-related changes in, 12.331
 - attachment of, to vitreous base, 12.307
 - composition of, 12.7
- Vitreous haze, in uveitis, 9.83**
- Vitreous hemorrhage, 2.254, 4.132–133**
- in central retinal vein occlusion, 12.135
 - echography for, 12.347
 - hemolytic/ghost cell glaucoma and, 4.133, 10.105, 10.106
 - intermediate uveitis/pars planitis and, 9.129, 9.131
 - peripheral neovascularization, 12.232
 - photocoagulation as cause of, 12.379
 - in polypoidal choroidal vasculopathy, 12.75
 - posterior vitreous detachment and, 12.309
 - in proliferative diabetic retinopathy, 12.103, 12.103f, 12.107–108, 12.386–387
 - SLE and, 9.134
 - trauma-related, 12.357
 - treatment of, 12.309
 - in Valsalva retinopathy, 12.171
 - vision loss caused by, 12.346
 - vitrectomy for, 12.366, 12.386–387
- Vitreous opacities**
- in amyloidosis, 4.134
 - fibrillar, 2.253
 - in uveitis, 9.290

- Vitreous pressure, positive, flat or shallow anterior chamber and, 11.134
- Vitreous seeds, in retinoblastoma, 4.292, 4.293f
- Vitreous tap, for specimen collection. *See* Vitreous biopsy
- Vitreous veils, 6.344
- Vitritis, 4.127, 9.290. *See also* Endophthalmitis
- in acute posterior multifocal placoid pigment epitheliopathy, 9.148
 - in acute retinal necrosis, 9.194, 9.194f
 - in acute zonal occult outer retinopathy, 9.164
 - Aspergillus* causing, 9.268
 - in *Bartonella*-associated neuroretinitis, 9.256
 - in birdshot uveitis, 9.144
 - chorioretinitis with/without, flowchart for evaluation of, 9.75–76t
 - in granulomatosis with polyangiitis (Wegener granulomatosis), 9.138
 - in HTLV-1 infection, 9.212
 - in intraocular (primary central nervous system) lymphoma, 4.135, 4.311, 9.129, 9.273
 - in Lyme disease, 9.245, 9.245f
 - in multifocal choroiditis and panuveitis syndrome, 9.155
 - in multiple sclerosis, 5.318, 9.132
 - in Rift Valley fever, 9.211
 - in sarcoidosis, 9.169, 9.169f
 - in subretinal fibrosis and uveitis syndrome, 9.160
 - in sympathetic ophthalmia, 9.172
 - in syphilis, 9.238, 9.298
 - in tubulointerstitial nephritis and uveitis syndrome, 9.117
 - in uveitis, 9.290
 - in Vogt-Koyanagi-Harada syndrome, 9.176, 9.178
 - in Whipple disease, 9.258
- Vittaforma/Vittaforma corneae*, 8.252
- corneal infection caused by, 8.280–281
- VKC. *See* Vernal keratoconjunctivitis
- VKH. *See* Vogt-Koyanagi-Harada (VKH) syndrome
- VKH disease. *See* Vogt-Koyanagi-Harada (VKH) syndrome
- VLDLs. *See* Very-low-density lipoproteins
- VLM. *See* Visceral larval/larvae migrans
- VMAs. *See* Vitreomacular adhesions
- VMD. *See* Vitelliform macular dystrophy
- VMD2 (vitelliform macular dystrophy/*BEST1*) gene, 10.11f
- VMT. *See* Vitreomacular traction (VMT) syndrome
- VN. *See* Vestibular nerve/nuclei
- VNS. *See* Vagus nerve stimulation
- VNTRs. *See* Variable/variable number of tandem repeats
- Vogt
- palisades of, 8.10
 - white limbal girdle of, 8.120, 8.120f
- Vogt-Koyanagi-Harada (VKH) syndrome, 4.186, 6.319, 9.175–182, 9.177f, 9.178f, 9.179t, 9.180f, 9.181f, 12.232f, 12.232–233
- diagnosis/differential diagnosis of, 9.179t, 9.179–181, 9.180f, 9.181f
 - glaucoma and, 9.182, 9.285
 - histologic findings in, 9.176
 - HLA association in, 9.67t, 9.176
 - Vogt striae, 6.254
 - in keratoconus, 8.162f, 8.163, 8.164f
- Vogt triad, 6.397
- Volitional saccades, 5.219, 5.220
- in progressive supranuclear palsy, 5.221
 - testing, 5.221
- Volume expansion
- for anaphylaxis, 1.302
 - for shock, 1.301
- Volume overload, 1.108
- avoidance of, in heart failure management, 1.111
- Volume rendering
- B-scans versus, 12.27
 - macular telangiectasia on, 12.31
- Voluntary convergence/vergence, 5.226, 6.40
- Voluntary flutter, 5.249–250, 5.309
- Voluntary “nystagmus,” 5.249–250, 5.309
- Vomiting. *See* Nausea and vomiting
- von Basedow disease. *See* Hyperthyroidism; Thyroid eye disease
- von Graefe knife, 11.90
- von Graefe sign, 7.25, 7.52
- von Hippel disease/syndrome, 4.284. *See also* Retinal angiomatosis
- with hemangioblastomas. *See* von Hippel-Lindau (VHL) disease/syndrome
- von Hippel internal ulcer, 4.74, 4.75f, 6.259
- von Hippel-Lindau (VHL) disease/syndrome, 4.144, 4.144f, 4.284–285, 5.330, 5.331f, 5.334t, 6.393t, 6.399–401, 6.400t, 6.400f, 12.165–168, 12.166–167f. *See also* Retinal angiomatosis
- von Kossa stain, 4.31t
- von Recklinghausen disease/neurofibromatosis. *See* Neurofibromatosis 1
- von Willebrand disease (vWD), 1.145
- von Willebrand factor (vWF), 1.145
- VOR. *See* Vestibular-ocular system/vestibular-ocular reflex
- VOR gain. *See* Vestibular-ocular reflex (VOR) gain
- Voriconazole, 1.280, 2.355t, 2.356
- for *Acanthamoeba* keratitis, 8.279
 - for fungal endogenous endophthalmitis
 - Aspergillus*, 9.269
 - Candida*, 9.267
 - coccidioidomycosis, 9.272
 - fungal endophthalmitis treated with, 12.239
 - for fungal keratitis, 8.275
 - yeast endophthalmitis treated with, 12.240
- Vortex (hurricane) keratopathy (cornea verticillata), 8.90, 8.129t, 8.130, 8.176, 8.177f
- in chloroquine/hydroxychloroquine toxicity, 8.130
 - in Fabry disease, 6.270, 8.176, 8.177f
- Vortex veins, 2.34f, 2.35, 5.21, 7.14f, 7.15f
- in choroid, 12.19
 - choroid drained by, 2.60
 - development of, 2.116t
 - extraocular muscles supplied by, 6.23
 - surgical considerations for, 6.30
 - varix of, 4.270f, 4.271
- Vorticose veins, 5.21f
- Vossius ring, 4.18, 11.53

VRE. *See* Vancomycin-resistant enterococci
 VRSA. *See* Vancomycin-resistant *Staphylococcus aureus*
 VSR. *See* Venous stasis retinopathy
 VT. *See* Ventricular tachycardia
 VTRs. *See* Variable/variable number of tandem repeats
 vWD. *See* von Willebrand disease
 vWF. *See* von Willebrand factor
 VZV. *See* Varicella-zoster virus

W

Waardenburg-Jonkers corneal dystrophy. *See* Thiel-
 Behnke corneal dystrophy
 Waardenburg syndrome, 2.152, 12.282*t*
 description of, 6.270
 type 1, 6.191, 6.192*f*
 Wagner disease, 12.342–343
 Wagner hereditary vitreoretinal degeneration, 12.282*t*
 WAGR syndrome, 2.193, 6.267, 10.155, 11.33
 Waite-Beetham lines, 8.41, 8.199
 Waldenström macroglobulinemia, crystalline corneal
 deposits in, 8.198, 8.199*f*
 Wall-eyed bilateral internuclear ophthalmoplegia
 (WEBINO), 5.189, 5.190*f*
 in multiple sclerosis, 5.318
 Wallenberg syndrome (Wallenberg lateral medullary
 syndrome), 5.20, 5.180, 5.217, 5.337
 Horner syndrome and, 5.260*t*, 5.337
 MRI in, 5.64*f*
 Wallerian degeneration, optic nerve, 4.245–246
 Wandering nystagmus, 12.266
 Warfarin/warfarin derivatives, 1.149
 for antiphospholipid antibody syndrome, 1.161
 for atrial fibrillation, 1.114
 cataract surgery in patient taking, 11.171
 DNA tests in dosage determination and, 1.142
 for heart failure, 1.111
 ocular effects of, 1.308*t*
 in perioperative setting, 1.286
 Wart (verruca/verruca vulgaris)
 of eyelid, 4.204, 4.205*f*, 7.167, 7.167*f*
 papillomavirus causing, 1.262, 4.204, 4.205*f*, 7.167,
 8.238
 Wasp stings, ocular injury caused by, 8.386–387
 Watchful waiting. *See* Observation
 Water and electrolyte balance, in lens, maintenance of,
 11.21, 11.22*f*
 Water channels (aquaporins), 2.242, 2.245, 11.16,
 11.20–21
 Water-insoluble lens proteins, 11.15, 11.15*f*
 aging affecting, 11.17
 Water molds, 8.251
 Water-soluble lens proteins, 2.243, 2.245, 11.15, 11.15*f*.
 See also Crystallins
 conversion of, to water-insoluble, 11.17
 Water transport, in retinal pigment epithelium, 12.18
 Watershed defects, 12.198
 Watershed zone, 2.91
 Watt, 3.106
 Watts per square centimeter (W/cm²), 3.108
 Watts per unit area (W/m²), 3.108
 Wave theory of light, 3.94–95, 3.95*f*

Wavefront
 definition of, 3.42, 3.94
 geometric, 3.70–71, 3.274
 in myopia, 3.73, 3.73*f*
 pictorial representation of, 3.94*f*
 Wavefront aberrations. *See also* Aberrations; Wavefront
 analysis; *specific type*
 coma, 3.40, 3.275*f*, 3.275–276, 13.9, 13.12, 13.12*f*,
 13.103*f*
 definition of, 3.274, 3.289
 description of, 3.70–74, 3.71–74*f*
 first-order, 13.11
 fourth-order, 3.276*f*, 13.12, 13.12*f*
 graphical representations of, 13.9–10, 13.10*f*
 higher-order, 13.11–13, 13.12*f*, 13.13*f*
 after LASIK, 13.11, 13.12, 13.102–103, 13.103*f*
 after surface ablation, 13.11, 13.12, 13.13, 13.102
 topography-guided laser ablation and, 13.32,
 13.77
 wavefront-guided/wavefront-optimized ablation
 and, 13.13, 13.31–32, 13.76–77
 hyperopia producing (negative defocus), 13.11
 irregular astigmatism, 13.17–19, 13.18*f*, 13.19*f*.
 See also Irregular astigmatism
 keratorefractive surgery and, 13.9–13, 13.10*f*, 13.11*f*,
 13.12*f*, 13.13*f*
 lower-order, 13.11, 13.11*f*
 measurement of, 13.9–10, 13.10*f*
 myopia producing (positive defocus), 13.11, 13.11*f*
 piston, 13.11
 postoperative, 13.102–103, 13.103*f*
 prisms, 13.11
 pupil position and, 3.275–276
 ray tracing for, 3.277
 regular astigmatism, 13.17, 13.18*f*. *See also* Regular
 astigmatism
 second-order, 3.276*f*, 13.11, 13.11*f*
 spherical, 13.9, 13.12, 13.12*f*, 13.102
 after LASIK, 13.12, 13.102
 after radial keratotomies, 13.50
 after surface ablation, 13.12, 13.102
 surfaces of, 3.277
 third-order, 3.276*f*, 13.12, 13.12*f*
 trefoil, 13.9, 13.12, 13.13*f*, 13.103*f*
 types of, 3.275–276, 3.276*f*
 Zernike polynomials, 3.277
 zero-order, 13.11
 Wavefront aberrometry/aberrometers, 3.289–292,
 3.290–291*f*. *See also* Wavefront analysis
 intraoperative, in IOL power determination/selection
 astigmatism and, 11.124
 after refractive surgery, 11.86
 Wavefront analysis, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*,
 13.13*f*, 13.46. *See also* Wavefront aberrations
 definition of, 3.268
 Fermat principle as basis of, 3.274
 graphical representations and, 13.9–10, 13.10*f*
 IOL power determination/selection after refractive
 surgery and, 13.194
 of irregular astigmatism, 3.273–277, 3.274–276*f*
 before LASIK, 13.80
 after photoablation, 13.102–103, 13.103*f*
 reference sphere in, 3.274, 3.274*f*

- before wavefront-guided ablation, 13.31, 13.46, 13.80
 - laser programming and, 13.31, 13.81
- Wavefront-guided (custom) laser ablation, 13.31, 13.46, 13.76–77
 - higher-order aberrations and, 13.13, 13.31–32, 13.76–77
 - for LASIK re-treatment/enhancement, 13.99
 - for mixed astigmatism, 13.97
 - multifocal, 13.167, 13.168*f*
 - outcomes of, 13.31–32, 13.97
 - overcorrection and, 13.102
 - patient selection/relative contraindications and, 13.80
 - postoperative aberrations and, 13.13, 13.102
 - preoperative planning/laser programming for, 13.31, 13.81
 - for presbyopia, 13.167, 13.168*f*
 - wavefront analysis before, 13.31, 13.46, 13.80
- Wavefront-guided lasers, 13.31–32, 13.76–77
 - programming, 13.31, 13.81
- Wavefront-mapping systems, 13.81
- Wavefront-optimized laser ablation, 13.31, 13.76–77.
 - See also* Wavefront-guided (custom) laser ablation
 - higher-order aberrations and, 13.13, 13.31–32
 - outcomes of, 13.31–32, 13.97
 - postoperative aberrations and, 13.13, 13.102
- Wavefront theory, 3.70–74
- Wavelength
 - anterior segment and, 3.118
 - color associations with, 3.94*t*
 - laser, 3.115
 - of light, 3.93, 3.94*t*
- Wave-particle duality of light, 3.94
- Wavescan imaging, 13.21*f*
- WDR36 gene, 10.11*t*
- Weakening procedures
 - for inferior oblique muscle
 - bilateral, 6.165
 - indications for, 6.118
 - for superior oblique muscle palsy, 6.123, 6.123*t*
 - surgical procedures for, 6.164*t*, 6.165–166
 - for V-pattern strabismus, 6.111
 - for oblique muscles, 6.164*t*, 6.165–166
 - for rectus muscles, 6.163, 6.164*t*
- Weber syndrome, 5.191
- WEBINO. *See* Wall-eyed bilateral internuclear ophthalmoplegia
- Wedl (bladder) cells, 4.121, 4.121*f*, 11.48, 11.152
 - in phakomatous choristoma, 4.202, 4.203*f*
- Wegener granulomatosis (granulomatosis with polyangiitis/GPA), 1.165*t*, 1.167–168, 7.61–62, 7.62*f*, 9.137–139, 9.138*f*
 - eyelid manifestations of, 4.207*t*
 - optic neuritis and, 5.115
 - scleritis/retinal vasculitis and, 7.61, 9.138
 - screening/diagnostic tests for, 7.33–34
- Weight, IGF-1, neonatal ROP (WINROP) algorithm, 12.182
- Weight reduction
 - cardiovascular disease risk modification and, 1.83*t*, 1.85
 - diabetes mellitus prevention/management and, 1.36, 1.38, 1.40
 - hypercholesterolemia management and, 1.85
 - hypertension management and, 1.66, 1.67*t*
 - for idiopathic intracranial hypertension, 5.112
- Weil disease, 9.248
- Weill-Marchesani syndrome, 6.309, 11.33
 - microspherophakia in, 10.130, 11.33
- Weiss ring, 12.308*f*
- Welch-Allyn retinoscope, 3.150–151, 3.160
- Well-differentiated pleomorphic tumors, 6.217
- Well-differentiated squamous cell carcinoma, of eyelid (keratoacanthoma), 4.209–210, 4.210*t*, 4.211*f*, 7.176–177, 7.177*f*
- Werner syndrome, 8.192*t*
- Wernicke disease, 1.192
- WESDR. *See* Wisconsin Epidemiologic Study of Diabetic Retinopathy
- West African crystalline retinopathy, 12.303–304, 12.305*f*
- West Nile virus (WNV), 9.208–210, 9.209*f*
 - chorioretinitis caused by, 9.209, 9.209*f*, 9.210, 12.246, 12.247*f*
- Western blot analysis, 2.145
 - in HIV infection/AIDS, 1.264
 - in HTLV-1 infection, 9.212
 - in Lyme disease, 1.251, 5.353, 9.246
- “Wet”/exudative age-related macular degeneration. *See* Neovascular (“wet”/exudative) age-related macular degeneration
- Wettability, of contact lenses, 3.213, 3.213*f*
- Wetting angle, 3.206, 3.213
- Wheezing, 1.129
- Whiplash injuries, 12.356–357
- Whipple disease, 9.258–259
 - eye movement abnormalities in, 5.251
- White blood cells (leukocytes), 1.135, 9.9–12. *See also specific type*
 - immunophenotyping of, flow cytometry for, 4.36
 - in inflammation, 4.7, 4.8*f*
- “White coat” hypertension, 1.62
- White dot syndromes, 9.140–166, 9.141–143*t*. *See also specific type*
 - acute posterior multifocal placoid pigment epitheliopathy, 12.220*t*, 12.221*f*, 12.221–222
 - birdshot uveitis, 12.220*t*, 12.224–225, 12.225*f*
 - characteristics of, 12.220*t*
 - multifocal choroiditis, 12.220*t*, 12.225–226, 12.226*f*
 - multifocal choroiditis and panuveitis syndrome, 12.220*t*
 - multiple evanescent (MEWDS), 5.101, 9.140, 9.141–143*t*, 9.161*f*, 9.161–163, 9.162*f*, 9.163*f*, 12.220*t*, 12.223–224, 12.224*f*
 - fundus autofluorescence in identification of, 5.90
 - OCT in identification of, 5.92, 5.101
 - punctate inner choroidopathy, 12.220*t*
 - serpiginous choroidopathy, 12.220*t*, 12.222–223, 12.223*f*
- White eye shunt syndrome, 5.201
- White-eyed blowout fracture, 6.380, 7.108
- White limbal girdle of Vogt, 8.120, 8.120*f*
- White Maddox rod, 5.184–185, 5.185*f*. *See also* Maddox rod/Maddox rod test
- White-matter lesions
 - in multiple sclerosis, 5.318
 - neuroimaging in evaluation of, 5.72*t*

- White pupil. *See* Leukocoria
- White ring, Coats, 8.115, 8.116f
- “White spot” (hypopigmented macule/ash-leaf spot), in tuberous sclerosis, 5.331f, 5.334t, 10.30
- Whitnall ligament (superior transverse ligament), 2.20f, 2.24, 7.7, 7.14f, 7.15f, 7.146f, 7.150, 7.150f, 7.251
- Whitnall tubercle, 2.7, 7.6f, 7.7, 7.7f
- WHO (World Health Organization), 1.187, 1.225
- cataract epidemiology and, 11.5
 - on lacrimal gland neoplasia classification, 4.229
 - on lymphoma classification, 4.231
- Whole-genome shotgun sequencing, 2.163f
- Wide-angle fluorescein angiography
- description of, 12.36, 12.37f
 - von Hippel–Lindau syndrome on, 12.167, 12.167f
- Wide complex tachycardias, 1.113
- Wilbrand knee, 2.92, 5.27–28
- Wilcoxon rank sum test, 1.7
- Wild type, 2.145
- Wildervanck syndrome, 6.131
- Willis, circle of, 1.120, 2.90, 2.90f, 2.105–107, 2.107f, 5.18
- aneurysms in, 1.126
- Wilms tumor, aniridia and, 2.193, 4.184, 10.155, 11.33
- Wilms tumor (*WT1*) gene, aniridia and, 10.155
- Wilms tumor–suppressor gene, imprinting of, 2.138, 2.153
- Wilson disease (hepatolenticular degeneration), 2.203, 6.270, 8.189f, 8.189–190, 11.62, 12.362
- cataracts associated with, 8.189, 11.62
 - oculogyric crisis in, 5.231
 - penicillamine for, 2.203, 8.189
- Window defect, hyperfluorescence in, 12.36
- “Wing” cells, 2.39, 2.40f, 2.223f, 2.224
- WINROP algorithm, 12.182
- Wipeout, after trabeculectomy, 10.199
- Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 12.92
- With movement, in retinoscopy, 3.152, 3.153f, 3.155
- With-the-rule astigmatism, 8.31f
- definition of, 3.19, 3.125
 - description of, 3.139
 - minus cylinder lens correction of, 3.20f
 - schematic diagram of, 3.20f
- Withdrawal (abstinence) syndrome. *See also specific drug*
- hypertension and, 1.79
- Wnt (ligand), gene expression/ocular development and, 2.127
- WNV. *See* West Nile virus
- Wolbachia*
- in onchocerciasis, 8.253
 - onchocerciasis treatment and, 9.235
- Wolf–Hirschhorn syndrome, 6.386t
- Wolfflin nodules, 6.272
- Wolfram (DIDMOAD/diabetes insipidus, diabetes mellitus, optic atrophy, and deafness) syndrome, 6.408–409
- pleiotropism in, 2.196
- Wolfring, glands of, 2.20f, 2.22f, 2.23t, 2.29, 2.216, 4.202, 7.146f, 7.152, 7.252, 8.4f
- Women’s Health Initiative, 1.211
- Working distance
- bifocal segment decentration and, 3.191
 - in retinoscopy, 3.154
- World Health Organization (WHO), 1.187, 1.225
- cataract epidemiology and, 11.5
 - on lacrimal gland neoplasia classification, 4.229
 - on lymphoma classification, 4.231
- Worm’s-eye view position, 7.24, 7.25f
- Worth 4-dot (red-green/duochrome) test, 6.51–52, 6.80f, 6.80–81
- in nonorganic disorder evaluation
 - monocular no light perception and, 5.303, 5.304f
 - monocular reduced vision and, 5.305
 - before refractive surgery, 13.39
- Wound closure, after cataract surgery
- complications associated with, 11.130–131
 - after ECCE, 11.197–198
 - after ICCE, 11.200–201
 - postoperative endophthalmitis and, 11.161
- Wound contraction, 4.13
- eyelid/orbit scarring and, 4.17
- Wound dehiscence/rupture, after cataract surgery, 11.131
- Wound healing/repair, 4.13–23, 4.14f. *See also specific tissue*
- of cornea, 4.13–16, 4.15f
 - keratorefractive surgery and, 13.32–33
 - delays in, 13.93–94, 13.108
 - of eyelid/orbit/lacrimal tissues, 4.17
 - histologic sequelae of trauma and, 4.17–23, 4.18f, 4.19f, 4.20f, 4.21f, 4.22f, 4.23f
 - of lens, 4.17
 - promotion of, in chemical injuries, 8.383–384
 - of retina, 4.17
 - of sclera, 4.16
 - of uvea, 4.16
 - of vitreous, 4.17
- Wound leaks
- after cataract surgery, 11.118, 11.130–131
 - flat anterior chamber and, 11.135
 - angle-closure glaucoma and, 10.144–145
 - after penetrating keratoplasty, 8.423
 - after trabeculectomy, 10.209, 10.210, 10.211
- Wound management, in tetanus, 1.222
- Wound misalignment, after penetrating keratoplasty, 8.423
- Wright–Giemsa stain, 4.31t
- Wrong-site surgery, 1.289
- Universal Protocol in avoidance of, 1.289–290
- WT1* gene, 6.267
- WT1* (Wilms tumor) gene, aniridia and, 10.155
- Wyburn–Mason syndrome (Bonnet–Dechaume–Blanc syndrome/racemose angioma/hemangioma), 4.286f, 4.286–287, 5.331, 5.333f, 5.334t, 6.222, 6.394t, 6.405t, 6.405–406, 12.168

X

- X chromosome, 2.147, 2.178, 2.179, 2.184, 2.189f
- genes for color vision on, 2.262–263
 - inactivation of (lyonization/Barr body), 2.132, 2.139, 2.153, 2.197–200
 - ocular findings in carrier states and, 2.197–200, 2.198–199f, 2.199t
 - mosaicism and, 2.191–192

X-linked cone dystrophy, 12.253f
 X-linked congenital stationary night blindness, 12.252
 X-linked disorders, 2.180–181. *See also* X-linked inheritance; *specific disorder*
 albinism (Nettleship-Falls), ocular findings in carriers of, 2.198–200, 2.199f
 blue-cone monochromatism. *See* X-linked disorders, S-cone (blue-cone) monochromatism
 dominant, 2.180–181
 Fabry disease, 8.176–178, 8.177f
 gene therapy for, 2.169
 Hunter syndrome, 8.175t
 ichthyosis, 8.202
 incontinentia pigmenti (IP/Bloch-Sulzberger syndrome), 2.180
 Lisch corneal dystrophy, 8.140
 megalocornea, 8.96t
 ocular findings in carriers of, 2.197–200, 2.198–199f, 2.199t
 retinitis pigmentosa (XLRP)
 electroretinography findings in, 12.50
 ocular findings in carriers of, 2.198f, 2.199t
 S-cone (blue-cone) monochromatism, 2.264
 ocular findings in carriers of, 2.199t
 X-linked inheritance (X-linked genes), 2.145, 2.178–181. *See also* X-linked disorders
 dominant, 2.179–180, 2.181t
 recessive, 2.179, 2.180t
 X-linked retinoschisis (XLRs)
 characteristics of, 12.278f, 12.278–279
 electroretinography findings in, 12.46, 12.47f
 X-pattern strabismus
 clinical features of, 6.110
 surgical treatment of, 6.113
 Xalacom. *See* Latanoprost, in combination preparations
 Xalatan. *See* Latanoprost
 Xanthelasma, 4.206, 4.206f, 7.169, 7.169f. *See also* Xanthomas
 in dyslipoproteinemia/hyperlipoproteinemia, 4.206, 4.207t
 Xanthine derivatives, for asthma, 1.133t
 Xanthocoria, 6.360
 Xanthogranuloma
 adult-onset (AOX), 7.90, 7.91
 juvenile, 7.91, 8.347, 9.277
 glaucoma associated with, 10.30
 of iris, 4.187, 4.260, 6.271
 uveal tract/uveitis and, 4.187, 4.188f
 necrobiotic (NBX), 7.90, 7.91, 8.347
 of orbit, 7.90–91
 periocular, with adult-onset asthma (AAPOX), 7.90, 7.91
 Xanthomas
 fibrous (fibrous histiocytoma), 8.347
 malignant, 4.112
 orbital, 4.235, 7.84
 scleral, 4.112, 4.113f
 in hyperlipoproteinemias, 4.206, 4.207t
 Xanthophylls (carotenoids), 3.119, 12.373, 12.374f
 antioxidant effects of, 2.284f, 2.288
 in lens, 2.285
 in macula, 4.140
 in retina, 2.77, 2.286, 2.288, 2.289f

Xanthopsia, 12.305
 Xeroderma pigmentosa/pigmentosum (XP), 8.202–203
 description of, 2.154, 7.178
 ocular surface squamous cell carcinoma and, 8.336
 Xerophthalmia, 8.196–197. *See also* Vitamin A, deficiency of
 dry eye and, 8.54, 8.54f
 Xerosis
 Corynebacterium xerosis and, 8.196–197, 8.246
 in vitamin A deficiency, 8.196, 8.197
 Xibrom. *See* Bromfenac
 XLM. *See* External limiting membrane
 XLRP. *See* X-linked disorders, retinitis pigmentosa
 XLRs. *See* X-linked retinoschisis
 XP. *See* Xeroderma pigmentosa/pigmentosum
 XYZ hypothesis, 8.11

Y

Y chromosome, 2.147, 2.178, 2.179, 2.184, 2.189f
 mosaicism and, 2.192
 Y-linked inheritance (Y-linked genes), 2.145
 Y-pattern strabismus
 clinical features of, 6.109–110
 surgical treatment of, 6.113
 Y-sutures, lens, 2.64, 2.65f, 11.13
 development of, 11.28, 11.28f
 opacification of (sutural/stellate cataract), 11.37, 11.37f
 Y-V-plasties
 for blepharophimosis-ptosis-epicanthus inversus syndrome, 7.155
 for epicanthus, 7.159
 YAC (yeast artificial chromosome), 2.145
 YAG lasers. *See* Lasers
 Yeast artificial chromosome (YAC), 2.145
 Yeasts, 5.353, 8.249, 8.249t, 8.250f, 8.250–251
 Candida, 1.255–256, 9.265, 9.266, 9.267f
 Cryptococcus neoformans, 9.270
 endophthalmitis caused by, 9.265–268, 9.266f, 9.267f, 9.270, 12.239–240, 12.240f
 keratitis caused by, 8.208t, 8.251, 8.273, 8.274–275
 as normal flora, 8.206t, 8.250
 Yellow fever vaccination, 1.224
 Yellow laser, 12.374
 Yellow spot. *See* Macula/macula lutea
Yersinia pseudotuberculosis, 6.240
 Yohimbine, 2.308t
 Yoke muscles, 6.38
 eccentric gaze and, 5.38
 Young, Thomas, double-slit experiments by, 3.94, 3.101, 3.101f, 3.105

Z

z-height/z-maps, 13.22, 13.22f
 Z-plasties
 for blepharophimosis-ptosis-epicanthus inversus syndrome, 7.155
 for epicanthus, 7.159
 for eyelid repair, 7.190
 for symblepharon, 7.208

- Z syndrome, 11.151
 Zador. *See* Ketotifen
 Zaleplon, 1.194
 Zanamivir, 1.220, 1.281
 Zeaxanthin, 2.77
 age-related macular degeneration managed with, 12.70*t*
 antioxidant effect of, 2.286, 2.288
 cataract risk affected by, 11.7
 description of, 12.367
 in retina, 2.286, 2.288
ZEB1 gene, in posterior polymorphous corneal dystrophy, 8.136*t*
 Zeis, glands of, 2.19, 2.22*f*, 2.23*t*, 2.215, 4.201, 7.170, 8.4, 8.4*f*
 chalazion and, 4.204, 4.206*f*
 chalazion/hordeolum and, 8.76, 8.77
 hordeolum and, 4.203–204, 7.163
 sebaceous adenocarcinoma arising in, 4.215, 7.183
 in tear film lipids/tear production, 2.215
 Zeiss 4-mirror gonioscopes, for gonioscopy, 10.33, 10.34*f*, 10.35
 in pediatric glaucoma, 10.159
 Zellweger syndrome, 12.283*t*, 12.290
 Zentmayer line, 10.94, 10.95*f*
 Zernike polynomials, 13.9, 13.11*f*, 13.12*f*, 13.13*f*
 definition of, 3.42, 3.71, 3.139, 3.277
 higher-order aberrations characterized by, 3.139
 low-order, 3.73, 3.73*f*
 second-order, 3.73
 third-order, 3.73
 wavefront aberrations, 3.277
 Zero-order aberrations, 13.11
 Zeus transport medium, as tissue fixative, 4.26*t*
 Zidovudine, 2.357*t*, 2.361
 Ziehl-Neelsen stain, 4.31*t*
 Zika virus
 chorioretinitis caused by, 12.247
 description of, 6.413
 Zimmerman tumor (phakomatous choristoma), 4.202–203, 4.203*f*
 Zinbryta. *See* Daclizumab
 Zinc
 age-related macular degeneration managed with, 12.69, 12.70*t*
 in aqueous humor, 2.232
 in intraocular foreign body, 12.362
 Zinc finger E box-binding homeobox 1 (*ZEB1*) gene, in posterior polymorphous corneal dystrophy, 8.136*t*
 Zinn
 annulus of, 2.8, 2.9*f*, 2.13*f*, 2.14*f*, 2.16–17, 2.87, 5.8*f*, 5.26, 5.45, 7.11, 7.12–13, 7.13*f*, 7.14*f*, 7.15*f*, 7.16
 circle of (circle of Zinn-Haller), 2.88*f*, 2.91, 5.17, 10.44, 10.46
 zonules of. *See* Zonular fibers, lens
 Zinn-Haller, circle of, 2.88*f*, 2.91, 5.17, 10.44, 10.46
 Zioptan. *See* Tafluprost
 Ziran. *See* Ganciclovir
 ZMC fractures. *See* Zygomaticomaxillary complex (ZMC) fractures
ZNF469 gene, 6.254
 Zollinger-Ellison syndrome, multiple endocrine neoplasia and, 1.58
 Zolpidem, 1.194
 Zonal granuloma, 4.119, 4.119*f*
 Zonal refractive multifocal intraocular lenses, 13.166, 13.166*f*. *See also* Multifocal lenses, intraocular
 Zone of discontinuity, 2.64
 Zonisamide, 1.202*t*
 Zonulae adherentes, in retinal pigment epithelium, 2.68
 Zonulae occludentes (tight junctions), 12.17
 in ciliary body epithelium, 2.57
 in corneal endothelium, 2.227
 in corneal epithelium, 8.8
 in retinal pigment epithelium, 2.68, 2.272
 Zonular apparatus, 2.252
 Zonular (lamellar) cataracts, 11.34–35, 11.36*f*
 Zonular dehiscence
 angle closure/pupillary block and, 10.119
 cataract surgery and, 11.181–183, 11.182*f*, 11.183*f*
 iris coloboma/corectopia and, 11.180
 Zonular fibers
 corneal epithelial, 2.39
 lens (zonules of Zinn), 2.37*f*, 2.46*f*, 2.63*f*, 2.65*f*, 2.66–67, 2.241, 4.115, 4.117, 11.9, 11.10*f*, 11.12
 absent/abnormal
 cataract surgery and, 11.179–184
 iris coloboma/corectopia and, 11.180
 nucleus rotation and, 11.111
 in glaucoma, 10.33*t*, 10.119
 in accommodation, 2.64*f*, 2.66, 13.159, 13.160, 13.160*f*, 13.161, 13.161*f*
 degenerations of, 4.124
 development of, 2.120, 2.120*f*, 11.29
 evaluation of
 before cataract surgery, 11.80
 in glaucoma, 10.33*t*
 pigment deposits on, in pigment dispersion syndrome, 10.94, 10.95*f*
 in pseudoexfoliation/exfoliation syndrome, 10.92, 10.93, 10.130, 10.131*f*, 11.65–66, 11.181, 11.182*f*, 11.184
 as tertiary vitreous, 2.123*f*, 4.125
 topography of, 2.37*f*, 4.117
 vitreous, 2.252
 tertiary, 2.123*f*, 4.125
 Zonular lamella, 11.11
 Zonular traction retinal tufts, 12.311, 12.312*f*
 Zonules
 corneal epithelial, 2.39
 of Zinn. *See* Zonular fibers, lens
 Zostavax, 1.221, 1.259
 Zoster. *See* Herpes zoster
 Zoster dermatitis, 8.227, 8.229
 Zoster sine herpete, 5.298, 9.191
 Zoster vaccine, 5.298, 8.229
 Zosyn (intravenous piperacillin and tazobactam), 1.276
 Zovirax. *See* Acyclovir
 Zygoma. *See* Zygomatic bone
 Zygomatic artery, 5.13*f*
 Zygomatic bone (zygoma), 2.5, 2.6*f*, 2.7, 5.5, 5.7, 5.7*f*, 5.9*f*, 7.6*f*, 7.7, 7.7*f*, 7.8, 7.8*f*
 fractures of, 7.103–105, 7.105*f*
 Zygomatic branch of cranial nerve VII (facial), 2.104, 5.51*f*, 5.52, 5.276–277*f*
 Zygomatic foramen, 2.8

- Zygomatic ligament, 7.141
 Zygomatic nerve, 5.8f, 5.48f, 5.49, 5.51f, 7.9, 7.14f, 7.15f, 7.17f, 7.142f, 7.144f
 Zygomaticofacial artery, 2.34f, 5.15f
 Zygomaticofacial canal, 7.9
 Zygomaticofacial foramen, 7.6f, 7.8f
 Zygomaticofacial nerve, 5.49, 7.14f, 7.15f, 7.17f, 7.143, 7.145f
 Zygomaticomaxillary complex (ZMC) fractures (quadripod fractures), 7.103–105, 7.105f
 Zygomaticomaxillary suture, 5.8
 Zygomaticotemporal artery, 2.34f, 5.15f
 Zygomaticotemporal canal, 7.9
 Zygomaticotemporal foramen/foramina, 5.11, 7.6f
 Zygomaticotemporal nerve, 5.49, 7.14f, 7.15f, 7.17f, 7.145f
 in reflex tear arc, 7.251
 Zygomaticus muscles, major and minor, 7.141, 7.143f
 Zygomycetes infection (zygomycosis/mucormycosis/phycomycosis), 5.355f, 5.355–356, 8.251
 cornea involved in (keratitis), 4.78
 optic nerve involved in, 4.243
 orbit involved in, 4.226–227, 4.228f, 5.355, 7.50
 exenteration in management of, 7.50, 7.136
 Zygote, 2.186
 Zylet. *See* Loteprednol, with tobramycin
 Zymar. *See* Gatifloxacin
 Zymaxid. *See* Gatifloxacin

Basic and Clinical Science Course™

Section 1	Update on General Medicine
Section 2	Fundamentals and Principles of Ophthalmology
Section 3	Clinical Optics
Section 4	Ophthalmic Pathology and Intraocular Tumors
Section 5	Neuro-Ophthalmology
Section 6	Pediatric Ophthalmology and Strabismus
Section 7	Orbit, Eyelids, and Lacrimal System
Section 8	External Disease and Cornea
Section 9	Intraocular Inflammation and Uveitis
Section 10	Glaucoma
Section 11	Lens and Cataract
Section 12	Retina and Vitreous
Section 13	Refractive Surgery

Master Index